-DOCSTART- -X- N

A DT N
scanning NN N
electron NN N
microscopic NN N
study NN N
of IN N
different JJ N
caries NNS P
removal VBP P
techniques NNS P
on IN P
human JJ P
dentin NN P
. . P

Scanning VBG N
electron NN N
microscopy NN N
(SEM) NNP N
evaluated VBD N
the DT N
effect NN N
of IN N
different JJ P
caries NNS P
removal VBP P
techniques NNS P
on IN P
human JJ P
dentin NN P
topography NN P
. . P

Thirty-six NNP P
extracted VBD P
human JJ P
carious JJ P
mandibular NN P
molars NNS P
were VBD P
randomly RB P
assigned VBN P
to TO P
six CD P
groups NNS P
according VBG P
to TO P
caries NNS P
removal NN P
technique NN P
. . P

Carious JJ N
tissue NN N
was VBD N
removed VBN N
by IN N
hand NN N
excavation NN N
bur NN N
excavation NN N
air-abrasion NN N
laser NN N
ablation NN N
chemomechanical JJ N
methods NNS N
and CC N
sono-abrasion NN N
. . N

The DT N
remaining VBG N
dentin NN N
surfaces NNS N
were VBD N
replicated VBN N
and CC N
gold-coated JJ N
. . N

The DT N
surfaces NNS N
were VBD N
examined VBN N
using VBG N
SEM NNP N
and CC N
distinct JJ N
differences NNS N
in IN N
appearance NN N
were VBD N
observed VBN N
among IN N
specimens NNS N
treated VBN N
with IN N
different JJ N
caries NNS N
removal NN N
techniques NNS N
. . N

While IN N
hand-excavated JJ N
bur-excavated JJ N
and CC N
air-abraded JJ N
carious JJ N
dentin NN N
surfaces NNS N
were VBD N
covered VBN N
with IN N
a DT N
residual JJ O
smear JJ O
layer NN O
sono-abrasion NN O
with IN N
patent JJ N
dentinal JJ N
tubules NNS N
completely RB N
removed VBD N
the DT N
smear JJ N
layer NN N
. . N

A DT N
few JJ N
patent NN N
orifices NNS N
of IN N
dentinal JJ N
tubules NNS N
were VBD N
observed VBN N
in IN N
dentin NN N
subjected VBN N
to TO N
laser VB N
ablation NN N
and CC N
chemo-mechanical JJ N
caries NNS N
removal NN N
. . N

-DOCSTART- -X- N

Combined VBN N
action NN N
of IN N
enalapril NN I
or CC I
timolol NN I
with IN I
hydrochlorothiazide JJ I
plus CC I
amiloride JJ I
in IN N
hypertension NN P
. . P

59 CD P
mild NN P
to TO P
moderate VB P
hypertensives NNS P
were VBD P
treated VBN P
for IN N
four CD N
weeks NNS N
with IN N
50 CD I
mg NNS I
hydrochlorothiazide JJ I
plus CC I
5 CD I
mg NN I
of IN I
amiloride NN I
then RB I
concomitantly RB N
with IN N
these DT N
diuretics NNS N
with IN N
either DT N
enalapril JJ I
(10-20 JJ N
mg) NN N
or CC I
timolol VB I
(10-20 JJ N
mg) NNS N
in IN N
two CD N
parallel JJ N
treatment NN N
groups NNS N
for IN N
an DT N
additional JJ N
12 CD N
weeks NNS N
in IN N
an DT N
open JJ N
study NN N
. . N

Addition NN N
of IN N
these DT N
drugs NNS N
lowered VBD N
the DT N
blood NN O
pressure NN O
by IN N
25 CD N
+/- JJ N
3/16 CD N
+/- JJ N
2 CD N
mm NN N
Hg NNP N
and CC N
15 CD N
+/- JJ N
3/14 CD N
+/- JJ N
1 CD N
mm NN N
Hg NNP N
respectively RB N
. . N

The DT N
difference NN N
of IN N
the DT N
reduction NN N
of IN N
the DT N
systolic JJ O
blood NN O
pressure NN O
between IN N
enalapril NN N
and CC N
timolol NN N
group NN N
at IN N
the DT N
end NN N
of IN N
the DT N
combined JJ N
treatment NN N
was VBD N
statistically RB N
significant JJ N
(p NNP N
less JJR N
than IN N
0.01) CD N
. . N

The DT N
mean JJ O
serum NN O
potassium NN O
was VBD N
elevated VBN N
by IN N
0.3 CD N
mmol/l NNS N
after IN N
addition NN N
of IN N
enalapril NN N
to TO N
the DT N
diuretic JJ N
treatment NN N
but CC N
none NN N
of IN N
the DT N
patients NNS N
developed VBD N
hyperkalaemia NN O
. . O

No DT N
adverse JJ O
effects NNS O
on IN N
other JJ N
routine JJ N
laboratory NN N
values NNS N
were VBD N
observed VBN N
. . N

Both DT N
drug NN N
combinations NNS N
can MD N
be VB N
considered VBN N
efficient JJ N
well RB N
tolerated VBN O
and CC O
safe JJ O
in IN N
the DT N
treatment NN N
of IN N
mild NN P
to TO P
moderate VB P
hypertension NN P
. . P

-DOCSTART- -X- N

Children NNP P
with IN P
autism's JJ P
response NN O
to TO N
novel VB I
stimuli NNS I
while IN N
participating VBG N
in IN N
interventions NNS I
targeting VBG I
joint JJ I
attention NN I
or CC I
symbolic JJ I
play NN I
skills NNS I
. . P

Thirty-five JJ P
children NNS P
diagnosed VBN P
with IN P
autism NN P
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
joint JJ I
attention NN I
or CC I
a DT I
symbolic JJ I
play NN I
intervention NN I
. . I

During IN N
the DT N
5-8 JJ N
week NN N
treatment NN N
three CD I
novel NN I
probes NNS I
were VBD N
administered VBN N
to TO N
determine VB N
mastery NN N
of IN N
joint JJ I
attention NN I
skills NNS N
. . N

The DT N
probes NNS N
consisted VBD N
of IN N
auditory NN I
and CC I
visual JJ I
stimuli NNS I
such JJ I
as IN I
a DT I
loud JJ I
spider NN I
crawling NN I
or CC I
a DT I
musical JJ I
ball NN I
bouncing NN I
. . I

The DT N
current JJ N
study NN N
examined VBD N
affect JJ O
gaze NN O
joint JJ O
attention NN O
behaviors NNS O
and CC O
verbalizations NNS O
at IN N
three CD N
different JJ N
time NN N
points NNS N
of IN N
intervention NN N
. . N

Results NNS N
revealed VBD N
that IN N
children NNS N
randomized VBN N
to TO N
the DT N
joint JJ I
attention NN I
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
acknowledge VB O
the DT O
probe NN O
and CC N
engage NN O
in IN O
shared VBN O
interactions NNS O
between IN N
intervener NN N
and CC N
probe NN N
upon IN N
termination NN N
of IN N
intervention NN N
. . N

Additionally RB N
the DT N
joint JJ I
attention NN I
group NN N
improved VBD N
in IN N
the DT N
proportion NN O
of IN O
time NN O
spent VBN O
sharing VBG O
coordinated VBN O
joint JJ O
looks NNS O
between IN N
intervener NN N
and CC N
probe NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
generalization NN N
of IN N
joint JJ I
attention NN I
skills NNS N
to TO N
a DT N
novel JJ N
probe NN N
did VBD N
occur VB N
for IN N
the DT N
group NN N
targeting VBG N
joint JJ I
attention NN I
and CC N
provides VBZ N
further JJ N
evidence NN N
of IN N
the DT N
effectiveness NN N
of IN N
the DT N
joint JJ I
attention NN I
intervention NN N
. . N

-DOCSTART- -X- N

Clonidine NN I
increases VBZ N
the DT N
sweating NN O
threshold NN O
but CC O
does VBZ N
not RB N
reduce VB N
the DT N
gain NN O
of IN O
sweating NN O
. . O

We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
clonidine NN I
produces VBZ N
a DT N
dose-dependent JJ N
increase NN O
in IN O
the DT O
sweating NN O
threshold NN O
but CC N
does VBZ N
not RB N
reduce VB O
the DT O
gain NN O
of IN O
sweating NN O
. . O

Six NNP P
healthy JJ P
male NN P
volunteers NNS P
were VBD P
evaluated VBN P
each DT P
on IN N
three CD N
separate JJ N
days NNS N
in IN N
random JJ N
order NN N
. . N

In IN N
one CD N
saline NN I
was VBD N
administered; VBN N
in IN N
another DT N
a DT N
2-micrograms/kg JJ I
bolus NN I
of IN I
clonidine NN I
was VBD I
followed VBN I
by IN I
an DT I
infusion NN I
at IN I
2 CD I
micrograms.kg-1.h-1 JJ I
and CC I
on IN I
a DT I
third JJ I
day NN I
a DT I
4-micrograms/kg JJ I
bolus NN I
was VBD I
followed VBN I
by IN I
an DT I
infusion NN I
at IN I
4 CD I
micrograms.kg-1.h-1 NN I
. . I

Core NN O
temperature NN O
was VBD N
measured VBN N
at IN N
the DT N
tympanic JJ N
membrane NN N
and CC N
mean JJ O
skin NN O
temperature NN O
was VBD N
determined VBN N
from IN N
four CD N
sites NNS N
. . N

A DT N
chest JJ O
sweating NN O
rate NN O
of IN N
40 CD N
g.m-2.h-1 NN N
was VBD N
considered VBN N
significant JJ N
. . N

The DT N
core NN N
temperature NN N
triggering VBG N
sweating VBG O
adjusted VBN O
to TO N
a DT N
designated VBN N
mean NN N
skin JJ N
temperature NN N
of IN N
34 CD N
degrees NNS N
C NNP N
identified VBD N
the DT N
threshold NN N
for IN N
this DT N
response NN N
. . N

Gain NN N
was VBD N
defined VBN N
by IN N
the DT N
adjusted VBN N
core NN O
temperature NN O
increase NN N
required VBN N
to TO N
augment VB N
sweating VBG N
from IN N
100 CD N
to TO N
300 CD N
g.m-2.h-1 NN N
. . N

degree JJ N
C-1 NNP N
. . N

Plasma NNP O
clonidine NN O
concentrations NNS O
were VBD N
0.8 CD N
+/- JJ N
0.1 CD N
and CC N
1.6 CD N
+/- JJ N
0.2 CD N
ng/mL NN N
on IN N
the DT N
small- JJ N
and CC N
large-dose JJ N
days NNS N
respectively RB N
. . N

Clonidine NNP I
administration NN N
increased VBD N
the DT N
sweating NN N
threshold VBD N
approximately RB N
0.4 CD N
degree JJ N
C NNP N
(P NNP N
< VBZ N
0.05) CD N
but CC N
the DT N
increase NN N
was VBD N
comparable JJ N
at IN N
each DT N
dose NN N
. . N

The DT N
gain NN O
of IN O
sweating NN O
was VBD N
approximately RB N
0.2 CD N
degree JJ N
C NNP N
and CC N
was VBD N
not RB N
influenced VBN N
by IN N
clonidine JJ I
administration NN N
. . N

The DT N
thermoregulatory JJ O
effects NNS O
of IN N
clonidine NN I
thus RB N
resemble JJ N
those DT N
of IN N
volatile JJ N
anesthetics NNS N
opioids NNS N
and CC N
propofol NN N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
the DT N
antishivering VBG N
effect NN N
of IN N
clonidine NN I
results NNS N
from IN N
central JJ N
thermoregulatory JJ N
inhibition NN N
rather RB N
than IN N
a DT N
specific JJ N
peripheral JJ N
action NN N
on IN N
thermogenic JJ N
muscular JJ N
activity NN N
. . N

Unlike IN N
other JJ N
sedatives NNS N
and CC N
anesthetics NNS N
the DT N
concentration-dependence NN N
of IN N
clonidine NN I
demonstrates VBZ N
a DT N
ceiling NN N
beyond IN N
which WDT N
the DT N
administration NN N
of IN N
an DT N
additional JJ N
drug NN N
fails NNS N
to TO N
enhance VB N
the DT N
effect NN N
suggesting VBG N
that IN N
the DT N
thermoregulatory JJ N
effect NN N
of IN N
clonidine NN I
may MD N
be VB N
limited VBN N
even RB N
at IN N
high JJ N
plasma NN N
concentrations NNS N
. . N

The DT N
gain NN N
of IN N
sweating NN N
was VBD N
well RB N
preserved JJ N
indicating VBG N
that IN N
this DT N
response NN N
remains VBZ N
effective JJ N
in IN N
the DT N
presence NN N
of IN N
sedatives NNS N
and CC N
anesthetics NNS N
. . N

-DOCSTART- -X- N

[Protective JJ N
effect NN N
of IN I
ischemia NN I
postconditioning VBG I
on IN N
reperfusion NN N
injury NN N
in IN N
patients NNS P
with IN P
ST-segment JJ P
elevation NN P
acute IN P
myocardial JJ P
infarction] NN P
. . N

OBJECTIVE NN N
To TO N
observe VB N
the DT N
effect NN N
of IN N
ischemia NN I
postconditioning VBG I
during IN N
the DT N
first JJ N
minutes NNS N
of IN N
reperfusion NN N
for IN N
the DT N
myocardial JJ N
reperfusion NN N
injury NN N
in IN N
ST-segment JJ P
elevation NN P
acute IN P
myocardial JJ P
infarction NN P
(STEMI) NN P
patients NNS P
undergoing JJ P
emergency NN P
percutaneous JJ P
coronary JJ P
intervention NN P
(PCI) NN P
. . P

METHODS NNP P
STEMI NNP P
patients NNS P
undergoing VBG P
emergency NN P
PCI NNP P
in IN P
affiliated JJ P
hospital NN P
of IN P
Beihua NNP P
University NNP P
between IN P
October NNP P
2006 CD P
and CC P
January NNP P
2009 CD P
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups: VBP N
the DT P
control NN P
group NN P
(n NNP P
= VBZ P
34) CD P
without IN I
any DT I
intervention NN I
after IN I
PTCA NNP I
and CC I
the DT I
postconditioning VBG P
group NN P
(n NNP P
= VBZ P
30) CD P
with IN I
ischemia NN I
postconditioning VBG I
within IN I
first JJ I
minutes NNS I
of IN I
reflow NN I
by IN I
3 CD I
episodes NNS I
of IN I
30-second JJ I
inflation NN I
and CC I
30-second JJ I
deflation NN I
with IN I
the DT I
angioplasty JJ I
balloon NN I
. . I

Reperfusion NN O
arrhythmias NNS O
CK NNP O
and CC O
CKMB NNP O
corrected VBD O
TIMI NNP O
frame NN O
count NN O
(CTFC) NNP O
wall NN O
motion NN O
score NN O
index NN O
(WMSI) NN O
and CC O
left VBD O
ventricular JJ O
ejection NN O
fraction NN O
(LVEF) NN O
by IN N
echocardiography NN N
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

MI NNP O
areas NNS O
were VBD N
evaluated VBN N
with IN N
the DT N
ECG-54 NNP N
criteria/32 NN N
system NN N
and CC N
myocardial JJ O
blush NN O
grade NN O
(MBG) NN O
was VBD N
measured VBN N
. . N

RESULTS VB N
The DT N
incidence NN N
of IN N
reperfusion NN O
arrhythmias-frequent JJ O
ventricular JJ O
premature NN O
(26.7% NNP N
vs NN N
. . N

52.9%) CD N
and CC N
short JJ O
array NN O
ventricular JJ O
tachycardia NN O
beat NN O
(23.3% JJ N
vs NN N
. . N

58.8%) CD N
as RB N
well RB N
as IN N
values NNS N
of IN N
peaks NNS N
CK NNP N
[(1162 NNP N
 VBD N
548) CD N
U/L NNP N
vs NN N
. . N

(1732 JJ N
 $ N
480) CD N
U/L NNP N
P NNP N
< VBD N
0.01] CD N
CKMB NNP N
[(165 NNP N
 VBD N
70) CD N
U/L NNP N
vs NN N
. . N

(280 NN N
 VBZ N
99) CD N
U/L NNP N
P NNP N
< VBD N
0.01] CD N
CTFC NNP N
(22.23 NNP N
 VBD N
3.81 CD N
vs NN N
. . N

26.97 CD N
 JJ N
3.42) CD N
WMSI NNP N
(1.27 NNP N
 VBD N
0.52 CD N
vs NN N
. . N

1.82 CD N
 JJ N
0.83) CD N
and CC N
infarction NN N
areas NNS N
determined VBN N
by IN N
ECG NNP N
methods NNS N
(10.60% NNP N
 VBD N
4.97% CD N
vs.14.65% NN N
 $ N
6.88% CD N
all DT N
P NNP N
< $ N
0.05) CD N
were VBD N
all DT N
significantly RB N
lower JJR I
in IN I
the DT I
postconditioning VBG I
group NN I
than IN I
in IN I
control NN I
group NN N
while IN N
LVEF NNP N
(0.55 NNP N
 VBD N
0.08 CD N
vs NN N
. . N

0.47 CD N
 JJ N
0.10) CD N
and CC N
MBG NNP N
(2.27 NNP N
 VBD N
0.64 CD N
vs NN N
. . N

1.47 CD N
 JJ N
0.61 CD N
all DT N
P NNP N
< $ N
0.05) CD N
were VBD N
significantly RB N
higher JJR I
in IN I
the DT I
postconditioning VBG I
group NN I
than IN I
in IN I
control NN I
group NN N
. . I

CONCLUSIONS NNP I
Ischemia NNP I
postconditioning NN I
can MD N
significantly RB N
reduce VB N
myocardial JJ N
reperfusion NN P
injury NN P
in IN P
patients NNS N
with IN N
STEMI NNP N
. . N

-DOCSTART- -X- N

A DT N
comparison NN N
of IN N
two CD N
double-injection NN I
techniques NNS I
for IN N
peribulbar NN P
block NN P
analgesia: VBD P
infero-temporal JJ I
plus CC I
supero-medial JJ I
vs NN I
. . I

infero-temporal JJ I
plus CC I
medial-percaruncular JJ I
. . I

BACKGROUND NNP N
Combinations NNP I
of IN I
infero-temporal JJ I
and CC I
either DT I
supero-nasal JJ I
('inferior-superior') NN I
or CC I
medial JJ I
percaruncular JJ I
('inferior-medial') JJ I
injections NNS I
are VBP N
popular JJ N
double-injection NN I
techniques NNS I
for IN N
establishing VBG N
peribulbar NN I
block NN I
analgesia NN I
. . I

This DT N
study NN N
compared VBN N
the DT N
efficacy NN N
of IN N
these DT N
two CD N
techniques NNS N
in IN N
achieving VBG N
ocular JJ I
and CC N
lid JJ I
akinesia NN I
. . I

METHODS NNP N
One CD P
hundred VBD P
patients NNS P
were VBD P
randomized VBN P
to TO N
receive VB N
inferior-superior JJ I
or CC I
inferior-medial JJ I
injections NNS I
in IN N
a DT N
study NN N
in IN N
which WDT N
injectate VBP I
injectate JJ I
volumes NNS I
5-min JJ I
ocular JJ I
akinesia NN I
scoring VBG I
(0-8) JJ I
lid JJ I
scoring VBG I
(0-2) JJ I
and CC I
supplemental JJ I
injection NN I
protocols NNS I
were VBD I
standardized VBN I
. . I

The DT N
numbers NNS N
of IN N
supplemental JJ N
injections NNS N
required VBN N
at IN N
each DT N
observation NN N
period NN N
and CC N
the DT N
total JJ N
volume NN N
of IN N
injectate NN N
required VBN N
to TO N
produce VB N
ocular JJ I
and CC N
lid JJ I
akinesia NN I
were VBD N
compared VBN N
. . N

RESULTS VB N
The DT N
two CD N
test NN N
groups NNS N
were VBD N
demographically RB N
similar JJ N
. . N

The DT N
inferior-medial JJ N
combination NN N
achieved VBN N
greater JJR N
ocular JJ O
akinesia NN O
than IN N
the DT N
inferior-superior JJ N
combination NN N
5 CD N
min NN N
after IN N
the DT N
initial JJ N
injections NNS N
(mean VBP N
score RB N
+/- JJ N
standard JJ N
deviation NN N
of IN N
1.74 CD N
+/- JJ N
1.86 CD N
vs NN N
. . N

2.66 CD N
+/- JJ N
2.39; CD N
P NNP N
< VBD N
0.05) CD N
with IN N
a DT N
reduced JJ N
requirement NN N
for IN N
supplementary JJ O
injections NNS O
(3 VBP N
vs NN N
. . N

23 CD N
supplementary JJ I
injections; NN I
P NNP N
< VBZ N
0.025) CD N
. . N

The DT I
inferior-superior JJ I
technique NN I
achieved VBN N
greater JJR N
lid JJ O
akinesia NN O
at IN O
5 CD O
min NN O
than IN N
the DT N
inferior-medial JJ I
technique NN I
(mean JJ N
score RB N
+/- JJ N
standard JJ N
deviation NN N
of IN N
0.7 CD N
+/- JJ N
0.9 CD N
vs NN N
. . N

0.3 CD N
+/- JJ N
0.58; CD N
P NNP N
< VBD N
0.005) CD N
. . N

A DT N
medial JJ O
subconjunctival NN O
hemorrhage NN O
occurred VBD N
in IN N
one CD N
patient NN N
in IN N
the DT N
inferior-medial JJ N
group NN N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
the DT N
inferior-superior JJ I
technique NN I
the DT I
inferior-medial JJ I
combination NN I
achieved VBD N
more RBR N
rapid JJ O
ocular JJ O
akinesia NN O
with IN N
less JJR N
need NN N
for IN N
supplementation NN N
but CC N
induced VBD N
less RBR N
efficient JJ N
lid JJ I
akinesia NN I
and CC N
had VBD N
a DT N
propensity NN N
to TO N
cause VB N
iatrogenic JJ O
subconjunctival JJ O
hemorrhage NN O
. . O

The DT N
latter JJ N
complication NN N
is VBZ N
considered VBN N
by IN N
our PRP$ N
surgeons NNS N
to TO N
be VB N
a DT N
contraindication NN N
to TO N
the DT N
inferior-medial JJ I
technique NN I
in IN N
patients NNS P
undergoing VBG P
trabeculectomy NN P
. . P

-DOCSTART- -X- N

Screening VBG I
brief JJ I
intervention NN I
and CC I
referral JJ I
to TO I
treatment NN I
(SBIRT) NN I
in IN N
a DT N
Polish JJ P
emergency NN P
department: VBD P
three-month JJ N
outcomes NNS N
of IN N
a DT N
randomized VBN N
controlled JJ I
clinical JJ N
trial NN N
. . N

OBJECTIVE IN N
A NNP N
randomized VBD N
controlled JJ N
trial NN N
of IN N
screening VBG I
brief JJ I
intervention NN I
and CC I
referral JJ I
to TO I
treatment NN I
(SBIRT) NN I
for IN I
drinking NN P
and CC P
related JJ P
problems NNS P
among IN P
at-risk JJ P
and CC P
dependent JJ P
drinkers NNS P
was VBD N
conducted VBN N
in IN N
an DT N
emergency NN P
department NN P
(ED) NN P
in IN P
Sosnowiec NNP P
Poland NNP P
among IN P
patients NNS P
ages VBZ P
18 CD P
years NNS P
and CC P
older JJR P
. . P

METHOD NNP P
Data NNP P
were VBD P
collected VBN P
over IN P
a DT P
23-week JJ P
period NN P
from IN P
4:00 CD P
PM NNP P
to TO P
midnight NN P
and CC P
resulted VBD P
in IN P
446 CD P
patients NNS P
being VBG P
recruited VBN P
into IN P
the DT P
study NN P
(90% NN P
of IN P
those DT P
who WP P
screened VBD P
positive) NN P
and CC N
randomized VBN N
to TO N
three CD N
conditions NNS N
following VBG N
a DT N
two-stage JJ N
process: NN N
screened VBD I
only RB I
(n JJ N
= $ N
147) CD N
assessed VBN I
(n NN N
= NN N
152) CD N
and CC N
received VBN I
intervention NN I
(n NNP N
= VBZ N
147) CD N
. . N

Patients NNS N
in IN N
the DT N
assessment NN I
(85%) NN N
and CC N
intervention NN I
(83%) NN N
conditions NNS N
were VBD N
blindly RB I
reassessed VBN I
at IN N
3 CD N
months NNS N
via IN N
a DT N
telephone NN N
interview NN N
. . N

RESULTS NN N
At IN N
3-month JJ N
follow-up JJ N
both DT N
groups NNS N
showed VBD N
significant JJ N
decreases NNS N
in IN N
the DT N
proportion NN N
who WP N
were VBD N
positive JJ N
for IN N
at-risk JJ N
drinking VBG N
the DT N
primary JJ N
outcome NN N
variable NN N
. . N

Both DT N
groups NNS N
also RB N
showed VBD N
significant JJ N
decreases NNS N
in IN N
drinking NN O
days NNS O
per IN O
week NN O
drinks NNS O
per IN O
drinking NN O
day NN O
maximum JJ O
drinks NNS O
per IN O
occasion NN O
and CC O
negative JJ O
consequences NNS O
of IN O
drinking NN O
. . O

Using VBG N
analysis NN N
of IN N
covariance NN N
to TO N
control VB N
for IN N
baseline NN N
measures NNS N
and CC N
demographic JJ N
characteristics NNS N
no DT N
difference NN N
in IN N
outcome JJ N
measures NNS N
was VBD N
found VBN N
between IN N
intervention NN I
and CC I
assessment JJ I
conditions NNS I
. . I

Subgroup NNP N
analysis NN N
found VBD N
some DT N
significant JJ N
interactions NNS N
between IN N
intervention NN I
and CC N
secondary JJ N
outcomes NNS N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
main JJ N
findings NNS N
were VBD N
similar JJ N
to TO N
those DT N
from IN N
other JJ N
brief-intervention NN I
studies NNS N
in IN N
Western JJ N
cultures NNS N
findings NNS N
here RB N
also RB N
suggest VBP N
that IN N
intervention NN I
may MD N
have VB N
differential JJ N
benefits NNS N
for IN N
specific JJ N
subgroups NNS N
of IN N
patients NNS N
in IN N
the DT N
ED NNP N
an DT N
area NN N
of IN N
research NN N
that WDT N
may MD N
warrant VB N
additional JJ N
study NN N
of IN N
brief JJ I
intervention NN I
in IN N
the DT N
ED NNP N
setting NN N
. . N

-DOCSTART- -X- N

Therapy NN I
for IN N
progressive JJ P
supranuclear JJ P
palsy: NN P
past NN N
and CC N
future NN N
. . N

Dysfunction NN N
of IN N
multiple JJ N
brain NN N
systems NNS N
in IN N
progressive JJ P
supranuclear JJ P
palsy NN P
(PSP) NN P
has VBZ N
complicated VBN N
attempts NNS N
to TO N
treat VB I
the DT N
disease NN N
. . N

Neurotransmitter NNP I
replacement NN I
strategies NNS I
targeting VBG I
the DT I
dopaminergic NN I
cholinergic NN I
and CC I
serotonergic JJ I
systems NNS I
have VBP N
been VBN N
unsuccessful JJ N
. . N

In IN N
order NN N
to TO N
bypass VB N
the DT N
degenerated JJ N
cortico-striato-pallidal JJ N
loop NN N
we PRP N
administered VBD N
the DT N
adrenergic JJ I
agonist NN I
idazoxan NN I
(IDA) NN I
to TO N
treat VB I
PSP NNP N
in IN N
two CD N
randomized JJ N
double-blind NN N
placebo NN I
controlled VBD I
crossover NN I
studies NNS N
. . N

Approximately RB N
one CD N
half NN N
of IN N
patients NNS P
enrolled VBN P
in IN P
these DT P
studies NNS P
showed VBD N
statistically RB N
significant JJ N
improvement NN O
in IN O
balance NN O
and CC O
manual JJ O
dexterity NN O
while IN N
taking VBG N
IDA NNP I
compared VBN N
to TO N
placebo VB I
. . I

These DT N
results NNS N
suggest VBP N
that IN N
new JJ I
therapies NNS I
that WDT I
target VBP I
structures NNS I
outside IN I
of IN I
the DT I
basal NN I
ganglia NN I
may MD N
be VB N
useful JJ N
for IN N
symptomatic JJ I
treatment NN I
of IN N
PSP NNP N
. . N

Applying VBG N
this DT N
strategy NN N
and CC N
developing VBG N
treatments NNS I
that WDT N
arrest VBP N
or CC N
reverse VB N
clinical JJ N
deterioration NN N
in IN N
PSP NNP N
will MD N
require VB N
improved JJ N
understanding NN N
of IN N
the DT N
process NN N
underlying VBG N
the DT N
illness NN N
. . N

-DOCSTART- -X- N

Double-blind JJ N
placebo-controlled JJ I
comparison NN N
of IN N
the DT N
analgesic JJ O
effects NNS O
of IN N
single JJ N
doses NNS N
of IN N
lornoxicam NN I
and CC I
aspirin NN I
in IN N
patients NNS P
with IN P
postoperative JJ P
dental NN P
pain NN P
. . P

The DT N
pain NN N
experienced VBD N
after IN N
third JJ I
molar JJ I
surgery NN I
was VBD N
used VBN N
as IN N
a DT N
model NN N
to TO N
evaluate VB N
the DT N
analgesic JJ O
efficacy NN O
of IN N
a DT N
new JJ N
non-steroidal JJ N
anti-inflammatory JJ N
drug NN N
lornoxicam NN I
in IN I
a DT N
Phase NNP N
II NNP N
study NN N
. . N

One CD P
hundred CD P
and CC P
fifty JJ P
fit NN P
young JJ P
adults NNS P
participated VBD P
in IN N
this DT N
randomised JJ N
single JJ N
dose JJ N
double-blind JJ N
parallel NN N
group NN N
clinical JJ N
study NN N
. . N

Three CD N
doses NNS N
of IN N
lornoxicam JJ I
(2 NNP N
mg NN N
4 CD N
mg NN N
and CC N
8 CD N
mg) NNS N
were VBD N
compared VBN N
with IN N
aspirin JJ I
650 CD I
mg NN I
and CC I
placebo NN I
. . I

Patients NNS P
suffering VBG P
from IN P
moderate JJ P
to TO P
severe VB P
pain NN P
following VBG P
surgery NN P
were VBD N
monitored VBN N
for IN N
up RB N
to TO N
8 CD N
hours NNS N
. . N

All DT N
indices NNS N
of IN N
efficacy NN O
showed VBD N
similar JJ N
results NNS N
all DT N
active JJ N
treatments NNS N
being VBG N
associated VBN N
with IN N
highly RB N
significant JJ N
(P NNP N
less JJR N
than IN N
0.0001) CD N
reductions NNS O
in IN O
pain NN O
during IN N
the DT N
study NN N
period NN N
. . N

Lornoxicam NNP I
8 CD N
mg NN N
demonstrated VBD N
significant JJ N
analgesic JJ O
efficacy NN O
as IN N
compared VBN N
with IN N
placebo NN I
. . I

The DT N
two CD N
lower JJR N
doses NNS N
of IN N
lornoxicam NN I
and CC N
aspirin VB I
all DT N
showed VBD N
apparent JJ N
degrees NNS N
of IN N
efficacy NN O
intermediate NN N
between IN N
that DT N
of IN N
placebo NN I
and CC N
lornoxicam $ I
8 CD N
mg CC N
although IN N
the DT N
trial NN N
proved VBD N
to TO N
have VB N
inadequate JJ N
power NN N
to TO N
show VB N
significant JJ N
differences NNS N
between IN N
these DT N
three CD N
treatments NNS N
. . N

Lornoxicam NNP I
was VBD N
very RB N
well RB O
tolerated VBN O
at IN N
all DT N
three CD N
doses NNS N
studied VBN N
with IN N
no DT N
adverse JJ O
events NNS O
definitely RB N
attributable JJ N
to TO N
its PRP$ N
administration NN N
. . N

-DOCSTART- -X- N

Adhesion-prevention JJ O
effects NNS O
of IN N
fibrin NN I
sealants NNS I
after IN P
laparoscopic JJ P
myomectomy NN P
as IN N
determined VBN N
by IN N
second-look JJ N
laparoscopy: NN I
a DT N
prospective JJ N
randomized NN N
controlled VBD N
study NN N
. . N

OBJECTIVE NN N
To TO N
examine VB N
the DT N
adhesion NN I
prevention NN N
effects NNS N
of IN N
2 CD N
types NNS N
of IN N
fibrin NN I
sealant NN I
after IN P
laparoscopic JJ P
myomectomy NN P
(LM) NN P
. . P

STUDY NNP I
DESIGN NNP N
A NNP N
prospective JJ N
randomized VBN N
study NN N
(Canadian JJ P
Task NNP N
Force NNP N
I) NNP P
was VBD N
conducted VBN N
at IN N
a DT N
University-affiliated JJ P
hospital NN P
. . P

A DT P
total NN P
of IN P
91 CD P
patients NNS P
showing VBG P
a DT P
minimal JJ P
myoma NN P
> VBD P
5 CD P
cm NN P
excluding VBG P
pedunculated VBN P
myomas JJ P
underwent JJ P
LM NNP P
alone: NN P
32 CD P
patients NNS P
in IN P
the DT P
control NN P
group NN P
29 CD P
in IN P
the DT P
fibrin NN P
gel NN P
group NN P
and CC P
30 CD P
patients NNS P
in IN P
the DT P
fibrin JJ P
sheet NN P
group NN P
. . P

After IN N
LM NNP N
postoperative JJ O
adhesions NNS O
were VBD N
evaluated VBN N
by IN N
second-look JJ I
laparoscopy NN I
. . I

The DT O
frequency NN O
of IN O
postoperative JJ O
adhesions NNS O
was VBD N
the DT N
main JJ N
outcome NN N
. . N

RESULTS VB N
The DT N
frequency NN N
of IN N
postoperative JJ O
adhesions NNS O
of IN N
the DT N
uterus NN I
was VBD N
significantly RB N
lower JJR N
(p NNP N
< VBD N
0.05) CD N
in IN N
the DT N
fibrin NN I
gel NN I
group NN N
with IN N
20/32 CD N
(62.5%) NNS N
in IN N
the DT N
control NN N
group NN N
10/29 CD N
(34.5%) NN N
in IN N
the DT N
fibrin NN I
gel NN I
group NN N
and CC N
20/30 CD N
(67.7%) NN N
in IN N
the DT N
fibrin JJ I
sheet NN I
group NN N
. . N

Although IN N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
the DT N
incidence NN N
of IN N
de FW N
novo FW I
adnexal JJ I
adhesions NNS I
the DT I
lowest JJS N
rate NN N
was VBD N
found VBN N
in IN N
the DT N
fibrin NN I
gel NN I
group NN N
with IN N
4/32 CD N
patients NNS N
(12.5%) VBP N
in IN N
the DT N
control NN N
group NN N
2/29 CD N
patients NNS N
(6.8%) VBP N
in IN N
the DT N
fibrin NN I
gel NN I
group NN N
and CC N
5/30 CD N
patients NNS N
(16.7%) VBP N
in IN N
the DT N
fibrin JJ I
sheet NN I
group NN N
. . N

No DT N
bilateral JJ I
adnexal NN I
adhesions NNS I
were VBD N
observed VBN N
in IN N
the DT N
3 CD N
groups NNS N
. . N

CONCLUSION NN N
After IN N
LM NNP N
for IN N
myomas NN I
as RB N
large JJ N
as IN N
> NN N
or CC N
= $ N
5 CD N
cm NN N
postoperative JJ I
adhesions NNS I
were VBD N
observed VBN N
in IN N
> NN N
or CC N
= $ N
50% CD N
of IN N
patients NNS N
. . N

The DT N
use NN N
of IN N
fibrin NN I
gel NN I
after IN I
LM NNP I
is VBZ N
recommended VBN N
. . N

-DOCSTART- -X- N

Handwarming VBG O
and CC O
relaxation NN O
in IN N
temperature NN N
feedback: NN N
positive JJ N
placebo NN I
effects NNS N
. . P

Sixteen JJ P
males NNS P
and CC P
females NNS P
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
temperature NN I
feedback NN I
groups NNS I
warm-relax JJ I
(WR) NNS I
or CC I
cool-relax JJ I
(CR) NN I
to TO N
determine VB N
how WRB N
successful JJ N
hand-warming NN N
and CC N
-cooling VBG N
alters NNS N
the DT N
subjective JJ N
report NN N
of IN N
relaxation NN N
. . N

After IN N
eight CD N
1/2-hour JJ N
sessions NNS N
the DT N
WR NNP I
and CC I
CR NNP I
demonstrated VBD N
a DT N
significant JJ N
difference NN N
in IN N
temperature NN O
change NN O
but CC O
there EX N
were VBD N
no DT N
significant JJ N
main JJ N
effects NNS N
in IN N
reported VBN N
subjective JJ O
relaxation NN O
. . O

The DT N
reported JJ N
feelings NNS N
of IN N
relaxation NN N
were VBD N
negatively RB N
correlated VBN N
to TO N
the DT N
directionality NN N
of IN N
temperature NN N
change NN N
and CC N
were VBD N
primarily RB N
attributed VBN N
to TO N
nonspecific JJ N
expectancies NNS N
. . N

-DOCSTART- -X- N

Breast NNP P
cancer NN P
screening VBG P
in IN P
Sweden NNP P
. . P

The DT N
single JJ N
modality NN N
approach NN N
. . P

Four CD P
population-based JJ P
breast NN P
cancer NN P
screening VBG P
projects NNS P
are VBP P
in IN P
progress NN P
in IN P
Sweden NNP P
three CD P
of IN N
which WDT N
are VBP N
randomized VBN N
studies NNS N
. . N

Mammography NN I
is VBZ N
the DT N
only JJ N
screening NN I
method NN N
. . N

51% CD N
of IN N
all DT N
carcinomas NN I
detected VBN N
at IN N
the DT N
first JJ N
screening NN I
were VBD N
either RB N
in IN N
situ NN N
or CC N
invasive JJ N
with IN N
a DT N
diameter NN N
of IN N
10 CD N
mm NN N
or CC N
less JJR N
. . N

Axillary JJ O
metastases NNS O
were VBD N
found VBN N
in IN N
16% CD N
of IN N
the DT N
patients NNS N
. . N

Sensitivity NN O
was VBD N
over RB N
90% CD N
in IN N
all DT N
projects NNS N
. . N

The DT N
ultimate JJ N
aim NN N
of IN N
the DT N
randomized JJ N
projects NNS N
is VBZ N
to TO N
demonstrate VB N
the DT N
effect NN N
of IN N
screening VBG I
on IN I
breast NN I
cancer NN I
mortality NN N
. . N

It PRP N
is VBZ N
estimated VBN N
that IN N
mortality NN N
statistics NNS N
will MD N
reach VB N
significant JJ N
levels NNS N
in IN N
1983 CD N
. . N

-DOCSTART- -X- N

Pilot NNP N
comparison NN N
between IN N
potassium NN I
titanyl NN I
phosphate NN I
laser NN I
and CC I
bipolar JJ I
radiofrequency NN I
in IN N
paediatric JJ P
tonsillectomy NN P
. . P

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
advantages NNS N
and CC N
disadvantages NNS N
of IN N
potassium NN I
titanyl NN I
phosphate NN I
laser NN I
with IN I
those DT I
of IN I
bipolar JJ I
radiofrequency NN I
techniques NNS I
in IN I
paediatric JJ N
tonsillectomy NN N
. . N

STUDY NNP N
DESIGN NNP N
Prospective NNP N
randomised VBD N
clinical JJ N
study NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
From NNP P
July NNP P
2004 CD P
to TO P
April NNP P
2006 CD P
80 CD P
patients NNS P
aged VBN P
between IN P
10 CD P
and CC P
15 CD P
years NNS P
with IN P
tonsillectomy NN P
planned VBN P
for IN P
chronic JJ P
tonsillitis NN P
were VBD P
included VBN P
in IN P
the DT P
study NN P
. . P

Children NNP N
were VBD N
prospectively RB N
randomised VBN N
into IN N
two CD N
equal JJ N
groups: NN N
potassium NN I
titanyl NN I
phosphate NN I
laser NN I
tonsillectomy NN I
and CC I
bipolar JJ I
radiofrequency NN I
tonsillectomy NN I
. . I

Operative JJ N
time NN N
and CC N
intra-operative JJ N
blood NN N
loss NN N
were VBD N
recorded VBN N
. . N

Patients NNS N
were VBD N
scheduled VBN N
for IN N
follow VB N
up RP N
during IN N
the DT N
first JJ N
second JJ N
and CC N
fourth JJ N
post-operative JJ N
weeks NNS N
. . N

They PRP N
were VBD N
asked VBN N
to TO N
record VB N
their PRP$ N
pain NN N
and CC N
discomfort NN N
on IN N
a DT N
standardised JJ N
visual JJ N
analogue NN N
scale NN N
from IN N
zero CD N
(no NNS N
pain) VBP N
to TO N
10 CD N
(severe RB N
pain) NN N
. . N

Post-operative JJ O
complications NNS O
were VBD N
also RB N
recorded VBN N
and CC N
managed VBN N
. . N

RESULTS VB N
The DT N
potassium NN I
titanyl NN I
phosphate VBP I
laser NN I
group NN I
showed VBD N
a DT N
slightly RB N
longer RBR O
operative JJ O
time NN O
(mean JJ N
12 CD N
minutes) NN N
than IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
(mean VBD N
10 CD N
minutes) NN N
. . N

Intra-operative JJ O
blood NN O
loss NN O
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
potassium NN I
titanyl NN I
phosphate VBP I
laser NN I
group NN N
(mean VBD N
21 CD N
cm3) NN N
than IN N
in IN N
the DT N
bipolar JJ I
radiofrequency NN I
group NN I
(mean VBD N
30 CD N
cm3) NN N
. . N

In IN N
the DT N
first JJ N
week NN N
post-operative JJ O
pain NN O
scores NNS O
were VBD N
less RBR N
in IN N
the DT N
potassium NN I
titanyl NN I
phosphate VBP I
laser NN I
group NN N
than IN N
in IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
(means VBZ N
7.5 CD N
and CC N
8.5 CD N
respectively) NN N
. . N

However RB N
in IN N
the DT N
second JJ N
week NN N
pain NN O
scores NNS O
increased VBD N
more RBR N
in IN N
the DT N
potassium NN N
titanyl NN N
phosphate VBP N
laser NN N
group NN N
than IN N
in IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
(means VBZ N
8.5 CD N
and CC N
6 CD N
respectively) NN N
. . N

In IN N
the DT N
fourth JJ N
week NN N
both DT N
groups NNS N
showed VBD N
equal JJ N
and CC N
nearly RB N
normal JJ N
pain NN N
scores NNS N
. . N

No DT N
case NN N
of IN N
reactionary JJ O
post-tonsillectomy JJ O
haemorrhage NN O
was VBD N
recorded VBN N
in IN N
either DT N
group NN N
. . N

Only RB N
one CD N
case NN N
of IN N
secondary JJ O
post-tonsillectomy JJ O
haemorrhage NN O
was VBD N
recorded VBN N
in IN N
the DT N
potassium NN N
titanyl NN N
phosphate VBP N
laser NN N
group NN N
(2.5 NNP N
per IN N
cent) NN N
managed VBD N
conservatively RB N
. . N

CONCLUSION NNP N
Both NNP N
the DT N
potassium NN I
titanyl NN I
phosphate NN I
and CC I
the DT I
bipolar JJ I
radiofrequency NN I
techniques NNS I
were VBD N
safe JJ O
and CC O
easy JJ O
to TO N
use VB N
for IN N
tonsillectomy NN N
with IN N
reduced JJ N
operative JJ O
time NN O
blood NN O
loss NN O
and CC O
complication NN O
rates NNS O
and CC N
better JJR N
post-operative JJ N
general JJ N
patient NN N
condition NN N
. . N

Potassium NNP I
titanyl NN I
phosphate NN I
laser NN I
resulted VBD N
in IN N
reduced JJ N
operative JJ O
bleeding NN O
and CC O
immediate JJ O
post-operative JJ O
pain NN O
compared VBN O
with IN N
the DT N
bipolar JJ N
radiofrequency NN N
technique NN N
. . N

However RB N
potassium NN I
titanyl NN I
phosphate VBP I
laser NN I
required VBN N
slightly RB N
more RBR N
operative JJ O
time NN O
and CC N
caused VBD N
more JJR N
late JJ O
post-operative JJ O
pain NN O
than IN N
the DT N
bipolar JJ N
radiofrequency NN N
technique NN N
. . N

The DT N
low JJ N
rate NN N
of IN N
recorded VBN N
complications NNS N
showed VBD N
that IN N
both DT N
techniques NNS N
cause VBP N
little JJ N
damage NN N
to TO N
the DT N
tonsillar JJ N
bed NN N
during IN N
dissection NN N
thus RB N
minimising VBG N
complications NNS N
. . N

-DOCSTART- -X- N

Effectiveness NN N
of IN N
the DT N
school NN I
dental JJ I
screening VBG I
programme NN I
in IN N
stimulating VBG N
dental JJ O
attendance NN O
for IN N
children NNS P
in IN P
need NN P
of IN P
treatment NN P
in IN P
Northern NNP P
Ireland NNP P
. . P

UNLABELLED IN P
The DT N
school NN I
dental JJ I
screening NN I
programme NN I
has VBZ N
been VBN N
in IN N
existence NN N
from IN N
the DT N
beginning NN N
of IN N
the DT N
20th JJ N
century NN N
yet RB N
its PRP$ N
value NN N
in IN N
encouraging JJ N
attendance NN N
among IN N
children NNS P
with IN P
a DT P
dental JJ P
health NN P
need NN P
is VBZ N
not RB N
fully RB N
established VBN N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
school NN I
dental JJ I
screening NN I
in IN N
promoting VBG N
dental JJ O
attendance NN O
among IN N
children NNS P
with IN P
a DT P
treatment NN P
need NN N
and CC N
to TO N
examine VB N
the DT N
relative JJ N
importance NN N
of IN N
screening VBG N
social JJ N
class NN N
and CC N
other JJ N
factors NNS N
in IN N
dental JJ O
attendance NN O
. . O

METHODS NNP N
Sixty-four CD P
participating VBG P
schools NNS P
were VBD N
assigned VBN N
to TO N
study VB N
and CC N
control VB N
groups NNS N
using VBG N
a DT N
stratified JJ N
blocked JJ N
randomisation NN N
technique NN N
. . N

The DT N
study NN N
group NN N
children NNS I
received VBD I
the DT I
standard JJ I
school NN I
dental JJ I
screening NN I
and CC N
the DT N
dental JJ O
attendance NN O
of IN I
those DT I
with IN I
a DT I
positive JJ I
screening NN I
result NN I
was VBD I
assessed VBN I
after IN I
2 CD I
months NNS I
by IN N
means NNS N
of IN N
a DT N
questionnaire NN N
issued VBN N
to TO N
the DT N
children's NN N
parents NNS N
. . N

The DT N
control NN I
group NN I
children NNS I
were VBD I
not RB I
at IN I
this DT I
stage NN I
screened VBD I
yet RB I
their PRP$ I
parents NNS I
received VBD I
the DT I
same JJ I
questionnaire NN I
assessing VBG I
dental JJ O
attendance NN O
over IN I
the DT I
2-month JJ I
period NN I
. . I

However RB N
only RB I
questionnaires VBZ I
from IN I
control NN I
group NN I
children NNS I
who WP I
had VBD I
a DT I
positive JJ I
result NN I
at IN I
a DT I
subsequent JJ I
screening NN I
were VBD I
retained VBN I
for IN I
analysis NN I
. . I

RESULTS VB N
A NNP P
total NN P
of IN P
2 CD P
321 CD P
children NNS P
were VBD P
screened VBN P
with IN P
980 CD P
having VBG P
a DT P
positive JJ P
result NN P
. . P

The DT N
mean JJ N
dmft NN N
of IN N
those DT N
screening VBG N
positive JJ N
was VBD N
4.85 CD N
. . N

In IN N
all DT N
664 CD P
completed VBN P
questionnaires NNS P
were VBD P
returned VBN P
giving VBG N
a DT N
response NN N
rate NN N
of IN N
67.8% CD N
. . N

Dental JJ O
attendance NN O
was VBD N
reported VBN N
among IN N
45.5% CD N
of IN N
the DT N
study NN N
group NN N
(n=352) NNP N
in IN N
the DT N
2 CD N
months NNS N
following VBG N
screening NN N
. . N

In IN N
the DT N
same JJ N
period NN N
27.6% CD N
of IN N
the DT N
control NN N
group NN N
(n=312) NNP N
claimed VBD N
attendance NN N
. . N

The DT N
effect NN N
was VBD N
found VBN N
to TO N
be VB N
significant JJ N
among IN N
the DT N
high JJ N
employed VBN N
group NN N
(P<0.01) NN N
and CC N
the DT N
unemployed JJ N
group NN N
(P<0.05) NNP N
. . N

CONCLUSION NNP N
School NNP N
dental JJ N
screening NN N
was VBD N
capable JJ N
of IN N
stimulating VBG N
dental JJ O
attendance NN O
. . O

The DT N
strong JJ N
effect NN N
among IN N
the DT N
lowest JJS N
socio-economic JJ N
group NN N
shows VBZ N
that IN N
school NN N
dental JJ N
screening NN N
may MD N
be VB N
used VBN N
to TO N
decrease VB N
dental JJ O
health NN O
inequalities NNS O
. . O

-DOCSTART- -X- N

A DT N
randomized JJ N
cross-over NN N
study NN N
of IN N
inhalation NN I
of IN I
diesel NN I
exhaust JJ I
hematological JJ I
indices NNS N
and CC N
endothelial JJ N
markers NNS N
in IN N
humans NNS N
. . N

BACKGROUND NNP N
Exposure NNP N
to TO N
traffic-related JJ N
air NN N
pollution NN N
(TRAP) NN N
is VBZ N
considered VBN N
a DT N
trigger NN N
for IN N
acute JJ N
cardiovascular JJ N
events NNS N
. . N

Diesel NNP N
Exhaust NNP N
(DE) NNP N
is VBZ N
a DT N
major JJ N
contributor NN N
to TO N
TRAP NNP N
in IN N
the DT N
world NN N
. . N

We PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
DE NNP I
inhalation NN I
on IN N
circulating VBG N
blood NN N
cell NN N
populations NNS N
hematological JJ N
indices NNS N
and CC N
systemic JJ N
inflammatory NN N
cytokines NNS N
in IN N
humans NNS N
using VBG N
a DT N
specialized JJ N
facility NN N
. . N

METHODS NNP N
In IN N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
study NN N
balanced VBD N
to TO N
order NN P
17 CD P
metabolic JJ P
syndrome NN P
(MetS) NN P
and CC P
15 CD P
healthy JJ P
subjects NNS P
inhaled VBN P
filtered VBD P
air NN P
(FA) NN P
or CC P
DE NNP P
exposure NN P
in IN P
two-hour JJ P
sessions NNS P
on IN P
different JJ P
days NNS P
with IN P
a DT P
minimum JJ P
2-week JJ P
washout NN P
period NN P
. . P

We PRP N
collected VBD N
blood NN N
pre-exposure NN N
7 CD N
and CC N
22 CD N
hours NNS N
after IN N
exposure NN N
initiation NN N
and CC N
measured VBD N
the DT N
complete JJ N
blood NN N
count NN N
and CC N
differential NN N
. . N

We PRP N
performed VBD N
multiplex JJ I
cytokine NN I
assay NN I
to TO N
measure VB N
the DT N
changes NNS N
in IN N
the DT N
systemic JJ N
inflammatory NN N
cytokines NNS N
and CC N
endothelial JJ N
adhesion NN N
molecules NNS N
(n=15) VBP N
. . N

A DT N
paired JJ N
analysis NN N
compared VBN N
the DT N
effect NN N
of IN N
DE NNP N
and CC N
FA NNP N
exposures NNS N
for IN N
the DT N
change NN N
from IN N
pre-exposure NN N
to TO N
the DT N
subsequent JJ N
time NN N
points NNS N
. . N

RESULTS VB N
A DT N
significant JJ N
increase NN O
in IN O
the DT O
hematocrit NN O
was VBD N
noted VBN N
7 CD N
hrs NNS N
after IN N
DE NNP N
[1.4% NNP N
(95% NNP N
CI: NNP N
0.9 CD N
to TO N
1.9%)] CD N
compared VBN N
to TO N
FA NNP N
exposure NN N
[0.5% NNP N
(95% NNP N
CI: NNP N
-0.09 NNP N
to TO N
1.0%); CD N
p=0.008 NN N
. . N

The DT N
hemoglobin NN O
levels NNS O
increased VBD N
non-significantly RB N
at IN N
7 CD N
hrs JJ N
post NN N
DE NNP N
[0.3 NNP N
gm/dL NN N
(95% NNP N
CI: NNP N
0.2 CD N
to TO N
0.5 CD N
gm/dL)] NNS N
versus JJ N
FA NNP N
exposure NN N
[0.2 NNP N
gm/dL NN N
(95% NNP N
CI: NNP N
0 CD N
to TO N
0.3 CD N
gm/dL)]; NN N
p=0.06 NN N
. . N

Furthermore RB N
the DT N
platelet NN O
count NN O
increased VBD N
22 CD N
hrs NN N
after IN N
DE NNP N
exposure NN N
in IN N
healthy JJ N
but CC N
not RB N
in IN N
MetS NNP N
subjects VBZ N
[DE: JJ N
16.6 CD N
(95% JJ N
CI: NNP N
10.2 CD N
to TO N
23) CD N
thousand NN N
platelets/mL NN N
versus NN N
[FA: VBZ N
3.4 CD N
(95% NN N
CI: NNP N
-9.5 NNP N
to TO N
16.3) CD N
thousand NN N
platelets/mL)]; NN N
p=0.04 NN N
. . N

No DT N
DE NNP O
effect NN N
was VBD N
observed VBN N
for IN N
WBC NNP O
neutrophils NNS O
lymphocytes VBZ O
or CC N
erythrocytes NNS O
. . O

Using VBG N
the DT N
multiplex JJ N
assay VBP N
small JJ N
borderline NN N
significant JJ N
increases NNS N
in IN N
matrix JJ O
metalloproteinase-9 JJ O
interleukins NNS O
(IL)-1 JJ O
beta NN O
6 CD O
and CC O
10 CD O
occurred VBD N
7 CD N
hrs NN N
post NN N
exposure NN N
initiation NN N
whereas IN N
E-selectin NNP N
intercellular JJ N
adhesion NN N
molecule-1 NN N
and CC N
vascular NN N
cell NN N
adhesion NN N
molecule NN N
-1 NNP N
and CC N
myeloperoxidase VB N
22 CD N
hrs NN N
post NN N
exposure NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
short-term JJ N
DE NNP N
exposure NN N
results NNS N
in IN N
hemoconcentration NN N
and CC N
thrombocytosis NN N
which WDT N
are VBP N
important JJ N
determinants NNS N
of IN N
acute JJ N
cardiovascular JJ N
events NNS N
. . N

Multiplex NNP N
assay VBP N
showed VBD N
a DT N
non-significant JJ N
increase NN N
in IN N
IL-1 NNP N
and CC N
IL-6 NNP N
immediately RB N
post NN N
exposure NN N
followed VBN N
by IN N
myeloperoxidase NN N
and CC N
endothelial JJ N
activation NN N
molecules NNS N
. . N

Further RB N
specific JJ N
assays NNS N
in IN N
a DT N
larger JJR N
population NN N
will MD N
improve VB N
our PRP$ N
understanding NN N
of IN N
the DT N
systemic JJ N
inflammatory JJ N
mechanisms NNS N
following VBG N
acute NN N
exposure NN N
to TO N
TRAP NNP N
. . N

-DOCSTART- -X- N

Comparison NNP N
of IN N
three CD N
solutions NNS N
of IN N
ropivacaine/fentanyl NN I
for IN N
postoperative JJ P
patient-controlled JJ P
epidural JJ P
analgesia NN P
. . P

BACKGROUND NNP N
Ropivacaine NNP I
0.2% CD I
is VBZ N
a DT N
new JJ N
local JJ N
anesthetic JJ N
approved VBN N
for IN N
epidural JJ N
analgesia NN N
. . N

The DT N
addition NN N
of IN N
4 CD N
microg/ml NNS I
fentanyl JJ I
improves NNS N
analgesia VBP N
from IN N
epidural JJ N
ropivacaine NN I
. . I

Use NNP N
of IN N
a DT N
lower JJR N
concentration NN N
of IN N
ropivacaine-fentanyl NN I
may MD N
further VB N
improve VB N
analgesia NN O
or CC N
decrease JJ N
side NN O
effects NNS O
. . O

METHODS NNP N
Thirty NNP P
patients NNS P
undergoing VBG P
lower JJR P
abdominal JJ P
surgery NN P
were VBD P
randomized VBN P
in IN N
a DT N
double-blinded JJ N
manner NN N
to TO N
receive VB N
one CD N
of IN N
three CD N
solutions: JJ N
0.2% CD I
ropivacaine-4 JJ I
microg NN I
fentanyl VBD I
0.1% CD I
ropivacaine-2 JJ I
microg NN I
fentanyl NN I
or CC I
0.05% CD I
ropivacaine-1 JJ I
microg NN I
fentanyl NN I
for IN N
patient-controlled JJ N
epidural JJ N
analgesia NN N
after IN N
standardized VBN N
combined JJ N
epidural JJ N
and CC N
general JJ N
anesthesia NN N
. . N

Patient-controlled JJ N
epidural JJ N
analgesia NN N
settings NNS N
and CC N
adjustments NNS N
for IN N
the DT N
three CD N
solutions NNS N
were VBD N
standardized VBN N
to TO N
deliver VB N
equivalent JJ N
drug NN N
doses NNS N
. . N

Pain NN O
scores NNS O
(rest VBP O
cough NN O
and CC O
ambulation) JJ O
side NN O
effects NNS O
(nausea VBP O
pruritus JJ O
sedation NN O
motor NN O
block NN O
hypotension NN O
and CC O
orthostasis) NN O
and CC O
patient-controlled JJ O
epidural JJ O
analgesia NN O
consumption NN O
were VBD N
measured VBN N
for IN N
48 CD N
h NN N
. . N

RESULTS NNP N
All NNP N
three CD N
solutions NNS N
produced VBD N
equivalent JJ N
analgesia NN N
. . N

Motor NNP O
block NN O
was VBD N
significantly RB N
more JJR N
common JJ N
(30 NNP N
vs NN N
. . N

0%) CD N
and CC N
more JJR N
intense JJ N
with IN N
the DT N
0.2% CD N
ropivacaine-4 JJ I
microg NN N
fentanyl JJ I
solution NN N
. . N

Other JJ N
side NN N
effects NNS N
were VBD N
equivalent JJ N
between IN N
solutions NNS N
and CC N
mild NN N
in IN N
severity NN O
. . O

A DT N
significantly RB N
smaller JJR N
volume NN N
of IN N
0.2% CD N
ropivacaine-4 JJ O
microg NN O
fentanyl JJ O
solution NN O
was VBD N
used VBN N
whereas IN N
the DT N
0.1% CD N
ropivacaine-2 JJ I
microg NN N
fentanyl NN I
group NN N
used VBD N
a DT N
significantly RB N
greater JJR N
amount NN N
of IN N
ropivacaine NN O
and CC O
fentanyl NN O
. . O

CONCLUSIONS NNP N
Lesser NNP N
concentrations NNS N
of IN N
ropivacaine NN I
and CC I
fentanyl JJ I
provide NN N
comparable JJ N
analgesia NN O
with IN N
less JJR N
motor NN O
block NN O
despite IN N
the DT N
use NN N
of IN N
similar JJ N
amounts NNS N
of IN N
ropivacaine NN I
and CC N
fentanyl NN I
. . I

This DT N
finding NN N
suggests VBZ N
that IN N
concentration NN N
of IN N
local JJ I
anesthetic JJ I
solution NN I
at IN N
low JJ N
doses NNS N
is VBZ N
a DT N
primary JJ N
determinant NN O
of IN O
motor NN O
block NN O
with IN N
patient-controlled JJ P
epidural JJ P
analgesia NN P
after IN P
lower JJR P
abdominal JJ P
surgery NN P
. . P

-DOCSTART- -X- N

Behavioral NNP N
and CC N
physiological JJ N
effects NNS N
of IN N
remifentanil NN I
and CC I
alfentanil NN I
in IN N
healthy JJ P
volunteers NNS P
. . P

BACKGROUND IN N
The DT I
subjective JJ I
and CC I
psychomotor JJ I
effects NNS I
of IN I
remifentanil NNS I
have VBP I
not RB I
been VBN I
evaluated VBN I
. . I

Accordingly RB I
the DT I
authors NNS I
used VBD I
mood NN I
inventories NNS I
and CC I
psychomotor NN I
tests NNS I
to TO I
characterize VB I
the DT I
effects NNS I
of IN I
remifentanil NN I
in IN I
healthy JJ P
non-drug-abusing JJ P
volunteers NNS P
. . P

Alfentanil NNP I
was VBD I
used VBN I
as IN I
a DT I
comparator NN I
drug NN I
. . I

METHODS NNP I
Ten NNP P
healthy JJ P
volunteers NNS P
were VBD P
enrolled VBN P
in IN I
a DT I
randomized JJ I
double-blinded JJ I
placebo-controlled JJ I
crossover NN I
trial NN I
in IN I
which WDT I
they PRP I
received VBD I
an DT I
infusion NN I
of IN I
saline JJ I
remifentanil NN I
or CC I
alfentanil NN I
for IN I
120 CD I
min NN I
. . I

The DT I
age- JJ I
and CC I
weight-adjusted JJ I
infusions NNS I
(determined VBN I
with IN I
STANPUMP NNP I
a DT I
computer NN I
modeling VBG I
software NN I
package) NN I
were VBD I
given VBN I
to TO I
achieve VB I
three CD I
predicted VBN I
constant JJ I
plasma NN I
levels NNS I
for IN I
40 CD I
min NNS I
each DT I
of IN I
remifentanil NN I
(0.75 $ I
1.5 CD I
and CC I
3 CD I
ng/ml) NNS I
and CC I
alfentanil JJ I
(16 NN I
32 CD I
and CC I
64 CD I
ng/ml) NN I
. . I

Mood NN I
forms NNS I
and CC I
psychomotor NN I
tests NNS I
were VBD I
completed VBN I
and CC I
miosis NN I
was VBD I
assessed VBN I
during IN I
and CC I
after IN I
the DT I
infusions NNS I
. . I

In IN I
addition NN I
analgesia NN I
was VBD I
tested VBN I
at IN I
each DT I
dose JJ I
level NN I
using VBG I
a DT I
cold-pressor JJ I
test NN I
. . I

RESULTS NNP N
Remifentanil NNP I
had VBD N
prototypic VBN O
micro-like JJ O
opioid JJ O
subjective JJ O
effects NNS O
impaired JJ O
psychomotor NN O
performance NN O
and CC O
produced VBD N
analgesia NNS O
. . O

Alfentanil NNP N
at IN N
the DT N
dose JJ N
range NN N
tested VBD N
had VBD N
more RBR N
mild JJ N
effects NNS N
on IN N
these DT N
measures NNS N
and CC N
the DT N
analgesia NN N
data NNS N
indicated VBD N
that IN N
a DT N
40:1 CD N
potency NN N
ratio NN N
rather RB N
than IN N
the DT N
20:1 CD N
ratio NN N
we PRP N
used VBD N
may MD N
exist VB N
between IN N
remifentanil NN N
and CC N
alfentanil NN N
. . N

A DT N
psychomotor NN N
test NN N
administered VBD N
60 CD N
min NN N
after IN N
the DT N
remifentanil NN N
infusion NN N
was VBD N
discontinued VBN N
showed VBD N
that IN N
the DT N
volunteers NNS P
were VBD P
still RB P
impaired VBN P
although IN P
they PRP N
reported VBD N
feeling VBG N
no DT N
drug NN N
effects NNS N
. . N

CONCLUSIONS NNP N
The DT N
notion NN N
that IN N
the DT N
pharmacodynamic JJ N
effects NNS N
of IN N
remifentanil NN I
are VBP N
extremely RB N
short-lived JJ N
after IN N
the DT N
drug NN N
is VBZ N
no DT N
longer RB N
administered VBN N
must MD N
be VB N
questioned VBN N
given VBN N
our PRP$ N
findings NNS N
that IN N
psychomotor NN N
effects NNS N
were VBD N
still RB N
apparent JJ N
1 CD N
h NN N
after IN N
the DT N
infusion NN N
was VBD N
discontinued VBN N
. . N

-DOCSTART- -X- N

Intervention NN I
targeting VBG I
development NN I
of IN I
socially RB I
synchronous JJ I
engagement NN I
in IN I
toddlers NNS P
with IN P
autism NN P
spectrum NN P
disorder: VBZ P
a DT N
randomized JJ N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Social NNP I
and CC I
communication NN I
impairments NNS I
are VBP N
core JJ N
deficits NNS N
and CC N
prognostic JJ N
indicators NNS N
of IN N
autism NN N
. . N

We PRP N
evaluated VBD N
the DT N
impact NN N
of IN N
supplementing VBG N
a DT N
comprehensive JJ I
intervention NN I
with IN N
a DT N
curriculum NN N
targeting VBG N
socially RB N
synchronous JJ N
behavior NN N
on IN N
social JJ N
outcomes NNS N
of IN N
toddlers NNS P
with IN P
autism NN P
spectrum NN P
disorders NNS P
(ASD) VBP P
. . P

METHODS NNP N
Fifty NNP P
toddlers NNS P
with IN P
ASD NNP P
ages VBZ P
21 CD P
to TO P
33 CD P
months NNS P
were VBD P
randomized VBN N
to TO N
one CD N
of IN N
two CD N
six-month JJ N
interventions: JJ N
Interpersonal NNP I
Synchrony NNP I
or CC I
Non-Interpersonal JJ I
Synchrony NNP I
. . I

The DT N
interventions NNS N
provided VBD N
identical JJ N
intensity NN N
(10 NNP N
hours NNS N
per IN N
week NN N
in IN N
classroom) JJ N
student-to-teacher JJ N
ratio NN N
schedule NN N
home-based JJ N
parent NN N
training NN N
(1.5 JJ N
hours NNS N
per IN N
month) NN N
parent NN N
education NN N
(38 NNP N
hours) NN N
and CC N
instructional JJ N
strategies NNS N
except IN N
the DT N
Interpersonal NNP N
Synchrony NNP N
condition NN N
provided VBD N
a DT N
supplementary JJ N
curriculum NN N
targeting VBG N
socially RB N
engaged VBN N
imitation NN N
joint JJ N
attention NN N
and CC N
affect JJ N
sharing; NN N
measures NNS N
of IN N
these DT N
were VBD N
primary JJ N
outcomes NNS N
. . N

Assessments NNS N
were VBD N
conducted VBN N
pre-intervention NN N
immediately RB N
post-intervention NN N
and CC N
to TO N
assess VB N
maintenance NN N
at IN N
six-month JJ N
follow-up NN N
. . N

Random NNP N
effects NNS N
models NNS N
were VBD N
used VBN N
to TO N
examine VB N
differences NNS N
between IN N
groups NNS N
over IN N
time NN N
. . N

Secondary JJ N
analyses NNS N
examined VBD N
gains NNS O
in IN O
expressive JJ O
language NN O
and CC O
nonverbal JJ O
cognition NN O
and CC O
time NN O
effects NNS O
during IN N
the DT N
intervention NN N
and CC N
follow-up JJ N
periods NNS N
. . N

RESULTS VB N
A DT N
significant JJ N
treatment NN N
effect NN N
was VBD N
found VBN N
for IN N
socially RB N
engaged VBN N
imitation NN N
(p NNP N
= NNP N
.02) VBZ N
with IN N
more JJR N
than IN N
doubling VBG N
(17% NN N
to TO N
42%) CD N
of IN N
imitated JJ N
acts NNS N
paired VBN N
with IN N
eye NN N
contact NN N
in IN N
the DT N
Interpersonal NNP N
Synchrony NNP N
group NN N
after IN N
the DT N
intervention NN N
. . N

This DT N
skill NN N
was VBD N
generalized VBN N
to TO N
unfamiliar VB N
contexts NN N
and CC N
maintained VBD N
through IN N
follow-up NN N
. . N

Similar JJ N
gains NNS N
were VBD N
observed VBN N
for IN N
initiation NN N
of IN N
joint JJ O
attention NN O
and CC N
shared VBD N
positive JJ N
affect NN N
but CC N
between-group JJ N
differences NNS N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
. . N

A DT N
significant JJ N
time NN N
effect NN N
was VBD N
found VBN N
for IN N
all DT N
outcomes NNS N
(p VBP N
< JJ N
.001); NNP N
greatest JJS N
change NN N
occurred VBD N
during IN N
the DT N
intervention NN N
period NN N
particularly RB N
in IN N
the DT N
Interpersonal NNP N
Synchrony NNP N
group NN N
. . N

CONCLUSIONS NN N
This DT N
is VBZ N
the DT N
first JJ N
ASD NNP N
randomized VBN N
trial NN N
involving VBG N
toddlers NNS P
to TO N
identify VB N
an DT N
active JJ N
ingredient NN N
for IN N
enhancing VBG N
socially RB N
engaged VBN N
imitation NN N
. . N

Adding VBG N
social JJ N
engagement JJ N
targets NNS N
to TO N
intervention VB N
improves NNS N
short-term JJ N
outcome NN N
at IN N
no DT N
additional JJ N
cost NN N
to TO N
the DT N
intervention NN N
. . N

The DT N
social JJ N
language NN N
and CC N
cognitive JJ N
gains NNS N
in IN N
our PRP$ N
participants NNS N
provide VBP N
evidence NN N
for IN N
plasticity NN N
of IN N
these DT N
developmental JJ N
systems NNS N
in IN N
toddlers NNS P
with IN P
ASD NNP P
. . P

http://www.clinicaltrials.gov/ct2/show/NCT00106210 JJ N
term NN N
= NNP N
landa&rank VBD N
= JJ N
3 CD N
. . N

-DOCSTART- -X- N

Teacher-implemented JJ I
joint JJ I
attention NN I
intervention: NN I
pilot NN N
randomized VBD N
controlled VBN N
study NN N
for IN N
preschoolers NNS P
with IN P
autism NN P
. . P

OBJECTIVE IN N
The DT N
vast JJ N
majority NN N
of IN N
children NNS P
with IN P
an DT P
autism NN P
spectrum NN P
disorder NN P
(ASD) NNP P
attend VBP P
public JJ P
preschools NNS I
at IN N
some DT N
point NN N
in IN N
their PRP$ N
childhood NN N
. . N

Community NNP N
preschool NN N
practices NNS N
often RB N
are VBP N
not RB N
evidence NN N
based VBN N
and CC N
almost RB N
none NN N
target NN N
the DT N
prelinguistic JJ N
core NN N
deficits NNS N
of IN N
ASD NNP N
. . N

This DT N
study NN N
investigated VBD N
the DT N
effectiveness NN N
of IN N
public JJ P
preschool NN P
teachers NNS P
implementing VBG I
a DT I
validated VBN I
intervention NN I
(the PRP I
Joint NNP I
Attention NNP I
and CC I
Symbolic NNP I
Play/Engagement NNP I
and CC I
Regulation NNP I
intervention; VBP I
JASP/ER) NNP I
on IN N
a DT N
core NN N
deficit NN N
of IN N
autism NN N
initiating VBG N
joint JJ N
attention NN N
. . N

METHOD NNP N
Sixteen NNP P
dyads VBZ P
(preschoolers NNS P
with IN P
ASD NNP P
and CC P
the DT P
public JJ P
school NN P
teachers NNS P
who WP P
worked VBD P
in IN P
the DT P
child's NN P
classroom) NN P
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
6-week JJ N
JASP/ER NNP I
intervention NN I
or CC I
a DT I
control NN I
group NN I
. . I

RESULTS NN I
At IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
JASP/ER NNP I
teachers NNS N
used VBD N
more RBR N
JASP/ER NNP I
strategies NNS I
than IN N
the DT N
control NN N
teachers NNS N
and CC N
JASP/ER NNP I
preschoolers NNS N
used VBD N
more RBR N
joint JJ O
attention NN O
in IN N
their PRP$ N
classroom NN N
than IN N
control NN N
children NNS N
. . N

Additionally RB N
JASP/ER NNP I
children NNS N
spent VBD N
more JJR N
time NN O
in IN O
supported JJ O
engagement NN O
and CC N
less JJR N
time NN O
in IN O
object JJ O
engagement NN O
than IN N
control NN N
preschoolers NNS N
on IN N
a DT N
taped VBN I
play NN I
interaction NN I
. . I

CONCLUSIONS NNP N
Findings NNP N
suggest VBP N
that IN N
teachers NNS N
were VBD N
able JJ N
to TO N
improve VB N
a DT N
core NN O
deficit NN O
of IN O
children NNS P
with IN P
ASD NNP P
in IN P
a DT P
public JJ P
preschool NN P
context NN N
. . N

-DOCSTART- -X- N

Melatonin NNP I
improves VBZ N
bone RB O
mineral JJ O
density NN O
at IN N
the DT N
femoral JJ N
neck NN N
in IN N
postmenopausal JJ P
women NNS P
with IN P
osteopenia: PRP P
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

Melatonin NNP I
is VBZ N
known VBN N
for IN N
its PRP$ N
regulation NN N
of IN N
circadian JJ N
rhythm NN N
. . N

Recently RB N
studies NNS N
have VBP N
shown VBN N
that IN N
melatonin NN I
may MD N
have VB N
a DT N
positive JJ N
effect NN N
on IN N
the DT N
skeleton NN N
. . N

By IN N
increasing VBG N
age NN N
the DT N
melatonin NN N
levels NNS N
decrease NN N
which WDT N
may MD N
lead VB N
to TO N
a DT N
further RB N
imbalanced JJ N
bone NN N
remodeling NN N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
whether IN N
treatment NN N
with IN N
melatonin NN I
could MD N
improve VB N
bone NN N
mass NN N
and CC N
integrity NN N
in IN N
humans NNS N
. . N

In IN N
a DT N
double-blind JJ N
RCT NNP N
we PRP N
randomized VBD N
81 CD P
postmenopausal NN P
osteopenic JJ P
women NNS P
to TO P
1-yr JJ N
nightly RB N
treatment NN P
with IN P
melatonin NN P
1 CD P
mg NN P
(N NNP P
= VBD P
20) CD P
3 CD P
mg NN P
(N NNP P
= VBZ P
20) CD P
or CC P
placebo VB P
(N JJ P
= JJ P
41) CD P
. . P

At IN N
baseline NN N
and CC N
after IN N
1-yr JJ N
treatment NN N
we PRP N
measured VBD N
bone JJ N
mineral JJ N
density NN N
(BMD) NN N
by IN N
dual JJ I
X-ray JJ I
absorptiometry NN I
quantitative NN I
computed VBD I
tomography NN I
(QCT) NN N
and CC N
high-resolution NN I
peripheral JJ I
QCT NNP I
(HR-pQCT) NN N
and CC N
determined VBD N
calciotropic NN N
hormones NNS N
and CC N
bone NN N
markers NNS N
. . N

Mean JJ N
age NN P
of IN P
the DT P
study NN P
subjects NNS P
was VBD P
63 CD P
(range JJ P
56-73) JJ P
yr NN P
. . P

Compared VBN N
to TO N
placebo VB I
femoral JJ O
neck NN O
BMD NNP O
increased VBN N
by IN N
1.4% CD N
in IN N
response NN N
to TO N
melatonin VB N
(P NNP N
< NNP N
0.05) CD N
in IN N
a DT N
dose-dependent JJ N
manner NN N
(P NNP N
< VBZ N
0.01) CD N
as IN N
BMD NNP O
increased VBD N
by IN N
0.5% CD N
in IN N
the DT N
1 CD N
mg/day NN N
group NN N
(P NNP N
= VBZ N
0.55) CD N
and CC N
by IN N
2.3% CD N
(P NNS N
< JJ N
0.01) CD N
in IN N
the DT N
3 CD N
mg/day NN N
group NN N
. . N

In IN N
the DT N
melatonin NN N
group NN N
trabecular JJ O
thickness NN O
in IN O
tibia NN O
increased VBN N
by IN N
2.2% CD N
(P NNS N
= JJ N
0.04) CD N
and CC N
volumetric JJ O
bone NN O
mineral JJ O
density NN O
(vBMD) NN O
in IN N
the DT N
spine NN N
by IN N
3.6% CD N
(P NNS N
= JJ N
0.04) CD N
in IN N
the DT N
3 CD N
mg/day NN N
. . N

Treatment NN N
did VBD N
not RB N
significantly RB N
affect JJ N
BMD NNP O
at IN N
other JJ N
sites NNS N
or CC N
levels NNS N
of IN N
bone NN N
turnover NN N
markers; NN N
however RB N
24-hr JJ O
urinary JJ O
calcium NN O
was VBD N
decreased VBN N
in IN N
response NN N
to TO N
melatonin VB I
by IN N
12.2% CD N
(P NNS N
= JJ N
0.02) CD N
. . N

In IN N
conclusion NN N
1-yr JJ N
treatment NN N
with IN N
melatonin NN I
increased VBN N
BMD NNP O
at IN N
femoral JJ O
neck NN O
in IN N
a DT N
dose-dependent JJ N
manner NN N
while IN N
high-dose JJ N
melatonin NN N
increased VBD N
vBMD NN O
in IN N
the DT N
spine NN N
. . N

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
assess VB N
the DT N
mechanisms NN N
of IN N
action NN N
and CC N
whether IN N
the DT N
positive JJ N
effect NN N
of IN N
nighttime JJ N
melatonin NN I
will MD N
protect VB N
against IN N
fractures NNS N
. . N

-DOCSTART- -X- N

An DT N
intervention NN N
to TO N
decrease VB N
stigma NN N
in IN N
young JJ P
adults NNS P
with IN P
sickle NN P
cell NN P
disease NN P
. . P

Young NN P
adults NNS P
with IN P
sickle NN P
cell NN P
disease NN P
(SCD) NNP P
are VBP N
often RB N
stigmatized VBN N
when WRB N
they PRP N
seek VBP N
care NN N
for IN N
pain NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
test VB N
an DT N
intervention NN N
to TO N
decrease VB N
health-related JJ N
stigma NN N
during IN N
care-seeking NN N
. . N

Young NN P
adults NNS P
with IN P
SCD NNP P
ages VBZ P
18 CD P
to TO P
35 CD P
years NNS P
(n JJ P
= RB P
90) CD P
were VBD N
randomized VBN N
to TO N
either VB N
the DT N
care-seeking JJ N
intervention NN N
(CSI) NN N
or CC N
an DT N
attention NN N
control NN N
group NN N
that WDT N
participated VBD N
in IN N
life NN N
review NN N
interviews NNS N
. . N

The DT N
two CD N
groups NNS N
were VBD N
compared VBN N
by IN N
t NN N
tests NNS N
and CC N
longitudinal JJ N
data NNS N
analyses NNS N
on IN N
the DT N
change NN N
from IN N
baseline NN N
to TO N
the DT N
last JJ N
time NN N
point NN N
in IN N
total JJ O
health-related JJ O
stigma NN O
and CC N
health-related JJ O
stigma NN O
by IN N
doctors NNS N
. . N

Findings NNS N
suggest VBP N
that IN N
the DT N
CSI NNP N
was VBD N
associated VBN N
with IN N
significant JJ N
increased JJ N
awareness NN O
of IN N
perceived JJ N
total JJ N
stigma NN N
and CC N
stigma NN N
by IN N
doctors NNS N
compared VBN N
with IN N
the DT N
attention NN N
control NN N
group NN N
. . N

These DT N
findings NNS N
are VBP N
promising VBG N
in IN N
terms NNS N
of IN N
lessons NNS N
learned VBN N
from IN N
a DT N
pilot NN N
intervention NN N
that WDT N
focused VBD N
on IN N
the DT N
role NN N
communication NN N
skills NNS N
play VBP N
in IN N
decreasing VBG N
health-related JJ N
stigma NN N
in IN N
young JJ P
adults NNS P
with IN P
SCD NNP P
. . P

-DOCSTART- -X- N

Vitamin NNP I
C NNP I
and CC N
acute JJ N
illness NN N
in IN N
Navajo NNP P
school NN P
children NNS P
. . P

To TO N
evaluate VB N
earlier JJR N
observations NNS N
including VBG N
our PRP$ N
own JJ N
showing NN N
usefulness NN N
of IN N
vitamin NN I
C NNP I
for IN I
managing VBG N
the DT N
common JJ N
cold NN N
we PRP N
performed VBD N
a DT N
double-blind JJ N
trial NN N
of IN N
vitamin NN I
C NNP I
versus NN I
placebo NN I
in IN N
868 CD P
children NNS P
. . P

There EX N
was VBD N
no DT N
difference NN N
in IN N
number NN O
becoming VBG O
ill JJ O
(133 NNP N
versus NN N
129) CD N
number NN O
of IN O
episodes NNS O
(166 NNP N
versus NN N
159) CD N
or CC N
mean VB O
illness JJ O
duration NN O
(5.5 NNP N
versus NN N
5.8 CD N
days) NN N
between IN N
the DT N
groups NNS N
. . N

Children NNP P
receiving VBG P
vitamin NN P
C NNP P
had VBD N
fewer JJR N
throat NN O
cultures NNS O
yielding VBG N
beta-hemolytic JJ N
streptococcus NN N
(six NNP N
versus NN N
13 CD N
P NNP N
less JJR N
than IN N
0.10) CD N
but CC N
no DT N
difference NN N
in IN N
overall JJ N
complicated JJ O
illness NN O
rate NN O
(24 NNP N
versus NN N
25) CD N
. . N

Plasma NNP O
ascorbic JJ O
acid NN O
levels NNS O
were VBD N
higher JJR N
in IN N
the DT N
vitamin NN N
group NN N
24 CD N
to TO N
26 CD N
hours NNS N
after IN N
supplementation NN N
(1.28 NNP N
versus NN N
1.04 CD N
mg NN N
per IN N
100 CD N
ml NN N
P NNP N
less JJR N
than IN N
0.01) CD N
. . N

Children NNP P
with IN P
high JJ P
plasma NN P
ascorbic JJ N
acid JJ N
concentrations NNS N
had VBD N
longer RBR N
mean JJ O
illness NN O
(6.8 NNP N
versus VBZ N
4.0 CD N
days NNS N
P NNP N
less JJR N
than IN N
0.05) CD N
than IN N
those DT N
with IN N
low JJ N
levels NNS N
. . N

Vitamin NNP I
C NNP I
does VBZ N
not RB N
seem VB N
to TO N
be VB N
an DT N
effective JJ N
prophylactic NN N
or CC N
therapeutic JJ N
agent NN N
for IN N
upper JJ N
respiratory NN N
illness NN N
. . N

-DOCSTART- -X- N

Evaluating VBG N
the DT N
acceptability NN N
and CC N
efficacy NN N
of IN N
a DT N
psycho-educational JJ I
intervention NN I
for IN I
coping VBG I
and CC I
symptom JJ I
management NN I
by IN N
children NNS P
with IN P
cancer: NN P
a DT N
randomized VBN N
controlled VBN N
study NN N
. . N

AIMS NNP N
To TO N
evaluate VB N
the DT N
acceptability NN N
and CC N
efficacy NN N
of IN N
a DT N
psycho-educational JJ I
intervention NN I
designed VBN N
to TO N
improve VB N
effective JJ N
coping NN N
and CC N
reduce VB N
symptom JJ N
severity NN N
in IN N
children NNS P
with IN P
cancer NN P
. . P

BACKGROUND NNP N
Cancer NNP I
treatments VBZ I
increase VB N
survival JJ N
rates NNS N
and CC N
also RB N
cause VB N
physical JJ N
and CC N
psychological JJ N
effects NNS N
on IN N
children NNS P
with IN P
cancer NN P
. . P

A DT N
psycho-educational JJ I
intervention NN I
is VBZ N
used VBN N
to TO N
assist VB N
children NNS P
and CC P
adolescents NNS P
with IN P
these DT P
effects NNS P
and CC N
its PRP$ N
efficacy NN N
has VBZ N
been VBN N
described VBN N
in IN N
several JJ N
studies NNS N
. . N

DESIGN VB N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

METHODS NNP N
Participants NNS P
being VBG P
treated VBN P
were VBD P
recruited VBN P
and CC P
randomly RB P
assigned VBN P
to TO P
two CD P
groups NNS P
from IN P
September NNP P
2011-February JJ P
2013 CD P
in IN P
Taiwan NNP P
. . P

The DT I
intervention NN I
group NN I
received VBD I
a DT I
psycho-educational JJ I
intervention NN I
in IN I
addition NN I
to TO I
standard VB I
care NN I
while IN I
the DT I
control NN I
group NN I
received VBD I
only RB I
standard JJ I
care NN I
. . I

Each DT N
participant NN N
was VBD N
assessed VBN N
using VBG N
a DT N
paediatric JJ N
cancer NN N
coping VBG N
scale NN N
and CC N
perceived VBD N
symptom JJ N
severity NN N
was VBD N
evaluated VBN N
at IN N
three CD N
time NN N
points NNS N
(baseline JJ N
1 CD N
month NN N
and CC N
3 CD N
months) NN N
. . N

A DT N
repeated-measures JJ N
analysis NN N
of IN N
variance NN N
was VBD N
used VBN N
to TO N
estimate VB N
the DT N
effects NNS I
of IN I
intervention NN I
. . I

Qualitative JJ N
findings NNS N
were VBD N
analysed VBN N
using VBG N
content JJ N
analysis NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
difference NN N
in IN N
coping VBG N
scores NNS N
was VBD N
found VBN N
between IN N
groups NNS N
but CC N
the DT N
experimental JJ I
group NN I
reported VBD N
significantly RB N
lower JJR N
scores NNS N
in IN N
gastrointestinal JJ O
problems NNS O
and CC O
pain NN O
. . O

Most JJS N
symptoms NNS N
decreased VBN N
significantly RB N
over IN N
time NN N
in IN N
both DT N
groups NNS N
except IN N
for IN N
gastrointestinal JJ N
problems NNS N
. . N

The DT N
scores NNS N
in IN N
pain NN O
bone NN O
marrow NN O
suppression NN O
and CC O
body NN O
image NN O
showed VBD N
significant JJ N
interaction NN N
effects NNS N
between IN N
groups NNS N
on IN N
changes NNS N
over IN N
time NN N
. . N

Qualitative JJ N
results NNS N
reported VBD N
that IN N
participants NNS N
evaluated VBD I
the DT I
intervention NN I
positively RB I
especially RB I
about IN N
receipt NN N
of IN N
psychological JJ N
support NN N
and CC N
learnt NN N
coping VBG N
skills NNS N
. . N

CONCLUSIONS VB N
The DT I
psycho-educational JJ I
intervention NN I
administered VBN I
was VBD I
acceptable JJ I
for IN I
children NNS P
with IN P
cancer NN P
and CC N
was VBD N
found VBN N
to TO N
reduce VB N
gastrointestinal JJ N
problems NNS N
and CC N
pain NN N
. . N

-DOCSTART- -X- N

A DT N
prospective JJ N
double-blind NN N
randomized VBD N
clinical JJ N
trial NN N
of IN N
levocarnitine NN I
to TO N
treat VB N
autism NN P
spectrum NN P
disorders NNS P
. . P

BACKGROUND NNP N
L-carnitine NNP I
was VBD N
proposed VBN N
as IN N
a DT N
potential JJ N
treatment NN N
for IN N
patients NNS P
diagnosed VBN P
with IN P
an DT P
autism NN P
spectrum NN P
disorder NN P
to TO N
improve VB N
mitochondrial JJ N
dysfunction NN N
but CC N
no DT N
prior JJ N
randomized VBN N
controlled VBN N
trials NNS N
have VBP N
been VBN N
conducted VBN N
. . N

MATERIAL/METHODS NNP N
Thirty NNP P
subjects NNS P
diagnosed VBD P
with IN P
an DT P
ASD NNP P
were VBD I
randomly RB I
assigned VBN I
to TO I
receive VB I
a DT I
standardized JJ I
regimen NN I
(50 NNP I
mg VBZ I
L-carnitine/kg NNP I
bodyweight/day) NN I
of IN I
liquid JJ I
L-carnitine JJ I
(n=19) NN I
or CC I
placebo NN I
(n=11) NN I
for IN I
3-months NNS I
. . I

Measures NNS I
included VBD I
changes NNS I
in IN I
professionally RB I
completed VBN I
Childhood NNP O
Autism NNP O
Rating NNP O
Scale NNP O
(CARS) NNP O
hand NN O
muscle NN O
testing NN O
and CC O
modified VBD O
clinical JJ O
global JJ O
impression NN O
(CGI) NN O
forms; NN O
parent NN O
completed VBD O
Autism NNP O
Treatment NNP O
Evaluation NNP O
Checklist NNP O
(ATEC) NNP O
treatment NN O
adherence NN O
measurement NN O
(TAM) NNP O
frequency NN O
and CC O
intensity NN O
of IN O
side JJ O
effect NN O
rating NN O
(FISER)/global JJ O
rating NN O
of IN O
side JJ O
effect NN O
burden NN O
(GRSEB)/patient JJ O
report NN O
of IN O
incidence NN O
of IN O
side NN O
effects NNS O
(PRISE) VBP O
forms; NN O
and CC O
lab NN O
testing NN O
. . O

RESULTS NNP N
Significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
CARS NNP O
(-2.03 JJ N
95% CD N
CI=-3.7 JJ N
to TO N
-0.31) VB N
CGI NNP O
(-0.69 JJ N
95% CD N
CI=-1.1 JJ N
to TO N
-0.06) VB N
and CC N
ATEC NNP O
scores NNS O
. . O

Significant JJ N
correlations NNS N
between IN N
changes NNS N
in IN N
serum JJ N
free-carnitine JJ N
levels NNS N
and CC N
positive JJ N
clinical JJ N
changes NNS N
were VBD N
observed VBN N
for IN N
hand NN O
muscle NN O
strength NN O
(R2=0.23 NNP N
P=0.046) NNP N
cognitive JJ O
scores NNS O
(R2=0.27 VBP N
P=0.019) NNP N
and CC N
CARS NNP O
scores VBZ O
(R2=0.20 JJ N
P=0.047) NNP N
. . N

Study NNP N
subjects NNS N
were VBD N
protocol-compliant JJ N
(average NN N
adherence NN N
was VBD N
>85%) JJ N
and CC N
generally RB N
well-tolerated VBD N
the DT N
L-carnitine JJ I
therapy NN I
given VBN N
. . N

CONCLUSIONS NNP N
L-carnitine NNP I
therapy NN I
(50 NNP N
mg/kilogram-bodyweight/day) NN N
administered VBD N
for IN N
3-months JJ N
significantly RB N
improved VBN N
several JJ N
clinical JJ N
measurements NNS N
of IN N
ASD NNP N
severity NN N
but CC N
subsequent JJ N
studies NNS N
are VBP N
recommended VBN N
. . N

-DOCSTART- -X- N

Randomized VBN N
trial NN N
of IN N
angiotensin JJ I
II-receptor NNP I
blocker NN I
vs NN N
. . N

dihydropiridine NN I
calcium NN I
channel NN I
blocker NN I
in IN N
the DT N
treatment NN N
of IN N
paroxysmal JJ P
atrial JJ P
fibrillation NN P
with IN P
hypertension NN P
(J-RHYTHM JJ P
II NNP P
study) NN N
. . N

AIMS NNP N
Atrial NNP N
fibrillation NN N
(AF) NNP N
is VBZ N
a DT N
common JJ N
arrhythmia NN N
frequently RB N
associated VBN N
with IN N
hypertension NN N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
lowering VBG N
blood NN N
pressure NN N
by IN N
angiotensin JJ I
II-receptor NNP I
blockers NNS I
(ARB) NNP I
has VBZ N
more JJR N
beneficial JJ N
effects NNS N
than IN N
by IN N
conventional JJ I
calcium NN I
channel NN I
blockers NNS I
(CCB) VBP I
on IN N
the DT N
frequency NN N
of IN N
paroxysmal JJ N
AF NNP N
with IN N
hypertension NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
Japanese JJ P
Rhythm NNP P
Management NNP P
Trial NNP P
II NNP P
for IN P
Atrial NNP P
Fibrillation NNP P
(J-RHYTHM NNP P
II NNP P
study) NN P
is VBZ N
an DT N
open-label JJ N
randomized JJ N
comparison NN N
between IN N
an DT N
ARB NNP I
(candesartan) NN I
and CC N
a DT N
CCB NNP I
(amlodipine) NN I
in IN N
the DT N
treatment NN N
of IN N
paroxysmal JJ N
AF NNP N
associated VBN N
with IN N
hypertension NN N
. . N

Using VBG N
daily JJ I
transtelephonic JJ I
monitoring NN I
we PRP I
examined VBD N
asymptomatic JJ O
and CC O
symptomatic JJ O
paroxysmal NN O
AF NNP O
episodes VBZ O
during IN N
a DT N
maximum JJ N
1 CD N
year NN N
treatment NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
difference NN O
in IN O
AF NNP O
frequency NN O
between IN O
the DT O
pre-treatment JJ O
period NN O
and CC O
the DT O
final JJ O
month NN O
of IN O
the DT O
follow-up NN O
. . O

The DT N
secondary JJ N
endpoints NNS N
included VBD N
cardiovascular JJ O
events NNS O
development NN O
of IN O
persistent JJ O
AF NNP O
left VBD O
atrial JJ O
dimension NN O
and CC O
quality-of-life JJ O
(QOL) NN O
. . O

The DT N
study NN P
enrolled VBD P
318 CD P
patients NNS P
(66 JJ P
years NNS P
male/female VBD P
219/99 CD P
158 CD P
in IN P
the DT P
ARB NNP P
group NN P
and CC P
160 CD P
in IN P
the DT P
CCB NNP P
group) NN P
treated VBD P
at IN P
48 CD P
sites NNS P
throughout IN P
Japan NNP P
. . P

At IN N
baseline PDT P
the DT P
frequency NN P
of IN P
AF NNP P
episodes FW P
(days/month) NNP P
was VBD P
3.8 CD P
 JJ I
5.0 CD P
in IN P
the DT P
ARB NNP P
group NN P
vs NN P
. . P

4.8 CD P
 JJ I
6.3 CD P
in IN P
the DT P
CCB NNP P
group NN P
(not NNP N
significant) NN N
. . N

During IN N
the DT N
follow-up JJ O
blood NN O
pressure NN O
was VBD N
significantly RB N
lower JJR N
in IN N
the DT I
CCB NNP I
group NN N
than IN N
in IN N
the DT I
ARB NNP I
group NN N
(P NNP N
< VBZ N
0.001) CD N
. . N

The DT O
AF NNP O
frequency NN O
decreased VBD N
similarly RB N
in IN N
both DT N
groups NNS N
and CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
primary JJ N
endpoint NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT N
development NN N
of IN O
persistent JJ O
AF NNP O
changes NNS N
in IN O
left JJ O
atrial JJ O
dimension NN O
occurrence NN N
of IN O
cardiovascular JJ O
events NNS O
or CC N
changes NNS N
in IN O
QOL NNP O
. . N

CONCLUSIONS NNP N
In IN P
patients NNS P
with IN P
paroxysmal JJ P
AF NNP P
and CC P
hypertension NN P
treatment NN I
of IN N
hypertension NN N
by IN I
candesartan NN I
did VBD N
not RB N
have VB N
an DT N
advantage NN N
over RP I
amlodipine NN I
in IN N
the DT N
reduction NN N
in IN N
the DT N
frequency NN N
of IN N
paroxysmal JJ N
AF NNP N
(umin NNP N
CTR NNP N
C000000427) NNP N
. . N

-DOCSTART- -X- N

Low-intensity NNP I
exercise NN I
and CC N
reduction NN N
of IN N
the DT N
risk NN O
for IN O
falls NNS P
among IN P
at-risk JJ P
elders NNS P
. . P

BACKGROUND NNP N
Among IN P
elderly JJ P
persons NNS P
falls VBZ P
account NN N
for IN N
87% CD N
of IN N
all DT N
fractures NNS N
and CC N
are VBP N
contributing VBG N
factors NNS N
in IN N
many JJ N
nursing NN N
home NN N
admissions NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
an DT N
easily RB I
implemented VBN I
low-intensity JJ I
exercise NN I
program NN I
on IN N
the DT N
incidence NN N
of IN N
falls NNS N
and CC N
the DT N
time NN N
to TO N
first VB N
fall NN N
among IN N
a DT P
clinically RB P
defined JJ P
population NN P
of IN P
elderly JJ P
men NNS P
and CC P
women NNS P
. . P

METHODS NNP N
This DT N
community-based JJ N
randomized JJ N
trial NN N
compared VBN N
the DT N
exercise NN I
intervention NN N
with IN N
a DT N
no-intervention JJ I
control NN I
. . I

The DT N
participants NNS P
were VBD P
294 CD P
men NNS P
and CC P
women NNS P
aged VBN P
60 CD P
years NNS P
or CC P
older JJR P
who WP P
had VBD P
either CC P
a DT P
hospital JJ P
admission NN P
or CC P
bed NN P
rest NN P
for IN P
2 CD P
days NNS P
or CC P
more JJR P
within IN P
the DT P
previous JJ P
month NN P
. . P

Exercise NN I
participants NNS N
were VBD N
scheduled VBN N
to TO N
attend VB N
exercise NN I
sessions NNS I
lasting VBG I
45 CD I
minutes NNS I
including VBG I
warm-up JJ I
and CC I
cool-down JJ I
3 CD I
times NNS N
a DT N
week NN N
for IN N
8 CD N
weeks NNS N
(24 JJ N
sessions) NN N
. . N

Assessments NNS N
included VBD N
gait NN O
and CC O
balance NN O
measures NNS N
self-reported JJ O
physical JJ O
function NN O
the DT O
number NN N
of IN N
medications NNS N
being VBG N
taking VBG N
at IN N
baseline NN N
participant NN N
age NN N
sex NN N
and CC N
history NN N
of IN N
falling VBG N
. . N

Falls NNS O
were VBD N
tracked VBN N
for IN N
1 CD N
year NN N
after IN N
each DT N
participant's NN N
baseline NN N
assessment NN N
. . N

RESULTS NNP N
29% CD N
of IN N
the DT N
study NN N
participants NNS N
reported VBD N
a DT N
fall NN O
during IN N
the DT N
study NN N
period NN N
. . N

The DT N
effect NN N
of IN N
exercise NN I
in IN N
preventing VBG O
falls NNS O
varied VBN N
significantly RB N
by IN N
baseline JJ N
physical JJ N
function NN N
level NN N
(p NNP N
< NNP N
or CC N
=.002) NNP N
. . N

The DT N
risk NN O
for IN O
falls NNS O
decreased VBN N
for IN N
exercise NN I
participants NNS N
with IN N
low JJ N
baseline NN N
physical JJ N
functioning VBG N
(hazard NN N
ratio NN N
.51) NNP N
but CC N
increased VBD N
for IN N
exercise NN I
participants NNS N
with IN N
high JJ N
baseline NN N
physical JJ N
functioning VBG N
(hazard NNP N
ratio NN N
3.51) CD N
. . N

CONCLUSIONS NNP N
This DT N
easily RB N
implemented VBN N
low-intensity JJ I
exercise NN I
program NN I
appears VBZ N
to TO N
reduce VB N
the DT N
risk NN O
for IN O
falls NNS O
among IN P
elderly JJ P
men NNS P
and CC P
women NNS P
recovering VBG P
from IN P
recent JJ P
hospitalizations NNS P
bed VBD P
rest NN P
or CC P
both DT P
who WP P
have VBP P
low JJ P
levels NNS P
of IN P
physical JJ P
functioning NN P
. . P

-DOCSTART- -X- N

A DT N
controlled JJ N
trial NN N
of IN N
'Senokot' NN I
in IN N
faecal JJ N
soiling NN N
treated VBN N
by IN N
behavioural JJ I
methods NNS I
. . I

A DT N
double-blind JJ N
randomly NN N
controlled VBD N
trial NN N
of IN N
one CD N
particular JJ N
laxative NN N
Senokot NNP I
used VBD I
in IN N
moderate JJ N
dosage NN N
was VBD N
carried VBN N
out RP N
on IN N
a DT N
group NN N
of IN N
40 CD P
children NNS P
with IN P
severe JJ P
and CC P
persistent JJ P
soiling NN P
and CC P
often RB P
with IN P
a DT P
history NN P
of IN P
faecal JJ P
retention NN P
. . P

Significant JJ N
improvement NN O
occurred VBD N
following VBG N
three CD N
months NNS N
of IN N
outpatient JJ N
treatment NN N
using VBG N
a DT N
behavioural JJ I
approach NN I
and CC I
either DT I
Senokot NNP I
placebo NN I
or CC I
no DT I
medication NN I
. . I

However RB N
there EX N
was VBD N
no DT N
evidence NN N
either RB N
during IN N
the DT N
trial NN N
or CC N
subsequently RB N
when WRB N
Senokot NNP N
was VBD N
employed VBN N
to TO N
supplement VB N
behavioural JJ N
treatment NN N
in IN N
every DT N
child NN N
who WP N
continued VBD N
with IN N
therapy NN N
that IN N
this DT N
laxative NN I
contributed VBD N
in IN N
any DT N
way NN N
to TO N
relieving VBG N
the DT N
problem NN N
in IN N
this DT N
group NN N
of IN N
cases NNS N
. . N

-DOCSTART- -X- N

Mefloquine NNP I
kinetics NNS I
in IN P
cured JJ P
and CC P
recrudescent JJ P
patients NNS P
with IN P
acute JJ P
falciparum NN P
malaria NN P
and CC P
in IN P
healthy JJ P
volunteers NNS P
. . P

Mefloquine JJ I
pharmacokinetics NNS I
were VBD N
compared VBN N
in IN N
a DT N
randomized JJ N
clinical JJ P
trial NN P
in IN P
Thailand NNP P
among IN P
patients NNS P
with IN P
malaria NNS P
and CC P
healthy JJ P
volunteers NNS P
. . P

A DT N
single JJ N
oral JJ I
dose NN I
of IN I
1500 CD I
mg NN I
mefloquine NN I
hydrochloride NN I
was VBD N
administered VBN P
to TO P
11 CD P
patients NNS P
and CC P
5 CD P
volunteers NNS P
and CC P
750 CD P
mg NN P
was VBD P
given VBN P
to TO P
16 CD P
patients NNS P
and CC P
5 CD P
volunteers NNS P
. . P

Efficacy NN N
was VBD N
82% CD N
for IN N
1500 CD N
mg NN N
and CC N
63% CD N
for IN N
750 CD N
mg NN N
. . N

In IN N
cured JJ P
patients NNS P
taking VBG P
750 CD P
mg JJ P
mefloquine NN P
peak NN P
plasma JJ P
drug NN P
concentration NN P
(Cmax) NNP P
and CC P
area NN P
under IN P
the DT P
plasma JJ P
concentration-time JJ P
curve NN P
(AUC) NN P
were VBD N
significantly RB N
greater JJR N
than IN N
in IN N
the DT N
patients NNS N
for IN N
whom WP N
treatment NN N
failed VBD N
(p RB N
less JJR N
than IN N
0.0005 CD N
and CC N
p RB N
less JJR N
than IN N
0.01 CD N
respectively) NN N
and CC N
plasma JJ O
mefloquine NN O
levels NNS O
were VBD N
significantly RB N
higher JJR N
from IN N
8 CD N
hours NNS N
to TO N
18 CD N
days NNS N
after IN N
treatment NN N
. . N

Mefloquine NNP I
AUC NNP N
was VBD N
reduced VBN N
and CC N
variable JJ N
in IN N
the DT N
presence NN N
of IN N
diarrhea NN N
. . N

Compared VBN N
with IN N
noninfected JJ N
volunteers NNS N
clinically RB N
ill VBP N
patients NNS N
displayed VBD N
a DT N
delayed JJ N
time NN N
to TO N
reach VB N
peak JJ O
concentration NN O
(p NNP N
less JJR N
than IN N
0.01) CD N
and CC N
significantly RB N
higher JJR N
mefloquine NN I
plasma NN N
levels NNS N
in IN N
the DT N
first JJ N
2 CD N
days NNS N
after IN N
administration NN N
of IN N
either CC N
the DT N
750 CD N
mg NN N
or CC N
the DT N
1500 CD N
mg NN N
dose NN N
. . N

Mefloquine NNP I
AUC NNP N
was VBD N
similar JJ N
in IN N
patients NNS P
with IN P
malaria NNS P
and CC P
healthy JJ P
volunteers NNS P
. . P

Because IN N
plasma JJ N
levels NNS N
increased VBN N
in IN N
temporal JJ N
relationship NN N
with IN N
clinical JJ N
illness JJ N
mefloquine NN I
volume NN N
of IN N
distribution NN N
or CC N
clearance NN N
(or CD N
both) NN N
was VBD N
reduced VBN N
during IN N
the DT N
acute JJ N
phase NN N
of IN N
illness NN N
. . N

-DOCSTART- -X- N

A DT N
comparison NN N
of IN N
the DT N
effectiveness NN N
and CC N
patient JJ N
tolerance NN N
of IN N
oral JJ I
sodium NN I
phosphate NN I
castor NN I
oil NN I
and CC I
standard NN I
electrolyte NN I
lavage NN I
for IN N
colonoscopy NN P
or CC P
sigmoidoscopy JJ P
preparation NN P
. . P

One CD P
hundred CD P
thirteen JJ P
patients NNS P
were VBD N
randomized VBN N
to TO N
receive VB N
either DT I
oral JJ I
sodium NN I
phosphate NN I
(Fleet VBD I
Phospho-Soda) NNP I
lemon-flavored JJ I
castor NN I
oil NN I
(Purge) NN I
or CC I
standard JJ I
polyethylene NN I
glycol-based JJ I
lavage NN I
solution NN I
(GoLYTELY) NN I
before IN I
elective JJ P
colonoscopy NN P
. . P

The DT N
study NN N
purpose NN N
was VBD N
to TO N
confirm VB N
the DT N
efficacy NN N
of IN N
oral JJ I
sodium NN I
phosphate NN I
and CC N
extend VB N
observations NNS N
to TO N
include VB N
castor JJ I
oil NN I
. . I

Overall JJ N
patients NNS N
reported VBD N
that IN N
sodium NN I
phosphate NN I
and CC I
castor NN I
oil NN I
were VBD N
easier JJR N
to TO N
complete VB N
(p NNP N
< NNP N
0.05) CD N
. . N

Scores NNS O
for IN O
cleansing VBG O
the DT O
entire JJ O
colon NN O
as IN I
determined VBN I
by IN I
endoscopists NNS I
who WP I
were VBD I
blinded VBN I
to TO I
the DT I
cathartic JJ I
agent NN I
were VBD I
highest JJS I
in IN I
patients NNS I
receiving VBG I
sodium NN I
phosphate NN I
(p NNP I
< VBZ I
0.02) CD I
. . I

Scores NNS O
of IN O
left-colon NN O
cleansing NN O
for IN O
flexible JJ O
sigmoidoscopy NN O
were VBD N
equally RB N
high JJ N
for IN N
the DT N
three CD N
methods NNS N
. . N

Scores NNS O
for IN O
taste NN O
and CC O
symptom JJ O
side NN O
effects NNS O
were VBD N
similar JJ N
for IN N
each DT N
preparation NN N
. . N

There EX N
were VBD N
no DT N
recognized VBN N
signs NNS O
or CC O
symptoms NNS O
of IN O
hypocalcemia NN O
in IN N
the DT N
sodium NN N
phosphate NN N
group NN N
. . N

Because IN N
of IN N
the DT N
low JJ N
cost NN N
of IN I
oral JJ I
sodium NN I
phosphate NN I
combined VBN I
with IN I
the DT I
lowest JJS I
repeat NN I
endoscopy NN I
rate NN I
for IN N
inadequate JJ N
cleansing NN N
patient JJ O
savings NNS O
were VBD N
projected VBN N
to TO N
be VB N
$5000 VBN N
per IN N
100 CD N
patients NNS N
at IN N
this DT N
center NN N
. . N

Oral JJ I
sodium NN I
phosphate NN I
is VBZ N
a DT N
cost-effective JJ N
colonoscopy NN N
preparation NN N
that WDT N
is VBZ N
better RBR N
tolerated VBN N
and CC N
more RBR N
effective JJ N
than IN N
the DT N
polyethylene JJ N
glycol-electrolyte JJ N
lavage NN N
solution NN N
or CC N
castor NN N
oil NN N
. . N

-DOCSTART- -X- N

Clinical JJ N
evaluation NN N
of IN N
Er NNP I
Cr:YSGG NNP I
and CC I
GaAlAs NNP I
laser NN I
therapy NN I
for IN N
treating VBG N
dentine NN P
hypersensitivity: NN P
A NNP N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
. . N

OBJECTIVE IN N
The DT N
advent NN N
of IN N
dental JJ N
lasers NNS N
has VBZ N
raised VBN N
another DT N
possible JJ N
treatment NN N
option NN N
for IN N
dentine NN O
hypersensitivity NN O
(DH) NNP O
and CC N
has VBZ N
become VBN N
a DT N
research NN N
interest NN N
in IN N
the DT N
last JJ N
decades NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
randomized VBN N
controlled VBD N
double-blind JJ N
split NN N
mouth RB N
clinical JJ N
study NN N
was VBD N
to TO N
evaluate VB O
and CC O
compare VB O
the DT N
desensitizing JJ N
effects NNS N
of IN N
erbium JJ I
chromium-doped:yttrium JJ I
scandium NN I
gallium NN I
and CC I
garnet NN I
(Er NN I
Cr:YSGG) NNP I
to TO I
galium-aluminium-arsenide JJ I
(GaAlAs) NNP I
laser NN I
on IN I
DH NNP I
. . I

METHODS NNP N
Fifty-one CD P
patients NNS P
participated VBN P
in IN P
this DT P
study NN P
for IN P
a DT P
total NN P
of IN P
174 CD P
teeth NNS P
. . P

DH NNP O
was VBD O
assessed VBN O
for IN N
all DT N
groups NNS N
with IN N
a DT N
visual JJ O
analog NN O
scale NN O
. . O

For IN N
each DT N
patient NN N
the DT N
teeth NNS N
were VBD N
randomized VBN N
to TO N
three CD N
groups NNS N
. . N

In IN N
the DT N
diode NN N
laser NN N
group NN N
sensitive JJ N
teeth NNS N
were VBD N
irradiated VBN I
with IN I
the DT I
GaAlAs NNP I
laser NN I
at IN I
8.5J/cm(2) CD I
energy NN I
density NN I
. . I

In IN N
the DT N
Er NNP I
Cr:YSGG NNP I
laser NN I
group NN N
sensitive JJ N
teeth NNS N
were VBD N
irradiated VBN I
with IN I
Er NNP I
Cr:YSGG NNP I
laser NN I
in IN I
the DT I
hard JJ I
tissue NN I
mode NN I
using VBG I
a DT I
none-contact JJ I
probe NN I
at IN I
an DT I
energy NN I
level NN I
of IN I
0.25W CD I
and CC I
repetition NN I
rate NN I
of IN I
20Hz CD I
0% CD I
water NN I
and CC I
10% CD I
air NN I
. . I

In IN N
the DT N
control NN N
group NN N
no DT I
treatment NN I
was VBD N
performed VBN N
. . N

Treatment JJ N
time NN N
was VBD N
60s CD N
for IN N
GaAlAs NNP I
laser NN I
and CC N
30s CD N
for IN N
Er NNP I
Cr:YSGG NNP I
laser NN I
. . I

RESULTS NN N
When WRB N
compared VBN N
with IN N
the DT N
control NN N
group NN N
and CC N
baseline NN N
data NNS N
in IN N
both DT N
laser NN N
groups NNS N
laser VBP I
irradiation NN I
provided VBD N
a DT N
desensitizing JJ O
effect NN O
immediately RB N
after IN N
treatment NN N
and CC N
this DT N
effect NN N
was VBD N
maintained VBN N
throughout IN N
the DT N
study NN N
(p<0.05) NNP N
. . N

No DT N
significant JJ N
differences NNS N
between IN N
Er NNP I
Cr:YSGG NNP I
and CC N
GaAlAs NNP I
laser NN I
groups NNS N
were VBD N
found VBN N
at IN N
any DT N
follow-up JJ N
examination NN N
(p>0.05) NN N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
these DT N
findings NNS N
it PRP N
may MD N
be VB N
concluded VBN N
that IN N
both DT N
Er NNP I
Cr:YSGG NNP I
and CC I
GaAlAs NNP I
lasers NNS I
were VBD N
effective JJ O
in IN N
the DT N
treatment NN N
of IN N
DH NNP N
following VBG N
a DT N
single JJ N
application NN N
. . N

-DOCSTART- -X- N

The DT N
Tiotropium NNP I
Safety NNP O
and CC O
Performance NNP O
in IN N
Respimat NNP I
Trial NNP N
(TIOSPIR) VBD N
a DT N
large JJ N
scale NN N
randomized VBD N
controlled JJ N
parallel-group JJ N
trial-design NN N
and CC N
rationale NN N
. . N

BACKGROUND NNP N
Tiotropium NNP I
bromide NN I
is VBZ N
an DT N
effective JJ N
therapy NN N
for IN N
COPD NNP P
patients NNS P
. . P

Comparing VBG N
across IN N
programs NNS N
tiotropium VBP I
Respimat NNP I
Soft NNP I
Mist NNP I
inhaler NN I
was VBD I
at IN I
least JJS I
as RB I
efficacious JJ I
as IN I
tiotropium NN I
HandiHaler NNP I
however RB I
concerns NNS N
have VBP N
been VBN N
raised VBN N
about IN N
tiotropium's NN I
safety NN N
when WRB N
given VBN N
via IN N
Respimat NNP N
. . N

METHODS NNP N
The DT N
TIOSPIR NNP N
trial NN N
(NCT01126437) NN N
compares VBZ N
the DT N
safety NN O
and CC O
efficacy NN O
of IN N
tiotropium NN I
Respimat NNP I
5 CD I
g NNP I
once RB I
daily JJ I
(marketed) NNS N
and CC N
2.5 CD N
g NNS N
once RB N
daily JJ N
(investigational) NNS N
with IN I
tiotropium NN I
HandiHaler NNP I
18 CD I
 NNP N
once RB I
daily JJ I
(marketed) NNS N
. . N

The DT N
hypotheses NNS N
to TO N
be VB N
tested VBN N
are VBP N
1) CD N
. . N

that DT I
tiotropium NN I
Respimat NNP I
5 CD N
g NNP N
once RB N
daily RB N
and CC I
Respimat NNP I
2.5 CD N
g NNP N
once RB N
daily RB N
are VBP N
non-inferior JJ I
to TO I
HandiHaler NNP I
in IN N
terms NNS N
of IN N
all-cause NN N
mortality NN N
and CC N
2) CD N
. . N

that DT I
tiotropium NN I
Respimat NNP I
5 CD N
g NNP N
once RB N
daily RB N
is VBZ N
superior JJ I
to TO I
HandiHaler NNP I
in IN N
terms NNS N
of IN N
time NN N
to TO N
first JJ N
exacerbation NN N
. . N

A DT N
spirometry NN N
substudy NN N
evaluates VBZ O
the DT O
bronchodilator NN O
efficacy NN O
. . N

The DT N
trial NN N
is VBZ N
a DT N
randomized JJ N
double-blind NN N
double JJ N
dummy JJ N
event-driven JJ N
parallel NN N
group NN N
study NN P
. . P

Participants NNS P
can MD P
use VB P
any DT P
background NN P
treatment NN P
for IN P
COPD NNP P
except IN P
inhaled JJ P
anticholinergic JJ I
agents NNS I
. . P

The DT P
study NN P
encompasses VBZ P
a DT P
wide JJ P
range NN P
of IN P
COPD NNP P
patients NNS P
e.g VBP P
. . P

patients NNS P
with IN P
stable JJ P
cardiac JJ P
diseases NNS P
including VBG P
arrhythmia NN P
can MD P
be VB P
included VBN P
. . N

Clinical JJ P
sites NNS P
are VBP P
international JJ P
and CC P
include VBP P
both DT P
primary JJ P
care NN P
as RB P
well RB P
as IN P
specialists NNS P
. . N

RESULTS NN N
To TO P
date NN P
over IN P
17 CD P
000 CD P
participants NNS P
have VBP P
been VBN P
randomized VBN P
from IN P
over IN P
1200 CD P
sites NNS P
in IN P
50 CD P
countries NNS P
with IN N
an DT N
anticipated JJ N
treatment NN N
duration NN N
of IN N
2-3 JJ N
years NNS N
. . N

CONCLUSION NNP N
TIOSPIR NNP N
will MD N
provide VB N
precise JJ N
estimates NNS N
of IN O
the DT O
relative JJ O
safety NN O
and CC O
efficacy NN O
of IN I
the DT I
Respimat NNP I
and CC I
HandiHaler NNP I
formulations NNS I
of IN I
tiotropium NN I
assess JJ N
potential JJ N
dose-dependence NN N
of IN N
important JJ N
outcomes NNS N
and CC N
provide VB N
information NN N
on IN N
the DT N
clinical JJ N
epidemiology NN N
of IN N
COPD NNP N
in IN N
a DT N
large JJ N
international JJ N
patient NN N
cohort NN N
. . N

-DOCSTART- -X- N

Effect NN N
of IN N
antipsychotic JJ P
drugs NNS P
on IN N
cortical JJ O
thickness NN O
. . O

A DT N
randomized VBN N
controlled VBN N
one-year JJ N
follow-up NN N
study NN N
of IN N
haloperidol NN I
risperidone NN I
and CC I
olanzapine NN I
. . I

BACKGROUND NNP N
Imaging NNP N
evidence NN N
indicates VBZ N
that IN N
brain NN N
alterations NNS N
are VBP N
primary JJ N
to TO N
the DT N
full-blown JJ N
onset NN N
of IN N
schizophrenia NN N
and CC N
seem VBP N
to TO N
progress VB N
across IN N
time NN N
. . N

The DT N
potential JJ N
effects NNS O
of IN N
antipsychotic JJ I
medication NN I
on IN N
brain NN N
structure NN N
represent VBP N
a DT N
key JJ N
factor NN N
in IN N
understanding VBG N
brain NN N
changes NNS N
in IN N
psychosis NN N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
low JJ N
doses NNS N
of IN N
haloperidol NN I
risperidone NN I
and CC I
olanzapine NN I
on IN N
cortical JJ N
thickness NN N
. . N

METHOD NNP N
We PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
risperidone NN P
(N=16) NNP P
olanzapine NN P
(N=18) NNP P
and CC P
low JJ P
doses NNS P
of IN P
haloperidol NN P
(N=18) NN P
in IN N
cortical JJ O
thickness NN O
changes NNS N
during IN N
1-year JJ N
follow-up JJ N
period NN N
in IN N
a DT N
large JJ P
and CC P
heterogeneous JJ P
sample NN P
of IN P
schizophrenia NN P
spectrum NN P
patients NNS P
. . P

The DT N
relationship NN N
between IN N
cortical JJ O
thickness NN O
changes NNS O
and CC N
clinical JJ O
and CC O
cognitive JJ O
outcome NN O
was VBD N
also RB N
assessed VBN N
. . N

A DT P
group NN P
of IN P
45 CD P
healthy JJ P
volunteers NNS P
was VBD P
also RB P
longitudinally RB P
evaluated VBN P
. . P

Magnetic JJ O
resonance NN O
imaging VBG O
brain NN O
scans NNS O
(1.5T) VBP N
were VBD N
obtained VBN N
and CC N
images NNS N
were VBD N
analyzed VBN N
by IN N
using VBG N
BRAINS2 NNP O
. . O

RESULTS RB N
There EX N
were VBD N
no DT N
significant JJ N
effects NNS N
of IN N
time NN N
(F(1 JJ N
47)<1.66; CD N
P>0.204) NNP N
treatment NN N
group NN N
(F(2 VBD N
47)<1.47; CD N
P>0.242) NNP N
or CC N
group-by-time JJ N
interaction NN N
(F(2 VBD N
47)<1.82; CD N
P>0.174) NNP N
for IN N
any DT N
of IN N
the DT N
cortical JJ O
thickness NN O
variables NNS N
. . N

When WRB N
the DT N
group NN N
of IN N
healthy JJ N
controls NNS N
was VBD N
included VBN N
in IN N
the DT N
analyses NNS N
it PRP N
is VBZ N
of IN N
note NN N
that IN N
group-by-time JJ N
interaction NN N
showed VBD N
a DT N
significant JJ N
result NN N
for IN N
the DT N
frontal JJ N
lobe NN N
at IN N
trend NN N
level NN N
(F(3 VBD N
81)=2.686; CD N
P=0.052) NNP N
. . N

After IN N
the DT N
Bonferroni NNP N
adjustment NN N
for IN N
multiple JJ N
comparisons NNS N
there EX N
were VBD N
no DT N
significant JJ N
associations NNS N
between IN N
changes NNS N
in IN N
cortical JJ O
thickness NN O
and CC N
clinical JJ O
and CC O
cognitive JJ O
outcome NN O
. . O

CONCLUSIONS NNP N
Low NNP N
doses NNS N
of IN N
haloperidol NN I
risperidone NN I
and CC I
olanzapine NN I
seem VBP N
to TO N
equally RB N
affect VB N
gray JJ O
matter NN O
cortical JJ O
thickness NN O
overall JJ O
and CC O
lobes NNS O
at IN O
the DT N
medium-term JJ N
(1 NNP N
year) NN N
. . N

The DT N
clinical JJ N
effectiveness NN N
of IN N
treatments NNS N
was VBD N
not RB N
significantly RB N
related VBN N
to TO N
changes NNS N
in IN N
cortical JJ O
thickness NN O
. . O

-DOCSTART- -X- N

A DT N
cost-benefit JJ N
comparison NN N
of IN N
intensive JJ I
diabetes NNS I
management NN I
with IN I
implantable JJ I
pumps NNS I
versus IN I
multiple JJ I
subcutaneous JJ I
injections NNS I
in IN N
patients NNS P
with IN P
type NN P
I PRP P
diabetes VBZ P
. . P

OBJECTIVE NN N
To TO N
investigate VB N
if IN N
intraperitoneal JJ I
(IP) NNP I
insulin NN I
infusion NN I
via IN I
programmable JJ I
implantable JJ I
pumps NNS I
is VBZ N
a DT N
potential JJ N
alternative NN N
to TO N
subcutaneous JJ I
(SC) JJ I
insulin NN I
via IN I
multiple JJ I
injections NNS I
. . I

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
We PRP N
compared VBN N
the DT N
cost-benefits NNS O
of IN N
the DT N
two CD N
methods NNS N
using VBG N
a DT N
randomized JJ N
prospective JJ N
6-month JJ N
crossover NN N
design NN N
in IN N
10 CD P
adult NN P
type NN P
I PRP P
diabetic JJ P
patients NNS P
. . P

RESULTS NN P
When WRB N
judged VBN N
on IN N
the DT N
last JJ N
month NN N
of IN N
IP NNP N
versus NN N
SC NNP N
periods NNS N
in IN N
the DT N
nine CD P
patients NNS P
who WP P
completed VBD P
the DT P
study NN P
metabolic JJ P
data NNS N
showed VBD N
better JJR N
glycemic JJ O
control NN O
(HbA1c: VBZ N
7.2 CD N
+/- JJ N
0.2 CD N
IP NNP N
vs NN N
. . N

8.5 CD N
+/- JJ N
0.7% CD N
SC JJ N
mean JJ N
+/- JJ N
SE NNP N
P NNP N
= VBD N
0.02) CD N
reduced JJ O
glycemic JJ O
fluctuations NNS O
(SD NN N
of IN N
capillary JJ N
glucose NN N
values: NNS N
3.4 CD N
+/- JJ N
0.2 CD N
IP NNP N
vs NN N
. . N

4.6 CD N
+/- JJ N
0.2 CD N
mM NN N
SC NNP N
P NNP N
< NNP N
0.01) CD N
and CC N
fewer JJR N
mild JJ N
hypoglycemic JJ O
events NNS O
(5.7 POS N
+/- JJ N
2.0 CD N
IP NNP N
vs NN N
. . N

10.0 CD N
+/- JJ N
3.1 CD N
events/month JJ N
SC NNP N
P NNP N
= VBD N
0.02) CD N
. . N

Quality NN O
of IN O
life NN O
judged VBN O
by IN O
Diabetes NNP O
Control NNP O
and CC O
Complications NNP O
Trial NNP O
questionnaires NNS O
was VBD O
unaffected VBN N
by IN N
pump NN I
therapy NN I
. . I

Direct JJ O
costs NNS O
including VBG O
pump JJ O
acquisition NN O
implantation NN O
and CC O
follow-up JJ N
were VBD N
2.6-fold JJ N
higher JJR N
with IN N
IP NNP N
than IN N
with IN N
SC NNP N
delivery NN N
. . N

CONCLUSIONS NNP N
The DT I
implantable JJ I
pump NN I
is VBZ N
more RBR N
effective JJ N
in IN N
the DT N
short JJ N
term NN N
equally RB N
accepted VBD N
but CC N
more RBR N
costly JJ N
than IN N
multiple JJ I
injections NNS I
and CC N
should MD N
be VB N
limited VBN N
to TO N
patients NNS N
with IN N
unsatisfactory JJ N
glycemic JJ P
control NN P
despite IN P
intensive JJ P
diabetes NNS P
management NN P
with IN P
SC NNP P
insulin NN P
. . P

In IN N
addition NN N
longer-term JJ N
larger-scale JJ N
and CC N
comparative JJ N
evaluation NN N
is VBZ N
required VBN N
. . N

-DOCSTART- -X- N

Antihypertensive JJ I
and CC I
volume-depleting JJ I
effects NNS I
of IN I
mild JJ I
exercise NN I
on IN I
essential JJ I
hypertension NN I
. . I

After IN N
a DT N
general JJ N
clinical JJ N
observation NN N
period NN N
of IN N
over IN N
4 CD N
weeks NNS N
20 CD P
essential JJ P
hypertensive JJ P
subjects NNS P
(Japanese) VBP P
were VBD P
randomly RB P
divided VBN P
into IN P
two CD P
groups NNS P
. . P

One CD P
group NN P
(n VBZ P
= VBZ P
10; CD P
4 CD P
men NNS P
and CC P
6 CD P
women; JJ P
51.4 CD P
+/- JJ P
2.8 CD P
years NNS P
of IN P
age) NNS P
agreed VBD P
to TO N
physical JJ I
training NN I
using VBG I
bicycle NN I
ergometer NN I
exercise NN I
with IN I
the DT I
intensity NN I
at IN I
blood NN I
lactate NN I
threshold NN I
for IN I
60 CD I
minutes NNS I
three CD I
times NNS I
a DT I
week NN I
for IN I
10 CD I
weeks NNS I
while IN I
the DT P
other JJ P
group NN P
(n NNP P
= VBZ P
10; CD P
4 CD P
men NNS P
and CC P
6 CD P
women; JJ P
51.0 CD P
+/- JJ N
2.9 CD N
years NNS N
of IN N
age) NN N
did VBD N
no DT I
particular JJ I
physical JJ I
training NN I
and CC I
was VBD I
followed VBN I
once RB I
a DT I
week NN I
as IN I
the DT I
control NN I
. . I

Changes NNS N
in IN N
blood NN O
pressure NN O
hemodynamics NNS O
and CC O
humoral JJ O
factors NNS O
of IN N
the DT N
exercised VBN I
group NN N
were VBD N
compared VBN N
with IN N
values NNS N
in IN N
the DT N
controls NNS N
. . N

The DT N
following JJ N
significant JJ N
changes NNS N
were VBD N
found VBN N
only RB N
in IN N
the DT N
exercised JJ I
group NN N
. . N

Blood NNP O
pressure NN O
was VBD N
significantly RB N
(p JJR N
less JJR N
than IN N
0.01) CD N
reduced JJ N
. . N

Whole JJ O
blood NN O
and CC O
plasma NN O
volume NN O
indices NNS O
were VBD N
significantly RB N
reduced VBN N
(p NNP N
less JJR N
than IN N
0.05 CD N
p NN N
less JJR N
than IN N
0.01 CD N
respectively) NN N
. . N

The DT N
change NN N
in IN N
ratio NN O
of IN O
serum NN O
sodium NN O
to TO O
potassium VB O
positively RB N
correlated VBN N
with IN N
the DT N
change NN N
in IN N
systolic JJ O
blood NN O
pressure NN O
(r NNP N
= VBZ N
0.76 CD N
p NN N
less JJR N
than IN N
0.02) CD N
. . N

Plasma NNP O
norepinephrine JJ O
concentrations NNS O
both DT N
at IN N
rest NN N
and CC N
at IN N
the DT N
workload NN N
of IN N
blood NN N
lactate NN N
threshold NN N
during IN N
graded JJ N
exercise NN N
tests NNS N
were VBD N
significantly RB N
reduced VBN N
(p NNP N
less JJR N
than IN N
0.05 CD N
p NN N
less JJR N
than IN N
0.02 CD N
respectively) NN N
after IN N
10 CD N
weeks NNS N
of IN N
exercise NN I
training NN I
. . I

The DT N
change NN N
in IN N
the DT N
resting VBG O
level NN O
of IN N
plasma JJ O
norepinephrine NN O
positively RB N
correlated VBN N
with IN N
that DT N
in IN N
the DT N
mean JJ N
blood NN O
pressure NN O
. . O

No DT N
such JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
the DT N
control NN N
group NN N
. . N

-DOCSTART- -X- N

Adjuvant NNP I
goserelin NN I
and CC I
ovarian JJ I
preservation NN I
in IN I
chemotherapy NN I
treated VBD N
patients NNS P
with IN P
early JJ P
breast NN P
cancer: NN P
results NNS N
from IN N
a DT N
randomized JJ N
trial NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
study NN N
was VBD N
to TO N
examine VB N
if IN N
goserelin JJ I
concomitant NN I
to TO I
CMF-chemotherapy NNP I
as IN I
adjuvant JJ I
treatment NN I
for IN N
premenopausal NN P
breast NN P
cancer NN P
protects VBZ N
the DT N
ovaries NNS N
from IN N
premature JJ N
failure NN N
. . N

A DT I
total NN I
of IN I
285 CD P
premenopausal NN P
breast NN P
cancer NN P
patients NNS P
in IN P
a DT P
randomized JJ P
adjuvant JJ P
trial NN P
(Zoladex NN P
in IN P
premenopausal NN P
patients NNS P
(ZIPP)) WDT P
were VBD P
assigned VBN I
to TO I
a DT I
study NN I
on IN I
ovarian JJ I
function NN I
. . I

Node NNP N
positive JJ N
patients NNS N
were VBD N
assigned VBN N
to TO N
CMF-(cyclophosphamide NNP I
methotrexate NN I
and CC I
5-fluorouracil) JJ I
chemotherapy NN I
in IN I
addition NN I
to TO I
endocrine VB I
therapy NN I
. . I

All DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
2 CD I
years NNS I
of IN I
goserelin NN I
goserelin NN I
plus CC I
tamoxifen JJ I
tamoxifen NN I
alone RB I
or CC I
no DT I
endocrine JJ I
treatment NN I
. . I

We PRP N
studied VBD N
if IN N
menses NNS N
were VBD N
affected VBN N
in IN N
the DT N
treatment NN N
groups NNS N
up RB N
to TO N
36 CD N
months NNS N
after IN N
randomization NN N
. . N

One CD N
year NN N
after IN N
completed VBN N
CMF- NNP N
and CC N
endocrine JJ N
therapy NN N
36% CD N
of IN N
the DT N
women NNS N
in IN N
the DT N
goserelin NN I
group NN N
reported VBD N
menses NNS O
compared VBN O
to TO N
7% CD N
in IN N
the DT N
goserelin NN I
plus CC I
tamoxifen JJ I
group NN N
13% CD N
in IN N
the DT N
tamoxifen NN I
group NN N
and CC N
10% CD N
of IN N
the DT N
controls NNS N
. . N

Among IN N
women NNS N
treated VBN N
with IN N
goserelin NN N
there EX N
was VBD N
a DT N
statistically RB N
significant JJ N
increase NN N
in IN N
the DT N
proportion NN O
of IN O
menstruating VBG O
women NNS O
1 CD O
year NN N
after IN N
completed VBN N
treatment NN N
compared VBN N
to TO N
at IN N
24 CD N
months NNS N
of IN N
treatment NN N
(P NNP N
= VBZ N
0.006) CD N
in IN N
contrast NN N
to TO N
all DT N
other JJ N
treatment NN N
groups NNS N
who WP N
were VBD N
unchanged JJ N
or CC N
more RBR N
often RB N
amenorrheic JJ N
. . N

In IN N
our PRP$ N
study NN N
there EX N
is VBZ N
some DT N
evidence NN N
of IN N
protective JJ N
effect NN N
of IN N
goserelin NN N
on IN N
ovarian JJ N
function NN N
in IN N
CMF NNP I
treated VBD N
women NNS N
. . N

This DT N
effect NN N
was VBD N
not RB N
observed VBN N
in IN N
the DT N
combined JJ I
tamoxifen NN I
and CC I
goserelin NN I
treatment NN I
. . I

-DOCSTART- -X- N

The DT N
effect NN N
of IN N
phenytoin NN I
on IN N
the DT N
absorption NN O
of IN O
synthetic JJ O
folic JJ O
acid NN O
polyglutamate NN O
. . O

The DT N
absorption NN O
of IN O
synthetic JJ O
pteroyltriglutamate NN O
has VBZ N
been VBN N
measured VBN N
in IN N
nine CD P
normal JJ P
students NNS P
with IN P
and CC P
without IN P
the DT P
anticonvulsant JJ P
drug NN P
phenytoin NN P
. . P

It PRP N
has VBZ N
been VBN N
shown VBN N
that IN N
phenytoin NN N
has VBZ N
no DT N
effect NN N
on IN N
the DT N
absorption NN N
of IN N
this DT N
folate JJ N
polyglutamate NN N
. . N

The DT N
reasons NNS N
are VBP N
discussed VBN N
for IN N
the DT N
disparity NN N
between IN N
this DT N
result NN N
and CC N
those DT N
reported VBN N
in IN N
the DT N
literature NN N
when WRB N
folate NN N
polyglutamates NNS N
derived VBN N
from IN N
yeast NN N
were VBD N
used VBN N
. . N

-DOCSTART- -X- N

Interference NN N
on IN N
metabolism NN N
induced VBN N
by IN N
muzolimine NN I
and CC I
chlorthalidone NN I
in IN N
type NN P
II NNP P
hypertensive NN P
diabetics NNS P
. . P

There EX P
is VBZ N
a DT N
very RB N
high JJ N
prevalence NN N
of IN N
hypertension NN P
in IN P
diabetic JJ P
subjects NNS P
which WDT P
makes VBZ N
it PRP N
necessary JJ N
to TO N
use VB N
an DT N
antihypertensive JJ I
drug NN I
with IN N
the DT N
least JJS N
possible JJ N
metabolic JJ N
interference NN N
. . N

For IN N
example NN N
in IN N
the DT N
early JJ N
phase NN N
of IN N
hypertension NN N
diuretics NNS I
usually RB N
worsen VBP N
the DT N
metabolic JJ N
equilibrium NN N
. . N

According VBG N
to TO N
recent JJ N
reports NNS N
a DT N
new JJ N
diuretic JJ N
muzolimine NN I
(MZ) NN I
which WDT I
acts VBZ N
on IN N
the DT N
loop NN N
of IN N
Henle NNP N
seems VBZ N
to TO N
present VB N
a DT N
minor JJ N
effect NN N
on IN N
carbohydrate NN N
metabolic JJ N
balance NN N
. . N

In IN N
order NN N
to TO N
determine VB N
whether IN N
this DT N
assumption NN N
was VBD N
correct JJ N
or CC N
not RB N
we PRP N
carried VBD N
out RP N
a DT N
clinical JJ N
trial NN N
on IN N
26 CD P
type JJ P
II NNP P
(non-insulin-dependent) NN P
diabetics NNS P
in IN P
fairly RB P
good JJ P
metabolic NN P
control NN P
and CC P
with IN P
moderate JJ P
hypertension NN P
(orthostatic JJ P
diastolic JJ P
pressure NN P
from IN P
100 CD P
to TO P
115 CD P
mmHg) NNS P
comparing VBG P
the DT N
effect NN N
of IN N
MZ NNP I
with IN N
those DT N
of IN N
chlorthalidone NN I
(CL) NN I
. . I

According VBG N
to TO N
a DT N
randomized VBN N
single-blind JJ N
cross-over NN N
design NN N
the DT N
patients NNS N
were VBD N
treated VBN N
with IN N
MZ NNP I
(20 NNP N
mg/day) NN N
or CC N
CL NNP I
(50 NNP N
mg/day) NN N
for IN N
the DT N
duration NN N
of IN N
4 CD N
weeks NNS N
. . N

After IN N
the DT N
treatment NN N
period NN N
with IN N
the DT N
first JJ N
drug NN N
there EX N
was VBD N
a DT N
2 CD N
week NN N
wash-out JJ N
period NN N
on IN N
placebo NN I
(PL) NN I
before IN N
the DT N
second JJ N
drug NN N
was VBD N
given VBN N
. . N

During IN N
the DT N
study NN N
a DT N
set NN N
of IN N
metabolic JJ O
and CC O
non-metabolic JJ O
parameters NNS O
was VBD N
monitored VBN N
as IN N
were VBD N
the DT N
clinostatic JJ O
and CC O
orthostatic JJ O
blood NN O
pressure NN O
values NNS N
. . N

The DT N
results NNS N
show VBP N
that IN N
the DT N
antihypertensive JJ N
effect NN N
of IN N
the DT N
two CD N
drugs NNS N
was VBD N
the DT N
same JJ N
(both NNP N
caused VBD N
a DT N
more RBR N
than IN N
10% CD N
decrease NN N
in IN N
systolic JJ O
and CC O
diastolic JJ O
blood NN O
pressure) NN O
. . N

No DT N
significant JJ N
changes NNS N
in IN N
plasma NN O
electrolyte NN O
levels NNS O
occurred VBD N
. . N

There EX N
was VBD N
a DT N
significant JJ N
(p NN N
less JJR N
than IN N
0.05) CD N
increase NN N
in IN N
urinary JJ O
aldosterone NN O
excretion NN O
after IN N
CL NNP I
(20.7 VBD N
+/- JJ N
11 CD N
micrograms/24 NN N
hours NNS N
vs VBP N
. . N

-DOCSTART- -X- N

The DT N
impact NN N
of IN N
the DT N
amount NN N
of IN N
social JJ I
evaluation NN I
on IN I
psychobiological JJ I
responses NNS I
to TO N
a DT N
body NN P
image NN P
threat NN P
. . P

The DT P
present JJ N
study NN N
examined VBD N
the DT N
impact NN N
of IN N
amount NN N
of IN N
social-evaluative JJ N
body NN N
image NN N
threat NN N
on IN N
psychobiological JJ N
responses NNS N
. . N

Women NNS P
(N=123) WDT P
were VBD P
randomized VBN P
into IN P
an DT P
individual-threat JJ P
group-threat NN P
or CC P
no-threat JJ P
condition NN P
. . P

Participants NNS N
completed VBD N
a DT N
measure NN I
of IN I
state NN I
body NN I
shame NN I
and CC N
provided VBD N
a DT N
sample NN I
of IN I
saliva JJ I
(to NNP N
assess NN N
cortisol) NN N
at IN N
baseline NN N
and CC N
following VBG N
their PRP$ N
condition NN N
. . N

Both DT N
threat NN N
conditions NNS N
had VBD N
higher JJR N
baseline-adjusted JJ N
body NN N
shame NN N
following VBG N
the DT N
threat NN N
compared VBN N
to TO N
the DT N
no-threat JJ N
condition; NN N
however RB N
no DT N
difference NN N
on IN N
baseline-adjusted JJ N
body NN N
shame NN N
between IN N
the DT N
threat NN N
conditions NNS N
was VBD N
found VBN N
. . N

The DT N
same JJ N
pattern NN N
of IN N
results NNS N
was VBD N
found VBN N
for IN N
cortisol NN I
- : N
both DT N
threat NN N
conditions NNS N
had VBD N
higher JJR N
baseline-adjusted JJ N
response NN N
cortisol NN N
than IN N
the DT N
no-threat JJ N
condition NN N
with IN N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
threat NN N
groups NNS N
. . N

Findings NNS N
suggest VBP N
that IN N
the DT N
magnitude NN N
of IN N
psychobiological JJ N
responses NNS N
to TO N
a DT N
social-evaluative JJ N
body NN N
image NN N
threat NN N
does VBZ N
not RB N
differ VB N
with IN N
the DT N
amount NN N
of IN N
social-evaluative JJ N
threat NN N
(individual- JJ N
versus NN N
group-threat) NN N
. . N

These DT N
findings NNS N
provide VBP N
insight RB N
into IN N
the DT N
context NN N
of IN N
body NN N
image NN N
threats NNS N
of IN N
women NNS P
. . P

-DOCSTART- -X- N

A DT N
comparative JJ N
study NN N
of IN N
ofloxacin NN I
and CC I
cefixime NN I
for IN N
treatment NN N
of IN N
typhoid JJ P
fever NN P
in IN P
children NNS P
. . P

The DT N
Dong NNP P
Nai NNP P
Pediatric NNP P
Center NNP P
Typhoid NNP N
Study NNP N
Group NNP N
. . N

BACKGROUND NNP N
Despite IN N
concerns NNS N
about IN N
safety NN N
in IN N
children NNS N
fluoroquinolone VBP I
antibiotics NNS I
have VBP N
become VBN N
the DT N
treatment NN N
of IN N
choice NN N
in IN N
patients NNS P
with IN P
multidrug-resistant JJ P
typhoid NN P
fever NN P
in IN P
Vietnam NNP P
. . P

However RB N
quinolone-resistant JJ N
strains NNS N
of IN N
Salmonella NNP N
typhi NN N
have VBP N
recently RB N
been VBN N
reported VBN N
from IN N
Vietnam; NNP N
and CC N
if IN N
quinolone JJ N
resistance NN N
becomes NNS N
established VBN N
alternative JJ N
oral JJ N
treatment NN N
options NNS N
will MD N
be VB N
needed VBN N
. . N

OBJECTIVE NNP N
Cefixime NNP I
an DT I
orally RB N
administered VBN N
third JJ I
generation NN I
cephalosporin NN I
was VBD I
compared VBN N
with IN N
ofloxacin NN I
for IN N
the DT N
treatment NN N
of IN N
uncomplicated JJ N
typhoid NN N
fever NN N
in IN N
children NNS N
. . N

METHODS NNP N
In IN N
an DT P
open JJ P
trial NN P
children NNS P
with IN P
suspected JJ P
typhoid NN P
fever NN P
were VBD P
randomized VBN N
to TO N
receive VB N
either DT N
ofloxacin JJ I
(10 NN N
mg/kg/day NN N
in IN N
two CD N
divided VBD N
doses) NN N
for IN N
5 CD N
days NNS N
or CC I
cefixime JJ I
(20 JJ N
mg/kg/day NN N
in IN N
two CD N
divided VBD N
doses) NN N
for IN N
7 CD N
days NNS N
. . N

RESULTS NNP N
S NNP N
. . N

typhi NN N
was VBD N
isolated VBN P
from IN P
82 CD P
patients NNS P
(44 VBP P
in IN P
the DT P
cefixime NN P
group NN P
38 CD P
in IN P
the DT P
ofloxacin NN P
group) NN P
and CC P
70 CD P
(85%) NN P
of IN P
the DT P
isolates NNS N
were VBD P
multidrug-resistant JJ P
. . P

Median JJ N
(95% NNP N
confidence NN N
interval NN N
range) NN N
fever NN O
clearance NN O
times NNS O
were VBD N
4.4 CD N
(4 NNS N
to TO N
5.2 CD N
0.2 CD N
to TO N
9.9) CD N
days NNS N
for IN N
ofloxacin JJ I
recipients NNS N
and CC N
8.5 CD N
(4.2 NN N
to TO N
9 CD N
1.8 CD N
to TO N
15.2) CD N
days NNS N
for IN N
cefixime-treated JJ P
patients NNS P
(P VBP N
< JJ N
0.0001) CD N
. . N

There EX N
were VBD N
11 CD N
treatment NN O
failures NNS O
(10 VBP N
acute NN N
and CC N
one CD N
relapse) NN N
in IN N
the DT N
cefixime NN I
group NN N
and CC N
1 CD N
acute NN O
treatment NN O
failure NN O
in IN N
the DT N
ofloxacin NN I
group NN N
(mean VBD N
difference NN N
22%; CD N
95% CD N
confidence NN N
interval NN N
9 CD N
to TO N
36%) CD N
. . N

CONCLUSION NNP N
Short NNP N
course NN N
treatment NN N
with IN N
cefixime NN I
may MD N
provide VB N
a DT N
useful JJ N
alternative JJ N
treatment NN N
in IN N
cases NNS N
of IN N
uncomplicated JJ P
typhoid NN P
fever NN P
in IN P
children NNS P
but CC P
it PRP N
is VBZ N
less RBR N
effective JJ N
than IN N
short JJ N
course NN N
treatment NN N
with IN N
ofloxacin NN I
. . I

-DOCSTART- -X- N

Injection NNP I
sclerotherapy NN I
versus NN I
electrocoagulation NN I
in IN N
the DT N
management NN N
outcome NN N
of IN N
early JJ P
haemorrhoids NNS P
. . P

OBJECTIVE NN N
To TO N
study VB N
the DT N
symptomatology NN N
of IN N
early JJ P
hemorrhoids NNS P
and CC N
to TO N
compare VB N
injection NN I
sclerotherapy NN I
(IS) NN I
with IN I
electrocoagulation NN I
(EC) NN I
in IN N
the DT N
management NN N
outcome NN N
of IN N
early JJ N
haemorrhoids NNS N
with IN N
respect NN N
to TO N
pain VB O
during IN N
the DT N
procedure NN N
reduction NN N
in IN N
bleeding VBG O
per IN N
rectum NN N
and CC N
overall JJ N
patient NN O
satisfaction NN O
score NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
102 CD P
patients NNS P
were VBD P
included VBN P
in IN P
this DT P
experimental JJ P
study NN P
at IN P
the DT P
POF NNP P
Hospital NNP P
Wah NNP P
Cantt NNP P
from IN P
October NNP P
2004 CD P
to TO P
June NNP P
2005 CD P
. . P

A DT N
detailed JJ N
history NN N
was VBD N
taken VBN N
and CC N
proctoscopic JJ N
examination NN N
was VBD N
performed VBN N
. . N

Patients NNS N
were VBD N
then RB N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
(Lottery JJ N
method) NN N
. . N

One CD N
group NN N
was VBD N
subjected VBN N
to TO N
EC NNP I
and CC N
the DT N
other JJ N
to TO N
IS NNP I
. . I

In IN N
the DT N
EC NNP N
using VBG N
the DT N
EC NNP N
machine NN N
(Wieda NNP N
China) NNP N
direct JJ I
current JJ I
of IN I
10-20 JJ I
mA NN I
was VBD N
applied VBN N
in IN N
the DT N
submucosal JJ N
plane NN N
of IN N
each DT N
pile NN N
core NN N
for IN N
5-7 JJ N
minutes NNS N
. . N

In IN N
the DT N
IS NNP N
1-2 JJ I
ml NN I
of IN I
5% CD I
phenol NN I
in IN I
almond NN I
oil NN I
was VBD N
injected VBN N
in IN N
the DT N
same JJ N
plane NN N
in IN N
each DT N
pile NN N
core NN N
. . N

Pain NN O
during IN O
the DT O
procedure NN O
reduction NN O
in IN O
bleeding VBG O
per IN O
rectum NN O
and CC N
overall JJ O
patient JJ O
satisfaction NN O
were VBD O
studied VBN N
as IN N
outcome JJ N
measures NNS N
. . N

RESULTS VB N
The DT P
mean JJ P
age NN P
of IN P
the DT P
patients NNS P
was VBD P
44 CD P
years NNS P
86 CD P
were VBD P
males NNS P
and CC P
16 CD P
were VBD P
females NNS P
. . P

Two CD P
thirds NNS P
of IN P
the DT P
patients NNS P
were VBD P
having VBG P
symptoms NNS P
for IN P
more JJR P
than IN P
6 CD P
months NNS P
. . P

A DT P
third JJ P
of IN P
patients NNS P
had VBD P
associated VBN P
local JJ P
pain NN P
while IN P
another DT P
third JJ P
had VBD P
associated VBN N
mucous JJ O
discharge NN O
. . O

Chronic JJ P
constipation NN P
was VBD P
present JJ P
in IN P
81% CD P
patients NNS P
. . P

Only RB N
24.5% CD P
of IN P
the DT P
patients NNS P
had VBD P
a DT P
positive JJ P
family NN P
history NN P
of IN P
haemorrhoids NNS P
. . P

Patients NNS N
in IN N
the DT N
electrocoagulation NN I
(EC) NNP I
group NN N
experienced VBD N
more JJR N
pain NN O
during IN N
the DT N
procedure NN N
than IN N
the DT N
injection NN I
sclerotherapy NN I
(IS) NNP I
group NN N
(P NNP N
< VBZ N
0.000) CD N
but CC N
EC NNP N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
IS NNP N
in IN N
terms NNS N
of IN N
reducing VBG N
the DT N
bleeding NN O
per IN N
rectum NN N
(P NN N
= $ N
0.039) CD N
and CC N
also RB N
significantly RB N
higher JJR N
number NN N
of IN N
patients NNS N
were VBD N
fully RB N
satisfied VBN O
with IN N
EC NNP I
than IN N
with IN N
IS NNP I
(P NNP N
< NNP N
0.04) CD N
. . N

CONCLUSION NNP N
EC NNP I
although IN I
more JJR N
painful JJ O
is VBZ O
a DT N
safe JJ O
more RBR O
effective JJ O
and CC N
a DT N
highly RB O
satisfying JJ O
procedure NN N
for IN N
treating VBG N
early JJ N
hemorrhoids NNS N
. . N

-DOCSTART- -X- N

Effectiveness NN N
of IN N
two CD I
quadruple JJ I
tetracycline- JJ I
or CC I
clarithromycin-containing JJ I
second-line JJ I
Helicobacter NNP P
pylori NN P
eradication NN O
therapies NNS O
. . O

BACKGROUND IN N
There EX N
are VBP N
no DT N
guidelines NNS N
on IN N
second-line JJ N
therapies NNS N
for IN N
Helicobacter NNP N
pylori FW N
eradication NN N
failures NNS N
of IN N
omeprazole-clarithromycin-amoxicillin JJ N
triple JJ N
therapy NN N
. . N

AIM NNP N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
two CD N
second-line JJ N
therapies NNS N
for IN N
persistent JJ N
H NNP N
. . N

pylori JJ N
infection NN N
. . N

METHODS NNP N
Over IN P
a DT P
6-year JJ P
period NN P
patients NNS P
with IN P
persistent JJ P
H NNP P
. . P

pylori JJ P
infection NN P
following VBG P
omeprazole-clarithromycin-amoxicillin JJ P
eradication NN P
therapy NN P
were VBD P
randomized VBN P
to TO I
receive VB I
omeprazole JJ I
20 CD I
mg JJ I
twice RB I
daily RB I
bismuth VBZ I
120 CD I
mg NN I
four CD I
times NNS I
daily JJ I
metronidazole VBD I
500 CD I
mg JJ I
twice RB I
daily RB I
and CC I
either RB I
tetracycline VB I
500 CD I
mg RB I
four CD I
times NNS I
daily RB I
or CC I
clarithromycin VB I
500 CD I
mg JJ I
twice RB I
daily RB I
given VBN I
for IN I
7 CD I
days NNS I
. . I

Before IN I
therapy NN I
patients NNS P
underwent JJ P
endoscopy NN P
with IN P
biopsies NNS P
for IN P
histology NN P
culture NN P
and CC P
antibiotic JJ P
susceptibility NN P
tests NNS P
. . P

H NNP P
. . P

pylori JJ P
infection NN P
was VBD P
confirmed VBN P
by IN P
histology NN P
. . P

RESULTS NN N
Of IN N
the DT N
95 CD P
randomized VBD P
patients NNS P
88 CD P
(93%) NNP P
completed VBD P
the DT P
study NN P
. . P

Age NNP N
sex NN N
smoking VBG N
ulcer/non-ulcer JJ N
dyspepsia NN N
ratio NN N
and CC N
antibiotic JJ N
resistance NN N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
treatment NN N
groups NNS N
. . N

On IN N
intention-to-treat JJ N
analysis NN N
eradication NN O
was VBD N
achieved VBN N
in IN N
41 CD N
of IN N
the DT N
49 CD N
patients NNS N
(84%; JJ N
95% CD N
confidence NN N
interval JJ N
70.4-92.7%) JJ N
and CC N
27 CD N
of IN N
the DT N
46 CD N
patients NNS N
(59%; JJ N
95% CD N
confidence NN N
interval JJ N
43.3-73.0%) CD N
of IN N
the DT N
tetracycline- JJ N
and CC N
clarithromycin-containing JJ N
groups NNS N
respectively RB N
(P=0.007) VBP N
. . N

On IN N
multivariate JJ N
regression NN N
analysis NN N
the DT N
sensitivity NN O
of IN O
H NNP O
. . O

pylori NN O
to TO O
metronidazole VB O
had VBD N
a DT N
likelihood NN N
ratio NN N
of IN N
5.2 CD N
(P=0.022) NN N
followed VBN N
by IN N
the DT N
type NN N
of IN N
quadruple JJ N
therapy NN N
(likelihood NN N
ratio NN N
4.4; CD N
P=0.036) NNP N
. . N

CONCLUSIONS NNP N
Tetracycline-containing NNP I
quadruple NN I
rescue NN I
therapy NN I
is VBZ N
highly RB N
effective JJ N
in IN N
treating VBG N
H NNP N
. . N

pylori JJ N
eradication NN N
failures NNS N
of IN N
the DT N
omeprazole-amoxicillin-clarithromycin JJ N
regimen NNS N
. . N

-DOCSTART- -X- N

Bronchodilatory JJ O
responses NNS O
to TO N
formoterol VB I
ipratropium NN I
and CC I
their PRP$ I
combination NN I
in IN N
patients NNS P
with IN P
stable JJ P
COPD NNP P
. . P

We PRP N
studied VBD N
27 CD P
patients NNS P
with IN P
stable JJ P
chronic JJ P
obstuctive JJ P
pulmonary JJ P
disease NN P
(COPD) NNP P
in IN N
a DT N
randomised JJ N
single-blind JJ N
within-patient JJ N
placebo-controlled JJ I
clinical JJ N
study NN N
. . N

Each DT N
patient NN N
was VBD N
assigned VBN N
on IN N
six CD N
separate JJ N
days NNS N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
drug NN I
regimens NNS N
in IN N
random NN N
order: IN N
A NNP N
. . N

40 CD N
micrograms NNS N
ipratropium JJ I
bromide JJ I
(Atrovent NN I
MDI NNP I
20 CD I
micrograms/puff) NN N
plus CC N
2 CD N
puffs NNS N
placebo; JJ I
B NNP N
. . N

12 CD N
micrograms NNS N
formoterol VBP I
fumarate JJ I
(Foradil NNP I
MDI NNP I
12 CD I
micrograms/puff) NN N
plus CC N
3 CD N
puffs NNS N
placebo; JJ I
C NNP N
. . N

80 CD I
micrograms NNS I
ipratropium; JJ I
D NNP I
. . I

24 CD I
micrograms NNS I
formoterol JJ I
plus CC I
2 CD I
puffs NNS I
placebo; JJ I
E NNP I
. . I

12 CD I
micrograms NNS I
formoterol JJ I
plus CC I
40 CD I
micrograms NNS I
ipratropium JJ I
plus CC I
1 CD I
puff NN I
placebo; NN I
F NNP N
. . N

4 CD N
puffs NNS N
placebo NN I
. . I

On IN N
each DT N
study NN N
day NN N
spirometric JJ O
indices NNS O
and CC O
vital JJ O
signs NNS O
were VBD N
measured VBN N
at IN N
5 CD N
10 CD N
15 CD N
and CC N
60 CD N
minutes NNS N
and CC N
hourly RB N
thereafter RB N
up IN N
to TO N
and CC N
including VBG N
12 CD N
hours NNS N
after IN N
study JJ N
drug NN I
administration NN N
. . N

Mean NNP O
peak NN O
FEV1 NNP O
change NN O
(primary NNP N
endpoint) NN N
was VBD N
maximum JJ N
with IN N
the DT N
administration NN N
of IN N
the DT N
combination NN N
of IN N
ipratropium NN I
and CC I
formoterol NN I
(335.2 NNP N
ml NN N
SE NNP N
24.6) CD N
and CC N
it PRP N
differed VBD N
significantly RB N
from IN N
the DT N
observed JJ N
peak NN N
changes NNS N
following VBG N
single JJ N
administration NN N
of IN N
the DT N
two CD N
tested VBD N
doses NNS N
of IN N
ipratropium NN I
(p NNP N
< VBZ N
0.05 CD N
and CC N
p VB N
< JJ N
0.05 CD N
respectively) NN N
. . N

Safety NN N
and CC N
tolerability NN N
were VBD N
satisfactory JJ N
throughout IN N
the DT N
study NN N
. . N

-DOCSTART- -X- N

Milk NNP N
protein NN N
quantity NN N
and CC N
quality NN N
in IN N
low-birth-weight JJ P
infants NNS P
. . P

IV NNP N
. . N

Effects NNS N
on IN N
tyrosine NN I
and CC I
phenylalanine NN I
in IN N
plasma NN N
and CC N
urine NN N
. . N

Well RB P
appropriate-for-gestational JJ P
age NN P
low-birth-weight JJ P
infants NNS P
were VBD P
divided VBN P
into IN P
three CD P
gestational JJ P
age NN P
groups NNS P
and CC P
assigned VBD P
randomly RB P
within IN P
each DT P
age NN P
group NN N
to TO N
one CD N
of IN N
five CD I
feeding VBG I
regimens: NN I
pooled VBD I
human JJ I
milk NN I
(BM); NNP I
formula NN I
1 CD I
(F1) NNP I
= VBD I
1.5 CD I
gm/dl NN I
protein NN I
60 CD I
parts NNS I
bovine NN I
whey VBP I
proteins: $ I
40 CD I
parts NNS I
bovine NN I
caseins; NN I
F2 NNP I
= VBZ I
3.0 CD I
gm/dl NN I
60:40; CD I
F3 NNP I
= VBD I
1.5 CD I
gm/dl NN I
18:82; CD I
F4 NNP I
= VBD I
3.0 CD I
gm/dl NN I
18:82 CD I
. . I

Plasma NNP O
and CC O
urine JJ O
concentrations NNS O
of IN O
tyrosine NN O
and CC O
phenylalanine NN O
were VBD N
far RB N
higher JJR N
in IN N
the DT N
infants NNS N
fed VBP N
F1 NNP I
to TO I
F4 NNP I
especially RB I
F2 NNP I
and CC N
F4 NNP I
than IN I
in IN N
the DT N
infants NNS N
fed VBN N
BM NNP I
. . I

These DT N
findings NNS N
offer VBP N
further JJ N
evidence NN N
for IN N
the DT N
limited JJ N
capacity NN N
of IN N
the DT N
low-birth-weight JJ N
infant NN N
to TO N
catabolize VB N
tyrosine NN N
. . N

Infants NNS N
fed VBN N
F3 NNP I
had VBD N
significantly RB N
higher JJR N
plasma JJ O
tyrosine NN O
concentrations NNS O
than IN N
infants NNS N
fed VBN N
F1 NNP I
and CC I
those DT N
fed VBN N
F4 NNP I
had VBD N
higher JJR N
concentrations NNS N
than IN N
those DT N
fed JJ N
F2 NNP I
. . I

Thus RB N
increased VBN N
plasma NN O
tyrosine NN O
concentrations NNS O
in IN N
low-birth-weight JJ N
infants NNS N
are VBP N
related VBN N
directly RB N
both DT N
to TO N
the DT N
quantity NN N
and CC N
to TO N
the DT N
quality NN N
of IN N
the DT N
protein NN N
in IN N
their PRP$ N
diets NNS N
. . N

-DOCSTART- -X- N

Inclusion NN N
of IN N
anti-phospholipase JJ I
A2 NNP I
antibody NN I
to TO I
backgrounding VBG I
diets NNS I
on IN N
performance NN N
feed NN N
efficiency NN N
in IN N
vitro JJ N
fermentation NN N
and CC N
the DT N
acute-phase JJ N
response NN N
of IN N
growing VBG P
beef NN P
calves NNS P
. . P

In IN P
Exp NNP N
. . N

1 CD N
individual JJ N
performance NN N
and CC N
daily JJ N
DMI NNP N
was VBD N
measured VBN N
on IN N
70 CD P
crossbred JJ P
weaned VBD P
calves NNS P
during IN P
a DT P
70-d JJ P
period NN P
using VBG P
a DT P
GrowSafe NNP P
system NN P
(GrowSafe JJ P
Systems NNPS P
Ltd NNP P
. . P

Airdrie NNP P
AB NNP P
Canada) NNP P
at IN P
the DT P
University NNP P
of IN P
Florida NNP P
North NNP P
Florida NNP P
Research NNP P
and CC P
Education NNP P
Center NNP P
Feed NNP P
Efficiency NNP P
Facility NNP P
(FEF) NNP P
. . P

Calves NNS N
were VBD N
fed VBN N
a DT N
low-concentrate JJ I
(LC) NN I
growing VBG I
diet JJ I
blocked VBN I
by IN N
weight NN N
and CC N
sex NN N
and CC N
then RB N
randomly RB N
assigned VBN N
to TO N
pens NNS N
to TO N
receive VB N
either RB I
no DT I
additional JJ I
supplement NN I
(CON; NNP I
n VBZ I
= $ I
35) CD I
or CC I
receive VB I
a DT I
supplement NN I
of IN I
anti-phospholipase JJ I
A2 NNP I
antibody NN I
(aPLA2) NN I
at IN N
an DT N
inclusion NN N
rate NN N
of IN N
0.6% CD N
of IN N
the DT N
diet JJ N
DM NNP N
(n NNP N
= VBD N
35) CD N
. . N

After IN N
the DT N
70-d JJ N
feed NN N
efficiency NN N
(FE) NNP N
trial NN N
(Phase NN N
1) CD N
calves NNS N
were VBD N
loaded VBN I
into IN I
a DT I
commercial JJ I
livestock NN I
trailer NN I
and CC I
were VBD I
driven VBN I
for IN I
approximately RB I
1 CD I
600 CD I
km NN I
during IN N
24 CD N
h NNS N
. . N

Upon IN N
return NN N
to TO N
the DT N
FEF NNP N
(Phase NNP N
2) CD N
calves NNS N
were VBD N
relocated VBN I
to TO I
the DT I
same JJ I
pens NNS I
and CC I
groups NNS I
and CC I
received VBD I
the DT I
same JJ I
diets NNS I
and CC I
treatments NNS I
for IN I
28 CD I
d NN I
. . I

Blood NN N
samples NNS N
from IN N
each DT N
calf NN N
were VBD N
collected VBN N
on IN N
d NN N
0 CD N
1 CD N
3 CD N
5 CD N
7 CD N
14 CD N
21 CD N
and CC N
28 CD N
relative NN N
to TO N
initiation NN N
of IN N
transportation NN N
and CC N
were VBD N
analyzed VBN N
for IN N
determination NN N
of IN N
concentrations NNS N
of IN N
plasma NN N
ceruloplasmin NN N
and CC N
haptoglobin NN N
. . N

In IN N
Phase NNP N
1 CD N
initial JJ N
BW NNP N
(242.0 NNP N
 VBD N
3.7 CD N
kg; NN N
P NNP N
= VBZ N
0.92) CD N
BW NNP N
at IN N
d NN N
70 CD N
(313.0 NNP N
 VBD N
4.1 CD N
kg; NN N
P NNP N
= VBZ N
0.79) CD N
and CC N
ADG NNP N
(1.01 NNP N
 VBD N
0.02 CD N
kg; NN N
P NNP N
= $ N
0.95) CD N
were VBD N
similar JJ N
between IN N
treatments NNS N
. . N

However RB O
daily JJ O
DMI NNP O
was VBD N
greater JJR N
(P JJ N
= NN N
0.01) CD N
for IN N
CON NNP N
(9.18 NNP N
 VBD N
0.15 CD N
kg) NN N
than IN N
aPLA2 JJ N
(8.53 NNP N
 NNP N
0.15 CD N
kg) NN N
. . N

In IN N
addition NN O
residual JJ O
feed NN O
intake NN O
was VBD N
greater JJR N
(P JJ N
= NN N
0.002) CD N
for IN N
CON NNP N
(0.389 NNP N
 VBD N
0.110 CD N
kg/d) NN I
than IN I
aPLA2 JJ N
calves NNS N
(-0.272 JJ N
 JJ N
0.110 CD N
kg/d) NN N
. . N

In IN N
Phase NNP N
2 CD N
after IN N
transportation NN N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
treatments NNS O
on IN O
BW NNP O
loss NN N
due JJ N
to TO N
transportation NN N
shrink VB N
(26.0 NNP N
 NNP N
0.6 CD N
kg; NN N
P NNP N
= VBZ N
0.86) CD N
BW NNP N
at IN N
d NN N
28 CD N
(339.0 NNP N
 VBD N
4.1 CD N
kg; NN N
P NNP N
= VBZ N
0.72) CD N
ADG NNP N
(1.28 NNP N
 VBD N
0.03 CD N
kg/d; NN N
P NNP N
= VBZ N
0.72) CD N
G:F NNP N
(0.164 NNP N
 VBD N
0.004; CD N
P NNP N
= VBD N
0.83) CD N
and CC N
concentrations NNS N
of IN N
plasma NN N
haptoglobin NN N
(0.08 NNP N
 VBZ N
0.02 CD N
mg/mL; NN N
P NNP N
= VBZ N
0.41) CD O
. . O

However RB O
concentrations NNS O
of IN O
plasma NN O
ceruloplasmin NN O
were VBD N
greater JJR N
(P JJ N
< NN N
0.001) CD N
for IN N
CON NNP N
calves NNS N
(14.3 VBP N
 $ N
0.3 CD N
mg/dL) NN N
compared VBN N
to TO N
aPLA2 VB N
calves NNS N
(13.0 NNP N
 VBD N
0.3 CD N
mg/dL) NN N
. . N

In IN N
Exp NNP N
. . N

2 CD N
the DT N
effects NNS N
of IN N
aPLA2 JJ N
inclusion NN N
on IN N
LC NNP N
and CC N
high-concentrate JJ N
(HC) NN N
substrates NNS O
on IN O
in IN O
vitro JJ O
fermentation NN O
parameters NNS N
were VBD N
assessed VBN N
. . I

Addition NN I
of IN N
aPLA2 NN N
had VBD N
no DT O
effects NNS O
on IN O
in IN O
vitro JJ O
fermentation NN O
parameters NNS N
of IN N
LC NNP N
and CC N
HC NNP N
substrates NNS N
. . N

In IN N
conclusion NN N
supplementation NN I
of IN N
aPLA2 NN N
improved VBN N
FE NNP N
of IN N
growing VBG N
beef NN N
calves NNS N
when WRB N
fed VBN N
LC NNP N
diets NNS N
in IN N
Phase NNP N
1 CD N
and CC N
addition NN N
of IN N
aPLA2 NN N
had VBD N
no DT N
effect NN N
on IN N
fermentation NN N
parameters NNS N
of IN N
LC NNP N
and CC N
HC NNP N
substrates NNS N
. . N

In IN N
addition NN N
calves NNS N
supplemented VBD I
with IN N
aPLA2 NN N
had VBD N
reduced VBN N
concentrations NNS N
of IN N
plasma NN N
ceruloplasmin NN N
after IN N
24 CD N
h NN N
of IN N
transportation NN N
. . N

-DOCSTART- -X- N

Neuroendocrine NNP O
effects NNS O
of IN N
sumatriptan NN I
. . I

The DT N
neuroendocrine JJ N
effects NNS N
of IN N
the DT N
5-HT JJ N
receptor NN N
agonist NN N
sumatriptan NN I
(6 NNP I
mg NN I
subcutaneously) NN I
were VBD N
studied VBN N
in IN N
11 CD P
healthy JJ P
male NN P
subjects NNS P
using VBG P
a DT P
placebo-controlled JJ P
cross-over NN P
design NN P
. . P

Compared VBN N
to TO N
placebo VB I
sumatriptan JJ I
significantly RB N
lowered VBN N
levels NNS O
of IN O
plasma NN O
prolactin NN O
but CC N
increased VBD N
those DT N
of IN N
plasma JJ O
growth NN O
hormone NN O
. . O

There EX N
was VBD N
no DT N
effect NN N
on IN N
plasma NN O
cortisol NN O
concentrations NNS O
. . O

The DT N
neuroendocrine JJ N
effects NNS N
of IN N
sumatriptan JJ I
differ NN N
from IN N
those DT N
of IN N
previously RB N
described VBN N
5-HT-receptor JJ N
agonists NNS N
and CC N
may MD N
be VB N
a DT N
consequence NN N
of IN N
selective JJ N
activation NN N
of IN N
5-HT1D JJ N
or CC N
5-HT1B JJ N
receptors NNS N
. . N

However RB N
the DT N
present JJ N
data NNS N
cannot NN N
exclude VBP N
the DT N
possibility NN N
that IN N
the DT N
neuroendocrine JJ N
changes NNS N
reflect VBP N
nonspecific JJ N
stress NN N
responses NNS N
or CC N
changes NNS N
in IN N
pituitary JJ N
blood NN N
flow NN N
. . N

-DOCSTART- -X- N

Evaluation NN N
of IN N
a DT N
new JJ N
wound NN N
closure NN N
device NN N
for IN N
linear JJ N
surgical JJ N
incisions: NN N
3M CD I
Steri-Strip JJ I
S NNP I
Surgical NNP I
Skin NNP I
Closure NNP I
versus IN I
subcuticular JJ I
closure NN I
. . I

BACKGROUND NNP I
Technological NNP N
innovations NNS N
are VBP N
often RB N
adopted VBN N
before IN N
scientific JJ N
comparison NN N
to TO N
an DT N
accepted JJ N
standard NN N
. . N

The DT N
authors' NN N
study NN N
compared VBN N
suture NN I
with IN I
a DT I
new JJ I
coaptive JJ I
film NN I
device NN I
3M CD I
Steri-Strip JJ I
S NNP I
Surgical NNP I
Skin NNP I
Closure NNP I
on IN I
linear JJ I
incisions NNS I
. . I

METHODS NNP N
Patients NNPS P
undergoing VBG P
Wise-pattern JJ P
breast NN P
reduction NN P
or CC P
abdominal JJ P
procedures NNS P
had VBD N
paired VBN N
incisions NNS N
randomly RB N
assigned VBN N
to TO N
Steri-Strip NNP I
S NNP I
or CC I
suture JJ I
closure NN I
. . I

Key NNP N
outcome NN N
measures NNS N
were VBD N
closure JJ N
time NN N
patient JJ N
comfort NN N
and CC N
scar NN N
quality NN N
at IN N
6 CD N
months NNS N
by IN N
patients NNS N
and CC N
surgeons NNS N
using VBG N
a DT N
new JJ I
scar NN I
evaluation NN I
tool NN I
visual JJ I
assessment NN N
of IN N
linear JJ N
scars NNS P
. . P

Statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
closure NN N
techniques NNS N
were VBD N
assessed VBN N
by IN N
Wilcoxon NNP N
signed VBD N
rank JJ N
test NN N
. . N

RESULTS NNP N
Of IN P
59 CD P
patients NNS P
eight CD P
were VBD P
excluded VBN P
from IN P
randomization NN P
(a NNP N
surgeon NN N
judged VBD N
Steri-Strip NNP I
S NNP I
to TO N
be VB N
a DT N
nonviable JJ N
closure NN N
technique NN N
for IN N
mismatched VBN N
wound NN N
edges) NN N
. . N

Fifty-one CD P
patients NNS P
(breast JJ P
n JJ P
= NN P
24; CD P
abdomen NNS P
n JJ P
= VBP P
27) CD P
were VBD N
randomized VBN N
. . N

Operative JJ O
time NN O
with IN N
Steri-Strip NNP I
S NNP I
for IN I
breast NN I
was VBD N
2.0 CD N
minutes NNS N
(SD VBP N
= $ N
1.1) CD N
versus NN N
suture NN I
closure NN I
at IN N
4.6 CD N
minutes NNS N
(SD VBP N
= $ N
1.5; CD N
p NN N
< VBD N
0.001) CD N
. . N

Similarly RB N
Steri-Strip NNP N
S NNP N
versus NN N
suture NN N
for IN N
the DT N
abdomen NNS N
was VBD N
faster RBR N
(p JJ N
< NNP N
0.001; CD N
4.9 CD N
minutes NNS N
SD NNP N
= VBD N
2.3 CD N
versus NN N
10.1 CD N
minutes NNS N
SD NNP N
= VBD N
3.4) CD N
. . N

Comfort NN O
scores NNS O
did VBD N
not RB N
differ VB N
between IN N
closures NNS N
[5.8 NNP N
(SD NNP N
= VBD N
2.7) CD N
versus NN N
6.9 CD N
(SD NNP N
= VBD N
2.0) CD N
respectively RB N
on IN N
breast NN N
(p NNP N
= VBZ N
0.142) CD N
and CC N
7.7 CD N
(SD NNS N
= VBD N
1.8) CD N
versus NN N
7.7 CD N
(SD NNP N
= VBD N
2.3) CD N
on IN N
abdomen NNS N
(p NNP N
= VBD N
0.903)] CD N
. . N

Complication NN O
rates NNS O
did VBD N
not RB N
differ VB N
between IN N
closure NN N
types NNS N
. . N

Patients' NNP O
visual JJ O
assessment NN O
of IN O
linear JJ O
scars NNS O
rating NN O
of IN O
breasts NNS O
was VBD N
3.8 CD N
(SD NNP N
= VBD N
2.9) CD N
for IN N
Steri-Strip NNP I
S NNP I
and CC N
better JJR N
at IN N
2.6 CD N
(SD JJ N
= $ N
2.9) CD N
for IN N
suture NN N
(p NNP N
= VBZ N
0.008) CD N
. . N

One CD N
surgeon NN N
rated VBN N
breast IN N
Steri-Strip NNP I
S NNP I
scars VBZ N
worse JJR N
than IN N
suture NN I
scars NNS N
(4.3 VBP N
versus IN N
3.7; CD N
p NN N
= VBD N
0.014) CD N
. . N

For IN N
abdominal JJ N
scars NNS N
there EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
patient NN N
or CC N
surgeon NN N
ratings NNS N
. . N

CONCLUSIONS NNP N
Steri-Strip NNP I
S NNP I
permits VBZ N
faster JJR N
wound IN O
closure NN O
than IN N
suture NN I
. . I

On IN N
the DT N
basis NN N
of IN N
patient JJ N
reports NNS N
of IN N
comfort NN N
and CC N
scar NN N
quality NN N
surgeons NNS N
increase VBP N
efficiency NN O
and CC N
maintain VBP N
quality NN O
with IN N
the DT N
use NN N
of IN N
Steri-Strip NNP I
S NNP I
on IN N
abdominal JJ N
wounds NNS N
but CC N
not RB N
on IN N
breast NN N
wounds NNS N
. . N

-DOCSTART- -X- N

Randomized NNP N
comparison NN N
of IN N
the DT N
efficacy NN O
and CC O
safety NN O
of IN N
zotarolimus-eluting JJ I
stents NNS I
vs NN I
. . I

sirolimus-eluting JJ I
stents NNS I
for IN N
percutaneous JJ P
coronary JJ P
intervention NN P
in IN P
chronic JJ P
total JJ P
occlusion--CAtholic JJ P
Total NNP P
Occlusion NNP N
Study NNP P
(CATOS) NNP P
trial NN P
. . P

BACKGROUND NNP N
Limited NNP N
data NNS N
are VBP N
available JJ N
regarding VBG N
the DT N
direct JJ N
comparison NN N
of IN N
angiographic JJ N
and CC N
clinical JJ N
outcomes NNS N
after IN N
percutaneous JJ I
coronary JJ I
intervention NN I
(PCI) NN I
with IN I
drug-eluting JJ I
stents NNS I
(DESs) VBP I
for IN N
chronic JJ P
total JJ P
occlusion NN P
(CTO) NN P
. . P

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
prospective JJ N
randomized VBN N
multicenter NN N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
non-inferiority NN N
of IN N
a DT N
zotarolimus-eluting JJ I
stent NN I
(ZES; NNP I
Endeavor NNP I
Sprint NNP I
n=80) NN N
to TO N
a DT I
sirolimus-eluting JJ I
stent NN I
(SES; NNP I
Cypher NNP I
n=80) NN N
in IN P
patients NNS P
with IN P
CTO NNP P
lesion NN P
with IN P
a DT P
reference NN P
vessel NN P
diameter NN P
 VBD I
2.5mm CD P
. . N

The DT N
primary JJ N
endpoint NN N
was VBD O
in-segment JJ O
binary JJ O
restenosis NN O
rate NN O
at IN N
9-month JJ N
angiographic JJ N
follow-up NN N
. . N

Key NNP N
secondary JJ N
endpoints NNS N
included VBD O
target NN O
vessel NN O
failure NN O
(TVF; NNP O
including VBG O
cardiac JJ O
death NN O
myocardial JJ O
infarction NN O
and CC O
target NN O
vessel NN O
revascularization) NN O
and CC N
Academic NNP N
Research NNP N
Consortium-defined NNP N
definite/probable JJ O
stent NN O
thrombosis NN O
(ST) NNP O
within IN N
12 CD N
months NNS N
. . N

The DT N
ZES NNP N
was VBD N
non-inferior JJ N
to TO N
the DT N
SES NNP N
with IN N
respect NN N
to TO N
the DT N
primary JJ N
endpoint NN N
which WDT N
occurred VBD N
in IN N
14.1% CD N
(95% JJ N
confidence NN N
interval JJ N
[CI]: JJ N
6.0-22.2) JJ N
and CC N
in IN N
13.7% CD N
(95%CI: JJ N
5.8-21.6) CD N
of IN N
patients NNS N
respectively RB N
(non-inferiority JJ N
margin NN N
15.0%; CD N
P NNP N
for IN N
non-inferiority JJ N
<0.001) NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
between-group JJ N
differences NNS N
in IN N
the DT N
rate NN O
of IN O
TVF NNP N
(10.0% NNP N
vs NN N
. . N

17.5%; CD N
P=0.168) NNP N
nor CC N
in IN N
the DT N
rate NN N
of IN N
ST NNP N
(0.0% NNP N
vs NN N
. . N

1.3%; CD N
P=0.316) NNP N
during IN N
the DT N
12-month JJ N
clinical JJ N
follow-up NN N
. . N

CONCLUSIONS NNP N
The DT N
effectiveness NN N
and CC N
safety NN I
of IN I
ZES NNP N
are VBP N
similar JJ N
to TO N
those DT I
of IN I
SES NNP N
and CC N
therefore VB N
it PRP N
is VBZ N
a DT N
good JJ N
treatment NN N
option NN P
in IN P
patients NNS P
undergoing VBG P
PCI NNP P
for IN P
CTO NNP P
with IN P
DESs NNP P
. . N

-DOCSTART- -X- N

Combination NNP N
hydrocodone NN I
and CC I
ibuprofen JJ I
versus NN I
combination NN I
codeine NN I
and CC I
acetaminophen NN I
for IN N
the DT N
treatment NN P
of IN P
chronic JJ P
pain NN P
. . P

OBJECTIVE IN P
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
combination NN I
hydrocodone NN I
7.5 CD I
mg NN I
and CC I
ibuprofen $ I
200 CD I
mg NN I
with IN N
that DT N
of IN N
combination NN I
codeine NN I
30 CD I
mg NN I
and CC I
acetaminophen $ I
300 CD I
mg NN I
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
pain NN N
. . N

BACKGROUND NNP N
Hydrocodone NNP I
7.5 CD N
mg NN N
with IN I
ibuprofen JJ I
200 CD N
mg NN N
is VBZ N
the DT N
only JJ N
approved VBD N
fixed-dose JJ N
combination NN N
analgesic IN N
containing VBG N
an DT N
opioid NN N
and CC N
ibuprofen NN N
. . N

METHODS NNP N
In IN N
this DT N
randomized JJ N
parallel-group JJ N
double-blind JJ N
repeated-dose JJ N
active-comparator JJ N
4-week JJ N
multicenter NN N
study NN N
469 CD P
patients NNS P
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
1-tablet JJ I
(n NN I
= VBZ I
156) CD I
or CC I
2-tablet JJ I
(n NN I
= $ I
153) CD I
dose NN I
of IN I
combination NN I
hydrocodone NN I
7.5 CD I
mg NN I
and CC I
ibuprofen $ I
200 CD I
mg NN I
(HI1 NN I
and CC N
HI2 NNP I
respectively) NN I
or CC N
a DT N
2-tablet JJ I
dose NN I
of IN I
combination NN I
codeine NN I
30 CD I
mg NN I
and CC I
acetaminophen $ I
300 CD I
mg NN I
(CA NNP I
n VBZ I
= $ N
160) CD N
the DT N
active JJ N
comparator NN N
every DT N
6 CD N
to TO N
8 CD N
hours NNS N
as IN N
needed VBN N
for IN N
pain NN N
. . N

Efficacy NN N
was VBD N
measured VBN N
through IN N
pain NN N
relief NN N
scores VBZ N
number NN N
of IN N
daily JJ N
doses NNS N
of IN N
study NN N
medication NN N
number NN N
of IN N
daily JJ N
doses NNS N
of IN N
supplemental JJ N
analgesics NNS N
number NN N
of IN N
patients NNS N
who WP N
discontinued VBD N
therapy NN N
due JJ N
to TO N
an DT N
unsatisfactory JJ N
analgesic JJ O
response NN N
and CC N
global JJ N
assessment NN N
scores NNS N
. . N

RESULTS NN N
Of IN N
the DT N
469 CD P
patients NNS P
255 CD P
(54.4%) NNS P
were VBD P
female JJ P
and CC P
214 CD P
(45.6%) NNS P
were VBD P
male JJ P
. . P

The DT N
mean JJ P
age NN P
was VBD P
51.1 CD P
years NNS P
. . P

Types NNS P
of IN P
chronic NN P
pain NN P
included VBD P
back RB P
(214; JJ P
45.6%) CD P
arthritic JJ P
(145; NN P
30.9%) CD P
other JJ P
musculoskeletal JJ P
(65; $ P
13.9%) CD P
cancer NN P
(6; VBD P
1.3%) CD P
diabetic JJ P
neuropathic JJ P
(3; $ P
0.6%) CD P
postherpetic JJ P
neuralgic JJ P
(5; NN P
1.1%) CD P
other JJ P
neurologic JJ P
(21; $ P
4.5%) CD P
and CC N
other JJ N
unclassified JJ N
chronic JJ N
pain NN N
(10; VBD N
2.1%) CD N
. . N

During IN N
the DT N
48 CD N
hours NNS N
prior RB N
to TO N
the DT N
study NN N
351 CD N
(74.8%) NN N
patients NNS N
had VBD N
been VBN N
treated VBN N
with IN N
opioid JJ N
or CC N
opioid-nonopioid JJ N
combination NN N
analgesics NNS N
. . N

The DT N
overall JJ N
mean JJ N
daily JJ O
pain NN O
relief NN O
score NN O
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
HI2 NNP N
group NN N
(2.25+/-0.89) CD N
than IN N
in IN N
the DT N
HI1 NNP I
group NN N
(1.98+/-0.87) NNP N
(P NNP N
= VBZ N
0.003) CD N
or CC N
the DT N
CA NNP I
group NN N
(1.85+/-0.96) NNP N
(P NNP N
< NNP N
0.001) CD N
. . N

The DT N
overall JJ N
mean JJ N
number NN O
of IN O
daily JJ O
doses NNS O
of IN O
study NN O
medication NN O
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP I
group NN N
(2.94+/-0.99) CD N
than IN N
in IN N
the DT N
HI1 NNP I
group NN N
(3.23+/-0.76) NNP N
(P NNP N
= VBZ N
0.036) CD N
or CC N
the DT N
CA NNP I
group NN N
(3.26+/-0.75) NNP N
(P NNP N
= NNP N
0.014) CD N
. . N

The DT N
overall JJ N
mean JJ N
number NN O
of IN O
daily JJ O
doses NNS O
of IN O
supplemental JJ O
analgesics NNS O
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP N
group NN N
(0.24+/-0.49) CD N
than IN N
in IN N
the DT N
HI1 NNP I
group NN N
(0.34+/-0.58) NNP N
(P NNP N
= VBZ N
0.021) CD N
or CC N
CA NNP I
group NN N
(0.49+/-0.85) NNP N
(P NNP N
= NNP N
0.010) CD N
. . N

The DT N
number NN N
of IN N
patients NNS N
who WP N
discontinued VBD N
treatment NN N
due JJ N
to TO N
an DT N
unsatisfactory JJ N
analgesic JJ N
response NN N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP I
group NN N
(2; VBD N
1.3%) CD N
than IN N
in IN N
the DT N
CA NNP I
group NN N
(12; VBD N
7.5%) CD N
(P NNP N
= VBD N
0.008) CD N
. . N

HI2 NNP I
was VBD N
more RBR N
effective JJ N
than IN N
HI1 NNP I
and CC N
CA NNP I
as IN N
measured VBN N
by IN N
pain NN N
relief NN N
scores NNS N
for IN N
week NN N
1 CD N
(P NN N
< VBD N
0.001 CD N
vs NN N
HI1 NNP I
and CC N
CA) NNP I
week NN N
2 CD N
(P NN N
< VBD N
0.001 CD N
vs NN N
HI1 NNP I
and CC N
CA) NNP I
and CC N
week NN N
3 CD N
(P NN N
= VBD N
0.008 CD N
vs NN N
HI1 NNP I
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA); NNP I
daily JJ N
doses NNS N
of IN N
study NN N
medication NN N
for IN N
week NN N
1 CD N
(P NN N
= VBD N
0.019 CD N
vs NN N
HI1 NNP I
and CC N
P NNP N
= NNP N
0.011 CD N
vs NN N
CA); NNP I
daily JJ N
doses NNS N
of IN N
supplemental JJ N
analgesics NNS N
for IN N
week NN N
1 CD N
(P NN N
= VBD N
0.010 CD N
vs NN N
HI1 NNP I
and CC N
CA); NNP I
and CC N
global JJ N
assessment NN N
scores NNS N
for IN N
week NN N
1 CD N
(P NN N
= VBD N
0.018 CD N
vs NN N
HI1 NNP I
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA) NNP I
week NN N
2 CD N
(P NN N
= VBD N
0.005 CD N
vs NN N
HI1 NNP I
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA) NNP I
and CC I
week NN N
4 CD N
(P NN N
= VBD N
0.013 CD N
vs NN N
HI1 NNP I
and CC N
P NNP N
= NNP N
0.023 CD N
vs NN N
CA) NNP I
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
HI1 NNP I
and CC N
CA NNP I
in IN N
any DT N
efficacy NN N
variable JJ N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
number NN O
of IN O
patients NNS O
experiencing VBG O
adverse JJ O
events NNS O
in IN N
the DT N
HI2 NNP I
(127; NNP N
83%) CD N
HI1 NNP I
(124; VBD N
79.5%) CD N
and CC N
CA NNP I
(129; VBP N
80.6%) CD N
groups NNS N
. . N

However RB N
the DT N
mean JJ O
number NN O
of IN O
patients NNS O
who WP N
discontinued VBD O
treatment NN O
due JJ N
to TO N
adverse JJ O
events NNS O
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
HI2 NNP I
group NN N
(40; VBD N
26.1%) CD N
than IN N
in IN N
the DT N
HI1 NNP I
group NN N
(23; VBD N
14.7%) CD N
(P NNP N
= VBD N
0.013) CD N
. . N

CONCLUSIONS NNP N
The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
2-tablet JJ I
doses NNS I
of IN I
combination NN I
hydrocodone NN I
7.5 CD I
mg NN I
and CC I
ibuprofen $ I
200 CD I
mg NN I
may MD N
be VB N
more RBR N
effective JJ N
than IN N
either DT N
1-tablet JJ N
doses NNS N
of IN N
this DT N
combination NN N
or CC N
2-tablet JJ I
doses NNS I
of IN I
combination NN I
codeine NN I
30 CD I
mg NN I
and CC I
acetaminophen $ I
300 CD I
mg NN I
. . N

Moreover RB N
1-tablet JJ N
doses NNS N
of IN N
combination NN I
hydrocodone NN I
7.5 CD I
mg NN I
and CC I
ibuprofen $ I
200 CD N
mg NN N
may MD N
be VB N
as RB N
effective JJ N
as IN N
2-tablet JJ N
doses NNS N
of IN N
combination NN I
codeine NN I
30 CD I
mg NN I
and CC I
acetaminophen $ I
300 CD N
mg NN N
. . N

-DOCSTART- -X- N

Impact NN N
of IN N
MET NNP I
expression NN I
on IN N
outcome NN N
in IN N
BRAF(V600E/K) NNP N
advanced VBD P
melanoma NN P
. . P

AIMS NNP P
Preclinical NNP N
data NN N
suggest NN N
that IN N
signalling VBG N
through IN N
the DT N
HGF-MET NNP N
pathway NN N
may MD N
confer VB N
resistance NN N
to TO N
BRAF NNP I
inhibition NN I
in IN N
BRAF(V600E/K) NNP N
melanoma NN N
. . N

Therefore RB N
blockade NN I
of IN I
HGF-MET NNP I
signalling NN I
might MD N
be VB N
a DT N
valid JJ N
therapeutic JJ I
strategy NN I
in IN I
combination NN I
with IN I
BRAF NNP I
inhibition NN I
in IN I
BRAF(V600E/K) NNP N
melanoma NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
clinical JJ N
relevance NN N
of IN N
these DT N
observations NNS N
by IN N
evaluating VBG N
the DT N
survival JJ N
impact NN N
of IN N
MET NNP N
expression NN N
in IN N
patients NNS P
with IN P
BRAF(V600E/K) NNP P
advanced VBD P
melanoma NNS P
treated VBN P
with IN P
vemurafenib NN P
. . P

METHODS NNP P
AND CC N
RESULTS NNP N
Formalin-fixed NNP P
tissue NN P
blocks NNS P
were VBD P
obtained VBN P
of IN P
tumours NNS P
from IN P
patients NNS P
enrolled VBN P
in IN P
the DT P
BRIM2 NNP P
(n NNP P
= NNP P
59) CD P
and CC P
BRIM3 NNP P
(n NNP P
= VBD P
150) CD P
trials NNS P
of IN P
vemurafenib NN P
in IN P
advanced JJ P
BRAF(V600E/K) NNP P
melanoma NN P
. . P

Immunohistochemistry NN N
for IN N
MET NNP N
(SP44 NNP N
rabbit VBZ N
monoclonal JJ N
antibody) NN N
was VBD N
performed VBN N
with IN N
a DT N
highly RB N
validated VBN N
assay NN N
and CC N
clinically RB N
validated VBN N
scoring NN N
system NN N
. . N

Pretreatment NNP N
MET NNP N
expression NN N
was VBD N
frequent JJ N
at IN N
the DT N
1 NNP N
+ NNP N
cutoff NN N
(BRIM3 VBD N
31%; CD N
BRIM2 NNP N
49%) CD N
but CC N
relatively RB N
infrequent JJ N
at IN N
the DT N
2 NNP N
+ NNP N
cutoff NN N
(BRIM3 VBD N
9%; CD N
BRIM2 NNP N
19%) CD N
. . N

Retrospective JJ N
subset NN N
analyses NNS N
showed VBD N
that IN N
irrespective NN N
of IN N
the DT N
cutoff NN N
used VBD N
or CC N
the DT N
treatment NN N
arm NN O
MET NNP O
expression NN O
did VBD N
not RB N
show VB N
prognostic JJ N
significance NN N
in IN N
terms NNS N
of IN N
objective JJ O
response NN O
rate NN O
progression-free JJ O
survival NN O
or CC O
overall JJ O
survival NN O
. . N

CONCLUSIONS NNP N
MET NNP N
is VBZ N
expressed VBN N
in IN N
a DT N
proportion NN N
of IN N
BRAF(V600E/K) NNP N
advanced VBD N
melanomas NNS N
. . N

Further JJ N
analyses NNS N
on IN N
appropriately RB N
powered VBN N
subsets NNS N
are VBP N
needed VBN N
to TO N
determine VB N
the DT N
prognostic JJ N
and CC N
predictive JJ N
significance NN N
of IN N
MET NNP I
in IN I
vemurafenib-treated JJ I
melanoma NN N
. . N

-DOCSTART- -X- N

Gastrointestinal NNP N
safety NN N
of IN N
NO-aspirin NNP I
(NCX-4016) NN I
in IN N
healthy JJ P
human JJ P
volunteers: NN P
a DT N
proof NN N
of IN N
concept NN N
endoscopic NN N
study NN N
. . N

BACKGROUND NNP N
AND NNP N
AIMS NNP N
NCX-4016 NNP I
is VBZ N
a DT N
nitric JJ N
oxide-releasing JJ N
derivative NN N
of IN N
aspirin NN N
with IN N
antiplatelet NN N
activity NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
NCX-4016 NNP I
on IN N
gastrointestinal JJ N
mucosa NN N
and CC N
platelet NN N
functions NNS N
in IN N
healthy JJ P
human JJ P
volunteers NNS P
. . P

METHODS NNP N
This DT N
was VBD N
a DT N
parallel-group JJ N
double-blind JJ N
placebo-controlled JJ I
study NN N
. . N

Forty NNP P
healthy JJ P
subjects NNS P
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB I
7 CD I
days NNS I
of IN I
treatment NN I
with IN I
NCX-4016 NNP I
(400 NNP I
and CC I
800 CD I
mg NN I
twice RB I
daily) VBD I
equimolar JJ I
doses NNS I
of IN I
aspirin JJ I
(200 NNP I
and CC I
420 CD I
mg NN I
twice RB I
daily) VBD I
or CC I
placebo NN I
. . I

Upper IN N
endoscopies NNS N
were VBD N
performed VBN N
before RB N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
period NN N
and CC N
gastroduodenal JJ N
lesions NNS N
were VBD N
graded VBN N
using VBG N
a DT N
predefined VBN N
scoring NN N
system NN N
. . N

Basal NNP O
and CC O
posttreatment JJ O
platelet NN O
aggregation NN O
in IN N
response NN N
to TO N
arachidonic JJ N
acid NN N
(AA) NN N
and CC N
serum NN N
thromboxane NN N
(TX) NNP N
B(2) NNP N
and CC N
AA-stimulated NNP N
platelet NN N
TXB(2) NNP N
production NN N
were VBD N
investigated VBN N
. . N

RESULTS NNP N
Mucosal NNP O
endoscopic JJ O
injury NN O
score NN O
on IN N
day NN N
7 CD N
was VBD N
0.63 CD N
+/- JJ N
0.16 CD N
in IN N
the DT N
placebo NN I
group NN N
and CC N
11.0 CD N
+/- JJ N
3.0 CD N
and CC N
16.1 CD N
+/- JJ N
1.6 CD N
in IN N
healthy JJ P
volunteers NNS P
treated VBD N
with IN N
200 CD N
and CC N
420 CD N
mg NN N
aspirin JJ I
twice RB N
daily RB N
(P JJ N
< $ N
0.0001 CD N
vs NN N
. . N

placebo) NN I
. . N

NCX-4016 NNP I
was VBD N
virtually RB N
devoid JJ N
of IN N
gastric JJ O
and CC O
duodenal JJ O
toxicity NN O
resulting VBG O
in IN N
a DT N
total JJ N
gastric NN O
and CC O
duodenal JJ O
endoscopic NN O
score NN O
of IN N
1.38 CD N
+/- JJ N
0.3 CD N
and CC N
1.25 CD N
+/- JJ N
0.5 CD N
(P JJ N
< $ N
0.0001 CD N
vs NN N
. . N

aspirin RB I
not RB I
significant JJ N
vs NN N
. . N

placebo) NN I
. . N

NCX-4016 JJ I
inhibited JJ N
AA-induced JJ O
platelet NN O
aggregation NN O
as RB N
well RB N
as IN N
serum NN N
TXB(2) NNP N
and CC N
platelet VB N
TXB(2) NNP N
generation NN N
induced VBN N
by IN N
AA NNP N
to TO N
the DT N
same JJ N
extent NN N
as IN N
aspirin NN I
(not NNP N
significant JJ N
vs NN N
. . N

aspirin) NN I
. . N

CONCLUSIONS NN N
In IN N
this DT N
study NN N
we PRP N
have VBP N
proven VBN N
the DT N
concept NN N
that IN N
addition NN N
of IN N
an DT N
NO-donating JJ N
moiety NN N
to TO N
aspirin VB I
results NNS N
in IN N
a DT N
new JJ N
chemical NN N
entity NN N
that WDT N
maintains VBZ N
cyclooxygenase-1 NN N
and CC N
platelet VB N
inhibitory JJ N
activity NN N
while IN N
nearly RB N
avoiding VBG N
gastrointestinal JJ O
damage NN O
. . O

-DOCSTART- -X- N

The DT N
role NN N
of IN N
routinely RB N
given VBN N
hyoscine-N-butylbromide NN I
in IN N
colonoscopy: NN P
a DT N
double-blind JJ N
randomized JJ N
placebo-controlled JJ I
clinical JJ I
trial NN N
. . N

OBJECTIVE NNP N
Hyoscine-N-butylbromide NNP I
(HBB) NNP I
has VBZ N
been VBN N
proposed VBN N
to TO N
ease VB N
colonoscopy NN O
and CC N
improve VB N
mucosal NN O
visualization NN O
yet RB O
the DT N
results NNS N
from IN N
previous JJ N
studies NNS N
are VBP N
conflicting VBG N
. . N

In IN N
our PRP$ N
prospective JJ N
double-blind JJ N
placebo-controlled JJ I
randomized VBN N
study NN N
we PRP N
aimed VBD N
at IN N
evaluating VBG N
whether IN N
routine JJ N
administration NN N
of IN N
HBB NNP I
before IN I
and CC N
during IN N
colonoscopy JJ I
ease VBP O
the DT O
procedure NN O
or CC O
increase VB O
the DT O
detection NN O
rate NN O
for IN O
polyps NNS O
. . O

MATERIAL NNP N
AND CC N
METHODS NNP N
One CD P
hundred VBD P
fifty JJ P
outpatients NNS P
scheduled VBN P
for IN P
an DT P
elective JJ P
colonoscopy NN P
were VBD N
randomized VBN N
to TO N
receive VB N
intravenous JJ I
injections NNS I
of IN I
either DT I
10 CD I
mg JJ I
hyoscine-N-butylbromide NN I
or CC I
saline NN I
before IN I
insertion NN I
and CC I
at IN I
cecum NN I
. . I

Patient JJ O
tolerance NN O
and CC O
technical JJ O
ease NN O
of IN O
colonoscopy NN O
were VBD N
evaluated VBN N
by IN N
visual JJ N
analogue NN N
scale NN N
(VAS) NN N
. . N

Procedure NN O
times NNS O
were VBD N
recorded VBN N
. . N

Number NNP O
of IN O
detected JJ O
polyps NNS O
per IN O
patient NN O
was VBD N
evaluated VBN N
as RB N
well RB N
. . N

Heart NNP O
rate NN O
was VBD N
monitored VBN N
with IN N
a DT N
pulse JJ N
oximetry NN N
. . N

RESULTS NNP N
HBB NNP I
did VBD N
not RB N
improve VB N
patient NN O
tolerance NN O
or CC O
technically RB O
ease VB O
the DT O
procedure NN O
as IN N
evaluated VBN N
by IN N
VAS NNP N
. . N

However RB N
HBB NNP I
led VBD N
to TO N
faster VB N
ileal JJ O
intubation NN O
(1.5 NNP N
vs VBZ N
2.0 CD N
min NN N
p NN N
< $ N
0.001) CD N
and CC N
shorter JJR N
total JJ O
procedure NN O
time NN O
(22.0 NNP N
vs NN N
24.0 CD N
min NN N
p NN N
= VBD N
0.03) CD N
. . N

Patients NNS N
who WP N
received VBD N
HBB NNP I
also RB N
needed VBD N
less RBR N
often RB N
external JJ O
abdominal JJ O
pressure NN O
(48.6 NNP N
vs VBZ N
66.7% CD N
p NN N
= VBD N
0.03) CD N
. . N

HBB NNP I
did VBD N
not RB N
improve VB N
polyp JJ O
detection NN O
rate NN O
(0.89 NNP N
vs VBZ N
0.91 CD N
p NN N
= VBD N
0.90) CD N
. . N

HBB NNP I
induced VBD N
a DT N
significant JJ N
rise NN N
in IN N
heart NN O
rate NN O
(p NNP N
< NNP N
0.001) CD N
and CC N
more JJR N
often RB N
tachycardia JJ O
(17.6 NNP N
vs NN N
0% CD N
p NN N
< VBD N
0.001) CD N
. . N

CONCLUSIONS NNP N
Routine NNP N
administration NN N
of IN N
HBB NNP I
before IN N
and CC N
during IN N
colonoscopy NN I
yields NNS N
only RB N
limited VBD N
improvement NN N
in IN N
the DT N
technical JJ O
performance NN O
of IN O
the DT O
examination NN O
compromised VBN N
by IN N
high JJ N
incidence NN N
of IN N
tachycardia NN O
. . O

-DOCSTART- -X- N

Treatment NN N
of IN N
recurrent NN P
chronic JJ P
hyperplastic JJ P
sinusitis NN P
with IN P
nasal JJ P
polyposis NN P
. . P

OBJECTIVE NN I
To TO N
demonstrate VB N
the DT N
long-term JJ N
efficacy NN N
of IN N
intranasal NN I
furosemide IN I
an DT I
inhibitor NN I
of IN I
the DT I
sodium NN I
chloride NN I
cotransporter NN I
channel NN I
at IN I
the DT I
basolateral JJ I
surface NN I
of IN I
the DT I
respiratory JJ I
epithelial JJ I
cell NN I
vs VBZ I
no DT I
therapeutic JJ I
intervention NN I
vs NN N
intranasal NN I
mometasone NN I
furoate VBP I
a DT I
corticosteroid NN I
in IN I
preventing VBG N
relapses NNS N
of IN N
chronic JJ N
hyperplastic JJ N
sinusitis NN N
with IN N
nasal JJ N
polyposis NN N
. . N

DESIGN NNP N
Randomized NNP N
prospective NN N
controlled VBD N
study NN N
. . N

Patients NNS N
were VBD N
examined VBN N
every DT N
6 CD N
months NNS N
during IN N
follow-up JJ N
(range JJ N
1-9 JJ N
years) NN N
. . N

PATIENTS NNP N
One CD P
hundred VBD P
seventy NN P
patients NNS P
with IN P
bilateral JJ P
obstructive CD P
or CC P
minimally RB P
obstructive JJ P
chronic JJ P
hyperplastic JJ P
sinusitis NN P
with IN P
nasal JJ P
polyposis NN P
. . P

INTERVENTION NNP P
All DT P
patients NNS P
were VBD P
surgically RB P
treated VBN P
in IN P
the DT P
ENT NNP P
Department NNP P
University NNP P
of IN P
Siena NNP P
Medical NNP P
School NNP P
. . P

One CD P
month NN P
after IN P
surgery NN P
group NN P
1 CD P
patients NNS P
(n JJ P
= JJ I
97) CD I
started VBD I
treatment NN I
with IN I
intranasal JJ I
furosemide JJ I
group NN I
2 CD I
(n NNP I
= VBD I
40) CD I
received VBD I
no DT I
therapeutic JJ I
treatment NN I
and CC I
group NN I
3 CD I
(n NNP I
= VBD I
33) CD I
were VBD I
treated VBN I
with IN I
mometasone NN I
. . I

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Clinical NNP O
and CC O
instrumental JJ O
evaluation NN O
of IN O
postoperative JJ O
outcomes NNS O
. . O

RESULTS NNP N
Seventeen NNP N
(17.5%) NNP N
of IN N
97 CD N
patients NNS N
in IN N
group NN I
1 CD I
12 CD I
(30.0%) NN N
of IN N
40 CD N
patients NNS N
in IN N
group NN I
2 CD I
and CC I
8 CD N
(24.2%) NN N
of IN N
33 CD N
patients NNS N
in IN N
group NN I
3 CD I
experienced VBD N
nasal JJ O
polyposis NN O
relapses NNS O
. . O

We PRP N
noted VBD N
a DT N
prevalence NN N
of IN N
early-stage JJ N
relapse NN N
in IN N
patients NNS P
treated VBN P
with IN P
furosemide NN I
or CC I
mometasone NN I
whereas JJ I
patients NNS P
who WP P
did VBD P
not RB P
receive VB P
any DT P
treatment NN P
experienced VBD N
more JJR N
severe JJ N
grades NNS O
of IN O
chronic JJ O
hyperplastic JJ O
sinusitis NN O
with IN O
nasal JJ O
polyposis NN O
(P<.005) NN N
. . N

CONCLUSION NNP N
Use NNP N
of IN N
intranasal NN I
furosemide JJ I
represents VBZ N
a DT N
valid JJ I
therapeutic JJ I
treatment NN I
in IN N
the DT N
prevention NN N
of IN N
chronic JJ P
hyperplastic JJ P
sinusitis NN P
with IN P
nasal JJ P
polyposis NN P
. . P

-DOCSTART- -X- N

A DT N
limited JJ N
sampling NN N
method NN N
for IN N
the DT N
estimation NN O
of IN O
flunarizine JJ O
area NN O
under IN O
the DT O
curve NN O
(AUC) NNP O
and CC O
maximum JJ O
plasma JJ O
concentration NN O
(Cmax) NN O
. . O

A DT N
limited JJ N
sampling NN N
model NN N
has VBZ N
been VBN N
developed VBN N
for IN N
flunarizine NN N
following VBG N
a DT N
30 CD N
mg JJ N
oral JJ N
dose NN N
in IN N
epileptic JJ P
patients NNS P
who WP P
were VBD P
receiving VBG P
phenytoin NN P
or CC P
carbamazepine NN P
or CC P
both DT P
to TO P
estimate VB O
the DT O
area NN O
under IN O
the DT O
curve NN O
(AUC) NNP O
and CC O
maximum JJ O
plasma JJ O
concentration NN O
(Cmax) NN O
. . O

The DT N
model NN N
was VBD N
developed VBN N
using VBG N
training VBG N
data NNS N
sets NNS N
from IN N
30 CD P
20 CD P
15 CD P
or CC P
10 CD P
patients NNS P
at IN P
one CD P
or CC P
two CD P
time NN P
points NNS P
. . P

The DT N
equations NNS N
describing VBG N
the DT N
models NNS N
for IN N
AUC NNP N
using VBG N
two CD N
time NN N
points NNS N
(3 JJ N
and CC N
24h) CD N
and CC N
Cmax NNP N
for IN N
the DT N
training NN N
data NNS N
set NN N
of IN N
30 CD N
subjects NNS N
were VBD N
AUCpredicted NNP N
= NNP N
11.1 CD N
C3h NNP N
+ VBD N
121.4 CD N
C24h NNP N
- : N
157 CD N
(r JJ N
= $ N
0.80) CD N
Cmax(predicted) NNP N
= VBD N
0.036 CD N
AUC NNP N
+ VBD N
42.9 CD N
(r NNP N
= VBD N
0.74) CD N
The DT N
model NN N
was VBD N
validated VBN N
on IN N
64 CD P
patients NNS P
who WP P
received VBD N
flunarizine JJ N
orally RB N
. . N

The DT N
model NN N
provided VBD N
reasonably RB N
good JJ N
estimates NNS N
for IN N
both DT N
AUC NNP N
and CC N
Cmax NNP N
. . N

The DT N
mean NN N
predicted VBD N
AUC NNP O
of IN O
flunarizine NN O
was VBD N
1230 CD N
+/- JJ N
717 CD N
ng JJ N
h JJ N
mL-1 JJ N
whereas IN N
the DT N
observed JJ N
AUC NNP N
was VBD N
1203 CD N
+/- JJ N
900 CD N
ng JJ N
h JJ N
mL-1 NN N
. . N

The DT N
bias NN N
of IN N
the DT N
prediction NN N
was VBD N
2% CD N
and CC N
precision NN N
was VBD N
28% CD N
. . N

The DT N
mean NN N
predicted VBD N
Cmax NNP O
of IN O
flunarizine NN O
was VBD N
86 CD N
+/- JJ N
32 CD N
ng JJ N
mL-1 NN N
as IN N
compared VBN N
to TO N
an DT N
observed JJ N
mean NN N
Cmax NNP N
of IN N
90 CD N
+/- JJ N
42 CD N
ng JJ N
mL-1 NN N
. . N

The DT N
bias NN O
and CC O
precision NN O
of IN O
the DT O
prediction NN O
were VBD N
4% CD N
and CC N
24% CD N
respectively RB N
. . N

The DT N
method NN N
described VBD N
here RB N
may MD N
be VB N
used VBN N
to TO N
estimate VB N
AUC NNP N
and CC N
Cmax NNP N
for IN N
flunarizine NN N
without IN N
detailed JJ N
pharmacokinetic JJ N
studies NNS N
. . N

-DOCSTART- -X- N

Barriers NNS I
to TO I
hypertension NN I
care NN I
and CC I
control NN I
in IN N
young JJ P
urban JJ P
black JJ P
men NNS P
. . P

Barriers NNS I
to TO I
high JJ O
blood NN O
pressure NN O
(HBP) NNP I
care NN I
and CC I
control NN I
have VBP N
been VBN N
reported VBN N
in IN N
the DT N
literature NN N
for IN N
> $ N
30 CD N
years NNS N
. . N

Few JJ N
reports NNS N
on IN N
barriers NNS N
however RB N
have VBP N
focused VBN N
on IN N
the DT N
young JJ P
black JJ P
man NN P
with IN P
HBP NNP P
the DT P
age/sex/race NN N
group NN N
with IN N
the DT N
highest JJS N
rates NNS N
of IN N
early JJ N
severe JJ N
and CC N
complicated JJ N
HBP NNP N
and CC N
the DT N
lowest JJS N
rates NNS N
of IN N
awareness NN N
treatment NN N
and CC N
control NN N
. . N

In IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
comprehensive JJ I
care NN I
for IN I
hypertensive JJ P
young JJ P
urban JJ P
black JJ P
men NNS P
factors NNS P
potentially RB N
associated VBN N
with IN N
care NN N
and CC N
control NN N
were VBD N
assessed VBN N
at IN N
baseline NN N
for IN N
the DT N
309 CD P
enrolled VBD P
men NNS P
. . P

A DT P
majority NN P
of IN P
the DT P
men NNS P
encountered VBD P
a DT P
variety NN P
of IN P
barriers NNS P
including VBG P
economic JJ P
social JJ P
and CC P
lifestyle JJ P
obstacles NNS P
to TO P
adequate VB P
BP NNP P
care NN P
and CC P
control NN P
including VBG P
no DT P
current JJ P
HBP NNP P
care NN P
(49%) NNP P
risk NN P
of IN P
alcoholism NN P
(62%) NNP P
use NN P
of IN P
illicit NN P
drugs NNS P
(45%) VBP P
social JJ P
isolation NN P
(47%) NNP P
unemployment NN P
(40%) NN N
and CC N
lack NN N
of IN N
health NN N
insurance NN N
(51%) NN N
. . N

Having VBG N
health NN P
insurance NN P
(odds NNS N
ratio VBP N
= $ N
7.20 CD N
P NNP N
= NNP N
.00) NNP N
and CC N
a DT N
negative JJ P
urine JJ P
drug NN P
screen NN P
(odds NNP N
ratio NN N
= NNP N
.56 NNP N
P NNP N
= NNP N
.04) NNP N
were VBD N
significant JJ N
predictors NNS N
of IN N
being VBG N
in IN N
HBP NNP N
care NN N
. . N

Low JJ O
alcoholism NN O
risk NN O
and CC N
employment NN O
were VBD N
identified VBN N
as IN N
significant JJ N
predictors NNS N
of IN N
compliance NN N
with IN N
HBP NNP N
medication-taking JJ N
behavior NN N
. . N

Men NNS P
currently RB P
using VBG P
illicit JJ P
drugs NNS P
were VBD N
2.64 CD N
times NNS N
less RBR N
likely JJ N
to TO N
have VB N
controlled VBN O
BP NNP O
compared VBN N
with IN N
their PRP$ N
counterparts NNS N
who WP P
did VBD P
not RB P
use VB P
illicit JJ P
drugs NNS P
and CC P
men NNS P
currently RB P
taking VBG P
HBP NNP P
medication NN P
were VBD N
63 CD N
times NNS N
more RBR N
likely JJ N
have VBP N
controlled VBN N
BP NNP N
compared VBN N
with IN N
men NNS P
not RB P
taking VBG P
HBP NNP P
medication NN P
. . P

Comprehensive JJ I
interventions NNS I
are VBP N
needed VBN N
to TO N
address VB N
socioeconomic JJ N
and CC N
lifestyle JJ N
issues NNS N
as RB N
well RB N
as IN N
other JJ N
barriers NNS I
to TO I
care VB I
and CC I
treatment NN I
if IN I
HBP NNP N
care NN N
is VBZ N
to TO N
be VB N
salient JJ N
and CC N
effective JJ N
in IN N
this DT N
high JJ P
risk NN P
group NN P
. . P

-DOCSTART- -X- N

Combining VBG I
afferent JJ I
stimulation NN I
and CC I
mirror NN I
therapy NN I
for IN N
rehabilitating VBG N
motor NN O
function NN O
motor NN O
control NN O
ambulation NN O
and CC O
daily JJ O
functions NNS O
after IN N
stroke NN N
. . N

BACKGROUND NNP N
Mirror NNP I
therapy NN I
(MT) NN I
and CC I
mesh JJ I
glove NN I
(MG) NNP I
afferent JJ I
stimulation NN I
may MD N
be VB N
effective JJ N
in IN N
reducing VBG N
motor NN P
impairment NN P
after IN P
stroke NN P
. . P

A DT N
hybrid JJ I
intervention NN I
of IN I
MT NNP I
combined VBD I
with IN I
MG NNP I
(MT NNP I
+ NNP I
MG) NNP I
may MD N
broaden VB N
aspects NNS N
of IN N
treatment NN I
benefits NNS N
. . N

OBJECTIVE NN N
To TO N
demonstrate VB N
the DT N
comparative JJ N
effects NNS N
of IN N
MG NNP I
+ NNP I
MT NNP I
MT NNP I
and CC I
a DT N
control NN I
treatment NN I
(CT) NN I
on IN N
the DT N
outcomes NNS N
of IN N
motor NN N
impairments NNS N
manual JJ N
dexterity NN N
ambulation NN N
function NN N
motor NN N
control NN N
and CC N
daily JJ N
function NN N
. . N

METHODS NNP N
Forty-three NNP P
chronic JJ P
stroke NN P
patients NNS P
with IN P
mild JJ P
to TO P
moderate VB P
upper JJ P
extremity NN P
impairment NN P
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
MT NNP I
+ NNP I
MG NNP I
MT NNP I
or CC I
CT NNP I
for IN N
1.5 CD N
hours/day JJ N
5 CD N
days/week NN N
for IN N
4 CD N
weeks NNS N
. . N

Outcome NN N
measures NNS N
were VBD N
the DT N
Fugl-Meyer NNP O
Assessment NNP O
(FMA) NNP O
and CC O
muscle NN O
tone NN O
measured VBN O
by IN O
Myoton-3 NNP O
for IN O
motor NN O
impairment NN O
and CC N
the DT N
Box NNP O
and CC O
Block NNP O
Test NNP O
(BBT) NN O
and CC N
10-Meter JJ O
Walk NNP O
Test NNP O
(10 NNP O
MWT) NNP O
for IN N
motor NN N
function NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
kinematic JJ O
parameters NNS O
for IN O
motor NN O
control NN O
and CC N
the DT N
Motor NNP O
Activity NNP O
Log NNP O
and CC N
ABILHAND NNP O
Questionnaire NNP O
for IN O
daily JJ O
function NN O
. . O

RESULTS NNP N
FMA NNP N
total JJ N
scores NNS N
were VBD N
significantly RB N
higher JJR N
and CC N
synergistic JJ N
shoulder NN N
abduction NN N
during IN N
reach NN N
was VBD N
less RBR N
in IN N
the DT N
MT NNP I
+ NNP I
MG NNP I
and CC N
MT NNP I
groups NNS N
compared VBN N
with IN N
the DT N
CT NNP I
group NN N
. . N

Performance NN N
on IN N
the DT N
BBT NNP N
and CC N
the DT N
10 CD N
MWT NNP N
(velocity NN N
and CC N
stride JJ N
length NN N
in IN N
self-paced JJ N
task NN N
and CC N
velocity NN N
in IN N
as-quickly-as-possible JJ N
task) NN N
were VBD N
improved VBN N
after IN N
MT NNP I
+ NNP I
MG NNP I
compared VBN N
with IN N
MT NNP I
. . I

CONCLUSIONS NNP I
MT NNP I
+ NNP I
MG NNP I
improved VBD N
manual JJ O
dexterity NN O
and CC O
ambulation NN O
. . O

MT NNP I
+ NNP I
MG NNP I
and CC N
MT NNP I
reduced VBD N
motor NN O
impairment NN O
and CC N
synergistic JJ O
shoulder NN O
abduction NN O
more JJR N
than IN N
CT NNP I
. . I

Future JJ N
studies NNS N
may MD N
integrate VB N
functional JJ N
task NN N
practice NN N
into IN N
treatments NNS I
to TO N
enhance VB N
functional JJ N
outcomes NNS N
in IN N
patients NNS N
with IN N
various JJ N
levels NNS N
of IN N
motor NN N
severity NN N
. . N

The DT N
long-term JJ N
effects NNS N
of IN N
MG NNP I
+ NNP I
MT NNP I
remain VBP N
to TO N
be VB N
evaluated VBN N
. . N

-DOCSTART- -X- N

Sulforaphane NNP I
treatment NN I
of IN N
autism NN N
spectrum NN N
disorder NN N
(ASD) NN N
. . N

Autism NNP P
spectrum NN P
disorder NN P
(ASD) NNP N
characterized VBN N
by IN N
both DT N
impaired JJ N
communication NN N
and CC N
social JJ N
interaction NN N
and CC N
by IN N
stereotypic JJ N
behavior NN N
affects NNS N
about IN N
1 CD N
in IN N
68 CD N
predominantly RB P
males NNS P
. . P

The DT N
medico-economic JJ N
burdens NNS N
of IN N
ASD NNP N
are VBP N
enormous JJ N
and CC N
no DT N
recognized VBN N
treatment NN N
targets VBZ N
the DT N
core NN N
features NNS N
of IN N
ASD NNP N
. . N

In IN N
a DT N
placebo-controlled JJ I
double-blind NN N
randomized VBN N
trial NN N
young JJ P
men NNS P
(aged VBD P
13-27) JJ P
with IN P
moderate JJ P
to TO P
severe VB P
ASD NNP P
received VBD N
the DT N
phytochemical JJ I
sulforaphane NN I
(n NNP I
= NNP I
29)--derived JJ I
from IN I
broccoli NN I
sprout NN I
extracts--or JJ I
indistinguishable JJ I
placebo NN I
(n NNP N
= VBZ N
15) CD N
. . N

The DT N
effects NNS N
on IN N
behavior NN N
of IN N
daily JJ N
oral JJ N
doses NNS N
of IN N
sulforaphane JJ I
(50-150 JJ N
mol) NN N
for IN N
18 CD N
wk NN N
followed VBN N
by IN I
4 CD I
wk NNS I
without IN I
treatment NN I
were VBD N
quantified VBN N
by IN N
three CD N
widely RB N
accepted VBD N
behavioral JJ N
measures NNS N
completed VBN N
by IN N
parents/caregivers NNS N
and CC N
physicians: VB N
the DT O
Aberrant NNP O
Behavior NNP O
Checklist NNP O
(ABC) NNP O
Social NNP O
Responsiveness NNP O
Scale NNP O
(SRS) NNP O
and CC O
Clinical NNP O
Global NNP O
Impression NNP O
Improvement NNP O
Scale NNP O
(CGI-I) NN O
. . N

Initial JJ N
scores NNS N
for IN O
ABC NNP O
and CC O
SRS NNP O
were VBD N
closely RB N
matched VBN N
for IN N
participants NNS N
assigned VBN N
to TO I
placebo VB I
and CC I
sulforaphane VB I
. . N

After IN N
18 CD N
wk JJ N
participants NNS N
receiving VBG I
placebo NN I
experienced VBD N
minimal JJ N
change NN N
(<3.3%) NNP N
whereas IN N
those DT N
receiving VBG I
sulforaphane NN I
showed VBD N
substantial JJ N
declines NNS N
(improvement NN N
of IN N
behavior): NN N
34% CD N
for IN N
ABC NNP N
(P NNP N
< VBD N
0.001 CD N
comparing VBG N
treatments) NN N
and CC N
17% CD N
for IN N
SRS NNP N
scores NNS N
(P NNP N
= VBD N
0.017) CD N
. . N

On IN N
CGI-I NNP N
a DT N
significantly RB N
greater JJR N
number NN N
of IN P
participants NNS P
receiving VBG P
sulforaphane NN I
had VBD N
improvement NN N
in IN O
social JJ O
interaction NN O
abnormal JJ O
behavior NN O
and CC O
verbal JJ O
communication NN O
(P NNP N
= NNP N
0.015-0.007) NN N
. . N

Upon IN N
discontinuation NN N
of IN I
sulforaphane JJ I
total JJ N
scores NNS N
on IN N
all DT N
scales NNS N
rose VBD N
toward IN N
pretreatment JJ N
levels NNS N
. . I

Dietary NNP I
sulforaphane NN I
of IN N
recognized VBN N
low JJ N
toxicity NN N
was VBD N
selected VBN N
for IN N
its PRP$ N
capacity NN N
to TO N
reverse VB N
abnormalities NNS N
that WDT N
have VBP N
been VBN N
associated VBN N
with IN N
ASD NNP N
including VBG N
oxidative JJ N
stress NN N
and CC N
lower JJR N
antioxidant NN N
capacity NN N
depressed VBD N
glutathione NN N
synthesis NN N
reduced VBD N
mitochondrial JJ N
function NN N
and CC N
oxidative JJ N
phosphorylation NN N
increased VBD N
lipid JJ N
peroxidation NN N
and CC N
neuroinflammmation NN N
. . N

-DOCSTART- -X- N

Boosting VBG N
uptake NN O
of IN N
influenza NN N
immunisation: VBP N
a DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
telephone NN I
appointing VBG I
in IN N
general JJ N
practice NN N
. . N

BACKGROUND NNP N
Immunisation NNP N
against IN N
influenza NN N
is VBZ N
an DT N
effective JJ N
intervention NN I
that WDT N
reduces VBZ N
serologically RB N
confirmed VBN N
cases NNS N
by IN N
between IN N
60% CD N
and CC N
70% CD N
. . N

Almost RB N
all DT N
influenza JJ N
immunisation NN N
in IN N
the DT N
UK NNP N
is VBZ N
done VBN N
within IN N
general JJ N
practice NN N
. . N

Current JJ N
evidence NN N
on IN N
the DT N
effectiveness NN N
of IN N
patient JJ I
reminders NNS I
for IN N
all DT N
types NNS N
of IN N
immunisation NN I
programmes NNS I
is VBZ N
largely RB N
based VBN N
on IN N
North JJ N
American JJ N
studies NNS N
. . N

AIM NNP N
To TO N
determine VB N
whether IN N
telephone NN I
appointments NNS I
offered VBD I
bygeneral JJ I
practice NN I
receptionists NNS I
increase VBP N
the DT N
uptake NN O
of IN O
irfluenza JJ O
immunisation NN O
among IN N
the DT N
registered JJ P
population NN P
aged VBD P
over IN P
65 CD P
years NNS P
in IN P
east JJ P
London NNP P
practices NNS P
. . P

DESIGN NN N
OF NNP N
STUDY NNP N
Randomised VBD N
controlled VBN I
trial NN N
. . N

SETTING NNP N
Three NNP N
research NN N
general JJ N
practices NNS N
within IN N
the DT N
East NNP P
London NNP P
and CC P
Essex NNP P
network NN P
of IN P
researchers NNS P
(ELENoR) NNP P
. . P

METHOD JJ N
Participants NNS P
were VBD P
1 CD P
820 CD P
low-risk JJ P
patients NNS P
aged VBD P
65 CD P
to TO P
74 CD P
years NNS P
who WP P
had VBD P
not RB P
previously RB P
been VBN P
in IN P
a DT P
recall NN P
system NN P
for IN P
influenza JJ P
immunisation NN P
at IN P
their PRP$ P
general JJ P
practice NN P
. . P

The DT N
intervention NN I
during IN I
October NNP N
2000 CD N
was VBD N
a DT N
telephone NN I
call NN I
from IN I
the DT I
practice NN I
receptionist NN I
to TO I
intervention NN I
group NN I
households VBZ I
offering VBG I
an DT N
appointment NN N
for IN N
influenza JJ N
immunisation NN N
at IN N
a DT N
nurse-run JJ N
. . N

clinic JJ N
Main NNP N
outcome NN N
measures NNS N
were VBD N
the DT N
numbers NNS O
of IN O
individuals NNS O
in IN O
each DT O
group NN O
receiving VBG O
immunisation NN O
and CC O
practice NN O
costs NNS O
of IN O
a DT O
telephone-appointing JJ O
programme NN O
. . O

RESULTS NNP N
intention NN I
to TO I
treat VB I
analysis NN N
showed VBD N
an DT N
immunisation NN O
rate NN O
in IN N
the DT N
control NN I
group NN I
of IN N
44% CD N
compared VBN N
with IN N
50% CD N
in IN N
the DT N
intervention NN I
group NN I
(odds VBZ N
ratio VBP N
= $ N
1.29 CD N
95% CD N
confidence NN N
interval NN N
= VBD N
1.03 CD N
to TO N
1.63) CD N
. . N

Of IN N
the DT N
patients NNS P
making VBG P
a DT P
telephone NN P
appointment NN P
88% CD P
recieved VBN N
immunisation NN O
while IN O
22% CD N
of IN N
those DT N
not RB N
wanting VBG N
an DT N
appointment NN N
went VBD N
on IN N
to TO N
be VB N
immunised VBN N
. . N

In IN N
the DT N
controlgroup JJ I
income NN I
generated VBD N
was VBD N
11.35 CD N
pounds NNS N
per IN N
immunisation NN N
for IN N
each DT N
additional JJ N
immunisation NN N
in IN N
the DT N
intervention NN I
group NN I
the DT N
income NN N
was VBD N
5.20 CD N
pounds NNS N
. . N

The DT N
'number NNP N
needed VBD N
to TO N
telephone' VB N
was VBD N
17 CD N
. . N

CONCLUSION NNP N
Uptake NNP N
of IN N
influenza JJ N
immunisation NN O
among IN N
the DT N
low-risk JJ P
older JJR P
population NN P
in IN P
inner-city JJ P
areas NNS P
can MD N
be VB N
boosted VBN N
by IN N
around IN N
6% CD N
using VBG N
a DT N
simple JJ N
intervention NN I
by IN I
receptionists NNS I
. . I

Immunisation NN O
rates NNS O
in IN N
this DT N
low-risk JJ N
group NN N
fell VBD N
well RB N
short RB N
of IN N
the DT N
60% CD N
government NN N
target NN N
. . N

Improving VBG N
immunisation NN O
rates NNS O
will MD N
require VB N
a DT N
sustained JJ I
public JJ I
health NN I
campaign NN I
. . I

Retaining VBG N
the DT N
item-of-service JJ N
payments NNS N
to TO N
practices NNS N
should MD N
support VB N
costs NNS N
of IN N
practice-based JJ I
interventions NNS I
. . I

-DOCSTART- -X- N

Pre-vaccination NNP N
immunity NN N
and CC N
immune JJ N
responses NNS N
to TO N
a DT N
cell NN N
culture-derived JJ N
whole-virus JJ N
H1N1 NNP N
vaccine NN N
are VBP N
similar JJ N
to TO N
a DT N
seasonal JJ N
influenza NN N
vaccine NN N
. . N

BACKGROUND NNP N
Immune NNP N
responses VBZ N
to TO N
novel VB N
pandemic JJ N
influenza NN N
vaccines NNS N
may MD N
be VB N
influenced VBN N
by IN N
previous JJ N
exposure NN N
to TO N
antigenically RB N
similar JJ N
seasonal JJ N
strains NNS N
. . N

METHODS NNP N
An DT N
open-label JJ N
randomized JJ N
phase NN N
I/II NNP N
study NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
immunogenicity NN N
and CC N
safety NN N
of IN N
a DT N
non-adjuvanted JJ N
inactivated JJ I
whole-virus JJ I
H1N1 NNP I
A/California/07/2009 NNP I
vaccine NN I
. . I

408 CD P
subjects NNS P
were VBD P
stratified VBN P
by IN P
age NN P
(18-59 JJ P
and CC P
>60 JJ P
years) NN P
and CC N
randomized VBD N
1:1 CD N
to TO N
receive VB N
two CD N
vaccinations NNS I
with IN I
either DT I
3.75 CD I
or CC I
7.5 CD I
g JJ I
hemagglutinin NN I
antigen NN I
21 CD I
days NNS I
apart RB I
. . N

Safety NNP N
immunogenicity NN N
and CC N
the DT N
influence NN N
of IN N
seasonal JJ N
influenza JJ N
vaccination NN N
and CC N
antibody NN N
cross-reactivity NN N
with IN N
a DT N
seasonal JJ N
H1N1 NNP N
strain NN N
was VBD N
assessed VBN N
. . N

RESULTS VB N
A DT N
single JJ N
vaccination NN N
with IN N
either DT N
dose NN N
induced VBD N
substantial JJ N
increases NNS N
in IN O
H1N1 NNP O
A/California/07/2009 NNP O
hemagglutination NN O
inhibition NN O
(HI) NNP O
and CC O
neutralizing VBG O
(MN) NNP O
antibody NN O
titers NNS O
in IN N
both DT N
adult NN N
and CC N
elderly JJ N
subjects NNS N
. . N

A DT N
single JJ N
7.5 CD N
g NN N
dose NN N
induced JJ O
seroprotection NN O
rates NNS O
of IN N
86.9% CD N
in IN N
adults NNS N
and CC N
75.2% CD N
in IN N
elderly JJ N
subjects NNS N
. . N

Two CD N
7.5 CD N
g JJ N
vaccinations NNS N
induced JJ O
seroprotection NN O
rates NNS O
in IN N
adult NN N
and CC N
elderly JJ N
subjects NNS N
of IN N
90.9% CD N
and CC N
89.1% CD N
respectively RB N
. . N

The DT N
robust JJ N
immune NN N
response NN N
to TO N
vaccination NN N
was VBD N
confirmed VBN N
by IN N
analyses NNS N
of IN N
neutralizing VBG N
antibody NN N
titers NNS N
. . N

Both DT O
HI NNP O
and CC O
MN NNP O
antibodies NNS O
persisted VBD N
for IN N
 JJ N
6 CD N
months NNS N
post-vaccination NN N
. . N

Between JJ N
34% CD N
and CC N
49% CD N
of IN N
subjects NNS O
had VBD O
seroprotective JJ O
levels NNS O
of IN O
H1N1 NNP O
A/California/07/2009 NNP O
antibodies NNS O
at IN N
baseline NN N
. . N

Higher JJR O
baseline NN O
HI NNP O
titers NNS O
were VBD N
associated VBN N
with IN N
receipt NN N
of IN N
the DT N
2008-09 JJ N
or CC N
2009-10 JJ N
seasonal JJ N
influenza NN N
vaccine NN N
. . N

High JJ O
baseline NN O
A/California/07/2009 NNP O
neutralizing VBG O
antibody NN O
titers NNS O
were VBD N
also RB N
associated VBN N
with IN N
high JJ N
baseline NN N
titers NNS N
against IN N
A/New NNP N
Caledonia/20/99 NNP N
a DT N
seasonal JJ N
H1N1 NNP N
strain NN N
which WDT N
circulated VBD N
and CC N
was VBD N
included VBN N
in IN N
the DT N
seasonal JJ N
vaccine NN N
from IN N
2000-01 JJ N
to TO N
2006-07 JJ N
. . N

Pre-adsorption NN N
with IN N
A/H1N1/New NNP N
Caledonia/20/99 NNP N
antigen NN N
reduced VBD O
A/H1N1/California/07/2009 NNP O
baseline NN O
titers NNS O
in IN N
55% CD N
of IN N
tested VBN N
sera NN N
. . N

The DT N
vaccine NN N
was VBD N
well RB O
tolerated VBN O
with IN N
low JJ N
rates NNS N
of IN N
fever NN N
. . N

CONCLUSIONS VB N
A DT N
whole-virus JJ N
H1N1 NNP N
A/California/07/2009 NNP N
vaccine NN N
was VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
and CC N
a DT N
single JJ N
dose NN N
induced VBN N
substantial JJ N
immune NN N
responses NNS N
similar JJ N
to TO N
seasonal JJ N
influenza NN N
vaccines NNS N
probably RB N
due JJ N
to TO N
immunological JJ N
priming NN N
by IN N
previous JJ N
seasonal JJ N
influenza NN N
vaccines NNS N
or CC N
infections NNS N
. . N

-DOCSTART- -X- N

Randomized VBN N
study NN N
of IN N
six CD P
umbilical JJ P
cord NN P
care NN P
regimens NNS P
. . P

Comparing VBG N
length NN N
of IN N
attachment JJ N
microbial JJ N
control NN N
and CC N
satisfaction NN N
. . P

Two CD P
hundred CD P
and CC P
seventy VB P
one CD P
infants NNS P
were VBD P
enrolled VBN P
in IN P
a DT P
study NN P
to TO P
compare VB P
six CD P
different JJ P
methods NNS P
of IN P
treating VBG P
the DT P
umbilical JJ P
cord NN P
. . P

Antimicrobial NNP I
control NN I
was VBD N
equal JJ N
for IN N
all DT N
methods NNS N
. . N

Repeated VBN I
triple JJ I
dye NN I
application NN I
was VBD N
considered VBN N
least JJS N
acceptable JJ O
by IN N
staff NN N
and CC N
parents NNS N
and CC N
had VBD N
the DT N
longest JJS O
attachment JJ O
time NN O
. . O

Povidone-iodine NN I
was VBD N
associated VBN N
with IN N
the DT N
shortest JJS N
attachment JJ O
time NN O
and CC N
was VBD N
most RBS N
liked JJ N
. . N

If IN N
there EX N
is VBZ N
no DT N
special JJ N
need NN N
to TO N
treat VB N
a DT N
specific JJ N
nosocomial JJ N
outbreak JJ N
duration NN N
of IN N
cord NN N
attachment NN N
and CC N
satisfaction NN N
of IN N
staff NN N
and CC N
parents NNS N
can MD N
help VB N
clinicians NNS N
decide VB N
on IN N
a DT N
cord NN I
care NN I
regimen NNS I
. . I

-DOCSTART- -X- N

[Clinical JJ N
benefits NNS N
of IN N
normothermic JJ I
cardiopulmonary JJ I
bypass NN I
on IN N
postoperative JJ N
systemic JJ N
metabolism] NN N
. . N

To TO N
evaluate VB N
the DT N
influence NN N
of IN N
body NN N
temperature NN N
during IN N
cardiopulmonary JJ I
bypass NN I
(CPB) NN I
on IN N
postoperative JJ O
systemic JJ O
metabolism NN O
32 CD P
patients NNS P
undergoing JJ P
elective JJ P
cardiac NN P
surgery NN P
were VBD P
randomly RB P
assigned VBN P
to TO P
either DT P
hypothermia NN P
(n NNP P
= VBZ P
16) CD P
or CC P
normothermia JJ P
(n NNP P
= NNP P
16) CD P
. . P

Serial JJ N
hemodynamic JJ N
parameters NNS N
and CC N
blood NN N
samples NNS N
were VBD N
obtained VBN N
after IN N
surgery NN N
. . N

CPB NNP O
and CC O
operation NN O
times NNS O
were VBD N
significantly RB N
shorter JJR N
and CC N
the DT N
platelet NN O
reduction NN O
ratio NN O
during IN N
CPB NNP I
[ NNP N
= NNP N
(platelets NNS N
before IN N
CPB-platelets NNS N
after IN N
CPB)/platelets NNPS N
before IN N
CPB] NNP N
was VBD N
significantly RB N
lower JJR N
in IN N
normothermic JJ I
patients NNS N
than IN N
in IN N
hypothermic JJ I
patients NNS N
. . N

The DT N
platelet NN O
reduction NN O
ratio NN O
was VBD N
dependent JJ N
on IN N
the DT N
minimum JJ N
rectal JJ N
temperature NN N
during IN N
CPB NNP O
the DT O
operation NN N
time NN N
and CC N
the DT N
CPB NNP O
time NN N
. . N

In IN N
the DT N
early JJ N
postoperative JJ N
period NN N
hypothermic JJ I
patients NNS N
had VBD N
abnormally RB N
high JJ N
systemic JJ O
vascular NN O
resistance NN O
and CC N
a DT N
reduced JJ N
cardiac JJ O
index NN O
compared VBN N
with IN N
the DT N
normothermic JJ I
patients NNS N
. . N

There EX N
were VBD N
no DT N
differences NNS N
between IN N
2 CD N
groups NNS N
in IN N
postoperative JJ O
hepatic JJ O
and CC O
renal JJ O
functions NNS O
changes NNS O
in IN O
oxygen NN O
consumption NN O
arterial-venous JJ O
PCO2 NNP O
or CC O
arterial-venous JJ O
pH JJ O
gradient NN O
. . O

This DT N
study NN N
suggested VBD N
a DT N
beneficial JJ N
influence NN N
of IN N
normothermic JJ I
CPB NNP I
on IN N
postoperative JJ N
hemodynamics NNS N
. . N

Normothermic NNP I
CPB NNP I
was VBD N
not RB N
associated VBN N
with IN N
adverse JJ O
effects NNS O
on IN N
postoperative JJ O
metabolic JJ O
recovery NN N
. . N

-DOCSTART- -X- N

Dose-response JJ N
effect NN N
of IN N
flecainide NN I
in IN N
patients NNS P
with IN P
symptomatic JJ P
paroxysmal JJ P
atrial JJ P
fibrillation NN P
and/or NN P
flutter NN P
monitored VBD P
with IN P
trans-telephonic JJ P
electrocardiography: NN P
a DT N
multicenter JJR N
placebo-controlled JJ I
double-blind JJ I
trial NN N
. . N

BACKGROUND IN N
A DT N
double-blind JJ N
randomized JJ N
parallel-group JJ N
placebo-controlled JJ I
trial NN N
was VBD N
conducted VBN N
in IN N
patients NNS P
with IN P
paroxysmal JJ P
atrial JJ P
fibrillation NN P
or CC P
flutter NN P
(PAF/PAFL) VBP P
experiencing VBG P
2 CD P
or CC P
more JJR P
episodes NNS P
of IN P
symptomatic JJ P
PAF/PAFL NNP P
during IN P
a DT P
28-day JJ P
observation NN P
period NN P
to TO P
determine VB P
the DT P
dose-response JJ P
effect NN P
and CC P
safety NN P
of IN P
flecainide NN P
. . P

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
total NN N
of IN N
143 CD P
patients NNS P
at IN P
30 CD P
centers NNS P
were VBD N
randomized VBN N
to TO N
receive VB N
25 CD I
50 CD I
or CC I
100 CD I
mg NN I
of IN I
flecainide NN I
or CC I
placebo VB I
twice JJ I
daily JJ I
(BID) NN N
. . N

In IN N
123 CD P
patients NNS P
(per JJ N
protocol NN N
set) VBP N
those DT N
remaining VBG N
free JJ N
from IN N
PAF/PAFL NNP N
after IN N
the DT N
treatment NN N
were VBD N
3.1% CD N
on IN N
placebo NN I
7.7% CD I
on IN N
25 CD N
mg/BID NNS N
9.4% CD N
on IN N
50 CD N
mg/BID NNS N
and CC N
39.4% CD N
on IN N
100 CD N
mg/BID NN N
of IN N
flecainide NN I
. . I

As IN N
a DT N
whole JJ N
group NN N
a DT N
significant JJ N
linear JJ O
dose-response JJ O
(p<0.001) NN N
was VBD N
observed VBN N
and CC N
a DT N
significant JJ N
difference NN N
between IN N
placebo NN I
and CC N
100 CD N
mg/BID NN N
was VBD N
observed VBN N
(p<0.001) NN N
. . N

A DT N
similar JJ N
dose-response NN N
between IN N
the DT N
present JJ N
study NN N
and CC N
Caucasian NNP N
study NN N
was VBD N
demonstrated VBN N
. . N

Although IN N
there EX N
were VBD N
5 CD N
patients NNS N
who WP N
needed VBD N
cardioversion NN I
or CC N
ablation NN I
because IN N
of IN N
frequent JJ N
episodes NNS N
of IN N
PAF/PAFL NNP N
(2 NNP N
in IN N
25 CD N
mg/BID NN N
1 CD N
in IN N
50 CD N
mg/BID NN N
and CC N
2 CD N
in IN N
100 CD N
mg/BID NN N
of IN N
flecainide) NN I
neither CC N
death NN O
nor CC O
ventricular JJ O
proarrhythmic JJ O
event NN O
was VBD N
reported VBN N
. . N

CONCLUSIONS NNP N
This DT N
study NN N
indicated VBD N
that IN N
flecainide NN I
exerted VBD N
a DT N
significant JJ N
dose-dependent JJ N
effect NN N
on IN N
the DT N
prevention NN N
of IN N
symptomatic JJ N
PAF/PAFL NNP N
recurrence NN N
and CC N
showed VBD N
that IN N
there EX N
was VBD N
no DT N
inter-ethnic JJ N
difference NN N
in IN N
the DT N
clinical JJ N
effect NN N
of IN N
flecainide NN I
in IN N
patients NNS P
with IN P
PAF/PAFL NNP P
. . P

-DOCSTART- -X- N

Lanthanum NNP I
carbonate NN I
(Fosrenol) NNP I
efficacy NN O
and CC O
tolerability NN O
in IN N
the DT N
treatment NN N
of IN N
hyperphosphatemic JJ P
patients NNS P
with IN P
end-stage JJ P
renal JJ P
disease NN P
. . P

AIMS NNP N
High NNP N
serum NN N
phosphorus NN N
levels NNS N
are VBP N
a DT N
common JJ N
problem NN N
in IN N
patients NNS P
receiving VBG P
long-term JJ P
dialysis NN P
treatment NN P
. . P

Lanthanum NNP I
carbonate NN I
(Fosrenol) NN I
is VBZ N
a DT N
new JJ N
non-aluminum JJ N
non-calcium JJ N
phosphate NN N
binder NN N
developed VBD N
for IN N
the DT N
treatment NN N
of IN N
hyperphosphatemia NN N
in IN N
patients NNS P
with IN P
end-stage JJ P
renal JJ P
disease NN P
(ESRD) NNP P
. . P

We PRP N
report VBP N
data NNS N
from IN N
a DT N
recent JJ N
trial NN N
which WDT N
for IN N
the DT N
first JJ N
time NN N
assessed VBD N
the DT N
efficacy NN O
and CC N
tolerability NN O
of IN N
lanthanum JJ I
carbonate NN I
treatment NN I
compared VBN I
with IN N
placebo NN I
in IN P
Chinese JJ P
patients NNS P
with IN P
ESRD NNP P
. . P

PATIENTS NNS N
AND CC N
METHODS NNP N
Following VBG N
a DT N
one- JJ N
to TO N
three-week JJ N
washout NN N
phase NN N
and CC N
a DT N
four-week JJ N
open-label JJ N
lanthanum NN I
carbonate NN I
dose-titration NN N
phase NN N
male NN P
and CC P
female JJ P
hemodialysis NN P
patients NNS P
were VBD N
randomized VBN N
(1:1) NN N
to TO N
receive VB N
either DT N
lanthanum NN I
carbonate NN I
or CC I
placebo NN I
for IN N
four CD N
weeks NNS N
. . N

The DT N
primary JJ N
efficacy NN N
parameter NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
control NN O
of IN O
serum JJ O
phosphorus NN O
levels NNS O
(< VBP N
or CC N
=1.8 VBP N
mmol/l JJ N
[< NN N
or CC N
= $ N
5.6 CD N
mg/dl]) NN N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
the DT O
profile NN O
of IN O
serum JJ O
phosphorus NN O
during IN O
titration NN O
and CC O
parathyroid VB O
hormone NN O
calcium NN O
and CC O
calcium NN O
x NNP O
phosphorus NN O
(Ca NNP O
x NNP O
P) NNP O
product NN O
levels NNS O
. . O

The DT O
safety NN O
and CC O
tolerability NN O
of IN O
lanthanum NN O
carbonate NN O
were VBD N
assessed VBN N
by IN N
monitoring VBG N
adverse JJ O
events NNS O
throughout IN N
the DT N
study NN N
. . N

RESULTS JJ N
Mean NNP O
serum NN O
phosphorus NN O
level NN O
at IN N
the DT N
end NN N
of IN N
washout NN N
was VBD N
2.5 CD N
+/- JJ N
0.5 CD N
mmol/l JJ N
(7.7 NNP N
+/- JJ N
1.5 CD N
mg/dl; NN N
n=73) NN N
and CC N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
a DT N
difference NN N
in IN N
levels NNS N
between IN N
the DT N
treatment NN N
groups NNS N
pre-randomization NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
lanthanum VBD I
carbonate-treated JJ I
patients NNS N
had VBD N
significantly RB N
lower JJR N
phosphorus NN O
levels NNS O
(1.6 VBP N
+/- JJ N
0.5 CD N
mmol/l JJ N
[5.1 NNP N
+/- JJ N
1.5 CD N
mg/dl]; NN N
n=30) NN N
than IN N
those DT N
receiving VBG N
placebo JJ I
(2.3 JJ N
+/- JJ N
0.4 CD N
mmol/l JJ N
[7.2 NNP N
+/- JJ N
1.3 CD N
mg/dl]; NN N
n=31; NN N
p NN N
< VBD N
0.001) CD N
. . N

In IN N
addition NN N
a DT N
significantly RB N
higher JJR N
proportion NN N
of IN N
patients NNS N
receiving VBG N
lanthanum JJ I
carbonate NN I
had VBD N
controlled VBN N
serum JJ O
phosphorus NN O
levels NNS O
(60%) VBP N
compared VBN N
with IN N
the DT N
placebo NN I
group NN N
(10%; NNP N
p VBZ N
< $ N
0.001) CD N
. . N

Ca NNP O
x NNP O
P NNP O
product NN O
levels NNS O
were VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
lanthanum NN I
carbonate NN I
group NN I
at IN N
the DT N
end NN N
of IN N
randomized JJ N
treatment NN N
(p NNP N
< VBZ N
0.001) CD N
. . N

Lanthanum NNP I
carbonate NN I
was VBD N
well RB N
tolerated; IN N
only RB N
one CD N
serious JJ N
adverse JJ O
event NN O
was VBD N
reported VBN N
which WDT N
was VBD N
unrelated JJ N
to TO N
treatment NN N
. . N

CONCLUSIONS NNP N
Lanthanum NNP I
carbonate NN I
was VBD N
shown VBN N
to TO N
be VB N
an DT N
effective JJ O
and CC N
well-tolerated JJ O
phosphate NN N
binder NN N
for IN N
the DT N
treatment NN N
of IN N
hyperphosphatemia NN N
in IN N
Chinese JJ P
patients NNS P
with IN P
ESRD NNP P
. . P

This DT N
finding NN N
supports VBZ N
the DT N
results NNS N
of IN N
previous JJ N
US NNP N
and CC N
European NNP N
studies NNS N
which WDT N
have VBP N
also RB N
shown VBN N
that IN N
lanthanum NN I
carbonate NN I
treatment NN I
effectively RB N
controls VBZ N
serum JJ O
phosphorus NN O
levels NNS O
. . O

-DOCSTART- -X- N

The DT N
evolving VBG N
clinical JJ N
status NN N
of IN N
patients NNS P
after IN P
a DT P
myocardial JJ P
infarction: NN P
the DT N
importance NN N
of IN N
post-hospital JJ I
data NNS I
for IN N
mortality NN N
prediction NN N
. . N

Studies NNS N
predicting VBG N
mortality NN N
after IN N
myocardial JJ P
infarction NN P
(MI) NNP P
usually RB N
rely VBP N
on IN N
in-hospital JJ I
data NNS I
and CC I
combine NN N
patients NNS P
admitted VBN P
for IN P
the DT P
first JJ P
MI NNP P
with IN P
recurrent JJ P
MI NNP P
patients NNS P
. . P

Since IN N
treatment NN N
decisions NNS N
are VBP N
often RB N
made VBN N
or CC N
modified VBN N
at IN N
the DT N
first JJ N
outpatient NN N
clinic JJ N
visit NN N
this DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
importance NN N
of IN N
post-hospital JJ I
data NNS I
on IN N
mortality NN N
prediction NN N
after IN N
a DT N
first JJ N
myocardial JJ N
infarction NN N
(MI) NN N
. . N

An DT N
inception NN N
cohort NN P
of IN P
patients NNS P
enrolled VBN P
in IN P
the DT P
Beta-Blocker NNP P
in IN P
Heart NNP P
Attack NNP P
Trial NNP P
(n NNP P
= VBD P
2830) CD P
was VBD P
included VBN P
. . P

Forty-three JJ P
variables NNS P
(including VBG P
in-hospital JJ P
and CC P
post-hospital JJ P
data) NN P
were VBD N
evaluated VBN N
using VBG N
stepwise NN I
logistic JJ I
regression NN I
. . I

Ten CD P
variables NNS P
were VBD P
independently RB P
associated VBN P
with IN P
1-year JJ P
mortality: NN P
five CD N
used VBN N
in-hospital JJ N
data NNS N
(history NN O
of IN O
hypertension NN O
hypercholesterolemia NN O
congestive JJ O
heart NN O
failure NN O
[CHF] NNP O
ventricular JJ O
tachycardia NN O
and CC O
age); NN O
and CC N
five CD N
variables NNS N
depended VBN N
on IN N
post-hospital JJ I
data NNS I
collected VBN N
at IN N
the DT N
first JJ N
outpatient JJ N
visit NN N
(CHF NN O
after IN O
discharge JJ O
New NNP O
York NNP O
Heart NNP O
Association NNP O
functional JJ O
class NN O
heart NN O
rate NN O
pulmonary JJ O
rates NNS O
and CC O
smoking) NN O
. . N

Two CD N
predictive JJ N
systems NNS N
were VBD N
developed VBN N
that IN N
partitioned JJ N
patients NNS N
into IN N
one CD N
of IN N
four CD N
classes NNS N
with IN N
distinct JJ N
mortality NN N
risks: VBP N
a DT I
composite JJ I
system NN I
using VBG I
the DT I
10 CD I
in- JJ I
and CC I
post-hospital JJ I
variables NNS I
and CC I
a DT I
system NN I
using VBG I
only RB I
the DT I
5 CD I
in-hospital JJ I
variables NNS I
. . I

Mortality NNP O
risk NN O
for IN N
the DT N
composite JJ N
system NN N
classes NNS N
ranged VBD N
from IN N
0.6 CD N
to TO N
20.0% CD N
(I NNS N
[n JJ N
= VBD N
861] CD N
0.6%; CD N
II NNP N
[n NNP N
= VBD N
1151] CD N
2.3%; CD N
III NNP N
[n NNP N
=698] VBD N
4.3%; CD N
IV NNP N
[n NNP N
= VBD N
120] CD N
20.0%) CD N
. . N

In IN N
contrast NN N
the DT N
range NN O
of IN O
mortality NN O
risk NN N
using VBG N
the DT N
in-hospital JJ I
data NNS I
only RB N
system NN N
was VBD N
less JJR N
(1 JJ N
to TO N
8.3%) CD N
. . N

Most JJS N
importantly RB N
a DT N
distinct JJ N
gradient NN N
within IN N
each DT N
class NN N
of IN N
the DT N
in-hospital JJ I
data NNS I
only RB N
system NN N
was VBD N
created VBN N
by IN N
the DT N
addition NN N
of IN N
the DT N
post-hospital JJ P
data NNS P
. . P

This DT N
study NN N
demonstrates VBZ N
that IN N
risk NN N
stratification NN N
after IN N
an DT N
acute NN N
first RB N
MI NNP N
is VBZ N
improved VBN N
by IN N
the DT N
addition NN N
of IN N
post-hospital JJ I
data NNS I
. . I

-DOCSTART- -X- N

Randomised VBN N
community-based JJ N
trial NN N
of IN N
annual JJ N
single-dose JJ N
diethylcarbamazine NN I
with IN N
or CC N
without IN N
ivermectin NN I
against IN N
Wuchereria NNP P
bancrofti JJ P
infection NN P
in IN P
human JJ P
beings NNS P
and CC P
mosquitoes NNS P
. . P

BACKGROUND NNP P
WHO NNP N
has VBZ N
targeted VBN N
lymphatic JJ N
filariasis NN N
for IN N
elimination NN N
. . N

Studies NNS N
of IN N
vector-parasite JJ N
relations NNS N
of IN N
Wuchereria NNP N
bancrofti NN N
suggest VBP N
that IN N
a DT N
reduction NN N
in IN N
the DT N
microfilarial JJ N
reservoir NN N
by IN N
mass NN N
chemotherapy NN N
may MD N
interrupt VB N
transmission NN N
and CC N
thereby RB N
eliminate VB N
infection NN N
. . N

However RB N
no DT N
field NN N
data NNS N
exist VBP N
on IN N
the DT N
impact NN N
of IN N
chemotherapy NN N
alone RB N
on IN N
vector NN N
efficiency NN N
and CC N
transmission NN N
intensity NN N
of IN N
W NNP N
bancrofti NN N
. . N

We PRP N
compared VBN N
the DT N
impact NN N
of IN N
an DT N
annual JJ N
community-wide JJ N
single-dose JJ N
treatment NN N
with IN N
diethylcarbamazine JJ N
alone NN N
or CC N
with IN N
ivermectin JJ N
on IN N
rate NN N
and CC N
intensity NN N
of IN N
microfilaraemia NN N
and CC N
transmission NN N
intensity NN N
in IN N
an DT N
area NN N
of IN N
Papua NNP N
New NNP N
Guinea NNP N
endemic VBZ N
for IN N
intense JJ N
W NNP N
bancrofti NN N
transmission NN N
. . N

METHODS NNP N
We PRP N
carried VBD N
out RP N
clinical JJ N
and CC N
parasitological JJ N
surveys NNS N
in IN N
14 CD P
communities NNS P
in IN P
matched JJ P
pairs NNS P
. . P

People NNS P
aged VBD P
5 CD P
years NNS P
or CC P
older JJR P
in IN P
seven CD P
communities NNS P
received VBD P
randomly RB P
assigned VBN P
diethylcarbamazine NN P
6 CD P
mg/kg NN P
and CC P
people NNS P
in IN P
the DT P
other JJ P
seven CD P
communities NNS P
received VBD N
diethylcarbamazine JJ I
6 CD I
mg/kg NN I
plus CC I
ivermectin JJ I
400 CD I
micrograms/kg NN I
. . I

We PRP N
made VBD N
physical JJ N
examinations NNS N
for IN N
hydroceles NNS N
and CC N
leg NN N
oedema NN N
and CC N
investigated JJ N
microfilarial JJ N
densities NNS N
by IN N
membrane NN N
filtration NN N
before IN N
and CC N
after IN N
treatment NN N
. . N

We PRP N
selected VBD N
five CD P
communities NNS P
for IN N
monthly JJ N
entomological JJ N
surveys NNS N
between IN N
September NNP P
1993 CD P
and CC P
September NNP P
1995 CD P
. . P

Mosquitoes NNS N
were VBD N
collected VBN N
in IN N
these DT N
communities NNS N
by IN N
the DT N
all-night JJ N
landing NN N
catch NN N
method NN N
and CC N
were VBD N
individually RB N
dissected VBN N
to TO N
identify VB N
rates NNS N
of IN N
infection NN N
and CC N
infectiveness NN N
. . N

FINDINGS NN N
2219 CD P
(87.6%) NN P
of IN P
2534 CD P
eligible JJ P
people NNS P
received VBD P
treatment NN P
. . P

Microfilarial JJ O
rate NN O
and CC O
density NN O
had VBD N
decreased VBN N
1 CD N
year NN N
after IN N
treatment NN N
in IN N
all DT N
14 CD N
communities; NN N
this DT N
decrease NN N
was VBD N
significantly RB N
higher JJR N
in IN N
communities NNS N
given VBN N
combined VBD N
therapy NN N
than IN N
in IN N
those DT N
given VBN N
diethylcarbamazine VBP N
alone JJ N
(mean JJ N
decreases VBZ N
57.5% CD N
and CC N
30.6% CD N
respectively; NN N
p NN N
= VBD N
0.0013) CD N
. . N

Greater NN N
decreases NNS N
were VBD N
also RB N
seen VBN N
in IN N
community-specific JJ N
microfilarial JJ N
intensity NN N
with IN N
combined JJ N
therapy NN N
(mean JJ N
reductions NNS N
91.1% CD N
and CC N
69.8% CD N
respectively; NN N
p NN N
= VBD N
0.0047) CD N
. . N

The DT N
rate NN O
of IN O
leg NN O
oedema NN O
was VBD N
not RB N
altered VBN N
but CC N
the DT N
frequency NN N
of IN N
advanced JJ N
hydroceles NNS N
decreased VBN N
by IN N
47% CD N
with IN N
combined VBN N
therapy NN N
and CC N
56% CD N
with IN N
diethylcarbamazine NN N
alone RB N
. . N

26 CD N
641 CD N
Anopheles NNS N
punctulatus RB N
mosquitoes NNS N
were VBD N
caught VBN N
during IN N
499 CD N
person-nights NNS N
of IN N
landing VBG N
catches NNS N
. . N

Exposure NN N
to TO N
infective VB O
third-stage NN O
larvae NN O
decreased VBN N
in IN N
all DT N
monitored JJ N
five CD N
communities NNS N
. . N

Annual JJ O
transmission NN O
potential NN O
decreased VBN N
by IN N
between IN N
75.7% CD N
and CC N
98.8% CD N
in IN N
combined-therapy JJ N
communities NNS N
and CC N
between IN N
75.6% CD N
and CC N
79.4% CD N
in IN N
communities NNS N
given VBN N
diethylcarbamazine JJ N
alone RB N
. . N

Transmission NN N
was VBD N
almost RB N
interrupted VBN N
in IN N
two CD N
communities NNS N
treated VBN N
with IN N
combined JJ N
therapy NN N
. . N

INTERPRETATION NNP N
Annual NNP N
single-dose JJ N
community-wide JJ N
treatment NN N
with IN N
diethylcarbamazine JJ N
alone NN N
or CC N
with IN N
ivermectin NN N
is VBZ N
effective JJ O
for IN N
the DT N
control NN N
of IN N
lymphatic JJ N
filariasis NN N
in IN N
highly RB N
endemic JJ N
areas NNS N
but CC N
combination NN N
therapy NN N
brings VBZ N
about IN N
greater JJR N
decreases NNS N
in IN N
rates NNS O
and CC O
intensity NN O
of IN O
microfilaraemia NN O
. . O

-DOCSTART- -X- N

Preschool NNP I
based VBN I
JASPER NNP I
intervention NN I
in IN I
minimally RB P
verbal JJ P
children NNS P
with IN P
autism: NN P
pilot NN I
RCT NNP I
. . I

In IN I
this DT I
pilot NN I
study NN I
we PRP I
tested VBD I
the DT I
effects NNS I
of IN I
a DT I
novel JJ I
intervention NN I
(JASPER NN I
Joint NNP I
Attention NNP I
Symbolic NNP I
Play NNP I
Engagement NNP I
and CC I
Regulation) NNP I
on IN I
3 CD P
to TO P
5year CD P
old JJ P
minimally RB P
verbal JJ P
children NNS P
with IN P
autism NN P
who WP P
were VBD P
attending VBG P
a DT P
non-public JJ P
preschool NN P
. . I

Participants NNS I
were VBD I
randomized VBN I
to TO I
a DT I
control NN I
group NN I
(treatment VBD I
as IN I
usual JJ I
30h CD I
of IN I
ABA-based JJ I
therapy NN I
per IN I
week) NN I
or CC I
a DT I
treatment NN I
group NN I
(substitution NN I
of IN I
30min CD I
of IN I
JASPER NNP I
treatment NN I
twice RB I
weekly RB I
during IN I
their PRP$ I
regular JJ I
program) NN I
. . I

A DT I
baseline NN I
of IN I
12 CD I
weeks NNS I
in IN I
which WDT I
no DT I
changes NNS I
were VBD I
noted VBN I
in IN O
core NN O
deficits NNS O
was VBD I
followed VBN I
by IN I
12weeks CD I
of IN I
intervention NN I
for IN I
children NNS I
randomized VBN I
to TO I
the DT I
JASPER NNP I
treatment NN I
. . I

Participants NNS I
in IN I
the DT I
treatment NN I
group NN I
demonstrated VBD O
greater JJR O
play NN O
diversity NN O
on IN O
a DT O
standardized JJ O
assessment NN O
. . I

Effects NNS I
also RB I
generalized VBD I
to TO I
the DT I
classroom NN I
where WRB I
participants NNS I
in IN I
the DT I
treatment NN I
group NN I
initiated VBD I
more JJR O
gestures NNS O
and CC O
spent VB O
less JJR O
time NN O
unengaged JJ O
. . I

These DT I
results NNS I
provide VBP I
further JJ I
support NN I
that WDT I
even RB I
brief VBP I
targeted JJ I
interventions NNS I
on IN I
joint JJ I
attention NN I
and CC I
play NN I
can MD I
improve VB I
core NN I
deficits NNS P
in IN P
minimally RB P
verbal JJ P
children NNS P
with IN P
ASD NNP P
. . N

-DOCSTART- -X- N

A DT N
randomised VBN N
controlled VBN N
trial NN N
comparing VBG N
Drawtex NNP I
with IN I
standard JJ I
dressings NNS I
for IN N
exuding VBG P
wounds NNS P
. . P

OBJECTIVE IN N
This DT N
randomised VBN N
controlled VBD N
clinical JJ N
trial NN N
compared VBN N
a DT N
capillary JJ I
dressing NN I
(Drawtex NN I
now RB I
rebranded VBN I
as IN I
Vibriant NNP I
RCD NNP I
[Vibriant NNP I
Technology NNP I
Services]) NNP I
with IN I
routine JJ I
practice NN I
for IN I
exuding VBG P
wounds NNS P
greater JJR P
than IN P
2.5 CD P
x JJ P
2.5 CD P
cm NN P
. . P

METHOD NNP N
The DT N
target NN P
population NN P
was VBD P
300 CD P
control NN P
and CC P
300 CD P
test NN P
subjects NNS P
across IN P
three CD P
sites NNS P
in IN P
the DT P
UK NNP P
but CC P
recruitment JJ P
difficulties NNS P
resulted VBD P
in IN P
only RB P
125 CD P
patients NNS P
being VBG P
evaluable JJ P
. . P

Wound NNP O
progress NN O
was VBD N
recorded VBN N
by IN N
nurses' JJ N
perception NN N
of IN N
the DT N
progress NN N
of IN N
wound NN N
healing NN N
and CC N
by IN N
objective JJ N
digital JJ N
imaging NN N
. . N

In IN N
the DT N
final JJ N
analysis NN N
digital JJ N
images NNS N
were VBD N
randomised VBN N
(in JJ N
time NN N
order) NN N
and CC N
a DT N
panel NN N
of IN N
nurses NNS N
who WP N
were VBD N
not RB N
otherwise RB N
involved VBN N
in IN N
the DT N
research NN N
project NN N
graded VBD N
the DT N
wound's NN N
progress NN N
. . N

RESULTS NN N
After IN N
deconvolution NN N
of IN N
the DT N
data NNS N
the DT N
subjective JJ N
(nurse NN N
perception) NN N
method NN N
of IN N
evaluation NN N
determined VBD N
that IN N
the DT N
new JJ N
dressing NN N
resulted VBD N
in IN N
wound NN O
improvement NN O
in IN N
12.7% CD N
more JJR N
patients NNS N
than IN N
did VBD N
routine JJ N
practice NN N
but CC N
the DT N
blinded JJ N
assessment NN N
method NN N
(based VBN N
on IN N
the DT N
digital JJ N
images) NN N
showed VBD N
that IN N
routine JJ N
practice NN N
was VBD N
better JJR N
by IN N
6.6% CD N
. . N

CONCLUSION NNP N
Evaluation NNP N
of IN N
wound NN O
progress NN O
is VBZ N
clearly RB N
difficult JJ N
. . N

Human JJ N
nature NN N
makes VBZ N
us PRP N
favour VB N
novelty NN N
if IN N
we PRP N
believe VBP N
it PRP N
is VBZ N
going VBG N
to TO N
be VB N
better JJR N
. . N

Making VBG N
interpretation NN N
more RBR N
objective JJ N
removed VBD N
that IN N
bias NN N
and CC N
did VBD N
not RB N
demonstrate VB N
a DT N
significant JJ N
advantage NN N
for IN N
the DT N
test NN N
dressing NN N
. . N

The DT N
findings NNS N
suggest VBP N
that IN N
unblinded JJ N
assessment NN N
by IN N
trial NN N
nurses NNS N
is VBZ N
unacceptable JJ N
on IN N
its PRP$ N
own JJ N
. . N

Blinded VBN N
assessments NNS N
may MD N
miss VB N
finer JJR N
nuances NNS N
of IN N
wound JJ O
progression NN O
but CC O
are VBP N
likely JJ N
to TO N
be VB N
more JJR N
accurate NN N
. . N

The DT N
authors NNS N
suggest VBP N
that IN N
the DT N
true JJ N
result NN N
lies VBZ N
somewhere RB N
in IN N
the DT N
middle NN N
with IN N
the DT N
trial NN N
dressing VBG N
likely JJ N
to TO N
be VB N
as RB N
effective JJ N
as IN N
but CC N
not RB N
more RBR N
effective JJ N
than IN N
a DT N
standard JJ N
dressing NN N
. . N

-DOCSTART- -X- N

Clinical JJ N
significance NN N
and CC N
prognostic JJ N
importance NN N
of IN N
left JJ N
ventricular JJ N
hypertrophy NN N
in IN N
non-Q-wave JJ P
acute JJ P
myocardial JJ P
infarction NN P
. . P

Left NNP N
ventricular JJ N
(LV) NNP N
hypertrophy NN N
is VBZ N
known VBN N
to TO N
be VB N
an DT N
independent JJ N
risk NN N
factor NN N
for IN N
cardiac JJ N
death NN N
but CC N
its PRP$ N
significance NN N
in IN N
non-Q-wave JJ P
acute JJ P
myocardial JJ P
infarction NN P
(AMI) NN P
has VBZ N
not RB N
been VBN N
assessed VBN N
previously RB N
. . N

In IN N
a DT N
randomized JJ I
diltiazem-placebo-controlled JJ I
therapeutic JJ I
trial NN I
of IN I
non-Q-wave JJ P
AMI NNP P
confirmed VBN P
by IN P
creatine JJ P
kinase-MB JJ P
(CK-MB) JJ P
126 CD P
of IN N
544 CD P
patients NNS P
(23%) RB N
exhibited VBD N
LV NNP N
hypertrophy NN N
using VBG N
standard JJ N
voltage NN N
criteria NNS N
. . N

Compared VBN N
to TO P
patients NNS P
without IN P
LV NNP P
hypertrophy NN P
patients NNS P
with IN P
LV NNP P
hypertrophy NN P
were VBD P
significantly RB P
older JJR P
(65 NNP P
vs IN P
60 CD P
years NNS P
p RB P
less JJR P
than IN P
0.0001) CD P
and CC P
had VBD P
smaller JJR P
peak NN P
adjusted VBN P
CK NNP P
levels NNS P
(490 VBP P
+/- JJ P
376 CD P
vs JJ P
666 CD P
+/- JJ P
726 CD P
IU/liter NNP P
p NN P
less JJR P
than IN P
0.001) CD P
than IN P
patients NNS P
without IN P
LV NNP P
hypertrophy NN P
. . P

Patients NNS P
with IN P
and CC P
without IN P
LV NNP P
hypertrophy NN P
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
acute JJ N
mortality NN O
during IN N
hospitalization NN O
progression NN O
to TO O
Q NNP O
waves NNS O
reinfarction NN O
by IN O
CK-MB NNP O
criteria NNS O
or CC O
angina NNS O
associated VBN N
with IN N
transient JJ N
electrocardiographic JJ N
changes NNS N
. . N

Compared VBN N
with IN N
patients NNS N
without IN N
LV NNP N
hypertrophy NN N
those DT N
patients NNS P
with IN P
non-Q-wave JJ P
AMI NNP P
and CC P
LV NNP P
hypertrophy NN P
had VBD N
a DT N
2-fold JJ N
higher JJR N
incidence NN N
of IN N
reinfarction NN O
(24 NNP N
vs VBZ N
12% CD N
p NN N
less JJR N
than IN N
0.005) CD N
and CC N
death NN N
(19 NN N
vs NN N
9% CD N
p NN N
= VBD N
0.044) CD N
during IN N
the DT N
first JJ N
year NN N
of IN N
follow-up NN N
. . N

Multivariate NNP N
regression NN N
analysis NN N
revealed VBD N
that IN N
the DT N
relative JJ N
risk NN N
of IN N
death NN O
and CC O
reinfarction NN O
during IN N
the DT N
initial JJ N
year NN N
after IN N
AMI NNP N
was VBD N
increased VBN N
by IN N
a DT N
factor NN N
of IN N
1.7 CD N
and CC N
2.1 CD N
among IN N
patients NNS N
with IN N
LV NNP N
hypertrophy NN N
respectively RB N
. . N

-DOCSTART- -X- N

Impact NN N
of IN N
a DT N
controlled VBN I
heated VBN I
breathing VBG I
tube NN I
humidifier NN I
on IN N
sleep JJ O
quality NN O
during IN N
CPAP NNP P
therapy NN P
in IN P
a DT P
cool JJ I
sleeping NN I
environment NN P
. . P

There EX N
are VBP N
conflicting VBG N
data NNS N
on IN N
the DT N
effect NN N
of IN N
adding VBG N
a DT N
heated VBN I
humidifier NN I
to TO N
nasal RB I
continuous JJ I
positive JJ I
airway NN I
pressure NN I
(CPAP) NNP I
therapy NN I
for IN N
patients NNS P
with IN P
obstructive JJ P
sleep JJ P
apnoea NN P
syndrome NN P
(OSAS) NN P
. . P

The DT N
effects NNS N
of IN N
heated JJ I
humidification NN I
on IN N
sleep JJ O
quality NN O
and CC O
treatment NN O
side-effects NNS O
for IN N
patients NNS N
who WP N
prefer VBP N
a DT N
cold JJ N
bedroom NN N
environment NN N
have VBP N
not RB N
been VBN N
studied VBN N
. . N

A DT N
randomised VBN N
controlled VBN N
crossover RB N
trial NN N
involving VBG N
19 CD P
patients NNS P
with IN P
a DT P
first-ever JJ P
diagnosis NN P
of IN P
OSAS NNP P
measured VBD N
the DT N
effect NN N
of IN N
conventional JJ I
heated JJ I
humidification NN I
added VBD I
to TO I
CPAP NNP I
compared VBN I
with IN I
a DT I
controlled VBN I
heated VBN I
breathing VBG I
tube NN I
humidifier NN I
(ThermoSmart(R); NNP I
Fisher NNP N
and CC N
Paykel NNP N
Healthcare NNP N
Auckland NNP N
New NNP N
Zealand) NNP N
on IN N
sleep JJ O
quality NN O
. . O

During IN N
the DT N
night NN N
in IN N
the DT N
sleep JJ N
laboratory NN N
at IN N
a DT N
mean JJ N
room NN N
temperature NN N
of IN N
14 CD N
degrees NNS N
C NNP N
less JJR N
condensation NN O
formed VBN N
with IN N
the DT N
controlled VBN I
heated VBD I
breathing VBG I
tube NN I
humidifier JJR I
(1.9 JJ N
mL NN N
versus NN N
35.3 CD N
mL) NN N
in IN N
the DT N
delivery NN N
system NN N
. . N

In IN N
addition NN N
the DT N
total JJ O
sleep JJ O
time NN O
time NN O
spent VBN O
in IN O
sleep JJ O
stages NNS O
3 CD O
and CC O
4 CD O
and CC O
rapid JJ O
eye NN O
movement NN O
sleep JJ O
phases NNS O
were VBD N
significantly RB N
longer RBR N
and CC N
the DT N
overall JJ O
side-effect JJ O
score NN O
was VBD N
lower JJR N
than IN N
with IN N
conventional JJ I
heated JJ I
humidification NN I
. . I

Patients NNS N
on IN N
nasal JJ N
continuous JJ I
positive JJ I
airway NN I
pressure NN I
desiring VBG N
a DT N
cool JJ N
bedroom NN N
temperature NN N
could MD N
benefit VB N
from IN N
controlled VBN I
heated VBN I
breathing VBG I
tube JJ I
humidification NN I
technology NN I
(with NNP N
inputs NNS N
from IN N
ambient JJ N
temperature NN N
set VBN N
pressure NN N
and CC N
flow) NN N
. . N

-DOCSTART- -X- N

Do VB N
physicians' NNS N
implicit VB N
views NNS N
of IN N
African JJ P
Americans NNPS P
affect VBP N
clinical JJ N
decision NN N
making VBG N
BACKGROUND NNP N
Total NNP I
knee FW I
replacement NN I
(TKR) NN I
is VBZ N
a DT N
cost-effective JJ N
treatment NN N
option NN N
for IN N
severe JJ N
osteoarthritis NN N
(OA) NN N
. . N

While IN N
prevalence NN N
of IN N
OA NNP P
is VBZ P
higher JJR P
among IN P
blacks NNS P
than IN P
whites NNS P
TKR NNP P
rates NNS N
are VBP N
lower JJR N
among IN N
blacks NNS N
. . N

Physicians' NNP N
implicit JJ N
preferences NNS N
might MD N
explain VB N
racial JJ N
differences NNS N
in IN N
TKR NNP I
recommendation NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
the DT N
magnitude NN N
of IN N
implicit JJ N
racial JJ O
bias NN O
predicts VBZ N
physician JJ N
recommendation NN N
of IN N
TKR NNP I
for IN N
black JJ N
and CC N
white JJ N
patients NNS N
with IN N
OA NNP N
and CC N
to TO N
assess VB N
the DT N
effectiveness NN O
of IN N
a DT N
web-based JJ I
instrument NN I
as IN N
an DT N
intervention NN N
to TO N
decrease VB N
the DT N
effect NN N
of IN N
implicit JJ N
racial JJ N
bias NN N
on IN N
physician JJ N
recommendation NN N
of IN N
TKR NNP I
. . I

METHODS NNP N
In IN N
this DT N
web-based JJ P
study NN P
543 CD P
family NN P
and CC P
internal JJ P
medicine NN P
physicians NNS P
were VBD I
given VBN I
a DT I
scenario NN I
describing VBG I
either CC I
a DT I
black JJ P
or CC P
white JJ P
patient NN P
with IN P
severe JJ P
OA NNP P
refractory NN P
to TO P
medical JJ P
treatment NN P
. . P

Questionnaires NNS I
evaluating VBG I
the DT I
likelihood NN I
of IN I
recommending VBG I
TKR NNP I
perceived VBD I
medical JJ I
cooperativeness NN I
and CC I
measures NNS I
of IN I
implicit JJ I
racial JJ I
bias NN I
were VBD I
administered VBN I
. . I

The DT I
main JJ I
outcome NN I
measures NNS I
included VBD I
TKR NNP O
recommendation NN O
implicit NN O
racial JJ O
preference NN O
and CC O
medical JJ O
cooperativeness NN O
stereotypes NNS O
measured VBN I
with IN I
implicit JJ I
association NN I
tests NNS I
. . I

RESULTS NNP N
Subjects NNP N
displayed VBD N
a DT N
strong JJ N
implicit JJ N
preference NN N
for IN N
whites NNS N
over IN N
blacks NNS N
(P VBP N
< JJ N
.0001) NNP N
and CC N
associated VBN N
"medically RB O
cooperative" JJ O
with IN N
whites NNS N
over IN N
blacks NNS N
(P VBP N
< JJ N
.0001) NN N
. . N

Physicians NNS N
reported VBN N
significantly RB N
greater JJR N
liking VBG O
for IN N
whites NNS N
over IN N
blacks NNS N
(P VBP N
< JJ N
.0001) NN N
and CC N
reported VBD N
believing VBG N
whites NNS N
were VBD N
more RBR N
medically RB O
cooperative JJ O
than IN N
blacks NNS N
(P VBP N
< JJ N
.0001) NN N
. . N

Participants NNS N
reported VBD N
providing VBG N
similar JJ N
care NN O
for IN N
white JJ N
and CC N
black JJ N
patients NNS N
(P JJ N
= JJ N
.10) NN N
but CC N
agreed VBD N
that IN N
subconscious JJ N
biases NNS N
could MD N
influence VB N
their PRP$ N
treatment NN N
decisions NNS N
(P VBP N
< JJ N
.0001) NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN O
of IN O
recommendation NN O
for IN O
TKR NNP O
when WRB N
the DT N
patient NN N
was VBD N
black JJ N
(47%) NNP N
versus NN N
white JJ N
(38%) NN N
(P NN N
= NNP N
.439) NNP N
and CC N
neither DT N
implicit JJ N
nor CC N
explicit JJ N
racial JJ N
biases NNS N
predicted VBD N
differential JJ N
treatment NN N
recommendations NNS N
by IN N
race NN N
(all NN N
P NNP N
> NNP N
.06) NNP N
. . N

Although IN N
participants NNS N
were VBD N
more RBR N
likely JJ N
to TO N
recommend VB O
TKR NNP O
when WRB N
completing VBG N
the DT N
implicit JJ N
association NN N
test NN N
before IN N
the DT N
decision NN N
patient NN N
race NN N
was VBD N
not RB N
significant JJ N
in IN N
the DT N
association NN N
(P NNP N
= NNP N
.960) NNP N
. . N

CONCLUSIONS NNP N
Physicians NNPS N
possessed VBD N
explicit NN N
and CC N
implicit JJ N
racial JJ N
biases NNS N
but CC N
those DT N
biases NNS N
did VBD N
not RB N
predict VB N
treatment NN N
recommendations NNS N
. . N

Clinicians' NNP N
biases VBZ N
about IN N
the DT N
medical JJ N
cooperativeness NN N
of IN N
blacks NNS N
versus VBP N
whites NNS N
however RB N
may MD N
have VB N
influenced VBN N
treatment NN N
decisions NNS N
. . N

-DOCSTART- -X- N

Implementing VBG N
a DT N
simplified JJ I
neonatal JJ P
resuscitation NN P
protocol-helping JJ P
babies NNS P
breathe VBP P
at IN P
birth NN P
(HBB) SYM I
- : N
at IN N
a DT N
tertiary JJ P
level NN P
hospital NN P
in IN P
Nepal NNP P
for IN N
an DT N
increased JJ N
perinatal NN N
survival NN N
. . N

BACKGROUND NNP N
Reducing NNP N
neonatal JJ N
death NN N
has VBZ N
been VBN N
an DT N
emerging VBG N
challenge NN N
in IN N
low JJ P
and CC P
middle JJ P
income NN P
countries NNS P
in IN N
the DT N
past JJ N
decade NN N
. . N

The DT N
development NN N
of IN N
the DT N
low JJ I
cost NN I
interventions NNS I
and CC N
their PRP$ N
effective JJ N
delivery NN N
are VBP N
needed VBN N
to TO N
reduce VB N
deaths NNS N
from IN N
birth NN N
asphyxia NN N
. . N

This DT N
study NN N
will MD N
assess VB N
the DT N
impact NN N
of IN N
a DT N
simplified JJ I
neonatal JJ I
resuscitation NN I
protocol NN I
provided VBN I
by IN I
Helping VBG I
Babies NNP I
Breathe NNP I
(HBB) NNP I
at IN N
a DT N
tertiary JJ P
hospital NN P
in IN P
Nepal NNP P
. . P

Perinatal JJ N
outcomes NNS N
and CC N
performance NN N
of IN N
skilled JJ P
birth NN P
attendants NNS P
on IN N
management NN N
of IN N
intrapartum-related JJ N
neonatal JJ N
hypoxia NN N
will MD N
be VB N
the DT N
main JJ N
measurements NNS N
. . N

METHODS/DESIGN NNP N
The DT N
study NN N
will MD N
be VB N
carried VBN N
out RP N
at IN N
a DT N
tertiary JJ P
level NN P
maternity NN P
hospital NN P
in IN P
Nepal NNP P
. . P

A DT N
prospective JJ N
cohort-study NN N
will MD N
include VB N
a DT N
six-month JJ N
baseline NN N
a DT N
six CD N
month NN N
intervention NN N
period NN N
and CC N
a DT N
three-month JJ N
post NN N
intervention NN N
period NN N
. . N

A DT N
quality NN N
improvement NN N
process NN N
cycle NN N
will MD N
introduce VB N
the DT N
neonatal JJ I
resuscitation NN I
protocol NN I
. . I

A DT N
surveillance NN I
system NN I
including VBG I
CCD NNP I
cameras NNS I
and CC I
pulse JJ I
oximeters NNS I
will MD I
be VB N
set VBN N
up RP N
to TO N
evaluate VB N
the DT N
intervention NN N
. . N

DISCUSSION NNP N
Along NNP N
with IN N
a DT N
technique NN N
to TO N
improve VB N
health NN O
workers NNS O
performance NN O
on IN N
the DT N
protocol NN N
the DT N
study NN N
will MD N
generate VB N
evidence NN N
on IN N
the DT N
research NN N
gap NN N
on IN N
the DT N
effectiveness NN N
of IN N
the DT N
simplified JJ I
neonatal JJ I
resuscitation NN I
protocol NN I
on IN N
intrapartum NN O
outcome NN O
and CC O
early JJ O
neonatal JJ O
survival NN O
. . O

This DT N
will MD N
generate VB N
a DT N
global JJ N
interest NN N
and CC N
inform NN N
policymaking NN N
in IN N
relation NN N
to TO N
delivery NN N
care NN N
in IN N
all DT N
income NN N
settings NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN97846009 NNP N
. . N

-DOCSTART- -X- N

Prognostic JJ N
value NN N
of IN N
clinical JJ N
laboratory NN N
and CC N
histological JJ N
characteristics NNS N
in IN N
multiple JJ N
myeloma: NN N
improved VBD N
definition NN N
of IN N
risk NN N
groups NNS N
. . N

Follow-up NNP N
data NNS N
of IN N
320 CD P
multiple JJ P
myeloma NN P
(MM) NN P
patients NNS P
entering VBG P
the DT P
German JJ P
Myeloma NNP P
Treatment NNP P
Group NNP P
(GMTG) NNP P
trial NN P
MM01 NNP P
were VBD P
analysed VBN N
for IN N
factors NNS N
predicting VBG N
overall JJ O
(OAS) NN O
and CC O
tumour NN O
related JJ O
survival NN O
(TRS) NN P
. . P

Response NN N
to TO N
primary JJ I
induction NN I
chemotherapy NN I
was VBD N
relevant JJ N
for IN N
prognosis NN N
if IN N
a DT N
limit NN N
of IN N
25% CD N
tumour NNS O
cell NN O
mass NN O
(TCM) NNP O
reduction NN N
was VBD N
used VBN N
to TO N
separate JJ N
responders NNS N
from IN N
non-responders NNS N
. . N

Furthermore RB N
TCM NNP N
histological JJ O
grading NN O
of IN O
myeloma NN O
cells NNS O
degree NN O
of IN O
bone NN O
marrow NN O
infiltration NN O
haemoglobin NN O
platelet NN O
counts VBZ O
calcium JJ O
creatinine NN O
albumin NN O
beta NN O
2M CD O
and CC O
Bence NNP O
Jones NNP O
proteinuria NNS O
correlated VBD N
to TO N
both DT N
OAS NNP N
and CC N
TRS NNP N
. . N

Age NNP N
was VBD N
relevant JJ N
for IN N
OAS NNP N
only RB N
. . N

The DT N
multivariate NN N
analysis NN N
revealed VBD N
histological JJ O
grading NN O
TCM NNP O
and CC O
platelets NNS O
as IN N
the DT N
most RBS N
reliable JJ N
prognostic JJ N
factors NNS N
. . N

Based VBN N
on IN N
these DT N
data NNS N
the DT N
Durie/Salmon NNP N
classification NN N
could MD N
be VB N
improved VBN N
by IN N
defining VBG P
poor JJ P
prognosis NN P
patients NNS P
(50% VBP P
TRS: NNP P
16 CD P
months) NN P
characterised VBN P
by IN P
pretreatment JJ P
platelets NNS P
of IN P
< NN P
or CC P
= VB P
150 CD P
000 CD P
and/or NNS P
poorly RB P
differentiated VBD P
myeloma NN P
cell NN P
morphology NN N
. . N

Patients NNS P
lacking VBG P
both DT P
risk NN P
factors NNS P
displayed VBD P
50% CD P
survival JJ P
times NNS P
of IN P
46 CD P
months NNS P
in IN P
stage NN P
III NNP P
and CC P
88 CD P
months NNS P
in IN P
stage NN P
II NNP P
. . P

-DOCSTART- -X- N

Clinical JJ N
trials NNS N
of IN N
intrasplenic JJ I
arterial JJ I
infusion NN I
of IN I
interleukin-2 JJ I
(IS-IL-2) JJ I
to TO N
patients NNS P
with IN P
advanced JJ P
cancer NN P
. . P

We PRP P
tried VBD N
a DT N
infusion NN I
of IN I
interleukin-2 JJ I
(IL-2) NN I
of IN N
a DT N
relatively RB N
low JJ N
dose NN N
via IN I
an DT I
intrasplenic JJ I
arterial JJ I
catheter NN I
connected VBN I
to TO I
a DT I
chronometric JJ I
infusion NN I
(IS-IL-2) NN I
. . I

Eighteen JJ P
patients NNS P
of IN P
colorectal JJ P
cancer NN P
with IN P
metastases NNS P
to TO P
the DT P
liver NN P
or CC P
lung NN P
or CC P
of IN P
unresectable JJ P
hepatoma NN P
received VBD N
a DT N
24 CD I
hour NN I
continuous JJ I
infusion NN I
with IN I
low JJ I
dose JJ I
recombinant NN I
of IN I
IL-2 NNP I
(mainly RB I
8 CD N
x JJ N
10(5) CD N
JRU/day) NNP N
for IN N
25-40 JJ N
days NNS N
. . N

All DT N
patients NNS N
tolerated VBD N
this DT N
protocol NN N
of IN N
the DT N
therapy NN N
and CC N
the DT N
main JJ N
toxic NN N
effects NNS N
were VBD N
fever RB O
and CC O
general JJ O
fatigue NN O
. . O

Such JJ N
serious JJ N
toxicity NN N
as IN N
previously RB N
reported VBN N
by IN N
high JJ I
dose JJ I
IL-2 NNP I
therapy NN I
was VBD N
not RB N
observed VBN N
. . N

Data NNP N
of IN N
hepatic JJ O
and CC O
renal JJ O
functions NNS O
were VBD N
normal JJ N
. . N

IS-IL-2 JJ I
therapy NN I
induced VBD N
a DT N
high JJ O
incidence NN O
of IN O
eosinophilia JJ O
(12/18) NNP O
and CC O
thrombocythemia NN O
(12/18) NN N
. . N

Peripheral JJ O
natural JJ O
killer NN O
(NK) NN O
and CC N
LAK NNP O
activities NNS O
were VBD N
augmented VBN N
in IN N
all DT N
patients NNS N
and CC N
total JJ O
white JJ O
blood NN O
cell NN O
counts NNS O
were VBD N
increased VBN N
during IN N
IS-IL-2 NNP I
therapy NN I
. . I

An DT N
increase NN N
in IN N
IL-2 NNP O
receptor NN O
expression NN O
of IN N
peripheral JJ N
blood NN N
mononuclear NN N
cells NNS N
and CC N
significant JJ N
rises NNS N
in IN N
numbers NNS N
of IN N
Leu11 NNP N
(CD16)+ NNP N
OKM1(CD11)+ NNP N
and CC N
OKIa1(HLA-DR)+ NNP N
were VBD N
observed VBN N
. . N

Of IN P
18 CD P
patients NNS P
12 CD P
were VBD P
evaluable JJ P
for IN N
their PRP$ N
response NN N
to TO N
therapy NN N
. . N

Partial JJ N
response NN N
(PR) NN N
was VBD N
observed VBN N
in IN N
one CD N
unresectable JJ N
hepatoma NN N
and CC N
11 CD N
demonstrated VBD N
no DT N
change NN N
(NC) VBD N
or CC N
progressive JJ N
disease NN N
(PD) NNP N
. . N

Six CD N
patients NNS N
were VBD N
not RB N
evaluable JJ N
because IN N
of IN N
additional JJ N
therapy NN N
(3 NNP N
cases) NN N
or CC N
decreasing VBG N
tumor NN N
cell NN N
markers NNS N
having VBG N
no DT N
measurable JJ N
lesions NNS N
(3 VBP N
cases) NN N
. . N

Three CD N
patients NNS N
of IN N
colorectal JJ N
cancer NN N
from IN N
an DT N
unresectable JJ N
group NN N
were VBD N
presumed VBN N
to TO N
have VB N
micrometastases NNS N
to TO N
the DT N
liver NN N
as IN N
suggested VBN N
by IN N
an DT N
elevated JJ N
serum NN N
CEA NNP N
level NN N
. . N

-DOCSTART- -X- N

The DT N
effect NN N
of IN N
inhaled JJ N
leukotriene NN I
D4 NNP I
and CC N
methacholine VB I
on IN N
sputum NN O
cell NN O
differentials NNS O
in IN N
asthma NN P
. . P

The DT I
cysteinyl NN I
leukotriene NN I
LTE4 NNP I
has VBZ N
been VBN N
shown VBN N
to TO N
induce VB N
airway RP O
eosinophilia NNS O
in IN N
asthmatics NNS N
in IN N
vivo NN N
. . N

This DT N
phenomenon NN N
has VBZ N
not RB N
yet RB N
been VBN N
reported VBN N
for IN N
LTD4 NNP I
. . I

Hence NN N
we PRP N
examined VBD N
the DT N
effect NN N
of IN N
inhaled JJ I
LTD4 NNP I
and CC I
a DT I
control NN I
bronchoconstrictor NN I
agent NN I
methacholine NN I
on IN I
cell NN N
differentials NNS N
in IN N
hypertonic JJ N
saline-induced JJ N
whole JJ N
sputum NN N
samples NNS N
of IN N
12 CD P
nonsmoking VBG P
atopic NN P
asthmatic JJ P
subjects NNS P
(three JJ P
women NNS P
nine CD P
men; $ P
21 CD P
to TO P
29 CD P
yr NN P
of IN P
age; JJ P
FEV1 NNP P
74 CD P
to TO P
120% CD P
pred; NNS P
PC20FEV1 NNP P
methacholine NN P
< NN P
9.6 CD P
mg/ml) NN P
. . P

The DT N
study NN N
had VBD N
a DT N
cross-over JJ N
placebo-controlled JJ I
design NN N
consisting NN N
of IN N
4 CD N
d NN N
separated VBN N
by IN N
> NN N
or CC N
= $ N
1 CD N
wk NN N
. . N

On IN N
each DT N
randomized VBN N
study NN N
day NN N
the DT N
subjects NNS N
inhaled VBD N
five CD N
serial JJ N
doses NNS N
of IN N
either DT N
LTD4 NNP I
(mean NNP N
cumulative JJ N
concentration: NN N
95.7 CD N
microM) NN N
or CC N
methacholine JJ I
(mean JJ N
cumulative JJ N
concentration: NN N
542 CD N
mM) NN N
or CC N
five CD N
doses NNS N
of IN N
their PRP$ N
respective JJ N
diluents NNS N
(PBS/ethanol VBP I
or CC N
PBS) NNP N
. . N

The DT N
airway NN N
response NN N
was VBD N
measured VBN N
by IN N
FEV1 NNP I
followed VBN I
by IN N
sputum JJ I
induction NN I
with IN I
4.5% CD I
NaCl NNP I
4 CD I
h NN I
postchallenge NN I
. . I

Inflammatory NNP N
cells NNS N
(> VBD N
or CC N
= $ N
250) CD N
were VBD N
counted VBN N
twice RB N
on IN N
coded JJ N
cytospins NNS N
and CC N
expressed VBD N
as IN N
percentages NNS N
of IN N
nonsquamous JJ N
cells NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
maximal JJ O
percent NN O
fall NN O
in IN O
FEV1 NNP O
from IN N
baseline NN N
between IN N
LTD4 NNP N
(mean NNP N
+/- NNP N
SEM NNP N
49.5 CD N
+/- JJ N
4.4% CD N
fall) NN N
and CC N
methacholine JJ N
(mean JJ N
+/- JJ N
SEM NNP N
55.9 CD N
+/- JJ N
3.4% CD N
fall) NN N
(p NNP N
= VBZ N
0.11) CD N
. . N

LTD4 NNP N
induced VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
percentage NN N
of IN N
sputum NN O
eosinophils NNS O
as IN N
compared VBN N
with IN N
its PRP$ N
diluent JJ N
(mean JJ N
+/- JJ N
SD NNP N
26.6 CD N
+/- JJ N
21.3% CD N
and CC N
10.2 CD N
+/- JJ N
8.8% CD N
respectively; NN N
p NN N
= VBD N
0.025) CD N
whereas IN N
a DT N
similar JJ N
trend NN N
for IN N
methacholine NN N
failed VBD N
to TO N
reach VB N
significance JJ N
(mean JJ N
+/- JJ N
SD NNP N
19.1 CD N
+/- JJ N
22.9% CD N
and CC N
7.8 CD N
+/- JJ N
5.8% CD N
respectively; NN N
p NN N
= VBD N
0.11) CD N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
changes NNS N
in IN N
the DT N
percentage NN O
of IN O
sputum NN O
eosinophils NNS O
between IN N
LTD4 NNP N
and CC N
methacholine JJ N
(mean JJ N
difference NN N
+/- JJ N
SD NNP N
7.5 CD N
+/- JJ N
12.5% CD N
eosinophils; NN N
p NN N
= VBD N
0.09) CD N
. . N

We PRP N
conclude VBP N
that IN N
LTD4 NNP I
induces NNS N
eosinophilia VBP O
in IN N
sputum NN N
of IN N
asthmatic JJ N
subjects NNS N
4 CD N
h NN N
after IN N
inhalation NN N
. . N

Our PRP$ N
data NNS N
suggest VBP N
that IN N
LTD4 NNP I
recruits VBZ N
eosinophils NNS O
into IN N
the DT N
airways NNS N
of IN N
asthmatics NNS N
in IN N
vivo NN N
possibly RB N
by IN N
virtue NN N
of IN N
direct JJ N
or CC N
indirect JJ N
chemotactic JJ N
properties NNS N
whereas VBP N
an DT N
additional JJ N
effect NN N
of IN N
vigourous JJ O
airway NN O
narrowing VBG O
per IN N
se FW N
cannot NN N
be VB N
excluded VBN N
. . N

-DOCSTART- -X- N

The DT N
paroxetine NN I
352 CD P
bipolar JJ P
trial: NN P
A DT N
study NN N
in IN N
medical JJ N
ghostwriting NN N
. . N

BACKGROUND IN N
The DT N
problem NN N
of IN N
ghostwriting VBG N
in IN N
corporate-sponsored JJ N
clinical JJ N
trials NNS N
is VBZ N
of IN N
concern NN N
to TO N
medicine VB N
bioethics NNS N
and CC N
government NN N
agencies NNS N
. . N

We PRP N
present VBP N
a DT N
study NN N
of IN N
the DT N
ghostwritten JJ N
archival JJ N
report NN N
of IN N
an DT N
industry-sponsored JJ N
trial NN N
comparing VBG N
antidepressant JJ I
treatments NNS I
for IN I
bipolar JJ P
depression: NN P
GlaxoSmithKline NNP I
(GSK) NNP P
paroxetine NN P
study NN P
352 CD P
. . P

This DT N
analysis NN N
is VBZ N
based VBN N
upon IN N
publicly RB N
available JJ N
evidence NN N
presented VBN N
in IN N
a DT N
complaint NN N
of IN N
research NN N
misconduct NN N
filed VBN N
with IN N
the DT N
Office NNP N
of IN N
Research NNP N
Integrity NNP N
of IN N
the DT N
Department NNP N
of IN N
Health NNP N
and CC N
Human NNP N
Services NNPS N
. . N

OBJECTIVES IN N
We PRP N
performed VBD N
a DT N
deconstruction NN N
of IN N
the DT N
published VBN N
study NN N
to TO N
show VB N
how WRB N
primary JJ O
and CC O
secondary JJ O
outcome NN O
analyses NNS N
were VBD N
conflated VBN N
turning VBG N
a DT N
'negative' JJ N
clinical JJ N
trial NN N
into IN N
a DT N
'positive' NN N
study NN N
- : N
with IN N
conclusions NNS N
and CC N
recommendations NNS N
that WDT N
could MD N
adversely RB N
affect VB N
patient JJ N
health NN N
. . N

METHODS NNP N
The DT I
paroxetine NN I
352 CD I
study NN I
was VBD I
a DT I
randomized JJ I
double-blind JJ I
placebo-controlled JJ I
19-site JJ I
trial NN I
comparing VBG I
paroxetine NN I
and CC I
imipramine NN I
in IN I
117 CD P
patients NNS P
with IN P
bipolar JJ P
type NN P
I PRP P
major JJ P
depressive JJ P
episode NN P
which WDT P
was VBD P
unresponsive JJ P
to TO P
prior VB P
lithium NN P
carbonate NN P
therapy NN P
. . P

RESULTS JJ N
Analysis NN N
of IN N
the DT N
primary JJ O
outcome NN O
measures NNS O
found VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
paroxetine NN I
or CC I
imipramine VB I
versus NN I
placebo NN I
. . I

However RB N
the DT N
published VBN N
article NN N
concluded VBD N
that IN N
both DT I
drugs NNS I
were VBD I
efficacious JJ O
versus NN I
placebo NN I
for IN N
a DT N
post NN N
hoc NN N
subgroup NN N
of IN N
patients NNS N
. . N

CONCLUSIONS NNP N
Few NNP N
industry-sponsored JJ N
studies NNS N
gain VBP N
public JJ N
scrutiny NN N
. . N

It PRP N
is VBZ N
important JJ N
to TO N
make VB N
these DT N
articles NNS N
transparent NN N
to TO N
the DT N
scientific JJ N
and CC N
medical JJ N
community NN N
. . N

-DOCSTART- -X- N

The DT N
effect NN N
of IN N
topical JJ N
nasal NN N
fluticasone NN I
on IN N
objective JJ O
sleep NN O
testing NN O
and CC N
the DT N
symptoms NNS O
of IN O
rhinitis NN O
sleep NN O
and CC O
daytime JJ O
somnolence NN O
in IN N
perennial JJ P
allergic JJ P
rhinitis NN P
. . P

Recent JJ P
data NNS N
suggested VBD N
that IN N
daytime JJ N
somnolence NN N
in IN N
patients NNS P
with IN P
allergic JJ P
rhinitis NN P
was VBD N
secondary JJ N
to TO N
disrupted VBN O
sleep NN O
caused VBN N
by IN N
nasal JJ N
congestion NN N
. . N

Medications NNS N
which WDT N
decreased VBD N
congestion NN N
would MD N
be VB N
expected VBN N
to TO N
improve VB N
sleep NN O
and CC O
daytime JJ O
somnolence NN O
. . O

Previously RB N
we PRP N
showed VBD N
that IN N
nasal JJ N
steroids NNS N
improved VBD N
all DT N
three CD N
symptoms NNS N
. . N

Presently RB N
we PRP N
have VBP N
not RB N
performed VBN N
objective JJ N
sleep NN N
testing VBG N
to TO N
determine VB N
if IN N
there EX N
is VBZ N
a DT N
correlation NN N
between IN N
subjective JJ N
improvement NN O
of IN O
congestion NN O
sleep NN O
and CC O
daytime JJ O
somnolence NN O
. . O

The DT N
objective NN N
of IN N
this DT N
8-week JJ N
double-blind JJ N
placebo-controlled JJ I
study NN N
was VBD N
to TO N
determine VB N
if IN N
topical JJ I
nasal NN I
fluticasone NN I
is VBZ N
effective JJ N
at IN N
decreasing VBG N
subjective JJ O
congestion NN O
and CC N
daytime JJ O
somnolence NN O
and CC N
improving VBG O
sleep NN O
and CC N
if IN N
this DT N
improvement NN N
correlated VBD N
with IN N
a DT N
change NN N
in IN N
overnight JJ O
sleep NN O
testing VBG O
(polysomnography) NN O
. . O

We PRP N
recruited VBD N
32 CD P
subjects NNS P
with IN P
perennial JJ P
allergic JJ P
rhinitis NN P
and CC P
randomized VBD P
them PRP P
in IN P
a DT P
double-blinded JJ P
cross-over JJ P
fashion NN P
to TO P
receive VB N
placebo NN I
or CC I
fluticasone NN I
(50 JJ N
micrograms VBZ N
a DT N
spray) JJ N
2 CD N
sprays NNS N
each DT N
side NN N
everyday RB N
using VBG N
Balaam's NNP N
design NN N
. . N

Questionnaires NNS O
quality NN O
of IN O
life NN O
instruments NNS O
daily JJ O
diary JJ O
Epworth NNP O
Sleepiness NNP O
Scale NNP O
and CC O
an DT O
overnight JJ O
sleep JJ O
test NN O
with IN O
polysomnograms NNS O
were VBD N
used VBN N
as IN N
tools NNS N
. . N

The DT N
last JJ N
2 CD N
weeks NNS N
of IN N
each DT N
4-week JJ N
treatment NN N
period NN N
were VBD N
summarized VBN N
scored VBN N
and CC N
compared VBN N
by IN N
PROC NNP N
MIXED NNP N
in IN N
SAS NNP N
. . N

Correlations NNS N
between IN N
arousals NNS N
on IN N
sleep NN O
tests NNS O
and CC O
subjective JJ O
tests NNS O
were VBD N
performed VBN N
. . N

Fluticasone CD I
improved JJ N
subjective JJ O
sleep NN O
when WRB N
compared VBN N
with IN N
placebo NN I
(p NNP N
= VBZ N
0.04); CD N
however RB N
there EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
apnea/hypopnea NN O
index NN O
in IN N
those DT N
that WDT N
were VBD N
treated VBN N
. . N

Daytime NNP O
sleepiness NN O
and CC O
fatigue NN O
were VBD N
decreased VBN N
by IN N
> JJ N
10% CD N
in IN N
the DT N
treated JJ N
group; NN N
however RB N
this DT N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

However RB N
fluticasone NN I
used VBN N
at IN N
approved JJ N
doses NNS N
improves VBZ N
subjective JJ O
sleep NN O
in IN N
patients NNS P
with IN P
perennial JJ P
allergic JJ P
rhinitis NN P
without IN N
a DT N
change NN N
in IN N
the DT N
apnea/hypopnea NN I
index NN N
. . N

-DOCSTART- -X- N

Cost-effectiveness NN O
of IN N
cognitive-behavioral JJ I
group NN I
therapy NN I
for IN N
dysfunctional JJ N
fear NN N
of IN N
progression NN N
in IN N
cancer NN P
patients NNS P
. . P

Anxiety NN P
and CC P
fear NN P
are VBP P
often RB P
associated VBN P
with IN P
chronic JJ P
conditions NNS P
such JJ P
as IN P
cancer NN P
. . P

This DT N
paper NN N
targets VBZ N
the DT N
cost-effectiveness JJ O
analysis NN O
of IN N
a DT N
cognitive-behavioral JJ I
group NN I
therapy NN I
(CBT) NN I
in IN N
comparison NN N
to TO N
a DT N
client-centered JJ I
supportive-experiential JJ I
group NN I
therapy NN I
(SET) NN I
in IN N
cancer NN P
patients NNS P
with IN P
dysfunctional JJ P
fear NN P
of IN P
progression NN P
. . P

An DT N
incremental JJ N
cost-effectiveness JJ O
analysis NN O
was VBD N
performed VBN N
using VBG N
data NNS N
from IN N
a DT N
randomized VBN N
controlled VBN I
trial NN N
among IN N
cancer NN P
patients NNS P
receiving VBG P
inpatient JJ P
rehabilitation NN P
. . P

The DT N
means NNS O
95% CD O
confidence NN O
intervals NNS O
[95% VBP O
CI] NNP O
incremental JJ O
cost-effectiveness JJ O
graphic NN O
and CC O
acceptability NN O
curve NN O
were VBD N
obtained VBN N
from IN N
1 CD N
000 CD N
bootstrap NN N
replications NNS N
. . N

A DT P
total NN P
of IN P
174 CD P
patients NNS P
were VBD P
included VBN P
in IN P
the DT P
economic JJ P
evaluation NN P
. . P

The DT N
estimated VBN O
means NNS O
[95% JJ N
CI] NNP N
of IN O
direct JJ O
costs NNS O
and CC O
reduction NN O
of IN O
fear NN O
of IN O
progression NN O
were VBD N
<euro>9 JJ N
045.03 CD N
[6 JJ N
359.07; CD N
12 CD N
091.87] CD N
and CC N
1.41 CD N
[0.93; NNS N
1.92] CD N
for IN N
patients NNS N
in IN N
the DT N
SET NNP N
and CC N
<euro>6 $ N
682.78 CD N
[4 NNP N
998.09; CD N
8 CD N
440.95] CD N
and CC N
1.44 CD N
[1.02; NNS N
1.09] CD N
for IN N
patients NNS N
in IN N
the DT N
CBT NNP I
. . I

The DT N
incremental JJ O
cost-effectiveness JJ O
ratio NN O
[95% NNP N
CI] NNP N
amounts NNS N
to TO N
minus NNS N
<euro>78 $ N
741.66 CD N
[-154 JJ N
987.20; CD N
110 CD N
486.32] CD N
for IN N
an DT N
additional JJ N
unit NN N
of IN N
effect NN N
. . N

Given VBN N
the DT N
acceptability NN O
curve NN O
there EX O
is VBZ N
a DT N
92.4% CD N
chance NN N
that IN N
the DT N
CBT NNP I
compared VBN I
with IN N
the DT N
SET NNP I
is VBZ I
cost-effective JJ O
without IN N
the DT N
need NN N
of IN N
additional JJ N
costs NNS N
to TO N
payers NNS N
. . N

Our PRP$ N
main JJ N
result NN N
is VBZ N
the DT N
superior JJ N
cost-effectiveness NN O
of IN N
the DT N
cognitive-behavioral JJ I
intervention NN I
program NN I
in IN N
comparison NN N
to TO N
the DT N
non-directive JJ I
encounter NN I
group NN I
for IN N
our PRP$ N
sample NN N
of IN N
cancer NN N
patients NNS N
with IN N
high JJ N
levels NNS N
of IN N
anxiety NN O
. . O

-DOCSTART- -X- N

Effect NN N
of IN N
intensive JJ I
insulin NN I
therapy NN I
on IN N
the DT N
somatotropic NN O
axis NN O
of IN N
critically RB P
ill JJ P
children NNS P
. . P

CONTEXT NNP P
Intensive NNP I
insulin NN I
therapy NN I
(IIT) NNP I
improved VBD N
outcome NN N
in IN N
the DT N
adult NN P
and CC P
pediatric JJ P
intensive JJ P
care NN P
unit NN P
(PICU) NNP P
compared VBN N
with IN N
conventional JJ I
insulin NN I
therapy NN I
(CIT) NN I
. . I

IIT NNP I
did VBD N
not RB N
increase VB N
the DT N
anabolic JJ N
hormone NN N
IGF-I NNP N
in IN N
critically RB N
ill JJ N
adults NNS N
but CC N
feeding VBG N
in IN N
critically RB P
ill JJ P
children NNS P
and CC N
pediatric JJ N
hormonal JJ N
responses NNS N
may MD N
differ VB N
. . N

Twenty-five JJ P
percent NN P
of IN P
the DT P
children NNS P
with IN P
IIT NNP P
experienced VBD P
hypoglycemia NN P
which WDT P
may MD N
have VB N
evoked VBN N
counterregulatory JJ N
responses NNS N
. . N

OBJECTIVE IN N
We PRP N
hypothesized VBD N
that IN N
IIT NNP I
reactivates VBZ N
the DT N
somatotropic NN N
axis NN N
and CC N
anabolism NN O
in IN N
PICU NNP P
patients NNS P
. . P

DESIGN NN N
This DT N
was VBD N
a DT N
preplanned JJ N
subanalysis NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
on IN N
IIT NNP I
. . I

PATIENTS NN I
We PRP P
studied VBD P
369 CD P
patients NNS P
who WP P
stayed VBD P
in IN P
PICU NNP P
for IN P
at IN P
least JJS P
3 CD P
d NN P
(study NN P
1) CD P
and CC P
126 CD P
patients NNS P
in IN P
a DT P
nested JJ P
case-control NN P
study NN P
(study VBD P
2) CD P
. . P

MAIN NNP P
OUTCOME NNP N
MEASURES NNP N
Circulating NNP O
insulin NN O
C-peptide NNP O
GH NNP O
IGF-I NNP O
bioavailable JJ O
IGF-I JJ O
IGF-binding JJ O
protein NN O
(IGFBP)-1 JJ O
IGFBP-3 NNP O
and CC O
acid-labile JJ O
subunit NN O
were VBD N
analyzed VBN N
upon IN N
admission NN N
and CC N
d NN N
3 CD N
. . N

In IN N
the DT N
nested JJ N
case-control NN N
study NN N
the DT N
somatotropic NN N
axis NN N
cortisol NN O
and CC O
glucagon NN O
were VBD N
analyzed VBN N
before IN N
and CC N
after IN N
hypoglycemia NN N
. . N

RESULTS NN N
On IN N
d JJ N
3 CD N
C-peptide NN O
was VBD N
more JJR N
than IN N
10-fold JJ N
lower JJR N
(P NN N
< VBD N
0.0001) CD N
in IN N
the DT N
IIT NNP I
group NN N
than IN N
in IN N
the DT N
CIT NNP I
group NN N
. . N

IIT NNP I
increased VBD N
circulating VBG O
GH NNP O
(P NNP N
= NNP N
0.04) CD N
and CC N
lowered VBD N
bioavailable JJ O
IGF-I JJ O
(P NN N
= $ N
0.002) CD N
. . N

IIT NNP I
also RB N
decreased VBD N
IGFBP-3 NNP O
(P NNP N
= POS N
0.0005) CD N
and CC N
acid-labile JJ O
subunit NN O
(P NNP N
= VBD N
0.007) CD N
while IN N
increasing VBG N
IGFBP-1 NNP O
(P NNP N
= POS N
0.04) CD N
and CC N
the DT N
urea/creatinine JJ O
ratio NN O
a DT O
marker NN N
of IN N
catabolism NN N
(P NNP N
= VBZ N
0.03) CD N
. . N

In IN N
the DT N
nested JJ N
case-control NN N
study NN N
IGFBP-1 NNP O
was VBD N
increased VBN N
after IN N
hypoglycemia NN N
whereas IN N
the DT N
somatotropic NN N
axis NN N
and CC N
the DT N
counterregulatory NN N
hormones NNS N
cortisol NN N
and CC N
glucagon NN N
did VBD N
not RB N
change NN N
. . N

CONCLUSIONS NNP N
Despite IN N
improved JJ N
PICU NNP N
outcome NN N
IIT NNP I
did VBD N
not RB N
counteract VB N
the DT N
catabolic JJ O
state NN O
of IN O
critical JJ O
illness NN O
. . O

Suppression NN I
of IN I
portal JJ I
insulin NN I
may MD N
have VB N
resulted VBN N
in IN N
lower JJR N
bioavailable JJ N
IGF-I NNP N
. . N

-DOCSTART- -X- N

Routine NNP I
antibiotic JJ I
use NN I
in IN N
preterm NN P
neonates: IN P
a DT N
randomised VBN N
controlled VBN N
trial NN N
. . N

The DT N
immature NN N
immune JJ N
system NN N
of IN N
preterm NN P
neonates NNS P
puts VBZ N
them PRP N
at IN N
higher JJR N
risk NN N
of IN N
neonatal JJ N
sepsis NN N
. . N

We PRP N
conducted VBD N
a DT N
part-blinded JJ N
randomised VBN N
controlled VBN N
trial NN N
to TO N
compare VB N
the DT N
effect NN N
of IN N
routine JJ I
antibiotic JJ I
treatment NN I
on IN N
the DT N
incidence NN N
of IN N
clinical JJ N
sepsis NN N
in IN N
preterm JJ P
neonates NNS P
. . P

Preterm NNP P
neonates NNS P
without IN P
other JJ P
risk NN P
factors NNS P
for IN P
infection NN P
admitted VBN P
in IN P
the DT P
first JJ P
12h CD P
of IN P
life NN P
were VBD N
randomised VBN N
to TO N
receive VB N
routine JJ I
antibiotics NNS I
or CC I
to TO I
a DT I
control NN I
group NN I
(no NNP I
antibiotics NNS I
unless IN I
clinically RB I
indicated) NN I
. . I

The DT N
primary JJ N
outcome NN N
variable NN N
was VBD N
the DT N
incidence NN O
of IN O
clinical JJ O
sepsis NN O
. . O

Secondary JJ N
outcomes NNS N
were VBD N
the DT N
incidence NN O
of IN O
positive JJ O
blood NN O
cultures NNS O
necrotising VBG O
enterocolitis NN O
(NEC) NNP O
stage NN O
II NNP O
or CC O
III NNP O
or CC O
death NN O
and CC O
the DT O
duration NN O
of IN O
hospital NN O
stay NN O
. . O

The DT N
incidence NN O
of IN O
clinical JJ O
sepsis NN O
was VBD N
comparable JJ N
in IN N
both DT N
groups NNS N
(intervention VBP I
31.9% CD N
control NN I
25.4%; CD N
P=0.392) NNP N
. . N

Mortality NNP O
was VBD N
equivalent JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
control NN I
group NN N
had VBD N
significantly RB N
more RBR N
positive JJ N
blood NN O
cultures NNS O
(P=0.002) VBP N
. . N

The DT N
incidence NN O
of IN O
NEC NNP O
and CC O
the DT O
duration NN O
of IN O
hospital NN O
stay NN O
were VBD N
comparable JJ N
in IN N
both DT N
groups NNS N
. . N

In IN N
low JJ P
risk NN P
preterm NN P
neonates VBZ P
we PRP N
found VBD N
no DT N
evidence NN N
that IN N
routine JJ I
antibiotic JJ I
use NN I
has VBZ N
a DT N
protective JJ O
effect NN O
. . O

-DOCSTART- -X- N

Effect NN N
of IN N
an DT N
induction NN N
period NN N
of IN N
pegylated JJ I
interferon-2a JJ I
and CC I
ribavirin VB I
on IN O
early JJ O
virological JJ O
response NN O
in IN P
HIV-HCV-coinfected NNP P
patients: NN P
results NNS N
from IN N
the DT N
CORAL-2 NNP N
study NN N
. . N

BACKGROUND IN N
It PRP N
is VBZ N
uncertain JJ N
whether IN N
a DT N
4-week JJ N
induction NN N
period NN N
of IN I
pegylated JJ I
interferon NN I
and CC I
ribavirin NN I
increases NNS O
early RB O
virological JJ O
response NN O
(EVR) NN O
in IN P
HIV-HCV-coinfected JJ P
patients NNS P
. . N

METHODS NNP P
HIV NNP P
and CC P
HCV NNP P
genotype VBP P
1- JJ P
and CC P
4-coinfected JJ P
subjects NNS P
were VBD N
randomized VBN N
to TO N
receive VB I
pegylated VBN I
interferon-2a JJ I
270 CD I
g/week JJ I
plus CC I
ribavirin JJ I
1 CD I
600 CD I
mg JJ I
daily JJ I
and CC I
epoetin- JJ I
for IN N
4 CD N
weeks NNS N
followed VBN N
by IN N
pegylated JJ N
interferon-2a NN N
at IN N
standard JJ N
dosages NNS N
plus CC N
weight-based JJ N
ribavirin NN N
(WBR) NNP N
dosage NN N
for IN N
8 CD N
weeks NNS N
(induction NN N
arm NN N
[IA]) NN I
or CC I
pegylated VBN I
interferon-2a JJ I
plus CC I
WBR NNP N
for IN N
12 CD N
weeks NNS N
(standard RB N
therapy VBP N
arm NN N
[SA]) NN O
. . O

HCV NNP O
RNA NNP N
was VBD N
determined VBN N
at IN N
weeks NNS N
0 CD N
1 CD N
2 CD N
3 CD N
4 CD N
8 CD N
and CC O
12 CD O
. . O

Ribavirin NNP O
plasma CC O
trough JJ O
concentrations NNS O
were VBD N
determined VBN N
at IN N
weeks NNS N
4 CD N
(RBV-C(4)) JJ N
and CC N
12 CD N
(RBV-C(12)) NN N
. . N

RESULTS VB P
A NNP P
total NN P
of IN P
67 CD P
patients NNS P
were VBD P
included; JJ P
33 CD N
in IN N
the DT N
SA NNP N
and CC N
34 CD N
in IN N
the DT N
IA NNP N
. . N

Overall JJ N
25% CD N
received VBD O
nucleoside JJ O
reverse NN O
transcriptase NN O
inhibitor NN O
(NRTI)-sparing JJ O
regimens NNS O
. . N

More JJR N
patients NNS N
achieved VBD O
an DT O
HCV NNP O
RNA NNP O
decrease NN O
1 NNP N
log(10) NN N
at IN N
week NN N
4 CD N
in IN N
the DT N
IA NNP N
than IN N
in IN N
the DT N
SA NNP N
(62% NNP N
versus VBD N
38%; CD N
P=0.017) NNP O
but CC O
EVR NNP O
rates NNS N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
(74% VBP N
versus $ N
59% CD N
in IN N
the DT N
IA NNP N
and CC N
SA NNP N
respectively; VBP N
P=0.15) NNP N
. . N

Independent JJ N
predictors NNS N
of IN O
faster NN O
HCV NNP O
RNA NNP O
decrease NN O
at IN N
12 CD N
weeks NNS N
were VBD N
higher JJR N
RBV-C(4) JJ N
and CC N
younger JJR O
age NN O
. . O

RBV-C(4) NNP O
were VBD N
higher JJR N
in IN N
patients NNS N
allocated VBN N
in IN N
the DT N
IA NNP N
and CC N
in IN N
those DT N
receiving VBG N
NRTIs NNP N
(P=0.039) NNP N
. . N

CONCLUSIONS VB N
A DT N
4-week JJ N
induction NN N
with IN N
pegylated JJ N
interferon-2a JJ N
plus CC N
ribavirin NN N
was VBD N
associated VBN N
with IN N
a DT O
greater JJR O
decrease NN O
in IN O
HCV NNP N
RNA NNP N
at IN N
week NN N
4; CD N
however RB N
this DT N
did VBD N
not RB N
translate VB N
into IN O
higher JJR O
EVR NN O
rates NNS N
. . N

Higher JJR N
RBV NNP N
doses NNS N
and CC N
avoidance NN N
of IN N
NRTI-sparing NNP N
antiretroviral JJ N
regimens NNS N
might MD O
improve VB O
HCV NNP O
treatment NN O
efficacy NN O
. . N

-DOCSTART- -X- N

Long-term JJ N
follow-up NN N
of IN N
three CD N
randomized JJ N
trials NNS N
comparing VBG N
idarubicin NN I
and CC I
daunorubicin NN I
as IN I
induction NN I
therapies NNS I
for IN N
patients NNS P
with IN P
untreated JJ P
acute NN P
myeloid NN P
leukemia NN P
. . P

BACKGROUND NNP P
Most NNP N
clinical JJ N
trials NNS N
for IN N
acute NN N
leukemia NN N
have VBP N
reported VBN N
results NNS N
after IN N
2-3 JJ N
years NNS N
of IN N
follow-up NN N
. . N

Comparisons NNS N
between IN N
the DT N
original JJ N
data NNS N
and CC N
longer-term JJ N
follow-up JJ N
data NNS N
may MD N
be VB N
of IN N
interest NN N
particularly RB N
with IN N
regard NN N
to TO N
promising VBG N
new JJ N
therapies NNS N
. . N

METHODS NNP N
In IN N
1996 CD N
survival NN N
data NNS N
were VBD N
updated VBN N
from IN P
three CD P
prospective JJ P
randomized VBN P
comparisons NNS P
of IN P
idarubicin NN P
and CC P
daunorubicin NN P
that WDT P
began VBD P
in IN P
1984 CD P
and CC P
1985 CD P
. . P

These DT N
were VBD P
trials NNS P
of IN P
the DT P
Memorial NNP P
Sloan-Kettering NNP P
Cancer NNP P
Center NNP P
(MSKCC) VBD P
the DT P
U.S NNP P
. . P

Multicenter NNP P
Study NNP P
Group NNP P
and CC P
the DT P
Southeastern NNP P
Cancer NNP P
Study NNP P
Group NNP P
(SEG) NNP P
. . P

The DT N
original JJ N
results NNS N
of IN N
these DT N
trials NNS N
were VBD N
reported VBN N
in IN N
1991 CD N
and CC N
1992 CD N
. . N

RESULTS VB N
The DT N
original JJ N
results NNS N
of IN N
the DT N
SEG NNP N
trial NN N
demonstrated VBD N
no DT N
significant JJ N
difference NN O
between IN O
idarubicin NN O
and CC O
daunorubicin NN O
. . O

The DT N
updated JJ N
survival NN O
analysis NN O
showed VBD N
similar JJ N
results NNS N
. . N

The DT N
MSKCC NNP N
trial NN N
revealed VBD N
a DT N
significant JJ N
advantage NN N
of IN N
idarubicin NNS I
compared VBN N
with IN N
daunorubicin NN I
in IN N
both CC N
the DT N
original JJ N
and CC N
the DT N
updated JJ N
analyses NNS N
. . N

The DT N
U.S NNP N
. . N

Multicenter NNP N
trial NN N
found VBD N
a DT N
significant JJ N
difference NN N
favoring VBG N
idarubicin NN I
in IN N
the DT N
original JJ N
analysis NN N
but CC N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
in IN N
the DT N
updated JJ N
analysis NN N
. . N

CONCLUSIONS NN N
It PRP N
is VBZ N
essential JJ N
that IN N
the DT N
median JJ N
length NN N
of IN N
follow-up JJ N
be VB N
clearly RB N
stated VBN N
in IN N
any DT N
clinical JJ N
trial NN N
. . N

When WRB N
the DT N
results NNS N
obtained VBD N
with IN N
a DT N
particularly RB N
promising JJ N
new JJ N
drug NN N
or CC N
procedure NN N
are VBP N
presented VBN N
early RB N
in IN N
the DT N
course NN N
of IN N
study NN N
(within IN N
1-2 JJ N
years) NN N
the DT N
investigators NNS N
should MD N
strongly RB N
consider VB N
a DT N
repeat NN N
evaluation NN N
after IN N
an DT N
additional JJ N
3-5 CD N
years NNS N
of IN N
follow-up NN N
. . N

-DOCSTART- -X- N

A DT N
randomized VBN N
controlled VBN N
trial NN N
to TO N
improve VB N
colon NN P
cancer NN P
screening VBG P
in IN P
rural JJ P
family NN P
medicine: VBZ P
an DT P
Iowa NNP P
Research NNP N
Network NNP N
(IRENE) NNP N
study NN N
. . N

BACKGROUND NNP N
Many NNP N
adults NNS N
have VBP N
not RB N
been VBN N
screened VBN N
for IN N
colon NN N
cancer NN N
a DT N
potentially RB N
preventable JJ N
cause NN N
of IN N
death NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
conducted VBN N
between IN N
December NNP P
2008 CD P
and CC P
April NNP P
2011 CD P
to TO P
improve VB P
CRC NNP P
screening VBG P
in IN P
16 CD P
rural JJ P
family NN P
physician NN P
offices NNS P
. . P

Subjects NNS P
due JJ P
for IN P
CRC NNP P
screening VBG P
were VBD N
randomized VBN N
within IN N
each DT N
practice NN N
to TO N
1 CD N
of IN N
4 CD N
groups: NNS N
(1) JJ N
usual JJ I
care; NN I
(2) NNP I
physician JJ I
chart NN I
reminder; NN I
(3) NNP I
physician JJ I
chart NN I
reminder NN I
mailed VBD I
education NN I
CRC NNP I
reminder NN I
magnet NN I
and CC I
fecal JJ I
immunochemical JJ I
test NN I
(FIT) NN I
(mailed VBD I
education/FIT); NN I
or CC I
(4) VB I
all PDT I
the DT I
preceding VBG I
plus CC I
a DT I
structured JJ I
telephone NN I
call NN I
to TO I
the DT I
patient NN I
from IN I
project JJ I
staff NN I
to TO I
provide VB I
education NN I
assess JJ I
interest NN I
in IN I
screening VBG I
explain VBP I
the DT I
screening NN I
tests NNS I
and CC I
address JJ I
barriers NNS I
(mailed VBD I
education/FIT JJ I
plus CC I
phone NN I
call) NN I
. . N

The DT N
main JJ N
outcome NN N
was VBD N
completion NN O
of IN O
any DT O
CRC NNP O
screening NN O
. . O

RESULTS VB I
This DT P
study NN P
enrolled VBD P
743 CD P
patients NNS P
. . P

CRC NNP I
screening NN I
was VBD N
completed VBN O
by IN N
17.8% CD N
in IN N
the DT N
usual JJ N
care NN N
group NN N
20.5% CD N
in IN N
the DT N
chart NN N
reminder NN N
group NN N
56.5% CD N
in IN N
the DT N
mailed JJ N
education/FIT NN N
group NN N
and CC N
57.2% CD N
in IN N
the DT N
mailed JJ N
education/FIT NN N
plus CC N
phone NN N
call NN N
group NN N
. . N

We PRP N
found VBD N
no DT N
effect NN N
from IN N
the DT N
chart NN N
reminder NN N
compared VBN N
with IN N
usual JJ N
care NN N
(odds NNS N
ratio VBP N
[OR] JJ N
1.2; CD N
95% CD N
confidence NN N
interval JJ N
[CI] JJ N
0.7-2.0); NN N
and CC N
a DT N
beneficial JJ O
effect NN O
from IN N
the DT N
mailed JJ N
education/FIT NN N
(OR VBD N
6.0; CD N
95% CD N
CI NNP N
3.7-9.6) CD N
and CC N
the DT N
mailed JJ N
education/FIT NN N
plus CC N
phone NN N
call NN N
(OR VBD N
6.2; CD N
95% CD N
CI NNP N
3.8-9.9) CD N
. . N

Both DT N
FIT NNP O
and CC O
colonoscopy JJ O
rates NNS O
increased VBD N
significantly RB N
in IN N
both DT N
mailed JJ N
education NN N
groups NNS N
. . N

CONCLUSION NNP N
CRC NNP O
screening VBG O
rates NNS O
increased VBD N
significantly RB N
among IN N
patients NNS N
who WP N
were VBD N
overdue JJ N
for IN N
screening VBG N
after IN N
they PRP N
received VBD N
mailed VBD N
educational JJ N
materials NNS N
and CC N
a DT N
FIT NNP N
. . N

The DT N
addition NN N
of IN N
a DT N
phone NN N
call NN N
did VBD N
not RB N
further JJ N
increase NN N
screening VBG N
rates NNS N
. . N

-DOCSTART- -X- N

Effectiveness NN N
and CC N
safety NN N
of IN N
donepezil NN I
in IN N
boys NNS P
with IN P
fragile JJ P
x NNS P
syndrome: VBD P
a DT N
double-blind JJ N
randomized NN N
controlled VBD N
pilot NN N
study NN N
. . N

The DT N
present JJ N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
12-week JJ N
randomized JJ N
double-blind JJ N
placebo-controlled JJ I
pilot NN N
study NN N
to TO N
evaluate VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
donepezil NN I
in IN N
boys NNS P
with IN P
fragile JJ P
X NNP P
syndrome NN P
. . P

Twenty NNP P
boys VBZ P
with IN P
fragile JJ P
X NNP P
syndrome NN P
were VBD P
randomized VBN P
to TO N
receive VB N
12 CD N
weeks NNS N
of IN N
treatment NN N
with IN N
either DT N
placebo NN I
or CC I
donepezil NN I
(2.5 VBP I
mg JJ I
daily JJ I
for IN I
initial JJ I
4 CD I
weeks NNS I
followed VBN I
by IN I
5 CD I
mg NNS I
daily RB I
for IN I
next JJ I
8 CD I
weeks) NN I
. . N

The DT N
outcome NN N
measures NNS N
included VBD N
change NN N
in IN N
intelligence NN N
quotient NN N
scores NNS N
on IN N
Stanford-Binet NNP O
Intelligence NNP O
Scale NNP O
(Hindi NNP O
adaptation NN O
by IN O
Kulshrestha) NNP O
change NN O
in IN O
behavioral JJ O
scores NNS O
by IN O
Conners NNS O
3 CD O
Parent NN O
Rating VBG O
Scale NNP O
(Short) NNP O
and CC O
Childhood NNP O
Autism NNP O
Rating NNP O
Scale NNP O
safety NN O
and CC O
tolerability NN O
of IN N
donepezil NN N
. . N

The DT N
study NN N
failed VBD N
to TO N
show VB N
significant JJ N
difference NN N
in IN N
intelligence NN N
quotient NN N
and CC N
behavioral JJ N
scales NNS N
with IN N
donepezil JJ I
therapy NN N
over IN N
12 CD N
weeks NNS N
. . N

However RB N
donepezil RB I
appeared VBD N
to TO N
be VB N
safe JJ N
and CC N
well RB N
tolerated VBN N
. . N

-DOCSTART- -X- N

Butorphanol NNP I
and CC I
meperidine NN I
compared VBN N
in IN N
patients NNS P
with IN P
acute JJ P
ureteral JJ P
colic NN P
. . P

Pain NN P
relief NN N
was VBD N
evaluated VBN N
in IN N
81 CD P
patients NNS P
with IN P
acute JJ P
ureteral JJ P
colic NN P
and CC P
the DT P
confirmed JJ P
presence NN P
of IN P
a DT P
calculus NN P
. . P

A DT P
randomized JJ P
double-blind JJ P
comparison NN P
of IN P
intramuscular JJ P
2 CD P
and CC P
4 CD P
mg NN P
. . P

butorphanol NN I
and CC P
80 CD P
mg NN P
. . P

meperidine NN I
was VBD N
used VBN N
. . N

Pain NNP O
intensity NN O
and CC O
pain NN O
relief NN O
were VBD N
evaluated VBN N
at IN N
half JJ N
hour NN N
and CC N
hourly JJ N
intervals NNS N
for IN N
4 CD N
hours NNS N
. . N

A DT N
2 CD I
mg NN I
. . I

dose NN I
of IN I
butorphanol NN I
was VBD N
found VBN N
to TO N
be VB N
analgesically RB N
equivalent JJ N
to TO N
80 CD I
mg NNS I
. . I

meperidine NN I
while IN I
a DT N
4 CD I
mg NN I
. . I

dose NN I
of IN I
butorphanol NN I
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
80 CD N
mg NN N
. . N

meperidine NN I
and CC N
2 CD N
mg NN N
. . N

butorphanol NN I
. . I

Each DT N
patient NN N
received VBD N
up RB N
to TO N
2 CD N
doses NNS N
of IN N
analgesic JJ N
medication NN N
when WRB N
necessary JJ N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
side JJ O
effects NNS O
among IN N
treatments NNS N
. . N

One CD N
patient NN N
had VBD N
visual JJ N
hallucinations NNS N
after IN N
a DT N
2 CD N
mg NN N
. . N

dose NN N
of IN N
butorphanol NN I
possibly RB I
owing VBG N
to TO N
its PRP$ N
antagonistic JJ N
activity NN N
to TO N
significant JJ N
narcotic JJ N
experience NN N
given VBN N
previously RB N
at IN N
another DT N
hospital NN N
. . N

There EX N
was VBD N
no DT N
other JJ N
evidence NN N
of IN N
toxicity NN O
with IN N
butorphanol NN I
. . I

It PRP N
was VBD N
found VBN N
to TO N
be VB N
a DT N
safe JJ O
effective JJ O
and CC O
wall RB O
tolerated JJ O
drug NN N
for IN N
the DT N
treatment NN N
of IN N
ureteral JJ N
colic NN N
and CC N
is VBZ N
recommended VBN N
in IN N
place NN N
of IN N
narcotics NNS I
. . I

-DOCSTART- -X- N

Repeatability NN N
and CC N
protocol JJ N
comparability NN N
of IN N
presyncopal JJ P
symptom NN P
limited VBD P
lower JJR P
body NN P
negative JJ P
pressure NN P
exposures NNS P
. . P

Data NNS N
on IN N
repeatability NN N
and CC N
comparability NN N
of IN N
different JJ I
presyncopal JJ I
symptom-limited JJ I
lower JJR I
body NN I
negative JJ I
pressure NN I
(PSL-LBNP) JJ I
exposure NN I
protocols NNS I
while IN I
scarce NN N
are VBP N
critical JJ N
to TO N
the DT N
interpretation NN N
of IN N
studies NNS N
using VBG N
PSL-LBNP NNP I
methods NNS N
. . N

To TO N
investigate VB N
if IN N
PSL-LBNP JJ N
tolerance NN O
heart NN O
rate NN O
and CC O
blood NN O
pressure NN O
were VBD N
repeatable JJ N
11 CD P
subjects NNS P
were VBD P
exposed VBN P
to TO P
4 CD P
PSL-LBNP JJ P
tests; NN P
each DT N
test NN N
occurring VBG N
at IN N
the DT N
same JJ N
time NN N
of IN N
day NN N
separated VBN N
by IN N
at IN N
least JJS N
72 CD N
h NN N
and CC N
using VBG N
the DT N
same JJ N
protocol NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
either CC N
the DT N
heart NN O
rate NN O
or CC O
blood NN O
pressure NN O
responses VBZ O
to TO N
the DT N
PSL-LBNP NNP I
or CC N
the DT N
tolerance NN N
indices NNS N
(cumulative JJ N
stress NN N
index; NN N
maximum JJ N
negative JJ N
pressure NN N
tolerated; NN N
and CC N
duration NN N
of IN N
negative JJ N
pressure NN N
exposure) NN N
. . N

To TO N
study VB N
the DT N
comparability NN N
of IN N
different JJ N
PSL-LBNP NNP I
protocols NNS I
nine CD P
subjects NNS P
were VBD P
exposed VBN P
randomly RB P
to TO N
five CD N
PSL-LBNP JJ I
tests NNS I
using VBG N
protocols NNS N
that WDT N
varied VBD N
in IN N
stage NN N
duration NN N
but CC N
not RB N
pressure NN N
profile NN N
. . N

The DT N
protocols NNS N
had VBD N
1- JJ N
3- JJ N
5- JJ N
7- JJ N
or CC N
9-min JJ N
stage NN N
durations NNS N
. . N

These DT N
PSL-LBNP JJ I
exposures NNS I
were VBD N
conducted VBN N
at IN N
the DT N
same JJ N
time NN N
of IN N
day NN N
and CC N
separated VBN N
by IN N
at IN N
least JJS N
72 CD N
h NN N
. . N

While IN N
no DT N
differences NNS N
were VBD N
noted VBN N
in IN N
either CC N
the DT N
response NN N
pattern NN N
or CC N
magnitude NN N
of IN N
heart NN O
rate NN O
or CC O
blood NN O
pressure NN O
to TO N
the DT N
differing NN N
protocols VBZ N
the DT N
cumulative JJ N
stress NN N
index NN N
and CC N
the DT N
duration NN N
of IN N
negative JJ N
pressure NN N
exposure NN N
varied VBD N
proportionally RB N
with IN N
the DT N
length NN N
of IN N
the DT N
stage NN I
durations NNS I
. . I

-DOCSTART- -X- N

Management NN N
of IN N
large JJ N
bowel NN N
obstruction NN N
with IN N
self-expanding JJ I
metal NN I
stents NNS I
. . I

A DT N
multicentre NN N
retrospective JJ N
study NN N
of IN N
factors NNS N
determining VBG N
outcome NN N
. . N

AIM NNP N
UK NNP N
cancer NN N
guidelines NNS N
recommend VBP N
patients NNS P
with IN P
colonic JJ P
obstruction NN P
due JJ P
to TO P
suspected JJ P
malignancy NN P
be VB N
considered VBN N
for IN N
stenting VBG I
with IN I
a DT I
self-expanding JJ I
metal NN I
stent NN I
(SEMS) NN I
. . I

Considerable JJ N
variation NN N
in IN N
practice NN N
exists NNS N
due JJ N
to TO N
a DT N
lack NN N
of IN N
expertise NN N
technical JJ N
difficulties NNS N
and CC N
other JJ N
as IN N
yet RB N
ill-defined JJ N
features NNS N
. . N

This DT N
retrospective JJ N
multi-centre NN N
study NN N
aims VBZ N
to TO N
determine VB N
the DT N
outcome NN N
following VBG N
colonic JJ I
stenting VBG I
for IN I
large JJ I
bowel NN I
obstruction NN I
and CC N
identify VB N
factors NNS N
associated VBN N
with IN N
successful JJ N
intervention NN N
. . N

METHOD NNP N
A NNP P
regional JJ P
programme NN P
of IN P
colonic JJ P
stenting VBG P
for IN P
large JJ P
bowel NN P
obstruction NN P
in IN P
five CD P
UK NNP P
centres NNS P
from IN P
2005 CD P
to TO P
2010 CD P
was VBD N
evaluated VBN N
for IN N
outcome NN N
including VBG N
technical JJ O
and CC O
clinical JJ O
success NN O
survival NN O
complications NNS O
and CC N
reoperation NN O
. . O

RESULTS VB N
A DT P
SEMS NNP P
was VBD P
inserted VBN P
in IN P
334 CD P
patients NNS P
including VBG P
264 CD P
(79.0%) NN P
for IN P
palliation NN P
and CC P
52 CD P
(15.6%) NN P
as IN P
a DT P
bridge NN P
to TO P
surgery NN P
. . P

Technical JJ O
success NN O
was VBD N
achieved VBN N
in IN N
292 CD N
(87.4%) JJ N
patients NNS N
with IN N
46 CD N
(13.8%) NNS N
experiencing VBG N
a DT N
complication NN N
or CC N
technical JJ N
failure NN N
. . N

Reoperation NN O
was VBD N
required VBN N
in IN N
39 CD N
(14.8%) JJ N
patients NNS N
stented VBN N
for IN N
palliation NN N
of IN N
colorectal JJ P
cancer NN P
of IN N
whom WP N
16 CD N
(6.1%) NNS N
subsequently RB N
required VBD N
a DT N
colostomy NN N
. . N

A DT N
one-stage JJ O
primary JJ O
anastomosis NN O
was VBD N
achieved VBN N
in IN N
35 CD N
(67.3%) NN N
of IN N
the DT N
52 CD P
patients NNS P
undergoing VBG P
stenting VBG P
as IN P
a DT P
bridge NN P
to TO P
resection NN P
. . P

Technical JJ N
success NN N
did VBD N
not RB N
vary JJ N
by IN N
indication NN N
or CC N
site NN N
of IN N
obstruction NN N
(P NNP N
= VBZ N
0.60) CD N
but CC N
was VBD N
higher JJR N
for IN N
operators NNS N
who WP N
had VBD N
performed VBN N
more JJR N
than IN N
10 CD N
procedures NNS N
(OR VBP N
3.34 CD N
P NNP N
= VBD N
0.001) CD N
. . N

ASA NNP N
grade VBD N
3 NNP N
predicted VBD N
a DT N
worse JJ N
clinical JJ N
outcome NN N
(OR VBD N
0.43 CD N
P NNP N
= VBD N
0.04) CD N
. . N

The DT N
through-the-scope JJ N
(TTS) NNP N
endoscopy NN N
technique NN N
was VBD N
more RBR O
successful JJ O
than IN N
radiological JJ N
placement NN N
alone RB N
(90.3% NNP N
vs VBD N
74.8% CD N
P NNP N
< VBD N
0.001) CD N
. . N

CONCLUSION NNP N
Experienced NNP N
operators NNS N
using VBG N
a DT N
TTS NNP N
technique NN N
achieved VBD N
a DT N
better JJR N
outcome NN N
for IN N
the DT N
emergency NN N
management NN N
of IN N
large JJ N
bowel NN N
obstruction NN N
. . P

Older JJR P
sicker NN P
patients NNS P
and CC P
those DT P
with IN P
extracolonic JJ P
and CC P
benign JJ P
strictures NNS P
fared VBD N
less JJR N
well RB N
. . N

-DOCSTART- -X- N

Hyperbaric NNP I
oxygen NN I
in IN N
the DT N
treatment NN N
of IN N
childhood NN P
autism: NN P
a DT N
randomised VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Promising NNP N
results NNS N
with IN N
hyperbaric JJ I
therapy NN I
for IN N
children NNS P
with IN P
autism NN P
have VBP N
been VBN N
reported VBN N
but CC N
most JJS N
involved VBD N
the DT N
use NN N
of IN N
only RB N
mild JJ N
pressure NN N
with IN N
oxygen NN N
supplementation NN N
. . N

To TO N
date NN N
there RB N
has VBZ N
been VBN N
no DT N
randomised VBN N
blinded VBD N
trial NN N
of IN N
100% CD I
oxygen NN I
administered VBN I
at IN I
hyperbaric JJ I
pressure NN I
. . I

This DT N
study NN N
evaluated VBD N
the DT N
efficacy NN O
of IN N
hyperbaric JJ N
oxygen NN N
therapy NN N
(HBOT) NN N
. . N

METHODS NNP N
Sixty NNP P
Thai NNP P
children NNS P
with IN P
autism NN P
aged VBN P
three CD P
to TO P
nine CD P
years NNS P
were VBD P
randomly RB P
assigned VBN P
to TO N
receive VB N
20 CD I
one-hour JJ I
sessions NNS I
of IN I
either DT I
HBOT NNP I
at IN I
153 CD I
kPa NNS I
(1.5 JJ N
ATA) NNP N
or CC I
sham VB I
air NN I
at IN I
116 CD I
kPa NNS I
(1.15 JJ N
ATA) NNP N
. . N

Effects NNS O
on IN O
behaviour NNS O
were VBD N
measured VBN N
using VBG N
the DT N
Autism NNP N
Treatment NNP N
Evaluation NNP N
Checklist NNP N
score NN N
(ATEC) NN N
and CC N
clinical JJ O
improvement NN O
was VBD N
measured VBN N
with IN N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
(CGI) NNP N
system; NN N
in IN N
particular JJ N
the DT N
clinical JJ N
change NN N
(CGIC) NNP N
and CC N
severity NN N
(CGIS) VBP N
sub-scores NNS N
. . N

These DT N
were VBD N
evaluated VBN N
by IN N
parents NNS N
and CC N
clinicians NNS N
both DT N
of IN N
whom WP N
were VBD N
blinded VBN N
to TO N
the DT N
actual JJ N
exposure NN N
. . N

RESULTS VB N
The DT N
mean JJ N
total JJ N
ATEC NNP N
scores NNS N
by IN N
both DT N
parents NNS N
and CC N
clinicians NNS N
were VBD N
significantly RB N
improved VBN N
after IN N
intervention NN N
in IN N
both DT N
arms NNS N
of IN N
the DT N
study NN N
compared VBN N
to TO N
the DT N
score NN N
before IN N
intervention NN N
(P NNP N
< VBZ N
0.001 CD N
in IN N
both DT N
groups NNS N
by IN N
parents NNS N
P NNP N
= VBD N
0.015 CD N
in IN N
HBOT NNP N
group NN N
and CC N
P NNP N
= NNP N
0.004 CD N
in IN N
sham NN N
group NN N
by IN N
clinician) NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
average JJ N
percentage NN N
changes NNS N
of IN N
total JJ N
ATEC NNP N
score NN N
and CC N
all DT N
subscales NNS N
scores NNS N
when WRB N
comparing VBG N
the DT N
HBOT NNP N
and CC N
sham NNP N
air NN N
groups NNS N
either CC N
by IN N
parents NNS N
or CC N
clinicians NNS N
. . N

Changes NNS N
in IN N
the DT N
CGI NNP N
scores NNS N
following VBG N
intervention NN N
were VBD N
inconsistent JJ N
between IN N
parents NNS N
and CC N
clinicians NNS N
. . N

For IN N
severity NN O
scores NNS O
(CGIS) VBP N
parents NNS N
rated VBN N
their PRP$ N
children NNS N
as IN N
more JJR N
improved JJ N
following NN N
HBOT NNP N
(P NNP N
= VBD N
0.005) CD N
while IN N
the DT N
clinicians NNS N
found VBD N
no DT N
significant JJ N
differences NNS N
(P VBP N
= JJ N
0.10) CD N
. . N

On IN N
the DT N
other JJ N
hand NN N
for IN N
change NN N
scores NNS N
(CGIC) VBP N
the DT N
clinicians NNS N
indicated VBD N
greater JJR N
improvement NN N
following VBG N
HBOT NNP N
(P NNP N
= VBZ N
0.03) CD N
but CC N
the DT N
parents NNS N
found VBD N
no DT N
such JJ N
difference NN N
(P NNP N
= VBZ N
0.28) CD N
. . N

CONCLUSIONS NNP N
Children NNP P
with IN P
autism NN P
who WP N
received VBD N
20 CD N
sessions NNS N
of IN N
either DT N
HBOT NNP I
or CC N
a DT N
sham JJ N
air NN N
exposure NN N
had VBD N
significant JJ N
improvements NNS N
in IN N
overall JJ O
behaviour NN O
but CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
improvement NN N
between IN N
groups NNS N
. . N

The DT N
inconsistent NN N
changes NNS N
on IN N
CGI NNP N
sub-scores NNS N
between IN N
parents NNS N
and CC N
clinicians NNS N
are VBP N
difficult JJ N
to TO N
interpret VB N
but CC N
no DT N
overall JJ N
clinically RB N
significant JJ N
benefit NN N
from IN N
HBOT NNP N
could MD N
be VB N
shown VBN N
. . N

Both DT N
interventions NNS N
were VBD N
safe JJ O
and CC O
well RB O
tolerated VBN O
with IN N
minimal JJ N
side NN O
effect NN O
from IN N
middle JJ N
ear JJ N
barotraumas NN N
. . N

-DOCSTART- -X- N

Effect NN N
of IN N
VX-770 NNP I
in IN N
persons NNS P
with IN P
cystic JJ P
fibrosis NN P
and CC P
the DT P
G551D-CFTR NNP P
mutation NN P
. . P

BACKGROUND NNP N
A NNP N
new JJ N
approach NN N
in IN N
the DT N
treatment NN N
of IN N
cystic JJ N
fibrosis NN N
involves VBZ N
improving VBG N
the DT N
function NN N
of IN N
mutant JJ N
cystic JJ N
fibrosis NN N
transmembrane NN N
conductance NN N
regulator NN N
(CFTR) NN N
. . N

VX-770 NNP I
a DT I
CFTR NNP I
potentiator NN I
has VBZ I
been VBN N
shown VBN N
to TO N
increase VB N
the DT N
activity NN N
of IN N
wild-type NN N
and CC N
defective JJ N
cell-surface NN N
CFTR NNP N
in IN N
vitro NN N
. . N

METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
39 CD P
adults NNS P
with IN P
cystic JJ P
fibrosis NN P
and CC P
at IN P
least JJS P
one CD P
G551D-CFTR JJ P
allele NN P
to TO N
receive VB N
oral JJ I
VX-770 NNP I
every DT I
12 CD I
hours NNS I
at IN I
a DT I
dose NN I
of IN I
25 CD I
75 CD I
or CC I
150 CD I
mg NN I
or CC I
placebo NN I
for IN N
14 CD N
days NNS N
(in NNP N
part NN N
1 CD N
of IN N
the DT N
study) NN N
or CC N
VX-770 JJ I
every DT N
12 CD N
hours NNS N
at IN N
a DT N
dose NN N
of IN N
150 CD N
or CC N
250 CD N
mg NN N
or CC N
placebo NN I
for IN N
28 CD N
days NNS N
(in NNP N
part NN N
2 CD N
of IN N
the DT N
study) NN N
. . N

RESULTS NNS N
At IN N
day NN N
28 CD N
in IN N
the DT N
group NN N
of IN N
subjects NNS N
who WP N
received VBD N
150 CD N
mg NNS N
of IN N
VX-770 NNP I
the DT I
median JJ N
change NN N
in IN N
the DT N
nasal JJ O
potential JJ O
difference NN O
(in NN N
response NN N
to TO N
the DT N
administration NN N
of IN N
a DT N
chloride-free JJ I
isoproterenol NN I
solution) NN I
from IN N
baseline NN N
was VBD N
-3.5 JJ N
mV JJ N
(range NN N
-8.3 NN N
to TO N
0.5; CD N
P=0.02 NNP N
for IN N
the DT N
within-subject JJ N
comparison NN N
P=0.13 NNP N
vs NN N
. . N

placebo) NN N
and CC N
the DT N
median JJ N
change NN N
in IN N
the DT N
level NN O
of IN O
sweat NN O
chloride NN O
was VBD N
-59.5 JJ N
mmol NN N
per IN N
liter NN N
(range NN N
-66.0 NN N
to TO N
-19.0; VB N
P=0.008 NNP N
within-subject JJ N
P=0.02 NNP N
vs NN N
. . N

placebo) NN I
. . N

The DT N
median JJ N
change NN N
from IN N
baseline NN N
in IN N
the DT N
percent NN N
of IN N
predicted VBN N
forced JJ O
expiratory NN O
volume NN O
in IN N
1 CD N
second NN N
was VBD N
8.7% CD N
(range NN N
2.3 CD N
to TO N
31.3; CD N
P=0.008 NNP N
for IN N
the DT N
within-subject JJ N
comparison NN N
P=0.56 NNP N
vs NN N
. . N

placebo) NN I
. . N

None NN N
of IN N
the DT N
subjects NNS N
withdrew VBD N
from IN N
the DT N
study NN N
. . N

Six CD N
severe JJ O
adverse JJ O
events NNS O
occurred VBD N
in IN N
two CD N
subjects NNS N
(diffuse IN O
macular JJ O
rash NN O
in IN N
one CD N
subject NN N
and CC N
five CD N
incidents NNS N
of IN N
elevated VBN O
blood NN O
and CC O
urine JJ O
glucose NN O
levels NNS O
in IN N
one CD N
subject NN N
with IN N
diabetes) NN O
. . N

All DT N
severe JJ N
adverse JJ N
events NNS N
resolved VBN N
without IN N
the DT N
discontinuation NN N
of IN N
VX-770 NNP I
. . I

CONCLUSIONS NNP I
This DT N
study NN N
to TO N
evaluate VB N
the DT N
safety NN O
and CC O
adverse-event JJ O
profile NN O
of IN N
VX-770 NNP I
showed VBD N
that IN N
VX-770 NNP I
was VBD N
associated VBN N
with IN N
within-subject JJ N
improvements NNS N
in IN N
CFTR NNP O
and CC O
lung NN O
function NN O
. . O

These DT N
findings NNS N
provide VBP N
support NN N
for IN N
further JJ N
studies NNS N
of IN N
pharmacologic JJ N
potentiation NN N
of IN N
CFTR NNP N
as IN N
a DT N
means NN N
to TO N
treat VB P
cystic JJ P
fibrosis NN P
. . P

(Funded VBN N
by IN N
Vertex NNP N
Pharmaceuticals NNP N
and CC N
others; JJ N
ClinicalTrials.gov NNP N
number NN N
NCT00457821.) NNP N
. . N

-DOCSTART- -X- N

A DT N
randomized VBN N
controlled VBN N
study NN N
on IN N
the DT N
influence NN N
of IN N
acetaminophen NN I
diclofenac NN I
or CC I
naproxen NN I
on IN I
aspirin-induced JJ I
inhibition NN N
of IN N
platelet NN O
aggregation NN O
. . O

Nonsteroidal NNP I
anti-inflammatory JJ I
drugs NNS I
(NSAID) VBP I
may MD N
interfere VB N
with IN N
aspirin JJ I
(acetylsalicylic JJ I
acid) NN I
and CC N
increase VB N
the DT N
risk NN N
for IN N
cardiovascular JJ O
events NNS O
. . O

The DT N
clinical JJ N
relevance NN N
is VBZ N
uncertain JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
analyse VB N
the DT N
influence NN N
of IN N
a DT N
co-administration NN N
of IN N
aspirin NN I
and CC N
NSAID NNP I
on IN N
platelet NN O
aggregation NN O
. . O

In IN N
a DT N
randomized JJ N
placebo NN I
controlled VBD N
trial NN N
eleven RB P
healthy JJ P
volunteers NNS P
were VBD P
studied VBN P
during IN P
4 CD P
separate JJ P
study NN P
periods NNS P
of IN P
4 CD P
days NNS P
each DT P
. . P

Individuals NNS N
were VBD N
treated VBN N
on IN N
each DT N
occasion NN N
with IN N
100 CD N
mg NNS N
aspirin JJ I
daily RB N
in IN N
combination NN N
with IN N
either DT N
3 CD I
x VBD I
1 CD I
g NNS I
acetaminophen RB I
3 CD I
x JJ I
50 CD I
mg JJ I
diclofenac NN I
3 CD I
x NN I
250 CD I
mg JJ I
naproxen NN I
or CC I
3 CD I
x JJ I
1 CD I
placebo NN I
. . I

Primary JJ O
hemostasis NN O
was VBD N
assessed VBN N
with IN N
a DT N
platelet NN N
function NN N
analyser IN N
(PFA-100) NNP N
which WDT N
measures VBZ N
the DT O
closure NN O
time NN O
(CT) NNP O
of IN O
a DT O
collagen- JJ O
and CC O
epinephrine-coated JJ O
pore NN O
by IN O
aggregating VBG O
platelets NNS O
in IN O
flowing VBG O
blood NN O
. . O

Naproxen NNP I
enhanced VBD N
the DT N
anti-aggregatory JJ N
action NN N
of IN N
aspirin NN I
after IN N
24 CD N
h NN N
(CT JJ O
rising VBG N
from IN N
104+/-16 JJ N
s NN N
at IN N
baseline NN N
to TO N
212+/-69 JJ N
s NN N
at IN N
24 CD N
h NN N
P<0.001) NNP N
which WDT N
was VBD N
not RB N
seen VBN N
with IN N
any DT N
other JJ N
drug NN N
combination NN N
. . N

Diclofenac NNP I
reduced VBD N
the DT N
anti-aggregatory JJ N
action NN N
of IN N
aspirin NN I
in IN N
the DT N
first JJ N
two CD N
days NNS N
since IN N
the DT N
CT NNP O
did VBD N
not RB N
rise VB N
significantly RB N
(109+/-19 JJ N
s JJ N
148+/-56 JJ N
s NN N
and CC N
168+/-66 JJ N
s NN N
at IN N
0 CD N
h NN N
24 CD N
h NN N
48 CD N
h NN N
respectively RB N
P>0.05) NNP N
. . N

Acetaminophen NNP I
had VBD N
no DT N
effect NN N
compared VBN N
with IN N
placebo NN I
. . I

After IN N
4 CD N
days NNS N
of IN N
treatment NN N
platelet NN O
aggregation NN O
was VBD N
similarly RB N
inhibited VBN N
by IN N
all DT N
combinations NNS N
. . N

We PRP N
conclude VBP N
that IN N
a DT N
co-administration NN N
of IN N
NSAID NNP I
and CC N
aspirin NN I
may MD N
interfere VB N
with IN N
platelet NN O
inhibition NN O
at IN N
the DT N
beginning NN N
of IN N
a DT N
treatment NN N
with IN N
an DT N
increase NN N
of IN N
naproxen JJ I
and CC N
a DT N
decrease NN N
of IN N
diclofenac NN I
. . I

This DT N
effect NN N
is VBZ N
lost VBN N
after IN N
4 CD N
days NNS N
suggesting VBG N
that IN N
a DT N
regular JJ N
daily JJ N
co-administration NN N
of IN N
NSAID NNP I
does VBZ N
not RB N
have VB N
an DT N
influence NN N
on IN N
platelet NN N
inhibition NN N
by IN N
aspirin NN I
. . I

-DOCSTART- -X- N

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
the DT N
efficacy NN N
of IN N
a DT N
heparin NN I
and CC I
vancomycin JJ I
solution NN I
in IN N
preventing VBG N
central JJ P
venous JJ P
catheter NN P
infections NNS P
in IN P
children NNS P
. . P

OBJECTIVE NN P
To TO N
determine VB N
whether IN N
adding VBG N
vancomycin NN I
to TO I
central JJ I
venous JJ I
catheter NN I
(CVC) NNP I
flush JJ I
solution NN N
would MD N
significantly RB N
reduce VB N
the DT N
incidence NN N
of IN N
bacteremia NN N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
vancomycin-susceptible JJ N
organisms NNS N
. . N

STUDY NNP N
DESIGN NNP N
Fifty-five JJ P
children NNS P
with IN P
cancer NN P
and CC P
eight CD P
children NNS P
given VBN P
total JJ P
parenteral JJ P
nutrition NN P
by IN P
the DT P
surgery NN P
or CC P
nutrition NN P
support NN P
services NNS P
were VBD P
randomly RB P
assigned VBN P
to TO N
receive VB I
a DT I
heparin NN I
CVC NNP I
flush JJ I
solution NN I
(n NNP N
= VBZ N
31) CD N
or CC N
a DT N
heparin-vancomycin JJ I
CVC NNP I
flush NN I
solution NN I
(n NNP N
= VBZ N
32) CD N
. . N

RESULTS NNP N
During IN N
9158 CD N
catheter NN N
days NNS N
6.5% CD N
of IN N
the DT N
patients NNS N
in IN N
the DT N
heparin NN N
group NN N
and CC N
15.6% CD N
of IN N
the DT N
patients NNS N
in IN N
the DT N
heparin-vancomycin JJ I
group NN N
had VBD N
bacteremia VBN N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
vancomycin-susceptible JJ I
organisms NNS N
(p VBP N
= JJ N
0.43) CD N
. . N

The DT N
mean JJ O
rates NNS O
of IN O
bacteremia NN O
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
vancomycin-susceptible JJ N
organisms NNS N
were VBD N
0.6/1000 CD N
catheter NN N
days NNS N
in IN N
the DT N
heparin NN N
group NN N
and CC N
1.4/1000 CD N
catheter NN N
days NNS N
in IN N
the DT N
heparin-vancomycin JJ N
group NN N
(p NNP N
= VBZ N
0.25) CD N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
when WRB N
the DT N
time NN N
to TO N
the DT N
first JJ N
episode NN N
of IN N
bacteremia NN N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
a DT N
vancomycin-susceptible JJ I
organism NN N
was VBD N
compared VBN N
by IN N
means NNS N
of IN N
Kaplan-Meier NNP N
survival NN N
estimates NNS N
. . N

Streptococcus NNP O
viridans NNS O
infection NN O
was VBD N
not RB N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
. . N

CONCLUSION NNP N
The DT N
addition NN N
of IN N
vancomycin NN I
to TO N
heparin VB I
CVC NNP I
flush JJ I
solution NN I
did VBD N
not RB N
reduce VB N
bacteremia NN N
with IN N
vancomycin-susceptible JJ N
organisms NNS N
. . N

Bacteremia NN N
with IN N
Streptococcus NNP N
viridans NNS N
was VBD N
not RB N
related VBN N
to TO N
the DT N
use NN N
of IN N
a DT N
CVC NNP I
. . I

-DOCSTART- -X- N

Safety NN N
and CC N
immunogenicity NN N
of IN N
a DT N
cluster NN I
specific JJ I
immunotherapy NN I
in IN N
children NNS P
with IN P
bronchial JJ P
asthma NN P
and CC P
mite NN P
allergy NN P
. . P

BACKGROUND NNP P
Cluster NNP I
specific JJ I
immunotherapy NN I
(SIT) NN I
is VBZ N
a DT N
modern JJ N
form NN N
of IN N
allergen NN I
immunotherapy NN I
allowing VBG N
safe JJ N
administration NN N
of IN N
high JJ N
allergen NN N
doses NNS N
in IN N
a DT N
short JJ N
time NN N
interval JJ N
compared VBN N
to TO N
classic JJ N
SIT NNP N
. . N

In IN N
the DT N
current JJ N
study NN N
we PRP N
investigated VBD N
the DT N
safety NN N
profile NN N
and CC N
immunological JJ O
effect NN O
of IN N
cluster NN N
SIT NNP N
in IN N
children NNS P
with IN P
allergic JJ P
asthma NNS P
due JJ P
to TO P
house NN P
dust NN P
mite NN P
allergy NN P
. . P

METHODS NNP N
A NNP N
total NN P
of IN P
34 CD P
children NNS P
(6-18 JJ P
years) NN P
with IN P
allergic JJ P
asthma NNS P
were VBD P
assigned VBN P
to TO P
cluster VB P
(n NNP P
= NNP P
22) CD P
or CC P
classic JJ P
SIT NNP P
(n NNP P
= VBD P
12) CD P
. . P

To TO N
achieve VB N
a DT N
maintenance NN N
dose NN N
of IN N
allergen NN N
extract JJ N
cluster NN N
patients NNS N
received VBD N
14 CD I
injections NNS I
of IN I
house NN I
dust NN I
mite NN I
allergen NN I
within IN I
6 CD I
weeks NNS I
whereas IN I
the DT I
classic JJ I
SIT NNP I
group NN I
received VBD I
14 CD I
injections NNS I
within IN I
14 CD I
weeks NNS I
. . I

Safety NN O
was VBD N
monitored VBN N
by IN N
recording VBG N
adverse JJ N
events NNS N
. . N

Immunogenicity NN O
was VBD N
measured VBN N
by IN N
specific JJ N
IgG(Mite) NNP N
and CC N
IgG4(Mite) NNP N
by IN N
antibody-blocking JJ N
properties NNS N
on IN N
basophil NN N
activation NN N
and CC N
by IN N
the DT N
T NNP N
cell NN N
subset NN N
transcription NN N
factors NNS N
Foxp3 NNP N
T-bet NNP N
and CC N
GATA-3 NNP N
. . N

RESULTS RB I
There EX I
were VBD I
no DT I
significant JJ I
differences NNS I
in IN I
local JJ O
and CC O
systemic JJ O
side NN O
effects NNS O
between IN I
the DT I
two CD I
groups NNS I
. . I

In IN N
the DT N
cluster NN N
group NN N
serum NN O
levels NNS O
of IN O
specific JJ O
IgG(Mite) NNP O
(p NNP N
< NNP N
0.001) CD N
and CC N
specific JJ O
IgG4(Mite) NNP O
(p NNP N
< VBD N
0.001) CD N
significantly RB N
increased VBN N
after IN N
8 CD N
weeks NNS N
while IN N
it PRP N
took VBD N
12 CD N
weeks NNS N
in IN N
the DT N
classic JJ N
SIT NNP N
group NN N
. . N

These DT N
data NNS N
were VBD N
confirmed VBN N
by IN N
blocking VBG N
CD63 NNP O
expression NN O
as RB N
well RB N
as IN N
release NN N
of IN N
cysteinyl NN N
leukotrienes NNS N
after IN N
in IN N
vitro JJ N
basophil JJ N
stimulation NN N
. . N

No DT N
differences NNS N
in IN N
transcription NN O
factor NN O
expression NN O
were VBD N
found VBN N
in IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Cluster NNP N
SIT NNP N
is VBZ N
safe JJ N
in IN N
children NNS P
. . P

Additionally RB N
our PRP$ N
data NNS N
demonstrated VBD N
an DT N
even RB N
more RBR N
rapid JJ N
induction NN N
of IN N
specific JJ O
immune JJ O
tolerance NN O
. . O

Cluster NNP N
SIT NNP N
is VBZ N
an DT N
attractive JJ N
alternative NN N
to TO N
conventional JJ I
up-dosing JJ I
schedules NNS I
with IN N
fewer JJR N
consultations NNS N
for IN N
the DT N
patients NNS N
. . N

-DOCSTART- -X- N

Beta-adrenoceptor NNP I
blockade NN N
and CC N
cardiovascular JJ N
response NN N
to TO N
the DT N
cold JJ N
pressor NN N
test NN N
. . P

Seven NNP P
healthy JJ P
subjects NNS P
immersed VBD N
a DT N
hand NN N
in IN N
random NN N
order NN N
in IN N
either CC N
warm JJ I
water NN I
or CC I
in IN I
cold JJ I
water NN I
at IN N
5 CD N
degrees NNS N
C NNP N
for IN N
2 CD N
min NN N
after IN N
taking VBG N
orally RB I
a DT I
single JJ I
dose NN I
of IN I
120 CD I
mg NN I
of IN I
propranolol NN I
or CC I
a DT I
placebo NN I
in IN N
a DT N
double JJ N
blind NN N
fashion NN N
. . N

The DT N
cold JJ N
stress NN N
resulted VBD N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
blood NN N
pressure NN N
and CC N
the DT N
rate NN N
pressure NN N
product NN N
without IN N
a DT N
change NN N
in IN N
heart NN N
rate NN N
. . N

Beta-adrenoceptor NNP I
blockade NN I
did VBD N
not RB N
affect VB N
the DT N
pressor NN N
response NN N
the DT N
cold NN N
. . N

The DT N
changes NNS N
induced VBN N
by IN N
the DT N
cold JJ N
stress NN N
in IN N
the DT N
cardiovascular JJ N
variables NNS N
in IN N
the DT N
placebo NN I
and CC N
propranolol NN I
experiments NNS N
were VBD N
not RB N
statistically RB N
different JJ N
. . N

The DT N
highest JJS N
rate NN O
pressure NN O
product NN N
during IN N
the DT N
cold JJ N
pressor NN N
test NN N
was VBD N
about IN N
109 CD N
units NNS N
. . N

This DT N
was VBD N
well RB N
below IN N
the DT N
pain NN N
threshold JJ N
value NN N
of IN N
about IN N
200 CD N
found NN N
during IN N
exercise NN N
in IN N
patients NNS P
with IN P
ischaemic JJ P
heart NN P
disease NN P
. . P

In IN N
the DT N
recovery NN N
phase NN N
the DT N
cardiovascular JJ N
variables NNS N
reverted VBN N
to TO N
pre-immersion NN N
values NNS N
within IN N
1 CD N
min JJ N
inspite NN N
of IN N
continued JJ N
low JJ N
hand NN N
skin NN N
temperature NN N
. . N

-DOCSTART- -X- N

Randomized VBN N
controlled JJ N
trial NN N
for IN N
early JJ I
intervention NN I
for IN I
autism: NN I
a DT N
pilot NN N
study NN N
of IN N
the DT N
Autism NNP I
1-2-3 JJ I
Project NNP I
. . I

We PRP N
piloted VBD N
a DT N
2-week JJ N
"Autism-1-2-3" JJ I
early JJ I
intervention NN I
for IN P
children NNS P
with IN P
autism NN P
and CC P
their PRP$ P
parents NNS P
immediately RB N
after IN N
diagnosis NN N
that WDT N
targeted VBD N
at IN N
(1) NNP I
eye NN I
contact NN I
(2) JJ I
gesture NN I
and CC I
(3) JJ I
vocalization/words NNS I
. . I

Seventeen JJ P
children NNS P
were VBD P
randomized VBN P
into IN P
the DT P
Intervention NNP P
(n NNP P
= NNP P
9) CD P
and CC P
Control NNP P
(n NNP P
= NNP P
8) CD P
groups NNS P
. . P

Outcome NNP N
measures NNS N
included VBD N
the DT N
Autism NNP O
Diagnostic NNP O
Observation NNP O
Schedule NNP O
Ritvo-Freeman NNP O
Real NNP O
Life NNP O
Rating NNP O
Scale NNP O
Symbolic NNP O
Play NNP O
Test NNP O
and CC O
Parenting NNP O
Stress NNP O
Index NNP O
. . O

Children NNP P
with IN P
autism NN P
improved VBN N
in IN N
language/communication NN O
reciprocal JJ O
social JJ O
interaction NN O
and CC O
symbolic JJ O
play NN O
. . O

Parents NNS N
perceived VBD N
significant JJ N
improvement NN N
in IN N
their PRP$ N
children's JJ O
language NN O
social JJ O
interaction NN O
and CC O
their PRP$ O
own JJ O
stress NN O
level NN O
. . O

This DT N
intervention NN I
can MD N
serve VB N
as IN N
short-term JJ I
training NN I
on IN I
communication NN I
and CC I
social JJ I
interaction NN I
for IN N
children NNS N
with IN N
autism NN N
and CC N
reduce VB N
the DT N
stress NN N
of IN N
their PRP$ N
parents NNS N
during IN N
the DT N
long JJ N
waiting NN N
time NN N
for IN N
public JJ N
health NN N
services NNS N
. . N

-DOCSTART- -X- N

Lack NN N
of IN N
benefit NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
synthetic JJ I
human JJ I
secretin NN I
in IN N
the DT N
treatment NN N
of IN N
autism NN P
and CC P
pervasive JJ P
developmental JJ P
disorder NN P
. . P

BACKGROUND NNP P
Secretin NNP I
is VBZ N
a DT N
peptide JJ N
hormone NN N
that WDT N
stimulates VBZ N
pancreatic JJ N
secretion NN N
. . N

After IN N
recent JJ N
publicity NN N
about IN N
a DT N
child NN N
with IN N
autism NN N
whose WP$ N
condition NN N
markedly RB N
improved VBN N
after IN N
a DT N
single JJ N
dose NN N
of IN N
secretin JJ I
thousands NNS P
of IN P
children NNS P
with IN P
autistic JJ P
disorders NNS P
may MD N
have VB N
received VBN N
secretin JJ I
injections NNS I
. . I

METHODS NNP N
We PRP N
conducted VBD N
a DT N
double-blind JJ N
placebo-controlled JJ I
trial NN N
of IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
of IN N
synthetic JJ I
human JJ I
secretin NN I
in IN N
60 CD P
children NNS P
(age RB P
3 CD P
to TO P
14 CD P
years) NNS P
with IN P
autism NN P
or CC P
pervasive JJ P
developmental JJ P
disorder NN P
. . P

The DT N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
an DT N
intravenous JJ N
infusion NN N
of IN N
synthetic JJ I
human JJ I
secretin NN I
(0.4 NN N
microg FW N
per IN N
kilogram NN N
of IN N
body NN N
weight) NN N
or CC N
saline NN I
placebo NN I
. . I

We PRP N
used VBD N
standardized JJ N
behavioral JJ O
measures NNS O
of IN N
the DT N
primary JJ N
and CC N
secondary JJ N
features NNS N
of IN N
autism NN N
including VBG N
the DT N
Autism NNP N
Behavior NNP N
Checklist NNP N
to TO N
assess VB N
the DT N
degree NN O
of IN O
impairment NN O
at IN N
base NN N
line NN N
and CC N
over IN N
the DT N
course NN N
of IN N
a DT N
four-week JJ N
period NN N
after IN N
treatment NN N
. . N

RESULTS NN N
Of IN N
the DT N
60 CD N
children NNS N
4 CD N
could MD N
not RB N
be VB N
evaluated VBN N
- : N
2 CD N
received VBD N
secretin NN I
outside IN N
the DT N
study NN N
and CC N
2 CD N
did VBD N
not RB N
return VB N
for IN N
follow-up NN N
. . N

Thus RB N
56 CD P
children NNS P
(28 RB P
in IN P
each DT P
group) NN P
completed VBD P
the DT P
study NN P
. . P

As IN N
compared VBN N
with IN N
placebo NN I
secretin NN I
treatment NN I
was VBD N
not RB N
associated VBN N
with IN N
significant JJ N
improvements NNS N
in IN N
any DT N
of IN N
the DT N
outcome NN N
measures NNS N
. . N

Among IN N
the DT N
children NNS N
in IN N
the DT N
secretin NN I
group NN I
the DT I
mean JJ N
total NN O
score NN O
on IN O
the DT O
Autism NNP O
Behavior NNP O
Checklist NNP O
at IN N
base NN N
line NN N
was VBD N
59.0 CD N
(range NN N
of IN N
possible JJ N
values NNS N
0 CD N
to TO N
158 CD N
with IN N
a DT N
larger JJR N
value NN N
corresponding VBG N
to TO N
greater JJR N
impairment) NNS N
and CC N
among IN N
those DT N
in IN N
the DT N
placebo NN I
group NN N
it PRP N
was VBD N
63.2 CD N
. . N

The DT N
mean JJ N
decreases NNS O
in IN O
scores NNS O
over IN N
the DT N
four-week JJ N
period NN N
were VBD N
8.9 CD N
in IN N
the DT N
secretin NN I
group NN N
and CC N
17.8 CD N
in IN N
the DT N
placebo NN I
group NN N
(mean JJ N
difference NN N
-8.9; VBD N
95 CD N
percent NN N
confidence NN N
interval NN N
-19.4 NN N
to TO N
1.6; CD N
P=0.11) NNP N
. . N

None NN N
of IN N
the DT N
children NNS N
had VBD N
treatment-limiting JJ O
adverse JJ O
effects NNS O
. . O

After IN N
they PRP N
were VBD N
told VBN N
the DT N
results NNS N
69 CD N
percent NN N
of IN N
the DT N
parents NNS N
of IN N
the DT N
children NNS N
in IN N
this DT N
study NN N
said VBD N
they PRP N
remained VBD N
interested JJ N
in IN N
secretin NN I
as IN N
a DT N
treatment NN N
for IN N
their PRP$ N
children NNS N
. . N

CONCLUSIONS VB N
A DT N
single JJ N
dose NN N
of IN N
synthetic JJ I
human JJ I
secretin NN I
is VBZ N
not RB O
an DT O
effective JJ O
treatment NN O
for IN N
autism NN P
or CC P
pervasive JJ P
developmental JJ P
disorder NN P
. . N

-DOCSTART- -X- N

Effects NNS O
of IN N
maternal JJ I
glucose JJ I
infusion NN I
on IN N
fetal JJ N
acid-base JJ N
status NN N
in IN N
human JJ P
pregnancy NN P
. . P

The DT N
maternal JJ O
and CC O
fetal JJ O
metabolic JJ O
effects NNS O
of IN N
three CD N
commonly NNS N
used VBD N
intravenous JJ N
fluids NNS N
administered VBD N
before IN N
regional JJ N
anesthesia NN N
were VBD N
studied VBN N
in IN N
32 CD P
gravid JJ P
women NNS P
undergoing VBG P
elective JJ P
cesarean JJ P
section NN P
at IN P
term NN P
. . P

Patients NNS N
were VBD N
randomized VBN N
into IN N
one CD N
of IN N
three CD N
groups NNS N
to TO N
receive VB N
1 CD I
L NNP I
of IN I
either CC I
5% CD I
dextrose JJ I
(50 NNP I
gm NN I
of IN I
glucose) NN I
or CC I
Ringer's NNP I
lactate VBP I
or CC I
isotonic JJ I
saline JJ I
solution NN I
before IN I
epidural JJ I
anesthesia NN I
. . I

Acute NNP N
glucose JJ N
infusion NN N
resulted VBD N
in IN N
maternal JJ O
hyperglycemia NN O
hyperinsulinemia NN O
and CC O
an DT O
increase NN O
in IN O
the DT O
blood NN O
lactate NN O
level NN O
. . O

Cord NNP O
blood NN O
glucose NN O
insulin NN O
and CC O
lactate NN O
levels NNS O
were VBD O
also RB O
increased VBN O
in IN O
this DT O
group NN O
. . O

The DT O
key JJ O
finding NN O
of IN O
this DT O
study NN O
was VBD O
the DT O
significant JJ O
lowering NN O
of IN O
pH NN O
in IN O
the DT O
umbilical JJ O
cord NN O
vein NN O
(7.31 VBD O
+/- JJ O
0.04) CD O
and CC O
artery JJ O
(7.21 NNP O
+/- JJ O
0.06) CD O
in IN O
the DT O
glucose-infused JJ O
group NN O
when WRB O
compared VBN O
with IN O
the DT O
non-glucose JJ O
infusion NN O
groups NNS O
(p VBP O
less JJR O
than IN O
0.05) CD O
. . O

Confounding VBG O
perinatal JJ O
factors NNS O
such JJ O
as IN O
maternal JJ O
position NN O
maternal JJ O
hypotension NN O
and CC O
prolonged JJ O
time NN O
of IN O
surgery NN O
did VBD O
not RB O
influence VB O
the DT O
fetal JJ O
acid-base JJ O
status NN O
. . O

Thus RB O
acute JJ O
maternal JJ O
glucose NN O
infusion NN O
in IN O
normal JJ O
patients NNS O
can MD O
cause VB O
fetal JJ O
hyperglycemia NN O
metabolic JJ O
acidosis NN O
and CC O
neonatal JJ O
hypoglycemia NN O
. . O

These DT N
findings NNS N
may MD N
be VB N
of IN N
particular JJ N
clinical JJ N
importance NN N
when WRB N
fetal JJ N
distress NN N
or CC N
fetal JJ N
hypoxemia NN N
is VBZ N
due JJ N
to TO N
other JJ N
perinatal JJ N
events NNS N
. . N

Under IN N
these DT N
circumstances NNS N
acute VBP N
maternal JJ N
glucose JJ N
infusion NN N
may MD N
further RB N
contribute VB N
to TO N
fetal JJ N
metabolic JJ N
acidosis NN N
. . N

-DOCSTART- -X- N

A DT N
double-blind JJ N
placebo NN I
controlled VBD N
trial NN N
of IN N
piracetam NN I
added VBN I
to TO I
risperidone VB I
in IN N
patients NNS P
with IN P
autistic JJ P
disorder NN P
. . P

It PRP N
has VBZ N
been VBN N
reported VBN N
that IN N
autism NN N
is VBZ N
a DT N
hypoglutamatergic JJ N
disorder NN N
. . N

Therefore IN N
it PRP N
was VBD N
of IN N
interest NN N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
piracetam NN I
a DT I
positive JJ N
modulator NN N
of IN N
AMPA-sensitive JJ N
glutamate NN N
receptors NNS N
in IN N
autistic JJ P
disorder NN P
. . P

About IN N
40 CD P
children NNS P
between IN P
the DT P
ages NNS P
three CD P
and CC P
11 CD P
years NNS P
(inclusive) RB P
with IN P
a DT P
DSM NNP P
IV NNP P
clinical JJ P
diagnosis NN P
of IN P
autism NN P
and CC P
who WP P
were VBD P
outpatients NNS P
from IN P
a DT P
specialty NN P
clinic NN P
for IN P
children NNS P
were VBD P
recruited VBN P
. . P

The DT N
children NNS P
presented VBN P
with IN P
a DT P
chief JJ P
complaint NN P
of IN P
severely RB P
disruptive JJ P
symptoms NNS P
related VBN P
to TO P
autistic JJ P
disorder NN P
. . P

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
piracetam VB I
+ NNP I
risperidone NN I
(Group NNP I
A) NNP I
or CC I
placebo VB I
+ JJ I
risperidone NN I
(Group NNP I
B) NNP I
for IN N
a DT N
10-week JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
. . N

The DT N
dose NN N
of IN N
risperidone NN I
was VBD I
titrated VBN I
up RB I
to TO I
2 CD I
mg/day NN I
for IN N
children NNS N
between IN N
10 CD N
and CC N
40 CD N
kg NN N
and CC N
3 CD N
mg/day NN N
for IN N
children NNS N
weighting VBG N
above IN N
40 CD N
kg NN N
. . N

The DT N
dose NN N
of IN N
piracetam NN I
was VBD N
titrated VBN N
up RB N
to TO N
800 CD N
mg/day NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
4 CD N
6 CD N
8 CD N
and CC N
10 CD N
weeks NNS N
of IN N
starting VBG N
medication NN N
. . N

The DT N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Aberrant NNP O
Behavior NNP O
Checklist-Community NNP O
(ABC-C) JJ O
Rating NNP O
Scale NNP O
(total JJ N
score) NN N
. . N

The DT N
ABC-C NNP O
Rating NNP O
Scale NNP O
scores VBZ O
improved VBN N
with IN N
piracetam NN I
. . I

The DT N
difference NN N
between IN N
the DT N
two CD N
protocols NNS N
was VBD N
significant JJ N
as IN N
indicated VBN N
by IN N
the DT N
effect NN N
of IN N
group NN N
the DT N
between IN N
subjects NNS N
factor VBP N
(F JJ N
= $ N
5.85 CD N
d.f NN N
. . N

= RB N
1 CD N
P NNP N
= VBD N
0.02) CD N
. . N

The DT N
changes NNS N
at IN N
the DT N
endpoint NN N
compared VBN N
with IN N
baseline NN N
were: NN N
-11.90 VBD N
+/- JJ N
3.79 CD N
(mean JJ N
+/- JJ N
SD) NNP N
and CC N
-5.15 NNP N
+/- JJ N
3.04 CD N
for IN N
group NN N
A NNP N
and CC N
B NNP N
respectively RB N
. . N

A DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
on IN N
the DT N
change NN N
in IN N
scores NNS N
in IN N
the DT N
ABC-C NNP O
Rating NNP O
Scale NNP O
in IN N
week NN N
10 CD N
compared VBN N
with IN N
baseline NN N
in IN N
the DT N
two CD N
groups NNS N
(t VBP N
= $ N
6.017 CD N
d.f NN N
. . N

= RB N
38 CD N
P NNP N
< VBD N
0.0001) CD N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
a DT N
combination NN N
of IN N
atypical JJ N
antipsychotic JJ N
medications NNS N
and CC N
a DT N
glutamate JJ N
agent NN N
such JJ N
as IN N
piracetam NN I
might MD I
have VB N
increase VBN N
synergistic JJ N
effects NNS N
in IN N
the DT N
treatment NN N
of IN N
autism NN N
. . N

-DOCSTART- -X- N

Timing NN N
of IN N
death NN O
and CC O
myocardial JJ P
infarction NN P
in IN P
patients NNS P
with IN P
non-ST JJ P
elevation NN P
acute NN P
coronary JJ P
syndromes: NN P
insights NNS N
from IN N
randomized VBN N
clinical JJ N
trials NNS N
. . N

BACKGROUND NNP N
Adverse NNP N
events NNS N
occur VBP N
following VBG N
non-ST JJ P
elevation NN P
acute NN P
coronary JJ P
syndromes NNS P
(NSTE VBP P
ACS) NNP P
. . P

However RB N
the DT N
timing NN N
of IN N
these DT N
events NNS N
in IN N
relation NN N
to TO N
index NN N
event NN N
is VBZ N
less RBR N
clear JJ N
. . N

METHODS NNP N
Accordingly NNP N
we PRP P
evaluated VBD P
26 CD P
466 CD P
NSTE NNP P
ACS NNP P
patients NNS P
from IN P
the DT P
Global NNP P
Use NNP P
of IN P
Strategies NNPS P
to TO P
Open VB P
Occluded NNP P
Arteries NNPS P
in IN P
Acute NNP P
Coronary NNP P
Syndromes NNP P
(GUSTO-IIb) JJ P
Platelet NNP P
Glycoprotein NNP P
IIb/IIIa NNP P
in IN P
Unstable NNP P
Angina: NNP P
Receptor NNP N
Suppression NNP N
Using NNP N
Integrilin NNP I
Therapy NNP I
(PURSUIT) NNP N
and CC N
Platelet NNP I
IIb/IIIa NNP I
Antagonism NNP I
for IN N
the DT N
Reduction NNP N
of IN N
Acute NNP N
Coronary NNP N
Syndrome NNP N
Events NNP N
in IN N
a DT N
Global NNP N
Organization NNP N
Network NNP N
(PARAGON) VBD N
A DT N
and CC N
B NNP N
trials NNS N
to TO N
ascertain VB N
the DT N
timing NN N
of IN N
adverse JJ N
events NNS N
. . N

Outcomes NNS N
of IN N
interest NN N
were VBD N
death NN O
myocardial JJ O
infarction NN O
(MI) NN O
and CC O
death NN O
or CC O
MI NNP O
at IN N
180 CD N
days NNS N
. . N

Logistic JJ N
regression NN N
modeling VBG N
for IN N
death NN N
was VBD N
used VBN N
to TO N
categorize VB N
patients NNS N
into IN N
low- JJ N
medium- JJ N
and CC N
high-risk JJ N
groups NNS N
. . N

RESULTS NN N
At IN N
6 CD N
months NNS N
6.2% CD N
of IN N
patients NNS N
died VBD O
12.1% CD O
had VBD N
MI NNP O
and CC O
15.7% CD N
suffered VBD N
death NN O
or CC O
MI NNP O
. . O

From IN N
15% CD N
to TO N
40% CD N
of IN N
these DT N
events NNS N
occurred VBD N
beyond IN N
30 CD N
days NNS N
. . N

At IN N
6 CD N
months NNS N
3% CD N
4% CD N
and CC N
13% CD N
of IN N
patients NNS N
died VBN N
in IN N
low- JJ N
medium- JJ N
and CC N
high-risk JJ N
groups NNS N
respectively RB N
. . N

However RB N
the DT N
proportion NN O
of IN O
patients NNS O
dying VBG O
beyond IN N
30 CD N
days NNS N
was VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
(44% VBP N
43% CD N
and CC N
41% CD N
of IN N
death NN N
respectively) NN N
. . N

Similarly RB N
whereas JJ N
death NN O
or CC O
MI NNP O
increased VBD N
with IN N
higher JJR N
risk NN N
(11% VBP N
14% CD N
and CC N
23% CD N
respectively) NN N
the DT N
proportion NN O
of IN O
patients NNS O
with IN N
this DT N
event NN N
beyond IN N
30 CD N
days NNS N
did VBD N
not RB N
differ VB N
in IN N
the DT N
three CD N
strata NNS N
(22% VBP N
20% CD N
and CC N
25% CD N
respectively) NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
study NN N
provides VBZ N
important JJ N
insights NNS N
into IN N
the DT N
timing NN N
of IN N
adverse JJ N
events NNS N
and CC N
suggests VBZ N
that IN N
the DT N
substantial JJ N
proportion NN N
of IN N
patients NNS N
suffer VBP N
subsequent JJ N
adverse JJ N
events NNS N
after IN N
their PRP$ N
index NN N
NSTE NNP N
ACS NNP N
. . N

Thus RB N
these DT N
data NNS N
call NN N
for IN N
continuous JJ N
surveillance NN N
for IN N
these DT N
events NNS N
and CC N
efforts NNS N
beyond IN N
the DT N
acute JJ N
phase NN N
at IN N
increasing VBG N
adherence NN N
to TO N
evidence-based JJ N
therapies NNS N
to TO N
improve VB N
the DT N
outcomes NNS N
of IN N
these DT N
patients NNS N
. . N

-DOCSTART- -X- N

Osteoporosis NN I
and CC I
gait NN I
and CC I
balance NN I
disturbances NNS I
in IN N
older JJR P
sarcopenic JJ P
obese JJ P
New NNP P
Zealanders NNP P
. . P

UNLABELLED NNP P
Bone NNP N
muscle NN N
and CC N
fat NN N
may MD N
affect VB N
gait NN N
and CC N
balance NN N
in IN N
older JJR P
adults NNS P
. . P

Osteoporosis NN P
was VBD P
prevalent JJ P
in IN P
low JJ P
muscle NN P
mass NN P
participants NNS P
and CC P
related VBN P
to TO P
gait VB P
and CC P
balance VB P
deficits NNS P
. . P

Low JJ N
muscle NN N
combined VBN N
with IN N
high JJ N
fat JJ N
mass NN N
had VBD N
more RBR N
functional JJ N
deficits NNS N
and CC N
poorer JJR N
bone NN N
health NN N
which WDT N
has VBZ N
implications NNS N
for IN N
falls NNS N
risk NN N
and CC N
fractures NNS N
. . N

INTRODUCTION NNP N
Decreasing NNP N
bone NN N
density NN N
and CC N
muscle NN N
mass NN N
and CC N
increasing VBG N
fat JJ N
mass NN N
may MD N
act VB N
synergistically RB N
to TO N
affect VB N
gait NN I
and CC I
balance NN I
in IN N
older JJR N
adults NNS N
. . N

METHODS NNP N
One CD P
hundred VBD P
eighty-three JJ P
older NN P
adults NNS P
(age VBP P
72.7 CD P
+/- JJ P
6 CD P
years NNS P
range VBP P
56-93; JJ P
body NN P
mass NN P
index NN P
28.2 CD P
+/- JJ P
4.9 CD P
range NN P
16.6-46.0) CD P
were VBD P
recruited VBN P
from IN P
a DT P
New NNP P
Zealand NNP P
falls VBZ P
prevention NN P
intervention NN P
trial NN P
. . P

Total JJ O
and CC P
appendicular JJ P
skeletal JJ P
muscle NN P
mass NN P
(ASM) NNP P
percent NN P
fat NN P
and CC P
bone NN P
mineralization NN P
were VBD P
assessed VBN P
by IN P
dual JJ P
energy NN P
X-ray JJ P
absorptiometry NN I
and CC P
used VBD P
to TO P
characterize VB P
normal JJ P
lean JJ P
(NL NNP P
n NN P
= VBD P
51) CD P
sarcopenic JJ P
(SS NN P
n NN P
= VBD P
18) CD P
sarcopenic JJ P
obese JJ P
(SO NN P
n NN P
= $ P
29) CD P
and CC P
obese JJ P
(OO NNP P
n NN P
= VBD P
85) CD P
phenotypes NNS P
. . P

Functional JJ I
performance NN I
was VBD N
assessed VBN N
using VBG N
timed VBN I
up RP I
and CC I
go VB I
chair NN I
stand VBP I
single JJ I
leg NN I
stand NN I
and CC I
step VB I
test NN I
. . I

Regression NN N
models NNS N
were VBD N
adjusted VBN N
for IN N
age NN N
sex NN N
medications NNS N
and CC N
physical JJ N
activity NN N
. . N

RESULTS NNP N
Femoral NNP O
neck NN O
osteoporosis NN O
was VBD N
present JJ N
in IN N
22% CD N
SS NNP N
17% CD N
SO NNP N
12% CD N
NL NNP N
and CC N
7% CD N
OO NNP N
. . N

Femoral NNP N
neck CC N
osteoporosis NN I
with IN N
low JJ N
ASM NNP N
predicted VBD N
poor JJ I
chair NN O
stand VBP O
performance NN O
(beta NNP N
-3.3 NNP N
standard VBD N
error NN N
1.6 CD N
p NN N
= VBD N
0.04) CD N
. . N

SO RB N
scored JJ N
lowest NN N
on IN N
the DT N
chair NN N
stand VBP N
(p NNP N
= NNP N
0.03) CD N
and CC N
step VB N
test RB N
(p NNP N
= VBD N
0.03) CD N
. . N

Higher JJR N
ASM NNP N
predicted VBD N
faster RBR N
timed VBN N
up RP N
and CC N
go VB N
performance NN N
(p NNP N
= VBZ N
0.001) CD N
. . N

CONCLUSIONS NNP N
Osteoporosis NNP I
was VBD N
prevalent VBN N
in IN N
low JJ P
ASM NNP P
groups NNS P
(SS NNP P
and CC N
SO) NNP N
and CC N
related VBN N
to TO N
gait VB I
and CC I
balance VB I
deficits NNS N
particularly RB N
in IN N
the DT N
SO NNP N
. . N

This DT N
has VBZ N
implications NNS N
for IN N
falls NNS N
risk NN N
fractures NNS N
and CC N
interventions NNS N
. . N

-DOCSTART- -X- N

Effects NNS N
of IN N
nitric JJ I
oxide JJ I
synthase NN I
inhibition NN I
on IN N
cutaneous JJ O
vasodilation NN O
in IN N
response NN N
to TO N
acupuncture VB I
stimulation NN N
in IN N
humans NNS P
. . P

OBJECTIVES IN I
The DT I
aim NN I
of IN I
the DT I
present JJ I
study NN I
was VBD I
to TO I
elucidate VB I
the DT I
mechanism NN I
of IN I
cutaneous JJ I
vasodilation NN I
following VBG I
acupuncture NN I
stimulation NN I
by IN I
investigating VBG I
the DT I
roles NNS I
of IN I
nitric JJ I
oxide NN I
(NO) NN I
and CC I
axon NN I
reflex JJ I
vasodilation NN I
. . I

METHODS NNP N
The DT N
subjects NNS P
were VBD P
17 CD P
healthy JJ P
male NN P
volunteers NNS P
. . P

The DT N
role NN N
of IN N
NO NNP N
was VBD N
investigated VBN N
by IN N
administering VBG N
N(G)-nitro-l-arginine NNP I
methyl NN I
ester NN I
hydrochloride VBD I
(L-NAME JJ I
20 CD I
mM) NN I
an DT I
NO NNP I
synthase NN I
inhibitor NN I
or CC I
Ringer's NNP I
solution NN I
(control NNP I
site) NN I
via IN I
intradermal JJ N
microdialysis NN N
(protocol VBD N
1; CD N
n=7) NN N
. . N

The DT N
role NN N
of IN N
axon JJ N
reflex JJ N
vasodilation NN N
by IN N
local JJ N
sensory NN N
neurones NNS N
was VBD N
investigated VBN N
by IN N
comparing VBG N
vasodilation NN N
at IN N
sites NNS N
treated VBN N
with IN N
'eutectic JJ I
mixture NN I
of IN I
local JJ I
anaesthetics' NN I
(EMLA) NNP I
cream NN I
(2.5% NNP I
lidocaine NN I
and CC I
2.5% CD I
prilocaine) NN I
with IN N
untreated JJ I
sites NNS N
(control VBP N
site) JJ N
(protocol $ N
2; CD N
n=10) NN N
. . N

After IN N
5 CD N
min NN N
of IN N
baseline NN N
recording VBG N
acupuncture NN I
was VBD N
applied VBN N
to TO N
PC4 NNP N
and CC N
a DT N
control NN N
site NN N
in IN N
proximity NN N
to TO N
PC4 NNP N
for IN N
10 CD N
min NNS N
and CC N
scanning NN N
was VBD N
performed VBN N
for IN N
60 CD N
min NN N
after IN N
acupuncture JJ I
stimulation NN N
. . N

Skin NNP O
blood NN O
flow NN O
(SkBF) NN O
was VBD N
evaluated VBN N
by IN N
laser NN N
Doppler NNP N
perfusion NN N
imaging NN N
. . N

Cutaneous JJ O
vascular JJ O
conductance NN O
(CVC) NN O
was VBD N
calculated VBN N
from IN N
the DT N
ratio NN N
of IN N
SkBF NNP N
to TO N
mean VB N
arterial JJ N
blood NN N
pressure NN N
. . N

RESULTS NN N
In IN N
the DT N
first JJ N
protocol NN N
sites NNS N
administered VBD N
L-NAME NNP I
showed VBD N
significant JJ N
reductions NNS N
in IN N
CVC NNP O
responses NNS O
following VBG N
acupuncture NN I
stimulation NN N
compared VBN N
to TO N
control VB N
sites NNS N
(administered VBN N
Ringer's NNP I
solution) JJ I
(p<0.05) NN N
. . N

In IN N
the DT N
second JJ N
protocol NN N
changes NNS O
in IN O
CVC NNP O
responses NNS O
after IN N
acupuncture JJ I
stimulation NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
treated VBN N
sites NNS N
with IN N
EMLA NNP I
cream NN N
and CC N
untreated JJ I
sites NNS N
(p>0.05) VBP N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
cutaneous JJ N
vasodilation NN N
in IN N
response NN N
to TO N
acupuncture VB I
stimulation NN N
may MD N
not RB N
occur VB N
through IN N
an DT N
axon JJ N
reflex NN N
as IN N
previously RB N
reported VBN N
. . N

Rather RB N
NO NNP N
mechanisms NN N
appear VBP N
to TO N
contribute VB N
to TO N
the DT N
vasodilator NN N
response NN N
. . N

-DOCSTART- -X- N

Effects NNS N
of IN N
fenoterol NN I
on IN N
inspiratory JJ N
effort NN N
sensation NN N
and CC N
fatigue NN N
during IN N
inspiratory JJ N
threshold JJ N
loading NN N
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
a DT N
single JJ I
dose NN I
of IN I
fenoterol NN I
on IN N
the DT N
relationship NN N
between IN N
inspiratory NN N
effort NN N
sensation NN N
(IES) NNP N
and CC N
inspiratory JJ N
muscle NN N
fatigue NN N
induced VBN N
by IN N
inspiratory NN N
threshold NN N
loading NN N
in IN N
healthy JJ P
subjects NNS P
. . P

The DT N
magnitude NN N
of IN N
the DT N
threshold NN N
was VBD N
60% CD N
of IN N
maximal JJ N
static JJ N
inspiratory NN N
mouth NN N
pressure NN N
(PI NNP N
mmax) NN N
at IN N
functional JJ N
residual JJ N
capacity NN N
and CC N
the DT N
duty NN N
cycle NN N
was VBD N
0.5 CD N
. . N

Subjects NNS N
continued VBD N
the DT N
threshold NN N
loaded VBD N
breathing NN N
until IN N
the DT N
target NN N
mouth NN N
pressure NN N
could MD N
no RB N
longer RB N
be VB N
maintained VBN N
(endurance NNP N
time) NN N
. . N

The DT N
intensity NN N
of IN N
the DT N
IES NNP N
was VBD N
scored VBN N
with IN N
a DT N
modified JJ N
Borg NNP N
scale NN N
. . N

Either DT N
fenoterol NN I
(5 NNP I
mg) NN I
or CC I
a DT I
placebo NN I
was VBD N
given VBN N
orally RB N
2 CD N
h NN N
before IN N
loading VBG N
in IN N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
protocol NN N
. . N

The DT N
endurance NN N
time NN N
with IN N
fenoterol JJ I
(34.4 NNP N
+/- JJ N
8.6 CD N
min) NN N
was VBD N
longer JJR N
than IN N
that DT N
with IN N
the DT N
placebo NN N
(22.2 VBD N
+/- JJ N
7.1 CD N
min; NN N
P NNP N
< VBZ N
0.05) CD N
. . N

The DT N
ratio NN O
of IN O
high- JJ O
to TO O
low-frequency JJ O
power NN O
of IN O
the DT O
diaphragmatic JJ O
electromyogram NN O
(EMGdi) NNS O
decreased VBD N
during IN N
loading; IN N
the DT N
decrease NN N
was VBD N
less RBR N
with IN N
fenoterol NN I
(P NNP N
< VBZ N
0.05) CD N
. . N

The DT N
EMGdi NNP O
also RB N
decreased VBD N
with IN N
loading; PDT N
the DT N
decrease NN N
was VBD N
greater JJR N
on IN N
fenoterol NN N
treatment NN N
(P NNP N
< VBZ N
0.01) CD N
. . N

The DT N
PI NNP O
mmax NN O
and CC O
maximal JJ O
transdiaphragmatic JJ O
pressure NN O
(Pdi) NN O
were VBD N
similarly RB N
decreased VBN N
after IN N
loading VBG N
on IN N
either DT N
treatment NN N
. . N

The DT N
intensity NN O
of IN O
the DT O
IES NNP O
rose VBD N
with IN N
time NN N
during IN N
loading VBG N
in IN N
both DT N
groups NNS N
but CC N
was VBD N
lower JJR N
with IN N
fenoterol NN I
than IN N
with IN N
the DT N
placebo NN I
(P NNP N
< VBZ N
0.05) CD N
. . N

The DT N
ratio NN O
of IN O
Pdi NNP O
to TO N
integrated JJ N
activity NN N
of IN N
the DT N
EMGdi NNP N
increased VBD N
with IN N
fenoterol NN I
(P NNP N
< VBZ N
0.05) CD N
. . N

Fenoterol NNP I
treatment NN I
increased VBD N
both DT N
superimposed VBN N
Pdi NNP O
twitch NN O
and CC O
Pdi NNP O
twitch NN O
of IN O
relaxed JJ O
diaphragm NN O
and CC N
decreased VBD N
the DT N
value NN N
of IN N
(1-superimposed JJ O
Pdi NNP O
twitch/Pdi NN O
twitch NN O
of IN O
relaxed JJ O
diaphragm) NN O
. . O

Thus RB N
we PRP N
conclude VBP N
that IN N
in IN N
normal JJ P
subjects NNS P
fenoterol JJ N
reduces NNS N
diaphragmatic JJ N
fatigue NN N
and CC N
decreases VBZ N
the DT N
motor NN N
command NN N
to TO N
the DT N
diaphragm NN N
resulting VBG N
in IN N
a DT N
decrease NN N
in IN N
IES NNP N
during IN N
inspiratory JJ N
threshold JJ N
loading NN N
and CC N
a DT N
prolongation NN N
of IN N
endurance NN N
. . N

-DOCSTART- -X- N

A DT N
search NN N
for IN N
serologic JJ N
correlates NNS N
of IN N
immunity NN N
to TO N
Bordetella NNP N
pertussis NN N
cough NN N
illnesses NNS N
. . N

In IN N
a DT N
pertussis NN P
vaccine NN P
efficacy NN P
trial NN P
in IN P
Germany NNP P
we PRP N
collected VBD N
sera NN N
from IN N
vaccinees NNS I
(DTaP CD I
or CC I
DTP) NNP I
after IN I
the DT I
third JJ I
and CC I
fourth JJ I
doses NNS I
of IN I
vaccine NN I
or CC N
at IN N
comparable JJ N
time NN N
periods NNS N
in IN N
DT NNP P
vaccine NN P
recipients NNS P
. . P

In IN N
addition NN N
sera NN N
were VBD N
collected VBN N
from IN N
a DT N
randomized JJ N
sample NN N
of IN N
subjects NNS P
in IN P
each DT P
vaccine NN P
group NN P
at IN P
approximately RB P
3-month JJ P
intervals NNS P
from IN N
which WDT N
antibody NN N
kinetic JJ N
curves NNS N
were VBD N
constructed VBN N
which WDT N
allowed VBD N
us PRP N
to TO N
estimate VB N
specific JJ N
antibody NN N
values NNS N
to TO N
pertussis VB I
toxin NN I
(PT) NNP I
filamentous JJ I
hemagglutinin NN I
(FHA) NNP I
pertactin NN I
and CC I
fimbriae-2 NN I
at IN N
the DT N
time NN N
of IN N
exposure NN N
in IN N
the DT N
household NN N
setting NN N
. . N

The DT N
imputed JJ N
geometric JJ N
mean NN N
antibody NN N
values NNS N
to TO N
PT NNP N
pertactin NN N
and CC N
fimbriae-2 NN N
at IN N
the DT N
time NN N
of IN N
household NN N
exposure NN N
to TO N
Bordetella NNP N
pertussis NN N
infection NN N
were VBD N
higher JJR N
(p JJ N
< $ N
0.07 CD N
or CC N
lower) VB N
in IN N
non-cases NNS N
compared VBN N
with IN N
cases NNS N
. . N

A DT N
multivariate JJ N
(classification NN N
tree) NN N
analysis NN N
found VBD N
that IN N
only RB N
pertactin NN N
and CC N
PT NNP N
were VBD N
significant JJ N
in IN N
protection NN N
. . N

Subjects NNS N
with IN N
an DT N
imputed JJ N
pertactin NN N
value NN N
of IN N
< $ N
7 CD N
EU NNP N
ml-1 NN N
had VBD N
a DT N
67% CD N
(18/27) JJ N
chance NN N
of IN N
infection NN N
regardless NN N
of IN N
the DT N
PT NNP N
value NN N
. . N

If IN N
the DT N
pertactin NN N
value NN N
was VBD N
> JJ N
or CC N
= JJ N
7 CD N
EU NNP N
ml-1 NN N
and CC N
the DT N
PT NNP N
value NN N
> NN N
or CC N
= $ N
66 CD N
EU NNP N
ml-1 CD N
all DT N
subjects NNS N
were VBD N
non-cases NNS N
. . N

If IN N
the DT N
pertactin NN N
value NN N
was VBD N
> JJ N
or CC N
= JJ N
7 CD N
and CC N
the DT N
PT NNP N
value NN N
was VBD N
< JJ N
66 CD N
EU NNP N
ml-1 CD N
the DT N
predicted JJ N
probability NN N
of IN N
being VBG N
a DT N
case NN N
was VBD N
31% CD N
(15/49) NN N
. . N

Logistic JJ O
regression NN O
analysis NN O
also RB N
found VBD N
that IN N
high JJ N
versus NN N
low JJ N
pertactin NN N
values NNS N
were VBD N
associated VBN N
with IN N
illness JJ N
prevention NN N
following VBG N
household NN N
exposure NN N
. . N

In IN N
the DT N
presence NN N
of IN N
antibody NN N
to TO N
pertactin VB N
PT NNP N
and CC N
fimbriae-2 JJ N
the DT N
additional JJ N
presence NN N
of IN N
antibody NN N
to TO N
FHA NNP N
did VBD N
not RB N
contribute VB N
to TO N
protection NN N
. . N

Our PRP$ N
data NNS N
support NN N
historical JJ N
data NNS N
indicating VBG N
that IN N
agglutinating VBG N
antibodies NNS N
are VBP N
associated VBN N
with IN N
protection NN N
and CC N
also RB N
recent JJ N
serologic JJ N
correlates NNS N
data NNS N
and CC N
clinical JJ N
efficacy NN N
data NNS N
which WDT N
indicate VBP N
that IN N
multicomponent NN I
vaccines NNS I
containing VBG I
pertactin NN I
and CC I
fimbriae NN I
have VBP N
better JJR N
efficacy NN N
than IN N
PT NNP N
or CC N
PT/FHA NNP N
vaccines NNS N
. . N

-DOCSTART- -X- N

Should MD N
insertion NN I
of IN I
intramedullary JJ I
nails NNS I
for IN I
tibial JJ I
fractures NNS I
be VB N
with IN N
or CC N
without IN N
reaming VBG I
A NNP I
prospective JJ N
randomized VBN N
study NN N
with IN N
3.8 CD N
years' JJ N
follow-up NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
if IN N
any DT N
differences NNS N
exist VBP N
in IN N
healing NN N
and CC N
complications NNS N
between IN N
reamed VBN I
and CC I
unreamed JJ I
nailing NN I
in IN N
patients NNS P
with IN P
tibial JJ P
shaft NN P
fractures NNS P
. . P

DESIGN NNP N
Prospective NNP N
randomized NN N
. . N

SETTING NNP N
Level NNP P
1 CD P
trauma NN P
center NN P
. . P

PATIENTS NNP N
Forty-five JJ P
patients NNS P
with IN P
displaced NNS P
closed VBD P
and CC P
open JJ P
Gustilo NNP P
type NN P
I-IIIA NNP P
fractures NNS P
of IN P
the DT P
central JJ P
two CD P
thirds NNS P
of IN P
the DT P
tibia NN P
. . P

INTERVENTION NNP N
Stabilization NNP I
of IN I
tibial JJ I
fractures NNS I
either CC I
with IN I
a DT I
slotted JJ I
stainless NN I
steel NN I
reamed VBD I
nail JJ I
or CC I
a DT I
solid JJ I
titanium NN I
unreamed JJ I
nail NN I
. . I

MAIN NNP I
OUTCOME NNP N
MEASUREMENTS NNP N
Nonunions NNP O
time NN O
to TO O
fracture VB O
healing VBG O
and CC O
rate NN O
of IN O
malunions NNS O
. . O

RESULTS VB N
The DT N
average JJ N
time NN O
to TO O
fracture VB O
healing NN O
was VBD N
16.7 CD N
weeks NNS N
in IN N
the DT N
reamed VBN I
group NN N
and CC N
25.7 CD N
weeks NNS N
in IN N
the DT N
unreamed JJ I
group NN N
. . N

The DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
(P NNP N
= NNP N
0.004) CD N
. . N

There EX N
were VBD N
three CD N
nonunions NNS O
all DT O
in IN N
the DT N
unreamed JJ I
nail NN I
group NN N
. . N

Two CD N
of IN N
these DT N
fractures NNS N
healed VBD O
after IN N
dynamization NN N
by IN N
removing VBG N
static JJ N
interlocking NN N
screws NNS N
. . N

The DT N
third JJ N
nonunion NN N
did VBD N
not RB N
heal VB N
despite IN N
exchange NN N
reamed VBD I
nailing JJ I
2 CD N
years NNS N
after IN N
the DT N
primary JJ N
surgery NN N
and CC N
dynamization NN N
with IN N
a DT N
fibular JJ N
osteotomy NN N
after IN N
an DT N
additional JJ N
1 CD N
year NN N
. . N

There EX N
were VBD N
two CD N
malunions NNS O
in IN N
the DT N
reamed VBN I
group NN N
and CC N
four CD N
malunions NNS N
in IN N
the DT N
unreamed JJ I
group NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
for IN N
all DT N
other JJ N
outcome NN N
measurements NNS N
. . N

CONCLUSION NNP N
Unreamed NNP I
nailing NN I
in IN I
patients NNS P
with IN P
tibial JJ P
shaft NN P
fractures NNS P
may MD N
be VB N
associated VBN N
with IN N
higher JJR N
rates NNS N
of IN N
secondary JJ N
operations NNS N
and CC N
malunions NNS N
compared VBN N
with IN N
reamed JJ I
nailing NN I
. . I

The DT N
time NN N
to TO N
fracture VB N
healing NN N
was VBD N
significantly RB N
longer RBR N
with IN N
unreamed JJ I
nails NNS I
. . I

-DOCSTART- -X- N

Clinical JJ N
evaluation NN N
of IN N
the DT N
WOMAC NNP I
3.0 CD I
OA NNP I
Index NNP I
in IN N
numeric JJ N
rating NN N
scale NN N
format NN N
using VBG N
a DT N
computerized JJ I
touch NN I
screen NN I
version NN I
. . I

BACKGROUND IN N
The DT N
Western NNP I
Ontario NNP I
and CC I
McMaster NNP I
Universities NNP I
(WOMAC) NNP I
Osteoarthritis NNP I
Index NNP I
is VBZ N
a DT N
previously RB N
described VBN N
self-administered JJ N
questionnaire NN N
covering VBG N
three CD N
domains: NN N
pain NN O
stiffness NN O
and CC O
function NN O
. . O

It PRP N
has VBZ N
been VBN N
validated VBN N
in IN N
patients NNS P
with IN P
osteoarthritis JJ P
(OA) NN P
of IN P
the DT P
hip NN P
or CC P
knee NN P
in IN N
a DT N
paper-based JJ N
format NN N
. . N

AIM NNP N
To TO N
validate VB N
the DT N
WOMAC NNP I
3.0 CD I
using VBG N
a DT N
numerical JJ N
rating NN N
scale NN N
in IN N
a DT N
computerized JJ N
touch NN N
screen NN N
format NN N
allowing VBG N
immediate JJ N
evaluation NN N
of IN N
the DT N
questionnaire NN N
. . N

In IN N
the DT N
computed JJ N
version NN N
cartoons NNS N
written VBN N
and CC N
audio JJ N
instruments NNS N
were VBD N
included VBN N
in IN N
order NN N
facilitate NN N
application NN N
. . N

METHODS NNP N
Fifty NNP P
patients NNS P
demographically RB P
balanced VBN P
with IN P
radiographically RB P
proven JJ P
primary JJ P
hip NN P
or CC P
knee NN P
OA NNP P
completed VBD P
the DT P
classical JJ P
paper NN P
and CC P
the DT P
new JJ P
computerized JJ I
WOMAC NNP P
version NN P
. . P

Subjects NNS N
were VBD N
randomized VBN N
either RB N
to TO N
paper NN N
format NN N
or CC N
computerized JJ N
format NN N
first RB N
to TO N
balance VB N
possible JJ N
order NN N
effects NNS N
. . N

RESULTS VB N
The DT N
intra-class JJ N
correlation NN N
coefficients NNS N
for IN N
pain NN O
stiffness NN O
and CC O
function NN O
values NNS O
were VBD N
0.915 CD N
0.745 CD N
and CC N
0.940 CD N
respectively RB N
. . N

The DT N
Spearman NNP N
correlation NN N
coefficients NNS N
for IN N
pain NN O
stiffness NN O
and CC O
function NN O
were VBD N
0.88 CD N
0.77 CD N
and CC N
0.87 CD N
respectively RB N
. . N

CONCLUSION NNP N
These DT N
data NNS N
indicate VBP N
that IN N
the DT N
computerized JJ N
WOMAC NNP N
OA NNP N
index NN N
3.0 CD N
is VBZ N
comparable JJ N
to TO N
the DT N
paper NN N
WOMAC NNP N
in IN N
all DT N
three CD N
dimensions NNS N
. . N

The DT I
computerized JJ I
version NN I
would MD N
allow VB N
physicians NNS N
to TO N
get VB N
an DT N
immediate JJ N
result NN N
and CC N
if IN N
present JJ N
a DT N
direct JJ N
comparison NN N
with IN N
a DT N
previous JJ N
exam NN N
. . N

-DOCSTART- -X- N

Double-blind JJ N
placebo-controlled JJ I
trial NN I
of IN I
risperidone NN I
plus CC I
amantadine NN I
in IN N
children NNS P
with IN P
autism: PDT P
a DT N
10-week JJ N
randomized NN N
study NN N
. . N

OBJECTIVE NN N
This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
adding VBG I
amantadine NN I
to TO I
risperidone VB I
for IN N
treatment NN N
of IN N
autism NN N
. . N

METHODS NNP N
Forty NNP P
outpatients NNS P
aged VBD P
4 CD P
to12 JJ P
years NNS P
who WP P
were VBD P
diagnosed VBN P
with IN P
autism NN P
spectrum NN P
disorders NNS P
based VBN P
on IN P
the DT P
Diagnostic NNP P
and CC P
Statistical NNP P
Manual NNP P
of IN P
Mental NNP P
Disorders NNP P
Fourth NNP P
Edition NNP P
Text NNP P
Revision NNP P
criteria NNS P
were VBD P
assigned VBN N
to TO N
this DT N
double-blind JJ N
clinical JJ N
trial NN N
. . N

The DT N
subjects NNS N
were VBD N
divided VBN N
randomly RB N
into IN N
2 CD N
groups NNS N
. . N

One CD N
group NN N
received VBD N
risperidone JJ I
plus CC I
amantadine JJ I
and CC I
the DT I
other JJ I
group NN I
received VBD I
risperidone JJ I
plus CC I
placebo NN I
. . I

The DT N
dose NN N
of IN N
risperidone NN I
was VBD N
titrated VBN N
between IN N
1 CD N
and CC N
2.0 CD N
mg/d NN N
and CC N
the DT N
dose NN N
of IN N
amantadine NN I
was VBD N
100 CD N
or CC N
150 CD N
mg/d NNS N
for IN N
patients NNS N
less JJR N
than IN N
30 CD N
kg NN N
or CC N
more JJR N
than IN N
30 CD N
kg NNS N
respectively RB N
. . N

The DT N
patients NNS N
were VBD N
assessed VBN N
using VBG N
the DT N
Aberrant NNP O
Behavioral NNP O
Checklist-Community NNP O
(ABC-C) NN O
and CC N
adverse JJ O
effects NNS O
checklist NN O
as RB N
well RB N
as IN N
clinical JJ O
global JJ O
impression-improvement JJ O
(CGI-I) JJ O
at2 NN N
checkpoints NNS N
of IN N
5-week JJ N
intervals NNS N
after IN N
the DT N
baseline NN N
. . N

Informed NNP N
consentwas NN N
obtained VBN N
from IN N
the DT N
parents NNS N
of IN N
each DT N
participant NN N
. . N

RESULTS NNP N
Among IN N
ABC-C NNP O
subscales NNS O
Hyperactivity NNP O
and CC O
Irritability NNP O
showed VBD N
significantly RB N
greater JJR N
reduction NN N
in IN N
the DT N
amantadine NN I
group NN N
than IN N
the DT N
placebo NN I
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
adverse JJ O
effects NNS O
between IN N
the DT N
2 CD N
groups NNS N
. . N

The DT N
CGI-I JJ O
scores NNS O
show VBP N
significant JJ N
improvement NN N
in IN N
the DT N
amantadine NN I
group NN N
compared VBN N
to TO N
the DT N
placebo NN I
group NN N
. . N

CONCLUSIONS NNP N
The DT N
present JJ N
study NN N
suggests VBZ N
that IN N
amantadine NN I
may MD N
be VB N
a DT N
potential JJ N
adjunctive JJ N
treatment NN N
strategy NN N
for IN N
autism NN N
and CC N
it PRP N
was VBD N
generally RB N
well RB N
tolerated VBN N
. . N

-DOCSTART- -X- N

[Supplementary JJ N
treatment NN N
with IN N
Esberitox NNP I
of IN N
female JJ P
patients NNS P
undergoing VBG P
curative JJ P
adjuvant JJ P
irradiation NN P
following VBG P
breast NN P
cancer] NN P
. . N

1 CD N
. . N

The DT N
study NN N
was VBD N
supposed VBN N
to TO N
investigate VB N
a DT N
possible JJ N
prevention NN N
or CC N
reduction NN N
of IN N
the DT N
toxicity NN N
of IN N
radiotherapy NN I
by IN N
an DT N
additional JJ N
treatment NN N
with IN N
Esberitox NNP I
. . I

This DT N
question NN N
arose VBD N
when WRB N
performing VBG N
an DT N
investigation NN N
about IN N
the DT N
effect NN N
of IN N
Esberitox NNP I
in IN I
a DT I
combined JJ I
chemo-radiotherapy NN I
. . I

Whereas IN N
the DT N
latter JJ N
induces NNS N
above IN N
all PDT N
a DT N
systemic JJ N
damage NN N
to TO N
the DT N
hemopoietic JJ N
system NN N
radiotherapy NN N
is VBZ N
a DT N
regional JJ N
noxa NN N
. . N

2 CD N
. . N

The DT N
present JJ N
prospective JJ N
randomized VBN N
study NN N
was VBD N
conducted VBN N
with IN N
50 CD P
patients NNS P
submitted VBN P
to TO P
curative VB P
adjuvant JJ P
irradiation NN P
following VBG P
surgery NN P
for IN P
mammary JJ P
carcinoma NN P
. . P

The DT N
radiotherapy NN I
was VBD N
performed VBN N
in IN N
the DT N
same JJ N
way NN N
in IN N
all DT N
patients NNS P
with IN P
irradiations NNS P
of IN P
the DT P
thoracic NN P
wall NN P
and CC P
the DT P
regional JJ P
lymph NN P
nodes NNS P
. . P

Two CD N
groups NNS N
were VBD N
built VBN N
by IN N
randomization NN N
. . N

The DT N
study NN N
group NN N
received VBD N
an DT N
additional JJ N
treatment NN N
with IN N
Esberitox NNP I
the DT I
control NN I
group NN I
did VBD I
not RB I
receive VB I
an DT I
additional JJ I
treatment NN I
. . I

3 CD N
. . N

As IN N
a DT N
result NN N
no DT N
protective JJ N
influence NN N
of IN N
Esberitox NNP N
could MD N
be VB N
demonstrated VBN N
. . N

The DT N
parameters NNS N
investigated VBN N
were VBD N
the DT N
peripheral JJ O
blood NN O
count NN O
(leucocytes VBZ O
granulocytes NNS O
lymphocytes VBZ O
monocytes NNS O
thrombocytes NNS O
hemoglobin VBP O
hematocrit) NN O
and CC O
the DT O
incidence NN O
of IN O
infections NNS O
. . O

4 CD N
. . N

This DT N
result NN N
diverging VBG N
from IN N
literature NN N
is VBZ N
discussed VBN N
. . N

It PRP N
is VBZ N
probably RB N
affected VBN N
by IN N
volume NN N
and CC N
extension NN N
of IN N
the DT N
injury NN N
induced VBN N
by IN N
a DT N
hematotoxic NN N
noxa NN N
and CC N
furthermore NN N
by IN N
the DT N
ability NN N
of IN N
regeneration NN N
. . N

If IN N
this DT N
ability NN N
is VBZ N
exhausted VBN N
the DT N
protective JJ N
effect NN N
of IN N
Esberitox NNP I
can MD N
act VB N
no DT N
longer JJR N
. . N

Therefore RB N
the DT N
essential JJ N
factor NN N
seems VBZ N
to TO N
be VB N
the DT N
duration NN N
of IN N
exposure NN N
to TO N
the DT N
noxa NN N
. . N

Esberitox NNP I
was VBD N
effective JJ N
in IN N
case NN N
of IN N
a DT N
short JJ N
toxicity NN N
it PRP N
was VBD N
ineffective JJ N
in IN N
case NN N
of IN N
prolonged JJ N
toxicity NN N
if IN N
the DT N
treatment NN N
continuity NN N
(noxa) NNP N
was VBD N
not RB N
broken VBN N
up RP N
by IN N
some DT N
regeneration NN N
intervals NNS N
. . N

The DT N
radiotherapy NN I
studied VBN N
in IN N
this DT N
trial NN N
had VBD N
a DT N
duration NN N
of IN N
50 CD N
days NNS N
and CC N
its PRP$ N
effect NN N
was VBD N
that IN N
of IN N
a DT N
longterm JJ N
injury NN N
. . N

-DOCSTART- -X- N

Cefprozil NNP I
versus NN I
penicillin NN I
V NNP I
in IN N
treatment NN N
of IN N
streptococcal JJ P
tonsillopharyngitis NN P
. . P

In IN N
a DT N
randomized JJ N
multicenter NN N
study VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
cefprozil NN I
were VBD N
compared VBN N
with IN N
those DT N
of IN N
penicillin NN I
in IN N
the DT N
treatment NN N
of IN N
group NN P
A NNP P
streptococcal JJ P
tonsillopharyngitis NN P
in IN P
children NNS P
. . P

Of IN P
the DT P
409 CD P
patients NNS P
enrolled VBD P
323 CD P
were VBD P
evaluable JJ P
for IN P
their PRP$ P
clinical JJ P
and CC P
bacteriological JJ P
responses; NN P
of IN P
these DT P
323 CD P
children NNS P
172 CD P
received VBD N
cefprozil NN I
and CC N
151 CD N
received VBD N
penicillin NN I
V NNP I
. . I

The DT N
clinical JJ O
responses NNS O
in IN N
patients NNS N
treated VBN N
with IN N
cefprozil NNS I
were VBD N
significantly RB N
better JJR N
than IN N
those DT N
in IN N
patients NNS N
who WP N
received VBD N
penicillin JJ I
(95.3 NNP N
versus NN N
88.1%; CD N
P NNP N
= VBD N
0.023) CD N
. . N

Eradication NN N
of IN N
the DT N
original JJ N
serotype NN N
of IN N
group NN N
A NNP N
streptococci NN N
was VBD N
achieved VBN N
in IN N
91.3% CD N
of IN N
patients NNS N
treated VBN N
with IN N
cefprozil NN I
and CC N
87.4% CD N
of IN N
patients NNS N
treated VBN N
with IN N
penicillin NN I
the DT I
difference NN N
not RB N
being VBG N
statistically RB N
significant JJ N
(P NNP N
= NNP N
0.125) CD N
. . N

However RB N
there EX N
were VBD N
significantly RB N
more RBR N
symptomatic JJ N
patients NNS N
among IN N
the DT N
bacteriological JJ N
failures NNS N
in IN N
the DT N
penicillin NN I
group NN N
(68.4%) NNP N
than IN N
in IN N
the DT N
cefprozil NN I
group NN N
(26.7%) NNP N
. . N

beta-Lactamase-producing JJ N
Staphylococcus NNP N
aureus NN N
was VBD N
more RBR N
frequently RB N
isolated VBN N
from IN N
the DT N
throat NN N
flora NN N
during IN N
penicillin NN I
therapy NN I
than IN N
during IN N
cefprozil JJ I
treatment NN I
. . I

No DT N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
adverse JJ O
events NNS O
probably RB N
related VBD N
or CC N
of IN N
unknown JJ N
relationship NN N
to TO N
the DT N
study NN N
drugs NNS N
was VBD N
observed VBN N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
(5.2% CD N
of IN N
those DT N
treated VBN N
with IN N
cefprozil NN I
and CC N
6.0% CD N
of IN N
those DT N
treated VBN N
with IN N
penicillin) NN I
. . N

Cefprozil NNP I
can MD N
be VB N
considered VBN N
a DT N
safe JJ N
and CC N
reliable JJ N
drug NN N
for IN N
the DT N
treatment NN N
of IN N
streptococcal JJ P
pharyngitis NN P
in IN P
children NNS P
. . P

-DOCSTART- -X- N

Examining VBG N
possible JJ N
gender NN N
differences NNS N
among IN N
cocaine-dependent JJ P
outpatients NNS P
. . P

Potential JJ N
differences NNS N
in IN N
sociodemographics NNS O
drug NN O
use NN O
and CC O
measures NNS O
of IN O
treatment NN O
outcome NN N
were VBD N
examined VBN N
among IN N
137 CD P
male NN P
and CC P
51 CD P
female JJ P
cocaine-dependent JJ P
outpatients NNS P
. . P

More JJR N
women NNS P
than IN P
men NNS P
were VBD P
unemployed JJ P
received VBN P
public JJ P
assistance NN P
and CC P
were VBD P
living VBG P
with IN P
their PRP$ P
children NNS P
. . P

Women NNS N
reported VBD N
fewer JJR N
years NNS N
of IN N
regular JJ N
cocaine NN N
use NN N
spending NN N
less JJR N
money NN N
per IN N
week NN N
on IN N
cocaine NN N
less CC N
prior JJ N
treatment NN N
for IN N
cocaine NN N
abuse NN N
and CC N
were VBD N
more RBR N
likely JJ N
than IN N
men NNS N
to TO N
test VB N
positive JJ N
for IN N
cocaine NN N
at IN N
intake NN N
. . N

With IN N
respect NN N
to TO N
other JJ N
drug NN N
use NN N
fewer JJR N
women NNS N
than IN N
men NNS N
reported VBN N
using VBG O
sedatives NNS O
and CC N
tested VBD N
positive JJ N
for IN N
sedatives NNS O
at IN O
intake NN O
. . O

Women NNP N
reported VBD N
a DT N
lower JJR N
frequency NN O
of IN O
alcohol NN O
use NN O
before IN O
intake NN O
and CC O
fewer JJR N
women NNS N
than IN N
men NNS N
met VBD N
criteria NNS N
for IN N
cannabis NN N
dependence NN N
. . N

Men NN N
and CC N
women NNS N
experienced VBD N
comparable JJ N
improvement NN N
during IN N
the DT N
course NN N
of IN N
treatment NN N
and CC N
follow-up NN N
. . N

-DOCSTART- -X- N

A DT N
prospective JJ N
randomized NN N
study NN N
concerning VBG N
the DT N
point NN N
A NNP N
dose NN I
in IN I
high-dose JJ I
rate NN I
intracavitary JJ I
therapy NN I
for IN N
carcinoma NN P
of IN P
the DT P
uterine JJ P
cervix NN P
. . P

The DT N
final JJ N
results NNS N
. . N

PURPOSE NNP N
High-dose NNP I
rate NN I
(HDR) NNP I
remote NN I
afterloading VBG I
intracavitary JJ I
therapy NN I
has VBZ N
been VBN N
recognized VBN N
as IN N
an DT N
effective JJ N
and CC N
safe JJ N
treatment NN N
modality NN N
for IN N
carcinoma NN P
of IN P
the DT P
uterine JJ P
cervix NN P
. . P

Since IN N
1983 CD N
a DT N
prospective JJ N
randomized NN N
study NN N
was VBD N
started VBN N
in IN N
order NN N
to TO N
investigate VB N
the DT N
more RBR N
advantageous JJ N
treatment NN N
schedule NN N
with IN N
keeping VBG N
the DT N
local JJ N
control NN N
rate NN N
. . N

This DT N
paper NN N
reports VBZ N
the DT N
final JJ N
results NNS N
in IN N
terms NNS N
of IN N
survival JJ N
local JJ N
control NN N
and CC N
complications NNS N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Between NNP P
January NNP P
1983 CD P
and CC P
February NNP P
1989 CD P
a DT P
total NN P
of IN P
165 CD P
patients NNS P
with IN P
carcinoma NN P
of IN P
the DT P
uterine JJ P
cervix NN P
was VBD P
entered VBN P
in IN P
a DT P
prospective JJ P
randomized NN P
study NN P
concerning VBG P
the DT P
point NN P
A NNP P
dose NN P
of IN P
HDR NNP P
therapy NN P
(6 NNP P
Gy/fraction NNP P
vs VBD P
7.5 CD P
Gy/fraction) NNP P
and CC P
external JJ P
irradiation NN P
dose NN P
at IN P
Department NNP P
of IN P
Radiation NNP P
Therapy NNP P
The DT P
Center NNP P
for IN P
Adult NNP P
Diseases NNP P
Osaka NNP N
. . N

UICC NNP P
[20] NNP P
stage NN P
distribution NN P
of IN P
patients NNS P
was VBD P
as IN P
follows: JJ P
stage NN P
IA NNP P
= VBZ P
4 CD P
stage NN P
IB NNP P
= VBZ P
33 CD P
stage NN P
IIA NNP P
= VBZ P
18 CD P
stage NN P
IIB NNP P
= VBZ P
38 CD P
stage NN P
III NNP P
= VBZ P
57 CD P
stage NN P
IV NNP P
= VBZ P
15 CD P
. . P

RESULTS NNP P
Overall NNP N
5-year JJ O
cause NN O
specific JJ O
survivals NNS O
were VBD N
as IN N
follows: JJ N
stage NN N
IA NNP N
= VBZ N
100% CD N
stage NN N
IB NNP N
= VBZ N
96% CD N
stage NN N
IIA NNP N
= VBZ N
92% CD N
stage NN N
IIB NNP N
= VBZ N
79% CD N
stage NN N
III NNP N
= VBZ N
57% CD N
stage NN N
IV NNP N
= VBZ N
27% CD N
. . N

In IN N
each DT N
stage NN N
5-year JJ O
survival NN O
rates NNS O
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
were VBD N
100% CD N
93% CD N
in IN N
stage NN N
I PRP N
82% CD N
and CC N
85% CD N
in IN N
stage NN N
II NNP N
62% CD N
and CC N
52% CD N
in IN N
stage NN N
II NNP N
and CC N
22% CD N
and CC N
31% CD N
in IN N
stage NN N
IV NNP N
respectively RB N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
among IN N
these DT N
survival JJ N
curves NNS N
in IN N
each DT N
stage NN N
. . N

Five-year JJ O
local JJ O
failure NN O
rates NNS O
were VBD N
16% CD N
in IN N
group NN N
A NNP N
and CC N
16% CD N
in IN N
group NN N
B NNP N
(p NNP N
= NNP N
0.9096) CD N
and CC N
corresponding VBG N
distant JJ N
failure NN N
rates NNS N
were VBD N
23% CD N
in IN N
group NN N
A NNP N
and CC N
19% CD N
in IN N
group NN N
B NNP N
(p NNP N
= VBD N
0.2955) CD N
. . N

Moderate-to-severe JJ O
complications NNS O
requiring VBG N
treatment NN N
(Kottmeier's NNP I
grade VBD I
2 CD I
or CC N
more) NNS N
were VBD N
noted VBN N
in IN N
6 CD N
patients NNS N
(7%) JJ N
in IN N
group NN N
A NNP N
and CC N
6 CD N
patients NNS N
(7%) JJ N
in IN N
group NN N
B NNP N
. . N

All DT N
of IN N
the DT N
bladder NN O
and CC O
rectal JJ O
complications NNS O
needed VBD N
medical JJ N
treatment NN N
(Kottmeier's NNP I
grade VBD I
2) CD I
. . N

Severe JJ O
complications NNS O
receiving VBG N
surgery NN I
were VBD N
noted VBN N
in IN N
4 CD N
patients NNS N
(A: JJ N
1; CD N
B: NNP N
3) CD N
i.e NN N
. . N

small JJ N
intestine NN N
3 CD N
and CC N
sigmoid JJ N
colon NN N
1 CD N
patient NN N
. . N

Another DT N
1 CD N
patient NN N
(A) NN N
was VBD N
dead JJ O
of IN N
ileus NN N
. . N

CONCLUSIONS NN N
There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
2 CD N
treatment NN N
schedules NNS N
in IN N
survival NN O
rates NNS O
failure VBP O
patterns NNS O
and CC O
complications NNS O
rates NNS O
. . O

This DT N
fact NN N
suggests VBZ N
that IN N
small JJ N
number NN N
of IN N
fractions NNS N
(7.5 NNP N
Gy/fraction) NNP N
may MD N
be VB N
advantageous JJ N
because IN N
of IN N
short JJ N
duration NN N
and CC N
a DT N
low JJ N
load NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- N

Long-term JJ N
quality NN I
of IN I
life NN I
measures NNS I
after IN N
functional JJ I
endoscopic NN I
sinus NN I
surgery NN I
. . I

BACKGROUND NNP N
Chronic NNP P
rhinosinusitis NN P
(CRS) NNP P
is VBZ N
a DT N
common JJ N
disease NN N
that WDT N
has VBZ N
a DT N
significant JJ N
impact NN N
on IN N
quality NN N
of IN N
life NN N
(QOL) NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
longer-term JJ N
effects NNS N
of IN N
combined JJ I
medical JJ I
and CC I
surgical JJ I
therapy NN I
for IN I
CRS NNP P
on IN N
overall JJ N
health NN N
status NN N
and CC N
QOL NNP N
. . N

METHODS NNP N
We PRP N
used VBD N
a DT N
prospective JJ N
study NN N
that WDT N
utilized VBD N
the DT N
Short-Form NNP I
36 CD I
Survey NNP I
at IN I
baseline JJ I
presentation NN I
and CC I
at IN I
a DT I
mean JJ I
time NN I
of IN I
3 CD I
years NNS P
post-functional JJ P
endoscopic NN P
sinus NN P
surgery NN P
to TO N
assess VB N
the DT N
general JJ N
health NN N
status NN N
of IN N
patients NNS P
who WP P
presented VBD P
for IN P
their PRP$ P
initial JJ P
visitfrom NN P
1996 CD P
to TO P
1998 CD P
. . P

Of IN N
the DT N
200 CD P
randomly RB P
selected VBN P
patients NNS P
150 CD P
respondents NNS N
completed VBN N
follow-up JJ N
surveys NNS N
(a VBP N
75% CD N
response NN N
rate) NN N
. . N

RESULTS NNP N
Eighty-nine NNP P
(59.3%) NNP P
women NNS P
and CC P
61 CD P
(40.7%) NNS P
men NNS P
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Baseline NNP N
QOL NNP N
scores NNS N
indicated VBD N
significant JJ N
differences NNS N
between IN N
patients NNS P
with IN P
CRS NNP P
and CC N
published VBN N
norms NNS N
in IN N
6/8 CD N
subscale JJ N
parameters NNS N
(role JJ O
physical JJ O
bodily RB O
pain VBP O
general JJ O
health NN O
social JJ O
function NN O
vitality NN O
and CC O
mental JJ O
health) NN O
. . N

Significant JJ N
improvement NN N
in IN N
all DT N
six CD N
categories NNS N
was VBD N
maintained VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
period NN N
(p NNP N
< VBZ N
0.05) CD N
with IN N
QOL NNP O
scores NNS O
within IN N
limits NNS N
of IN N
published VBN N
norms NNS N
for IN N
the DT N
general JJ N
population NN N
. . N

CONCLUSION NNP N
Our PRP$ N
data NNS N
indicate VBP N
that IN N
functional JJ I
endoscopic NN I
sinus NN I
surgery NN I
combined VBN I
with IN I
appropriate JJ I
postoperative JJ I
care NN I
is VBZ I
effective JJ N
at IN N
maintaining VBG N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
overall JJ N
general JJ N
health NN N
status NN N
of IN N
patients NNS N
for IN N
at IN N
least JJS N
3 CD N
years NNS N
after IN N
surgical JJ N
intervention NN N
and CC N
that IN N
the DT N
overall JJ N
scores NNS N
return VBP N
to TO N
a DT N
range NN N
of IN N
normative JJ N
values NNS N
for IN N
the DT N
general JJ N
population NN N
. . N

-DOCSTART- -X- N

The DT N
FLT3ITD NNP I
mRNA NN I
level NN I
has VBZ N
a DT N
high JJ N
prognostic JJ N
impact NN N
in IN N
NPM1 NNP P
mutated VBD P
but CC P
not RB P
in IN P
NPM1 NNP P
unmutated VBD P
AML NNP P
with IN P
a DT P
normal JJ P
karyotype NN P
. . P

The DT N
impact NN N
of IN N
a DT N
FLT3-internal JJ I
tandem NN I
duplication NN I
(FLT3ITD) NN I
on IN N
prognosis NN N
of IN N
patients NNS P
with IN P
acute JJ P
myeloid NN P
leukemia NN P
(AML) NNP P
is VBZ N
dependent JJ N
on IN N
the DT N
ratio NN N
of IN N
mutated VBN I
to TO N
wild-type JJ I
allele NN I
. . I

In IN N
648 CD P
normal JJ P
karyotype NN P
(NK) NNP P
AML NNP P
patients NNS P
we PRP P
found VBD N
a DT N
significant JJ N
independent JJ N
effect NN N
of IN N
the DT N
quantitative JJ O
FLT3ITD NNP O
mRNA NN O
level--measured JJ O
as IN I
(FLT3ITD/wtFLT3)/(FLT3ITD/wtFLT3+1)--on JJ I
outcome NN N
. . N

Moreover RB N
this DT N
effect NN N
was VBD N
clearly RB N
seen VBN N
in IN N
329 CD P
patients NNS P
with IN P
a DT P
mutated VBN P
NPM1 NNP P
gene NN P
(NPM1+) NNS P
but CC P
not RB N
in IN N
319 CD P
patients NNS P
without IN P
a DT P
NPM1 NNP P
mutation NN P
(wtNPM1) NN P
. . P

In IN N
a DT N
multivariate NN N
Cox NNP N
regression NN N
model NN N
the DT N
quantitative JJ N
FLT3ITD NNP I
mRNA NN I
level NN N
showed VBD N
an DT N
independent JJ N
prognostic JJ N
impact NN N
on IN N
overall JJ N
survival NN O
(OS) NN N
and CC N
relapse-free JJ O
survival NN O
(RFS) NNP N
only RB N
in IN N
the DT N
NPM1+ NNP P
subgroup NN P
(OS: NNP N
hazard NN N
ratio NN N
5.9; CD N
[95% NN N
confidence NN N
interval JJ N
[CI]: JJ N
3.1-11.2]; JJ N
RFS: NNP N
hazard NN N
ratio NN N
7.5 CD N
[95% JJ N
CI: NNP N
3.4-16.5]) CD N
. . N

The DT N
FLT3ITD NNP I
mRNA MD I
level VB I
contributes NNS N
to TO N
relapse VB N
risk NN N
stratification NN N
and CC N
might MD N
help VB N
to TO N
guide VB N
postremission NN N
therapy NN N
in IN N
NPM1-mutated JJ P
AML NNP P
. . P

-DOCSTART- -X- N

Benefits NNS N
of IN N
an DT N
oxygen NN I
reservoir NN I
cannula NN I
versus IN I
a DT I
conventional JJ I
nasal JJ I
cannula NN I
during IN N
exercise NN I
in IN N
hypoxemic JJ P
COPD NNP P
patients: NN P
a DT N
crossover NN N
trial NN N
. . N

BACKGROUND IN N
The DT I
Oxymizer NNP I
is VBZ I
a DT I
special JJ I
nasal NN I
cannula NN I
that WDT N
provides VBZ N
a DT N
higher JJR N
luminal JJ N
diameter NN N
in IN N
combination NN N
with IN N
an DT I
incorporated JJ I
oxygen NN I
(O2) NNP I
reservoir NN I
. . N

It PRP N
is VBZ N
assumed VBN N
that IN N
a DT N
higher JJR N
O2 NNP N
concentration NN N
can MD N
be VB N
delivered VBN N
breath NN N
by IN N
breath NN N
in IN N
order NN N
to TO N
increase VB N
oxygenation NN N
. . N

OBJECTIVE IN N
We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
the DT I
Oxymizer NNP I
on IN N
endurance NN N
time NN N
in IN N
comparison NN N
to TO N
a DT I
conventional JJ I
nasal JJ I
cannula NN I
(CNC) NN I
. . I

METHODS NNP P
Forty-three JJ P
patients NNS P
with IN P
severe JJ P
chronic JJ P
obstructive JJ P
pulmonary JJ P
disease NN P
(COPD NNP P
age NN P
60 CD P
 JJ I
9 CD P
years NNS P
FEV1 NNP P
37 CD P
 VBD I
16% CD P
pred.) NN P
and CC P
indications NNS P
for IN P
LTOT NNP P
were VBD P
recruited VBN P
during IN P
pulmonary JJ P
rehabilitation NN P
for IN P
this DT P
cross-over NN P
study NN P
. . N

After IN N
an DT N
initial JJ I
maximal JJ I
incremental JJ I
cycle NN I
test NN I
all DT N
patients NNS N
performed VBD I
4 CD I
cycling VBG I
endurance NN I
time NN I
tests NNS I
at IN I
70% CD I
of IN I
their PRP$ I
peak JJ I
work NN I
rate NN I
(twice NN N
with IN N
the DT I
Oxymizer NNP I
and CC N
twice RB N
with IN I
a DT I
CNC NNP I
in IN N
reverse NN N
order) NN N
. . N

RESULTS VB N
The DT O
endurance NN O
time NN O
was VBD N
significantly RB N
higher JJR N
when WRB N
patients NNS I
cycled VBD I
while IN N
using VBG N
the DT I
Oxymizer NNP I
in IN N
comparison NN N
to TO N
while IN N
using VBG N
the DT I
CNC NNP I
[858 NNP N
 VBD N
754 CD N
vs NN N
. . N

766 CD N
 JJ N
652 CD N
s; JJ N
between-group JJ N
difference NN N
92 CD N
s NN N
(95% NN N
confidence NN N
interval JJ N
32-152) JJ N
p NN N
< $ N
0.001] CD N
. . N

In IN N
addition NN N
to TO O
a DT O
longer RBR O
cycling JJ O
duration NN O
O2 NNP O
saturation NN O
at IN O
isotime NN O
was VBD N
significantly RB N
higher JJR N
with IN I
the DT I
Oxymizer NNP I
(93.5 NNP N
 VBD N
5.4 CD N
vs NN N
. . N

90.4 CD N
 JJ N
5.3%; CD N
p NN N
= VBD N
0.027) CD N
. . N

Furthermore RB N
there EX N
was VBD N
a DT N
positive JJ N
correlation NN N
(r NNP N
= VBZ N
0.427 CD N
p NN N
= VBD N
0.002) CD N
between IN O
the DT O
O2 NNP O
flow NN O
rate NN O
and CC O
improvements NNS O
in IN O
the DT O
constant JJ O
work NN O
rate NN O
test NN N
showing VBG N
greater JJR N
improvements NNS N
in IN N
favor NN N
of IN I
the DT I
Oxymizer NNP I
in IN N
patients NNS N
with IN N
a DT N
higher JJR N
demand NN N
for IN N
O2 NNP N
( NNP N
4 CD N
liters/min) NN N
. . N

CONCLUSION NN N
We PRP N
show VBP N
that IN N
O2 NNP N
delivery NN I
via IN I
the DT I
Oxymizer NNP N
is VBZ N
superior JJ I
to TO N
a DT N
CNC NNP N
with IN N
regard NN O
to TO O
endurance VB O
capacity NN O
and CC O
oxygenation NN O
during IN I
exercise NN P
in IN P
patients NNS P
with IN P
severe JJ P
COPD NNP N
. . N

It PRP N
seems VBZ N
that IN N
patients NNS N
with IN N
a DT N
higher JJR N
demand NN N
for IN N
O2 NNP N
( NNP N
4 CD N
liters/min) NN N
in IN N
particular JJ N
may MD N
benefit VB N
more JJR N
from IN N
the DT N
use NN I
of IN I
the DT I
Oxymizer NNP N
. . N

-DOCSTART- -X- N

Web-based JJ I
weight NN I
management NN I
programs NNS I
in IN N
an DT N
integrated JJ N
health NN N
care NN N
setting: VBZ N
a DT N
randomized JJ N
controlled JJ N
trial NN N
. . N

OBJECTIVE NN N
To TO N
assess VB N
the DT N
efficacy NN O
of IN N
a DT N
Web-based JJ I
tailored JJ I
behavioral JJ I
weight JJ I
management NN I
program NN I
compared VBN N
with IN N
Web-based JJ I
information-only JJ I
weight NN I
management NN I
materials NNS I
. . I

RESEARCH NNP N
METHODS NNP N
AND NNP N
PROCEDURES NNP N
Participants NNP N
2862 CD P
eligible JJ P
overweight NN P
and CC P
obese JJ P
(BMI NNP P
= $ P
27 CD P
to TO P
40 CD P
kg/m2) NNS P
members NNS P
from IN P
four CD P
regions NNS P
of IN P
Kaiser NNP P
Permanente's NNP P
integrated VBD P
health NN P
care NN P
delivery NN P
system NN P
were VBD P
randomized VBN N
to TO N
receive VB N
either CC I
a DT I
tailored VBN I
expert NN I
system NN I
or CC I
information-only JJ I
Web-based JJ I
weight NN I
management NN I
materials NNS I
. . I

Weight NNP O
change NN O
and CC O
program NN O
satisfaction NN O
were VBD N
assessed VBN N
by IN N
self-report NN N
through IN N
an DT N
Internet-based JJ N
survey NN N
at IN N
3- JJ N
and CC N
6-month JJ N
follow-up JJ N
periods NNS N
. . N

RESULTS NNP N
Significantly NNP N
greater JJR N
weight JJ O
loss NN O
at IN N
follow-up NN N
was VBD N
found VBN N
among IN N
participants NNS N
assigned VBN N
to TO N
the DT N
tailored VBN I
expert NN I
system NN I
than IN N
among IN N
those DT N
assigned VBN N
to TO N
the DT N
information-only JJ I
condition NN I
. . I

Subjects NNS N
in IN N
the DT N
tailored VBN I
expert NN I
system NN I
lost VBD N
a DT N
mean NN N
of IN N
3 CD N
+/- JJ N
0.3% CD N
of IN N
their PRP$ N
baseline NN N
weight NN O
whereas JJ O
subjects NNS N
in IN N
the DT N
information-only JJ I
condition NN I
lost VBD N
a DT N
mean NN N
of IN N
1.2 CD N
+/- JJ N
0.4% CD N
(p JJ N
< RB N
0.0004) CD N
. . N

Participants NNS N
were VBD N
also RB N
more RBR N
likely JJ N
to TO N
report VB N
that IN N
the DT N
tailored VBN I
expert NN I
system NN I
was VBD N
personally RB O
relevant JJ O
helpful NN O
and CC O
easy JJ O
to TO O
understand VB O
. . O

Notably RB N
36% CD P
of IN P
enrollees NNS P
were VBD P
African-American JJ P
with IN P
enrollment NN P
rates NNS P
higher RBR P
than IN P
the DT P
general JJ P
proportion NN P
of IN P
African JJ P
Americans NNPS P
in IN P
any DT P
of IN P
the DT P
study NN P
regions NNS P
. . P

DISCUSSION NNP N
The DT N
results NNS N
of IN N
this DT N
large JJ N
randomized VBD N
control NN N
trial NN N
show VBP N
the DT N
potential JJ N
benefit NN N
of IN N
the DT N
Web-based JJ I
tailored VBN I
expert NN I
system NN I
for IN I
weight JJ I
management NN I
compared VBN N
with IN N
a DT N
Web-based JJ I
information-only JJ I
weight JJ I
management NN I
program NN I
. . I

-DOCSTART- -X- N

Anesthesia NNP I
for IN N
in IN P
vitro NN P
fertilization: VBP P
the DT N
addition NN N
of IN N
fentanyl NN I
to TO N
1.5% CD N
lidocaine NN I
. . I

UNLABELLED NNP N
Ultrasonically NNP N
guided VBD N
transvaginal JJ N
oocyte NN N
retrieval NN N
is VBZ N
relatively RB N
short JJ N
procedure NN N
that WDT N
is VBZ N
performed VBN N
on IN N
an DT N
out-patient JJ N
basis NN N
. . N

The DT N
optimal JJ N
anesthetic JJ N
technique NN N
should MD N
allow VB N
good JJ N
surgical JJ N
anesthesia NN N
with IN N
minimal JJ N
side NN N
effects NNS N
a DT N
short JJ N
recovery NN N
time NN N
and CC N
if IN N
possible JJ N
a DT N
high JJ N
rate NN N
of IN N
successful JJ N
pregnancy NN N
. . N

Spinal JJ I
anesthesia NN I
is VBZ N
often RB N
used VBN N
in IN N
this DT N
institution NN N
as RB N
well RB N
as IN N
many JJ N
others NNS N
for IN N
this DT N
procedure NN N
. . N

The DT N
addition NN N
of IN N
fentanyl NN N
may MD N
be VB N
effective JJ N
for IN N
both DT N
intraoperative JJ N
and CC N
postoperative JJ N
pain NN N
relief NN N
. . N

We PRP N
assessed VBD N
the DT N
effect NN N
of IN N
adding VBG N
fentanyl NN I
to TO N
1.5% CD N
lidocaine NN I
in IN N
women NNS P
undergoing VBG P
ultrasonically RB P
guided VBN P
oocyte NN P
retrieval NN P
. . P

Seventy-eight JJ P
women NNS P
were VBD N
randomized VBN N
to TO N
receive VB N
45 CD I
mg NN I
of IN I
hyperbaric JJ I
1.5% CD I
lidocaine NN I
with IN I
or CC I
without IN I
10 CD I
microg NN I
of IN I
fentanyl NN I
. . I

Visual JJ O
analog NN O
scale NN O
(VAS) NNP O
pain NN O
scores NNS O
were VBD N
lower JJR O
in IN N
the DT N
operating NN N
room NN N
(OR) NNP N
(P NNP N
< NNP N
0.05) CD N
and CC N
postanesthesia NNS N
care VBP N
unit NN N
(PACU) NNP N
(P NNP N
< VBZ N
0.0005) CD N
for IN N
the DT N
group NN N
that WDT N
received VBD N
fentanyl NNS I
. . I

In IN N
addition NN N
the DT N
amount NN O
of IN O
narcotic JJ O
required VBN O
in IN N
the DT N
PACU NNP N
was VBD N
less RBR N
in IN N
the DT N
fentanyl NN N
group NN N
(P NNP N
< VBZ N
0.005) CD N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
VAS NNP O
scores VBZ O
the DT N
evening NN N
of IN N
or CC N
24 CD N
h NN N
after IN N
the DT N
procedure NN N
. . N

The DT N
amount NN O
of IN O
analgesics NNS O
and CC O
narcotics NNS O
required VBN O
after IN O
discharge NN O
was VBD N
the DT N
same JJ N
for IN N
both DT N
groups NNS N
. . N

Timed VBN O
variables NNS O
such JJ O
as IN O
time NN O
to TO O
urination VB O
ambulation NN O
and CC O
discharge NN O
were VBD O
the DT N
same JJ N
for IN N
both DT N
groups NNS N
of IN N
women NNS N
. . N

The DT N
addition NN N
of IN N
fentanyl NN N
to TO N
lidocaine VB I
for IN N
transvaginal JJ N
oocyte NN N
retrieval NN N
results NNS N
in IN N
a DT N
more RBR N
comfortable JJ N
patient NN N
in IN N
the DT N
OR NNP N
and CC N
PACU NNP N
. . N

IMPLICATIONS NNP N
This DT N
study NN N
demonstrates VBZ N
that IN N
when WRB N
fentanyl NN I
is VBZ N
added VBN N
to TO N
a DT N
local JJ N
anesthetic JJ N
lidocaine NN I
with IN I
spinal JJ N
anesthesia NN N
for IN N
egg NN N
retrieval NN N
procedures NNS N
patients NNS N
are VBP N
more RBR N
comfortable JJ N
during IN N
the DT N
procedure NN N
compared VBN N
with IN N
those DT N
who WP N
receive VBP N
lidocaine NN N
alone RB N
. . N

In IN N
addition NN N
the DT N
narcotic JJ N
requirements NNS N
of IN N
patients NNS N
are VBP N
less RBR N
in IN N
the DT N
postanesthesia NN N
care NN N
unit NN N
. . N

-DOCSTART- -X- N

Pulsatile NNP O
insulin NN O
delivery NN O
is VBZ N
more RBR N
efficient JJ N
than IN N
continuous JJ I
infusion NN I
in IN N
modulating VBG N
islet NN N
cell NN N
function NN N
in IN N
normal JJ P
subjects NNS P
and CC P
patients NNS P
with IN P
type JJ P
1 CD P
diabetes NNS P
. . P

The DT N
respective JJ N
modulating NN N
effects NNS N
of IN N
continuous JJ I
and CC I
intermittent JJ I
insulin NN I
delivery NN I
on IN N
pancreatic JJ N
islet NN N
cell NN N
function NN N
were VBD N
studied VBN N
in IN N
seven CD P
normal JJ P
men NNS P
and CC P
nine CD P
insulin-dependent JJ P
(type JJ P
1) CD P
diabetic JJ P
patients NNS P
. . P

In IN N
the DT N
normal JJ P
men NNS P
saline VBP P
or CC I
continuous JJ I
(0.8 JJ I
mU JJ I
kg-1 JJ I
min-1) NN I
or CC I
pulsatile NN I
(5.2 JJ I
mU JJ I
kg-1 JJ I
min-1 NN I
with IN I
a DT I
switching VBG I
on/off RP I
length NN I
of IN I
2/11 CD I
min) NNS I
human JJ I
insulin NN I
were VBD I
delivered VBN I
on IN N
different JJ N
days NNS N
and CC N
in IN N
random JJ N
order NN N
. . N

Despite IN N
hyperinsulinemia JJ N
blood NN N
glucose NN N
was VBD N
kept VBN N
close RB N
to TO N
its PRP$ N
basal NN N
value NN N
by IN N
the DT N
glucose JJ N
clamp NN N
technique NN N
. . N

The DT N
diabetic JJ P
patients NNS P
also RB N
were VBD N
infused VBN N
in IN N
random JJ N
order NN N
and CC N
on IN N
different JJ N
days NNS N
with IN N
either DT I
saline NN I
or CC I
a DT I
smaller JJR I
amount NN I
of IN I
insulin NN I
delivered VBN I
continuously RB I
(0.15 JJ I
mU JJ I
kg-1 JJ I
min-1) NN I
or CC I
in IN I
a DT I
pulsatile JJ I
manner NN I
(0.97 JJ N
mU JJ N
kg-1 JJ N
min-1 NN N
for IN N
2 CD N
min NN N
followed VBN N
by IN N
11 CD N
min NNS N
during IN N
which WDT N
no DT N
insulin NN N
was VBD N
infused) NN N
. . N

In IN N
all DT N
experiments NNS N
5 CD I
g NNS I
arginine NN I
were VBD N
given VBN N
iv NNS N
as IN N
a DT N
bolus NN N
dose JJ N
30 CD N
min NN N
before IN N
the DT N
end NN N
of IN N
the DT N
study NN N
and CC N
plasma VB O
C-peptide NNP O
and CC O
glucagon NN O
levels NNS O
were VBD N
determined VBN N
to TO N
assess VB N
islet NN N
cell NN N
function NN N
. . N

In IN N
the DT N
normal JJ P
men NNS P
insulin VBP P
administration NN N
resulted VBD N
in IN N
a DT N
significant JJ N
decline NN N
of IN N
basal NN O
plasma NN O
glucagon NN O
and CC O
C-peptide JJ O
levels NNS O
and CC N
in IN N
a DT N
clear-cut JJ N
decrease NN N
in IN N
the DT N
arginine-induced JJ N
glucagon NN N
response NN N
. . N

These DT N
effects NNS N
of IN N
insulin NN N
were VBD N
significantly RB N
more RBR N
marked JJ N
when WRB N
insulin NN N
was VBD N
delivered VBN N
in IN N
a DT N
pulsatile NN N
rather RB N
than IN N
a DT N
continuous JJ N
manner NN N
. . N

In IN N
the DT N
insulin-dependent JJ P
diabetic JJ P
patients NNS P
the DT P
lower JJR I
dose NN I
of IN I
insulin NN I
infused VBN I
continuously RB N
did VBD N
not RB N
alter VB N
the DT N
basal NN N
or CC N
arginine-stimulated JJ O
glucagon NN O
response NN O
. . O

In IN N
contrast NN N
when WRB N
the DT N
same JJ I
amount NN I
of IN I
insulin NN I
was VBD I
delivered VBN I
intermittently RB I
arginine-induced JJ O
glucagon NN O
release NN N
was VBD N
greatly RB N
reduced VBN N
. . N

Thus RB N
these DT N
data NNS N
support NN N
the DT N
concept NN N
that WDT N
insulin VBZ N
per IN N
se NN N
is VBZ N
a DT N
potent JJ N
physiological JJ N
modulator NN N
of IN N
islet NN N
A- NNP N
and CC N
B-cell NNP N
function NN N
. . N

Furthermore RB N
they PRP N
suggest VBP N
that IN N
these DT N
effects NNS N
of IN N
insulin NN N
are VBP N
reinforced VBN N
when WRB N
the DT N
hormone NN I
is VBZ I
administered VBN I
in IN I
an DT I
intermittent JJ I
manner NN I
in IN I
an DT I
attempt NN I
to TO I
reproduce VB I
the DT I
pulsatile NN I
physiological JJ I
release NN I
of IN I
insulin NN I
. . I

-DOCSTART- -X- N

A DT N
comparison NN N
of IN N
intermittent JJ I
vaginal JJ I
administration NN I
of IN I
misoprostol NN I
with IN N
continuous JJ I
dinoprostone NN I
for IN I
cervical JJ I
ripening NN I
and CC N
labor NN I
induction NN I
. . I

OBJECTIVE IN N
Our PRP$ N
purpose NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
vaginal JJ I
administration NN I
of IN I
misoprostol JJ I
(Cytotec) NN I
with IN N
that DT N
of IN N
dinoprostone NN I
(Cervidil) NN I
on IN N
cervical JJ N
ripening NN N
and CC N
labor NN N
induction NN N
. . N

STUDY NNP N
DESIGN NNP N
Two CD P
hundred VBD P
patients NNS P
with IN P
indications NNS P
for IN P
induction NN P
of IN P
labor NN P
and CC P
unfavorable JJ P
cervical JJ P
examinations NNS P
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
vaginally RB N
administered VBN N
misoprostol NN I
(prostaglandin NN I
E1) NNP I
or CC N
the DT N
dinoprostone NN I
(prostaglandin NNP I
E2) NNP I
vaginal JJ N
insert NN N
. . N

Twenty-five JJ I
microgram JJ I
tablets NNS I
of IN I
misoprostol NN I
were VBD N
placed VBN N
in IN N
the DT N
posterior JJ N
vaginal JJ N
fornix NN N
every DT N
4 CD N
hours NNS N
for IN N
a DT N
maximum NN N
of IN N
six CD N
doses NNS N
. . N

Additional NNP N
misoprostol NN I
was VBD N
not RB N
given VBN N
after IN N
either DT N
spontaneous JJ N
rupture NN N
of IN N
membranes NNS N
adequate JJ N
cervical JJ N
ripening NN N
(Bishop NN N
score NN N
of IN N
> NN N
or CC N
= VB N
8 CD N
or CC N
cervical JJ N
dilatation NN N
of IN N
> NN N
or CC N
= $ N
3 CD N
cm) NN N
or CC N
beginning NN N
of IN N
active JJ N
labor NN N
. . N

The DT N
vaginal JJ N
insert NN N
Cervidil NNP I
containing VBG I
10 CD I
mg NN I
of IN I
dinoprostone NN I
in IN N
a DT N
timed-release JJ N
preparation NN N
was VBD N
placed VBN N
in IN N
the DT N
posterior JJ N
vaginal JJ N
formix NN N
for IN N
a DT N
maximum JJ N
period NN N
of IN N
24 CD N
hours NNS N
. . N

The DT N
vaginal JJ N
insert NN N
was VBD N
removed VBN N
for IN N
spontaneous JJ N
rupture NN N
of IN N
membranes NNS N
entry NN N
into IN N
active JJ N
labor NN N
adequate JJ N
cervical JJ N
ripening NN N
or CC N
abnormality NN N
of IN N
uterine JJ N
contractile NN N
pattern NN N
or CC N
fetal JJ N
cardiac JJ N
activity NN N
. . N

RESULTS NN N
Of IN P
the DT P
200 CD P
patients NNS P
enrolled VBD P
99 CD P
were VBD P
randomized VBN P
to TO N
misoprostol VB I
and CC I
101 CD I
to TO I
dinoprostone VB I
. . I

The DT N
average JJ O
interval NN O
from IN O
start NN O
of IN O
induction NN O
to TO O
vaginal JJ O
delivery NN O
was VBD N
1 CD N
hour NN N
shorter NN N
in IN N
the DT N
misoprostol NN I
group NN N
(1296.7 VBD N
+/- JJ N
722.1 CD N
minutes) NN N
than IN N
in IN N
the DT N
dinoprostone NN I
group NN N
(1360.0 VBD N
+/- JJ N
792.0 CD N
minutes) NN N
but CC N
this DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
(p NNP N
= NNP N
0.97) CD N
. . N

Oxytocin NNP I
augmentation NN N
of IN N
labor NN N
was VBD N
used VBN N
in IN N
50 CD N
(50.5%) JJ N
misoprostol-treated JJ I
patients NNS N
and CC N
43 CD N
(43.5%) JJ N
dinoprostone-treated JJ I
patients NNS N
(relative JJ N
risk NN N
1.14 CD N
95% CD N
confidence NN N
interval NN N
0.86 CD N
to TO N
1.51 CD N
p NNS N
= JJ N
0.35) CD N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
routes NNS N
of IN N
delivery NN N
with IN N
misoprostol NN I
or CC N
dinoprostone NN I
. . I

Overall JJ N
38 CD P
patients NNS P
(19.3%) JJ P
had VBD P
cesarean JJ P
deliveries NNS P
. . P

There EX N
was VBD N
a DT N
significantly RB N
lower JJR N
prevalence NN N
of IN N
tachysystole JJ O
(six NN N
or CC N
more JJR N
uterine JJ N
contractions NNS N
in IN N
a DT N
10-minute JJ N
window NN N
for IN N
two CD N
consecutive JJ N
10-minute JJ N
periods) NN N
in IN N
the DT N
misoprostol NN I
group NN N
(7.1%) NNP N
than IN N
in IN N
the DT N
dinoprostone NN I
group NN N
(18.4%) NNP N
(relative NNP N
risk NN N
0.52 CD N
95% CD N
confidence NN N
interval NN N
0.31 CD N
to TO N
0.89 CD N
p NNS N
= JJ N
0.02) CD N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
frequency NN O
of IN O
uterine JJ O
hyperstimulation NN O
or CC O
hypertonus NN O
. . O

Abnormal NNP O
fetal JJ O
heart NN O
rate NN O
tracings NNS N
were VBD N
found VBN N
in IN N
23 CD N
(23.2%) NN N
of IN N
misoprostol-treated JJ I
patients NNS N
and CC N
35 CD N
(35.7%) NN N
of IN N
dinoprostone-treated JJ I
patients NNS N
(relative JJ N
risk NN N
0.73 CD N
95% CD N
confidence NN N
interval NN N
0.52 CD N
to TO N
1.01 CD N
p NNS N
= JJ N
0.0546) CD N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
meconium JJ N
passage NN N
1- JJ N
or CC N
5-minute JJ N
Apgar NNP N
scores NNS N
< VBP N
7 CD N
neonatal JJ N
resuscitations NNS N
or CC N
admissions NNS N
to TO N
the DT N
neonatal JJ N
intensive JJ N
care NN N
unit NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Vaginally NNP N
administered VBD N
misoprostol NN I
is VBZ N
as RB N
effective JJ N
as IN N
dinoprostone NN I
for IN N
cervical JJ O
ripening NN O
and CC O
the DT O
induction NN O
of IN O
labor NN O
. . O

Mean JJ N
time NN N
intervals NNS N
to TO N
delivery NN N
need NN N
for IN N
oxytocin JJ I
augmentation NN N
and CC N
routes NNS N
of IN N
delivery NN N
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Incidence NN N
of IN N
uterine JJ N
tachysystole NN N
with IN N
misoprostol NN I
every DT N
4 CD N
hours NNS N
was VBD N
significantly RB N
less JJR N
than IN N
with IN N
dinoprostone NN I
. . I

-DOCSTART- -X- N

Zinc NNP N
and CC N
copper NN N
balances NNS N
in IN N
preterm JJ P
infants NNS P
. . P

Preterm JJ P
infants NNS P
are VBP N
at IN N
risk NN N
for IN N
copper NN N
and CC N
zinc NN N
depletion NN N
if IN N
sufficient JJ N
quantities NNS N
of IN N
these DT N
nutrients NNS N
are VBP N
not RB N
provided VBN N
in IN N
a DT N
bioavailable JJ N
form NN N
in IN N
postnatal JJ N
life NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
the DT N
use NN N
of IN N
a DT N
whey-predominant JJ N
50% CD N
medium NN N
chain NN N
triglyceride IN N
formula NN N
with IN N
relatively RB N
high JJ N
concentrations NNS N
of IN N
zinc NN N
and CC N
copper NN N
would MD N
promote VB N
the DT N
achievement NN N
of IN N
the DT N
in IN N
utero JJ O
accretion NN O
rate NN O
for IN N
zinc NN N
and CC N
copper NN N
in IN N
the DT N
preterm NN P
infant NN P
. . P

Two CD P
groups NNS P
of IN P
five CD P
preterm JJ P
infants NNS P
were VBD N
fed VBN N
a DT N
diet JJ N
containing VBG N
12.5 CD N
mg/L NN N
of IN N
zinc NN N
and CC N
either DT N
0.9 CD N
mg/L NN N
or CC N
2.1 CD N
mg/L NN N
of IN N
copper NN N
. . N

Seventy-two-hour JJ N
metabolic JJ N
balance NN N
studies NNS N
were VBD N
performed VBN N
at IN N
an DT N
average JJ N
postconceptual JJ N
age NN N
of IN N
34 CD N
weeks NNS N
and CC N
an DT N
average JJ N
weight NN N
of IN N
1 CD N
549 CD N
g NN N
. . N

All DT N
infants NNS N
were VBD N
in IN N
positive JJ O
zinc NN O
balance NN O
and CC N
nine CD N
of IN N
ten NNS N
achieved VBN N
the DT N
in IN N
utero JJ O
accretion NN O
rate NN O
for IN N
zinc NN N
for IN N
a DT N
34-week JJ N
gestation NN N
fetus NN N
(greater NN N
than IN N
or CC N
equal JJ N
to TO N
0.432 CD N
mg/d) NNS N
. . N

Three CD N
infants NNS N
receiving VBG N
the DT N
high JJ N
copper NN N
formula NN N
and CC N
two CD N
receiving VBG N
the DT N
lower JJR N
copper NN N
formula NN N
were VBD N
in IN N
positive JJ O
copper NN O
balance NN O
. . O

Two CD N
infants NNS N
from IN N
each DT N
group NN N
achieved VBD N
the DT N
in IN N
utero JJ O
accretion NN O
rate NN O
for IN O
copper NN O
for IN N
a DT N
34-week JJ N
gestation NN N
fetus NN N
(0.088 NNP N
mg/d) NN N
. . N

A DT N
formula NN N
that WDT N
provides VBZ N
12.5 CD N
mg/L NN N
of IN N
zinc NN N
permits NNS N
positive JJ O
zinc NN O
balance NN O
and CC O
zinc NN O
retention NN O
similar JJ N
to TO N
in IN N
utero JJ N
rates NNS N
. . N

A DT N
formula NN N
that WDT N
provides VBZ N
as RB N
much JJ N
as IN N
2.1 CD N
mg/L NN N
of IN N
copper NN N
however RB N
may MD N
not RB N
always RB N
permit VBP N
positive JJ N
copper NN O
balance NN O
. . O

-DOCSTART- -X- N

Comparison NNP N
of IN N
three CD N
methods NNS N
to TO N
increase VB N
knowledge NN O
about IN N
breast NN N
cancer NN N
and CC N
breast NN N
cancer NN N
screening VBG N
in IN N
screening VBG P
mammography NN P
patients NNS P
. . P

RATIONALE NNP P
AND CC N
OBJECTIVES NNP N
The DT N
specific JJ N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
which WDT N
of IN N
several JJ N
cost-effective JJ I
interventions NNS I
is VBZ N
best RBS N
able JJ N
to TO N
improve VB N
the DT N
breast NN N
cancer NN N
knowledge NN N
of IN N
women NNS P
who WP P
present VBP P
for IN P
screening VBG P
mammography NN P
. . P

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP P
total NN P
of IN P
198 CD P
English-speaking JJ P
women NNS P
with IN P
no DT P
personal JJ P
or CC P
family NN P
history NN P
of IN P
breast NN P
cancer NN P
were VBD P
recruited VBN P
and CC P
randomized VBN P
to TO P
four CD P
groups NNS P
when WRB P
they PRP P
presented VBD P
to TO P
the DT P
clinic NN P
for IN P
a DT P
screening NN P
mammogram NN P
. . P

All DT N
women NNS N
filled VBN N
in IN N
a DT N
demographic JJ N
data NN N
form NN N
and CC N
answered VBD N
a DT N
questionnaire NN I
containing VBG N
nine CD N
questions NNS N
about IN N
breast NN N
cancer NN N
risk NN N
and CC N
screening VBG N
to TO N
assess VB N
their PRP$ N
knowledge NN N
and CC N
perception NN N
. . N

Three CD I
educational JJ I
interventions NNS I
were VBD N
tested VBN N
in IN N
this DT N
study NN N
. . N

The DT I
first JJ I
consisted VBN I
of IN I
a DT I
brochure NN I
which WDT I
provided VBD I
answers NNS I
to TO I
the DT I
questionnaire NN I
items NNS I
and CC I
addressed VBD I
the DT I
issues NNS I
in IN I
more JJR I
depth NN I
. . I

The DT N
second JJ N
intervention NN N
was VBD N
an DT N
educational JJ I
conversation NN I
with IN I
a DT I
specially RB I
trained JJ I
mammography NN I
technologist NN I
. . I

She PRP N
reviewed VBD N
the DT N
subject's NN N
answers NNS N
to TO N
the DT N
questionnaire NN N
items NNS N
correcting VBG N
and/or NN N
clarifying VBG N
them PRP N
. . N

The DT N
third JJ N
intervention NN N
consisted VBD N
of IN N
the DT N
brochure NN I
together RB I
with IN I
the DT I
conversation NN I
with IN I
a DT I
trained JJ I
technologist NN I
. . I

There EX N
was VBD N
also RB N
a DT N
control NN I
group NN I
that WDT N
just RB N
filled VBN N
in IN N
the DT N
study NN I
questionnaire NN I
but CC I
did VBD I
not RB I
receive VB I
an DT I
educational JJ I
intervention NN I
. . I

The DT N
same JJ N
questionnaire NN N
was VBD N
administered VBN N
by IN N
telephone NN N
4 CD N
to TO N
6 CD N
weeks NNS N
after IN N
the DT N
screening NN N
experience NN N
to TO N
all DT N
study NN N
subjects NNS N
. . N

Changes NNS N
in IN N
their PRP$ N
knowledge NN O
and CC O
perceptions NNS O
of IN N
breast NN N
cancer NN N
were VBD N
measured VBN N
and CC N
compared VBN N
. . N

RESULTS VB N
A NNP N
statistically RB N
significant JJ N
increase NN N
in IN N
knowledge NN O
was VBD N
found VBN N
in IN N
all DT N
of IN N
the DT N
three CD N
investigated VBD N
groups NNS N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
amount NN N
of IN N
increase NN N
between IN N
women NNS N
who WP N
underwent VBP N
different JJ N
interventions NNS N
. . N

CONCLUSIONS NNP N
All NNP N
three CD N
interventions NNS N
resulted VBD N
in IN N
increased VBN N
knowledge NN O
about IN N
breast NN N
cancer NN N
and CC N
screening NN N
. . N

No DT N
differences NNS N
in IN N
the DT N
amount NN N
of IN N
knowledge NN O
increase NN N
were VBD N
found VBN N
between IN N
three CD N
interventions NNS N
tested VBN N
. . N

The DT N
educational JJ I
brochure NN I
seems VBZ N
to TO N
represent VB N
the DT N
most RBS N
convenient JJ N
and CC N
least JJS N
costly JJ N
method NN N
to TO N
increase VB N
knowledge NN N
about IN N
breast NN N
cancer NN N
and CC N
screening VBG N
among IN N
women NNS P
who WP P
present VBP P
for IN P
screening VBG P
mammography NN P
. . P

-DOCSTART- -X- N

The DT N
impact NN N
of IN N
daily JJ I
sodium NN I
intake NN I
on IN N
posttransplant JJ P
hypertension NN P
in IN P
kidney NN P
allograft NN P
recipients NNS P
. . P

INTRODUCTION NNP P
Posttransplant NNP O
hypertension NN O
is VBZ N
a DT N
well-known JJ N
risk NN N
factor NN N
for IN N
long-term JJ P
allograft NN P
failure NN P
and CC P
mortality NN P
in IN P
kidney NN P
recipients NNS P
. . P

Although IN N
dietary JJ I
sodium NN I
restriction NN I
is VBZ N
a DT N
widely RB N
recommended JJ N
nonpharmacological JJ N
measure NN N
for IN N
control NN N
of IN N
blood NN N
pressure NN N
(BP) VBZ N
no DT N
detailed JJ N
investigation NN N
has VBZ N
been VBN N
conducted VBN N
regarding VBG N
the DT N
impact NN N
of IN N
dietary JJ I
sodium NN I
restriction NN I
on IN N
this DT N
condition NN N
. . N

METHODS NNP N
Thirty-two CD P
patients NNS P
on IN P
antihypertensive JJ P
treatment NN P
completed VBD P
the DT P
study NN P
. . P

They PRP N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups: NN N
controls NNS I
(group VBP I
1) CD I
versus NN I
strict JJ I
sodium NN I
diet JJ I
(group VBZ I
2; CD I
80 CD I
to TO I
100 CD I
mmol NNS I
sodium JJ I
daily) NN I
. . I

After IN N
randomization NN N
24-hour JJ N
urine NN N
for IN N
sodium NN N
measurement NN N
BP NNP N
and CC N
allograft JJ N
functions NNS N
were VBD N
recorded VBN N
at IN N
baseline NN N
and CC N
after IN N
3 CD N
months NNS N
. . N

BP NNP N
treatment NN N
was VBD N
reevaluated VBN N
at IN N
each DT N
visit NN N
throughout IN N
the DT N
study NN N
. . N

RESULTS NN N
At IN N
baseline NN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
age NN N
sex NN N
serum NN N
creatinine NN N
systolic NN N
and CC N
diastolic JJ N
BP NNP N
antihypertensive JJ N
drugs NNS N
or CC N
24-hour JJ N
urinary JJ N
sodium NN N
levels NNS N
between IN N
the DT N
groups NNS N
. . N

After IN N
3 CD N
months NNS N
daily RB O
urinary JJ O
sodium NN O
excretion NN O
(from IN N
190+/-75 JJ N
to TO N
106+/-48 JJ N
mEq/d NN N
P<.0001) NNP N
systolic JJ O
BP NNP O
(from NNP N
146+/-21 JJ N
to TO N
116+/-11 JJ N
mm NN N
Hg) NNP N
and CC N
diastolic JJ O
BP NNP O
(from NNP N
89+/-8 CD N
to TO N
72+/-10 CD N
mm NN N
Hg) NNP N
had VBD N
significantly RB N
decreased VBN N
in IN N
group NN N
2 CD N
while IN N
no DT N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
group NN N
1 CD N
. . N

CONCLUSION NNP N
Low NNP I
sodium NN I
intake NN I
in IN I
combination NN I
with IN I
antihypertensive JJ I
treatment NN I
appears VBZ N
to TO N
efficiently VB N
control NN N
BP NNP O
in IN N
kidney NN P
allograft NN P
recipients NNS P
with IN P
hypertension NN P
. . P

Twenty-four-hour JJ N
urinary JJ N
sodium NN N
excretion NN N
should MD N
be VB N
checked VBN N
regularly RB N
in IN N
these DT N
patients NNS N
as IN N
a DT N
useful JJ N
marker NN N
to TO N
indicate VB N
whether IN N
the DT N
patient NN N
complies NNS N
with IN N
low JJ I
sodium NN I
intake NN I
. . I

-DOCSTART- -X- N

Evaluation NN N
of IN N
oral JJ I
zinc NN I
sulfate NN I
effect NN N
on IN N
obsessive-compulsive JJ P
disorder: NN P
a DT N
randomized VBN N
placebo-controlled JJ I
clinical JJ N
trial NN N
. . N

OBJECTIVE NNP N
Obsessive-compulsive JJ N
disorder NN N
is VBZ N
a DT N
common JJ N
neuropsychiatric JJ N
condition NN N
. . N

Although IN N
various JJ N
pharmaceutical JJ N
agents NNS N
are VBP N
available JJ N
for IN N
the DT N
treatment NN N
of IN N
obsessive-compulsive JJ N
disorder NN N
psychiatrists NNS N
often RB N
find VBP N
that IN N
many JJ N
patients NNS N
cannot VBP N
tolerate VB N
the DT N
side NN N
effects NNS N
of IN N
these DT N
medications NNS N
the DT N
patients NNS N
do VBP N
not RB N
respond VB N
properly RB N
to TO N
the DT N
treatment NN N
or CC N
the DT N
medications NNS N
lose VBP N
their PRP$ N
effectiveness NN N
after IN N
a DT N
period NN N
of IN N
treatment NN N
. . N

The DT N
augmentation NN N
with IN N
safe JJ N
supplementation NN N
of IN N
medication NN N
such JJ N
as IN N
with IN N
trace NN N
elements NNS N
may MD N
be VB N
a DT N
solution NN N
to TO N
some DT N
of IN N
these DT N
problems NNS N
. . N

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
prospective JJ N
double-blinded JJ N
8-wk JJ N
trial NN N
. . N

Twelve CD P
patients NNS P
were VBD P
given VBN P
fluoxetine JJ P
(20 NNP P
mg/d) NN P
plus CC P
zinc NN P
(440 NNP P
mg/d) NN P
and CC P
11 CD P
patients NNS P
were VBD P
given VBN P
fluoxetine JJ P
plus CC P
placebo NN P
for IN P
8wk CD P
. . N

RESULTS NNP N
Both NNP N
groups NNS N
showed VBD N
a DT N
decrease NN N
in IN N
the DT O
mean JJ O
Yale-Brown JJ O
Obsessive-Compulsive JJ O
Scale NNP O
score NN O
. . N

Based VBN N
on IN N
t NN N
tests NNS N
in IN N
weeks NNS N
2 CD N
and CC N
8 CD N
patients NNS N
treated VBN N
with IN I
fluoxetine JJ I
plus CC I
zinc NN I
had VBD N
significantly RB N
lower JJR N
scores NNS N
than IN N
those DT N
treated VBN N
with IN I
fluoxetine JJ I
plus CC I
placebo NN I
. . N

CONCLUSION NNP N
The DT N
results NNS N
show VBP N
that DT I
zinc NN I
as IN N
adjuvant JJ N
agent NN N
for IN N
obsessive-compulsive JJ N
disorder NN N
produces VBZ N
improved VBN N
outcomes NNS N
. . N

-DOCSTART- -X- N

Survey NNP I
response NN N
inducements NNS N
for IN N
registered JJ P
nurses NNS P
. . P

The DT N
past JJ N
20 CD N
years NNS N
have VBP N
seen VBN N
an DT N
overall JJ N
decline NN N
in IN N
survey NN I
response NN I
rates NNS I
and CC N
an DT N
even RB N
more RBR N
pronounced JJ N
decline NN N
in IN N
samples NNS N
of IN N
health NN P
care NN P
professionals NNS P
. . P

The DT N
authors NNS N
tested VBD N
the DT N
use NN N
of IN N
a DT N
"thank JJ I
you" NN I
or CC I
"reminder" VB I
postcard RB I
as IN N
a DT N
method NN N
by IN N
which WDT N
to TO N
stem VB N
the DT N
tide NN N
of IN N
declining VBG N
response NN N
rates NNS N
. . N

The DT N
authors NNS N
conducted VBD N
a DT I
mail NN P
and CC P
telephone NN P
survey NN P
of IN P
49 CD P
605 CD P
registered JJ P
nurses NNS P
for IN P
the DT P
2000 CD P
National NNP P
Sample NNP P
Survey NNP P
of IN P
Registered NNP P
Nurses NNP P
and CC N
sent VBD I
an DT I
extra JJ I
mailing NN I
to TO I
a DT I
random JJ I
subsample NN I
(n NNP I
= VBD I
4 CD I
968) CD I
. . N

They PRP N
then RB N
compared VBN N
response NN O
rates NNS N
for IN N
both DT N
groups NNS N
. . N

Contrary JJ N
to TO N
prior VB N
research NN N
this DT N
study NN N
found VBD N
that IN N
reminder NN N
postcards NNS N
did VBD N
not RB N
improve VB N
response NN O
rates NNS O
or CC O
rates NNS O
of IN O
return NN O
. . O

There EX N
may MD N
be VB N
several JJ N
reasons NNS N
for IN N
this DT N
finding NN N
including VBG N
the DT N
general JJ N
familiarity NN N
with IN N
and CC N
high JJ N
saliency NN N
of IN N
this DT N
research NN N
project NN N
for IN N
the DT N
nursing NN N
community NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
even RB N
widely RB N
accepted VBN N
best JJS N
practices NNS N
for IN N
survey NN N
methods NNS N
deserve VBP N
scrutiny NN N
when WRB N
applied VBN N
to TO N
special JJ N
subpopulations NNS N
. . N

-DOCSTART- -X- N

Caudal NNP I
epidural JJ I
analgesia NN I
using VBG I
lidocaine JJ I
alone RB I
or CC I
in IN I
combination NN I
with IN I
ketamine NN I
in IN N
dromedary JJ P
camels NNS P
Camelus NNP P
dromedarius NN P
. . P

This DT P
study NN N
was VBD N
performed VBN N
to TO N
investigate VB N
the DT N
analgesic JJ N
effect NN N
of IN N
lidocaine NN I
and CC I
a DT I
combination NN I
of IN I
lidocaine NN I
and CC I
ketamine NN I
following VBG N
epidural JJ N
administration NN N
in IN N
dromedary JJ P
camels NNS P
. . P

Ten CD P
12-18-month-old JJ P
camels NNS P
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
equal JJ N
groups NNS N
. . N

In IN N
group NN I
L NNP I
the DT I
animals NNS N
received VBD N
2% CD I
lidocaine JJ I
(0.22 NNP N
mg/kg) NN N
and CC N
in IN N
group NN N
LK NNP I
the DT N
animals NNS N
received VBD N
a DT N
mixture NN I
of IN I
10% CD I
ketamine NN I
(1 NNP N
mg/kg) NN N
and CC N
2% CD I
lidocaine NN I
(0.22 NNP I
mg/kg) NN I
administered VBD I
into IN N
the DT N
first JJ N
intercoccygeal JJ I
(Co1-Co2) JJ N
epidural JJ N
space NN N
while IN N
standing VBG N
. . N

Onset NNP O
time NN O
and CC O
duration NN O
of IN O
caudal JJ O
analgesia JJ O
sedation NN O
level NN O
and CC O
ataxia NN O
were VBD N
recorded VBN N
after IN N
drug NN N
administration NN N
. . N

Data NNS N
were VBD N
analysed VBN N
by IN N
U NNP N
Mann-Whitney NNP N
tests NNS N
and CC N
significance NN N
was VBD N
taken VBN N
as IN N
p JJ N
&lt; $ N
0.05 CD N
. . N

The DT N
results NNS N
showed VBD N
that IN N
epidural JJ I
lidocaine NN I
and CC I
co-administration NN I
of IN I
lidocaine NN I
and CC I
ketamine VB I
produced VBN N
complete JJ O
analgesia NN O
in IN N
the DT N
tail NN N
anus NN N
and CC N
perineum NN N
. . N

Epidural JJ I
administration NN I
of IN I
the DT I
lidocaine-ketamine JJ I
mixture NN I
resulted VBD N
in IN N
mild NN O
to TO O
moderate VB O
sedation NN O
whilst IN O
the DT N
animals NNS N
that WDT N
received VBD N
epidural JJ I
lidocaine NN I
alone RB I
were VBD N
alert JJ N
and CC N
nervous JJ N
during IN N
the DT N
study NN N
. . N

Ataxia NNP N
was VBD N
observed VBN N
in IN N
all DT N
test NN N
subjects NNS N
and CC N
was VBD N
slightly RB N
more JJR N
severe JJ N
in IN N
camels NNS N
that WDT N
received VBD N
the DT N
lidocaine-ketamine JJ I
mixture NN I
. . I

It PRP N
was VBD N
concluded VBN N
that IN N
epidural JJ I
administration NN I
of IN I
lidocaine JJ I
plus CC I
ketamine JJ I
resulted VBN N
in IN N
longer JJR N
caudal NN N
analgesia NN N
in IN N
standing VBG P
conscious JJ P
dromedary JJ P
camels NNS P
compared VBN N
with IN N
the DT N
effect NN N
of IN N
administering VBG N
lidocaine JJ I
alone RB N
. . N

-DOCSTART- -X- N

Intermittent JJ I
theta-burst JJ I
transcranial JJ I
magnetic JJ I
stimulation NN I
for IN N
treatment NN N
of IN N
Parkinson NNP P
disease NN P
. . P

OBJECTIVE NN P
To TO N
investigate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
intermittent JJ I
theta-burst JJ I
stimulation NN I
(iTBS) NN I
in IN N
the DT N
treatment NN N
of IN N
motor NN N
symptoms NNS N
in IN N
Parkinson NNP N
disease NN N
(PD) NNP N
. . N

BACKGROUND NNP N
Progression NNP N
of IN N
PD NNP N
is VBZ N
characterized VBN N
by IN N
the DT N
emergence NN N
of IN N
motor NN N
deficits NNS N
which WDT N
eventually RB N
respond VBZ N
less JJR N
to TO N
dopaminergic VB N
therapy NN N
and CC N
pose VB N
a DT N
therapeutic JJ N
challenge NN N
. . N

Repetitive JJ I
transcranial JJ I
magnetic JJ I
stimulation NN I
(rTMS) NN I
has VBZ N
shown VBN N
promising JJ N
results NNS N
in IN N
improving VBG O
gait NN O
a DT O
major JJ N
cause NN N
of IN N
disability NN N
and CC N
may MD N
provide VB N
a DT N
therapeutic JJ N
alternative NN N
. . N

iTBS NN I
is VBZ N
a DT N
novel JJ N
type NN N
of IN N
rTMS NN I
that WDT N
may MD N
be VB N
more RBR N
efficacious JJ N
than IN N
conventional JJ N
rTMS NN I
. . I

METHODS NNP N
In IN N
this DT N
randomized JJ N
double-blind JJ N
sham-controlled JJ N
study NN N
we PRP N
investigated VBD N
safety NN N
and CC N
efficacy NN N
of IN N
iTBS NN I
of IN N
the DT N
motor NN N
and CC N
dorsolateral JJ N
prefrontal NN N
cortices NNS N
in IN N
8 CD N
sessions NNS N
over IN N
2 CD N
weeks NNS N
(evidence NN N
Class NNP N
I) NNP N
. . N

Assessment NN N
of IN N
safety NN N
and CC N
clinical JJ N
efficacy NN N
over IN N
a DT N
1-month JJ N
period NN N
included VBD N
timed JJ N
tests NNS N
of IN N
gait NN O
and CC O
bradykinesia NN O
Unified NNP O
Parkinson's NNP O
Disease NNP O
Rating NNP O
Scale NNP O
(UPDRS) NNP O
and CC O
additional JJ O
clinical JJ O
neuropsychological JJ O
and CC O
neurophysiologic JJ O
measures NNS O
. . O

RESULTS NNP N
We PRP N
investigated VBD N
26 CD P
patients NNS P
with IN P
mild JJ P
to TO P
moderate VB P
PD: NNP P
13 CD P
received VBD P
iTBS NN I
and CC P
13 CD P
sham JJ P
stimulation NN P
. . P

We PRP N
found VBD N
beneficial JJ N
effects NNS N
of IN N
iTBS NN I
on IN N
mood NN O
but CC O
no DT N
improvement NN N
of IN N
gait NN O
bradykinesia NN O
UPDRS NNP O
and CC O
other JJ O
measures NNS O
. . O

EEG/EMG NNP N
monitoring NN N
recorded VBD N
no DT N
pathologic JJ N
increase NN O
of IN O
cortical JJ O
excitability NN O
or CC O
epileptic JJ O
activity NN O
. . O

Few JJ N
reported VBD N
discomfort NN O
or CC O
pain NN O
and CC N
one CD N
experienced JJ N
tinnitus NN N
during IN N
real JJ N
stimulation NN N
. . N

CONCLUSION NNP N
iTBS NN I
of IN N
the DT N
motor NN N
and CC N
prefrontal JJ N
cortices NNS N
appears VBZ N
safe JJ N
and CC N
improves VBZ N
mood NN O
but CC O
failed VBD N
to TO N
improve VB N
motor NN O
performance NN O
and CC O
functional JJ O
status NN O
in IN N
PD NNP N
. . N

CLASSIFICATION NN N
OF NNP N
EVIDENCE NNP N
This DT N
study NN N
provides VBZ N
Class NNP N
I PRP N
evidence NN N
that IN N
iTBS NN I
was VBD N
not RB N
effective JJ N
for IN N
gait NN O
upper JJ O
extremity NN O
bradykinesia NN O
or CC O
other JJ O
motor NN O
symptoms NNS O
in IN N
PD NNP N
. . N

-DOCSTART- -X- N

A DT N
comparative JJ N
study NN N
of IN N
netilmicin-cefoxitin JJ I
and CC I
gentamicin-cefoxitin JJ I
in IN N
surgical JJ P
patients NNS P
with IN P
serious JJ P
systemic JJ P
infection NN P
. . P

A DT N
double-blind JJ N
randomized JJ N
study NN N
of IN N
gentamicin NN I
and CC I
netilmicin JJ I
each DT I
in IN I
combination NN I
with IN I
cefoxitin NN I
was VBD I
done VBN N
to TO N
compare VB N
their PRP$ N
respective JJ N
efficacy NN O
and CC O
toxicity NN O
in IN N
patients NNS P
with IN P
serious JJ P
systemic JJ P
infection NN P
. . P

Thirty-seven JJ P
surgical JJ P
patients NNS P
were VBD P
evaluated VBN P
for IN P
efficacy NN P
and CC P
46 CD P
patients NNS P
were VBD P
evaluated VBN P
for IN P
toxicity NN P
. . P

The DT N
most RBS N
frequently RB N
cultured VBN N
organisms NNS N
were VBD N
Escherichia NNP N
coli NNS N
(15) NNP N
Klebsiella NNP N
sp VBD N
(9) NNP N
Proteus NNP N
sp NN N
(6) NN N
and CC N
Bacteroides NNP N
sp VBP N
(4) NNP N
. . N

For IN N
23 CD P
patients NNS P
treated VBN P
with IN P
gentamicin-cefoxitin JJ I
(G-C) JJ N
the DT N
clinical JJ O
response NN O
was VBD N
favorable JJ N
in IN N
20/21 CD N
(95.2%) NNS N
evaluable JJ N
cases NNS N
and CC N
elimination NN N
or CC N
marked VBN N
reduction NN N
of IN N
33/34 CD N
(97.1%) JJ N
organisms NNS N
was VBD N
achieved VBN N
. . N

For IN N
14 CD P
patients NNS P
treated VBN P
with IN P
netilmicin-cefoxitin JJ I
(N-C) JJ N
the DT N
clinical JJ N
response NN N
was VBD N
favorable JJ N
in IN N
13/13 CD N
(100%) NNS N
evaluable JJ N
cases NNS N
and CC N
19/20 CD N
(95%) NNS N
organisms NNS N
were VBD N
eliminated VBN N
or CC N
markedly RB N
reduced VBN N
. . N

Nephrotoxicity NN O
was VBD N
defined VBN N
as IN N
an DT N
increase NN N
in IN N
serum JJ N
creatinine NN N
to TO N
greater JJR N
than IN N
25% CD N
over IN N
baseline NN N
with IN N
an DT N
absolute JJ N
rise NN N
of IN N
at IN N
least JJS N
0.5 CD N
mg/100 JJ N
ml NN N
to TO N
a DT N
value NN N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
1.3 CD N
mg/100 NN N
ml NN N
. . N

Based VBN N
on IN N
these DT N
criteria NNS N
nephrotoxicity NN O
was VBD N
seen VBN N
in IN N
2/27 CD N
(7.4%) JJ N
patients NNS N
treated VBN N
with IN N
G-C NNP N
and CC N
in IN N
3/19 CD N
(15.8%) JJ N
patients NNS N
treated VBN N
with IN N
N-C NNP N
. . N

Ototoxicity NN O
was VBD N
defined VBN N
as IN N
a DT N
greater JJR N
than IN N
20 CD N
dB JJ N
loss NN N
at IN N
any DT N
frequency NN N
. . N

Based VBN N
on IN N
these DT N
criteria NNS N
ototoxicity NN O
was VBD N
seen VBN N
in IN N
5/27 CD N
(18.5%) JJ N
patients NNS N
treated VBN N
with IN N
G-C NNP N
and CC N
2/19 CD N
(10.5%) NN N
patients NNS N
treated VBN N
with IN N
N-C NNP N
. . N

The DT N
data NN N
show NN N
no DT N
significant JJ N
difference NN N
in IN N
toxicity NN O
and CC N
suggest VBP N
that IN N
netilmicin NN N
and CC N
gentamicin NN N
are VBP N
both DT N
highly RB N
effective JJ N
in IN N
combination NN N
with IN N
cefoxitin NN N
in IN N
patients NNS P
who WP P
have VBP P
serious JJ P
infections NNS P
after IN P
surgery NN P
. . P

-DOCSTART- -X- N

Ascorbic NNP I
acid NN I
and CC N
performance NN N
in IN N
man NN N
. . N

Effects NNS I
on IN I
performance NN O
of IN I
1 CD I
2 CD I
and CC I
4 CD I
g NN I
ascorbic JJ I
acid NN I
were VBD I
studied VBN I
from IN I
0.5-5.5 JJ I
h NN I
after IN I
ingestion NN I
in IN I
six CD P
healthy JJ P
females NNS P
. . P

Diazepam NNP I
(5 NNP I
mg) NN I
was VBD I
included VBN I
as IN I
an DT I
active JJ I
control NN I
and CC I
it PRP N
impaired VBD N
digit JJ O
symbol NN O
substitution NN O
visuomotor NN O
coordination NN O
and CC O
complex JJ O
reaction NN O
time NN O
. . O

There EX N
were VBD N
no DT N
effects NNS N
of IN N
any DT N
dose NN N
of IN N
ascorbic JJ I
acid NN I
on IN N
performance NN O
. . O

-DOCSTART- -X- N

Reactivation NN O
of IN O
unstable JJ P
angina NN P
after IN N
the DT N
discontinuation NN I
of IN I
heparin NN I
. . I

BACKGROUND NNP N
Heparin NNP I
is VBZ N
an DT N
effective JJ N
widely RB N
used VBN N
treatment NN N
for IN N
unstable JJ P
angina NN P
. . P

Among IN N
patients NNS N
enrolled VBN N
in IN N
a DT N
double-blind JJ N
randomized JJ N
placebo-controlled JJ I
trial NN I
comparing VBG N
intravenous JJ I
heparin NN I
aspirin IN I
both DT I
treatments NNS I
and CC I
neither DT I
during IN N
the DT N
acute JJ N
phase NN N
of IN N
unstable JJ N
angina NN N
we PRP N
encountered VBD N
patients NNS P
in IN P
whom WP P
unstable JJ P
angina NN P
was VBD N
reactivated VBN N
after IN N
heparin NN I
was VBD N
discontinued VBN N
. . N

METHODS NNP N
The DT N
study NN P
population NN P
included VBD P
403 CD P
of IN P
the DT P
original JJ P
479 CD P
patients NNS P
in IN P
the DT P
trial NN P
who WP P
had VBD P
completed VBN P
six CD P
days NNS P
of IN P
blinded JJ P
therapy NN P
without IN P
refractory JJ P
angina NN P
or CC P
myocardial JJ P
infarction NN P
. . P

After IN N
the DT N
discontinuation NN N
of IN N
therapy NN N
clinical JJ O
events NNS O
including VBG O
reactivation NN O
of IN O
unstable JJ O
angina NN O
and CC O
myocardial JJ O
infarction NN O
occurring VBG O
within IN O
96 CD O
hours NNS O
after IN O
hospitalization NN O
were VBD O
closely RB N
monitored VBN N
. . N

RESULTS NNP N
Early JJ O
reactivation NN O
occurred VBD N
in IN N
14 CD P
of IN P
the DT P
107 CD P
patients NNS P
who WP P
received VBD P
heparin RB P
alone RB P
as IN P
compared VBN N
with IN N
only RB N
5 CD N
patients NNS N
in IN N
each DT N
of IN N
the DT N
other JJ N
three CD N
study NN N
groups NNS N
(P NNP N
less JJR N
than IN N
0.01) CD N
. . N

These DT N
reactivations NNS N
required VBD N
urgent JJ N
intervention NN N
(thrombolysis NN N
angioplasty NN N
or CC N
coronary-bypass NN N
surgery) NN N
in IN N
11 CD P
patients NNS P
treated VBN P
with IN N
heparin JJ I
alone RB N
but CC N
in IN N
only RB N
2 CD N
patients NNS N
in IN N
the DT N
other JJ N
groups NNS N
combined VBN N
(P RB N
less JJR N
than IN N
0.01) CD N
. . N

Four CD N
of IN N
the DT N
six CD N
patients NNS P
who WP P
had VBD P
a DT P
myocardial JJ P
infarction NN P
during IN N
a DT N
reactivation NN N
of IN N
their PRP$ N
disease NN N
were VBD N
in IN N
the DT N
heparin NN I
group NN N
. . N

Reactivations NNS O
in IN N
this DT N
group NN N
occurred VBD N
in IN N
a DT N
cluster NN N
a DT N
mean JJ N
(+/- JJ N
SD) NNP N
of IN N
9.5 CD N
+/- JJ N
5 CD N
hours NNS N
after IN N
the DT N
discontinuation NN N
of IN N
the DT N
study NN N
drug NN N
but CC N
were VBD N
randomly RB N
distributed VBN N
over IN N
the DT N
initial JJ N
96 CD N
hours NNS N
in IN N
the DT N
other JJ N
three CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Although IN N
heparin NN I
is VBZ N
beneficial JJ N
in IN N
treating VBG N
unstable JJ N
angina IN N
the DT N
disease NN N
process NN N
may MD N
be VB N
reactivated VBN N
within IN N
hours NNS N
of IN N
the DT N
discontinuation NN N
of IN N
this DT N
drug NN N
. . N

Concomitant JJ N
therapy NN N
with IN N
aspirin NN N
may MD N
prevent VB N
this DT N
withdrawal NN N
phenomenon NN N
. . N

-DOCSTART- -X- N

An DT N
evaluation NN N
of IN N
an DT N
adaptive JJ I
automation NN I
system NN I
using VBG N
a DT N
cognitive JJ I
vigilance NN I
task NN I
. . I

The DT N
performance NN N
of IN N
an DT N
adaptive JJ I
automation NN I
system NN I
was VBD N
evaluated VBN N
using VBG N
a DT N
cognitive JJ N
vigilance NN N
task NN N
. . N

Participants NNS N
responded VBD N
to TO N
the DT N
presence NN I
of IN I
a DT I
green JJ I
"K" NN I
in IN I
an DT I
array NN I
of IN I
two CD I
five CD I
or CC I
nine CD I
distractor NN I
stimuli NNS I
during IN I
a DT I
40-min JJ I
vigil NN I
. . I

The DT N
array NN N
with IN N
the DT N
target NN N
stimulus NN N
was VBD N
presented VBN N
once RB N
each DT N
minute NN N
. . N

Participants NNS N
EEG NNP I
was VBD N
recorded VBN N
and CC N
an DT N
engagement JJ O
index NN O
(EI VBD N
= $ N
20 CD N
x NNP N
beta/(alpha NN N
+ NNP N
theta)) NN N
was VBD N
derived VBN N
. . N

In IN N
the DT N
negative JJ N
feedback NN N
condition NN N
increases NNS N
in IN N
the DT N
EI NNP O
caused VBD N
the DT N
number NN O
of IN O
stimuli NNS O
in IN O
the DT O
array NN O
to TO N
decrease VB N
while IN N
decreases NNS N
in IN N
the DT N
EI NNP O
caused VBD O
the DT O
number NN O
of IN O
stimuli NNS O
to TO O
increase VB O
. . O

For IN N
the DT N
positive JJ N
feedback NN N
condition NN N
increases NNS N
in IN N
the DT N
index NN O
caused VBD O
an DT O
increase NN O
in IN O
the DT O
array NN O
size NN O
(AS) NN O
while IN N
decreases NNS N
caused VBD N
a DT N
decrease NN N
in IN N
the DT N
array NN O
size NN O
. . O

Each DT N
experimental JJ N
participant NN N
had VBD P
a DT P
yoked VBN P
control NN P
partner NN P
who WP N
received VBD N
the DT N
same JJ N
pattern NN N
of IN N
changes NNS N
in IN N
array JJ N
irrespective NN N
of IN N
their PRP$ N
engagement JJ N
index NN N
. . N

A DT N
vigilance NN N
decrement NN N
was VBD N
seen VBN N
only RB N
for IN N
the DT N
positive JJ N
feedback NN N
experimental JJ P
group NN P
. . P

-DOCSTART- -X- N

Cost-effectiveness NN I
of IN I
ablation NN I
surgery NN I
in IN I
patients NNS P
with IN P
atrial JJ P
fibrillation NN P
undergoing VBG P
cardiac JJ P
surgery NN P
. . P

This DT I
study NN I
was VBD I
performed VBN I
to TO I
assess VB I
the DT I
cost-effectiveness NN I
of IN I
concomitant JJ I
ablation NN I
surgery NN I
(AS) NN I
compared VBN I
to TO I
regular VB I
cardiac JJ I
surgery NN I
in IN I
atrial JJ P
fibrillation NN P
(AF) NN P
patients NNS P
over IN I
a DT I
one-year JJ I
follow-up NN I
. . I

Cost NN I
analysis NN I
was VBD I
performed VBN I
from IN I
a DT I
societal JJ I
perspective NN I
alongside IN I
a DT I
prospective JJ I
randomised VBN I
double-blinded JJ I
multicentre JJ I
trial NN I
. . I

One CD P
hundred CD P
and CC P
fifty JJ P
patients NNS P
with IN P
documented JJ P
AF NNP P
were VBD I
randomly RB I
assigned VBN I
to TO I
undergo VB I
cardiac JJ I
surgery NN I
with IN I
or CC I
without IN I
AS NNP I
. . I

One CD P
hundred CD P
and CC P
thirty-two JJ P
patients NNS P
were VBD P
included VBN P
in IN P
the DT P
cost-effectiveness NN P
study NN P
. . P

All DT I
costs NNS O
(medical JJ I
and CC I
non-medical) JJ I
were VBD I
measured VBN I
during IN I
follow-up NN I
. . I

Costs NNS O
data NNS O
were VBD I
combined VBN I
with IN I
quality NN I
adjusted VBN I
life NN I
years NNS I
(QALYs) VBP I
to TO I
obtain VB I
the DT I
incremental JJ I
costs NNS I
per IN I
QALY NNP I
. . I

Total JJ I
costs NNS O
of IN I
the DT I
AS NNP I
group NN I
were VBD I
significantly RB I
higher JJR I
compared VBN I
to TO I
the DT I
regular JJ I
cardiac NN I
surgery NN I
group NN I
[cost VBD I
difference NN I
bootstrap: NN I
4 VBD I
724; CD I
95% CD I
uncertainty NN I
interval NN I
(UI) NNP I
2 NNP I
770-6 JJ I
678] CD I
. . I

The DT I
bootstrapped JJ I
difference NN O
in IN O
QALYs NNP I
was VBD I
not RB I
statistically RB I
significant JJ I
(0.06; JJ I
95% CD I
UI: NNP I
-0.024 NNP I
to TO I
0.14) CD I
. . I

The DT I
incremental JJ I
cost-effectiveness JJ I
ratio NN I
is VBZ I
73 JJ I
359 CD I
per IN I
QALY NNP I
. . I

The DT I
acceptability NN I
curve NN I
showed VBD I
that IN I
even RB I
in IN I
the DT I
case NN I
of IN I
a DT I
maximum JJ I
threshold JJ I
value NN I
of IN I
80 $ I
000 CD I
per IN I
QALY NN I
gained VBD I
the DT I
probability NN I
of IN I
AS NNP I
being VBG I
more RBR I
cost-effective JJ I
than IN I
regular JJ I
cardiac JJ I
surgery NN I
did VBD I
not RB I
reach VB I
beyond IN I
50% CD I
. . I

Concluding VBG I
that DT I
concomitant NN I
AS IN I
in IN I
AF NNP I
is VBZ I
not RB I
cost-effective JJ I
after IN I
a DT I
one-year JJ I
follow-up NN I
compared VBN I
to TO I
regular VB I
cardiac JJ I
surgery NN I
. . N

-DOCSTART- -X- N

Effectiveness NN O
of IN N
aromatherapy JJ I
massage NN I
in IN N
the DT N
management NN N
of IN N
anxiety NN P
and CC P
depression NN P
in IN P
patients NNS P
with IN P
cancer: NN P
a DT N
multicenter NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

PURPOSE NN N
To TO N
test VB N
the DT N
effectiveness NN N
of IN N
supplementing VBG N
usual JJ N
supportive JJ N
care NN N
with IN N
aromatherapy JJ I
massage NN I
in IN N
the DT N
management NN N
of IN N
anxiety NN P
and CC P
depression NN P
in IN P
cancer NN P
patients NNS P
through IN N
a DT N
pragmatic JJ N
two-arm NN N
randomized VBD N
controlled JJ I
trial NN I
in IN N
four CD P
United NNP P
Kingdom NNP P
cancer NN P
centers NNS P
and CC P
a DT P
hospice NN P
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Two CD P
hundred VBD P
eighty-eight JJ P
cancer NN P
patients NNS P
referred VBD P
to TO P
complementary JJ P
therapy NN P
services NNS P
with IN P
clinical JJ P
anxiety NN P
and/or NN P
depression NN P
were VBD P
allocated VBN N
randomly RB N
to TO N
a DT N
course NN N
of IN N
aromatherapy JJ I
massage NN I
or CC I
usual JJ I
supportive JJ I
care NN I
alone RB I
. . I

RESULTS JJ I
Patients NNS N
who WP N
received VBD N
aromatherapy JJ I
massage NN I
had VBD N
no DT N
significant JJ N
improvement NN N
in IN N
clinical JJ O
anxiety NN O
and/or NN O
depression NN O
compared VBN N
with IN N
those DT N
receiving VBG N
usual JJ N
care NN N
at IN N
10 CD N
weeks NNS N
postrandomization NN N
(odds NNS N
ratio VBP N
[OR] JJ N
1.3; CD N
95% CD N
CI NNP N
0.9 CD N
to TO N
1.7; CD N
P NNP N
= NNP N
.1) NNP N
but CC N
did VBD N
at IN N
6 CD N
weeks NNS N
postrandomization NN N
(OR VBD N
1.4; CD N
95% CD N
CI NNP N
1.1 CD N
to TO N
1.9; CD N
P NNP N
= NNP N
.01) NNP N
. . N

Patients NNS N
receiving VBG N
aromatherapy JJ I
massage NN I
also RB N
described VBD N
greater JJR N
improvement NN N
in IN N
self-reported JJ O
anxiety NN O
at IN N
both DT N
6 CD N
and CC N
10 CD N
weeks NNS N
postrandomization NN N
(OR VBD N
3.4; CD N
95% CD N
CI NNP N
0.2 CD N
to TO N
6.7; CD N
P NNP N
= NNP N
.04 NNP N
and CC N
OR NNP N
3.4; CD N
95% CD N
CI NNP N
0.2 CD N
to TO N
6.6; CD N
P NNP N
= NNP N
.04) NNP N
respectively RB N
. . N

CONCLUSION NNP N
Aromatherapy NNP I
massage NN I
does VBZ N
not RB N
appear VB N
to TO N
confer VB N
benefit NN N
on IN N
cancer NN P
patients' NN P
anxiety NN O
and/or JJ O
depression NN O
in IN N
the DT N
long-term JJ N
but CC N
is VBZ N
associated VBN N
with IN N
clinically RB N
important JJ N
benefit NN N
up IN N
to TO N
2 CD N
weeks NNS N
after IN N
the DT N
intervention NN N
. . N

-DOCSTART- -X- N

[A JJ N
comparison NN N
of IN N
2 CD N
methods NNS N
of IN N
plastic NN I
cast NN I
fixation NN I
in IN N
treatment NN N
of IN N
loco NN P
classico NN P
radius NN P
fracture NN P
. . P

A DT N
prospective JJ N
randomized VBN N
study] NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
functional JJ N
and CC N
radiological JJ N
result NN N
of IN N
two CD N
different JJ N
positions NNS N
of IN N
the DT N
wrist NN N
in IN N
a DT N
plaster NN I
cast NN I
following VBG N
Colles' NNP N
fracture NN N
. . N

For IN N
this DT N
prospective JJ N
study NN N
each DT N
of IN N
50 CD P
patients NNS P
with IN P
type NN P
A DT P
2.2 CD P
A DT P
3.3 CD P
C NNP P
1.2 CD P
or CC P
C NNP P
2.2 CD P
(AO NNP P
classification) NN P
fractures NNS P
of IN P
the DT P
radius NN P
was VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
. . N

Both DT N
groups NNS N
were VBD N
treated VBN N
in IN N
the DT N
same JJ N
way NN N
as IN N
far RB N
as IN N
anaesthesia NN N
and CC N
reduction NN N
were VBD N
concerned VBN N
. . N

The DT N
only JJ N
difference NN N
in IN N
treatment NN N
lay NN N
in IN N
the DT N
position NN N
of IN N
fixation NN N
in IN N
plaster NN N
. . N

In IN N
group NN N
1 CD N
the DT I
wrist NN I
was VBD I
immobilized VBN I
in IN I
neutral JJ I
flexion-extension NN I
. . I

In IN N
group NN N
2 CD N
the DT I
wrist NN I
was VBD I
dorsiflexed JJ I
20 CD I
degrees NNS I
while IN I
the DT I
carpus NN I
was VBD I
pushed VBN I
in IN I
a DT I
volar JJ I
direction NN I
by IN I
an DT I
impression NN I
in IN I
the DT I
plaster NN I
cast NN I
. . I

At IN N
review JJ N
2-7 CD N
years NNS N
after IN N
the DT N
accidents NNS N
the DT N
two CD N
groups NNS N
were VBD N
compared VBN N
with IN N
reference NN N
to TO N
symptoms VB O
range NN O
of IN O
motion NN O
at IN O
the DT O
wrist JJ O
power NN O
of IN O
first JJ O
closure NN O
and CC O
radiographic JJ O
appearance NN O
. . O

In IN N
group NN N
1 CD N
there EX N
were VBD N
5 CD P
patients NNS P
with IN P
significant JJ P
disability NN P
compared VBN P
with IN P
only RB P
1 CD P
in IN P
group NN P
2 CD P
. . P

A DT N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
range NN O
of IN O
movement NN O
between IN N
the DT N
two CD N
groups NNS N
for IN N
flexion NN N
and CC N
ulnar JJ N
abduction NN N
(p NNP N
< VBZ N
0.01) CD N
. . N

The DT N
loss NN O
of IN O
power NN O
of IN O
first JJ O
clenching VBG O
(difference NN N
between IN N
injured VBN N
and CC N
healthy JJ N
hand) NN N
was VBD N
6.2 CD N
mmHg NN N
for IN N
group NN N
1 CD N
and CC N
3.8 CD N
mmHg NN N
for IN N
group NN N
2 CD N
(not NN N
significant) NN N
. . N

-DOCSTART- -X- N

The DT N
Effects NNPS N
of IN N
Valsartan NNP I
and CC I
Amlodipine NNP I
on IN N
the DT N
Levels NNP I
of IN I
Irisin NNP I
Adropin NNP I
and CC I
Perilipin NNP I
. . I

BACKGROUND NNP I
Hypertension NNP P
and CC P
obesity NN P
are VBP N
two CD N
major JJ N
threats NNS N
for IN N
public JJ N
health NN N
. . N

Up RB N
to TO N
the DT N
present JJ N
antihypertensive JJ I
medications NNS I
have VBP N
been VBN N
used VBN N
to TO N
lower VB N
blood NN N
pressure NN N
which WDT N
seem VBP N
to TO N
provide VB N
a DT N
better JJR N
life NN N
with IN N
lower JJR N
morbidity NN N
and CC N
mortality NN N
rates NNS N
. . N

Their PRP$ N
effect NN N
on IN N
etiopathogenesis NN N
of IN N
hypertension NN N
is VBZ N
now RB N
an DT N
area NN N
of IN N
developing VBG N
research NN N
. . N

The DT N
association NN N
between IN N
hypertension NN N
and CC N
obesity NN N
also RB N
suggests VBZ N
the DT N
link NN N
between IN N
antihypertensive JJ N
agents NNS N
and CC N
energy NN N
hemostasis NN N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
antihypertensive JJ N
treatment NN N
on IN N
the DT N
irisin NN I
adropin NN I
and CC I
perilipin NN I
levels NNS I
in IN N
patients NNS P
with IN P
essential JJ P
hypertension NN P
and CC N
to TO N
compare VB N
them PRP N
with IN N
healthy JJ P
volunteers NNS P
in IN N
terms NNS N
of IN N
their PRP$ N
effect NN N
on IN N
energy NN N
hemostasis NN N
. . N

METHODS NNP N
In IN N
total JJ N
85 CD P
newly RB P
diagnosed VBN P
patients NNS P
with IN P
untreated JJ P
essential JJ P
hypertension NN P
were VBD P
admitted VBN P
to TO P
the DT P
outpatient NN P
clinic NN P
. . P

Patients NNS N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
treatment NN N
protocols: JJ N
amlodipine NN I
or CC I
valsartan NN I
for IN I
a DT I
12 CD I
week NN I
period NN I
. . I

42 CD P
patients NNS P
were VBD P
randomized VBN P
into IN P
the DT P
valsartan NN P
group NN P
and CC P
43 CD P
patients NNS P
into IN P
the DT P
amlodipine NN P
group NN P
. . P

Serum NNP O
perilipin NN O
irisin NN O
and CC O
adropin NN O
levels NNS O
were VBD N
measured VBN N
before IN N
and CC N
after IN N
drug NN N
treatment NN N
by IN N
ELISA NNP I
kits NNS I
. . I

RESULTS NN N
We PRP N
discovered VBD N
that IN N
the DT N
hypertensive JJ N
patients NNS N
have VBP N
lower JJR N
levels NNS O
of IN O
perilipin NN O
and CC N
higher JJR N
levels NNS O
of IN O
adropin NN O
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Both DT N
amlodipine NN I
and CC I
valsartan NN I
increased VBD N
the DT N
levels NNS O
of IN O
perilipin NN O
irisin NN O
and CC O
adropin NN O
after IN N
12 CD N
weeks NNS N
of IN N
treatment NN N
. . N

CONCLUSIONS NNP N
In IN N
conclusion NN N
in IN N
regulating VBG N
energy NN N
balance NN N
perilipin NN N
irisin NN N
and CC N
adropin NN N
could MD N
be VB N
of IN N
pathogenic JJ N
importance NN N
in IN N
obesity-induced JJ P
hypertension NN P
. . P

Hence NNP N
ongoing VBG N
trials NNS N
need VBP N
to TO N
elucidate VB N
this DT N
mechanism NN N
. . N

-DOCSTART- -X- N

Chumnguh NNP I
thleum: NN I
understanding VBG N
liver NN P
illness NN P
and CC P
hepatitis NN P
B NNP P
among IN P
Cambodian JJ P
immigrants NNS P
. . P

Cambodian JJ P
immigrants NNS P
are VBP N
over IN N
25 CD N
times NNS N
more RBR N
likely JJ N
to TO N
have VB N
evidence NN N
of IN N
chronic JJ N
hepatitis NN N
B NNP N
infection NN N
than IN N
the DT N
general JJ N
US NNP N
population NN N
. . N

Carriers NNS N
of IN N
HBV NNP N
are VBP N
over IN N
100 CD N
times NNS N
more RBR N
likely JJ N
to TO N
develop VB N
liver RB N
cancer NN N
than IN N
non-carriers NNS N
. . N

Liver NNP N
cancer NN N
incidence NN N
is VBZ N
the DT N
second JJ N
leading JJ N
cancer NN N
for IN N
Cambodian JJ P
men NNS P
and CC P
the DT P
sixth JJ P
for IN P
Cambodian JJ P
women NNS P
. . P

Despite IN N
this DT N
this DT N
underserved JJ P
population NN P
has VBZ N
received VBN N
very RB N
little JJ N
attention NN N
from IN N
health NN N
disparities NNS N
researchers NNS N
. . N

Culturally RB I
and CC I
linguistically RB I
appropriate JJ I
interventions NNS I
are VBP N
necessary JJ N
to TO N
increase VB N
hepatitis NN O
B NNP O
knowledge NN O
serologic NN O
testing VBG O
and CC O
vaccination NN O
among IN N
Cambodian JJ N
Americans NNPS N
. . N

Eight NNP I
group NN I
interviews NNS O
were VBD N
held VBN N
with IN N
Cambodian JJ P
American JJ P
men NNS P
(48) NNPS P
and CC P
women NNS P
(49) NNP P
. . P

Focus NNP I
group NN I
discussion NN I
revealed VBD N
unanticipated JJ O
information NN O
about IN O
sociocultural JJ O
influences NNS O
on IN O
participants' NN O
understanding VBG O
about IN O
hepatitis NN O
B NNP O
transmission NN O
disease NN O
course NN O
and CC O
prevention NN O
and CC O
treatment NN O
informed VBN N
by IN N
humoral JJ O
theories NNS O
underlying VBG O
Khmer NNP O
medicine NN O
by IN O
biomedicine NN O
and CC O
by IN N
migration NN O
experiences NNS O
. . O

Our PRP$ N
findings NNS N
reveal VBP N
the DT N
value NN O
of IN N
qualitative JJ N
exploration NN N
to TO N
providing VBG I
cultural JJ O
context NN O
to TO I
biomedical JJ I
information--a JJ I
formula NN N
for IN N
effective JJ O
health NN O
promotion NN O
and CC N
practice NN O
. . O

-DOCSTART- -X- N

A DT N
dose-ranging JJ N
study NN N
of IN N
pramipexole NN N
for IN N
the DT N
symptomatic JJ N
treatment NN N
of IN N
restless NN P
legs NNS P
syndrome: VBP P
polysomnographic JJ N
evaluation NN N
of IN N
periodic JJ N
leg NN N
movements NNS N
and CC N
sleep JJ N
disturbance NN N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
both DT N
polysomnographically RB N
and CC N
by IN N
subjective JJ N
scales NNS N
the DT N
efficacy NN O
and CC N
safety NN O
profile NN N
of IN N
pramipexole NN N
for IN N
restless JJ P
legs JJ P
syndrome NN P
(RLS) NNP P
via IN N
a DT N
3-week JJ N
double-blind JJ N
placebo-controlled JJ N
parallel-group JJ N
dose-ranging NN N
study NN N
. . N

METHODS NNP N
At IN N
baseline NN N
and CC N
after IN N
3 CD N
weeks NNS N
periodic JJ O
limb NN O
movements NNS O
(PLM) CD O
and CC N
sleep JJ O
parameters NNS O
were VBD N
assessed VBN N
by IN N
polysomnography NN O
and CC O
patients NNS N
self-assessed JJ N
their PRP$ N
sleep JJ O
disturbance NN O
and CC N
overall JJ N
RLS NNP O
severity NN O
using VBG N
the DT N
international JJ N
RLS NNP N
study NN N
group NN N
rating NN N
scale NN N
(IRLS) NNP N
. . N

Four CD N
pramipexole NN N
doses NNS N
were VBD N
evaluated: RB N
0.125 CD N
0.25 CD N
0.50 CD N
and CC N
0.75mg/d CD N
. . N

Data NNS N
from IN N
107 CD P
patients NNS P
were VBD N
included VBN N
in IN N
the DT N
intent-to-treat JJ N
(ITT) NN N
analysis NN N
. . N

RESULTS NNP N
For IN N
pramipexole JJ N
recipients NNS N
the DT N
primary JJ N
outcome JJ N
measure NN N
PLM NNP O
per IN O
hour NN O
in IN O
bed NN O
asleep NN O
or CC O
awake VB O
(the JJ N
PLM NNP N
index NN N
or CC N
PLMI) NNP N
decreased VBN N
by IN N
a DT N
median NN N
of IN N
-26.55 NN N
to TO N
-52.70 VB N
depending VBG N
on IN N
dosage NN N
group NN N
vs NN N
. . N

-3.00 NN N
for IN N
placebo NN N
(p<0.01 NN N
or CC N
0.001 CD N
for IN N
each DT N
group NN N
vs NN N
. . N

placebo; JJ N
Wilcoxon-Mann-Whitney NNP N
test) NN N
. . N

Improvements NNS N
in IN N
the DT N
secondary JJ N
endpoints NNS N
of IN N
PLM NNP O
while IN O
asleep RB O
and CC O
while IN O
awake NN O
were VBD N
also RB N
significantly RB N
superior JJ N
for IN N
pramipexole NN N
. . N

At IN N
3 CD N
weeks NNS N
all DT N
pramipexole VBP N
doses NNS N
reduced VBD N
the DT N
median NN O
for IN O
PLM NNP O
while IN N
asleep RB N
to TO N
levels NNS N
considered VBN N
normal JJ N
(<5PLM/h) NNS N
. . N

Except IN N
for IN N
delta-sleep JJ N
time NN N
and CC N
awakenings/arousals NNS N
sleep VBP N
parameters NNS N
remained VBD N
unchanged JJ N
or CC N
favored JJ N
pramipexole NN N
. . N

Median JJ O
sleep NN O
latency NN O
was VBD N
reduced VBN N
by IN N
-5.00 NN N
to TO N
-11.75min VB N
in IN N
the DT N
pramipexole NN N
groups NNS N
vs NN N
. . N

-2.00 NN N
for IN N
placebo NN N
(p<0.05 NN N
for IN N
all DT N
groups NNS N
except IN N
0.25mg/d) CD N
. . N

Median JJ O
total JJ O
sleep JJ O
time NN O
increased VBN N
by IN N
25.75-66.75min JJ N
vs NN N
. . N

25.50 CD N
(p<0.05 NN N
for IN N
0.50mg/d) CD N
and CC N
median JJ N
time NN N
in IN N
stages NNS N
2-4/rapid JJ N
eye NN N
movement NN N
(REM) JJ N
sleep NN N
increased VBN N
by IN N
37.00-68.00min JJ N
vs NN N
. . N

26.75 CD N
(p<0.05 NN N
for IN N
0.50mg/d) CD N
. . N

By IN N
subjective JJ N
IRLS NNP N
ratings NNS N
all DT N
pramipexole VBP N
doses NNS N
were VBD N
significantly RB N
superior JJ N
to TO N
placebo VB N
. . N

Safety NN N
analysis NN N
demonstrated VBD N
no DT N
dose-dependent JJ N
increase NN N
in IN N
adverse JJ O
events NNS O
and CC O
no DT N
drug-related JJ N
increase NN N
in IN N
daytime JJ O
somnolence NN O
was VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Pramipexole NNP N
is VBZ N
effective JJ N
and CC N
well RB N
tolerated VBN N
in IN N
RLS NNP N
most RBS N
notably RB N
among IN N
objective JJ N
measures NNS N
for IN N
reducing VBG N
PLM NNP N
and CC N
decreasing VBG N
sleep JJ N
latency NN N
. . N

Although IN N
other JJ N
sleep JJ N
parameters NNS N
showed VBD N
lesser RBR N
usually RB N
insignificant JJ N
change NN N
patients' NN N
subjective JJ N
ratings NNS N
of IN N
RLS NNP N
severity NN N
and CC N
sleep JJ N
disturbance NN N
were VBD N
significantly RB N
improved VBN N
(p0.0023) NN N
. . N

-DOCSTART- -X- N

[Comparative JJ I
study NN I
between IN I
5% CD I
prilocaine NN I
and CC I
2% CD I
mepivacaine NN I
by IN I
the DT I
subarachnoid JJ I
route NN I
in IN I
transurethral JJ P
resections] NN P
. . I

OBJECTIVE NN I
To TO I
compare VB I
the DT I
duration NN I
of IN I
spinal JJ I
block NN I
with IN I
5% CD I
prilocaine NN I
and CC I
2% CD I
mepivacaine NN I
in IN I
short JJ I
procedures NNS I
for IN I
transurethral JJ I
resection NN I
and CC I
to TO I
assess VB I
possible JJ I
complications NNS I
in IN I
the DT I
immediate JJ I
postoperative JJ I
period NN I
. . I

MATERIAL NNP I
AND NNP I
METHODS NNP I
Fifty-seven NNP P
patients NNS P
scheduled VBN P
for IN P
transurethral JJ P
resection NN P
of IN P
the DT P
prostate NN P
or CC P
a DT P
vesical JJ P
tumor NN P
. . P

Patients NNS P
were VBD P
ASA NNP P
I-III NNP P
over IN P
55 CD P
years NNS P
of IN P
age NN P
and CC I
randomly RB I
assigned VBN I
to TO I
two CD I
groups NNS I
to TO I
receive VB I
5% CD I
prilocaine NN I
(1 NNP I
mg/kg NN I
n NN I
= VBZ I
27) CD I
or CC I
2% CD I
mepivacaine NN I
(0.8 NNP I
mg/kg NN I
n NN I
= VBD I
30) CD I
. . I

We PRP I
collected VBD I
data NNS I
on IN I
anesthetic JJ O
technique NN O
levels NNS O
of IN O
extension NN O
of IN O
motor NN O
and CC O
sensory JJ O
blockades NNS O
duration NN O
of IN O
blockades NNS O
and CC O
complications NNS O
within IN O
the DT O
first JJ O
24 CD O
hours NNS O
after IN I
surgery NN I
. . I

RESULTS NNP I
Demographic NNP I
data VBZ I
ASA NNP I
classification NN I
and CC I
duration NN I
of IN I
surgery NN I
were VBD I
similar JJ I
in IN I
both DT I
groups NNS I
. . I

We PRP I
found VBD I
statistically RB I
significant JJ I
differences NNS I
(p VBP I
< JJ I
0.05) CD I
in IN I
duration NN O
of IN O
sensory JJ O
blockade NN O
(120.92 VBD I
+/- JJ I
36.21 CD I
min NN I
with IN I
prilocaine NN I
and CC I
145.83 CD I
+/- JJ I
35.81 CD I
min NN I
with IN I
mepivacaine) NN I
and CC I
in IN I
motor NN O
blockade NN O
(106.29 VBD I
+/- JJ I
38.16 CD I
min NN I
with IN I
prilocaine NN I
and CC I
133.16 CD I
+/- JJ I
42.21 CD I
min NN I
with IN I
mepivacaine) NN I
. . I

Five CD I
cases NNS I
of IN I
hypotension NN O
and CC I
4 CD I
of IN I
bradycardia NN I
occurred VBN I
in IN I
each DT I
group NN I
and CC I
one CD I
patient NN I
in IN I
the DT I
mepivacaine NN I
group NN I
suffered VBD I
slight JJ I
postoperative JJ I
cephalea NN I
. . I

CONCLUSIONS NNP I
Both NNP I
local JJ I
anesthetics NNS I
offer VBP I
good JJ I
surgical JJ O
conditions NNS O
with IN I
hemodynamic JJ I
stability NN I
and CC I
few JJ I
complications NNS O
. . O

The DT I
duration NN I
of IN I
sensory NN I
and CC I
motor NN I
blockade NN I
is VBZ I
shorter JJR I
with IN I
prilocaine NN I
than IN I
with IN I
mepivacaine NN I
making VBG I
prilocaine NN I
more JJR I
appropriate JJ I
for IN I
short JJ I
interventions NNS I
. . I

-DOCSTART- -X- N

Early JJ N
psychosocial JJ N
intervention NN I
in IN N
Alzheimer's NNP P
disease: NN P
cost NN I
utility NN I
evaluation NN I
alongside IN N
the DT N
Danish NNP P
Alzheimer's NNP P
Intervention NNP N
Study NNP N
(DAISY) NNP N
. . N

OBJECTIVE NN N
To TO N
assess VB N
the DT N
cost NN I
utility NN I
of IN N
early JJ N
psychosocial JJ N
intervention NN I
for IN N
patients NNS P
with IN P
Alzheimer's NNP P
disease NN P
and CC P
their PRP$ P
primary JJ P
caregivers NNS P
. . P

DESIGN NN P
Cost NNP I
utility NN I
evaluation NN N
alongside IN N
a DT N
multicentre NN N
randomised VBD N
controlled VBN N
trial NN I
with IN N
3 CD N
years NNS N
of IN N
follow-up NN N
. . N

SETTING NN N
Primary NNP P
care NN P
and CC P
memory NN P
clinics NNS P
in IN P
five CD P
Danish JJ P
districts NNS P
. . P

PARTICIPANTS NNS N
330 CD P
community-dwelling JJ P
patients NNS P
and CC P
their PRP$ P
primary JJ P
caregivers NNS P
. . P

INTERVENTION NNP N
Psychosocial NNP I
counselling NN I
and CC I
support NN I
lasting VBG I
8-12 JJ I
months NNS I
after IN N
diagnosis NN N
and CC N
follow-up NN I
at IN N
3 CD N
6 CD N
12 CD N
and CC N
36 CD N
months NNS N
in IN N
the DT N
intervention NN N
group NN N
or CC N
follow-up NN I
only RB I
in IN N
the DT N
control NN I
group NN I
. . I

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
cost NN O
of IN O
additional JJ O
quality-adjusted JJ O
life NN O
years NNS O
(QALYs) VBP O
. . O

Costs NNS O
were VBD N
measured VBN N
from IN N
a DT N
societal JJ N
perspective NN N
including VBG N
the DT N
costs NNS O
of IN O
healthcare JJ O
social JJ O
care NN O
informal JJ O
care NN O
and CC O
production NN O
loss NN O
. . O

QALYs NNP O
were VBD N
estimated VBN N
separately RB N
for IN N
the DT N
patient NN N
and CC N
the DT N
caregiver NN N
before IN N
aggregation NN N
for IN N
the DT N
main JJ N
analysis NN N
. . N

RESULTS NNP N
None NN N
of IN N
the DT N
observed JJ N
cost NN O
and CC O
QALY NNP O
measures NNS O
were VBD N
significantly RB N
different JJ N
between IN N
the DT N
intervention NN N
and CC N
control NN I
groups NNS I
although IN I
a DT N
tendency NN N
was VBD N
noted VBN N
for IN N
psychosocial JJ N
care NN N
leading VBG N
to TO N
cost NN N
increases NNS N
with IN N
informal JJ N
care NN N
that WDT N
was VBD N
not RB N
outweighed VBN N
by IN N
the DT N
tendency NN N
for IN N
cost NN N
savings NNS N
with IN N
formal JJ N
care NN N
. . N

The DT N
probability NN N
of IN N
psychosocial JJ N
intervention NN I
being VBG N
cost-effective JJ O
did VBD N
not RB N
exceed VB N
36% CD N
for IN N
any DT N
threshold JJ N
value NN N
. . N

The DT N
alternative JJ N
scenario NN N
analysis NN N
showed VBD N
that IN N
the DT N
probability NN N
of IN N
cost-effectiveness NN O
increased VBN O
over IN N
the DT N
range NN N
of IN N
threshold NN N
values NNS N
used VBN N
if IN N
the DT N
cost NN N
perspective NN N
was VBD N
restricted VBN N
to TO N
formal JJ N
healthcare NN N
. . N

CONCLUSIONS VB N
A NNP N
multifaceted JJ N
psychosocial JJ N
intervention NN I
programme NN N
was VBD N
found VBN N
unlikely RB N
to TO N
be VB N
cost-effective JJ N
from IN N
a DT N
societal JJ N
perspective NN N
. . N

The DT N
recommendation NN N
for IN N
practice NN N
in IN N
settings NNS N
that WDT N
are VBP N
similar JJ N
to TO N
the DT N
Danish JJ N
setting NN N
is VBZ N
to TO N
provide VB N
follow-up JJ N
with IN N
referral JJ N
to TO N
available JJ N
local JJ N
support NN N
programmes NNS N
when WRB N
needed VBN N
and CC N
to TO N
restrict VB N
large JJ N
multifaceted VBN N
intervention NN N
programmes NNS N
to TO N
patients NNS P
and CC P
caregivers NNS P
with IN P
special JJ P
needs NNS P
until IN N
further JJ N
evidence NN N
for IN N
cost-effectiveness JJ N
emerges NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
The DT N
study NN N
was VBD N
registered VBN N
in IN N
the DT N
Clinical JJ N
Trial NNP N
Database NNP N
as IN N
ISRCTN74848736 NNP N
. . N

-DOCSTART- -X- N

Pharmacist NNP I
directed VBD I
home NN I
medication NN I
reviews NNS I
in IN N
patients NNS P
with IN P
chronic JJ P
heart NN P
failure: VBZ P
a DT N
randomised JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Chronic NNP P
heart NN P
failure NN P
(CHF) JJ P
accounts NNS N
for IN N
significant JJ N
morbidity NN N
mortality NN N
and CC N
health NN N
expenditure NN N
. . N

Furthermore RB N
patients NNS P
with IN P
CHF NNP P
are VBP N
often RB N
on IN N
numerous JJ N
pharmacological JJ N
agents NNS N
for IN N
their PRP$ N
comorbidities NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
a DT N
pharmacist NN I
directed VBD I
home NN I
medication NN I
review NN I
intervention NN N
had VBD N
positive JJ N
effects NNS N
on IN N
CHF NNP P
patient NN P
outcomes NNS N
. . N

METHODS NNP N
A NNP P
total NN P
of IN P
120 CD P
patients NNS P
hospitalised VBN P
for IN P
CHF NNP P
were VBD P
randomised VBN N
to TO N
receive VB N
a DT N
pharmacist NN I
directed VBD I
post-discharge JJ I
home NN I
medication NN I
review NN I
(n NNP P
= VBD P
64 CD P
53.3%) CD P
or CC P
standard JJ P
care NN P
(n NNP P
= VBD P
56 CD P
46.7%) CD P
. . N

Participants NNS N
were VBD N
followed VBN N
for IN N
6 CD N
months NNS N
. . N

Primary JJ N
outcomes NNS N
were VBD N
death NN N
CHF NNP N
hospitalisation NN N
and CC N
length NN N
of IN N
hospital NN N
stay NN N
. . N

RESULTS RB N
There EX N
were VBD N
no DT N
between IN N
group NN N
differences NNS N
in IN N
mortality NN O
(hazard NNP N
ratio NN N
= VBD N
1.41 CD N
0.50 CD N
to TO N
3.97; CD N
P NNP N
= $ N
0.514) CD N
or CC N
CHF NNP O
hospitalizations NNS O
(incidence NN N
rate NN N
ratio NN N
[IRR] NNP N
= VBD N
1.74 CD N
95% CD N
CI: NNP N
0.85-3.60 JJ N
P NNP N
= NNP N
0.131) CD N
over IN N
the DT N
6 CD N
month NN N
follow-up JJ N
period NN N
. . N

Days NNS O
of IN O
hospital NN O
stay NN O
for IN O
CHF NNP O
exacerbations NNS O
in IN N
the DT N
6 CD N
month NN N
follow-up NN N
were VBD N
significantly RB N
greater JJR N
in IN N
the DT N
intervention NN N
group NN N
(IRR NNP N
= VBZ N
2.34 CD N
95% CD N
CI: NNP N
1.80-3.05 JJ N
P NNP N
= NNP N
0.000) CD N
. . N

CONCLUSIONS NNP N
Post-discharge NNP I
pharmacy NN I
directed VBD I
home NN I
medication NN I
review NN I
appeared VBD N
to TO N
have VB N
no DT N
effect NN N
on IN N
mortality NN N
and CC N
health NN N
care NN N
utilisation NN N
above IN N
that DT N
achieved VBD N
with IN N
standard JJ N
care NN N
. . N

The DT N
post-acute JJ N
management NN N
of IN N
CHF NNP N
must MD N
be VB N
a DT N
collaborative JJ N
multi-disciplinary JJ N
effort NN N
by IN N
the DT N
health NN N
care NN N
team NN N
as IN N
it PRP N
is VBZ N
the DT N
additive JJ N
effect NN N
of IN N
interventions NNS N
that WDT N
are VBP N
most RBS N
effective JJ N
. . N

-DOCSTART- -X- N

Neuropsychological JJ O
effects NNS O
of IN N
risperidone NN N
in IN N
children NNS P
with IN P
pervasive JJ P
developmental JJ P
disorders: NN P
a DT N
blinded JJ N
discontinuation NN N
study NN N
. . N

OBJECTIVE NNP N
Little NNP N
is VBZ N
known VBN N
about IN N
the DT N
neuropsychological JJ N
effects NNS N
of IN N
risperidone NN N
in IN N
children NNS P
with IN P
pervasive JJ P
developmental NN P
disorders NNS P
. . P

METHOD NNP N
Twenty-four CD P
children NNS P
(aged VBD P
5-17 JJ P
years) NN P
with IN P
pervasive JJ P
developmental NN P
disorders NNS P
and CC P
co-morbid JJ P
disruptive JJ P
behavior NN P
who WP P
responded VBD P
favorably RB P
to TO P
open-label JJ P
treatment NN P
with IN P
risperidone NN P
as IN P
part NN P
of IN P
a DT P
previously RB P
described VBN P
controlled VBN P
discontinuation NN P
study NN P
completed VBD N
two CD N
different JJ N
computerized JJ N
attention NN N
tasks NNS N
at IN N
baseline JJ N
weeks NNS N
4 CD N
8 CD N
and CC N
24 CD N
of IN N
open-label JJ N
treatment NN N
and CC N
at IN N
8 CD N
weeks NNS N
after IN N
random JJ N
assignment NN N
to TO N
either DT N
placebo NN N
or CC N
risperidone NN N
. . N

The DT N
primary JJ N
efficacy NN N
measures NNS N
were VBD N
response NN O
latencies NNS O
to TO O
visually RB O
presented VBN O
stimuli JJ O
requiring VBG O
two CD O
different JJ O
types NNS O
of IN O
attention-controlled JJ O
processing NN O
i.e NN O
. . O

focused VBN O
and CC O
divided VBN O
attention NN O
. . O

RESULTS NNS N
About IN N
half NN N
of IN N
the DT N
clinical JJ N
responders NNS N
did VBD N
not RB N
produce VB N
valid JJ O
performance NN O
measures NNS O
. . O

These DT N
could MD N
be VB N
shown VBN N
to TO N
be VB N
of IN N
younger JJR N
mental JJ N
age NN N
and CC N
less RBR N
adaptive JJ N
as IN N
measured VBN N
by IN N
the DT N
Vineland NNP N
Behavior NNP N
Scales NNP N
. . N

For IN N
the DT N
valid JJ N
task NN N
performers NNS N
divided VBD N
attention NN N
(serial JJ O
search NN O
in IN O
working VBG O
memory) NN O
was VBD N
shown VBN N
to TO N
regress VB N
in IN N
the DT N
placebo NN N
group NN N
(n NNP N
= VBZ N
7) CD N
while IN N
in IN N
the DT N
risperidone NN N
group NN N
(n NNP N
= VBZ N
7) CD N
there EX N
was VBD N
further JJ N
improvement NN N
. . N

No DT N
such JJ N
group NN N
difference NN N
was VBD N
found VBN N
for IN N
focused JJ N
attention NN N
. . N

CONCLUSIONS NNP N
The DT N
study NN N
suggests VBZ N
a DT N
beneficial JJ N
effect NN N
of IN N
risperidone NN N
after IN N
several JJ N
months NNS N
of IN N
treatment NN N
enhancing VBG N
divided VBN N
attention NN N
in IN N
children NNS P
with IN P
pervasive JJ P
developmental NN P
disorders NNS P
. . P

-DOCSTART- -X- N

BNP-guided JJ N
vs NN N
symptom-guided JJ N
heart NN N
failure NN N
therapy: VBD N
the DT N
Trial NNP N
of IN N
Intensified NNP N
vs FW N
Standard NNP N
Medical NNP N
Therapy NNP N
in IN P
Elderly JJ P
Patients NNS P
With IN P
Congestive NNP P
Heart NNP P
Failure NNP P
(TIME-CHF) JJ P
randomized JJ N
trial NN N
. . N

CONTEXT NN N
It PRP N
is VBZ N
uncertain JJ N
whether IN N
intensified JJ N
heart NN N
failure NN N
therapy NN N
guided VBN N
by IN N
N-terminal JJ N
brain NN N
natriuretic JJ N
peptide NN N
(BNP) NNP N
is VBZ N
superior JJ N
to TO N
symptom-guided JJ N
therapy NN N
. . N

OBJECTIVE NN N
To TO N
compare VB N
18-month JJ N
outcomes NNS N
of IN N
N-terminal JJ N
BNP-guided JJ N
vs NN N
symptom-guided JJ N
heart NN N
failure NN N
therapy NN N
. . N

DESIGN NNP N
SETTING NNP N
AND NNP N
PATIENTS NNP N
Randomized NNP N
controlled VBD N
multicenter RBR N
Trial NNP N
of IN N
Intensified NNP N
vs FW N
Standard NNP N
Medical NNP N
Therapy NNP N
in IN N
Elderly JJ P
Patients NNS P
With IN P
Congestive NNP P
Heart NNP P
Failure NNP P
(TIME-CHF) NN P
of IN P
499 CD P
patients NNS P
aged VBN P
60 CD P
years NNS P
or CC P
older JJR P
with IN P
systolic JJ P
heart NN P
failure NN P
(ejection NN P
fraction NN P
< NN P
or CC P
= VB P
45%) CD P
New NNP P
York NNP P
Heart NNP P
Association NNP P
(NYHA) NNP P
class NN P
of IN P
II NNP P
or CC P
greater JJR P
prior JJ P
hospitalization NN P
for IN N
heart NN N
failure NN N
within IN N
1 CD N
year NN N
and CC N
N-terminal JJ N
BNP NNP N
level NN N
of IN N
2 CD N
or CC N
more JJR N
times NNS N
the DT N
upper JJ N
limit NN N
of IN N
normal JJ N
. . N

The DT N
study NN N
had VBD N
an DT N
18-month JJ N
follow-up NN N
and CC N
it PRP N
was VBD N
conducted VBN N
at IN N
15 CD P
outpatient NN P
centers NNS P
in IN P
Switzerland NNP P
and CC P
Germany NNP P
between IN P
January NNP P
2003 CD P
and CC P
June NNP P
2008 CD P
. . P

INTERVENTION NNP N
Uptitration NNP N
of IN N
guideline-based JJ N
treatments NNS N
to TO N
reduce VB N
symptoms NNS N
to TO N
NYHA NNP N
class NN N
of IN N
II NNP N
or CC N
less JJR N
(symptom-guided JJ N
therapy) NN N
and CC N
BNP NNP N
level NN N
of IN N
2 CD N
times NNS N
or CC N
less JJR N
the DT N
upper JJ N
limit NN N
of IN N
normal JJ N
and CC N
symptoms NNS N
to TO N
NYHA NNP N
class NN N
of IN N
II NNP N
or CC N
less JJR N
(BNP-guided JJ N
therapy) NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
outcomes NNS N
were VBD N
18-month JJ O
survival JJ O
free JJ O
of IN O
all-cause JJ O
hospitalizations NNS O
and CC O
quality NN O
of IN O
life NN O
as IN O
assessed VBN O
by IN O
structured JJ O
validated JJ O
questionnaires NNS O
. . O

RESULTS NNP N
Heart NNP N
failure NN N
therapy NN N
guided VBN N
by IN N
N-terminal JJ N
BNP NNP N
and CC N
symptom-guided JJ N
therapy NN N
resulted VBD N
in IN N
similar JJ N
rates NNS N
of IN N
survival JJ O
free JJ O
of IN O
all-cause JJ O
hospitalizations NNS O
(41% VBP N
vs JJ N
40% CD N
respectively; JJ N
hazard NN N
ratio NN N
[HR] VBD N
0.91 CD N
[95% JJ N
CI NNP N
0.72-1.14]; JJ N
P NNP N
= NNP N
.39) NNP N
. . N

Patients' NNP N
quality-of-life JJ O
metrics NNS O
improved VBN N
over IN N
18 CD N
months NNS N
of IN N
follow-up JJ N
but CC N
these DT N
improvements NNS N
were VBD N
similar JJ N
in IN N
both DT N
the DT N
N-terminal JJ N
BNP-guided JJ N
and CC N
symptom-guided JJ N
strategies NNS N
. . N

Compared VBN N
with IN N
the DT N
symptom-guided JJ N
group NN N
survival VBD O
free JJ O
of IN O
hospitalization NN O
for IN O
heart NN O
failure NN O
a DT O
secondary JJ N
end NN N
point NN N
was VBD N
higher JJR N
among IN N
those DT N
in IN N
the DT N
N-terminal JJ N
BNP-guided NNP N
group NN N
(72% NNP N
vs VBZ N
62% CD N
respectively; NN N
HR NNP N
0.68 CD N
[95% NNP N
CI NNP N
0.50-0.92]; JJ N
P NNP N
= NNP N
.01) NNP N
. . N

Heart NNP N
failure NN N
therapy NN N
guided VBN N
by IN N
N-terminal NNP N
BNP NNP N
improved VBD N
outcomes NNS N
in IN N
patients NNS P
aged VBD P
60 CD P
to TO P
75 CD P
years NNS P
but CC N
not RB N
in IN N
those DT P
aged VBN P
75 CD P
years NNS P
or CC P
older JJR P
(P NNS N
< VBP N
.02 NN N
for IN N
interaction) JJ N
CONCLUSION NNP N
Heart NNP N
failure NN N
therapy NN N
guided VBN N
by IN N
N-terminal JJ N
BNP NNP N
did VBD N
not RB N
improve VB N
overall JJ N
clinical JJ N
outcomes NNS O
or CC N
quality NN O
of IN O
life NN O
compared VBN N
with IN N
symptom-guided JJ N
treatment NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
isrctn.org NN N
Identifier: NNP N
ISRCTN43596477 NNP N
. . N

-DOCSTART- -X- N

Bioavailability NN O
of IN N
omega-3 JJ P
essential JJ P
fatty JJ P
acids NNS P
from IN P
perilla NN P
seed NN P
oil NN P
. . P

Increased VBN N
dietary JJ I
intake NN I
of IN I
fish JJ I
oil NN I
omega-3 JJ I
fatty JJ I
acids NNS I
eicosapentanoic VBP I
acid NN I
and CC N
docosohexanoic NN I
acid NN I
and CC I
their PRP$ N
precursor NN N
alpha-linolenic JJ I
acid NN I
(ALA) NN I
is VBZ I
associated VBN N
with IN N
various JJ N
health NN N
benefits NNS N
. . N

Enteric-coating NNP N
(Entrox) NNP I
which WDT N
improves VBZ N
stability NN N
of IN N
omega-3 JJ I
capsules NNS I
has VBZ I
been VBN N
shown VBN N
to TO N
facilitate VB N
fish JJ N
oil NN N
absorption NN N
after IN N
chronic JJ N
treatment NN N
. . N

To TO N
assess VB N
the DT N
effect NN N
of IN N
Entrox NNP N
coating VBG N
on IN N
the DT N
short-term JJ N
bioavailability NN O
of IN O
ALA NNP O
administered VBD N
in IN N
the DT N
form NN N
of IN N
ALA-rich NNP I
Perilla NNP I
seed NN I
oil NN I
12 CD P
healthy JJ P
subjects NNS P
(6 JJ P
males NNS P
and CC P
6 CD P
females) NNS P
received VBN N
in IN N
a DT N
random JJ N
order NN N
Entrox-coated JJ I
and CC I
non-coated JJ I
ALA NNP I
formulations NNS I
each DT I
as IN N
a DT N
single JJ N
6g CD N
dose NN N
separated VBN N
by IN N
a DT N
3-week JJ N
washout NN N
period NN N
. . N

Measurements NNS N
of IN N
plasma NN O
ALA NNP O
concentrations NNS O
from IN N
0 CD N
to TO N
24h CD N
showed VBD N
no DT N
difference NN N
in IN N
ALA NNP O
pharmacokinetics NNS O
between IN O
the DT N
two CD N
formulations NNS N
. . N

However RB N
significantly RB N
greater JJR N
increases NNS N
in IN N
plasma JJ O
ALA NNP O
levels NNS O
from IN N
baseline NN N
to TO N
24h CD N
were VBD N
observed VBN N
after IN N
ingestion NN N
of IN N
Entrox NNP I
vs NN N
. . N

non-coated JJ I
product NN I
suggesting VBG I
a DT N
possible JJ N
benefit NN N
of IN N
Entrox NNP I
with IN N
long-term JJ N
treatment NN N
. . N

-DOCSTART- -X- N

Ranitidine NNP N
improves VBZ N
lymphocyte JJ N
function NN N
after IN N
severe JJ P
head NN P
injury: JJ P
results NNS N
of IN N
a DT N
randomized JJ N
double-blind NN N
study NN N
. . N

OBJECTIVE NN N
To TO N
study VB N
the DT N
immunomodulatory JJ N
effect NN N
of IN N
the DT N
histamine NN N
receptor NN N
antagonist JJ N
ranitidine NN N
in IN N
patients NNS P
admitted VBN P
to TO P
the DT P
intensive JJ P
care NN P
unit NN P
after IN P
severe JJ P
head NN P
injury NN P
. . P

DESIGN NNP N
Randomized NNP N
prospective JJ N
double-blind NN N
study NN N
. . N

SETTING NNP N
Surgical NNP N
intensive JJ P
care NN P
unit NN P
of IN P
a DT P
university NN P
Level NNP P
I PRP P
trauma VBP P
center NN P
. . P

PATIENTS NNP P
Twenty NNP P
patients NNS P
admitted VBD P
with IN P
a DT P
Glasgow NNP P
Coma NNP P
Scale NNP P
score NN P
of IN P
< $ P
10 CD P
who WP N
were VBD N
enrolled VBN N
as IN N
part NN N
of IN N
a DT N
prospective JJ N
multicenter NN N
trial NN N
to TO N
assess VB N
the DT N
impact NN N
of IN N
multiple JJ N
risk NN N
factors NNS N
and CC N
ranitidine VB N
prophylaxis NN N
on IN N
the DT N
development NN N
of IN N
stress-related JJ N
upper JJ N
gastrointestinal NN N
bleeding NN N
. . N

INTERVENTIONS NNP N
Continuous NNP N
infusion NN N
of IN N
ranitidine NN N
at IN N
6.25 CD N
mg/hr NN N
(n NNP N
= VBZ N
9) CD N
or CC N
placebo VB N
(n JJ N
= $ N
11) CD N
for IN N
a DT N
maximum NN N
of IN N
5 CD N
days NNS N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Before IN N
the DT N
patients NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
and CC N
on IN N
completion NN N
of IN N
treatment NN N
lymphocyte JJ N
cell-surface NN N
antigen NN N
expression NN N
was VBD N
determined VBN N
by IN N
flow JJ N
cytometry NN N
(n NNP N
= VBZ N
14 CD N
patients); JJ N
mitogen-stimulated JJ O
interferon-gamma JJ O
and CC O
interleukin-2 JJ O
production NN O
were VBD N
measured VBN N
by IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
(n NNP N
= VBZ N
19 CD N
patients) NN N
. . N

Treatment NN N
with IN N
ranitidine NN N
but CC N
not RB N
placebo NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN N
in IN N
CD4+ NNP O
lymphocytes VBZ O
(33% VBP N
to TO N
49%; CD N
p NNS N
< JJ N
.05) NNP N
and CC N
a DT N
significant JJ N
decrease NN N
in IN N
CD8+ NNP N
lymphocytes VBZ N
(41% VBP N
to TO N
27%; CD N
p NNS N
< JJ N
.05) NNP N
. . N

Also RB N
the DT N
mitogen-stimulated JJ O
interferon-gamma JJ O
production NN O
increased VBD N
from IN N
121 CD N
to TO N
269 CD N
pg/mL NNS N
(p JJ N
< NNP N
.05) NNP N
in IN N
patients NNS N
treated VBN N
with IN N
ranitidine NN N
but CC N
not RB N
in IN N
patients NNS N
treated VBN N
with IN N
placebo NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
interleukin-2 JJ O
production NN O
or CC N
circulating VBG O
B-cell NNP O
concentrations NNS O
between IN N
both DT N
groups NNS N
. . N

CONCLUSION NN N
This DT N
study NN N
demonstrates VBZ N
an DT N
immunostimulatory JJ N
effect NN N
of IN N
the DT N
histamine-2-receptor JJ N
antagonist NN N
ranitidine VB N
both DT N
at IN N
the DT N
cellular JJ N
and CC N
mediator NN N
levels NNS N
in IN N
patients NNS P
after IN P
head JJ P
injury NN P
. . P

-DOCSTART- -X- N

[Clinical JJ N
trial NN N
of IN N
2 CD N
tobacco NN I
use NN I
cessation NN I
interventions NNS I
in IN N
primary JJ N
care] NN N
. . N

OBJECTIVE NN N
To TO N
study VB N
the DT N
efficacy NN N
of IN N
two CD N
types NNS N
of IN N
intervention NN N
to TO N
stop VB N
tobacco NN N
dependency NN N
. . N

DESIGN NNP N
Randomised VBD N
clinical JJ I
trial NN I
. . I

SETTING NN N
Primary NNP N
care NN N
centre NN N
. . N

PATIENTS NNS N
AND CC N
OTHER NNP N
PARTICIPANTS NNP N
Smokers NNP P
recruited VBD P
from IN P
among IN P
the DT P
health NN P
centre NN P
users NNS P
through IN P
the DT P
preventive JJ P
activities NNS P
and CC P
health NN P
promotion NN P
programme NN P
. . P

INTERVENTIONS NNP P
INDEPENDENT NNP I
VARIABLE NNP I
type NN I
of IN I
intervention NN I
. . I

General NNP N
variables: NN N
age NN N
sex NN N
marital JJ N
status NN N
educational JJ N
level NN N
work NN N
situation NN N
cohabitation NN N
with IN N
children NNS N
smokers NNS N
at IN N
home NN N
number NN N
of IN N
years NNS N
smoking VBG N
type NN N
of IN N
tobacco NN N
. . N

There EX N
were VBD N
two CD N
types NNS N
of IN N
intervention: NN N
a) NN N
Minimal NNP I
Intervention NNP I
(MI) NNP I
. . I

b) NN N
Advanced NNP I
Intervention NNP I
(AI) NNP I
. . I

54 CD P
patients NNS P
were VBD P
included VBN P
with IN P
6 CD P
losses NNS P
. . P

21 CD N
were VBD N
assigned VBN N
at IN N
random NN N
to TO N
the DT N
MI NNP P
group NN P
and CC P
27 CD P
to TO P
the DT P
AI NNP P
group NN P
. . P

Progress NN N
was VBD N
measured VBN N
at IN N
15 CD N
days NNS N
1 CD N
month NN N
3 CD N
months NNS N
6 CD N
months NNS N
and CC N
a DT N
year NN N
. . N

RESULTS NN N
In IN N
the DT N
MI NNP I
23.8% CD I
were VBD N
abstinent NN O
at IN N
15 CD N
days; NN N
the DT N
same JJ N
percentage NN N
at IN N
one CD N
month NN N
and CC N
3 CD N
months; NN N
19% CD N
at IN N
6 CD N
months; NN N
and CC N
14.3% CD N
remained VBD N
abstinent NN O
after IN O
a DT O
year NN O
. . O

In IN N
the DT N
AI NNP I
51.9% CD I
were VBD N
abstinent NN O
at IN N
15 CD N
days; NN N
48.1% CD N
at IN N
both DT N
one CD N
and CC N
3 CD N
months; NN N
25.9% CD N
at IN N
6 CD N
months; NN N
and CC N
22.2% CD N
were VBD N
still RB N
not RB O
smoking VBG O
after IN O
a DT O
year NN O
. . O

No DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
interventions NNS I
were VBD N
found VBN N
in IN N
any DT N
of IN N
the DT N
observations NNS N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
do VBP N
not RB N
show VB N
that IN N
one CD N
intervention NN I
is VBZ N
better RBR N
than IN N
the DT N
other JJ N
. . N

With IN N
the DT N
passage NN N
of IN N
time NN N
the DT N
effect NN N
of IN N
the DT N
intervention NN I
decreased VBN N
in IN N
both DT N
groups NNS N
. . N

-DOCSTART- -X- N

CD4+FOXP3+ NNP N
regulatory JJ N
T NNP N
cell NN N
depletion NN N
by IN N
low-dose JJ I
cyclophosphamide NN I
prevents NNS N
recurrence NN O
in IN N
patients NNS P
with IN P
large JJ P
condylomata NNS P
acuminata NNS P
after IN P
laser NN P
therapy NN P
. . P

Condylomata NNP P
acuminata NN P
(CA) NN P
caused VBN N
by IN N
human JJ N
papillomavirus NN N
(HPV) NN N
is VBZ N
a DT N
common JJ N
sexually RB N
transmitted JJ N
disease NN N
with IN N
half PDT N
a DT N
million CD N
new JJ N
cases NNS P
diagnosed VBN P
in IN P
the DT P
United NNP P
States NNPS P
per IN P
year NN P
and CC N
the DT N
annual JJ N
increase NN N
in IN N
incidence NN N
in IN N
China NNP N
. . N

Recurrence NN O
is VBZ N
a DT N
major JJ N
challenge NN N
for IN N
CA NNP N
treatment NN N
. . N

Recently RB N
we PRP N
demonstrated VBD N
that IN N
FOXP3(+) NNP N
regulatory JJ N
T NNP N
(Treg) NNP N
cells NNS N
mediate VBP N
the DT N
immunosuppression NN O
in IN O
large JJ O
genital JJ O
warts NNS O
. . O

Here RB N
we PRP N
further VBP N
report VB N
that IN N
low-dose JJ I
cyclophosphamide NN I
(CY) VBD I
a DT I
conventional JJ I
chemotherapy JJ I
drug NN N
can MD N
effectively RB N
prevent VB N
the DT N
recurrence NN O
of IN O
large JJ O
CA NNP O
in IN N
clinical JJ P
patients NNS P
after IN P
laser NN P
therapy NN P
. . P

Surprisingly RB N
although IN N
9 CD N
out IN N
of IN N
52 CD P
patients NNS P
recur JJ N
six CD N
weeks NNS N
after IN N
the DT N
combination NN I
treatment NN I
the DT I
re-administration NN N
of IN N
low-dose JJ I
CY NNP I
alone RB N
completely RB N
eliminates VBZ N
most JJS N
recurred JJ O
lesions NNS O
. . O

We PRP N
provide VBP N
evidence NN N
that IN N
low-dose JJ I
CY NNP I
not RB N
only RB N
depletes VBZ N
patients' JJ O
Treg NNP O
cells NNS O
and CC N
enhances NNS N
function NN O
of IN O
HPV-specific NNP O
T NNP O
cells NNS O
and CC O
NK NNP O
cells NNS O
in IN N
the DT N
periphery NN N
but CC N
also RB N
ameliorates VBZ N
the DT N
immune JJ O
milieu NN O
of IN O
the DT O
lesion NN O
site NN O
leading VBG O
to TO N
the DT N
elimination NN O
of IN O
remnant JJ O
viruses NNS O
. . O

These DT N
findings NNS N
have VBP N
important JJ N
clinical JJ N
significance NN N
and CC N
potentially RB N
lead JJ N
to TO N
a DT N
therapeutic JJ N
breakthrough NN N
for IN N
the DT N
treatment NN O
of IN O
CA NNP O
. . O

-DOCSTART- -X- N

Predictors NNS N
of IN N
incident NN N
depression NN N
after IN P
hip NN P
fracture NN P
surgery NN P
. . P

OBJECTIVE NNP N
Depression NNP N
after IN N
hip NN I
fracture NN I
surgery NN I
is VBZ N
prevalent JJ N
and CC N
associated VBN N
with IN N
increased JJ N
mortality NN N
rates NNS N
and CC N
impaired JJ N
functional JJ N
recovery NN N
. . N

The DT N
incidence NN N
of IN N
new-onset JJ N
depressive NN N
symptoms NNS N
in IN N
patients NNS N
initially RB N
not RB N
depressed VBN N
after IN N
hip NN I
fracture NN I
surgery NN I
and CC N
their PRP$ N
relationship NN N
with IN N
functional JJ N
recovery NN N
is VBZ N
unknown JJ N
. . N

METHODS NNP N
A NNP N
cohort NN N
of IN N
139 CD P
nondepressed JJ P
elderly JJ P
patients NNS P
(>60 VBP P
years) RB P
hospitalized VBN P
for IN P
hip NN P
fracture NN P
surgery NN P
were VBD I
followed VBN I
up RP I
for IN I
six CD I
months NNS I
. . I

Clinically RB N
significant JJ N
depressive JJ N
symptoms NNS N
were VBD N
defined VBN N
as IN N
a DT N
score NN N
of IN N
7 CD N
or CC N
more JJR N
on IN N
the DT N
15-item JJ I
Geriatric NNP I
Depression NNP I
Scale NNP I
. . I

RESULTS VB N
The DT N
authors NNS N
found VBD N
a DT N
cumulative JJ N
incidence NN N
rate NN N
of IN N
20.5% CD N
adjusted VBN N
for IN N
dropouts NNS N
. . N

Multiple JJ I
Cox-regression NNP I
analyses NNS I
yielded VBD N
the DT N
presence NN N
of IN N
subthreshold JJ N
symptoms NNS N
of IN N
depression NN O
anxiety NN O
pain NN O
and CC O
cognitive JJ O
impairment NN O
at IN N
baseline NN N
the DT N
premorbid NN N
level NN N
of IN N
mobility NN N
and CC N
a DT N
history NN N
of IN N
(treated) JJ N
depression NN N
as IN N
risk NN N
factors NNS N
for IN N
incident JJ N
depression NN N
(p NNP N
<0.05) NNP N
. . N

A DT N
forward JJ N
conditional JJ N
procedure NN N
identified VBN N
postoperative JJ O
pain NN O
(hazard NNP N
ratio NN N
[HR] NNP N
= VBD N
1.32 CD N
95% CD N
confidence NN N
interval JJ N
[CI]: JJ N
1.14-1.53 JJ N
Wald NNP N
chi(2) NN N
= VBD N
13.57 CD N
df NN N
= VBD N
1 CD N
p NN N
<0.001) NN N
and CC N
baseline NN O
anxiety NN O
(HR NNP N
= VBD N
1.25 CD N
95% CD N
CI: NNP N
1.08-1.44 JJ N
Wald NNP N
chi(2) NN N
= VBD N
8.86 CD N
df NN N
= VBD N
1 CD N
p NN N
= RB N
0.003) CD N
as IN N
the DT N
strongest JJS N
independent JJ N
risk NN N
factors NNS N
. . N

Incident NNP N
depression NN O
was VBD N
associated VBN N
with IN N
a DT N
less RBR N
favorable JJ N
outcome NN N
at IN N
3 CD N
months NNS N
follow-up RB N
. . N

CONCLUSION NN N
This DT N
exploratory NN N
study NN N
identified VBD N
two CD N
treatable JJ N
baseline NN N
characteristics NNS N
that WDT N
predicted VBD N
incident JJ N
depression NN N
in IN N
nondepressed JJ P
patients NNS P
after IN P
hip-fracture JJ P
surgery NN P
. . P

-DOCSTART- -X- N

The DT N
impact NN N
on IN N
outcome NN N
of IN N
the DT N
addition NN I
of IN I
all-trans NNS I
retinoic JJ I
acid NN I
to TO I
intensive JJ I
chemotherapy NN I
in IN N
younger JJR P
patients NNS P
with IN P
nonacute JJ P
promyelocytic JJ P
acute NN P
myeloid NN P
leukemia: NN P
overall JJ N
results NNS N
and CC N
results NNS N
in IN N
genotypic JJ P
subgroups NNS P
defined VBN P
by IN P
mutations NNS P
in IN P
NPM1 NNP P
FLT3 NNP P
and CC P
CEBPA NNP P
. . P

We PRP N
investigated VBD N
the DT N
benefit NN N
of IN N
adding VBG N
all-trans JJ I
retinoic NN I
acid NN I
(ATRA) NN I
to TO I
chemotherapy VB P
for IN P
younger JJR P
patients NNS P
with IN P
nonacute JJ P
promyelocytic JJ P
acute NN P
myeloid NN N
leukemia NN N
and CC N
high-risk JJ N
myelodysplastic JJ N
syndrome NN N
and CC N
considered VBN N
interactions NNS N
between IN N
treatment NN N
and CC N
molecular JJ N
markers NNS N
. . N

Overall JJ N
1075 CD P
patients NNS P
less RBR P
than IN P
60 CD P
years NNS P
of IN P
age NN P
were VBD N
randomized VBN N
to TO N
receive VB I
or CC I
not RB I
receive JJ I
ATRA NNP I
in IN N
addition NN N
to TO N
daunorubicin/Ara-C/thioguanine JJ I
chemotherapy NN I
with IN I
Ara-C NNP I
at IN I
standard NN I
or CC I
double JJ I
standard NN I
dose NN I
. . I

There EX N
were VBD N
data NNS N
on IN N
FLT3 NNP N
internal JJ N
tandem NN N
duplications NNS N
and CC N
NPM1 NNP P
mutations NNS P
(n VBP P
= $ P
592) CD N
CEBPA NNP N
mutations NNS P
(n VBP P
= JJ P
423) CD P
and CC N
MN1 NNP N
expression NN N
(n NNP P
= VBZ P
195) CD P
. . P

The DT N
complete JJ O
remission NN O
rate NN O
was VBD N
68% CD N
with IN N
complete JJ N
remission NN N
with IN N
incomplete JJ N
count NN N
recovery NN N
in IN N
an DT N
additional JJ N
16%; CD N
8-year JJ O
overall JJ O
survival NN O
was VBD N
32% CD N
. . N

There EX N
was VBD N
no DT N
significant JJ N
treatment NN N
effect NN N
for IN N
any DT N
outcome NN N
with IN N
no DT N
significant JJ N
interactions NNS N
between IN N
treatment NN N
and CC N
demographics NNS N
or CC N
cytarabine JJ N
randomization NN N
. . N

Importantly RB N
there EX N
were VBD N
no DT N
interactions NNS N
by IN N
FLT3/internal NNP O
tandem NN O
duplications NNS O
NPM1 NNP O
or CC O
CEBPA NNP O
mutation NN O
. . O

There EX N
was VBD N
a DT N
suggestion NN N
that IN N
ATRA NNP I
reduced VBD N
relapse NN O
in IN N
patients NNS N
with IN N
lower JJR N
MN1 NNP N
levels NNS N
but CC N
no DT N
significant JJ N
effect NN N
on IN N
overall JJ O
survival NN O
. . O

Results NNS N
were VBD N
consistent JJ N
when WRB N
restricted VBN N
to TO N
patients NNS P
with IN P
normal JJ P
karyotype NN P
. . P

ATRA NNP I
has VBZ N
no DT N
overall JJ N
effect NN N
on IN N
treatment NN N
outcomes NNS N
in IN N
this DT N
group NN N
of IN N
patients NNS N
. . N

The DT N
study NN N
did VBD N
not RB N
identify VB N
any DT N
subgroup NN N
of IN N
patients NNS N
likely JJ N
to TO N
derive VB N
a DT N
significant JJ N
survival JJ N
benefit NN N
from IN N
the DT N
addition NN N
of IN N
ATRA NNP N
to TO N
chemotherapy VB N
. . N

-DOCSTART- -X- N

Effects NNS N
of IN N
topical JJ I
boswellic JJ I
acid NN I
on IN N
photo NN P
and CC P
age-damaged JJ P
skin: NN P
clinical JJ O
biophysical NN O
and CC O
echographic JJ O
evaluations NNS O
in IN N
a DT N
double-blind JJ N
randomized JJ N
split-face NN N
study NN N
. . N

Boswellic JJ I
acids NNS I
(BAs) NNS I
are VBP N
pentacyclic JJ I
triterpenes NNS I
with IN N
strong JJ N
anti-inflammatory JJ N
activity; VBP N
their PRP$ N
most RBS N
important JJ N
source NN N
is VBZ N
the DT N
extract NN N
of IN N
the DT N
gum NN N
resin NN N
of IN N
Boswellia NNP N
serrata VBD N
a DT N
tropical JJ N
tree NN N
that WDT N
grows VBZ N
in IN N
India NNP N
and CC N
Africa NNP N
. . N

In IN N
the DT N
present JJ N
randomized JJ N
double-blind JJ N
split-face NN N
comparative NN N
study NN N
we PRP N
have VBP N
assessed VBN N
efficacy NN O
tolerability NN O
and CC O
safety NN O
of IN N
a DT I
base NN I
cream NN I
containing VBG I
0.5 CD I
% NN I
BAs NNP I
as IN I
compared VBN I
to TO I
the DT I
same JJ I
cream NN I
without IN I
these DT I
active JJ I
ingredients NNS I
in IN N
the DT N
treatment NN N
of IN N
clinical JJ N
manifestations NNS N
of IN N
photoaging NN P
of IN P
facial JJ P
skin NN P
. . P

Fifteen NNP P
female JJ P
volunteers NNS P
were VBD P
enrolled; RB P
they PRP N
applied VBD N
creams NNS N
once RB N
daily RB N
for IN N
30 CD N
days NNS N
. . N

At IN N
baseline NN N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
and CC N
after IN N
a DT N
2-month JJ N
follow-up JJ N
clinical JJ N
findings NNS N
were VBD N
assessed VBN N
according VBG N
to TO N
the DT N
Dover NNP O
classification NN O
scale NN O
for IN O
photoaging VBG O
and CC N
by IN N
biophysical JJ O
and CC O
ecographic JJ O
measurements NNS O
. . O

We PRP N
registered VBD N
a DT N
significant JJ N
improvement NN N
of IN N
tactile JJ O
roughness NN O
and CC O
fine JJ O
lines NNS O
in IN N
the DT N
half JJ N
side NN N
of IN N
the DT N
face NN N
treated VBD N
with IN N
BAs; NNP I
noninvasive JJ N
instrumental JJ N
diagnostic JJ N
investigations NNS N
showed VBD N
an DT N
improvement NN N
of IN N
elasticity NN O
a DT O
decrease NN N
of IN N
sebum JJ O
excretion NN O
and CC O
a DT N
change NN N
of IN N
echographic JJ O
parameters NNS O
suggesting VBG N
a DT N
reshaping NN N
of IN N
dermal JJ N
tissue NN N
. . N

The DT N
treatment NN N
was VBD N
always RB N
well RB N
tolerated VBN N
without IN N
adverse JJ O
effects NNS O
. . O

The DT N
present JJ N
findings NNS N
seem VBP N
to TO N
indicate VB N
that IN N
the DT N
topical JJ N
application NN N
of IN N
BAs NNP I
may MD N
represent VB N
a DT N
suitable JJ N
treatment NN N
option NN N
for IN N
selected VBN N
features NNS N
of IN N
skin NN P
photoaging NN P
. . P

-DOCSTART- -X- N

Eltrombopag NNP I
dose JJ N
predictors NNS N
in IN N
thrombocytopenic JJ P
subjects NNS P
with IN P
hepatitis NN P
C NNP P
virus NN P
infection NN P
. . P

This DT N
study NN N
aims VBZ N
to TO N
identify VB N
patient JJ N
characteristics NNS N
that WDT N
predict VBP N
effective JJ N
eltrombopag NN N
dosage NN N
for IN N
the DT N
treatment NN N
of IN N
Hepatitis NNP P
C NNP P
virus POS P
(HCV)-related JJ P
thrombocytopenia NN P
. . P

Demographic NNP N
clinical JJ N
and CC N
genetic JJ N
data NNS N
collected VBN N
from IN N
thrombocytopenic JJ P
patients NNS P
(n VBP P
= JJ P
1463 CD P
age NN P
 VBD I
18 CD P
years) NN P
with IN P
chronic JJ P
HCV NNP P
infection NN P
who WP P
were VBD P
able JJ P
to TO P
achieve VB P
a DT P
target NN P
platelet NN P
count NN P
of IN P
> $ P
90 CD P
 $ I
10(9) CD P
/L NN P
following VBG P
eltrombopag JJ P
treatment NN P
. . N

Patients NNS N
were VBD N
categorized VBN N
into IN N
four CD N
groups NNS I
(25 VBP I
50 CD I
75 CD I
and CC I
100 CD I
mg) NNS I
based VBN N
on IN N
the DT I
eltrombopag NN I
dose NN I
needed VBN N
to TO N
achieve VB N
the DT N
target NN N
platelet NN N
count NN I
. . I

Eltrombopag NNP I
dose JJ N
predictors NNS N
were VBD N
identified VBN N
using VBG N
a DT N
two CD N
stage NN N
approach NN N
. . N

First RB I
bivariate NN I
analysis NN I
using VBG N
anova NN N
for IN N
continuous JJ N
variables NNS N
and CC N
Chi-square NNP N
test NN N
for IN N
categorical JJ N
variables NNS N
was VBD N
performed VBN N
to TO N
identify VB N
possible JJ N
predictors NNS N
of IN N
eltrombopag NN N
dose NN N
(P NNP N
< VBZ N
0.05) CD N
. . N

Second JJ I
ordinal JJ I
logistic JJ I
regression NN I
with IN I
stepwise NN I
addition NN I
followed VBN I
by IN I
backward NN I
deletion NN I
was VBD N
then RB N
performed VBN N
using VBG N
predictors NNS N
identified VBN N
in IN N
bivariate NN N
analysis NN N
step NN N
to TO N
produce VB N
final JJ N
model NN N
containing VBG N
independent JJ N
predictors NNS N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

Ordinal NNP N
logistic JJ N
model NN N
identified VBD N
several JJ N
predictors NNS N
of IN N
eltrombopag NN N
dose NN N
. . N

Predictors NNS N
of IN N
higher JJR I
eltrombopag NN I
dose VBP N
include: NN O
having VBG O
a DT O
HCV NNP O
genotype NN O
2 CD O
or CC O
3 CD O
being VBG O
Central/South NNP O
Asian JJ O
being VBG O
White NNP O
(Caucasian NN O
or CC O
European JJ O
heritage) NN O
increased VBD O
weight NN O
and CC O
increased VBD O
spleen JJ O
length NN O
. . N

Predictors NNS N
of IN N
lower JJR N
eltrombopag NN N
dose JJ N
include: JJ O
female JJ O
gender NN O
increased VBD O
age NN O
having VBG O
a DT O
higher JJR O
ALP NNP O
plasma JJ O
concentration NN O
increased VBD O
creatinine JJ O
clearance NN O
increased VBD O
baseline NN O
lymphocytes NNS O
count NN O
and CC N
increased VBD N
baseline NN N
platelet NN N
count NN N
. . N

In IN N
conclusion NN N
this DT N
study NN N
identified VBD N
patient JJ N
characteristics NNS N
that WDT N
predict VBP N
effective JJ N
eltrombopag NN N
dose NN N
for IN N
the DT N
treatment NN N
of IN P
HCV-related NNP P
thrombocytopenia NN P
. . N

Early JJ N
selection NN N
of IN N
the DT N
optimal JJ N
eltrombopag NN N
dose NN N
expedites VBZ N
the DT N
initiation NN N
of IN N
antiviral JJ N
therapy NN N
. . N

This DT N
is VBZ N
expected VBN N
to TO N
improve VB N
the DT N
antiviral JJ N
therapy NN N
outcome NN N
before IN N
the DT N
patient NN N
progress NN N
into IN N
liver JJ N
decompensation NN N
. . N

-DOCSTART- -X- N

Response NN N
to TO N
familiar JJ I
faces VBZ I
newly RB I
familiar JJ I
faces VBZ I
and CC I
novel JJ I
faces VBZ I
as IN N
assessed VBN N
by IN N
ERPs NNP N
is VBZ N
intact JJ N
in IN N
adults NNS P
with IN P
autism NN P
spectrum NN P
disorders NNS P
. . P

Individuals NNS P
with IN P
autism NN P
spectrum NN P
disorders NNS P
(ASD) VBP P
have VBP N
pervasive JJ N
impairments NNS N
in IN N
social JJ N
functioning NN N
which WDT N
may MD N
include VB N
problems NNS N
with IN N
processing NN N
and CC N
remembering NN N
faces VBZ N
. . N

In IN N
this DT N
study NN N
we PRP N
examined VBD N
whether IN N
posterior JJ I
ERP NNP I
components NNS I
associated VBN N
with IN N
identity NN N
processing NN N
(P2 NNP N
N250 NNP N
and CC N
face-N400) JJ N
and CC N
components NNS N
associated VBN N
with IN N
early-stage JJ N
face NN N
processing NN N
(P1 NN N
and CC N
N170) NNP N
are VBP N
atypical JJ N
in IN N
ASD NNP N
. . N

We PRP N
collected VBD N
ERP NNP O
responses NNS O
to TO I
a DT I
familiar JJ I
repeated JJ I
face NN I
(Familiar) NNP I
an DT I
unfamiliar JJ I
repeated JJ I
face NN I
(Other) NNP I
and CC I
novel JJ I
faces VBZ I
(Novels) NN I
in IN P
29 CD P
high-functioning JJ P
adults NNS P
with IN P
ASD NNP P
and CC P
matched VBD P
controls NNS P
. . P

For IN N
both DT N
groups NNS N
the DT N
P2 NNP N
and CC N
N250 NNP N
were VBD N
sensitive JJ N
to TO N
repetition VB N
(Other RB N
vs NN N
. . N

Novels) NN N
and CC N
personal JJ N
familiarity NN N
(Familiar NNP N
vs NN N
. . N

Other) NNP N
and CC N
the DT N
face-N400 NN N
was VBD N
sensitive JJ N
to TO N
repetition NN N
. . N

Adults NNS P
with IN P
ASD NNP P
did VBD N
not RB N
show VB N
significantly RB N
atypical JJ N
processing NN O
of IN O
facial JJ O
familiarity NN O
and CC O
repetition NN O
in IN N
an DT N
ERP NNP N
paradigm NN N
despite IN N
showing VBG N
significantly RB N
poorer JJR N
performance NN N
than IN N
controls NNS I
on IN N
a DT N
behavioral JJ N
test NN N
of IN N
face NN N
memory NN N
. . N

This DT N
study NN N
found VBD N
no DT N
evidence NN N
that IN N
early-stage JJ I
facial JJ I
identity NN I
processing NN I
is VBZ N
a DT N
primary JJ N
contributor NN N
to TO N
the DT N
face NN N
recognition NN N
deficit NN N
in IN N
high-functioning JJ P
ASD NNP P
. . P

-DOCSTART- -X- N

A DT N
controlled VBN N
comparison NN N
between IN N
single JJ N
doses NNS N
of IN N
intravenous JJ I
and CC I
intramuscular JJ I
morphine NN I
with IN N
respect NN N
to TO N
analgesic JJ O
effects NNS O
and CC O
patient JJ O
safety NN O
. . O

UNLABELLED VBN N
BACKGROUND NNP N
AND NNP N
AIM NNP N
OF NNP N
INVESTIGATION: NNP N
Intramuscular NNP N
(IM) NNP N
administration NN N
has VBZ N
been VBN N
considered VBN N
to TO N
be VB N
safer JJR N
than IN N
intravenous JJ N
(IV) NN N
for IN N
opioids NNS I
on IN N
wards NNS N
but CC N
a DT N
comparative JJ N
knowledge NN N
of IN N
patient JJ O
safety NN O
and CC O
analgesic JJ O
potency NN O
following VBG N
a DT N
single JJ N
dose NN N
of IN N
IV NNP N
and CC N
IM NNP N
administration NN N
is VBZ N
lacking VBG N
. . N

This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
compare VB N
patient JJ O
safety NN O
and CC O
analgesic JJ O
efficacy NN O
of IN N
a DT N
single JJ N
and CC N
high JJ N
dose NN N
of IN N
morphine NN I
given VBN I
IM NNP I
or CC I
IV NNP I
for IN N
post-operative JJ N
pain NN N
management NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Thirty-eight NNP P
patients NNS P
with IN P
post-operative JJ P
pain NN P
following VBG P
hip NN P
replacement NN P
surgery NN P
were VBD N
given VBN N
IM NNP I
or CC I
IV NNP I
morphine VBP I
10 CD I
mg NN I
at IN N
a DT N
specified JJ N
pain NN N
level NN N
. . N

The DT N
study NN N
was VBD N
randomized VBN N
and CC N
double JJ N
blinded VBN N
. . N

Time NN O
to TO O
onset VB O
of IN O
analgesic JJ O
effect NN O
(11-point JJ O
numeric JJ O
rating NN O
scale) NN O
respiratory JJ O
function NN O
(p(a)CO2 NNP O
p(a)O2 NN O
and CC O
respiratory NN O
rate) VBP O
level NN O
of IN O
sedation NN O
(5-point NN O
verbal NN O
rating NN O
scale) NN O
and CC O
hemodynamic JJ O
function NN O
were VBD N
recorded VBN N
. . N

RESULTS NN N
In IN N
the DT N
IV NNP N
group NN N
there EX N
was VBD N
a DT N
slight JJ N
but CC N
significant JJ N
increase NN N
in IN N
p(a)CO2 NN O
after IN N
5 CD N
10 CD N
and CC N
15 CD N
min NNS N
compared VBN N
with IN N
the DT N
IM NNP N
group NN N
(5.2 NNP N
vs NN N
. . N

4.8 CD N
5.4 CD N
vs NN N
. . N

5.0 CD N
and CC N
5.5 CD N
vs NN N
. . N

5.1 CD N
kPa NN N
respectively) NN N
. . N

The DT N
IV NNP N
group NN N
had VBD N
a DT N
significantly RB N
faster RBR N
onset NN O
of IN O
analgesic JJ O
effect NN O
than IN N
the DT N
IM NNP N
group NN N
(5 NNP N
vs NN N
. . N

20 CD N
min) NN N
. . N

Between JJ N
5 CD N
and CC N
25 CD N
min NN N
after IN N
morphine JJ I
administration NN N
pain NN O
status NN O
in IN N
the DT N
IV NNP N
group NN N
was VBD N
significantly RB N
improved VBN N
compared VBN N
with IN N
the DT N
IM NNP N
group NN N
. . N

Patients NNS N
in IN N
the DT N
IV NNP N
group NN N
were VBD N
slightly RB N
more RBR N
sedated JJ O
than IN N
the DT N
IM NNP N
group NN N
5 CD N
and CC N
10 CD N
min NN N
after IN N
morphine NN N
. . N

CONCLUSION NNP N
A DT N
10 CD N
mg NN N
bolus NN N
dose NN N
of IN N
IV NNP N
morphine NN N
given VBN N
to TO N
patients NNS N
with IN N
moderate JJ N
pain NN N
after IN N
surgery NN I
does VBZ N
not RB N
cause VB N
severe JJ O
respiratory NN O
depression NN O
but CC O
provides VBZ N
more RBR N
rapid JJ N
and CC N
better RBR N
initial JJ O
analgesia NN O
than IN N
10 CD N
mg NNS N
given VBN N
IM NNP N
. . N

IV NNP N
morphine NN I
even RB N
at IN N
a DT N
dose NN N
as RB N
high JJ N
as IN N
10 CD N
mg NN N
IV NNP N
is VBZ N
well RB N
tolerated VBN N
if IN N
there EX N
is VBZ N
a DT N
certain JJ N
level NN N
of IN N
pain NN N
at IN N
its PRP$ N
administration NN N
. . N

The DT N
safety NN N
of IN N
IV NNP N
morphine NN I
on IN N
the DT N
general JJ N
ward NN N
needs VBZ N
to TO N
be VB N
further RB N
explored VBN N
in IN N
adequately RB N
controlled JJ N
studies NNS N
. . N

-DOCSTART- -X- N

Randomized VBN N
controlled VBD N
study NN N
of IN N
chemoprophylaxis NN N
in IN N
transurethral JJ P
prostatectomy NN P
. . P

We PRP N
studied VBD N
599 CD P
evaluable JJ P
patients NNS P
with IN P
benign JJ P
prostatic JJ P
hypertrophy NN P
at IN P
7 CD P
urological JJ P
units NNS P
. . P

Before IN N
transurethral JJ P
prostatectomy NN P
the DT N
patients NNS N
were VBD N
randomized VBN N
into IN N
3 CD N
groups: JJ P
group NN P
1--197 JJ P
patients NNS P
given VBN P
single-dose JJ P
ceftriaxone NN P
(2 NNP P
gm.) NN P
group NN P
2--203 JJ P
patients NNS P
given VBN P
160/800 CD P
mg NN P
. . P

trimethoprimsulfamethoxazole NN N
and CC P
group NN P
3--199 JJ P
controls NNS P
given VBN P
no DT P
antimicrobial JJ P
prophylaxis NN P
. . P

Patients NNS P
with IN P
a DT P
preoperative JJ P
indwelling NN P
catheter NN P
positive JJ P
urine JJ P
culture NN P
signs NNS P
of IN P
active JJ P
infection NN P
or CC P
preoperative JJ P
antibiotic JJ P
treatment NN P
were VBD P
excluded VBN P
. . P

Postoperative NNP O
infectious JJ O
complications NNS O
were VBD N
demonstrated VBN N
in IN N
15 CD N
of IN N
197 CD N
(7.6%) JJ N
25 CD N
of IN N
203 CD N
(12.3%) NNS N
and CC N
43 CD N
of IN N
199 CD N
(21.6%) JJ N
patients NNS N
in IN N
the DT N
study NN N
groups NNS N
respectively RB N
. . N

The DT N
difference NN N
in IN N
infectious JJ O
complications NNS O
between IN N
groups NNS N
1 CD N
and CC N
3 CD N
was VBD N
statistically RB N
highly RB N
significant JJ N
(p NNP N
< NNP N
0.01) CD N
and CC N
between IN N
groups NNS N
2 CD N
and CC N
3 CD N
it PRP N
was VBD N
significant JJ N
(p NNP N
< NNP N
0.05) CD N
. . N

Single-dose JJ N
antibiotic JJ N
prophylaxis NN N
proved VBD N
to TO N
be VB N
useful JJ N
in IN N
the DT N
prevention NN N
of IN N
serious JJ N
infectious JJ O
complications NNS O
after IN N
transurethral JJ P
prostatectomy NN P
. . P

-DOCSTART- -X- N

Impact NN N
of IN N
a DT N
16-community JJ P
trial NN P
to TO P
promote VB P
judicious JJ P
antibiotic JJ P
use NN P
in IN P
Massachusetts NNP P
. . P

OBJECTIVES NNP N
Reducing NNP N
unnecessary JJ N
antibiotic JJ I
use NN N
particularly RB N
among IN N
children NNS N
continues VBZ N
to TO N
be VB N
a DT N
public JJ N
health NN N
priority NN N
. . N

Previous JJ N
intervention NN N
studies NNS N
have VBP N
been VBN N
limited VBN N
by IN N
size NN N
or CC N
design NN N
and CC N
have VBP N
shown VBN N
mixed JJ N
results NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
impact NN N
of IN N
a DT N
multifaceted JJ I
community-wide JJ I
intervention NN I
on IN I
overall JJ I
antibiotic JJ I
use NN I
for IN N
young JJ P
children NNS P
and CC N
on IN N
use NN N
of IN N
broad-spectrum JJ N
agents NNS N
. . N

In IN N
addition NN N
we PRP N
sought VBD N
to TO N
compare VB N
the DT N
intervention's JJ N
impact NN N
on IN N
commercially RB P
and CC P
Medicaid-insured JJ P
children NNS P
. . P

METHODS NNP N
We PRP N
conducted VBD N
a DT N
controlled VBN N
community-level NN P
cluster-randomized JJ P
trial NN P
in IN P
16 CD P
nonoverlapping VBG P
Massachusetts NNP P
communities NNS P
studied VBN P
from IN P
1998 CD P
to TO P
2003 CD P
. . P

During IN N
3 CD N
years NNS N
we PRP N
implemented VBD N
a DT N
physician JJ I
behavior-change NN I
strategy NN I
that WDT I
included VBD I
guideline JJ I
dissemination NN I
small-group JJ I
education NN I
frequent NN I
updates NNS I
and CC I
educational JJ I
materials NNS I
and CC I
prescribing VBG I
feedback NN I
. . I

Parents NNS I
received VBD I
educational JJ I
materials NNS I
by IN I
mail NN I
and CC I
in IN I
primary JJ I
care NN I
practices NNS I
pharmacies NNS I
and CC I
child NN I
care NN I
settings NNS I
. . I

Using VBG N
health-plan JJ I
data NNS I
we PRP I
measured VBD N
changes NNS N
in IN N
antibiotics NNS I
dispensed VBN N
per IN N
person-year NN N
of IN N
observation NN N
among IN N
children NNS P
who WP P
were VBD P
aged VBN P
3 CD P
to TO P
<72 VB P
months NNS P
resided VBN P
in IN P
study NN P
communities NNS P
and CC P
were VBD P
insured VBN P
by IN P
a DT P
participating VBG P
commercial JJ P
health NN P
plan NN P
or CC P
Medicaid NNP P
. . P

RESULTS VB N
The DT N
data NNS N
include VBP N
223 CD P
135 CD P
person-years NNS P
of IN P
observation NN P
. . P

Antibiotic-use JJ O
rates NNS O
at IN N
baseline NN N
were VBD N
2.8 CD N
1.7 CD N
and CC N
1.4 CD N
antibiotics NNS N
per IN N
person-year NN N
among IN N
those DT N
aged VBN N
3 CD N
to TO N
<24 VB N
24 CD N
to TO N
<48 VB N
and CC N
48 CD N
to TO N
<72 VB N
months NNS N
respectively RB N
. . N

We PRP N
observed VBD N
a DT N
substantial JJ N
downward JJ N
trend NN N
in IN N
antibiotic JJ O
prescribing VBG N
even RB N
in IN N
the DT N
absence NN N
of IN N
intervention NN N
. . N

The DT N
intervention NN N
had VBD N
no DT N
additional JJ N
effect NN N
among IN N
children NNS P
aged VBD P
3 CD P
to TO P
<24 VB P
months NNS N
but CC N
was VBD N
responsible JJ N
for IN N
a DT N
4.2% CD N
decrease NN N
among IN N
those DT N
aged VBN P
24 CD P
to TO P
<48 VB P
months NNS N
and CC N
a DT N
6.7% CD N
decrease NN N
among IN N
those DT N
aged VBN N
48 CD N
to TO N
<72 VB N
months NNS N
. . N

The DT N
intervention NN N
effect NN N
was VBD N
greater JJR N
among IN N
Medicaid-insured JJ P
children NNS P
and CC N
for IN N
broad-spectrum JJ N
agents NNS N
. . N

CONCLUSIONS VB N
A DT N
sustained JJ N
multifaceted VBN N
community-level JJ N
intervention NN N
was VBD N
only RB N
modestly RB N
successful JJ N
at IN N
decreasing VBG N
overall JJ N
antibiotic JJ I
use NN N
beyond IN N
substantial JJ N
secular JJ N
trends NNS N
. . N

The DT N
more JJR N
robust JJ N
impact NN N
among IN N
Medicaid-insured JJ P
children NNS P
and CC N
for IN N
specific JJ N
medication NN N
classes NNS N
provides VBZ N
an DT N
argument NN N
for IN N
specific JJ N
targeting NN N
of IN N
resources NNS N
for IN N
patient NN I
and CC I
physician JJ I
behavior NN I
change NN I
. . I

-DOCSTART- -X- N

Home-based JJ I
reach-to-grasp JJ I
training NN P
for IN P
people NNS P
after IN P
stroke: NN P
study NN P
protocol NN P
for IN N
a DT N
feasibility NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
This DT N
feasibility NN N
study NN N
is VBZ N
intended VBN N
to TO N
assess VB N
the DT N
acceptability NN N
of IN N
home-based JJ I
task-specific JJ I
reach-to-grasp JJ I
(RTG) NN I
training NN I
for IN N
people NNS P
with IN P
stroke NN P
and CC P
to TO N
gather VB N
data NNS N
to TO N
inform VB N
recruitment JJ N
retention NN N
and CC N
sample NN N
size NN N
for IN N
a DT N
definitive JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

METHODS/DESIGN NNP N
This DT N
is VBZ N
to TO N
be VB N
a DT N
randomized JJ N
controlled JJ N
feasibility NN N
trial NN N
recruiting VBG N
50 CD P
individuals NNS P
with IN P
upper-limb JJ P
motor NN P
impairment NN P
after IN P
stroke NN P
. . P

Participants NNS P
will MD P
be VB P
recruited VBN P
after IN P
discharge NN P
from IN P
hospital NN P
and CC P
up RB P
to TO P
12 CD P
months NNS P
post-stroke RB P
from IN P
hospital NN P
stroke NN P
services NNS P
and CC P
community NN P
therapy-provider NN P
services NNS P
. . P

Participants NNS N
will MD N
be VB N
assessed VBN N
at IN N
baseline NN N
and CC N
then RB N
electronically RB N
randomized VBN N
and CC N
allocated VBN N
to TO N
group NN N
by IN N
minimization NN N
based VBN N
on IN N
the DT N
time NN N
post-stroke JJ N
and CC N
extent NN N
of IN N
upper-limb JJ N
impairment NN N
. . N

The DT N
intervention NN N
group NN N
will MD N
receive VB I
14 CD I
training NN I
sessions NNS I
each DT I
1 CD I
hour NN I
long RB I
with IN I
a DT I
physiotherapist NN I
over IN I
6 CD I
weeks NNS I
and CC I
will MD I
be VB I
encouraged VBN I
to TO I
practice NN I
independently RB I
for IN I
1 CD I
hour/day NN I
to TO I
give VB I
a DT I
total NN I
of IN I
56 CD I
hours NNS I
of IN I
training NN I
time NN I
per IN I
participant NN I
. . I

Participants NNS N
allocated VBD N
to TO N
the DT N
control NN I
group NN N
will MD N
receive VB N
arm NN I
therapy NN I
in IN I
accordance NN I
with IN I
usual JJ I
care NN I
. . I

Participants NNS N
will MD N
be VB N
measured VBN N
at IN N
7 CD N
weeks NNS N
post-randomization NN N
and CC N
followed-up NN N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
post-randomization NN N
. . N

Primary JJ N
outcome NN N
measures NNS N
for IN N
assessment NN N
of IN N
arm NN N
function NN N
are VBP N
the DT N
Action NNP O
Research NNP O
Arm NNP O
Test NNP O
(ARAT) NN O
and CC O
Wolf NNP O
Motor NNP O
Function NNP O
Test NNP O
(WMFT) NN O
. . O

Secondary JJ N
measures NNS N
are VBP N
the DT N
Motor NNP O
Activity NNP O
Log NNP O
Stroke NNP O
Impact NNP O
Scale NNP O
Carer NNP O
Strain NNP O
Index NNP O
and CC O
health NN O
and CC O
social JJ O
care NN O
resource NN O
use NN O
. . O

All DT N
assessments NNS N
will MD N
be VB N
conducted VBN N
by IN N
a DT N
trained JJ N
assessor NN N
blinded VBD N
to TO N
treatment NN N
allocation NN N
. . N

Recruitment JJ O
adherence NN O
withdrawals NNS O
adverse JJ O
events NNS O
(AEs) NN O
and CC O
completeness NN O
of IN O
data NNS O
will MD N
be VB N
recorded VBN N
and CC N
reported VBN N
. . N

DISCUSSION NN N
This DT N
study NN N
will MD N
determine VB N
the DT N
acceptability NN N
of IN N
the DT N
intervention NN N
the DT N
characteristics NNS N
of IN N
the DT N
population NN N
recruited VBD N
recruitment NN N
and CC N
retention NN N
rates NNS N
descriptive VBP N
statistics NNS N
of IN N
outcomes NNS N
and CC N
incidence NN N
of IN N
AEs NNP N
. . N

It PRP N
will MD N
provide VB N
the DT N
information NN N
needed VBN N
for IN N
planning VBG N
a DT N
definitive JJ N
trial NN N
to TO N
test VB N
home-based JJ I
RTG NNP I
training NN I
. . I

TRIAL NNP N
REGISTRATION NNP N
ISRCTN NNP N
ISRCTN56716589 NNP N
. . N

-DOCSTART- -X- N

Effect NN N
of IN N
propranolol NN I
on IN N
facial JJ N
scanning NN N
in IN N
autism NN P
spectrum NN P
disorder: VBZ P
a DT N
preliminary JJ N
investigation NN N
. . N

BACKGROUND NNP N
Autism NNP P
spectrum VBD P
disorder NN P
(ASD) NN P
is VBZ N
a DT N
neurodevelopmental JJ N
disorder NN N
characterized VBN N
by IN N
social JJ N
communication NN N
impairments NNS N
and CC N
restricted VBD N
repetitive JJ N
behaviors NNS N
. . N

Whereas NNP N
current JJ N
pharmacological JJ I
interventions NNS I
for IN I
ASD NNP I
focus VBP N
primarily RB N
on IN N
psychiatric JJ N
symptoms NNS N
including VBG N
agitation NN N
and CC N
obsessive JJ N
behaviors NNS N
few JJ N
agents NNS N
target VB N
core NN N
symptomatology NN N
. . N

It PRP N
has VBZ N
been VBN N
previously RB N
hypothesized VBN N
that IN N
abnormalities NNS N
in IN N
facial JJ N
scanning NN N
such JJ N
as IN N
reduced JJ N
eye NN N
contact NN N
or CC N
increased VBN N
mouth JJ N
fixation NN N
contribute NN N
to TO N
social JJ N
communication NN N
deficits NNS N
in IN N
ASD NNP N
. . N

In IN N
addition NN N
previous JJ N
reports NNS N
have VBP N
suggested VBN N
elevated JJ N
stress NN N
and CC N
anxiety NN N
in IN N
ASD NNP N
symptoms NNS N
that WDT N
are VBP N
believed VBN N
to TO N
impact VB N
facial JJ N
scanning NN N
patterns NNS N
. . N

OBJECTIVES IN N
The DT I
present JJ I
pilot NN I
study NN I
sought VBD I
to TO I
explore VB I
the DT I
effects NNS I
of IN I
pharmacological JJ I
intervention NN I
via IN I
propranolol NN I
a DT I
nonselective JJ I
-adrenergic JJ I
antagonist NN I
and CC I
known VBN I
anxiolytic JJ I
on IN I
facial JJ I
scanning NN I
in IN I
ASD NNP I
. . I

Specifically RB I
we PRP I
wished VBD I
to TO I
determine VB I
whether IN I
there EX I
is VBZ I
an DT I
increase NN I
in IN I
eye NN I
contact NN I
and CC I
a DT I
decrease NN I
in IN I
mouth JJ I
fixation NN I
with IN I
administration NN I
of IN I
propranolol NN I
. . I

METHOD NNP P
A NNP P
sample NN P
of IN P
14 CD P
participants NNS P
with IN P
ASD NNP P
and CC P
14 CD P
matched VBD P
controls NNS P
participated VBN P
in IN I
two CD I
study NN I
sessions NNS I
in IN I
which WDT I
propranolol NN I
and CC I
placebo NN I
were VBD I
administered VBN I
in IN I
a DT I
counterbalanced JJ I
double-blinded JJ I
manner NN I
. . I

At IN I
each DT I
session NN I
ocular JJ I
fixation NN I
data NNS I
were VBD I
collected VBN I
during IN I
presentation NN I
of IN I
video JJ I
stimuli NNS I
of IN I
16 CD I
human JJ I
faces VBZ I
. . I

Fixation NN I
time NN I
on IN I
the DT I
eye NN I
nose NN I
and CC I
mouth JJ I
regions NNS I
of IN I
the DT I
face NN I
stimuli NN I
was VBD I
analyzed VBN I
. . N

RESULTS VB N
The DT N
baseline JJ N
fixation NN N
patterns NNS N
for IN N
the DT P
ASD NNP P
and CC P
control NN P
groups NNS P
did VBD N
not RB N
significantly RB N
differ; VB N
however RB I
administration NN I
of IN I
propranolol NN I
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN O
mouth NN O
fixation NN O
for IN N
the DT P
ASD NNP P
group NN P
. . N

Additionally RB N
mouth JJ N
fixation NN N
was VBD N
positively RB N
related VBN N
to TO N
nonverbal JJ N
communication NN N
impairment NN N
in IN N
the DT N
ASD NNP N
group NN N
. . N

CONCLUSIONS NNP N
Although IN N
eye NN N
fixation NN N
in IN N
ASD NNP N
appears VBZ N
typical JJ N
in IN N
the DT N
present JJ N
study NN N
the DT N
effect NN N
of IN I
propranolol NN I
in IN N
reducing VBG N
mouth JJ N
fixation NN N
suggests VBZ N
an DT N
important JJ N
focus NN N
for IN N
further JJ N
research NN N
. . N

Future JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
better RBR N
characterize VB N
the DT N
relationship NN N
between IN N
stress NN N
and CC N
anxiety NN N
and CC N
facial JJ N
scanning NN N
in IN N
ASD NNP N
as RB N
well RB N
as IN N
the DT N
effects NNS N
of IN I
pharmacological JJ I
intervention NN I
. . N

-DOCSTART- -X- N

Avatar NNP I
assistant: VBZ I
improving VBG N
social JJ O
skills NNS O
in IN N
students NNS P
with IN P
an DT P
ASD NNP P
through IN N
a DT N
computer-based JJ I
intervention NN I
. . I

This DT N
study NN N
assessed VBD N
the DT N
efficacy NN O
of IN I
FaceSay NNP I
a DT I
computer-based JJ I
social JJ O
skills NNS O
training VBG I
program NN I
for IN I
children NNS P
with IN P
Autism NNP P
Spectrum NNP P
Disorders NNP P
(ASD) NNP P
. . P

This DT N
randomized VBD N
controlled VBN N
study NN P
(N=49) NN P
indicates VBZ N
that IN N
providing VBG P
children NNS P
with IN P
low-functioning JJ P
autism NN P
(LFA) NNP P
and CC P
high JJ P
functioning NN P
autism NN P
(HFA) NNP P
opportunities VBZ N
to TO I
practice NN I
attending VBG I
to TO I
eye NN I
gaze NN I
discriminating VBG I
facial JJ I
expressions NNS I
and CC I
recognizing VBG I
faces VBZ I
and CC I
emotions NNS I
in IN N
FaceSay's NNP N
structured VBD N
environment NN N
with IN N
interactive JJ N
realistic JJ I
avatar NN I
assistants NNS I
improved VBD N
their PRP$ O
social JJ O
skills NNS O
abilities NNS O
. . N

The DT P
children NNS P
with IN P
LFA NNP P
demonstrated VBD N
improvements NNS N
in IN N
two CD N
areas NNS N
of IN N
the DT N
intervention: JJ O
emotion NN O
recognition NN O
and CC O
social JJ O
interactions NNS O
. . N

The DT P
children NNS P
with IN P
HFA NNP P
demonstrated VBD N
improvements NNS N
in IN N
all DT N
three CD N
areas: NNS O
facial JJ O
recognition NN O
emotion NN O
recognition NN O
and CC O
social JJ O
interactions NNS O
. . N

These DT N
findings NNS N
particularly RB N
the DT N
measured JJ N
improvements NNS N
to TO N
social JJ N
interactions NNS N
in IN N
a DT N
natural JJ N
environment NN N
are VBP N
encouraging VBG N
. . N

-DOCSTART- -X- N

Direct JJ I
trocar NN I
insertion NN I
vs NN I
. . I

Verres NNS I
needle VBP I
use NN I
for IN N
laparoscopic JJ P
sterilization NN P
. . P

A DT P
randomized JJ P
prospective JJ P
trial NN P
was VBD P
designed VBN P
to TO P
compare VB P
direct JJ P
trocar NN P
insertion NN P
with IN P
prior JJ P
peritoneal JJ P
insufflation NN P
with IN P
a DT P
Verres NNP P
needle NN P
for IN P
laparoscopic NN P
tubal JJ P
sterilization NN P
. . P

Direct JJ I
trocar NN I
insertion NN I
resulted VBD N
in IN N
fewer JJR N
instrument NN O
insertions NNS O
(21.8% VBP N
vs NN N
. . N

7.8%) CD N
and CC N
use NN N
of IN N
smaller JJR N
volumes NNS O
of IN O
CO2 NNP O
(2.67 NNP N
vs NN N
. . N

2.32 CD N
L) NNP N
. . N

Direct JJ I
trocar NN I
use NN I
resulted VBD N
in IN N
a DT N
decrease NN N
in IN N
operating NN O
time NN O
from IN N
9 CD N
minutes NNS N
40 CD N
seconds NNS N
in IN N
the DT N
needle JJ N
group NN N
to TO N
7 CD N
minutes NNS N
30 CD N
seconds NNS N
in IN N
the DT N
trocar NN P
group NN P
. . P

Minor NNP O
omental JJ O
injuries NNS O
occurred VBD N
in IN N
a DT N
small JJ N
percentage NN N
of IN N
each DT N
group NN N
while IN N
serious JJ N
complications NNS N
occurred VBD N
once RB N
in IN N
each DT N
group NN N
. . N

-DOCSTART- -X- N

Hexetidine NNP I
('Oraldene'): VBZ I
a DT N
report NN N
on IN N
its PRP$ N
antibacterial JJ O
and CC O
antifungal JJ O
properties NNS O
on IN N
the DT N
oral JJ N
flora NNS N
in IN N
healthy JJ P
subjects NNS P
. . P

A DT P
randomized JJ N
double-blind NN N
crossover NN N
trial NN N
in IN N
10 CD P
adult NN P
healthy JJ P
subjects NNS P
was VBD P
carried VBN P
out IN P
to TO P
compare VB N
the DT N
antibacterial JJ O
and CC O
antifungal JJ O
activity NN O
of IN N
a DT N
0.1% CD I
solution NN I
of IN I
hexetidine NN I
with IN P
that DT P
of IN P
placebo NN P
. . P

The DT N
pre-dosing JJ N
oral JJ N
flora NN N
of IN N
the DT N
subjects NNS N
was VBD N
assessed VBN N
from IN N
saliva NN O
samples NNS O
cultured VBD N
for IN N
aerobic JJ O
and CC O
anaerobic JJ O
bacteria NNS O
as RB O
well RB N
as IN N
Candida NNP O
albicans NNS O
. . O

Subjects NNS N
then RB N
rinsed VBD N
their PRP$ N
mouths NNS N
for IN N
1 CD N
minute JJ N
3-times NNS N
a DT N
day NN N
with IN N
15 CD N
ml NNS N
0.1% CD I
hexetidine NN I
or CC I
placebo NN I
saliva NN I
samples NNS N
being VBG N
collected VBN N
at IN N
2 CD N
minutes NNS N
30 CD N
minutes NNS N
1 CD N
hour NN N
3 CD N
hours NNS N
and CC N
5 CD N
hours NNS N
post-dosing JJ N
. . N

Dosing NN N
was VBD N
continued VBN N
for IN N
8 CD N
consecutive JJ N
days NNS N
on IN N
each DT N
treatment NN N
with IN N
an DT N
intervening VBG N
wash-out JJ N
period NN N
of IN N
1 CD N
week NN N
. . N

Hexetidine NNP I
reduced VBD N
aerobic JJ O
bacterial JJ O
counts NNS O
on IN N
Day NNP N
1 CD N
and CC N
Day NNP N
8 CD N
by IN N
a DT N
maximum NN N
of IN N
83% CD N
and CC N
86% CD N
respectively RB N
at IN N
2 CD N
minutes NNS N
post-dosing JJ N
. . N

The DT N
reductions NNS N
were VBD N
statistically RB N
significantly RB N
lower JJR N
than IN N
placebo VB I
up IN N
to TO N
1 CD N
hour NN N
post-dose JJ N
on IN N
Day NNP N
1 CD N
and CC N
up RB N
to TO N
3 CD N
hours NNS N
post-dose JJ N
on IN N
Day NNP N
8 CD N
. . N

Similarly RB N
for IN N
anaerobic JJ O
bacterial JJ O
counts NNS O
92% CD O
and CC N
88% CD N
maximum JJ N
reductions NNS N
were VBD N
recorded VBN N
on IN N
Day NNP N
1 CD N
and CC N
Day NNP N
8 CD N
which WDT N
again RB N
were VBD N
significantly RB N
lower JJR N
than IN N
placebo NN I
for IN N
up IN N
to TO N
3 CD N
hours NNS N
post-dose JJ N
. . N

For IN N
Candida NNP O
albicans NNS O
however RB O
the DT N
maximum JJ N
reduction NN N
was VBD N
91% CD N
on IN N
the DT N
first JJ N
day NN N
and CC N
67% CD N
on IN N
Day NNP N
8 CD N
maintained VBD N
for IN N
30 CD N
minutes NNS N
post-dosing JJ N
. . N

Although IN N
not RB N
eradicating VBG O
completely RB O
aerobic JJ O
and CC O
anaerobic JJ O
bacteria NNS O
it PRP O
is VBZ N
concluded VBN N
that IN N
the DT N
substantial JJ N
reduction NN O
in IN N
their PRP$ N
numbers NNS N
should MD N
prove VB N
clinically RB N
useful JJ N
. . N

-DOCSTART- -X- N

[Tocolysis NN N
with IN N
hexoprenalin NN I
and CC N
salbutamol NN I
in IN N
a DT N
clinical JJ N
comparison] NN N
. . P

140 CD P
patients NNS P
with IN P
a DT P
threatening JJ P
premature NN P
birth NN P
at IN P
the DT P
greater JJR P
than IN P
or CC P
equal JJ P
to TO P
24-less JJ P
than IN P
37 CD P
week NN P
of IN P
gestation NN P
were VBD N
in IN N
this DT N
study NN N
randomly RB N
treated VBN N
with IN N
hexoprenalin NN I
or CC I
salbutamol NN I
. . I

In IN N
77% CD P
in IN P
the DT P
hexoprenalin NN P
and CC P
in IN P
74% CD P
in IN P
the DT P
salbutamol NN P
group NN P
the DT P
weight NN P
of IN P
the DT P
newborn NN P
was VBD P
greater JJR P
than IN P
or CC P
equal JJ P
to TO P
2500 CD N
g NN N
. . N

In IN N
66% CD P
in IN P
both DT P
study NN P
groups NNS P
the DT N
birth NN N
occurred VBD N
after IN N
the DT N
completed VBN N
37 CD N
weeks NNS O
of IN O
gestation NN O
. . O

During IN N
infusion NN N
of IN N
hexoprenalin JJ I
tachycardia NN O
in IN N
mothers NNS N
occurred VBD N
statistically RB N
highly RB N
significantly RB N
less JJR N
than IN N
during IN N
salbutamol NN I
. . I

11% CD P
of IN P
the DT P
mothers NNS P
in IN P
the DT P
hexoprenalin NN P
group NN P
had VBD P
side-effects NNS P
during IN P
infusion NN P
compared VBN P
to TO P
30% CD P
in IN P
the DT P
salbutamol NN P
group NN P
. . P

The DT N
correlation NN N
between IN N
the DT N
tocolysis-index NN O
(Baumgarten) NN O
and CC N
the DT N
prolongation-index NN O
(Richter) NNP O
given VBN N
by IN N
the DT N
regression NN N
lines NNS N
facilitates NNS N
in IN N
some DT N
measure NN N
the DT N
comparison NN N
of IN N
different JJ N
tocolytic JJ I
drugs NNS I
concerning VBG N
its PRP$ N
tocolytic JJ N
effect NN N
. . N

-DOCSTART- -X- N

The DT N
role NN N
of IN N
nasal JJ I
IgA NNP I
in IN N
children NNS P
vaccinated VBN P
with IN P
live JJ P
attenuated VBN P
influenza JJ P
vaccine NN P
. . P

BACKGROUND NNP N
Immunoglobulin NNP I
A NNP I
(IgA) NN I
is VBZ N
the DT N
predominant JJ N
antibody NN N
produced VBN N
in IN N
response NN N
to TO N
mucosal VB N
infections NNS N
. . N

The DT N
role NN N
of IN N
IgA NNP I
in IN N
providing VBG N
protection NN N
against IN N
influenza NN N
in IN N
children NNS P
vaccinated VBN P
with IN P
live JJ P
attenuated VBN P
influenza JJ P
vaccine NN P
(LAIV) NN P
has VBZ N
not RB N
been VBN N
well RB N
described VBN N
. . N

METHODS NNP N
Nasal NNP O
IgA NNP O
responses NNS O
were VBD N
assessed VBN N
using VBG N
data NNS N
from IN N
3 CD N
prospective JJ N
2-year JJ N
randomized JJ N
studies NNS N
comparing VBG N
LAIV NNP I
with IN N
placebo NN I
in IN N
children NNS P
6-36 JJ P
months NNS P
of IN P
age NN P
. . P

In IN N
each DT N
study NN N
samples NNS N
were VBD N
collected VBN N
in IN N
a DT N
subset NN N
of IN N
patients; NN N
a DT N
new JJ N
cohort NN N
was VBD N
enrolled VBN N
each DT N
year NN N
. . N

Ratios NNS N
of IN N
strain-specific JJ N
nasal JJ I
IgA NNP I
to TO N
total VB N
nasal JJ N
IgA NNP N
were VBD N
calculated VBN N
and CC N
prevaccination NN N
to TO N
postvaccination NN N
geometric JJ N
mean JJ N
fold-rises NNS N
(GMFRs) NNS N
were VBD N
evaluated VBN N
. . N

Mean JJ O
postvaccination NN O
IgA NNP O
ratios NNS O
were VBD N
compared VBN N
for IN N
subjects NNS N
with IN N
and CC N
without IN N
confirmed VBN N
influenza NN N
illness NN N
by IN N
study NN N
and CC N
in IN N
pooled JJ N
analyses NNS N
. . N

RESULTS NNP N
Across NNP N
studies NNS N
a DT N
higher JJR N
percentage NN N
of IN N
children NNS N
receiving VBG N
LAIV NNP I
had VBD N
a DT N
 JJ N
2-fold JJ N
increase NN N
in IN O
strain-specific JJ O
IgA NNP O
ratio NN O
compared VBN N
with IN N
placebo NN N
recipients NNS N
. . N

GMFRs NNP N
after IN I
LAIV NNP I
in IN N
years NNS N
1 CD N
and CC N
2 CD N
ranged VBD N
from IN N
1.2 CD N
to TO N
6.2 CD N
compared VBN N
with IN N
0.5-2.2 JJ N
among IN N
placebo JJ N
recipients NNS N
. . N

Similar JJ N
responses NNS N
were VBD N
observed VBN N
in IN N
subjects NNS N
who WP N
were VBD N
baseline JJ N
seronegative JJ N
and CC N
seropositive JJ N
based VBN N
on IN N
serum JJ N
hemagglutination NN N
inhibition NN N
antibody NN N
titers NNS N
. . N

In IN N
years NNS N
1 CD N
and CC N
2 CD N
the DT N
mean JJ N
postvaccination NN N
strain-specific NN N
to TO N
total JJ N
IgA NNP N
ratio NN N
was VBD N
3.1-fold JJ N
(P<0.01) NN N
and CC N
2.0-fold JJ N
(P<0.03) NN N
higher JJR N
among IN N
LAIV JJ N
recipients NNS N
with IN N
no DT N
evidence NN N
of IN N
culture-confirmed JJ N
influenza NN N
illness NN N
compared VBN N
with IN N
LAIV NNP N
recipients NNS N
who WP N
developed VBD N
culture-confirmed JJ N
influenza NN N
illness; VB N
a DT N
similar JJ N
and CC N
consistent JJ N
trend NN N
was VBD N
observed VBN N
for IN N
each DT N
individual NN N
study NN N
and CC N
type/subtype NN N
. . N

CONCLUSIONS VB N
The DT N
current JJ N
analysis NN N
demonstrates VBZ N
that IN N
nasal JJ N
IgA NNP N
contributes VBZ N
to TO N
the DT N
efficacy NN N
of IN I
LAIV NNP I
and CC N
can MD N
provide VB N
evidence NN N
of IN N
vaccine-induced JJ N
immunity NN N
. . N

However RB N
the DT N
inherent JJ N
heterogeneity NN N
in IN N
nasal JJ N
antibody NN N
levels NNS N
and CC N
variability NN N
in IN N
nasal JJ N
specimen NNS N
collection NN N
hinders VBZ N
the DT N
precise JJ N
evaluation NN N
of IN N
mucosal NN N
antibody NN N
responses NNS N
. . N

Other JJ N
studies NNS N
have VBP N
demonstrated VBN N
that IN I
LAIV-induced NNP I
immunity NN N
is VBZ N
also RB N
partially RB N
explained VBN N
by IN N
T-cell NNP N
immunity NN N
serum NN N
antibody NN N
responses NNS N
and CC N
innate VB N
immunity NN N
consistent NN N
with IN N
the DT N
multi-faceted JJ N
nature NN N
of IN N
immunity NN N
induced VBN N
by IN N
wild-type JJ N
influenza JJ N
infection NN N
and CC N
other JJ N
live JJ N
virus NN N
vaccines NNS N
. . N

-DOCSTART- -X- N

A DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ I
study NN N
of IN N
the DT N
efficacy NN O
and CC O
safety NN O
of IN N
2 CD N
doses NNS N
of IN N
vortioxetine NN I
in IN N
adults NNS P
with IN P
major JJ P
depressive JJ P
disorder NN P
. . P

BACKGROUND IN P
This DT N
8-week JJ N
randomized JJ N
double-blind JJ N
placebo-controlled JJ I
study NN N
conducted VBD N
August NNP N
2010-May JJ N
2012 CD N
in IN N
the DT N
United NNP N
States NNPS N
evaluated VBD N
the DT N
safety NN O
and CC O
efficacy NN O
of IN N
vortioxetine NN I
10 CD N
mg NN N
and CC N
15 CD N
mg NNS N
in IN N
patients NNS P
with IN P
major JJ P
depressive JJ P
disorder NN P
(MDD) NN P
. . P

The DT N
mechanism NN N
of IN N
action NN N
of IN N
vortioxetine NN I
is VBZ N
thought VBN N
to TO N
be VB N
related VBN N
to TO N
direct JJ N
modulation NN N
of IN N
serotonin JJ N
(5-HT) JJ N
receptor NN N
activity NN N
and CC N
inhibition NN N
of IN N
the DT N
serotonin NN N
transporter NN N
. . N

METHOD NNP N
Adults NNP P
aged VBD P
18-75 CD P
years NNS P
with IN P
MDD NNP P
(DSM-IV-TR) JJ P
and CC P
Montgomery-Asberg JJ P
Depression NNP P
Rating NNP P
Scale NNP P
(MADRS) NNP P
total JJ P
score NN P
 VBD I
26 CD P
were VBD P
randomized VBN P
(1:1:1) NN P
to TO P
receive VB P
vortioxetine NN P
10 CD P
mg NN P
or CC P
15 CD P
mg NN N
or CC I
placebo NN I
once RB N
daily JJ N
with IN N
the DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
being VBG N
change NN N
from IN N
baseline NN N
at IN N
week NN N
8 CD N
in IN N
MADRS NNP N
analyzed VBN N
by IN N
mixed JJ N
model NN N
for IN N
repeated JJ N
measures NNS N
. . O

Adverse JJ O
events NNS O
were VBD N
recorded VBN N
during IN N
the DT N
study NN O
suicidal JJ O
ideation NN O
and CC O
behavior NN O
were VBD N
assessed VBN N
using VBG N
the DT N
Columbia-Suicide JJ N
Severity NNP N
Rating NNP N
Scale NNP N
(C-SSRS) JJ N
and CC O
sexual JJ O
dysfunction NN O
was VBD N
assessed VBN N
using VBG N
the DT N
Arizona NNP N
Sexual NNP N
Experience NNP N
(ASEX) NNP N
scale NN N
. . N

RESULTS NN P
Of IN P
the DT P
1 CD P
111 CD P
subjects NNS P
screened VBD P
469 CD P
subjects NNS P
were VBD P
randomized: JJ P
160 CD P
to TO P
placebo VB P
157 CD P
to TO P
vortioxetine VB P
10 CD P
mg NN P
and CC P
152 CD P
to TO P
vortioxetine VB P
15 CD P
mg NN P
. . N

Differences NNS N
from IN I
placebo NN I
in IN N
the DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
were VBD N
not RB N
statistically RB N
significant JJ N
for IN I
vortioxetine NN I
10 CD N
mg NN N
or CC I
vortioxetine NN I
15 CD N
mg NN N
. . O

Nausea NNP O
headache NN O
dry JJ O
mouth NN O
constipation NN O
diarrhea NN O
vomiting VBG O
dizziness NN O
and CC O
flatulence NN O
were VBD N
reported VBN N
in IN N
 JJ N
5% CD N
of IN N
subjects NNS N
receiving VBG N
vortioxetine NN N
. . N

Discontinuation NN N
due JJ N
to TO N
adverse JJ N
events NNS N
occurred VBD N
in IN N
7 CD N
subjects NNS N
(4.4%) VBN N
in IN N
the DT I
placebo NN I
group NN N
8 CD N
(5.2%) NN N
in IN N
the DT I
vortioxetine NN I
10 CD N
mg NN N
group NN N
and CC N
12 CD N
(7.9%) NN N
in IN N
the DT I
vortioxetine NN I
15 CD N
mg NN N
group NN N
. . N

ASEX NNP N
total JJ N
scores NNS N
were VBD N
similar JJ N
across IN N
groups NNS N
. . N

There EX N
were VBD N
no DT N
clinically RB N
significant JJ N
trends NNS N
within IN N
or CC N
between IN N
treatment NN N
groups NNS N
on IN N
the DT N
C-SSRS NNP N
laboratory NN N
values NNS N
electrocardiogram VBP N
or CC N
vital JJ N
sign NN N
parameters NNS N
. . N

CONCLUSIONS NN N
In IN N
this DT N
study NN I
vortioxetine NN I
did VBD N
not RB N
differ VB N
significantly RB N
from IN I
placebo NN I
on IN N
MADRS NNP N
total NN N
score NN N
after IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
in IN N
MDD NNP N
subjects NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
identifier: NN N
NCT01179516 NNP N
. . N

-DOCSTART- -X- N

[Diabetic JJ P
constipation NN P
treated VBN N
with IN N
acupoint NN I
embedding VBG I
therapy NN I
and CC I
forlax: VB I
a DT N
randomized NN N
controlled VBN N
trial] NN N
. . N

OBJECTIVE NN N
To TO N
compare VB N
the DT N
difference NN N
among IN N
the DT N
combined JJ I
method NN I
of IN I
oral JJ I
administration NN I
of IN I
forlaxand NN I
acupoint NN I
embedding VBG I
therapy NN I
the DT I
simple JJ I
acupoint NN I
embedding VBG I
therapy NN I
and CC I
the DT I
simple JJ I
oral JJ I
administration NN I
of IN I
for-lax JJ I
in IN I
the DT N
clinical JJ N
efficacy NN N
on IN N
diabetic JJ P
constipation NN P
. . P

METHODS NNP N
One CD P
hundred CD P
and CC P
fifty JJ P
patients NNS P
were VBD P
randomized VBN P
intoa RB P
comprehensive JJ P
group NN P
an DT P
acupoint NN I
embedding VBG I
group NN I
and CC I
a DT I
forlax JJ I
group NN I
50 CD I
cases NNS N
in IN N
each DT N
one CD N
. . N

In IN N
the DT N
acupointembedding VBG I
group NN I
the DT I
embedding VBG I
therapy NN I
was VBD I
applied VBN I
to TO I
bilateral JJ I
Tianshu NNP I
(ST NNP I
25) CD I
Daheng NNP I
(SP VBD I
15) CD I
Shangjuxu(ST NNP I
37) CD I
and CC I
Dachangshu NNP I
(BL NNP N
25) CD N
once RB N
a DT N
week NN N
. . N

In IN N
the DT N
forlax NN I
group NN I
forlax VBD I
(polyethylene NNP I
glycol) NN I
was VBD N
prescribedfor JJ N
oral JJ N
administration NN N
once RB N
a DT N
day NN N
10 CD N
g NN N
each DT N
time NN N
. . N

In IN N
the DT N
comprehensive JJ I
group NN I
the DT I
acupoint NN I
embedding VBG I
therapyand NN I
forlax NNS I
were VBD I
combined VBN I
and CC I
the DT I
methods NNS I
were VBD I
the DT I
same JJ I
as IN I
the DT I
first JJ I
two CD I
groups NNS I
. . I

The DT N
treatment NN N
for IN N
4 CD N
weeks NNS N
wasas VBP N
one CD N
session NN N
and CC N
2 CD N
sessions NNS N
were VBD N
required VBN N
in IN N
the DT N
three CD N
groups NNS N
. . N

Separately RB N
in IN N
4 CD N
weeks NNS N
8 CD N
weeks NNS N
of IN N
treatment NN N
and2 JJ N
months NNS N
after IN N
treatment NN N
the DT N
constipation NN O
symptom NN O
scores NNS O
were VBD N
compared VBN N
among IN N
the DT N
three CD N
groups NNS N
. . N

At IN N
the DT N
end NN N
of2 NN N
sessions NNS N
of IN N
treatment NN N
the DT N
clinical JJ O
efficacy NN O
and CC O
adverse JJ O
reactions NNS O
were VBD N
compared VBN N
among IN N
the DT N
three CD N
groups NNS N
. . N

In2 NNP N
months NNS N
after IN N
treatment NN N
the DT N
recurrence NN N
rate NN N
was VBD N
compared VBN N
among IN N
the DT N
three CD N
groups NNS N
. . N

RESULTS VB N
The DT N
total JJ O
effectiverate NN O
was VBD N
98 CD N
. . N

0% CD N
(49/50) NN N
in IN N
the DT N
comprehensive JJ I
group NN I
better RBR I
than IN N
86 CD N
. . N

0% CD N
(43/50) NN N
in IN N
the DT N
acupoint NN I
embeddinggroup NN I
and CC N
78 CD N
. . N

0% CD N
(11/50) NN N
in IN N
the DT N
forlax NN I
group NN I
(both NNP N
P<0 NNP N
. . N

01) CD N
. . N

In IN N
the DT N
4 CD N
weeks NNS N
and CC N
8 CD N
weeks NNS N
of IN N
treatment NN N
the DT N
con-stipation NN O
symptom NN O
scores NNS O
were VBD N
reduced VBN N
significantly RB N
as IN N
compared VBN N
with IN N
those DT N
before IN N
treatment NN N
in IN N
the DT N
three CD N
groups(all NN N
P<0 NNP N
. . N

05) CD N
. . N

The DT N
results NNS N
in IN N
the DT N
comprehensive JJ I
group NN I
were VBD N
lower JJR N
than IN N
those DT N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
(all JJ N
P<0 NNP N
. . N

05) CD N
. . N

In IN N
the DT N
4 CD N
weeks NNS N
of IN N
treatment NN N
the DT N
scores NNS N
were VBD N
not RB N
different JJ N
significantly RB N
between IN N
the DT N
acupoint NN N
embedding VBG N
group NN N
and CC N
the DT N
forlax NN N
group NN N
(P>0.05) NNP N
. . N

In IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
and CC N
2 CD N
months NNS N
after IN N
treatment NN N
the DT N
scores NNS N
in IN N
the DT N
acupoint NN I
embedding VBG I
group NN I
were VBD N
better JJR N
tan NN N
those DT N
in IN N
the DT N
forlax NN N
group NN N
(all NNP N
p<0.05) NN N
. . N

There EX N
were VBD N
2 CD N
cases NNS N
of IN N
drug NN N
adverse JJ N
reaction NN N
in IN N
the DT N
comprehensive JJ I
group NN I
6 CD I
cases NNS N
in IN N
the DT N
forlax NN I
group NN I
and CC N
0 CD N
case NN N
in IN N
the DT N
acupoint NN I
embedding VBG I
group NN I
. . I

The DT N
recurrence NN O
rate NN O
was VBD N
8.1% CD N
(4/49) NN N
in IN N
the DT N
comprehensive JJ I
group NN I
lower JJR I
than IN N
32.6% CD N
(14/43) NN N
in IN N
the DT N
acupoint NN I
embedding VBG I
group NN I
and CC N
59.0% CD N
(23/39) NN N
in IN N
the DT N
forlax NN I
group NN I
(both NNP N
P<0.01) NNP N
. . N

CONCLUSION NNP N
the DT N
combined JJ I
therapy NN I
of IN I
acupoint NN I
embedding NN I
and CC I
forlax JJ I
achieves VBZ N
the DT N
better JJR N
clinical JJ N
efficacy NN N
on IN N
diabetic JJ P
constipation NN P
and CC P
constipation NN P
symptom NN O
scores VBZ O
as IN N
compared VBN N
with IN N
the DT N
simple JJ I
acupoint NN I
embedding VBG I
therapy NN I
and CC N
the DT N
oral JJ I
administration NN I
of IN I
forlax JJ I
the DT N
short-term JJ N
efficacy NN N
of IN N
the DT N
simple JJ N
acupoint NN N
embedding VBG N
therapy NN N
is VBZ N
not RB N
different JJ N
significantly RB N
from IN N
the DT N
simple JJ I
forlax JJ I
medication NN I
but CC I
the DT N
long-term JJ N
efficacy NN N
and CC N
safety NN N
are VBP N
better JJR N
than IN N
those DT N
of IN N
simple JJ N
forlax JJ N
medicaiton NN N
. . N

-DOCSTART- -X- N

Incidence NN N
and CC N
clinical JJ N
significance NN N
of IN N
false-negative JJ P
sextant JJ P
prostate NN P
biopsies NNS P
. . P

PURPOSE NNP N
Since IN N
most JJS N
patients NNS N
do VBP N
not RB N
undergo VB N
repeat NN N
sextant JJ I
prostate NN I
biopsies NNS I
after IN N
a DT N
biopsy NN N
is VBZ N
positive JJ N
for IN N
prostate NN N
cancer NN N
the DT N
true JJ N
incidence NN N
of IN N
false-negative JJ N
biopsies NNS N
is VBZ N
not RB N
well RB N
defined VBN N
. . N

We PRP N
assess VBP N
the DT N
incidence NN N
and CC N
clinical JJ N
significance NN N
of IN N
false-negative JJ P
sextant JJ P
prostate NN P
biopsies NNS P
in IN P
patients NNS P
undergoing VBG P
radical JJ P
prostatectomy NN P
. . P

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP P
total NN P
of IN P
118 CD P
patients NNS P
with IN P
biopsy NN P
proved VBN P
prostate JJ P
cancer NN P
underwent JJ N
repeat NN I
sextant JJ I
prostate NN I
biopsy NN I
before IN N
enrollment NN N
in IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
radical JJ I
prostatectomy NN I
with IN I
or CC I
without IN I
neoadjuvant JJ I
hormonal JJ I
therapy NN I
. . I

Clinical JJ O
parameters NNS O
were VBD N
assessed VBN N
to TO N
determine VB N
potential JJ N
sources NNS N
of IN N
bias NN N
. . N

Pathological JJ O
parameters NNS O
and CC O
prostate NN O
specific JJ O
antigen NN O
relapse-free JJ O
survival NN O
rates NNS O
were VBD N
compared VBN N
to TO N
determine VB N
the DT N
clinical JJ N
significance NN N
of IN N
false-negative JJ N
biopsies NNS N
. . N

RESULTS NN N
Of IN N
the DT N
118 CD P
patients NNS P
27 CD N
(23%) NNP N
had VBD N
a DT N
negative JJ O
repeat NN O
sextant JJ I
biopsy NN I
. . I

Except IN N
for IN N
initial JJ N
clinical JJ N
stage NN N
no DT O
differences NNS O
were VBD N
noted VBN N
in IN N
the DT N
clinical JJ O
or CC O
pathological JJ O
parameters NNS O
or CC O
prostate NN O
specific JJ O
antigen NN O
relapse NN O
rates NNS O
in IN N
patients NNS N
with IN N
negative JJ N
versus NN N
positive JJ N
repeat NN N
biopsies NNS I
. . I

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
suggest VBP N
that IN N
this DT N
23% CD N
incidence NN N
of IN N
false-negative JJ N
biopsies NNS N
represents VBZ N
significant JJ N
cancer NN N
. . N

This DT N
relatively RB N
high JJ N
incidence NN N
is VBZ N
important JJ N
to TO N
consider VB N
in IN N
treatment NN N
modalities NNS N
in IN N
which WDT N
prostate VBP I
biopsy NN I
may MD N
be VB N
performed VBN N
to TO N
determine VB N
response NN N
to TO N
therapy NN I
. . I

-DOCSTART- -X- N

Effects NNS N
of IN N
a DT N
Chinese JJ I
medical JJ I
herbs NN I
complex NN I
on IN N
cellular JJ O
immunity NN O
and CC O
toxicity-related JJ P
conditions NNS P
of IN P
breast NN P
cancer NN P
patients NNS P
. . P

Rose NNP I
geranium NN I
(Pelargonium NN I
graveolens NNS I
Geraniaceae) NNP I
has VBZ N
anti-cancer NN N
and CC N
anti-inflammatory JJ N
properties NNS N
and CC N
promotes NNS N
wound IN N
healing NN N
. . N

Similarly RB N
Ganoderma NNP N
tsugae NN N
(Ganodermataceae) NNP N
Codonopsis NNP N
pilosula NN N
(Campanulaceae) NN N
and CC N
Angelica NNP N
sinensis NN N
(Apiaceae) NN N
are VBP N
traditional JJ N
Chinese JJ N
herbs NNS N
associated VBN N
with IN N
immunomodulatory JJ N
functions NNS N
. . N

In IN N
the DT N
present JJ N
study NN N
a DT N
randomised JJ N
double-blind JJ N
placebo-controlled JJ I
study NN N
was VBD N
conducted VBN N
to TO N
examine VB N
whether IN N
the DT N
Chinese NNP I
medicinal JJ I
herb NN I
complex JJ I
RG-CMH NNP I
which WDT I
represents VBZ I
a DT I
mixture NN I
of IN I
rose VBD I
geranium NN I
and CC I
extracts NNS I
of IN I
G NNP I
. . I

tsugae NN I
C NNP I
. . I

pilosula NN I
and CC I
A NNP I
. . I

sinensis NN I
can MD I
improve VB N
the DT N
immune NN O
cell NN O
count NN O
of IN N
cancer NN P
patients NNS P
receiving VBG P
chemotherapy NN P
and/or NN P
radiotherapy NN P
to TO N
prevent VB N
leucopenia NN N
and CC N
immune JJ N
impairment NN N
that WDT N
usually RB N
occurs VBZ N
during IN N
cancer NN N
therapy NN N
. . N

A DT N
total NN N
of IN N
fifty-eight JJ P
breast NN P
cancer NN P
patients NNS P
who WP P
received VBD P
chemotherapy NN P
or CC P
radiotherapy NN P
were VBD P
enrolled VBN P
. . P

Immune NNP O
cell NN O
levels NNS O
in IN O
patient NN O
serum NN O
were VBD N
determined VBN N
before IN N
and CC N
following VBG N
6 CD N
weeks NNS N
of IN N
cancer NN N
treatment NN N
for IN N
patients NNS N
receiving VBG N
either DT N
an DT N
RG-CMH JJ I
or CC I
a DT I
placebo NN I
. . I

Administration NN N
of IN N
RG-CMH NNP I
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
levels NNS O
of IN O
leucocytes NNS O
from IN N
315% CD N
for IN N
the DT N
placebo NN N
group NN N
to TO N
134% CD N
for IN N
the DT N
RG-CMH NNP N
group NN N
. . N

Similarly RB O
levels NNS O
of IN O
neutrophils NNS O
significantly RB N
decreased VBN N
from IN N
356% CD N
for IN N
the DT N
placebo NN N
group NN N
to TO N
110% CD N
for IN N
the DT N
RG-CMH NNP I
group NN I
. . I

RG-CMH JJ I
intervention NN I
was VBD N
also RB N
associated VBN N
with IN N
a DT N
decrease NN O
in IN O
levels NNS O
of IN O
T NNP O
cells NNS O
helper JJ O
T NNP O
cells NNS O
cytotoxic JJ O
T NNP O
cells NNS O
and CC O
natural JJ O
killer NN O
cells NNS N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
. . N

However RB N
these DT N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

In IN N
conclusion NN N
administration NN I
of IN I
RG-CMH NNP I
to TO I
patients NNS I
receiving VBG I
chemotherapy/radiotherapy NN I
may MD N
have VB N
the DT N
capacity NN N
to TO N
delay VB N
or CC N
ease VB N
the DT N
reduction NN O
in IN O
levels NNS O
of IN O
leucocytes NNS O
and CC O
neutrophils NNS O
that WDT N
are VBP N
experienced VBN N
by IN N
patients NNS N
during IN N
cancer NN N
treatment NN N
. . N

-DOCSTART- -X- N

Pruritus NN N
in IN N
HIV-1 NNP N
disease: NN N
therapy NN I
with IN I
drugs NNS I
which WDT I
may MD I
modulate VB I
the DT I
pattern NN I
of IN I
immune JJ I
dysregulation NN I
. . I

BACKGROUND NNP N
Pruritus NNP P
in IN P
HIV-1+ NNP P
patients NNS P
is VBZ N
common JJ N
and CC N
increases VBZ N
with IN N
disease NN N
progression NN N
. . N

The DT N
causes NNS N
of IN N
pruritus NN N
are VBP N
numerous JJ N
including VBG N
xerosis JJ N
drug NN N
and CC N
photoeruptions NNS N
follicular JJ N
and CC N
papular JJ N
eruptions NNS N
as RB N
well RB N
as IN N
infestations NNS N
and CC N
infections NNS N
by IN N
a DT N
wide JJ N
range NN N
of IN N
organisms NNS N
. . N

One CD N
other JJ N
possible JJ N
factor NN N
contributing VBG N
to TO N
pruritus VB N
is VBZ N
the DT N
pattern NN N
of IN N
immune JJ N
dysregulation NN N
. . N

With IN N
advancing VBG N
HIV-1 JJ N
disease NN N
there EX N
is VBZ N
Th1 NNP N
to TO N
Th2 NNP N
cytokine NN N
switching NN N
. . N

METHODS NNP N
After IN N
some DT N
positive JJ N
results NNS N
with IN N
prostaglandin JJ N
inhibitors NNS N
we PRP N
undertook VBP N
a DT N
study NN N
in IN N
which WDT N
we PRP N
randomly VBP P
placed VBN P
patients NNS P
on IN P
four CD P
different JJ P
forms NNS P
of IN P
therapy NN P
for IN P
their PRP$ P
pruritus NN P
. . P

The DT N
therapies NNS N
included VBD N
hydroxyzine NN I
with IN I
or CC I
without IN I
doxepin NN I
at IN I
night NN I
pentoxifylline NN I
indomethacin NN I
and CC I
topical JJ I
moisturization NN I
with IN I
medium-strength JJ I
topical JJ I
steroids NNS I
. . I

All DT N
patients NNS N
were VBD N
evaluated VBN N
for IN N
both DT N
subjective JJ O
relief NN O
as RB N
well RB N
as IN N
side NN O
effects NNS O
. . O

RESULTS JJ N
Patients NNS N
placed VBN N
on IN N
indomethacin NN N
obtained VBN N
relief NN O
more RBR N
consistently RB N
and CC N
more RBR N
completely RB N
. . N

Patients NNS N
on IN N
pentoxifylline NN N
had VBD N
the DT N
fewest JJS N
side NN N
effects NNS N
of IN N
all DT N
oral JJ N
therapies NNS N
. . N

Patients NNS N
on IN N
antihistamines NNS N
with IN N
or CC N
without IN N
doxepin NN N
had VBD N
the DT N
highest JJS N
incidence NN N
of IN N
side NN N
effects NNS N
although IN N
more JJR N
of IN N
these DT N
patients NNS N
reported VBD N
a DT N
greater JJR N
degree NN N
of IN N
relief NN O
than IN N
patients NNS N
on IN N
pentoxifylline NN N
. . N

All DT N
patients NNS N
on IN N
oral JJ I
therapy NN I
overall NN N
had VBD N
greater JJR N
relief NN N
than IN N
patients NNS N
using VBG N
topical JJ I
steroids NNS I
. . I

CONCLUSION NNP N
The DT N
systemic JJ I
therapies NNS I
which WDT N
may MD N
modulate VB N
the DT N
pattern NN N
of IN N
immune JJ N
dysregulation NN N
seen VBN N
in IN N
HIV-1 NNP N
disease NN N
may MD N
be VB N
beneficial JJ N
in IN N
the DT N
pruritus NN N
seen VBN N
in IN N
late-stage JJ N
patients NNS N
. . N

-DOCSTART- -X- N

Prophylactic JJ I
lidocaine NN I
in IN N
the DT N
early JJ N
phase NN N
of IN N
suspected JJ N
myocardial JJ N
infarction NN N
. . P

Four CD P
hundred VBD P
two CD P
patients NNS P
with IN P
suspected JJ P
myocardial JJ P
infarction NN P
seen VBN P
within IN P
6 CD P
hours NNS P
of IN P
the DT P
onset NN P
of IN P
symptoms NNS P
entered VBD N
a DT N
double-blind JJ N
randomized JJ N
trial NN N
of IN N
lidocaine NN I
vs NN I
placebo NN I
. . I

During IN N
the DT N
1 CD N
hour NN N
after IN N
administration NN N
of IN N
the DT N
drug NN N
the DT N
incidence NN N
of IN N
ventricular JJ N
fibrillation NN N
or CC N
sustained VBN N
ventricular JJ N
tachycardia NN N
among IN N
the DT N
204 CD P
patients NNS P
with IN P
acute JJ P
myocardial JJ P
infarction NN P
was VBD P
low JJ P
1.5% CD P
. . P

Lidocaine NNP I
given VBN I
in IN I
a DT I
300 CD I
mg NN I
dose VBD I
intramuscularly RB I
followed VBN I
by IN I
100 CD I
mg NNS I
intravenously RB I
did VBD I
not RB N
prevent VB N
sustained JJ O
ventricular JJ O
tachycardia NN O
although IN O
there EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
number NN O
of IN O
patients NNS O
with IN O
warning VBG O
arrhythmias NNS O
between IN N
15 CD N
and CC N
45 CD N
minutes NNS N
after IN N
the DT N
administration NN N
of IN N
lidocaine JJ I
(p NNP N
less JJR N
than IN N
0.05) CD N
. . N

The DT N
average JJ O
plasma JJ O
lidocaine JJ O
level NN O
10 CD N
minutes NNS N
after IN N
administration NN N
for IN N
patients NNS N
without IN N
a DT N
myocardial JJ N
infarction NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
for IN N
patients NNS N
with IN N
an DT N
acute JJ N
infarction NN N
. . N

The DT N
mean JJ O
plasma NN O
lidocaine JJ O
level NN O
of IN N
patients NNS N
on IN N
beta-blocking JJ I
agents NNS I
was VBD N
no DT N
different JJ N
from IN N
that DT N
in IN N
patients NNS N
not RB N
on IN N
beta NN N
blocking VBG N
agents NNS N
. . N

During IN N
the DT N
1-hour JJ N
study NN N
period NN N
the DT N
incidence NN O
of IN O
central JJ O
nervous JJ O
system NN O
side NN O
effects NNS O
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
lidocaine NN I
group NN N
hypotension NN N
occurred VBD N
in IN N
11 CD P
patients NNS P
nine CD P
of IN P
whom WP P
had VBD P
received VBN P
lidocaine JJ P
and CC P
four CD P
patients NNS P
died VBD P
from IN P
asystole JJ P
three CD P
of IN P
whom WP P
had VBD P
had VBN P
lidocaine NN P
. . P

We PRP N
cannot VBP N
advocate VB N
the DT N
administration NN N
of IN N
lidocaine JJ I
prophylactically RB I
in IN N
the DT N
early JJ N
hours NNS N
of IN N
suspected JJ N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -X- N

Comparison NNP I
of IN I
adaptive JJ I
pacing VBG I
therapy NN I
cognitive JJ I
behaviour NN I
therapy NN I
graded VBD I
exercise NN I
therapy NN I
and CC I
specialist NN I
medical JJ I
care NN I
for IN I
chronic JJ P
fatigue NN P
syndrome NN P
(PACE): VBP I
a DT I
randomised JJ I
trial NN I
. . I

BACKGROUND NNP I
Trial NNP I
findings NNS I
show VBP I
cognitive JJ I
behaviour NN I
therapy NN I
(CBT) NN I
and CC I
graded VBD I
exercise NN I
therapy NN I
(GET) NN I
can MD I
be VB I
effective JJ I
treatments NNS I
for IN I
chronic JJ I
fatigue JJ I
syndrome NN I
but CC I
patients' JJ I
organisations NNS I
have VBP I
reported VBN I
that IN I
these DT I
treatments NNS I
can MD I
be VB I
harmful JJ I
and CC I
favour JJ I
pacing NN I
and CC I
specialist NN I
health NN I
care NN I
. . I

We PRP I
aimed VBD I
to TO I
assess VB I
effectiveness NN I
and CC I
safety NN I
of IN I
all DT I
four CD I
treatments NNS I
. . I

METHODS NN I
In IN I
our PRP$ I
parallel-group NN I
randomised VBN I
trial NN I
patients NNS P
meeting NN P
Oxford NNP P
criteria NN P
for IN P
chronic JJ P
fatigue NN P
syndrome NN P
were VBD P
recruited VBN P
from IN P
six CD P
secondary-care JJ P
clinics NNS P
in IN P
the DT P
UK NNP P
and CC I
randomly RB I
allocated VBN I
by IN I
computer-generated JJ I
sequence NN I
to TO I
receive VB I
specialist NN I
medical JJ I
care NN I
(SMC) NNP I
alone RB I
or CC I
with IN I
adaptive JJ I
pacing VBG I
therapy NN I
(APT) NNP I
CBT NNP I
or CC I
GET NNP I
. . I

Primary JJ I
outcomes NNS I
were VBD I
fatigue JJ O
(measured VBN O
by IN O
Chalder NNP O
fatigue NN O
questionnaire NN O
score) NN O
and CC I
physical JJ O
function NN O
(measured VBN O
by IN O
short JJ O
form-36 JJ O
subscale NN O
score) VBD O
up RB I
to TO I
52 CD I
weeks NNS I
after IN I
randomisation NN I
and CC I
safety NN I
was VBD I
assessed VBN I
primarily RB I
by IN I
recording VBG I
all DT I
serious JJ I
adverse JJ I
events NNS I
including VBG I
serious JJ I
adverse JJ I
reactions NNS I
to TO I
trial NN I
treatments NNS I
. . I

Primary JJ I
outcomes NNS I
were VBD I
rated VBN I
by IN I
participants NNS I
who WP I
were VBD I
necessarily RB I
unmasked VBN I
to TO I
treatment NN I
assignment; VB I
the DT I
statistician NN I
was VBD I
masked VBN I
to TO I
treatment NN I
assignment NN I
for IN I
the DT I
analysis NN I
of IN I
primary JJ I
outcomes NNS I
. . I

We PRP I
used VBD I
longitudinal JJ I
regression NN I
models NNS I
to TO I
compare VB I
SMC NNP I
alone RB I
with IN I
other JJ I
treatments NNS I
APT IN I
with IN I
CBT NNP I
and CC I
APT NNP I
with IN I
GET NNP I
. . I

The DT I
final JJ I
analysis NN I
included VBD I
all DT I
participants NNS I
for IN I
whom WP I
we PRP I
had VBD I
data NNS I
for IN I
primary JJ I
outcomes NNS I
. . I

This DT I
trial NN I
is VBZ I
registered VBN I
at IN I
http://isrctn.org JJ I
number NN I
ISRCTN54285094 NNP I
. . I

FINDINGS IN I
We PRP I
recruited VBD I
641 CD P
eligible JJ P
patients NNS P
of IN P
whom WP P
160 CD P
were VBD P
assigned VBN P
to TO I
the DT I
APT NNP I
group NN I
161 CD I
to TO I
the DT I
CBT NNP I
group NN I
160 CD I
to TO I
the DT I
GET NNP I
group NN I
and CC I
160 CD I
to TO I
the DT I
SMC-alone NNP I
group NN I
. . I

Compared VBN I
with IN I
SMC NNP I
alone RB I
mean JJ I
fatigue NN O
scores NNS I
at IN I
52 CD I
weeks NNS I
were VBD I
34 CD I
(95% NNP I
CI NNP I
18 CD I
to TO I
50) CD I
points NNS I
lower JJR I
for IN I
CBT NNP I
(p NNP I
= NNP I
00001) CD I
and CC I
32 CD I
(17 NN I
to TO I
48) CD I
points NNS I
lower JJR I
for IN I
GET NNP I
(p NNP I
= NNP I
00003) CD I
but CC I
did VBD I
not RB I
differ VB I
for IN I
APT NNP I
(07 NNP I
[-09 NN I
to TO I
23] CD I
points NNS I
lower; JJ I
p JJ I
= NN I
038) CD I
. . I

Compared VBN I
with IN I
SMC NNP I
alone RB I
mean VB I
physical JJ I
function NN I
scores NNS I
were VBD I
71 CD I
(20 NNS I
to TO I
121) CD I
points NNS I
higher JJR I
for IN I
CBT NNP I
(p NNP I
= NNP I
00068) CD I
and CC I
94 CD I
(44 NN I
to TO I
144) CD I
points NNS I
higher JJR I
for IN I
GET NNP I
(p NNP I
= NNP I
00005) CD I
but CC I
did VBD I
not RB I
differ VB I
for IN I
APT NNP I
(34 NNP I
[-16 NN I
to TO I
84] CD I
points NNS I
lower; JJ I
p=018) NN I
. . I

Compared VBN I
with IN I
APT NNP I
CBT NNP I
and CC I
GET NNP I
were VBD I
associated VBN I
with IN I
less JJR I
fatigue JJ I
(CBT NN I
p NN I
= $ I
00027; CD I
GET NNP I
p JJ I
= NNP I
00059) CD I
and CC I
better JJR I
physical JJ I
function NN I
(CBT NNP I
p=00002; NN P
GET NNP P
p<00001) NN P
. . P

Subgroup NNP P
analysis NN P
of IN P
427 CD P
participants NNS P
meeting VBG P
international JJ P
criteria NNS P
for IN P
chronic JJ P
fatigue NN P
syndrome NN P
and CC P
329 CD P
participants NNS P
meeting VBG I
London NNP I
criteria NNS I
for IN I
myalgic JJ I
encephalomyelitis NN I
yielded VBN I
equivalent JJ I
results NNS I
. . I

Serious JJ I
adverse JJ I
reactions NNS I
were VBD I
recorded VBN I
in IN I
two CD I
(1%) NN I
of IN I
159 CD I
participants NNS I
in IN I
the DT I
APT NNP I
group NN I
three CD I
(2%) NN I
of IN I
161 CD I
in IN I
the DT I
CBT NNP I
group NN I
two CD I
(1%) NN I
of IN I
160 CD I
in IN I
the DT I
GET NNP I
group NN I
and CC I
two CD I
(1%) NN I
of IN I
160 CD I
in IN I
the DT I
SMC-alone NNP I
group NN I
. . I

INTERPRETATION NNP I
CBT NNP I
and CC I
GET NNP I
can MD I
safely RB I
be VB I
added VBN I
to TO I
SMC NNP I
to TO I
moderately RB I
improve VB I
outcomes NNS I
for IN I
chronic JJ I
fatigue JJ I
syndrome NN I
but CC I
APT NNP I
is VBZ I
not RB I
an DT I
effective JJ I
addition NN I
. . I

FUNDING NN I
UK NNP I
Medical NNP I
Research NNP I
Council NNP I
Department NNP I
of IN I
Health NNP I
for IN I
England NNP I
Scottish NNP I
Chief NNP I
Scientist NNP I
Office NNP I
Department NNP I
for IN N
Work NNP N
and CC N
Pensions NNP N
. . N

-DOCSTART- -X- N

Prevention NN N
of IN N
acute JJ O
postoperative JJ O
pressure NN O
rises VBZ N
in IN N
glaucoma NN P
patients NNS P
undergoing JJ P
cataract JJ P
extraction NN P
with IN P
posterior JJ P
chamber NN P
lens NNS P
implant VBP P
. . P

Acute JJ I
elevations NNS N
in IN N
intraocular JJ O
pressure NN O
(IOP) VBZ O
commonly RB N
follow JJ N
extracapsular JJ I
cataract NN I
extraction NN I
and CC I
lens VBZ I
implant NN I
in IN N
glaucoma NN P
patients NNS P
. . P

Thirty NNP P
six CD P
patients NNS P
with IN P
glaucoma JJ P
undergoing JJ P
cataract NN P
extraction NN P
and CC P
posterior JJ P
chamber NN P
lens VBZ P
implantation NN P
received VBD P
one CD P
of IN P
three CD P
treatments NNS P
. . P

Group NNP N
1: CD N
500 CD N
mg NN N
of IN N
Diamox NNP I
Sustets NNP I
(acetazolamide) VBD I
1 CD N
hour NN N
preoperatively RB N
(10 JJ N
patients); NN N
Group NNP N
2: CD N
peroperative JJ I
intracameral JJ I
Miochol NNP I
(acetylcholine) NNP I
(11 NNP N
patients); NN N
Group NNP N
3: CD N
the DT N
above NN I
treatments NNS I
combined VBN I
(15 JJ N
patients) NN N
. . N

IOPs NNP O
were VBD N
measured VBN N
at IN N
3 CD N
6 CD N
9 CD N
and CC N
24 CD N
hours NNS N
postoperatively RB N
. . N

The DT N
average NN O
of IN O
the DT O
maximum JJ O
pressure NN O
rises VBZ O
above IN N
the DT N
preoperative JJ N
level NN N
over IN N
the DT N
24 CD N
hour NN N
period NN N
was VBD N
greatest JJS N
for IN N
the DT N
group NN N
receiving VBG N
acetazolamide IN I
only RB N
at IN N
8.9 CD N
mm NNS N
Hg; NNP N
for IN N
the DT N
acetylcholine NN I
group NN N
the DT N
average NN N
maximum JJ N
rise NN N
was VBD N
6.3 CD N
mm NNS N
Hg; NNP N
while IN N
the DT N
combined JJ I
treatment NN I
group NN N
showed VBD N
a DT N
decrease NN N
of IN N
0.7 CD N
mm NN N
Hg NNP N
. . N

IOP NNP O
rises NNS O
of IN N
> $ N
6 CD N
mm NN N
Hg NNP N
were VBD N
seen VBN N
in IN N
7% CD N
of IN N
patients NNS N
(one CD N
of IN N
15) CD N
in IN N
the DT N
combined JJ I
treatment NN I
group NN N
45% CD N
(five NN N
of IN N
11) CD N
of IN N
the DT N
acetylcholine NN I
group NN N
and CC N
70% CD N
(seven NN N
of IN N
10) CD N
of IN N
the DT N
acetazolamide NN I
group NN N
. . N

IOP NNP O
rises NNS O
of IN N
> $ N
10 CD N
mm NN N
Hg NNP N
were VBD N
seen VBN N
in IN N
7% CD N
of IN N
the DT N
combined JJ I
treatment NN I
group NN N
in IN N
18% CD N
of IN N
the DT N
acetylcholine NN I
only RB N
group NN N
and CC N
in IN N
50% CD N
of IN N
the DT N
acetazolamide NN I
only RB N
group NN N
. . N

A DT N
pressure NN O
rise NN O
> VBZ N
20 CD N
mm NN N
Hg NNP N
was VBD N
seen VBN N
in IN N
one CD N
patient NN N
receiving VBG N
acetazolamide IN I
only RB N
and CC N
one CD N
patient NN N
receiving VBG N
acetylcholine NN I
only RB N
. . N

The DT N
difference NN N
between IN N
the DT N
acetylcholine NN I
group NN N
and CC N
the DT N
combined VBN I
group NN N
for IN N
rises NNS O
> VBP N
6 CD N
mm NN N
Hg NNP N
was VBD N
significant JJ N
using VBG N
the DT N
chi NN N
2 CD N
test NN N
while IN N
the DT N
acetazolamide NN I
group NN N
showed VBD N
a DT N
significant JJ N
difference NN N
for IN N
rises NNS N
> VBP N
6 CD N
and CC N
10 CD N
mm NN N
Hg NNP N
compared VBN N
with IN N
the DT N
combined VBN I
group NN N
. . N

All DT N
acute JJ O
pressure NN O
rises NNS O
were VBD N
recorded VBN N
before RB N
or CC N
at IN N
9 CD N
hours NNS N
following VBG N
operation NN N
except IN N
in IN N
the DT N
combined JJ I
treatment NN I
patient NN N
where WRB N
the DT N
rise NN N
occurred VBD N
at IN N
24 CD N
hours NNS N
. . N

To TO N
prevent VB N
the DT N
acute JJ O
IOP NNP O
rises VBZ N
seen VBN N
following VBG N
cataract NN P
surgery NN P
with IN P
lens NNS P
implant VBP P
in IN P
glaucoma NN P
patients NNS P
we PRP N
recommend VBP N
combined VBN N
ocular JJ I
hypotensive JJ I
therapy NN I
. . I

-DOCSTART- -X- N

Noninvasive JJ I
detection NN I
of IN I
candidate NN I
molecular JJ I
biomarkers NNS I
in IN P
subjects NNS P
with IN P
a DT P
history NN P
of IN P
insulin NN P
resistance NN P
and CC P
colorectal JJ P
adenomas NN P
. . P

We PRP N
have VBP N
developed VBN N
novel JJ I
molecular JJ I
methods NNS I
using VBG I
a DT I
stool NN I
sample NN I
which WDT I
contains VBZ N
intact JJ N
sloughed VBN N
colon NN N
cells NNS N
to TO N
quantify VB N
colonic JJ N
gene NN N
expression NN N
profiles NNS N
. . N

In IN N
this DT N
study NN N
our PRP$ N
goal NN N
was VBD N
to TO N
identify VB N
diagnostic JJ N
gene NN N
sets NNS N
(combinations) VBP N
for IN N
the DT N
noninvasive JJ N
classification NN N
of IN N
different JJ N
phenotypes NNS N
. . N

For IN N
this DT N
purpose NN N
the DT N
effects NNS N
of IN N
a DT N
legume-enriched JJ I
low JJ I
glycemic JJ I
index NN I
high JJ I
fermentable JJ I
fiber NN I
diet NN I
was VBD N
evaluated VBN N
in IN N
subjects NNS P
with IN P
four CD P
possible JJ P
combinations NNS P
of IN P
risk NN P
factors NNS P
including VBG P
insulin NN P
resistance NN P
and CC P
a DT P
history NN P
of IN P
adenomatous JJ P
polyps NNS P
. . P

In IN N
a DT N
randomized JJ I
crossover NN I
design NN I
controlled VBD I
feeding NN I
study NN I
each DT I
participant NN N
(a NNP N
total NN P
of IN P
23; CD P
5-12 JJ N
per IN N
group) NN N
consumed VBD N
the DT N
experimental JJ I
diet JJ I
(1.5 NNP I
cups NN I
of IN I
cooked JJ I
dry JJ I
beans) NN I
and CC I
a DT I
control NN I
diet JJ I
(isocaloric JJ I
average JJ I
American JJ I
diet) NN I
for IN I
4 CD I
weeks NNS I
with IN I
a DT I
3-week JJ I
washout NN I
period NN I
between IN I
diets NNS I
. . I

Using VBG N
prior JJ N
biological JJ N
knowledge NN N
the DT N
complexity NN N
of IN N
feature NN N
selection NN N
was VBD N
reduced VBN N
to TO N
perform VB N
an DT N
exhaustive JJ N
search NN N
on IN N
all DT N
allowable JJ N
feature NN N
(gene) NNP N
sets NNS N
of IN N
size NN N
3 CD N
and CC N
among IN N
these DT N
27 CD N
had VBD N
(unbiased) VBN N
error NN N
estimates NNS N
of IN N
0.15 CD N
or CC N
less JJR N
. . N

Linear JJ O
discriminant JJ O
analysis NN O
was VBD N
successfully RB N
used VBN N
to TO N
identify VB N
the DT N
best JJS N
single JJ N
genes NNS N
and CC N
two- JJ N
to TO N
three-gene JJ N
combinations NNS N
for IN N
distinguishing VBG N
subjects NNS P
with IN P
insulin NN P
resistance NN P
a DT P
history NN P
of IN P
polyps NNS P
or CC P
exposure NN P
to TO P
a DT P
chemoprotective JJ I
legume-rich JJ I
diet NN P
. . P

These DT N
results NNS N
support VBD N
our PRP$ N
premise NN N
that IN N
gene NN N
products NNS N
(RNA) RB N
isolated VBN N
from IN N
stool NN N
have VBP N
diagnostic JJ N
value NN N
in IN N
terms NNS N
of IN N
assessing VBG N
colon NN N
cancer NN N
risk NN N
. . N

-DOCSTART- -X- N

Physostigmine JJ I
reverses VBZ N
propofol-induced JJ N
unconsciousness NN N
and CC N
attenuation NN N
of IN N
the DT N
auditory NN N
steady JJ N
state NN N
response NN N
and CC N
bispectral JJ N
index NN N
in IN N
human JJ P
volunteers NNS P
. . P

BACKGROUND IN N
It PRP N
is VBZ N
postulated VBN N
that IN N
alteration NN N
of IN N
central JJ N
cholinergic JJ N
transmission NN N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
the DT N
mechanism NN N
by IN N
which WDT N
anesthetics NNS N
produce VBP N
unconsciousness JJ N
. . N

The DT N
authors NNS N
investigated VBD N
the DT N
effect NN N
of IN N
altering VBG N
central JJ N
cholinergic JJ N
transmission NN N
by IN N
physostigmine NN I
and CC N
scopolamine NN I
on IN I
unconsciousness NN N
produced VBN N
by IN N
propofol NN N
. . N

METHODS NNP N
Propofol NNP I
was VBD N
administered VBN N
to TO N
American NNP P
Society NNP P
of IN P
Anesthesiologists NNP P
physical JJ P
status NN P
1 CD P
(n NNP P
= VBD P
17) CD P
volunteers NNS P
with IN N
use NN N
of IN N
a DT N
computer-controlled JJ N
infusion NN N
pump NN N
at IN N
increasing VBG N
concentrations NNS N
until IN N
unconsciousness JJ N
resulted VBD N
(inability NN N
to TO N
respond VB N
to TO N
verbal VB N
commands NNS N
abolition NN N
of IN N
spontaneous JJ N
movement) NN N
. . N

Central NNP O
nervous JJ O
system NN O
function NN O
was VBD N
assessed VBN N
by IN N
use NN N
of IN N
the DT N
Auditory NNP O
Steady NNP O
State NNP O
Response NNP O
(ASSR) NN O
and CC O
Bispectral NNP O
Index NNP O
(BIS) NNP O
analysis NN O
of IN O
electrooculogram NN O
. . O

During IN N
continuous JJ N
administration NN N
of IN N
propofol JJ N
reversal NN O
of IN O
unconsciousness NN O
produced VBN N
by IN N
physostigmine NN I
(28 NNP N
microgram/kg) NN N
and CC N
block NN O
of IN O
this DT O
reversal NN O
by IN N
scopolamine JJ I
(8.6 NN I
microgram/kg) NN I
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Propofol NNP N
produced VBD N
unconsciousness JJ O
at IN N
a DT N
plasma JJ O
concentration NN O
of IN N
3.2 CD N
+/- JJ N
0.8 CD N
(+/- JJ N
SD) NNP N
microgram/ml NN N
(n NNP N
= VBZ N
17) CD N
. . N

Unconsciousness NN O
was VBD N
associated VBN N
with IN N
reductions NNS O
in IN N
ASSR NNP O
(0.10 NNP N
+/- JJ N
0.08 CD N
microV NNS N
[awake VBP N
baseline JJ N
0.32 CD N
+/- JJ N
0.18 CD N
microV] NN N
P NNP N
< VBZ N
0.001) CD N
and CC N
BIS NNP O
(55.7 NNP N
+/- JJ N
8.8 CD N
[awake JJ N
baseline NN N
92.4 CD N
+/- JJ N
3.9] CD N
P NNP N
< VBD N
0.001) CD N
. . N

Physostigmine NN I
restored VBD O
consciousness NN O
in IN N
9 CD N
of IN N
11 CD N
subjects NNS N
with IN N
concomitant JJ N
increases NNS O
in IN N
ASSR NNP O
(0.38 NNP N
+/- JJ N
0.17 CD N
microV NN N
P NNP N
< VBZ N
0.01) CD N
and CC N
BIS NNP O
(75.3 NNP N
+/- JJ N
8.3 CD N
P NNP N
< VBD N
0.001) CD N
. . N

In IN N
all DT N
subjects NNS N
(n VBP N
= $ N
6) CD N
scopolamine NN I
blocked VBD N
the DT N
physostigmine-induced JJ O
reversal NN O
of IN O
unconsciousness NN O
and CC N
the DT N
increase NN O
of IN O
the DT O
ASSR NNP O
and CC O
BIS NNP O
(ASSR NNP O
and CC O
BIS NNP O
during IN N
propofol-induced JJ N
unconsciousness: JJ N
0.09 CD N
+/- JJ N
0.09 CD N
microV NN N
and CC N
58.2 CD N
+/- JJ N
7.5 CD N
respectively; NN N
ASSR NNP O
and CC O
BIS NNP O
after IN N
physostigmine NN N
administration: RB N
0.08 CD N
+/- JJ N
0.06 CD N
microV NN N
and CC N
56.8 CD N
+/- JJ N
6.7 CD N
respectively RB N
NS) NNP N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
unconsciousness NN N
produced VBN N
by IN N
propofol NN N
is VBZ N
mediated VBN N
at IN N
least JJS N
in IN N
part NN N
via IN N
interruption NN N
of IN N
central JJ N
cholinergic NN I
muscarinic JJ I
transmission NN N
. . N

-DOCSTART- -X- N

Effect NN N
of IN N
chelation NN I
therapy NN I
on IN N
progressive JJ N
diabetic JJ N
nephropathy NN N
in IN N
patients NNS P
with IN P
type JJ P
2 CD P
diabetes NNS P
and CC P
high-normal JJ P
body NN P
lead JJ P
burdens NNS P
. . P

BACKGROUND IN P
A NNP N
previous JJ N
study NN N
in IN N
type NN P
2 CD P
diabetic JJ P
patients NNS P
with IN P
high-normal JJ N
body NN N
lead NN N
burdens VBZ N
showed VBD N
that IN N
EDTA NNP I
chelation NN I
therapy NN I
for IN N
3 CD N
months NNS N
slows VBZ N
progressive JJ N
diabetic JJ N
nephropathy NN N
during IN N
a DT N
12-month JJ N
follow-up NN N
. . N

The DT N
effect NN N
of IN N
a DT N
longer JJR N
course NN N
of IN N
therapy NN N
on IN N
kidney NN N
function NN N
decrease NN N
over IN N
a DT N
longer JJR N
follow-up NN N
is VBZ N
not RB N
known VBN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
12-month JJ N
run-in JJ N
phase NN N
then RB N
a DT N
randomized VBN N
single-blind NN N
study NN N
with IN N
a DT N
27-month JJ N
intervention NN N
. . N

SETTING NNP N
& CC N
PARTICIPANTS NNP N
University NNP P
medical JJ P
center; NN P
50 CD P
patients NNS P
(serum JJ P
creatinine JJ P
1.5-3.9 JJ P
mg/dL) NN P
with IN P
high-normal JJ P
body NN P
lead JJ P
burden JJ P
(80-<600 JJ P
g) NNS P
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT I
treatment NN I
and CC I
control NN I
groups NNS I
. . N

INTERVENTION NNP N
The DT N
treatment NN N
group NN N
received VBD I
weekly JJ I
chelation NN I
therapy NN I
for IN I
3 CD I
months NNS I
to TO N
reduce VB N
their PRP$ N
body NN N
lead JJ N
burden NN N
to TO N
<60 VB N
g NNP N
and CC N
then RB N
as IN N
needed VBN N
for IN N
24 CD N
months NNS N
to TO N
maintain VB N
this DT N
level NN N
. . N

The DT N
control NN N
group NN N
received VBD I
placebo NN I
for IN I
3 CD I
months NNS I
and CC I
then RB I
weekly VB I
for IN I
5 CD I
weeks NNS I
at IN I
6-month JJ I
intervals NNS I
for IN I
24 CD I
months NNS I
. . N

OUTCOMES IN N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
change NN O
in IN O
estimated VBN O
glomerular JJ O
filtration NN O
rate NN O
(eGFR) NN O
over IN O
time NN O
. . N

A DT N
secondary JJ N
end NN N
point NN N
was VBD O
a DT O
2-fold JJ O
increase NN O
in IN O
baseline JJ O
serum NN O
creatinine NN O
level NN O
or CC O
the DT O
requirement NN O
for IN O
renal JJ O
replacement NN O
therapy NN O
. . N

MEASUREMENTS NNP N
Body NNP N
lead JJ N
burdens NNS N
were VBD N
assessed VBN N
by IN N
EDTA NNP N
mobilization NN N
tests NNS N
and CC N
eGFR NN N
was VBD N
calculated VBN N
using VBG N
the DT N
equation NN N
for IN P
Chinese JJ P
patients NNS P
with IN P
type JJ P
2 CD P
diabetes NNS P
. . N

RESULTS JJ O
Mean NNP O
baseline NN O
eGFRs NN O
in IN N
the DT N
treatment NN N
and CC N
control NN N
groups NNS N
were VBD N
similar JJ N
. . N

After IN N
3 CD N
months NNS I
of IN I
chelation NN I
therapy IN I
the DT O
change NN O
in IN O
eGFR NN O
in IN N
the DT N
treatment NN N
group NN N
(+1.0 NNP N
 VBZ N
4.8 CD N
mL/min/1.73 NN N
m(2)) NN N
differed VBD N
significantly RB N
from IN N
that DT N
in IN N
the DT N
control NN N
group NN N
(-1.5 NNP N
 NNP N
4.8 CD N
mL/min/1.73 NN N
m(2); NN N
P NNP N
= VBZ N
0.04) CD N
. . N

In IN N
the DT N
subsequent JJ N
24-month JJ N
intervention NN N
the DT N
yearly JJ O
rate NN O
of IN O
decrease NN O
in IN O
eGFR JJ N
(5.6 NNP N
 NNP N
5.0 CD N
mL/min/1.73 NN N
m(2) NN N
per IN N
year) NN N
in IN N
the DT N
treatment NN N
group NN N
was VBD N
slower JJR N
than IN N
that DT N
(9.2 NNP N
 VBD N
3.6 CD N
mL/min/1.73 NN N
m(2) NN N
per IN N
year; NN N
P NNP N
= VBZ N
0.04) CD N
in IN N
the DT N
control NN P
group NN P
. . P

17 CD P
(68%) JJ P
control-group JJ P
patients NNS P
and CC P
9 CD P
(36%) JJ P
treatment-group JJ P
patients NNS P
achieved VBD N
the DT N
secondary JJ N
end NN N
point NN N
. . N

LIMITATIONS NNP N
Small NNP N
sample NN N
size NN N
not RB N
double RB N
blind NN N
. . N

CONCLUSIONS VB N
A DT N
27-month JJ N
course NN I
of IN I
EDTA NNP I
chelation NN I
therapy NN N
retards VBZ N
the DT N
progression NN N
of IN N
diabetic JJ N
nephropathy NN P
in IN P
type NN P
2 CD P
diabetic JJ P
patients NNS P
with IN P
high-normal JJ P
body NN P
lead JJ P
burdens NNS P
. . N

-DOCSTART- -X- N

[Comparison NN N
of IN N
the DT N
efficacy/tolerability NN O
ratio NN O
of IN N
cibenzoline NN I
and CC I
propafenone NN I
in IN N
the DT N
treatment NN N
of IN N
ventricular JJ P
arrhythmia] NN P
. . N

Cibenzoline NNP I
(C) NNP I
was VBD N
compared VBN N
with IN N
propafenone NN I
(P) NN I
in IN N
18 CD P
adult NN P
patients NNS P
(7 JJ P
women NNS P
and CC P
11 CD P
men) NNS P
aged VBD P
50 CD P
+/- JJ P
7 CD P
in IN N
double-blind JJ N
placebo-controlled JJ I
crossover NN N
trial NN N
. . N

After IN N
a DT N
therapeutic JJ N
wash-out NN N
period NN N
corresponding VBG N
to TO N
5 CD N
times NNS N
the DT N
half-life NN N
of IN N
previous JJ N
anti-arrhythmic JJ I
drugs NNS I
patients NNS P
with IN P
more JJR P
than IN P
100 CD P
premature JJ P
ventricular JJ P
contractions NNS P
(PVC) VBP P
per IN P
hour NN P
in IN P
two CD P
24 CD P
hour NN P
Holter NNP P
records NNS P
obtained VBN P
at IN P
an DT P
interval NN P
of IN P
7 CD P
days NNS P
were VBD N
treated VBN N
in IN N
succession NN N
and CC N
after IN N
randomised VBN N
by IN N
C NNP I
(390 NNP N
mg/day NN N
in IN N
3 CD N
divided JJ N
doses) NN N
and CC N
P NNP I
(900 NNP N
mg/day NN N
in IN N
3 CD N
divided VBD N
doses) NN N
for IN N
a DT N
period NN N
of IN N
two CD N
weeks NNS N
each DT N
active JJ N
sequence NN N
being VBG N
followed VBN N
by IN N
a DT N
two CD N
week NN N
wash-out JJ N
period NN N
. . N

Efficacy NN O
(based VBD O
upon IN O
the DT O
decrease NN O
in IN O
PVC/hour NNP O
in IN O
a DT O
24 CD O
hour NN O
Holter) NNP O
and CC O
tolerability NN O
were VBD N
evaluated VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
sequence NN N
with IN N
samples NNS N
drawn VBN N
at IN N
the DT N
same JJ N
times NNS N
for IN N
assay NN N
of IN N
the DT N
study NN N
drugs NNS N
. . N

Three CD P
patients NNS P
dropped VBD P
out IN P
of IN P
the DT P
trial NN P
1 CD P
with IN P
each DT P
active JJ P
drug NN P
(for NNP P
epigastric NN P
pain) NN P
and CC P
1 CD P
with IN P
dummy NN P
. . P

No DT N
significant JJ N
difference NN N
was VBD N
seen VBN N
between IN N
the DT N
two CD N
drugs NNS N
regarding VBG N
the DT N
decrease NN N
in IN N
the DT N
total JJ N
number NN N
of IN N
PVC/hour NNP O
in IN N
the DT N
15 CD N
patients NNS N
completing VBG N
the DT N
cross-over JJ N
protocol NN N
. . N

A DT N
reduction NN N
in IN N
PVC/hour NNP O
of IN N
more JJR N
than IN N
70 CD N
per IN N
cent NN N
was VBD N
seen VBN N
in IN N
7 CD N
patients NNS N
with IN N
C NNP I
and CC N
in IN N
9 CD N
patients NNS N
with IN N
P NNP I
. . I

C NNP I
was VBD N
better RBR N
tolerated VBN N
than IN N
P NNP I
on IN N
the DT N
basis NN N
of IN N
both DT N
clinical JJ N
and CC N
electrocardiographic JJ N
parameters NNS N
. . N

One CD N
patient NN N
developed VBD N
troublesome JJ N
adverse JJ O
reactions NNS O
with IN N
C NNP I
as IN N
compared VBN N
with IN N
4 CD N
patients NNS N
in IN N
the DT N
case NN N
of IN N
P NNP I
. . I

A DT N
more JJR N
than IN N
20 CD N
per IN N
cent NN N
increase NN O
in IN O
QRS NNP O
was VBD N
seen VBN N
in IN N
7 CD N
patients NNS N
with IN N
C NNP I
and CC N
in IN N
10 CD N
patients NNS N
with IN N
P NNP I
the DT I
figures NNS N
for IN N
PR NNP N
being VBG N
2 CD N
and CC N
6 CD N
patients NNS N
respectively RB N
. . N

One CD N
patient NN N
showed VBD N
a DT N
proarrhythmic JJ O
effect NN O
with IN N
P NNP I
. . I

Plasma NNP O
levels NNS O
of IN O
C NNP O
were VBD N
significantly RB N
higher JJR N
in IN N
responders NNS N
(328 VBP N
+/- JJ N
149 CD N
ng/ml) NN N
than IN N
in IN N
non-responders JJ N
(137 JJ N
+/- JJ N
41 CD N
ng/ml JJ N
p NN N
less JJR N
than IN N
0.05) CD N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
concerning VBG N
plasma NN N
levels NNS O
of IN N
P NNP I
(578 NNP N
+/- JJ N
477 CD N
ng/ml NNS N
compared VBN N
with IN N
646 CD N
+/- JJ N
457 CD N
ng/ml JJ N
p NN N
greater JJR N
than IN N
0.05) CD N
. . N

In IN N
conclusion NN N
the DT N
efficacy/tolerability NN O
ratio NN O
in IN N
this DT N
population NN P
with IN P
a DT P
low JJ P
risk NN P
of IN P
serious JJ P
rhythm JJ P
events NNS P
appeared VBD N
to TO N
be VB N
better JJR N
with IN N
C NNP I
than IN N
with IN N
P NNP I
. . I

-DOCSTART- -X- N

The DT N
additional JJ N
value NN N
of IN N
a DT N
night NN I
splint NN I
to TO I
eccentric VB I
exercises NNS I
in IN N
chronic JJ P
midportion NN P
Achilles NNP P
tendinopathy: VBZ P
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

AIM NNP N
To TO N
assess VB N
whether IN N
the DT N
use NN I
of IN I
a DT I
night NN I
splint NN I
is VBZ N
of IN N
added JJ N
benefit NN N
on IN N
functional JJ N
outcome NN N
in IN N
treating VBG P
chronic JJ P
midportion NN P
Achilles NNP P
tendinopathy NN P
. . P

METHODS NNP P
This DT N
was VBD N
a DT N
single-blind JJ N
prospective JJ N
single JJ P
centre NN P
randomised VBD P
controlled JJ P
trial NN P
set NN P
in IN P
the DT P
Sports NNP P
Medical NNP P
Department NNP P
The DT P
Hague NNP P
Medical NNP P
Centre NNP P
The DT P
Netherlands NNP P
. . P

Inclusion NNP P
criteria NNS P
were: JJ P
age NN P
18-70 CD P
years NNS P
active JJ P
participation NN P
in IN P
sports NNS P
and CC P
tendon NN P
pain NN P
localised VBD P
at IN P
2-7 JJ P
cm NN P
from IN P
distal JJ P
insertion NN P
. . P

Exclusion NN P
criteria NNS P
were: VBP P
insertional JJ P
disorders NNS P
partial JJ P
or CC P
complete JJ P
ruptures NNS P
or CC P
systemic JJ P
illness NN P
. . P

70 CD P
tendons NNS P
were VBD P
included VBN P
and CC N
randomised VBN N
into IN N
one CD N
of IN N
two CD N
treatment NN N
groups: NN N
eccentric JJ I
exercises NNS I
with IN I
a DT I
night NN I
splint NN I
(night NNP I
splint NN I
group NN I
n VBD I
= $ I
36) CD I
or CC I
eccentric JJ I
exercises NNS I
only RB I
(eccentric NNP N
group NN N
n VBD N
= RB N
34) CD N
. . N

INTERVENTIONS NNP N
Both NNP N
groups NNS N
completed VBD N
a DT N
12-week JJ N
heavy-load NN I
eccentric JJ I
training NN I
programme NN I
. . I

One CD N
group NN N
received VBD N
a DT N
night NN I
splint NN I
in IN I
addition NN I
to TO I
eccentric JJ I
exercises NNS I
. . I

At IN N
baseline NN N
and CC N
follow-up NN N
at IN N
12 CD N
weeks NNS N
patient JJ N
satisfaction NN N
Victorian NNP O
Institute NNP O
of IN O
Sport NNP O
Assessment-Achilles NNP O
questionnaire NN O
(VISA-A) NN O
score NN O
and CC N
reported VBD N
compliance NN N
were VBD N
recorded VBN N
by IN N
a DT N
single-blind NN N
trained JJ N
researcher NN N
who WP N
was VBD N
blinded VBN N
to TO N
the DT N
treatment NN N
. . N

RESULTS NNP N
After IN N
12 CD N
weeks NNS N
patient JJ N
satisfaction NN N
in IN N
the DT N
eccentric JJ N
group NN N
was VBD N
63% CD N
compared VBN N
with IN N
48% CD N
in IN N
the DT N
night NN I
splint NN I
group NN N
. . N

The DT N
VISA-A NNP O
score NN O
significantly RB N
improved VBN N
in IN N
both DT N
groups; NN N
in IN N
the DT N
eccentric JJ N
group NN N
from IN N
50.1 CD N
to TO N
68.8 CD N
(p NNS N
= JJ N
0.001) CD N
and CC N
in IN N
the DT N
night NN N
splint NN N
group NN P
from IN P
49.4 CD P
to TO P
67.0 CD N
(p<0.001) NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
VISA-A NNP O
score NN O
(p NNP N
= VBZ N
0.815) CD N
and CC N
patient JJ O
satisfaction NN O
(p NNP N
= VBZ N
0.261) CD N
. . N

CONCLUSION VB N
A DT I
night NN I
splint NN I
is VBZ I
not RB N
beneficial JJ N
in IN N
addition NN N
to TO N
eccentric VB I
exercises NNS I
in IN N
the DT N
treatment NN N
of IN N
chronic JJ P
midportion NN P
Achilles NNP P
tendinopathy NN P
. . P

-DOCSTART- -X- N

[Comparative JJ N
effects NNS N
of IN N
nebivolol NN I
and CC I
valsartan NN I
on IN N
atrial JJ O
electromechanical JJ O
coupling NN O
in IN N
newly RB P
diagnosed VBN P
stage NN P
1 CD P
hypertensive JJ P
patients] NN P
. . N

OBJECTIVES NNP N
Hypertension NNP N
is VBZ N
an DT N
important JJ N
cardiovascular NN N
risk NN N
factor NN N
for IN N
the DT N
development NN N
of IN N
atrial JJ O
fibrillation NN O
(AF) NN O
. . O

Increased VBN N
atrial JJ N
electromechanical JJ N
coupling NN N
time NN N
interval NN N
measured VBN N
by IN N
tissue NN N
Doppler NNP N
is VBZ N
accepted VBN N
as IN N
an DT N
important JJ N
factor NN N
for IN N
prediction NN N
of IN N
AF NNP O
development NN O
in IN N
hypertensive JJ P
patients NNS P
. . P

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
valsartan NN I
an DT I
angiotensin NN N
receptor NN N
blocker NN N
and CC N
nebivolol VB I
a DT I
beta-blocker NN N
on IN N
atrial JJ N
electromechanical JJ N
coupling NN N
in IN N
newly RB P
diagnosed VBN P
stage NN P
1 CD P
hypertensive JJ P
patients NNS P
. . P

STUDY NNP N
DESIGN NNP N
The DT N
study NN P
included VBD P
60 CD P
newly RB P
diagnosed VBN P
stage NN P
1 CD P
hypertensive JJ P
patients NNS P
with IN P
no DT P
other JJ P
systemic JJ P
disease NN P
. . P

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB P
nebivolol JJ P
5 CD P
mg NN P
(30 NNP P
patients; VBZ P
21 CD P
women NNS P
9 CD P
men; JJ P
mean JJ P
age NN P
48.4 CD P
 NN I
11.4 CD P
years) NN P
and CC P
valsartan $ P
160 CD P
mg NN P
(30 NNP P
patients; VBZ P
21 CD P
women NNS P
9 CD P
men; JJ P
mean JJ P
age NN P
49.8 CD P
 NN I
11.3 CD P
years) NN P
. . N

All PDT N
the DT N
patients NNS N
underwent JJ N
tissue NN I
Doppler NNP I
echocardiographic JJ I
examination NN I
before IN N
and CC N
three CD N
months NNS N
after IN N
treatment NN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
the DT N
two CD N
drugs NNS N
on IN O
atrial JJ O
electromechanical JJ O
coupling NN O
. . N

RESULTS NNP O
Baseline NNP O
blood NN O
pressures NNS O
electrocardiographic JJ O
and CC O
echocardiographic JJ O
findings NNS O
and CC O
atrial JJ O
electromechanical JJ O
coupling NN O
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
(p>0.05) VBP N
. . N

Both DT N
drugs NNS N
significantly RB N
reduced VBD O
blood NN O
pressure NN O
after IN N
treatment NN N
with IN N
similar JJ N
efficacy NN N
(p>0.05) NN N
. . O

Atrial JJ O
electromechanical JJ O
coupling NN O
time NN O
intervals NNS O
showed VBD N
significant JJ N
decreases NNS N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP O
Prolonged NNP O
interatrial JJ O
electromechanical JJ O
time NN O
intervals NNS O
in IN N
hypertensives NNS N
are VBP N
improved VBN N
with IN N
antihypertensive JJ N
treatment NN N
. . N

-DOCSTART- -X- N

Tolfenamic NNP I
acid NN I
and CC I
caffeine: VB I
a DT N
useful JJ N
combination NN N
in IN N
migraine NN P
. . P

Tolfenamic NNP I
acid NN I
is VBZ N
a DT N
potent JJ N
inhibitor NN N
of IN N
prostaglandin NN N
biosynthesis NN N
which WDT N
has VBZ N
been VBN N
proved VBN N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
migraine NN N
attacks NNS N
. . N

The DT N
usefulness NN N
of IN N
caffeine NN I
metoclopramide NN I
and CC I
pyridoxine NN I
as IN N
adjuncts NNS N
to TO N
tolfenamic VB I
acid NN I
was VBD N
tested VBN N
in IN N
acute JJ P
migraine NN P
attacks NNS P
in IN P
ten JJ P
patients NNS P
. . P

A DT N
combination NN N
of IN N
tolfenamic JJ I
acid NN I
(200 NNP I
mg) NN I
with IN I
either DT I
caffeine NN I
(100 NN I
mg) NN I
metoclopramide NN I
(10 NNP I
mg) NN I
or CC I
pyridoxine NN I
(300 CD I
mg) NN I
was VBD N
given VBN N
twice RB N
to TO N
each DT N
patient NN N
in IN N
random JJ N
order NN N
. . N

Thus RB N
60 CD P
attacks NNS P
were VBD N
treated VBN N
. . N

The DT N
tolfenamic JJ I
acid-caffeine JJ I
combination NN I
proved VBD N
the DT N
most RBS N
effective JJ N
as IN N
judged VBN N
by IN N
duration NN O
and CC O
intensity NN O
of IN O
attacks NNS O
working VBG O
ability NN O
vigilance NN O
and CC O
overall JJ O
evaluation NN O
of IN N
the DT N
drugs NNS I
by IN N
the DT N
patients NNS N
. . N

Metoclopramide NNP I
was VBD N
somewhat RB N
better JJR N
than IN N
pyridoxine NN I
as IN N
an DT N
additive NN N
. . N

-DOCSTART- -X- N

Can MD N
a DT N
home-visit JJ P
invitation NN P
increase NN P
Pap NNP P
smear JJ P
screening NN P
in IN P
Samliem NNP P
Khon NNP P
Kaen NNP P
Thailand NNP P
Our PRP$ P
objective NN N
was VBD N
to TO N
assess VB N
the DT N
efficiency NN N
of IN N
a DT N
home-visit JJ I
invitation NN I
aimed VBN N
to TO N
increase VB N
uptake NN N
of IN N
cervical JJ P
cancer NN P
screening VBG P
in IN P
women NNS P
between IN P
35 CD P
and CC P
60 CD P
years NNS P
of IN P
age NN P
. . P

From NN N
May NNP N
2006 CD N
we PRP N
conducted VBD N
a DT N
quasi-randomized JJ N
trial NN N
to TO N
determine VB N
if IN N
an DT N
in-home JJ I
education NN I
and CC I
invitation NN I
intervention NN I
would MD N
increase VB N
uptake NN N
of IN N
cervical JJ N
cancer NN N
screening NN N
. . N

We PRP N
randomly RB P
recruited VBD P
304 CD P
women NNS P
from IN P
the DT P
Samliem NNP P
inner-city NN P
community NN P
Khon NNP P
Kaen NNP P
Northeast NNP P
Thailand NNP P
and CC P
assigned VBD P
participants NNS P
to TO N
either VB N
the DT N
intervention NN I
or CC I
control VB I
zone NN I
. . I

Baseline NNP N
screening VBG N
coverage NN N
interviews NNS N
were VBD N
then RB N
performed: JJ N
58 CD P
of IN P
158 CD P
women NNS P
in IN P
the DT P
intervention NN P
zone NN P
and CC P
46 CD P
of IN P
146 CD P
in IN P
the DT P
control NN P
zone NN P
were VBD P
excluded VBN P
from IN P
the DT P
study NN P
because IN P
of IN P
having VBG P
had VBD P
a DT P
Pap NNP P
smear NN P
within IN P
5 CD P
years NNS P
but CC P
these DT P
were VBD P
included VBN P
in IN P
the DT P
final JJ P
analysis NN P
. . P

First RB N
100 CD N
women NNS N
in IN N
the DT N
intervention NN I
group NN N
were VBD N
visited VBN I
in IN I
their PRP$ I
homes NNS I
by IN I
one CD I
of IN I
the DT I
researchers NNS I
who WP I
provided VBD I
culturally-sensitive JJ I
health NN I
education NN I
that WDT I
emphasized VBD I
the DT I
need NN I
for IN I
screening VBG I
. . I

Four CD N
months NNS N
later RB N
post-intervention JJ N
screening-coverage JJ I
interviews NNS I
were VBD I
again RB I
performed VBN I
in IN I
both DT I
groups NNS I
in IN I
combination NN I
with IN I
the DT I
same JJ I
health NN I
education NN I
for IN I
100 CD I
women NNS I
in IN I
the DT I
control NN I
group NN I
for IN I
a DT I
comparison NN I
. . I

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
baseline NN O
Pap NNP O
smear JJ O
screening-coverage NN O
rate NN O
in IN N
the DT N
intervention NN I
vs NN N
. . N

control NN I
zones VBZ N
(36.7 NNP N
vs NN N
. . N

31.5% CD N
p=0.339) NN N
. . N

One CD N
hundred JJ N
women NNS N
in IN N
the DT N
intervention NN I
group NN N
completed VBD N
the DT N
intervention NN I
interviews NNS N
and CC N
after IN N
four CD N
months NNS N
100 CD N
women NNS N
in IN N
the DT N
intervention NN I
group NN N
and CC N
100 CD N
in IN N
the DT N
control NN I
group NN N
also RB N
completed VBD N
the DT N
post-intervention NN N
interviews NNS N
. . N

The DT N
increased VBN N
screening-coverage NN O
rate NN O
in IN N
the DT N
intervention NN I
zone NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
the DT N
control NN I
zone NN N
(43.6 NNP N
vs NN N
. . N

34.9% CD N
p=0.119); NN N
however RB N
there EX N
was VBD N
a DT N
borderline NN N
significant JJ N
increase NN N
in IN N
the DT N
intervention NN I
zone NN N
compared VBN N
with IN N
baseline NN N
(36.7 NN N
to TO N
43.6% CD N
p=0.070) NN N
. . N

Therefore RB N
home NN I
visit NN I
education NN I
and CC I
invitation NN I
intervention NN I
produced VBD N
only RB N
a DT N
nominal JJ N
effect NN N
on IN N
increasing VBG N
Pap NNP N
smear JJ N
coverage NN N
within IN N
a DT N
4-month JJ N
study NN N
period NN N
. . N

-DOCSTART- -X- N

A DT N
controlled VBN N
trial NN N
with IN N
diclofensine NN I
a DT I
new JJ N
psychoactive JJ I
drug NN N
in IN N
the DT N
treatment NN N
of IN N
depression NN N
. . N

Diclofensine NNP I
inhibits VBZ I
the DT N
uptake NN N
of IN N
serotonin JJ N
noradrenaline NN N
and CC N
dopamine NN N
. . N

In IN N
a DT N
controlled JJ N
study NN N
out-patients NNS P
suffering VBG P
from IN P
moderate JJ P
to TO P
severe JJ P
depression NN P
were VBD N
treated VBN N
with IN N
the DT N
objective NN N
of IN N
assessing VBG N
the DT N
new JJ N
drug's NN N
therapeutically RB N
effective JJ N
dose NN N
range NN N
. . N

Maprotiline NNP I
was VBD N
used VBN N
as IN N
a DT N
reference NN N
drug: NN N
fourteen JJ P
patients NNS P
were VBD P
assigned VBN P
to TO P
receive VB P
diclofensine NN P
and CC P
thirteen NN P
to TO P
receive VB P
maprotiline NN P
in IN P
a DT P
double-blind JJ P
design NN P
. . P

Depending VBG N
on IN N
tolerance NN N
and CC N
efficacy NN N
they PRP N
were VBD N
treated VBN N
for IN N
periods NNS N
ranging VBG N
from IN N
5 CD N
to TO N
150 CD N
days NNS N
. . N

Doses NNS N
were VBD N
titrated VBN N
to TO N
the DT N
optimum NN N
. . N

Findings NNS N
suggest VBP N
that IN N
a DT N
50 CD N
mg JJ N
daily JJ N
dose NN N
of IN N
diclofensine NN I
would MD N
be VB N
sufficient JJ N
for IN N
the DT N
majority NN N
of IN N
the DT N
patients NNS N
. . N

The DT N
dosage NN N
can MD N
be VB N
safely RB N
increased VBN N
up RP N
to TO N
150 CD N
mg NNS N
daily RB N
but CC N
this DT N
offers VBZ N
few JJ N
therapeutic JJ N
advantages NNS N
. . N

While IN N
the DT N
efficacy NN O
index NN O
of IN N
the DT N
two CD N
drugs NNS N
was VBD N
similar JJ N
(approximately RB N
60%) CD N
they PRP N
differed VBD N
greatly RB N
in IN N
their PRP$ N
profile NN N
of IN N
side-effects NNS O
. . O

No DT N
signs NNS N
of IN N
abrupt JJ O
dissipation NN O
of IN N
the DT N
achieved JJ N
clinical JJ N
effects NNS N
were VBD N
observed VBN N
during IN N
continued JJ N
treatment NN N
and CC N
no DT N
withdrawal NN O
reactions NNS O
were VBD N
observed VBN N
when WRB N
the DT N
treatment NN N
was VBD N
stopped VBN N
. . N

The DT N
new JJ N
drug NN N
may MD N
be VB N
more RBR N
effective JJ N
in IN N
treating VBG N
patients NNS P
in IN P
whom WP P
a DT P
psycho-energizing NN P
and CC P
mood NN P
alleviating VBG P
effect NN P
is VBZ N
desired VBN N
. . N

-DOCSTART- -X- N

[Stent NN I
and CC I
surgery NN I
for IN N
symptomatic JJ P
carotid NN P
stenosis NN P
. . P

SPACE NNP N
study NN N
results] NN N
. . N

The DT N
SPACE NNP N
trial NN N
compared VBN N
risk NN N
and CC N
effectiveness NN N
of IN N
stent-supported JJ I
angioplasty JJ I
(CAS) NN I
vs NN I
carotid NN I
endarterectomy NN I
(CEA) NNP I
using VBG N
a DT N
noninferiority NN N
design NN N
in IN N
patients NNS P
with IN P
symptomatic JJ P
stenoses NNS P
. . P

Intention-to-treat JJ N
analysis NN N
of IN N
the DT N
entire JJ N
study NN N
population NN P
of IN P
1 CD P
214 CD P
patients NNS P
showed VBD N
that IN N
primary JJ N
endpoint NN N
events NNS N
(ipsilateral JJ N
stroke VBD N
or CC N
death NN N
between IN N
randomisation NN N
and CC N
day NN N
30) CD N
occurred VBD N
in IN N
6.92% CD N
of IN N
the DT N
CAS NNP I
group NN I
and CC N
6.45% CD N
of IN N
the DT N
CEA NNP I
group NN I
. . I

The DT N
95% CD N
confidence NN N
interval JJ N
(CI) NN N
of IN N
the DT N
absolute NN O
risk NN O
difference NN O
ranged VBD N
from IN N
-1.94% NN N
to TO N
+2.87% VB N
therefore RB N
the DT N
noninferiority NN N
was VBD N
not RB N
proven RB N
. . N

The DT N
same JJ N
was VBD N
true JJ N
for IN N
the DT N
analysis NN O
of IN O
protocols NNS O
. . O

No DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
treatment NN N
methods NNS N
were VBD N
found VBN N
in IN N
primary JJ N
or CC N
any DT N
of IN N
the DT N
secondary JJ N
endpoints NNS N
. . N

There EX N
were VBD N
also RB N
no DT N
differences NNS N
in IN N
short-term JJ O
prevention NN O
. . O

The DT N
endpoint JJ N
'ipsilateral JJ O
ischemic JJ O
stroke NN O
or CC O
vascular JJ O
death NN O
between IN N
randomisation NN N
and CC N
6 CD N
months' NN N
occurred VBD N
in IN N
7.4% CD N
of IN N
the DT N
CAS NNP I
and CC N
6.5% CD N
of IN N
the DT N
CEA NNP I
patients NNS N
(odds VBP N
ratio JJ N
1.16 CD N
95% CD N
confidence NN N
interval JJ N
0.74-1.82) NN N
. . N

Instent JJ O
restenoses NNS O
were VBD N
significantly RB N
more JJR N
common JJ N
in IN N
the DT N
CAS NNP I
group NN I
(4.6% NNP N
vs VBZ N
2.2% CD N
odds NNS N
ratio VBD N
2.14 CD N
95% CD N
CI NNP N
1.10-4.18) CD N
. . N

Surgery NN I
remains VBZ N
the DT N
gold JJ N
standard NN N
in IN N
treatment NN N
of IN N
patients NNS P
with IN P
symptomatic JJ P
carotid NN P
artery NN P
stenosis NN P
. . P

Stent-supported JJ I
angioplasty NN I
can MD N
be VB N
an DT N
alternative JJ N
only RB N
in IN N
the DT N
hands NNS N
of IN N
an DT N
experienced JJ N
interventionalist NN N
with IN N
proven JJ N
low JJ N
periprocedural JJ N
complication NN N
rate NN N
. . N

-DOCSTART- -X- N

Comparison NNP N
of IN N
the DT N
hypotensive JJ N
effects NNS N
of IN N
bendrofluazide JJ I
bumetanide NN I
and CC I
xipamide NN I
. . I

A DT I
randomized JJ N
triple NN N
crossover NN N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
24 CD P
elderly JJ P
patients NNS P
requiring VBG P
chronic JJ P
diuretic JJ P
therapy NN P
to TO N
assess VB N
the DT N
different JJ N
hypotensive JJ N
effects NNS N
of IN N
a DT N
fixed JJ N
daily JJ I
dose NN I
of IN I
5 CD I
mg NNS I
bendrofluazide RB I
1 CD I
mg NNS I
bumetanide RB I
and CC I
40 CD I
mg NN I
xipamide NN I
. . I

Each DT N
treatment NN N
was VBD N
given VBN N
for IN N
3 CD N
months NNS N
. . N

The DT N
results NNS N
showed VBD N
that IN N
no DT N
significant JJ N
weight NN O
change NN O
took VBD N
place NN N
during IN N
the DT N
study NN N
period NN N
. . N

There EX N
was VBD N
however RB N
a DT N
significant JJ N
(p NN N
less JJR N
than IN N
0.001) CD N
decrease NN N
compared VBN N
to TO N
baseline VB O
values NNS O
both DT O
in IN O
systolic NN O
and CC O
diastolic JJ O
blood NN O
pressure NN O
during IN N
the DT N
xipamide JJ N
period NN N
and CC N
a DT N
decrease NN N
in IN N
diastolic JJ O
blood NN O
pressure NN O
(p VBZ N
less JJR N
than IN N
0.05) CD N
when WRB N
taking VBG N
bumetanide NN I
. . I

Only RB N
minor JJ O
side-effects NNS O
were VBD N
reported VBN N
. . N

-DOCSTART- -X- N

Immunologic NNP O
and CC O
hemodynamic JJ O
effects NNS O
of IN N
"low-dose" JJ I
hydrocortisone NN I
in IN N
septic JJ P
shock: NN P
a DT N
double-blind JJ N
randomized JJ N
placebo-controlled JJ I
crossover NN N
study NN N
. . N

Within IN N
the DT N
last JJ N
few JJ N
years NNS N
increasing VBG N
evidence NN N
of IN N
relative JJ N
adrenal JJ P
insufficiency NN P
in IN P
septic JJ P
shock NN P
evoked VBD N
a DT N
reassessment NN N
of IN N
hydrocortisone NN I
therapy NN I
. . I

To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
hydrocortisone NN I
on IN N
the DT N
balance NN N
between IN N
proinflammatory NN N
and CC N
antiinflammation NN N
40 CD P
patients NNS P
with IN P
septic JJ P
shock NN P
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
crossover NN N
study NN N
to TO N
receive VB N
either CC N
the DT N
first JJ N
100 CD I
mg NN I
of IN I
hydrocortisone NN I
as IN I
a DT I
loading NN I
dose NN I
and CC I
10 CD I
mg NNS I
per IN I
hour NN I
until IN I
Day NNP I
3 CD I
(n NNP I
= $ I
20) CD I
or CC I
placebo VB I
(n JJ N
= $ N
20) CD N
followed VBN N
by IN N
the DT N
opposite JJ N
medication NN N
until IN N
Day NNP N
6 CD N
. . N

Hydrocortisone CD I
infusion NN N
induced VBD N
an DT N
increase NN N
of IN N
mean JJ O
arterial JJ O
pressure NN O
systemic JJ O
vascular JJ O
resistance NN O
and CC O
a DT N
decline NN N
of IN N
heart NN O
rate NN O
cardiac JJ O
index NN O
and CC O
norepinephrine JJ O
requirement NN O
. . O

A DT N
reduction NN N
of IN N
plasma NN O
nitrite/nitrate NN O
indicated VBD N
inhibition NN N
of IN N
nitric JJ N
oxide JJ N
formation NN N
and CC N
correlated VBN N
with IN N
a DT N
reduction NN N
of IN N
vasopressor NN N
support NN N
. . N

The DT N
inflammatory JJ O
response NN O
(interleukin-6 JJ O
and CC O
interleukin-8) JJ O
endothelial JJ O
(soluble JJ O
E-selectin) JJ O
and CC O
neutrophil JJ O
activation NN O
(expression NN O
of IN O
CD11b NNP O
CD64) NNP O
and CC O
antiinflammatory JJ O
response NN O
(soluble JJ O
tumor NN O
necrosis NN O
factor NN O
receptors NNS O
I PRP O
and CC O
II NNP O
and CC O
interleukin-10) NNS O
were VBD N
attenuated VBN N
. . N

In IN N
peripheral JJ N
blood NN N
monocytes NNS N
human JJ O
leukocyte JJ O
antigen-DR JJ O
expression NN O
was VBD N
only RB N
slightly RB N
depressed VBN N
whereas NNS N
in IN N
vitro JJ O
phagocytosis NN O
and CC O
the DT O
monocyte-activating JJ O
cytokine JJ O
interleukin-12 NN O
increased VBD N
. . N

Hydrocortisone NNP I
withdrawal NN N
induced VBD N
hemodynamic JJ N
and CC N
immunologic JJ N
rebound NN N
effects NNS N
. . N

In IN N
conclusion NN N
hydrocortisone NN I
therapy NN I
restored VBD I
hemodynamic JJ N
stability NN N
and CC N
differentially RB N
modulated VBD N
the DT N
immunologic JJ N
response NN N
to TO N
stress VB N
in IN N
a DT N
way NN N
of IN N
antiinflammation NN N
rather RB N
than IN N
immunosuppression NN N
. . N

-DOCSTART- -X- N

Probiotics NNS I
prevent VBP N
IgE-associated JJ N
allergy NN N
until IN N
age NN N
5 CD N
years NNS P
in IN P
cesarean-delivered JJ P
children NNS P
but CC N
not RB N
in IN N
the DT N
total JJ N
cohort NN N
. . N

BACKGROUND NNP N
Less NNP N
microbial JJ N
exposure NN N
in IN N
early JJ N
childhood NN N
is VBZ N
associated VBN N
with IN N
more RBR N
allergic JJ N
disease NN N
later RB N
. . N

Allergic NNP P
children NNS P
have VBP N
a DT N
different JJ N
fecal JJ N
microflora NN N
with IN N
less JJR N
lactobacilli NN N
and CC N
bifidobacteria NN N
. . N

Beneficial JJ N
effects NNS N
regarding VBG N
the DT N
development NN N
of IN N
allergy NNS N
have VBP N
been VBN N
suggested VBN N
to TO N
come VB N
through IN N
probiotic JJ I
supplementation NN N
. . N

OBJECTIVE IN N
We PRP N
sought VBD N
to TO N
study VB N
the DT N
effect NN N
of IN N
probiotic JJ I
and CC I
prebiotic JJ I
supplementation NN I
in IN N
preventing VBG N
allergies NNS N
. . N

METHODS NNP N
In IN N
a DT N
double-blinded JJ N
placebo-controlled JJ I
study NN N
we PRP N
randomized VBD N
1223 CD P
mothers NNS P
with IN P
infants NNS P
at IN P
high JJ P
risk NN P
for IN P
allergy NN P
to TO N
receive VB N
a DT N
probiotic JJ I
mixture NN I
(2 NNP I
lactobacilli NN I
bifidobacteria NN I
and CC I
propionibacteria) NN I
or CC I
placebo NN I
during IN N
the DT N
last JJ P
month NN P
of IN P
pregnancy NN P
and CC P
their PRP$ P
infants NNS P
to TO P
receive VB P
it PRP P
from IN P
birth NN P
until IN P
age NN P
6 CD P
months NNS P
. . P

Infants NNS N
also RB N
received VBD N
a DT N
prebiotic JJ I
galacto-oligosaccharide NN I
or CC I
placebo NN I
. . I

At IN N
5 CD N
years NNS N
we PRP N
evaluated VBD N
the DT N
cumulative JJ N
incidence NN N
of IN N
allergic JJ O
diseases NNS O
(eczema VBP O
food NN O
allergy NN O
allergic NN O
rhinitis NN O
and CC O
asthma) NN O
and CC O
IgE NNP O
sensitization NN O
. . O

RESULTS NN N
Of IN P
the DT P
1018 CD P
intent-to-treat NN P
infants NNS P
891 CD P
(88%) NNS P
attended VBD P
the DT P
5-year JJ P
visit NN P
. . P

Frequencies NNS O
of IN O
allergic JJ O
and CC O
IgE-associated JJ O
allergic JJ O
disease NN O
and CC N
sensitization NN O
in IN N
the DT N
probiotic JJ I
and CC N
placebo JJ I
groups NNS N
were VBD N
similar: JJ N
52.6% CD N
versus NN N
54.9% CD N
and CC N
29.5% CD N
versus NN N
26.6% CD N
respectively RB N
and CC N
41.3% CD N
in IN N
both DT N
. . N

No DT N
significant JJ N
difference NN N
appeared VBD N
in IN N
frequencies NNS O
of IN O
eczema NN O
(39.3% NNP N
vs VBZ N
43.3%) CD N
atopic NN O
eczema NN O
(24.0% NNP N
vs VBZ N
25.1%) CD N
allergic JJ O
rhinitis NN O
(20.7% NNP N
vs VBZ N
19.1%) CD N
or CC N
asthma VB O
(13.0% JJ N
vs NN N
14.1%) CD N
between IN N
groups NNS N
. . N

However RB N
less JJR N
IgE-associated JJ O
allergic JJ O
disease NN O
occurred VBD N
in IN N
cesarean-delivered JJ N
children NNS N
receiving VBG N
probiotics NNS I
(24.3% JJ N
vs VBP N
40.5%; CD N
odds NNS N
ratio VBD N
0.47; CD N
95% CD N
CI NNP N
0.23% CD N
to TO N
0.96%; CD N
P NNP N
= NNP N
.035) NNP N
. . N

CONCLUSIONS NNP N
No NNP N
allergy-preventive JJ N
effect NN N
that WDT N
extended VBD N
to TO N
age NN N
5 CD N
years NNS N
was VBD N
achieved VBN N
with IN N
perinatal JJ N
supplementation NN N
of IN N
probiotic JJ I
bacteria NNS I
to TO N
high-risk JJ P
mothers NNS P
and CC P
children NNS P
. . P

It PRP N
conferred VBD N
protection NN N
only RB N
to TO N
cesarean-delivered JJ N
children NNS N
. . N

-DOCSTART- -X- N

Clinical JJ N
and CC N
prognostic JJ N
significance NN N
of IN N
serum NN I
magnesium NN I
concentration NN N
in IN N
patients NNS P
with IN P
severe JJ P
chronic JJ P
congestive JJ P
heart NN P
failure: VBZ P
the DT N
PROMISE NNP N
Study NNP N
. . N

OBJECTIVES IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
prognostic JJ N
significance NN N
of IN N
alterations NNS N
in IN N
serum JJ I
magnesium NN I
in IN N
patients NNS P
with IN P
moderate JJ P
to TO P
severe VB P
congestive JJ P
heart NN P
failure NN P
. . P

BACKGROUND NNP N
Reductions NNP N
in IN N
serum NN I
magnesium NN I
have VBP N
been VBN N
postulated VBN N
to TO N
play VB N
a DT N
role NN N
in IN N
promoting VBG N
arrhythmias NN N
and CC N
to TO N
have VB N
an DT N
adverse JJ N
impact NN N
on IN N
survival NN N
in IN N
congestive JJ N
heart NN N
failure NN N
although IN N
support NN N
for IN N
this DT N
postulate NN N
is VBZ N
lacking VBG N
. . N

METHODS NNP N
Serum NNP O
magnesium NN O
levels NNS O
were VBD N
measured VBN N
in IN N
1 CD P
068 CD P
patients NNS P
enrolled VBN P
in IN P
a DT P
survival NN P
study NN P
of IN P
class NN P
III NNP P
or CC P
IV NNP P
heart NN P
failure NN P
at IN P
the DT P
time NN P
of IN P
double-blind JJ P
randomization NN P
to TO P
milrinone VB P
a DT P
phosphodiesterase NN P
inhibitor NN P
or CC P
placebo NN P
. . P

All DT N
patients NNS N
received VBD N
conventional JJ I
therapy NN I
with IN I
digoxin NN I
diuretic JJ I
drugs NNS I
and CC N
a DT I
converting VBG I
enzyme NN I
inhibitor NN I
throughout IN N
the DT N
trial NN N
. . N

The DT N
median JJ N
follow-up JJ N
period NN N
was VBD N
6.1 CD N
months NNS N
(range JJ N
1 CD N
day NN N
to TO N
20 CD N
months) NNS N
. . N

RESULTS JJ N
Patients NNS N
with IN N
high JJ N
serum NN I
magnesium NN I
(defined VBD N
as IN N
> NN N
or CC N
= $ N
1.9 CD N
mEq/liter NN N
n NN N
= $ N
242) CD N
were VBD N
less RBR N
likely JJ N
to TO N
survive VB O
than IN N
were VBD N
patients NNS N
with IN N
a DT N
normal JJ N
magnesium NN N
level NN N
(n NNP N
= VBZ N
627) CD N
(p NN N
< VBD N
0.05 CD N
risk NN N
ratio NN N
= VBD N
1.41) CD N
. . N

Patients NNS N
with IN N
a DT N
low JJ N
magnesium NN N
level NN N
(defined VBD N
as IN N
< NN N
or CC N
= $ N
1.5 CD N
mEq/liter NN N
n NN N
= VBD N
199) CD N
had VBD N
no DT N
difference NN N
in IN N
survival NN O
compared VBN N
with IN N
the DT N
group NN N
with IN N
a DT N
normal JJ N
magnesium NN N
level NN N
(p NNP N
= NNP N
NS NNP N
risk NN N
ratio NN N
= VBD N
0.89) CD N
. . N

At IN N
baseline PDT N
the DT N
patients NNS N
in IN N
the DT N
high JJ N
magnesium NN N
group NN N
were VBD P
older JJR P
and CC P
had VBD P
more RBR P
severe JJ P
functional JJ P
and CC P
renal JJ P
impairment NN P
. . P

An DT N
analysis NN N
after IN N
adjustment NN N
for IN N
these DT N
variables NNS N
demonstrated VBD N
no DT N
difference NN N
in IN N
survival NN O
comparing VBG N
the DT N
low JJ N
normal JJ N
and CC N
high JJ N
magnesium NN N
groups NNS N
. . N

Although IN N
the DT N
three CD N
groups NNS N
had VBD N
no DT N
difference NN N
in IN N
frequency NN N
of IN N
ventricular JJ O
tachycardia NN O
length NN O
of IN N
longest JJS N
run NN N
or CC N
frequency NN O
of IN O
ventricular JJ O
premature NN O
beats NNS O
on IN N
baseline NN N
Holter NNP O
monitoring VBG O
the DT O
group NN N
with IN N
hypomagnesemia NN N
had VBD N
more RBR N
frequent JJ N
ventricular JJ N
couplets NNS N
. . N

CONCLUSIONS NNP N
Serum NNP I
magnesium NN I
does VBZ N
not RB N
appear VB N
to TO N
be VB N
an DT N
independent JJ N
risk NN N
factor NN N
for IN N
either DT N
sudden JJ O
death NN O
or CC N
death NN O
due JJ N
to TO N
all DT N
causes NNS N
in IN N
patients NNS N
with IN N
moderate JJ N
to TO N
severe VB N
heart NN N
failure NN N
. . N

Hypomagnesemia NNP N
is VBZ N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
the DT N
frequency NN N
of IN N
certain JJ N
forms NNS N
of IN N
ventricular JJ N
ectopic NN N
activity NN N
but CC N
this DT N
is VBZ N
not RB N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
clinical JJ N
events NNS N
. . N

The DT N
higher JJR N
mortality NN N
rate NN N
among IN N
the DT N
patients NNS N
with IN N
hypermagnesemia NN N
is VBZ N
attributable JJ N
to TO N
older JJR N
age NN N
more RBR N
advanced JJ N
heart NN N
failure NN N
and CC N
renal JJ N
insufficiency NN N
. . N

-DOCSTART- -X- N

Double-blind NNP N
placebo-controlled JJ N
study NN N
of IN N
amantadine JJ N
hydrochloride NN N
in IN N
the DT N
treatment NN N
of IN N
children NNS P
with IN P
autistic JJ P
disorder NN P
. . P

OBJECTIVE NN P
To TO N
test VB N
the DT N
hypothesis NN N
that WDT N
amantadine JJ N
hydrochloride NN N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
treatment NN N
for IN N
behavioral JJ N
disturbances--for JJ N
example NN N
hyperactivity NN N
and CC N
irritability--in JJ N
children NNS P
with IN P
autism NN P
. . P

METHOD NNP N
Thirty-nine JJ P
subjects NNS P
(intent JJ P
to TO P
treat; VB P
5-19 JJ P
years NNS P
old; MD P
IQ NNP P
> VB P
35) CD P
had VBD P
autism NN P
diagnosed VBN P
according VBG P
to TO P
DSM-IV NNP P
and CC P
ICD-10 NNP P
criteria NNS P
using VBG P
the DT P
Autism NNP P
Diagnostic NNP P
Interview-Revised JJ P
and CC P
the DT P
Autism NNP P
Diagnostic NNP P
Observation NNP P
Schedule-Generic NNP P
. . P

The DT N
Aberrant NNP O
Behavior NNP O
Checklist-Community NNP O
Version NNP O
(ABC-CV) NN N
and CC N
Clinical NNP O
Global NNP O
Impressions NNP O
(CGI) NNP N
scale NN N
were VBD N
used VBN N
as IN N
outcome JJ N
variables NNS N
. . N

After IN N
a DT N
1-week JJ N
single-blind JJ N
placebo NN N
run-in JJ N
patients NNS N
received VBD N
a DT N
single JJ N
daily JJ N
dose NN N
of IN N
amantadine JJ N
(2.5 NNP N
mg/kg NN N
per IN N
day) NN N
or CC N
placebo NN N
for IN N
the DT N
next JJ N
week NN N
and CC N
then RB N
bid VB N
dosing VBG N
(5.0 JJ N
mg/kg NN N
per IN N
day) NN N
for IN N
the DT N
subsequent JJ N
3 CD N
weeks NNS N
. . N

RESULTS NN N
When WRB N
assessed VBN N
on IN N
the DT N
basis NN N
of IN N
parent-rated JJ N
ABC-CV NNP O
ratings NNS O
of IN O
irritability NN O
and CC O
hyperactivity NN O
the DT O
mean JJ N
placebo NN N
response NN N
rate NN N
was VBD N
37% CD N
versus NN N
amantadine NN N
at IN N
47% CD N
(not JJ N
significant) NN N
. . N

However RB N
in IN N
the DT N
amantadine-treated JJ N
group NN N
there EX N
were VBD N
statistically RB N
significant JJ N
improvements NNS N
in IN N
absolute JJ N
changes NNS N
in IN N
clinician-rated JJ N
ABC-CVs NNP O
for IN O
hyperactivity NN O
(amantadine NNP N
-6.4 NNP N
versus NN N
placebo NN N
-2.1; NNP N
p NN N
= NNP N
.046) NNP N
and CC N
inappropriate JJ O
speech NN O
(-1.9 JJ N
versus NN N
0.4; CD N
p NN N
= NNP N
.008) NNP N
. . N

CGI NNP O
scale JJ O
ratings NNS O
were VBD N
higher JJR N
in IN N
the DT N
amantadine NN N
group: NN N
53% CD N
improved VBN N
versus NN N
25% CD N
(p NN N
= NNP N
.076) NNP N
. . N

Amantadine NN N
was VBD N
well RB N
tolerated VBN N
. . N

CONCLUSIONS NNP N
Parents NNPS N
did VBD N
not RB N
report VB N
statistically RB N
significant JJ N
behavioral JJ O
change NN O
with IN N
amantadine NN N
. . N

However RB N
clinician-rated JJ N
improvements NNS N
in IN N
behavioral JJ O
ratings NNS O
following VBG N
treatment NN N
with IN N
amantadine JJ N
suggest VBP N
that IN N
further JJ N
studies NNS N
with IN N
this DT N
or CC N
other JJ N
drugs NNS N
acting VBG N
on IN N
the DT N
glutamatergic NN N
system NN N
are VBP N
warranted VBN N
. . N

The DT N
design NN N
of IN N
these DT N
and CC N
similar JJ N
drug NN N
trials NNS N
in IN N
children NNS P
with IN P
autistic JJ P
disorder NN P
must MD N
take VB N
into IN N
account NN N
the DT N
possibility NN N
of IN N
a DT N
large JJ N
placebo NN N
response NN N
. . N

-DOCSTART- -X- N

Enhancing VBG I
the DT I
self-esteem NN O
of IN N
inpatient JJ P
alcoholics NNS P
. . P

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
pairing VBG I
inpatient JJ P
alcoholics NNS P
with IN P
nursing NN P
home NN P
residents NNS P
(NHRs) VBP P
on IN P
the DT P
alcoholics' JJ P
self-esteem NN P
. . P

In IN N
this DT N
PALS NNP I
program NN I
the DT I
alcoholic JJ N
inpatients NNS N
assumed VBD I
a DT I
helping-companion NN I
relationship NN I
with IN I
the DT I
NHRs NNP I
for IN N
2 CD N
hr NNS N
per IN N
day NN N
during IN N
their PRP$ N
last JJ N
2 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Fifty NNP P
alcoholic JJ P
inpatients NNS P
were VBD P
randomly RB P
assigned VBN P
to TO P
the DT P
PALS NNP P
program NN P
(n NNP P
= VBZ P
25) CD P
or CC P
to TO P
the DT P
library NN P
for IN P
free JJ P
reading NN P
time NN P
(n NNP P
= VBZ P
25) CD P
. . P

The DT N
Tennessee NNP O
Self-Concept NNP O
Scale NNP O
(TSCS) NNP O
was VBD N
administered VBN N
to TO N
all DT N
subjects NNS N
in IN N
both DT N
groups NNS N
before IN N
and CC N
after IN N
the DT N
interventions NNS N
. . N

Of IN N
the DT N
nine CD N
TSCS NNP I
scales VBZ N
the DT N
improvement NN N
on IN N
the DT N
Moral-Ethical JJ O
scale NN O
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
PALS NNP N
group NN N
. . N

Because IN N
the DT N
alcoholic JJ N
inpatients NNS N
in IN N
the DT N
PALS NNP I
group NN I
engaged VBD N
in IN N
altruistic JJ N
(moral) NN N
behavior NN N
this DT N
study NN N
provides VBZ N
a DT N
logical JJ N
link NN N
between IN N
the DT N
intervention NN N
and CC N
the DT N
outcome NN N
which WDT N
has VBZ N
been VBN N
a DT N
prevalent JJ N
weakness NN N
in IN N
previous JJ N
studies NNS N
of IN N
self-esteem NN N
in IN N
alcoholics NNS N
. . N

-DOCSTART- -X- N

Effects NNS I
of IN I
sodium NN I
and CC I
potassium NN I
supplementation NN I
on IN I
blood NN O
pressure NN O
and CC O
arterial JJ O
stiffness: NN O
a DT I
fully RB I
controlled VBN I
dietary JJ I
intervention NN I
study NN I
. . I

We PRP I
performed VBD I
a DT I
randomised JJ I
placebo-controlled JJ I
crossover NN I
study NN I
to TO I
examine VB I
the DT I
effects NNS I
of IN I
sodium NN I
and CC I
potassium NN I
supplementation NN I
on IN I
blood NN P
pressure NN P
(BP) NNP P
and CC P
arterial JJ P
stiffness NN P
in IN P
untreated JJ P
(pre)hypertensive JJ P
individuals NNS P
. . P

During IN I
the DT I
study NN I
subjects NNS P
were VBD P
on IN P
a DT P
fully RB P
controlled VBN P
diet NN P
that WDT P
was VBD P
relatively RB P
low JJ P
in IN P
sodium NN P
and CC P
potassium NN P
. . P

After IN I
a DT I
1-week JJ I
run-in JJ I
period NN I
subjects NNS I
received VBD I
capsules NNS I
with IN I
supplemental JJ I
sodium NN I
(3gd(-1) JJ I
equals NNS I
7.6gd(-1) CD I
of IN I
salt) JJ I
supplemental JJ I
potassium NN I
(3gd(-1)) NN I
or CC I
placebo NN I
for IN I
4 CD I
weeks NNS I
each DT I
in IN I
random JJ I
order NN I
. . I

Fasting VBG I
office NN O
BP NNP O
24-h JJ O
ambulatory NN O
BP NNP I
and CC I
measures NNS O
of IN O
arterial JJ O
stiffness NN I
were VBD I
assessed VBN I
at IN I
baseline NN I
and CC I
every DT P
4 CD P
weeks NNS P
. . P

Of IN P
37 CD P
randomized JJ P
subjects NNS P
36 CD P
completed VBD P
the DT I
study NN I
. . I

They PRP I
had VBD I
a DT I
mean JJ I
pre-treatment JJ O
BP NNP I
of IN I
145/81mmHg CD O
and CC O
69% CD O
had VBD I
systolic JJ I
BP NNP I
140mmHg NNP I
. . I

Sodium NNP I
excretion NN I
was VBD I
increased VBN I
by IN I
98 CD I
mmol NNS I
per IN I
24h CD I
and CC I
potassium JJ I
excretion NN I
by IN I
63 CD I
mmol NNS I
per IN I
24h CD I
during IN I
active JJ I
interventions NNS I
compared VBN I
with IN I
placebo NN I
. . I

During IN O
sodium JJ O
supplementation NN O
office NN I
BP NNP I
was VBD I
significantly RB I
increased VBN O
by IN I
7.5/3.3mmHg CD O
24-h JJ O
BP NNP O
by IN O
7.5/2.7mmHg CD I
and CC I
central JJ I
BP NNP I
by IN I
8.5/3.6mmHg CD O
. . O

During IN O
potassium JJ I
supplementation NN I
24-h JJ I
BP NNP I
was VBD I
significantly RB I
reduced VBN I
by IN I
3.9/1.6mmHg CD O
and CC O
central JJ O
pulse JJ O
pressure NN O
by IN O
2.9mmHg CD O
. . I

Pulse NNP I
wave VBP I
velocity NN I
and CC I
augmentation NN I
index NN I
were VBD I
not RB I
significantly RB I
affected VBN I
by IN I
sodium NN I
or CC I
potassium NN I
supplementation NN I
. . I

In IN I
conclusion NN I
increasing VBG I
the DT I
intake NN O
of IN I
sodium NN P
caused VBD P
a DT P
substantial JJ P
increase NN P
in IN I
BP NNP I
in IN I
subjects NNS I
with IN I
untreated JJ I
elevated JJ I
BP NNP I
. . I

Increased VBN I
potassium NN I
intake NN I
on IN I
top NN I
of IN I
a DT I
relatively RB O
low-sodium JJ O
diet NN O
had VBD O
a DT I
beneficial JJ I
effect NN I
on IN I
BP NNP I
. . I

Arterial JJ I
stiffness NN I
did VBD I
not RB I
materially RB I
change VBP I
during IN I
4-week JJ I
interventions NNS N
with IN N
sodium NN N
or CC N
potassium NN N
. . N

-DOCSTART- -X- N

Controlled VBN N
clinical JJ N
trial NN N
of IN N
IV NNP I
cyclophosphamide NN I
versus NN I
IV NNP I
methylprednisolone NN I
in IN N
severe JJ P
neurological JJ P
manifestations NNS P
in IN P
systemic JJ P
lupus NN P
erythematosus NN P
. . P

BACKGROUND NNP P
Severe NNP P
neurological JJ P
involvement NN P
in IN P
systemic JJ P
lupus NN P
erythematosus NN P
(NPSLE) NN P
is VBZ N
one CD N
of IN N
the DT N
most RBS N
dreadful JJ N
complications NNS N
of IN N
the DT N
disease NN N
. . N

OBJECTIVE NN N
To TO N
identify VB N
the DT N
best JJS N
drug NN N
dose NN N
and CC N
treatment NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
controlled JJ N
clinical JJ N
trial NN N
at IN N
two CD P
tertiary JJ P
care NN P
centres NNS P
of IN P
patients NNS P
with IN P
SLE NNP P
according VBG P
to TO P
the DT P
ACR NNP P
criteria NNS P
with IN P
incident JJ P
(no NNS P
more JJR P
than IN P
15 CD P
days) JJ P
onset NN P
of IN P
severe JJ P
NP NNP P
manifestations NNS P
such JJ P
as IN P
seizures NNS P
optic JJ P
neuritis JJ P
peripheral NN P
or CC P
cranial JJ P
neuropathy JJ P
coma NN P
brainstem NN P
disease NN P
or CC P
transverse NN P
myelitis NN P
. . P

Induction NNP I
treatment NN I
with IN N
3 CD I
g NN I
of IN I
IV NNP I
methylprednisolone NN I
(MP) NN N
followed VBN N
by IN N
either DT N
IV NNP N
monthly JJ N
cyclophosphamide NN I
(Cy) NNP I
versus NN I
IV NNP I
MP NNP I
bimonthly RB I
every DT N
4 CD N
months NNS N
for IN N
1 CD N
year NN N
and CC N
then RB N
IV NNP I
Cy NNP I
or CC I
IV NNP I
MP NNP I
every DT N
3 CD N
months NNS N
for IN N
another DT N
year NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
response NN O
to TO O
treatment: VB O
at IN N
least JJS N
20% CD N
improvement NN N
from IN N
basal JJ N
conditions NNS N
on IN N
clinical JJ O
laboratory NN O
or CC O
specific JJ O
neurological JJ O
testing NN O
variables NNS O
. . O

RESULTS NNP N
Overall NNP N
a DT N
response NN O
rate NN O
of IN N
75% CD N
was VBD N
observed VBN N
. . N

Of IN N
the DT N
32 CD P
patients NNS P
studied VBD P
18/19 CD P
receiving VBG N
Cy NNP I
and CC N
7/13 CD N
receiving VBG N
MP NNP I
responded VBD N
to TO N
treatment NN N
(p<0.03) NN N
. . N

CONCLUSIONS NNP N
Cy NNP I
seems VBZ N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
MP NNP I
in IN N
the DT N
treatment NN N
of IN N
acute NN N
severe JJ N
NPSLE NNP N
. . N

-DOCSTART- -X- N

Home NN I
based VBN I
management NN I
in IN N
multiple JJ P
sclerosis: JJ P
results NNS N
of IN N
a DT N
randomised VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Home NNP I
based VBN I
medical JJ I
care NN I
is VBZ N
a DT N
popular JJ N
alternative NN N
to TO N
standard VB N
hospital NN N
care NN N
but CC N
there EX N
is VBZ N
uncertainty NN N
about IN N
its PRP$ N
cost-effectiveness NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
effectiveness NN O
and CC O
the DT O
costs NNS O
of IN N
multidisciplinary JJ I
home NN I
based VBN I
care NN I
in IN N
multiple JJ P
sclerosis NN P
with IN N
hospital NN N
care NN N
in IN N
a DT N
prospective JJ N
randomised VBN N
controlled VBN N
trial NN N
with IN N
a DT N
one CD N
year NN N
follow VB N
up RP N
. . N

METHODS NNP N
201 CD P
patients NNS P
with IN P
clinically RB P
definite JJ P
multiple JJ P
sclerosis NN P
were VBD N
studied VBN N
. . N

They PRP N
were VBD N
randomised VBN N
in IN N
a DT N
ratio NN N
2:1 CD N
to TO N
an DT N
intervention NN N
group NN N
(133) VBD N
or CC N
a DT N
control NN N
group NN N
(68) NNP N
. . N

They PRP N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
one CD N
year NN N
after IN N
randomisation NN N
with IN N
validated JJ N
measures NNS N
of IN N
physical JJ O
and CC O
psychological JJ O
impairment NN O
and CC O
quality NN O
of IN O
life NN O
(SF-36 JJ N
health NN N
survey) NN N
. . N

The DT N
costs NNS N
to TO N
the DT N
National NNP N
Health NNP N
Service NNP N
over IN N
the DT N
one CD N
year NN N
follow VBP N
up RP N
were VBD N
calculated VBN N
by IN N
a DT N
cost NN N
minimisation NN N
analysis NN N
. . N

RESULTS RB N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
functional JJ N
status NN N
between IN N
the DT N
home NN N
based VBN N
care NN N
group NN N
and CC N
the DT N
hospital NN N
group NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
favouring VBG N
home NN N
based VBN N
management NN N
in IN N
four CD N
SF-36 JJ O
health NN O
dimensions-general JJ O
health NN O
bodily RB O
pain VB O
role-emotional JJ O
and CC O
social JJ O
functioning VBG O
(all JJ N
p NN N
< NN N
or CC N
= $ N
0.001) CD N
. . N

The DT N
cost NN O
of IN N
home NN N
based VBN N
care NN N
was VBD N
slightly RB N
less JJR N
(822 JJ N
euros/patient/year) NN N
than IN N
hospital NN N
care NN N
mainly RB N
as IN N
a DT N
result NN N
of IN N
a DT N
reduction NN N
in IN N
hospital JJ N
admissions NNS N
. . N

CONCLUSIONS NNP N
Comprehensive NNP I
planning NN I
of IN I
home NN I
based VBN I
intervention NN I
implemented VBN N
by IN N
an DT N
interdisciplinary JJ N
team NN N
and CC N
designed VBN N
specifically RB N
for IN N
people NNS P
with IN P
multiple JJ P
sclerosis NN P
may MD N
provide VB N
a DT N
cost-effective JJ N
approach NN N
to TO N
management NN N
and CC N
improve VB N
the DT N
quality NN N
of IN N
life NN N
. . N

-DOCSTART- -X- N

Safety NNP N
tolerability NN N
and CC N
changes NNS N
in IN N
amyloid JJ O
beta NN O
concentrations NNS O
after IN N
administration NN N
of IN N
a DT N
gamma-secretase JJ N
inhibitor NN N
in IN N
volunteers NNS P
. . P

Amyloid NNP P
beta NN N
(Abeta) NN N
may MD N
play VB N
a DT N
central JJ N
role NN N
in IN N
the DT N
pathogenesis NN N
of IN N
Alzheimer NNP N
disease NN N
. . N

A DT N
functional JJ N
gamma-secretase NN N
inhibitor NN N
LY450139 NNP N
was VBD N
developed VBN N
that IN N
inhibits NNS N
Abeta NNP N
formation NN N
in IN N
whole JJ N
cell NN N
assays VBZ N
transgenic JJ N
mice NN N
and CC N
beagle JJ N
dogs NNS N
. . N

The DT N
authors NNS N
wished VBD N
to TO N
determine VB N
the DT N
safety NN N
and CC N
tolerability NN N
of IN N
this DT N
drug NN N
and CC N
the DT N
reduction NN N
of IN N
Abeta NNP O
in IN O
plasma NN O
and CC O
cerebrospinal JJ O
fluid NN O
(CSF) NN O
after IN N
multiple JJ N
doses NNS N
. . N

Volunteer NNP P
subjects NNS P
(N NNP P
= VBD P
37) CD P
were VBD N
studied VBN N
using VBG N
doses NNS N
from IN N
5 CD N
to TO N
50 CD N
mg/day NN N
given VBN N
for IN N
14 CD N
days NNS N
. . N

Plasma NNP O
and CC O
CSF NNP O
concentrations NNS O
of IN N
LY450139 NNP N
Abeta(1-40) NNP N
and CC N
Abeta(1-X) NNP O
("Abeta(total)") NNP N
were VBD N
determined VBN N
and CC N
safety NN N
and CC N
tolerability NN N
were VBD N
assessed VBN N
. . N

The DT N
plasma JJ N
half-life NN N
of IN N
LY450139 NNP N
was VBD N
approximately RB N
2.5 CD N
hours NNS N
. . N

Pharmacokinetic JJ N
analyses NNS N
showed VBD N
a DT N
linear JJ N
relationship NN N
between IN N
dose NN N
and CC N
plasma JJ N
concentrations NNS N
with IN N
a DT N
Cmax NNP N
of IN N
828 CD N
+/- JJ N
19.2 CD N
ng/mL NN N
after IN N
a DT N
50-mg JJ N
dose NN N
. . N

Plasma NNP O
Abeta NNP O
concentrations NNS O
decreased VBD N
in IN N
a DT N
dose-dependent JJ N
manner NN N
over IN N
a DT N
6-hour JJ N
interval NN N
following VBG N
drug NN N
administration NN N
with IN N
a DT N
maximum JJ N
decrease NN N
of IN N
approximately RB N
40% CD N
relative JJ N
to TO N
baseline VB N
. . N

After IN N
returning VBG N
to TO N
baseline VB N
Abeta NNP O
concentrations NNS O
were VBD N
transiently RB N
increased VBN N
. . N

CSF NNP O
Abeta NNP O
concentrations NNS O
were VBD N
unchanged JJ N
. . N

Adverse JJ O
events NNS O
reported VBN N
by IN N
subjects NNS N
taking VBG N
5-mg JJ N
20-mg JJ N
or CC N
40-mg JJ N
doses NNS N
were VBD N
similar JJ N
to TO N
those DT N
reported VBN N
by IN N
subjects NNS P
taking VBG P
placebo NN P
. . P

Two CD N
of IN N
7 CD N
subjects NNS N
taking VBG N
50 CD N
mg/day NN N
experienced VBD N
adverse JJ N
events NNS N
that WDT N
may MD N
have VB N
been VBN N
drug NN N
related VBN N
. . N

In IN N
this DT N
phase NN N
1 CD N
volunteer NN N
study NN N
reported VBD N
adverse JJ N
events NNS N
after IN N
taking VBG N
LY450139 NNP N
were VBD N
manageable JJ N
. . N

A DT N
dose-dependent JJ N
reduction NN N
in IN N
plasma NN N
Abeta NNP O
was VBD N
demonstrated VBN N
and CC N
changes NNS N
in IN N
plasma NN N
Abeta NNP N
concentrations NNS N
were VBD N
temporally RB N
related VBN N
to TO N
the DT N
pharmacokinetic JJ N
characteristics NNS N
of IN N
LY450139 NNP N
. . N

-DOCSTART- -X- N

Closure NN I
of IN I
the DT I
femoral JJ P
artery NN P
after IN P
cardiac JJ P
catheterization: NN P
a DT I
comparison NN I
of IN I
Angio-Seal NNP I
StarClose NNP I
and CC I
manual JJ I
compression NN I
. . I

OBJECTIVES NNP I
To TO I
compare VB I
Angio-Seal NNP I
(AS) NNP I
and CC I
StarClose NNP I
(SC) NNP I
and CC I
manual JJ I
compression NN I
(MC) NN I
on IN I
efficacy NN I
of IN I
hemostasis NN O
complication NN O
rate NN O
safety NN O
of IN O
early JJ O
mobilization NN O
and CC O
patient JJ O
comfort NN O
. . O

BACKGROUND NNP I
Closure NNP I
of IN I
the DT I
femoral JJ I
artery NN I
after IN I
cardiac JJ I
catheterization NN I
can MD I
be VB I
obtained VBN I
through IN I
different JJ I
methods NNS I
. . I

Today NN I
physicians NNS I
can MD I
choose VB I
from IN I
a DT I
number NN I
of IN I
different JJ I
devices NNS I
to TO I
achieve VB I
arterial JJ I
closure NN I
. . I

METHODS NNP I
In IN I
a DT P
prospective JJ P
trial NN P
450 CD P
patients NNS P
were VBD P
randomized VBN P
to TO P
AS NNP P
SC NNP P
or CC P
MC NNP I
. . I

Patients NNS P
were VBD P
mobilized VBN P
1 CD P
to TO P
2 CD P
hr NN P
after IN P
device NN P
placement NN P
and CC P
6 CD P
hr NN P
after IN P
MC NNP I
. . I

Data NNS I
were VBD I
collected VBN I
during IN I
hospital JJ I
admission NN I
and CC I
by IN I
telephone NN I
at IN I
one CD I
month NN I
after IN I
hospital JJ I
discharge NN I
. . I

RESULTS JJ I
Devices NNPS I
were VBD I
used VBN I
in IN I
138/150 CD I
allocated JJ I
to TO I
AS NNP I
and CC I
124/150 CD I
allocated VBN I
to TO I
SC NNP I
patients NNS I
(92% JJ I
vs NN I
. . I

83% CD I
P NNP I
= VBD I
0.015) CD I
Patients NNS I
with IN I
MC NNP I
experienced VBD I
more JJR I
pain NN O
during IN O
sheath NN O
removal NN O
than IN I
patients NNS I
receiving VBG I
a DT I
device NN I
and CC I
rated VBN I
their PRP$ I
period NN I
of IN I
bed NN O
rest NN O
as IN I
less RBR I
comfortable JJ I
. . I

Oozing VBG O
and CC O
need VB O
for IN O
pressure NN O
bandage NN O
at IN I
the DT I
puncture NN I
site NN I
were VBD I
observed VBN I
in IN I
37 CD I
AS IN I
patients NNS I
and CC I
57 CD I
SC NNP I
patients NNS I
(25% JJ I
vs NN I
. . I

38% CD I
P NNP I
= VBD I
0.002) CD I
. . I

Hematoma NNP O
occurred VBD I
in IN I
15 CD I
AS IN I
patients NNS I
in IN I
17 CD I
SC NNP I
patients NNS I
and CC I
in IN I
14 CD I
MC NNP I
patients NNS I
(11 JJ I
vs NN I
. . I

14 CD I
vs NN I
. . I

9% CD I
ns) NN I
. . I

CONCLUSION NNP I
There EX I
is VBZ I
no DT I
difference NN I
in IN I
safety NN I
between IN I
the DT I
three CD I
methods NNS I
of IN I
arterial JJ I
closure NN I
. . I

SC NNP I
was VBD I
more RBR I
often RB I
not RB I
used VBN I
or CC I
successfully RB I
deployed VBN I
. . I

SC JJ I
patients NNS I
more RBR I
often RB I
had VBD I
continuing VBG I
oozing NN I
. . I

On IN I
patient JJ I
comfort NN I
closure NN I
devices NNS I
performed VBD I
better JJR I
than IN I
MC NNP I
. . I

Early JJ I
ambulation NN I
in IN I
patients NNS I
with IN I
a DT I
closure NN I
device NN I
is VBZ I
safe JJ I
. . I

AS IN I
is VBZ I
the DT I
preferred JJ I
method NN I
of IN I
arterial JJ I
closure NN I
after IN I
cardiac JJ I
catheterization NN I
. . I

-DOCSTART- -X- N

The DT I
NORwegian JJ I
study NN I
on IN I
DIstrict NNP I
treatment NN I
of IN I
ST-elevation NNP P
myocardial JJ P
infarction NN P
(NORDISTEMI) NN I
. . I

OBJECTIVES NNP I
Thrombolysis NNP I
is VBZ I
the DT I
treatment NN I
of IN I
choice NN I
for IN I
patients NNS P
with IN P
ST-elevation NNP P
myocardial JJ P
infarction NN P
(STEMI) NN P
living NN P
in IN P
rural JJ P
areas NNS P
with IN P
long JJ P
transfer NN P
delays NNS P
to TO P
percutaneous JJ P
coronary JJ P
intervention NN P
(PCI) NN P
. . P

This DT I
trial NN I
compares VBZ I
two CD I
different JJ I
strategies NNS I
following VBG I
thrombolysis: NN I
to TO I
transfer VB I
all DT I
patients NNS I
for IN I
immediate JJ I
coronary JJ I
angiography NN I
and CC I
intervention NN I
or CC I
to TO I
manage VB I
the DT I
patients NNS I
more RBR I
conservatively RB I
. . I

DESIGN NNP I
The DT I
NORwegian JJ I
study NN P
on IN P
DIstrict NNP P
treatment NN P
of IN P
STEMI NNP P
(NORDISTEMI) NNP P
is VBZ I
an DT I
open JJ I
prospective JJ I
randomized VBN I
controlled JJ I
trial NN I
in IN I
patients NNS P
with IN P
STEMI NNP P
of IN P
less JJR P
than IN P
6 CD P
hours NNS P
of IN P
duration NN P
and CC P
more JJR P
than IN P
90 CD P
minutes NNS P
expected VBD P
time NN P
delay NN P
to TO P
PCI NNP P
. . P

A DT P
total NN P
of IN P
266 CD P
patients NNS P
will MD I
receive VB I
full-dose JJ I
thrombolysis NN I
preferably RB I
pre-hospital JJ I
and CC I
then RB I
be VB I
randomized VBN I
to TO I
either DT I
strategy NN I
. . I

Our PRP$ I
primary JJ I
endpoint NN I
is VBZ I
the DT I
one CD I
year NN I
combined VBN I
incidence NN I
of IN I
death NN O
reinfarction NN O
stroke VBD O
or CC O
new JJ O
myocardial JJ O
ischaemia NN O
. . O

The DT I
study NN I
is VBZ I
registered VBN I
with IN I
ClinicalTrials.gov NNP I
number NN I
NCT00161005 NNP I
. . I

RESULTS VBN I
By IN I
April NNP P
2006 CD P
109 CD P
patients NNS P
have VBP I
been VBN I
randomized VBN I
. . I

Thrombolysis NN I
has VBZ I
been VBN I
given VBN I
pre-hospital JJ I
to TO I
52% CD I
of IN I
patients NNS I
. . I

The DT I
median JJ I
transport NN I
distance NN I
from IN I
first JJ I
medical JJ I
contact NN I
to TO I
catheterization NN I
laboratory NN I
was VBD I
155 CD I
km JJ I
(range NN I
90-396 CD I
km) NN I
. . I

Results NNS I
of IN I
the DT I
study NN I
are VBP I
expected VBN I
in IN I
2008 CD I
. . I

-DOCSTART- -X- N

High-dose JJ I
vitamin NN I
D3 NNP I
supplementation NN I
in IN N
children NNS P
and CC P
young JJ P
adults NNS P
with IN P
HIV: NNP P
a DT N
randomized JJ N
placebo-controlled JJ I
trial NN I
. . I

BACKGROUND NNP N
Suboptimal NNP N
vitamin NNP N
D NNP N
status NN N
is VBZ N
prevalent JJ N
in IN N
HIV-infected JJ P
patients NNS P
and CC N
associated VBN N
with IN N
increased JJ N
risk NN N
of IN N
disease NN N
severity NN N
and CC N
morbidity NN N
. . N

We PRP N
aimed VBD N
to TO N
determine VB N
12-month JJ N
safety NN O
and CC O
efficacy NN O
of IN N
daily JJ I
7000 CD I
IU NNP I
vitamin FW I
D3 NNP I
(vitD3) NNP I
versus NN I
placebo NN I
to TO N
sustain VB N
increased JJ O
serum NN O
25-hydroxyvitamin JJ O
D NNP O
(25(OH)D) NN O
and CC N
improve VB N
immune NN O
status NN O
in IN N
HIV-infected JJ P
subjects NNS P
. . P

METHODS NNP N
This DT N
was VBD N
a DT N
double-blind JJ N
trial NN N
of IN N
perinatally RB P
acquired VBN P
HIV NNP P
(PHIV)-infected JJ P
subjects NNS P
or CC P
behaviorally RB P
acquired VBN P
HIV NNP P
(BHIV)-infected JJ P
subjects NNS P
(5.0-24.9 JJ P
years) NN P
. . P

Safety NNP O
25(OH)D-related JJ O
parameters NNS O
and CC O
immune JJ O
status NN O
were VBD N
assessed VBN N
at IN N
baseline NN N
3 CD N
6 CD N
and CC N
12 CD N
months NNS N
. . N

RESULTS NNP N
Fifty-eight JJ P
subjects NNS P
enrolled VBD P
(67% JJ P
male NN P
85% CD P
African JJ P
American NNP P
and CC P
64% CD P
BHIV) NNP P
and CC P
50 CD P
completed VBN P
with IN P
no DT P
safety NN P
concerns NNS P
. . P

In IN N
unadjusted JJ N
analyses NNS N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
randomization NN N
groups NNS N
at IN N
baseline; NN N
at IN N
3 CD N
6 CD N
and CC N
12 CD N
months NNS N
25(OH)D CD N
was VBD N
higher JJR N
with IN N
supplementation NN N
than IN N
baseline NN N
and CC N
higher JJR N
than IN N
with IN N
placebo JJ I
(P NNP N
< NNP N
0.05) CD N
. . N

In IN N
adjusted VBN N
mixed JJ N
models NNS N
in IN N
the DT N
supplementation NN N
group NN N
the DT N
fixed JJ N
effect NN N
of IN N
25(OH)D CD N
was VBD N
higher JJR N
(P JJ N
< $ N
0.001) CD N
. . N

Percentage NN N
of IN N
naive JJ O
T-helper NNP O
cells NNS O
(Th JJ O
naive%) NNS O
were VBD N
significantly RB N
(P JJ N
< $ N
0.01) CD N
and CC N
T-helper NNP O
cells NNS O
(CD4%) NNP O
marginally RB N
(P VBZ N
< JJ N
0.10) CD N
increased VBD N
with IN N
supplementation NN N
in IN N
those DT N
taking VBG N
highly RB N
active JJ I
antiretroviral JJ I
therapy NN I
(HAART) NN I
and CC I
RNA NNP N
viral JJ N
load NN N
was VBD N
reduced VBN N
(P NNP N
 $ N
0.05) CD N
. . N

In IN N
exploratory JJ N
linear JJ N
models NNS N
change VBP N
in IN N
25(OH)D CD N
predicted VBD N
RNA NNP N
viral JJ N
load NN N
at IN N
3 CD N
and CC N
12 CD N
months NNS N
and CC N
CD4% NNP N
at IN N
3 CD N
months NNS N
(P JJ N
< JJ N
0.05) CD N
. . N

CONCLUSIONS NNP I
Daily NNP I
7000 CD I
IU NNP I
vitD3 NN I
for IN N
12 CD N
months NNS N
was VBD N
safe JJ N
in IN N
HIV-infected JJ N
subjects NNS N
and CC N
effective JJ N
in IN N
increasing VBG N
25(OH)D CD N
. . N

Supplementation NNP N
improved VBD N
some DT N
clinically RB N
important JJ N
HIV NNP N
immune NN N
markers NNS N
in IN N
subjects NNS N
on IN N
HAART NNP N
. . I

Adjunct NNP I
therapy NN I
with IN I
high-dose JJ I
daily JJ I
vitD3 NN I
for IN I
HIV-infected JJ N
subjects NNS N
and CC N
for IN N
those DT N
on/off JJ N
HAART NNP N
requires VBZ N
further JJ N
investigation NN N
. . N

-DOCSTART- -X- N

The DT N
effect NN N
of IN N
patient JJ I
position NN I
on IN N
the DT N
reproducibility NN N
of IN N
cardiac JJ N
output NN N
measurements NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
effect NN N
of IN N
patient JJ I
position NN I
on IN N
the DT N
reproducibility NN N
of IN N
cardiac JJ N
output NN N
measurements NNS N
. . N

DESIGN NNP N
Prospective JJ N
two-group JJ N
quasi-experimental JJ N
design NN N
. . N

Convenience NN N
sample NN N
. . N

SETTING VBG N
The DT N
study NN N
involved VBD N
two CD P
intensive JJ P
care NN P
units NNS P
in IN P
two CD P
adult NN P
acute NN P
care NN P
hospitals NNS P
. . P

PATIENTS NNP P
Thirty NNP P
patients NNS P
admitted VBD P
to TO P
the DT P
intensive JJ P
care NN P
unit NN P
who WP P
had VBD P
a DT P
thermodilution NN P
pulmonary JJ P
artery NN P
catheter NN P
in IN P
place NN P
. . P

Ages NNS P
ranged VBD P
from IN P
39 CD P
to TO P
80 CD P
years NNS P
(mean CD P
of IN P
66.4 CD P
+/- JJ P
11.3 CD P
years) NN P
. . P

OUTCOME NNP P
MEASURES NNP N
Thermodilution NNP N
cardiac NN N
output NN N
measurements NNS N
. . N

INTERVENTION NNP N
The DT N
subjects NNS N
were VBD N
placed VBN N
in IN N
one CD N
of IN N
two CD N
groups NNS N
initially RB N
by IN N
flipping VBG N
a DT N
coin NN N
then RB N
into IN N
alternate NN N
groups NNS N
. . N

Group NNP N
A NNP N
subjects NNS N
were VBD N
placed VBN I
supine NN I
and CC I
after IN I
5 CD I
minutes NNS I
had VBD I
cardiac JJ I
output NN I
measurements NNS I
performed VBN I
. . I

They PRP N
were VBD N
then RB N
placed VBN N
in IN N
the DT N
45-degree JJ I
upright JJ I
position NN I
and CC I
after IN N
an DT N
additional JJ N
5 CD N
minutes NNS N
had VBD N
cardiac JJ N
output NN N
measurements NNS N
performed VBN N
. . N

Group NNP N
B NNP N
subjects NNS N
were VBD N
first RB N
placed VBN N
in IN N
the DT N
45-degree JJ I
upright JJ I
position NN I
and CC I
after IN N
5 CD N
minutes NNS N
had VBD N
cardiac JJ N
output NN N
measurements NNS N
performed VBN N
. . N

They PRP N
were VBD N
then RB N
placed VBN N
in IN N
the DT N
supine NN I
flat JJ I
position NN I
and CC I
after IN N
an DT N
additional JJ N
5 CD N
minutes NNS N
had VBD N
cardiac JJ N
output NN N
measurements NNS N
performed VBN N
. . N

RESULTS NNP N
Seventy NNP N
percent NN N
(n NNP N
= NNP N
30) CD N
of IN N
the DT N
sample JJ N
population NN N
displayed VBD N
a DT N
lower JJR O
cardiac NN O
output NN O
in IN N
the DT N
45-degree JJ N
upright JJ N
position NN N
than IN N
that DT N
obtained VBN N
in IN N
the DT N
supine JJ N
position NN N
with IN N
the DT N
decrease NN N
ranging VBG N
from IN N
1% CD N
to TO N
32% CD N
(mean JJ N
decrease NN N
11%) CD N
. . N

Forty NNP N
percent NN N
(n NNP N
= NNP N
30) CD N
of IN N
cardiac JJ O
output NN O
measurements NNS O
obtained VBN N
in IN N
the DT N
45-degree JJ N
upright NN N
were VBD N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
10% CD N
less JJR N
than IN N
those DT N
obtained VBN N
in IN N
the DT N
supine NN N
flat JJ N
position NN N
. . N

The DT N
differences NNS N
in IN N
cardiac JJ O
output NN O
were VBD N
analyzed VBN N
with IN N
the DT N
paired JJ N
t JJ N
test NN N
. . N

which WDT N
produced VBD N
a DT N
95% CD N
confidence NN N
interval NN N
from IN N
-0.539 NN N
to TO N
-0.083 VB N
. . N

The DT I
two-group JJ I
Wilcoxon NNP I
test NN I
was VBD N
used VBN N
to TO N
analyze VB N
the DT N
mean JJ O
cardiac JJ O
output NN O
with IN N
the DT N
patient NN N
in IN N
the DT N
supine NN N
flat JJ N
position NN N
and CC N
in IN N
the DT N
45-degree JJ N
upright JJ N
position NN N
. . N

The DT N
mean JJ O
cardiac JJ O
output NN O
at IN N
0 CD N
degrees NNS N
was VBD N
found VBN N
to TO N
be VB N
statistically RB N
significant JJ N
higher JJR N
(p NN N
= VBZ N
0.0083) CD N
than IN N
the DT N
mean JJ N
cardiac JJ N
output NN N
at IN N
45 CD N
degrees NNS N
. . N

The DT N
effect NN N
of IN N
coexisting VBG N
variables NNS N
was VBD N
analyzed VBN N
with IN N
the DT N
Kruskal-Wallis NNP N
. . N

The DT N
use NN N
of IN N
vasoconstrictors NNS N
was VBD N
the DT N
only JJ N
variable NN N
that WDT N
had VBD N
a DT N
statistically RB N
significant JJ N
change NN N
in IN N
cardiac JJ O
output NN O
associated VBN N
with IN N
a DT N
change NN N
in IN N
position NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
indicate VBP N
that IN N
cardiac JJ N
output NN N
measurements NNS N
are VBP N
affected VBN N
by IN N
alterations NNS N
in IN N
patient JJ N
position NN N
. . N

To TO N
ensure VB N
accurate JJ N
comparisons NNS N
between IN N
consecutive JJ N
cardiac JJ N
output NN N
measurements NNS N
the DT N
researchers NNS N
recommend VBP N
that IN N
the DT N
position NN N
in IN N
which WDT N
the DT N
cardiac NN N
output NN N
measurements NNS N
are VBP N
performed VBN N
be VB N
documented VBN N
and CC N
the DT N
cardiac JJ N
output NN N
measurements NNS N
be VB N
conducted VBN N
in IN N
a DT N
uniform JJ N
position NN N
. . N

-DOCSTART- -X- N

A DT N
double-blind JJ N
placebo-controlled JJ I
study NN N
to TO N
evaluate VB N
valacyclovir NN I
alone RB I
and CC N
with IN I
aspirin NN I
for IN N
asymptomatic JJ N
HSV-1 NNP N
DNA NNP N
shedding VBG P
in IN P
human JJ P
tears NNS P
and CC P
saliva NN P
. . P

PURPOSE NN N
To TO N
test VB N
the DT N
effect NN N
of IN N
valacyclovir NN I
alone RB I
and CC N
with IN I
aspirin NN I
on IN N
the DT N
asymptomatic JJ N
shedding NN N
of IN N
HSV-1 NNP N
DNA NNP N
in IN P
tears NNS P
and CC P
saliva NN P
of IN P
healthy JJ P
individuals NNS P
. . P

METHOD NNP N
. . N

The DT N
subjects NNS P
(n VBP P
= JJ P
45) CD P
were VBD N
randomized VBN N
into IN N
three CD N
groups NNS N
without IN N
regard NN N
to TO N
age NN N
sex NN N
or CC N
race NN N
. . N

Group NNP N
1 CD N
(n NNP N
= VBD N
14) CD N
received VBD N
the DT N
placebo NN I
group NN I
2 CD N
(n NNP N
= VBD N
15) CD N
received VBD N
a DT N
dose NN N
of IN N
500 CD I
mg NNS I
valacyclovir JJ I
once RB I
daily JJ I
and CC I
group NN N
3 CD N
(n NNP N
= VBD N
16) CD N
received VBD N
a DT N
dose NN N
of IN N
500 CD I
mg NNS I
valacyclovir JJ I
once RB I
daily JJ I
and CC I
350 CD I
mg NN I
aspirin JJ I
twice RB I
daily RB I
for IN I
30 CD I
days NNS I
. . I

Ocular JJ N
and CC N
oral JJ N
swabs NNS N
were VBD N
collected VBN N
twice RB N
daily RB N
for IN N
30 CD N
days NNS N
. . N

DNA NN N
was VBD N
extracted VBN N
from IN N
all DT N
swabs NNS N
and CC N
HSV-1 NNP N
DNA NNP N
copy NN N
numbers NNS N
were VBD N
determined VBN N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
to TO N
compare VB N
the DT N
DNA NNP N
copy NN N
numbers NNS N
of IN N
the DT N
three CD N
groups NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
HSV-1 NNP O
DNA NNP O
copy NN O
numbers NNS O
in IN N
the DT N
tears NNS N
or CC N
saliva NN N
among IN N
any DT N
of IN N
the DT N
three CD N
treatment NN I
groups NNS N
. . N

The DT N
mean JJ N
copy NN N
numbers NNS N
+/- JJ N
SE NNP N
of IN N
mean JJ N
(SEM) NN N
of IN N
HSV-1 NNP N
DNA NNP N
in IN N
tears NNS N
were VBD N
340 CD N
+/- JJ N
35 CD N
1074 CD N
+/- JJ N
320 CD N
and CC N
630 CD N
+/- JJ N
51 CD N
for IN N
groups NNS N
1 CD N
2 CD N
and CC N
3 CD N
and CC N
in IN N
saliva NN N
were VBD N
238 CD N
+/- JJ N
35 CD N
963 CD N
+/- JJ N
462 CD N
and CC N
493 CD N
+/- JJ N
25 CD N
respectively RB N
for IN N
groups NNS N
1 CD N
2 CD N
and CC N
3 CD N
. . N

CONCLUSIONS NNP N
No NNP N
correlation NN N
was VBD N
found VBN N
between IN N
HSV-1 NNP N
shedding VBG N
and CC N
valacyclovir NNS I
and CC N
valacyclovir NN I
with IN I
aspirin JJ I
treatment NN I
. . I

The DT N
HSV-1 NNP N
DNA NNP N
copy NN N
number NN N
was VBD N
not RB N
reduced VBN N
by IN N
treatment NN I
with IN N
500 CD N
mg NNS N
of IN N
valacyclovir JJ I
daily JJ N
or CC N
with IN N
a DT N
combination NN N
of IN N
daily JJ N
valacyclovir NNS I
(500 VBP I
mg) JJ I
plus CC I
twice-daily JJ I
doses NNS I
of IN I
aspirin JJ I
(350 NNP N
mg) NN N
over IN N
30 CD N
days NNS N
. . N

-DOCSTART- -X- N

Randomized VBN N
Controlled JJ N
Trial NNP N
of IN N
Mind NNP I
Reading NNP I
and CC I
In IN I
Vivo NNP I
Rehearsal NNP I
for IN N
High-Functioning NNP P
Children NNP P
with IN P
ASD NNP P
. . P

This DT N
randomized VBD N
controlled JJ N
trial NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
a DT N
computer NN I
software NN I
(i.e NNP I
. . I

Mind NNP I
Reading) NNP I
and CC I
in IN I
vivo JJ I
rehearsal NN I
treatment NN I
on IN N
the DT N
emotion NN O
decoding NN O
and CC O
encoding VBG O
skills NNS O
autism NN O
symptoms NNS O
and CC O
social JJ O
skills NNS O
of IN N
43 CD P
children NNS P
ages VBZ P
7-12years NNS P
with IN P
high-functioning JJ P
autism NN P
spectrum NN P
disorder NN P
(HFASD) NN P
. . N

Children NNP N
in IN I
treatment NN I
(n=22) NN N
received VBD N
the DT I
manualized VBN I
protocol NN I
over IN N
12weeks CD N
. . N

Primary JJ N
analyses NNS N
indicated VBD N
significantly RB N
better JJR O
posttest JJS O
performance NN O
for IN N
the DT I
treatment NN I
group NN I
(compared VBD I
to TO I
controls) VB I
on IN N
3 CD N
of IN N
the DT N
4 CD N
measures NNS O
of IN O
emotion NN O
decoding NN O
and CC O
encoding NN O
and CC N
these DT N
were VBD N
maintained VBN N
at IN N
5-week JJ N
follow-up NN N
. . N

Analyses NNS N
of IN N
secondary JJ N
measures NNS N
favored VBD N
the DT I
treatment NN I
group NN I
for IN N
1 CD N
of IN N
the DT N
2 CD N
measures; NNS N
specifically RB N
ASD NNP N
symptoms NNS N
were VBD N
significantly RB N
lower JJR N
at IN N
posttest NN N
and CC N
follow-up NN N
. . N

-DOCSTART- -X- N

Teriparatide NNP I
improves VBZ N
early JJ N
callus NN O
formation NN O
in IN N
distal JJ P
radial JJ P
fractures NNS P
. . P

BACKGROUND NNP N
Teriparatide NNP I
(parathyreoid NNP I
hormone; NN I
PTH NNP I
1-34) JJ I
increases NNS N
skeletal JJ N
mass NN N
in IN N
humans NNS N
and CC N
improves VBZ N
fracture NN N
healing VBG N
in IN N
animals NNS N
. . N

A DT N
recent JJ N
randomized JJ P
multicenter NN P
trial NN P
of IN P
nonoperated JJ P
distal JJ P
radial NN P
fractures NNS P
showed VBD N
a DT N
moderate JJ N
shortening NN N
of IN N
the DT N
time NN N
to TO N
restoration NN N
of IN N
cortical JJ N
continuity NN N
by IN N
treatment NN I
with IN I
20 CD I
microg NNS I
(low-dose) JJ I
teriparatide JJ I
per IN I
day NN I
but CC I
not RB I
with IN I
40 CD I
microg JJ I
(high-dose) NN I
. . I

As IN N
radiographic JJ N
cortical JJ N
continuity NN N
appears VBZ N
late RB N
in IN N
the DT N
healing NN N
process NN N
perhaps RB N
too RB N
late JJ N
for IN N
clinical JJ N
relevance NN N
we PRP I
studied VBD I
the DT I
qualitative JJ I
appearance NN I
of IN I
the DT I
callus JJ I
5 CD I
weeks NNS I
after IN I
fracture NN I
. . I

METHODS NNP N
One CD P
third NN P
of IN P
the DT P
patients NNS P
of IN P
the DT P
international JJ P
trial NN P
were VBD P
treated VBN P
at IN P
Linkping NNP P
University NNP P
Hospital NNP P
. . N

The DT N
multicenter NN N
trial NN N
did VBD N
not RB N
evaluate VB N
early JJ N
callus NN N
formation NN N
. . N

We PRP N
therefore RB N
made VBD N
a DT I
blinded JJ I
qualitative JJ I
scoring NN I
of IN I
the DT I
callus NN I
at IN N
5 CD N
weeks NNS N
in IN N
our PRP$ P
27 CD P
patients NNS P
. . I

Callus NNP I
formation NN I
was VBD N
arbitrarily RB N
classified VBN N
as IN N
rich JJ N
intermediate NN N
or CC N
poor JJ N
. . N

RESULTS $ N
9 CD N
patients NNS N
were VBD N
classified VBN N
as IN N
rich JJ N
(none NN N
had VBD N
received VBN I
placebo RB I
3 CD I
low-dose JJ I
teriparatide NN I
and CC N
6 CD I
high-dose JJ I
teriparatide) NN I
. . N

9 CD N
patients NNS N
were VBD N
classified VBN N
as IN N
intermediate JJ N
(1 NN N
had VBD N
received VBN N
placebo RB N
5 CD N
low-dose JJ N
and CC N
3 CD N
high-dose) NN N
. . N

9 CD N
patients NNS N
were VBD N
classified VBN N
as IN N
poor JJ N
(7 NN N
had VBD N
received VBN N
placebo RB N
1 CD N
low-dose JJ N
and CC N
1 CD N
high-dose) JJ N
(p NNP N
< NNP N
0.001) CD N
. . N

INTERPRETATION NN N
This DT N
is VBZ N
a DT N
post NN N
hoc NN N
subgroup NN N
analysis NN N
of IN N
an DT N
outcome NN N
variable NN N
which WDT N
was VBD N
not RB N
in IN N
the DT N
official JJ N
protocol NN N
. . N

The DT N
results NNS N
must MD N
therefore RB N
be VB N
interpreted VBN N
with IN N
caution NN N
. . N

However RB N
in IN N
combination NN N
with IN N
the DT N
results NNS N
of IN N
the DT N
larger JJR N
trial NN N
the DT N
data NN N
suggest NN N
that IN N
radiographic JJ N
quality NN N
at IN N
an DT N
early JJ N
time NN N
point NN N
might MD N
be VB N
a DT N
sensitive JJ N
variable JJ N
perhaps RB N
better RBR N
than IN N
time NN N
to TO N
cortical JJ N
continuity NN N
. . N

Moreover RB I
teriparatide RB I
appeared VBD N
to TO N
improve VB N
early JJ N
callus NN N
formation NN N
in IN P
distal JJ P
radial JJ P
fractures NNS P
. . P

-DOCSTART- -X- N

Randomized VBN N
controlled VBD N
trial NN N
to TO N
compare VB N
the DT N
early JJ N
and CC N
mid-term JJ N
results NNS N
of IN N
stapled JJ P
versus NN P
open JJ P
hemorrhoidectomy NN P
. . P

BACKGROUND NNP N
The DT N
new JJ N
technique NN N
of IN N
circular JJ I
stapler NN I
for IN P
the DT P
treatment NN P
of IN P
hemorrhoids NNS P
has VBZ N
shown VBN N
early JJ N
promise NN N
in IN N
terms NNS N
of IN N
minimal NN N
or CC N
no DT N
postoperative JJ N
pain NN N
early JJ N
discharge NN N
from IN N
hospital NN N
and CC N
quick JJ N
return NN N
to TO N
work VB N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
stapled VBN P
technique NN P
with IN P
the DT P
well-accepted JJ P
conventional JJ P
Milligan NNP P
Morgan NNP P
hemorrhoidectomy NN P
. . P

METHODS NNP I
After IN N
fulfilling VBG N
the DT N
selection NN N
criteria NNS N
84 CD P
patients NNS P
were VBD P
randomly RB P
allocated VBN P
to TO P
the DT P
stapled VBN P
(n NNP P
= $ P
42) CD P
or CC P
open JJ P
group NN P
(n NNP P
= VBZ P
42) CD P
. . P

All DT P
patients NNS P
were VBD P
operated VBN P
on IN P
under IN P
spinal JJ P
anesthesia NN P
. . P

The DT N
2 CD I
techniques NNS I
were VBD N
evaluated VBN N
with IN N
respect NN N
to TO N
the DT N
operative JJ O
time NN O
pain NN O
scores NNS O
complications NNS O
day NN O
of IN O
discharge NN O
return NN O
to TO O
work VB O
and CC O
level NN O
of IN O
satisfaction NN O
. . O

RESULTS VB N
The DT N
mean JJ P
age NN P
of IN P
patients NNS P
was VBD P
46.02 CD P
years NNS P
(SD RB P
12.33) CD P
in IN P
the DT P
stapled JJ P
group NN P
and CC P
48.64 CD P
years NNS P
(14.57) RB P
in IN P
the DT P
open JJ P
group NN P
. . P

Grade NNP P
III NNP P
or CC P
IV NNP P
hemorrhoids NNS P
were VBD P
more JJR P
common JJ P
in IN P
men NNS P
(ie VBP P
80.9% CD P
and CC P
85.7% CD P
in IN P
the DT P
stapled JJ P
and CC P
open JJ P
group NN P
respectively) NN P
. . P

The DT N
mean JJ O
operative JJ O
time NN O
was VBD N
shorter RBR N
in IN N
the DT N
stapled JJ I
group NN N
24.28 CD N
minutes NNS N
(4.25) VBP N
versus IN N
45.21 CD N
minutes NNS N
(5.36) VBP N
in IN N
the DT N
Milligan-Morgan NNP I
group NN N
(P NNP N
< NNP N
.001) NNP N
. . N

The DT N
blood NN O
loss NN O
pain NN O
scores NNS O
and CC O
requirement NN O
of IN O
analgesics NNS O
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
stapled JJ I
group NN N
. . N

Mean NNP O
hospital NN O
stay NN O
was VBD N
1.24 CD N
days NNS N
(0.62) NNP N
and CC N
2.76 CD N
days NNS N
(1.01) NNP N
(P NNP N
< NNP N
.001) NNP N
in IN N
the DT N
stapled JJ N
and CC N
open JJ N
group NN N
respectively RB N
. . N

The DT N
patients NNS N
in IN N
the DT N
stapled JJ I
group NN N
returned VBD O
to TO O
work VB O
or CC O
routine VB O
activities NNS O
earlier RBR N
(ie RB N
within IN N
8.12 CD N
days NNS N
[2.48]) RB N
as IN N
compared VBN N
with IN N
17.62 CD N
(5.59) NNS N
in IN N
the DT N
open JJ I
group NN N
. . N

Only RB N
88.1% CD N
of IN N
patients NNS N
were VBD N
satisfied VBN O
by IN N
the DT N
open JJ I
method NN I
compared VBN N
with IN N
97.6% CD N
after IN N
the DT N
stapled JJ I
technique NN I
. . I

The DT N
median JJ N
follow-up JJ I
period NN I
was VBD I
11 CD N
months NNS N
with IN N
a DT N
maximum JJ N
follow-up NN I
of IN N
19 CD N
months NNS N
(range JJ N
2-19 JJ N
months) NN N
. . N

CONCLUSIONS NNP N
Stapled NNP I
hemorrhoidectomy NN I
is VBZ I
a DT N
safe JJ O
and CC N
effective JJ O
day-care JJ N
procedure NN N
for IN N
the DT N
treatment NN N
of IN N
grade NN P
III NNP P
and CC P
grade VBD P
IV NNP P
hemorrhoids NNS P
. . P

It PRP N
ensures VBZ N
lesser RBR N
postoperative JJ O
pain NN O
early JJ O
discharge NN O
less JJR O
time NN O
off RP O
work NN O
complications NNS O
similar JJ N
to TO N
the DT N
open JJ I
technique NN I
and CC I
in IN N
the DT N
end NN N
a DT N
more RBR N
satisfied JJ N
patient NN N
with IN N
no DT N
perianal JJ N
wound NN N
. . N

However RB N
more RBR N
such JJ N
randomized JJ N
trials NNS N
are VBP N
essential JJ N
to TO N
deny VB N
any DT N
long-term JJ N
complication NN N
. . N

-DOCSTART- -X- N

Spatial JJ O
orientation NN O
adjustments NNS I
in IN N
children NNS P
with IN P
autism NN P
in IN P
Hong NNP P
Kong NNP P
. . P

Abnormal JJ P
spatial JJ O
orientation NN O
and CC O
body NN O
postures NNS O
in IN N
children NNS P
with IN P
autism NN P
often RB N
interfere RB N
with IN N
visual JJ N
abilities NNS N
to TO N
attend VB N
tasks NNS N
and CC N
social JJ N
interactions NNS N
. . N

Twenty-four JJ P
children NNS P
diagnosed VBN P
with IN P
autism NN P
from IN P
Kowloon NNP P
Hong NNP P
Kong NNP P
were VBD N
assessed VBN N
for IN N
spatial JJ O
orientation NN O
and CC O
spatial JJ O
management NN O
abilities NNS O
. . O

Positive JJ O
changes NNS O
in IN O
spatial JJ O
orientation NN O
were VBD N
evident JJ N
when WRB N
the DT N
children NNS I
wore VBD I
ambient JJ I
prism NN I
lenses NNS I
and CC N
included VBD N
changes NNS O
in IN O
posture NN O
from IN N
slanted VBN N
to TO N
erect VB N
. . N

Adjustments NNS I
in IN I
spatial JJ O
management NN O
were VBD N
evident JJ N
in IN N
improved JJ O
ball NN O
catching VBG O
ability NN O
a DT O
task NN O
requiring VBG O
visual JJ O
tracking NN O
and CC O
eye-hand JJ O
coordination NN O
. . O

The DT N
findings NNS N
suggest VBP N
that IN N
alterations NNS I
to TO I
the DT I
sensory JJ I
systems NNS I
may MD N
lead VB N
to TO N
behavioral JJ N
change NN N
in IN N
some DT N
children NNS N
. . N

-DOCSTART- -X- N

Effects NNS N
of IN N
aerobic JJ I
exercise NN I
on IN N
cognition NN N
and CC N
hippocampal JJ N
volume NN N
in IN N
Alzheimer's NNP P
disease: NN P
study NN N
protocol NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
(The NN N
FIT-AD NNP N
trial) NN N
. . N

BACKGROUND NNP N
Alzheimer's NNP P
disease VB P
a DT P
global JJ N
public JJ N
health NN N
issue NN N
accounts NNS N
for IN N
60 CD N
to TO N
80% CD N
of IN N
all DT N
dementias NNS N
. . N

Alzheimer's NNP N
disease NN N
primarily RB N
causes VBZ N
cognitive JJ N
impairment NN N
and CC N
drugs NNS N
have VBP N
only RB N
modest JJ N
short-term JJ N
effects NNS N
highlighting VBG N
a DT N
pressing VBG N
need NN N
to TO N
develop VB N
effective JJ N
interventions NNS N
. . N

Aerobic NNP I
exercise NN I
holds VBZ N
promise NN N
for IN N
treating VBG N
cognitive JJ N
impairment NN N
in IN N
Alzheimer's NNP P
disease NN P
through IN N
biologically RB N
sound JJ N
mechanisms NNS N
. . N

Nonetheless RB N
aerobic JJ I
exercise NN I
studies NNS N
in IN N
Alzheimer's NNP N
disease NN N
are VBP N
limited VBN N
with IN N
mixed JJ N
findings NNS N
. . N

METHODS/DESIGN NNP N
This DT N
pilot NN N
randomized VBD N
controlled VBN N
trial NN N
will MD N
investigate VB N
the DT N
effects NNS N
of IN N
a DT N
6-month JJ N
individualized JJ I
moderate-intensity NN I
cycling NN I
intervention NN I
(20 NN I
to TO I
50 CD I
minutes NNS I
per IN I
session NN I
3 CD I
times NNS I
a DT I
week) NN I
on IN I
cognition NN I
and CC I
hippocampal JJ I
volume NN I
in IN I
community-dwelling JJ P
older NN P
adults NNS P
with IN P
mild-to-moderate JJ P
Alzheimer's NNP P
disease NN P
. . P

The DT N
specific NN N
aims NNS N
are VBP N
to: JJ N
1) CD N
determine NN N
the DT N
immediate JJ N
effect NN N
of IN N
the DT N
cycling NN I
intervention NN I
on IN N
cognition NN N
in IN N
Alzheimer's NNP N
disease; VBD N
2) CD N
examine NN N
if IN N
the DT N
cycling NN I
intervention NN I
slows VBZ N
cognitive JJ N
decline NN N
in IN N
Alzheimer's NNP N
disease NN N
from IN N
baseline NN N
to TO N
12 CD N
months; NNS N
and CC N
3) CD N
assess NN N
the DT N
effect NN N
of IN N
aerobic JJ I
exercise NN I
on IN N
hippocampal JJ N
volume NN N
over IN N
12 CD N
months NNS N
. . N

Ninety NNP P
subjects NNS P
will MD P
be VB P
randomized VBN P
on IN N
a DT N
2:1 CD N
allocation NN N
ratio NN N
to TO N
cycling NN I
or CC I
attention NN I
control NN N
(low-intensity JJ I
stretching) NN I
and CC N
followed VBD N
for IN N
another DT N
6 CD N
months NNS N
. . N

Allocations NNS N
will MD N
be VB N
concealed VBN N
to TO N
all DT N
investigators NNS N
and CC N
outcome JJ N
assessors NNS N
will MD N
be VB N
blinded VBN N
to TO N
group NN N
assignments NNS N
and CC N
previous JJ N
data NNS N
. . N

Cognition NN N
will MD N
be VB N
measured VBN N
by IN N
the DT N
Alzheimer's NNP O
disease NN O
Assessment NNP O
Scale-Cognition NN O
at IN N
baseline NN N
before IN N
randomization NN N
and CC N
at IN N
3 CD N
6 CD N
9 CD N
and CC N
12 CD N
months NNS N
. . N

Hippocampal JJ O
volume NN O
will MD N
be VB N
measured VBN N
by IN N
magnetic JJ N
resonance NN N
imaging NN N
at IN N
baseline NN N
and CC N
6 CD N
and CC N
12 CD N
months NNS N
. . N

The DT N
sample JJ P
size NN P
of IN P
90 CD P
will MD N
give VB N
80% CD N
power NN N
to TO N
detect VB N
a DT N
2.5-point JJ N
difference NN N
in IN N
within-group JJ N
changes NNS N
in IN N
the DT N
Alzheimer's NNP N
disease NN N
Assessment NNP N
Scale-Cognition NN N
at IN N
6 CD N
months NNS N
for IN N
the DT N
cycling NN I
group NN N
. . N

DISCUSSION NNP N
Findings NNS N
from IN N
this DT N
study NN N
will MD N
address VB N
the DT N
critical JJ N
gap NN N
of IN N
exercise NN I
efficacy NN O
in IN N
Alzheimer's NNP N
disease NN N
and CC N
use NN N
of IN N
magnetic JJ N
resonance NN N
imaging NN N
as IN N
an DT N
outcome NN N
measure NN N
in IN N
clinical JJ N
trials NNS N
. . N

This DT N
study NN N
will MD N
provide VB N
a DT N
potential JJ N
treatment NN N
that WDT N
may MD N
increase VB N
physical JJ O
function NN O
and CC O
quality NN O
of IN O
life NN O
and CC N
curb VB N
the DT N
prohibitive JJ O
costs NNS O
for IN N
the DT N
growing VBG N
dementia JJ N
population NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Primary NNP N
registration: VBD N
(NCT01954550; JJ N
date NN N
of IN N
registration: NN N
20 CD N
September NNP N
2013) CD N
. . N

Secondary JJ N
registration: NN N
(NCT01954550; NNP N
date NN N
of IN N
registration: NN N
1 CD N
October NNP N
2013) CD N
. . N

-DOCSTART- -X- N

Immediately RB I
restored VBN I
single-tapered JJ I
implants NNS P
in IN P
the DT P
anterior JJ P
maxilla: NN P
prosthodontic JJ N
and CC N
aesthetic JJ N
outcomes NNS N
after IN N
1 CD N
year NN N
. . N

BACKGROUND NNP N
Conventional NNP N
implant JJ N
protocols NNS I
advocate VBP N
a DT N
two-stage NN N
technique NN N
with IN N
a DT N
load-free JJ N
submerged JJ N
healing NN N
period NN N
. . N

Recent JJ N
studies NNS N
suggest VBP N
that IN N
immediate JJ N
restoration NN N
of IN N
single JJ N
implants NNS N
may MD N
be VB N
a DT N
viable JJ N
treatment NN I
option NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
prosthodontic JJ O
and CC O
aesthetic JJ O
peri-implant JJ P
mucosal NN O
outcomes NNS N
of IN N
immediately RB P
restored VBN P
Southern NNP P
single-tapered JJ P
implants NNS P
in IN P
the DT P
anterior JJ P
maxilla NN P
after IN P
1 CD P
year NN P
. . P

MATERIALS NNP P
AND CC N
METHODS NNP N
Participants NNP P
(mean NNP P
age: VBD P
43.25 CD P
years; JJ P
range: JJ P
23-71 JJ P
years) NN P
satisfying VBG P
specified VBN P
inclusion NN P
criteria NNS P
were VBD N
randomly RB N
allocated VBN N
to TO N
conventional JJ I
two-stage JJ I
restoration NN I
(control NNP N
group; NN N
n=14) NN N
and CC N
immediate JJ I
restoration NN I
groups NNS I
(test VBP N
group; JJ N
n JJ N
=14) NN N
in IN N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
. . N

Tapered VBN I
roughened-surface NN I
Southern JJ I
implants NNS I
were VBD N
placed VBN N
using VBG N
a DT N
standardized JJ N
technique NN N
and CC N
implant JJ N
level NN N
bone NN N
impressions NNS N
were VBD N
made VBN N
. . N

Provisional JJ I
screw-retained JJ I
crowns NNS I
out IN I
of IN N
occlusion NN N
were VBD N
placed VBN N
at IN N
second-stage NN N
surgery NN I
after IN N
26 CD N
weeks NNS N
for IN N
the DT N
conventional JJ N
restoration NN N
group NN N
and CC N
within IN N
4 CD N
hours NNS N
of IN N
implant JJ N
placement NN N
for IN N
the DT N
immediate JJ N
restoration NN N
group NN N
. . N

Both DT N
groups NNS N
had VBD N
definitive JJ I
screw-retained JJ I
metal-ceramic JJ I
crowns NNS I
placed VBN N
in IN N
occlusion NN N
8 CD N
weeks NNS N
later RB N
. . N

Peri-implant JJ O
mucosal NN O
response NN O
and CC O
papilla NN O
index NN O
were VBD N
recorded VBN N
4 CD N
weeks NNS N
after IN N
definitive JJ N
crown JJ N
placement NN N
to TO N
allow VB N
for IN N
mucosal JJ N
maturation NN N
and CC N
at IN N
1 CD N
year NN N
. . N

Prosthodontic JJ O
and CC O
aesthetic JJ O
outcomes NNS I
were VBD N
assessed VBN N
using VBG N
established VBN N
criteria NNS N
. . N

RESULTS RB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
within IN N
or CC N
between IN N
the DT N
control NN N
and CC N
test NN N
groups NNS N
for IN N
age NN N
gender NN N
bone NN O
quality NN O
or CC O
quantity NN O
implant JJ O
stability NN O
measurements NNS N
at IN N
surgery NN I
or CC I
implant JJ N
length NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
implant JJ O
success NN O
rate NN O
as IN N
determined VBN N
by IN N
radiographic JJ N
bone NN O
loss NN O
and CC N
stability NN N
tests NNS N
after IN N
1 CD N
year NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
prosthodontic JJ O
maintenance NN O
peri-implant JJ O
mucosal NN O
response NN O
and CC O
papilla NN O
index NN O
between IN N
the DT N
two CD N
groups NNS N
over IN N
1 CD N
year NN N
. . N

CONCLUSIONS NNP N
Tapered NNP I
roughened-surface NN I
implants NNS I
immediately RB N
restored VBN I
with IN N
single JJ N
provisional JJ N
crowns NNS N
at IN N
surgery NN I
and CC N
definitive JJ N
crowns NNS N
8 CD N
weeks NNS N
later RB N
were VBD N
as IN N
prosthodontically RB N
and CC N
aesthetically RB N
successful JJ N
as IN N
conventionally RB N
restored VBN N
two-stage JJ N
implants NNS N
during IN N
the DT N
first JJ N
year NN N
of IN N
service NN I
. . I

Restoring VBG I
single JJ I
implants NNS I
immediately RB N
with IN N
screw-retained JJ N
crowns NNS N
is VBZ N
an DT N
efficient JJ N
procedure NN N
but CC N
the DT N
short-term JJ N
outcome NN N
is VBZ N
by IN N
no DT N
means NNS N
superior VBP N
to TO N
a DT N
conventional JJ N
two-stage JJ N
approach NN N
. . N

-DOCSTART- -X- N

Capsaicin NNP I
jelly RB I
against IN N
migraine NN P
pain NN P
. . P

OBJECTIVE NNP N
Recent NNP N
studies NNS N
support VBP N
the DT N
role NN N
of IN N
extracranial JJ N
perivascular JJ N
afferents NNS N
in IN N
a DT N
substantial JJ N
percentage NN N
of IN N
migraineurs NNS P
. . P

Perivascular JJ N
afferent NN N
fibres NNS N
of IN N
the DT N
superficial JJ N
temporal JJ N
artery NN N
contain NN N
peptides NNS N
like IN N
calcitonin NN N
gene-related JJ N
peptide NN N
(CGRP) NN N
and CC N
substance NN N
P NNP N
(SP) NNP N
. . N

CGRP NNP N
and CC N
SP NNP N
are VBP N
considered VBN N
relevant JJ N
in IN N
the DT N
genesis NN N
of IN N
migraine NN N
pain NN N
. . N

Capsaicin NNP I
is VBZ N
an DT N
agonist NN N
of IN N
the DT N
transient NN N
receptor NN N
potential JJ N
vanilloid NN N
type NN N
1 CD N
. . N

It PRP N
causes VBZ N
membrane JJ N
depolarisation NN N
of IN N
sensory JJ N
neurons NNS N
which WDT N
release VBP N
CGRP NNP N
SP NNP N
and CC N
other JJ N
pain NN N
peptides; JJ N
excitation NN N
is VBZ N
followed VBN N
by IN N
a DT N
refractory NN N
state NN N
causing VBG N
inactivation NN N
. . N

Topical JJ I
capsaicin NN I
has VBZ N
been VBN N
found VBN N
to TO N
be VB N
efficacious JJ N
in IN N
several JJ N
types NNS N
of IN N
neuropathic JJ O
pain NN O
. . O

We PRP N
attempted VBD N
to TO N
verify VB N
whether IN N
topical JJ I
periarterial JJ I
capsaicin NN I
could MD N
ameliorate VB N
pain NN O
in IN O
absence NN O
of IN O
and CC O
during IN O
a DT O
migraine JJ O
attack NN O
. . O

METHODS NNP N
On IN N
23 CD P
migraineurs NNS P
showing VBG P
pain NN P
at IN P
pressure NN P
on IN P
scalp JJ P
arteries NNS P
we PRP P
administered VBD N
topical JJ I
capsaicin NN I
0.1% CD I
or CC I
vaseline VB I
jelly RB I
on IN N
painful JJ N
arteries NNS N
in IN N
absence NN N
of IN N
migraine JJ N
attack NN N
. . N

In IN N
those DT N
having VBG N
pain NN N
reduction NN N
> VBZ N
50% CD N
we PRP N
made VBD N
the DT N
same JJ N
comparison NN N
during IN N
a DT N
migraine JJ N
attack NN N
. . N

RESULTS NNP N
Topical NNP I
capsaicin NN I
caused VBD N
> JJ N
50% CD N
reduction NN N
of IN N
arterial JJ O
pain NN O
in IN N
absence NN N
of IN N
attack NN N
in IN N
17/23 CD N
patients NNS N
as IN N
opposed VBN N
to TO N
two CD N
with IN N
vaseline NN I
. . I

During IN N
attacks NNS N
of IN N
mild- NN N
to TO N
moderate-intensity NN N
> JJ N
50% CD N
improvement NN N
was VBD N
obtained VBN N
in IN N
11/17 CD N
with IN N
capsaicin NN I
and CC N
in IN N
one CD N
with IN N
vaseline NN I
. . I

CONCLUSIONS NNP N
Although IN N
referring VBG N
to TO N
a DT N
small JJ N
number NN N
of IN N
patients NNS N
our PRP$ N
data NNS N
show VBP N
that IN N
topical JJ I
capsaicin NN I
may MD N
relieve VB N
arterial JJ O
pain NN O
in IN N
absence NN N
of IN N
and CC N
during IN N
a DT N
migraine JJ N
attack NN N
in IN N
a DT N
substantial JJ N
number NN N
of IN N
patients NNS P
experiencing VBG P
scalp JJ P
arterial JJ P
tenderness NN P
. . P

More RBR N
active JJ I
capsacinoids NNS I
might MD N
be VB N
tried VBN N
in IN N
the DT N
future NN N
and CC N
could MD N
provide VB N
a DT N
new JJ N
method NN N
for IN N
treating VBG N
migraine NN P
attacks NNS P
. . P

-DOCSTART- -X- N

Heparin NNP I
plus CC I
dipyridamole NN I
in IN N
childhood NN P
hemolytic-uremic JJ P
syndrome: NN P
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

From IN P
1976 CD P
to TO P
1985 CD P
a DT P
total NN P
of IN P
58 CD P
infants NNS P
and CC P
children NNS P
with IN P
the DT P
hemolytic-uremic JJ P
syndrome NN P
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
either RB N
with IN N
heparin NN I
and CC I
dipyridamole NN I
or CC I
with IN I
supportive JJ I
management NN I
only RB I
. . I

In IN N
the DT N
treatment NN I
group NN I
two CD I
patients NNS N
died VBD N
in IN N
the DT N
early JJ N
weeks NNS N
of IN N
the DT N
disease NN N
. . N

Analysis NN N
of IN N
clinical JJ N
and CC N
laboratory NN N
data NNS N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
either DT N
group NN N
of IN N
patients NNS N
as IN N
to TO N
the DT N
evolution NN N
of IN N
their PRP$ N
illness NN N
except IN N
for IN N
a DT N
significantly RB N
higher JJR N
incidence NN N
of IN N
anuria NNS O
and CC N
a DT N
significantly RB N
faster RBR O
recovery NN O
from IN N
hypertension NN N
in IN N
the DT N
treated JJ N
group NN N
. . N

Renal JJ N
biopsy NN N
studies NNS N
showed VBD N
no DT N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
incidence NN N
and CC N
severity NN N
of IN N
the DT N
histologic JJ N
lesions NNS N
. . N

The DT N
long-term JJ N
data NNS N
on IN N
blood NN O
pressure NN O
and CC N
creatinine JJ O
clearance NN O
values NNS O
in IN N
the DT N
survivors NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

This DT N
study NN N
indicates VBZ N
that IN N
treatment NN I
with IN I
heparin NN O
and CC O
dipyridamole NN O
has VBZ N
no DT N
benefit NN O
over IN O
symptomatic JJ O
therapy NN O
alone RB I
in IN N
the DT N
typical JJ N
form NN N
of IN N
childhood NN P
hemolytic-uremic JJ P
syndrome NN P
. . P

-DOCSTART- -X- N

Effect NN N
of IN N
zoledronic JJ I
acid NN I
on IN N
disseminated JJ N
tumour NN N
cells NNS N
in IN N
women NNS P
with IN P
locally RB P
advanced VBN P
breast NN P
cancer: NN P
an DT N
open JJ N
label NN N
randomised VBD N
phase NN N
2 CD N
trial NN N
. . N

BACKGROUND NNP N
Treatment NNP N
with IN N
bisphosphonates NNS I
decreases NNS N
bone VBP N
loss NN N
and CC N
can MD N
increase VB N
disease-free JJ N
survival NN N
in IN N
patients NNS P
with IN P
breast JJ P
cancer NN P
. . P

The DT N
aim NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effect NN N
of IN N
zoledronic JJ I
acid NN I
on IN N
clearance NN O
of IN O
disseminated JJ O
tumour NN O
cells NNS O
(DTCs) VBP O
from IN N
the DT N
bone NN N
marrow NN N
in IN N
women NNS P
undergoing VBG P
neoadjuvant JJ P
chemotherapy NN P
for IN P
breast NN P
cancer NN P
. . P

METHODS JJ P
Patients NNS P
were VBD P
recruited VBN P
for IN P
this DT P
open-label JJ P
phase NN P
2 CD P
randomised VBD P
trial NN P
between IN P
March NNP P
17 CD P
2003 CD P
and CC P
May NNP P
19 CD P
2006 CD P
at IN P
a DT P
single JJ P
centre NN P
. . P

Eligible JJ P
patients NNS P
had VBD P
clinical JJ P
stage NN P
II-III JJ P
(> NN P
or CC P
= VB P
T2 NNP P
and/or JJ P
> NN P
or CC P
= VB P
N1) NNP P
newly RB P
diagnosed VBD P
breast NN P
cancer NN P
Eastern NNP P
Cooperative NNP P
Oncology NNP P
Group NNP P
performance NN P
status NN P
of IN P
0 CD P
or CC P
1 CD P
and CC P
normal JJ P
cardiac JJ P
renal NN P
and CC P
liver NN P
function NN P
. . P

120 CD P
women NNS P
were VBD P
randomly RB P
assigned VBN P
using VBG P
allocation NN N
concealment NN N
to TO N
receive VB N
4 CD I
mg NN I
zoledronic JJ I
acid NN I
intravenously RB I
every DT I
3 CD I
weeks NNS I
(n=60) CD N
or CC I
no DT I
zoledronic JJ I
acid NN I
(n=60) NN N
for IN N
1 CD N
year NN N
concomitant NN N
with IN N
four CD I
cycles NNS I
of IN I
neoadjuvant JJ I
epirubicin NN I
(75 NNP I
mg/m(2)) NN I
plus CC I
docetaxel JJ I
(75 NNP I
mg/m(2)) NN I
and CC I
two CD I
cycles NNS I
of IN I
adjuvant JJ I
epirubicin JJ I
plus CC I
docetaxel NN I
. . I

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
number NN O
of IN O
patients NNS O
with IN O
detectable JJ O
DTCs NNP O
at IN N
3 CD N
months NNS N
. . N

Final JJ N
analysis NN N
was VBD N
done VBN N
1 CD N
year NN N
after IN N
the DT N
last JJ N
patient NN N
was VBD N
enrolled VBN N
. . N

Analyses NNS N
were VBD N
done VBN N
for IN N
all DT N
patients NNS N
with IN N
available JJ N
data NNS N
at IN N
3 CD N
months NNS N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
number NN N
NCT00242203 NNP N
. . N

FINDINGS NNP N
Of IN N
the DT N
120 CD P
patients NNS P
initially RB P
enrolled VBD P
one CD P
withdrew NN P
after IN P
signing VBG P
consent NN P
and CC P
one CD P
patient's NN P
baseline NN P
bone NN P
marrow NN P
was VBD P
not RB P
available JJ P
. . P

Both DT N
of IN N
these DT N
patients NNS N
were VBD N
in IN N
the DT N
control NN N
group NN N
. . N

At IN N
3 CD N
months NNS N
109 CD P
bone-marrow JJ P
samples NNS P
were VBD P
available JJ P
for IN N
analysis NN N
. . N

In IN N
the DT N
zoledronic JJ N
acid NN N
group NN N
bone NN N
marrow NN N
was VBD N
not RB N
collected VBN N
from IN N
one CD N
patient NN N
because IN N
of IN N
disease NN N
progression NN N
one CD N
patient NN N
was VBD N
taken VBN N
off RP N
study NN N
because IN N
of IN N
severe JJ N
diarrhoea NN N
and CC N
two CD N
patients NNS N
had VBD N
not RB N
consented VBN N
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

In IN N
the DT N
control NN N
group NN N
bone NN N
marrow NN N
was VBD N
not RB N
collected VBN N
from IN N
two CD N
patients NNS N
because IN N
of IN N
disease NN N
progression NN N
one CD N
patient NN N
withdrew VBD N
consent NN N
and CC N
three CD N
patients NNS N
were VBD N
not RB N
consented VBN N
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

At IN N
baseline NN N
DTCs NNP N
were VBD N
detected VBN N
in IN N
26 CD N
of IN N
60 CD N
patients NNS N
in IN N
the DT N
zoledronic JJ I
acid NN I
group NN N
and CC N
28 CD N
of IN N
58 CD N
patients NNS N
in IN N
the DT N
control NN N
group NN N
. . N

At IN N
3 CD N
months NNS N
17 CD N
of IN N
56 CD N
patients NNS N
receiving VBG N
zoledronic JJ N
acid NN N
versus IN N
25 CD N
of IN N
53 CD N
patients NNS N
who WP N
did VBD N
not RB N
receive VB N
zoledronic JJ I
acid NN I
had VBD N
detectable JJ N
DTCs NNP N
(p=0.054) NNP N
. . N

The DT N
most RBS N
common JJ N
grade NN N
3-4 JJ N
toxicities NNS N
were VBD N
infection JJ N
(five NNP N
of IN N
60 CD N
patients NNS N
in IN N
the DT N
zoledronic JJ N
acid NN N
group NN N
and CC N
six CD N
of IN N
59 CD N
in IN N
the DT N
control NN N
group) NN N
and CC N
thrombosis NN N
(five NN N
of IN N
60 CD N
in IN N
the DT N
zoledronic JJ I
acid NN I
and CC N
two CD N
of IN N
59 CD N
in IN N
the DT N
control NN N
group) NN N
. . N

There EX N
was VBD N
one CD N
documented JJ N
case NN N
of IN N
osteonecrosis NN N
in IN N
the DT N
zoledronic JJ N
acid NN N
group NN N
. . N

INTERPRETATION NNP N
Zoledronic NNP I
acid NN I
administered VBD N
with IN N
chemotherapy NN N
resulted VBN N
in IN N
a DT N
decreased JJ N
proportion NN N
of IN N
patients NNS N
with IN N
DTCs NNP O
detected VBD N
in IN N
the DT N
bone NN N
marrow NN N
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

Our PRP$ N
study NN N
supports VBZ N
the DT N
hypothesis NN N
that IN N
the DT N
antimetastatic JJ N
effects NNS N
of IN N
zoledronic JJ I
acid NN I
may MD N
be VB N
through IN N
effects NNS N
on IN N
DTCs NNP N
. . N

FUNDING NN N
Novartis NNP N
Pharmaceuticals NNP N
and CC N
Pfizer NNP N
Inc NNP N
. . N

-DOCSTART- -X- N

Intranasal NNP I
recombinant JJ I
alfa-2b JJ I
interferon NN I
treatment NN O
of IN N
naturally RB P
occurring VBG P
common JJ P
colds NNS P
. . P

In IN P
a DT N
double-blind JJ N
placebo-controlled JJ I
study NN N
patients NNS P
with IN P
naturally RB P
occurring VBG P
common JJ P
colds NNS P
of IN P
less JJR P
than IN P
or CC P
equal JJ P
to TO P
48 CD P
h NNS P
duration NN P
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
nasal JJ I
sprays NNS I
of IN I
recombinant JJ I
alfa-2b JJ I
interferon NN I
at IN I
10 CD I
or CC I
20 CD I
MU/day NNPS I
or CC N
placebo VB I
four CD I
times NNS I
per IN N
day NN N
for IN N
5 CD N
days NNS N
. . N

The DT N
10-MU JJ P
(n NNP P
= $ P
74) CD P
20-MU JJ P
(n NNP P
= NNP P
74) CD P
and CC P
placebo VB P
(n NNP P
= NNP P
72) CD P
groups NNS P
had VBD N
comparable JJ N
frequencies NNS N
of IN N
documented JJ N
rhinovirus NN N
colds NNS N
(50 VBP N
to TO N
65%) CD N
and CC N
mean JJ N
durations NNS N
of IN N
pretreatment NN N
symptoms NNS N
(26 VBP N
to TO N
27 CD N
h) NN N
. . N

The DT N
median JJ O
duration NN O
of IN O
colds NNS O
tended VBD N
to TO N
be VB N
longer RBR N
in IN N
the DT N
20-MU JJ N
group NN N
(10 NNP N
days) NN N
than IN N
the DT N
10-MU JJ N
group NN N
(8 NNP N
days) NN N
or CC N
placebo NN I
group NN N
(8 NNP N
days) VBZ N
(P NNP N
= NNP N
0.06) CD N
. . N

In IN N
those DT N
with IN N
proven JJ N
rhinovirus NN N
colds NNS N
treated VBD N
within IN N
24 CD N
h PDT N
the DT N
median JJ O
duration NN O
was VBD N
significantly RB N
longer RBR N
in IN N
the DT N
20-MU JJ N
group NN N
(9 NNP N
days) NN N
than IN N
in IN N
the DT N
placebo NN I
group NN N
(6 NNP N
days) NN N
. . N

No DT N
differences NNS N
favoring VBG N
interferon NN N
treatment NN N
were VBD N
found VBN N
in IN N
respiratory JJ O
symptom JJ O
scores NNS O
or CC O
resolution NN O
of IN O
specific JJ O
symptoms NNS O
. . O

On IN N
days NNS N
5 CD N
and CC N
7 CD N
nasal JJ I
washings NNS I
from IN N
compliant JJ N
subjects NNS N
with IN N
proven JJ N
rhinovirus NN N
colds NNS N
yielded VBD N
rhinoviruses NNS N
more RBR N
often RB N
in IN N
placebo JJ I
(47 NN N
and CC N
48% CD N
respectively) NN N
than IN N
in IN N
interferon NN I
(15 NN N
and CC N
16% CD N
respectively) NN N
recipients NNS N
(P VBZ N
less JJR N
than IN N
0.02) CD N
but CC N
no DT N
differences NNS N
in IN N
new JJ N
respiratory NN O
illness JJ O
occurrence NN O
were VBD N
observed VBN N
in IN N
household NN N
contacts NNS N
. . N

Interferon NNP I
recipients NNS N
had VBD N
significantly RB N
higher JJR N
frequencies NNS N
of IN N
blood NN O
in IN O
nasal JJ O
mucus NN O
(16 NN N
to TO N
18%) CD N
than IN N
did VBD N
placebo VB I
recipients NNS N
(4%) VB N
during IN N
treatment NN N
. . N

Antibiotics NNS I
for IN N
presumed JJ N
secondary JJ N
infections NNS N
were VBD N
given VBN N
more RBR N
often RB N
in IN N
the DT N
20-MU JJ N
group NN N
(11%) NNP N
than IN N
in IN N
the DT N
placebo NN I
group NN N
(0%) NNP N
(P NNP N
less JJR N
than IN N
0.01) CD N
. . N

Nasal NNP I
sprays NNS I
of IN I
recombinant JJ I
alfa-2b JJ I
interferon NN I
were VBD N
not RB N
an DT N
effective JJ O
treatment NN O
for IN O
natural JJ O
colds NNS O
and CC N
were VBD N
associated VBN N
with IN N
toxicity NN O
. . O

-DOCSTART- -X- N

[Effect NN N
of IN N
electroacununcture NN I
on IN N
sex NN N
hormone NN N
levels NNS N
in IN N
patients NNS P
with IN P
Sjgren's NNP P
syndrome] NN P
. . N

OBJECTIVE NN N
To TO N
observe VB N
the DT N
effect NN N
of IN I
electroacupuncture NN I
(EA) NN I
on IN N
serum NN N
testosterone NN N
(T) NNP N
estradiol VBZ N
(F2) NNP N
luteotropic NN N
hormone NN N
(LH) VBD N
follicle-stimulating JJ N
hormone NN N
(FSH) NNP N
progesterone NN N
(P) NN N
and CC N
prolactin NN N
(PRL) NN N
in IN P
patients NNS P
with IN P
Sjgren's NNP P
Syndrome NNP P
(SS) NNP P
in IN N
order NN N
to TO N
analyze VB N
the DT N
correlation NN N
between IN N
the DT N
adjustment NN N
effect NN N
of IN I
EA NNP I
and CC N
changes NNS N
of IN N
hormone NN N
levels NNS N
. . N

METHODS NNP P
Fifty-seven NNP P
middle-aged JJ P
and CC P
old JJ P
women NNS P
with IN P
SS NNP P
were VBD N
divided VBN N
into IN I
medication NN I
group NN N
(n=27) NNP N
and CC I
acupuncture NN I
group NN N
(n=30) NNP N
. . N

Patients NNS N
in IN I
acupuncture NN I
group NN I
were VBD I
treated VBN I
with IN I
EA NNP I
(80 NNP I
Hz NNP I
2.5 CD I
mA) NN I
of IN I
Shenshu NNP I
(BL NNP I
23) CD I
Taixi NNP I
(KI VBD I
3) CD I
Hegu NNP I
(LI VBD I
4) CD I
etc NN I
. . I

for IN I
30 CD I
min NN I
once RB I
every DT I
other JJ I
day NN I
and CC I
those DT I
of IN I
medication NN I
group NN I
were VBD I
treated VBN I
with IN I
oral JJ I
administration NN I
of IN I
hydroxyl-chloroquine JJ I
(6 NNP I
mg/kg NN I
per IN I
day) NN I
oral JJ I
transfer NN I
agent NN I
liquid JJ I
Vit NNP I
B1 NNP I
Vit NNP I
B2 NNP I
Vit NNP I
C NNP I
fish-liver JJ I
oil NN I
one CD I
tablet/time NN I
t.i.d NN I
. . I

and CC I
pilocarpine VB I
(20 NNP I
mg/d) NNP I
continuously RB I
for IN I
2 CD I
months NNS I
. . I

Venous JJ I
blood NN I
samples NNS I
were VBD I
collected VBN I
before IN I
and CC I
after IN I
the DT I
treatment NN I
to TO I
examine VB I
contents NNS I
of IN I
the DT I
abovementioned JJ I
sex NN I
hormones NNS I
by IN I
using VBG I
electro-chemiluminescent JJ I
immunoassay NN I
(CLIA) NN I
. . N

RESULTS NNP N
(1) VBD N
Before IN N
the DT N
treatment NN N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
two CD N
groups NNS N
in IN N
the DT N
levels NNS N
of IN O
serum NN O
T NNP O
E2 NNP O
LH NNP O
FSH NNP O
P NNP O
and CC O
PRL NNP O
(P NNP N
> VBD N
0.05) CD N
. . N

After IN N
the DT N
treatment NN N
self-comparison NN N
of IN N
each DT N
group NN N
showed VBD N
that IN O
serum NN O
EF NNP O
and CC O
T NNP O
contents NNS O
in IN N
acupuncture NN N
group NN N
increased VBD N
significantly RB N
(P JJ N
< $ N
0.01) CD N
and CC O
serum JJ O
LH NNP O
content NN O
decreased VBD N
significantly RB N
(P NNP N
< VBD N
0.01); CD N
while IN N
in IN N
medication NN N
group NN N
only RB O
serum VBZ O
LH NNP O
decreased VBD N
markedly RB N
(P JJ N
< $ N
0.05) CD N
in IN N
comparison NN N
with IN N
its PRP$ N
basic JJ N
value NN N
of IN N
pretreatment NN N
. . I

No DT I
significant JJ I
changes NNS I
were VBD I
found VBN I
in IN O
serum NN O
P NNP O
FSH NNP O
and CC O
PRL NNP O
levels NNS O
in IN I
both DT I
groups NNS I
after IN I
the DT I
treatment NN I
(P NNP I
> VBZ I
0.05) CD I
. . N

The DT N
results NNS N
suggested VBD N
that IN N
the DT N
therapeutic JJ N
effect NN N
of IN N
acupuncture NN N
group NN N
was VBD N
better JJR N
than IN N
that DT N
of IN N
medication NN N
group NN N
in IN N
regulating VBG N
multiple JJ O
sex NN O
hormones NNS O
. . N

CONCLUSION NNP I
EA NNP I
can MD N
effectively RB N
adjust VB N
E2 NNP N
T NNP N
and CC N
LH NNP N
levels NNS N
in IN P
Sjgren's NNP P
Syndrome NNP P
patients NNS P
and CC N
improve VB N
most RBS N
patients' JJ N
clinical JJ N
symptoms NNS N
and CC N
the DT N
therapeutic JJ N
effect NN N
of IN I
EA NNP N
is VBZ N
better JJR N
than IN N
that DT N
of IN I
medication NN I
. . N

-DOCSTART- -X- N

Intravenous JJ I
flecainide NN I
versus NN I
verapamil NN I
for IN N
acute JJ N
conversion NN N
of IN N
paroxysmal JJ P
atrial JJ P
fibrillation NN P
or CC P
flutter NN P
to TO P
sinus VB P
rhythm NN P
. . P

In IN N
a DT N
single-blind JJ N
randomized NN N
study NN N
the DT N
efficacy NN N
of IN N
intravenous JJ I
flecainide JJ I
(2 NNP I
mg/kg/10 NN I
minutes) NN I
versus NN I
verapamil NN I
(10 NNP I
mg/1 NN I
minute) NN I
was VBD N
assessed VBN N
in IN N
40 CD P
patients NNS P
with IN P
paroxysmal JJ P
atrial JJ P
fibrillation NN P
(AF) NN P
or CC P
atrial JJ P
flutter NN P
(AFI) NN P
. . P

The DT N
treatment NN N
was VBD N
considered VBN N
successful JJ N
if IN N
sinus JJ N
rhythm NN N
occurred VBD N
within IN N
1 CD N
hour NN N
. . N

Of IN P
20 CD P
patients NNS P
receiving VBG P
flecainide JJ P
14 CD P
of IN P
17 CD P
(82%) NNS P
with IN P
AF NNP P
converted VBD P
to TO P
sinus VB P
rhythm NN P
but CC P
in IN P
3 CD P
patients NNS P
with IN P
AFI NNP P
flecainide NN P
failed VBD P
. . P

All DT N
patients NNS N
treated VBN N
with IN N
verapamil JJ I
(17 NNP N
AF NNP N
3 CD N
AFI) NNP N
showed VBD N
lower JJR N
ventricular NN N
rates NNS N
after IN N
1 CD N
hour; NN N
however RB N
only RB N
1 CD N
(6%) NNS N
with IN N
AF NNP N
converted VBD N
to TO N
sinus VB N
rhythm NN N
and CC N
1 CD N
(6%) NNS N
converted VBN N
to TO N
AFI NNP N
. . N

Patients NNS N
who WP N
did VBD N
not RB N
convert VB N
to TO N
sinus VB N
rhythm NN N
after IN N
treatment NN N
with IN N
verapamil NNS I
were VBD N
treated VBN N
with IN N
flecainide NN I
and CC N
observed VBD N
for IN N
another DT N
hour NN N
. . N

After IN N
the DT N
change NN N
to TO N
flecainide VB I
9 CD P
of IN P
15 CD P
patients NNS P
(60%) JJ P
with IN P
AF NNP P
still RB N
converted VBD O
. . O

Thus RB N
23 CD P
of IN P
32 CD P
patients NNS P
(72%) JJ P
with IN P
AF NNP P
and CC P
none NN P
of IN P
7 CD P
with IN P
AFI NNP P
converted VBD N
to TO N
sinus VB O
rhythm NN O
after IN N
treatment NN N
with IN N
flecainide NN I
. . I

Conversion NN O
to TO O
sinus VB O
rhythm NN O
was VBD N
achieved VBN N
in IN N
19 CD P
of IN P
22 CD P
patients NNS P
(86%) JJ P
when WRB P
AF NNP P
lasted VBD N
less JJR N
than IN N
24 CD N
hours NNS N
and CC N
in IN N
4 CD N
of IN N
10 CD N
(40%) NN N
when WRB N
the DT N
arrhythmia NN N
lasted VBD N
greater JJR N
than IN N
24 CD N
hours NNS N
. . N

Transient JJ O
adverse JJ O
effects NNS O
were VBD N
noted VBN N
in IN N
10 CD P
patients NNS P
(26%) VBP P
after IN N
flecainide NN I
. . I

In IN N
summary JJ N
flecainide NN I
is VBZ N
an DT N
effective JJ O
and CC O
safe JJ O
drug NN O
for IN N
conversion NN N
of IN N
paroxysmal JJ N
AF NNP N
to TO N
sinus VB N
rhythm NN N
but CC N
ineffective JJ N
for IN N
AFI NNP N
. . N

Verapamil NNP I
appears VBZ N
to TO N
be VB N
of IN N
no DT O
use NN O
for IN N
conversion NN N
of IN N
AF NNP N
or CC N
AFI NNP N
to TO N
sinus VB N
rhythm NN N
. . N

-DOCSTART- -X- N

Use NNP N
of IN N
topical JJ I
selamectin NN I
for IN N
the DT N
treatment NN N
of IN N
Syphacia NNP P
muris NNP P
infection NN P
in IN P
laboratory NN P
rats NNS P
. . P

Efficacy NN P
of IN N
selamectin NN I
was VBD N
studied VBN N
in IN N
naturally RB P
acquired VBN P
S NNP P
. . P

muris JJ P
infections NNS P
in IN P
rats NNS P
. . P

Fourty-eight JJ P
S NNP P
. . P

muris-positive JJ P
rats NNS P
were VBD N
divided VBN N
into IN N
six CD N
treated JJ N
and CC N
two CD N
control NN N
groups NNS N
. . N

Selamectin NNP I
(6 NNP N
mg/kg) NN N
was VBD N
applied VBN N
topically RB N
to TO N
the DT N
skin NN N
in IN N
a DT N
single JJ N
spot NN N
at IN N
the DT N
base NN N
of IN N
the DT N
neck NN N
in IN N
the DT N
treatment NN N
group NN N
. . N

The DT N
rats NNS N
of IN N
treated JJ N
and CC N
control NN N
groups NNS N
were VBD N
necropsied VBN N
on IN N
the DT N
24th CD N
day NN N
after IN N
the DT N
treatment NN N
. . N

Topical JJ I
selamectin NN I
was VBD N
found VBN N
to TO N
be VB N
40.7-63.3% JJ N
effective JJ O
(based VBN N
on IN N
egg NN N
per IN N
gram NN N
method) NN N
in IN N
eliminating VBG O
S NNP O
. . O

muris JJ O
infection NN N
in IN N
rats NNS N
. . N

The DT N
efficacy NN O
of IN O
the DT O
treatment NN O
against IN N
S NNP N
. . N

muris NNS N
(based VBN N
on IN N
adult NN N
worm NN N
counts) NN N
in IN N
male NN P
and CC P
female JJ P
rats NNS P
was VBD N
35.14-58.88% JJ N
respectively RB N
(mean JJ N
48.39%) CD N
. . N

-DOCSTART- -X- N

-Blockers NNS P
in IN P
patients NNS P
with IN P
intermittent JJ P
claudication NN P
and CC P
arterial JJ P
hypertension: NN P
results NNS N
from IN N
the DT I
nebivolol NN I
or CC I
metoprolol NN I
in IN N
arterial JJ N
occlusive JJ N
disease NN N
trial NN N
. . N

The DT N
use NN N
of IN I
-receptor NN I
blockers NNS I
in IN N
peripheral JJ N
arterial JJ N
disease NN N
is VBZ N
controversial JJ N
for IN N
their PRP$ N
impact NN N
on IN N
vasomotor NN N
tone NN N
. . N

The DT I
-blocker NN I
nebivolol NN I
possesses VBZ N
vasodilating VBG N
endothelium-dependent JJ N
NO-releasing JJ N
properties NNS N
that WDT N
might MD N
be VB N
beneficial JJ N
in IN N
peripheral JJ N
arterial JJ N
disease NN N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
and CC N
tolerability NN N
of IN I
nebivolol NN I
in IN N
comparison NN N
with IN I
metoprolol NN P
in IN P
these DT P
patients NNS P
. . P

A DT P
total NN P
of IN P
128 CD P
patients NNS P
with IN P
intermittent JJ P
claudication NN P
and CC P
essential JJ P
hypertension NN P
were VBD N
included VBN N
and CC N
double-blind JJ N
randomized VBN N
to TO N
receive VB I
5 CD I
mg NN I
of IN I
nebivolol JJ I
(N=65) NNP N
or CC I
95 CD I
mg NN I
of IN I
metoprolol NN I
(N=63) NNP N
once RB N
daily RB N
. . N

End NN N
points NNS N
were VBD N
changes NNS N
in IN O
ankle-brachial JJ O
index NN O
initial JJ O
and CC O
absolute JJ O
claudication NN O
distance NN O
endothelial JJ O
function NN O
assessed VBN N
by IN N
flow-mediated JJ N
dilatation NN N
of IN N
the DT N
brachial JJ N
artery NN O
blood NN O
pressure NN O
and CC O
quality NN O
of IN O
life NN O
using VBG N
the DT I
claudication NN I
scale NN I
questionnaire NN I
. . N

End NN N
point NN N
analysis NN N
was VBD N
possible JJ P
in IN P
109 CD P
patients NNS P
(85.2%) JJ N
. . N

After IN N
the DT N
48-week JJ N
treatment NN N
period NN O
ankle-brachial JJ O
index NN O
and CC O
absolute JJ O
claudication NN O
distance NN O
improved VBD N
significantly RB N
in IN N
both DT N
patient JJ N
groups NNS N
(P<0.05 VBP N
for IN N
both) NN N
with IN N
no DT N
difference NN N
across IN N
treatments NNS N
. . N

A DT N
significant JJ N
increase NN N
of IN O
initial JJ O
claudication NN O
distance NN O
was VBD N
found VBN N
in IN N
the DT I
nebivolol JJ I
group NN I
. . N

Adjusted VBN N
mean JJ N
change NN N
of IN O
initial JJ O
claudication NN O
distance NN O
was VBD N
33.9% CD N
after IN I
nebivolol JJ I
(P=0.003) NN N
and CC N
16.6% CD N
after IN I
metoprolol JJ I
(P=0.12) JJ N
treatment NN O
. . O

Quality NN O
of IN O
life NN O
was VBD N
not RB N
influenced VBN N
by IN N
either DT N
treatment NN N
and CC N
there EX N
was VBD N
no DT N
relevant JJ N
change NN N
in IN N
flow-mediated JJ N
dilatation NN N
in IN N
patients NNS N
treated VBN N
with IN I
nebivolol NN I
or CC I
metoprolol NN I
(P=0.16) NN N
. . N

Both DT N
drugs NNS N
were VBD N
equally RB N
effective JJ N
in IN N
lowering VBG O
blood NN O
pressure NN O
. . N

In IN N
conclusion NN I
-blocker NN I
therapy NN I
was VBD N
well RB N
tolerated VBN P
in IN P
patients NNS P
with IN P
intermittent JJ P
claudication NN P
and CC P
arterial JJ P
hypertension NN P
during IN N
a DT N
treatment NN N
period NN N
of IN N
1 JJ N
year NN N
. . N

In IN N
the DT N
direct JJ N
comparison NN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN I
nebivolol NNS I
and CC I
metoprolol NN I
. . N

-DOCSTART- -X- N

Optimized VBN N
strategy NN N
for IN N
detection NN N
of IN N
early JJ P
stage NN P
curable JJ P
prostate NN P
cancer: JJ P
role NN N
of IN N
prescreening VBG I
with IN I
prostate-specific JJ I
antigen NN I
. . I

In IN N
1 CD P
002 CD P
men NNS P
aged VBN P
45-80 JJ P
y NN P
81% CD P
of IN N
the DT N
cancers NNS N
detectable JJ N
by IN N
serum JJ I
prostate-specific JJ P
antigen NN P
(PSA) NNP P
digital JJ P
rectal JJ P
examination NN P
(DRE) NN P
and CC P
transrectal JJ P
ultrasonography NN P
(TRUS) NN I
were VBD N
present JJ N
in IN N
a DT N
subpopulation NN N
(19% NN N
of IN N
total) NN N
identified VBN N
by IN N
serum NN I
PSA NNP I
above IN N
the DT N
threshold JJ N
value NN N
of IN N
3.0 CD N
micrograms/L NN N
. . N

This DT N
study NN N
was VBD N
extended VBN P
to TO P
7 CD P
350 CD P
men NNS P
using VBG P
serum NN P
PSA NNP P
and CC P
DRE NNP P
as IN P
first JJ P
approach NN P
followed VBN P
by IN P
TRUS NNP P
only RB P
when WRB P
1 CD P
of IN P
these DT P
2 CD P
tests NNS P
was VBD P
abnormal JJ P
. . P

Because IN N
the DT N
aim NN N
of IN N
prostate NN N
cancer NN N
detection NN N
is VBZ N
to TO N
find VB N
cancers NNS N
at IN N
an DT N
early JJ N
potentially RB N
curable JJ N
stage NN N
it PRP N
is VBZ N
of IN N
major JJ N
interest NN N
that IN N
71.8% CD N
of IN N
evaluable JJ N
cancers NNS N
were VBD N
clinical JJ N
stage NN N
B; NNP N
8.4% CD N
and CC N
10.7% CD N
were VBD N
stages NNS N
C1 NNP N
and CC N
C2 NNP N
respectively; VBD N
only RB N
9.2% CD N
were VBD N
stage NN N
D NNP N
(metastatic) NNP N
at IN N
first JJ N
visit NN N
while IN N
none NN N
was VBD N
at IN N
stage NN N
D NNP N
at IN N
follow-up JJ N
visits NNS N
. . N

This DT N
study NN N
the DT N
first JJ N
performed VBN N
in IN N
an DT N
unselected JJ P
unscreened JJ P
population NN P
shows VBZ P
that IN N
serum NN O
PSA NNP O
is VBZ N
the DT N
most RBS N
sensitive JJ N
technique NN N
to TO N
identify VB N
men NNS N
at IN N
high JJ N
risk NN N
of IN N
having VBG N
prostate NN N
cancer NN N
and CC N
that IN N
12% CD N
more JJR N
cancers NNS N
can MD N
be VB N
found VBN N
at IN N
first JJ N
visit NN N
by IN N
doing VBG N
DRE NNP I
in IN I
addition NN I
to TO I
PSA NNP I
. . I

Follow-ups NNS N
can MD N
be VB N
done VBN N
every DT N
second JJ N
year NN N
using VBG N
serum JJ I
PSA NNP I
alone RB I
as IN I
97% CD N
of IN N
the DT N
cancers NNS N
detected VBD N
at IN N
annual JJ N
follow-up NN N
by IN N
DRE NNP I
+ NNP I
PSA NNP I
were VBD N
PSA+ NNP I
. . I

Cancers NNS N
are VBP N
discovered VBN N
by IN N
the DT N
present JJ N
approach NN N
at IN N
an DT N
estimated JJ O
cost NN O
of IN N
$2 $ N
665 CD N
per IN N
cancer NN N
. . N

Such JJ N
cancers NNS N
are VBP N
potentially RB N
curable JJ O
in IN N
at IN N
least JJS N
80% CD N
of IN N
cases NNS N
detected VBN N
at IN N
first JJ N
visit NN N
and CC N
in IN N
97% CD N
of IN N
cases NNS N
at IN N
follow-up NN N
. . N

This DT N
strategy NN N
offers VBZ N
the DT N
possibility NN N
to TO N
improve VB N
markedly RB N
morbidity NN O
and CC O
mortality NN O
from IN N
prostate NN N
cancer NN N
presently RB N
the DT N
second JJ N
leading JJ N
cause NN N
of IN N
cancer NN N
death NN N
in IN N
North JJ N
American JJ N
men NNS N
. . N

-DOCSTART- -X- N

Socio-demographic JJ I
anthropometric NN I
and CC I
psychosocial JJ I
predictors NNS I
of IN I
attrition NN I
across IN I
behavioral JJ I
weight-loss JJ I
trials NNS I
. . I

Preventing VBG I
attrition NN I
is VBZ I
a DT I
major JJ I
concern NN I
in IN I
behavioral JJ I
weight JJ I
loss NN I
intervention NN I
studies NNS I
. . I

The DT I
purpose NN I
of IN I
this DT I
analysis NN I
was VBD I
to TO I
identify VB I
baseline NN I
and CC I
six-month JJ I
predictors NNS I
associated VBN I
with IN I
participant JJ I
attrition NN I
across IN I
three CD I
independent JJ I
clinical JJ I
trials NNS I
of IN I
behavioral JJ I
weight JJ I
loss NN I
interventions NNS I
(PREFER VBP I
SELF NNP I
and CC I
SMART) NNP I
that WDT I
were VBD I
conducted VBN I
over IN I
10 CD I
years NNS I
. . I

Baseline NNP I
measures NNS I
included VBD I
body NN O
mass NN O
index NN O
Barriers NNP O
to TO O
Healthy NNP O
Eating NNP O
Beck NNP O
Depression NNP O
Inventory-II NNP O
(BDI) NNP O
Hunger NNP O
Satiety NNP O
Scale NNP O
(HSS) NNP O
Binge NNP O
Eating NNP O
Scale NNP O
(BES) NNP O
Medical NNP O
Outcome NNP O
Study NNP O
Short NNP O
Form NNP O
(MOS NNP O
SF-36 NNP O
v2) NN O
and CC O
Weight NNP O
Efficacy NNP O
Lifestyle NNP O
Questionnaire NNP O
(WEL) NNP O
. . O

We PRP I
also RB I
examined VBD I
early JJ O
weight NN O
loss NN O
and CC O
attendance NN O
at IN I
group NN I
sessions NNS I
during IN I
the DT I
first JJ I
6 CD I
months NNS I
. . I

Attrition NN O
was VBD I
recorded VBN I
at IN I
the DT I
end NN I
of IN I
the DT I
trials NNS I
. . I

Participants NNS P
included VBD P
504 CD P
overweight NN P
and CC P
obese JJ P
adults NNS P
seeking VBG P
weight JJ P
loss NN P
treatment NN P
. . P

The DT I
sample NN P
was VBD P
84.92% CD P
female JJ P
and CC P
73.61% CD P
white JJ P
with IN P
a DT P
mean JJ P
( NN P
SD) NNP P
age NN P
of IN P
47.35 CD P
 JJ I
9.75 CD P
years NNS P
. . I

After IN I
controlling VBG I
for IN I
the DT I
specific JJ I
trial NN I
for IN O
every DT O
one CD O
unit NN O
increase NN O
in IN O
BMI NNP O
the DT O
odds NNS O
of IN O
attrition NN O
increased VBN O
by IN I
11% CD I
. . I

For IN I
every DT I
year NN O
increase NN O
in IN O
education NN O
the DT O
odds NNS O
of IN O
attrition NN O
decreased VBN O
by IN I
10% CD I
. . I

Additional JJ I
predictors NNS I
of IN I
attrition NN I
included VBD P
previous JJ P
attempts NNS P
to TO P
lose VB P
50-79 JJ P
lbs NN P
age NN P
not RB P
possessing VBG P
health NN P
insurance NN P
and CC P
BES NNP P
BDI NNP P
and CC P
HSS NNP P
scores NNS P
. . I

At IN I
6 CD I
months NNS I
the DT I
odds NNS I
of IN O
attrition NN O
increased VBN I
by IN I
10% CD I
with IN I
reduced VBN I
group NN I
session NN I
attendance NN I
. . I

There EX I
was VBD I
also RB I
an DT I
interaction NN I
between IN I
percent NN I
weight NN I
change NN I
and CC I
trial NN I
(p<.001) NN I
. . I

Multivariate NNP I
analysis NN I
of IN I
the DT I
three CD I
trials NNS I
showed VBD O
education NN O
age NN O
BMI NNP O
and CC O
BES NNP O
scores NNS O
were VBD O
independently RB O
associated VBN O
with IN I
attrition NN I
(ps NNP I
 NNP N
.01) NNP I
. . I

These DT I
findings NNS I
may MD I
inform VB I
the DT I
development NN I
of IN I
more JJR I
robust JJ I
strategies NNS I
for IN I
reducing VBG I
attrition NN I
. . N

-DOCSTART- -X- N

The DT N
value-congruence JJ N
model NN N
of IN N
memory NN O
for IN O
emotional JJ O
experiences: NN O
an DT N
explanation NN N
for IN N
cultural JJ N
differences NNS N
in IN P
emotional JJ P
self-reports NNS P
. . P

In IN N
3 CD N
studies NNS N
the DT N
authors NNS N
found VBD N
support NN N
for IN N
the DT N
value-congruence NN I
model NN I
that WDT N
accounts VBZ N
for IN N
cultural JJ N
variations NNS N
in IN N
memory NN O
for IN O
emotional JJ O
experiences NNS O
. . O

In IN N
Study NNP N
1 CD N
the DT N
authors NNS N
found VBD N
that IN N
in IN N
the DT N
made-in-the-U.S NN I
. . I

scenario NN I
condition NN N
European JJ P
Americans NNPS P
were VBD P
more JJR P
accurate JJ P
than IN P
were VBD P
Asian JJ P
Americans NNPS P
in IN N
their PRP$ N
retrospective JJ O
frequency NN O
judgments NNS O
of IN O
emotions NNS O
. . O

However RB N
in IN N
the DT N
made-in-Japan JJ P
scenario NN P
condition NN P
European JJ P
Americans NNPS P
were VBD P
less JJR P
accurate JJ P
than IN P
were VBD P
Asian JJ P
Americans NNPS P
. . P

In IN N
Study NNP N
2 CD N
the DT N
authors NNS N
demonstrated VBD N
that IN N
value NN N
orientation NN N
mediates VBZ N
the DT N
CulturexType NNP N
of IN N
Event NNP N
congruence NN O
effect NN O
. . O

In IN N
Study NNP N
3 CD N
(a NNP N
daily JJ I
event NN I
sampling VBG I
study) VBD I
the DT N
authors NNS N
showed VBD N
that IN N
the DT N
congruence NN O
effect NN O
was VBD N
explained VBN N
by IN N
the DT N
importance NN N
of IN N
parental JJ N
approval NN N
. . N

In IN N
sum JJ N
emotional JJ N
events NNS N
congruent NN N
with IN N
personal JJ O
values NNS O
remain VBP N
in IN N
memory NN N
longer NN N
and CC N
influence NN N
retrospective JJ N
frequency NN N
judgments NNS N
of IN N
emotion NN N
more JJR N
than IN N
do VB N
incongruent JJ N
events NNS N
. . N

-DOCSTART- -X- N

Novel NNP I
population NN I
pharmacokinetic JJ I
method NN I
compared VBN I
to TO I
the DT I
standard JJ I
noncompartmental JJ I
approach NN I
to TO N
assess VB N
bioequivalence NN I
of IN I
iron NN I
gluconate NN I
formulations NNS I
. . I

PURPOSE NNP N
Iron-containing JJ I
products NNS I
are VBP N
atypical JJ N
in IN N
terms NNS N
of IN N
their PRP$ N
pharmacokinetic JJ N
properties NNS N
because IN N
iron NN N
is VBZ N
only RB N
removed VBN N
by IN N
plasma NN N
sampling NN N
and CC N
is VBZ N
non-linear JJ N
. . N

This DT N
study NN N
aims VBZ N
to TO N
present VB N
a DT N
novel JJ N
way NN N
of IN N
assessing VBG N
the DT N
relative JJ N
bioavailability NN N
of IN N
two CD I
sodium NN I
ferric JJ I
gluconate NN I
complex JJ I
(SFGC) NN I
formulations NNS I
and CC N
compare VB N
this DT N
approach NN N
to TO N
a DT N
standard NN N
previously RB N
published VBN N
noncompartmental JJ N
approach NN N
. . N

METHODS NNP N
Data NNP N
were VBD N
from IN N
open-label JJ N
randomized VBN N
single-dose JJ N
studies NNS N
(Study VBP N
1 CD N
was VBD N
parallel JJ N
whereas NNS N
Study VBP N
2 CD N
was VBD N
crossover) NN N
. . N

Subjects NNS P
with IN P
low JJ P
but CC P
normal JJ P
iron NN P
levels NNS P
were VBD N
infused VBN I
IV NNP I
SFGC NNP I
in IN I
sucrose JJ I
by IN N
GeneraMedix NNP N
Inc NNP N
. . N

and/or NN N
Ferrlecit NNP I
 NNP N
Injection NNP I
(Watson NNP N
Laboratories NNPS N
Inc.) NNP N
. . N

In IN P
Study NNP P
1 CD P
(n=240) NNP P
125 CD P
mg NN P
was VBD P
infused VBN P
over IN P
10 CD P
minutes NNS P
. . N

In IN P
Study NNP P
2 CD P
(n=29) NNP P
62.5 CD P
mg NN P
was VBD P
infused VBN P
over IN P
30 CD P
minutes NNS P
. . N

Samples NNS N
were VBD N
assayed VBN N
for IN O
total JJ O
iron NN O
(TI) NN O
and CC O
transferrin-bound NN O
iron NN O
(TBI) NN O
over IN O
36 CD O
hours NNS O
(Study VBP O
1) CD O
or CC O
72 CD O
hours NNS O
(Study VBD O
2) CD O
post-dose JJ O
. . N

Studies NNS N
1 CD N
and CC N
2 CD N
used JJ N
standard NN N
noncompartmental JJ N
analysis NN N
. . N

Study NNP N
2 CD N
also RB N
used VBN O
population NN O
PK NNP O
(PPK) NNP O
analyses VBZ O
with IN N
ADAPT NNP N
5 CD N
. . N

The DT N
final JJ N
model NN N
predicted VBD I
SFGC NNP I
area-under-the-curve JJ N
(AUCpred) NN N
and CC N
maximal JJ N
concentration NN N
(Cmaxpred) NN N
. . N

Analyses NNS N
of IN N
variance NN N
was VBD N
conducted VBN N
on IN N
ln-transformed JJ N
PK NNP N
parameters NNS N
. . N

Ratios NNS N
of IN N
means NNS N
and CC N
90% CD N
confidence NN N
intervals NNS N
(CIs) VBP N
were VBD N
estimated VBN N
. . N

Bioequivalence NN N
was VBD N
demonstrated VBN N
if IN N
values NNS N
were VBD N
within IN N
80-125% JJ N
. . N

RESULTS NNP N
For IN N
Study NNP N
1 CD N
ratios NNS N
and CC N
90% CD N
CIs NNP N
for IN N
TI NNP N
baseline-corrected JJ N
Cmax NNP N
and CC N
AUC0-36 NNP N
were VBD N
100.4 CD N
(96.5 NNP N
- : N
104.5) CD N
and CC N
99.7 CD N
(94.2 NNP N
- : N
105.5) CD N
. . N

For IN N
TBI NNP N
results NNS N
for IN N
TI NNP N
baseline-corrected JJ N
Cmax NNP N
and CC N
AUC0-36 NNP N
were VBD N
86.8 CD N
(82.7 NNP N
- : N
91.1) CD N
and CC N
92.4 CD N
(85.6 NNP N
- : N
99.7) CD N
. . N

For IN N
Study NNP N
2 CD N
a DT N
multi-compartmental JJ N
model NN N
simultaneously RB N
described VBD N
the DT N
PK NNP N
of IN N
TI NNP N
TBI NNP N
and CC N
SFGC NNP N
. . N

Ratios NNS N
and CC N
90% CD N
CIs NNP N
for IN I
SFGC NNP I
Cmaxpred NNP N
and CC N
AUCpred NNP N
were VBD N
89.9 CD N
(85.9 NNP N
- : N
94.0) CD N
and CC N
89.7 CD N
(85.7 NNP N
- : N
93.9) CD N
while IN N
ratios NNS N
and CC N
90% CD N
CI NNP N
obtained VBN N
from IN N
the DT N
noncompartmental JJ N
analysis NN N
of IN N
Study NNP N
2 CD N
did VBD N
not RB N
meet VB N
BE NNP N
criteria NNS N
because IN N
of IN N
low JJ N
power NN N
. . N

CONCLUSIONS NNP N
Both NNP N
the DT I
standard NN I
and CC I
PPK NNP I
modeling VBG I
approach NN I
suggested VBD N
bioequivalence NN N
between IN N
the DT I
iron NN I
products NNS I
. . N

However RB N
with IN N
the DT I
PPK NNP I
method NN I
less JJR N
subjects NNS N
were VBD N
required VBN N
to TO N
meet VB N
study NN N
objectives NNS N
compared VBN N
to TO N
the DT I
standard JJ I
noncompartmental NN I
approach NN I
which WDT N
required VBD N
considerably RB N
more RBR N
subjects NNS N
(29 VBP N
vs JJ N
240) CD N
. . N

-DOCSTART- -X- N

Erlotinib NNP I
is VBZ N
effective JJ N
in IN N
pancreatic JJ P
cancer NN P
with IN P
epidermal JJ P
growth NN P
factor NN P
receptor NN P
mutations: VBD P
a DT N
randomized JJ N
open-label JJ N
prospective JJ N
trial NN N
. . N

OBJECTIVE NN N
To TO N
analyze VB N
the DT N
efficacy NN N
of IN N
gemcitabine NN I
with IN I
or CC I
without IN I
erlotinib NN I
for IN I
pancreatic JJ I
cancer NN I
and CC I
to TO N
determine VB N
the DT N
predictive JJ N
role NN N
of IN N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
(EGFR) NN N
and CC N
KRAS NNP N
mutations NNS N
in IN N
these DT N
patients NNS N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
single-center JJ N
randomized JJ N
open-label JJ N
prospective JJ N
trial NN N
. . N

Eighty-eight JJ P
chemotherapy-nave JJ P
metastatic JJ P
pancreatic JJ P
cancer NN P
patients NNS P
were VBD P
randomized VBN P
for IN P
treatment NN P
with IN P
gemcitabine NN P
or CC P
gemcitabine NN P
plus CC P
erlotinib NN I
. . N

EGFR NNP N
and CC N
KRAS NNP N
mutations NNS N
were VBD N
analyzed VBN N
respectively RB N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT O
disease NN O
control NN O
rate NN O
. . N

RESULTS NNP O
Disease NNP O
control NN O
rate NN O
(64% NNP N
vs NN N
. . N

25%; CD N
P NNP N
< VBD N
0.001) CD O
progression-free JJ O
survival NN O
(median JJ N
3.8 CD N
vs NN N
. . N

2.4 CD N
months; NN N
P NNP N
< VBZ N
0.001) CD N
and CC O
overall JJ O
survival NN O
(median JJ N
7.2 CD N
vs NN N
. . N

4.4 CD N
months; NN N
P NNP N
< $ N
0.001) CD N
were VBD N
better RBR N
in IN N
the DT I
gemcitabine NN I
plus CC I
erlotinib NN I
group NN N
than IN N
in IN N
the DT I
gemcitabine NN I
alone RB I
group NN N
. . N

In IN N
the DT I
gemcitabine NN I
plus CC I
erlotinib JJ I
group NN O
disease NN O
control NN O
(85% NNP N
vs NN N
. . N

33%; CD N
P NNP N
= VBD N
0.001) CD O
progression-free JJ O
survival NN O
(median JJ N
5.9 CD N
vs NN N
. . N

2.4 CD N
months; NN N
P NNP N
= VBZ N
0.004) CD N
and CC O
overall JJ O
survival NN O
(median JJ N
8.7 CD N
vs NN N
. . N

6.0 CD N
months; NN N
P NNP N
= $ N
0.044) CD N
were VBD N
better JJR N
in IN P
patients NNS P
with IN P
EGFR NNP P
mutations NNS P
than IN P
in IN P
those DT P
without IN P
EGFR NNP P
mutations NNS P
. . N

KRAS NNP N
mutation NN N
was VBD N
not RB N
associated VBN N
with IN N
treatment NN N
response NN N
or CC N
survival NN N
. . N

CONCLUSIONS NNP I
Gemcitabine NNP I
plus CC I
erlotinib NN I
is VBZ N
more RBR N
effective JJ N
than IN I
gemcitabine VB I
alone JJ I
for IN N
treating VBG P
metastatic JJ P
pancreatic JJ P
cancer NN P
patients NNS P
especially RB P
those DT P
with IN P
EGFR NNP P
mutations NNS P
. . N

ClinicalTrials.gov NNP N
number NN N
NCT01608841 NNP N
. . N

-DOCSTART- -X- N

Postoperative JJ N
dreaming NN N
. . N

A DT N
comparison NN N
of IN N
the DT N
incidence NN N
following VBG N
pentazocine NN I
and CC I
morphine JJ I
premedication NN I
. . I

The DT N
incidence NN N
of IN N
postoperative JJ O
dreaming NN O
following VBG N
the DT N
use NN N
of IN N
morphine NN I
and CC I
pentazocine NN I
as IN N
premedicants NNS I
in IN N
an DT N
otherwise RB N
standard JJ N
anaesthetic JJ I
sequence NN I
is VBZ N
compared VBN N
in IN N
healthy JJ P
volunteers NNS P
. . P

No DT O
statistically RB O
significant JJ O
difference NN O
was VBD O
demonstrated VBN O
between IN O
the DT O
two CD O
drugs NNS O
. . O

The DT N
causes NNS N
of IN N
psychotomimetic JJ I
problems NNS I
in IN N
the DT N
postoperative JJ N
period NN N
and CC N
the DT N
difficulty NN N
of IN N
precise JJ N
definition NN N
of IN N
hallucinations NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- N

A DT N
randomised JJ N
double-blind NN N
parallel JJ N
design NN N
multi-institutional JJ N
non-inferiority JJ N
phase NN N
IV NNP I
trial NN I
of IN I
imidafenacin JJ I
versus NN I
fesoterodine NN I
for IN N
overactive JJ P
bladder NN P
. . P

AIMS NNP N
Our PRP$ N
objective NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN O
and CC O
safety NN O
of IN N
imidafenacin NN I
over IN N
fesoterodine NN I
in IN N
patients NNS P
with IN P
overactive JJ P
bladder NN P
(OAB) NN P
. . P

METHODS NNP P
This DT N
study NN N
is VBZ N
a DT N
randomised JJ N
double-blind JJ N
parallel-group JJ N
fesoterodine-controlled JJ I
study NN N
in IN N
patients NNS P
with IN P
continuous JJ P
OAB NNP P
symptoms NNS P
for IN P
3months JJ P
daily JJ P
mean NN P
voiding VBG P
frequency NN P
(DMVF) NNP P
8 NNP P
and CC P
daily JJ P
mean JJ P
urgency NN P
or CC P
urgency NN P
incontinence NN P
frequency NN P
2 NNP N
. . N

A DT N
twice-daily JJ I
0.1mg CD I
imidafenacin NN I
with IN I
placebo NN N
or CC N
once-daily RB I
4mg CD I
fesoterodine NN I
with IN I
placebo NN N
were VBD N
administered VBN N
for IN N
12weeks CD N
. . N

The DT N
primary JJ N
efficacy NN N
end-point NN N
was VBD N
the DT N
difference NN O
in IN N
DMVF NNP N
at IN N
12weeks CD N
. . N

The DT N
secondary JJ N
efficacy NN N
end-points NNS N
were VBD N
differences NNS O
in IN O
daily JJ O
mean: NN O
(i) NNP O
voiding NN O
frequency NN O
at IN O
4 CD O
and CC O
8weeks; CD O
(ii) JJ O
urgency NN O
frequency; NN O
(iii) NNP O
urgency NN O
incontinence NN O
frequency; NN O
(iv) NNP O
incontinence NN O
frequency; NN O
(v) NNP O
nocturia CC O
frequency; NN O
and CC O
(vi) NNP O
quality NN O
of IN N
life NN N
score NN N
. . N

The DT O
variables NNS O
for IN O
safety NN O
analysis NN O
were VBD O
adverse JJ O
events NNS O
vital JJ O
signs NNS O
residual JJ O
urine JJ O
volume NN O
and CC O
clinical JJ O
laboratory NN O
tests NNS N
. . N

An DT N
efficacy NN N
analysis NN N
was VBD N
conducted VBN N
in IN N
per-protocol JJ N
patients NNS N
and CC N
the DT N
safety NN N
analysis NN N
was VBD N
conducted VBN N
in IN N
all DT N
randomised JJ N
patients NNS N
. . N

RESULTS VB N
The DT N
differences NNS N
in IN N
DMVF NNP N
at IN N
12weeks CD N
were VBD N
-3.383.63 NNS N
and CC N
-2.453.73 NN I
in IN I
the DT I
imidafenacin NN I
and CC N
fesoterodine NN N
groups NNS N
respectively RB N
and CC N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
between IN I
the DT I
two CD I
groups NNS N
. . N

Imidafenacin NNP I
was VBD I
non-inferior JJ I
to TO N
fesoterodine VB N
and CC N
the DT N
lower JJR N
limit NN N
of IN N
95% CD N
two-sided JJ N
confidence NN N
intervals NNS N
was VBD N
-0.53 RB N
. . N

The DT N
other JJ N
six CD N
secondary JJ N
end-points NNS N
and CC N
variables NNS N
for IN N
safety NN N
analysis NN N
showed VBD N
no DT N
difference NN N
between IN N
the DT N
two CD I
groups NNS I
. . I

CONCLUSIONS NNP I
Imidafenacin NNP I
was VBD I
non-inferior JJ I
to TO N
fesoterodine VB N
in IN N
terms NNS N
of IN N
efficacy NN N
and CC N
showed VBD N
no DT N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
safety NN N
. . N

-DOCSTART- -X- N

Loss NNP N
of IN N
tooth JJ N
substance NN N
during IN N
root NN I
planing VBG I
with IN I
various JJ I
periodontal JJ I
instruments: NN I
an DT N
in IN N
vitro NN N
study NN N
. . N

Ultrasonic JJ I
and CC I
power-driven JJ I
instrumentation NN I
is VBZ N
gaining VBG N
in IN N
significance NN N
as IN N
an DT N
acceptable JJ N
alternative NN N
to TO N
manual JJ I
periodontal JJ I
root NN I
treatment NN I
. . I

Some DT N
question NN N
whether IN N
they PRP N
do VBP N
not RB N
remove VB N
too RB N
much JJ N
tooth DT N
substance NN N
. . N

Various JJ I
ultrasonic JJ I
scalers NNS I
hand NN I
instruments NNS I
and CC I
two CD I
power-driven JJ I
systems NNS I
were VBD N
compared VBN N
by IN N
assessing VBG N
the DT N
loss NN O
of IN O
tooth JJ O
substance NN O
due JJ N
to TO N
root VB N
instrumentation NN N
. . N

Quantitative JJ N
analysis NN N
of IN N
this DT N
effect NN N
of IN N
the DT N
instruments NNS N
used VBN N
was VBD N
performed VBN N
on IN N
20 CD P
freshly RB P
extracted VBN P
non-periodontally RB P
involved JJ P
large JJ P
human JJ P
molars NNS P
. . P

In IN N
the DT N
first JJ N
study NN N
40 CD P
specimens NNS P
were VBD N
randomly RB N
assigned VBN N
to TO N
four CD N
groups NNS N
of IN N
treatment: NN N
combined VBN I
use NN I
of IN I
ultrasonic JJ I
scaler NN I
and CC I
Periopolisher NNP I
diamond-coated JJ I
inserts NNS I
(US-POL) JJ I
hand NN I
instruments NNS I
(MANUAL) VBP I
Perioplaner-Periopolisher NNP I
system NN I
(PPL-POL) JJ I
and CC I
Periokit NNP I
ultrasonic-designed JJ I
scalers NNS I
(PERIOKIT) POS I
. . I

The DT N
second JJ N
study NN N
involved VBN N
two CD N
treatment NN N
groups NNS N
ultrasonic JJ I
scaler NN I
alone RB I
and CC I
hand NN I
instruments NNS I
each DT I
allocated VBN N
with IN N
20 CD N
teeth NNS N
(small JJ N
root NN N
fragments) NN N
. . N

An DT N
unpaired JJ N
two-tailed JJ N
t NN N
test NN N
was VBD N
carried VBN N
out RP N
for IN N
both DT N
studies NNS N
to TO N
compare VB N
the DT N
average JJ N
weight JJ O
loss NN O
of IN O
root JJ O
substance NN O
with IN N
the DT N
modes NNS N
of IN N
instrumentation NN N
. . N

The DT N
level NN N
of IN N
significance NN N
was VBD N
set VBN N
at IN N
p<or=0.05 NN N
. . N

The DT N
overall JJ N
results NNS N
of IN N
the DT N
first JJ N
and CC N
second JJ N
experimental JJ N
trials NNS N
did VBD N
not RB N
reveal VB N
obvious JJ N
differences NNS N
in IN N
weight JJ O
loss NN O
between IN N
the DT N
manual JJ N
ultrasonic JJ N
or CC N
power-driven JJ N
root NN I
treatments NNS I
. . I

Based VBN N
on IN N
the DT N
results NNS N
of IN N
these DT N
two CD N
comparative NN N
studies NNS N
the DT N
power-driven JJ I
inserts NNS I
or CC N
the DT N
various JJ N
ultrasonic JJ N
scalers NNS N
tested VBD N
did VBD N
not RB N
remove VB N
more RBR N
tooth JJ O
substance NN O
than IN N
conventional JJ N
hand NN N
instruments NNS N
. . N

They PRP N
may MD N
thus RB N
be VB N
a DT N
useful JJ N
alternative NN N
for IN N
the DT N
debridement NN N
of IN N
root NN N
surfaces NNS N
. . N

-DOCSTART- -X- N

Single-needle JJ I
acupuncture NN I
alleviates VBZ N
gag JJ N
reflex NN N
during IN P
transesophageal JJ P
echocardiography: FW P
a DT N
blinded VBN N
randomized NN N
controlled VBD N
pilot JJ N
trial NN N
. . N

OBJECTIVES NNP N
To TO N
study VB N
the DT N
effect NN N
of IN N
single-needle JJ I
acupuncture NN I
in IN N
suppressing VBG N
gag-reflex JJ N
in IN N
transesophageal JJ N
echocardiography NN N
(TEE) NN N
. . N

DESIGN NNP N
Prospective NNP N
blinded VBD N
trial NN N
. . N

Settings/locations: JJ N
Patients NNS P
with IN P
ischemic JJ P
stroke NN P
or CC P
transient JJ P
ischemic JJ P
attack NN P
undergoing JJ P
TEE NNP P
because IN P
of IN P
presumed JJ P
cardioembolic JJ P
origin NN P
in IN P
a DT P
specialized JJ P
stroke NN P
unit NN P
of IN P
the DT P
Johann NNP P
Wolfgang NNP P
Goethe-University NNP P
Frankfurt/Main NNP P
Germany NNP P
. . P

Subjects/Study NNP N
interventions: VBZ N
Forty-one CD P
(41) NN P
patients NNS P
were VBD P
studied VBN P
. . P

Patients NNS N
received VBD N
single-needle JJ I
acupuncture NN I
with IN N
a DT N
0.2 CD N
x NN N
13 CD N
mm NN N
disposable JJ N
acupuncture NN N
needle JJ N
(Suzhou NNP N
Medical NNP N
Appliances NNP N
China) NNP N
10-mm JJ N
deep NN N
either NN N
at IN N
Chengjiang NNP N
(midline VBP N
between IN N
lower JJR N
lip NN N
and CC N
chin) NN N
or CC N
superficially RB N
at IN N
a DT N
sham JJ I
point NN I
(tip NN N
of IN N
the DT N
chin) NN N
during IN N
TEE NNP N
or CC N
no DT I
acupuncture NN I
for IN N
alleviating VBG N
gag NN N
reflex NN N
. . N

OUTCOME NNP N
MEASURES NNP N
Severity NNP O
of IN O
gagging NN O
was VBD N
rated VBN N
on IN N
a DT N
visual-analogue JJ O
scale NN O
. . O

RESULTS VB N
The DT N
acupuncture NN I
group NN I
experienced VBD N
significantly RB N
less RBR O
gagging VBG O
than IN N
the DT N
sham NN N
group NN N
(p NNP N
= VBZ N
0.037) CD N
or CC N
the DT N
nonacupuncture NN N
group NN N
(p NNP N
= VBZ N
0.013) CD N
. . N

CONCLUSIONS NNP N
Acupuncture NNP I
of IN I
CV24 NNP I
is VBZ N
an DT N
easy JJ N
to TO N
apply VB N
and CC N
effective JJ N
method NN N
to TO N
reduce VB N
gag NN O
reflex NN O
during IN N
TEE NNP N
. . N

-DOCSTART- -X- N

Comparison NNP N
of IN N
long-term JJ O
efficacy NN O
and CC O
safety NN O
of IN N
risperidone NN I
and CC I
haloperidol NN I
in IN N
children NNS P
and CC P
adolescents NNS P
with IN P
autistic JJ P
disorder NN P
. . P

An DT N
open JJ N
label NN N
maintenance NN N
study NN N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
safety NN O
efficacy NN O
and CC O
tolerability NN O
of IN N
risperidone NN I
in IN N
comparison NN N
with IN N
haloperidol NN I
in IN N
the DT N
long-term JJ N
treatment NN N
of IN N
autistic JJ P
disorder NN P
. . P

METHODS NNP N
This DT N
was VBD N
an DT N
open-label JJ N
continuation NN N
study NN N
of IN N
the DT N
randomized JJ N
double-blind NN N
controlled VBD N
trial NN N
of IN N
risperidone NN I
and CC I
haloperidol NN I
study NN N
for IN N
12 CD N
week NN N
in IN P
autistic JJ P
children NNS P
and CC P
adolescents NNS P
. . P

A DT P
total NN P
of IN P
28 CD P
subjects NNS P
between IN P
8 CD P
and CC P
18 CD P
ages NNS P
with IN P
autistic JJ P
disorder NN P
were VBD N
enrolled VBN N
to TO N
the DT N
open JJ N
label NN N
phase NN N
of IN N
the DT N
study NN N
. . N

Behavioral JJ O
rating NN O
scales NNS O
(Clinical JJ O
Global NNP O
Impression NNP O
Scale NNP O
[CGI-I] JJ O
Ritvo-Freeman NNP O
Real NNP O
Life NNP O
Rating NNP O
Scale NNP O
[RF-RLRS]) JJ O
Aberrant NNP O
Behavior NNP O
Checklist NNP O
[ABC] NNP O
Turgay NNP O
DSM-IV NNP O
Pervasive NNP O
Developmental NNP O
Disorder NNP O
Rating NNP O
Scale NNP O
[TPDDRS]) NNP O
and CC O
safety NN O
assessment NN O
scales NNS O
(Extrapyramidal VBP O
Symptoms NNP O
Rating NNP O
Scale NNP O
[ESRS] NNP O
UKU-Side JJ O
Effect NNP O
Rating NNP O
Scale) NNP O
were VBD N
performed VBN N
at IN N
12 CD N
16 CD N
20 CD N
and CC N
24 CD N
weeks NNS N
following VBG N
the DT N
12 CD N
week NN N
double-blind JJ N
phase NN N
. . N

Risperidone NN I
and CC I
haloperidol NN I
treatments NNS N
were VBD N
applied VBN N
with IN N
a DT N
once RB N
daily JJ N
dosage NN N
regimen NNS N
as IN N
0.01-0.08 JJ N
mg/kg/day NN N
. . N

RESULTS NNP N
Risperidone NNP I
led VBD N
to TO N
a DT N
significant JJ N
greater JJR N
reduction NN N
on IN N
CGI NNP N
scale NN N
. . N

There EX N
was VBD N
significant JJ N
improvement NN N
on IN N
RF-RLRS NNP N
sensory JJ N
motor NN N
and CC N
language NN N
subscale NN N
and CC N
ABC NNP N
scores NNS N
in IN N
risperidone NN I
group NN N
. . N

Weight NNP O
gain NN O
was VBD N
observed VBN N
more RBR N
frequently RB N
in IN N
the DT N
haloperidol NN N
group NN N
at IN N
week NN N
24 CD N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
demonstrate VBP N
that IN N
risperidone NN I
is VBZ N
more RBR N
efficacious JJ N
and CC N
well RB N
tolerated VBN N
than IN N
haloperidol NN N
in IN N
the DT N
long-term JJ N
maintenance NN N
treatment NN N
of IN N
autistic JJ N
disorder NN N
. . N

-DOCSTART- -X- N

[Acute NN N
cardiovascular NN N
and CC N
metabolic JJ N
changes NNS O
in IN N
interval NN N
and CC N
endurance NN N
training NN N
in IN N
selected VBN P
patients NNS P
following VBG P
aortocoronary JJ P
bypass NN P
operation] NN P
. . N

UNLABELLED IN N
This DT N
study NN N
compared VBN N
the DT N
acute NN O
changes NNS O
of IN O
cardiovascular NN O
and CC O
metabolic JJ O
reactions NNS O
during IN N
interval NN N
and CC N
continuous JJ N
training NN N
after IN P
coronary JJ P
bypass NN P
surgery NN P
. . P

Two CD P
groups NNS P
of IN P
9 CD P
male JJ P
patients NNS P
(age: JJ P
59 CD P
+/- JJ P
4 CD P
and CC P
56 CD P
+/- JJ P
6 CD P
years NNS P
resp.) JJ P
each DT P
trained VBN P
on IN P
bicycle NN P
ergometer JJ P
start NN P
on IN P
post-operative JJ P
days NNS P
24 CD P
and CC P
26 CD P
resp NN P
. . P

In IN N
both DT N
training NN N
groups NNS N
training VBG O
heart NN O
rate NN O
was VBD N
set VBN N
at IN N
86% CD N
of IN N
individual JJ N
maximum JJ N
heart NN N
rate NN N
. . N

In IN N
the DT N
last JJ N
week NN N
of IN N
training VBG N
the DT N
exercise NN N
intensity NN N
in IN N
the DT N
group NN N
of IN N
patients NNS N
who WP N
were VBD N
trained VBN N
by IN N
the DT N
continuous JJ N
method NN N
was VBD N
at IN N
83 CD N
watts NNS N
and CC N
at IN N
20:121 CD N
watts NN N
in IN N
the DT N
group NN N
of IN N
patients NNS N
who WP N
were VBD N
trained VBN N
by IN N
interval JJ N
method NN N
(rest:work NNP N
each DT N
1:1 CD N
min) NN N
. . N

At IN N
this DT N
exercise NN N
training NN N
that WDT N
lasted VBD N
for IN N
20 CD N
min PDT N
the DT N
acute JJ O
response NN O
of IN O
heart NN O
rate NN O
blood NN O
pressure NN O
rate-pressure JJ O
product NN O
glucose JJ O
lactate NN O
and CC O
catecholamines NNS O
was VBD N
measured VBN N
. . N

RESULTS NN N
In IN N
both DT N
methods NNS N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
systolic JJ O
and CC O
diastolic JJ O
pressure NN O
rate-pressure JJ O
product NN O
in IN O
glucose JJ O
or CC O
catecholamine JJ O
levels NNS O
. . O

However RB N
there EX N
was VBD N
a DT N
significantly RB N
higher JJR N
rate NN N
of IN N
lactate NN O
in IN N
the DT N
second JJ N
10 CD N
min NN N
of IN N
the DT N
interval JJ N
training NN N
. . N

And CC N
in IN N
spite NN N
of IN N
higher JJR N
peripheral JJ N
exercise NN N
intensity NN N
by IN N
interval JJ N
training NN N
there EX N
was VBD N
no DT N
higher JJR N
cardiac NN N
work NN N
than IN N
by IN N
the DT N
continuous JJ N
training NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
interval JJ N
training NN N
strains VBZ N
the DT N
oxidative JJ N
capacity NN N
of IN N
the DT N
trained JJ N
muscles NNS N
in IN N
a DT N
more RBR N
intensive JJ N
and CC N
direct JJ N
way NN N
than IN N
does VBZ N
continuous JJ N
training NN N
. . N

-DOCSTART- -X- N

Children's NNP I
Yale-Brown JJ I
Obsessive NNP I
Compulsive NNP I
Scale NNP I
modified VBD I
for IN I
pervasive JJ I
developmental NN I
disorders NNS I
. . I

OBJECTIVE NN N
To TO N
examine VB N
the DT N
psychometric JJ N
properties NNS N
of IN N
the DT N
Children's NNP P
Yale-Brown NNP P
Obsessive NNP P
Compulsive NNP P
Scales NNP P
(CYBOCS) NNP I
modified VBD I
for IN I
pervasive JJ I
developmental NN I
disorders NNS I
(PDDs) VBP I
. . I

METHOD NNP N
Raters NNPS N
from IN N
five CD N
Research NNP N
Units NNS N
on IN N
Pediatric NNP N
Psychopharmacology NNP N
(RUPP) NNP N
Autism NNP N
Network NNP N
were VBD N
trained VBN N
to TO N
reliability NN N
. . N

The DT N
modified VBN I
scale NN I
(CYBOCS-PDD) NN I
which WDT I
contains VBZ I
only RB I
the DT I
five CD I
Compulsion NNP I
severity NN I
items NNS I
(range VBP N
0-20) NN N
was VBD N
administered VBN P
to TO P
172 CD P
medication-free JJ P
children NNS P
(mean JJ P
8.2 CD P
+/- JJ P
2.6 CD P
years) NN P
with IN P
PDD NNP P
(autistic JJ P
disorder NN P
n NN P
= VBD P
152; CD P
Asperger's NNP P
disorder NN P
n NN P
= VBD P
6; CD P
PDD NNP P
not RB P
otherwise RB P
specified VBN P
n JJ P
= $ N
14) CD N
participating VBG N
in IN N
RUPP NNP N
clinical JJ N
trials NNS N
. . N

Reliability NN N
was VBD N
assessed VBN N
by IN N
intraclass NN N
correlation NN N
coefficient NN N
(ICC) NNP N
and CC N
internal JJ N
consistency NN N
by IN N
Cronbach's NNP N
alpha JJ N
coefficient NN N
. . N

Correlations NNS N
with IN N
ratings NNS N
of IN N
repetitive JJ N
behavior NN N
and CC N
disruptive JJ N
behavior NN N
were VBD N
examined VBN N
for IN N
validity NN N
. . N

RESULTS NNP N
Eleven NNP N
raters NNS N
showed VBD N
excellent JJ N
reliability NN O
(ICC NNP N
= VBZ N
0.97) CD N
. . N

The DT N
mean JJ O
CYBOCS NNP O
score NN N
was VBD N
14.4 CD N
(+/- JJ N
3.86) CD N
with IN N
excellent JJ N
internal JJ N
consistency NN N
(alpha NNP N
= NNP N
.85) NNP N
. . N

Correlations NNS N
with IN N
other JJ N
measures NNS N
of IN N
repetitive JJ N
behavior NN N
ranged VBD N
from IN N
r NN N
= $ N
0.11 CD N
to TO N
r VB N
= JJ N
0.28 CD N
and CC N
were VBD N
similar JJ N
to TO N
correlations NNS N
with IN N
measures NNS N
of IN N
irritability NN O
(r NNP N
= VBZ N
0.24) CD N
and CC N
hyperactivity NN O
(r NNP N
= VBZ N
0.25) CD N
. . N

Children NNS P
with IN P
higher JJR P
scores NNS P
on IN P
the DT P
CYBOCS-PDD NNP P
had VBD N
higher JJR N
levels NNS N
of IN N
maladaptive JJ O
behaviors NNS O
and CC O
lower JJR O
adaptive JJ O
functioning NN O
. . O

CONCLUSIONS VB N
The DT N
five-item JJ I
CYBOCS-PDD NNP I
is VBZ N
reliable JJ N
distinct NN N
from IN N
other JJ N
measures NNS N
of IN N
repetitive JJ N
behavior NN N
and CC N
sensitive JJ N
to TO N
change VB N
. . N

-DOCSTART- -X- N

A DT I
pilot NN I
study NN I
to TO I
improve VB I
venipuncture NN O
compliance NN O
in IN I
children NNS P
and CC P
adolescents NNS P
with IN P
autism NN P
spectrum NN P
disorders NNS P
. . P

OBJECTIVE NNP P
Medical NNP I
procedures NNS I
particularly RB I
venipuncture VBP I
(the JJ I
puncture NN I
of IN I
a DT I
vein NN I
especially RB I
for IN I
the DT I
withdrawal NN I
of IN I
blood) NN I
can MD I
cause VB I
serious JJ I
distress NN I
and CC I
behavior JJ I
disturbance NN I
for IN I
many JJ I
children NNS I
. . I

Noncompliance NN I
to TO I
blood VB I
draws NNS I
can MD I
have VB I
significant JJ I
ramifications NNS I
in IN I
both DT I
research NN I
and CC I
clinical JJ I
settings NNS I
. . I

The DT I
negative JJ I
reactions NNS I
may MD I
be VB I
exacerbated VBN I
in IN I
individuals NNS P
with IN P
autism NN P
spectrum NN P
disorders NNS P
. . P

Even RB I
so RB I
there EX I
has VBZ I
been VBN I
little JJ I
research NN I
into IN I
the DT I
prevalence NN I
of IN I
the DT I
problem NN I
or CC I
effective JJ I
intervention NN I
procedures NNS I
. . I

In IN I
response NN I
to TO I
these DT I
concerns NNS I
we PRP I
developed VBD I
and CC I
evaluated VBD I
the DT I
Blood NNP I
Draw NNP I
Intervention NNP I
Program NNP I
. . I

The DT I
program NN I
was VBD I
designed VBN I
to TO I
be VB I
easy JJ I
to TO I
use VB I
require JJ I
little JJ I
provider NN I
or CC I
family NN I
time NN I
effectively RB I
reduce VB I
negative JJ I
behaviors NNS I
and CC I
increase VB I
blood NN I
draw JJ I
compliance NN I
. . I

METHOD NNP I
In IN I
a DT I
quasi-randomized JJ I
trial NN I
over IN I
the DT I
course NN I
of IN I
 JJ N
18 CD I
months NNS P
58 CD P
of IN P
210 CD P
families NNS P
with IN P
children NNS P
with IN P
autism NN P
spectrum NN P
disorders NNS P
participating VBG P
in IN P
a DT P
larger JJR P
study NN P
of IN P
phenotypic NN P
and CC P
genotypic NN P
factors NNS P
reported VBD P
significant JJ P
concerns NNS P
about IN P
blood NN P
draws NNS P
and CC P
elected VBN P
to TO P
use VB P
the DT P
Blood NNP P
Draw NNP P
Intervention NNP P
Program NNP P
. . I

RESULTS NNP I
Completion NNP I
of IN I
the DT I
program NN I
increased VBD O
blood NN O
draw NN O
compliance NN O
rates NNS I
from IN I
85.4% CD I
to TO I
96.6% CD I
(odds NNS I
ratio VBP I
= JJ I
4.80; CD I
95% CD I
confidence NN I
interval NN I
= VBD I
1.12 CD I
20.59; CD I
p NN I
= NNP I
.03) NNP I
. . I

CONCLUSION NNP I
Results NNP I
indicate VBP I
the DT I
efficacy NN I
of IN I
the DT I
program NN I
in IN I
a DT I
research NN I
setting NN I
and CC I
suggest VB I
a DT I
potential JJ I
clinical JJ I
application NN I
. . I

The DT I
current JJ I
intervention NN I
unlike IN I
many JJ I
others NNS I
for IN I
the DT I
same JJ I
or CC I
similar JJ I
difficulties NNS I
proposed VBN I
in IN I
the DT I
past NN I
was VBD I
successful JJ I
without IN I
requiring VBG I
extensive JJ I
time NN I
training NN I
or CC I
effort NN I
on IN I
the DT I
part NN I
of IN I
providers NNS I
and CC I
parents NNS I
or CC I
their PRP$ I
children NNS I
nor CC I
did VBD I
it PRP I
require VB I
large-scale JJ I
institutional JJ I
changes NNS I
. . I

-DOCSTART- -X- N

Is VBZ N
Na+ NNP I
modeling VBG I
necessary JJ N
in IN N
high JJ I
flux JJ I
dialysis NN I
One CD I
important JJ N
pathogenic JJ N
factor NN N
in IN N
dialysis NN N
hypotension NN N
is VBZ N
the DT N
drop NN N
in IN N
plasma JJ N
osmolality NN N
. . N

Increasing VBG N
the DT N
dialysate NN I
Na+ NNP I
concentration NN I
decreases VBZ N
hypotensive JJ N
episodes NNS N
. . N

The DT N
authors NNS N
studied VBD N
39 CD P
patients NNS P
being VBG P
treated VBN P
with IN P
high JJ P
flux JJ P
dialysis NN P
. . P

During IN N
a DT N
9 CD N
week NN N
period NN N
the DT N
patients NNS N
were VBD N
on IN N
a DT N
standard JJ I
Na+ NNP I
dialysate NN I
(Na+ NNP I
= VBZ I
140 CD I
meq/L) NN I
basal NN N
period NN N
(B); VBD N
9% CD I
(Na+ NNP I
= VBD I
149 CD I
meq/L) NN I
linear JJ I
(L); JJ N
step NN N
drop NN N
(S); NN N
and CC N
exponential JJ N
drop NN N
(E) NN N
. . N

The DT N
Na+ NNP I
program NN I
was VBD N
changed VBN N
weekly RB N
at IN N
random NN N
. . N

The DT N
results NNS N
obtained VBD N
with IN N
the DT N
three CD N
Na+ NNP I
modeling VBG I
programs NNS I
were VBD N
similar JJ N
. . N

We PRP N
compared VBN N
the DT N
periods NNS N
with IN N
and CC N
without IN N
Na+ NNP I
modeling: VBZ I
no DT N
differences NNS N
were VBD N
found VBN N
in IN N
weight NN O
gained VBN O
interdialysis JJ O
mean JJ O
blood NN O
pressure NN O
predialysis NN O
and CC O
postdialysis NN O
and CC O
hemoconcentration NN O
. . O

Serum NNP O
Na+ NNP O
levels NNS O
were VBD N
significantly RB N
higher JJR N
predialysis NN N
and CC N
postdialysis NN N
for IN N
those DT N
patients NNS N
on IN N
Na+ NNP I
modeling NN I
. . I

Hypotensive NNP O
episodes NNS O
and CC O
cramps NNS O
decreased VBD N
50% CD N
with IN N
Na+ NNP I
modeling NN I
. . I

The DT N
amount NN O
of IN O
hypertonic JJ O
and CC O
normal JJ O
saline NN O
given VBN N
during IN N
dialysis NN N
was VBD N
markedly RB N
reduced VBN N
. . N

Na+ NNP I
modeling NN I
should MD N
always RB N
be VB N
used VBN N
in IN N
patients NNS P
being VBG P
maintained VBN P
on IN P
high JJ P
flux JJ P
dialysis NN P
. . P

-DOCSTART- -X- N

Twice-a-day JJ N
versus NN N
four-times-a-day JJ N
ofloxacin JJ N
treatment NN N
of IN N
external JJ N
ocular JJ N
infection NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacies NNS N
of IN N
0.3% CD N
ofloxacin NNS N
eyedrops VBP N
when WRB N
given VBN N
twice-a-day JJ N
(BID) JJ N
versus NN N
four-times-a-day JJ N
(QID) NN N
for IN N
the DT N
treatment NN N
of IN N
external JJ N
ocular JJ N
disease NN N
. . N

METHOD NNP N
Fifty NNP P
patients NNS P
with IN P
blepharitis NN P
conjuctivitis NN P
or CC P
blepharoconjunctivitis NN P
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
0.3% CD N
ofloxacin JJ N
eyedrops NNS N
BID NNP N
or CC N
QID NNP N
for IN N
10 CD N
days NNS N
. . N

Signs NNS N
symptoms NNS N
and CC N
cultures NNS N
were VBD N
evaluated VBN N
at IN N
the DT N
beginning NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

RESULTS VB N
The DT N
clinical JJ N
outcome NN N
was VBD N
virtually RB N
identical JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
clinical JJ O
scores NNS O
in IN N
the DT N
BID NNP N
and CC N
QID NNP N
groups NNS N
by IN N
days NNS N
3 CD N
to TO N
5 CD N
(2.6-3.0 JJ N
points) NN N
and CC N
a DT N
further JJ N
decrease NN N
by IN N
day NN N
11 CD N
(4.3-5.0 JJ N
points) NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
at IN N
any DT N
time NN N
interval NN N
. . N

Microbiologic NNP N
studies NNS N
showed VBD N
a DT N
reduction NN N
in IN N
colony-forming JJ O
units NNS O
in IN N
87% CD N
of IN N
the DT N
BID NNP N
group NN N
and CC N
in IN N
80% CD N
of IN N
the DT N
QID NNP N
group NN N
. . N

CONCLUSION NNP N
The DT N
treatment NN N
of IN N
external JJ N
ocular JJ N
disease NN N
with IN N
0.3% CD N
ofloxacin JJ N
eyedrops NNS N
was VBD N
equally RB N
effective JJ N
when WRB N
given VBN N
BID NNP N
or CC N
QID NNP N
. . N

-DOCSTART- -X- N

Fasting VBG N
and CC N
meal-stimulated JJ N
plasma NN N
levels NNS N
of IN N
neurotensin NN N
in IN N
obese JJ P
patients NNS P
after IN P
jejunoileal JJ P
bypass NN P
with IN P
3:1 CD P
or CC P
1:3 CD P
jejunoileal NN P
ratio NN P
. . P

The DT N
functional JJ N
role NN N
of IN N
the DT N
jejunum NN I
and CC I
ileum NN I
with IN N
regard NN N
to TO N
peripheral JJ N
plasma NN N
levels NNS N
of IN N
intact JJ N
neurotensin JJ N
and CC N
NH2-terminal JJ N
immunoreactivity NN N
of IN N
neurotensin NN N
was VBD N
studied VBN N
by IN N
using VBG N
jejunoileal JJ N
bypass NN N
as IN N
a DT N
model NN N
. . N

Plasma NN N
levels NNS N
were VBD N
measured VBN N
by IN N
radioimmunoassay NN I
before IN N
and CC N
after IN N
jejunoileal JJ N
bypass NN N
randomized VBN N
to TO N
different JJ N
jejunoileal JJ N
ratios NNS N
. . N

Seven CD P
patients NNS P
were VBD P
studied VBN P
before IN P
bypass NN P
surgery NN P
and CC P
28 CD P
were VBD P
examined VBN P
after IN P
end-to-side JJ P
jejunoileal JJ P
bypass NN P
with IN P
50 CD P
cm NNS P
intestine NN P
in IN P
continuity NN P
and CC P
a DT P
3:1 CD P
or CC P
1:3 CD P
ratio NN P
between IN P
the DT P
length NN P
of IN P
the DT P
jejunal NN P
and CC P
ileal JJ P
segments NNS P
. . P

Fasting VBG O
levels NNS O
of IN O
intact JJ O
neurotensin NNS O
were VBD N
unchanged JJ N
by IN N
surgery NN N
whereas NN N
levels NNS N
of IN N
NH2-terminal JJ O
immunoreactivity NN O
were VBD N
higher JJR N
in IN N
bypass NN N
patients NNS N
with IN N
a DT N
long JJ N
ileal NN N
segment NN N
(37.5 NNP N
cm) NN N
than IN N
in IN N
unoperated JJ N
patients NNS N
and CC N
in IN N
those DT N
with IN N
a DT N
short JJ N
ileal NN N
segment NN N
(12.5 NNP N
cm) NN N
. . N

Meal-stimulated JJ O
levels NNS O
of IN O
intact JJ O
neurotensin NNS O
were VBD N
higher JJR N
after IN N
1:3 CD N
than IN N
3:1 CD N
jejunoileal JJ N
bypass NN N
. . N

The DT N
levels NNS O
of IN O
NH2-terminal JJ O
immunoreactivity NN O
in IN N
patients NNS P
with IN P
a DT P
short JJ P
ileal NN P
segment NN P
and CC P
in IN P
controls NNS P
were VBD N
lower JJR N
than IN N
in IN N
patients NNS P
with IN P
a DT P
long JJ P
ileal NN P
segment NN P
. . P

The DT N
results NNS N
show VBP N
that IN N
postprandial JJ O
levels NNS O
of IN O
both DT O
intact JJ O
neurotensin NN O
and CC O
NH2-terminal JJ O
immunoreactivity NN O
are VBP N
related VBN N
to TO N
the DT N
length NN N
of IN N
the DT N
functioning NN N
ileum NN I
and CC N
that IN N
even RB N
a DT N
difference NN N
in IN N
length NN N
of IN N
25 CD N
cm NN N
is VBZ N
reflected VBN N
in IN N
the DT N
circulating NN N
levels NNS N
of IN N
neurotensin NN N
. . N

-DOCSTART- -X- N

Gonadotropin-releasing VBG I
hormone NN I
agonist NN I
in IN N
the DT N
treatment NN N
of IN N
premenstrual JJ P
symptoms NNS P
with IN P
and CC P
without IN P
ongoing VBG P
dysphoria: NN N
a DT N
controlled VBN N
study NN N
. . N

Gonadotropin-releasing VBG I
hormone NN I
(GnRH) NN I
agonists NNS I
have VBP N
been VBN N
shown VBN N
to TO N
reduce VB N
symptoms NNS O
of IN O
premenstrual JJ P
syndrome NN P
(PMS) NN P
. . P

This DT N
randomized VBD N
placebo-controlled JJ I
study NN N
examined VBD N
the DT N
efficacy NN N
of IN N
the DT N
GnRH NNP I
agonist NN I
leuprolide NN I
acetate NN I
depot NN I
in IN P
a DT P
clearly RB P
defined VBN P
PMS NNP P
sample JJ P
versus NNS P
women NNS P
with IN P
premenstrual JJ P
symptoms NNS P
in IN P
combination NN P
with IN P
dysphoric NN P
symptoms NNS P
throughout IN P
the DT P
cycle NN P
termed VBD P
the DT P
premenstrual JJ P
exacerbation NN P
(PME) NNP P
group NN P
. . P

Evaluation NN N
included VBD N
the DT N
Structured NNP O
Clinical NNP O
Interview NNP O
for IN O
DSM-III-R NNP O
administered VBD O
in IN N
the DT N
follicular JJ N
phase NN N
and CC N
the DT N
subject NN O
Penn NNP O
Dally NNP O
Symptoms NNP O
Report NNP O
(DSR) NNP O
maintained VBD N
throughout IN N
the DT N
study NN N
. . N

Thirty-three JJ P
eligible JJ P
women NNS P
were VBD N
randomized VBN N
to TO N
double-blind VB N
treatment NN N
and CC N
administered VBD N
3.75 CD I
mg NN I
of IN I
depot NN I
leuprolide NN I
or CC I
a DT I
placebo NN I
once RB N
a DT N
month NN N
for IN N
3 CD N
months NNS N
. . N

The DT N
subjects NNS N
were VBD N
seen VBN N
for IN N
efficacy NN N
evaluations NNS N
at IN N
the DT N
end NN N
of IN N
each DT N
cycle NN N
. . N

Outcome NN N
measures NNS N
were VBD N
the DT N
DSRs NNP O
and CC O
the DT O
17-item JJ O
Hamilton NNP O
Depression NNP O
Rating NNP O
Scale NNP O
(HAM-D17) NN O
. . O

The DT N
PMS NNP I
leuprolide JJ I
subjects NNS N
improved VBN N
significantly RB N
compared VBN N
with IN N
the DT N
PMS NNP I
placebo NN I
and CC I
PME NNP I
leuprolide RB I
groups NNS N
. . N

The DT N
PME NNP I
leuprolide NN I
group NN N
who WP N
had VBD N
dysphoric NN O
symptoms NNS O
throughout IN N
the DT N
cycle NN N
did VBD N
not RB N
improve VB N
. . N

Depression NN O
symptoms NNS O
were VBD N
at IN N
clinical JJ N
levels NNS N
premenstrually RB N
in IN N
the DT N
PMS NNP N
and CC N
PME NNP N
groups; VBP N
following VBG N
treatment NN N
they PRP N
remitted VBD N
in IN N
the DT N
PMS NNP N
group NN N
but CC N
not RB N
in IN N
the DT N
PME NNP N
leuprolide JJ I
subjects NNS N
. . N

Efficacy NN N
did VBD N
not RB N
occur VB N
until IN N
after IN N
several JJ N
months NNS N
of IN N
leuprolide JJ I
treatment NN N
but CC N
there EX N
was VBD N
no DT N
evidence NN N
that IN N
PMS NNP O
symptoms NNS O
worsened VBD N
with IN N
the DT N
onset NN N
of IN N
treatment NN N
. . N

These DT N
results NNS N
replicate VBP N
the DT N
findings NNS N
in IN N
our PRP$ N
preliminary JJ N
open-label NN N
study NN N
. . N

Leuprolide NNP I
reduced VBD N
PMS NNP N
symptoms NNS N
to TO N
minimal JJ N
levels NNS N
where WRB N
symptoms NNS N
were VBD N
limited VBN N
to TO N
the DT N
luteal JJ N
phase NN N
. . N

Leuprolide NNP I
was VBD N
not RB N
effective JJ N
for IN N
women NNS P
with IN P
ongoing VBG P
dysphoric NN P
symptoms NNS P
suggesting VBG P
that IN N
premenstrual JJ N
depression NN N
may MD N
have VB N
mechanisms NNS N
different JJ N
from IN N
those DT N
of IN N
other JJ N
dysphoric JJ N
mood NN N
disorders NNS N
. . N

-DOCSTART- -X- N

A DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
St NNP N
. . N

John's NNP I
wort NN I
for IN N
smoking VBG P
cessation NN P
. . P

INTRODUCTION NNP N
St NNP N
. . N

John's NNP I
wort NN I
(SJW) NN I
is VBZ N
a DT N
widely RB N
used VBN N
herbal JJ N
supplement NN N
. . N

The DT N
predominant JJ N
mechanism(s) NN N
accounting NN N
for IN N
the DT N
activity NN N
of IN N
SJW NNP I
in IN N
vivo NN N
are VBP N
however RB N
unclear JJ N
. . N

The DT I
purpose NN I
of IN I
this DT I
study NN I
was VBD I
to TO I
investigate VB I
the DT I
efficacy NN I
of IN I
SJW NNP I
for IN I
smoking VBG I
cessation NN I
. . I

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
blinded VBN N
placebo-controlled JJ N
three-arm JJ N
dose-ranging JJ N
clinical JJ N
trial NN N
. . N

A DT N
total NN N
of IN N
118 CD P
subjects NNS P
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
SJW NNP I
300 CD I
mg NN I
600 CD I
mg NN I
or CC I
a DT I
matching JJ I
placebo NN I
tablet NN I
3 CD I
times NNS I
a DT I
day NN I
combined VBN I
with IN I
a DT I
behavioral JJ I
intervention NN I
for IN I
12 CD I
weeks NNS I
. . I

Self-reported JJ N
smoking NN N
abstinence NN N
was VBD N
biochemically RB N
confirmed VBN N
with IN N
expired JJ N
air NN N
carbon NN N
monoxide NN N
. . N

RESULTS JJ N
Mean NNP P
age NN P
of IN P
the DT P
study NN P
participants NNS P
was VBD P
37.6 CD P
+/- JJ P
12.4 CD P
years; NN P
they PRP P
smoked VBD P
an DT P
average NN P
of IN P
20.0 CD P
+/- JJ P
6.6 CD P
cigarettes NNS P
per IN P
day NN P
for IN P
20 CD P
+/- JJ P
12.1 CD P
years NNS P
. . P

The DT N
study NN P
dropout NN P
rate NN P
was VBD P
high JJ P
(43%) NN P
. . P

By IN N
intention-to-treat JJ N
analysis NN N
no DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
abstinence NN N
rates NNS N
at IN N
12 CD N
and CC N
24 CD N
weeks NNS N
between IN N
SJW NNP I
dose VBP N
groups NNS N
and CC N
placebo NN I
. . I

SJW NNP I
did VBD N
not RB N
attenuate VB N
withdrawal NN N
symptoms NNS N
among IN N
abstinent JJ N
subjects NNS N
. . N

Abstinence NN N
rates NNS N
did VBD N
not RB N
differ VB N
by IN N
study NN N
group NN N
among IN N
subjects NNS N
who WP N
took VBD N
at IN N
least JJS N
75% CD N
of IN N
their PRP$ N
study NN N
medication NN N
. . N

No DT N
significant JJ N
side-effects NNS N
were VBD N
noted VBN N
with IN N
SJW NNP I
. . I

CONCLUSIONS NN N
In IN N
this DT N
randomized JJ N
trial NN N
SJW NNP I
did VBD N
not RB N
increase VB N
smoking VBG N
abstinence JJ N
rates NNS N
. . N

Our PRP$ N
data NNS N
in IN N
combination NN N
with IN N
data NNS N
from IN N
other JJ N
studies NNS N
suggest VBP N
that IN N
SJW NNP I
has VBZ N
little JJ N
role NN N
in IN N
the DT N
treatment NN N
of IN N
tobacco NN P
dependence NN P
. . P

-DOCSTART- -X- N

Nurse NNP I
and CC I
patient JJ I
communication NN I
profiles NNS N
in IN N
a DT N
home-based JJ I
telehealth NN I
intervention NN I
for IN N
heart NN N
failure NN N
management NN N
. . N

OBJECTIVE NN N
This DT N
study NN N
compared VBN N
differences NNS N
in IN N
nurse JJ P
and CC P
patient JJ P
communication NN N
profiles NNS N
between IN N
two CD N
telehealth NN N
modes: NN N
telephone NN I
and CC N
videophone NN I
and CC I
evaluated VBD N
longitudinal JJ N
changes NNS O
in IN O
communication NN O
nurse NN O
perceptions NNS O
and CC O
patient JJ O
satisfaction NN O
. . O

METHODS NNP N
Subjects NNPS P
were VBD P
enrolled VBN P
in IN P
a DT P
randomized NN P
controlled VBD P
clinical JJ P
trial NN P
evaluating VBG P
a DT P
90-day JJ P
home-based JJ P
intervention NN P
for IN P
heart NN P
failure NN P
. . P

Telephone NNP I
(n=14) NNP P
and CC P
videophone NN P
(n=14) JJ P
interactions NNS I
were VBD N
audio JJ N
taped VBN N
and CC N
analyzed VBN N
using VBG N
the DT N
Roter NNP I
Interaction NNP I
Analysis NNP I
System NNP I
. . I

RESULTS JJ N
Nurses NNS P
were VBD N
more RBR N
likely JJ N
to TO N
use VB N
open-ended JJ O
questions NNS O
back-channel JJ O
responses NNS O
friendly JJ O
jokes NNS O
and CC O
checks NNS O
for IN O
understanding VBG O
on IN N
the DT N
telephone NN I
compared VBN N
to TO N
videophone VB I
. . I

Compliments NNS O
given VBN N
and CC N
partnership NN O
were VBD N
more JJR N
common JJ N
on IN N
the DT N
videophone NN I
. . I

Patients NNS N
were VBD N
more RBR N
likely JJ N
to TO N
give VB N
lifestyle JJ O
information NN O
and CC O
approval NN O
comments NNS O
on IN N
the DT N
telephone NN I
and CC I
used VBD N
more JJR N
closed-ended JJ O
questions NNS O
on IN N
the DT N
videophone NN I
. . I

Nurses NNS N
perceptions NNS O
of IN N
the DT N
interactions NNS N
were VBD N
not RB N
different JJ N
between IN N
the DT N
telephone NN I
and CC N
videophone NN I
nor CC I
did VBD N
their PRP$ N
perceptions NNS N
change VBP N
significantly RB N
over IN N
the DT N
course NN N
of IN N
the DT N
intervention NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
patient JJ O
satisfaction NN O
between IN N
the DT N
telephone NN I
and CC N
videophone NN I
. . I

CONCLUSIONS NNP N
The DT N
results NNS N
of IN N
this DT N
study NN N
did VBD N
not RB N
support VB N
use NN N
of IN N
a DT N
videophone NN I
over IN N
the DT N
telephone NN I
. . I

PRACTICE NNP N
IMPLICATIONS NNP N
It PRP N
is VBZ N
critical JJ N
to TO N
match VB N
technologies NNS N
to TO N
patient VB N
needs NNS N
and CC N
use VB N
the DT N
least JJS N
complex JJ N
technology NN N
possible JJ N
. . N

When WRB N
considering VBG N
use VBP N
a DT N
videophone NN I
health NN I
care NN N
providers NNS N
should MD N
critically RB N
examine VB N
the DT N
trade-offs NNS N
between IN N
additional JJ N
complexities NNS N
with IN N
the DT N
added JJ N
value NN N
of IN N
the DT N
visual JJ N
interaction NN N
. . N

-DOCSTART- -X- N

An DT N
evaluation NN N
of IN N
chemical JJ I
arthrodesis NN I
of IN N
the DT N
proximal JJ P
interphalangeal NN P
joint NN P
in IN P
the DT P
horse NN P
by IN N
using VBG N
monoiodoacetate NN I
. . I

The DT N
use NN N
of IN N
monoiodoacetate NN I
(MIA) NN I
for IN I
arthrodesis NN N
of IN N
the DT N
proximal JJ N
interphalangeal NN N
joint NN N
(PIJ) NN N
and CC N
the DT N
effect NN N
of IN N
exercise NN I
on IN N
the DT N
degree NN N
of IN N
fusion NN N
were VBD N
investigated VBN N
. . N

Eight CD P
horses NNS P
received VBD N
3 CD N
injections NNS N
(Weeks VBP N
0 CD N
3 CD N
6) CD N
of IN N
MIA NNP I
(2 NNP N
mL; VBD N
60 CD N
mg/mL) NN N
into IN N
the DT N
right NN N
or CC N
left VBD N
front JJ N
PIJ NNP N
. . N

Peri-operatively RB N
the DT N
horses NNS N
received VBD N
phenylbutazone NN I
butorphanol NN I
and CC I
abaxial JJ I
sesamoidean NN I
nerve NN I
blocks NNS I
to TO N
relieve VB N
pain NN N
. . N

During IN N
the DT N
study NN N
the DT N
horses NNS N
were VBD N
monitored VBN N
for IN N
general JJ N
health NN N
lameness NN N
and CC N
swelling VBG N
around IN N
the DT N
injection NN N
area NN N
. . N

Radiographs NNP N
were VBD N
taken VBN N
biweekly RB N
to TO N
evaluate VB N
bony NN N
fusion NN N
. . N

Horses NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
non-exercised JJ I
and CC I
exercised JJ I
groups NNS I
. . I

Exercise NN I
consisted VBN N
of IN N
20 CD N
minutes NNS N
of IN N
trotting VBG I
on IN I
a DT I
treadmill NN I
(4 NNP N
m/s) VBZ N
3 CD N
days NNS N
per IN N
week NN N
for IN N
13 CD N
weeks NNS N
. . N

The DT N
horses NNS N
were VBD N
euthanized VBN N
at IN N
24 CD N
weeks NNS N
. . N

Slab NNP O
sections NNS O
of IN O
the DT O
PIJ NNP O
were VBD N
evaluated VBN N
grossly RB N
and CC N
radiographically RB N
for IN N
bony NN N
fusion NN N
. . N

Histologic JJ N
examinations NNS N
were VBD N
performed VBN N
to TO N
evaluate VB O
articular JJ O
cartilage NN O
. . O

Three CD P
horses NNS P
were VBD P
excluded VBN P
from IN P
the DT P
study NN P
after IN P
developing VBG P
soft JJ P
tissue NN P
necrosis NN P
around IN P
the DT P
injection NN P
site NN P
septic JJ P
arthritis NN P
and CC P
necrotic JJ N
tendinitis NN N
. . N

The DT N
remaining VBG N
horses NNS N
remained VBD N
healthy JJ N
developed VBD N
a DT N
grade NN N
1 CD N
to TO N
4 CD N
lameness NN N
with IN N
minimal JJ N
to TO N
severe VB N
swelling VBG N
in IN N
the DT N
PIJ NNP N
region NN N
. . N

All DT N
5 CD N
horses NNS N
showed VBD N
radiographic JJ N
evidence NN N
of IN N
bony NN O
fusion NN O
however RB O
no DT N
fusion NN N
was VBD N
present JJ N
when WRB N
injected JJ N
joints NNS N
were VBD N
examined VBN N
on IN N
postmortem NN N
examination NN N
. . N

Histologic NNP N
examination NN N
revealed VBD N
thinning NN N
of IN N
the DT N
cartilage NN N
diffuse NN N
necrosis NN N
of IN N
chondrocytes NNS N
with IN N
the DT N
calcified JJ N
zone NN N
intact NN N
. . N

Subjectively RB N
exercise NN I
did VBD N
not RB N
influence VB N
the DT N
degree NN N
of IN N
cartilage NN O
destruction NN O
. . O

Based VBN N
on IN N
this DT N
study NN N
chemical JJ I
arthrodesis NN I
cannot NN N
be VB N
advocated VBN N
in IN N
clinical JJ N
cases NNS N
because IN N
of IN N
the DT N
high JJ N
complication NN N
rate NN N
and CC N
lack NN N
of IN N
bony NN N
fusion NN N
. . N

-DOCSTART- -X- N

TRANSCONJUNCTIVAL NNP I
NONVITRECTOMIZING NNP I
VITREOUS NNP I
SURGERY NNP I
VERSUS NNP I
25-GAUGE JJ I
VITRECTOMY NNP I
IN NNP N
PATIENTS NNP N
WITH NNP N
EPIRETINAL NNP N
MEMBRANE: NNP N
A NNP N
Prospective NNP N
Randomized NNP N
Study NNP N
. . N

PURPOSE NN N
To TO N
compare VB N
the DT N
clinical JJ N
outcomes NNS N
and CC N
the DT N
rate NN N
of IN N
complications NNS N
of IN N
27-gauge JJ I
transconjunctival NN I
nonvitrectomizing VBG I
vitreous JJ I
surgery NN I
(NVS) NN I
and CC N
of IN N
25-gauge JJ I
transconjunctival NN I
sutureless NN I
vitrectomy NN I
surgery NN P
for IN P
idiopathic JJ P
epiretinal JJ P
membrane NN P
removal NN P
. . P

METHODS NNP P
In IN N
this DT N
prospective JJ N
randomized NN N
study NN N
83 CD P
phakic JJ P
eyes NNS P
of IN P
83 CD P
consecutive JJ P
patients NNS P
with IN P
an DT P
idiopathic JJ P
epiretinal JJ P
membrane NN P
were VBD P
randomized VBN P
to TO P
receive VB P
27-gauge JJ P
NVS NNP P
(NVS-group) CD P
or CC P
25-gauge JJ P
vitrectomy JJ P
(Standard-group) NN P
. . P

Main NNP N
outcome NN N
measures NNS N
were VBD N
best-corrected JJ N
visual JJ N
acuity NN N
central JJ N
retinal JJ N
thickness NN N
nuclear JJ N
density NN N
units' JJ N
changes NNS N
and CC N
rate NN N
of IN N
complications NNS N
. . N

RESULTS NNP N
Thirty-nine JJ P
eyes NNS P
of IN P
the DT P
Standard-group NNP P
and CC P
40 CD P
of IN P
the DT P
NVS-group NNP P
were VBD P
considered VBN P
in IN P
final JJ P
analysis NN P
. . P

Mean JJ O
best-corrected JJ O
visual JJ O
acuity NN O
improved VBN N
significantly RB N
in IN N
both DT N
groups NNS N
with IN N
a DT N
significant JJ N
better RBR N
result NN N
at IN N
12 CD N
months NNS N
in IN N
NVS-group NNP I
(P NNP N
= VBD N
0.039; CD N
t-test) NN N
. . N

Central JJ O
retinal JJ O
thickness NN O
decreased VBN N
significantly RB N
in IN N
both DT N
groups NNS N
(P VBP N
< $ N
0.001 CD N
Tukey NNP N
test) NN N
without IN N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
at IN N
any DT N
time NN N
point NN N
. . N

At IN N
12 CD N
months NNS N
nuclear JJ O
density NN O
increased VBD N
significantly RB N
in IN N
the DT N
Standard-group JJ I
(analysis NN N
of IN N
variance NN N
P NNP N
< VBZ N
0.001) CD N
and CC N
it PRP N
did VBD N
not RB N
change VB N
in IN N
the DT N
NVS-group NNP I
(analysis NN N
of IN N
variance NN N
P NNP N
= VBZ N
0.537) CD N
. . N

Epiretinal NNP O
membrane NN O
recurred VBD N
in IN N
5.1% CD N
of IN N
eyes NNS N
in IN N
the DT N
Standard-group NNP I
and CC N
in IN N
7.5% CD N
of IN N
eyes NNS N
in IN N
the DT N
NVS-group NNP I
(Fisher's NNP N
exact JJ N
test NN N
P NNP N
= VBZ N
1.000) CD N
. . N

CONCLUSION VB N
The DT N
27-gauge JJ I
NVS NNP I
is VBZ N
an DT N
effective JJ N
surgical JJ N
procedure NN N
in IN N
eyes NNS N
with IN N
epiretinal JJ N
membrane NN N
and CC N
it PRP N
induces VBZ N
less JJR N
progression NN N
of IN N
nuclear JJ N
sclerosis NN N
than IN N
25-gauge JJ N
vitrectomy NN N
. . N

-DOCSTART- -X- N

Diode NNP I
laser NN I
photocoagulation NN I
for IN N
threshold JJ P
retinopathy NN P
of IN P
prematurity NN P
. . P

A DT N
randomized JJ N
study NN N
. . N

BACKGROUND NNP N
Although IN N
peripheral JJ I
cryotherapy NN I
decreases VBZ N
the DT N
incidence NN N
of IN N
unfavorable JJ N
anatomic JJ N
outcomes NNS N
in IN N
threshold JJ N
retinopathy NN P
of IN P
prematurity NN P
(ROP) NNP P
apnea NN P
bradycardia NN O
and CC O
lid JJ O
edema NN O
can MD N
occur VB N
. . N

Argon NNP I
laser NN I
indirect JJ I
ophthalmoscope NN I
photocoagulation NN I
has VBZ N
been VBN N
used VBN N
as IN N
an DT N
alternative NN N
to TO N
cryotherapy VB I
with IN I
fewer JJR N
adverse JJ N
effects NNS N
. . N

Retinal JJ N
lesions NNS N
placed VBN N
with IN N
diode NN I
lasers NNS I
are VBP N
deeper JJR N
than IN N
similar JJ N
argon NN I
laser NN I
lesions NNS I
and CC I
it PRP N
is VBZ N
not RB N
known VBN N
whether IN N
this DT N
difference NN N
could MD N
influence VB N
the DT N
response NN N
to TO N
ablative JJ I
therapy NN I
. . I

METHODS JJ N
Patients NNS P
were VBD N
enrolled VBN N
under IN N
a DT N
prospective JJ N
randomized VBN N
protocol NN N
. . N

One CD N
eye NN N
of IN N
each DT N
patient NN N
with IN N
symmetric JJ N
threshold JJ N
ROP NNP N
was VBD N
treated VBN I
with IN N
an DT N
814/815 CD I
nm JJ I
diode NNS I
laser RBR I
while IN I
the DT N
other JJ N
eye NN N
was VBD N
treated VBN I
with IN N
cryotherapy NN I
. . I

Patients NNS N
with IN N
asymmetric JJ N
diseases NNS N
also RB N
were VBD N
randomized VBN N
for IN N
treatment NN I
in IN N
the DT N
threshold NN N
eye NN N
. . N

RESULTS NNP N
Nineteen NNP P
infants VBZ P
(33 JJ P
eyes) NNS P
were VBD P
treated VBN P
ranging VBG P
from IN P
485 CD P
to TO P
863 CD P
g NNS P
birth JJ P
weight VBD P
(23 NN P
to TO P
27 CD P
weeks NNS P
gestational JJ P
age); JJ P
18 CD P
patients NNS P
(32 JJ P
eyes) NNS P
were VBD N
followed VBN N
for IN N
3 CD N
months NNS N
or CC N
longer JJR N
. . N

Four CD P
patients NNS P
(8 JJ P
eyes) NN P
had VBD P
bilateral JJ P
zone CD P
1 CD P
disease NN P
. . P

Postconceptional JJ P
age NN P
was VBD P
36 CD P
to TO P
45 CD P
weeks NNS P
at IN P
the DT P
time NN P
of IN P
treatment NN P
. . P

The DT N
diode NN I
laser NN I
treatment NN I
was VBD N
better RBR N
tolerated VBN O
than IN N
cryotherapy NN I
and CC I
the DT N
treatment NN I
apparatus NN I
was VBD N
more RBR N
easily RB N
transported VBN N
. . N

Apneic NNP O
episodes VBZ O
requiring VBG O
intubation NN O
resulted VBD N
from IN N
two CD N
cryotherapy NN I
sessions NNS N
but CC N
no DT N
diode NN I
laser NN I
sessions NNS I
. . I

Five CD N
cryotherapy-treated JJ I
eyes NNS N
required VBN N
retreatment NN O
because IN N
of IN N
persistent JJ N
disease NN N
with IN N
adjacent JJ N
skip NN N
areas NNS N
. . N

In IN N
the DT N
group NN N
followed VBD N
for IN N
3 CD N
to TO N
15 CD N
months NNS N
1 CD N
cryotherapy-treated JJ I
eye NN N
and CC N
1 CD N
diode NN I
laser-treated JJ I
eye NN I
progressed VBD N
to TO N
stage VB O
5 CD O
retinal JJ O
detachment NN O
. . O

CONCLUSION NNP N
Compared NNP N
with IN N
cryotherapy NN I
the DT I
diode NN I
laser NN I
was VBD N
more RBR O
convenient JJ O
technically RB O
easier JJR O
to TO O
administer VB O
and CC O
better JJR O
tolerated VBN O
by IN N
the DT N
patient NN N
. . N

Although IN N
the DT N
number NN N
of IN N
patients NNS N
was VBD N
too RB N
small JJ N
for IN N
meaningful JJ N
statistical JJ N
analysis NN N
of IN N
outcome JJ N
diode NN I
laser RBR I
peripheral JJ I
retinal JJ I
ablation NN I
appeared VBD N
to TO N
be VB N
as RB N
effective JJ N
as IN N
cryotherapy NN I
for IN N
the DT N
treatment NN I
of IN N
threshold JJ N
ROP NNP N
. . N

-DOCSTART- -X- N

Using VBG N
a DT N
choice NN I
assessment NN I
to TO N
predict VB N
reinforcer NN N
effectiveness NN N
. . N

A DT I
choice NN I
assessment NN I
has VBZ N
been VBN N
found VBN N
to TO N
be VB N
a DT N
more RBR N
accurate JJ N
method NN N
of IN N
identifying VBG N
preferences NNS N
than IN N
is VBZ N
single-item JJ N
presentation NN N
. . N

However RB N
it PRP N
is VBZ N
not RB N
clear JJ N
whether IN N
the DT O
effectiveness NN O
of IN N
reinforcement NN N
varies NNS N
positively RB N
with IN N
the DT N
degree NN N
of IN N
preference NN N
(i.e NN N
. . N

whether IN N
the DT N
relative JJ N
preference NN N
based VBN N
on IN N
the DT N
results NNS N
of IN N
a DT N
choice NN N
assessment NN N
predicts VBZ N
relative JJ N
reinforcer NN N
effectiveness) NN N
. . N

In IN N
the DT N
current JJ N
study NN N
we PRP N
attempted VBD N
to TO N
address VB N
this DT N
question NN N
by IN N
categorizing VBG N
stimuli NNS N
as IN N
high JJ N
middle NN N
and CC N
low JJ N
preference NN N
based VBN N
on IN N
the DT N
results NNS N
of IN N
a DT N
choice NN N
assessment NN N
and CC N
then RB N
comparing VBG N
the DT N
reinforcing VBG N
effectiveness NN N
of IN N
these DT N
stimuli NNS N
using VBG N
a DT N
concurrent NN O
operants VBZ O
paradigm NN O
. . O

High-preference NNP N
stimuli NNS N
consistently RB N
functioned VBN O
as IN N
reinforcers NNS N
for IN N
all DT N
4 CD P
clients NNS P
. . P

Middle-preference NNP N
stimuli NN N
functioned VBD N
as IN N
reinforcers NNS N
for IN N
2 CD P
clients NNS P
but CC P
only RB N
when WRB N
compared VBN N
with IN N
low-preference NN N
stimuli NNS N
. . N

Low-preference NNP N
stimuli NNS N
did VBD N
not RB N
function NN N
as IN N
reinforcers NNS N
when WRB N
compared VBN N
to TO N
high- JJ N
and CC N
middle-preference JJ N
stimuli NNS N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
a DT N
choice NN I
assessment NN I
can MD N
be VB N
used VBN N
to TO N
predict VB N
the DT N
relative JJ N
reinforcing VBG O
value NN O
of IN O
various JJ O
stimuli NNS O
which WDT O
in IN N
turn NN N
may MD N
help VB N
to TO N
improve VB N
programs NNS N
for IN N
clients NNS P
with IN P
severe JJ P
to TO P
profound VB P
disabilities NNS P
. . P

-DOCSTART- -X- N

Increased VBN N
5-reductase JJ O
type NN O
2 CD O
expression NN O
in IN P
human JJ P
breast NN P
carcinoma NN P
following VBG P
aromatase NN P
inhibitor NN P
therapy: VBD P
the DT N
correlation NN N
with IN O
decreased JJ O
tumor NN O
cell NN O
proliferation NN O
. . O

Tumor NNP O
cell NN O
proliferation NN O
and CC O
progression NN O
of IN O
breast NN O
cancer NN O
are VBP N
influenced VBN N
by IN N
female JJ N
sex NN N
steroids NNS N
. . N

However RB N
not RB N
all DT P
breast NN P
cancer NN P
patients NNS P
respond VBP N
to TO I
aromatase VB I
inhibitors NNS I
(AI) NNP I
and CC N
many JJ N
patients NNS N
become VBP N
unresponsive JJ N
or CC N
relapse NN N
. . N

Recent JJ N
studies NNS N
demonstrate VBP N
that IN N
not RB N
only RB N
estrogens VBZ N
but CC N
also RB N
androgens VBZ N
may MD N
serve VB N
as IN N
regulators NNS N
of IN N
estrogen-responsive JJ N
as RB N
well RB N
as IN P
estrogen-unresponsive JJ P
human JJ P
breast NN P
cancers NNS P
. . N

However RB N
the DT N
mechanism NN N
underlying VBG N
these DT N
androgenic JJ N
actions NNS N
has VBZ N
remained VBN N
relatively RB N
unknown JJ N
. . N

Therefore RB N
in IN N
this DT N
study NN N
we PRP O
evaluated VBD O
the DT O
effects NNS O
of IN O
AI NNP O
upon IN N
the DT O
expression NN O
of IN O
enzymes NNS O
involved VBN O
in IN O
intratumoral JJ O
androgen NN O
production NN O
including VBG O
17-hydroxysteroid JJ O
dehydrogenase NN O
type NN O
5 CD O
(17HSD5) JJ O
5-reductase JJ O
types NNS O
1 CD O
and CC O
2 CD O
(5Red1 NN O
and CC O
5Red2) CD O
as RB O
well RB O
as IN O
androgen NN O
receptor NN O
(AR) NN O
levels NNS O
and CC N
correlated VBD N
the DT N
findings NNS O
with IN O
therapeutic JJ O
responses NNS O
including VBG O
Ki67 NNP O
labeling VBG O
index NN O
(Ki67) NN P
. . P

Eighty-two JJ P
postmenopausal NN P
invasive JJ P
ductal JJ P
carcinoma NN P
patients NNS P
were VBD P
enrolled VBN P
in IN P
CAAN NNP P
study NN P
from IN P
November NNP P
2001 CD P
to TO P
April NNP P
2004 CD I
. . I

Pre- JJ I
and CC I
post-treatment JJ I
specimens NNS I
of IN N
29 CD N
cases NNS N
were VBD N
available JJ N
for IN N
this DT N
study NN N
. . N

The DT N
status NN O
of IN O
17HSD5 CD O
5Red1 CD O
5Red2 CD O
and CC O
Ki67 NNP N
in IN N
pre- JJ N
and CC N
post-treatment JJ N
specimens NNS N
were VBD N
evaluated VBN N
. . N

The DT N
significant JJ N
increments NNS O
of IN O
5Red2 CD O
as RB O
well RB O
as IN N
AR NNP N
were VBD N
detected VBN N
in IN N
biological JJ N
response NN N
group NN O
whose WP$ O
Ki67 NNP N
LI NNP N
decreased VBN N
by IN N
more JJR N
than IN N
40% CD N
of IN N
the DT N
pre-treatment JJ N
level NN N
. . N

This DT N
is VBZ N
the DT N
first JJ N
study NN N
demonstrating VBG N
an DT N
increment NN O
of IN O
5Red2 CD O
and CC N
AR NNP N
in IN N
the DT N
group NN N
of IN N
the DT N
patients NNS N
associated VBN O
with IN N
Ki67 NNP N
decrement NN N
following VBG N
AI NNP N
treatment NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN O
increased VBD O
5Red2 CD O
and CC N
AR NNP N
following VBG N
AI NNP N
treatment NN N
may MD N
partly RB N
contribute VB N
to TO N
reduce VB N
the DT N
tumor NN N
cell NN N
proliferation NN N
through IN N
increasing VBG N
intratumoral JJ N
androgen NN N
concentrations NNS N
and CC N
its PRP$ N
receptor NN N
. . N

-DOCSTART- -X- N

[Hepatoprotective JJ O
activity NN O
of IN N
remaxol NN I
in IN N
patients NNS P
with IN P
chronic JJ P
hepatic JJ P
disorders] NN P
. . N

This DT N
milticentre NN N
randomized VBD N
clinical JJ N
study NN N
of IN N
the DT N
efficiency NN N
of IN N
remaxol JJ I
infusion NN I
solution NN I
(hepatoprotective JJ I
medicine NN I
for IN I
chronic JJ I
liver NN I
dysfunction) NN I
included VBD N
494 CD P
patients NNS P
with IN P
chronic JJ P
hepatitis NN P
B NNP P
and CC P
C NNP P
. . P

294 CD N
of IN N
them PRP N
staying VBG N
in IN N
7 CD N
clinics NNS N
were VBD N
given VBN I
remaxol NNS I
and CC I
200 CD I
ones NNS I
received VBD I
placebo NN I
. . I

Randomization NN N
was VBD N
achieved VBN N
by IN N
the DT N
envelope NN N
method NN N
. . N

A DT N
detailed JJ N
description NN N
of IN N
clinical JJ N
and CC N
laboratory JJ N
characteristics NNS N
of IN N
the DT N
diseases NNS N
is VBZ N
presented VBN N
. . N

Effects NNS N
of IN N
remaxol NN I
vs NN I
placebo NN I
on IN N
the DT N
functional JJ O
activity NN O
of IN N
affected VBN N
liver NN N
are VBP N
discussed VBN I
. . I

Results NNS N
of IN N
laboratory NN N
and CC N
clinical JJ N
analysis NN N
indicate VBP N
that IN N
mechanism NN N
of IN N
remaxol JJ I
action NN N
is VBZ N
based VBN N
on IN N
hepatoprotective JJ O
antioxidative NN O
and CC O
anticholestatic JJ O
activities NNS O
of IN N
the DT N
drug NN N
. . N

-DOCSTART- -X- N

A DT N
randomized JJ N
multicenter NN N
multivendor NN N
study NN N
of IN N
myocardial JJ I
perfusion NN I
imaging VBG I
with IN N
regadenoson NN I
CT NNP I
perfusion NN I
vs NN I
single JJ I
photon NN I
emission NN I
CT NNP I
. . I

BACKGROUND NNP N
Myocardial NNP I
CT NNP I
perfusion NN I
(CTP) NNP I
is VBZ N
a DT N
promising JJ N
tool NN N
for IN N
the DT N
detection NN N
of IN N
myocardial JJ P
ischemia NN P
. . P

We PRP N
hypothesize VBP N
that IN N
regadenoson NN I
CTP NNP I
is VBZ N
noninferior JJ N
to TO N
regadenoson VB I
single JJ I
photon NN I
emission NN I
CT NNP I
(SPECT) NNP I
for IN N
detecting VBG N
or CC N
excluding VBG N
myocardial JJ P
ischemia NN P
. . P

METHODS NNP N
Patients NNPS P
(men NNP P
 NNP I
45 CD P
years; NN P
women NNS P
 VBD I
50 CD P
years) NN P
with IN P
known VBN P
or CC P
suspected VBN P
coronary JJ P
artery NN P
disease NN P
(n NNP P
= VBZ P
124) CD P
were VBD I
randomized VBN I
to TO I
1 CD I
of IN I
2 CD I
diagnostic JJ I
sequences: NN I
rest NN I
and CC I
regadenoson NN I
SPECT NNP I
on IN I
day NN I
1 CD I
then RB I
regadenoson NN I
CTP NNP I
and CC I
rest VB I
CTP NNP I
(and NNP I
coronary JJ I
CT NNP I
angiography NN I
[CTA]) NNP I
(CTA; NNP I
same JJ I
acquisition) NN I
on IN I
day NN I
2 CD I
or CC I
regadenoson VB I
CTP NNP I
and CC I
rest VB I
CTP NNP I
(and NNP I
CTA) NNP I
on IN I
Day NNP I
1 CD I
then RB I
rest NN I
and CC I
regadenoson NN I
SPECT NNP I
on IN I
day NN I
2 CD I
. . I

Scanning VBG I
platforms NNS I
included VBD I
64- JJ I
128- JJ I
256- JJ I
and CC I
320-slice JJ I
systems NNS I
. . N

The DT N
primary JJ N
analysis NN N
examined VBD N
the DT O
agreement NN O
rate NN O
between IN O
CTP NNP O
and CC O
SPECT NNP O
for IN O
detecting VBG O
or CC O
excluding VBG O
reversible JJ O
ischemia NN O
in IN N
 $ N
2 CD N
myocardial JJ N
segments NNS N
as IN N
assessed VBN N
by IN N
independent JJ N
blinded JJ N
readers NNS N
. . N

RESULTS NNP N
Complete NNP N
and CC N
interpretable JJ I
CTP NNP I
and CC I
SPECT NNP N
scans NNS N
were VBD N
obtained VBN P
for IN P
110 CD P
patients NNS P
. . I

Regadenoson NNP I
CTP NNP N
was VBD N
noninferior JJ I
to TO I
SPECT NNP N
for IN N
detecting VBG N
or CC N
excluding VBG O
reversible JJ O
ischemia NN O
with IN N
an DT N
agreement NN N
rate NN N
of IN N
0.87 CD N
(95% JJ N
confidence NN N
interval JJ N
[CI] JJ N
0.77-0.97) NN N
and CC N
sensitivity NN N
and CC N
specificity NN N
of IN N
0.90 CD N
(95% JJ N
CI NNP N
0.71-1.00) NN N
and CC N
0.84 CD N
(95% JJ N
CI NNP N
0.77-0.91) NN N
respectively RB N
. . N

The DT N
agreement NN N
rate NN N
for IN N
detecting VBG N
or CC N
excluding VBG N
 JJ N
1 CD N
fixed VBN N
defects NNS I
by IN I
regadenoson NN I
CTP NNP I
and CC I
SPECT NNP N
was VBD N
0.86 CD N
(95% JJ N
CI NNP N
0.74-0.98) NN I
. . I

With IN I
SPECT NNP N
as IN N
the DT N
reference NN N
standard VBD N
the DT N
diagnostic JJ N
accuracies NNS N
for IN N
detecting VBG N
or CC N
excluding VBG N
ischemia NN I
by IN I
regadenoson NN I
CTP NNP I
and CC I
CTA NNP I
alone RB N
were VBD N
0.85 CD N
(95% JJ N
CI NNP N
0.78-0.91) NN N
and CC N
0.69 CD N
(95% JJ N
CI NNP N
0.60-0.77) NN N
respectively RB N
. . N

CONCLUSIONS NNP N
This DT N
study NN N
establishes VBZ N
the DT N
noninferiority NN I
of IN I
regadenoson NN I
CTP NNP I
to TO I
SPECT NNP N
for IN N
detecting VBG N
or CC N
excluding VBG P
myocardial JJ P
ischemia NN P
. . N

-DOCSTART- -X- N

Benefit NN N
of IN N
adjuvant JJ I
interferon JJ I
alfa-2b JJ I
(IFN-) JJ I
therapy NN I
in IN P
melanoma NN P
patients NNS P
with IN P
high JJ P
serum NN P
MMP-8 NNP P
levels NNS P
. . N

Matrix NNP N
metalloproteinases NNS N
(MMPs) NNP N
are VBP N
important JJ N
enzymes NNS N
in IN N
tissue NN N
turnover NN N
and CC N
various JJ N
inflammatory JJ N
processes NNS N
. . N

In IN N
this DT N
study NN N
it PRP N
was VBD N
evaluated VBN N
whether IN N
serum JJ N
MMP-8 NNP N
can MD N
predict VB N
the DT N
response NN N
to TO I
adjuvant VB I
interferon JJ I
alfa-2b JJ I
(IFN-) JJ I
therapy NN I
in IN P
patients NNS P
with IN P
operated JJ P
high-risk JJ P
cutaneous JJ P
melanoma NN P
. . N

Pre-treatment JJ N
sera NN N
from IN P
460 CD P
patients NNS P
with IN P
stage JJ P
IIB-IIIC JJ P
melanoma NN P
were VBD P
analyzed VBN P
for IN P
MMP-8 NNP P
. . N

The DT N
patients NNS N
were VBD N
randomized VBN N
after IN I
surgery NN I
to TO I
adjuvant VB I
IFN- NNP I
for IN I
12 CD I
or CC I
24 CD I
months NNS I
(n JJ N
= VBP N
313) CD N
or CC I
observation NN I
only RB I
(n NNP N
= VBD N
147) CD N
. . N

The DT O
median JJ O
serum NN O
MMP-8 NNP O
level NN O
was VBD N
used VBN N
to TO N
classify VB N
the DT N
patients NNS N
into IN N
a DT N
low JJ N
MMP-8 NNP N
(n NNP N
= POS N
232) CD N
and CC N
a DT N
high JJ N
MMP-8 NNP N
(n NNP N
= NNP N
228) CD N
group NN N
. . N

In IN N
the DT N
high JJ N
MMP-8 NNP N
subgroup NN I
IFN- NNP I
therapy NN I
significantly RB N
improved VBN O
relapse-free JJ O
survival NN O
(RFS) NN O
. . N

RFS NNP N
was VBD N
36.8 CD N
months NNS P
in IN P
patients NNS P
with IN P
high JJ P
MMP-8 JJ P
levels NNS P
receiving VBG I
IFN- NNP I
therapy NN I
whereas NNS N
RFS NNP N
for IN N
those DT N
with IN N
high JJ N
MMP-8 JJ N
levels NNS N
with IN N
observation NN N
only RB N
was VBD N
10.6 CD N
months NNS N
(P JJ N
= JJ N
0.027) CD O
. . O

Median JJ O
overall JJ O
survival NN P
for IN P
patients NNS P
with IN P
high JJ P
MMP-8 NNP P
and CC N
observation NN N
only RB N
was VBD N
36.7 CD N
versus NN N
71.7 CD N
months NNS N
in IN N
those DT N
receiving VBG I
IFN- NNP I
(P NNP N
= NNP N
0.13) CD N
. . N

In IN N
a DT N
multivariate JJ N
model NN I
IFN- NNP I
therapy NN I
was VBD N
a DT N
significant JJ N
predictor NN N
of IN N
favorable JJ N
RFS NNP N
(HR NNP N
0.74; CD N
95 CD N
% NN N
CI NNP N
0.55-0.99; CD N
P NNP N
= NNP N
0.048) CD N
after IN N
adjustment NN N
for IN N
pre-treatment JJ N
MMP-8 NNP N
(HR NNP N
1.17; CD N
95 CD N
% NN N
CI NNP N
0.88-1.55; CD N
P NNP N
= $ N
0.28) CD N
gender NN N
(HR VBD N
1.16; CD N
95 CD N
% NN N
CI NNP N
0.86-1.56; CD N
P NNP N
= $ N
0.32) CD N
age NN N
(HR VBD N
1.00; CD N
95 CD N
% NN N
CI NNP N
1.00-1.02; CD N
P NNP N
= $ N
0.12) CD N
ulceration NN N
(HR VBD N
1.09; CD N
95 CD N
% NN N
CI NNP N
0.81-1.46; CD N
P NNP N
= POS N
0.58) CD N
and CC N
the DT N
presence NN N
of IN N
node JJ N
metastases NNS N
(HR VBP N
1.36; CD N
95 CD N
% NN N
CI NNP N
1.17-1.58; CD N
P NNP N
< $ N
0.0001) CD N
. . N

In IN N
conclusion NN P
patients NNS P
with IN P
high JJ P
serum NN P
MMP-8 NNP P
levels NNS N
may MD N
benefit VB I
from IN I
adjuvant JJ I
IFN- JJ I
therapy NN I
but CC N
this DT N
observation NN N
should MD N
be VB N
further RB N
investigated VBN N
. . N

-DOCSTART- -X- N

Effect NN N
of IN N
direct JJ I
current JJ I
pulse NN I
stimulating VBG I
acupoints NNS I
of IN I
JiaJi NNP I
(T10-13) NNP I
and CC I
Ciliao NNP I
(BL VBD I
32) CD I
with IN I
Han's NNP I
Acupoint NNP I
Nerve NNP I
Stimulator NNP I
on IN N
labour NN P
pain NN P
in IN P
women: NN P
a DT N
randomized VBN N
controlled VBN N
clinical JJ N
study NN N
. . N

OBJECTIVE NN N
To TO N
assess VB N
the DT N
clinical JJ N
effect NN N
and CC N
safety NN N
of IN N
direct JJ I
current JJ I
(DC) NN I
pulse NN I
produced VBN I
by IN I
Han's NNP I
Acupoint NNP I
Nerve NNP I
Stimulator NNP I
in IN N
reduction NN N
(HANS) NN I
of IN N
labor NN O
pain NN O
. . O

METHODS NNP N
Totally RB P
120 CD P
participants NNS P
were VBD P
enrolled VBN P
in IN N
this DT N
clinical JJ N
trial NN N
and CC N
were VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
groups NNS N
including: JJ N
HANS NNP I
group NN I
patient NN I
controlled VBD I
intravenous JJ I
analgesia NN I
(PCIA) NNP I
group NN I
patient-controlled JJ I
epidural JJ I
analgesia NN I
(PCEA) NNP I
group NN I
and CC I
control NN I
group NN I
. . I

The DT N
HANS NNP I
group NN N
was VBD N
treated VBN N
by IN N
stimulating VBG I
the DT I
acupoints NNS I
of IN I
JiaJi NNP I
(T10-L3) NNP I
and CC I
Ciliao NNP I
(BL VBD I
32) CD I
with IN I
DC NNP I
pulse NN I
of IN I
100 CD I
Hz NNP I
and CC I
15-30 JJ I
mA NN I
produced VBN I
by IN I
a DT I
portable JJ I
battery-powered JJ I
Han's NNP I
Acupoint NNP I
Nerve NNP I
Stimulator NNP I
for IN N
30 CD N
min NN N
. . N

The DT N
PCIA NNP I
group NN N
was VBD N
intravenously RB N
infused JJ N
Ondansetron NNP I
(8 NNP N
mg) NN N
for IN N
5 CD N
min NNS N
then RB N
tramadol VB I
injection NN I
(1.5 NNP N
mg/kg) NN N
was VBD N
slowly RB N
dripped VBN N
by IN N
using VBG N
BaxterAP NNP N
II NNP N
electronic JJ N
pump NN N
with IN N
50 CD I
mL NNS I
tramadol JJ I
(0.70%) NNP I
+ NNP I
ondansetron NNP I
(8 NNP N
mg) NN N
background NN N
infusion NN N
2 CD N
mL/h NN N
PCA NNP I
dose NN N
of IN N
2 CD N
mL NNS N
lockout IN N
interval NN N
of IN N
10 CD N
min NN N
. . N

In IN N
PCEA NNP I
group NN N
women NNS N
received VBD N
intrathecal JJ I
injection NN I
ropivacaine NN I
(3 NNP N
mg) NN N
in IN N
L2-3 NNP N
and CC N
epidural JJ I
catheter NN I
was VBD I
connected VBN I
to TO I
BaxterAP NNP I
II NNP I
electronic JJ I
pump NN I
with IN I
100 CD I
mL NNS I
Ropivacaine NNP I
(0.1%) NN I
and CC I
Sufentanil NNP I
(50 NNP I
ug) JJ I
background NN I
infusion NN I
5 CD I
mL NN I
Patient NNP I
controlled VBD I
analgesia JJ I
(PCA) NNP I
dose NN I
of IN I
5 CD I
mL NNS I
lockout IN I
interval NN I
of IN I
10 CD I
min NN I
. . I

The DT N
control NN I
group NN N
was VBD N
not RB I
received VBN I
analgesia NN I
. . I

The DT O
visual JJ O
analogue NN O
scale NN O
(VAS) NNP O
stage NN O
and CC O
manner NN O
of IN O
labor NN O
Apgar NNP O
score NN O
of IN O
newborn JJ O
neonatal JJ O
weights NNS O
oxytocin JJ O
dosage NN O
postpartum NN O
hemorrhage NN O
and CC O
side NN O
effects NNS O
were VBD N
monitored VBN N
in IN N
all DT N
groups NNS N
. . N

RESULTS VB N
The DT N
vital JJ N
signs NNS N
were VBD N
all DT N
stable JJ N
in IN N
the DT N
four CD N
analgesic JJ N
groups NNS N
. . N

After IN N
analgesia NN N
there EX N
was VBD N
statistical JJ N
difference NN N
in IN N
VAS NNP N
score NN N
between IN N
HANS NNP I
group NN N
and CC N
control NN I
group NN N
between IN N
PCEA NNP I
group NN N
and CC N
the DT N
control NN I
group NN N
between IN N
PCIA NNP I
group NN N
and CC N
control NN I
group NN N
. . N

The DT N
analgesic JJ O
effect NN O
in IN N
the DT N
PCEA NNP I
group NN N
was VBD N
significantly RB N
better JJR N
than IN N
that DT N
of IN N
other JJ N
two CD N
groups NNS N
. . N

The DT N
second JJ N
stage NN N
of IN N
labor NN N
in IN N
the DT N
PCEA NNP I
group NN N
was VBD N
longer JJR N
than IN N
the DT N
other JJ N
three CD N
groups NNS N
showing VBG N
significant JJ N
difference NN N
between IN N
them PRP N
. . N

The DT N
Apgar NNP N
score NN N
of IN N
newborn JJ N
1 CD N
min NN N
after IN N
birth NN N
in IN N
the DT N
PCIA NNP I
group NN N
was VBD N
slightly RB N
lower JJR N
than IN N
that DT N
of IN N
the DT N
other JJ N
two CD N
groups NNS N
showing VBG N
significant JJ N
difference NN N
between IN N
them PRP N
. . N

The DT N
neonatal JJ N
weights NNS N
between IN N
four CD N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

The DT N
rate NN O
of IN O
cesarean JJ O
section NN O
in IN N
the DT N
control NN I
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
of IN N
the DT N
labor NN I
analgesia NN I
group NN N
there EX N
was VBD N
statistically RB N
difference NN N
in IN N
four CD N
groups NNS N
. . N

The DT N
number NN N
of IN N
PCIA NNP I
group NN N
that WDT N
used VBD N
oxytocin NN I
was VBD N
lower JJR N
than IN N
that DT N
of IN N
other JJ N
three CD N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
postpartum JJ O
hemorrhage NN O
between IN N
four CD N
groups NNS N
. . N

The DT N
side NN N
effects NNS N
of IN N
the DT N
PCEA NNP I
group NN N
were VBD N
itching VBG O
uroschesis NN O
and CC O
neonatal JJ O
asphyxia NN O
and CC N
PCIA NNP I
group NN N
were VBD N
nausea RB O
and CC O
vomiting VBG O
and CC O
neonatal JJ O
asphyxia NN O
. . O

However RB N
fewer JJR N
side-effects NNS O
were VBD N
observed VBN N
in IN N
the DT N
HANS NNP I
group NN N
. . N

CONCLUSION NNP N
The DT N
DC NNP I
pulse NN I
produced VBN N
by IN N
HANS NNP I
may MD N
be VB N
a DT N
non-pharmacological JJ I
alternative NN I
to TO N
labor NN N
pain NN N
with IN N
fewer JJR N
side NN N
effects NNS N
. . N

-DOCSTART- -X- N

Rationale NNP N
and CC N
design NN N
of IN N
the DT N
Clinical NNP N
Evaluation NNP N
of IN N
Magnetic NNP I
Resonance NNP I
Imaging NNP I
in IN N
Coronary NNP N
heart NN N
disease NN N
2 CD N
trial NN N
(CE-MARC JJ N
2): CD N
a DT N
prospective JJ P
multicenter NN P
randomized VBN P
trial NN P
of IN P
diagnostic JJ P
strategies NNS P
in IN P
suspected JJ P
coronary JJ P
heart NN P
disease NN P
. . P

BACKGROUND NNP P
A NNP N
number NN N
of IN N
investigative JJ N
strategies NNS N
exist VBP N
for IN N
the DT N
diagnosis NN N
of IN N
coronary JJ N
heart NN N
disease NN N
(CHD) NNP N
. . N

Despite IN N
the DT N
widespread JJ N
availability NN N
of IN N
noninvasive JJ N
imaging VBG N
invasive JJ I
angiography NN I
is VBZ N
commonly RB N
used VBN N
early RB N
in IN N
the DT N
diagnostic JJ N
pathway NN N
. . N

Consequently RB N
approximately RB N
60% CD N
of IN N
angiograms NNS N
reveal VBP N
no DT N
evidence NN N
of IN N
obstructive JJ N
coronary JJ N
disease NN N
. . N

Reducing VBG N
unnecessary JJ N
angiography NN N
has VBZ N
potential JJ N
financial JJ N
savings NNS N
and CC N
avoids NNS N
exposing VBG N
the DT N
patient NN N
to TO N
unnecessary JJ N
risk NN N
. . N

There EX N
are VBP N
no DT N
large-scale JJ N
comparative JJ N
effectiveness NN N
trials NNS N
of IN N
the DT N
different JJ N
diagnostic JJ N
strategies NNS N
recommended VBD N
in IN N
international JJ N
guidelines NNS N
and CC N
none NN N
that WDT N
have VBP N
evaluated VBN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
cardiovascular JJ N
magnetic JJ N
resonance NN N
. . N

TRIAL NNP N
DESIGN NNP N
CE-MARC NNP N
2 CD N
is VBZ N
a DT N
prospective JJ N
multicenter NN N
3-arm JJ N
parallel JJ N
group NN N
randomized VBD N
controlled VBN N
trial NN N
of IN N
patients NNS P
with IN P
suspected JJ P
CHD NNP P
(pretest JJS P
likelihood NN P
10%-90%) JJ P
requiring VBG P
further JJ P
investigation NN P
. . P

A DT P
total NN P
of IN P
1 CD P
200 CD P
patients NNS P
will MD P
be VB P
randomized VBN P
on IN N
a DT N
2:2:1 JJ N
basis NN N
to TO N
receive VB N
3.0-T JJ I
cardiovascular JJ I
magnetic JJ I
resonance-guided JJ I
care NN I
single-photon JJ I
emission NN I
computed VBD I
tomography-guided JJ I
care NN I
(according VBG I
to TO I
American NNP I
College NNP I
of IN I
Cardiology/American NNP I
Heart NNP I
Association NNP I
appropriate-use NN I
criteria) NN I
or CC I
National NNP I
Institute NNP I
for IN I
Health NNP I
and CC I
Care NNP I
Excellence NNP I
guidelines-based JJ I
management NN I
. . I

The DT N
primary JJ N
(efficacy) JJ N
end NN N
point NN N
is VBZ N
the DT N
occurrence NN O
of IN O
unnecessary JJ O
angiography NN O
as IN N
defined VBN N
by IN N
a DT N
normal JJ N
(>0.8) NNP N
invasive JJ O
fractional JJ O
flow NN O
reserve NN O
. . O

Safety NN O
of IN N
each DT N
strategy NN N
will MD N
be VB N
assessed VBN N
by IN N
3-year JJ N
major JJ N
adverse JJ N
cardiovascular JJ N
event NN N
rates NNS N
. . N

Cost-effectiveness JJ O
and CC O
health-related JJ O
quality-of-life JJ O
measures NNS O
will MD N
be VB N
performed VBN N
. . N

CONCLUSIONS VB N
The DT N
CE-MARC NNP N
2 CD N
trial NN N
will MD N
provide VB N
comparative JJ N
efficacy NN O
and CC N
safety NN O
evidence NN N
for IN N
3 CD N
different JJ N
strategies NNS N
of IN N
investigating VBG N
patients NNS P
with IN P
suspected JJ P
CHD NNP P
with IN P
the DT N
intension NN N
of IN N
reducing VBG N
unnecessary JJ O
invasive JJ O
angiography NN O
rates NNS O
. . O

Evaluation NN N
of IN N
these DT N
management NN N
strategies NNS N
has VBZ N
the DT N
potential NN N
to TO N
improve VB N
patient NN O
care NN O
health-related JJ O
quality NN O
of IN O
life NN O
and CC O
the DT O
cost-effectiveness NN O
of IN N
CHD NNP N
investigation NN N
. . N

-DOCSTART- -X- N

Quantitative JJ N
angiographic JJ N
methods NNS N
for IN N
appropriate JJ N
end-point JJ O
analysis NN O
edge-effect JJ O
evaluation NN O
and CC O
prediction NN O
of IN O
recurrent NN P
restenosis NN P
after IN P
coronary JJ P
brachytherapy NN P
with IN P
gamma JJ P
irradiation NN P
. . P

OBJECTIVES IN N
The DT N
study NN N
was VBD N
done VBN N
to TO N
investigate VB N
the DT N
relationship NN N
between IN N
clinical JJ N
restenosis NN N
and CC N
the DT N
relative JJ N
angiographic JJ N
location NN N
of IN N
the DT N
recurrent NN N
restenotic JJ N
lesion NN N
after IN N
treatment NN P
of IN P
in-stent JJ P
restenosis NN P
with IN P
vascular JJ P
brachytherapy NN P
in IN P
the DT P
Washington NNP P
Radiation NNP P
for IN P
In-Stent NNP P
Restenosis NNP P
Trial NNP P
(WRIST) NNP P
. . P

BACKGROUND NNP N
Intracoronary NNP I
radiation NN I
therapy NN I
reduces VBZ N
recurrence NN N
of IN N
in-stent JJ N
restenosis NN N
. . N

We PRP N
investigated VBD N
the DT N
above JJ N
objective NN N
in IN N
patients NNS P
enrolled VBN P
in IN P
WRIST NNP N
. . N

METHODS NNP N
The DT N
WRIST NNP P
study NN P
randomized VBD P
130 CD P
patients NNS P
to TO P
double-blinded JJ P
therapy NN P
with IN P
gamma JJ P
irradiation NN P
(iridium-192 JJ P
[(192)Ir]) NNP P
versus NN P
placebo NN P
after IN P
interventional JJ P
treatment NN P
of IN P
diffuse NN P
in-stent JJ P
restenosis NN P
. . P

After IN N
the DT N
intervention NN N
and CC N
at IN N
follow-up JJ N
three CD N
vessel NN N
segments NNS N
were VBD N
individually RB N
analyzed VBN N
with IN N
quantitative JJ N
coronary JJ N
angiography: NN N
1) CD N
the DT N
"stent NN N
" VBZ N
2) CD N
the DT N
"radiation NN N
ribbon NN N
" NNP N
and CC N
3) CD N
the DT N
"ribbon+margin" NN N
segment NN N
(including VBG N
5 CD N
mm NN N
on IN N
either DT N
end NN N
of IN N
the DT N
injured JJ N
or CC N
radiation-ribbon JJ N
segment) NN N
. . N

Receiver NNP O
operator NN O
curves NNS O
(ROC) WDT O
were VBD N
used VBN N
to TO N
assess VB N
the DT N
value NN N
of IN N
the DT N
follow-up JJ O
percent NN O
diameter NN O
stenosis NN O
(DS) NN O
for IN N
each DT N
of IN N
the DT N
three CD N
analyzed VBD N
segments NNS N
in IN N
predicting VBG N
target NN O
vessel NN O
revascularization NN O
(TVR) NN O
. . O

RESULTS NNP N
(192)Ir NNP N
reduced VBD N
recurrent JJ O
restenosis NN O
(23.7% NNP N
vs NN N
. . N

60.7% CD N
p NN N
< NN N
0.001) CD N
and CC N
the DT N
length NN O
of IN O
recurrent JJ O
restenosis NN O
(8.99 VBD N
+/- JJ N
4.34 CD N
mm NN N
vs NN N
. . N

17.54 CD N
+/- JJ N
10.48 CD N
mm NN N
p NN N
< VBD N
0.001) CD N
at IN N
follow-up JJ N
compared VBN N
to TO N
placebo VB N
. . N

Isolated VBN O
stent NN O
edge NN O
(3.4%) NNP N
and CC N
ribbon NN O
edge NN O
(1.7%) NN N
restenoses NNS N
were VBD N
infrequent JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
best JJS N
angiographic JJ N
surrogate NN N
of IN N
TVR NNP N
was VBD N
the DT N
50% CD N
follow-up JJ N
DS NNP N
obtained VBD N
from IN N
the DT N
ribbon+margin NN N
analysis NN N
(ROC NNP N
area NN N
0.806) CD N
. . N

CONCLUSIONS NNP N
In IN N
WRIST NNP N
not RB N
only RB N
was VBD N
(192)Ir JJ I
therapy NN I
effective JJ N
in IN N
reducing VBG N
restenosis NN N
but CC N
it PRP N
also RB N
reduced VBD N
the DT N
lesion NN N
length NN N
of IN N
treatment NN N
failures NNS N
by IN N
50% CD N
and CC N
it PRP N
was VBD N
not RB N
associated VBN N
with IN N
edge NN N
proliferation NN N
. . N

The DT N
restenosis NN N
rate NN N
obtained VBN N
from IN N
the DT N
vessel NN N
segment NN N
inclusive NN N
of IN N
the DT N
dose JJ N
fall-off JJ N
zones NNS N
was VBD N
the DT N
best JJS N
correlate NN N
of IN N
TVR NNP N
and CC N
should MD N
become VB N
a DT N
standard JJ N
analysis NN N
site NN N
in IN N
all DT N
vascular JJ N
brachytherapy NN I
trials NNS N
. . N

-DOCSTART- -X- N

Long-term JJ I
treatment NN I
with IN I
atomoxetine NN I
for IN N
attention-deficit/hyperactivity NN P
disorder NN P
symptoms NNS P
in IN P
children NNS P
and CC P
adolescents NNS P
with IN P
autism NN P
spectrum NN P
disorder: VBD P
an DT N
open-label JJ N
extension NN N
study NN N
. . N

OBJECTIVE IN N
The DT N
efficacy NN O
and CC O
tolerability NN O
of IN I
long-term JJ I
treatment NN I
with IN I
atomoxetine NN I
for IN N
symptoms NNS O
of IN O
attention-deficit/hyperactivity JJ P
disorder NN P
(ADHD) NN P
in IN P
children NNS P
with IN P
autism NN P
spectrum NN P
disorder NN P
(ASD) NNP P
has VBZ N
not RB N
been VBN N
established VBN N
. . N

METHODS NNP N
In IN N
this DT N
study NN N
88 CD P
patients NNS P
6-17 JJ P
years NNS P
of IN P
age NN P
with IN P
ADHD NNP P
and CC P
ASD NNP P
were VBD P
treated VBN N
with IN N
1.2 CD I
mg/kg/day JJ I
atomoxetine NN I
for IN N
20 CD N
weeks NNS N
as IN N
follow-up NN N
of IN N
an DT N
8 CD N
week NN N
double-blind JJ I
placebo-controlled JJ I
period NN N
. . N

Primary JJ N
endpoint NN N
was VBD N
the DT N
ADHD NNP O
Rating NNP O
Scale NNP O
(ADHD-RS) NN O
. . O

RESULTS NNP N
After IN N
8 CD N
weeks NNS N
of IN N
initial JJ N
treatment NN I
the DT I
mean JJ O
total JJ O
inattention NN O
and CC O
hyperactivity-impulsivity NN O
ADHD-RS NNP O
further RB N
decreased VBD O
significantly RB N
from IN N
34.9 CD N
to TO N
27.0 CD N
for IN N
the DT N
total JJ N
ADHD-RS NNP N
from IN N
18.3 CD N
to TO N
14.5 CD N
for IN N
the DT N
ADHD-RS NNP O
inattention NN O
subscale NN O
and CC O
from IN N
16.5 CD N
to TO N
12.6 CD N
for IN N
the DT N
hyperactivity-impulsivity JJ O
subscale NN O
. . O

Adverse JJ O
events NNS O
were VBD N
mild JJ N
and CC N
tended VBD N
to TO N
diminish VB N
over IN N
time NN N
during IN N
continued JJ N
treatment NN I
especially RB I
regarding VBG N
nausea NN O
and CC O
fatigue NN O
. . O

There EX N
were VBD N
no DT N
serious JJ O
adverse JJ O
events NNS O
. . O

CONCLUSIONS NNP N
The DT N
results NNS N
of IN N
the DT N
present JJ N
analysis NN N
suggest NN N
that WDT N
continued VBD N
treatment NN I
with IN I
atomoxetine NN I
up RB N
to TO N
28 CD N
weeks NNS N
further RBR N
improve VB O
ADHD NNP P
symptoms NNS P
in IN P
children NNS P
and CC P
adolescents NNS P
with IN P
ASD NNP P
while IN P
adverse JJ O
events NNS O
tend VBP N
to TO N
subside VB N
. . N

Future JJ N
studies NNS N
investigating VBG N
the DT N
long-term JJ I
efficacy NN I
of IN I
atomoxetine NN I
in IN N
children NNS P
and CC P
adolescents NNS P
with IN P
ASD NNP P
should MD N
be VB N
randomized VBN N
and CC N
placebo VB I
controlled VBN N
. . N

This DT N
study NN N
has VBZ N
been VBN N
registered VBN N
in IN N
ClinicalTrials.gov NNP N
( ( N
www.clinicaltrials.gov NN N
) ) N
under IN N
registration NN N
number NN N
NCT00380692 NNP N
. . N

-DOCSTART- -X- N

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
guided JJ I
self-help NN I
for IN N
improving VBG N
the DT N
experience NN O
of IN O
caring VBG O
for IN O
carers NNS P
of IN P
clients NNS P
with IN P
depression NN P
. . P

AIM NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
cognitive JJ I
behaviour NN I
therapy NN I
guided VBD I
self-help JJ I
manual JJ I
for IN N
enhancing VBG N
the DT N
experience NN O
of IN O
caregiving NN O
of IN O
family NN P
carers NNS P
of IN P
individuals NNS P
with IN P
depression NN P
. . P

BACKGROUND IN N
The DT N
prevalence NN N
of IN N
depression NN N
is VBZ N
increasing VBG N
markedly RB N
in IN P
Thailand NNP P
. . P

While IN N
primary JJ P
carers NNS P
give VBP P
most JJS P
of IN P
the DT P
support NN P
for IN P
individuals NNS P
with IN P
depression NN P
they PRP P
receive VBP P
little JJ P
support NN P
from IN P
mental JJ P
health NN P
services NNS P
in IN P
this DT N
critical JJ N
role NN N
. . N

DESIGN VB N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

METHOD NNP N
Carers NNPS P
were VBD P
randomized VBN P
to TO P
guided VB P
self-help JJ P
(n NNP P
= NNP P
27) CD P
while IN P
the DT P
control NN P
group NN P
received VBD P
standard JJ P
information NN P
and CC P
support NN P
(n NNP P
= VBZ P
27) CD P
. . P

Both DT I
groups NNS I
also RB I
received VBD I
a DT I
short JJ I
weekly JJ I
telephone NN I
call NN I
. . I

Participants NNS I
were VBD I
assessed VBN I
at IN I
three CD I
time NN I
points; VBZ I
the DT I
outcome NN I
measure NN I
was VBD I
the DT I
Experience NN I
of IN I
Caregiving NNP I
Inventory NNP I
. . I

A DT N
doubly RB N
multivariate JJ N
analysis NN N
of IN N
variance NN I
(anova) JJ I
procedure NN I
including VBG I
between-group JJ N
and CC N
within-group JJ N
factors NNS N
was VBD N
implemented VBN N
. . N

Fieldwork NN N
was VBD N
from IN N
October NNP N
2007-May JJ N
2008 CD N
. . N

RESULTS NNP N
Fifty-four JJ P
carers NNS P
completed VBD N
the DT N
study NN N
and CC N
intent-to-treat JJ N
analyses NNS N
were VBD N
undertaken JJ N
. . N

The DT N
findings NNS N
showed VBD N
there EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
total JJ O
negative JJ O
experience NN O
of IN O
caring VBG O
from IN O
baseline NN N
to TO N
post-treatment NN N
in IN N
the DT N
intervention NN N
group NN N
recipients NNS N
of IN N
the DT N
manual JJ N
compared VBN N
with IN N
the DT N
control NN N
group NN N
and CC N
treatment NN N
effects NNS N
were VBD N
maintained VBN N
at IN N
one-month JJ N
follow-up NN N
. . N

Similarly RB N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
total JJ O
positive JJ O
experience NN O
of IN O
caring VBG O
occurred VBN N
from IN N
baseline NN N
to TO N
post-treatment NN N
in IN N
the DT N
intervention NN N
group NN N
in IN N
contrast NN N
with IN N
the DT N
control NN N
group NN N
and CC N
these DT N
outcomes NNS N
were VBD N
sustained VBN N
at IN N
one-month JJ N
follow-up NN N
. . N

CONCLUSION NNP N
Guided VBD I
self-help NN I
strengthen NN I
carers' NN P
positive JJ N
and CC N
reduces VBZ N
their PRP$ N
negative JJ N
experience NN O
of IN O
caring NN O
. . O

The DT N
study NN N
contributes VBZ N
to TO N
the DT N
limited JJ N
evidence NN N
base NN N
about IN N
this DT N
approach NN N
in IN N
a DT N
developing JJ P
country NN P
such JJ P
as IN P
Thailand NNP P
. . P

-DOCSTART- -X- N

Blind NNP I
versus NN I
open JJ I
approach NN I
to TO I
laparoscopic VB I
cholecystectomy: VB I
a DT N
randomized JJ N
study NN N
. . N

Intraabdominal JJ N
structures NNS N
may MD N
be VB N
damaged VBN N
during IN N
blind JJ N
introduction NN N
of IN N
the DT N
first JJ N
trocar NN N
for IN N
laparoscopic JJ I
operations NNS I
. . I

In IN N
this DT N
study NN N
150 CD P
patients NNS P
with IN P
gallbladder JJ P
lithiasis NN P
who WP P
underwent JJ P
laparoscopy NN P
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
a DT N
blind JJ I
(V JJ N
group) NN N
or CC N
an DT N
open JJ I
(H NN N
group) NN N
in IN N
order NN N
to TO N
compare VB N
the DT N
results NNS N
and CC N
the DT N
rate NN O
of IN O
complications NNS O
. . O

No DT N
mortality NN O
was VBD N
observed VBN N
. . N

Major JJ O
complications NNS O
occurred VBD N
in IN N
3/75 CD N
(4%) JJ N
patients NNS N
of IN N
the DT N
V NNP N
group NN N
and CC N
in IN N
1/75 CD N
(1.3%) JJ N
patient NN N
of IN N
the DT N
H NNP N
group NN N
(p NNP N
< VBZ N
0.05) CD N
. . N

Minor JJ O
complications NNS O
occurred VBD N
in IN N
5/75 CD N
(6.7%) JJ N
patients NNS N
of IN N
either DT N
group NN N
. . N

The DT N
achievement NN O
of IN O
pneumoperitoneum NN O
required VBN N
4.5+/-0.4 JJ N
min NN N
in IN N
the DT N
V NNP N
group NN N
and CC N
3.2+/-0.2 JJ N
min NN N
in IN N
the DT N
H NNP N
group NN N
(p NNP N
< VBZ N
0.05) CD N
. . N

The DT N
open JJ I
laparoscopic NN I
technique NN I
is VBZ N
safer JJR N
and CC N
faster RBR N
than IN N
the DT N
blind JJ I
approach; NN I
therefore IN N
it PRP N
is VBZ N
proposed VBN N
that IN N
this DT N
approach NN N
be VB N
routinely RB N
used VBN N
in IN N
all DT N
laparoscopic NN I
procedures NNS I
. . I

-DOCSTART- -X- N

Celecoxib NNP I
as IN N
adjunctive JJ N
treatment NN N
to TO N
risperidone VB N
in IN N
children NNS P
with IN P
autistic JJ P
disorder: NN P
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
trial NN N
. . N

RATIONAL JJ N
Autism NNP N
is VBZ N
associated VBN N
with IN N
activation NN N
of IN N
the DT N
inflammatory NN N
response NN N
system NN N
. . N

OBJECTIVE NN N
This DT N
study NN N
aims VBZ N
to TO N
assess VB N
the DT N
efficacy NN O
of IN N
a DT N
cyclooxygenase-2 JJ I
inhibitor NN I
celecoxib NN I
as IN I
adjunctive JJ N
therapy NN N
in IN N
the DT N
treatment NN N
of IN N
autism NN N
METHODS NNP N
In IN N
a DT N
10-week JJ N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
40 CD P
outpatient JJ P
children NNS P
with IN P
a DT P
Diagnostic NNP P
and CC P
Statistical NNP P
Manual NNP P
of IN P
Mental NNP P
Disorders NNP P
fourth JJ P
edition NN P
text NN P
revision NN P
clinical JJ P
diagnosis NN P
of IN P
autism NN P
were VBD N
randomly RB N
allocated VBN N
to TO N
celecoxib VB I
plus CC I
risperidone VB I
or CC I
placebo VB I
plus CC I
risperidone VB I
. . I

The DT N
dose NN N
of IN N
risperidone NN I
and CC I
celecoxib NN I
were VBD N
titrated VBN N
up RB N
to TO N
3 CD N
and CC N
300 CD N
mg/day NN N
respectively RB N
. . N

Patients NNS P
were VBD P
assessed VBN P
at IN P
baseline NN P
and CC P
after IN P
2 CD P
4 CD P
6 CD P
and CC P
10 CD P
weeks NNS P
of IN P
starting VBG P
medication NN P
using VBG P
the DT P
Aberrant NNP P
Behavior NNP P
Checklist-Community NNP P
(ABC-C) JJ P
Rating NNP O
Scale NNP O
. . O

Primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
change NN O
in IN O
irritability NN O
subscale NN O
of IN O
ABC-C NNP O
. . O

RESULTS NNP O
Significant NNP N
timetreatment JJ N
interaction NN N
was VBD N
observed VBN O
for IN O
Irritability NNP O
(F NNP N
(1.658 VBD N
63.021)=13.580 CD N
P<0.001) NNP O
Lethargy/Social NNP O
Withdrawal NNP N
(F NNP N
(1.948 VBD N
74.032)=16.811 CD O
P<0.001) NNP O
and CC O
Stereotypic NNP N
Behavior NNP N
(F(1.742 NNP N
66.198)=12.104 CD O
P<0.001) NNP O
but CC O
not RB O
for IN O
Hyperactivity/Noncompliance NNP N
(F NNP N
(2.564 VBD N
97.424)=1.469 CD O
P=0.232) NNP O
and CC N
Inappropriate NNP N
Speech NNP N
subscales VBZ N
(F NNP N
(1.607 NNP N
61.075)=0.173 CD I
P=0.794) NNP I
. . N

By IN N
week NN N
10 CD N
patients NNS N
in IN N
the DT N
celecoxib NN N
group NN N
showed VBD O
significantly RB O
greater JJR N
improvement NN O
in IN O
the DT O
Irritability NNP O
(P<0.001) NNP O
Lethargy/Social NNP O
Withdrawal NNP N
(P<0.001) NNP O
and CC O
Stereotypic NNP O
Behavior NNP O
(P<0.00) NNP O
but CC O
not RB O
in IN O
Hyperactivity/Noncompliance NNP O
(P=0.202) NNP N
and CC N
Inappropriate NNP N
Speech NNP N
(P=0.802) NNP N
subscales NNS N
than IN N
the DT N
placebo NN N
group NN N
. . N

Complete JJ N
response NN N
was VBD N
achieved VBN N
by IN N
four CD N
(20 NNS N
%) JJ N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
and CC N
11 CD N
(55 NNS N
%) JJ N
patients NNS N
in IN N
the DT N
celecoxib NN N
group NN N
( NNP N
(2) NNP N
(1)=5.227 NNP N
P=0.022) NNP N
. . N

Frequency NN N
of IN N
side NN I
effects NNS I
was VBD I
similar JJ I
between IN I
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Combination NNP N
of IN O
risperidone NN O
and CC O
celecoxib NN O
was VBD O
superior JJ O
to TO O
risperidone VB P
alone RB P
in IN P
treating VBG P
irritability NN N
social JJ N
withdrawal NN N
and CC N
stereotypy NN N
of IN N
children NNS N
with IN N
autism NN N
. . N

(Registration NN N
www.irct.ir NN N
; : N
IRCT138711091556N2) NNP N
. . N

-DOCSTART- -X- N

Iobitridol NNP I
300 CD I
compared VBN N
to TO N
iopromide VB I
300--a JJ I
double-blind JJ N
randomized VBN N
phase-III NN N
study NN N
of IN N
clinical JJ N
tolerance NN N
in IN N
total JJ N
body NN O
CT NNP O
. . O

UNLABELLED NNP N
PURPOSE NNP N
MATERIAL NNP N
AND NNP N
METHODS: NNP N
The DT N
clinical JJ O
safety NN O
of IN N
iobitriodol JJ I
300 CD I
mg NN I
I/ml NNP I
and CC I
iopromide RB I
300 CD I
mg NNS I
I/ml NNP I
were VBD N
compared VBN N
in IN N
a DT N
randomized JJ N
double JJ N
blind IN N
phase-III JJ N
study NN N
conducted VBD N
on IN N
60 CD P
patients NNS P
undergoing JJ P
abdominal JJ P
CT NNP P
for IN P
a DT P
variety NN P
of IN P
indications NNS P
. . P

Each DT N
examination NN N
was VBD N
rated VBN N
as IN N
diagnostic JJ O
or CC O
nondiagnostic JJ O
and CC N
the DT N
image NN O
quality NN O
was VBD N
noted VBN N
. . N

Nature NN O
onset VBN O
intensity NN O
as RB N
well RB N
as IN N
outcome NN O
of IN O
each DT O
adverse JJ O
reaction NN O
were VBD N
recorded VBN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
imaging VBG O
quality NN O
and CC O
side NN O
effects NNS O
between IN N
the DT N
contrast NN N
media NNS N
. . N

In IN N
this DT N
study NN N
both DT N
iobitridol NNS I
and CC N
iopromide NN I
provided VBD N
excellent JJ O
image NN O
quality NN O
and CC N
a DT N
low JJ O
rate NN O
of IN O
side NN O
effects NNS O
. . O

CONCLUSION NNP N
Iobitridol NNP I
is VBZ N
a DT N
safe JJ O
and CC O
effective JJ O
nonionic JJ O
contrast NN O
agent NN O
for IN N
contrast-enhanced JJ N
body NN N
CT NNP N
. . N

-DOCSTART- -X- N

Folate NN N
levels NNS N
determine VBP N
effect NN N
of IN N
antioxidant JJ I
supplementation NN I
on IN N
micronuclei NN O
in IN N
subjects NNS P
with IN P
cardiovascular JJ P
risk NN P
. . P

We PRP P
have VBP N
investigated VBN N
the DT N
effect NN N
of IN N
modest JJ N
supplementation NN I
with IN I
alpha-tocopherol JJ I
(100 JJ I
mg/day) NN I
beta-carotene JJ I
(6 NNP I
mg/day) NN I
vitamin NN I
C NNP I
(100 NNP I
mg/day) NN I
and CC I
selenium NN I
(50 NNP I
microg/day) NN I
on IN I
oxidative JJ I
stress NN I
and CC I
chromosomal JJ I
damage NN I
and CC I
the DT I
influence NN I
of IN I
methylenetetrahydrofolate NN I
reductase NN I
(MTHFR) NNP I
genotype NN I
on IN I
these DT I
end-points NNS I
. . I

Subjects NNS I
were VBD I
two CD P
groups NNS P
of IN P
middle-aged JJ P
men NNS P
differing VBG P
in IN P
cardiovascular JJ P
risk; NN P
46 CD P
survivors NNS P
of IN P
myocardial JJ P
infarction NN P
before IN P
age NN P
50 CD P
and CC P
60 CD P
healthy JJ P
controls NNS P
. . P

They PRP N
were VBD N
randomly RB N
divided VBN N
into IN N
equal JJ I
groups NNS I
to TO I
receive VB I
antioxidants NNS I
or CC I
placebo NN I
for IN I
12 CD I
weeks NNS I
. . I

Twenty-eight JJ P
patients NNS P
and CC P
58 CD P
controls NNS P
completed VBD P
the DT P
intervention NN P
. . P

Micronucleus NNP O
levels NNS O
in IN N
peripheral JJ N
lymphocytes NNS N
and CC N
changes NNS N
seen VBN N
after IN N
intervention NN N
were VBD N
studied VBN N
in IN N
relation NN N
to TO N
the DT N
MTHFR NNP N
C677T NNP N
genotype NN N
basal NN N
homocysteine NN N
and CC N
plasma JJ N
folate NN N
levels NNS N
. . N

Ferric NNP O
reducing VBG O
ability NN O
of IN O
plasma NN O
and CC O
concentration NN O
of IN O
malondialdehyde NNS O
were VBD I
measured VBN I
to TO I
assess VB I
the DT I
antioxidant JJ I
effect NN I
of IN I
supplementation NN I
. . I

There EX N
was VBD N
no DT N
association NN N
of IN N
micronuclei NN N
with IN N
folate JJ N
homocysteine NN N
or CC N
malondialdehyde NN N
levels NNS N
before IN N
supplementation NN N
. . N

Micronucleus NNP O
frequencies NNS O
and CC O
plasma JJ O
folate NN O
levels NNS O
did VBD N
not RB N
vary JJ N
significantly RB N
with IN N
MTHFR NNP N
genotype NN N
. . N

Homocysteine NN O
levels NNS O
in IN N
subjects NNS P
with IN P
the DT P
TT NNP P
variant NN P
genotype NN P
were VBD N
significantly RB N
higher JJR N
compared VBN N
with IN N
CT NNP N
or CC N
CC NNP N
(P NNP N
= VBD N
0.001) CD N
especially RB N
in IN N
subjects NNS P
with IN P
low JJ P
folate NN P
(P NN P
= VBD P
0.012) CD N
. . N

In IN N
the DT N
placebo NN N
control NN N
group NN N
an DT N
increase NN N
in IN N
micronuclei JJ O
(P NNP N
= VBD N
0.04) CD N
was VBD N
detected VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
period NN N
. . N

This DT N
effect NN N
was VBD N
not RB N
seen VBN N
in IN N
the DT N
supplemented JJ N
group NN N
. . N

In IN N
antioxidant-supplemented JJ P
myocardial JJ P
infarction NN P
survivors NNS P
we PRP N
found VBD N
an DT N
increase NN N
in IN N
the DT N
ferric JJ N
reducing VBG N
ability NN N
of IN N
plasma NN N
(P NNP N
< VBZ N
0.001) CD N
and CC N
a DT N
decrease NN N
in IN N
malondialdehyde JJ N
(P NNP N
= NNP N
0.001) CD N
. . N

Micronucleus NNP O
frequency NN N
showed VBD N
a DT N
decrease NN N
strongest NN N
in IN N
subjects NNS P
with IN P
normal JJ P
folate NN P
levels NNS P
(P VBP P
= RB P
0.015) CD P
. . P

In IN N
subjects NNS P
with IN P
low JJ P
folate NN P
levels NNS P
a DT P
high JJ N
correlation NN N
was VBD N
found VBN N
between IN N
micronuclei NN N
after IN N
supplementation NN N
and CC N
homocysteine VB N
both DT N
before IN N
(r NNP N
= VBD N
0.979 CD N
P NNP N
= VBD N
0.002) CD N
and CC N
after IN N
supplementation NN N
(r NNP N
= VBZ N
0.922 CD N
P NNP N
= VBD N
0.009) CD N
. . N

Thus RB N
folate JJ N
deficiency NN N
may MD N
amplify VB N
the DT N
effect NN N
of IN N
other JJ N
risk NN N
factors NNS N
such JJ N
as IN N
elevated JJ N
homocysteine NN N
levels NNS N
or CC N
variant JJ N
MTHFR NNP N
genotype NN N
as RB N
well RB N
as IN N
influencing VBG N
the DT N
ability NN N
of IN N
antioxidant JJ I
supplementation NN I
to TO N
protect VB N
against IN N
genetic JJ N
damage NN N
. . N

-DOCSTART- -X- N

MRI NNP O
signal JJ O
hyperintensities NNS I
in IN N
geriatric JJ P
depression NN P
. . P

OBJECTIVE IN N
The DT N
authors NNS N
rated VBD N
periventricular JJ N
and CC N
subcortical JJ N
signal NN N
hyperintensities NNS N
on IN N
magnetic JJ I
resonance NN I
imaging VBG I
(MRI) JJ I
scans NNS N
in IN N
elderly JJ P
patients NNS P
with IN P
depression NN P
and CC P
in IN P
normal JJ P
subjects NNS P
with IN P
similar JJ P
demographic JJ P
features NNS P
to TO N
examine VB N
whether IN N
such JJ N
changes NNS N
discriminate VBP N
patients NNS N
with IN N
depression NN I
from IN N
normal JJ I
subjects NNS I
and CC N
whether IN N
they PRP N
are VBP N
associated VBN N
with IN N
any DT N
clinical JJ N
variables NNS N
. . N

METHOD NNP N
Two CD P
established VBD P
hyperintensity NN P
rating NN P
systems NNS P
were VBD P
used VBN P
to TO P
compare VB P
the DT P
MRI NNP P
brain NN P
scans NNS P
of IN P
48 CD P
elderly JJ P
patients NNS P
with IN P
depression NN P
diagnosed VBN P
according VBG P
to TO P
DSM-III-R NNP P
with IN P
the DT P
scans NNS P
of IN P
39 CD P
normal JJ P
elderly JJ P
subjects NNS P
. . P

RESULTS NNP P
Elderly NNP P
depressed VBD P
patients NNS P
manifested VBN N
significantly RB N
more RBR N
severe JJ N
hyperintensity NN O
ratings NNS O
in IN N
the DT N
subcortical JJ N
gray NN N
matter NN N
than IN N
age-matched JJ N
comparison NN I
subjects NNS N
. . N

Significant JJ N
differences NNS N
were VBD N
not RB N
identified VBN N
between IN N
patients NNS N
with IN N
similar JJ N
current JJ N
ages NNS N
and CC N
cerebrovascular JJ N
disease NN N
risk NN N
who WP N
had VBD N
early-onset NN N
or CC N
late-onset JJ N
depression NN I
. . I

CONCLUSIONS NNP N
These DT N
findings NNS N
support VBP N
those DT N
of IN N
neuroimaging VBG N
studies NNS N
implicating VBG N
the DT N
basal NN N
ganglia NN N
in IN N
depression NN I
and CC N
geriatric JJ N
depression NN I
. . I

The DT N
data NN N
suggest NN N
that IN N
the DT N
relationship NN N
observed VBD N
in IN N
some DT N
reports NNS N
between IN N
late-onset JJ N
depression NN I
and CC N
MRI NNP I
hyperintensities NNS I
is VBZ N
most RBS N
likely JJ N
a DT N
function NN N
of IN N
cerebrovascular JJ N
disease NN N
risk NN N
and CC N
age NN N
. . N

-DOCSTART- -X- N

Ciprofloxacin/dexamethasone NNP I
drops VBZ I
decrease VB N
the DT N
incidence NN N
of IN N
physician JJ N
and CC N
patient JJ N
outcomes NNS N
of IN N
otorrhea NN N
after IN N
tube JJ N
placement NN N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
ciprofloxacin NN I
0.3%/dexamethasone CD I
0.1% CD N
(CIPRODEX JJ I
Alcon NNP I
Ft NNP I
. . I

Worth JJ I
TX) NNP I
for IN N
the DT N
prevention NN N
of IN N
early JJ N
post-operative JJ N
otorrhea NN N
following VBG N
TT NNP N
placement NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
single-center JJ N
randomized JJ N
evaluator-blinded JJ N
parallel-group NN N
study NN N
. . N

Two CD P
hundred JJ P
children NNS P
undergoing VBG P
bilateral JJ P
TT NNP P
placement NN P
were VBD P
categorized VBN P
as IN P
having VBG P
unilateral JJ P
("wet/dry") JJ P
bilateral JJ P
("wet/wet") NN P
or CC P
no DT P
("dry/dry") JJ P
effusion NN P
at IN P
the DT P
time NN P
of IN P
surgery NN P
. . P

All DT P
patients NNS P
received VBD P
Ciprodex NNP P
or CC P
no DT P
treatment NN P
for IN P
5 CD P
days NNS P
post-operatively RB P
and CC P
returned VBN P
at IN P
2 CD P
weeks NNS P
. . P

RESULTS NNP N
Physician-observed NNP O
otorrhea NN O
was VBD N
reported VBN N
in IN N
5 CD N
(4.95%) JJ N
patients NNS N
receiving VBG N
Ciprodex NNP N
and CC N
39 CD N
(39.39%) NN N
patients NNS N
receiving VBG N
no DT N
treatment NN N
(p<0.0001) NN N
. . N

Treatment NN N
decreased VBD N
otorrhea NNS O
in IN N
all DT N
groups NNS N
while IN N
the DT N
greatest JJS N
benefit NN N
was VBD N
observed VBN N
in IN N
patients NNS N
with IN N
bilateral JJ N
effusion NN N
(93% NNP N
reduction) NN N
. . N

Ciprodex NN N
treatment NN N
also RB N
decreased VBD N
the DT N
rate NN N
of IN N
clinically RB O
diagnosed VBN O
otitis NN O
media NNS O
(OM) NN O
and CC O
effusion NN O
following VBG N
TT NNP N
placement JJ N
(p< NN N
or CC N
=0.0006) NN N
. . N

CONCLUSION NNP N
Ciprodex NNP N
reduced VBD N
early JJ N
post-operative JJ N
otorrhea NN O
clinically RB O
diagnosed VBN N
OM NNP N
and CC N
effusion NN N
following VBG N
TT NNP N
insertion NN N
. . N

The DT N
greatest JJS N
reduction NN N
in IN N
otorrhea NN O
was VBD N
observed VBN N
in IN N
patients NNS N
with IN N
bilateral JJ N
effusion NN N
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

-DOCSTART- -X- N

Randomized VBN N
placebo NN I
controlled VBN N
human JJ P
volunteer NN P
trial NN P
of IN N
a DT N
live JJ I
oral JJ I
cholera NN I
vaccine NN I
VA1.3 NNP I
for IN N
safety NN O
and CC N
immune JJ N
response NN N
. . N

A DT N
live JJ I
oral JJ I
cholera NN I
vaccine NN I
developed VBN I
from IN I
a DT I
non-toxigenic JJ I
Vibrio NNP I
cholerae NN I
O1 NNP I
El NNP I
Tor NNP I
strain NN I
VA1.3 NNP I
was VBD N
tested VBN N
in IN N
a DT N
double-blind JJ N
randomized JJ N
placebo NN I
controlled VBD N
study NN N
for IN N
safety NN N
and CC N
immunogenicity NN N
in IN N
304 CD P
men NNS P
aged VBN P
between IN P
16 CD P
and CC P
50 CD P
years NNS P
from IN P
Kolkata NNP P
India NNP P
. . P

A DT N
dose NN N
of IN N
5 CD N
x JJ N
10(9)CFU CD I
(n=186) NN N
or CC N
a DT N
placebo NN I
(n=116) NN N
containing VBG N
the DT N
diluent NN N
buffer NN N
was VBD N
administered VBN N
. . N

The DT N
vaccine NN I
did VBD N
not RB N
elicit JJ N
adverse JJ O
events NNS O
except IN N
in IN N
two CD N
vaccine NN N
recipients NNS N
with IN N
mild JJ O
diarrhoea NN O
and CC O
vomiting NN O
. . O

None NN O
excreted VBD O
the DT N
vaccine NN I
strain NN N
. . N

Vibriocidal NNP O
antibody NN O
response NN O
developed VBD N
in IN N
105/186 CD N
(57%) NNS N
and CC N
5/116 CD N
(4%) NN N
in IN N
vaccine NN I
and CC I
placebo NN I
recipients NNS N
respectively RB N
. . N

In IN N
a DT N
subgroup JJ N
anti-CT JJ O
antibody NN O
rose VBD O
(> CD N
or CC N
=2-folds) NNS N
in IN N
23/30 CD N
(77%) NNS N
and CC N
6/19 CD N
(32%) NN N
in IN N
vaccine NN I
and CC I
placebo NN I
recipients NNS N
respectively RB N
. . N

These DT N
studies NNS N
demonstrate VBP N
that IN N
VA1.3 NNP I
at IN N
a DT N
dose NN N
of IN N
5 CD N
x JJ N
10(9) CD N
is VBZ N
safe JJ O
and CC O
immunogenic JJ O
in IN N
adults NNS P
from IN P
a DT P
cholera NN P
endemic JJ P
region NN P
. . P

-DOCSTART- -X- N

MRI-detected JJ N
skull-base JJ N
invasion: NN N
prognostic JJ N
value NN N
and CC N
therapeutic JJ N
implication NN N
in IN N
intensity-modulated JJ N
radiotherapy NN N
treatment NN N
for IN N
nasopharyngeal JJ P
carcinoma NN P
. . P

PURPOSE NN P
With IN N
advances NNS N
in IN N
imaging VBG N
and CC N
radiotherapy VB N
the DT N
prognostic JJ N
value NN N
of IN N
skull-base JJ N
invasion NN N
in IN N
nasopharyngeal JJ P
carcinoma NN P
(NPC) NN N
needs VBZ N
to TO N
be VB N
reassessed VBN N
. . N

We PRP N
aimed VBD N
to TO N
define VB N
a DT N
classification NN N
system NN N
and CC N
evaluate VB N
the DT N
prognostic JJ N
value NN N
of IN N
the DT N
classification NN N
of IN N
magnetic JJ N
resonance NN N
imaging VBG N
(MRI)-detected JJ N
skull-base JJ N
invasion NN N
in IN N
NPC NNP N
treated VBD N
with IN N
intensity-modulated JJ I
radiotherapy NN I
(IMRT) NN N
. . N

PATIENTS NNS N
AND CC N
MATERIALS NNP N
We PRP N
retrospectively RB P
reviewed VBD P
749 CD P
patients NNS P
who WP P
underwent VBP P
MRI NNP P
and CC P
were VBD P
subsequently RB P
histologically RB P
diagnosed VBN P
with IN P
nondisseminated JJ P
NPC NNP P
and CC P
treated VBN P
with IN P
IMRT NNP P
. . P

RESULTS JJ N
MRI-detected JJ N
skull-base JJ N
invasion NN N
was VBD N
not RB N
found VBN N
to TO N
be VB N
an DT N
independent JJ N
prognostic JJ N
factor NN N
for IN N
overall JJ O
survival NN O
(OS) NN O
distant JJ O
metastasis-free JJ O
survival NN O
(DMFS) NNP O
local JJ O
relapse-free JJ O
survival NN O
(LRFS) NN O
or CC O
disease-free JJ O
survival NN O
(DFS; NNP O
p>0.05 NN N
for IN N
all) NN N
. . N

Skull-base JJ N
invasion NN N
was VBD N
classified VBN N
according VBG N
to TO N
the DT N
incidence NN N
of IN N
each DT N
site NN N
(type NN N
I PRP N
sites VBZ N
inside IN N
pharyngobasilar JJ N
fascia NN N
and CC N
clivus NN N
vs NN N
. . N

type NN N
II NNP N
sites VBZ N
outside IN N
pharyngobasilar JJ N
fascia) NN N
. . N

The DT O
5-year JJ O
OS NNP O
DMFS NNP O
LRFS NNP O
and CC O
DFS NNP O
rates NNS O
in IN N
the DT N
classification NN N
of IN N
skull-base JJ N
invasion NN N
in IN N
NPC NNP N
were VBD N
83 CD N
vs NN N
. . N

67% CD N
85 CD N
vs.75% NN N
95 CD N
vs NN N
. . N

88% CD N
and CC N
76 CD N
vs NN N
. . N

62% CD N
respectively RB N
(p<0.05 JJ N
for IN N
all) NN N
. . N

Multivariate NNP N
analysis NN N
indicated VBD N
the DT N
classification NN N
of IN N
skull-base JJ N
invasion NN N
was VBD N
an DT N
independent JJ N
prognostic JJ N
factor NN N
. . N

CONCLUSION NNP N
MRI-detected JJ N
skull-base JJ N
invasion NN N
is VBZ N
not RB N
an DT N
independent JJ N
prognostic JJ P
factor NN P
in IN P
patients NNS P
with IN N
NPC NNP N
treated VBD N
with IN N
IMRT NNP N
. . N

However RB N
classification NN N
according VBG N
to TO N
the DT N
site NN N
of IN N
invasion NN N
has VBZ N
prognostic JJ N
value NN P
. . P

Therefore RB P
patients NNS P
with IN N
various JJ N
subclassifications NNS N
of IN N
stage NN N
T3 NNP N
disease NN N
may MD N
receive VB N
treatment NN N
with IN N
different JJ N
intensities; NN N
however RB N
further JJ N
studies NNS N
are VBP N
warranted VBN N
to TO N
prove VB N
this DT N
. . N

-DOCSTART- -X- N

A DT N
comparison NN N
of IN N
a DT N
short JJ I
nurse-based JJ I
and CC I
a DT I
long JJ I
multidisciplinary JJ I
version NN I
of IN I
structured JJ I
patient JJ P
education NN P
in IN P
irritable JJ P
bowel NN P
syndrome NN P
. . P

OBJECTIVE RB P
Structured NNP I
multidisciplinary JJ I
patient NN I
group NN I
education NN I
has VBZ N
positive JJ N
effects NNS N
on IN N
symptoms NNS N
health-related JJ N
quality NN N
of IN N
life NN N
and CC N
disease-related JJ N
knowledge NN N
in IN N
patients NNS P
with IN P
irritable JJ P
bowel NN P
syndrome NN P
(IBS) NN P
but CC P
few JJ N
studies NNS N
comparing VBG N
different JJ N
forms NNS N
of IN N
educational JJ I
interventions NNS I
are VBP N
available JJ N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
long JJ I
multidisciplinary JJ I
group NN I
education NN I
with IN I
a DT I
short JJ I
nurse-based JJ I
group NN I
education NN I
with IN I
regard NN N
to TO N
symptoms NNS N
knowledge VB N
quality NN N
of IN N
life NN N
and CC N
satisfaction NN N
with IN N
the DT N
intervention NN N
in IN N
IBS NNP P
patients NNS P
. . P

METHODS NNP N
Patients NNS P
with IN P
IBS NNP P
according VBG P
to TO P
the DT P
Rome NNP P
II NNP P
criteria NNS P
were VBD N
randomized VBN N
to TO N
either DT N
short JJ I
nurse-based JJ I
or CC I
a DT I
long JJ I
multidisciplinary-based JJ I
education NN I
. . I

The DT N
effects NNS N
were VBD N
evaluated VBN N
by IN N
self-administered JJ I
questionnaires NNS I
at IN I
3 CD I
6 CD I
and CC I
12 CD I
months NNS I
after IN N
baseline NN N
and CC N
compared VBN N
between IN N
the DT N
groups NNS N
. . N

RESULTS NNP N
No NNP N
differences NNS N
in IN N
effects NNS N
were VBD N
detected VBN N
in IN N
the DT N
between-group JJ N
comparisons NNS N
at IN N
any DT N
of IN N
the DT N
follow-up JJ N
assessments NNS N
. . N

However RB N
positive JJ N
effects NNS N
on IN N
symptoms NNS O
knowledge VBP O
quality NN O
of IN O
life NN O
and CC O
satisfaction NN O
with IN N
the DT N
intervention NN I
were VBD N
found VBN N
in IN N
both CC N
the DT N
short JJ N
and CC N
the DT N
long JJ N
version NN N
. . N

CONCLUSION VB N
A DT I
short JJ I
nurse-based JJ I
educational JJ I
intervention NN I
seems VBZ N
to TO N
be VB N
as RB N
efficacious JJ N
as IN N
a DT N
longer RBR I
multidisciplinary JJ I
version NN I
. . I

In IN N
both DT N
groups NNS N
positive JJ N
effects NNS N
on IN N
patients' JJ N
well-being NN N
were VBD N
found VBN N
to TO N
a DT N
similar JJ N
extent NN N
. . N

This DT N
is VBZ N
an DT N
important JJ N
finding NN N
that IN N
from IN N
a DT N
cost-effective JJ N
perspective NN N
could MD N
contribute VB N
toward IN N
an DT N
optimized JJ N
management NN N
of IN N
patients NNS N
with IN N
IBS NNP N
. . N

-DOCSTART- -X- N

Assessment NN N
of IN N
therapeutic JJ N
response NN N
of IN N
Plasmodium NNP I
falciparum NN I
to TO N
chloroquine VB I
and CC I
sulfadoxine-pyrimethamine VB I
in IN P
an DT P
area NN P
of IN P
low JJ P
malaria NNS P
transmission NN P
in IN P
Colombia NNP P
. . P

Although IN N
chloroquine NN I
(CQ) FW I
resistance NN N
was VBD N
first RB N
reported VBN N
in IN N
Colombia NNP N
in IN N
1961 CD N
and CC N
sulfadoxine-pyrimethamine JJ I
(SP) NN I
resistance NN N
in IN N
1981 CD N
the DT N
frequency NN N
of IN N
treatment NN N
failures NNS N
to TO N
these DT N
drugs NNS N
in IN N
Colombia NNP N
is VBZ N
unclear JJ N
. . N

A DT N
modified JJ N
World NNP N
Health NNP N
Organization NNP N
14-day JJ N
in IN N
vivo JJ I
drug NN I
efficacy NN I
test NN I
for IN P
uncomplicated JJ P
Plasmodium NNP P
falciparum NN P
malaria NN P
in IN P
areas NNS P
with IN P
intense JJ N
malaria NNS N
transmission NN N
was VBD N
adapted VBN N
to TO N
reflect VB N
the DT N
clinical JJ N
and CC P
epidemiologic JJ P
features NNS P
of IN P
a DT P
low-intensity JJ P
malaria NN P
transmission NN P
area NN P
in IN P
the DT P
Pacific NNP P
Coast NNP P
Region NNP P
of IN P
Colombia NNP P
. . P

Patients NNS P
> VBP P
or CC P
=1 JJ P
year NN P
of IN P
age NN P
with IN P
a DT P
parasite JJ P
density NN P
> NN P
or CC P
=1 $ P
000 CD P
asexual JJ P
parasites NNS P
per IN P
microliter NN P
were VBD P
enrolled VBN P
in IN P
this DT P
study NN P
. . P

Forty-four CD P
percent NN P
(24 NN P
of IN P
54) CD P
of IN P
the DT P
CQ-treated JJ P
patients NNS P
were VBD P
therapeutic JJ P
failures NNS P
including VBG P
7 CD P
early JJ P
treatment NN P
failures NNS P
(ETFs) NNP P
and CC P
17 CD P
late JJ P
treatment NN P
failures NNS P
(LTFs) VBP P
. . P

Four CD P
(6%) NN P
of IN P
67 CD P
SP-treated JJ P
patients NNS P
were VBD P
therapeutic JJ P
failures NNS P
(2 VBP P
ETFs NNP P
and CC P
2 CD P
LTFs) NNP P
. . P

Therapeutic JJ N
failure NN N
in IN N
the DT N
CQ-treated JJ I
group NN N
was VBD N
associated VBN N
with IN N
an DT N
age NN N
<15 CD N
years NNS N
old JJ N
(P JJ N
< NN N
0.01) CD N
but CC N
was VBD N
not RB N
associated VBN N
with IN N
initial JJ N
parasite JJ N
density NN N
the DT N
presence NN N
of IN N
CQ NNP I
or CC N
sulfa-containing JJ N
drugs NNS N
in IN N
urine NN N
or CC N
a DT N
history NN N
of IN N
malaria NN N
. . N

The DT N
high JJ N
level NN N
of IN N
therapeutic JJ N
failures NNS N
to TO N
CQ NNP I
detected VBN N
in IN N
this DT N
study NN N
underscores VBZ N
the DT N
need NN N
and CC N
importance NN N
of IN N
drug NN N
efficacy NN N
evaluation NN N
in IN N
the DT N
development NN N
of IN N
a DT N
rational JJ N
national JJ N
antimalarial JJ N
drug NN N
policy NN N
. . N

The DT N
relatively RB N
low JJ N
level NN N
of IN N
therapeutic JJ N
failures NNS N
to TO N
SP NNP I
compared VBN N
with IN N
other JJ N
South JJ N
American JJ N
countries NNS N
raises VBZ N
further JJ N
questions NNS N
regarding VBG N
factors NNS N
that WDT N
might MD N
have VB N
prevented VBN N
the DT N
rapid JJ N
development NN N
of IN N
in IN N
vivo NN N
resistance NN N
to TO N
this DT N
drug NN N
combination NN N
. . N

-DOCSTART- -X- N

Intravenous JJ I
levosimendan NN I
treatment NN I
is VBZ N
cost-effective JJ N
compared VBN N
with IN N
dobutamine NN I
in IN N
severe JJ P
low-output JJ P
heart NN P
failure: VBZ P
an DT N
analysis NN N
based VBN N
on IN N
the DT N
international JJ N
LIDO NNP N
trial NN N
. . N

BACKGROUND NNP N
Levosimendan NNP I
a DT I
novel JJ N
calcium NN N
sensitiser NN N
improves VBZ N
cardiac JJ N
performance NN N
and CC N
symptoms NNS N
without IN N
increasing VBG N
oxygen NN N
consumption NN N
and CC N
decreases VBZ N
the DT N
mortality NN N
of IN N
patients NNS P
with IN P
low-output JJ P
heart NN P
failure NN P
. . P

AIMS NNP N
To TO N
estimate VB N
the DT N
cost-effectiveness NN N
of IN N
intravenous JJ N
treatment NN N
with IN N
levosimendan NNS I
compared VBN N
with IN N
dobutamine NN I
in IN N
patients NNS N
with IN N
severe JJ N
low-output JJ N
heart NN N
failure NN N
. . N

METHODS NNP N
This DT N
economic JJ N
evaluation NN N
was VBD N
based VBN N
on IN N
a DT N
European JJ N
clinical JJ N
trial NN N
(LIDO) NN N
in IN N
which WDT N
203 CD P
patients NNS P
with IN P
severe JJ P
heart NN P
failure NN P
randomly RB N
received VBD N
a DT N
24 CD N
h NN N
infusion NN N
with IN N
either DT N
levosimendan NN I
or CC I
dobutamine NN I
. . I

Survival NN N
and CC N
resource NN N
utilisation NN N
data NNS N
were VBD N
collected VBN N
for IN N
6 CD N
months; NNS N
survival NN N
was VBD N
extrapolated VBN N
assuming VBG N
a DT N
mean JJ N
additional JJ N
lifetime NN N
of IN N
3 CD N
years NNS N
based VBN N
on IN N
data NNS N
from IN N
the DT N
Cooperative NNP N
North NNP N
Scandinavian JJ N
Enalapril NNP N
Survival NNP N
Study NNP N
trial NN N
. . N

Costs NNS N
were VBD N
based VBN N
on IN N
study JJ N
drug NN N
usage NN N
and CC N
hospitalisation NN N
in IN N
the DT N
6-month JJ N
follow-up NN N
. . N

A DT N
sensitivity NN N
analysis NN N
on IN N
dosage NN O
of IN O
drug NN O
and CC O
duration NN O
of IN O
survival NN O
was VBD N
performed VBN N
. . N

RESULTS VB N
The DT N
mean JJ N
survival NN N
over IN N
6 CD N
months NNS N
was VBD N
157+/-52 JJ N
days NNS N
in IN N
the DT N
levosimendan NN I
group NN N
and CC N
139+/-64 JJ N
days NNS N
in IN N
the DT N
dobutamine NN I
group NN N
(P<0.01) NNP N
. . N

When WRB N
extrapolated VBN N
up RB N
to TO N
3 CD N
years NNS N
the DT N
gain NN O
in IN O
life NN O
expectancy NN O
was VBD N
estimated VBN N
at IN N
0.35 CD N
years NNS N
(discounted VBD N
at IN N
3%) CD N
. . N

Levosimendan NNP I
increased VBD N
the DT N
mean NN O
cost NN O
per IN O
patient NN O
by IN N
1108 CD N
which WDT N
was VBD N
entirely RB N
due JJ N
to TO N
the DT N
cost NN N
of IN N
the DT N
study NN N
drug NN N
. . N

The DT N
incremental JJ N
cost NN N
per IN N
life-year JJ N
saved VBD N
(LYS) NN N
was VBD N
3205 CD N
at IN N
the DT N
European NNP N
level; NN N
in IN N
the DT N
individual JJ N
countries NNS N
the DT N
cost NN N
per IN N
LYS NNP N
ranged VBD N
between IN N
3091 CD N
and CC N
3331 CD N
. . N

The DT N
result NN N
was VBD N
robust JJ N
in IN N
the DT N
sensitivity NN N
analysis NN N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
patients NNS N
in IN N
the DT N
levosimendan NN I
group NN N
were VBD N
alive JJ N
for IN N
more JJR N
days NNS N
and CC N
thus RB N
at IN N
risk NN N
of IN N
hospitalisation NN N
for IN N
longer JJR N
there EX N
was VBD N
no DT N
increase NN N
in IN N
hospitalisation NN N
or CC N
hospitalisation NN N
costs NNS N
with IN N
levosimendan JJ I
treatment NN N
. . N

The DT N
cost NN N
per IN N
LYS NNP N
using VBG N
levosimendan JJ I
compares NNS N
favourably RB N
with IN N
other JJ N
cost-effectiveness JJ N
analyses NNS N
in IN N
cardiology NN N
. . N

-DOCSTART- -X- N

Treatment NN N
of IN N
acute JJ N
asthma NN N
. . N

Lack NN N
of IN N
therapeutic JJ N
benefit NN N
and CC N
increase NN N
of IN N
the DT N
toxicity NN N
from IN N
aminophylline JJ I
given VBN N
in IN N
addition NN N
to TO N
high JJ N
doses NNS N
of IN N
salbutamol NN I
delivered VBN N
by IN N
metered-dose JJ N
inhaler NN N
with IN N
a DT N
spacer NN N
. . N

We PRP N
conducted VBD N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ I
study NN N
to TO N
determine VB N
if IN N
intravenous JJ I
aminophylline NN I
adds VBZ N
any DT N
benefit NN N
to TO N
high JJ N
doses NNS N
of IN N
inhaled JJ N
salbutamol NN I
in IN N
patients NNS P
who WP P
presented VBD P
for IN P
treatment NN P
of IN P
acute JJ P
asthma NN P
. . P

We PRP N
studied VBD N
94 CD P
patients NNS P
(mean JJ P
age NN P
35.6 CD P
+/- JJ P
11.2 CD P
years) NN P
with IN P
moderate JJ P
to TO P
severe VB P
acute JJ P
asthma NN P
. . P

All DT N
patients NNS N
received VBD N
therapy NN N
with IN N
salbutamol NN I
delivered VBN N
with IN N
metered-dose JJ I
inhaler NN I
(MDI) NNP I
into IN I
a DT I
spacer NN I
device NN I
(Volumatic) NNP I
in IN I
four CD I
puffs NNS I
(400 VBP I
micrograms) NN I
at IN I
10-min JJ I
interval NN I
and CC I
intravenous JJ I
hydrocortisone NN I
(500 NN N
mg) NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either CC N
a DT N
loading NN N
dose NN N
of IN N
intravenous JJ N
aminophylline NN I
followed VBN N
by IN N
a DT N
routine JJ N
infusion NN N
(n NNP N
= VBZ N
45) CD N
or CC N
an DT N
equal JJ N
volume NN N
of IN N
placebo NN I
as IN N
a DT N
loading NN N
dose NN N
and CC N
infusion NN N
(n NNP N
= VBZ N
49) CD N
. . N

The DT N
two CD N
groups NNS N
showed VBD N
no DT N
differences NNS N
in IN N
measurements NNS N
of IN N
peak JJ O
expiratory NN O
flow NN O
FEV1 NNP O
and CC O
FVC NNP O
at IN N
baseline NN N
and CC N
at IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

However RB N
the DT N
patients NNS N
treated VBN N
with IN N
aminophylline NN I
had VBD N
significantly RB N
more RBR N
adverse JJ O
effects NNS O
(p VBP N
< JJ N
0.05) CD N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
final JJ N
mean NN N
dose NN N
of IN N
salbutamol JJ N
(6.3 NNP N
+/- JJ N
44.5 CD N
mg NN N
for IN N
the DT N
placebo NN I
group NN N
and CC N
5.8 CD N
+/- JJ N
4.2 CD N
mg NN N
for IN N
the DT N
aminophylline NN N
group) NN N
hospital JJ O
admission NN O
rate NN O
(10.2 NNP N
percent NN N
for IN N
the DT N
placebo NN N
group NN N
and CC N
9.0 CD N
percent NN N
for IN N
the DT N
aminophylline NN I
group) NN N
and CC N
mean JJ O
duration NN O
of IN O
Emergency NNP O
Department NNP O
treatment NN O
(2.5 NNP N
+/- JJ N
1.83 CD N
h NN N
for IN N
the DT N
placebo NN I
group NN N
and CC N
2.37 CD N
+/- JJ N
1.75 CD N
h NN N
for IN N
the DT N
aminophylline NN I
group) NN N
. . N

The DT N
results NNS N
were VBD N
similar JJ N
when WRB N
the DT N
patients NNS N
were VBD N
divided VBN N
in IN N
accord NN N
with IN N
the DT N
degree NN O
of IN O
respiratory NN O
obstruction NN O
(baseline NNP N
FEV1 NNP N
< VBD N
30 CD N
percent NN N
of IN N
predicted) NN N
and CC N
theophylline JJ O
level NN O
at IN N
30 CD N
min NN N
of IN N
treatment NN N
(placebo NNP N
group NN N
patients NNS N
with IN N
theophylline JJ I
level NN N
< VBD N
10 CD N
mg/L NN N
vs NN N
aminophylline NN I
group NN N
patients NNS N
with IN N
theophylline JJ N
level NN N
> NN N
or CC N
= $ N
10 CD N
mg/L) NN N
. . N

We PRP N
conclude VBP N
that DT N
intravenous JJ N
aminophylline NN N
adds VBZ N
to TO N
the DT N
toxicity NN O
but CC N
not RB N
the DT N
efficacy NN O
of IN N
inhaled JJ N
salbutamol NN I
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
exacerbations NNS N
of IN N
asthma NN N
. . N

-DOCSTART- -X- N

Serum NNP O
bactericidal NN O
activities NNS O
and CC O
comparative JJ O
pharmacokinetics NNS O
of IN N
meropenem NN N
and CC N
imipenem-cilastatin NN N
. . N

The DT N
pharmacokinetics NNS N
and CC N
serum NN O
bactericidal NN O
activities NNS O
(SBAs) NNP O
of IN N
imipenem NN N
and CC N
meropenem NN N
were VBD N
investigated VBN N
in IN N
a DT N
randomized VBN N
crossover NN N
study NN N
. . N

Twelve NNP P
healthy JJ P
male NN P
volunteers NNS P
received VBD N
a DT N
constant JJ N
30-min JJ N
infusion NN N
of IN N
either CC N
1 CD N
g NN N
of IN N
imipenem JJ N
plus CC N
1 CD N
g NN N
of IN N
cilastatin NN N
or CC N
1 CD N
g NN N
of IN N
meropenem NN N
. . N

The DT N
concentrations NNS O
of IN O
the DT O
drugs NNS O
in IN O
serum NN O
and CC O
urine NN O
were VBD O
determined VBN O
by IN N
bioassay NN N
and CC N
high-pressure NN N
liquid NN N
chromatography NN N
. . N

Pharmacokinetic JJ N
parameters NNS N
were VBD N
based VBN N
on IN N
an DT N
open JJ N
two-compartment JJ N
model NN N
and CC N
a DT N
noncompartmental JJ N
technique NN N
. . N

At IN N
the DT N
end NN N
of IN N
infusion NN N
the DT N
mean JJ O
concentrations NNS O
of IN O
imipenem NN O
and CC O
meropenem NN O
measured VBN O
in IN O
serum NN O
were VBD N
61.2 CD N
+/- JJ N
9.8 CD N
and CC N
51.6 CD N
+/- JJ N
6.5 CD N
mg/liter NN N
respectively; NN N
urinary JJ O
recoveries NNS O
were VBD N
48.6% CD N
+/- JJ N
8.2% CD N
and CC N
60.0% CD N
+/- JJ N
6.5% CD N
of IN N
the DT N
dose NN N
in IN N
12 CD N
h NN N
respectively; NN N
and CC N
the DT N
areas NNS O
under IN O
the DT O
concentration-time JJ O
curve NN O
from IN N
time NN N
zero CD N
to TO N
infinity NN N
were VBD N
96.1 CD N
+/- JJ N
14.4 CD N
and CC N
70.5 CD N
+/- JJ N
10.3 CD N
mg.h/liter NN N
respectively RB N
(P JJ N
< NN N
or CC N
= $ N
0.02) CD N
. . N

Imipenem NNP N
had VBD N
a DT N
mean JJ N
half-life NN N
of IN N
66.7 CD N
+/- JJ N
10.4 CD N
min; NN N
that IN N
of IN N
meropenem NN N
was VBD N
64.4 CD N
+/- JJ N
6.9 CD N
min NN N
. . N

The DT N
volumes NNS N
of IN N
distribution NN N
at IN N
steady JJ N
state NN N
of IN N
imipenem NN N
and CC N
meropenem NN N
were VBD N
15.3 CD N
+/- JJ N
3.3 CD N
and CC N
18.6 CD N
+/- JJ N
3.0 CD N
liters/70 NN N
kg NN N
respectively RB N
and CC N
the DT N
mean JJ N
renal JJ N
clearances NNS N
per IN N
1.73 CD N
m2 NNS N
were VBD N
85.6 CD N
+/- JJ N
17.6 CD N
and CC N
144.6 CD N
+/- JJ N
26.0 CD N
ml/min NN N
respectively RB N
. . N

Both DT N
antibiotics NNS N
were VBD N
well RB N
tolerated VBN N
in IN N
this DT N
single-dose JJ N
administration NN N
study NN N
. . N

The DT N
SBAs NNP N
were VBD N
measured VBN N
by IN N
the DT N
microdilution NN N
method NN N
of IN N
Reller NNP N
and CC N
Stratton NNP N
(L NNP N
. . N

B NNP N
. . N

Reller NNP N
and CC N
C NNP N
. . N

W NNP N
. . N

Stratton NNP N
J NNP N
. . N

Infect NNP N
. . N

Dis NNP N
. . N

136:196-204 JJ N
1977) CD N
against IN N
40 CD N
clinically RB N
isolated JJ N
strains NNS N
. . N

Mean NNP O
reciprocal JJ O
bactericidal NN O
titers NNS O
were VBD N
measured VBN N
1 CD N
and CC N
6 CD N
h NN N
after IN N
administration NN N
. . N

After IN N
1 CD N
and CC N
6 CD N
h NN N
the DT N
median JJ N
SBAs NNP N
for IN N
imipenem NN N
and CC N
meropenem NN N
were VBD N
409 CD N
and CC N
34.9 CD N
and CC N
97.9 CD N
and CC N
5.8 CD N
respectively RB N
against IN N
Staphylococcus NNP N
aureus VBD N
19.9 CD N
and CC N
4.4 CD N
and CC N
19.4 CD N
and CC N
4.8 CD N
respectively RB N
against IN N
Pseudomonas NNP N
aeruginosa VBD N
34.3 CD N
and CC N
2.2 CD N
and CC N
232 CD N
and CC N
15.5 CD N
respectively RB N
against IN N
Enterobacter NNP N
cloacae NN N
and CC N
13.4 CD N
and CC N
2.25 CD N
and CC N
90.7 CD N
and CC N
7.9 CD N
respectively RB N
against IN N
Proteus NNP N
mirabilis NN N
. . N

Both DT N
drugs NNS N
had VBD N
rather RB N
short JJ N
biological JJ N
elimination NN N
half-lives NNS P
and CC P
a DT P
predominantly RB P
renal JJ P
route NN P
of IN N
elimination NN N
. . N

Both DT N
carbapenems NNS N
revealed VBD N
high JJ N
SBAs NNP O
against IN O
clinically RB O
important JJ O
pathogens NNS O
at IN N
1 CD N
h; NN N
meropenem NN N
had VBD N
a DT N
higher JJR N
SBA NNP N
against IN N
E NNP N
. . N

cloacae NN N
and CC N
P NNP N
. . N

mirabilis NN N
and CC N
the DT N
SBA NNP N
of IN N
imipenem NN N
against IN N
S NNP N
. . N

aureus NN N
was VBD N
greater JJR N
than IN N
the DT N
SBA NNP N
of IN N
meropenem NN N
. . N

-DOCSTART- -X- N

Desmopressin NNP I
has VBZ N
no DT N
beneficial JJ N
effect NN N
on IN N
excessive JJ N
postoperative JJ O
bleeding NN P
or CC P
blood NN P
product NN P
requirements NNS P
associated VBN P
with IN P
cardiopulmonary JJ P
bypass NN P
. . P

Cardiopulmonary JJ P
bypass NN I
during IN N
open-heart JJ N
surgery NN N
is VBZ N
sometimes RB N
associated VBN N
with IN N
excessive JJ N
perioperative JJ O
bleeding NN O
. . O

Following VBG N
a DT N
non-randomized JJ N
study NN N
suggesting VBG N
that IN N
desmopressin NN I
acetate NN I
(desmopressin) NNP I
reduced VBD I
blood NN N
product NN N
requirements NNS N
in IN N
these DT N
patients NNS N
we PRP N
conducted VBD N
a DT N
double-blind JJ N
placebo-controlled JJ I
randomized VBN N
trial NN N
of IN N
desmopressin NN I
(0.3 NNP I
micrograms/kg NN I
i NN I
. . I

v.) NN I
in IN I
92 CD P
patients NNS P
with IN P
overt JJ P
bleeding NN P
and CC P
a DT P
prolonged JJ P
bleeding NN P
time NN P
. . P

Mean JJ I
blood NN O
loss NN O
during IN I
the DT I
first JJ I
24 CD I
h JJ I
post-treatment NN I
was VBD I
similar JJ I
in IN I
the DT I
desmopressin NN I
and CC I
placebo NN I
groups NNS I
(582 VBP N
vs JJ N
465 CD N
ml NN N
respectively; NN N
p NN N
= VBD N
0.15) CD N
. . N

Red-cell NNP N
(p NNP N
= NNP N
0.76) CD N
fresh JJ N
frozen JJ N
plasma NN N
(r NNP N
= VBZ N
0.66) CD N
and CC N
platelet VB N
unit NN N
(p NNP N
= VBZ N
0.74) CD N
requirements NNS N
were VBD N
also RB N
similar JJ N
. . N

The DT N
haemostatic JJ N
effect NN N
of IN N
desmopressin NN N
has VBZ N
been VBN N
attributed VBN N
to TO N
the DT N
release NN N
of IN N
von JJ O
Willebrand NNP O
factor NN O
(vWF) NN O
and CC N
a DT N
reduced JJ N
bleeding NN O
time NN O
. . O

In IN N
our PRP$ N
study NN N
vWF NN O
and CC O
factor NN O
VIII:C NNP O
levels NNS O
increased VBN N
while IN N
the DT N
bleeding NN O
time NN O
decreased VBN N
significantly RB N
at IN N
90 CD N
min NN N
and CC N
24 CD N
h NN N
in IN N
both DT N
groups NNS N
and CC N
although IN N
vWF NN O
and CC O
factor NN O
VIII:C NNP O
levels NNS O
were VBD N
slightly RB N
higher JJR N
in IN N
desmopressin-treated JJ N
patients NNS N
at IN N
90 CD N
min NN N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

Thrombin-antithrombin JJ O
III NNP O
complex NN O
fibrinogen NN O
degradation NN O
product NN O
and CC O
tissue NN O
plasminogen NN O
activator NN O
levels NNS O
reflecting VBG O
activation NN O
of IN O
the DT O
coagulation NN O
and CC O
fibrinolytic JJ O
systems NNS O
respectively RB O
decreased VBD I
uniformly RB I
in IN I
both DT I
groups NNS I
. . I

We PRP N
conclude VBP N
that DT N
desmopressin NN I
is VBZ N
not RB N
useful JJ N
in IN N
reducing VBG N
blood NN O
loss NN O
or CC O
blood NN O
product NN O
requirements NNS O
in IN N
patients NNS P
with IN P
excessive JJ P
immediate JJ P
postoperative JJ P
bleeding NN P
. . P

-DOCSTART- -X- N

Effect NN N
of IN N
vitamin NN I
K2 NNP I
on IN N
the DT N
recurrence NN N
in IN N
patients NNS P
with IN P
hepatocellular JJ P
carcinoma NN P
. . P

BACKGROUND/AIMS NNP N
Vitamin NNP I
K2 NNP I
(VK2) NNP I
appears VBZ N
to TO N
have VB N
a DT N
potent JJ N
inhibitory NN N
activity NN N
for IN N
cell NN N
growth NN N
including VBG N
HCC NNP N
cells NNS N
. . N

We PRP N
investigated VBD N
whether IN N
VK2 NNP I
could MD N
reduce VB N
incidence NN N
of IN N
tumor NN N
recurrence NN N
after IN N
treatment NN N
of IN N
HCC NNP N
. . N

Forty-five JJ P
patients NNS P
with IN P
cured JJ P
or CC P
possibly RB P
cured VBN P
HCC NNP P
were VBD N
randomly RB N
selected VBN N
assigning VBG N
patients NNS N
to TO N
treatment NN I
(n=21) NNP N
or CC I
control VB I
group NN I
(n=24) NNP N
with IN N
randomization NN N
list NN N
. . N

METHODOLOGY NNP N
For IN N
the DT N
treatment NN N
group NN N
forty-five JJ I
mg NN I
of IN I
Glakay NNP I
was VBD N
given VBN N
orally RB N
every DT N
day NN N
after IN N
therapy NN N
for IN N
HCC NNP N
. . N

No DT N
patients NNS N
complained VBD N
of IN N
adverse JJ O
effects NNS O
. . O

Abdominal NNP I
ultrasonography NN I
and CC I
dynamic JJ I
CT NNP I
were VBD N
performed VBN N
at IN N
3-month JJ N
intervals NNS N
. . N

Recurrence NN N
was VBD N
confirmed VBN N
by IN N
abdominal JJ I
angiography NN I
. . I

RESULTS NNP N
Recurrence NNP O
of IN O
HCC NNP O
occurred VBD N
in IN N
7 CD N
cases NNS N
(33.3%) VBP N
for IN N
the DT N
treatment NN N
group NN N
and CC N
12 CD N
cases NNS N
(50.0%) VBP N
for IN N
the DT N
control NN N
group NN N
during IN N
mean JJ N
observation NN N
periods NNS N
of IN N
19.5 CD N
and CC N
16.5 CD N
months NNS N
respectively RB N
. . N

Administration NN N
of IN N
VK2 NNP I
was VBD N
not RB N
an DT N
independent JJ N
variable NN N
for IN N
the DT N
recurrence NN N
on IN N
univariate JJ N
analysis NN N
. . N

Cumulative JJ N
incidence NN N
of IN N
HCC NNP O
recurrence NN O
did VBD N
not RB N
differ VB N
between IN N
the DT N
two CD N
groups NNS N
and CC N
the DT N
cumulative JJ O
survival NN O
rate NN O
tended VBD N
to TO N
be VB N
high JJ N
in IN N
treatment NN N
group NN N
(p NNP N
=0.054) NNP N
. . N

Cox NNP N
regression NN N
analysis NN N
revealed VBD N
that IN N
serum NN N
albumin JJ N
concentration NN N
alone RB N
was VBD N
an DT N
independent JJ N
factor NN N
affecting VBG N
the DT N
recurrence NN N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
VK2 NNP I
does VBZ N
not RB N
appear VB N
to TO N
prevent VB N
recurrence NN O
of IN O
HCC NNP O
after IN N
curative JJ N
treatment NN N
. . N

Our PRP$ N
study NN N
is VBZ N
preliminary JJ N
and CC N
large-scale JJ N
trials NNS N
are VBP N
needed VBN N
to TO N
determine VB N
whether IN N
VK2 NNP I
is VBZ N
of IN N
benefit NN N
to TO N
decrease VB N
the DT N
recurrence NN N
of IN N
HCC NNP N
. . N

-DOCSTART- -X- N

Quitting VBG N
a DT N
weight JJ I
loss NN I
program NN I
is VBZ N
associated VBN N
with IN N
anhedonia: JJ N
preliminary JJ N
findings NNS N
of IN P
the DT P
Lifestyle NNP P
Intervention NNP P
Treatment NNP P
Evaluation NNP P
Study NNP P
in IN P
northern JJ P
Finland NNP P
. . P

OBJECTIVES NNP P
To TO N
examine VB N
whether IN N
a DT N
diagnosis NN N
for IN N
major JJ P
depression NN P
chronic JJ P
depression NN P
or CC P
specific JJ P
symptoms NNS P
of IN P
depression NN P
is VBZ N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
quitting VBG N
a DT N
weight JJ I
loss NN I
program NN I
. . I

STUDY NNP N
DESIGN NNP N
The DT N
study NN N
involved VBD P
82 CD P
overweight JJ P
adults NNS P
participating VBG P
in IN P
the DT P
Lifestyle NNP P
Intervention NNP P
Treatment NNP P
Evaluation NNP P
(LITE) NNP P
follow-up NN P
study NN P
at IN P
Oulu NNP P
University NNP P
Hospital NNP P
in IN P
northern JJ P
Finland NNP P
. . P

METHODS NNP P
Psychiatric NNP O
diagnostic JJ O
assessments NNS O
were VBD I
based VBN I
on IN I
the DT I
Structured NNP O
Clinical NNP O
Interview NNP O
for IN O
DSMIV NNP O
disorders NNS O
(SCID-I) RB O
conducted VBN I
by IN I
a DT I
clinical JJ I
psychiatrist NN I
. . I

Anhedonia NNP O
(lack NN O
of IN O
pleasure) NN O
was VBD O
assessed VBN O
as IN N
one CD N
of IN N
the DT N
core NN N
symptoms NNS N
of IN N
major JJ O
depression NN O
and CC O
chronic JJ O
depression NN O
(dysthymia) NN N
. . N

Anhedonia NNP O
was VBD N
defined VBN N
to TO N
be VB N
present JJ N
if IN N
the DT N
participants NNS N
reported VBD N
having VBG N
suffered VBD N
a DT N
major JJ N
loss NN N
of IN N
interest NN N
during IN N
the DT N
previous JJ N
month NN N
. . N

RESULTS NNP N
Twenty NNP N
participants NNS N
(24.4%) VBP N
quit NN N
during IN N
the DT N
6-month JJ N
intervention NN N
period NN N
. . N

Anhedonia NNP N
put VBD N
individuals NNS N
at IN N
risk NN N
of IN N
quitting VBG N
the DT N
weight JJ N
loss NN N
program NN N
(bivariate JJ N
analysis NN N
OR NNP N
3.1 CD N
95% CD N
CI NNP N
0.8-11.6 JJ N
p=0.091 NN N
multivariate NN N
analysis NN N
OR NNP N
6.5 CD N
95% CD N
CI NNP N
1.1-38.2 JJ N
p=0.038) NN N
. . N

However RB N
a DT N
diagnosis NN N
for IN N
major JJ N
depression NN N
or CC N
chronic JJ N
depression NN N
did VBD N
not RB N
predict JJ N
quitting NN N
. . N

CONCLUSIONS NNP N
Individual NNP N
assessments NNS N
of IN N
obesity NN N
and CC N
overweight NN N
should MD N
also RB N
include VB N
an DT N
assessment NN N
for IN N
subthreshold JJ N
depression NN N
mainly RB N
anhedonia RB N
. . N

-DOCSTART- -X- N

Vaginal NNP O
pH NN O
and CC O
microflora NN O
related VBN N
to TO N
yeast VB P
infections NNS P
and CC P
treatment NN P
. . P

The DT P
relationship NN N
between IN N
vaginal JJ O
pH NN O
microflora NNS O
and CC O
yeast JJ P
infection NN P
was VBD P
investigated VBN P
in IN P
93 CD P
women NNS P
randomly RB P
treated VBN P
with IN P
either DT P
nystatin NN P
or CC P
miconazole JJ P
pessaries NNS P
and CC P
cream NN P
for IN P
two CD P
weeks NNS P
. . P

The DT N
vaginal JJ O
pH NN O
was VBD N
measured VBN N
in IN N
a DT N
control NN P
group NN P
of IN P
48 CD P
women NNS P
. . P

In IN N
the DT N
study NN N
group NN N
37 CD N
patients NNS N
defaulted VBD N
39 CD N
were VBD N
cured VBN N
and CC N
17 CD N
required JJ N
treatment NN N
during IN N
the DT N
six-month JJ N
follow-up JJ N
period NN N
. . N

In IN N
both DT N
study NN N
and CC N
control NN I
groups NNS I
before IN N
and CC N
after IN N
treatment NN N
the DT N
mean JJ O
vaginal JJ O
pH NN O
was VBD N
in IN N
the DT N
range NN N
of IN N
4.3-4.6 JJ N
. . N

Lactobacilli NNP O
were VBD N
plentiful JJ N
in IN N
78 CD N
(91%) NNS N
out IN N
of IN N
86 CD N
patients NNS N
and CC N
shows VBZ N
that IN N
lactobacilli NN N
and CC N
yeasts NNS N
commonly RB N
coexist VBP N
. . N

The DT N
influence NN N
of IN N
other JJ N
organisms NNS N
appeared VBD N
to TO N
be VB N
negligible JJ N
. . N

The DT N
trial NN N
showed VBD N
that IN N
nystatin NN I
and CC I
micromazole NN I
were VBD N
equallly RB N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
vaginal JJ P
yeast NN P
infection NN P
and CC N
that IN N
the DT N
broad-spectrum JJ N
activity NN N
of IN N
micronazole NN I
offered VBN N
no DT N
advantage NN N
in IN N
this DT N
condition NN N
. . N

-DOCSTART- -X- N

Prospectively RB N
randomized VBN N
toxicity NN O
study NN N
of IN N
high-dose JJ I
versus NN N
low-dose JJ I
treatment NN N
strategies NNS N
for IN N
lymphoblastoid JJ P
interferon NN P
. . P

It PRP N
is VBZ N
unclear JJ N
from IN N
preliminary JJ N
laboratory NN N
studies NNS N
whether IN N
a DT N
high- NN I
or CC I
a DT I
low-dose JJ I
interferon NN I
treatment NN I
strategy NN N
is VBZ N
optimal JJ O
. . O

As IN N
part NN N
of IN N
an DT N
ongoing JJ N
study NN N
of IN N
mechanisms NNS N
of IN N
interferon JJ I
action NN N
we PRP N
have VBP N
evaluated VBN N
toxicity NN O
in IN N
a DT N
two-arm JJ N
protocol NN N
in IN N
which WDT N
patients NNS P
were VBD P
randomly RB P
assigned VBN P
to TO P
receive VB P
lymphoblastoid JJ P
interferon NN P
by IN N
either CC N
a DT N
low-dose JJ I
treatment NN I
strategy NN N
(2 NNP N
X NNP N
10(6) CD N
units/m2 JJ N
daily JJ N
X $ N
28 CD N
days NNS N
then RB N
daily JJ N
X NNP N
5 CD N
days NNS N
every DT N
other JJ N
week NN N
by IN N
im JJ N
injection) NN N
or CC N
a DT N
high-dose JJ I
treatment NN I
strategy NN N
(5 NNP N
X NNP N
10(6) CD N
units/m2 JJ N
by IN N
continuous JJ N
iv JJ N
infusion NN N
over IN N
24 CD N
hours NNS N
escalating VBG N
by IN N
5 CD N
X NNS N
10(6) CD N
units/m2/day JJ N
as IN N
tolerated VBN N
over IN N
10 CD N
days NNS N
repeated VBN N
every DT N
28 CD N
days) NN N
. . N

The DT N
main JJ O
toxic NN O
effects NNS O
in IN N
both DT N
arms NNS N
were VBD N
fever JJ O
fatigue NN O
and CC O
anorexia NN O
. . O

Marked VBN N
interpatient JJ O
differences NNS O
within IN N
each DT N
dose JJ N
arm NN N
were VBD N
greater JJR O
than IN N
differences NNS O
between IN N
arms NNS N
. . N

Additional JJ O
significant JJ O
toxic NN O
effects NNS O
included VBD O
nausea NN O
and CC O
vomiting VBG O
hypotension NN O
leukopenia NN O
thrombocytopenia NN O
and CC O
evidence NN O
of IN O
hepatic JJ O
toxicity NN O
. . O

Minor JJ N
changes NNS O
in IN O
serum NN O
electrolytes NNS O
were VBD N
noted VBN N
. . N

Coagulation NN O
studies NNS O
were VBD N
normal JJ O
. . O

The DT N
dose-limiting JJ O
toxic NN O
effect NN O
for IN O
the DT O
high-dose JJ O
arm NN O
was VBD O
myelosuppression NN O
. . O

Median JJ O
maximum NN O
tolerated VBD O
dose JJ O
among IN N
high-dose JJ I
strategy NN N
patients NNS N
was VBD N
18 CD N
X JJ N
10(6) CD N
units/m2 JJ N
but CC N
there EX N
was VBD N
marked VBN N
interpatient JJ N
variation NN N
. . N

We PRP N
conclude VBP N
that IN N
both DT O
dose JJ O
schedules NNS O
were VBD O
relatively RB O
well-tolerated JJ O
. . O

Because IN N
of IN N
individual JJ N
variation NN O
in IN O
tolerance NN O
high-dose JJ O
treatment NN N
should MD N
include VB N
a DT N
dose JJ N
escalation NN N
strategy NN N
. . N

-DOCSTART- -X- N

Phase NNP N
II NNP N
study NN N
of IN N
efficacy NN O
and CC O
safety NN O
of IN N
bevacizumab NN I
in IN I
combination NN I
with IN I
chemotherapy NN I
or CC I
erlotinib NN I
compared VBN I
with IN I
chemotherapy NN I
alone RB I
for IN N
treatment NN P
of IN P
recurrent NN P
or CC P
refractory NN P
non JJ P
small-cell JJ P
lung NN P
cancer NN P
. . P

PURPOSE NNP P
Bevacizumab NNP I
a DT I
humanized JJ N
anti-vascular JJ N
endothelial JJ N
growth NN N
factor NN N
monoclonal JJ N
antibody NN N
and CC N
erlotinib VB I
a DT I
reversible JJ N
orally RB N
available JJ N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
tyrosine NN N
kinase NN N
inhibitor NN N
have VBP N
demonstrated VBN N
evidence NN N
of IN N
a DT N
survival JJ N
benefit NN N
in IN N
the DT N
treatment NN N
of IN N
non-small-cell JJ P
lung NN P
cancer NN P
(NSCLC) NN P
. . P

A DT N
single-arm JJ N
phase NN N
I PRP N
and CC N
II NNP N
study NN N
of IN N
bevacizumab NN I
plus CC I
erlotinib NN I
demonstrated VBD N
encouraging JJ N
efficacy NN N
with IN N
a DT N
favorable JJ N
safety NN N
profile NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
A NNP N
multicenter NN N
randomized VBN N
phase NN N
II NNP N
trial NN N
evaluated VBD N
the DT N
safety NN N
of IN N
combining VBG I
bevacizumab NN I
with IN I
either DT I
chemotherapy NN I
(docetaxel NN I
or CC I
pemetrexed) NN I
or CC I
erlotinib NN I
and CC N
preliminarily RB N
assessed VBN N
these DT N
combinations NNS N
versus VBP N
chemotherapy NN I
alone RB I
as IN I
measured VBN N
by IN N
progression-free JJ O
survival NN O
(PFS) NN O
. . O

All DT P
patients NNS P
had VBD P
histologically RB P
confirmed VBN P
nonsquamous JJ P
NSCLC NNP P
that WDT P
had VBD P
progressed VBN P
during IN P
or CC P
after IN P
one CD P
platinum-based JJ P
regimen NNS P
. . P

RESULTS NNP N
One CD P
hundred VBD P
twenty NN P
patients NNS P
were VBD P
randomly RB P
assigned VBN P
and CC P
treated VBN P
. . P

No DT N
unexpected JJ N
adverse JJ O
events NNS O
were VBD N
noted VBN N
. . N

Fewer JJR N
patients NNS N
(13%) RBR N
in IN N
the DT N
bevacizumab-erlotinib JJ I
arm NN I
discontinued VBN N
treatment NN N
as IN N
a DT N
result NN N
of IN N
adverse JJ O
events NNS O
than IN N
in IN N
the DT N
chemotherapy NN I
alone RB I
(24%) CD N
or CC N
bevacizumab-chemotherapy JJ I
(28%) NN N
arms NNS N
. . N

The DT N
incidence NN N
of IN N
grade NN O
5 CD O
hemorrhage NN O
in IN N
patients NNS N
receiving VBG N
bevacizumab NN I
was VBD N
5.1% CD N
. . N

Although IN N
not RB N
statistically RB N
significant JJ N
relative JJ N
to TO N
chemotherapy VB I
alone RB N
the DT N
risk NN O
of IN O
disease NN O
progression NN O
or CC O
death NN O
was VBD N
0.66 CD N
(95% NNP N
CI NNP N
0.38 CD N
to TO N
1.16) CD N
among IN N
patients NNS P
treated VBN P
with IN P
bevacizumab-chemotherapy NN P
and CC P
0.72 CD N
(95% NNS N
CI NNP N
0.42 CD N
to TO N
1.23) CD P
among IN P
patients NNS P
treated VBN P
with IN P
bevacizumab-erlotinib NN P
. . I

One-year JJ O
survival NN O
rate NN O
was VBD N
57.4% CD N
for IN N
bevacizumab-erlotinib NN I
and CC N
53.8% CD N
for IN N
bevacizumab-chemotherapy NN I
compared VBN N
with IN N
33.1% CD N
for IN N
chemotherapy NN I
alone RB I
. . I

CONCLUSION NNP N
Results NNP N
for IN N
PFS NNP O
and CC O
overall JJ O
survival NN O
favor NN N
combination NN N
of IN N
bevacizumab NN I
with IN N
either DT N
chemotherapy NN I
or CC I
erlotinib NN I
over IN N
chemotherapy NN I
alone RB I
in IN N
the DT N
second-line JJ N
setting NN N
. . N

No DT N
unexpected JJ N
safety NN O
signals NNS O
were VBD N
noted VBN N
. . N

The DT N
rate NN N
of IN N
fatal JJ O
pulmonary JJ O
hemorrhage NN O
was VBD N
consistent JJ N
with IN N
previous JJ N
bevacizumab NN I
trials NNS N
. . N

The DT N
toxicity NN O
profile NN N
of IN N
the DT N
bevacizumab-erlotinib JJ I
combination NN I
is VBZ N
favorable JJ N
compared VBN N
with IN N
either DT N
chemotherapy-containing JJ I
group NN N
. . N

-DOCSTART- -X- N

Superior JJ I
modulation NN I
of IN N
activation NN N
levels NNS N
of IN N
stimulus JJ N
representations NNS N
does VBZ N
not RB N
underlie JJ N
superior JJ N
discrimination NN N
in IN N
autism NN P
. . P

The DT N
performance NN N
of IN N
children NNS P
with IN P
and CC P
without IN P
autism NN P
was VBD N
compared VBN N
in IN N
object-based JJ I
positive JJ I
and CC I
negative JJ I
priming NN I
tasks NNS I
within IN I
a DT I
visual JJ I
search NN I
procedure NN I
. . I

Object-based JJ O
positive JJ O
and CC O
negative JJ O
priming NN O
effects NNS O
were VBD N
found VBN N
in IN N
both DT N
groups NNS N
of IN N
children NNS N
. . N

This DT N
result NN O
provides VBZ N
the DT N
first JJ N
evidence NN O
for IN N
the DT N
activation NN O
of IN O
object-based JJ O
representations NNS O
during IN I
visual JJ O
search NN O
task NN O
performance NN O
and CC N
further JJ N
supports NNS O
the DT N
notion NN N
that IN N
both DT O
excitatory NN O
and CC O
inhibitory JJ O
guidance NN O
mechanisms NNS O
are VBP O
involved VBN O
in IN O
target NN O
location NN O
in IN O
visual JJ O
search NN O
. . O

The DT N
children NNS P
with IN P
autism NN P
were VBD N
overall JJ O
better JJR O
than IN N
the DT N
typically RB N
developing VBG N
children NNS N
at IN N
visual JJ O
search NN O
thus RB O
replicating VBG N
demonstrations NNS N
of IN N
superior JJ N
discrimination NN N
in IN N
autism NN N
. . N

Furthermore RB N
there EX N
was VBD N
no DT O
difference NN O
between IN N
the DT N
magnitude NN N
of IN N
the DT N
positive JJ N
nor CC N
the DT N
negative JJ N
priming NN O
effects NNS O
of IN N
the DT N
groups NNS N
. . N

This DT N
finding NN N
suggests VBZ O
that IN N
excitatory NN O
and CC O
inhibitory NN O
control NN O
operate NN O
comparably RB O
in IN N
autism NN N
and CC N
normal JJ O
development NN O
. . O

These DT N
results NNS N
are VBP N
discussed VBN N
in IN N
the DT N
light NN N
of IN N
the DT N
superior JJ N
ability NN N
of IN N
individuals NNS P
with IN P
autism NN P
to TO N
discriminate VB N
between IN N
items NNS N
. . N

More RBR N
specifically RB N
it PRP N
is VBZ N
argued VBN N
that IN N
superior JJ N
discrimination NN N
in IN N
autism NN N
does VBZ N
not RB N
result VB N
from IN N
enhanced VBN N
top-down JJ N
excitatory NN N
and CC N
inhibitory NN N
control NN N
. . N

-DOCSTART- -X- N

A DT N
comparative JJ N
analysis NN N
of IN N
the DT N
effects NNS N
of IN N
the DT N
fixed JJ I
combination NN I
of IN I
timolol NN I
and CC I
dorzolamide VB I
versus NN N
latanoprost NN I
plus CC I
timolol NN I
on IN N
ocular JJ O
hemodynamics NNS O
and CC O
visual JJ O
function NN O
in IN N
patients NNS P
with IN P
primary JJ P
open-angle JJ P
glaucoma NN P
. . P

AIMS IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
fixed JJ N
combination NN I
of IN I
timolol NN I
and CC I
dorzolamide NN I
and CC I
latanoprost NN I
plus CC I
timolol NN I
on IN N
retinal JJ O
choroidal NN O
and CC O
retrobulbar NN O
hemodynamics NNS O
and CC N
visual JJ O
function NN O
in IN N
primary JJ P
open-angle JJ P
glaucoma NN P
(OAG) NNP P
subjects NNS P
. . P

METHODS NNP N
Sixteen NNP P
(16) NNP P
OAG NNP P
patients NNS P
(age VB P
63.5 CD P
+/- JJ P
10.8 CD P
years; NN P
9 CD P
male) NN P
were VBD N
evaluated VBN N
in IN N
a DT N
randomized JJ N
crossover NN N
double-blind NN N
study NN N
design NN N
after IN N
4 CD N
weeks NNS N
of IN N
treatment NN N
of IN N
latanoprost NN I
with IN I
timolol NN I
and CC N
fixed JJ N
combination NN I
of IN I
timolol NN I
and CC I
dorzolamide NN I
. . I

After IN N
randomization NN N
9 CD P
right JJ P
eyes NNS P
and CC P
7 CD P
left JJ P
eyes NNS P
were VBD N
included VBN N
in IN N
the DT N
hemodynamic JJ N
portion NN N
of IN N
the DT N
study NN N
. . N

Measurements NNS N
included: JJ N
adverse JJ O
events NNS O
check VBP O
visual JJ O
acuity NN O
contrast NN O
sensitivity NN O
blood NN O
pressure NN O
heart NN O
rate NN O
intraocular JJ O
pressure NN O
(IOP) NN O
and CC O
fundus JJ O
examination NN O
. . O

Ocular JJ O
blood NN O
flow NN O
was VBD O
assessed VBN O
using VBG O
confocal JJ O
scanning VBG O
laser NN O
Doppler NNP O
flowmetry NN O
color NN O
Doppler NNP O
imaging NN O
and CC O
scanning VBG O
laser NN O
ophthalmoscopy NN O
. . O

RESULTS NNP N
Both NNP N
therapies NNS N
were VBD N
effective JJ N
at IN N
lowering VBG N
IOP NNP O
whereas IN O
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
latanoprost NN I
plus CC I
timolol NN I
and CC N
the DT N
fixed JJ I
combination NN I
of IN I
timolol NN I
and CC I
dorzolamide VB I
(13.9% NNP N
and CC N
12.2% CD N
reduction NN N
respectively; NN N
P NNP N
= VBZ N
0.5533) CD N
. . N

Fixed NNP I
combination NN I
of IN I
timolol NN I
and CC I
dorzolamide VB I
significantly RB N
increased JJ N
central JJ O
retinal JJ O
artery NN O
end NN O
diastolic NN O
blood NN O
flow NN O
velocity NN O
(P NNP N
= VBZ N
0.0168) CD N
and CC N
lowered VBD N
resistance NN O
to TO O
flow VB O
(P NNP N
= NNP N
0.0279) CD N
. . N

Temporal JJ O
posterior JJ O
ciliary JJ O
artery NN O
peak NN O
systolic NN O
and CC O
end VB O
diastolic JJ O
velocities NNS O
were VBD N
significantly RB N
increased VBN N
with IN N
the DT N
fixed JJ I
combination NN I
of IN I
timolol NN I
and CC I
dorzolamide VB I
(P NNP N
= NNP N
0.0125 CD N
and CC N
0.0238 CD N
respectively) NN N
. . N

Latanoprost NNP I
plus CC I
timolol NN I
had VBD N
no DT N
significant JJ N
effects NNS N
on IN N
ocular JJ O
blood NN O
flow NN O
during IN N
4 CD N
weeks NNS N
of IN N
treatment NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
adverse JJ O
events NNS O
blood NN O
pressure NN O
heart NN O
rate NN O
visual JJ O
acuity NN O
contrast NN O
sensitivity NN O
scanning VBG O
laser NN O
ophthalmoscopy NN O
or CC O
Heidelberg NNP O
Retinal NNP O
Flowmeter NNP O
for IN N
any DT N
treatment NN N
period NN N
. . N

CONCLUSIONS NNP N
Fixed NNP I
combination NN I
of IN I
timolol NN I
and CC I
dorzolamide JJ I
therapy NN I
might MD N
increase VB N
blood NN O
flow NN O
in IN N
OAG NNP P
patients NNS P
while IN N
attaining VBG N
a DT N
similar JJ N
IOP NNP O
reduction NN N
compared VBN N
to TO N
latanoprost VB I
plus JJ I
timolol NN I
. . I

Visual JJ O
function NN O
however RB O
was VBD N
not RB N
different JJ N
in IN N
this DT N
short-term JJ N
comparison NN N
between IN N
the DT N
two CD N
treatments NNS N
. . N

-DOCSTART- -X- N

Evaluating VBG I
proton NN O
stereotactic JJ O
body NN O
radiotherapy NN O
to TO N
reduce VB N
chest JJS O
wall NN O
dose NN O
in IN N
the DT N
treatment NN N
of IN N
lung NN P
cancer NN P
. . P

Stereotactic JJ P
body NN I
radiotherapy NN I
(SBRT) NN I
can MD N
produce VB N
excellent JJ N
local JJ N
control NN N
of IN N
several JJ N
types NNS N
of IN N
solid JJ N
tumor; NN N
however RB N
toxicity NN N
to TO N
nearby RB N
critical JJ N
structures NNS N
is VBZ N
a DT N
concern NN N
. . N

We PRP N
found VBD N
previously RB N
that IN N
in IN N
SBRT NNP I
for IN N
lung NN N
cancer NN N
the DT N
chest JJS O
wall NN O
(CW) NN O
volume NN O
receiving VBG N
20 CD I
30 CD I
or CC I
40Gy CD I
(V20 JJ I
V30 NNP I
or CC I
V40) NNP I
was VBD N
linked VBN N
with IN N
the DT N
development NN N
of IN N
neuropathy NN N
. . N

Here RB N
we PRP N
sought VBD N
to TO N
determine VB N
whether IN N
the DT N
dosimetric JJ N
advantages NNS N
of IN N
protons NNS N
could MD N
produce VB N
lower JJR N
CW NNP O
doses NNS O
than IN N
traditional JJ I
photon-based JJ I
SBRT NNP I
. . I

We PRP N
searched VBD N
an DT N
institutional JJ N
database NN N
to TO N
identify VB N
patients NNS P
treated VBN P
with IN P
photon NN P
SBRT NNP P
for IN P
lung NN P
cancer NN P
with IN P
tumors NNS P
within IN P
< JJ P
2.5cm CD P
of IN P
the DT P
CW NNP P
. . P

We PRP P
found VBD P
260 CD P
cases; NN P
of IN P
these DT P
chronic JJ P
grade NN P
 VBD I
2 CD P
CW NNP P
pain NN P
was VBD P
identified VBN P
in IN P
23 CD P
patients NNS P
. . N

We PRP N
then RB P
selected VBD P
10 CD P
representative JJ P
patients NNS P
from IN P
this DT P
group NN P
and CC P
generated VBD P
proton NN P
SBRT NNP P
treatment NN P
plans NNS P
using VBG N
the DT N
identical JJ N
dose NN N
of IN N
50Gy CD N
in IN N
4 CD N
fractions NNS N
and CC N
assessed JJ N
potential NN N
differences NNS N
in IN O
CW NNP O
dose NN O
between IN N
the DT N
2 CD N
plans NNS N
. . N

The DT I
proton NN I
SBRT NNP I
plans VBZ I
reduced VBD N
the DT O
CW NNP O
doses NNS O
at IN N
all DT N
dose JJ N
levels NNS N
measured VBN N
. . N

The DT O
median JJ O
CW NNP O
V20 NNP O
was VBD N
364.0cm(3) CD N
and CC N
160.0cm(3) CD N
(p NNS N
< VBD N
0.0001) CD N
V30 NNP N
was VBD N
144.6cm(3)vs CD N
77.0cm(3) CD N
(p NN N
= VBD N
0.0012) CD N
V35 NNP N
was VBD N
93.9cm(3)vs CD N
57.9cm(3) CD N
(p NN N
= VBD N
0.005) CD N
V40 NNP N
was VBD N
66.5cm(3)vs CD N
45.4cm(3) CD N
(p NN N
= NN N
0.0112) CD N
and CC O
mean JJ O
lung NN O
dose NN O
was VBD N
5.9Gy CD N
vs JJ N
3.8Gy CD N
(p JJ N
= $ N
0.0001) CD N
for IN N
photons NNS N
and CC N
protons NNS N
respectively RB N
. . O

Coverage NN O
of IN O
the DT O
planning NN O
target NN O
volume NN O
(PTV) NNP O
was VBD N
comparable JJ N
between IN N
the DT N
2 CD N
sets NNS N
of IN N
plans NNS N
(96.4% VBP N
for IN N
photons NNS N
and CC N
97% CD N
for IN N
protons) NN N
. . N

From IN N
a DT N
dosimetric JJ N
standpoint NN I
proton NN I
SBRT NNP I
can MD N
achieve VB N
the DT N
same JJ N
coverage NN N
of IN N
the DT N
PTV NNP N
while IN N
significantly RB N
reducing VBG N
the DT O
dose NN O
to TO O
the DT O
CW NNP O
and CC O
lung RB O
relative JJ O
to TO O
photon VB O
SBRT NNP O
and CC N
therefore RB N
may MD N
be VB N
beneficial JJ N
for IN N
the DT N
treatment NN N
of IN N
lesions NNS N
closer VBP N
to TO N
critical JJ N
structures NNS N
. . N

-DOCSTART- -X- N

Randomized VBN I
double-blind JJ I
multicenter NN I
trial NN I
comparing VBG I
two CD I
doses NNS I
of IN I
arzoxifene NN I
(LY353381) NN I
in IN I
hormone-sensitive JJ P
advanced JJ P
or CC P
metastatic JJ P
breast NN P
cancer NN P
patients NNS P
. . P

BACKGROUND NNP I
This DT I
randomized VBD I
double-blind JJ I
phase NN I
II NNP I
study NN I
assessed VBD I
two CD I
doses NNS I
of IN I
the DT I
selective JJ I
estrogen NN I
receptor NN I
modulator NN I
arzoxifene NN I
in IN I
women NNS P
with IN P
advanced JJ P
breast NN P
cancer NN P
. . P

The DT I
primary JJ I
end NN I
point NN I
was VBD I
to TO I
choose VB I
the DT I
best JJS I
of IN I
two CD I
doses NNS I
of IN I
arzoxifene NN I
based VBN I
on IN I
the DT I
response NN O
rate NN O
or CC I
the DT I
clinical JJ O
benefit NN O
rate NN O
(CBR) NN O
. . O

Pharmacokinetics NNS I
and CC I
toxicities NNS I
were VBD I
also RB I
assessed VBN I
. . I

PATIENTS NNS I
AND CC I
METHODS NNP I
Ninety-two NNP P
patients NNS P
with IN P
advanced JJ P
breast NN P
cancer NN P
received VBD P
arzoxifene JJ P
20 CD P
or CC P
50 CD P
mg/day NN P
. . P

Tumor NN O
response NN O
was VBD I
assessed VBN I
using VBG I
World NNP I
Health NNP I
Organization NNP I
criteria NNS I
. . I

Toxicities NNS O
were VBD I
graded VBN I
according VBG I
to TO I
the DT I
National NNP I
Cancer NNP I
Institute NNP I
Common NNP I
Toxicity NNP I
Criteria NNP I
(NCI-CTC) JJ I
system NN I
. . I

Pharmacokinetic JJ O
data NNS O
were VBD I
analyzed VBN I
using VBG I
the DT I
NONMEM NNP I
software NN I
program NN I
(GloboMax NNP I
Hanover NNP I
MD NNP I
USA) NNP I
. . I

RESULTS JJ I
Response NNP O
rates NNS O
in IN I
the DT I
20 CD I
mg NN I
arm NN I
were VBD I
numerically RB I
higher JJR I
than IN I
the DT I
50-mg JJ I
arm NN I
according VBG I
to TO I
the DT I
investigator NN I
(40.5% NNP I
versus NN I
36.4%) CD I
and CC I
the DT I
independent JJ I
review NN I
panel NN I
(42.9% NNP I
versus NN I
27.3%) CD I
. . I

CBR NNP O
was VBD I
higher RBR I
in IN I
the DT I
20 CD I
mg NN I
arm NN I
according VBG I
to TO I
the DT I
investigator NN I
(64.3% NNP I
versus NN I
61.4%) CD I
and CC I
the DT I
independent JJ I
review NN I
panel NN I
(59.5% NNP I
versus NN I
47.7%) CD I
. . I

Arzoxifene NNP I
was VBD I
well RB I
tolerated VBN I
. . I

There EX I
were VBD I
no DT I
study NN I
drug-related JJ O
deaths NNS O
. . O

Mean NNP I
observed VBD I
steady-state JJ O
plasma JJ O
concentrations NNS O
of IN I
arzoxifene NN I
were VBD I
3.62 CD I
and CC I
7.48 CD I
ng/ml NN I
for IN I
the DT I
20 CD I
and CC I
50 CD I
mg NN I
doses NNS I
respectively RB I
. . I

CONCLUSIONS NN I
There EX I
were VBD I
no DT I
significant JJ I
differences NNS I
in IN I
efficacy NN O
or CC I
safety NN O
between IN I
20 CD I
and CC I
50 CD I
mg NN I
of IN I
arzoxifene NN I
. . I

Accordingly RB I
arzoxifene JJ I
20 CD I
mg/day NN I
was VBD I
selected VBN I
for IN I
further JJ I
study NN I
in IN I
patients NNS I
with IN I
breast JJ I
cancer NN I
. . I

-DOCSTART- -X- N

Effect NN N
of IN N
testosterone NN I
and CC I
a DT I
nutritional JJ I
supplement NN I
alone RB I
and CC I
in IN I
combination NN I
on IN I
hospital JJ N
admissions NNS N
in IN N
undernourished JJ P
older JJR P
men NNS P
and CC P
women NNS P
. . P

BACKGROUND NNP P
In IN N
older JJR P
people NNS P
undernutrition NN P
is VBZ N
associated VBN N
with IN N
increased JJ N
hospitalization NN N
rates NNS N
and CC N
mortality NN N
. . N

Because IN N
weight JJ N
loss NN N
in IN N
older JJR N
people NNS N
often RB N
reflects VBZ N
a DT N
disproportionate JJ N
reduction NN N
of IN N
skeletal JJ N
muscle NN N
anabolic JJ N
treatments NNS N
may MD N
be VB N
beneficial JJ N
. . N

OBJECTIVE NNP N
Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
hypothesis NN N
that WDT N
testosterone NN I
treatment NN I
and CC N
a DT N
nutritional JJ I
supplement NN I
have VBP N
additive JJ N
benefits NNS N
. . N

DESIGN NNP N
Oral NNP I
testosterone NN I
undecanoate NN I
(40 NNP I
mg VBZ I
daily RB I
for IN I
women NNS I
80 CD I
mg JJ I
twice RB I
daily RB I
for IN I
men) NN I
and CC I
an DT I
oral JJ I
nutritional JJ I
supplement NN I
(475 NN I
kcal/d) NN I
were VBD I
administered VBN I
alone RB I
or CC I
combined VBN I
for IN I
1 CD N
y NNS N
to TO N
49 CD P
community-dwelling NN P
undernourished JJ P
people NNS P
[Mini VBP P
Nutritional JJ P
Assessment NNP P
score NN P
<24 NN P
and CC P
low JJ P
body NN P
weight VBD P
(body JJ P
mass NN P
index NN P
in IN P
kg/m(2): NN P
<22) NN P
or CC P
recent JJ P
weight JJ P
loss NN P
(>7.5% NN P
over IN N
3 CD N
mo)] NNS N
aged VBN N
>65 JJ N
y JJ N
(mean JJ N
age: NN N
77 CD N
y; NN N
26 CD N
women NNS N
and CC N
23 CD N
men) NN N
. . N

Hospital JJ N
admissions NNS N
and CC N
other JJ N
variables NNS N
were VBD N
assessed VBN N
. . N

RESULTS NNP N
In IN N
subjects NNS N
receiving VBG N
combined VBN I
testosterone NN I
and CC I
nutritional JJ I
supplements NNS I
(n VBP N
= RB N
11) CD N
there EX N
were VBD N
no DT N
hospital JJ N
admissions NNS N
whereas IN N
there EX N
were VBD N
9 CD N
admissions NNS N
(2 VBP N
elective) NN N
in IN N
13 CD N
subjects NNS N
in IN N
the DT N
no-treatment JJ I
group NN I
4 CD I
in IN N
the DT N
testosterone-treated JJ I
group NN I
(n NNP N
= VBZ N
12) CD N
and CC N
5 CD N
in IN N
the DT N
supplement-treated JJ I
group NN I
(n NNP N
= VBZ N
13); CD N
P NNP N
= VBD N
0.06 CD N
with IN N
no-treatment JJ I
compared VBN N
with IN N
combined JJ I
treatment NN I
. . I

When WRB N
compared VBN N
with IN N
the DT N
no-treatment JJ I
group NN N
the DT N
combined-treatment JJ I
group NN I
had VBD N
significantly RB N
fewer JJR N
subjects NNS N
admitted VBN N
to TO N
hospital VB N
(0 NNS N
compared VBN N
with IN N
5 CD N
P NNP N
= VBD N
0.03) CD N
fewer JJR N
days NNS N
in IN N
hospital NN N
(0 NNS N
compared VBN N
with IN N
74 CD N
P NNP N
= VBD N
0.041) CD N
and CC N
a DT N
longer JJR N
time NN N
to TO N
hospital VB N
admission NN N
(P NNP N
= VBZ N
0.017) CD N
. . N

CONCLUSIONS NNP N
In IN N
undernourished JJ P
older JJR P
people NNS P
combined VBN P
treatment NN I
with IN I
testosterone NN I
and CC I
nutritional JJ I
supplementation NN I
reduced VBD N
the DT N
number NN N
of IN N
people NNS N
hospitalized VBN N
and CC N
the DT N
duration NN N
of IN N
hospital NN N
admissions NNS N
which WDT N
are VBP N
important JJ N
endpoints NNS N
in IN N
this DT N
group NN N
. . N

Larger NNP N
confirmatory NN N
studies NNS N
are VBP N
now RB N
needed VBN N
. . N

This DT N
trial NN N
was VBD N
registered VBN N
before IN N
commencement NN N
at IN N
clinical JJ N
trials.gov NN N
as IN N
NCT00117000 NNP N
. . N

-DOCSTART- -X- N

[Comparison NN N
between IN N
anterior JJ I
rhinomanometry NN I
and CC I
impulse-oscillometric JJ I
rhinometry NN I
found VBD I
within IN I
nasal JJ P
allergen NN P
provocation] NN I
. . N

UNLABELLED NNP N
Besides NNP N
the DT N
standard JJ I
method NN I
of IN I
anterior JJ I
rhinomanometry NN I
(aR) VBD I
the DT I
impulse-oscillometric JJ I
rhinometry NN I
(IOS) NN I
is VBZ N
available JJ N
for IN N
measurements NNS N
of IN N
the DT N
nasal JJ N
resistance NN N
. . N

The DT N
aR NN I
is VBZ N
a DT N
procedure NN N
dependent NN N
on IN N
the DT N
cooperation NN N
of IN N
the DT N
patient NN N
whereas JJ N
IOS NNP I
is VBZ N
measured VBN N
regardless RB N
from IN N
the DT N
breathing NN N
activities NNS N
of IN N
the DT N
patient NN N
. . N

We PRP N
examined VBD N
weather RP N
the DT N
resistance-measurement NN N
by IN N
means NNS N
of IN N
IOS NNP I
in IN N
comparison NN N
to TO N
the DT N
aR NN I
is VBZ N
a DT N
more RBR N
suitable JJ N
method NN N
for IN N
nasal JJ N
allergic JJ N
provocation NN N
. . N

METHOD NNP I
17 CD P
patients NNS P
with IN P
anamnestic JJ P
known VBN P
rhinokonjunktivitis NN P
(6 NN P
f VBD P
11 CD P
m) NN P
had VBD P
a DT P
pricktest NN P
and CC P
then RB P
a DT P
nasal JJ P
provocation NN P
testing VBG P
with IN P
an DT P
allergen NN P
which WDT P
provoked VBD P
a DT P
reaction NN P
on IN P
the DT P
skin NN P
. . P

The DT I
complete JJ I
resistance NN I
of IN I
the DT I
nose NN I
was VBD I
measured VBN I
in IN I
a DT I
randomized JJ I
order NN I
by IN I
means NNS I
of IN I
aR NN I
and CC I
IOS NNP I
. . I

RESULTS VB N
The DT N
complete JJ N
resistance NN N
showed VBD N
neither CC N
in IN N
the DT N
basic JJ N
measurement NN N
(aR VBD I
0 CD N
38 CD N
+/- JJ N
0 CD N
14 CD N
kPa/l/s; NN N
IOS NNP I
0 CD N
38 CD N
+/- JJ N
0 CD N
11 CD N
kPa/l/s) NNS N
nor CC N
in IN N
the DT N
control NN N
solution NN N
(aR VBD I
0 CD N
38 CD N
+/- JJ N
0 CD N
14; CD N
IOS NNP I
0 CD N
39 CD N
+/- JJ N
0 CD N
14) CD N
nor CC N
after IN N
application NN N
of IN N
the DT N
allergenic JJ N
solution NN N
(15 NNP N
min: NN N
aR VBD I
0 CD N
69 CD N
+/- JJ N
0 CD N
27; CD N
IOS NNP I
0 CD N
77 CD N
+/- JJ N
0 CD N
42; CD N
30 CD N
min: NN N
aR VBD I
0 CD N
65 CD N
+/- JJ N
0 CD N
29; CD N
IOS NNP I
0 CD N
6 CD N
+/- JJ N
0 CD N
38) CD N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
. . N

The DT N
results NNS N
of IN N
the DT N
measurement NN O
of IN O
aR NN O
and CC O
IOS NNP O
after IN N
the DT N
allergenic JJ N
solution NN N
showed VBD N
a DT N
positive JJ N
correlation NN N
(15 NNP N
min: NN N
r NN N
= VBD N
0 CD N
63 CD N
p NN N
< VBD N
0 CD N
01; CD N
30 CD N
min: NN N
r NN N
= VBD N
0 CD N
67 CD N
p NN N
< VBD N
0 CD N
01) CD N
. . N

We PRP N
found VBN N
by IN N
means NNS N
of IN N
clinic NN N
and CC N
measurement NN N
methods NNS N
in IN N
the DT N
aR NN I
of IN N
7 CD P
patients NNS P
a DT P
positive JJ P
reaction NN P
within IN P
7 CD P
patient NN P
a DT P
negative JJ P
reaction NN P
3 CD P
patients NNS P
had VBD P
a DT P
unspecific JJ P
nasal NN P
hyperreactivity NN P
. . P

There EX N
was VBD N
a DT N
correspondence NN N
in IN N
6 CD P
of IN P
the DT P
7 CD P
patients NNS P
with IN P
positive JJ P
reaction NN P
in IN P
aR NN I
between IN N
both DT N
methods NNS N
. . N

4 CD P
of IN P
the DT P
7 CD P
results NNS P
with IN P
negative JJ P
reaction NN P
in IN N
the DT N
aR NN N
would MD N
have VB N
been VBN N
positive JJ N
then RB N
underlying VBG N
the DT N
same JJ N
criteria NNS N
in IN N
the DT N
IOS NNP I
without IN N
announcing VBG N
the DT N
symptomscore NN N
a DT N
relevant JJ N
clinical JJ N
symptomatic NN N
while IN N
testing VBG N
. . N

CONCLUSION NNP N
IOS NNP I
is VBZ N
a DT N
suitable JJ N
procedure NN N
for IN N
nasal JJ N
provocation NN N
testing VBG N
and CC N
provides VBZ N
results NNS N
similar JJ N
to TO N
the DT N
aR NN N
. . N

In IN N
comparison NN N
to TO N
aR VB I
IOS NNP I
is VBZ N
not RB N
dependent JJ N
on IN N
the DT N
patients NNS N
cooperation NN N
. . N

Due JJ N
to TO N
its PRP$ N
higher JJR N
sensitivity NN N
the DT N
valid JJ N
limits NNS N
of IN N
the DT N
aR NN N
at IN N
provocation NN N
testings NNS N
cannot VBP N
be VB N
transferred VBN N
to TO N
IOS NNP I
to TO N
avoid VB N
a DT N
false JJ N
positive JJ N
reaction NN N
. . N

-DOCSTART- -X- N

Granulocyte-macrophage JJ I
colony-stimulating JJ I
factor NN I
as IN N
immunomodulating VBG N
factor NN N
together RB N
with IN N
influenza JJ I
vaccination NN I
in IN P
stem NN P
cell NN P
transplant NN P
patients NNS P
. . P

The DT N
effect NN N
of IN N
granulocyte-macrophage JJ I
colony-stimulating JJ I
factor NN I
(GM-CSF) NN I
on IN N
the DT N
serological JJ N
response NN N
at IN N
influenza JJ I
vaccination NN I
was VBD N
studied VBN N
in IN P
117 CD P
patients NNS P
who WP P
had VBD P
undergone JJ P
stem NN P
cell NN P
transplantation NN P
(SCT) NN P
. . P

The DT N
vaccine NN I
response NN N
was VBD N
evaluated VBN N
as IN N
significant JJ N
increases NNS N
in IN N
levels NNS N
of IN N
influenza JJ I
hemagglutination-inhibition NN I
(HAI) NN I
antibodies NNS N
and CC N
of IN N
IgG NNP N
antibodies NNS N
measured VBN N
by IN N
enzyme-linked JJ I
immunosorbent NN I
assay NN I
(ELISA) NN I
. . I

There EX N
was VBD N
no DT N
difference NN N
in IN N
antibody NN O
response NN O
to TO N
either DT N
influenza VB I
A NNP I
or CC I
B NNP I
in IN N
64 CD N
patients NNS N
who WP N
received VBD N
GM-CSF NNP I
at IN I
vaccination NN I
compared VBN I
with IN N
the DT N
53 NNS N
who WP N
did VBD N
not RB N
. . N

In IN N
the DT N
subgroup NN P
of IN P
allogeneic JJ P
SCT NNP P
patients NNS P
HAI NNP P
showed VBD N
that IN N
the DT N
response NN O
rate NN O
to TO N
the DT N
influenza NN I
B NNP I
vaccine NN I
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
treatment NN N
group NN N
(P<.05) NNP N
. . N

ELISA NN N
showed VBD N
that IN N
autologous JJ P
SCT NNP P
patients NNS P
with IN P
breast JJ P
cancer NN P
who WP N
received VBD N
GM-CSF NNP I
had VBD N
a DT N
better JJR N
response NN N
to TO N
influenza VB I
A NNP I
(P<.05) NNP N
and CC N
B NNP N
(P<.01) NNP N
. . N

At IN N
early JJ N
vaccination NN I
4-12 JJ I
months NNS N
after IN N
stem NN N
cell NN N
transplantation NN N
these DT N
responses NNS N
were VBD N
more RBR N
pronounced JJ N
. . N

GM-CSF JJ I
appears VBZ N
to TO N
improve VB N
the DT N
response NN N
to TO N
influenza VB I
vaccination NN I
in IN N
some DT N
groups NNS N
of IN N
SCT NNP P
patients NNS P
but CC P
only RB N
to TO N
a DT N
limited JJ N
extent NN N
. . N

-DOCSTART- -X- N

Cardiovascular JJ N
effects NNS N
of IN N
non-depolarizing JJ I
neuromuscular JJ I
blockers NNS I
in IN N
patients NNS P
with IN P
aortic JJ P
valve NN P
disease NN P
. . P

To TO N
compare VB N
haemodynamic JJ N
responses NNS N
associated VBN N
with IN N
equipotent JJ N
doses NNS N
of IN N
neuromuscular JJ I
blockers NNS I
and CC I
high-dose JJ I
fentanyl NN I
(50 NNP N
micrograms.kg-1) JJ N
40 CD P
patients NNS P
with IN P
aortic JJ P
valve NNS P
stenosis NN P
(AS) NN P
and CC P
20 CD P
patients NNS P
with IN P
aortic JJ P
insufficiency NN P
(AI) NNP P
were VBD N
randomized VBN N
to TO N
four CD N
study NN N
groups NNS N
to TO N
receive VB N
the DT N
following: NN N
(1) NNP N
pancuronium NN I
0.12 CD I
mg.kg-1 JJ I
(2) NNP I
vecuronium NN I
0.12 CD I
mg.kg-1 JJ I
(3) NNP I
atracurium NN I
0.4 CD I
mg.kg-1 NN I
or CC I
(4) VB I
pancuronium-metocurine JJ I
mixture NN I
(0.4 NNP I
mg NN I
+ VBD I
1.6 CD I
mg/ml): NN I
1 CD I
ml/10 NN I
kg) NN I
. . I

Neuromuscular JJ I
blockers NNS I
were VBD I
injected VBN I
at IN I
the DT I
same JJ I
time NN I
with IN I
the DT I
fentanyl; NN I
haemodynamics NNS N
were VBD N
recorded VBN N
with IN N
the DT N
patients NNS N
awake VBP N
(baseline) NNS N
at IN N
two CD N
minutes NNS N
post-induction JJ N
and CC N
at IN N
two CD N
and CC N
five CD N
minutes NNS N
after IN N
intubation NN N
. . N

In IN N
patients NNS P
with IN P
AS NNP P
pancuronium NN P
increased VBD N
heart NN O
rate NN O
more JJR N
than IN N
vecuronium NN I
or CC N
atracurium; JJ I
heart NN O
rates NNS O
were VBD N
also RB N
higher JJR N
with IN N
the DT N
pancuronium-metocurine JJ I
mixture NN I
than IN I
with IN I
vecuronium NN I
. . I

Although IN N
there EX N
were VBD N
no DT N
ECG NNP N
signs NNS N
of IN N
ischaemia NN O
one CD O
patient NN N
given VBN N
pancuronium NN I
developed VBD N
severe JJ O
hypotension NN O
associated VBN O
with IN O
tachycardia NN O
. . O

Reductions NNS N
in IN N
SVR NNP N
after IN N
atracurium NN I
allowed VBD N
small JJ N
but CC N
significant JJ N
(p NNP N
less JJR N
than IN N
0.01) CD N
decreases NNS N
in IN N
MAP NNP O
which WDT N
were VBD N
well RB N
tolerated; JJ N
one CD N
patient NN N
however RB N
did VBD N
develop VB N
severe JJ O
hypotension NN O
. . O

Intubation NN N
resulted VBD N
in IN N
significant JJ N
(p NN N
less JJR N
than IN N
0.01) CD N
increases NNS N
in IN N
MAP NNP O
in IN N
the DT N
pancuronium-metocurine JJ I
mixture NN I
group NN N
. . N

Vecuronium NN I
permitted VBD N
the DT N
most RBS N
stable JJ N
overall JJ N
haemodynamic JJ O
course NN N
at IN N
all DT N
measurement JJ N
times NNS N
. . N

In IN N
contrast NN N
patients NNS N
with IN N
AI NNP N
showed VBD N
stable JJ N
haemodynamics NNS O
after IN N
vecuronium NN I
pancuronium NN I
and CC I
the DT I
pancuronium-metocurine JJ I
mixture; NN I
one CD N
patient NN N
became VBD N
tachycardic JJ O
following VBG N
vecuronium NN I
. . I

Atracurium NN I
caused VBD N
unexplained JJ N
elevations NNS O
in IN O
diastolic JJ O
and CC O
mean JJ O
arterial NN O
pressures NNS O
which WDT N
were VBD N
significant JJ N
when WRB N
compared VBN N
to TO N
vecuronium VB I
(p NNP N
less JJR N
than IN N
0.01) CD N
. . N

These DT N
results NNS N
in IN N
increases NNS N
in IN N
PCWP; NNP O
mean JJ O
PA NNP O
pressures NNS O
and CC O
CVP NNP O
were VBD N
also RB N
increased VBN N
. . N

These DT N
effects NNS N
of IN N
atracurium NN I
inpatients NNS N
with IN N
Al NNP N
need VBP N
further JJ N
evaluation NN N
. . N

-DOCSTART- -X- N

Comparison NNP O
of IN N
high JJ N
and CC N
low JJ N
dose NN N
of IN N
the DT N
inhaled JJ I
steroid NN I
budesonide NN I
as IN I
an DT N
initial JJ N
treatment NN N
in IN N
newly RB P
detected VBN P
asthma NN P
. . P

The DT P
importance NN O
of IN N
early JJ N
initiation NN N
of IN N
inhaled JJ I
steroids NNS I
even RB N
in IN N
mild JJ N
asthma NN O
has VBZ N
been VBN N
documented VBN N
in IN N
several JJ N
studies NNS N
. . N

It PRP N
is VBZ N
not RB N
however RB N
clear JJ N
whether IN N
the DT N
treatment NN N
should MD N
be VB N
started VBN N
with IN N
a DT N
high JJ N
or CC N
a DT N
low JJ N
dose NN N
of IN N
the DT N
inhaled JJ N
steroid NN N
. . N

We PRP N
have VBP N
compared VBN O
the DT O
effects NNS O
of IN N
high JJ I
and CC I
low JJ I
dose NN I
inhaled VBN I
steroid JJ I
budesonide NN I
in IN I
patients NNS P
with IN P
newly RB P
detected VBN P
asthma NN P
. . P

We PRP N
studied VBD N
101 CD P
adult NN P
patients NNS P
with IN P
newly RB P
detected VBN P
bronchial JJ P
asthma NN P
who WP P
were VBD P
without IN P
inhaled VBN P
steroid NN P
or CC P
any DT P
regular JJ P
pharmacological JJ P
treatment NN P
for IN P
their PRP$ P
asthma NN P
. . P

The DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
treatment NN N
groups: VBD N
one CD N
to TO N
receive VB N
800 CD I
microg NN I
inhaled VBD I
budesonide JJ I
per IN I
day NN I
and CC N
the DT N
other JJ N
to TO N
receive VB N
200 CD I
microg NN I
inhaled VBD I
budesonide JJ I
per IN I
day NN N
. . N

The DT N
drugs NNS N
were VBD N
given VBN N
with IN N
a DT N
Turbuhaler NNP O
dry JJ O
powder NN O
inhaler NN O
. . O

During IN N
the DT N
3-month JJ N
treatment NN N
period NN N
no DT O
significant JJ O
differences NNS O
between IN N
the DT N
treatment NN N
groups NNS N
were VBD N
noted VBN N
in IN N
morning NN O
or CC O
evening NN O
PEF NNPS O
values NNS O
in IN O
spirometric JJ O
parameters NNS O
in IN O
asthmatic JJ O
symptoms NNS O
or CC O
in IN O
the DT O
use NN O
of IN O
rescue NN O
beta2-agonists NNS O
. . O

The DT N
decrease NN O
in IN O
bronchial JJ O
hyperresponsiveness NN O
was VBD O
however RB O
more JJR O
marked VBN O
in IN N
the DT N
high JJ N
dose JJ N
budesonide NN I
group NN N
reaching VBG N
a DT N
borderline NN O
significance NN O
(P=0.10 NNP N
high JJ N
vs NN N
. . N

low JJ N
dose NN N
budesonide) NN I
. . N

In IN N
addition NN N
in IN N
serum JJ O
markers NNS O
of IN O
asthmatic JJ O
inflammation NN O
significant JJ O
differences NNS O
were VBD N
shown VBN N
between IN N
the DT N
treatment NN N
groups NNS N
. . N

The DT N
decrease NN O
in IN O
the DT O
number NN O
of IN O
blood NN O
eosinophils NNS O
during IN O
the DT O
treatment NN O
was VBD O
more RBR O
marked JJ O
in IN N
the DT N
high JJ N
dose JJ N
budesonide NN I
group NN N
(P=0.02; NNP N
high JJ N
vs NN N
. . N

low JJ N
dose NN N
budesonide) NN I
. . N

In IN N
serum JJ O
ECP NNP O
no DT O
change NN O
was VBD O
observed VBN O
in IN N
the DT N
low JJ N
dose JJ N
budesonide NN I
group NN N
but CC N
a DT N
marked JJ O
decrease NN O
in IN N
the DT N
high-dose JJ N
budesonide NN N
group NN N
(P=0.008; NNP N
high JJ N
vs NN N
. . N

low JJ N
dose NN N
budesonide) NN I
. . N

The DT N
change NN O
was VBD O
even RB O
more JJR O
marked JJ O
with IN O
regard NN O
to TO O
serum VB O
EPX NNP O
(P=0.005; NNP N
high JJ N
vs NN N
. . N

low JJ N
dose NN N
budesonide) NN N
. . N

Our PRP$ N
results NNS O
support VB N
the DT N
view NN N
that IN N
the DT N
treatment NN N
of IN N
newly RB N
detected VBN N
asthma NN N
should MD N
be VB N
started VBN N
with IN N
a DT N
high JJ N
dose NN N
of IN N
inhaled JJ N
steroid NN N
. . N

The DT N
low JJ N
dose NN N
may MD N
not RB N
be VB N
enough RB N
to TO N
suppress VB O
asthmatic JJ O
inflammation NN O
despite IN N
good JJ O
clinical JJ O
primary JJ O
response NN O
. . O

-DOCSTART- -X- N

The DT N
effect NN N
of IN N
vitamin JJ I
A-fortified NNP I
coconut NN I
cooking VBG I
oil NN I
on IN N
the DT N
serum NN P
retinol JJ P
concentration NN P
of IN P
Filipino NNP P
children NNS P
4-7 CD P
years NNS P
old JJ P
. . P

A DT P
6-month JJ N
intervention NN N
trial NN N
was VBD N
conducted VBN N
among IN N
542 CD P
Filipino NNP P
children NNS P
aged VBD P
4 CD P
to TO P
7 CD P
years NNS P
to TO N
determine VB N
the DT N
effect NN N
of IN N
vitamin JJ I
A-fortified NNP I
coconut NN I
cooking VBG I
oil NN I
intake NN N
on IN N
their PRP$ N
vitamin NN N
A DT N
status NN N
and CC N
to TO N
identify VB N
factors NNS N
that WDT N
influence NN N
this DT N
. . N

Children NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
Experimental NNP I
group NN I
with IN I
vitamin JJ I
A-fortified JJ I
cooking NN I
oil NN I
ration; NN I
to TO N
Control-1 NNP I
group NN I
with IN I
unfortified JJ I
cooking NN I
oil NN I
ration; NN I
and CC N
to TO N
Control-2 NNP I
group NN I
without IN I
cooking VBG I
oil NN I
ration NN I
. . I

In IN N
all DT N
groups NNS N
children's VBP N
serum JJ N
retinol NN O
concentration NN O
improved VBD N
. . N

Relative JJ N
change NN N
in IN N
serum NN O
retinol NN O
concentration NN O
was VBD N
significantly RB N
higher JJR N
among IN N
the DT N
Experimental NNP I
group NN I
with IN I
one-third NN N
of IN N
total JJ N
vitamin FW N
A DT N
intake NN N
coming VBG N
from IN N
vitamin JJ I
A-fortified JJ I
cooking NN I
oil NN I
intake NN N
than IN N
in IN N
the DT N
Control NNP I
groups NNS I
with IN I
more JJR N
than IN N
half NN N
of IN N
intake NN N
from IN N
other JJ N
vitamin JJ N
A-rich JJ N
foods NNS N
. . N

Determinants NNS N
of IN N
post-intervention NN N
serum NN N
retinol NN N
concentration NN N
included VBD N
baseline JJ N
serum NN N
retinol NN N
concentration NN N
caregiver's NN N
education NN N
receipt NN N
of IN N
high-dose JJ N
vitamin NN N
A NNP N
capsule NN N
interaction NN N
between IN N
consumption NN N
of IN N
vitamin JJ I
A-fortified JJ I
cooking NN I
oil NN I
and CC N
of IN N
other JJ N
vitamin JJ I
A-rich NNP I
foods NNS I
and CC I
between IN N
households NNS N
purchasing VBG N
cooking JJ N
oil NN N
and CC N
food NN N
expenditure NN N
. . N

Intake NNP I
of IN I
vitamin JJ I
A-fortified JJ I
cooking NN I
oil NN I
combined VBN N
with IN N
vitamin JJ I
A-rich NNP I
foods NNS I
was VBD N
necessary JJ N
to TO N
increase VB N
serum NN O
retinol JJ O
concentration NN O
. . O

It PRP N
is VBZ N
recommended VBN N
to TO N
vigorously RB N
promote VB N
the DT N
consumption NN N
of IN N
vitamin JJ I
A-fortified JJ I
cooking NN I
oil NN I
together RB N
with IN N
other JJ N
vitamin JJ I
A-rich JJ I
sources NNS I
to TO N
sustain VB N
the DT N
prevention NN N
and CC N
control NN N
of IN N
vitamin FW N
A DT N
deficiency NN N
. . N

-DOCSTART- -X- N

Is VBZ N
EEG-biofeedback NNP I
an DT N
effective JJ N
treatment NN N
in IN N
autism NN P
spectrum NN P
disorders VBZ P
A NNP P
randomized NN N
controlled VBN N
trial NN N
. . N

EEG-biofeedback NN I
has VBZ N
been VBN N
reported VBN N
to TO N
reduce VB N
symptoms NNS N
of IN N
autism NN P
spectrum NN P
disorders NNS P
(ASD) VBP P
in IN N
several JJ N
studies NNS N
. . N

However RB N
these DT N
studies NNS N
did VBD N
not RB N
control VB N
for IN N
nonspecific JJ N
effects NNS N
of IN N
EEG-biofeedback NNP I
and CC N
did VBD N
not RB N
distinguish VB N
between IN N
participants NNS N
who WP N
succeeded VBD N
in IN N
influencing VBG N
their PRP$ N
own JJ N
EEG NNP N
activity NN N
and CC N
participants NNS N
who WP N
did VBD N
not RB N
. . N

To TO N
overcome VB N
these DT N
methodological JJ N
shortcomings NNS N
this DT N
study NN N
evaluated VBD N
the DT N
effects NNS O
of IN N
EEG-biofeedback NNP N
in IN N
ASD NNP N
in IN N
a DT N
randomized JJ N
pretest-posttest JJ N
control NN N
group NN N
design NN N
with IN N
blinded JJ N
active JJ N
comparator NN N
and CC N
six CD N
months NNS N
follow-up RB N
. . N

Thirty-eight JJ P
participants NNS P
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
EEG-biofeedback NNP I
skin NN I
conductance NN I
(SC)-biofeedback NN I
or CC I
waiting VBG I
list NN I
group NN I
. . I

EEG- JJ I
and CC I
SC-biofeedback JJ I
sessions NNS I
were VBD N
similar JJ N
and CC N
participants NNS N
were VBD N
blinded VBN N
to TO N
the DT N
type NN N
of IN N
feedback NN N
they PRP N
received VBD N
. . N

Assessments NNS N
pre-treatment JJ N
post-treatment JJ N
and CC N
after IN N
6 CD N
months NNS N
included VBN N
parent JJ O
ratings NNS O
of IN O
symptoms NNS O
of IN O
ASD NNP O
executive NN O
function NN O
tasks NNS O
and CC O
19-channel JJ O
EEG NNP O
recordings NNS O
. . O

Fifty-four CD N
percent NN N
of IN N
the DT N
participants NNS N
significantly RB N
reduced VBD N
delta JJ O
and/or NN O
theta NN O
power NN O
during IN N
EEG-biofeedback JJ I
sessions NNS I
and CC N
were VBD N
identified VBN N
as IN N
EEG-regulators NNS I
. . I

In IN N
these DT N
EEG-regulators NNS I
no DT I
statistically RB N
significant JJ N
reductions NNS N
of IN N
symptoms NNS O
of IN O
ASD NNP O
were VBD N
observed VBN N
but CC N
they PRP N
showed VBD N
significant JJ N
improvement NN N
in IN N
cognitive JJ O
flexibility NN O
as IN N
compared VBN N
to TO N
participants NNS N
who WP N
managed VBD N
to TO N
regulate VB N
SC NNP N
. . N

EEG-biofeedback NN I
seems VBZ N
to TO N
be VB N
an DT N
applicable JJ N
tool NN N
to TO N
regulate VB N
EEG NNP N
activity NN N
and CC N
has VBZ N
specific JJ N
effects NNS N
on IN N
cognitive JJ O
flexibility NN O
but CC O
it PRP N
did VBD N
not RB N
result VB N
in IN N
significant JJ N
reductions NNS N
in IN N
symptoms NNS O
of IN O
ASD NNP O
. . O

An DT N
important JJ N
finding NN N
was VBD N
that IN N
no DT N
nonspecific JJ N
effects NNS N
of IN N
EEG-biofeedback NNP I
were VBD N
demonstrated VBN N
. . N

-DOCSTART- -X- N

A DT N
preliminary JJ N
trial NN N
of IN N
ascorbic JJ I
acid NN I
as IN N
supplemental JJ N
therapy NN N
for IN N
autism NN P
. . P

1 CD N
. . N

This DT N
study NN N
presents VBZ N
the DT N
results NNS N
of IN N
a DT N
30-week JJ N
double-blind JJ N
placebo-controlled JJ I
trial NN N
exploring VBG N
the DT N
effectiveness NN N
of IN N
ascorbic JJ I
acid JJ I
(8g/70kg/day) NN N
as IN N
a DT N
supplemental JJ N
pharmacological JJ N
treatment NN N
for IN N
autistic JJ P
children NNS P
in IN P
residential JJ P
treatment NN P
. . P

2 CD N
. . N

Residential JJ P
school NN P
children NNS P
(N VBP P
= $ P
18) CD P
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
ascorbate-ascorbate-placebo JJ I
treatment NN I
order NN I
group NN I
or CC I
ascorbate-placebo-ascorbate JJ I
treatment NN I
order NN I
group NN I
. . I

Each DT N
treatment NN N
phase NN N
lasted VBD N
10 CD N
weeks NNS N
and CC N
behaviors NNS N
were VBD N
rated VBN N
weekly JJ N
using VBG N
the DT N
Ritvo-Freeman NNP N
scale NN N
. . N

3 CD N
. . N

Significant NNP N
group NN N
by IN N
phase NN N
interactions NNS N
were VBD N
found VBN N
for IN N
total JJ N
scores NNS N
and CC N
also RB N
sensory JJ O
motor NN O
scores NNS O
indicating VBG N
a DT N
reduction NN N
in IN N
symptom JJ O
severity NN O
associated VBN N
with IN N
the DT N
ascorbic JJ I
acid NN I
treatment NN I
. . I

4 CD N
. . N

These DT N
results NNS N
were VBD N
consistent JJ N
with IN N
a DT N
hypothesized VBN N
dopaminergic NN N
mechanism NN N
of IN N
action NN N
of IN N
ascorbic JJ I
acid NN I
. . I

-DOCSTART- -X- N

Reducing VBG I
breast NN P
cancer NN P
recurrence NN I
with IN I
weight JJ I
loss NN I
a DT I
vanguard NN N
trial: IN N
the DT N
Exercise NNP N
and CC N
Nutrition NNP N
to TO N
Enhance VB N
Recovery NNP N
and CC N
Good NNP N
Health NNP N
for IN N
You PRP N
(ENERGY) VBP N
Trial JJ N
. . N

Breast NNP N
cancer NN N
is VBZ N
the DT N
most RBS N
common JJ N
invasive JJ N
cancer NN N
among IN N
women NNS N
in IN N
developed JJ N
countries NNS N
. . N

Obesity NN N
is VBZ N
a DT N
major JJ N
risk NN N
factor NN N
for IN N
breast NN N
cancer NN N
recurrence NN N
and CC N
mortality NN N
in IN N
both DT N
pre- JJ P
and CC P
postmenopausal JJ P
women NNS P
. . P

Co-morbid NNP N
medical JJ N
conditions NNS N
are VBP N
common JJ N
among IN N
breast JJ N
cancer NN N
survivors NNS N
. . N

The DT N
Exercise NNP N
and CC N
Nutrition NNP N
to TO N
Enhance VB N
Recovery NNP N
and CC N
Good NNP N
Health NNP N
for IN N
You PRP N
(ENERGY) VBP N
study NN N
is VBZ N
a DT N
4-year JJ N
randomized JJ N
clinical JJ N
trial NN N
of IN P
693 CD P
overweight/obese JJ P
women NNS P
aged VBN P
21years NNS P
diagnosed VBD P
with IN P
any DT P
early JJ P
stage NN P
breast NN P
cancer NN P
(stages VBZ P
I[1cm]-III) NNP P
within IN P
the DT P
previous JJ P
five CD P
years NNS P
designed VBN N
to TO N
demonstrate VB N
the DT N
feasibility NN N
of IN N
achieving VBG N
sustained JJ N
weight JJ N
loss NN N
and CC N
to TO N
examine VB N
the DT N
impact NN N
of IN N
weight JJ N
loss NN N
on IN N
quality NN N
of IN N
life NN N
and CC N
co-morbidities NNS N
and CC N
to TO N
enable VB N
future JJ N
exploration NN N
of IN N
biochemical JJ N
mechanisms NNS N
linking VBG N
obesity NN N
to TO N
lower JJR N
likelihood NN N
of IN N
disease-free JJ N
survival NN N
. . N

This DT N
trial NN N
is VBZ N
strategically RB N
designed VBN N
as IN N
a DT N
vanguard NN N
for IN N
a DT N
fully-powered JJ N
trial NN N
of IN N
women NNS N
who WP N
will MD N
be VB N
evaluated VBN N
for IN O
breast NN O
cancer NN O
recurrence NN O
and CC O
disease-free JJ O
survival NN P
. . P

Participants NNS P
were VBD P
recruited VBN P
between IN P
2010 CD P
and CC P
2012 CD P
at IN P
four CD P
sites NNS P
had VBD P
completed VBN P
initial JJ P
therapies NNS P
and CC P
had VBD P
a DT P
body NN P
mass NN P
index NN P
between IN P
25 CD P
and CC P
45kg/m(2) CD P
. . N

The DT N
intervention NN N
featured VBD I
a DT I
group-based JJ I
cognitive-behavioral JJ I
weight JJ I
loss NN I
program NN I
with IN I
telephone NN I
counseling NN I
and CC I
tailored VBD I
newsletters NNS I
to TO I
support VB I
initial JJ I
weight NN I
loss NN I
and CC I
subsequent JJ I
maintenance NN I
with IN I
the DT I
goal NN I
of IN I
7% CD I
weight JJ I
loss NN I
at IN I
two CD I
years NNS I
. . N

This DT N
study NN N
has VBZ N
high JJ N
potential NN N
to TO N
have VB N
a DT N
major JJ N
impact NN I
on IN I
clinical JJ I
management NN I
and CC N
outcomes NNS N
after IN N
a DT N
breast NN N
cancer NN N
diagnosis NN N
. . N

This DT N
trial NN N
initiates VBZ N
the DT N
effort NN I
to TO I
establish VB I
weight NN I
loss NN I
support NN I
for IN P
overweight NN P
or CC P
obese JJ P
breast NN P
cancer NN P
survivors NNS P
as IN N
a DT N
new JJ N
standard NN N
of IN N
clinical JJ N
care NN N
. . N

-DOCSTART- -X- N

[Efficacy NN N
of IN N
immunomodulating VBG I
treatment NN I
in IN N
patients NNS P
with IN P
different JJ P
degrees NNS P
of IN P
immunosuppression] NN P
. . N

Immunodepression NN N
is VBZ N
a DT N
common JJ N
condition NN N
in IN N
patients NNS P
undergoing JJ P
elective JJ P
operations NNS P
and CC N
it PRP N
constitutes VBZ N
a DT N
high JJ N
risk NN N
for IN N
the DT N
onset NN N
of IN N
postoperative JJ N
infective JJ N
complications NNS N
. . N

The DT N
use NN N
of IN N
immunomodulatory NN I
drugs NNS I
has VBZ N
proved VBN N
useful JJ N
in IN N
the DT N
prophylaxis NN N
of IN N
these DT N
complications NNS N
although IN N
the DT N
precise JJ N
indications NNS N
for IN N
each DT N
drug NN N
have VBP N
not RB N
yet RB N
been VBN N
clearly RB N
codified VBN N
. . N

The DT N
present JJ N
study NN N
aimed VBN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
thymostimulin NN I
in IN N
patients NNS P
with IN P
different JJ P
degrees NNS P
of IN P
immunodepression NN P
by IN P
evaluating VBG N
both PDT N
the DT N
incidence NN N
of IN N
postoperative JJ O
infections NNS O
and CC N
the DT N
changes NNS N
induced VBN N
in IN N
various JJ N
immunological JJ N
parameters NNS N
. . N

The DT N
results NNS N
obtained VBD N
indicated JJ N
that IN N
those DT N
subjects NNS N
with IN N
the DT N
highest JJS N
degree NN N
of IN N
immunodepression NN N
(hypo-anergic) NN N
benefited VBD N
most JJS N
from IN N
drug NN I
therapy NN I
in IN N
comparison NN N
to TO N
those DT N
with IN N
a DT N
lesser JJR N
degree NN N
of IN N
immunodepression NN N
(relatively RB N
hypo-ergic) JJ N
. . N

The DT N
advantages NNS N
were VBD N
evident JJ N
in IN N
hypo-anergic JJ N
subjects NNS N
both DT N
with IN N
regard NN N
to TO N
the DT N
frequency NN N
of IN N
early JJ O
postoperative JJ O
infections NNS O
and CC O
with IN N
regard NN N
to TO N
immunological JJ N
parameters NNS N
. . N

On IN N
the DT N
other JJ N
hand NN N
in IN N
relatively RB N
hypo-ergic JJ N
subjects NNS N
benefits NNS N
were VBD N
limited VBN N
to TO N
the DT N
improvement NN N
of IN N
some DT N
immunological JJ O
parameters NNS O
. . O

In IN N
our PRP$ N
opinion NN N
the DT N
use NN N
of IN N
thymostimulin NN I
is VBZ N
of IN N
particular JJ N
use NN N
only RB N
in IN N
those DT N
subjects NNS N
with IN N
marked JJ N
immunodepression NN N
since IN N
the DT N
incidence NN N
of IN N
post-operative JJ O
sepsis NN O
is VBZ N
highest JJS N
in IN N
this DT N
group NN N
. . N

-DOCSTART- -X- N

Pulsed VBN I
electromagnetic JJ I
fields NNS I
for IN N
postmenopausal NN P
osteoporosis NN P
and CC P
concomitant JJ P
lumbar NN P
osteoarthritis NN P
in IN P
southwest JJ P
China NNP P
using VBG N
proximal JJ O
femur NN O
bone NN O
mineral JJ O
density NN O
as IN N
the DT N
primary JJ N
endpoint: NN N
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Osteoporosis NNP P
(OP) NNP P
and CC P
osteoarthritis NN P
(OA) NNS P
are VBP N
prevalent JJ N
skeletal JJ N
disorders NNS N
among IN N
postmenopausal JJ P
women NNS P
. . P

Coexistence NN N
is VBZ N
common JJ N
especially RB N
that IN N
of IN N
postmenopausal JJ N
osteoporosis NN N
(PMO) NN N
and CC N
lumbar NN N
OA NNP N
. . N

An DT N
hypothesis NN N
has VBZ N
been VBN N
raised VBN N
that IN N
OP NNP N
and CC N
OA NNP N
might MD N
share NN N
the DT N
same JJ N
pathogenic JJ N
mechanism NN N
and CC N
pulsed VBD I
electromagnetic JJ I
fields NNS I
(PEMFs) WDT I
were VBD N
reported VBN N
to TO N
have VB N
anti-osteoporosis NN N
and CC N
anti-osteoarthritis NN N
properties NNS N
but CC N
this DT N
suggestion NN N
was VBD N
based VBN N
primarily RB N
on IN N
biomarker NN N
data NNS N
. . N

Therefore RB N
whether IN N
these DT N
two CD N
effects NNS N
could MD N
take VB N
place NN N
simultaneously RB N
has VBZ N
not RB N
yet RB N
been VBN N
investigated VBN N
. . N

This DT N
randomized VBD N
controlled JJ N
trial NN N
(RCT) NN N
is VBZ N
designed VBN N
to TO N
explore VB N
the DT N
effect NN N
of IN N
PEMFs NNP I
for IN N
PMO NNP N
and CC N
concomitant JJ N
lumbar NN N
OA NNP N
. . N

METHODS/DESIGN NNP N
The DT N
study NN N
will MD N
include VB N
PMO NNP P
patients NNS P
(postmenopausal VBP P
women; RB P
aged VBN P
between IN P
50 CD P
and CC P
70 CD P
years; NNS P
have VBP P
been VBN P
postmenopausal VBN P
for IN P
at IN P
least JJS P
5 CD P
years NNS P
and CC P
diagnosed VBD P
with IN P
OP NNP P
using VBG P
proximal JJ P
femur JJ P
T-score) NN P
with IN P
concomitant JJ P
lumbar NN P
OA NNP P
(patients NNS P
with IN P
confounding VBG P
disorders NNS P
like IN P
diabetes NNS P
hypertension VBP P
hyperlipidemia NN P
and CC P
previous JJ P
fracture NN P
history NN P
etcetera NN P
will MD P
be VB N
excluded) VBN N
will MD N
be VB N
randomly RB N
assigned VBN N
to TO N
two CD N
arms: NNS N
PEMFs NNP I
group NN I
and CC N
sham NN I
PEMFs NNP I
group NN I
. . I

There EX N
will MD N
be VB N
25 CD P
participants NNS P
in IN P
each DT P
arm NN P
(50 NN P
in IN P
total) NN P
and CC N
the DT N
outcome NN N
assessment NN N
including VBG N
the DT N
primary JJ N
endpoint NN N
(proximal JJ O
femur NN O
bone NN O
mineral NN O
density) NN O
will MD N
be VB N
performed VBN N
at IN N
5 CD N
weeks NNS N
3 CD N
months NNS N
and CC N
6 CD N
months NNS N
after IN N
enrollment NN N
. . N

DISCUSSION NNP N
PMO NNP N
and CC N
lumbar NN N
OA NNP N
are VBP N
prominent JJ N
public JJ N
health NN N
problem NN N
especially RB N
for IN N
postmenopausal JJ P
women NNS P
. . P

We PRP N
hope VBP N
this DT N
RCT NNP N
will MD N
provide VB N
scientific JJ N
evidence NN N
to TO N
primary JJ N
care NN N
of IN N
the DT N
postmenopausal JJ N
women NNS N
regarding VBG N
the DT N
use NN N
of IN N
these DT N
nonpharmaceutical JJ I
noninvasive NN I
modalities NNS I
PEMFs NNP I
in IN I
managing VBG N
PMO NNP N
and CC N
lumbar NN N
OA NNP N
. . N

TRIAL NNP N
REGISTRATION NNP N
Chinese NNP N
Clinical NNP N
Trial NNP N
Registry: NNP N
ChiCTR-TRC-14005156 NNP N
(28 NNP N
August NNP N
2014) CD N
. . N

-DOCSTART- -X- N

[Effect NN N
of IN N
Yufeining VBG I
on IN N
induced JJ N
sputum JJ N
interleukin-8 NN N
in IN N
patients NNS P
with IN P
chronic JJ P
obstructive JJ P
pulmonary JJ P
disease NN P
at IN P
the DT P
stable JJ P
phase] NN P
. . P

OBJECTIVE NN P
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
Yufeining VBG I
a DT I
traditional JJ N
Chinese JJ N
medicine NN N
on IN N
induced JJ N
sputum JJ N
interleukin-8 JJ N
(IL-8) NN N
in IN N
patients NNS P
with IN P
chronic JJ P
obstructive JJ P
pulmonary JJ P
disease NN P
(COPD) NN P
at IN P
the DT P
stable JJ P
phase NN P
. . P

METHODS NNP N
Thirty-six JJ P
patients NNS P
with IN P
COPD NNP P
were VBD P
divided VBN P
into IN P
trial NN P
group NN P
(18 NNP P
cases) NN P
and CC P
control NN P
group NN P
(18 NNP P
cases) NN P
randomly RB P
. . P

The DT N
trial NN N
group NN N
was VBD N
treated VBN N
with IN N
Yufeining VBG I
pills NNS I
taken VBN I
orally RB I
for IN I
half PDT I
a DT I
year; JJ I
the DT I
control NN I
group NN I
was VBD I
not RB I
given VBN I
any DT I
medicine NN I
. . I

Routine NNP N
lung NN O
function NN O
was VBD N
recorded VBN N
before IN N
and CC N
after IN N
treatment NN N
. . N

Total JJ O
cell NN O
count NN O
(TCC) NNP O
differential NN O
cell NN O
counts VBZ O
(DCCs) JJ O
and CC O
IL-8 NNP O
in IN O
induced JJ O
sputum NN O
were VBD N
determined VBN N
at IN N
the DT N
baseline NN N
and CC N
6 CD N
months NNS N
later RB N
. . N

RESULTS VB N
The DT N
indices NNS O
of IN O
lung NN O
function NN O
improved VBD N
significantly RB N
after IN N
6 CD N
months' NN N
treatment NN N
in IN N
trial NN N
group NN N
(P NNP N
< VBZ N
0.05); CD N
TCC NNP O
and CC O
absolute JJ O
neutrophil NN O
count NN O
decreased VBD N
significantly RB N
compared VBN N
with IN N
baseline NN N
in IN N
the DT N
trial NN N
group NN N
(P NNP N
< VBZ N
0.05); CD N
Sputum NNP O
IL-8 NNP O
concentration NN O
dropped VBD N
significantly RB N
after IN N
6 CD N
months' JJ N
treatment NN N
from IN N
a DT N
mean NN N
of IN N
5.216 CD N
+/- JJ N
2.914 CD N
microg/L NN N
to TO N
4.222 CD N
+/- JJ N
2.140 CD N
microg/L NN N
(P NNP N
< VBZ N
0.05) CD N
. . N

There EX N
were VBD N
insignificant JJ N
changes NNS N
in IN N
the DT N
parameters NNS N
in IN N
the DT N
control NN N
group NN N
between IN N
baseline NN N
and CC N
6 CD N
months NNS N
later RB N
. . N

CONCLUSION NNP N
Yufeining NNP N
could MD N
improve VB N
lung NN N
function NN N
decrease NN N
sputum NN O
TCC NNP O
absolute NN O
neutrophil NN O
count NN O
and CC O
IL-8 NNP O
concentration NN O
and CC O
relieve VB N
airway NN O
inflammation NN O
in IN N
patients NNS P
with IN P
COPD NNP P
in IN P
the DT P
stable JJ P
phase NN P
. . P

-DOCSTART- -X- N

Primary JJ P
vitrectomy NN P
for IN P
combined VBN P
rhegmatogenous JJ P
retinal JJ P
detachment NN P
and CC P
choroidal JJ P
detachment NN P
with IN P
or CC P
without IN P
oral JJ P
corticosteroids: NN P
a DT N
pilot NN N
study NN N
. . N

PURPOSE VB N
The DT N
occurrence NN N
of IN N
choroidal JJ P
detachment NN P
(CD) NN P
in IN P
eyes NNS P
with IN P
primary JJ P
rhegmatogenous JJ P
retinal JJ P
detachment NN P
(RRD) NN P
is VBZ N
relatively RB N
uncommon JJ N
(2%-4.5%) NN N
. . N

Recent JJ N
reports NNS N
suggest VBP N
that IN N
primary JJ I
vitrectomy NN I
yields NNS N
better RBR N
anatomic JJ N
success NN N
than IN N
scleral JJ I
buckling NN I
. . I

However RB N
for IN N
these DT N
inflamed JJ N
eyes NNS P
with IN P
low JJ P
intraocular JJ P
pressure NN P
the DT P
influence NN N
of IN N
preoperative JJ N
oral JJ N
steroids NNS I
on IN N
reattachment NN N
rates NNS N
has VBZ N
not RB N
been VBN N
elucidated VBN N
yet RB N
. . N

METHODS NNP N
Twenty NNP P
eyes NNS P
with IN P
combined JJ P
RRD NNP P
and CC P
CD NNP P
that WDT P
underwent JJ P
primary JJ P
vitrectomy NN P
were VBD P
randomized VBN P
to TO P
receive VB P
oral JJ P
steroids NNS P
(for VBD P
1 CD P
week) NN P
or CC P
no DT P
oral JJ P
steroids NNS P
before IN P
surgery NN P
. . P

RESULTS NNP N
Preoperative NNP N
clinical JJ N
data NNS N
such JJ N
as IN N
mean JJ N
age NN N
lens VBZ N
status NN N
Snellen NNP N
visual JJ N
acuity NN N
duration NN N
of IN N
macular JJ N
detachment JJ N
CD NN N
(size NNS N
and CC N
extent) NN N
and CC N
retinal JJ N
detachment NN N
characteristics NNS N
(e.g VBP N
. . N

extent JJ N
number NN N
of IN N
retinal JJ N
breaks NNS N
atrophic JJ N
or CC N
tractional JJ N
retinal JJ N
break NN N
size NN N
of IN N
retinal JJ N
break NN N
and CC N
location NN N
of IN N
retinal JJ N
break) NN N
were VBD N
similarly RB N
distributed VBN N
in IN N
both DT N
groups NNS N
. . N

Single-operation JJ O
anatomic JJ O
success NN O
was VBD N
81.8% CD N
(9/11) NN N
among IN N
those DT N
patients NNS N
who WP N
received VBD N
preoperative JJ I
oral JJ I
steroids NNS I
and CC N
was VBD N
66.7% CD N
(6/9) NN N
among IN N
those DT N
who WP N
did VBD I
not RB I
receive VB I
preoperative JJ I
oral JJ I
steroids NNS I
. . I

After IN N
reoperation NN N
anatomic JJ O
success NN O
was VBD N
100% CD N
in IN N
both DT N
groups NNS N
. . N

The DT N
mean JJ N
follow-up NN N
was VBD N
20.1 CD N
months NNS N
. . N

CONCLUSION NNP N
The DT N
results NNS N
suggest VBP N
that IN N
administration NN I
of IN I
oral JJ I
steroids NNS I
before IN I
primary JJ P
vitrectomy NN P
in IN P
eyes NNS P
with IN P
combined JJ P
RRD NNP P
and CC P
CD NNP P
improves VBZ N
reattachment JJ N
rates NNS N
. . N

-DOCSTART- -X- N

Lack NN N
of IN N
lipotoxicity NN N
effect NN N
on IN N
{beta}-cell NNP N
dysfunction NN N
in IN N
ketosis-prone NN P
type NN P
2 CD P
diabetes NNS P
. . P

OBJECTIVE NN N
Over IN P
half NN P
of IN P
newly RB P
diagnosed VBN P
obese JJ P
African JJ P
Americans NNPS P
with IN P
diabetic JJ P
ketoacidosis NN P
(DKA) NNP P
discontinue NN N
insulin NN N
therapy NN N
and CC N
go VB N
through IN N
a DT N
period NN N
of IN N
near-normoglycemia JJ N
remission NN N
. . N

This DT N
subtype NN N
of IN N
diabetes NNS N
is VBZ N
known VBN N
as IN N
ketosis-prone NN N
type NN N
2 CD N
diabetes NNS N
(KPDM) VBP N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
To TO N
investigate VB N
the DT N
role NN N
of IN N
lipotoxicity NN N
on IN N
beta-cell NN N
function NN N
eight CD P
obese JJ P
African JJ P
Americans NNPS P
with IN P
KPDM NNP P
eight CD P
obese JJ P
subjects NNS P
with IN P
type JJ P
2 CD P
diabetes NNS P
with IN P
severe JJ P
hyperglycemia NN P
without IN P
ketosis NN P
(ketosis-resistant JJ P
type NN P
2 CD P
diabetes) NN P
and CC P
nine CD P
nondiabetic JJ P
obese NNS P
control NN P
subjects VBZ P
underwent JJ P
intravenous JJ P
infusion NN P
of IN P
20% CD P
intralipid NNS P
at IN P
40 CD P
ml/h NN P
for IN P
48 CD P
h NN N
. . N

beta-Cell NN O
function NN O
was VBD N
assessed VBN N
by IN N
changes NNS N
in IN N
insulin NN N
and CC N
C-peptide JJ N
concentration NN N
during IN N
infusions NNS N
and CC N
by IN N
changes NNS N
in IN N
acute JJ N
insulin NN N
response NN N
to TO N
arginine VB N
stimulation NN N
(AIR(arg)) NN N
before IN N
and CC N
after IN N
lipid JJ I
infusion NN I
. . I

RESULTS VB N
The DT N
mean JJ N
time NN N
to TO N
discontinue VB N
insulin NN N
therapy NN N
was VBD N
11.0 CD N
+/- JJ N
8.0 CD N
weeks NNS N
in IN N
KPDM NNP N
and CC N
9.6 CD N
+/- JJ N
2.2 CD N
weeks NNS N
in IN N
ketosis-resistant JJ N
type NN N
2 CD N
diabetes NNS N
(P JJ N
= NNP N
NS) NNP N
. . N

At IN N
remission NN N
KPDM NNP N
and CC N
ketosis-resistant JJ N
type NN N
2 CD N
diabetes NNS N
had VBD N
similar JJ N
glucose JJ N
(94 JJ N
+/- JJ N
14 CD N
vs NN N
. . N

109 CD N
+/- JJ N
20 CD N
mg/dl) NN N
A1C NNP N
(5.7 NNP N
+/- JJ N
0.4 CD N
vs NN N
. . N

6.3 CD N
+/- JJ N
1.1%) CD N
and CC N
baseline VB N
AIR(arg) NNP N
response NN N
(34.8 VBD N
+/- JJ N
30 CD N
vs NN N
. . N

64 CD N
+/- JJ N
69 CD N
microU/ml) NN N
. . N

P NNP N
= NNP N
NS NNP N
despite IN N
a DT N
fourfold JJ N
increase NN N
in IN N
free JJ O
fatty JJ O
acid NN O
(FFA) NN N
levels NNS N
(0.4 VBP N
+/- JJ N
0.3 CD N
to TO N
1.8 CD N
+/- JJ N
1.1 CD N
mmol/l NN N
P NNP N
< VBZ N
0.01) CD N
during IN N
the DT N
48-h JJ N
intralipid JJ I
infusion; IN I
the DT N
response NN N
to TO N
AIR(arg) NNP N
stimulation NN N
as RB N
well RB N
as IN N
changes NNS N
in IN N
insulin NN N
and CC N
C-peptide JJ N
levels NNS N
were VBD N
similar JJ N
among IN N
obese JJ P
patients NNS P
with IN P
KPDM NNP P
patients NNS P
with IN P
ketosis-resistant JJ P
type NN P
2 CD P
diabetes NNS P
and CC P
nondiabetic JJ P
control NN P
subjects NNS P
. . P

CONCLUSIONS NNP N
Near-normoglycemia NNP N
remission NN N
in IN N
obese JJ P
African JJ P
American JJ P
patients NNS P
with IN P
KPDM NNP P
and CC P
ketosis-resistant JJ P
type NN P
2 CD P
diabetes NNS P
is VBZ N
associated VBN N
with IN N
a DT N
remarkable JJ N
recovery NN N
in IN N
basal NN N
and CC N
stimulated VBD N
insulin NN N
secretion NN N
. . N

A DT N
high JJ N
FFA NNP N
level NN N
by IN N
intralipid JJ I
infusion NN I
for IN N
48 CD N
h NN N
was VBD N
not RB N
associated VBN N
with IN N
beta-cell JJ N
decompensation NN N
(lipotoxicity) NN N
in IN N
KPDM NNP P
patients NNS P
. . P

-DOCSTART- -X- N

Lactobacillus NNP I
plantarum NN I
CECT7315 NNP I
and CC I
CECT7316 NNP I
stimulate VBP N
immunoglobulin NN O
production NN O
after IN P
influenza JJ P
vaccination NN P
in IN P
elderly JJ P
. . P

OBJECTIVE IN N
The DT N
effectiveness NN N
of IN N
influenza JJ I
vaccination NN I
in IN N
preventing VBG N
illness NN N
is VBZ N
lower RBR N
in IN N
the DT N
elderly; NN N
this DT N
is VBZ N
why WRB N
the DT N
ability NN N
of IN N
Lactobacillus NNP I
plantarum NN I
CECT NNP I
7315/7316 CD I
to TO N
stimulate VB O
the DT O
response NN O
to TO O
influenza VB P
vaccination NN P
in IN P
elderly JJ P
was VBD N
evaluated VBN N
. . N

RESEARCH NNP N
METHODS NNP N
AND NNP N
PROCEDURES NNP N
A NNP P
randomized VBD P
double-blind JJ P
placebo-controlled JJ P
human JJ P
trial NN P
including VBG P
60 CD P
institutionalized JJ P
volunteers NNS P
aged VBN P
65-85 CD P
years NNS P
was VBD P
performed VBN P
. . P

All PDT N
the DT N
volunteers NNS N
were VBD N
vaccinated VBN I
with IN I
a DT I
trivalent JJ I
influenza NN I
vaccine NN I
(A/Wisconsin/67/2005 NNP I
NYMC NNP I
X-161B NNP I
(H3N2) NNP I
A/Solomon NNP I
Islands/3/2006 NNP I
(H1N1) NNP I
and CC I
B/Malaysia/2506/2004) NNP P
for IN P
the DT P
Spanish JJ P
vaccine NN P
campaign NN N
2006/2007 CD N
. . N

The DT N
consumption NN N
of IN N
the DT N
probiotic JJ I
began VBD N
between IN N
three CD N
and CC N
four CD N
months NNS N
after IN N
the DT N
vaccination NN N
. . N

Volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
following VBG N
groups: NN N
group NN I
A NNP I
(receiving VBG I
5*10(9) CD I
cfu/day NN I
of IN I
L NNP I
. . I

plantarum NN I
CECT NNP I
7315/7316 CD I
in IN I
20 CD I
g NN I
powdered VBD I
skim JJ I
milk) NN I
group NN I
B NNP I
(receiving VBG I
5*10(8) CD I
cfu/day NN I
of IN I
L NNP I
. . I

plantarum NN I
CECT NNP I
7315/7316 CD I
in IN I
20 CD I
g NN I
powdered VBD I
skim JJ I
milk) NN I
and CC N
group NN I
C NNP I
or CC I
placebo VB I
(20 JJ I
g NN I
powered VBD I
skim JJ I
milk) NN I
. . I

The DT N
participants NNS N
consumed VBD N
the DT N
probiotic JJ N
during IN N
3 CD N
months NNS N
. . N

RESULTS VB N
The DT N
consumption NN N
of IN N
L NNP I
. . I

plantarum NN I
CECT NNP I
7315/7316 CD I
during IN N
3 CD N
months NNS N
after IN N
influenza JJ I
vaccination NN I
increased VBD N
the DT N
levels NNS O
of IN O
influenza-specific JJ O
IgA NNP O
and CC O
IgG NNP O
antibodies NNS O
. . O

Moreover RB N
a DT N
trend NN N
towards IN N
an DT N
increase NN N
in IN N
influenza-specific JJ O
IgM NNP O
antibodies NNS O
was VBD N
also RB N
observed VBN N
. . N

CONCLUSION NNP N
L NNP I
. . I

plantarum NN I
CECT7315/7316 NNP I
has VBZ N
an DT N
immunostimulating JJ N
effect NN N
and CC N
could MD N
be VB N
used VBN N
to TO N
improve VB N
the DT N
response NN N
to TO N
influenza VB I
vaccination NN I
in IN N
elderly JJ N
. . N

-DOCSTART- -X- N

Do NNP N
cognitive JJ N
measures NNS N
and CC N
brain NN N
circuitry NN N
predict VBP N
outcomes NNS N
of IN N
exercise NN I
in IN N
Parkinson NNP P
Disease: NNP P
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
emerging VBG N
research NN N
detailing VBG N
the DT N
relationship NN N
between IN N
balance/gait/falls NNS N
and CC N
cognition NN N
. . N

Imaging VBG I
studies NNS I
also RB N
suggest VBP N
a DT N
link NN N
between IN N
structural JJ N
and CC N
functional JJ N
changes NNS N
in IN N
the DT N
frontal JJ N
lobe NN N
(a NNP N
region NN N
commonly RB N
associated VBN N
with IN N
cognitive JJ N
function) NN N
and CC N
mobility NN N
. . N

People NNS P
with IN P
Parkinson's NNP P
disease NN P
have VBP N
important JJ N
changes NNS N
in IN N
cognitive JJ N
function NN N
that WDT N
may MD N
impact VB N
rehabilitation NN N
efficacy NN N
. . N

Our PRP$ N
underlying JJ N
hypothesis NN N
is VBZ N
that IN N
cognitive JJ N
function NN N
and CC N
frontal JJ N
lobe NN N
connections NNS N
with IN N
the DT N
basal NN N
ganglia NN N
and CC N
brainstem NN N
posture/locomotor NN N
centers NNS N
are VBP N
responsible JJ N
for IN N
postural JJ N
deficits NNS N
in IN N
people NNS N
with IN N
Parkinson's NNP N
disease NN N
and CC N
play VB N
a DT N
role NN N
in IN N
rehabilitation NN N
efficacy NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
1) CD N
determine NN N
if IN N
people NNS N
with IN N
Parkinson's NNP N
disease NN N
can MD N
improve VB N
mobility NN O
and/or IN O
cognition NN O
after IN N
partaking VBG N
in IN N
a DT N
cognitively RB I
challenging JJ I
mobility NN I
exercise NN I
program NN I
and CC N
2) CD N
determine NN N
if IN N
cognition NN N
and CC N
brain NN N
circuitry NN N
deficits NNS N
predict VBP N
responsiveness NN N
to TO N
exercise VB I
rehabilitation NN I
. . I

METHODS/DESIGN NNP I
This DT N
study NN N
is VBZ N
a DT N
randomized JJ N
cross-over NN N
controlled VBN N
intervention NN N
to TO N
take VB P
place NN P
at IN P
a DT P
University NNP P
Balance NNP P
Disorders NNP P
Laboratory NNP P
. . P

The DT N
study NN N
participants NNS N
will MD N
be VB N
people NNS P
with IN P
Parkinson's NNP P
disease NN P
who WP P
meet VBZ P
inclusion NN P
criteria NNS P
for IN P
the DT P
study NN P
. . P

The DT I
intervention NN I
will MD I
be VB I
6 CD I
weeks NNS I
of IN I
group NN I
exercise NN I
(case) NNP I
and CC I
6 CD I
weeks NNS I
of IN I
group NN I
education NN I
(control) NNP I
. . I

The DT I
exercise NN I
is VBZ I
a DT I
cognitively JJ I
challenging VBG I
program NN I
based VBN I
on IN I
the DT I
Agility NNP I
Boot NNP I
Camp NNP I
for IN I
people NNS I
with IN I
PD NNP I
. . I

The DT I
education NN I
program NN I
is VBZ I
a DT I
6-week JJ I
program NN I
to TO I
teach VB I
people NNS I
how WRB I
to TO I
better RBR I
live JJ I
with IN I
a DT I
chronic JJ I
disease NN I
. . I

The DT N
primary JJ N
outcome JJ N
measure NN N
is VBZ N
the DT N
MiniBESTest NNP O
and CC N
the DT N
secondary JJ N
outcomes NNS N
are VBP N
measures NNS N
of IN N
mobility NN O
cognition NN O
and CC O
neural JJ O
imaging NN O
. . O

DISCUSSION NNP N
The DT N
results NNS N
from IN N
this DT N
study NN N
will MD N
further VB N
our PRP$ N
understanding NN N
of IN N
the DT N
relationship NN N
between IN N
cognition NN N
and CC N
mobility NN N
with IN N
a DT N
focus NN N
on IN N
brain NN N
circuitry NN N
as IN N
it PRP N
relates VBZ N
to TO N
rehabilitation VB N
potential NN N
. . N

TRIAL DT N
REGISTRATION NNP N
This DT N
trial NN N
is VBZ N
registered VBN N
at IN N
clinical JJ N
trials.gov NN N
(NCT02231073) NN N
. . N

-DOCSTART- -X- N

Investigations NNS N
into IN N
the DT N
potential JJ N
effects NNS N
of IN N
multiple JJ N
dose JJ N
ketorolac NN N
on IN N
the DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
racemic JJ N
warfarin NN N
. . N

1 CD N
. . N

The DT N
potential JJ N
interaction NN N
between IN N
racemic JJ N
warfarin NN N
given VBN N
as IN N
a DT N
25 CD N
mg NN N
single JJ N
oral JJ N
dose NN N
and CC N
chronically RB N
administered VBD N
ketorolac NN N
was VBD N
studied VBN N
in IN N
12 CD P
young JJ P
healthy JJ P
male NN P
volunteers NNS P
. . P

2 CD N
. . N

Ketorolac NNP N
produced VBD N
no DT O
major JJ O
change NN O
in IN N
the DT N
pharmacokinetics NNS N
of IN N
(R)- JJ N
or CC N
(S)-warfarin JJ N
. . N

3 CD N
. . N

Ketorolac NNP N
did VBD O
not RB O
alter VB O
the DT O
pharmacodynamic JJ O
profile NN O
of IN N
racemic JJ N
warfarin NN N
. . N

4 CD N
. . N

Ketorolac NNP N
increased VBD O
template VB O
bleeding NN O
time NN O
by IN N
a DT N
factor NN N
of IN N
1.35 CD N
as IN N
compared VBN N
with IN N
placebo NN N
. . N

5 CD N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
the DT N
ketorolac-warfarin JJ N
interaction NN N
is VBZ N
unlikely JJ N
to TO N
be VB N
of IN N
major JJ N
clinical JJ N
significance; NN N
however RB N
combined VBN N
use NN N
of IN N
ketorolac NN N
and CC N
warfarin NN N
in IN N
patients NNS N
should MD N
be VB N
undertaken VBN N
with IN N
due JJ N
caution NN N
and CC N
appropriate JJ N
monitoring NN N
. . N

-DOCSTART- -X- N

Comparative JJ N
drug NN N
effects NNS N
and CC N
abuse NN N
liability NN N
of IN N
lorazepam JJ I
buspirone NN I
and CC I
secobarbital NN I
in IN P
nondependent JJ P
subjects NNS P
. . P

The DT N
pharmacologic JJ N
effects NNS I
of IN I
lorazepam JJ I
(2 NNP I
mg) NN I
buspirone NN I
(20 NNP I
mg VBZ I
10 CD I
mg) NN I
secobarbital JJ I
(100 NNP I
mg) NN I
and CC I
placebo NN I
were VBD N
compared VBN N
in IN P
15 CD P
male NN P
experienced VBD P
intermittent JJ P
nontherapeutic JJ P
drug NN P
users NNS P
. . P

All DT N
drugs NNS N
produced VBD N
a DT N
"drug JJ N
effect NN N
" NNP N
however RB N
buspirone RB I
20 CD I
mg NN I
was VBD N
significantly RB N
less JJR N
liked JJ N
than IN N
were VBD N
lorazepam JJ I
secobarbital JJ I
or CC I
buspirone NN I
10 CD I
mg NN I
(p NN I
less JJR I
than IN I
.05) NNS I
but CC I
not RB I
placebo VB I
. . I

Lorazepam NNP I
was VBD N
liked VBN N
better RBR N
than IN N
were VBD N
other JJ N
drugs NNS N
only RB N
at IN N
1 CD N
hour NN N
and CC N
only RB N
compared VBN N
with IN N
buspirone NN I
20 CD I
and CC N
placebo NN I
. . I

Compared VBN N
with IN N
other JJ N
drugs NNS N
lorazepam JJ I
drug NN N
effects NNS N
were VBD N
greater JJR N
and CC N
resulted VBD N
in IN N
more RBR N
prolonged JJ N
impairment NN N
of IN N
a DT N
motor NN O
tracking VBG O
task NN O
standing VBG O
steadiness NN O
and CC O
memory NN O
. . O

Buspirone CD I
20 CD I
mg NNS I
significantly RB N
impaired JJ N
memory NN N
at IN N
1 CD N
hour NN N
compared VBN N
with IN N
placebo NN I
. . I

Subjects NNS N
were VBD N
more RBR N
likely JJ N
to TO N
identify VB N
buspirone NN I
as IN N
unfamiliar NN N
. . N

Because IN N
buspirone NN I
20 CD I
mg NN I
was VBD N
less JJR N
liked JJ N
than IN N
were VBD N
other JJ N
drugs NNS N
dose JJ N
escalation NN N
as IN N
part NN N
of IN N
drug NN N
abuse NN N
is VBZ N
not RB N
likely JJ N
to TO N
occur VB N
. . N

Lorazepam NNP I
also RB N
was VBD N
not RB N
particularly RB N
liked VBN N
and CC N
was VBD N
not RB N
different JJ N
from IN N
placebo NN I
on IN N
most JJS N
subjective JJ N
abuse-relevant JJ N
measures NNS N
. . N

-DOCSTART- -X- N

Ultracision NNP I
versus NN I
electrocautery NN I
in IN N
performing VBG N
modified JJ N
radical JJ N
mastectomy NN N
and CC N
axillary JJ N
lymph NN N
node NN N
dissection NN N
for IN N
breast NN P
cancer: NN P
a DT N
prospective JJ N
randomized VBN N
control NN N
trial NN N
. . N

BACKGROUND NNP N
Treatment NNP N
for IN N
breast NN N
cancer NN N
has VBZ N
improved VBN N
dramatically RB N
over IN N
the DT N
decades NNS N
. . N

Nevertheless RB N
modified VBN N
radical JJ N
mastectomy NN N
with IN N
axillary JJ N
dissection NN N
remains VBZ N
the DT N
standard JJ N
treatment NN N
for IN N
most JJS N
patients NNS N
especially RB N
those DT N
with IN N
big JJ N
tumours NNS N
. . N

The DT N
conventional JJ N
technology NN N
is VBZ N
to TO N
use VB N
diathermy NN N
to TO N
cut VB N
and CC N
coagulate VB N
blood NN N
vessels NNS N
. . N

The DT N
Ultracision NNP N
dissector NN N
has VBZ N
been VBN N
widely RB N
used VBN N
in IN N
laparoscopic NN N
surgery NN N
and CC N
is VBZ N
documented VBN N
to TO N
be VB N
safe JJ N
and CC N
fast JJ N
for IN N
cutting VBG N
and CC N
coagulating VBG N
tissue NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
compare VB N
ultracision NN I
to TO I
electrocautery VB I
looking VBG I
in IN N
terms NNS N
of IN N
amount NN N
of IN N
post NN N
operative JJ N
drainage NN N
duration NN N
of IN N
drain NN N
days NNS N
seroma VBP N
formation NN N
and CC N
other JJ N
complications NNS N
. . N

METHODOLOGY NNP N
This DT N
study NN N
was VBD N
a DT N
prospective JJ P
randomized VBN P
control NN P
trial NN P
of IN P
modified JJ P
radical JJ P
mastectomy NN P
performed VBD P
for IN P
breast NN P
cancer NN P
in IN P
Pusat NNP P
Perubatan NNP P
Universiti NNP P
Kebangsaan NNP P
Malaysia NNP P
(PPUKM) NNP P
between IN P
1st CD P
June NNP P
2007 CD P
to TO P
31st CD P
December NNP P
2008 CD P
. . P

Patients NNS P
were VBD P
randomized VBN P
in IN P
two CD P
groups: NNS P
group NN P
A NNP P
(n NNP P
= NNP P
20) CD P
underwent NN P
modified VBD P
radical JJ P
mastectomy NN P
using VBG P
ultracision JJ P
(UC) NNP P
and CC P
group NN P
B NNP P
(n NNP P
= VBD P
20) CD P
with IN P
the DT P
conventional JJ P
electrocautery NN P
(EC) NN P
method NN P
. . P

Main NNP N
outcome NN N
measures NNS N
were VBD N
amount NN O
of IN O
drainage NN O
and CC O
duration NN O
of IN O
drain NN O
days NNS O
. . O

An DT N
unpaired JJ N
2-tailed JJ N
Student's NNP N
t NN N
test NN N
and CC N
the DT N
2 JJ N
test NN N
to TO N
compare VB N
the DT N
groups NNS N
. . N

RESULTS VB P
A NNP P
total NN P
of IN P
40 CD P
patients NNS P
were VBD P
involved VBN P
in IN P
this DT P
study NN P
. . N

The DT P
majority NN P
of IN P
patients NNS P
were VBD P
Malay NNP P
(55%) NNP P
followed VBN P
by IN P
Chinese JJ P
(35%) NNP P
Indian NNP P
(5%) NNP P
and CC P
others NNS P
(5%) VBP P
. . N

The DT O
mean JJ O
volume NN O
of IN O
drainage NN O
from IN O
the DT O
axilla NN O
in IN N
the DT N
EC NNP N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
UC NNP N
group NN N
[489.5 NNP N
versus VBZ N
188.1 CD N
mls NN N
(p NNP N
< VBZ N
0.001)] CD N
. . N

The DT O
mean JJ O
volume NN O
of IN O
drainage NN O
from IN O
the DT O
breast NN O
and CC O
the DT O
total JJ O
drainage NN O
from IN O
both CC O
the DT O
breast NN O
and CC O
axilla NN O
was VBD N
also RB N
significantly RB N
higher RBR N
in IN N
the DT N
EC NNP N
group NN N
compared VBN N
to TO N
UC NNP N
[169.3 NNP N
versus VBD N
58.8 CD N
mls NN N
(p NNP N
= VBZ N
0.004) CD N
and CC N
663.7 CD N
versus NN N
247.0 CD N
mls NN N
(p NNP N
< VBZ N
0.002) CD N
respectively] NN N
. . N

The DT N
drainage NN N
consequently RB N
showed VBD N
significant JJ O
reduction NN O
in IN N
terms NNS N
of IN O
drain NN O
days NNS O
in IN N
the DT N
axilla NN N
[6 NNP N
days NNS N
versus VBP N
3 CD N
days NNS N
(p NNP N
< VBP N
0.002)] CD N
and CC N
the DT N
breast NN N
[3 NNP N
days NNS N
versus VBP N
2 CD N
days NNS N
(p NNP N
< VBP N
0.002)] CD N
in IN N
the DT N
UC NNP N
compared VBN N
to TO N
the DT N
EC NNP N
. . N

There EX N
was VBD N
no DT N
significant JJ O
complication NN O
in IN N
both DT N
arms NNS N
. . N

In IN N
conclusion NN N
the DT N
use NN N
of IN N
ultracision NN N
able JJ N
to TO N
reduce VB N
the DT O
amount NN O
of IN O
drainage NN O
and CC O
the DT O
number NN O
of IN O
drain NN O
days NNS O
after IN N
performing VBG N
modified VBD N
radical JJ N
mastectomy NN N
. . N

In IN N
doing VBG N
so RB N
the DT N
use NN N
of IN N
this DT N
technology NN N
enable JJ N
us PRP N
to TO N
discharge VB N
patients NNS N
earlier RBR N
without IN N
significant JJ N
morbidities NNS N
. . N

-DOCSTART- -X- N

Use NNP N
of IN N
a DT N
clay NN I
modeling VBG I
task NN I
to TO N
reduce VB N
chocolate NN P
craving NN P
. . P

Elaborated VBN N
Intrusion NNP N
theory NN N
(EI NNP N
theory; NN N
Kavanagh NNP N
Andrade NNP N
& CC N
May NNP N
2005) CD N
posits NNS N
two CD N
main JJ N
cognitive JJ N
components NNS N
in IN N
craving: JJ N
associative JJ N
processes NNS N
that WDT N
lead VBP N
to TO N
intrusive VB N
thoughts NNS N
about IN N
the DT N
craved JJ N
substance NN N
or CC N
activity NN N
and CC N
elaborative JJ N
processes NNS N
supporting VBG N
mental JJ N
imagery NN N
of IN N
the DT N
substance NN N
or CC N
activity NN N
. . N

We PRP N
used VBD N
a DT N
novel JJ N
visuospatial JJ I
task NN I
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
visual JJ N
imagery NN N
plays VBZ N
a DT N
key JJ N
role NN N
in IN N
craving VBG N
. . N

Experiment NN N
1 CD N
showed VBD N
that IN N
spending VBG N
10 CD N
min JJ N
constructing VBG I
shapes NNS I
from IN I
modeling VBG I
clay NN I
(plasticine) NN I
reduced VBD N
participants' JJ P
craving NN P
for IN P
chocolate NN P
compared VBN N
with IN N
spending NN N
10 CD N
min NN N
'letting VBG I
your PRP$ I
mind NN I
wander' NN I
. . I

Increasing VBG N
the DT N
load NN N
on IN N
verbal JJ N
working VBG N
memory NN N
using VBG N
a DT N
mental JJ N
arithmetic JJ N
task NN N
(counting VBG I
backwards NNS I
by IN I
threes) NN I
did VBD N
not RB N
reduce VB N
craving VBG N
further RB N
. . N

Experiment NN N
2 CD N
compared VBN N
effects NNS N
on IN N
craving NN N
of IN N
a DT N
simpler NN I
verbal JJ I
task NN I
(counting VBG I
by IN I
ones) NN I
and CC I
clay NN I
modeling NN I
. . I

Clay NNP I
modeling VBG I
reduced VBN N
overall JJ O
craving NN O
strength NN O
and CC N
strength NN O
of IN O
craving VBG O
imagery NN O
and CC O
reduced VBD N
the DT N
frequency NN N
of IN N
thoughts NNS O
about IN O
chocolate NN O
. . O

The DT N
results NNS N
are VBP N
consistent JJ N
with IN N
EI NNP N
theory NN N
showing VBG N
that IN N
craving NN N
is VBZ N
reduced VBN N
by IN N
loading VBG I
the DT I
visuospatial JJ I
sketchpad NN I
of IN N
working VBG N
memory NN N
but CC N
not RB N
by IN N
loading VBG I
the DT I
phonological JJ I
loop NN I
. . I

Clay NNP I
modeling NN I
might MD N
be VB N
a DT N
useful JJ N
self-help JJ N
tool NN N
to TO N
help VB N
manage VB N
craving VBG P
for IN P
chocolate NN P
snacks NNS P
and CC P
other JJ P
foods NNS P
. . P

-DOCSTART- -X- N

Naltrexone NNP N
plasma NN N
levels NNS N
clinical JJ N
response NN N
and CC N
effect NN N
on IN N
weight NN N
in IN N
autistic JJ P
children NNS P
. . P

This DT P
research NN N
measured VBD N
naltrexone NN N
levels NNS N
in IN N
plasma NN N
to TO N
assess VB N
the DT N
relationship NN N
between IN N
behavioral JJ N
response NN N
to TO N
naltrexone CD N
and CC N
plasma NN N
levels NNS N
and CC N
the DT N
effects NNS N
of IN N
naltrexone NN N
on IN N
weight NN N
in IN N
hospitalized VBN P
autistic JJ P
children NNS P
(n VBP P
= $ P
41) CD P
. . P

A DT N
double-blind JJ N
placebo-controlled JJ N
parallel NN N
groups NNS N
design NN N
with IN N
fixed JJ N
dose NN N
was VBD N
used VBN N
with IN N
random JJ N
assignment NN N
to TO N
naltrexone CD N
or CC N
placebo NN N
. . N

Drug NNP O
plasma NN O
levels NNS O
were VBD N
analyzed VBN N
by IN N
gas NN N
chromatography/mass NN N
spectrometry NN N
and CC N
weights NNS N
were VBD N
obtained VBN N
weekly RB N
. . N

Naltrexone NN N
levels NNS N
measured VBN N
in IN N
17 CD P
children NNS P
ranged VBD N
from IN N
0.12 CD N
to TO N
5.60 CD N
ng/mL JJ N
(mean JJ N
= NN N
0.71 CD N
standard JJ N
error NN N
of IN N
the DT N
mean JJ N
= NN N
0.32) CD N
. . N

There EX N
was VBD N
no DT N
relationship NN N
between IN N
plasma NN N
levels NNS N
and CC N
age NN N
level NN N
of IN N
intellectual JJ N
functioning NN N
scores NNS N
on IN N
the DT N
14 CD P
selected VBN P
Children's NNP P
Psychiatric NNP O
Rating NNP O
Scale NNP O
(CPRS) NNP O
items NNS O
Clinical NNP O
Global NNP O
Impressions NNP O
Global NNP O
Clinical NNP O
Consensus NNP O
and CC O
the DT O
CPRS NNP O
hyperactivity NN O
factor NN O
. . O

There EX N
was VBD N
a DT N
trend NN N
(p NN N
= NNP N
.06) NNP N
for IN N
children NNS N
receiving VBG N
naltrexone NN N
in IN N
the DT N
highest JJS N
weight NN N
percentile NN N
(> NN N
or CC N
= $ N
90th) CD N
to TO N
lose VB N
weight JJ N
(mean JJ N
= NNP N
-0.42 NNP N
kg) NN N
but CC N
this DT N
was VBD N
not RB N
the DT N
case NN N
for IN N
those DT N
in IN N
the DT N
lower JJR N
weight NN N
percentiles NNS N
(mean VBP N
= NNP N
+0.03 NNP N
kg) NN N
. . N

-DOCSTART- -X- N

The DT N
safety NN N
and CC N
efficacy NN N
of IN N
terazosin NN I
in IN N
the DT N
treatment NN N
of IN N
essential JJ P
hypertension NN P
in IN P
blacks NNS P
. . P

Terazosin VB P
a DT I
new JJ N
selective JJ N
alpha NN I
1-adrenergic JJ I
receptor NN I
antagonist NN I
has VBZ I
been VBN N
found VBN N
to TO N
be VB N
an DT N
effective JJ N
antihypertensive JJ N
agent NN N
. . N

In IN N
a DT N
series NN N
of IN N
studies NNS N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
terazosin NN I
alone RB I
and CC I
in IN I
combination NN I
with IN I
other JJ I
antihypertensive JJ I
agents NNS I
were VBD I
evaluated VBN N
in IN P
1180 CD P
black JJ P
patients NNS P
with IN P
mild JJ P
to TO P
moderate VB P
essential JJ P
hypertension NN P
. . P

Terazosin NNP I
was VBD N
effective JJ N
in IN N
lowering VBG N
blood NN N
pressure NN N
when WRB N
administered VBN N
alone RB N
(in JJ N
dosages NNS I
of IN I
1 CD I
to TO I
80 CD I
mg/day) NNS I
and CC I
when WRB I
prescribed VBN I
(in JJ I
dosages NNS I
of IN I
1 CD I
to TO I
20 CD I
mg/day) NNS I
in IN I
combination NN I
with IN I
other JJ I
antihypertensive JJ I
agents NNS I
. . I

In IN N
elderly JJ P
black JJ P
patients NNS P
terazosin VBP P
1 CD I
to TO N
10 CD N
mg NNS N
daily RB N
was VBD N
as IN N
effective JJ N
in IN N
lowering VBG N
blood NN O
pressure NN O
as IN N
propranolol NN I
(40 NN N
to TO N
120 CD N
mg NN N
twice RB N
daily) RB N
. . N

Changes NNS N
(mean VBP N
+/- JJ N
SE) NNP N
in IN N
sitting VBG O
diastolic JJ O
blood NN O
pressure NN O
from IN O
baseline NN O
were VBD N
-8.1 JJ N
+/- JJ N
1.4 CD N
mm NN N
Hg NNP N
for IN N
terazosin NN I
and CC N
-5.0 VB N
+/- JJ N
1.5 CD N
mm NN N
Hg NNP N
for IN N
propranolol NN I
. . I

Terazosin NNP I
(5 NNP I
mg) NN I
combined VBN I
with IN I
methyclothiazide JJ I
(2.5 NN N
to TO N
5 CD N
mg) NNS N
produced VBD N
a DT N
significantly RB N
greater JJR N
(p NN N
less JJR N
than IN N
0.01) CD N
antihypertensive JJ O
effect NN O
than IN N
that DT N
of IN N
terazosin NN I
alone RB I
. . I

Changes NNS N
(mean VBP N
+/- JJ N
SE) NNP N
in IN N
standing VBG O
diastolic JJ O
blood NN O
pressure NN O
from IN O
baseline NN O
were VBD N
-7.9 JJ N
+/- JJ N
2.0 CD N
mm NN N
Hg NNP N
for IN N
terazosin NN I
alone RB N
-15.1 VBD N
+/- JJ N
2.1 CD N
mm NN N
Hg NNP N
for IN N
terazosin NN I
plus CC I
2.5 CD I
mg NN I
of IN I
methyclothiazide NN I
and CC I
-15.0 VB N
+/- JJ N
2.0 CD N
mm NN N
Hg NNP N
for IN N
terazosin NN I
plus CC I
5 CD I
mg NN I
of IN I
methyclothiazide NN I
. . I

Terazosin NNP I
had VBD N
a DT N
favorable JJ N
effect NN N
on IN N
serum NN O
lipid JJ O
levels NNS O
and CC N
appeared VBD N
to TO N
compensate VB N
for IN N
the DT N
negative JJ N
lipid JJ N
effects NNS N
associated VBN N
with IN N
diuretics NNS I
and CC I
beta-blockers NNS I
when WRB N
used VBN N
in IN N
combination NN N
with IN N
these DT N
agents NNS N
. . N

Terazosin NNP I
alone RB I
and CC N
combined VBN N
with IN N
other JJ N
antihypertensive JJ N
agents NNS N
was VBD N
well RB N
tolerated VBN O
with IN N
minimal JJ N
side NN N
effects NNS N
in IN N
black JJ P
hypertensive JJ P
patients NNS P
. . P

-DOCSTART- -X- N

The DT N
Coping NNP I
Cat NNP I
program NN I
for IN I
children NNS P
with IN P
anxiety NN P
and CC P
autism NN P
spectrum NN P
disorder: VBZ P
a DT N
pilot NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
a DT N
modified JJ I
version NN I
of IN I
the DT I
Coping NNP I
Cat NNP I
program NN I
could MD N
be VB N
effective JJ N
in IN N
reducing VBG N
anxiety NN N
in IN N
children NNS P
with IN P
autism NN P
spectrum NN P
disorder NN P
(ASD) NN P
. . P

Twenty-two JJ P
children NNS P
(ages VBZ P
8-14; JJ P
IQ70) NNP P
with IN P
ASD NNP P
and CC P
clinically RB P
significant JJ P
anxiety NN P
were VBD P
randomly RB P
assigned VBN P
to TO P
16 CD I
sessions NNS I
of IN I
the DT I
Coping NNP I
Cat NNP I
program NN I
(cognitive-behavioral JJ I
therapy; NN I
CBT) NNP I
or CC I
a DT I
16-week JJ I
waitlist NN I
. . N

Children NNP N
in IN N
the DT N
CBT NNP N
condition NN N
evidenced VBD N
significantly RB N
larger JJR N
reductions NNS O
in IN O
anxiety NN O
than IN N
those DT N
in IN N
the DT N
waitlist NN N
. . N

Treatment NN N
gains NNS N
were VBD N
largely RB N
maintained VBN N
at IN N
two-month JJ N
follow-up NN N
. . N

Results NNS N
provide VBP N
preliminary JJ N
evidence NN N
that IN I
a DT I
modified JJ I
version NN I
of IN I
the DT I
Coping NNP I
Cat NNP I
program NN I
may MD N
be VB N
a DT N
feasible JJ N
and CC N
effective JJ N
program NN N
for IN N
reducing VBG O
clinically RB O
significant JJ O
levels NNS O
of IN O
anxiety NN P
in IN P
children NNS P
with IN P
high-functioning JJ P
ASD NNP P
. . N

-DOCSTART- -X- N

Impact NN N
of IN N
angiotensin NN I
II NNP I
receptor NN I
blocker NN I
therapy NN I
(olmesartan NN I
or CC I
valsartan) NN I
on IN N
coronary JJ N
atherosclerotic JJ N
plaque NN N
volume NN N
measured VBN N
by IN N
intravascular JJ N
ultrasound NN N
in IN N
patients NNS P
with IN P
stable JJ P
angina JJ P
pectoris NN P
. . P

Coronary JJ P
plaques NNS O
can MD N
be VB N
reduced VBN N
by IN N
some DT N
medications NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
2 CD N
angiotensin NN I
II NNP I
receptor NN I
blockers NNS I
(olmesartan VBP I
at IN I
20 CD I
mg/day NN I
or CC I
valsartan NN I
at IN I
80 CD I
mg/day) NN I
on IN N
coronary JJ N
plaque NN N
by IN N
coronary JJ I
intravascular JJ I
ultrasound NN I
. . I

One CD P
hundred CD P
hypertensive JJ P
patients NNS P
with IN P
stable JJ P
angina NNS P
pectoris NNS P
who WP P
underwent VBP P
elective JJ P
percutaneous JJ P
coronary JJ P
intervention NN P
were VBD N
randomly RB N
selected VBN N
to TO N
receive VB N
1 CD N
of IN N
the DT N
2 CD I
angiotensin NN I
II NNP I
receptor NN I
blockers NNS I
after IN N
coronary JJ N
intervention NN N
. . N

Nontarget NNP O
coronary JJ O
lesions NNS O
with IN O
mild NN O
to TO O
moderate VB O
stenosis NN O
were VBD N
measured VBN N
by IN N
volumetric JJ N
intravascular JJ N
ultrasound NN N
at IN N
baseline NN N
and CC N
after IN N
6 CD N
months NNS N
. . N

After IN N
6 CD N
months NNS N
both CC N
the DT N
olmesartan NN I
and CC N
the DT N
valsartan NN I
groups NNS N
showed VBD N
significant JJ N
reduction NN N
of IN N
the DT N
examined JJ O
coronary JJ O
plaque NN O
volume NN O
(46.2 NNP N
 VBZ N
24.1 CD N
mm NN N
at IN N
baseline NN N
vs NN N
41.6 CD N
 NN N
21.1 CD N
mm NN N
at IN N
6 CD N
months: NN N
4.7% CD N
decrease NN N
p NN N
= $ N
0.0002; CD N
and CC N
47.2 CD N
 NNS N
32.7 CD N
mm NN N
at IN N
baseline NN N
vs NN N
42.5 CD N
 NN N
30.2 CD N
mm NN N
at IN N
6 CD N
months: NN N
4.8% CD N
decrease NN N
p NN N
= VBD N
0.002 CD N
respectively) NN N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN O
of IN O
plaque JJ O
regression NN O
between IN N
the DT N
2 CD N
groups NNS N
(p VBP N
= JJ N
0.96) CD N
. . N

In IN N
conclusion NN N
there EX N
was VBD N
a DT N
significant JJ N
decrease NN N
from IN N
baseline NN O
in IN O
the DT O
coronary JJ O
plaque NN O
volume NN P
in IN P
patients NNS P
with IN P
stable JJ P
angina NNS P
pectoris NN P
who WP P
received VBD P
olmesartan PRP I
or CC I
valsartan VB I
for IN N
6 CD N
months NNS N
. . N

In IN N
addition NN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN O
in IN O
the DT O
reduction NN O
of IN O
plaque NN O
volume NN N
achieved VBN N
by IN N
these DT N
2 CD N
medications NNS N
. . N

-DOCSTART- -X- N

Event-related JJ I
potentials NNS I
and CC I
monoamines NNS I
in IN N
autistic JJ P
children NNS P
on IN P
a DT P
clinical JJ P
trial NN P
of IN P
fenfluramine NN P
. . P

In IN N
a DT N
double JJ N
blind NN N
crossover NN N
study NN N
of IN N
the DT N
response NN N
of IN N
autistic JJ P
subjects NNS P
to TO N
fenfluramine VB I
event-related JJ I
potentials NNS I
(ERPs) VBP I
were VBD N
recorded VBN N
from IN N
7 CD P
subjects NNS P
on IN N
an DT N
attention-demanding JJ N
auditory NN N
choice NN N
reaction NN N
time NN N
task NN N
(ACRT) NN N
. . N

ACRT NNP I
IQ NNP I
and CC I
biochemical JJ I
measures NNS I
were VBD I
taken VBN I
after IN I
5 CD I
months NNS I
placebo NN I
and CC I
5 CD I
months NNS I
fenfluramine JJ I
treatment NN I
. . I

After IN N
fenfluramine JJ I
treatment NN N
blood NN N
serotonin NN N
levels NNS N
fell VBD N
urinary JJ N
catecholamine NN N
levels NNS N
fell VBD N
and CC N
the DT N
HVA/DA NNP N
ratio NN N
rose VBD N
. . N

IQ NNP O
and CC O
ACRT NNP O
performance NN N
improved VBD N
. . N

On IN N
the DT N
ACRT NNP N
subjects NNS N
were VBD N
asked VBN N
to TO N
press VB N
a DT N
button NN N
to TO N
a DT N
rare JJ N
target NN N
(500 NNP N
Hz NNP N
P NNP N
= NNP N
0.14) CD N
and CC N
to TO N
ignore VB N
higher JJR N
pitched VBN N
rare JJ N
(2 $ N
000 CD N
Hz NNP N
P NNP N
= NNP N
0.14) CD N
and CC N
frequent JJ N
non-targets NNS N
(1 $ N
000 CD N
Hz) NNP N
. . N

After IN N
fenfluramine JJ I
treatment NN I
N1 NNP O
latencies NNS O
increased VBD N
. . N

The DT N
scalp JJ N
distribution NN N
of IN N
ERP NNP N
maxima NNP N
changes NNS N
slightly RB N
with IN N
treatment NN N
. . N

P3 NNP N
maxima NN N
elicited VBN N
by IN N
rare JJ N
non-targets NNS N
were VBD N
recorded VBN N
more RBR N
rostrally RB N
after IN N
fenfluramine JJ I
treatment NN I
. . I

After IN N
rare JJ N
non-targets NNS N
N1 NNP O
amplitudes NNS O
at IN O
Fz NNP O
decreased VBD N
but CC N
P3 NNP N
amplitudes NNS N
at IN N
Pz NNP N
increased VBD N
. . N

Early JJ N
negativity NN N
after IN N
the DT N
rare JJ N
non-target JJ N
(particularly RB N
on IN N
the DT N
right JJ N
side) NN N
was VBD N
negatively RB N
correlated VBN N
with IN N
the DT N
HVA/DA NNP N
ratio NN N
. . N

Subtraction NN N
of IN N
the DT N
P3 NNP N
component NN N
elicited VBN N
in IN N
a DT N
passive JJ N
condition NN N
where WRB N
no DT N
response NN N
was VBD N
required VBN N
from IN N
the DT N
active JJ N
condition NN N
showed VBD N
that IN N
P3 NNP N
positivity NN N
to TO N
targets NNS N
was VBD N
halved VBN N
with IN N
treatment NN N
. . N

(In JJ N
contrast NN N
Nd NNP N
increased VBD N
on IN N
fenfluramine NN N
treatment) NN N
. . N

Overall JJ N
N1 NNP N
and CC N
P3 NNP N
components NNS N
showed VBD N
greatest JJS N
responsiveness NN N
to TO N
rare VB N
non-targets NNS N
on IN N
fenfluramine NN I
. . I

N1 NNP N
but CC N
not RB N
P3 NNP N
changes NNS N
may MD N
represent VB N
slight JJ N
improvement NN N
of IN N
attention-related JJ N
function NN N
with IN N
treatment NN N
. . N

Small JJ N
changes NNS N
in IN N
ERP NNP N
latency NN N
and CC N
distribution NN N
associated VBN N
with IN N
the DT N
neuroleptic JJ N
action NN N
of IN N
fenfluramine NN I
may MD N
be VB N
partly RB N
responsible JJ N
for IN N
a DT N
mild JJ N
improvement NN N
of IN N
IQ NNP N
and CC N
ACRT NNP N
performance NN N
on IN N
medication NN N
. . N

-DOCSTART- -X- N

The DT N
effect NN N
of IN N
posture NN I
on IN N
Cheyne-Stokes NNP N
respirations NNS N
and CC N
hemodynamics NNS N
in IN N
patients NNS P
with IN P
heart NN P
failure NN P
. . P

STUDY NNP N
OBJECTIVES NNP N
Cheyne-Stokes NNP N
respirations NNS N
occur VBP N
in IN N
40% CD N
of IN N
patients NNS P
with IN P
heart NN P
failure NN P
. . P

Orthopnea NNP N
is VBZ N
a DT N
cardinal JJ N
symptom NN N
of IN N
heart NN N
failure NN N
and CC N
may MD N
affect VB N
the DT N
patient's NN N
sleeping VBG N
angle NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
respiratory NN N
and CC N
hemodynamic JJ N
response NN N
to TO N
sleeping VBG I
angle NN I
in IN N
a DT N
group NN P
of IN P
subjects NNS P
with IN P
stable JJ P
heart NN P
failure NN P
. . P

DESIGN NNP N
Twenty-five JJ P
patients NNS P
underwent JJ N
overnight JJ N
polysomnography NN N
with IN N
simultaneous JJ N
and CC N
continuous JJ N
impedance NN N
cardiographic JJ N
monitoring NN N
. . N

Sleeping VBG N
polysomnographic JJ N
and CC N
impedance JJ N
cardiographic JJ N
data NNS N
were VBD N
recorded VBN N
. . N

SETTING VBG N
The DT N
study NN N
was VBD N
conducted VBN N
in IN N
a DT N
sleep JJ N
center NN N
. . N

PATIENTS NNP N
All DT P
25 CD P
patients NNS P
had VBD P
clinically RB P
stable JJ P
heart NN P
failure NN P
and CC P
left VBD P
ventricular JJ P
ejection NN P
fractions NNS P
< VBP P
40% CD P
. . P

INTERVENTIONS NNP N
The DT N
patients NNS N
slept VBD I
at IN I
0 CD I
degrees NNS I
15 CD I
degrees NNS I
30 CD I
degrees NNS I
and CC I
45 CD I
degrees NNS I
in IN I
random JJ I
order NN I
. . I

MEASUREMENTS NNS N
AND CC N
RESULTS NNP N
Seventeen NNP N
patients NNS N
had VBD N
Cheyne-Stokes NNP O
apneas NNS O
(index VBP N
> $ N
5/h) CD N
and CC N
23 CD N
patients NNS N
had VBD N
hypopneas JJ O
(index NN N
> VBD N
5/h) CD N
. . N

The DT N
hypopnea NN O
index NN O
showed VBD N
no DT N
response NN N
to TO N
sleeping VBG I
angle NN I
. . I

The DT N
Cheyne-Stokes NNP O
apnea NN O
index NN O
decreased VBD N
with IN N
increasing VBG N
sleeping VBG N
angle NN N
(P NNP N
< VBZ N
0.001) CD N
. . N

This DT N
effect NN N
was VBD N
seen VBN N
only RB N
during IN N
supine JJ N
sleep NN N
and CC N
non-rapid JJ N
eye NN N
movement NN N
sleep NN N
and CC N
was VBD N
absent VBN N
in IN N
non-supine JJ N
sleep NN N
rapid JJ N
eye NN N
movement NN N
sleep NN N
and CC N
during IN N
periods NNS N
of IN N
wakefulness NN N
. . N

Thoracic NNP O
fluid NN O
content NN O
index NN O
and CC O
left VBD O
ventricular JJ O
hemodynamics NNS O
measured VBN N
by IN N
impedance NN N
cardiography NN N
showed VBD N
no DT N
response NN N
to TO N
sleeping VBG I
angle NN I
. . I

CONCLUSIONS NNP N
Changing VBG N
the DT N
heart NN N
failure NN N
patient's NN N
sleeping VBG N
angle NN N
from IN N
0 CD N
degrees NNS N
to TO N
45 CD N
degrees NNS N
results NNS N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
Cheyne-Stokes NNP N
apneas NNS N
. . N

This DT N
decrease NN N
occurs VBZ N
on IN N
a DT N
constant JJ N
base NN N
of IN N
hypopneas NNS N
. . N

The DT N
changes NNS N
in IN N
Cheyne-Stokes NNP N
apneas NNS N
are VBP N
not RB N
related VBN N
to TO N
changes NNS N
in IN N
lung NN N
congestion NN N
and CC N
left VBD N
ventricular JJ N
hemodynamics NNS N
. . N

-DOCSTART- -X- N

Assessing VBG N
the DT N
benefit NN O
of IN N
a DT N
personalized JJ I
EHR-generated JJ I
informed JJ I
consent NN I
in IN N
a DT N
dental JJ P
school NN P
setting NN P
. . P

Informed VBN I
consents NNS I
are VBP N
routinely RB N
used VBN N
as IN N
an DT N
important JJ N
source NN N
of IN N
information NN N
to TO N
help VB N
patients NNS P
make VB N
appropriate JJ N
clinical JJ N
decisions NNS N
. . N

However RB N
current JJ N
standard JJ N
consent NN N
forms NNS N
may MD N
not RB N
accomplish VB N
their PRP$ N
intended VBN N
purpose NN N
due JJ N
to TO N
the DT N
variety NN N
of IN N
patient JJ N
literacy NN N
and CC N
experiences NNS N
and CC N
in IN N
the DT N
dental JJ N
school NN N
setting VBG N
the DT N
developing VBG N
competence NN N
of IN N
students NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
test VB N
the DT N
efficacy NN O
of IN N
a DT N
personalized VBN I
informed JJ I
consent NN I
generated VBD I
through IN I
an DT I
electronic JJ I
health NN I
record NN I
(EHR) NN I
at IN N
one CD N
dental JJ N
school NN N
and CC N
its PRP$ N
role NN N
in IN N
patient JJ N
decision NN N
making NN N
. . N

In IN N
the DT N
study NN N
a DT N
set NN N
of IN N
informed JJ N
consents NNS N
or CC N
SmartConsents NNS I
were VBD I
developed VBN N
for IN N
specific JJ N
diagnoses NNS N
and CC N
procedures NNS N
enhanced VBN N
with IN N
graphics NNS N
and CC N
delivered VBN N
through IN N
the DT N
school's NN N
EHR NNP I
. . I

Fifty JJ P
patients NNS P
were VBD P
recruited VBN P
in IN P
the DT P
school's NN P
Urgent NNP P
Care NNP P
Clinic NNP P
and CC N
divided VBN N
evenly RB N
into IN N
two CD N
groups: VBP N
one CD N
(control) NN I
receiving VBG N
the DT N
standard JJ I
consent NN I
with IN I
the DT N
second JJ N
receiving VBG N
a DT N
SmartConsent NN I
. . I

Following VBG N
treatment NN N
patients NNS N
were VBD N
assessed VBN N
based VBN N
on IN N
demographics NNS O
decisional JJ O
conflict NN O
satisfaction NN O
health NN O
literacy NN O
and CC O
knowledge NN O
. . O

Overall JJ N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
main JJ N
effects NNS N
between IN N
SmartConsent NNP I
and CC N
standard NN I
informed VBD I
consents NNS I
for IN N
decisional JJ O
conflict NN O
and CC O
satisfaction NN O
although IN O
significant JJ N
differences NNS N
were VBD N
identified VBN N
during IN N
secondary JJ N
analysis NN N
of IN N
satisfaction NN O
gender NN O
and CC N
ethnicity NN N
. . N

The DT N
study NN N
also RB N
demonstrated VBD N
the DT N
potential NN N
for IN N
consents NNS N
to TO N
aid VB N
the DT N
student NN N
provider NN N
in IN N
better JJR N
communicating NN N
with IN N
patients NNS P
. . P

-DOCSTART- -X- N

Effectiveness NN N
of IN N
norgestimate NN I
and CC I
ethinyl NN I
estradiol NN I
in IN N
treating VBG N
moderate JJ P
acne NN P
vulgaris NN P
. . P

BACKGROUND NNP P
An DT N
excess NN N
of IN N
androgen NN N
is VBZ N
believed VBN N
to TO N
contribute VB N
to TO N
development NN N
of IN N
acne NN N
in IN N
some DT N
patients NNS N
. . N

Because IN N
oral JJ I
contraceptives NNS I
(OCs) VBP N
may MD N
reduce VB N
the DT N
active JJ N
androgen NN N
level NN N
hormonal JJ I
therapy NN I
with IN N
OCs NNP N
has VBZ N
been VBN N
used VBN N
successfully RB N
to TO N
treat VB N
patients NNS P
with IN P
acne JJ P
although IN P
this DT N
treatment NN N
has VBZ N
previously RB N
not RB N
been VBN N
studied VBN N
in IN N
placebo-controlled JJ I
trials NNS N
. . N

OBJECTIVE IN N
Our PRP$ N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
triphasic JJ I
combination NN I
OC NNP I
(ORTHO NNP I
TRI-CYCLEN NNP I
[Ortho-McNeil JJ I
Pharmaceutical NNP I
Raritan NNP I
N.J.] NNP I
norgestimate/ethinyl MD I
estradiol) VB I
compared VBN N
with IN N
placebo NN I
in IN N
the DT N
treatment NN N
of IN N
moderate JJ N
acne NN N
vulgaris NN N
. . N

METHODS NNP N
Two CD P
hundred VBD P
fifty-seven RB P
healthy JJ P
female NN P
subjects VBZ P
15 CD P
to TO P
49 CD P
years NNS P
of IN P
age NN P
with IN P
moderate JJ P
acne NNS P
vulgaris NNS P
were VBD P
enrolled VBN N
in IN N
a DT N
multicenter NN N
randomized VBN N
double-blind JJ N
placebo-controlled JJ I
clinical JJ N
trial NN N
. . N

Each DT N
month NN N
for IN N
6 CD N
months NNS N
subjects VBZ N
received VBN N
either RB N
3 CD I
consecutive JJ I
weeks NNS I
of IN I
the DT I
OC NNP I
(i.e NNP N
. . N

tablets NNS N
containing VBG N
a DT N
fixed VBN N
dose NN N
of IN N
ethinyl JJ I
estradiol NN I
[0.035 NNP I
mg] NN I
and CC I
increasing VBG I
doses NNS I
of IN I
norgestimate JJ I
[0.180 NNP N
mg NN N
0.215 CD N
mg NN N
0.250 CD N
mg]) NN N
followed VBN N
by IN N
7 CD I
days NNS I
of IN I
inactive JJ I
drug NN I
or CC I
placebo VB I
(color-matched JJ N
tablets) NN N
. . N

Efficacy NN N
was VBD N
assessed VBN N
by IN N
facial JJ O
acne JJ O
lesion NN O
counts VBZ O
an DT O
investigator's NN N
global JJ N
assessment NN N
a DT N
subject's JJ N
self-assessment NN N
and CC N
an DT N
analysis NN N
of IN N
within-cycle JJ N
variation NN N
(cycle NN N
6) CD N
in IN N
lesion NN N
counts NNS N
. . N

RESULTS NN N
Of IN N
the DT N
160 CD P
subjects NNS P
in IN N
whom WP N
efficacy NN N
could MD N
be VB N
evaluated VBN N
the DT N
OC NNP I
group NN N
showed VBD N
a DT N
statistically RB N
significantly RB N
greater JJR N
improvement NN N
than IN N
the DT N
placebo NN I
group NN N
for IN N
all DT N
primary JJ N
efficacy NN N
measures NNS N
. . N

The DT N
mean JJ N
decrease NN O
in IN O
inflammatory JJ O
lesion NN O
count NN O
from IN N
baseline NN N
to TO N
cycle NN N
6 CD N
was VBD N
11.8 CD N
(62.0%) NNP N
versus NN N
7.6 CD N
(38.6%) NN N
(p NNP N
= VBZ N
0.0001) CD N
and CC N
the DT N
mean JJ N
decrease NN O
in IN O
total JJ O
lesion NN O
count NN O
was VBD N
29.1 CD N
(53.1%) NNP N
versus NN N
14.1 CD N
(26.8%) NN N
(p NNP N
= VBZ N
0.0001) CD N
in IN N
the DT N
OC NNP N
and CC N
placebo NN I
groups NNS N
respectively RB N
. . N

In IN N
the DT N
investigator's NN N
global JJ N
assessment NN N
93.7% CD N
of IN N
the DT N
active JJ N
treatment NN N
group NN N
versus VBD N
65.4% CD N
of IN N
the DT N
placebo NN I
group NN N
were VBD N
rated VBN N
as IN N
improved VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
(p NNP N
< NNP N
0.001) CD N
. . N

Six CD N
of IN N
the DT N
seven CD N
secondary JJ N
efficacy NN N
measures NNS N
(total JJ O
comedones NNS O
open JJ O
comedones NNS O
closed VBD O
comedones NNS O
papules NNS O
pustules NNS O
and CC O
the DT O
subject's JJ O
self-assessment NN O
of IN O
study NN O
treatment) NNS O
were VBD N
also RB N
significantly RB N
more RBR N
favorable JJ N
in IN N
the DT N
OC NNP N
group NN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
. . N

CONCLUSION NNP N
An DT N
OC NNP I
containing VBG N
0.035 CD N
mg NN N
of IN N
ethinyl JJ I
estradiol NN I
combined VBN N
with IN N
the DT N
triphasic JJ I
regimen NNS I
of IN I
norgestimate NN I
is VBZ N
a DT N
safe JJ O
and CC O
effective JJ O
treatment NN N
of IN N
moderate JJ P
acne NNS P
vulgaris VBP P
in IN P
women NNS P
with IN P
no DT P
known VBN P
contraindication NN P
to TO P
OC NNP P
therapy NN P
. . P

-DOCSTART- -X- N

Tracheal NNP N
soiling VBG N
with IN N
blood NN N
during IN N
intranasal JJ I
surgery--comparison NN I
of IN N
two CD N
endotracheal JJ N
tubes NNS N
. . P

Sixty NNP P
adult NN P
patients NNS P
ASA VBP P
Classes NNP P
I PRP P
& CC P
II NNP P
were VBD P
involved VBN N
in IN N
a DT N
study NN N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
Mallinckrodt NNP I
Hi-Lo-Evac NNP I
tube NN I
and CC I
Portex NNP I
blue JJ I
line NN I
tube NN I
in IN N
preventing VBG N
soiling NN N
of IN N
the DT N
lower JJR N
airways NNS N
during IN N
intranasal NN N
surgery NN I
. . I

The DT N
Hi-Lo-Evac NNP I
tube NN I
with IN N
and CC N
without IN N
pack NN N
was VBD N
significantly RB N
more RBR N
effective JJ O
than IN N
the DT N
Portex NNP I
tube NN I
with IN I
pharyngeal JJ I
pack NN I
(P NNP N
less JJR N
than IN N
0.002) CD N
and CC N
(P NNP N
less JJR N
than IN N
0.01 CD N
respectively) NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
when WRB N
the DT N
Hi-Lo-Evac NNP I
tube NN I
was VBD N
used VBN N
with IN N
or CC N
without IN N
a DT N
pack NN N
(P NN N
greater JJR N
than IN N
0.2) CD N
. . N

The DT N
more RBR N
effective JJ O
protection NN O
of IN O
the DT O
lower JJR O
airways NNS O
by IN N
the DT N
Hi-Lo-Evac NNP I
tube NN I
is VBZ N
attributed VBN N
to TO N
the DT N
facility NN N
of IN N
subglottic JJ N
aspiration NN N
during IN N
surgery NN N
. . N

It PRP N
is VBZ N
suggested VBN N
that IN N
the DT N
Hi-Lo-Evac NNP I
tube NN I
could MD N
be VB N
used VBN N
with IN N
safety NN N
during IN N
intranasal JJ N
surgery NN N
in IN N
order NN N
to TO N
reduce VB N
postoperative JJ O
morbidity NN O
associated VBN N
with IN N
the DT N
use NN N
of IN N
pharyngeal JJ N
pack NN N
. . N

-DOCSTART- -X- N

Nicotine NNP I
infusion NN I
acutely RB N
impairs JJ N
insulin NN N
sensitivity NN N
in IN N
type NN P
2 CD P
diabetic JJ P
patients NNS P
but CC P
not RB P
in IN P
healthy JJ P
subjects NNS P
. . P

OBJECTIVES IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
if IN N
an DT N
acute JJ I
nicotine NN I
infusion NN I
alters NNS N
insulin VBP N
sensitivity NN N
to TO N
a DT N
similar JJ N
degree NN N
in IN N
type NN N
2 CD N
diabetic JJ N
patients NNS N
as IN N
in IN N
healthy JJ N
control NN N
subjects NNS N
. . N

DESIGN NNP N
. . N

Double-blind JJ N
cross-over JJ N
placebo-controlled JJ N
randomized VBN I
experimental JJ I
study NN N
. . N

Nicotine NNP N
0.3 CD I
microg JJ I
kg-1 JJ I
min(-1) NN I
or CC I
NaCl NNP I
was VBD I
infused VBN I
(2 JJ I
h) NN N
during IN N
a DT N
euglycaemic JJ N
hyperinsulinaemic JJ I
clamp NN I
(4 NNP I
h) NN I
to TO I
assess VB I
insulin JJ I
sensitivity NN I
. . I

SETTING NNP I
University NNP N
research NN N
laboratory NN N
. . N

SUBJECTS NNP N
Six NNP N
male NN P
and CC P
female JJ P
type NN P
2 CD P
diabetic JJ P
patients NNS P
[DM2; JJ P
age NN P
54 CD P
+/- JJ P
10 CD P
(mean JJ P
+/- JJ P
SD) NNP P
years; NN P
body NN P
mass NN P
index NN P
(BMI) VBD P
25.6 CD P
+/- JJ P
2.9 CD P
kg JJ P
m(-2)] NNS P
treated VBN P
with IN P
diet JJ P
or CC P
one CD P
oral JJ P
hypoglycaemic JJ P
agent NN P
and CC P
six CD P
age- JJ P
and CC P
BMI-matched JJ P
control NN P
subjects VBZ P
(Ctr) NNP P
. . P

MAIN NNP P
OUTCOME NNP P
MEASURE NNP N
Insulin NNP N
sensitivity NN O
(rate NN O
of IN O
glucose JJ O
infusion NN O
per IN O
kg NN O
fat JJ O
free JJ O
body NN O
mass NN O
and CC O
minute) NN O
nicotine NN O
and CC O
free JJ O
fatty NN O
acid NN O
(FFA) NN O
levels NNS O
pulse JJ O
rate NN O
and CC O
blood NN O
pressure NN O
. . O

RESULTS VB O
The DT N
infusions NNS N
produced VBD N
similar JJ N
nicotine NN N
levels NNS N
in IN N
both DT N
groups NNS N
. . N

In IN N
the DT N
absence NN N
of IN N
nicotine JJ N
DM2 NNP I
were VBD I
more JJR N
insulin NN N
resistant NN O
than IN O
Ctr NNP N
(6.7 NNP N
+/- JJ N
0.4 CD N
vs NN N
. . N

10.9 CD N
+/- JJ N
0.3 CD N
mg JJ N
kg-1 JJ N
LBM NNP N
min(-1) NN N
respectively; NN N
P NNP N
< VBZ N
0.0001) CD N
. . N

This DT N
insulin NN N
resistance NN O
was VBD O
further RBR N
aggravated VBN N
by IN N
the DT N
nicotine JJ N
infusion NN I
in IN N
DM2 NNP N
but CC N
not RB N
in IN N
Ctr NNP N
(4.6 NNP N
+/- JJ N
0.3 CD N
vs NN N
. . N

10.9 CD N
+/- JJ N
0.3 CD N
mg JJ N
kg(-1) JJ N
LBM NNP N
min(-1); NN N
P NNP N
< VBZ N
0.0001) CD N
. . N

Only RB N
minor JJ N
differences NNS N
were VBD N
seen VBN N
in IN N
FFA NNP N
levels NNS O
pulse VBP O
rates NNS O
and CC O
blood NN O
pressure NN O
. . O

CONCLUSIONS NN O
At IN N
this DT N
low JJ N
infusion NN N
rate NN N
nicotine NN N
aggravated VBD I
the DT N
insulin NN N
resistance NN O
in IN O
DM2 NNP N
but CC N
not RB N
in IN N
Ctr NNP N
. . N

This DT N
finding NN N
may MD N
be VB N
because IN N
of IN N
the DT N
(dysmetabolic) NNP N
diabetic JJ N
state NN N
per IN N
se NN N
or CC N
to TO N
an DT N
increased VBN N
sensitivity NN N
to TO N
environmental JJ N
factors NNS N
associated VBN N
with IN N
a DT N
genetic JJ N
predisposition NN N
for IN N
type NN N
2 CD N
diabetes NNS N
. . N

These DT N
results NNS N
show VBP N
that IN N
diabetic JJ N
subjects NNS N
are VBP N
particularly RB N
susceptible JJ N
to TO N
the DT N
detrimental JJ N
effects NNS N
of IN N
nicotine NN N
. . I

-DOCSTART- -X- N

Effects NNS N
of IN N
a DT N
long-term JJ I
vitamin NN I
D NNP I
and CC I
calcium NN I
supplementation NN I
on IN N
falls NNS N
and CC N
parameters NNS N
of IN N
muscle NN N
function NN N
in IN N
community-dwelling JJ P
older NN P
individuals NNS P
. . P

UNLABELLED VBN N
In IN N
242 CD P
community-dwelling JJ P
seniors NNS P
supplementation NN P
with IN N
either DT N
1000 CD I
mg NN I
of IN I
calcium NN I
or CC I
1000 CD I
mg NN I
of IN I
calcium NN I
plus CC I
vitamin NN I
D NNP I
resulted VBD N
in IN N
a DT N
decrease NN N
in IN N
the DT N
number NN N
of IN N
subjects NNS N
with IN N
first JJ N
falls NNS N
of IN N
27% CD N
at IN N
month NN N
12 CD N
and CC N
39% CD N
at IN N
month NN N
20 CD N
. . N

Additionally RB N
parameters NNS N
of IN N
muscle NN N
function NN N
improved VBD N
significantly RB N
. . N

INTRODUCTION NNP N
The DT N
efficacy NN N
of IN N
vitamin NN I
D NNP I
and CC I
calcium NN I
supplementation NN I
on IN N
risk NN N
of IN N
falling VBG N
in IN N
the DT N
elderly JJ N
is VBZ N
discussed VBN N
controversially RB N
. . N

Randomized VBN N
controlled JJ N
trials NNS N
using VBG N
falls NNS N
as IN N
primary JJ N
outcome NN N
are VBP N
needed VBN N
. . N

We PRP N
investigated VBD N
long-term JJ N
effects NNS N
of IN N
calcium NN I
and CC I
vitamin NN I
D NNP I
on IN N
falls NNS O
and CC N
parameters NNS O
of IN O
muscle NN O
function NN O
in IN N
community-dwelling JJ P
elderly JJ P
women NNS P
and CC P
men NNS P
. . P

METHODS NNP N
Our PRP$ N
study NN N
population NN N
consisted VBD N
of IN N
242 CD P
individuals NNS P
recruited VBN P
by IN P
advertisements NNS P
and CC P
mailing VBG P
lists NNS P
(mean JJ P
[ NNP P
+/- NN P
SD] NNP P
age NN P
77 CD P
+/- JJ P
4 CD P
years) NN P
. . P

All DT P
serum JJ P
25-hydroxyvitamin JJ P
D NNP P
(25[OH]D) NN P
levels NNS P
were VBD P
below IN P
78 CD P
nmol/l NNS P
. . P

Individuals NNS N
received VBN N
in IN N
a DT N
double JJ N
blinded JJ N
fashion NN N
either DT N
1000 CD N
mg NN N
of IN N
calcium NN I
or CC N
1000 CD N
mg NN N
of IN N
calcium NN I
plus CC N
800 CD N
IU NNP N
of IN N
vitamin NNP I
D NNP I
per IN N
day NN N
over IN N
a DT N
treatment NN N
period NN N
of IN N
12 CD N
months NNS N
which WDT N
was VBD N
followed VBN N
by IN N
a DT N
treatment-free JJ N
but CC N
still RB N
blinded VBD N
observation JJ N
period NN N
of IN N
8 CD N
months NNS N
. . N

Falls NNS N
were VBD N
documented VBN N
using VBG N
diaries NNS N
. . N

The DT N
study NN P
took VBD P
place NN P
in IN P
Bad NNP P
Pyrmont NNP P
Germany NNP P
(latitude VBP P
52 CD P
degrees NNS P
) ) P
and CC P
Graz NNP P
Austria NNP P
(latitude VBP P
46 CD P
degrees NNS P
) ) P
. . P

RESULTS RB P
Compared NNP N
to TO N
calcium VB I
mono JJ I
supplementation NN I
with IN I
calcium NN I
plus CC I
vitamin NN I
D NNP I
resulted VBD N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
the DT N
number NN N
of IN N
subjects NNS N
with IN N
first JJ N
falls NNS N
of IN N
27% CD N
at IN N
month NN N
12 CD N
(RR NN N
= VBD N
0.73; CD N
CI NNP N
= NNP N
0.54-0.96) NN N
and CC N
39% CD N
at IN N
month NN N
20 CD N
(RR NN N
= VBD N
0.61; CD N
CI NNP N
= NNP N
0.34-0.76) NN N
. . N

Concerning VBG N
secondary JJ N
endpoints NNS N
we PRP N
observed VBD N
significant JJ N
improvements NNS O
in IN O
quadriceps JJ O
strength NN O
of IN N
8% CD N
a DT N
decrease NN N
in IN N
body NN O
sway NN O
of IN N
28% CD N
and CC N
a DT N
decrease NN N
in IN N
time NN O
needed VBN O
to TO O
perform VB O
the DT O
TUG NNP O
test NN O
of IN N
11% CD N
. . N

DISCUSSION NNP N
Combined NNP I
calcium NN I
and CC I
vitamin NN I
D NNP I
supplementation NN I
proved VBD N
superior JJ N
to TO N
calcium VB N
alone RB N
in IN N
reducing VBG N
the DT N
number NN N
of IN N
falls NNS N
and CC N
improving VBG N
muscle NN N
function NN N
in IN N
community-dwelling JJ P
older NN P
individuals NNS P
. . P

-DOCSTART- -X- N

Milk NN O
production NN O
in IN N
cows NNS P
with IN P
endotoxin-induced JJ P
mastitis NN P
treated VBN I
with IN I
isotonic JJ I
or CC I
hypertonic JJ I
sodium NN I
chloride NN I
solution NN I
. . I

Milk NN O
production NN O
was VBD N
monitored VBN I
in IN P
16 CD P
cows NNS P
for IN P
6 CD P
milkings NNS P
after IN N
intramammary JJ I
infusion NN N
of IN N
1 CD I
mg NN I
of IN I
endotoxin NN I
in IN N
a DT N
single JJ N
forequarter NN N
. . N

The DT N
cows NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
treatment NN I
groups; NN N
8 CD P
cows NNS P
were VBD P
treated VBN P
with IN P
isotonic JJ P
saline NN P
solution NN P
and CC P
8 CD P
cows NNS P
were VBD P
treated VBN P
with IN P
hypertonic JJ P
saline JJ P
solution NN P
. . P

Saline JJ I
solutions NNS I
were VBD N
administered VBN I
IV NNP I
(5 NNP N
ml/kg NN N
of IN N
body NN N
weight) JJ N
4 CD N
hours NNS N
after IN N
infusion NN I
of IN N
endotoxin NN I
. . I

Mean NNP N
cumulative JJ N
change NN O
in IN O
milk NN O
yield NN O
and CC O
interval JJ O
change NN O
in IN O
milk NN O
yield NN O
were VBD N
greater JJR N
in IN N
cows NNS P
treated VBN P
with IN P
isotonic JJ I
saline NN I
solution NN I
than IN N
in IN N
cows NNS N
treated VBN N
with IN N
hypertonic JJ I
saline JJ I
solution NN I
. . I

Significant JJ N
differences NNS N
between IN N
treatment NN I
groups NNS N
were VBD N
not RB N
detected VBN N
. . N

-DOCSTART- -X- N

Verapamil NNP I
augmentation NN I
of IN I
lithium NN I
treatment NN I
improves VBZ N
outcome VBN N
in IN N
mania NN N
unresponsive JJ P
to TO P
lithium VB P
alone: JJ P
preliminary JJ N
findings NNS N
and CC N
a DT N
discussion NN N
of IN N
therapeutic JJ I
mechanisms NNS I
. . I

OBJECTIVES NNP N
Attenuation NNP I
of IN I
protein NN I
kinase NN I
C NNP I
(PKC) NNP I
is VBZ I
a DT I
mechanism NN I
common JJ N
to TO N
both DT N
established VBN I
(lithium NN I
valproate) NN I
and CC I
some DT I
novel JJ I
(tamoxifen) NNP I
antimanic NN I
agents NNS I
. . I

Verapamil NNP I
although IN I
primarily RB N
known VBN N
as IN N
a DT N
calcium NN I
channel NN I
blocker NN I
also RB I
has VBZ N
PKC NNP I
inhibitory NN I
activity NN I
. . I

Verapamil NNP I
has VBZ N
shown VBN N
antimanic JJ N
activity NN N
in IN N
some DT N
but CC N
not RB N
all DT N
studies NNS N
. . N

Therefore IN N
we PRP N
investigated VBD N
verapamil NNS I
used VBN I
alone RB I
or CC I
as IN I
an DT I
adjunctive JJ I
treatment NN I
in IN I
manic JJ P
patients NNS P
who WP P
did VBD P
not RB P
respond VB P
to TO P
an DT P
initial JJ P
adequate JJ P
trial NN P
of IN P
lithium NN P
. . P

METHODS NNP P
Each DT N
study NN N
phase NN N
lasted VBD N
three CD N
weeks NNS N
. . N

Subjects NNS N
were VBD N
treated VBN I
openly RB I
with IN I
lithium NN I
in IN I
Phase NNP I
1 CD I
(n NNP P
= VBD P
45) CD P
. . P

Those DT N
who WP N
failed VBD N
to TO N
respond VB N
were VBD N
randomly RB N
assigned VBN N
to TO N
double-blind VB I
treatment NN I
in IN I
Phase NNP I
2 CD I
with IN I
either DT I
verapamil NN I
(n NNP I
= VBZ I
10) CD I
or CC I
continued-lithium JJ I
(n NN I
= $ I
8) CD I
. . I

Phase NNP N
2 CD N
nonresponders NNS N
(n VBP N
= JJ N
10) CD N
were VBD N
assigned VBN N
to TO N
combined VB I
verapamil/lithium NN I
in IN I
Phase NNP I
3 CD I
. . I

RESULTS NNP N
Response NNP N
in IN N
Phase NNP N
2 CD N
did VBD N
not RB N
differ VB N
significantly RB N
between IN I
verapamil NNS I
and CC I
continued-lithium NN I
. . I

During IN N
Phase NNP N
3 CD N
response NN N
to TO N
combined VBN I
treatment NN I
was VBD N
significantly RB N
better JJR N
than IN N
overall JJ N
response NN N
to TO N
monotherapy VB I
in IN N
Phase NNP N
2 CD N
(Fisher's NNP O
Exact NNP O
test NN O
p NN O
= VBD N
0.043) CD N
. . N

Mania NNP O
ratings NNS O
improved VBN N
during IN N
combined JJ I
treatment NN I
in IN N
Phase NNP N
3 CD N
by IN N
88.2% CD N
(linear JJ N
mixed JJ N
model NN N
analysis NN N
F NNP N
= VBZ N
4.34 CD N
p NN N
= VBD N
0.013) CD N
compared VBN N
with IN N
10.5% CD N
improvement NN N
during IN N
Phase NNP N
2 CD N
. . N

CONCLUSIONS NN N
In IN N
this DT N
preliminary JJ N
investigation NN I
verapamil NN I
monotherapy NN I
did VBD N
not RB N
demonstrate VB N
antimanic JJ N
efficacy NN N
. . N

By IN N
contrast NN N
the DT N
combination NN I
of IN I
verapamil JJ I
plus CC I
lithium NN I
was VBD N
highly RB N
efficacious JJ N
. . N

Our PRP$ N
findings NNS N
thus RB N
suggest VBP N
that IN N
verapamil NN I
may MD N
have VB N
potential JJ N
utility NN N
as IN N
an DT N
adjunct NN N
to TO N
lithium NN I
. . I

This DT N
effect NN N
may MD N
be VB N
mediated VBN N
by IN N
additive JJ I
actions NNS I
on IN I
PKC NNP I
inhibition NN I
which WDT I
may MD N
be VB N
an DT N
important JJ N
mechanism NN N
for IN N
antimanic JJ I
agents NNS I
in IN N
general JJ N
. . N

-DOCSTART- -X- N

Anaerobic NNP N
infection NN N
in IN N
cancer NN P
patients: NN P
comparative JJ N
evaluation NN N
of IN N
clindamycin NN I
and CC I
cefoxitin NN I
. . I

Clindamycin NNP I
and CC I
cefoxitin NN I
with IN I
or CC I
without IN I
gentamicin NNS I
were VBD I
administered VBN I
to TO N
cancer NN P
patients NNS P
having VBG P
localized VBN P
infections NNS P
presumably RB N
caused VBN N
by IN N
anaerobic JJ N
pathogens NNS N
. . N

The DT N
rates NNS N
of IN N
favorable JJ O
response NN O
were VBD N
89% CD N
in IN N
patients NNS N
receiving VBG N
clindamycine NN I
alone RB I
and CC N
78% CD N
in IN N
patients NNS N
receiving VBG N
cefoxitin NN I
alone RB I
. . I

When WRB N
the DT N
total JJ N
experience NN N
is VBZ N
considered VBN N
(clindamycin JJ I
or CC I
cefoxitin NN I
with IN I
and CC I
without IN I
gentamicin) JJ I
20 CD N
of IN N
24 CD N
patients NNS N
(83%) RB N
responded VBD N
to TO N
clindamycin VB I
and CC N
18 CD N
of IN N
22 CD N
(82%) NNS N
responded VBD N
to TO N
cefoxitin VB I
. . I

Both DT N
therapies NNS N
were VBD N
well RB N
tolerated VBN O
. . O

Clindamycin NNP I
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
cefoxitin NN I
in IN N
eradicating VBG O
the DT O
offending VBG O
anaerobic JJ O
pathogens NNS O
from IN N
the DT N
site NN N
of IN N
infection NN N
. . N

Aerobic JJ N
pathogens NNS N
were VBD N
frequently RB N
isolated VBN N
along IN N
with IN N
anaerobes NNS N
from IN N
the DT N
infectious JJ N
sites NNS N
in IN N
this DT N
series; VBP N
their PRP$ N
susceptibility NN N
or CC N
resistance NN N
to TO N
clindamycin VB I
or CC N
cefoxitin VB I
did VBD N
not RB N
influence VB N
the DT N
therapeutic JJ N
response NN N
. . N

-DOCSTART- -X- N

Oesophageal JJ P
intubation NN P
can MD N
be VB N
undetected VBN N
by IN N
auscultation NN I
of IN N
the DT N
chest NN N
. . N

Prompt NNP N
detection NN N
of IN N
oesophageal JJ I
intubation NN I
is VBZ N
a DT N
primary JJ N
concern NN N
in IN N
anaesthetic JJ N
practice NN N
. . N

This DT N
blind NN N
randomised VBD N
study NN N
evaluates NNS N
three CD N
widely RB I
used JJ I
tests NNS I
of IN I
intubation NN I
. . I

Forty NN P
patients NNS P
had VBD P
both DT P
their PRP$ P
trachea NN P
and CC P
oesophagus RB P
intubated JJ P
each DT P
patient NN P
was VBD P
studied VBN P
twice RB P
. . P

Auscultation NN N
of IN N
the DT N
epigastrium NN N
right NN N
and CC N
left VBD N
axilla NN N
is VBZ N
more RBR N
reliable JJ N
than IN N
auscultation NN N
of IN N
the DT N
chest NN N
and CC N
the DT N
anaesthetist's NN P
feeling NN P
when WRB P
he PRP N
squeezes VBZ N
the DT P
bag NN P
. . P

P NNP N
= VBZ N
0.001 CD N
and CC N
P NNP N
= NNP N
0.048 CD N
respectively RB N
. . N

The DT N
tests NNS N
were VBD N
carried VBN N
out RP N
after IN N
gastric JJ N
distension NN N
with IN N
gas NN N
had VBD N
occurred VBN N
. . N

We PRP N
conclude VBP N
that DT N
auscultation NN N
of IN N
epigastrium NN N
right NN N
and CC N
left VBD N
axilla NN N
are VBP N
recommended VBN N
. . N

-DOCSTART- -X- N

Ultrasound NNP I
therapy NN I
for IN N
recalcitrant JJ P
diabetic JJ P
foot NN P
ulcers: JJ P
results NNS N
of IN N
a DT N
randomized JJ N
double-blind NN N
controlled VBD N
multicenter NN N
study NN N
. . N

An DT N
estimated JJ N
15% CD N
of IN N
patients NNS P
with IN P
diabetes NNS P
will MD N
develop VB N
a DT N
foot NN O
ulcer NN O
sometime RB N
in IN N
their PRP$ N
life NN N
making VBG N
them PRP N
30 CD N
to TO N
40 CD N
times NNS N
more RBR N
likely JJ N
to TO N
undergo VB N
amputation NN N
due JJ N
to TO N
a DT N
non-healing JJ N
foot NN N
ulcer NN N
than IN N
the DT N
non-diabetic JJ P
population NN P
. . P

To TO N
determine VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
a DT N
new JJ I
non-contact JJ I
kilohertz NN I
ultrasound JJ I
therapy NN I
for IN N
the DT N
healing NN N
of IN N
recalcitrant JJ P
diabetic JJ P
foot NN P
ulcers NNS P
- : N
as RB N
well RB N
as IN N
to TO N
evaluate VB N
the DT N
impact NN N
on IN N
total JJ N
closure NN N
and CC N
quantitative JJ N
bacterial JJ N
cultures NNS N
and CC N
the DT N
effect NN N
on IN N
healing NN N
of IN N
various JJ N
levels NNS N
of IN N
sharp/surgical JJ N
debridement NN N
- : N
a DT N
randomized JJ N
double-blinded JJ N
sham-controlled JJ N
multicenter NN N
study NN N
was VBD N
conducted VBN N
in IN N
hospital-based JJ N
and CC N
private JJ N
wound NN N
care NN N
clinics NNS N
. . N

Patients NNS P
(55 VBP P
met VBN P
criteria NNS P
for IN P
efficacy NN P
analysis) RB P
received VBD P
standard NN P
of IN P
care NN P
which WDT P
included VBD P
products NNS P
that WDT P
provide VBP P
a DT P
moist NN P
environment NN P
offloading VBG P
diabetic JJ P
shoes NNS P
and CC P
socks NNS P
debridement VBP P
wound JJ P
evaluation NN P
and CC P
measurement NN P
. . P

The DT N
"therapy" NN N
was VBD N
either RB N
active JJ I
40 CD I
KHz NNP I
ultrasound NN I
delivered VBN I
by IN I
a DT I
saline JJ I
mist NN I
or CC I
a DT I
"sham NNP I
device" NN I
which WDT I
delivered VBD I
a DT I
saline JJ I
mist NN I
without IN I
the DT I
use NN I
of IN I
ultrasound NN I
. . I

After IN N
12 CD N
weeks NNS N
of IN N
care NN N
the DT N
proportion NN O
of IN O
wounds NNS O
healed VBN O
(defined VBD N
as IN N
complete JJ N
epithelialization NN N
without IN N
drainage) NN N
in IN N
the DT N
active JJ I
ultrasound NN I
therapy NN I
device NN N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
in IN N
the DT N
sham NN I
control NN N
group NN N
(40.7% NNP N
versus VBZ N
14.3% CD N
P NNP N
= VBD N
0.0366 CD N
Fisher's NNP N
exact JJ N
test) NN N
. . N

The DT I
ultrasound JJ I
treatment NN I
was VBD N
easy JJ N
to TO N
use VB N
and CC N
no DT N
difference NN N
in IN N
the DT N
number NN N
and CC N
type NN N
of IN N
adverse JJ O
events NNS O
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
was VBD N
noted VBN N
. . N

Of IN N
interest NN N
wounds NNS N
were VBD N
debrided VBN N
at IN N
baseline NN N
followed VBN N
by IN N
a DT N
quantitative JJ N
culture NN N
biopsy NN N
. . N

The DT N
results NNS N
of IN N
these DT N
cultures NNS N
demonstrated VBD N
a DT N
significant JJ N
bioburden NN N
(greater NN N
than IN N
10(5)) CD N
in IN N
the DT N
majority NN N
of IN N
cases NNS N
despite IN N
a DT N
lack NN N
of IN N
clinical JJ N
signs NNS N
of IN N
infection NN N
. . N

Compared VBN N
to TO N
control VB N
this DT N
therapeutic JJ N
modality NN N
was VBD N
found VBN N
to TO N
increase VB N
the DT N
healing VBG O
rate NN O
of IN N
recalcitrant JJ N
diabetic JJ N
foot NN N
ulcers NNS N
. . N

-DOCSTART- -X- N

Effects NNS N
of IN N
the DT N
cholinomimetic JJ I
SDZ NNP I
ENS-163 NNP I
on IN N
scopolamine-induced JJ N
cognitive JJ O
impairment NN P
in IN P
humans NNS P
. . P

Scopolamine-induced JJ P
cognitive JJ P
impairment NN P
was VBD P
used VBN P
in IN P
healthy JJ P
men NNS P
to TO N
evaluate VB N
the DT N
central JJ N
nervous JJ N
system NN N
activity NN N
of IN N
the DT N
new JJ I
cholinomimetic JJ I
SDZ NNP I
ENS-163 NNP I
. . I

Eighteen JJ P
subjects NNS P
were VBD N
treated VBN N
in IN N
a DT N
crossover NN N
design NN N
with IN N
oral JJ I
placebo/intravenous JJ I
saline NN I
50 CD I
mg NN I
of IN I
oral JJ I
SDZ NNP I
ENS-163/intravenous JJ I
saline JJ I
oral JJ I
placebo/0.4 NN I
mg NN I
of IN I
intravenous JJ I
scopolamine NN I
and CC I
50 CD I
mg NN I
of IN I
oral JJ I
SDZ NNP I
ENS-163/0.4 NNP I
mg NN I
of IN I
intravenous JJ I
scopolamine NN I
. . I

The DT N
administration NN N
of IN N
placebo NN I
with IN N
scopolamine NN I
caused VBN N
significant JJ N
cognitive JJ O
impairment NN O
as IN O
assessed VBN N
by IN N
the DT N
Computerized NNP N
Neuropsychological NNP N
Test NNP N
Battery NNP N
(CNTB) NN N
and CC N
also RB N
decreased VBN N
salivation NN O
and CC O
heart NN O
rate NN O
. . O

In IN N
contrast NN N
SDZ NNP N
ENS-163 NNP N
with IN N
saline NN N
had VBD N
no DT N
effect NN N
on IN N
CNTB NNP O
scores NNS O
increased VBD O
salivation NN O
and CC O
increased JJ O
heart NN O
rate NN O
. . O

Despite IN N
the DT N
observed JJ N
cholinomimetic JJ N
effects NNS O
of IN N
SDZ NNP I
ENS-163 NNP I
when WRB N
administered VBN N
with IN N
saline NN I
the DT I
changes NNS N
in IN N
CNTB NNP O
scores NNS O
heart NN O
rate NN O
and CC O
salivation NN O
were VBD N
indistinguishable JJ N
between IN N
placebo/scopolamine NN I
and CC I
SDZ NNP I
ENS-163/scopolamine NNP I
. . I

Thus RB N
50 CD N
mg NN N
of IN N
oral JJ N
SDZ NNP I
ENS-163 NNP I
has VBZ N
cholinomimetic JJ O
activity NN O
in IN N
normal JJ N
men NNS N
but CC N
this DT N
dose NN N
is VBZ N
insufficient JJ N
to TO N
reverse VB N
the DT N
muscarinic JJ O
effects NNS O
of IN N
0.4 CD N
mg NN N
of IN N
intravenous JJ N
scopolamine NN I
. . I

-DOCSTART- -X- N

Conservative JJ I
surgery NN I
with IN I
and CC I
without IN I
radiotherapy NN I
in IN N
elderly JJ P
patients NNS P
with IN P
early-stage JJ P
breast NN P
cancer: NN P
a DT N
prospective JJ N
randomised VBN N
multicentre JJ N
trial NN N
. . N

Breast NNP I
conserving VBG I
therapy NN I
(BCT) NN I
including VBG I
postoperative JJ I
irradiation NN I
of IN I
the DT I
remaining VBG I
breast NN I
tissue NN I
is VBZ N
generally RB N
accepted VBN N
as IN N
the DT N
best JJS N
treatment NN N
for IN N
the DT N
majority NN N
of IN N
patients NNS P
with IN P
early-stage JJ P
breast NN P
cancer NN P
. . P

The DT N
question NN N
is VBZ N
whether IN N
there EX N
is VBZ N
a DT N
necessity NN N
for IN N
irradiating VBG N
all DT N
patients NNS N
. . N

Between JJ P
2001 CD P
and CC P
2005 CD P
749 CD P
women NNS P
aged VBN P
55-75 JJ P
years NNS P
with IN P
infiltrating VBG P
breast NN P
carcinoma NN P
were VBD N
randomly RB N
assigned VBN N
to TO N
breast VB I
conservative JJ I
surgery NN I
with IN I
or CC I
without IN I
radiotherapy JJ I
(RT) NN I
to TO I
evaluate VB N
the DT N
incidence NN O
of IN O
in-breast JJ O
recurrence NN O
(IBR) NN O
. . O

After IN N
5 CD N
years NNS N
of IN N
median JJ N
follow-up NN N
the DT N
cumulative JJ O
incidence NN O
of IN O
IBR NNP O
was VBD N
2.5% CD N
in IN N
the DT N
surgery-only JJ I
arm NN N
and CC N
0.7% CD N
in IN N
the DT N
surgery NN I
plus CC I
RT NNP I
arm NN N
. . N

There EX N
are VBP N
no DT O
differences NNS O
in IN N
terms NNS N
of IN N
overall JJ O
survival NN O
and CC O
distant JJ O
disease-free JJ O
survival NN O
. . O

The DT N
preliminary JJ N
evaluation NN N
suggests VBZ N
that IN N
breast NN I
irradiation NN I
after IN I
conservative JJ I
surgery NN I
can MD N
be VB N
avoided VBN N
without IN N
exposing VBG N
these DT N
patients NNS N
to TO N
an DT N
increased VBN N
risk NN N
of IN N
distant-disease JJ N
recurrence NN N
. . N

Prolonged VBN N
follow-up NN N
will MD N
further RBR N
clarify VB N
the DT N
possible JJ N
risks NNS N
and CC N
late JJ N
sequelae NN N
potentially RB N
induced VBN N
by IN N
breast NN I
RT NNP I
. . I

-DOCSTART- -X- N

Studies NNS O
on IN O
section NN O
2D1 CD O
monoclonal JJ O
antibodies NNS O
. . O

Monoclonal JJ O
antibodies NNS O
in IN O
"Other NNP O
Blood NNP O
Groups" NNP O
were VBD O
tested VBN O
with IN N
random JJ P
blood NN P
samples NNS P
collected VBN P
from IN P
the DT P
various JJ P
ethnic JJ P
groups NNS P
in IN P
KwaZulu-Natal NNP P
South NNP P
Africa NNP P
and CC P
with IN P
samples NNS P
of IN P
selected VBN P
red JJ P
cell NN P
phenotypes NNS P
. . P

Standard NNP I
red VBD I
cell NN I
serological JJ I
techniques NNS I
were VBD N
used VBN N
. . N

-DOCSTART- -X- N

Effectiveness NN N
and CC N
safety NN N
of IN N
the DT N
Levitan NNP I
FPS NNP I
Scope NNP I
for IN P
tracheal JJ P
intubation NN P
under IN P
general JJ P
anesthesia NN P
with IN P
a DT P
simulated JJ P
difficult JJ P
airway NN P
. . N

PURPOSE NNP N
Studies NNP N
show VBP N
that IN N
the DT I
Levitan NNP I
FPS NNP I
(first NNP I
pass NN I
success) NN I
Scope NNP I
(LFS) NNP I
is VBZ N
analogous JJ N
to TO N
a DT N
bougie NN N
in IN N
simulated JJ N
difficult JJ N
airways NNS N
with IN N
comparable JJ I
tracheal JJ I
intubation NN I
success NN N
rates NNS N
. . N

In IN N
this DT N
study NN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
tracheal JJ N
intubation NN N
with IN N
the DT N
LFS NNP N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
the DT I
Macintosh NNP I
laryngoscope NN I
utilizing VBG N
manual JJ N
in-line JJ N
stabilization NN N
(MILS) NN N
to TO N
simulate VB N
difficult JJ N
airways NNS N
. . N

METHODS NNP P
Ninety-four JJ P
subjects NNS P
successfully RB P
completed VBD P
the DT P
trial NN P
. . I

Manual JJ I
in-line JJ I
stabilization NN I
of IN I
the DT I
cervical JJ I
spine NN I
was VBD I
applied VBN I
and CC I
the DT I
initial JJ I
laryngoscopy NN I
was VBD I
performed VBN I
using VBG I
either CC I
the DT I
Macintosh NNP I
or CC I
the DT I
LFS NNP I
in IN I
conjunction NN I
with IN I
the DT I
Macintosh NNP I
. . I

Following VBG I
the DT I
initial JJ I
grading VBG I
a DT I
second JJ I
laryngoscopy NN I
was VBD I
repeated VBN I
using VBG I
the DT I
second JJ I
randomized JJ I
technique NN O
. . O

Cormack-Lehane NNP O
grades NNS O
percentage NN O
of IN O
glottic JJ O
opening NN O
(POGO) NN O
scores NNS O
time NN O
to TO O
intubate VB O
number NN O
of IN O
intubation NN O
attempts NNS O
and CC O
the DT O
use NN O
of IN O
alternate NN O
techniques NNS O
were VBD N
recorded VBN N
. . N

The DT N
anesthesiologist NN N
rated VBD N
the DT N
subjective JJ N
difficulty NN N
in IN N
using VBG N
each DT N
technique NN N
with IN O
a DT O
numeric JJ O
rating NN O
scale NN O
and CC O
a DT O
visual JJ O
rating NN O
scale NN O
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
primary JJ N
outcome NN O
"good NN O
laryngoscopic NN O
views" IN O
(Cormack-Lehane NNP O
grade VBD O
1 CD O
and CC O
2) CD N
compared VBN N
with IN O
"poor NNP O
laryngoscopic NN O
views" NN O
(Cormack-Lehane JJ O
grade NN O
3 CD O
and CC O
4) CD N
between IN N
the DT N
LFS NNP N
and CC N
the DT N
Macintosh NNP N
. . N

There EX N
were VBD N
higher JJR O
POGO NNP O
scores NNS O
with IN N
the DT I
LFS NNP N
compared VBN N
with IN N
the DT I
Macintosh NNP I
(80% NNP N
vs VBD N
20% CD N
respectively; NN N
P NNP N
< VBZ N
0.0001) CD N
but CC N
this DT N
did VBD N
not RB N
translate VB N
to TO N
easier JJR N
intubations NNS N
as IN N
documented VBN N
by IN N
the DT N
need NN N
for IN N
an DT N
alternate JJ N
intubation NN N
technique NN N
or CC N
time NN N
to TO N
intubate VB N
(< JJ N
30 CD N
and CC N
< $ N
60 CD N
sec NN N
respectively) NN N
. . N

The DT N
incidence NN O
of IN O
mucosal NN O
trauma NN O
sore NN O
throat NN O
and CC O
hemodynamic JJ O
responses NNS O
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
techniques NNS N
. . N

CONCLUSION NNP N
The DT I
LFS NNP N
in IN N
conjunction NN N
with IN N
the DT I
Macintosh NNP I
laryngoscope NN I
does VBZ N
not RB N
improve VB N
the DT N
efficacy NN N
or CC N
safety NN P
of IN P
tracheal JJ P
intubation NN P
in IN P
a DT P
simulated JJ P
difficult JJ P
airway NN P
. . N

-DOCSTART- -X- N

Adequacy NN N
of IN N
vitamin NN I
B6 NNP I
supplementation NN I
during IN N
pregnancy: NN P
a DT N
prospective JJ N
study NN N
. . N

This DT N
prospective JJ N
study NN N
assesses VBZ N
the DT N
effect NN I
of IN I
2.5 CD I
4 CD I
and CC I
10 CD I
mg NN I
of IN I
pyridoxine JJ I
supplementation NN I
during IN P
pregnancy NN P
on IN P
maternal JJ P
and CC P
fetal JJ P
plasma NN P
levels NNS P
of IN O
pyridoxal JJ O
5'-phosphate JJ O
(PLP) NN O
and CC I
on IN I
the DT I
degree NN I
of IN I
coenzyme NN I
saturation NN I
(activation NNP I
factor) NN I
of IN I
aspartate JJ I
aminotransferase NN I
and CC I
alanine JJ I
aminotransferase NN I
(alphaEGOT NNP I
and CC I
alphaEGPT) NN I
in IN I
maternal JJ I
erythrocytes NNS I
. . I

More JJR N
than IN N
4 CD I
mg NN I
of IN I
pyridoxine JJ I
supplementation NN I
daily RB I
was VBD N
required VBN N
for IN N
most JJS N
pregnancies NNS N
to TO N
maintain VB N
maternal JJ N
plasma NN N
PLP NNP N
levels NNS N
within IN N
the DT N
range NN N
observed VBD N
during IN N
the DT N
first JJ N
trimester NN N
and CC N
in IN N
the DT N
nonpregnant JJ N
state NN N
. . N

The DT N
plasma NN N
PLP NNP N
concentrations NNS N
in IN N
maternal JJ N
and CC N
cord JJ N
blood NN N
were VBD N
highly RB N
correlated VBN N
and CC N
indicated VBD N
a DT N
dependence NN N
of IN N
fetal JJ N
vitamin NN I
B6 NNP I
nutrition NN I
on IN N
maternal JJ N
circulating NN N
PLP NNP N
. . N

Measurements NNS N
of IN N
alphaEGOT NN O
and CC O
alphaEGPT NN O
were VBD N
not RB N
as RB N
reproducible JJ N
as IN I
plasma JJ N
PLP NNP N
assays NNS N
and CC N
were VBD N
less RBR N
sensitive JJ N
and CC N
quantitative JJ N
indicators NNS N
. . N

In IN N
the DT N
majority NN N
of IN N
subjects NNS N
the DT N
changes NNS N
in IN N
alphaEGOT NN O
and CC O
alphaEGPT NN O
with IN N
time NN N
correlated VBN N
poorly RB N
with IN N
the DT N
changes NNS N
in IN N
plasma NN N
PLP NNP N
. . N

However RB N
when WRB N
the DT N
data NNS N
were VBD N
analyzed VBN N
without IN N
regard NN N
for IN N
their PRP$ N
dependence NN N
on IN N
time NN N
they PRP N
demonstrated VBD N
a DT N
negative JJ N
linear JJ N
correlation NN N
between IN N
alphaEGOT NN N
and CC N
log NN N
plasma NN N
PLP NNP N
and CC N
between IN N
alphaEGPT NN N
and CC N
log NN N
plasma NN N
PLP NNP N
for IN N
the DT N
group NN N
on IN N
2.5 CD N
mg NN N
of IN N
pyridoxine NN I
and CC N
for IN N
all PDT N
the DT N
subjects NNS N
combined VBN N
. . N

Finally RB N
the DT N
dietary NN N
records NNS N
showed VBD N
that IN N
most JJS N
of IN N
the DT N
subjects NNS N
consumed VBD N
less JJR N
than IN N
2 CD N
mg NN N
of IN N
vitamin JJ I
B6 NNP I
daily RB N
from IN N
their PRP$ N
food NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
the DT N
current JJ N
Recommended NNP N
Dietary NNP N
Allowance NNP N
for IN N
vitamin NN I
B6 NNP I
during IN I
pregnancy NN I
(2.5 NNP I
mg) NN I
is VBZ N
too RB N
low JJ N
and CC N
that DT N
supplementation NN N
of IN N
this DT N
vitamin NN N
in IN N
an DT N
amount NN N
more JJR N
than IN N
4 CD N
mg JJ N
daily JJ N
is VBZ N
recommended VBN N
. . N

-DOCSTART- -X- N

Effects NNS N
of IN N
telephone NN I
call NN I
interventions NNS I
on IN N
patients' JJ P
well-being NN P
in IN P
a DT P
radiation NN P
therapy NN P
department NN P
. . P

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
telephone NN I
call NN I
interventions NNS I
by IN N
a DT N
collaborative JJ N
team NN N
on IN N
patients' JJ P
well-being NN P
. . P

Fifty-five JJ P
subjects NNS P
undergoing VBG P
radiation NN P
therapy NN P
for IN P
cure NN P
and CC P
who WP P
were VBD P
able JJ P
to TO P
communicate VB P
by IN P
telephone NN P
comprised VBD P
the DT P
sample NN P
. . P

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
control NN P
group NN P
who WP P
received VBD P
the DT P
usual JJ P
care NN P
or CC P
to TO P
an DT P
experimental JJ P
group NN P
who WP P
received VBD I
a DT I
weekly JJ I
telephone NN I
call NN I
intervention NN I
in IN I
addition NN I
to TO I
the DT I
usual JJ I
care NN I
. . I

Speilberger's NNP O
State NNP O
Trait NNP O
Inventory NNP O
the DT O
Side NNP O
Effects NNPS O
Profile NNP O
and CC O
the DT N
Coping NNP O
Strategies NNP O
Profile NNP O
were VBD N
used VBN N
along IN N
with IN N
a DT N
telephone NN N
survey NN N
to TO N
collect VB N
data NNS N
. . N

Analysis NN N
of IN N
the DT N
data NN N
showed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
anxiety NN O
severity NN O
of IN O
side NN O
effects NNS O
helpfulness NN O
of IN O
self-care JJ O
strategies NNS O
and CC O
coping VBG O
strategies NNS O
. . O

However RB N
the DT N
survey NN N
indicated VBD N
that IN N
the DT N
telephone NN N
calls VBZ N
were VBD N
clinically RB N
significant JJ N
and CC N
provided VBD N
a DT N
mechanism NN N
for IN N
demonstrating VBG N
that IN N
the DT N
health NN N
care NN N
professionals NNS N
cared VBD N
about IN N
their PRP$ N
patients NNS N
and CC N
provided VBD N
an DT N
opportunity NN N
for IN N
patients NNS N
to TO N
talk VB N
about IN N
their PRP$ N
concerns NNS N
. . N

The DT N
investigators NNS N
believe VBP N
that IN N
collaboration NN N
caring NN N
and CC N
communication NN N
are VBP N
the DT N
essence NN N
of IN N
exemplary JJ N
health NN N
care NN N
. . N

-DOCSTART- -X- N

The DT N
effect NN N
of IN N
pain-free JJ I
treadmill NN I
training VBG I
on IN N
fibrinogen NN N
haematocrit NN N
and CC N
lipid JJ N
profile NN N
in IN N
patients NNS P
with IN P
claudication NN P
. . P

OBJECTIVE NN P
To TO N
assess VB N
the DT N
effect NN N
of IN N
pain-free JJ I
treadmill NN I
training VBG I
on IN N
changes NNS N
of IN N
plasma NN N
fibrinogen NN N
haematocrit NN N
lipid JJ N
profile NN N
and CC N
walking VBG N
ability NN N
in IN N
patients NNS P
with IN P
claudication NN P
. . P

DESIGN NNP N
Randomized NNP N
control NN N
trial NN N
. . N

METHODS NNP N
Sixty-eight JJ P
patients NNS P
with IN P
peripheral JJ P
obstructive JJ P
arterial JJ P
disease NN P
and CC P
intermittent JJ P
claudication NN P
(Fontaine NN P
stage NN P
II) NNP P
were VBD N
randomly RB I
assigned VBN I
into IN I
the DT I
treadmill NN I
training VBG I
(repetitive JJ I
intervals NNS I
to TO I
onset VB I
of IN I
claudication NN I
pain NN I
three CD I
times NNS I
a DT I
week) NN I
or CC I
a DT I
control NN I
group NN I
(no NNP I
change NN I
in IN I
physical JJ I
activity) NN I
over IN I
3 CD I
months NNS I
. . I

Both DT I
groups NNS I
performed VBD I
treadmill JJ I
test NN I
to TO I
assess VB I
pain-free JJ I
walking NN O
time NN O
(PFWT) NNP I
and CC I
maximal JJ I
walking NN I
time NN I
(MWT) NNP I
and CC I
had VBD I
blood NN O
analyses NNS O
[for VBP I
haematocrit NN I
fibrinogen NN I
triglycerides NNS I
and CC I
cholesterol: JJ I
total JJ I
high-density NN I
lipoprotein NN I
(HDL) CD I
and CC I
low-density JJ I
lipoprotein NN I
(LDL)] VBZ I
done VBN I
at IN I
baseline NN I
and CC I
after IN I
6 CD I
and CC I
12 CD I
weeks NNS I
of IN I
the DT I
study NN I
. . I

RESULTS NNP N
Total NNP O
and CC O
LDL NNP O
cholesterol NN O
levels NNS O
in IN N
the DT N
training NN I
group NN I
decreased VBD N
(p<0.05) VBN N
by IN N
14.8% CD N
and CC N
20 CD N
5% CD N
respectively RB N
. . N

Significant JJ N
(p<0.05) NNP O
HDL NNP O
cholesterol NN O
increased VBD N
(14.6%) NN O
and CC O
triglycerides NNS O
decreased VBD N
(19%) NN I
in IN I
the DT I
training NN I
group NN N
but CC N
changes NNS N
of IN N
all PDT N
these DT N
lipids NNS N
were VBD N
insignificant JJ I
in IN I
the DT I
control NN P
group NN P
over IN P
the DT P
3 CD P
months NNS O
. . O

Haematocrit NNP O
and CC O
fibrinogen NN O
changes NNS N
were VBD N
insignificant JJ N
in IN N
both DT N
groups NNS O
. . N

PFWT NNP N
was VBD N
prolonged VBN N
by IN N
109% CD O
and CC N
MWT NNP N
increased VBN N
by IN N
54% CD I
in IN I
the DT I
training NN I
group NN N
(p<0.01) NNP N
but CC I
not RB I
in IN I
the DT I
control NN I
group NN N
. . N

CONCLUSION NNP N
The DT N
improvement NN N
in IN N
walking VBG N
time NN N
over IN N
3 CD I
months NNS I
of IN I
pain-free JJ I
treadmill NN I
training NN N
parallels NNS N
with IN N
progressive JJ N
normalization NN N
of IN N
lipid JJ N
profiles NNS P
in IN P
patients NNS P
with IN P
claudication NN P
. . N

-DOCSTART- -X- N

Comparison NNP N
of IN N
acustimulation NN N
and CC N
ondansetron NN N
for IN N
the DT N
treatment NN N
of IN N
established VBN P
postoperative JJ P
nausea NN P
and CC P
vomiting NN P
. . P

BACKGROUND NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
transcutaneous JJ N
electrical JJ N
acupoint NN N
stimulation NN N
(acustimulation) IN N
using VBG N
the DT N
ReliefBand NNP N
compared VBN N
with IN N
ondansetron NN N
for IN N
the DT N
treatment NN P
of IN P
established VBN P
postoperative JJ P
nausea NN P
and CC P
vomiting VBG P
(PONV) NN P
after IN P
outpatient JJ P
laparoscopic NN P
surgery NN P
. . P

METHODS NNP N
After IN N
the DT N
authors NNS N
obtained VBD N
institutional JJ N
review NN N
board NN N
approval NN N
and CC N
written VBN N
informed JJ N
consent NN N
268 CD P
outpatients NNS P
were VBD P
enrolled VBN P
in IN N
this DT N
randomized JJ N
double-blind JJ N
placebo- NN N
and CC N
sham-controlled JJ N
study NN N
. . N

All DT N
patients NNS N
received VBN N
antiemetic JJ N
prophylaxis NN N
with IN N
metoclopramide JJ N
10 CD N
mg NN N
intravenously RB N
or CC N
droperidol VB N
0.625 CD N
mg NN N
intravenously RB N
after IN N
induction NN N
of IN N
anesthesia NN N
. . N

A DT N
total NN N
of IN N
90 CD P
patients NNS P
developed VBD P
PONV NNP P
in IN N
the DT N
recovery NN N
units NNS N
and CC N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
treatment NN N
groups: NN N
(1) VBD N
the DT N
ondansetron NN N
group NN N
received VBD N
4 CD N
mg NNS N
intravenous JJ N
ondansetron NN N
and CC N
a DT N
sham NN N
ReliefBand; NNP N
(2) VBZ N
the DT N
acustimulation NN N
group NN N
received VBD N
2 CD N
ml NNS N
intravenous JJ N
saline NN N
and CC N
a DT N
ReliefBand; NNP N
and CC N
(3) VB N
the DT N
combination NN N
group NN N
received VBD N
4 CD N
mg NNS N
intravenous JJ N
ondansetron NN N
and CC N
a DT N
ReliefBand NNP N
. . N

A DT N
rescue NN N
antiemetic JJ N
(10 NNP N
mg NN N
intravenous JJ N
metoclopramide) NN N
was VBD N
administered VBN N
only RB N
if IN N
the DT N
PONV NNP N
symptoms NNS N
persisted VBD N
for IN N
15 CD N
min NN N
or CC N
longer JJR N
after IN N
initiating VBG N
the DT N
treatment NN N
. . N

A DT N
blinded VBN N
observer NN N
recorded VBD N
the DT N
recovery NN O
times RB O
emetic JJ O
symptoms NNS O
rescue VBP O
antiemetics NNS O
maximum JJ O
nausea JJ O
scores NNS O
complete JJ O
response NN O
to TO O
study VB O
treatment NN O
and CC O
time NN O
to TO N
achieve VB N
discharge NN N
criteria NNS N
. . N

Postdischarge NNP N
side JJ N
effects NNS N
as RB N
well RB N
as IN N
patient JJ N
satisfaction NN N
and CC N
quality NN N
of IN N
recovery NN N
scores NNS N
were VBD N
assessed VBN N
at IN N
24 CD N
and CC N
72 CD N
h NN N
after IN N
surgery NN N
. . N

RESULTS VB N
The DT N
combination NN N
group NN N
had VBD N
a DT N
significantly RB N
higher JJR N
complete JJ N
response NN N
rate NN N
than IN N
the DT N
acustimulation NN N
group NN N
(73% NNP N
vs.40% NN N
P NNP N
<0.01) NNP N
. . N

In IN N
addition NN N
fewer NN N
patients NNS N
(8 JJ N
vs NN N
. . N

18) CD N
in IN N
the DT N
combination NN N
(vs NN N
. . N

acustimulation) NN N
group NN N
experienced VBD N
subsequent JJ N
emetic JJ O
events NNS O
(P VBP N
< JJ N
0.03) CD N
. . N

However RB N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
three CD N
groups NNS N
with IN N
respect NN N
to TO N
patient JJ O
satisfaction NN O
and CC O
quality NN O
of IN O
recovery NN O
scores NNS O
. . O

CONCLUSIONS NNP N
Acustimulation NNP N
with IN N
the DT N
ReliefBand NNP N
can MD N
be VB N
used VBN N
as IN N
an DT N
alternative NN N
to TO N
ondansetron VB N
for IN N
the DT N
treatment NN N
of IN N
established VBN N
PONV NNP N
. . N

However RB N
the DT N
use NN N
of IN N
ondansetron NN N
(4 NNP N
mg NN N
intravenously) NN N
in IN N
combination NN N
with IN N
the DT N
ReliefBand NNP N
device NN N
improved VBD N
the DT N
complete JJ N
response NN N
rate NN N
to TO N
the DT N
acustimulation NN N
therapy NN N
. . N

-DOCSTART- -X- N

Effects NNS N
of IN N
nifedipine NN I
on IN N
gastric JJ P
acid JJ P
secretion NN P
and CC P
gastrin NN P
release NN P
in IN P
man NN P
. . P

As IN N
calcium NN N
is VBZ N
important JJ N
in IN N
the DT N
regulation NN N
of IN N
gastric JJ N
acid JJ N
secretion NN N
and CC N
gastrin JJ N
release NN N
we PRP N
have VBP N
examined VBN N
the DT N
effect NN N
of IN N
the DT N
calcium NN I
antagonist NN I
nifedipine NN I
on IN N
these DT N
processes NNS N
in IN N
man NN P
. . P

Nifedipine NNP I
30 CD I
mg NN I
orally RB N
inhibited VBN N
basal NN N
acid NN N
output NN N
by IN N
37% CD N
(p NNS N
less JJR N
than IN N
0.025) CD N
and CC N
that IN N
stimulated VBN N
by IN N
low JJ N
infusion NN N
rates NNS N
of IN N
pentagastrin--that NN I
is VBZ N
0.031 CD N
and CC N
0.062 CD N
microgram/kg/h NN N
by IN N
44% CD N
(p NNS N
= JJ N
0.05) CD N
and CC N
39% CD N
(p NN N
less JJR N
than IN N
0.02) CD N
respectively RB N
. . N

On IN N
increasing VBG N
the DT N
pentagastrin JJ I
infusion NN I
rate NN N
the DT N
inhibition NN N
was VBD N
surmounted VBN N
suggesting VBG N
it PRP N
was VBD N
competitive JJ N
in IN N
type NN N
. . N

Nifedipine NN I
did VBD N
not RB N
affect VB N
basal NN O
or CC O
Oxo NNP O
meal NN O
stimulated VBD O
gastrin JJ O
concentrations NNS O
in IN N
normal JJ P
volunteers NNS P
nor CC N
did VBD N
it PRP N
affect VB N
resting VBG O
serum JJ O
gastrin NN O
or CC O
calcium NN O
stimulated JJ O
increase NN O
in IN O
gastrin NN O
in IN N
a DT N
single JJ P
patient NN P
with IN P
Zollinger-Ellison NNP P
syndrome NN P
. . P

These DT N
findings NNS N
are VBP N
consistent JJ N
with IN N
the DT N
transmembrane NN N
flux NN N
of IN N
calcium NN N
ions NNS N
being VBG N
involved VBN N
in IN N
basal NN N
and CC N
pentagastrin NN I
stimulated VBD N
acid JJ P
secretion NN P
in IN P
man NN P
. . P

-DOCSTART- -X- N

Pathological JJ I
features NNS I
and CC N
inhaled JJ I
corticosteroid NN I
response NN I
of IN N
eosinophilic JJ P
and CC P
non-eosinophilic JJ P
asthma NN P
. . P

BACKGROUND NNP N
Non-eosinophilic NNP N
asthma NN N
is VBZ N
a DT N
potentially RB N
important JJ N
clinicopathological JJ N
phenotype NN N
since IN N
there EX N
is VBZ N
evidence NN N
that IN N
it PRP N
responds VBZ N
poorly RB N
to TO N
inhaled VB I
corticosteroid JJ I
therapy NN I
. . I

However RB N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
underlying JJ N
airway NN N
immunopathology NN I
and CC N
there EX N
are VBP N
no DT N
data NNS N
from IN N
placebo-controlled JJ N
studies NNS N
examining VBG N
the DT N
effect NN N
of IN N
inhaled JJ I
corticosteroids NNS I
. . I

METHODS NNP N
Airway NNP N
immunopathology NN N
was VBD N
investigated VBN N
using VBG N
induced JJ O
sputum NN O
bronchial JJ O
biopsies NNS O
bronchial JJ O
wash NN O
and CC N
bronchoalveolar JJ O
lavage NN O
in IN N
12 CD P
patients NNS P
with IN P
symptomatic JJ P
eosinophilic JJ P
asthma NN P
11 CD P
patients NNS P
with IN P
non-eosinophilic JJ P
asthma NN P
and CC P
10 CD P
healthy JJ P
controls NNS P
. . P

The DT N
patients NNS P
with IN P
non-eosinophilic JJ P
asthma NN P
and CC P
6 CD P
different JJ P
patients NNS P
with IN P
eosinophilic JJ P
asthma NN P
entered VBD N
a DT N
randomised JJ N
double-blind JJ N
placebo-controlled JJ I
crossover NN N
study NN N
in IN N
which WDT N
the DT N
effects NNS N
of IN N
inhaled JJ I
mometasone NN I
400 CD I
microg NN I
once RB I
daily JJ I
for IN N
8 CD N
weeks NNS N
on IN N
airway NN O
responsiveness NN O
and CC N
asthma JJ O
quality NN O
of IN O
life NN O
were VBD N
investigated VBN N
. . N

RESULTS JJ N
Patients NNS P
with IN P
non-eosinophilic JJ P
asthma NN P
had VBD N
absence NN N
of IN N
eosinophils NNS O
in IN O
the DT O
mucosa NN O
(median JJ N
4.4 CD N
cells/mm(2) NN N
vs NN N
23 CD N
cells/mm(2) NN N
in IN N
eosinophilic JJ N
asthma NN N
and CC N
0 CD N
cells/mm(2) NN N
in IN N
normal JJ N
controls; NN N
p NN N
= $ N
0.03) CD N
and CC N
normal JJ N
subepithelial JJ O
layer NN O
thickness NN O
(5.8 NN N
microm NN N
vs NN N
10.3 CD N
microm NN N
in IN N
eosinophilic JJ N
asthma NN N
and CC N
5.1 CD N
microm NN N
in IN N
controls NNS N
p VBP N
= JJ N
0.002) CD N
. . N

Non-eosinophilic JJ P
and CC P
eosinophilic JJ P
asthma NN P
groups NNS P
had VBD N
increased VBN N
mast RB O
cell NN O
numbers NNS N
in IN N
the DT N
airway NN N
smooth JJ N
muscle NN N
compared VBN N
with IN N
normal JJ N
controls NNS N
(9 VBP N
vs RB N
8 CD N
vs NNS N
0 CD N
cells/mm(2) NN N
p NN N
= VBD N
0.016) CD N
. . N

Compared VBN N
with IN N
placebo JJ I
8 CD I
weeks NNS N
of IN N
treatment NN I
with IN I
inhaled JJ I
mometasone NN I
led VBD N
to TO N
less RBR N
improvement NN O
in IN N
methacholine NN N
PC(20) NNP N
(0.5 NNP N
vs VBD N
5.5 CD N
doubling VBG N
concentrations NNS N
95% CD N
CI NNP N
of IN N
difference NN N
1.1 CD N
to TO N
9.1; CD N
p NNS N
= JJ N
0.018) CD N
and CC N
asthma JJ O
quality NN O
of IN O
life NN O
(0.2 NNP N
vs VBD N
1.0 CD N
points NNS N
95% CD N
CI NNP N
of IN N
difference NN N
0.27 CD N
to TO N
1.43; CD N
p NNS N
= JJ N
0.008) CD N
. . N

CONCLUSIONS NNP N
Non-eosinophilic NNP N
asthma NN N
represents VBZ N
a DT N
pathologically RB N
distinct JJ N
disease NN N
phenotype NN N
which WDT N
is VBZ N
characterised VBN N
by IN N
the DT N
absence NN N
of IN N
airway RB O
eosinophilia JJ O
normal JJ O
subepithelial JJ O
layer NN O
thickness NN O
and CC N
a DT N
poor JJ N
short-term JJ O
response NN O
to TO O
treatment NN O
with IN N
inhaled JJ I
corticosteroids NNS I
. . I

-DOCSTART- -X- N

A DT N
randomised JJ N
trial NN N
evaluating VBG N
pain NN O
and CC O
bleeding NN O
after IN P
a DT P
first JJ P
trimester NN P
miscarriage NN P
treated VBD P
surgically RB P
or CC P
medically RB P
. . P

Miscarriage NN P
treated VBD N
surgically RB N
and CC N
medically RB N
were VBD N
compared VBN N
in IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
evaluating VBG N
pain NN N
and CC N
bleeding NN N
. . N

Surgery NN N
is VBZ N
associated VBN N
with IN N
less JJR O
pain NN O
(P NNP N
< VBZ N
0.03) CD N
and CC N
vaginal JJ O
bleeding NN O
(duration NN N
and CC N
severity NN N
P NNP N
= VBZ N
0.001) CD N
than IN N
medical JJ N
treatment NN N
fewer JJR O
daily JJ O
hospital NN O
attendances NNS O
(2.5 VBP N
compared VBN N
with IN N
three CD N
P NNP N
= VBD N
0.04) CD N
but CC N
a DT N
greater JJR N
drop NN N
in IN N
haemoglobin JJ N
concentration NN N
(difference NN N
1 CD N
g/dl; NN N
CI95% NNP N
= NNP N
0.3-1.6) NN N
. . N

-DOCSTART- -X- N

Neostigmine NNP I
and CC I
edrophonium JJ I
antagonism NN I
of IN I
moderate JJ I
neuromuscular JJ I
block NN I
induced VBN I
by IN I
pancuronium NN I
or CC I
tubocurarine NN I
. . I

Edrophonium NN I
and CC I
neostigmine NN I
are VBP I
anticholinesterase JJ I
drugs NNS I
used VBN I
commonly RB I
to TO I
antagonize VB I
competitive JJ I
neuromuscular JJ O
block NN O
. . O

Although IN I
it PRP I
has VBZ I
a DT I
faster RBR I
onset NN I
of IN I
action NN I
than IN I
neostigmine JJ I
edrophonium NN I
is VBZ I
unreliable JJ I
when WRB I
used VBN I
to TO I
antagonize VB I
deep JJ I
neuromuscular JJ O
block NN O
. . O

We PRP I
have VBP I
compared VBN I
the DT I
antagonist NN O
characteristics NNS O
of IN I
these DT I
two CD I
drugs NNS I
when WRB I
used VBN I
to TO I
antagonize VB I
a DT I
moderate JJ I
degree NN I
of IN I
pancuronium- NN I
or CC I
tubocurarine-induced JJ I
neuromuscular JJ I
block NN I
. . I

Forty NNP P
ASA NNP P
I PRP P
or CC P
II NNP P
patients NNS P
undergoing VBG P
surgical JJ P
procedures NNS P
were VBD I
allocated VBN I
randomly RB I
to TO I
receive VB I
either DT I
pancuronium NN I
70 CD I
micrograms JJ I
kg-1 NN I
or CC I
tubocurarine VB I
0.5 CD I
mg JJ I
kg-1 NN I
and CC I
to TO I
receive VB I
either DT I
edrophonium NN I
0.5 CD I
mg JJ I
kg-1 NN I
or CC I
neostigmine JJ I
0.05 CD I
mg JJ I
kg-1 NN I
. . I

Antagonism NN I
was VBD I
attempted VBN I
when WRB I
the DT I
first JJ I
response NN I
to TO I
train-of-four JJ I
(TOF) JJ I
stimulation NN I
recovered VBD I
spontaneously RB I
to TO I
25% CD I
of IN I
the DT I
control NN I
height NN I
. . I

Neuromuscular JJ O
function NN O
was VBD I
monitored VBN I
using VBG I
the DT I
evoked VBN O
integrated JJ O
electromyogram NN O
of IN I
the DT I
first JJ I
dorsal NN I
interosseous JJ I
muscle NN I
of IN I
the DT I
hand NN I
. . I

Adequate JJ I
recovery NN I
was VBD I
defined VBN I
as IN I
the DT I
achievement NN I
of IN I
a DT I
TOF NNP I
ratio NN I
of IN I
0.70 CD I
or CC I
greater JJR I
. . I

Only RB I
seven CD I
of IN I
20 CD P
patients NNS P
who WP P
received VBD P
edrophonium NN I
demonstrated VBD I
adequate JJ I
recovery NN I
30 CD I
min NN I
after IN I
antagonism NN I
. . I

Under IN I
the DT I
conditions NNS I
described VBN I
in IN I
this DT I
study NN I
edrophonium VBD I
0.5 CD I
mg JJ I
kg-1 NN I
was VBD I
less RBR I
effective JJ I
as IN I
an DT I
antagonist NN I
than IN I
neostigmine JJ I
0.05 CD I
mg JJ I
kg-1 NN I
. . I

-DOCSTART- -X- N

Falls NNS O
and CC O
mobility NN O
in IN N
Parkinson's NNP P
disease: NN P
protocol NN N
for IN N
a DT N
randomised VBN N
controlled JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Although IN N
physical JJ I
therapy NN I
and CC I
falls VBZ I
prevention NN I
education NN I
are VBP N
argued VBN N
to TO N
reduce VB N
falls NNS O
and CC N
disability NN O
in IN N
people NNS P
with IN P
idiopathic JJ P
Parkinson's NNP P
disease NN P
this DT P
has VBZ N
not RB N
yet RB N
been VBN N
confirmed VBN N
with IN N
a DT N
large JJ N
scale NN N
randomised VBD N
controlled JJ N
clinical JJ N
trial NN N
. . N

The DT N
study NN N
will MD N
investigate VB N
the DT N
effects NNS N
on IN N
falls NNS O
mobility NN O
and CC O
quality NN O
of IN O
life NN O
of IN N
(i) JJ I
movement NN I
strategy NN I
training NN I
combined VBN I
with IN I
falls NNS I
prevention JJ I
education NN I
(ii) NNP I
progressive JJ I
resistance NN I
strength NN I
training NN I
combined VBN I
with IN I
falls NNS I
prevention JJ I
education NN I
(iii) VBD I
a DT I
generic JJ I
life-skills JJ I
social JJ I
program NN I
(control NN I
group) NN I
. . I

METHODS/DESIGN JJ N
People NNS P
with IN P
idiopathic JJ P
Parkinson's NNP P
disease NN P
who WP P
live VBP P
at IN P
home NN P
will MD N
be VB N
recruited VBN N
and CC N
randomly RB N
allocated VBD N
to TO N
one CD N
of IN N
three CD N
groups NNS N
. . N

Each DT N
person NN N
shall MD N
receive VB P
therapy NN P
in IN P
an DT P
out-patient JJ P
setting NN P
in IN P
groups NNS P
of IN P
3-4 JJ P
. . P

Each DT N
group NN N
shall MD N
be VB N
scheduled VBN I
to TO I
meet VB I
once RB I
per IN I
week NN I
for IN I
2 CD I
hours NNS I
for IN I
8 CD I
consecutive JJ I
weeks NNS I
. . I

All DT P
participants NNS P
will MD P
also RB P
have VB P
a DT P
structured JJ P
2 CD P
hour NN P
home NN P
practice NN P
program NN P
for IN I
each DT I
week NN I
during IN I
the DT I
8 CD I
week NN I
intervention NN I
phase NN I
. . I

Assessments NNS N
will MD N
occur VB N
before IN N
therapy NN I
after IN I
the DT N
8 CD N
week NN N
therapy NN I
program NN I
and CC I
at IN N
3 CD N
and CC N
12 CD N
months NNS N
after IN N
the DT N
intervention NN I
. . I

A DT N
falls VBZ N
calendar NN N
will MD N
be VB N
kept VBN N
by IN N
each DT N
participant NN N
for IN N
12 CD N
months NNS N
after IN N
outpatient JJ I
therapy.Consistent NN I
with IN N
the DT N
recommendations NNS N
of IN N
the DT N
Prevention NNP N
of IN N
Falls NNP N
Network NNP N
Europe NNP N
group NN N
three CD N
falls VBZ N
variables NNS N
will MD N
be VB N
used VBN N
as IN N
the DT N
primary JJ N
outcome NN N
measures: VBD N
the DT O
number NN O
of IN O
fallers NNS O
the DT O
number NN O
of IN O
multiple JJ O
fallers NNS O
and CC O
the DT O
falls JJ O
rate NN O
. . O

In IN N
addition NN N
to TO N
quantifying VBG N
falls NNS O
we PRP O
shall MD N
measure VB N
mobility NN O
activity NN O
limitations NNS O
and CC O
quality NN O
of IN O
life NN O
as IN N
secondary JJ N
outcomes NNS N
. . N

DISCUSSION NN N
This DT N
study NN N
has VBZ N
the DT N
potential NN N
to TO N
determine VB N
whether IN N
outpatient JJ I
movement NN I
strategy NN I
training NN I
combined VBN I
with IN I
falls NNS I
prevention JJ I
education NN I
or CC I
progressive JJ I
resistance NN I
strength NN I
training NN I
combined VBN I
with IN I
falls NNS I
prevention JJ I
education NN I
are VBP N
effective JJ N
for IN N
reducing VBG N
falls NNS O
and CC N
improving VBG N
mobility NN O
and CC N
life NN O
quality NN O
in IN N
people NNS P
with IN P
Parkinson's NNP P
disease NN P
who WP P
live VBP P
at IN P
home NN P
. . P

TRIAL NNP N
REGISTRATION NNP N
Australia NNP N
and CC N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Register NNP N
(ANZCTR): NNP N
ACTRN12606000344594 NNP N
. . N

-DOCSTART- -X- N

The DT N
effect NN N
of IN N
the DT N
video NN I
game NN I
Mindlight NNP I
on IN P
anxiety NN P
symptoms NNS P
in IN P
children NNS P
with IN P
an DT P
Autism NNP P
Spectrum NNP P
Disorder NNP P
. . P

BACKGROUND NNP N
In IN N
the DT N
clinical JJ N
setting VBG N
a DT N
large JJ N
proportion NN N
of IN N
children NNS P
with IN P
an DT P
autism NN P
spectrum NN P
disorder NN P
(ASD) NNP P
experience NN P
anxiety NN P
symptoms NNS P
. . P

Because IN N
anxiety NN N
is VBZ N
an DT N
important JJ N
cause NN N
of IN N
impairment NN N
for IN N
children NNS P
with IN P
an DT P
ASD NNP P
it PRP P
is VBZ N
necessary JJ N
that IN N
effective JJ N
anxiety NN N
interventions NNS N
are VBP N
implemented VBN N
for IN N
these DT N
children NNS N
. . N

Recently RB N
a DT N
serious JJ I
game NN I
called VBN I
Mindlight NNP I
has VBZ N
been VBN N
developed VBN N
that DT N
is VBZ N
focused VBN N
on IN N
decreasing VBG N
anxiety NN N
in IN N
children NNS N
. . N

This DT N
approach NN N
is VBZ N
based VBN N
on IN N
recent JJ N
research NN N
suggesting VBG N
that IN N
video JJ I
games NNS I
might MD N
be VB N
suitable JJ N
as IN N
an DT N
intervention NN N
vehicle NN N
to TO N
enhance VB N
mental JJ N
health NN N
in IN N
children NNS N
. . N

In IN N
the DT N
present JJ N
study NN N
it PRP N
will MD N
be VB N
investigated VBN N
whether IN N
Mindlight NNP I
is VBZ N
effective JJ N
in IN N
decreasing VBG N
(sub) JJ N
clinical JJ O
anxiety NN O
symptoms NNS O
in IN N
children NNS P
who WP P
are VBP P
diagnosed VBN P
with IN P
an DT P
ASD NNP P
. . P

METHODS/DESIGN NNP N
The DT N
present JJ N
study NN N
involves VBZ N
a DT N
randomized NN N
controlled VBN N
trial NN N
(RCT) NN N
with IN N
two CD N
conditions NNS N
(experimental JJ I
versus NN I
control) NN I
in IN N
which WDT N
it PRP N
is VBZ N
investigated VBN N
whether IN N
Mindlight NNP I
is VBZ N
effective JJ N
in IN N
decreasing VBG N
(sub) JJ N
clinical JJ N
anxiety NN O
symptoms NNS O
in IN N
children NNS N
with IN N
an DT N
ASD NNP N
. . N

For IN N
this DT N
study NN N
children NNS P
of IN P
8-16 CD P
years NNS P
old JJ P
with IN P
a DT P
diagnosis NN P
of IN P
an DT P
ASD NNP P
and CC P
(sub) NNP P
clinical JJ P
anxiety NN P
symptoms NNS P
will MD P
be VB P
randomly RB P
assigned VBN P
to TO P
the DT P
experimental JJ P
(N NNP P
= NNP P
60) CD P
or CC P
the DT P
control NN P
(N NNP P
= NNP P
60) CD P
condition NN P
. . P

Children NNP N
in IN N
the DT N
experimental JJ N
condition NN N
will MD N
play VB I
Mindlight NNP I
for IN I
one CD I
hour NN I
per IN I
week NN I
for IN I
six CD N
consecutive JJ N
weeks NNS N
. . N

Children NNP N
in IN N
the DT N
control NN N
condition NN N
will MD N
play VB N
the DT N
puzzle NN I
game NN I
Triple NNP I
Town NNP I
also RB I
for IN I
one CD I
hour NN I
per IN I
week NN I
and CC I
for IN I
six CD I
consecutive JJ I
weeks NNS I
. . I

All DT N
children NNS N
will MD N
complete VB N
assessments NNS N
at IN N
baseline JJ N
post-intervention NN N
and CC N
3-months JJ N
follow-up NN N
. . N

Furthermore RB N
parents NNS N
and CC N
teachers NNS N
will MD N
also RB N
complete JJ N
assessments NNS N
at IN N
the DT N
same JJ N
time NN N
points NNS N
. . N

The DT N
primary JJ N
outcome NN N
will MD N
be VB N
child JJ N
report NN N
of IN N
anxiety NN O
symptoms NNS O
. . O

Secondary JJ N
outcomes NNS N
will MD N
be VB N
parent JJ O
report NN O
of IN O
child JJ O
anxiety NN O
child/parent JJ O
report NN O
of IN O
depressive JJ O
symptoms NNS O
and CC O
parent/teacher JJ O
report NN O
of IN O
social JJ O
functioning NN O
and CC O
behavior NN O
problems NNS O
. . O

DISCUSSION NN N
This DT N
paper NN N
aims VBZ N
to TO N
describe VB N
a DT N
study NN N
that WDT N
will MD N
examine VB N
the DT N
effect NN N
of IN N
the DT N
serious JJ N
game NN I
Mindlight NNP I
on IN N
(sub) NNP N
clinical JJ N
anxiety NN N
symptoms NNS N
of IN N
children NNS N
with IN N
an DT N
ASD NNP N
in IN N
the DT N
age NN N
of IN N
8-16 CD N
years NNS N
old JJ N
. . N

It PRP N
is VBZ N
expected VBN N
that IN N
children NNS N
in IN N
the DT N
experimental JJ N
condition NN N
will MD N
show VB N
lower JJR N
levels NNS N
of IN N
anxiety NN O
symptoms NNS O
at IN N
3-months JJ N
follow-up JJ N
compared VBN N
to TO N
children NNS N
in IN N
the DT N
control NN N
condition NN N
. . N

If IN N
Mindlight NNP I
turns VBZ N
out RP N
to TO N
be VB N
effective JJ N
it PRP N
could MD N
be VB N
an DT N
important JJ N
contribution NN N
to TO N
the DT N
already RB N
existing JJ N
interventions NNS N
for IN N
anxiety NN N
in IN N
children NNS N
with IN N
an DT N
ASD NNP N
. . N

Mindlight NNP I
could MD N
then RB N
be VB N
implemented VBN N
as IN N
an DT N
evidence-based JJ I
treatment NN I
for IN N
anxiety NN O
symptoms NNS O
in IN N
children NNS P
with IN P
an DT P
ASD NNP P
in IN N
mental JJ N
health NN N
institutes NNS N
and CC N
special JJ N
education NN N
schools NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Dutch NNP N
Trial NNP N
Register NNP N
NTR5069 NNP N
. . N

Registered VBN N
20 CD P
April NNP P
2015 CD P
. . P

-DOCSTART- -X- N

Effect NN N
of IN N
Ezetimibe NNP I
on IN N
LDL-C NNP N
Lowering NNP N
and CC N
Atherogenic NNP N
Lipoprotein NNP N
Profiles NNP N
in IN N
Type NNP P
2 CD P
Diabetic NNP P
Patients NNPS P
Poorly NNP P
Controlled VBN P
by IN P
Statins NNP P
. . P

BACKGROUND NNP P
There EX N
exists VBZ N
a DT N
subpopulation NN N
of IN N
T2DM NNP N
in IN N
whom WP N
first-line JJ N
doses NNS N
of IN N
statin NN I
are VBP N
insufficient JJ N
for IN N
optimally RB N
reducing VBG N
LDL-C NNP N
representing VBG N
a DT N
major JJ N
risk NN N
of IN N
CVD NNP N
. . N

The DT N
RESEARCH NNP N
study NN N
focuses VBZ N
on IN N
LDL-C NNP N
reduction NN N
in IN N
this DT N
population NN N
along IN N
with IN N
modifications NNS N
of IN N
the DT N
lipid JJ N
profiles NNS N
leading VBG N
to TO N
residual JJ N
risks NNS N
. . N

METHODS NNP N
Lipid NNP O
changes NNS O
were VBD N
assessed VBN N
in IN N
a DT N
randomized JJ N
multicenter NN N
12-week JJ N
open-label JJ N
study NN N
comparing VBG N
a DT N
high-potency NN I
statin NN I
(10mg NN I
of IN I
atorvastatin NN I
or CC I
1mg CD I
of IN I
pitavastatin) NN I
plus CC I
ezetimibe JJ I
(EAT: NNP I
n NN N
= VBD N
53) CD N
with IN N
a DT N
double JJ I
dose NN I
of IN I
statin JJ I
(20mg NN I
of IN I
atorvastatin NN I
or CC I
2mg CD I
of IN I
pitavastatin) NN I
(DST: NNP I
n VBZ N
= $ N
56) CD N
in IN N
DM NNP P
subjects NNS P
who WP P
had VBD P
failed VBN P
to TO P
achieve VB P
the DT P
optimal JJ P
LDL-C NNP P
targets NNS P
. . P

Lipid JJ N
variables NNS N
were VBD N
compared VBN N
with IN N
a DT N
primary JJ N
focus NN N
on IN N
LDL-C NNP N
and CC N
with IN N
secondary JJ N
focuses NNS N
on IN N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
reached VBD N
the DT N
LDL-C NNP N
targets NNS N
and CC N
changes NNS N
in IN N
the DT N
levels NNS N
of IN N
RLP-C NNP O
(remnant NNP N
like IN N
particle NN N
cholesterol) NN N
and CC N
sd-LDL-C JJ N
two CD N
characteristic JJ N
atherogenic JJ N
risks NNS N
of IN N
DM NNP N
. . N

RESULTS VB N
The DT N
reduction NN N
of IN N
LDL-C NNP O
(%) NNP N
the DT N
primary JJ N
endpoint NN N
differed VBD N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
(-24.6 JJ N
in IN N
EAT NNP I
vs NN N
. . N

-10.9 NN N
in IN N
DST) NNP I
. . N

In IN N
the DT N
analyses NNS N
of IN N
the DT N
secondary JJ N
endpoints NNS N
EAT NNP N
treatment NN N
brought VBD N
about RB N
significantly RB N
larger JJR N
reductions NNS N
in IN N
sd-LDL-C JJ O
(-20.5 JJ N
vs NN N
. . N

-3.7) NN N
and CC N
RLP-C JJ O
(-19.7 JJ N
vs NN N
. . N

+5.5) NN N
. . N

In IN N
total JJ N
89.4% CD N
of IN N
the DT N
patients NNS N
receiving VBG N
EAT NNP I
reached VBD N
the DT N
optimized JJ N
treatment NN N
goal NN N
compared VBN N
to TO N
51.0% CD N
of IN N
the DT N
patients NNS N
receiving VBG N
DST NNP I
. . I

The DT N
changes NNS N
in IN N
TC NNP O
(-16.3 JJ N
vs NN N
. . N

-6.3) NN N
and CC N
non-HDL-C JJ O
(-20.7 JJ N
vs NN N
. . N

-8.3) NN N
differed VBD N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Ezetimibe NNP I
added VBD I
to TO I
high-potency NN I
statin NN I
(10 NNP I
mg NN I
of IN I
atorvastatin NN I
or CC I
1 CD I
mg NN I
of IN I
pitavastatin) NN I
was VBD N
more RBR N
effective JJ N
than IN N
the DT N
intensified-dose JJ I
statin NN I
(20 NNP I
mg NN I
of IN I
atorvastatin NN I
or CC I
2 CD I
mg NN I
of IN I
pitavastatin) NN I
treatment NN I
not RB N
only RB N
in IN N
helping VBG N
T2DM NNP N
patients NNS N
attain VBP N
more JJR N
LDL-C JJ O
reduction NN N
but CC N
also RB N
in IN N
improving VBG N
their PRP$ N
atherogenic JJ N
lipid JJ N
profiles NNS N
including VBG N
their PRP$ N
levels NNS N
of IN N
sd-LDL-C JJ O
and CC O
RLP-C NNP O
. . O

We PRP N
thus RB N
recommend VBP N
the DT N
addition NN N
of IN N
ezetimibe NN I
to TO N
high-potency NN N
statin NN N
as IN N
a DT N
first JJ N
line NN N
strategy NN N
for IN N
T2DM NNP N
patients NNS N
with IN N
insufficient JJ N
statin NN I
response NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
The DT N
UMIN NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
UMIN000002593 NNP N
. . N

-DOCSTART- -X- N

Faux NNP I
pas CC I
detection NN I
and CC N
intentional JJ N
action NN N
in IN N
Asperger NNP P
Syndrome NNP P
. . P

A DT N
replication NN N
on IN N
a DT N
French JJ N
sample NN N
. . N

In IN N
the DT N
present JJ N
study NN N
we PRP N
investigated VBD N
mind NN N
reading NN N
abilities NNS N
in IN N
a DT N
group NN P
of IN P
adults NNS P
with IN P
Asperger NNP P
Syndrome NNP P
(AS) NN P
by IN N
using VBG N
the DT N
faux JJ I
pas NN I
task NN I
an DT I
advanced JJ I
test NN I
of IN I
theory NN I
of IN I
mind NN I
(Baron-Cohen JJ N
et NN N
al NN N
. . N

(1999) NN N
. . N

Journal NNP N
of IN N
Autism NNP N
and CC N
Developmental NNP N
Disorders NNP N
29 CD N
407-418) NN N
. . N

The DT N
faux JJ I
pas NN I
is VBZ N
a DT N
particular JJ N
case NN N
of IN N
a DT N
non-intentional JJ N
action NN N
reflecting VBG N
an DT N
involuntary JJ N
socially RB N
inappropriate JJ N
behavior NN N
. . N

Here RB N
individuals NNS P
with IN P
AS NNP P
over-detected JJ P
faux NN I
pas NN I
stories NNS N
failed VBD N
to TO N
provide VB N
correct JJ O
justifications NNS O
of IN N
the DT N
speaker's JJ N
behavior NN N
and CC N
were VBD N
unaware NN N
of IN N
the DT N
mistaken JJ N
belief NN N
and CC N
of IN N
the DT N
resulting JJ N
emotional JJ N
impact NN N
whereas IN N
they PRP N
appeared VBD N
to TO N
be VB N
responsive JJ N
to TO N
social JJ N
rule NN N
violations NNS N
. . N

We PRP N
hypothesized VBD N
that IN N
because IN N
of IN N
an DT N
impaired JJ N
theory-of-mind JJ N
individuals NNS P
with IN P
AS NNP P
may MD N
develop VB N
compensatory JJ N
cognitive JJ N
strategies NNS N
based VBN N
on IN N
overlearned JJ N
abstract JJ N
knowledge NN N
about IN N
normative JJ N
rules NNS N
. . N

-DOCSTART- -X- N

Comparison NNP N
of IN N
injection NN N
comfort NN N
of IN N
a DT N
new JJ N
category NN N
of IN N
cohesive JJ I
hyaluronic JJ I
acid NN I
filler NN I
with IN I
preincorporated JJ I
lidocaine NN I
and CC I
a DT I
hyaluronic JJ I
acid NN I
filler NN I
alone RB I
. . I

BACKGROUND NNP N
A NNP N
smooth JJ N
cohesive JJ N
24-mg/mL JJ I
hyaluronic JJ I
acid NN I
(HA) NNP I
gel NN I
with IN N
uniform JJ N
consistency NN N
even RB N
flow JJ N
characteristics NNS N
and CC N
extended JJ N
duration NN N
was VBD N
designed VBN N
for IN N
injection NN N
into IN N
the DT N
mid NN N
to TO N
deep VB N
dermis NN N
. . N

OBJECTIVE NN N
To TO N
compare VB N
injection NN O
pain NN O
of IN N
a DT N
HA NNP I
gel NN I
with IN I
preincorporated JJ I
lidocaine NN I
with IN I
that DT I
with IN I
a DT I
non-lidocaine JJ I
formulation NN I
. . I

METHODS NNP N
& CC N
MATERIALS NNP N
This DT N
double-blind NN N
study NN N
at IN N
three CD P
centers NNS P
enrolled VBD P
60 CD P
subjects NNS P
injected VBN P
with IN P
both DT P
products NNS P
randomly RB P
assigned VBN P
to TO P
left VBD P
or CC P
right JJ P
nasolabial JJ P
fold NN P
. . P

The DT N
injecting NN N
physician NN N
assessed VBD N
severity NN N
of IN N
pain NN O
and CC N
ease NN O
of IN O
injection NN O
. . O

Subjects NNS P
used VBD P
a DT P
visual JJ P
analog NN P
scale JJ P
(0-10) NN P
for IN P
pain NN P
assessment NN P
. . P

Adverse JJ O
events NNS O
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Physician NNP N
assessment NN N
of IN N
injection NN O
pain NN O
was VBD N
none NN N
or CC N
mild NN N
in IN N
81% CD N
of IN N
HA NNP I
gel NN N
injections NNS N
with IN N
preincorporated JJ N
lidocaine NN I
and CC N
36% CD N
of IN N
HA-alone NNP I
injections NNS N
(p<.001) NNP N
. . N

Mean NNP O
pain NN O
assessment NN O
by IN N
subjects NNS N
was VBD N
3.6 CD N
for IN N
HA+lidocaine NNP I
and CC N
5.8 CD N
for IN N
HA NNP I
alone RB I
(p<.001) NNP N
. . N

Ninety-five JJ N
percent NN N
of IN N
the DT N
injections NNS N
were VBD N
considered VBN N
easy JJ N
or CC N
very RB N
easy; VB N
a DT N
greater JJR N
percentage NN N
of IN N
HA+lidocaine NNP I
injections NNS N
were VBD N
rated VBN N
very RB N
easy JJ N
. . N

Mild NNP N
to TO N
moderate VB N
adverse JJ N
events NNS N
were VBD N
reported VBN N
for IN N
both DT N
products NNS N
. . N

CONCLUSION NNP N
The DT N
smooth JJ N
cohesive JJ N
HA NNP I
gel NN N
with IN N
preincorporated JJ N
lidocaine NN I
increased VBD N
subject JJ N
comfort NN N
during IN N
treatment NN N
and CC N
improved VBD N
the DT N
injection NN N
experience NN N
. . N

-DOCSTART- -X- N

Effects NNS N
of IN N
single JJ N
dose NN N
intranasal NN N
oxytocin NN I
on IN N
social JJ O
cognition NN O
in IN N
schizophrenia NN P
. . P

Deficits NNS N
in IN N
social JJ O
cognition NN O
are VBP N
common JJ N
in IN N
schizophrenia NN N
and CC N
predict JJ N
poor JJ N
community NN N
functioning NN N
. . N

Given VBN N
the DT N
current JJ N
limitations NNS N
of IN N
psychosocial JJ N
treatments NNS I
and CC N
the DT N
lack NN N
of IN N
pharmacological JJ N
treatments NNS I
for IN N
social JJ N
cognitive JJ N
deficits NNS N
the DT N
development NN N
of IN N
novel JJ N
therapeutic JJ I
agents NNS I
could MD N
greatly RB N
enhance VB N
functional JJ N
recovery NN N
in IN N
schizophrenia NN N
. . N

This DT N
study NN N
evaluated VBD N
whether IN N
a DT N
single JJ N
dose NN N
of IN N
intranasal JJ N
oxytocin FW I
acutely RB N
improves VBZ N
social JJ O
cognitive JJ O
functioning NN O
in IN N
schizophrenia NN P
. . P

Twenty-three JJ P
male NN P
veterans NNS P
with IN P
schizophrenia NN P
completed VBN P
baseline JJ P
assessments NNS P
of IN P
social JJ P
cognition NN N
that WDT N
were VBD P
divided VBN P
into IN P
lower-level JJ P
(facial JJ P
affect NN O
perception NN O
social JJ O
perception NN O
detection NN O
of IN O
lies) NN O
and CC N
higher-level JJ N
(detection NN O
of IN O
sarcasm NN O
and CC O
deception NN O
empathy) NN O
processes VBZ N
. . N

One CD N
week NN N
later RB N
patients NNS N
received VBD N
the DT N
same JJ N
battery NN N
after IN N
being VBG N
randomized VBN N
to TO N
a DT N
single JJ N
dose NN N
of IN N
40 CD I
IU NNP I
intranasal NN I
oxytocin NN I
or CC I
placebo NN I
. . I

Though IN N
the DT N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
on IN N
the DT N
social JJ O
cognition NN O
composite JJ O
score NN O
oxytocin NNS O
improved VBN O
performance NN O
for IN O
the DT O
higher-level JJ O
social JJ O
cognitive NN O
tasks NNS O
(Cohen's VBP O
d=1.0 JJ N
p=0.045) NN N
. . N

Subjects NNS N
were VBD N
unable JJ N
to TO N
accurately RB N
guess VB N
which WDT N
treatment NN I
they PRP N
had VBD N
received VBN N
. . N

The DT N
improvements NNS N
found VBN N
in IN N
higher-level JJ O
social JJ O
cognition NN O
encourage VB N
further JJ N
studies NNS N
into IN N
the DT N
therapeutic JJ N
potential NN N
of IN N
oxytocin NN I
in IN N
schizophrenia NN P
. . P

-DOCSTART- -X- N

Relation NN N
between IN N
early JJ N
mitral JJ N
regurgitation NN N
and CC N
left VBD N
ventricular JJ N
thrombus NN N
formation NN N
after IN N
acute JJ N
myocardial JJ N
infarction: NN N
results NNS N
of IN N
the DT N
GISSI-3 NNP N
echo NN N
substudy NN N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
prevalence NN N
and CC N
correlates NNS N
of IN N
left JJ N
ventricular JJ N
thrombosis NN N
in IN N
patients NNS P
with IN P
acute JJ P
myocardial JJ P
infarction NN P
and CC P
whether IN N
the DT N
occurrence NN N
of IN N
early JJ N
mitral JJ N
regurgitation NN N
has VBZ N
a DT N
protective JJ N
effect NN N
against IN N
the DT N
formation NN N
of IN N
left JJ N
ventricular JJ N
thrombus NN N
. . N

DESIGN NNP N
AND CC N
SETTING NNP N
Multicentre NNP N
clinical JJ N
trial NN N
carried VBD N
out IN N
in IN N
47 CD P
Italian JJ P
coronary JJ P
care NN P
units NNS P
. . P

PATIENTS NNS N
AND CC N
METHODS NNP N
757 CD P
patients NNS P
from IN P
the DT P
GISSI-3 NNP P
echo NN P
substudy NN P
population NN P
with IN P
their PRP$ P
first JJ P
acute JJ P
myocardial JJ P
infarct NN P
were VBD P
studied VBN P
by IN N
echocardiography NN I
at IN I
24-48 JJ I
hours NNS I
from IN I
symptom JJ I
onset VBN I
(S1) NN N
at IN N
discharge NN N
(S2) NN N
at IN N
six CD N
weeks NNS N
(S3) RB N
and CC N
at IN N
six CD N
months NNS N
(S4) RB N
. . N

The DT N
diagnosis NN N
of IN N
left JJ N
ventricular JJ N
thrombosis NN N
was VBD N
based VBN N
on IN N
the DT N
detection NN N
of IN N
an DT N
echo JJ N
dense NN N
mass NN N
with IN N
defined JJ N
margins NNS N
visible JJ N
throughout IN N
the DT N
cardiac JJ N
cycle NN N
in IN N
at IN N
least JJS N
two CD N
orthogonal JJ N
views NNS N
. . N

RESULTS NNP N
In IN N
64 CD N
patients NNS N
(8%) JJ N
left VBD O
ventricular JJ O
thrombosis NN O
was VBD N
detected VBN N
in IN N
one CD N
or CC N
more JJR N
examinations NNS N
. . N

Compared VBN N
with IN N
the DT N
remaining VBG N
693 CD P
patients NNS P
subjects NNS P
with IN P
left JJ P
ventricular JJ P
thrombosis NN P
were VBD P
older JJR P
(mean JJ P
(SD) NNP P
age: NN P
64.6 CD P
(13.0) NNP P
v NN P
59.8 CD P
(11.7) CD P
years NNS P
p VBP N
< RB N
0.005) CD N
and CC N
had VBD N
larger JJR N
infarcts NNS N
(extent NN N
of IN N
wall NN N
motion NN N
asynergy: VBZ N
40.9 CD N
(11.5)% NN N
v NN N
24.9 CD N
(14)% NN N
p NN N
< $ N
0.001) CD N
greater JJR N
depression NN N
of IN N
left JJ O
ventricular JJ O
ejection NN N
fraction NN N
at IN N
S1 NNP N
(43.3 NNP N
(6.9)% NNP N
v VBD N
48.1 CD N
(6.8)% NNP N
p NN N
< VBD N
0.001) CD N
and CC N
greater JJR N
left VBD O
ventricular JJ O
volumes NNS O
at IN O
S1 NNP O
(end NNP N
diastolic JJ N
volume: NN N
87 CD N
(22) NNP N
v NN N
78 CD N
(18) NN N
ml/m(2) NN N
p NN N
< VBD N
0.001; CD N
end NN N
systolic NN N
volume: VBD N
50 CD N
(17) NNP N
v NN N
41 CD N
(14) NN N
ml/m(2) NN N
p NN N
< VBD N
0.001) CD N
. . N

The DT N
prevalence NN N
of IN N
moderate JJ N
to TO N
severe VB N
mitral JJ N
regurgitation NN N
on IN N
colour NN N
Doppler NNP N
at IN N
S1 NNP N
was VBD N
greater JJR N
in IN N
patients NNS N
who WP N
had VBD N
left VBN N
ventricular JJ N
thrombosis NN N
at IN N
any DT N
time NN N
(10.2% JJ N
v NN N
4.2% CD N
p NN N
< VBD N
0.05) CD N
. . N

On IN N
stepwise NN N
multiple JJ N
logistic JJ N
regression NN N
analysis NN N
the DT N
only JJ N
independent JJ N
variables NNS N
related VBN N
to TO N
the DT N
presence NN N
of IN N
left JJ N
ventricular JJ N
thrombosis NN N
were VBD N
the DT N
extent NN N
of IN N
wall NN N
motion NN N
asynergy NN N
and CC N
anterior JJ N
site NN N
of IN N
infarction NN N
. . N

CONCLUSIONS NNP N
Left NNP N
ventricular JJ N
thrombosis NN N
is VBZ N
not RB N
reduced VBN N
and CC N
may MD N
even RB N
be VB N
increased VBN N
by IN N
early RB N
moderate JJ N
to TO N
severe VB N
mitral JJ N
regurgitation NN N
after IN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

The DT N
only JJ N
independent JJ N
determinant NN N
of IN N
left JJ N
ventricular JJ N
thrombosis NN N
is VBZ N
the DT N
extent NN N
of IN N
the DT N
akinetic-dyskinetic JJ N
area NN N
detected VBN N
on IN N
echocardiography NN N
between IN N
24-48 JJ N
hours NNS N
from IN N
symptom JJ N
onset NN N
. . N

-DOCSTART- -X- N

Results NNS N
of IN N
a DT N
phase NN N
III NNP N
8-week JJ N
multicenter NN N
prospective JJ N
randomized VBN N
double-blind JJ N
parallel-group JJ N
clinical JJ N
trial NN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
amlodipine JJ N
camsylate NN N
versus NN N
amlodipine NN N
besylate NN N
in IN N
Korean JJ P
adults NNS P
with IN P
mild NN P
to TO P
moderate VB P
hypertension NN P
. . P

BACKGROUND NNP N
Amlodipine NNP N
besylate NN N
has VBZ N
been VBN N
used VBN N
in IN N
Korea NNP N
for IN N
the DT N
treatment NN N
of IN N
hypertension NN N
for IN N
>17 JJ N
years NNS N
with IN N
well-established JJ N
efficacy NN N
and CC N
tolerability NN N
. . N

Amlodipine NNP N
camsylate NN N
is VBZ N
a DT N
newer JJR N
formulation NN N
developed VBD N
for IN N
generic JJ N
use NN N
. . N

It PRP N
has VBZ N
been VBN N
assessed VBN N
in IN N
terms NNS N
of IN N
physical JJ N
stability NN N
and CC N
pharmacokinetic JJ N
and CC N
pharmacodynamic JJ N
properties NNS N
and CC N
been VBN N
found VBN N
to TO N
be VB N
effective JJ N
in IN N
lowering VBG N
blood NN N
pressure NN N
in IN N
preclinical JJ N
and CC N
Phase NNP N
I PRP N
and CC N
II NNP N
trials NNS N
. . N

However RB N
to TO N
date NN N
no DT N
studies NNS N
have VBP N
compared VBN N
the DT N
clinical JJ N
effectiveness NN N
of IN N
amlodipine JJ N
camsylate NN N
and CC N
amlodipine JJ N
besylate NN N
in IN N
treating VBG N
hypertension NN N
. . N

OBJECTIVE NN N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
the DT N
effectiveness NN N
and CC N
tolerability NN N
of IN N
amlodipine JJ N
camsylate NN N
compared VBN N
with IN N
amlodipine JJ N
besylate NN N
in IN N
Korean JJ P
patients NNS P
with IN P
mild JJ P
to TO P
moderate VB P
hypertension NN P
. . P

METHODS NNP P
This DT N
Phase NNP N
III NNP N
8-week JJ N
prospective JJ N
randomized VBN N
double-blind JJ N
parallel-group NN N
study NN N
was VBD N
conducted VBN N
in IN N
13 CD P
cardiology NN P
centers NNS P
across IN P
the DT P
Republic NNP P
of IN P
Korea NNP P
. . P

Male NN P
and CC P
female JJ P
Korean JJ P
patients NNS P
aged VBD P
18 CD P
to TO P
75 CD P
years NNS P
having VBG P
uncomplicated JJ P
mild NN P
to TO P
moderate VB P
essential JJ P
hypertension NN P
(sitting VBG P
diastolic JJ P
blood NN P
pressure NN P
[SiDBP] VBZ P
90-<110 CD P
mm NN P
Hg) NNP P
and CC P
receiving VBG P
no DT P
antihypertensives NNS P
in IN P
the DT P
2 CD P
weeks NNS P
before IN P
randomization NN P
were VBD P
eligible JJ P
. . P

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
oral JJ N
treatment NN N
with IN N
amlodipine JJ N
camsylate NN N
or CC N
amlodipine JJ N
besylate NN N
. . N

For IN N
the DT N
first JJ N
4 CD N
weeks NNS N
patients NNS N
received VBD N
amlodipine JJ N
5 CD N
mg NN N
QD NNP N
(morning) NNP N
. . N

After IN N
4 CD N
weeks NNS N
if IN N
either DT N
blood NN O
pressure NN O
was VBD N
> JJ N
or CC N
=140/ JJ N
> NN N
or CC N
=90 VB N
mm JJ N
Hg NNP N
or CC N
SiDBP NNP N
had VBD N
not RB N
decreased VBN N
by IN N
> NN N
or CC N
=10 VB N
mm JJ N
Hg NNP N
from IN N
baseline NN N
the DT N
dose NN N
of IN N
amlodipine NN N
was VBD N
increased VBN N
to TO N
10 CD N
mg NNS N
QD NNP N
for IN N
4 CD N
weeks NNS N
. . N

Trough NNP N
blood NN O
pressure NN O
and CC O
heart NN O
rate NN O
were VBD N
measured VBN N
in IN N
duplicate NN N
with IN N
the DT N
patient NN N
in IN N
the DT N
sitting VBG N
position NN N
at IN N
each DT N
clinic JJ N
visit NN N
(baseline NNP N
[week VBZ N
0] CD N
and CC N
weeks NNS N
4 CD N
and CC N
8 CD N
of IN N
treatment); JJ N
mean JJ N
values NNS N
were VBD N
calculated VBN N
and CC N
recorded VBN N
. . N

At IN N
weeks NNS N
4 CD N
and CC N
8 CD N
tolerability NN N
was VBD N
assessed VBN N
using VBG N
history NN N
taking NN N
and CC N
laboratory NN N
analysis NN N
and CC N
compliance NN N
was VBD N
assessed VBN N
using VBG N
pill NN N
counts NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
change NN N
from IN N
baseline NN N
in IN N
SiDBP NNP N
at IN N
week NN N
8 CD N
. . N

Secondary JJ N
end NN N
points NNS N
were VBD N
change NN N
from IN N
baseline NN N
in IN N
sitting VBG N
systolic JJ N
blood NN N
pressure NN N
(SiSBP) NN N
at IN N
week NN N
8 CD N
in IN N
the DT N
total JJ N
population NN N
and CC N
in IN N
the DT N
subgroup NN N
of IN N
patients NNS N
who WP N
had VBD N
previously RB N
received VBN N
antihypertensive JJ N
treatment NN N
versus IN N
those DT N
who WP N
had VBD N
not RB N
. . N

RESULTS VB N
A NNP P
total NN P
of IN P
189 CD P
patients NNS P
were VBD P
enrolled VBN P
(mean JJ P
age NN P
53 CD P
years; NN P
105 CD P
women NNS P
84 CD P
men; JJ P
mean NN P
body NN P
weight VBD P
65.8 CD P
kg) NN P
. . P

One CD N
patient NN N
in IN N
the DT N
amlodipine JJ N
camsylate NN N
group NN N
dropped VBD N
out IN N
of IN N
the DT N
study NN N
at IN N
week NN N
0 CD N
of IN N
treatment NN N
(this NNP N
patient NN N
did VBD N
not RB N
use VB N
any DT N
study NN N
medication) NN N
and CC N
was VBD N
excluded VBN N
from IN N
the DT N
modified VBN N
intent-to-treat NN N
(ITT) NN N
analysis NN N
. . N

Thus RB N
188 CD P
patients NNS P
were VBD P
treated VBN P
and CC P
included VBN P
in IN P
the DT P
ITT NNP P
analysis NN P
(94 NN N
patients NNS N
per IN N
treatment NN N
group; NN N
ITT NNP N
analysis); VBZ N
161 CD N
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
perprotocol NN N
(PP) NNP N
analysis NN N
(n NNP N
= VBZ N
80 CD N
for IN N
amlodipine JJ N
camsylate NN N
n NNS N
= VBP N
81 CD N
for IN N
amlodipine NN N
besylate) NN N
(14 NN N
patients NNS N
in IN N
the DT N
amlodipine JJ N
camsylate NN N
group NN N
and CC N
13 CD N
patients NNS N
in IN N
the DT N
amlodipine JJ N
besylate NN N
group NN N
were VBD N
excluded VBN N
from IN N
the DT N
PP NNP N
analysis NN N
due JJ N
to TO N
consistent JJ N
withdrawal NN N
or CC N
protocol NN N
violation) NN N
. . N

Mean NNP N
(SD) NNP N
SiSBP NNP O
and CC O
SiDBP NNP O
were VBD N
significantly RB N
decreased VBN N
from IN N
baseline NN N
in IN N
both DT N
groups NNS N
(amlodipine VBP N
camsylate NN N
from IN N
146.7 CD N
[12.3]/96.6 NNS N
[5.4] VBP N
to TO N
127.9 CD N
[14.8]/83.4 NNS N
[7.7] JJ N
mm JJ N
Hg NNP N
[both NNP N
P NNP N
< VBD N
0.001]; CD N
amlodipine JJ N
besylate NN N
from IN N
146.8 CD N
[12.8]/96.7 NNS N
[5.1] VBP N
to TO N
128.0 CD N
[10.1]/83.8 NNS N
[7.5] JJ N
mm JJ N
Hg NNP N
[both NNP N
P NNP N
< VBD N
0.001]) CD N
. . N

The DT N
differences NNS N
in IN N
SiSBP/SiDBP NNP O
between IN N
the DT N
2 CD N
groups NNS N
at IN N
week NN N
8 CD N
were VBD N
not RB N
significant JJ N
. . N

The DT N
SiDBP NNP O
response NN O
rates NNS N
in IN N
the DT N
subgroups NNS N
that WDT N
had VBD N
and CC N
had VBD N
not RB N
been VBN N
previously RB N
treated VBN N
with IN N
antihypertensives NNS N
were VBD N
statistically RB N
similar JJ N
(56/69 NNP N
[81.2%] NNP N
and CC N
83/92 CD N
[90.2%] JJ N
respectively) NN N
. . N

The DT N
prevalences NNS N
of IN N
clinical JJ N
adverse JJ N
events NNS N
(AEs) WDT N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
2 CD N
treatment NN N
groups NNS N
(amlodipine VBP N
camsylate JJ N
27.3 CD N
%; JJ N
amlodipine NN N
besylate NN N
28.7%) CD N
. . N

The DT N
most RBS N
common JJ N
AEs NNP N
were VBD N
dizziness JJ N
and CC N
dyspnea JJ N
(both NNP N
in IN N
3/94 CD N
[3.2%] NNS N
and CC N
1/94 CD N
[1.1%] JJ N
patients NNS N
who WP N
received VBD N
amlodipine JJ N
camsylate NN N
and CC N
amlodipine JJ N
besylate NN N
respectively) NN N
. . N

CONCLUSION NNP N
The DT N
effectiveness NN N
and CC N
tolerability NN N
of IN N
amlodipine JJ N
camsylate NN N
were VBD N
not RB N
significantly RB N
different JJ N
from IN N
those DT N
of IN N
amlodipine JJ N
besylate NN N
in IN N
these DT N
Korean JJ P
adults NNS P
with IN P
mild NN P
to TO P
moderate VB P
hypertension NN P
. . P

-DOCSTART- -X- N

The DT N
Impact NNP N
of IN N
Pupillary NNP I
Dilation NNP I
on IN N
Intraocular NNP N
Pressure NNP N
and CC N
Anterior NNP N
Segment NNP N
Morphology NNP N
in IN N
Subjects NNP P
with IN P
and CC P
without IN P
Pseudoexfoliation NNP P
. . P

PURPOSE NNP P
To TO N
investigate VB N
the DT N
change NN N
in IN N
pre- JJ N
and CC N
post-dilation JJ N
anterior JJ N
segment NN N
parameters NNS N
and CC N
intraocular JJ N
pressure NN N
(IOP) NN N
of IN N
patients NNS P
with IN P
and CC P
without IN P
pseudoexfoliation NN P
after IN P
topical JJ I
application NN I
of IN I
phenylephrine NN I
HCl NNP I
10% CD I
and CC I
tropicamide RB I
1% CD I
. . I

MATERIALS NNP I
AND CC N
METHODS NNP N
Totally NNP P
129 CD P
eyes NNS P
of IN P
129 CD P
patients NNS P
were VBD P
included VBN P
in IN P
the DT P
study NN P
. . P

Of IN P
the DT P
129 CD P
eyes; NN P
31 CD P
had VBD P
pseudoexfoliation NN P
syndrome NN P
(PXS) VBD P
37 CD P
had VBD P
pseudoexfoliation NN P
glaucoma NN P
(PXG) VBD P
31 CD P
eyes NNS P
were VBD P
the DT P
fellow JJ P
eyes NNS P
of IN P
subjects NNS P
with IN P
unilateral JJ P
pseudoexfoliation NN P
syndrome JJ P
(subclinical JJ P
PXS) NNP P
and CC P
30 CD P
eyes NNS P
were VBD P
the DT P
eyes NNS P
of IN P
subjects NNS P
without IN P
PXS NNP P
(controls) NNP P
. . P

Patients NNS N
underwent JJ N
Pentacam NNP I
analysis NN I
and CC I
IOP NNP I
measurement NN I
before IN N
and CC N
after IN N
dilation NN N
. . N

The DT N
changes NNS O
in IN O
IOP NNP O
anterior JJ O
chamber NN O
depth NN O
(ACD) NNP O
anterior JJ O
chamber NN O
volume NN O
(ACV) NNP O
anterior JJ O
chamber NN O
angle NN O
(ACA) NNP O
central JJ O
corneal NN O
thickness NN O
(CCT) NN O
and CC O
pupillary JJ O
diameter NN O
(PD) NN O
were VBD N
investigated VBN N
30min CD N
after IN N
the DT I
application NN I
of IN I
mydriatic JJ I
agents NNS I
. . N

RESULTS VB N
The DT O
mean JJ O
change NN O
of IN O
IOP NNP O
in IN N
eyes NNS N
with IN N
PXS NNP N
in IN N
eyes NNS N
with IN N
PXG NNP N
in IN N
eyes NNS N
with IN N
subclinical JJ N
PXS NNP N
and CC N
eyes NNS N
of IN N
control NN N
subjects NNS N
were VBD N
1.452.03mmhg CD N
0.272.25mmhg CD N
-0.351.58mmHg NN N
and CC N
-1.061.59mmHg NNP O
respectively RB O
. . N

Post-dilation NN N
IOP NNP N
values NNS N
were VBD N
lower JJR N
(p=0.001) NN N
in IN N
eyes NNS N
of IN N
controls NNS N
but CC N
higher JJR N
(p<0.001) NN N
in IN N
eyes NNS N
of IN N
PXS NNP N
than IN N
the DT N
pre-dilation NN N
levels NNS N
. . N

All DT N
patients NNS N
exhibited VBN O
statistically RB O
significant JJ O
increase NN I
in IN I
ACD NNP I
ACV NNP I
and CC N
PD NNP N
after IN N
the DT N
dilation NN N
procedure NN O
(p<0.001) NN O
. . N

Additionally RB N
post JJ N
dilation NN N
CCT NNP N
values NNS N
were VBD N
significantly RB N
lower JJR N
than IN N
pre-dilation NN N
values NNS N
in IN N
all DT N
groups; VBP N
the DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
only RB N
for IN N
eyes NNS N
with IN N
PXG NNP N
eyes NNS N
with IN N
subclinical JJ N
PXS NNP N
and CC N
eyes NNS N
of IN N
controls NNS N
. . N

CONCLUSION NNP O
Eyes NNP O
with IN O
PXS NNP O
had VBD N
a DT I
higher JJR I
tendency NN I
of IN I
IOP NNP N
elevation NN N
after IN N
pupillary JJ N
dilation NN N
. . N

Eyes NNS N
with IN N
subclinical JJ N
PXS NNP N
however RB N
exhibited VBD N
a DT N
minor JJ N
increase NN N
in IN N
IOP NNP N
reflecting VBG N
the DT I
asymmetrical JJ I
character NN I
of IN I
the DT N
disease NN N
. . N

Anti-glaucoma JJ O
medications NNS N
may MD N
have VB I
blunted VBN I
any DT I
IOP NNP I
elevation NN N
induced VBN N
by IN N
pupillary JJ N
dilation NN N
in IN N
eyes NNS N
with IN N
PXG NNP N
. . N

-DOCSTART- -X- N

Efficacy NN O
of IN N
porcine NN I
secretin NN I
in IN N
children NNS P
with IN P
autism NN P
and CC P
pervasive JJ P
developmental JJ P
disorder NN P
. . P

Secretin NNP P
a DT I
gastrointestinal JJ N
(GI) NN N
hormone NN N
was VBD N
reported VBN N
in IN N
a DT N
preliminary JJ N
study NN N
to TO N
improve VB O
language NN O
and CC O
behavior NN O
in IN N
children NNS P
with IN P
autism/pervasive JJ P
developmental JJ P
disorder NN P
(PDD) NN P
and CC P
chronic JJ P
diarrhea NN P
. . P

To TO N
determine VB N
the DT N
efficacy NN O
of IN N
secretin NN I
we PRP I
completed VBD N
a DT N
double-blind JJ N
placebo-controlled JJ I
crossover NN I
(3 NNP N
weeks) NN N
study NN N
in IN N
children NNS P
with IN P
autism/PDD NN P
and CC P
various JJ P
GI NNP P
conditions NNS P
using VBG N
a DT N
single JJ N
dose NN N
of IN N
intravenous JJ I
porcine NN I
secretin NN I
. . I

Children NNP P
with IN P
chronic JJ P
active JJ P
diarrhea NN P
showed VBD N
a DT N
reduction NN O
in IN O
aberrant JJ O
behaviors NNS O
when WRB N
treated VBN I
with IN N
the DT N
secretin NN I
but CC N
not RB N
when WRB N
treated VBN I
with IN N
the DT N
placebo NN I
. . I

Children NNP P
with IN P
no DT P
GI NNP P
problems NNS P
are VBP N
unaffected VBN O
by IN N
either DT N
secretin NN I
or CC I
placebo NN I
. . I

The DT N
improvement NN N
seen VBN N
with IN N
secretin NN I
in IN N
children NNS P
with IN P
autism/PDD NN P
and CC P
chronic JJ P
diarrhea NN P
suggests VBZ N
that IN N
there EX N
may MD N
be VB N
a DT N
subtype NN P
of IN P
children NNS P
with IN P
autism/PDD NN P
who WP P
respond VBZ P
to TO N
secretin VB N
. . N

-DOCSTART- -X- N

Phase NNP N
III NNP N
comparative JJ N
study NN N
of IN N
high-dose JJ I
cisplatin NN I
versus IN N
a DT N
combination NN I
of IN I
paclitaxel NN I
and CC I
cisplatin NN I
in IN N
patients NNS P
with IN P
advanced JJ P
non-small-cell JJ P
lung NN P
cancer NN P
. . P

PURPOSE NNP P
New NNP N
effective JJ N
chemotherapy NN N
is VBZ N
needed VBN N
to TO N
improve VB N
the DT N
outcome NN N
of IN N
patients NNS P
with IN P
advanced JJ P
non-small-cell JJ P
lung NN P
cancer NN P
(NSCLC) NN P
. . P

Paclitaxel RB I
administered VBN N
as IN N
a DT N
single JJ N
agent NN N
or CC N
in IN N
combination NN N
with IN N
cisplatin NN I
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
a DT N
potentially RB N
new JJ N
useful JJ N
agent NN N
for IN N
the DT N
treatment NN N
of IN N
NSCLC NNP N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Between NNP P
January NNP P
1995 CD P
and CC P
April NNP P
1996 CD P
414 CD P
patients NNS P
with IN P
stage NN P
IIIB NNP P
or CC P
IV NNP P
NSCLC NNP P
were VBD P
randomized VBN P
to TO P
received VB P
either RB P
a DT P
control NN P
arm NN P
of IN P
high-dose JJ P
cisplatin NN P
(100 NN P
mg/m(2)) NN P
or CC P
a DT P
combination NN P
of IN P
paclitaxel JJ P
(175 NNP P
mg/m(2) NN P
3-hour CD P
infusion) NN P
and CC P
cisplatin NN P
(80 NN P
mg/m(2)) NN P
every DT P
21 CD P
days NNS P
. . P

RESULTS NNS N
Compared VBD N
with IN N
the DT N
cisplatin-only JJ I
arm NN N
there EX N
was VBD N
a DT N
9% CD N
improvement NN N
(95% NN N
confidence NN N
interval NN N
0% CD N
to TO N
19%) CD N
in IN N
overall JJ N
response NN N
rate NN N
for IN N
the DT N
paclitaxel/cisplatin NN I
arm NN N
(17% NNP N
v NN N
26% CD N
respectively; NN N
P=.028) NNP N
. . N

Median JJ O
time NN O
to TO O
progression NN O
was VBD N
2.7 CD N
and CC N
4.1 CD N
months NNS N
in IN N
the DT N
control NN I
and CC N
paclitaxel/cisplatin NN I
arm NN N
respectively RB N
(P=.026) NNP N
. . N

The DT N
study NN N
however RB N
failed VBD N
to TO N
show VB N
a DT N
significant JJ N
improvement NN N
in IN N
median JJ O
survival NN O
for IN N
the DT N
paclitaxel/cisplatin NN I
arm NN N
(8.6 NNP N
months NNS N
in IN N
the DT N
control NN N
arm NN N
v NN N
8.1 CD N
months NNS N
in IN N
the DT N
paclitaxel/cisplatin NN I
arm NN N
P=.862) NNP N
. . N

There EX I
was VBD I
more JJR I
hematotoxicity JJ O
peripheral JJ O
neuropathy NN O
and CC O
arthralgia/myalgia NN O
on IN I
the DT I
paclitaxel/cisplatin NN I
arm NN I
whereas IN I
the DT I
high-dose JJ I
cisplatin NN I
arm NN I
produced VBD I
more JJR I
ototoxicity NN O
nausea NN O
vomiting NN O
and CC O
nephrotoxicity NN O
. . O

Quality NN O
of IN O
life NN O
(QOL) NNP O
was VBD N
similar JJ N
overall JJ N
between IN N
the DT N
two CD N
arms NNS N
. . N

CONCLUSION NN N
This DT N
large JJ N
randomized JJ N
phase NN N
III NNP N
trial NN N
failed VBD N
to TO N
show VB N
a DT N
significant JJ N
improvement NN N
in IN N
survival NN N
for IN N
the DT N
paclitaxel/cisplatin NN I
combination NN N
compared VBN N
with IN N
high-dose JJ I
cisplatin NN I
in IN N
patients NNS N
with IN N
advanced JJ N
NSCLC NNP N
. . N

However RB N
the DT N
paclitaxel/cisplatin NN I
combination NN N
did VBD N
produce VB N
a DT N
better JJR N
clinical JJ N
response NN N
resulting VBG N
in IN N
an DT N
increased JJ N
time NN N
to TO N
progression NN N
while IN N
providing VBG N
a DT N
similar JJ N
QOL NNP N
. . N

-DOCSTART- -X- N

Randomized VBN N
trial NN N
of IN N
a DT N
secondhand NN N
smoke NN N
exposure NN N
reduction NN N
intervention NN N
among IN N
hospital-based JJ P
pregnant JJ P
women NNS P
. . P

OBJECTIVE NN N
This DT N
study NN N
sought VBD N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
a DT N
secondhand NN N
tobacco NN N
smoke VBD N
(SHS) JJ N
prevention NN N
program NN N
based VBN N
on IN N
an DT N
expanded VBN N
Health NNP O
Belief NNP O
Model NNP O
(HBM) NNP N
incorporating VBG N
self-efficacy NN N
among IN N
pregnant JJ P
women NNS P
in IN P
a DT P
hospital NN P
setting NN P
in IN P
Taiwan NNP P
. . P

METHODOLOGY NNP N
This DT N
study NN N
utilized VBD N
a DT N
two-group JJ N
longitudinal JJ N
randomized VBN N
controlled JJ N
trial NN N
design NN N
. . N

Participants NNS P
in IN P
the DT P
intervention NN P
group NN P
(n=50) NNP P
enrolled VBD P
in IN P
a DT P
SHS NNP P
prevention NN P
program NN P
based VBN P
on IN P
the DT P
HBM NNP P
while IN P
participants NNS P
in IN P
the DT P
comparison NN P
group NN P
(n=50) NNP P
received VBD N
standard JJ N
government-mandated JJ N
counseling NN N
care NN N
. . N

Both DT N
groups NNS N
were VBD N
given VBN N
questionnaires NNS O
as IN N
a DT N
pre-test JJ N
two CD N
weeks NNS N
into IN N
the DT N
intervention NN N
and CC N
one CD N
month NN N
following VBG N
the DT N
conclusion NN N
of IN N
the DT N
intervention NN N
. . N

The DT N
questionnaire NN N
and CC N
intervention NN N
were VBD N
developed VBN N
based VBN N
on IN N
the DT N
understanding NN N
gained VBN N
through IN N
a DT N
series NN N
of IN N
in-depth JJ N
interviews NNS N
and CC N
a DT N
focus-group JJ N
conducted VBN N
among IN N
pregnant JJ N
women NNS N
. . N

Exhaled VBN O
carbon NN O
monoxide NN O
was VBD N
also RB N
measured VBN N
and CC N
used VBN N
as IN N
a DT N
proxy NN N
for IN N
SHS NNP O
exposure NN O
. . O

RESULTS NNP N
Intervention NNP N
group NN N
scores NNS N
were VBD N
all DT N
significantly RB N
higher JJR N
than IN N
comparison NN N
group NN N
scores VBZ N
(p<0.001) NNP N
indicating VBG N
a DT N
significant JJ N
increase NN N
in IN N
knowledge NN O
HBM NNP O
scores VBZ O
cues NNS O
to TO O
action NN O
self-efficacy NN O
preventative JJ O
behaviors NNS O
and CC O
a DT O
significant JJ O
decrease NN O
in IN O
smoking NN O
exposure NN O
. . O

These DT N
differences NNS N
remained VBD N
significant JJ N
at IN N
the DT N
one-month JJ N
follow-up JJ N
assessment NN N
(p<0.001) NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
should MD N
encourage VB N
health NN N
professionals NNS N
to TO N
educate VB N
pregnant JJ P
women NNS P
regarding VBG N
the DT N
harms NNS N
of IN N
SHS NNP N
while IN N
both DT N
empowering VBG N
and CC N
equipping VBG N
them PRP N
with IN N
the DT N
tools NNS N
to TO N
confront VB N
their PRP$ N
family NN N
members NNS N
and CC N
effectively RB N
reduce VB N
their PRP$ N
SHS NNP O
exposure NN O
while IN N
promoting VBG N
smoke-free JJ N
social JJ N
norms NNS N
. . N

-DOCSTART- -X- N

A DT N
comparative JJ N
study NN N
of IN N
administration NN N
methods NNS N
of IN N
granisetron NN I
injection NN I
used VBN N
to TO N
treat VB N
nausea/vomiting VBG N
induced VBN N
by IN N
cancer NN P
chemotherapy NN P
without IN P
cisplatin NN P
in IN P
tumors NNS P
of IN P
hematopoietic JJ P
organs NNS P
. . P

Keihanshin NNP N
Study NNP N
Group NNP N
of IN N
Hematological NNP N
Malignancies NNP N
. . N

PURPOSE VB N
The DT N
antiemetic JJ N
effect NN N
of IN N
granisetron NN I
injection NN I
at IN N
a DT N
dose NN N
of IN N
40 CD N
microg/kg NNS N
used VBN N
in IN N
the DT N
treatment NN N
of IN N
nausea/vomiting VBG N
induced VBN N
by IN N
multidrug NN P
combined VBN P
cancer NN P
chemotherapy NN P
excluding VBG I
cisplatin NN I
in IN N
patients NNS P
with IN P
tumors NNS P
of IN P
hematopoietic JJ P
organs NNS P
was VBD N
evaluated VBN N
by IN N
comparing VBG N
a DT N
30-min JJ I
infusion NN I
and CC I
a DT I
slow JJ I
intravenous JJ I
injection NN I
given VBN I
over IN I
30 CD I
s NNS I
. . I

METHODS NNP N
A DT N
two-group JJ N
random-allocation NN N
comparative NN N
study NN N
was VBD N
performed VBN N
with IN N
the DT N
cooperation NN N
of IN P
multiple JJ P
institutions NNS P
using VBG N
a DT N
central JJ N
registration NN N
system NN N
. . N

RESULTS NN N
In IN N
the DT N
treatment NN N
of IN N
acute JJ N
clinical JJ N
symptoms NNS N
appetite NN N
was VBD N
described VBN N
as IN N
"similar JJ N
to TO N
that IN N
during IN N
good JJ N
health" NN N
by IN N
61.1% CD N
of IN N
patients NNS P
(55/93) VBP P
in IN N
the DT N
instillation NN N
group NN N
and CC N
by IN N
47.3% CD N
(44/93) NNS N
in IN N
the DT N
slow JJ N
injection NN N
group NN N
a DT N
significant JJ N
advantage NN N
in IN N
the DT N
infusion NN N
group NN N
. . N

However RB N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
number NN O
of IN O
episodes NNS O
of IN O
vomiting VBG O
the DT O
severity NN O
of IN O
nausea NN O
or CC O
clinical JJ O
efficacy NN O
were VBD N
found VBN N
. . N

In IN N
the DT N
final JJ N
clinical JJ N
evaluation NN N
and CC N
assessment NN N
of IN N
usefulness NN N
based VBN N
on IN N
the DT N
subjective JJ N
judgement NN N
of IN N
physicians NNS N
throughout IN N
the DT N
entire JJ N
therapeutic JJ N
period NN N
no DT N
differences NNS N
were VBD N
discernible JJ N
. . N

No DT N
side NN N
effects NNS N
were VBD N
reported VBN N
for IN N
either DT N
method NN N
and CC N
there EX N
was VBD N
no DT N
indication NN N
of IN N
a DT N
sex NN N
difference NN N
concerning VBG N
efficacy NN N
. . N

However RB N
the DT N
efficacy NN O
in IN N
patients NNS N
with IN N
an DT N
anemic JJ N
tendency NN N
was VBD N
slightly RB N
inferior JJ N
. . N

CONCLUSIONS NNP N
The DT N
maintenance NN N
of IN N
appetite NN N
during IN N
the DT N
administration NN N
of IN N
anticancer NN N
drugs NNS N
is VBZ N
very RB N
important JJ N
to TO N
maintain VB N
patients' JJ N
daily JJ N
activities NNS N
and CC N
quality NN N
of IN N
life NN N
. . N

The DT N
present JJ N
results NNS N
support VB N
the DT N
usefulness NN N
of IN N
infusion NN N
of IN N
granisetron NN N
as IN N
an DT N
administration NN N
method NN N
during IN N
chemotherapy NN N
for IN N
malignant JJ N
hemopathy NN N
. . N

-DOCSTART- -X- N

Effect NN N
of IN N
ischaemic JJ I
preconditioning NN I
cardiopulmonary JJ I
bypass NN I
and CC I
myocardial JJ I
ischaemic/reperfusion NN I
on IN N
free JJ P
radical JJ P
generation NN P
in IN P
CABG NNP P
patients NNS P
. . P

OBJECTIVE NN N
To TO N
investigate VB N
the DT N
free JJ O
radicals NNS O
(FR) VBP O
generation NN O
after IN N
ischaemic JJ I
preconditioning NN I
and CC N
cardiopulmonary JJ I
bypass NN I
and CC N
during IN N
reperfusion NN N
in IN N
CABG NNP P
patients NNS P
and CC P
the DT N
role NN N
of IN N
ischaemic JJ I
preconditioning NN I
. . I

METHODS NNP N
Forty-three NNP P
CABG NNP P
patients NNS P
were VBD N
randomised VBN N
into IN N
an DT N
ischaemic JJ I
preconditioning NN I
and CC N
a DT N
control NN I
group NN I
. . I

The DT N
protocol NN N
for IN N
ischaemic JJ I
preconditioning NN I
was VBD N
two CD I
cycles NNS I
of IN I
2-min JJ I
ischaemia NN I
followed VBN I
by IN I
3-min JJ I
reperfusion NN I
. . I

Free JJ O
radicals NNS O
were VBD N
measured VBN N
using VBG N
electron NN I
spin NN I
resonance NN I
spectroscopy NN I
. . I

Global NNP O
and CC O
right JJ O
heart NN O
functions NNS O
were VBD N
collected VBN N
. . N

RESULTS VB N
The DT N
free JJ O
radicals NNS O
generation NN O
in IN O
coronary JJ O
sinus NN O
blood NN O
in IN N
the DT N
ischaemic JJ I
preconditioning NN I
group NN N
was VBD N
9.7 CD N
and CC N
16.6% CD N
after IN N
the DT N
ischaemic JJ I
preconditioning NN I
protocol NN I
and CC N
10 CD N
min NN N
after IN N
declamping VBG N
6.8 CD N
and CC N
13.3% CD N
in IN N
the DT N
controls NNS I
. . I

The DT N
free JJ O
radicals NNS O
in IN O
arterial JJ O
samples NNS O
were VBD N
respectively RB N
21 CD N
14 CD N
10 CD N
and CC N
9% CD N
at IN N
10 CD N
min NNS N
1 CD N
2 CD N
and CC N
24 CD N
h NN N
after IN N
reperfusion NN N
. . N

Cardiac NNP O
index NN O
(CI) NN O
and CC O
right JJ O
ventricular NN O
ejection NN O
fraction NN O
(RVEF) NNP O
were VBD N
improved VBN N
by IN N
ischaemic JJ I
preconditioning NN I
. . I

CONCLUSION NNP N
Both NNP N
ischaemic JJ I
preconditioning NN I
and CC N
cardiopulmonary JJ I
bypass NN I
induced VBD N
free JJ O
radicals NNS O
generation NN O
. . O

Although IN N
ischaemic JJ I
preconditioning NN I
had VBD N
no DT N
effect NN N
on IN N
free JJ O
radicals NNS O
generation NN O
after IN N
the DT N
operation NN N
it PRP N
protected VBD N
against IN N
postoperative JJ N
stunning NN N
. . N

-DOCSTART- -X- N

Tacrolimus NNP I
monotherapy NN I
without IN I
steroids NNS I
after IN P
liver JJ P
transplantation--a JJ P
prospective JJ N
randomized VBN N
double-blinded JJ I
placebo-controlled JJ I
trial NN I
. . I

Early JJ I
steroid NN I
withdrawal NN I
after IN P
liver JJ P
transplantation NN P
(LT) NN P
is VBZ N
desirable JJ N
in IN N
order NN N
to TO N
reduce VB N
steroid JJ I
side NN I
effects NNS I
. . I

Between NNP P
February NNP P
2000 CD P
and CC P
August NNP P
2004 CD P
110 CD P
patients NNS P
after IN P
LT NNP P
were VBD N
included VBN N
in IN N
this DT N
prospective JJ N
randomized VBN N
double-blind JJ I
placebo-controlled JJ I
trial NN I
. . I

Randomization NN I
was VBD N
performed VBN N
before IN N
LT NNP I
. . I

In IN N
all DT N
patients NNS N
tacrolimus WDT I
was VBD I
used VBN I
without IN I
induction NN I
therapy NN I
. . I

All DT P
patients NNS P
received VBD P
methylprednisolon NN P
for IN P
14 CD P
days NNS P
thereafter RB P
a DT I
double-blinded JJ I
medication NN I
containing VBG I
either CC I
placebo JJ I
(n NNP N
= NNP N
56) CD N
or CC N
methylprednisolon VB I
(n JJ N
= $ N
54) CD N
for IN N
6 CD N
months NNS N
which WDT N
was VBD N
completely RB N
stopped JJ N
thereafter RB N
. . N

End NN N
points NNS N
were VBD N
patient JJ O
and CC O
graft JJ O
survival NN O
acute NN O
and CC O
chronic JJ O
rejection NN O
and CC O
incidence NN O
of IN O
steroid JJ O
side NN O
effects NNS O
during IN N
the DT N
first JJ N
year NN N
after IN N
LT NNP I
. . I

One-year JJ N
patient NN I
survival NN I
was VBD N
85.7% CD N
(placebo) NN I
and CC N
88.8% CD N
(steroid) NN I
(p NNP N
= VBZ N
0.572) CD N
. . N

Twenty-seven JJ P
(48.2%) NN P
and CC N
19 CD N
(35.2%) NN N
patients NNS N
experienced VBD N
acute JJ I
rejection NN I
(placebo NNP I
versus NN N
steroid NN I
respectively; NN I
p NN N
= VBD N
0.116) CD N
. . N

Two CD P
patients NNS P
in IN P
the DT P
placebo NN P
group NN P
but CC P
none NN P
in IN P
the DT P
steroid NN P
group NN P
experienced VBD N
chronic JJ I
rejection NN I
(p NNP N
= VBZ N
0.257) CD N
. . N

The DT N
rates NNS N
of IN N
side JJ N
effects NNS N
were VBD N
(placebo JJ I
versus NN I
steroid NN I
respectively): NN I
CMV NNP O
infection NN O
25% CD N
versus NN N
33% CD N
(p NNP N
= VBD N
0.336) CD N
post-transplant JJ O
diabetes NNS O
30% CD N
versus NN N
53% CD N
(p NNP N
= VBD N
0.024) CD N
hypertension NN O
39% CD N
versus NN N
52% CD N
(p NNP N
= VBD N
0.248) CD N
hypercholesterolemia NN O
10% CD N
versus NN N
41% CD N
(p NNP N
= VBD N
0.002) CD N
and CC N
hypertriglyceridemia $ O
32% CD N
versus NN N
54% CD N
(p NNP N
= VBD N
0.046) CD N
. . N

In IN N
conclusion NN N
early JJ N
steroid NN I
withdrawal NN I
after IN P
LT NNP P
is VBZ N
feasible JJ N
under IN N
tacrolimus NN I
monotherapy NN I
without IN N
increased JJ N
rejection NN I
rates NNS N
and CC N
with IN N
a DT N
lower JJR N
rate NN N
of IN N
side NN N
effects NNS N
. . N

-DOCSTART- -X- N

Heat-exercise JJ P
performance NN P
of IN P
pyridostigmine-treated JJ P
subjects NNS P
wearing VBG P
chemical NN P
protective JJ P
clothing NN P
. . P

Pyridostigmine NNP P
bromide NN I
is VBZ N
currently RB N
the DT N
pretreatment NN N
of IN N
choice NN N
for IN N
operation NN N
in IN N
a DT N
chemical NN N
warfare NN N
(CW) NNP N
environment NN N
. . N

Under IN N
CW NNP N
conditions NNS N
subjects NNS N
are VBP N
exposed VBN N
to TO N
thermal VB P
stress NN P
caused VBN P
by IN P
CW NNP P
protective JJ P
clothing NN P
. . P

This DT N
investigation NN N
was VBD N
conducted VBN N
to TO N
determine VB N
if IN N
pyridostigmine JJ I
affects VBZ N
various JJ N
physiological JJ N
and CC N
biophysical JJ N
parameters NNS N
of IN N
human JJ N
temperature NN N
regulation NN N
in IN N
subjects NNS N
wearing VBG N
CW NNP N
protective JJ N
clothing NN N
. . N

Pyridostigmine NNP I
was VBD I
administered VBN I
orally RB I
in IN I
a DT I
randomized JJ I
double-blind JJ I
cross-over NN I
study NN I
in IN I
four CD I
doses NNS I
of IN I
30 CD I
mg NN I
every DT I
8 CD I
h NN I
. . I

An DT N
average NN N
of IN N
33% CD N
whole JJ N
blood NN N
cholinesterase NN N
inhibition NN N
was VBD N
induced VBN N
in IN N
the DT N
pyridostigmine NN I
treated VBD N
group NN N
4 CD N
h NN N
after IN N
ingestion NN N
of IN N
last JJ N
tablet NN N
. . N

The DT N
subjects NNS N
were VBD N
exposed VBN N
to TO N
170 CD N
min NNS N
exercise-heat JJ I
stress NN I
(Tdb NNP N
= VBZ N
33 CD N
degrees NNS N
C; NNP N
rh VBP N
= $ N
60%) CD N
consisting NN N
of IN N
60 CD N
min NNS N
in IN N
a DT N
sitting JJ N
position NN N
and CC N
two CD N
50-min JJ N
walks NNS N
(1.39 VBP N
m.s-1 JJ N
5% CD N
grade) NN N
separated VBN N
by IN N
10 CD N
min NN N
of IN N
rest NN N
. . N

Non-evaporative NNP O
heat NN O
exchange NN O
was VBD N
significantly RB N
higher JJR N
-14.0 NN N
and CC N
-10.6 JJ N
W.m-2 NNP N
(p NNP N
less JJR N
than IN N
0.03) CD N
for IN N
the DT N
pyridostigmine-treated JJ I
subjects NNS N
. . N

-DOCSTART- -X- N

Chloroprocaine NNP I
and CC I
lidocaine JJ I
decrease NN I
hospital NN I
stay NN I
and CC I
admission NN I
rate NN I
after IN I
outpatient JJ P
epidural JJ P
anesthesia NN P
. . P

Lumbar NNP P
epidural JJ I
anesthesia NN I
with IN I
20 CD I
ml NN I
of IN I
either DT I
3% CD I
2-chloroprocaine JJ I
(C) NN I
1.5% CD I
lidocaine NN I
(L) NN I
or CC I
1.5% CD I
mepivacaine NN I
(M) NN I
with IN I
epinephrine NN I
was VBD I
studied VBN I
in IN I
84 CD P
outpatients NNS P
undergoing JJ P
surgery NN P
(extracorporeal NN P
shock NN P
wave VBP P
lithotripsy VBN P
(ESWL] NN P
. . P

The DT I
average JJ O
duration NN O
of IN O
the DT O
procedure NN O
was VBD I
31.9 CD I
minutes NNS I
. . I

The DT I
total JJ O
duration NN O
of IN O
sensory JJ O
anesthesia NN O
was VBD I
133 CD I
+/- JJ I
28 CD I
minutes NNS I
(C) JJ I
182 CD I
+/- JJ I
38 CD I
(L) NN I
and CC I
247 CD I
+/- JJ I
42 CD I
(M) JJ I
(p NNP I
less JJR I
than IN I
0.05) CD I
. . I

Times NNS O
to TO O
discharge VB O
were VBD I
269 CD I
+/- JJ I
62 CD I
minutes NNS I
(C) JJ I
284 CD I
+/- JJ I
62 CD I
(L) NN I
and CC I
357 CD I
+/- JJ I
71 CD I
(M) NN I
. . I

The DT I
time NN O
to TO O
discharge VB O
with IN I
M NNP I
almost RB I
six CD I
hours NNS I
was VBD I
significantly RB I
longer JJR I
than IN I
with IN I
C NNP I
or CC I
L NNP I
. . I

There EX I
was VBD I
a DT I
trend NN I
to TO I
an DT I
increasing VBG I
rate NN I
of IN I
unplanned JJ O
overnight JJ O
hospital NN O
admission NN O
with IN I
increasing VBG I
duration NN I
of IN I
the DT I
local JJ I
anesthetic JJ I
drug NN I
employed VBN I
. . I

Continuous JJ I
epidural JJ I
anesthesia NN I
with IN I
C NNP I
L NNP I
or CC I
M NNP I
appears VBZ I
safe JJ I
and CC I
effective JJ I
for IN I
outpatient JJ I
surgical JJ I
procedures NNS I
such JJ I
as IN I
ESWL NNP I
. . I

In IN I
contrast NN I
to TO I
previous JJ I
understanding JJ I
mepivacaine NN I
produces VBZ I
significantly RB I
longer JJR I
anesthesia NN I
and CC I
recovery NN I
times NNS I
and CC I
may MD I
not RB I
be VB I
optimal JJ I
for IN I
outpatient JJ I
epidural JJ I
use NN I
. . I

-DOCSTART- -X- N

A DT N
comparison NN N
of IN N
a DT N
spiritually RB I
based VBN I
and CC I
non-spiritually RB I
based VBN I
educational JJ I
intervention NN I
for IN N
informed JJ N
decision NN N
making NN N
for IN N
prostate NN N
cancer NN N
screening VBG N
among IN N
church-attending JJ P
African-American JJ P
men NNS P
. . P

INTRODUCTION NNP N
Health NNP I
communication NN I
interventions NNS I
have VBP N
been VBN N
modestly RB N
effective JJ N
for IN N
increasing VBG N
informed JJ N
decision NN N
making NN N
for IN N
prostate NN N
cancer NN N
screening VBG N
among IN P
African-American JJ P
men; NNS P
however RB N
knowledge VBP N
and CC N
informed JJ N
decision NN N
making NN N
is VBZ N
still RB N
questionable JJ N
even RB N
with IN N
screening NN N
. . N

Church-based JJ I
programs NNS I
may MD N
be VB N
more RBR N
effective JJ N
if IN N
they PRP N
are VBP N
spiritually RB N
based VBN N
in IN N
nature NN N
. . N

OBJECTIVE IN N
The DT N
aims NNS N
of IN N
the DT N
present JJ N
study NN N
were VBD N
to TO N
implement VB N
and CC N
provide VB N
an DT N
initial JJ N
evaluation NN N
of IN N
a DT N
spiritually RB N
based VBN N
prostate NN N
cancer NN N
screening VBG N
informed JJ N
decision NN N
making VBG N
intervention NN N
for IN N
African-American JJ P
men NNS P
who WP P
attend VBP P
church NN P
and CC P
determine VB N
its PRP$ N
efficacy NN N
for IN N
increasing VBG N
informed JJ N
decision NN N
making NN N
. . N

DESIGN NNP N
AND NNP N
METHOD NNP N
Churches NNP P
were VBD P
randomized VBN N
to TO N
receive VB N
either CC N
the DT N
spiritually RB I
based VBN I
or CC I
the DT I
non-spiritual JJ I
intervention NN I
. . I

Trained VBN N
community NN N
health NN N
advisors NNS N
who WP N
were VBD N
African-American JJ P
male JJ P
church NN P
members NNS P
led VBD N
an DT N
educational JJ O
session NN O
and CC I
distributed VBD I
educational JJ O
print NN O
materials NNS O
. . O

Participants NNS N
completed VBN N
baseline NN N
and CC N
immediate JJ O
follow-up JJ O
surveys NNS O
to TO N
assess VB N
the DT N
intervention NN N
impact NN O
on IN O
study NN O
outcomes NNS O
. . O

RESULTS VB N
The DT N
spiritually RB N
based VBN N
intervention NN N
appeared VBD N
to TO N
be VB N
more RBR N
effective JJ N
in IN N
areas NNS N
such JJ N
as IN N
knowledge NN O
and CC O
men NNS N
read VBP N
more JJR N
of IN N
their PRP$ N
materials NNS O
in IN N
the DT N
spiritually RB N
based VBN N
group NN N
than IN N
in IN N
the DT N
non-spiritual JJ N
group NN N
. . N

CONCLUSIONS NNP N
Further NNP N
examination NN N
of IN N
the DT N
efficacy NN O
of IN N
the DT N
spiritually RB N
based VBN N
approach NN N
to TO N
health NN N
communication NN N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -X- N

The DT N
effect NN O
of IN N
splinting NN P
of IN P
teeth NNS P
in IN P
combination NN P
with IN P
reconstructive JJ P
periodontal NN P
surgery NN P
in IN P
humans NNS P
. . P

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN O
of IN N
splinting VBG I
teeth NNS I
on IN N
the DT N
results NNS N
of IN N
periodontal JJ I
reconstructive JJ I
surgery NN I
using VBG N
a DT N
specific JJ I
carbonate NN I
bone NN I
replacement NN I
graft NN I
(BRG) NNP I
material NN I
. . I

Forty-five JJ P
patients NNS P
were VBD P
randomly RB P
treated VBN P
with IN P
a DT P
periodontal JJ P
surgery NN P
approach NN P
. . P

Natural JJ I
coral JJ I
calcium NN I
BRG NNP I
was VBD N
utilised VBN N
in IN N
33 CD P
patients NNS P
. . P

This DT N
33-patient JJ N
group NN N
was VBD N
divided VBN N
into IN N
three CD N
equal JJ N
groups NNS N
. . N

In IN N
the DT N
presplint NN N
group NN N
teeth WDT I
were VBD I
splinted VBN I
to TO I
at IN I
least JJS I
two CD I
rigid JJ I
teeth NNS I
before IN I
surgery NN I
in IN I
the DT N
postsplint NN N
group NN N
teeth WDT I
were VBD I
splinted VBN I
at IN I
suture NN I
removal NN I
and CC I
in IN N
the DT N
nonsplint NN N
group NN N
the DT N
treated VBN I
teeth NNS I
were VBD I
not RB I
splinted VBN I
at IN I
all DT I
. . I

In IN N
12 CD N
patients NNS N
teeth NNS N
were VBD N
treated VBN N
with IN N
surgical JJ I
debridement NN I
(DEBR) NNP I
alone RB I
and CC N
not RB N
splinted VBN N
. . N

Periodontal JJ O
probing VBG O
depth NN O
(PPD) NNP O
clinical JJ O
probing VBG O
attachment JJ O
level NN O
(CPAL) NN O
and CC O
tooth DT O
mobility NN O
were VBD N
measured VBN N
using VBG N
desmodontometry NN N
(DDM) NN N
and CC N
periotest JJS N
(PTV) NN N
with IN N
reproducible JJ N
methods NNS N
before IN N
surgery NN I
and CC N
at IN N
various JJ N
periods NNS N
up RB N
to TO N
1 CD N
year NN N
afterwards NNS N
. . N

A DT N
decrease NN O
in IN O
PPD NNP O
(5.4 NNP N
mm VBD N
SD NNP N
1.4 CD N
mm) NN N
and CC N
tooth DT O
mobility NN O
(DDM-horizontal JJ N
257 CD N
microns NNS N
SD NNP N
60 CD N
microns) NN N
and CC N
a DT N
gain NN O
of IN O
CPAL NNP O
(5.1 NNP N
mm VBD N
SD NNP N
1.4 CD N
mm) NN N
were VBD N
seen VBN N
following VBG N
the DT N
use NN N
of IN N
BRG NNP N
in IN N
presplint NN N
teeth NNS N
. . N

In IN N
the DT N
same JJ N
group NN N
PPD NNP O
and CC O
tooth JJ O
mobility NN O
were VBD N
significantly RB O
reduced VBN O
compared VBN N
to TO N
nonsplint VB N
teeth NNS N
. . N

DEBR NNP N
alone RB N
showed VBD N
reductions NNS O
in IN O
tooth DT O
mobility NN O
and CC O
PPD NNP O
and CC N
a DT N
significantly RB N
smaller JJR O
gain NN O
in IN N
CPAL NNP O
than IN N
in IN N
presplint NN N
teeth NNS N
treated VBN N
with IN N
BRG NNP N
. . N

The DT N
less RBR N
favourable JJ N
improvement NN N
in IN N
periodontal JJ N
function NN N
of IN N
postsplint NN N
or CC N
nonsplint NN N
teeth NNS N
seemed VBD N
to TO N
be VB N
due JJ N
to TO N
the DT N
loss NN O
of IN O
BRG NNP O
material NN O
caused VBN N
by IN N
tooth DT O
mobility NN O
. . O

These DT N
results NNS N
indicate VBP N
that IN N
an DT N
undisturbed JJ N
wound NN N
healing VBG N
process NN N
using VBG N
BRG NNP N
together RB N
with IN N
tooth DT N
stability NN N
is VBZ N
beneficial JJ N
to TO N
overall JJ N
clinical JJ N
success NN N
. . N

-DOCSTART- -X- N

Levels NNS N
of IN N
metals NNS I
in IN N
the DT N
blood NN N
and CC N
specific JJ N
porphyrins NNS I
in IN N
the DT N
urine NN N
in IN N
children NNS P
with IN P
autism NN P
spectrum NN P
disorders NNS P
. . P

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
levels NNS N
of IN N
metals NNS O
in IN O
blood NN O
(zinc NN O
(Zn) NNP O
copper NN O
(Cu) NNP O
aluminium NN O
(Al) NNP O
lead NN O
(Pb) NN O
and CC O
mercury NN O
(Hg)) NN O
as RB N
well RB N
as IN N
the DT N
specific JJ N
porphyrin NN N
levels NNS N
in IN N
the DT N
urine NN N
of IN N
patients NNS P
with IN P
autism NN P
spectrum NN P
disorder NN P
(ASD) NNS P
compared VBN P
with IN P
patients NNS P
with IN P
other JJ P
neurological JJ P
disorders NNS P
. . P

The DT N
study NN N
was VBD N
performed VBN N
in IN N
a DT N
group NN P
of IN P
children NNS P
with IN P
ASD NNP P
(N=52 NNP P
average JJ P
age=6.2years) JJ P
anda NN P
control NN P
group NN P
of IN P
children NNS P
with IN P
other JJ P
neurological JJ P
disorders NNS P
(N=22 JJ P
average JJ P
age=6.6years) NN P
matched VBN P
in IN P
terms NNS P
of IN P
intellectual JJ P
abilities NNS P
(Mann-Whitney JJ N
U=565.0 NNP I
p=0.595) NN O
. . O

Measurement NN O
of IN I
metals NNS I
in IN I
blood NN I
was VBD I
performed VBN I
by IN I
atomic JJ I
absorption NN I
spectrometry NN I
while IN I
the DT I
HPLC NNP I
method NN I
via IN I
a DT I
fluorescence NN I
detector NN I
was VBD I
used VBN I
to TO I
test VB I
urinary JJ N
porphyrin NN N
levels NNS N
. . N

Results NNS N
were VBD N
compared VBN N
across IN N
groups NNS N
using VBG N
a DT N
multivariate JJ N
analysis NN N
of IN N
covariance NN N
(MANCOVA) NN N
. . N

In IN N
addition NN N
a DT N
generalized JJ N
linear JJ N
model NN N
was VBD N
used VBN N
to TO N
establish VB N
the DT N
impact NN N
of IN O
group NN O
membership NN O
on IN N
the DT N
blood NN O
Cu/Zn NNP O
ratio NN O
. . O

In IN O
terms NNS O
of IN N
blood NN N
levels NNS N
of IN N
metals NNS N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
was VBD N
found VBN N
. . N

However RB N
compared VBN N
to TO N
the DT N
control NN N
group NN N
ASD NNP N
group NN N
had VBD O
significantly RB O
elevated VBN N
blood NN N
Cu/Zn NNP N
ratio NN N
(Wald NNP N
 NNP N
(2)=6.6 NNP N
df=1 NN N
p=0.010) NN N
. . N

Additionally RB N
no DT N
significant JJ N
difference NN N
between IN O
the DT O
groups NNS O
was VBD O
found VBN O
in IN O
terms NNS O
of IN O
uroporphyrin NN O
I PRP O
heptacarboxyporphyrin VBP O
I PRP O
hexacarboxyporphyrin VBP O
and CC O
pentacarboxyporphyrin VBP O
I PRP O
. . O

However RB O
the DT O
levels NNS O
of IN O
coproporphyrin NN N
I PRP N
and CC N
coproporphyrin VB N
III NNP N
were VBD N
lower JJR N
in IN N
the DT N
ASD NNP N
group NN N
compared VBN N
to TO O
the DT O
controls NNS O
. . N

Due JJ N
to TO N
observed VB N
higher JJR N
Cu/Zn NNP N
ratio NN N
it PRP N
is VBZ N
suggested VBN N
to TO P
test VB P
blood NN P
levels NNS P
of IN N
Zn NNP N
and CC N
Cu NNP N
in IN I
all DT I
autistic JJ I
children NNS N
and CC N
give VB N
them PRP N
a DT N
Zn NNP N
supplement NN N
if IN N
needed VBN N
. . N

-DOCSTART- -X- N

Body NNP N
Mass NNP N
Index NNP N
and CC N
Adverse NNP N
Outcomes NNP N
in IN N
Elderly JJ P
Patients NNS P
With IN P
Atrial NNP P
Fibrillation: NNP P
The DT N
AMADEUS NNP N
Trial NNP N
. . N

BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
Obesity NNP N
has VBZ N
been VBN N
associated VBN N
with IN N
increased JJ N
cardiovascular NN N
risk NN N
in IN N
atrial JJ N
fibrillation NN N
but CC N
little JJ N
is VBZ N
known VBN N
in IN N
elderly JJ P
patients NNS P
with IN P
atrial JJ P
fibrillation NN P
. . P

METHODS NNP P
Post NNP N
hoc NN N
analysis NN N
of IN N
data NNS N
from IN N
the DT N
AMADEUS NNP N
(Evaluating VBG N
the DT N
Use NNP N
of IN N
SR34006 NNP I
Compared NNP N
to TO N
Warfarin NNP I
or CC I
Acenocoumarol NNP I
in IN N
Patients NNP P
With IN P
Atrial NNP P
Fibrillation) NNP P
trial NN N
. . N

RESULTS NNP N
We PRP N
studied VBD N
1588 CD P
elderly JJ P
patients NNS P
who WP P
were VBD P
categorized VBN P
as IN P
normal JJ P
body NN P
mass NN P
index NN P
(BMI VBD P
18.5-25 JJ P
kg/m(2); NN P
n=515 NN P
[32.4%]) NNP P
overweight VBD P
(BMI NNP P
25-30 JJ P
kg/m(2); NN P
n=711 NN P
[44.8%]) NNP P
and CC P
obese JJ P
(BMI30 NNP P
kg/m(2); NN P
n=362 NN P
[22.8%]) NN P
. . N

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
composite JJ N
outcome NN N
of IN O
cardiovascular JJ O
death NN O
and CC O
stroke/systemic JJ O
embolism NN O
with IN N
increasing VBG N
BMI NNP N
category NN N
being VBG N
5.0% CD N
3.2% CD N
and CC N
1.5% CD N
per IN N
100 CD N
patient-years NNS N
respectively RB N
(P VBP N
for IN N
trend=0.01) NN N
. . N

Cox NNP N
proportional JJ N
hazards NNS N
analysis NN N
found VBD N
obesity NN N
to TO N
be VB N
associated VBN N
with IN N
a DT N
lower JJR N
risk NN N
of IN N
the DT N
primary JJ N
composite JJ N
outcome NN N
(hazard NNP N
ratio VBZ N
0.29; CD N
95% CD N
confidence NN N
interval JJ N
0.11-0.77; JJ N
P=0.01) NNP N
. . N

In IN N
the DT I
warfarin NN I
arm NN I
(n=814) NN N
multivariate NN N
logistic JJ N
regression NN N
analysis NN N
demonstrated VBD N
that IN N
obesity NN N
was VBD N
independently RB N
related VBN N
to TO N
higher JJR N
odds NNS N
of IN N
time NN N
in IN N
therapeutic JJ N
range NN N
60% NNP N
(odds NNP N
ratio VBD N
1.84; CD N
95% CD N
confidence NN N
interval JJ N
1.21-2.80; JJ N
P=0.004) NNP N
. . N

CONCLUSION NNP N
Obesity NNP N
was VBD N
associated VBN N
with IN O
a DT O
lower JJR O
stroke NN O
and CC O
mortality NN O
rate NN P
in IN P
elderly JJ P
anticoagulated VBN P
atrial JJ P
fibrillation NN P
patients NNS P
. . N

Obesity NN N
was VBD N
related VBN N
to TO N
good JJ N
quality NN N
anticoagulation NN N
control NN N
. . N

-DOCSTART- -X- N

Competitive JJ O
employment NN O
for IN N
youth NN P
with IN P
autism NN P
spectrum NN P
disorders: VBD P
early JJ N
results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

For IN N
most JJS N
youth NN P
with IN P
autism NN P
spectrum NN P
disorders NNS P
(ASD) VBP P
employment NN P
upon IN N
graduation NN N
from IN N
high JJ N
school NN N
or CC N
college NN N
is VBZ N
elusive JJ N
. . N

Employment JJ O
rates NNS O
are VBP N
reported VBN N
in IN N
many JJ N
studies NNS N
to TO N
be VB N
very RB N
low JJ N
despite IN N
many JJ N
years NNS N
of IN N
intensive JJ I
special JJ I
education NN I
services NNS N
. . N

This DT N
paper NN N
presented VBD N
the DT N
preliminary JJ I
results NNS I
of IN I
a DT I
randomized JJ I
clinical JJ I
trial NN I
of IN I
Project NNP I
SEARCH NNP I
plus CC I
ASD NNP I
Supports NNP I
on IN I
the DT I
employment NN O
outcomes NNS O
for IN N
youth NN P
with IN P
ASD NNP P
between IN P
the DT P
ages NNS P
of IN P
18-21 JJ P
years NNS P
of IN P
age NN P
. . P

This DT N
model NN N
provides VBZ N
very RB N
promising JJ N
results NNS N
in IN N
that DT N
the DT N
employment NN N
outcomes NNS N
for IN N
youth NN N
in IN N
the DT N
treatment NN I
group NN N
were VBD N
much RB N
higher JJR N
in IN N
non-traditional JJ N
jobs NNS N
with IN N
higher JJR N
than IN N
minimum JJ N
wage NN N
incomes NNS N
than IN N
for IN N
youth NN N
in IN N
the DT N
control NN I
condition NN N
. . N

Specifically RB N
21 CD N
out IN N
of IN N
24 CD N
(87.5 JJ N
%) NNP P
treatment NN P
group NN P
participants NNS P
acquired VBD N
employment NN N
while IN N
1 CD N
of IN N
16 CD N
(6.25 JJ N
%) NN P
of IN P
control NN P
group NN P
participants NNS P
acquired VBD N
employment NN N
. . N

-DOCSTART- -X- N

Hematologic NNP P
patients' CC P
clinical JJ P
and CC P
psychosocial JJ P
experiences NNS P
with IN P
implanted JJ P
long-term JJ P
central JJ P
venous JJ P
catheter: NN P
self-management JJ I
versus NN N
professionally RB I
controlled VBN I
care NN I
. . I

BACKGROUND IN N
A NNP N
significant JJ N
decrease NN N
in IN N
catheter-related JJ N
infections NNS N
was VBD N
demonstrated VBN N
in IN N
our PRP$ N
earlier JJR N
randomized VBN N
controlled JJ N
trial NN N
of IN N
central JJ I
venous JJ I
catheter NN I
(CVC) NNP I
care NN N
in IN N
hematologic JJ P
patients NNS P
. . P

OBJECTIVE NN N
This DT N
article NN N
focuses VBZ N
on IN N
patients' NN O
clinical JJ O
and CC O
psychosocial JJ O
experiences NNS O
with IN N
CVC NNP I
self-care NN I
compared VBN N
with IN N
professionally RB I
controlled VBN I
CVC NNP I
care NN I
. . I

METHODS NNP N
Eighty-two JJ P
patients NNS P
with IN P
tunneled JJ P
CVCs NNP P
were VBD P
enrolled VBN P
in IN P
the DT P
randomized NN P
controlled VBD P
trial NN P
. . P

The DT N
intervention NN N
group NN N
(n NNP N
= VBD N
42) CD N
was VBD N
trained VBN N
to TO N
perform VB N
CVC NNP I
self-care NN I
. . I

The DT N
control NN I
group NN N
(n NNP N
= VBZ N
40) CD N
followed JJ N
standard NN I
CVC NNP I
procedure NN I
provided VBN I
by IN I
nurses NNS I
. . I

Eighteen JJ N
patients NNS N
were VBD N
selected VBN N
for IN N
semistructured JJ N
interviews NNS N
focusing VBG N
on IN N
patients' JJ N
clinical JJ N
and CC N
psychosocial JJ N
experiences NNS N
with IN N
CVCs NNP I
. . N

RESULTS NNP N
Methods NNP N
of IN N
CVC NNP I
care NN I
have VBP N
different JJ N
influences NNS N
on IN N
the DT N
patients' JJ N
clinical JJ O
and CC O
psychosocial JJ O
outcomes NNS O
depending VBG O
on IN N
whether IN N
they PRP N
were VBD N
hospitalized VBN P
or CC P
outpatients NNS P
. . P

Central NNP I
venous JJ I
catheter NN I
was VBD N
viewed VBN N
as IN N
important JJ N
because IN N
it PRP N
was VBD N
the DT N
main JJ N
port NN N
of IN N
treatment NN N
toward IN N
a DT N
cure NN N
although IN N
patients NNS N
constantly RB N
fear VBP N
complications NNS N
. . N

Central NNP I
venous JJ I
catheter NN I
self-care NN I
increased VBD N
patients' JJ O
independence NN O
from IN O
health NN O
professionals NNS O
and CC O
supported VBD O
perceived VBN O
self-efficacy NN O
and CC O
control NN O
. . O

Central NNP I
venous JJ I
catheters NNS I
cause VBP N
psychosocial JJ O
problems NNS O
including VBG O
altered VBD O
body NN O
perception NN O
sexual JJ O
activity NN O
avoidance NN O
and CC O
feeling NN O
stigmatized VBN O
. . O

CONCLUSIONS JJ N
Patients NNS N
experience NN N
increased VBD N
perceived VBN O
self-control NN O
and CC O
independence NN O
when WRB N
individually RB N
supervised VBN N
and CC N
trained VBN N
in IN N
CVC NNP I
self-management NN I
. . I

Assuming VBG N
ownership NN N
of IN N
CVC NNP I
care NN N
can MD N
encourage VB N
patients NNS N
to TO N
feel VB N
less RB N
inhibited VBN N
about IN N
sexual JJ O
activity NN O
and CC O
socialization NN O
. . O

IMPLICATIONS NNP O
FOR NNP N
PRACTICE NNP N
Placement NNP N
of IN N
a DT N
tunneled JJ N
CVC NNP N
should MD N
engage VB N
nurses NNS N
to TO N
organize VB N
individualized JJ N
structured VBN N
and CC N
supervised VBN N
patient JJ N
education NN N
. . N

Stigma NNP N
originating VBG N
from IN N
CVCs NNP I
should MD N
be VB N
carefully RB N
considered VBN N
by IN N
health NN N
professionals NNS N
when WRB N
maintaining VBG N
CVC NNP N
insertion NN N
for IN N
longer JJR N
periods NNS N
. . N

Central NNP I
venous JJ I
catheters NNS I
should MD N
be VB N
removed VBN N
whenever WRB N
the DT N
potential JJ N
risks NNS N
exceed VBP N
the DT N
catheter's JJ N
functional JJ N
necessity NN N
. . N

-DOCSTART- -X- N

-Smooth JJ O
muscle NN O
actin NN O
expression NN O
and CC O
desmoplastic JJ O
stromal JJ O
reaction NN O
in IN P
pancreatic JJ P
cancer: NN P
results NNS N
from IN N
the DT N
CONKO-001 NNP N
study NN N
. . N

BACKGROUND NNP N
Previous NNP N
investigations NNS N
in IN N
pancreatic JJ N
cancer NN N
suggest VBP N
a DT N
prognostic JJ N
role NN N
for IN N
-smooth JJ N
muscle NN N
actin IN N
(-SMA) JJ N
expression NN N
and CC N
stromal JJ N
density NN N
in IN N
the DT N
peritumoural JJ N
stroma NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
further JJ N
validate VB N
the DT N
impact NN N
of IN N
-SMA JJ N
expression NN N
and CC N
stromal JJ N
density NN P
in IN P
resectable JJ P
pancreatic JJ P
cancer NN P
patients NNS P
treated VBN P
with IN P
adjuvant JJ P
gemcitabine NN P
compared VBN P
with IN P
untreated JJ P
patients NNS P
. . N

METHODS NNP N
CONKO-001 NNP N
was VBD N
a DT N
prospective JJ N
randomised JJ N
phase NN N
III NNP N
study NN N
investigating VBG N
the DT N
role NN I
of IN I
adjuvant JJ I
gemcitabine NN I
as IN N
compared VBN N
with IN N
observation NN N
. . N

Tissue NN P
samples NNS P
of IN P
162 CD P
patients NNS P
were VBD P
available JJ P
for IN N
immunohistochemistry NN N
on IN N
tissue NN N
microarrays NNS N
to TO N
evaluate VB N
the DT O
impact NN O
of IN O
-SMA JJ O
expression NN O
and CC O
stromal JJ O
density NN O
impact NN O
on IN O
patient JJ O
outcome NN O
. . N

RESULTS RB N
High JJ N
-SMA JJ N
expression NN N
in IN N
tumour JJ N
stroma NN N
was VBD N
associated VBN O
with IN O
worse JJ O
patient NN O
outcome NN O
(DFS: NNP N
P=0.05 NNP N
OS: NNP N
P=0.047) NNP N
. . N

A DT N
dense NN N
stroma NN N
reaction NN N
was VBD N
associated VBN N
with IN N
improved JJ O
disease-free JJ O
survival NN O
(DFS) NN O
and CC O
overall JJ O
survival NN O
(OS) NN N
in IN N
the DT N
overall JJ N
study NN N
population NN N
(DFS: NNP N
P=0.001 NNP N
OS: NNP N
P=0.001) NNP N
. . N

This DT N
positive JJ O
prognostic JJ O
impact NN O
was VBD N
restricted VBN N
to TO N
patients NNS I
with IN I
no DT I
adjuvant JJ I
treatment NN I
(DFS: NNP N
P<0.001 NNP N
OS: NNP N
P<0.001) NNP N
. . N

In IN N
multivariable JJ N
analysis NN N
-SMA NN N
and CC N
stromal JJ N
density NN N
expression NN N
were VBD N
independently RB N
predictive JJ N
factors NNS O
for IN O
survival NN O
. . N

CONCLUSIONS NNP N
Our PRP$ N
data NNS N
confirm VBP N
the DT N
negative JJ O
prognostic JJ O
impact NN N
of IN N
high JJ N
-SMA JJ N
expression NN P
in IN P
pancreatic JJ P
cancer NN P
patients NNS P
after IN P
curatively RB P
intended VBN P
resection NN P
. . N

In IN N
contrast NN N
to TO N
former JJ N
investigations NNS N
we PRP N
found VBD N
a DT N
positive JJ O
prognostic JJ O
impact NN N
for IN N
a DT N
dense NN N
stroma NN N
. . N

This DT N
significant JJ N
influence NN N
was VBD N
restricted VBN N
to TO N
patients NNS N
who WP N
received VBD I
no DT I
adjuvant JJ I
therapy NN I
. . N

-DOCSTART- -X- N

Short-term JJ N
effects NNS N
of IN N
denopamine NN I
on IN N
anaerobic JJ N
threshold NN N
and CC N
related JJ N
parameters NNS N
in IN N
patients NNS P
with IN P
chronic JJ P
heart NN P
failure: VBZ P
a DT N
double-blind JJ N
crossover NN N
study NN N
. . N

BACKGROUND IN N
The DT N
short-term JJ N
effects NNS N
of IN N
denopamine NN I
an DT I
orally RB N
available JJ N
beta-stimulant JJ I
on IN I
exercise NN I
capacity NN I
were VBD N
studied VBN N
in IN N
patients NNS P
with IN P
chronic JJ P
heart NN P
failure NN P
. . P

METHODS NNP N
AND CC N
RESULTS NNP N
Nineteen NNP P
patients NNS P
entered VBD P
the DT P
study NN P
. . P

Three CD P
patients NNS P
had VBD P
ischemic JJ P
heart NN P
disease NN P
13 CD P
had VBD P
dilated VBN P
cardiomyopathy NN P
and CC P
three CD P
had VBD P
valvular JJ P
disease; NN P
16 CD P
patients NNS P
were VBD P
in IN P
New NNP P
York NNP P
Heart NNP P
Association NNP P
class NN P
II NNP P
and CC P
three CD P
patients NNS P
were VBD P
in IN P
New NNP P
York NNP P
Heart NNP P
Association NNP P
class NN P
III NNP P
. . P

Symptom-limited JJ I
exercise NN I
testing VBG I
(ramp NNP I
protocol) NN I
on IN I
a DT I
bicycle NN I
ergometer NN I
with IN I
gas NN I
exchange NN I
analysis NN I
was VBD N
conducted VBN N
1 CD N
hour NN N
after IN N
oral JJ I
administration NN I
of IN I
either CC I
20 CD I
mg NN I
denopamine NN I
or CC I
placebo NN I
. . I

Drug NNP N
administration NN N
sequence NN N
was VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
double-blind JJ N
crossover NN N
method NN N
with IN N
1 CD N
week NN N
between IN N
drugs NNS N
. . N

Peak NNP O
VO2 NNP O
was VBD N
20.4 CD N
+/- JJ N
3.2 CD N
and CC N
21.2 CD N
+/- JJ N
3.1 CD N
ml/min/kg NN N
respectively RB N
for IN N
those DT N
administered VBN N
the DT N
placebo NN I
and CC N
the DT N
drug NN N
and CC N
anaerobic JJ N
threshold NN N
was VBD N
13.1 CD N
+/- JJ N
2.1 CD N
and CC N
14.0 CD N
+/- JJ N
2.0 CD N
ml/min/kg NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
peak JJ O
VO2 NNP O
(p NNP N
< NNP N
0.05) CD N
and CC N
anaerobic JJ O
threshold NN O
(p NNP N
< VBZ N
0.01) CD N
with IN N
denopamine JJ I
whereas NNS I
no DT N
significant JJ N
change NN N
was VBD N
observed VBN N
in IN N
peak JJ N
work NN N
rate NN N
or CC N
exercise NN N
time NN N
. . N

Denopamine NNP I
increased VBD N
heart NN O
rate NN O
in IN N
patients NNS P
with IN P
atrial JJ P
fibrillation NN P
but CC N
had VBD N
little JJ N
effect NN N
on IN N
heart NN O
rate NN O
in IN N
patients NNS P
with IN P
sinus JJ P
rhythm NN P
. . P

CONCLUSION NNP N
Data NNP N
obtained VBD N
from IN N
gas NN N
exchange NN N
analysis NN N
are VBP N
more RBR N
sensitive JJ N
and CC N
potentially RB N
more RBR N
useful JJ N
in IN N
the DT N
detection NN N
of IN N
short-term JJ N
changes NNS N
in IN N
exercise NN N
capacity NN N
than IN N
data NNS N
obtained VBN N
from IN N
either CC N
exercise JJ N
time NN N
or CC N
peak JJ N
work NN N
rate NN N
indexes NNS N
that WDT N
are VBP N
commonly RB N
used VBN N
to TO N
assess VB N
drug NN N
therapy NN N
. . N

Patients NNS P
with IN P
mild-to-moderate JJ P
heart NN P
failure NN P
with IN P
sinus NN P
rhythm NNS P
but CC P
not RB P
those DT P
with IN P
atrial JJ P
fibrillation NN P
because IN P
of IN P
its PRP$ P
frequent JJ P
induction NN P
of IN P
tachycardia NN P
may MD P
be VB N
good JJ N
candidates NNS N
for IN N
denopamine NN I
therapy NN N
. . N

-DOCSTART- -X- N

Nasal NNP N
oxytocin MD I
for IN N
social JJ N
deficits NNS N
in IN N
childhood NN P
autism: NN P
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

The DT N
last JJ N
two CD N
decades NNS N
have VBP N
witnessed VBN N
a DT N
surge NN N
in IN N
research NN N
investigating VBG N
the DT N
application NN N
of IN N
oxytocin NN I
as IN N
a DT N
method NN N
of IN N
enhancing VBG N
social JJ N
behaviour NN N
in IN N
humans NNS N
. . N

Preliminary JJ N
evidence NN N
suggests VBZ N
oxytocin NN I
may MD N
have VB N
potential NN N
as IN N
an DT N
intervention NN N
for IN N
autism NN N
. . N

We PRP N
evaluated VBD N
a DT N
5-day JJ N
'live-in' JJ I
intervention NN I
using VBG N
a DT N
double-blind JJ N
randomized VBN N
control NN N
trial NN N
. . N

38 CD P
male JJ P
youths NNS P
(7-16 JJ P
years NNS P
old) IN P
with IN P
autism NN P
spectrum NN P
disorders NNS P
were VBD N
administered VBN N
24 CD I
or CC I
12 CD I
international JJ I
units NNS I
(depending VBG I
on IN I
weight) NN I
intranasal NN I
placebo NN I
or CC I
oxytocin JJ I
once RB N
daily RB N
over IN N
four CD N
consecutive JJ N
days NNS N
. . N

The DT N
oxytocin NN I
or CC I
placebo NN I
was VBD N
administered VBN N
during IN N
parent-child JJ N
interaction NN N
training NN N
sessions NNS N
. . N

Parent NN N
and CC N
child NN N
behaviours NNS N
were VBD N
assessed VBN N
using VBG N
parent NN O
reports NNS O
clinician JJ O
ratings NNS O
and CC O
independent JJ O
observations NNS O
at IN O
multiple JJ N
time NN N
points NNS N
to TO N
measure VB O
side-effects; JJ O
social JJ O
interaction NN O
skills; VBD O
repetitive JJ O
behaviours; NN O
emotion NN O
recognition NN O
and CC O
diagnostic JJ O
status NN O
. . O

Compared VBN N
to TO N
placebo VB I
intranasal JJ I
oxytocin NNS I
did VBD N
not RB N
significantly RB N
improve VB N
emotion NN O
recognition NN O
social JJ O
interaction NN O
skills NNS O
or CC O
general JJ O
behavioral JJ O
adjustment NN O
in IN N
male JJ P
youths NNS P
with IN P
autism NN P
spectrum NN P
disorders NNS P
. . P

The DT N
results NNS N
show VBP N
that IN N
the DT N
benefits NNS N
of IN N
nasal JJ N
oxytocin NN I
for IN N
young JJ P
individuals NNS P
with IN P
autism NN P
spectrum NN P
disorders NNS P
may MD N
be VB N
more JJR N
circumscribed JJ N
than IN N
suggested VBN N
by IN N
previous JJ N
studies NNS N
and CC N
suggest JJS N
caution NN N
in IN N
recommending VBG N
it PRP N
as IN N
an DT N
intervention NN N
that WDT N
is VBZ N
broadly RB N
effective JJ N
. . N

-DOCSTART- -X- N

Effect NN N
of IN N
ozone NN I
application NN I
on IN N
the DT N
resin-dentin JJ O
microtensile NN O
bond NN O
strength NN O
. . O

When WRB N
ozone NN I
is VBZ N
used VBN N
during IN N
caries NNS N
treatment NN N
bond NN N
strength NN N
can MD N
be VB N
compromised VBN N
by IN N
the DT N
release NN N
of IN N
oxygen NN N
. . N

The DT N
use NN N
of IN N
antioxidant JJ N
agents NNS N
neutralizes VBZ N
the DT N
free JJ N
oxygen NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
ozone NN I
and CC I
sodium NN I
ascorbate NN I
on IN N
resin-dentin JJ O
microtensile NN O
bond NN O
strength NN O
(TBS) NN O
. . P

Forty NNP P
human JJ P
third JJ P
molars NNS P
were VBD N
divided VBN N
into IN N
four CD N
groups: NN N
Group NNP N
1 CD I
not RB I
treated VBN I
with IN I
ozone; JJ I
Group NNP N
2 CD I
ozone NN I
application NN I
followed VBN I
by IN I
acid JJ I
etching; NN I
Group NNP N
3 CD I
acid NN I
etching VBG I
followed VBN I
by IN I
ozone NN I
application; NN I
and CC N
Group NNP N
4 CD I
ozone NN I
and CC I
application NN I
of IN I
sodium NN I
ascorbate NN I
. . N

Bonded VBN N
beams NNS N
(1.0 VBP N
mm(2)) NNS N
were VBD N
tested VBN N
under IN N
tension NN N
(0.5 NNP N
mm VBZ N
min(-1)) NN N
. . N

The DT O
TBS NN O
values NNS N
were VBD N
analyzed VBN N
using VBG N
one-way JJ N
analysis NN N
of IN N
variance NN N
(ANOVA) NN N
and CC N
the DT N
Tukey NNP N
test NN N
(p=0.05) NN N
. . N

All DT N
beams NNS N
that WDT N
fractured VBD N
were VBD N
analyzed VBN N
under IN N
stereomicroscopy NN N
(40) NN N
. . N

Group NNP N
1 CD N
had VBD N
significantly RB N
higher JJR N
TBS NN N
values NNS N
than IN N
Group NNP N
2 CD N
or CC N
3 CD N
. . N

The DT O
TBS JJ O
values NNS N
of IN N
Groups NNP N
1 CD N
and CC N
4 CD N
were VBD N
similar JJ N
and CC N
higher JJR N
than IN N
those DT N
of IN N
Group NNP N
2 CD N
. . N

The DT N
use NN I
of IN I
ozone NN I
in IN N
Group NNP N
2 CD N
resulted VBD N
in IN N
lower JJR N
values NNS O
of IN O
TBS NN N
in IN N
all DT N
conditions NNS N
evaluated VBN N
. . N

The DT N
predominant JJ N
failure NN N
mode NN N
was VBD N
adhesive JJ N
. . N

The DT N
application NN I
of IN I
ozone NN N
decreased VBD N
the DT N
TBS NN N
of IN N
the DT N
dentin-composite JJ N
resin NN N
interface NN N
. . N

These DT N
values NNS N
were VBD N
reversed VBN N
when WRB N
compared VBN N
with IN N
Groups NNP N
1 CD N
and CC N
2 CD I
when WRB I
sodium NN I
ascorbate NN I
was VBD N
used VBN N
. . N

-DOCSTART- -X- N

Effect NN I
of IN I
unfractionated JJ I
and CC I
low-molecular-weight JJ I
heparin NN I
on IN I
OPG NNP I
sRANKL NN I
and CC I
von NN I
Willebrand NNP I
factor NN I
concentrations NNS I
during IN I
hemodialysis NN P
. . P

BACKGROUND NNP I
Endothelial NNP I
dysfunction NN I
marker NN I
von NN I
Willebrand NNP I
factor NN I
(vWF) NN I
is VBZ I
physically RB I
connected VBN I
with IN I
osteoprotegerin JJ I
(OPG) NN I
in IN I
the DT I
Weibel-Palade JJ I
bodies NNS I
. . I

We PRP I
aimed VBD I
to TO I
compare VB I
the DT I
effect NN I
of IN I
unfractionated JJ I
(UFH) NN I
and CC I
low-molecular-weight JJ I
(LMWH NNP I
enoxaparin) NN I
heparin NN I
used VBN I
as IN I
anticoagulants NNS I
during IN I
hemodialysis NN P
(HD) NN P
on IN I
plasma NN I
levels NNS I
and CC I
relationships NNS I
of IN I
OPG NNP I
soluble JJ I
receptor NN I
activator NN I
of IN I
nuclear JJ I
factor NN I
B NNP I
Ligand NNP I
(sRANKL) NNP I
and CC I
vWF NN I
. . I

METHODS NNP I
Totally RB P
21 CD P
clinically RB P
stable JJ P
chronic JJ P
HD NNP P
patients NNS P
were VBD I
randomly RB I
assigned VBN I
to TO I
either DT I
enoxaparin JJ I
(n NNP I
= NNP I
10) CD I
or CC I
UFH NNP I
(n NNP I
= VBD I
11) CD I
anticoagulation NN I
and CC I
followed VBD I
prospectively RB I
for IN I
12 CD I
weeks NNS I
before IN I
crossing VBG I
over IN I
to TO I
the DT I
alternate NN I
therapy NN I
for IN I
further JJ I
12 CD I
weeks NNS I
. . I

The DT O
OPG NNP O
RANKL NNP O
and CC O
vWF NN O
levels NNS I
were VBD I
measured VBN I
at IN I
T0 NNP I
T10 NNP I
and CC I
T180 NNP I
of IN I
HD NNP I
session NN I
after IN I
each DT I
period NN I
of IN I
evaluation NN I
. . I

RESULTS VB I
The DT O
baseline NN O
sRANKL NN O
level NN O
was VBD I
higher JJR I
under IN I
UFH NNP I
treatment NN I
. . I

Its PRP$ I
over-HD JJ I
level NN I
does VBZ I
not RB I
behave VB I
significantly RB I
different JJ I
under IN I
enoxaparin NN I
and CC I
UFH NNP I
treatment NN I
. . O

Plasma NNP O
OPG NNP O
levels NNS O
expressly RB I
changed VBN I
during IN I
both DT I
enoxaparin JJ I
((2) NN I
analysis NN I
of IN I
variance NN I
[ANOVA] NNP I
= VBZ I
31.13 CD I
P NNP I
< NNP I
.016) NNP I
and CC I
UFH NNP I
((2) NNP I
ANOVA NNP I
= VBD I
8.26 CD I
P NNP I
= NNP I
.016) NNP I
anticoagulation NN I
and CC I
its PRP$ I
increment NN I
at IN I
T10 NNP I
and CC I
T180 NNP I
was VBD I
significantly RB I
different JJ I
between IN I
both DT I
the DT I
heparins NNS I
. . I

The DT I
main JJ I
negative JJ I
predictor NN I
of IN I
OPG NNP I
concentration NN I
was VBD I
the DT I
total JJ I
cholesterol NN I
level NN I
( NNP I
= NNP I
-.51 NNP I
P NNP I
= NNP I
.025) NNP O
. . O

von NN O
Willebrand NNP O
factor NN O
concentration NN I
remained VBD I
stable JJ I
during IN I
UFH NNP I
anticoagulation NN I
whereas NNS I
constant VBP I
no DT I
significant JJ I
increments NNS I
were VBD I
noticed VBN I
under IN I
enoxaparin NN I
treatment NN I
. . I

After IN I
10 CD I
minutes NNS I
of IN I
HD NNP I
especially RB I
under IN I
enoxaparin NN I
use NN I
a DT I
positive JJ I
correlation NN I
between IN I
OPG NNP I
and CC I
vWF JJ I
increase NN I
was VBD I
noticed VBN I
(P JJ I
= NNP I
.03 NNP I
R NNP I
= NNP I
.45) NNP I
. . I

CONCLUSIONS NNP I
Impact NNP I
of IN I
heparin NN I
on IN I
endothelial JJ I
cells NNS I
and CC I
simultaneously RB I
on IN I
OPG/RANK/RANKL NNP I
axis NN I
reinforces VBZ I
the DT I
presumption NN I
of IN I
the DT I
pathophysiological JJ I
linkage NN I
between IN I
bone NN I
mineralization NN I
and CC I
endothelial JJ I
dysfunction NN P
in IN P
end-stage JJ P
renal JJ P
disease NN P
. . N

-DOCSTART- -X- N

Hyperfractionated VBN I
accelerated JJ I
radiation NN I
therapy NN I
(HART) NN I
of IN I
70.6 CD I
Gy NNP I
with IN I
concurrent JJ I
5-FU/Mitomycin JJ I
C NNP I
is VBZ N
superior JJ N
to TO N
HART NNP I
of IN I
77.6 CD I
Gy NNP I
alone RB I
in IN N
locally RB P
advanced JJ P
head NN P
and CC P
neck NN P
cancer: VBP P
long-term JJ N
results NNS N
of IN N
the DT N
ARO NNP N
95-06 CD N
randomized JJ N
phase NN N
III NNP N
trial NN N
. . N

PURPOSE NNP N
To TO N
report VB N
the DT N
long-term JJ N
results NNS N
of IN N
the DT N
ARO NNP N
95-06 CD N
randomized JJ N
trial NN N
comparing NN N
hyperfractionated VBD I
accelerated JJ I
chemoradiation NN I
with IN I
mitomycin JJ I
C/5-fluorouracil JJ I
(C-HART) NN I
with IN N
hyperfractionated VBN I
accelerated JJ I
radiation NN I
therapy NN I
(HART) NNP I
alone RB I
in IN N
locally RB P
advanced JJ P
head NN P
and CC P
neck NN P
cancer NN P
. . P

PATIENTS NNS N
AND CC N
METHODS NNP N
The DT N
primary JJ N
endpoint NN N
was VBD N
locoregional JJ O
control NN O
(LRC) NNP O
. . O

Three CD P
hundred VBD P
eighty-four JJ P
patients NNS P
with IN P
stage NN P
III NNP P
(6%) NNP P
and CC P
IV NNP P
(94%) NNP P
oropharyngeal MD P
(59.4%) VB P
hypopharyngeal JJ P
(32.3%) NNS P
and CC P
oral JJ P
cavity NN P
(8.3%) NN P
cancer NN P
were VBD N
randomly RB N
assigned VBN N
to TO N
30Gy/2Gy CD I
daily JJ I
followed VBN I
by IN I
twice-daily RB I
1.4Gy CD I
to TO I
a DT I
total NN I
of IN I
70.6Gy CD I
concurrently RB I
with IN I
mitomycin JJ I
C/5-FU JJ I
(C-HART) NN I
or CC I
16Gy/2Gy CD I
daily JJ I
followed VBN I
by IN I
twice-daily RB I
1.4Gy CD I
to TO I
a DT I
total JJ I
dose NN I
of IN I
77.6Gy CD I
alone JJ I
(HART) NN N
. . N

Statistical JJ N
analyses NNS N
were VBD N
done VBN N
with IN N
the DT N
log-rank JJ N
test NN N
and CC N
univariate NN N
and CC N
multivariate NN N
Cox NNP N
regression NN N
analyses NNS N
. . N

RESULTS VB N
The DT N
median JJ N
follow-up JJ N
time NN N
was VBD N
8.7years CD N
(95% JJ N
confidence NN N
interval JJ N
[CI]: JJ N
7.8-9.7years) NNS N
. . N

At IN N
10years CD O
the DT O
LRC NNP N
rates NNS N
were VBD I
38.0% CD I
(C-HART) JJ N
versus NN I
26.0% CD I
(HART NN N
P=.002) NNP O
. . O

The DT O
cancer-specific JJ O
survival NN O
and CC O
overall JJ O
survival NN O
rates NNS N
were VBD N
39% CD I
and CC I
10% CD I
(C-HART) JJ N
versus NN N
30.0% CD I
and CC I
9% CD N
(HART NN N
P=.042 NNP N
and CC N
P=.049) NNP N
respectively RB N
. . N

According VBG N
to TO N
multivariate VB N
Cox NNP N
regression NN N
analysis NN N
the DT N
combined JJ N
treatment NN N
was VBD N
associated VBN O
with IN O
improved JJ O
LRC NNP N
(hazard NNP N
ratio NN N
[HR]: VBD N
0.6 CD N
[95% JJ N
CI: NNP N
0.5-0.8; JJ N
P=.002]) NNP N
. . N

The DT N
association NN N
between IN N
combined VBN N
treatment NN N
arm NN N
and CC O
increased VBD O
LRC NNP N
appeared VBD N
to TO N
be VB N
limited VBN N
to TO N
oropharyngeal VB N
cancer NN N
(P=.003) NNP N
as IN N
compared VBN N
with IN N
hypopharyngeal NN N
or CC N
oral JJ N
cavity NN N
cancer NN N
(P=.264) NN N
. . N

CONCLUSIONS NNP I
C-HART NNP N
remains VBZ N
superior JJ I
to TO N
HART NNP N
in IN N
terms NNS N
of IN N
LRC NNP N
. . N

However RB N
this DT N
effect NN N
may MD N
be VB N
limited VBN P
to TO P
oropharyngeal VB P
cancer NN P
patients NNS P
. . N

-DOCSTART- -X- N

Association NNP N
between IN N
frequency NN N
of IN N
ready-to-eat JJ I
cereal NN I
consumption NN I
nutrient NN I
intakes NNS I
and CC I
body NN O
mass NN O
index NN O
in IN N
fourth- JJ P
to TO P
sixth-grade JJ P
low-income JJ P
minority NN P
children NNS P
. . P

BACKGROUND IN N
The DT N
consumption NN N
of IN N
non-ready-to-eat JJ I
cereal NN I
and CC I
ready-to-eat JJ I
cereal NN I
(RTEC) NN I
breakfasts NNS N
have VBP N
been VBN N
associated VBN N
with IN N
increased JJ N
nutrient NN O
intakes NNS O
and CC N
lower JJR N
body NN O
mass NN O
index NN O
(BMI) NNP O
. . O

These DT N
relationships NNS N
have VBP N
not RB N
been VBN N
examined VBN N
in IN N
low-income JJ P
minority NN P
children NNS P
. . P

OBJECTIVES NNP N
To TO N
evaluate VB N
in IN N
low-income JJ P
minority NN P
children NNS P
whether IN P
there EX N
is VBZ N
a DT N
relationship NN N
among IN N
the DT N
frequency NN O
of IN O
RTEC NNP O
consumption NN O
and CC O
nutrient JJ O
intakes NNS O
measured VBN N
at IN N
baseline NN N
and CC N
whether IN N
there EX N
is VBZ N
a DT N
relationship NN N
between IN N
the DT N
frequency NN N
of IN N
RTEC NNP I
and CC N
BMI NNP O
controlling VBG N
for IN N
age NN N
sex NN N
ethnicity NN N
and CC N
energy NN N
intake NN N
. . N

DESIGN VB N
A DT N
longitudinal JJ N
study NN N
design NN N
where WRB N
a DT N
cohort NN N
was VBD N
followed VBN N
for IN N
3 CD N
years NNS N
. . N

SUBJECTS/SETTING NN N
Participants NNS P
were VBD P
625 CD P
fourth- JJ P
through IN P
sixth-grade JJ P
low-income JJ P
children NNS P
living VBG P
in IN P
San NNP P
Antonio NNP P
Texas NNP P
and CC P
enrolled VBN P
in IN P
the DT P
control NN P
arm NN P
of IN P
the DT P
Bienestar NNP P
Diabetes NNP P
Prevention NNP P
Program's NNP P
cluster NN P
randomized VBD P
trial NN P
. . P

Three CD I
multiple-pass JJ I
24-hour JJ I
dietary JJ I
recalls NNS I
were VBD N
collected VBN N
at IN N
the DT N
beginning NN N
of IN N
their PRP$ N
fourth-grade JJ N
year NN N
and CC N
at IN N
the DT N
end NN N
of IN N
their PRP$ N
fifth- JJ N
and CC N
sixth-grade JJ N
years NNS N
. . N

Children's NNP P
age NN P
sex NN P
ethnicity NN P
and CC P
height NN N
and CC N
weight NN N
(used VBN N
to TO N
calculate VB N
BMI) NNP N
were VBD N
collected VBN N
between IN N
August NNP P
2001 CD P
and CC P
May NNP P
2004 CD P
. . N

STATISTICAL JJ N
ANALYSES NNP N
PERFORMED NNP N
Descriptive NNP N
and CC N
inferential JJ N
statistical JJ N
analyses NNS N
were VBD N
performed VBN N
. . N

The DT N
frequency NN N
of IN N
breakfast NN N
consumption NN N
was VBD N
examined VBN N
using VBG N
a DT N
64 CD N
cross-tabulation NN N
table NN N
with IN N
(2) JJ N
test NN N
to TO N
establish VB N
categorical JJ N
differences NNS N
. . N

The DT N
degree NN N
of IN N
association NN N
between IN O
BMI NNP O
percentile NN N
and CC O
frequency NN O
of IN O
RTEC NNP O
consumption NN O
adjusted VBD N
for IN N
age NN N
sex NN N
ethnicity NN N
and CC N
nutrition-related JJ N
parameters NNS N
were VBD N
calculated VBN N
using VBG N
a DT N
partial JJ N
correlation NN N
multivariate NN N
linear JJ N
model NN N
analysis NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
positive JJ N
relationship NN N
between IN N
the DT N
frequency NN N
of IN I
RTEC NNP I
consumption NN N
and CC O
nutrient JJ O
intakes NNS O
measured VBN N
at IN N
baseline NN N
. . N

There EX N
was VBD N
also RB N
a DT N
significant JJ N
inverse NN N
relationship NN N
between IN N
frequency NN N
of IN I
RTEC NNP I
consumption NN N
and CC O
BMI NNP O
percentile NN N
over IN N
the DT N
cumulative JJ N
3-year JJ N
period NN N
controlling VBG N
for IN N
age NN N
sex NN N
ethnicity NN N
and CC N
energy NN N
intake NN N
. . N

CONCLUSIONS NNP P
Children NNP P
who WP N
frequently RB N
consumed VBD I
RTEC NNP I
had VBD N
greater JJR N
intakes NNS N
of IN O
essential JJ O
nutrients NNS O
at IN N
baseline NN N
and CC N
significantly RB N
lower JJR O
BMI NNP O
over IN N
a DT N
3-year JJ N
period NN N
. . N

-DOCSTART- -X- N

Effects NNS N
of IN N
insufficient JJ I
sleep NN I
on IN N
blood NN N
pressure NN N
in IN N
hypertensive JJ P
patients: NN P
a DT N
24-h JJ N
study NN N
. . N

The DT N
influence NN N
of IN N
acute JJ I
sleep JJ I
deprivation NN I
during IN N
the DT N
first JJ N
part NN N
of IN N
the DT N
night NN N
on IN N
24-h JJ I
blood NN I
pressure NN I
monitoring VBG I
(ABPM) NN N
was VBD N
studied VBN N
in IN N
36 CD P
never-treated JJ P
mild NN P
to TO P
moderate VB P
hypertensive JJ P
patients NNS P
. . P

According VBG N
to TO N
a DT N
crossover NN N
design NN N
they PRP N
were VBD N
randomized VBN N
to TO N
have VB N
either DT N
sleep JJ I
deprivation NN I
or CC N
a DT N
full JJ I
night's NN I
sleep VBD I
1 CD N
week NN N
apart RB N
during IN N
which WDT N
they PRP N
were VBD N
monitored VBN N
with IN N
ABPM NNP N
. . N

Urine NN I
samples NNS I
for IN N
analysis NN N
of IN N
nocturnal JJ N
urinary JJ N
excretion NN N
of IN N
norepinephrine NN N
were VBD N
collected VBN N
. . N

During IN N
the DT N
sleep-deprivation JJ I
day NN N
both DT N
mean VBP N
24-h JJ N
blood NN O
pressure NN O
and CC N
mean JJ N
24-h JJ N
heart NN N
rate NN N
were VBD N
higher JJR N
in IN N
comparison NN N
with IN N
those DT N
recorded VBN N
during IN N
the DT N
routine JJ N
workday NN N
the DT N
difference NN N
being VBG N
more RBR N
pronounced JJ N
during IN N
the DT N
nighttime JJ N
(P NNP N
< NNP N
.01) NNP N
. . N

Urinary JJ O
excretion NN O
of IN O
norepinephrine NN O
showed VBD N
a DT N
significant JJ N
increase NN N
at IN N
night NN N
during IN N
sleep JJ I
deprivation NN I
(P NNP N
< NNP N
.05) NNP N
. . N

Blood NNP O
pressure NN O
and CC O
heart NN O
rate NN O
significantly RB N
increased VBN N
in IN N
the DT N
morning NN N
after IN N
a DT N
sleep-insufficient JJ I
night NN I
(P NNP N
< NNP N
.05) NNP N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
lack NN I
of IN I
sleep NN I
in IN N
hypertensive JJ N
patients NNS N
may MD N
increase VB N
sympathetic JJ N
nervous JJ N
activity NN N
during IN N
the DT N
night NN N
and CC N
the DT N
following JJ N
morning NN N
leading VBG N
to TO N
increased VBN N
blood NN N
pressure NN N
and CC N
heart NN N
rate NN N
. . N

This DT N
situation NN N
might MD N
represent VB N
an DT N
increased VBN N
risk NN N
for IN N
both DT N
target NN N
organ JJ N
damage NN N
and CC N
acute JJ N
cardiovascular JJ N
diseases NNS N
. . N

-DOCSTART- -X- N

Potentiation NN N
of IN N
bradykinin-induced JJ N
tissue NN N
plasminogen NN N
activator NN N
release NN N
by IN N
angiotensin-converting JJ I
enzyme JJ I
inhibition NN I
. . I

OBJECTIVES IN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN O
of IN N
angiotensin-converting JJ I
enzyme NN I
(ACE) NNP I
inhibition NN I
on IN N
the DT N
local JJ N
stimulated VBD N
release NN N
of IN N
tissue NN N
plasminogen NN N
activator NN N
(t-PA) NN N
from IN N
the DT N
endothelium NN N
. . N

BACKGROUND NNP N
Angiotensin-converting NNP I
enzyme NN I
inhibitor NN I
therapy NN I
may MD N
exert VB N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
endogenous JJ N
fibrinolytic JJ N
balance NN N
. . N

METHODS NNP N
Blood NNP O
flow NN O
and CC O
plasma JJ O
fibrinolytic JJ O
factors NNS O
were VBD N
measured VBN N
in IN N
both DT P
forearms NNS P
of IN P
eight CD P
healthy JJ P
males NNS P
who WP P
received VBD P
unilateral JJ P
brachial JJ P
artery NN P
infusions NNS P
of IN P
the DT P
endothelium-dependent JJ P
vasodilators NNS P
substance NN P
P NNP P
(2 NNP P
to TO P
8 CD P
pmol/min) NN P
and CC P
bradykinin NN P
(100 NN P
to TO P
1 CD P
000 CD P
pmol/min) NN P
and CC P
the DT P
endothelium-independent JJ P
vasodilator NN P
sodium NN P
nitroprusside RB P
(2 NNP P
to TO P
8 CD P
microg/min) NNS P
. . P

These DT N
measurements NNS N
were VBD N
performed VBN N
on IN N
each DT N
of IN N
three CD N
occasions NNS N
following VBG N
one CD N
week NN N
of IN N
matched JJ N
placebo NN I
quinapril VBD I
40 CD I
mg NN I
or CC I
losartan JJ I
50 CD I
mg JJ I
daily RB N
administered VBN N
in IN N
a DT N
double-blind JJ N
randomized JJ N
crossover NN N
design NN N
. . N

RESULTS NNP N
Sodium NNP I
nitroprusside JJ I
substance NN I
P NNP I
and CC I
bradykinin NN I
produced VBD N
dose-dependent JJ N
increases NNS O
in IN O
the DT O
blood NN O
flow NN O
of IN N
infused JJ N
forearm JJ N
(analysis NN N
of IN N
variance NN N
[ANOVA] NNP N
p NN N
< VBD N
0.001 CD N
for IN N
all) NN N
. . N

Although IN N
sodium JJ I
nitroprusside RB I
did VBD N
not RB N
affect VB N
plasma JJ O
t-PA JJ O
concentrations NNS O
they PRP O
were VBD N
increased VBN N
dose-dependently RB N
in IN N
the DT N
infused JJ N
forearm NN N
by IN N
substance NN I
P NNP I
and CC I
bradykinin JJ I
infusion NN I
(ANOVA NNP N
p NN N
< VBD N
0.001 CD N
for IN N
both) NN N
. . N

Bradykinin-induced JJ N
release NN O
of IN O
active JJ O
t-PA NN O
was VBD N
more RBR N
than IN N
doubled VBD N
during IN N
treatment NN I
with IN I
quinapril NN I
in IN N
comparison NN N
to TO N
placebo VB I
or CC N
losartan VB I
(two-way JJ N
ANOVA: NNP N
p NN N
< VBD N
0.003 CD N
for IN N
treatment NN N
group NN N
p VBD N
< $ N
0.001 CD N
for IN N
t-PA JJ N
response NN N
and CC N
p NN N
= NNP N
ns NN N
for IN N
interaction) JJ N
whereas IN N
the DT N
substance NN O
P NNP O
response NN O
was VBD O
unaffected VBN O
. . O

CONCLUSIONS NN N
We PRP N
have VBP N
shown VBN N
a DT N
selective JJ N
and CC N
marked JJ N
augmentation NN N
of IN N
bradykinin-induced JJ N
t-PA JJ N
release NN N
during IN N
ACE NNP I
inhibition NN I
. . I

These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
beneficial JJ N
clinical JJ O
and CC O
vascular JJ O
effects NNS O
of IN N
ACE NNP I
inhibition NN I
may MD N
in IN N
part NN N
be VB N
mediated VBN N
through IN N
local JJ N
augmentation NN N
of IN N
bradykinin-induced JJ N
t-PA JJ N
release NN N
. . N

-DOCSTART- -X- N

Safety NN N
and CC N
immunogenicity NN N
of IN N
a DT N
chimpanzee JJ I
adenovirus-vectored JJ I
Ebola NNP I
vaccine NN I
in IN N
healthy JJ P
adults: NN P
a DT N
randomised JJ N
double-blind JJ N
placebo-controlled JJ I
dose-finding JJ I
phase NN N
1/2a CD N
study NN N
. . N

BACKGROUND IN N
The DT N
ongoing JJ N
Ebola NNP N
outbreak NN N
led VBD N
to TO N
accelerated VBN N
efforts NNS N
to TO N
test VB N
vaccine NN N
candidates NNS N
. . N

On IN N
the DT N
basis NN N
of IN N
a DT N
request NN N
by IN N
WHO WP N
we PRP N
aimed VBD N
to TO N
assess VB N
the DT N
safety NN N
and CC N
immunogenicity NN N
of IN N
the DT N
monovalent NN I
recombinant NN I
chimpanzee NN I
adenovirus IN I
type-3 JJ I
vector-based JJ I
Ebola NNP I
Zaire NNP I
vaccine NN I
(ChAd3-EBO-Z) NN I
. . I

METHODS NNP N
We PRP N
did VBD N
this DT N
randomised VBN N
double-blind JJ N
placebo-controlled JJ I
dose-finding JJ I
phase NN N
1/2a CD N
trial NN N
at IN N
the DT N
Centre NNP N
Hospitalier NNP N
Universitaire NNP N
Vaudois NNP P
Lausanne NNP P
Switzerland NNP P
. . P

Participants NNS P
(aged VBD P
18-65 JJ P
years) NN P
were VBD P
randomly RB P
assigned VBN P
(2:2:1) JJ N
via IN N
two CD I
computer-generated JJ I
randomisation NN I
lists NNS P
for IN P
individuals NNS P
potentially RB P
deployed VBN P
in IN P
endemic JJ P
areas NNS P
and CC P
those DT P
not RB P
deployed VBN P
to TO P
receive VB N
a DT N
single JJ I
intramuscular NN I
dose NN I
of IN I
high-dose JJ I
vaccine NN I
(510(10) NNP N
viral JJ N
particles) NN I
low-dose JJ I
vaccine NN I
(2510(10) NNP N
viral JJ N
particles) NN I
or CC I
placebo NN N
. . N

Deployed VBN N
participants NNS N
were VBD N
allocated VBN N
to TO N
only RB N
the DT N
vaccine NN N
groups NNS N
. . N

Group NNP N
allocation NN N
was VBD N
concealed VBN N
from IN N
non-deployed JJ N
participants NNS N
investigators NNS N
and CC N
outcome JJ N
assessors NNS N
. . N

The DT N
safety NN N
evaluation NN N
was VBD N
not RB N
masked VBN N
for IN N
potentially RB N
deployed VBN N
participants NNS N
who WP N
were VBD N
therefore RB N
not RB N
included VBN N
in IN N
the DT N
safety NN N
analysis NN N
for IN N
comparison NN N
between IN N
the DT N
vaccine NN N
doses NNS N
and CC N
placebo NNS N
but CC N
were VBD N
pooled VBN N
with IN N
the DT N
non-deployed JJ N
group NN N
to TO N
compare VB N
immunogenicity NN N
. . N

The DT N
main JJ N
objectives NNS N
were VBD N
safety NN N
and CC N
immunogenicity NN I
of IN I
ChAd3-EBO-Z NNP I
. . N

We PRP N
did VBD N
analysis NN N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
number NN N
NCT02289027 NNP N
. . P

FINDINGS NNP P
Between NNP P
Oct NNP P
24 CD P
2014 CD P
and CC P
June NNP P
22 CD P
2015 CD P
we PRP P
randomly VBP P
assigned VBN P
120 CD P
participants NNS P
of IN P
whom WP P
18 CD P
(15%) NN P
were VBD P
potentially RB P
deployed VBN P
and CC P
102 CD P
(85%) NNS P
were VBD P
non-deployed JJ P
to TO P
receive VB P
high-dose JJ P
vaccine NN P
(n=49) NNP P
low-dose JJ P
vaccine NN P
(n=51) NN P
or CC P
placebo NN P
(n=20) NN N
. . N

Participants NNS N
were VBD N
followed VBN N
up RP N
for IN N
6 CD N
months NNS N
. . N

No DT N
vaccine-related JJ O
serious JJ O
adverse JJ O
events NNS N
were VBD N
reported VBN N
. . N

We PRP O
recorded VBD O
local JJ O
adverse JJ O
events NNS N
in IN N
30 CD N
(75%) NN N
of IN N
40 CD N
participants NNS N
in IN N
the DT N
high-dose JJ N
group NN N
33 CD N
(79%) NN N
of IN N
42 CD N
participants NNS N
in IN N
the DT N
low-dose JJ N
group NN N
and CC N
five CD N
(25%) NNS N
of IN N
20 CD N
participants NNS N
in IN N
the DT N
placebo NN O
group NN O
. . O

Fatigue NNP O
or CC N
malaise NN N
was VBD N
the DT N
most RBS N
common JJ N
systemic JJ N
adverse JJ N
event NN N
reported VBD N
in IN N
25 CD N
(62%) JJ N
participants NNS N
in IN N
the DT N
high-dose JJ N
group NN N
25 CD N
(60%) NN N
participants NNS N
in IN N
the DT N
low-dose JJ N
group NN N
and CC N
five CD N
(25%) JJ N
participants NNS N
in IN N
the DT N
placebo NN N
group NN N
followed VBD N
by IN N
headache NN N
reported VBN N
in IN N
23 CD N
(57%) JJ N
25 CD N
(60%) NN N
and CC N
three CD N
(15%) NN N
participants NNS N
respectively RB O
. . N

Fever RB N
occurred VBD N
24 CD N
h NN N
after IN N
injection NN N
in IN N
12 CD N
(30%) JJ N
participants NNS N
in IN N
the DT N
high-dose JJ N
group NN N
and CC N
11 CD N
(26%) JJ N
participants NNS N
in IN N
the DT N
low-dose JJ N
group NN N
versus IN N
one CD N
(5%) NN N
participant NN N
in IN N
the DT N
placebo NN O
group NN O
. . O

Geometric JJ O
mean JJ O
concentrations NNS O
of IN O
IgG NNP O
antibodies NNS N
against IN N
Ebola NNP N
glycoprotein NN N
peaked VBD N
on IN N
day NN N
28 CD N
at IN N
51 CD N
g/mL JJ N
(95% JJ N
CI NNP N
411-633) NN N
in IN N
the DT N
high-dose JJ N
group NN N
449 CD N
g/mL JJ N
(258-563) NN N
in IN N
the DT N
low-dose JJ N
group NN N
and CC N
52 CD N
g/mL JJ N
(35-76) NN N
in IN N
the DT N
placebo NN N
group NN N
with IN N
respective JJ N
response NN N
rates NNS N
of IN N
96% CD N
(95% JJ N
CI NNP N
857-995) JJ N
96% CD N
(865-995) JJ O
and CC O
5% CD O
(01-249) NN O
. . O

Geometric JJ O
mean NN N
concentrations NNS N
decreased VBN N
by IN N
day NN N
180 CD N
to TO N
255 CD N
g/mL NNS N
(95% JJ N
CI NNP N
206-315) CD N
in IN N
the DT N
high-dose JJ N
group NN N
221 CD N
g/mL JJ N
(193-286) NN N
in IN N
the DT N
low-dose JJ N
group NN N
and CC N
32 CD N
g/mL JJ N
(24-49) NN N
in IN N
the DT N
placebo NN N
group NN N
. . N

28 CD N
(57%) JJ N
participants NNS N
given VBN N
high-dose JJ N
vaccine NN N
and CC N
31 CD N
(61%) JJ N
participants NNS O
given VBN O
low-dose JJ O
vaccine NN O
developed VBD O
glycoprotein-specific JJ O
CD4 NNP N
cell NN N
responses NNS N
and CC N
33 CD N
(67%) NN N
and CC N
35 CD N
(69%) NN N
respectively RB N
developed VBD N
CD8 NNP N
responses NNS O
. . N

INTERPRETATION NNP O
ChAd3-EBO-Z NNP O
was VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
although IN N
mild NN N
to TO N
moderate VB N
systemic JJ N
adverse JJ N
events NNS N
were VBD N
common JJ N
. . N

A DT N
single JJ N
dose NN N
was VBD N
immunogenic JJ N
in IN N
almost RB N
all DT N
vaccine NN N
recipients NNS N
. . N

Antibody NN N
responses NNS N
were VBD N
still RB N
significantly RB N
present JJ N
at IN N
6 CD N
months NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
doses NNS N
for IN N
safety NN N
and CC N
immunogenicity NN N
outcomes NNS N
. . N

This DT N
acceptable JJ N
safety NN N
profile NN N
provides VBZ N
a DT N
reliable JJ N
basis NN N
to TO N
proceed VB N
with IN N
phase NN N
2 CD N
and CC N
phase VB N
3 CD N
efficacy NN N
trials NNS N
in IN N
Africa NNP N
. . N

FUNDING NN N
Swiss JJ N
State NNP N
Secretariat NNP N
for IN N
Education NNP N
Research NNP N
and CC N
Innovation NNP N
(SERI) NNP N
through IN N
the DT N
EU NNP N
Horizon NNP N
2020 CD N
Research NNP N
and CC N
Innovation NNP N
Programme NNP N
. . N

-DOCSTART- -X- N

Effects NNS N
of IN N
water NN I
extracts NNS I
of IN I
Graptopetalum NNP I
paraguayense NN I
on IN N
blood NN O
pressure NN O
fasting VBG O
glucose JJ O
and CC O
lipid JJ O
profiles NNS O
of IN N
subjects NNS P
with IN P
metabolic JJ P
syndrome NN P
. . P

This DT N
study NN N
was VBD N
aimed VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
water NN I
extracts NNS I
of IN I
Graptopetalum NNP I
paraguayense NN I
(WGP VBD I
4 CD I
g/d) NN I
on IN N
blood NN N
pressure NN N
blood NN N
glucose JJ N
level NN N
and CC N
lipid JJ N
profiles NNS N
in IN N
subjects NNS P
with IN P
metabolic JJ P
syndrome NN P
(MS) NN P
. . P

Participants NNS P
with IN P
MS NNP P
(n NNP P
= VBD P
54) CD P
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
placebo NN I
(n NNP N
= VBZ N
28) CD N
and CC N
WGP NNP I
groups NNS N
(n NNP N
= VBD N
26) CD N
and CC N
the DT N
intervention NN N
was VBD N
administered VBN N
for IN N
12 CD N
weeks NNS N
. . N

Systolic JJ O
blood NN O
pressure NN O
(SBP) NNP O
diastolic JJ O
blood NN O
pressure NN O
(DBP) NNP O
fasting VBG O
glucose JJ O
(FG) NNP O
lipid NN O
profiles NNS O
(total VBP O
cholesterol NN O
(TC) NNP O
triglyceride IN O
(TG) NNP O
low JJ O
density NN O
lipoprotein NN O
cholesterol NN O
(LDL-C) JJ O
and CC O
high JJ O
density NN O
lipoprotein VBP O
(HDL-C)) JJ O
and CC O
antioxidant JJ O
enzymes NNS O
activities NNS I
(catalase NNP I
(CAT) NNP I
superoxide JJ I
dismutase NN I
(SOD) NNP I
and CC I
glutathione NN I
peroxidase NN I
(GPx)) NNP I
were VBD N
measured VBN N
. . N

Forty-two JJ P
subjects NNS P
completed VBD P
the DT P
study NN P
(placebo NNP P
n VBZ P
= $ P
19; CD P
WGP NNP P
n JJ P
= VBD P
23) CD P
. . P

FG NNP O
SBP NNP O
and CC O
LDL-C NNP O
levels NNS O
were VBD I
significantly RB I
lower JJR I
and CC I
HDL-C NNP O
level NN O
and CC O
antioxidant JJ O
enzymes NNS O
activities NNS O
(CAT NNP O
and CC O
SOD) NNP O
were VBD I
significantly RB I
higher JJR I
after IN I
WGP NNP I
supplementation NN I
. . I

Blood NNP O
pressure NN O
FG NNP O
and CC O
lipid JJ O
profiles NNS O
were VBD N
significantly RB N
correlated VBN N
with IN N
antioxidant JJ N
enzymes NNS N
activities NNS N
after IN N
supplementation NN N
(P NNP N
< VBZ N
0.05) CD N
. . N

The DT N
present JJ N
study NN N
demonstrated VBD N
a DT N
significant JJ N
reduction NN N
in IN N
blood NN O
pressure NN O
blood NN O
glucose NN O
and CC O
lipid JJ O
profiles NNS O
and CC N
an DT N
increase NN N
in IN N
antioxidant JJ O
enzymes NNS O
activities NNS O
in IN N
subjects NNS P
with IN P
MS NNP P
after IN N
WGP NNP I
supplementation NN N
. . N

Taken VBN N
together RB N
the DT N
antioxidative JJ N
capacity NN N
of IN N
WGP NNP I
might MD N
exert VB N
a DT N
beneficial JJ N
effect NN N
on IN N
MS NNP N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
NCT01463748 NNP N
. . N

-DOCSTART- -X- N

Predictors NNS N
of IN N
mental JJ N
health NN N
problems NNS N
and CC N
negative JJ N
caregiving NN N
experiences NNS N
in IN N
carers NNS P
of IN P
adolescents NNS P
with IN P
bulimia NN P
nervosa NN P
. . P

OBJECTIVE IN N
This DT N
exploratory NN N
study NN N
focuses VBZ N
on IN N
the DT N
mental JJ O
health NN O
(MH) NN O
and CC I
caregiving VBG I
experience NN I
of IN I
carers NNS I
of IN I
adolescents NNS P
with IN P
Bulimia NNP P
Nervosa NNP P
(BN)/Eating VBG P
Disorder NNP P
not RB P
otherwise RB P
specified VBN P
(EDNOS) NN P
aiming VBG P
to TO N
determine: VB N
levels NNS N
of IN N
MH NNP N
problems NNS N
in IN N
carers NNS N
and CC N
if IN N
a DT N
negative JJ N
experience NN N
of IN N
caregiving VBG N
predicts NNS N
carer VBP N
MH NNP N
status NN N
and CC N
which WDT N
factors NNS N
predict VBP N
a DT N
negative JJ N
experience NN N
of IN N
caregiving NN N
. . N

METHOD NNP N
Hundred NNP P
and CC P
twelve VB P
carers NNS P
and CC P
68 CD P
adolescents NNS P
with IN P
BN/EDNOS NNP P
completed VBD P
self-report JJ P
measures NNS P
(General JJ P
Health NNP P
Questionnaire NNP P
Experience NNP P
of IN O
Caregiving NNP O
Inventory NNP P
Level NNP P
of IN P
Expressed JJ O
Emotion NNP P
Self-report NNP P
Family NNP P
Inventory NNP P
Inventory NNP P
of IN P
Interpersonal NNP O
Problems) NNP O
. . O

RESULTS NNP N
Over NNP N
half NN N
of IN N
the DT N
carers NNS N
reported VBD N
some DT N
MH NNP O
problems NNS O
and CC N
a DT N
minority NN N
(5.4%) NN N
were VBD N
experiencing VBG N
considerable JJ N
difficulties NNS N
. . N

A DT O
negative JJ O
experience NN O
of IN O
caregiving VBG O
predicted VBN N
carer NN N
MH NNP N
status NN N
. . N

Higher JJR O
weekly JJ O
contact NN O
hours NNS O
and CC O
patient JJ O
ratings NNS O
of IN O
expressed JJ O
emotion NN O
(EE) NNP O
predicted VBD N
a DT N
negative JJ N
experience NN N
of IN N
caregiving NN N
. . N

CONCLUSIONS NNP N
Interventions NNP I
focusing VBG I
on IN I
reducing VBG I
EE NNP O
and CC I
contact NN O
hours NNS O
could MD N
prove VB N
beneficial JJ N
for IN N
both DT N
patient NN N
and CC N
caregiver NN N
outcomes NNS N
. . N

-DOCSTART- -X- N

A DT N
placebo-controlled JJ I
fixed-dose JJ N
study NN N
of IN N
aripiprazole NN I
in IN N
children NNS P
and CC P
adolescents NNS P
with IN P
irritability NN P
associated VBN P
with IN P
autistic JJ P
disorder NN P
. . P

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
short-term JJ N
efficacy NN N
and CC N
safety NN N
of IN N
aripiprazole NN I
in IN N
the DT N
treatment NN N
of IN N
irritability NN N
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
autistic JJ N
disorder NN N
. . N

METHOD NNP N
Two CD P
hundred VBD P
eighteen JJ P
children NNS P
and CC P
adolescents NNS P
(aged VBD P
6-17 JJ P
years) NN P
with IN P
a DT P
diagnosis NN P
of IN P
autistic JJ P
disorder NN P
and CC P
with IN P
behaviors NNS P
such JJ P
as IN P
tantrums NNS P
aggression IN P
self-injurious JJ P
behavior NN P
or CC P
a DT P
combination NN P
of IN P
these DT P
symptoms NNS P
were VBD P
randomized VBN N
1:1:1:1 CD N
to TO N
aripiprazole VB I
(5 JJ I
10 CD I
or CC I
15 CD I
mg/day) NN I
or CC I
placebo NN I
in IN I
this DT I
8-week JJ I
double-blind JJ N
randomized VBN N
placebo-controlled JJ I
parallel-group NN N
study NN N
. . N

Efficacy NN N
was VBD N
evaluated VBN N
using VBG N
the DT N
caregiver-rated JJ N
Aberrant NNP O
Behavior NNP O
Checklist NNP O
Irritability NNP O
subscale JJ O
(primary JJ O
efficacy NN O
measure) NN O
and CC N
the DT N
clinician-rated JJ N
Clinical JJ O
Global NNP O
Impressions-Improvement NNP O
score NN O
. . O

Safety NN N
and CC N
tolerability NN N
were VBD N
also RB N
assessed VBN N
. . N

RESULTS NN N
At IN N
week NN N
8 CD N
all DT N
aripiprazole JJ I
doses NNS N
produced VBN N
significantly RB N
greater JJR N
improvement NN N
than IN N
placebo NN I
in IN N
mean JJ N
Aberrant NNP O
Behavior NNP O
Checklist NNP O
Irritability NNP O
subscale NN N
scores NNS N
(5 VBP N
mg/day JJ N
-12.4; $ N
10 CD N
mg/day JJ N
-13.2; $ N
15 CD N
mg/day JJ N
-14.4; NNP N
versus NN N
placebo NN N
-8.4; NNP N
all DT N
p VBP N
< JJ N
.05) NN N
. . N

All DT N
aripiprazole JJ I
doses NNS N
demonstrated VBN N
significantly RB N
greater JJR N
improvements NNS N
in IN N
mean JJ N
Clinical JJ O
Global NNP O
Impressions-Improvement NNP O
score NN O
than IN N
placebo NN I
at IN N
week NN N
8 CD N
. . N

Discontinuation NN N
rates NNS N
due JJ N
to TO N
adverse JJ N
events NNS N
were VBD N
as IN N
follows: JJ N
placebo NN I
7.7% CD N
aripiprazole JJ I
5 CD N
mg/day JJ N
9.4% CD N
10 CD N
mg/day NN N
13.6% CD N
and CC N
15 CD N
mg/day NN N
7.4% CD N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
event NN N
leading VBG N
to TO N
discontinuation NN N
was VBD N
sedation NN O
. . O

There EX N
were VBD N
two CD N
serious JJ N
adverse JJ N
events: NN N
presyncope NN O
(5 NNP N
mg/day) NN N
and CC N
aggression NN O
(10 NNP N
mg/day) NN N
. . N

At IN N
week NN N
8 CD N
mean JJ N
weight NN N
change NN N
(last NNP N
observation NN N
carried VBD N
forward) NN N
was VBD N
as IN N
follows: JJ N
placebo NN I
+0.3 NNP N
kg NNP N
aripiprazole VBD I
5 CD N
mg/day JJ N
+1.3 NNP N
kg VBD N
10 CD N
mg/day JJ N
+1.3 NNP N
kg NN N
and CC N
15 CD N
mg/day NN N
+1.5 NNP N
kg; VBZ N
all DT N
p JJ N
< NNP N
.05 NNP N
versus NN N
placebo NN I
. . I

CONCLUSIONS NNP N
Aripiprazole NNP I
was VBD N
efficacious JJ N
and CC N
generally RB N
safe JJ N
and CC N
well RB N
tolerated VBN N
in IN N
the DT N
treatment NN N
of IN N
children NNS N
and CC N
adolescents NNS N
with IN N
irritability NN N
associated VBN N
with IN N
autistic JJ N
disorder NN N
. . N

-DOCSTART- -X- N

Bilateral NNP I
transversus NN I
abdominis NN I
plane NN I
block NN I
does VBZ N
not RB N
decrease VB N
postoperative JJ N
pain NN N
after IN N
laparoscopic NN N
cholecystectomy NN N
when WRB N
compared VBN N
with IN N
local JJ I
anesthetic JJ I
infiltration NN I
of IN I
trocar NN I
insertion NN I
sites NNS I
. . I

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Transversus NNP I
abdominis VBZ I
plane NN I
(TAP) NN I
block NN I
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
pain NN N
and CC N
analgesic JJ N
requirements NNS N
after IN N
abdominal JJ N
surgery NN N
. . N

Our PRP$ N
hypothesis NN N
was VBD N
that IN N
bilateral JJ I
TAP NNP I
blocks NNS I
decrease NN N
pain NN N
after IN N
laparoscopic NN N
cholecystectomy NN N
when WRB N
compared VBN N
with IN N
local JJ I
anesthetic JJ I
infiltration NN I
of IN I
trocar NN I
insertion NN I
sites NNS I
. . I

METHODS NNP N
Eighty NNP P
patients NNS P
undergoing VBG P
laparoscopic JJ P
cholecystectomy NN P
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
bilateral JJ I
TAP NNP I
blocks NNS I
or CC I
local JJ I
anesthetic JJ I
infiltration NN I
of IN I
trocar NN I
insertion NN I
sites VBZ I
with IN I
ropivacaine NN I
0.5% CD I
. . I

Postoperative JJ O
pain NN O
scores NNS N
and CC N
analgesic JJ N
use NN N
for IN N
the DT N
first JJ N
24 CD N
hrs NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Eighty NNP P
patients NNS P
were VBD P
enrolled VBN P
in IN N
the DT N
study NN N
. . N

After IN N
exclusions NNS N
data NNS N
were VBD N
analyzed VBN N
on IN N
39 CD N
patients NNS N
in IN N
group NN N
T NNP N
(bilateral NNP N
TAP NNP N
block) NN N
and CC N
35 CD N
patients NNS N
in IN N
group NN N
I PRP N
(infiltration) VBP N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
pain NN O
scores NNS O
on IN N
the DT N
numeric JJ N
analog NN N
scale JJ N
(0-10) NN N
between IN N
the DT N
groups NNS N
at IN N
4 CD N
hrs NN N
after IN N
surgery NN N
(P NN N
= VBP N
0.18) CD N
or CC N
during IN N
the DT N
24 CD N
hrs NN N
after IN N
surgery NN N
(P NN N
= VBD N
0.23) CD N
. . N

The DT N
time NN O
interval NN O
from IN O
anesthesia JJ O
start NN O
to TO N
surgery VB N
start NN N
was VBD N
greater JJR N
in IN N
group NN N
T NNP N
than IN N
group NN N
I PRP N
(48 VBP N
vs JJ N
35 CD N
mins NNS N
P NNP N
< VBD N
0.001) CD N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
found VBD N
in IN N
analgesic JJ N
use NN N
during IN N
the DT N
first JJ N
24 CD N
hrs NN N
after IN N
surgery NN N
. . N

CONCLUSIONS NNP N
Bilateral NNP I
ultrasound-guided JJ I
TAP NNP I
block NN I
is VBZ N
equivalent JJ N
to TO N
local JJ I
anesthetic JJ I
infiltration NN I
of IN I
trocar NN I
insertion NN I
sites VBZ I
for IN N
overall JJ N
postoperative JJ O
pain NN O
in IN N
a DT N
heterogeneous JJ N
group NN N
of IN N
patients NNS N
undergoing VBG N
laparoscopic JJ N
cholecystectomy NN N
. . N

-DOCSTART- -X- N

Effect NN N
of IN N
parent NN I
training NN I
vs NN I
parent NN I
education NN I
on IN I
behavioral JJ P
problems NNS P
in IN P
children NNS P
with IN P
autism NN P
spectrum NN P
disorder: VBZ P
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE NNP N
Disruptive NNP N
behavior NN N
is VBZ N
common JJ N
in IN N
children NNS P
with IN P
autism NN P
spectrum NN P
disorder NN P
. . P

Behavioral JJ I
interventions NNS I
are VBP N
used VBN N
to TO N
treat VB N
disruptive JJ N
behavior NN N
but CC N
have VBP N
not RB N
been VBN N
evaluated VBN N
in IN N
large-scale JJ N
randomized JJ N
trials NNS N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
parent NN I
training NN I
for IN I
children NNS P
with IN P
autism NN P
spectrum NN P
disorder NN P
and CC P
disruptive JJ P
behavior NN P
. . P

DESIGN NNP N
SETTING NNP N
AND CC N
PARTICIPANTS NNP N
This DT N
24-week JJ N
randomized JJ N
trial NN N
compared VBN N
parent NN P
training VBG P
(n=89) NN P
to TO P
parent VB P
education NN P
(n=91) NN P
at IN P
6 CD P
centers NNS P
(Emory JJ P
University NNP P
Indiana NNP P
University NNP P
Ohio NNP P
State NNP P
University NNP P
University NNP P
of IN P
Pittsburgh NNP P
University NNP P
of IN P
Rochester NNP P
Yale NNP P
University) NNP P
. . P

We PRP P
screened VBD P
267 CD P
children; NN P
180 CD P
children NNS P
(aged VBD P
3-7 JJ P
years) NN P
with IN P
autism NN P
spectrum NN P
disorder NN P
and CC P
disruptive JJ P
behaviors NNS P
were VBD P
randomly RB P
assigned VBN P
(86% NNP P
white JJ P
88% CD P
male) NN P
between IN P
September NNP P
2010 CD P
and CC P
February NNP P
2014 CD N
. . N

INTERVENTIONS NNP I
Parent NNP I
training VBG I
(11 NNP I
core NN I
2 CD I
optional JJ I
sessions; NN I
2 CD I
telephone NN I
boosters; NN I
2 CD I
home NN I
visits) NN I
provided VBD I
specific JJ I
strategies NNS I
to TO I
manage VB I
disruptive JJ I
behavior NN I
. . I

Parent NN I
education NN I
(12 NNP I
core NN I
sessions NNS I
1 CD I
home NN I
visit) NN I
provided VBN I
information NN I
about IN I
autism NN I
but CC I
no DT I
behavior JJ I
management NN I
strategies NNS I
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP O
Parents NNP O
rated VBD O
disruptive JJ O
behavior NN O
and CC O
noncompliance NN O
on IN O
co-primary JJ O
outcomes: IN O
the DT O
Aberrant NNP O
Behavior NNP O
Checklist-Irritability NNP O
subscale JJ O
(range NN O
0-45) NN O
and CC O
the DT O
Home NNP O
Situations NNP O
Questionnaire-Autism NNP O
Spectrum NNP O
Disorder NNP O
(range NNP O
0-9) NN N
. . N

On IN N
both DT N
measures NNS N
higher JJR N
scores NNS N
indicate VBP N
greater JJR N
severity NN N
and CC N
a DT N
25% CD N
reduction NN N
indicates VBZ N
clinical JJ N
improvement NN N
. . N

A DT N
clinician JJ N
blind NN N
to TO N
treatment NN N
assignment NN N
rated VBD N
the DT N
Improvement NNP N
scale NN N
of IN N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
(range NNP N
1-7) CD N
a DT N
secondary JJ N
outcome NN N
with IN N
a DT N
positive JJ N
response NN N
less JJR N
than IN N
3 CD N
. . N

RESULTS NN N
At IN N
week NN N
24 CD O
the DT O
Aberrant NNP O
Behavior NNP O
Checklist-Irritability NNP O
subscale NN O
declined VBD N
47.7% CD I
in IN I
parent NN I
training NN I
(from $ N
23.7 CD N
to TO N
12.4) CD N
compared VBN N
with IN N
31.8% CD I
for IN I
parent NN I
education NN I
(23.9 NNP N
to TO N
16.3) CD N
(treatment JJ N
effect NN N
-3.9; VBZ N
95% CD N
CI NNP N
-6.2 NN N
to TO N
-1.7; VB N
P<.001 NNP N
standardized JJ N
effect NN N
size=0.62) NN O
. . O

The DT O
Home NNP O
Situations NNP O
Questionnaire-Autism NNP O
Spectrum NNP O
Disorder NNP N
declined VBD N
55% CD N
(from $ N
4.0 CD N
to TO N
1.8) CD N
compared VBN I
with IN I
34.2% CD I
in IN I
parent NN I
education NN N
(3.8 NNP N
to TO N
2.5) CD N
(treatment JJ N
effect NN N
-0.7; VBZ N
95% CD N
CI NNP N
-1.1 NN N
to TO N
-0.3; VB N
P<.001 NNP N
standardized JJ N
effect NN N
size=0.45) NN N
. . N

Neither DT N
measure NN N
met VBD N
the DT N
prespecified VBN N
minimal JJ N
clinically RB N
important JJ N
difference NN N
. . N

The DT N
proportions NNS N
with IN N
a DT N
positive JJ O
response NN O
on IN O
the DT O
Clinical JJ O
Global NNP O
Impression-Improvement NNP O
scale NN I
were VBD I
68.5% CD I
for IN N
parent NN I
training NN I
vs NN I
39.6% CD I
for IN N
parent NN N
education NN N
(P<.001) NNP N
. . N

CONCLUSIONS NNP P
AND CC P
RELEVANCE NNP P
For IN P
children NNS P
with IN P
autism NN N
spectrum NN I
disorder VB I
a DT I
24-week JJ I
parent NN N
training NN I
program NN I
was VBD I
superior JJ I
to TO N
parent VB N
education NN N
for IN N
reducing VBG N
disruptive JJ N
behavior NN N
on IN N
parent-reported JJ N
outcomes NNS N
although IN N
the DT N
clinical JJ N
significance NN N
of IN N
the DT N
improvement NN N
is VBZ N
unclear JJ N
. . N

The DT N
rate NN N
of IN N
positive JJ N
response NN N
judged VBN N
by IN N
a DT N
blinded JJ I
clinician NN I
was VBD I
greater JJR I
for IN I
parent NN I
training NN I
vs NN N
parent NN N
education NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier: NNP N
NCT01233414 NNP N
. . N

-DOCSTART- -X- N

Effects NNS N
of IN N
omeprazole NN I
and CC I
amoxycillin NN I
on IN N
the DT N
human JJ N
oral JJ N
and CC N
gastrointestinal JJ N
microflora NNS N
in IN N
patients NNS P
with IN P
Helicobacter NNP P
pylori JJ P
infection NN P
. . P

Fourteen JJ P
patients NNS P
with IN P
Helicobacter NNP P
pylori FW P
infection NN P
were VBD N
treated VBN N
with IN N
omeprazole JJ I
capsules NNS N
20 CD N
mg NNS N
and CC N
amoxycillin NN I
capsules NNS N
1000 CD N
mg JJ N
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
and CC N
14 CD N
patients NNS N
with IN N
omeprazole JJ I
capsules NNS N
20 CD N
mg NNS N
and CC N
placebo VB I
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
. . N

Samples NNS N
from IN N
saliva JJ N
dental JJ N
plaque NN N
and CC N
faeces NNS N
and CC N
biopsies NNS N
from IN N
antrum NN N
and CC N
corpus NN N
were VBD N
analysed VBN N
in IN N
order NN N
to TO N
determine VB N
the DT N
ecological JJ N
changes NNS N
in IN N
the DT N
normal JJ N
microflora NN N
. . N

Several JJ N
microorganisms NNS N
were VBD N
affected VBN N
by IN N
both DT N
treatment NN N
regimens NNS N
. . N

Two CD N
patients NNS N
were VBD N
colonised VBN N
with IN N
enterobacteria NNS N
in IN N
the DT N
oral JJ N
cavity NN N
and CC N
stomach NN N
during IN N
the DT N
omeprazole JJ I
plus CC I
amoxycillin JJ I
treatment NN I
. . I

A DT N
general JJ N
increase NN N
in IN N
the DT N
number NN O
of IN O
microorganisms NNS O
from IN N
gastric JJ N
mucosa NN N
was VBD N
observed VBN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

A DT N
selection NN N
of IN N
resistant JJ O
enterobacteria NN O
and CC N
an DT N
increase NN O
in IN O
beta-lactamase JJ O
production NN O
was VBD N
observed VBN N
in IN N
the DT N
faecal JJ N
samples NNS N
during IN N
the DT N
omeprazole JJ I
plus CC I
amoxycillin JJ I
treatment NN N
. . N

Eradication NN O
of IN O
H NNP O
. . O

pylori NN O
in IN N
the DT N
omeprazole-amoxycillin JJ I
group NN N
was VBD N
50% CD N
and CC N
in IN N
the DT N
omeprazole JJ I
placebo NN I
group NN N
0% CD N
four CD N
weeks NNS N
after IN N
treatment NN N
. . N

No DT N
viable JJ N
H NNP N
. . N

pylori NNS N
were VBD N
cultivated VBN N
in IN N
the DT N
saliva JJ N
dental JJ N
plaque NN N
or CC N
faecal JJ N
samples NNS N
. . N

Treatment NN N
with IN N
omeprazole JJ I
20 CD I
mg NN I
and CC I
amoxycillin NN I
1000 CD I
mg NN I
twice RB I
daily RB N
for IN N
14 CD N
days NNS N
altered VBD N
the DT N
normal JJ N
microflora NN N
in IN N
the DT N
oral JJ N
gastric NN N
and CC N
intestinal JJ N
tract NN N
and CC N
antibiotic JJ N
resistant JJ N
microorganisms NNS N
increased VBD N
in IN N
numbers NNS N
in IN N
the DT N
intestinal JJ N
microflora NN N
. . N

-DOCSTART- -X- N

Interferon NNP I
treatment NN I
for IN N
hairy NN P
cell NN P
leukemia NN P
. . P

An DT N
update NN O
on IN N
a DT N
cohort NN P
of IN P
69 CD P
patients NNS P
treated VBN P
from IN P
1983 CD P
to TO P
1986 CD P
. . P

We PRP N
report VBP N
follow-up JJ N
information NN N
on IN N
69 CD P
hairy NN P
cell NN P
leukemia NN P
(HCL) NN P
patients NNS P
treated VBN P
with IN P
interferon JJ P
alfa-2b JJ P
(IFN) NN P
as IN P
primary JJ P
treatment NN P
from IN P
1983 CD P
to TO P
1986 CD P
. . P

Follow-up NNP N
through IN N
April NNP N
1993 CD N
shows VBZ N
that IN N
only RB N
14 CD N
patients NNS N
have VBP N
expired VBN O
. . O

Forty-seven CD N
of IN N
the DT N
61 CD N
patients NNS N
completing VBG N
the DT N
intended JJ N
12 CD N
or CC N
more JJR N
months NNS N
of IN N
initial JJ N
IFN NNP I
treatment NN N
were VBD N
eventually RB N
considered VBN N
IFN NNP O
failures NNS O
. . O

Forty-three CD N
required JJ N
re-treatment JJ O
(41 NN N
received VBD N
a DT N
second JJ N
course NN N
of IN N
IFN NNP I
and CC N
2 CD N
received VBD N
pentostatin) NN I
. . N

Four CD N
patients NNS N
died VBD O
without IN N
further JJ N
therapy NN N
for IN N
HCL NNP O
. . O

The DT N
median JJ O
time NN O
to TO O
interferon VB O
failure NN O
was VBD N
31.3 CD N
months NNS N
. . N

Fourteen JJ N
patients NNS N
are VBP N
alive JJ O
and CC N
have VBP N
not RB N
required VBN N
further RBR N
treatment NN N
after IN N
completing VBG N
their PRP$ N
initial JJ N
12 CD N
or CC N
more JJR N
months NNS N
of IN N
interferon NN I
. . I

Fifteen JJ N
patients NNS N
underwent VBD N
a DT N
third JJ N
course NN N
of IN N
interferon NN I
therapy NN I
at IN N
a DT N
median JJ N
time NN N
after IN N
completion NN N
of IN N
a DT N
second JJ N
course NN N
of IN N
IFN NNP I
of IN N
1.0 CD N
year NN N
. . N

Eighteen JJ N
patients NNS N
were VBD N
eventually RB N
treated VBN N
with IN N
pentostatin NN I
and CC N
ten VB N
with IN N
2-chlorodeoxyadenosine JJ I
(2-CdA) NN I
. . I

Thirteen JJ N
patients NNS N
developed VBD N
a DT N
second JJ O
malignancy; NN O
six CD N
of IN N
these DT N
patients NNS N
developed VBD N
a DT N
hematologic JJ O
malignancy NN O
between IN N
44.6 CD N
months NNS N
and CC N
99.1 CD N
months NNS N
after IN N
initiation NN N
of IN N
interferon NN I
therapy NN N
. . N

We PRP N
conclude VBP N
that IN N
although IN N
interferon NN I
provides VBZ N
excellent JJ O
palliation NN O
that IN O
most JJS N
patients NNS N
will MD N
eventually RB N
require VB N
further JJ N
treatment NN N
with IN N
interferon NN I
or CC N
chemotherapy NN I
. . I

Future JJ N
trials NNS N
in IN N
HCL NNP N
must MD N
be VB N
aware JJ N
of IN N
the DT N
risk NN N
of IN N
second JJ O
malignancies NNS O
. . O

-DOCSTART- -X- N

Electrical JJ N
sources NNS N
of IN N
P300 NNP N
event-related JJ N
brain NN N
potentials NNS N
revealed VBN N
by IN N
low JJ N
resolution NN N
electromagnetic JJ N
tomography NN N
. . N

2 CD N
. . N

Effects NNS N
of IN N
nootropic JJ I
therapy NN I
in IN N
age-associated JJ P
memory NN P
impairment NN P
. . P

In IN N
a DT N
double-blind JJ N
placebo-controlled JJ I
study NN N
the DT N
effects NNS N
of IN N
Actovegin NNP I
on IN N
frontal JJ N
and CC N
parietal JJ N
electrical JJ N
P300 NNP N
sources NNS N
revealed VBN N
by IN N
low JJ N
resolution NN N
electromagnetic JJ N
tomography NN N
(LORETA) NN N
were VBD N
studied VBN N
in IN N
age-associated JJ P
memory NN P
impairment NN P
(AAMI) NN P
patients NNS P
. . P

Actovegin NNP N
is VBZ N
a DT N
protein-free JJ N
metabolically RB N
active JJ N
hemoderivative JJ N
improving NN N
oxygen NN N
and CC N
glucose JJ N
utilization NN N
. . N

Each DT N
patient NN N
had VBD N
in IN N
randomized VBN N
order NN N
a DT I
treatment NN I
of IN I
2 CD I
weeks NNS I
with IN I
250 CD I
ml NNS I
20% CD I
Actovegin NNP I
and CC I
250 CD I
ml NNS I
placebo JJ I
daily RB I
. . I

Auditory JJ I
ERPs NNP I
were VBD I
recorded VBN I
before RB I
and CC I
5 CD I
h NN I
after IN I
drug NN I
administration NN I
on IN I
day NN I
1 CD I
(acute NN I
effect) NN I
and CC I
on IN I
day NN I
15 CD I
(subacute NN I
and CC I
superimposed VBD I
effect) NN I
. . N

Compared VBN N
to TO N
age- JJ N
and CC N
sex-matched JJ N
normal JJ N
controls NNS N
AAMI NNP P
patients NNS P
showed VBD N
a DT N
trend NN N
towards VBZ N
P300 NNP O
latency NN O
prolongation NN O
and CC N
a DT N
significantly RB N
reduced VBN N
P300 NNP O
global JJ O
field NN O
power NN O
(GFP) NNP N
. . N

Maximal NNP O
LORETA NNP O
source NN O
strength NN O
did VBD N
not RB N
differ VB N
from IN N
controls NNS N
. . N

After IN N
Actovegin NNP I
parietal JJ N
P300 NNP O
scalp NN O
amplitudes NNS O
increased VBD N
while IN N
frontal JJ O
and CC O
temporal JJ O
amplitudes NNS O
decreased VBD N
as IN N
compared VBN N
to TO N
placebo VB I
. . I

This DT N
increase NN N
in IN N
hilliness NN O
measured VBN O
by IN N
the DT N
GFP NNP N
was VBD N
significant JJ N
. . N

Moreover RB N
the DT N
parietal JJ O
P300 NNP O
source NN O
strength NN O
increased VBD N
after IN N
acute JJ N
subacute NN N
and CC N
superimposed JJ N
infusion NN N
of IN N
Actovegin NNP I
as IN N
compared VBN N
to TO N
placebo VB I
. . I

This DT N
may MD N
reflect VB N
improved JJ N
availability NN N
of IN N
cognitive JJ N
processing NN N
resources NNS N
in IN N
the DT N
parietal JJ N
cortex NN N
an DT N
area NN N
that WDT N
on IN N
the DT N
one CD N
hand NN N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
fundamental JJ N
aspects NNS N
of IN N
attention NN N
and CC N
on IN N
the DT N
other JJ N
hand NN N
has VBZ N
been VBN N
found VBN N
to TO N
be VB N
functionally RB N
impaired VBN N
in IN N
dementia NN N
. . N

-DOCSTART- -X- N

The DT N
effectiveness NN N
of IN N
a DT N
calcium NN I
sodium NN I
phosphosilicate NN I
desensitizer NN I
in IN N
reducing VBG N
cervical JJ P
dentin NN P
hypersensitivity: VBD P
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
NovaMin NNP N
(NovaMin NNP N
Technology NNP N
Alachua NNP N
Fla.) NNP N
was VBD N
introduced VBN N
into IN N
the DT N
dental JJ N
market NN N
as IN N
a DT N
desensitizer NN N
in IN N
December NNP N
2004 CD N
. . N

However RB N
to TO N
the DT N
authors' NN N
knowledge NN N
no DT N
researchers NNS N
yet RB N
have VBP N
evaluated VBN N
the DT N
effectiveness NN N
of IN N
100 CD N
percent NN N
NovaMin NNP I
powder NN I
with IN I
NovaMin-containing NNP I
toothpaste NN I
in IN N
reducing VBG N
dentin JJ N
hypersensitivity NN N
compared VBN N
with IN N
the DT N
effectiveness NN N
of IN N
NovaMin-containing NNP N
toothpaste NN N
only RB N
and CC N
a DT N
desensitizing NN N
toothpaste NN N
containing VBG N
potassium NN N
nitrate NN N
as IN N
a DT N
control NN N
. . N

METHODS NNP N
The DT I
authors NNS I
divided VBD P
60 CD P
participants NNS P
randomly RB I
into IN I
three CD I
groups: NNS I
NovaMin NNP I
powder NN I
with IN I
NovaMin-containing NNP I
toothpaste NN I
(group VBZ I
1) CD I
a DT I
placebo NN I
powder NN I
with IN I
NovaMin-containing NNP I
toothpaste NN I
(group NN I
2) CD I
and CC I
a DT I
placebo NN I
powder NN I
with IN I
the DT I
control NN I
toothpaste NN I
(group $ I
3) CD I
. . I

The DT I
authors NNS I
used VBN I
tactile NN I
and CC I
cold JJ I
stimuli NN I
and CC I
a DT I
visual JJ I
analog NN I
scale NN I
to TO I
evaluate VB I
participants' NN I
pain NN I
at IN I
baseline NN I
immediately RB I
after IN I
powder NN I
application NN I
and CC I
at IN I
one CD I
week NN I
two CD I
weeks NNS I
and CC I
four CD I
weeks NNS I
after IN I
powder NN I
application NN I
. . I

They PRP N
analyzed VBD N
data NNS N
by IN N
using VBG N
Friedman NNP N
and CC N
Wilcoxon NNP N
signed-rank JJ N
tests NNS N
for IN N
within-group JJ N
comparison NN N
. . N

They PRP N
used VBD N
Kruskal-Wallis NNP N
and CC N
Mann-Whitney NNP N
U NNP N
tests NNS N
for IN N
between-group JJ N
comparison NN N
. . N

They PRP N
considered VBD N
P NNP N
< NNP N
.05 NNP N
to TO N
be VB N
statistically RB N
significant JJ N
. . N

RESULTS NNP N
Groups NNP N
1 CD N
and CC N
2 CD N
showed VBD N
significant JJ N
hypersensitivity NN N
reduction NN N
over IN N
baseline NN N
at IN N
all DT N
time NN N
points NNS N
. . N

Group NNP N
3 CD N
showed VBD N
significant JJ N
hypersensitivity NN N
reduction NN N
at IN N
one CD N
week NN N
onward NN N
. . N

Group NNP N
1 CD N
showed VBD N
significant JJ N
improvement NN N
compared VBN N
with IN N
groups NNS N
2 CD N
and CC N
3 CD N
except IN N
for IN N
response NN N
to TO N
tactile VB N
stimulus NN N
at IN N
four CD N
weeks NNS N
with IN N
group NN N
2 CD N
. . N

Between NNP N
groups NNS N
2 CD N
and CC N
3 CD N
there EX N
were VBD N
significant JJ N
differences NNS N
at IN N
two CD N
and CC N
four CD N
weeks NNS N
. . N

CONCLUSIONS NNP N
and CC N
CLINICAL NNP N
IMPLICATIONS NNP N
The DT N
use NN N
of IN N
NovaMin NNP I
powder NN I
and CC I
NovaMin-containing NNP I
toothpaste NN I
for IN N
hypersensitivity NN N
reduction NN N
is VBZ N
more RBR N
effective JJ N
than IN N
the DT N
use NN N
of IN N
a DT N
desensitizing VBG N
toothpaste NN N
containing VBG N
potassium NN N
nitrate NN N
and CC N
fluoride NN N
. . N

-DOCSTART- -X- N

[Efficacy NN N
observation NN N
on IN N
chronic JJ P
tension-type JJ P
headache NN P
treated VBN N
with IN N
acupuncture NN I
at IN N
galea NN N
tendon-muscle NN N
node] NN N
. . N

OBJECTIVE NN N
To TO N
explore VB N
the DT N
better JJR N
therapy NN I
for IN I
chronic JJ P
tension-type JJ P
headache NN P
(CTTH) NN P
. . P

METHODS NNP N
Two CD P
hundred VBD P
and CC P
eighty-eight JJ P
cases NNS P
were VBD P
randomized VBN P
into IN P
a DT I
sticking VBG I
needling VBG I
group NN I
(150 NNP I
cases) NN I
and CC I
an DT I
acupuncture NN I
group NN I
(138 NNP I
cases) NN I
. . I

In IN I
the DT I
sticking VBG I
needling NN I
group NN I
the DT I
manual JJ I
sticking NN I
needling NN I
technique NN I
was VBD I
adopted VBN I
to TO I
stimulate VB I
the DT I
galea NN I
tendon-muscle NN I
node NN I
. . I

In IN I
the DT I
acupuncture NN I
group NN I
the DT I
conventional JJ I
acupuncture NN I
therapy NN I
was VBD I
applied VBN I
to TO I
Baihui NNP I
(GV NNP I
20) CD I
Sishencong NNP I
(EX-HN JJ I
1) CD I
Fengchi NNP I
(GB VBD I
20) CD I
Taiyang NNP I
(EX-HN JJ I
5) CD I
Touwei NNP I
(ST VBD I
18) CD I
Hegu NNP I
(LI VBD I
4) CD I
etc NN I
. . I

The DT I
treatment NN I
was VBD I
given VBN I
once RB I
a DT I
day NN I
and CC I
30 CD I
days NNS I
made VBD I
one CD I
session NN I
. . I

After IN I
two CD I
sessions NNS I
of IN I
treatment NN I
and CC I
after IN I
three CD I
months NNS I
follow-up JJ I
CTTH NNP O
score NN O
(including VBG O
the DT O
score NN O
of IN O
headache NN O
attack NN O
frequency NN O
and CC O
the DT O
score NN O
of IN O
headache NN O
severity) NN O
was VBD I
observed VBN I
and CC I
compared VBN I
before IN I
and CC I
after IN I
treatment NN I
separately RB I
. . I

The DT N
efficacy NN N
was VBD N
evaluated VBN N
in IN N
two CD N
groups NNS N
. . N

RESULTS NNP N
CTTH NNP O
score NN O
was VBD N
all DT N
reduced VBN N
after IN N
treatment NN N
in IN N
the DT N
two CD N
groups NNS N
(both CC N
P<0.01) NNP N
the DT N
score NN N
in IN N
the DT N
sticking VBG I
needling VBG I
group NN I
was VBD N
lower JJR N
than IN N
that DT N
in IN N
the DT N
acupuncture NN I
group NN I
(2.38 VBD N
+/- JJ N
1.22 CD N
vs JJ N
4.16 CD N
+/- JJ N
2.54 CD N
P NNP N
< VBD N
0.01) CD N
. . N

The DT N
effective JJ O
rate NN O
was VBD N
97.3% CD N
(146/150) NN N
in IN N
the DT N
sticking VBG I
needling NN I
group NN N
which WDT N
was VBD N
better JJR N
than IN N
88.4% CD N
(122/138) NN N
in IN N
the DT N
acupuncture NN I
group NN N
(P NNP N
< VBZ N
0.05) CD N
. . N

CONCLUSION NNP N
The DT I
manual JJ I
sticking NN I
needling NN I
technique NN I
at IN N
galea JJ N
tendon-muscle JJ N
node NN N
achieves VBZ N
the DT N
superior JJ N
results NNS N
of IN N
reducing VBG N
the DT N
pain NN O
attack NN O
frequency NN O
and CC O
severity NN O
of IN O
CTTH NNP O
as IN N
compared VBN N
with IN N
the DT N
acupuncture NN I
therapy NN I
of IN I
the DT I
routine JJ I
acupoint NN I
selection NN I
. . I

-DOCSTART- -X- N

Use NNP I
of IN I
a DT I
DNAemia NNP I
cut-off NN I
for IN I
monitoring VBG I
human JJ I
cytomegalovirus NN I
infection NN I
reduces VBZ N
the DT N
number NN O
of IN O
preemptively RB O
treated VBN P
children NNS P
and CC P
young JJ P
adults NNS P
receiving VBG P
hematopoietic JJ P
stem-cell JJ P
transplantation NN P
compared VBN P
with IN P
qualitative JJ I
pp65 NN I
antigenemia NN I
. . I

We PRP N
performed VBD N
a DT N
randomized JJ N
trial NN N
comparing VBG N
the DT N
use NN N
of IN N
quantitative JJ I
DNAemia NNP I
versus NN I
positive JJ I
antigenemia NN I
for IN N
starting VBG N
preemptive JJ I
antihuman NN I
cytomegalovirus NN I
(HCMV) NNP I
therapy NN I
in IN N
hematopoietic JJ P
stem-cell JJ P
transplantation NN P
(HSCT) NN P
recipients NNS P
. . P

In IN N
the DT N
DNAemia NNP I
arm NN N
antiviral JJ I
therapy NN I
was VBD N
initiated VBN N
on IN N
reaching VBG N
a DT N
DNAemia NNP I
cut-off NN I
of IN I
10 CD I
000 CD I
DNA NNP I
copies/mL NN I
of IN I
whole JJ I
blood NN I
whereas NNS I
in IN N
the DT N
antigenemia NN I
arm NN N
therapy NN I
was VBD N
started VBN N
in IN N
the DT N
presence NN I
of IN I
a DT I
positive JJ I
antigenemia NN I
. . I

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
number NN N
of IN N
patients NNS N
treated VBN N
in IN N
the DT N
2 CD N
arms NNS N
. . N

On IN N
the DT N
whole JJ N
178 CD P
patients NNS P
(89 JJ P
in IN P
each DT P
arm) NN P
receiving VBG P
unmanipulated JJ P
HSCT NNP P
from IN P
either CC P
a DT P
relative NN P
or CC P
an DT P
unrelated JJ P
donor NN P
completed VBD P
the DT N
study NN N
. . N

Although IN N
the DT N
incidence NN N
of IN N
HCMV NNP O
infection NN O
was VBD N
comparable JJ N
in IN N
DNAemia NNP I
and CC N
antigenemia NN I
arms NNS N
(34% VBP N
vs JJ N
42% CD N
respectively RB N
P NNP N
= NNP N
.259) VBZ N
the DT N
number NN N
of IN N
patients NNS N
treated VBN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
DNAemia NNP I
arm NN N
(18% NNP N
vs NN N
31% CD N
P NNP N
= NNP N
.026) NNP N
. . N

No DT N
patient NN N
developed VBD N
HCMV NNP N
disease NN N
. . N

The DT N
use NN N
of IN N
a DT N
DNAemia NNP I
cut-off NN I
avoids NNS N
unnecessary JJ N
antiviral JJ I
treatment NN I
. . I

-DOCSTART- -X- N

Effects NNS N
of IN N
amlodipine NN I
and CC I
enalapril NN I
on IN N
platelet NN P
function NN P
in IN P
patients NNS P
with IN P
mild JJ P
to TO P
moderate VB P
hypertension NN P
. . P

OBJECTIVE IN P
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO O
compare VB O
the DT O
effect NN O
of IN N
amlodipine NN I
and CC I
enalapril NN I
on IN N
platelet NN O
aggregation NN O
and CC O
platelet NN O
production NN O
of IN O
malondialdehyde NN O
in IN N
patients NNS P
with IN P
mild JJ P
to TO P
moderate VB P
arterial JJ P
hypertension NN P
. . P

PATIENTS NNS N
AND CC N
METHODS NNP N
A NNP N
parallel JJ N
double-blind JJ N
placebo-controlled JJ I
study NN N
was VBD N
carried VBN N
out RP N
in IN N
24 CD P
patients NNS P
(2 JJ P
groups NNS P
of IN P
12 CD P
patients NNS P
each) JJ P
. . P

Initially RB N
all DT N
patients NNS N
received VBD N
placebo NNS I
for IN I
four CD I
weeks; NN I
then RB I
amlodipine VBZ I
5 CD I
mg JJ I
daily JJ I
or CC I
enalapril JJ I
20 CD I
mg JJ I
daily RB I
taken VBN N
once RB N
a DT N
day NN N
at IN N
7 CD N
am VBP N
. . N

Dosage NN N
was VBD N
doubled VBN N
after IN N
4 CD N
weeks NNS N
when WRB N
diastolic JJ O
blood NN O
pressure NN O
was VBD N
> JJ N
90 CD N
mmHg NN N
in IN N
sitting VBG N
position NN N
the DT N
treatment NN N
was VBD N
continued VBN N
for IN N
12 CD N
weeks NNS N
. . N

At IN N
the DT N
end NN N
of IN N
placebo NN I
and CC N
active JJ N
phases NNS N
a DT N
platelet NN O
aggregation NN O
test NN O
using VBG O
adenosine JJ O
diphosphate NN O
collagen NN O
and CC O
adrenaline NN O
and CC O
a DT O
platelet NN O
malondialdehyde NN O
production NN O
test NN O
either NN O
in IN O
basal JJ O
conditions NNS O
(MDA-basal) NNS O
and CC O
after IN O
the DT O
stimulation NN O
of IN O
arachidonic JJ O
acid NNS O
pathway RB O
by IN O
adding VBG O
ethylmaleimide JJ O
(MDA-activated) JJ O
were VBD O
carried VBN O
out RP O
. . O

RESULTS NNP N
Blood NNP O
pressure NN O
was VBD N
reduced VBN N
by IN N
both DT N
agents NNS N
enalapril VBP I
and CC I
amlodipine VBP I
. . I

Enalapril NNP I
controlled VBD N
58.3% CD N
of IN N
hypertensive JJ P
patients NNS P
with IN N
an DT N
average JJ N
dosage NN N
of IN N
31.7 CD N
mg/daily RB N
. . N

Amlodipine NNP I
controlled VBD N
75% CD N
of IN N
patients NNS N
with IN N
a DT N
dosage NN N
of IN N
7.1 CD N
mg/daily RB N
. . N

Platelet NNP O
aggregation NN O
was VBD N
reduced VBN N
by IN N
amlodipine NN I
in IN N
15.9% CD N
for IN N
ADP NNP N
(10 NNP N
microM); VBD N
17.4% CD N
for IN N
collagen NN N
(2 NNP N
microg/ml) NN N
and CC N
19.9% CD N
for IN N
adrenaline NN N
(2 NNP N
microM) NN N
(p NNP N
< VBZ N
0.025) CD N
. . N

Meanwhile RB N
enalapril VBZ I
slightly RB N
increased VBN N
platelet NN O
aggregation NN O
by IN N
6.7% CD N
1.3% CD N
and CC N
5.6% CD N
for IN N
the DT N
three CD N
agents NNS N
respectively RB N
(p VBP N
> JJ N
0.05 CD N
ns) NN N
. . N

Malondialdehyde NNP O
was VBD N
reduced VBN N
by IN N
amlodipine NN I
in IN N
45.33% CD N
(p JJ N
< $ N
0.05) CD N
for IN N
MDA-basal; NNP N
3.76% CD N
(p NNP N
> VBD N
0.05) CD N
for IN N
MDA-activated; NNP N
and CC N
the DT N
ratio NN N
MDA-basal:MDA-activated NNP N
in IN N
36.79% CD N
(p JJ N
< RB N
0.005) CD N
. . N

Meanwhile RB N
enalapril NN I
increased VBD N
MDA-basal NNP O
in IN N
2.89%; CD N
MDA-activated JJ O
in IN N
3.58% CD N
and CC N
reduced VBD N
the DT N
ratio NN O
MDA-basal:MDA-activated NNP O
in IN O
10.34% CD N
(p JJ N
> RB N
0.05) CD N
. . N

CONCLUSION NNP N
Both NNP N
agents NNS N
enalapril NN I
and CC I
amlodipine NN I
reduced VBN I
blood NN O
pressure NN O
but CC O
only RB N
amlodipine VB I
reduced VBN N
platelet JJ O
aggregation NN O
and CC O
platelet NN O
production NN O
of IN O
malondialdehyde NN O
indicating VBG O
its PRP$ N
action NN O
on IN O
the DT O
arachidonic JJ O
acid NN O
metabolic JJ O
pathway NN O
. . O

-DOCSTART- -X- N

Comparison NNP N
of IN N
5-aminosalicylic JJ I
acid NN I
(3 NNP N
g) NN N
and CC N
prednisolone NN I
phosphate NN I
sodium NN I
enemas NN I
(30 NNP N
mg) NN N
in IN N
the DT N
treatment NN N
of IN N
distal JJ P
ulcerative JJ P
colitis NN P
. . P

A DT N
prospective JJ N
randomized VBN N
double-blind JJ N
trial NN N
. . P

Twenty-nine JJ P
patients NNS P
with IN P
attacks NNS P
of IN P
distal JJ P
ulcerative JJ P
colitis NN P
were VBD N
treated VBN N
randomly RB N
with IN N
3 CD I
g JJ I
5-aminosalicylic JJ I
acid JJ I
(5-ASA) NN I
or CC I
30 CD I
mg NN I
of IN I
prednisolone NN I
phosphate NN I
sodium NN I
(PP) NNP I
enemas VBZ I
(40 NNP N
ml) NN N
. . N

Endoscopic NNP O
clinical JJ O
and CC O
histologic JJ O
improvement NN O
were VBD N
comparable JJ N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Our PRP$ N
study NN N
showed VBD N
that IN N
topical JJ N
treatment NN N
with IN N
5-ASA JJ I
is VBZ N
as RB N
efficacious JJ N
as IN N
PP NNP I
in IN N
improving VBG N
distal JJ P
ulcerative JJ P
colitis NN P
. . P

-DOCSTART- -X- N

Ultrasound NN I
is VBZ N
at IN N
least JJS N
as RB N
good JJ N
as IN N
magnetic JJ I
resonance NN I
imaging NN I
in IN N
predicting VBG N
tumour JJ N
size NN N
post-neoadjuvant JJ P
chemotherapy NN P
in IN P
breast NN P
cancer NN P
. . P

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
accuracy NN N
of IN N
clinical JJ I
imaging NN I
of IN I
the DT I
primary JJ I
breast NN I
tumour JJ I
post-neoadjuvant JJ I
chemotherapy NN I
(NAC) NN I
related VBN N
to TO N
the DT N
post-neoadjuvant JJ N
histological JJ N
tumour NN N
size NN N
(gold NNP N
standard) NN N
and CC N
whether IN N
this DT N
varies NNS N
with IN N
breast NN P
cancer NN P
subtype NN P
. . P

In IN N
this DT N
study NN N
results NNS N
of IN N
both DT N
magnetic JJ I
resonance NN I
imaging NN I
(MRI) NN I
and CC I
ultrasound JJ I
(US) NN I
were VBD N
reported VBN N
. . N

METHODS NNP N
Patients NNS P
with IN P
invasive JJ P
breast NN P
cancer NN P
were VBD P
enrolled VBN P
in IN P
the DT P
INTENS NNP P
study NN P
between IN P
2006 CD P
and CC P
2009 CD P
. . P

We PRP N
included VBD P
182 CD P
patients NNS P
of IN P
whom WP P
data NNS P
were VBD P
available JJ P
for IN P
post-NAC JJ P
MRI NNP P
(n=155) NNP P
US NNP P
(n=123) NNP P
and CC P
histopathological JJ P
tumour NN P
size NN P
. . P

RESULTS NNP P
MRI NNP I
estimated VBD N
residual JJ N
tumour NN N
size NN N
with IN N
<10-mm JJ N
discordance NN N
in IN N
54% CD N
of IN N
patients NNS N
overestimated VBN N
size NN N
in IN N
28% CD N
and CC N
underestimated JJ N
size NN N
in IN N
18% CD N
of IN N
patients NNS N
. . N

With IN N
US NNP I
this DT I
was VBD N
63% CD N
20% CD N
and CC N
17% CD N
respectively RB N
. . N

The DT N
negative JJ N
predictive JJ N
value NN N
in IN N
hormone JJ N
receptor-positive JJ N
tumours NN N
for IN N
both DT N
MRI NNP I
and CC N
US NNP I
was VBD N
low JJ N
26% CD N
and CC N
33% CD N
respectively RB N
. . N

The DT N
median JJ O
deviation NN O
in IN O
clinical JJ O
tumour NN O
size NN O
as IN O
percentage NN O
of IN N
pathological JJ N
tumour NN N
was VBD N
63% CD N
(P25=26 JJ N
P75=100) NNP N
and CC N
49% CD N
(P25=22 NNS N
P75=100) NNP N
for IN N
MRI NNP I
and CC N
US NNP I
respectively RB I
(P=0.06) VBZ N
. . N

CONCLUSIONS NN N
In IN N
this DT N
study NN N
US NNP I
was VBD N
at IN N
least JJS N
as RB N
good JJ N
as IN N
breast NN I
MRI NNP I
in IN N
providing VBG N
information NN N
on IN N
residual JJ N
tumour NN N
size NN N
post-neoadjuvant JJ I
chemotherapy NN I
. . I

However RB N
both DT N
modalities NNS N
suffered VBD N
from IN N
a DT N
substantial JJ N
percentage NN N
of IN N
over- JJ N
and CC N
underestimation NN N
of IN N
tumour JJ N
size NN N
and CC N
in IN N
addition NN N
both DT N
showed VBD N
a DT N
low JJ N
negative JJ N
predictive JJ N
value NN N
of IN N
pathologic JJ N
complete JJ N
remission NN N
(Gov NNP N
nr: NN N
NCT00314977) NNP N
. . N

-DOCSTART- -X- N

Gemcitabine NNP I
and CC N
split-dose JJ N
paclitaxel NN I
or CC N
docetaxel NN I
in IN P
metastatic JJ P
breast NN P
cancer: NN P
a DT N
randomised JJ N
phase NN N
II NNP N
study NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
activity NN O
and CC N
toxicity NN O
of IN N
split-dose JJ I
paclitaxel NN I
or CC I
docetaxel NN I
in IN I
combination NN I
with IN I
gemcitabine NN I
in IN P
patients NNS P
with IN P
metastatic JJ P
breast NN P
cancer NN P
(MBC) NN P
who WP P
had VBD P
previously RB P
received VBN P
anthracyclines NNS P
. . P

PATIENTS NNS P
AND CC N
METHODS NNP N
A NNP P
total NN P
of IN P
210 CD P
patients NNS P
were VBD I
randomly RB I
assigned VBN I
to TO I
one CD I
of IN I
three CD I
treatment NN I
arms: JJ I
gemcitabine NN I
1 CD I
250 CD I
mg/m(2) NN I
Days VBZ I
1 CD I
and CC I
8 CD I
and CC I
paclitaxel VB I
175 CD I
mg/m(2) NN I
as IN I
a DT I
3-h JJ I
infusion NN I
on IN I
Day NNP I
1 CD I
(GP1); NNP I
gemcitabine NN I
1 CD I
000 CD I
mg/m(2) NN I
Days VBZ I
1 CD I
and CC I
8 CD I
and CC I
paclitaxel VB I
100 CD I
mg/m(2) NN I
as IN I
a DT I
1-h JJ I
infusion NN I
on IN I
Days NNP I
1 CD I
and CC I
8 CD I
(GP2); NNS I
gemcitabine VBP I
1 CD I
000 CD I
mg/m(2) NN I
Days VBZ I
1 CD I
and CC I
8 CD I
and CC I
docetaxel VB I
40 CD I
mg/m(2) NN I
as IN I
a DT I
1-h JJ I
infusion NN I
on IN I
Days NNP I
1 CD I
and CC I
8 CD I
(GD) NN I
. . I

Cycles NNS I
were VBD I
repeated VBN I
every DT I
3 CD I
weeks NNS I
. . I

RESULTS NN N
For IN N
the DT N
204 CD P
patients NNS P
evaluable JJ P
for IN P
response NN P
assessment NN P
the DT P
response NN N
rates NNS N
were VBD N
48.6% CD N
for IN N
GP1 NNP N
52.2% CD N
for IN N
GP2 NNP N
and CC N
52.3% CD N
for IN N
GD NNP N
. . N

Median JJ O
response NN O
duration NN O
time NN O
to TO O
treatment NN O
failure NN O
and CC O
time NN O
to TO O
progression VB O
(TTP) NNP O
were VBD N
similar JJ N
in IN N
each DT N
arm NN N
. . N

Median JJ N
TTP NNP N
for IN N
GP1 NNP N
GP2 NNP N
and CC N
GD NNP N
was VBD N
7.5 CD N
7.0 CD N
and CC N
7.4 CD N
months NNS N
respectively RB N
. . N

For IN N
the DT N
208 CD P
patients NNS P
evaluable JJ P
for IN P
safety NN N
the DT N
most RBS N
common JJ N
grade NN N
3/4 CD N
toxicity NN O
for IN N
each DT N
regimen NN N
was VBD N
neutropaenia VBN O
with IN O
64% CD N
57% CD N
and CC N
68% CD N
for IN N
GP1 NNP N
GP2 NNP N
and CC N
GD NNP N
respectively RB N
. . N

Grade $ N
4 CD N
neutropaenia NN O
grade VBD O
3/4 CD N
anaemia NN O
febrile NN O
neutropaenia NN O
and CC O
diarrhoea NN O
were VBD N
more JJR N
common JJ N
in IN N
the DT N
docetaxel NN N
arm NN N
as IN N
was VBD N
the DT N
use NN N
of IN N
intravenous JJ N
antibiotics NNS N
and CC N
blood NN N
transfusions NNS N
. . N

CONCLUSION NNP N
The DT N
study NN N
confirmed VBD N
the DT N
high JJ N
activity NN N
of IN N
gemcitabine-taxane JJ I
combinations NNS N
in IN N
MBC NNP N
. . N

Split-dose JJ N
paclitaxel NN N
had VBD N
similar JJ N
activity NN N
and CC N
toxicity NN O
to TO N
the DT N
3-weekly JJ N
administration NN N
. . N

The DT N
split-dose JJ N
docetaxel NN I
regimen NNS N
had VBD N
similar JJ N
activity NN N
to TO N
the DT N
paclitaxel NN I
combinations NNS N
though IN N
associated VBN N
with IN N
higher JJR N
toxicity NN O
. . O

-DOCSTART- -X- N

Phase NNP N
II NNP N
trial NN N
of IN N
nab-paclitaxel JJ N
compared VBN N
with IN N
docetaxel NN N
as IN N
first-line JJ N
chemotherapy NN N
in IN N
patients NNS P
with IN P
metastatic JJ P
breast NN P
cancer: NN P
final JJ N
analysis NN N
of IN N
overall JJ N
survival NN N
. . N

BACKGROUND IN N
A NNP N
randomized JJ N
phase NN N
II NNP N
study NN N
in IN N
first-line JJ N
MBC NNP N
demonstrated VBD N
superior JJ N
efficacy NN N
and CC N
safety NN N
of IN N
weekly JJ N
nab-paclitaxel NNS N
compared VBN N
with IN N
docetaxel NN N
. . N

Final NNP N
survival NN N
analyses NNS N
and CC N
updated JJ N
safety NN N
results NNS N
are VBP N
reported VBN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Three NNP P
hundred VBD P
two CD P
patients NNS P
with IN P
no DT P
previous JJ P
chemotherapy NN P
for IN P
MBC NNP P
were VBD N
randomized VBN N
to TO N
receive VB N
nab-paclitaxel JJ N
300 CD N
mg/m(2) JJ N
q3w JJ N
nab-paclitaxel JJ N
100 CD N
mg/m(2) NN N
or CC N
150 CD N
mg/m(2) NN N
the DT N
first JJ N
3 CD N
of IN N
4 CD N
weeks NNS N
(qw RB N
3/4) CD N
or CC N
docetaxel VB N
100 CD N
mg/m(2) NN N
q3w NN N
. . N

The DT N
trial NN N
was VBD N
powered VBN N
for IN N
analyses NNS N
of IN N
antitumor NN N
activity NN N
and CC N
safety NN N
. . N

RESULTS NNP N
Treatment NNP N
with IN N
nab-paclitaxel JJ N
150 CD N
mg/m(2) NN N
qw NN N
3/4 CD N
resulted VBD N
in IN N
a DT N
median JJ N
overall JJ N
survival NN O
(OS) NN N
of IN N
33.8 CD N
months NNS N
compared VBN N
with IN N
22.2 CD N
27.7 CD N
and CC N
26.6 CD N
months NNS N
for IN N
nab-paclitaxel JJ N
100 CD N
mg/m(2) NN N
qw NN N
3/4 CD N
nab-paclitaxel JJ N
300 CD N
mg/m(2) NN N
q3w NN N
and CC N
docetaxel NN N
respectively RB N
(overall JJ N
P NNP N
= NNP N
.047) NNP N
. . N

Patients NNS N
receiving VBG N
150 CD N
mg/m(2)nab-paclitaxel JJ N
had VBD N
prolonged VBN N
median JJ N
OS NNP O
compared VBN N
with IN N
those DT N
in IN N
the DT N
100 CD N
mg/m(2)nab-paclitaxel JJ N
arm NN N
(hazard NNP N
ratio NN N
0.575; CD N
P NNP N
= NNP N
.008) NNP N
. . N

A DT N
trend NN N
toward IN N
a DT N
longer JJR N
OS NNP N
was VBD N
noted VBN N
in IN N
the DT N
150 CD N
mg/m(2)nab-paclitaxel JJ N
arm NN N
versus NN N
docetaxel NN N
arm NN N
(hazard NNP N
ratio NN N
0.688) CD N
. . N

Grade VB O
3 CD O
or CC O
4 CD O
fatigue NN O
neutropenia NN O
and CC O
febrile JJ O
neutropenia NN O
were VBD N
less JJR N
frequent JJ N
in IN N
all DT N
nab-paclitaxel JJ N
arms NNS N
compared VBN N
with IN N
docetaxel NN N
. . N

CONCLUSIONS NNP N
Consistent NNP N
with IN N
previously RB N
published VBN N
efficacy NN N
results NNS N
these DT N
data NNS N
suggest VBP N
that IN N
150 CD N
mg/m(2) NNS N
qw RB N
3/4 CD N
may MD N
represent VB N
the DT N
most RBS N
clinically RB N
efficacious JJ N
nab-paclitaxel JJ N
dosing VBG N
regimen NNS N
for IN N
patients NNS P
with IN P
no DT P
previous JJ P
chemotherapy NN P
for IN P
MBC NNP P
. . P

A DT N
phase NN N
III NNP N
trial NN N
confirming VBG N
these DT N
results NNS N
would MD N
be VB N
necessary JJ N
and CC N
prudent JJ N
before RB N
widespread JJ N
adoption NN N
of IN N
the DT N
150 CD N
mg/m(2) NN N
dose NN N
in IN N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- N

Comparison NNP N
between IN N
the DT N
central JJ N
effects NNS N
of IN N
camazepam NN I
and CC I
temazepam NN I
. . I

Computerized JJ N
analysis NN N
of IN N
sleep JJ N
recordings NNS N
. . N

The DT N
effects NNS N
of IN N
acute JJ I
administration NN I
per IN I
os NN I
of IN I
30 CD I
mg NNS I
camazepam NN I
and CC I
the DT I
same JJ I
dose NN I
of IN I
temazepam NN I
were VBD I
compared VBN N
with IN N
placebo NN I
in IN P
8 CD P
young JJ P
male NN P
volunteers NNS P
fully RB P
adapted VBN P
to TO P
the DT P
laboratory NN P
environment NN P
by IN P
6 CD P
nights NNS P
of IN P
adaptation NN P
. . P

The DT N
study NN N
was VBD N
double-blind RB N
in IN N
a DT N
random JJ N
order NN N
10 CD N
days NNS N
separating VBG N
each DT N
session NN N
. . N

Spectral JJ N
analysis NN N
was VBD N
performed VBN N
on IN N
the DT N
all-night JJ N
records NNS N
(1-min JJ N
epochs) NN N
and CC N
the DT N
relative JJ N
power NN N
of IN N
six CD N
frequency NN N
bands NNS N
calculated VBN N
. . N

Concerning VBG N
sleep JJ O
parameters NNS O
temazepam VBP O
induces VBZ N
a DT N
statistically RB N
significant JJ N
reduction NN N
of: IN N
phase NN N
shifts; JJ N
number NN N
of IN N
awakenings; JJ N
percent JJ N
duration NN N
of IN N
sleep JJ N
stages NNS N
I PRP N
and CC N
IV NNP N
. . N

A DT N
significant JJ N
increase NN N
of IN N
the DT N
percent NN O
duration NN O
of IN O
stage NN O
II NNP O
and CC O
sleep JJ O
efficiency NN O
was VBD N
also RB N
found VBN N
. . N

Camazepam NN I
shows VBZ N
modification NN N
with IN N
the DT N
same JJ N
trend NN N
but CC N
not RB N
reaching VBG N
statistical JJ N
significance NN N
. . N

Concerning VBG N
spectral JJ N
analysis NN N
temazepam NN I
induces VBZ N
a DT N
light JJ N
increase NN N
of IN N
the DT N
relative JJ N
power NN N
of IN N
the DT N
slowest JJS N
frequencies NNS N
paralleled VBN N
by IN N
an DT N
increase NN N
of IN N
the DT N
fast JJ N
bands NNS N
while IN N
major JJ N
effects NNS N
are VBP N
found VBN N
on IN N
the DT N
characteristic JJ N
periodicity NN N
of IN N
delta NN N
activities NNS N
which WDT N
appear VBP N
disrupted VBN N
by IN N
the DT N
drug NN N
. . N

These DT N
effects NNS N
are VBP N
not RB N
evident JJ N
with IN N
camazepam NN I
which WDT I
does VBZ N
not RB N
seem VB N
to TO N
distort VB N
the DT N
normal JJ N
sleep JJ N
pattern NN N
. . N

-DOCSTART- -X- N

Effect NN N
of IN N
adhesive JJ N
system NN N
type NN N
and CC N
tooth DT N
region NN N
on IN N
the DT N
bond NN N
strength NN N
to TO N
dentin VB N
. . N

PURPOSE NN N
This DT N
study NN N
evaluated VBD N
the DT N
bond NN N
strength NN N
of IN N
two CD I
etch-and-rinse JJ I
adhesive JJ I
systems NNS I
(two- JJ I
and CC I
three-step) JJ I
and CC I
a DT I
self-etching JJ I
system NN I
to TO N
coronal VB N
and CC N
root VB N
canal JJ N
dentin NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
The DT N
root NN P
canals NNS P
of IN P
30 CD P
human JJ P
incisors NNS P
and CC P
canines NNS P
were VBD P
instrumented VBN N
and CC P
prepared VBN P
with IN P
burs NNS P
. . P

The DT I
posts NNS I
used VBD I
for IN I
luting VBG I
were VBD I
duplicated VBN I
with IN I
dual JJ I
resin NN I
cement NN I
(Duo-link) JJ I
inside IN I
Aestheti NNP I
Plus NNP I
#2 NNP I
molds NNS I
. . I

Thus RB N
three CD P
groups NNS P
were VBD P
formed VBN P
(n JJ I
= NN I
10) CD I
according VBG I
to TO I
the DT I
adhesive JJ I
system NN I
employed: VBD I
All-Bond NNP I
2 CD I
(TE3) NNP I
+ NNP I
resin NN I
cement NN I
post NN I
(rcp) NNP I
+ NNP I
Duo-link NNP I
(Dl); NNP I
One-Step NNP I
Plus NNP I
(TE2) NNP I
+ NNP I
rcp NN I
+ NNP I
Dl; NNP I
Tyrian/One-Step NNP I
Plus NNP I
(SE) NNP I
+ NNP I
rcp NN I
+ NNP I
Dl NNP I
. . I

Afterwards NNS I
8 CD I
transverse JJ I
sections NNS I
(1.5 VBP I
mm) NNS I
were VBD I
cut VBN I
from IN I
4 CD I
mm NNS I
above IN I
the DT I
CEJ NNP I
up RB I
to TO I
4 CD I
mm NNS I
short JJ I
of IN I
the DT I
root NN I
canal JJ I
apex NN I
comprising VBG I
coronal JJ I
and CC I
root JJ I
canal JJ I
dentin NN I
. . I

The DT I
sections NNS I
were VBD I
submitted VBN I
to TO I
push-out JJ I
testing NN I
in IN I
a DT I
universal JJ I
testing VBG I
machine NN I
EMIC NNP I
(1 NNP I
mm/min) NN I
. . N

Bond NN O
strength NN O
data NNS O
were VBD N
analyzed VBN N
with IN N
two-way JJ N
repeated JJ N
measures NNS N
ANOVA NNP O
and CC O
Tukey's NNP O
test NN O
(p NN N
< VBD N
0.05) CD N
. . N

RESULTS VB N
The DT N
relationship NN N
between IN N
the DT N
adhesives NNS N
was VBD N
not RB N
the DT N
same JJ N
in IN N
the DT N
different JJ N
regions NNS N
(p VBP N
< JJ N
0.05) CD N
. . N

Comparison NNP N
of IN N
the DT N
means NNS N
achieved VBN N
with IN N
the DT N
adhesives NNS N
in IN N
each DT N
region NN N
(Tukey; FW N
p NN N
< $ N
0.05) CD N
revealed VBD N
that IN N
TE3 NNP N
(mean NNP N
+/- JJ N
standard NN N
deviation: VBZ N
5.22 CD N
+/- JJ N
1.70) CD N
was VBD N
higher JJR N
than IN N
TE2 NNP N
(2.60 NNP N
+/- JJ N
1.74) CD N
and CC N
SE NNP N
(1.68 NNP N
+/- JJ N
1.85) CD N
. . N

CONCLUSION NNP N
Under IN N
the DT N
experimental JJ N
conditions NNS N
better RBR N
bonding VBG N
to TO N
dentin VB N
was VBD N
achieved VBN N
using VBG N
the DT N
three-step JJ N
etch-and-rinse JJ N
system NN N
especially RB N
in IN N
the DT N
coronal JJ N
region NN N
. . N

Therefore IN N
the DT N
traditional JJ N
etch-and-rinse JJ N
three-step NN N
adhesive JJ N
system NN N
seems VBZ N
to TO N
be VB N
the DT N
best JJS N
choice NN N
for IN N
teeth NN N
needing VBG N
adhesive JJ N
endodontic JJ P
restorations NNS P
. . P

-DOCSTART- -X- N

Sun NNP I
protection NN I
counseling VBG I
for IN I
children: NN I
primary NN N
care NN N
practice NN N
patterns NNS N
and CC N
effect NN N
of IN N
an DT N
intervention NN N
on IN N
clinicians NNS P
. . P

OBJECTIVES NNP N
To TO N
describe VB N
current JJ I
primary JJ I
care NN I
sun NN I
protection NN I
advice NN I
for IN N
children NNS N
and CC N
assess VB N
the DT N
effect NN N
on IN N
clinicians NNS N
of IN N
an DT N
intervention NN N
to TO N
enhance VB N
their PRP$ N
sun NN I
protection NN I
advocacy NN I
. . I

SETTING NN N
Primary NNP P
care NN P
practices NNS P
caring VBG P
for IN P
children NNS P
in IN P
New NNP P
Hampshire NNP P
with IN P
special JJ P
attention NN P
to TO P
clinicians NNS P
serving VBG P
10 CD P
towns NNS P
that WDT P
were VBD P
involved VBN P
in IN P
a DT P
randomized NN P
controlled VBN P
trial NN P
of IN P
the DT P
multicomponent NN P
SunSafe NNP P
intervention NN P
involving VBG P
schools NNS P
recreation NN P
areas NNS P
and CC P
primary JJ P
care NN P
practices NNS P
. . P

DESIGN/INTERVENTION NNP P
A NNP P
statewide JJ P
survey NN P
of IN P
all DT P
primary JJ P
care NN P
clinicians NNS P
serving VBG P
children NNS P
addressed VBD N
their PRP$ N
self-reported JJ N
sun NN I
protection NN I
advocacy NN I
practices NNS I
. . I

Clinicians NNS N
in IN P
10 CD P
systematically RB P
selected VBN P
rural JJ P
towns NNS P
were VBD N
involved VBN N
in IN N
the DT N
subsequent JJ N
intervention NN N
study NN N
. . N

The DT I
primary JJ I
care NN I
intervention NN I
provided VBD I
assistance NN I
to TO I
practices NNS I
in IN I
establishing VBG I
an DT I
office NN I
system NN I
that WDT I
promoted VBD I
sun JJ I
protection NN I
advice NN I
to TO I
children NNS I
and CC I
their PRP$ I
parents NNS I
during IN I
office NN I
visits NNS I
. . I

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Sun NNP I
protection NN I
promotion NN I
activities NNS I
of IN N
primary JJ N
care NN N
clinicians NNS N
as IN N
determined VBN N
by IN N
their PRP$ N
self JJ N
report NN N
research NN N
assistant JJ N
observation NN N
and CC N
parent NN N
interviews NNS N
. . N

RESULTS NNP N
Of IN N
261 CD P
eligible JJ P
clinicians NNS P
responding VBG P
to TO P
the DT P
statewide NN P
survey NN P
about IN P
half JJ N
provide VBP N
sun JJ I
protection NN I
counseling VBG I
"most NN N
of IN N
the DT N
time" NN N
or CC N
"almost VB N
always" NN N
during IN N
summer NN N
well RB N
care VB N
visits NNS N
. . N

Pediatricians NNS N
do VBP N
so RB N
more RBR N
often RB N
than IN N
family NN N
physicians NNS N
. . N

Clinicians NNS N
involved VBN N
in IN N
the DT N
intervention NN I
increased VBD N
their PRP$ N
use NN O
of IN O
handouts NNS O
waiting VBG O
room NN O
educational JJ O
materials NNS O
and CC O
sunscreen JJ O
samples NNS O
. . O

Compared VBN N
with IN N
control NN N
town NN N
parents NNS N
parents NNS N
in IN N
intervention NN I
towns NNS N
reported VBD N
an DT N
increase NN N
in IN N
clinician JJ O
sun NN O
protection NN O
advice NN O
. . O

CONCLUSIONS NNP N
The DT N
SunSafe NNP I
primary JJ I
care NN I
intervention NN I
increased VBD N
sun JJ O
protection NN O
counseling VBG O
activities NNS O
of IN P
participating VBG P
clinicians NNS P
. . P

A DT I
single-focus JJ I
preventive JJ I
service NN I
office NN I
system NN I
is VBZ N
feasible JJ N
to TO N
include VB N
in IN N
community NN I
interventions NNS I
to TO N
promote VB N
sun NN N
protection NN N
. . N

-DOCSTART- -X- N

Effect NN N
of IN N
glycemic JJ I
load NN I
on IN N
eating VBG O
behavior JJ O
self-efficacy NN O
during IN N
weight JJ N
loss NN N
. . N

High JJ N
eating VBG N
behavior JJ N
self-efficacy NN N
may MD N
contribute VB N
to TO N
successful JJ N
weight JJ N
loss NN N
. . N

Diet JJ I
interventions NNS I
that WDT N
maximize VBP N
eating VBG N
behavior JJ N
self-efficacy NN N
may MD N
therefore VB N
improve VB N
weight NN N
loss NN N
outcomes NNS N
. . N

However RB N
data NNS N
on IN N
the DT N
effect NN N
of IN N
diet JJ N
composition NN N
on IN N
eating VBG N
behavior JJ N
self-efficacy NN N
are VBP N
sparse NN N
. . N

To TO N
determine VB N
the DT N
effects NNS N
of IN N
dietary JJ N
glycemic JJ N
load NN N
(GL) NN N
on IN N
eating VBG N
behavior JJ N
self-efficacy NN N
during IN N
weight JJ N
loss NN N
body NN O
weight NN O
and CC O
eating VBG O
behavior JJ O
self-efficacy NN O
were VBD N
measured VBN N
every DT N
six CD N
months NNS N
in IN N
overweight JJ P
adults NNS P
participating VBG P
in IN P
a DT P
12-mo JJ P
randomized JJ P
trial NN P
testing VBG P
energy-restricted JJ P
diets NNS P
differing VBG P
in IN P
GL NNP P
. . P

All DT N
food NN N
was VBD N
provided VBN N
during IN N
the DT N
first JJ N
six CD N
months NNS N
and CC N
self-selected JJ N
thereafter NN N
. . N

Total JJ N
mean JJ O
weight NN O
loss NN O
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
and CC N
GL-level NNP N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
eating VBG O
behavior JJ O
self-efficacy NN O
. . O

In IN N
the DT N
combined JJ N
cohort NN N
individuals NNS N
losing VBG N
the DT N
most RBS N
weight JJ N
reported VBD N
improvements NNS N
in IN N
eating VBG O
behavior JJ O
self-efficacy JJ O
whereas NNS O
those DT N
achieving VBG N
less JJR N
weight JJ O
loss NN O
reported VBD N
decrements NNS N
in IN N
eating VBG O
behavior JJ O
self-efficacy NN O
. . O

Decrements NNS N
in IN N
eating VBG O
behavior JJ O
self-efficacy NN O
were VBD N
associated VBN N
with IN N
subsequent JJ N
weight NN N
regain NN N
when WRB N
diets NNS N
were VBD N
self-selected JJ N
. . N

While IN N
GL NNP N
does VBZ N
not RB N
appear VB N
to TO N
influence VB N
eating VBG N
behavior JJ N
self-efficacy JJ N
lesser NN N
amounts NNS N
of IN N
weight JJ N
loss NN N
on IN N
provided-food JJ I
energy NN I
restricted VBN I
diets NNS I
may MD N
deter VB N
successful JJ N
maintenance NN N
of IN N
weight JJ N
loss NN N
by IN N
attenuating VBG N
improvements NNS N
in IN N
eating VBG N
behavior JJ N
self-efficacy NN N
. . N

-DOCSTART- -X- N

Effects NNS N
of IN N
two CD N
different JJ N
short-term JJ I
training NN I
programs NNS I
on IN N
the DT N
physical JJ N
and CC N
technical JJ N
abilities NNS N
of IN N
adolescent JJ P
basketball NN P
players NNS P
. . P

This DT P
study NN I
evaluated VBD I
and CC I
compared VBN I
the DT I
effectiveness NN I
of IN I
two CD I
different JJ I
off-season JJ I
short-term JJ I
basketball NN I
training NN I
programs NNS I
on IN I
physical JJ I
and CC I
technical JJ I
abilities NNS I
of IN I
young JJ P
basketball NN P
players NNS P
. . P

Twenty-seven JJ P
adolescent NN P
basketball NN P
players NNS P
(14.7+/-0.5 JJ P
years; NN P
Tanner NNP P
stage: VBD P
3.5+/-0.5) CD P
were VBD P
randomly RB P
divided VBN P
into IN P
a DT P
specialized JJ P
basketball NN P
training NN I
group NN I
(SP NNP I
n=10) VBZ I
a DT I
mixed JJ I
basketball NN I
plus CC I
conditioning VBG I
training VBG I
group NN I
(MX NNP I
n=10) NN I
and CC I
a DT I
control NN I
group NN I
(n=7) NNP I
. . I

Training NN I
included VBD I
five CD I
sessions NNS I
per IN I
week NN I
(100-120 JJ I
min NN I
each) NN I
and CC I
was VBD I
performed VBN I
for IN I
4 CD I
weeks NNS I
. . I

Maximal NNP O
oxygen NN O
uptake NN O
was VBD N
similarly RB N
improved VBN N
after IN N
SP NNP N
(4.9+/-1.8%) JJ N
and CC N
MX NNP N
(4.9+/-1.4%) NN N
but CC N
there EX N
was VBD N
no DT N
effect NN N
on IN N
ventilatory NN O
threshold NN O
. . O

Peak NNP O
and CC O
mean JJ O
power NN O
output NN O
measured VBD N
during IN N
the DT N
Wingate NNP N
test NN N
were VBD N
also RB N
improved VBN N
by IN N
a DT N
similar JJ N
magnitude NN N
after IN N
SP NNP N
(21+/-5%) JJ N
and CC N
MX NNP N
(15+/-6%) NNP N
. . N

Trunk NNP O
muscle NN O
endurance NN O
was VBD N
equally RB N
increased JJ N
(SP: JJ N
23+/-4% JJ N
MX: NNP N
25+/-5%) CD N
but CC N
arms NNS O
endurance NN O
was VBD N
improved VBN N
significantly RB N
more RBR N
after IN N
MX NNP N
(50+/-11%) JJ N
compared VBN N
to TO N
SP NNP N
(11+/-14% JJ N
p<0.05) NN N
. . N

Performance NN O
in IN O
four CD O
basketball NN O
technical JJ O
skills NNS O
was VBD N
similarly RB N
increased VBN N
(by JJ N
17-27%) JJ N
in IN N
both DT N
groups NNS N
with IN N
a DT N
tendency NN N
for IN N
greater JJR N
improvement NN N
of IN N
the DT N
SP NNP N
groups NNS N
in IN N
the DT N
technical JJ N
skills NNS N
of IN N
shooting NN N
and CC N
passing NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
a DT N
SP NNP I
basketball NN I
training NN I
program NN I
performed VBN I
exclusively RB N
on-court NN N
was VBD N
as RB N
effective JJ N
as IN N
a DT N
MX NNP I
training NN I
program NN I
in IN N
terms NNS N
of IN N
aerobic NN O
and CC O
anaerobic JJ O
fitness NN O
improvement NN O
. . O

Furthermore RB N
the DT N
decrease NN N
of IN N
the DT N
total JJ N
on-court JJ N
training NN N
time NN N
in IN N
the DT N
MX NNP I
group NN I
resulted VBD N
in IN N
a DT N
tendency NN N
for IN N
a DT N
smaller JJR N
improvement NN N
of IN N
basketball NN N
technical JJ N
skills NNS N
. . N

In IN N
conclusion NN N
both DT N
SP NNP I
and CC I
MX NNP I
training NN I
are VBP N
equally RB N
effective JJ N
in IN N
order NN N
to TO N
limit VB N
and/or JJ N
reverse VB N
the DT N
detraining NN O
effects NNS O
that WDT N
occur VBP N
during IN N
the DT N
off-season NN N
in IN N
basketball NN N
. . N

-DOCSTART- -X- N

Prospective NNP N
controlled VBD N
study NN N
of IN N
androgen NN I
therapy NN I
in IN N
the DT N
anemia NN P
of IN P
chronic JJ P
renal JJ P
disease: NN P
effects NNS N
on IN N
iron NN N
kinetics NNS N
. . N

Ferrokinetic JJ O
and CC O
RBC NNP O
mass NN O
determinations NNS O
were VBD N
made VBN N
at IN N
3-month JJ N
intervals NNS N
in IN N
iron-replete JJ P
hemodialysis NN P
patients NNS P
randomized VBN N
to TO N
a DT N
control NN I
group NN I
or CC I
to TO I
nandrolone CD I
decanoate NN I
therapy NN I
. . I

After IN N
3 CD N
months NNS N
RBC NNP O
mass NN O
increased VBD N
in IN N
two CD N
of IN N
4 CD P
androgen-treated JJ P
patients NNS P
. . P

Erythron NNP O
iron NN O
turnover NN O
an DT O
index NN N
of IN N
RBC NNP N
production NN N
increased VBD N
in IN N
the DT N
one CD N
responder NN N
studied VBD N
but CC N
not RB N
in IN N
the DT N
two CD N
nonresponders NNS N
. . N

Similarly RB N
in IN N
a DT N
fifth JJ N
subject NN N
who WP N
was VBD N
not RB N
restudied VBN N
until IN N
6 CD N
months NNS N
of IN N
androgen NN I
therapy NN I
were VBD N
completed VBN N
an DT N
increase NN N
in IN N
RBC NNP O
mass NN O
was VBD N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
erythron NNP N
iron NN N
turnover NN N
. . N

However RB N
between IN N
3 CD N
and CC N
6 CD N
months NNS N
RBC NNP O
mass NN O
increased VBD N
in IN N
all DT N
4 CD P
androgen-treated JJ P
patients NNS P
studied VBD N
even RB N
though IN N
erythron NN N
iron NN N
turnovers NNS N
remained VBD N
unchanged JJ N
and CC N
dialysis-associated JJ O
blood NN O
losses NNS O
did VBD N
not RB N
decrease VB N
. . N

Thus RB N
at IN N
least JJS N
two CD N
androgen-treated JJ I
patients NNS N
had VBD N
increases NNS N
in IN N
RBC NNP O
mass NN O
without IN N
ever RB N
increasing VBG N
their PRP$ N
erythron NN O
iron NN O
turnover NN O
. . O

Two CD N
of IN N
three CD N
control NN N
subjects NNS N
also RB N
had VBD N
increased VBN N
erythron RB O
iron NN O
turnovers NNS O
which WDT O
in IN N
one CD N
case NN N
was VBD N
related VBN N
to TO N
increased VBN N
dialysis-associated JJ O
blood NN O
losses NNS O
. . O

Changes NNS N
in IN N
RBC NNP O
mass NN O
were VBD N
not RB N
consistently RB N
paralleled VBN N
by IN N
changes NNS N
in IN N
Hb NNP N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
increases NNS N
in IN N
RBC NNP O
mass NN O
during IN N
nandrolone JJ N
decanoate NN N
therapy NN N
result NN N
from IN N
two CD N
mechanisms: NNS N
increased VBD N
erythropoiesis NN N
(shown VBN N
by IN N
simultaneous JJ N
increases NNS N
in IN N
RBC NNP O
mass NN O
and CC N
erythron NN O
iron NN O
turnover) NN O
and CC N
increased VBD N
RBC NNP O
survival NN O
(indirectly RB N
shown VBN N
by IN N
increases NNS N
in IN N
RBC NNP O
mass NN O
without IN N
increases NNS N
in IN N
erythron NN O
iron NN O
turnover) NN O
. . N

The DT N
importance NN N
of IN N
control NN N
groups NNS N
RBC NNP O
mass NN O
determinations NNS N
and CC N
the DT N
monitoring NN N
of IN N
dialysis-associated JJ O
blood NN O
losses NNS O
in IN N
studying VBG N
the DT N
effects NNS N
of IN N
androgens NNS N
on IN N
erythropoiesis NN N
in IN N
chronic JJ P
hemodialysis NN P
patients NNS P
is VBZ N
also RB N
demonstrated VBN N
. . N

-DOCSTART- -X- N

Effect NN N
of IN N
negative JJ N
air NN N
ionization NN N
on IN N
hyperactive JJ P
and CC P
autistic JJ P
children NNS P
. . P

Twenty-one CD P
attention NN P
deficit NN P
disorder NN P
with IN P
hyperactivity NN P
and CC P
seven CD P
autistic JJ P
children NNS P
were VBD N
randomly RB N
exposed VBN N
to TO N
negatively RB N
ionized JJ N
and CC N
ambient JJ N
atmospheres NNS N
under IN N
rigorously RB N
controlled VBN N
experimental JJ N
conditions NNS N
. . N

The DT N
negatively RB N
ionized JJ N
condition NN N
did VBD N
not RB N
significantly RB N
affect JJ N
measurements NNS N
of IN N
activity NN O
level NN O
impulsivity NN O
reality NN O
orientation NN O
destructive/constructiveness NN O
attention NN O
or CC O
task NN O
performance NN O
. . O

Significant JJ N
results NNS N
might MD N
be VB N
obtained VBN N
if IN N
subgroups NNS N
of IN N
known JJ N
hyperserotoninemic JJ N
autistic NN P
and CC P
attention NN P
deficit NN P
disorder NN P
children NNS P
were VBD N
exposed VBN N
to TO N
negatively RB N
ionized JJ N
conditions NNS N
. . N

-DOCSTART- -X- N

The DT N
effect NN N
of IN N
magnesium NN I
added VBN I
to TO I
levobupivacaine VB I
for IN N
femoral JJ N
nerve NN N
block NN N
on IN N
postoperative JJ N
analgesia NN N
in IN N
patients NNS P
undergoing VBG P
ACL NNP P
reconstruction NN P
. . P

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
randomised VBD N
double-blind NN N
study NN N
is VBZ N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
magnesium NN I
added VBN I
to TO I
local JJ I
anaesthetics NNS I
on IN N
postoperative JJ N
VAS NNP N
scores NNS N
total JJ N
opioid JJ I
consumption NN N
time NN N
to TO N
first JJ N
mobilisation NN N
patient NN N
satisfaction NN N
and CC N
rescue NN N
analgesic JJ N
requirements NNS N
in IN N
arthroscopic JJ N
ACL NNP N
reconstruction NN N
surgery NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
107 CD P
American JJ P
Society NNP P
of IN P
Anaesthesiologists NNP P
physical JJ P
status NN P
grade NN P
I PRP P
and CC P
II NNP P
patients NNS P
between IN P
18 CD P
and CC P
65 CD P
years NNS P
of IN P
age NN P
who WP P
were VBD P
scheduled VBN P
to TO P
undergo VB P
elective JJ P
anterior JJ P
crucial JJ P
ligament NN P
(ACL) NNP P
reconstruction NN P
with IN P
hamstring VBG P
autografts NNS P
were VBD P
enrolled VBN P
in IN P
the DT P
study NN P
. . P

The DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
Groups NNP N
L NNP N
(n NNP N
= NNP N
51) CD N
and CC N
LM NNP N
(n NNP N
= VBD N
56) CD N
using VBG N
the DT N
closed-envelope NN N
method NN N
. . N

Group NNP N
LM NNP N
was VBD N
administered VBN N
19 CD I
ml NN I
of IN I
0.25% CD I
levobupivacaine NN I
and CC I
1 CD I
ml NN I
of IN I
15% CD I
magnesium NN I
sulphate NN I
while IN I
Group NNP I
L NNP I
was VBD I
administered VBN I
20 CD I
ml NN I
of IN I
0.25% CD I
levobupivacaine NN I
for IN I
femoral JJ I
blockade NN I
. . I

General NNP I
anaesthesia NN I
was VBD N
administered VBN N
using VBG N
laryngeal JJ N
airway RB N
masks NNS N
following VBG N
neural JJ N
blockade NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
patients NNS N
were VBD N
evaluated VBN N
for IN N
heart NN O
rate NN O
and CC N
mean VB O
arterial JJ O
pressure NN O
oxygen NN O
saturation NN O
visual JJ O
analogue NN O
score NN O
(VAS) NNP O
verbal NN O
rating NN O
scale NN O
(VRS) NNP O
rescue NN O
analgesic NN O
requirements NNS O
total JJ O
opioid JJ O
consumption NN O
side NN O
effects NNS N
and CC N
time NN N
to TO N
first JJ N
mobilisation NN N
at IN N
the DT N
1st CD N
2nd CD N
4th CD N
6th CD N
12th CD N
and CC N
24th CD N
hours NNS N
postoperatively RB N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
demographic JJ O
data NNS O
mean VBP O
arterial JJ O
pressure NN O
heart NN O
rate NN O
or CC N
oxygen NN O
saturation NN O
between IN N
groups NNS N
. . N

The DT N
area NN O
under IN O
the DT O
curve NN O
VAS NNP O
and CC O
VRS NNP O
scores NNS O
were VBD N
lower JJR N
at IN N
4 CD N
6 CD N
12 CD N
and CC N
24 CD N
h NN N
in IN N
Group NNP N
LM NNP N
(p NNP N
= VBD N
0.001 CD N
p NN N
= VBD N
0.016 CD N
respectively) NN N
. . N

The DT N
rescue NN O
analgesic JJ O
requirement NN O
and CC O
the DT O
total JJ O
opioid JJ O
consumption NN O
were VBD N
significantly RB N
lower JJR N
in IN N
Group NNP N
LM NNP N
(p NNP N
= VBD N
0.015 CD N
p NN N
= VBD N
0.019 CD N
respectively) NN N
. . N

The DT N
time NN O
to TO O
first JJ O
mobilisation NN O
and CC O
the DT O
Likert NNP O
score NN O
(completely RB N
comfortable; JJ N
quite RB N
comfortable; JJ N
slight JJ N
discomfort; NN N
painful; NN N
very RB N
painful) RB N
were VBD N
higher JJR N
and CC N
the DT N
block NN O
onset VBD O
time NN O
was VBD N
lower JJR N
in IN N
Group NNP N
LM NNP N
(p NNP N
= NNP N
0.014 CD N
and CC N
p VB N
= JJ N
0.012 CD N
respectively) NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
terms NNS N
of IN N
side NN N
effects NNS N
. . N

CONCLUSIONS NNP N
The DT N
addition NN N
of IN N
magnesium NN I
to TO N
levobupivacaine VB I
prolongs NNS N
the DT N
sensory NN N
and CC N
motor NN N
block NN N
duration NN N
without IN N
increasing VBG N
side NN N
effects NNS N
enhances VBZ N
the DT N
quality NN N
of IN N
postoperative JJ N
analgesia NN N
and CC N
increases VBZ N
patient JJ N
satisfaction; NN N
however RB N
the DT N
addition NN N
of IN N
magnesium NN I
delays VBZ N
the DT N
time NN N
to TO N
first JJ N
mobilisation NN N
and CC N
decreases VBZ N
rescue NN N
analgesic JJ N
requirements NNS N
. . N

-DOCSTART- -X- N

Cross-modal JJ I
attention-switching NN I
is VBZ I
impaired VBN I
in IN I
autism NN P
spectrum NN P
disorders NNS P
. . P

This DT I
investigation NN I
aimed VBN I
to TO I
determine VB I
if IN I
children NNS P
with IN P
ASD NNP P
are VBP I
impaired VBN I
in IN I
their PRP$ I
ability NN I
to TO I
switch VB O
attention NN O
between IN I
different JJ I
tasks NNS I
and CC I
whether IN I
performance NN I
is VBZ I
further RB I
impaired JJ I
when WRB I
required VBN I
to TO I
switch VB I
across IN I
two CD I
separate JJ I
modalities NNS I
(visual JJ I
and CC I
auditory) NN I
. . I

Eighteen JJ P
children NNS P
with IN P
ASD NNP P
(9-13 CD P
years NNS P
old) MD P
were VBD P
compared VBN P
with IN P
18 CD P
typically-developing JJ P
children NNS P
matched VBN P
with IN P
the DT P
ASD NNP P
group NN P
for IN P
mental JJ P
age NN P
and CC P
also RB P
with IN P
18 CD P
subjects NNS P
with IN P
learning VBG P
difficulties NNS P
matched VBN P
with IN P
the DT P
ASD NNP P
group NN P
for IN P
mental JJ P
and CC P
chronological JJ P
age NN P
. . P

Individuals NNS I
alternated VBN I
between IN I
two CD I
different JJ I
visual JJ I
tasks NNS I
and CC I
between IN I
a DT I
different JJ I
visual JJ I
task NN I
and CC I
an DT I
auditory JJ I
task NN I
. . I

Children NNP P
with IN P
ASD NNP P
performed VBD I
worse JJR I
than IN I
both DT I
comparison JJ I
groups NNS I
at IN I
both DT I
switching VBG O
tasks NNS O
. . O

Moreover RB I
children NNS P
with IN P
ASD NNP P
had VBD I
greater JJR I
difficulty NN I
when WRB I
different JJ I
modalities NNS I
were VBD I
required VBN I
than IN I
where WRB I
only RB I
one CD I
modality NN I
was VBD I
required VBN I
in IN I
the DT I
switching NN O
task NN O
in IN I
comparison NN I
with IN I
participants NNS I
matched VBN I
in IN I
terms NNS I
of IN I
mental NN I
and CC I
chronological JJ I
age NN I
. . I

-DOCSTART- -X- N

A DT N
prospective JJ N
randomized VBN N
comparative JJ N
trial NN N
of IN N
a DT N
COX-2 NNP I
selective JJ I
nonsteroidal JJ I
anti-inflammatory JJ I
drug NN I
versus NN I
placebo NN I
in IN N
inguinal JJ P
herniorrhaphy NN P
patients NNS P
. . P

OBJECTIVE IN N
The DT I
standard JJ I
opioid NN I
treatment NN I
for IN N
postoperative JJ N
pain NN N
can MD N
be VB N
associated VBN N
with IN N
nausea NN N
vomiting NN N
and CC N
constipation NN N
. . N

In IN N
addition NN N
opioids NNS I
often RB N
provide VBP N
insufficient JJ N
pain NN N
relief NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
postoperative JJ N
pain NN N
and CC N
functional JJ N
outcomes NNS N
in IN N
patients NNS P
undergoing JJ P
inguinal JJ P
herniorrhaphy NN P
who WP P
receive VBP P
a DT P
COX-2 NNP I
selective JJ I
nonsteroidal JJ I
anti-inflammatory JJ I
drug NN I
(COX-2) CD I
or CC I
placebo VB I
preoperatively RB N
and CC N
for IN N
4 CD N
days NNS N
postoperatively RB N
. . N

METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
blinded VBD N
placebo-controlled JJ I
trial NN N
was VBD N
conducted VBN N
in IN N
adults NNS P
undergoing VBG P
elective JJ P
outpatient JJ P
unilateral JJ P
inguinal JJ P
herniorrhaphy NN P
. . P

Patients NNS N
received VBD N
rofecoxib JJ I
(50 NNP I
mg NN I
1 CD I
h NN I
prior RB I
to TO I
incision) VB I
or CC I
placebo VB I
. . I

Doses NNS I
were VBD I
re-administered JJ I
once RB I
daily JJ I
on IN I
postoperative JJ I
days NNS I
1-4 CD I
. . I

Patients NNS N
were VBD N
also RB N
given VBN N
hydrocodone NN I
bitartrate NN I
for IN I
use NN I
as IN I
needed VBN I
in IN N
the DT N
postoperative JJ N
period NN N
. . N

Pain NN O
outcomes NNS N
were VBD N
assessed VBN N
including VBG N
pain NN O
intensity NN O
(1-10 JJ N
visual-analogue JJ N
scale) NN N
and CC N
the DT N
use NN N
of IN N
hydrocodone NN N
bitartrate NN N
. . N

In IN N
addition NN N
functional JJ N
outcomes NNS N
such JJ N
as IN N
activity NN O
and CC O
return NN O
of IN O
bowel NN O
function NN O
were VBD N
examined VBN N
for IN N
5 CD N
postoperative JJ N
days NNS N
. . N

Incidence NN N
and CC N
severity NN O
of IN O
side NN O
effects NNS O
were VBD N
examined VBN N
. . N

Statistics NNS N
are VBP N
mean JJ N
+/- JJ N
standard NN N
deviation NN N
. . N

RESULTS NNP N
Fifty-five JJ P
subjects NNS P
completed VBD P
the DT P
study NN P
. . P

Twenty-six JJ P
patients NNS P
received VBN P
rofecoxib JJ P
and CC P
29 CD P
patients NNS P
received VBD P
placebo NN P
. . P

Patients NNS N
who WP N
received VBD N
COX-2 NNP I
demonstrated VBD N
improved JJ N
bowel NN O
function NN O
as IN N
reflected VBN N
by IN N
more JJR N
bowel NN N
movements NNS N
on IN N
postoperative JJ N
day NN N
2 CD N
and CC N
postoperative JJ N
day NN N
3 CD N
. . N

COX-2-treated JJ I
patients NNS N
also RB N
reported VBD N
better RBR N
oral JJ O
intake NN O
on IN N
these DT N
same JJ N
days NNS N
. . N

In IN N
addition NN N
COX-2-treated JJ I
patients NNS N
had VBD N
less RBR N
difficulty NN O
coughing VBG O
on IN N
postoperative JJ N
day NN N
1 CD N
. . N

Overall JJ N
satisfaction NN O
with IN O
pain NN O
management NN O
was VBD N
better RBR N
in IN N
COX-2-treated JJ I
patients NNS N
(very JJ N
satisfied JJ N
vs NN N
. . N

satisfied) NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
the DT N
amount NN N
of IN N
hydrocodone NN N
bitartrate NN N
consumption NN N
. . N

There EX N
were VBD N
no DT N
complications NNS O
during IN N
the DT N
study NN N
period NN N
. . N

CONCLUSIONS NNP N
Administration NNP N
of IN N
a DT N
COX-2 NNP I
selective JJ N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
prior RB N
to TO N
and CC N
following VBG N
outpatient JJ N
inguinal JJ N
herniorrhaphy NN N
improves VBZ N
functional JJ N
outcomes NNS N
when WRB N
compared VBN N
with IN N
placebo NN N
and CC N
increases VBZ N
patient JJ N
satisfaction NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
multimodal NN N
pain NN N
therapy NN N
with IN N
COX-2 NNP I
inhibitors NNS I
may MD N
have VB N
a DT N
role NN N
in IN N
outpatient JJ P
inguinal JJ P
hernia NN P
repair NN P
. . P

-DOCSTART- -X- N

Randomized VBN N
controlled VBD N
crossover JJ N
trial NN N
of IN N
methylphenidate NN I
in IN N
pervasive JJ N
developmental NN N
disorders NNS N
with IN N
hyperactivity NN N
. . N

CONTEXT NNP N
Hyperactivity NNP N
and CC N
inattention NN N
are VBP N
common JJ N
symptoms NNS N
in IN N
children NNS P
with IN P
autistic JJ P
disorder NN P
and CC P
related JJ P
pervasive JJ P
developmental NN P
disorders NNS P
but CC N
studies NNS N
of IN N
stimulants NNS I
in IN N
these DT N
conditions NNS N
have VBP N
been VBN N
inconclusive JJ N
. . N

OBJECTIVES NN N
To TO N
determine VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
methylphenidate JJ I
hydrochloride NN P
in IN P
children NNS P
with IN P
pervasive JJ P
developmental NN P
disorders NNS P
and CC N
hyperactivity NN N
. . N

DESIGN NNP N
Double-blind NNP I
placebo-controlled JJ I
crossover NN I
trial NN N
followed VBN N
by IN N
open-label JJ N
continuation NN N
. . N

SETTING NN N
Five CD N
academic JJ N
outpatient NN N
clinics NNS N
. . N

PARTICIPANTS JJ N
Seventy-two JJ P
drug-free JJ P
children NNS P
aged VBD P
5 CD P
to TO P
14 CD P
years NNS P
with IN P
pervasive JJ P
developmental NN P
disorders NNS P
accompanied VBN P
by IN P
moderate JJ P
to TO P
severe JJ P
hyperactivity NN P
. . P

INTERVENTIONS NNP P
Prior NNP N
to TO N
randomization VB N
subjects NNS P
entered VBD P
a DT N
1-week JJ I
test-dose JJ I
phase NN I
in IN I
which WDT I
each DT I
subject NN I
received VBD I
placebo NN I
for IN I
1 CD I
day NN I
followed VBN I
by IN I
increasing VBG I
doses NNS I
of IN I
methylphenidate NN I
(low NNP I
medium NN I
and CC I
high JJ I
doses) NN I
that WDT I
were VBD I
each DT I
given VBN I
for IN I
2 CD I
days NNS I
. . I

The DT N
low JJ N
medium NN N
and CC N
high JJ N
doses NNS I
of IN I
methylphenidate NN I
hydrochloride NN I
were VBD N
based VBN N
on IN N
weight NN N
and CC N
they PRP N
ranged VBD N
from IN N
7.5 CD N
mg/d NNS N
to TO N
50.0 CD N
mg/d NNS N
in IN N
divided JJ N
doses NNS N
. . N

Subjects NNS P
who WP P
tolerated VBD P
the DT P
test NN P
dose NN P
(n NNP N
= $ N
66) CD N
were VBD N
assigned VBN N
to TO N
receive VB I
placebo NN I
for IN I
1 CD I
week NN I
and CC I
then RB I
3 CD I
methylphenidate NN I
doses NNS I
in IN I
random JJ I
order NN I
during IN N
a DT N
double-blind JJ N
crossover NN N
phase NN N
. . N

Children NNP P
responding VBG P
to TO P
methylphenidate VB P
then RB N
entered VBD N
8 CD N
weeks NNS N
of IN N
open-label JJ I
treatment NN I
at IN I
the DT N
individually RB N
determined VBN N
best JJS N
dose NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
teacher-rated JJ O
hyperactivity NN O
subscale NN O
of IN O
the DT O
Aberrant NNP O
Behavior NNP O
Checklist NNP O
. . O

Response NNP N
was VBD N
defined VBN N
as IN N
"much JJ N
improved" NN N
or CC N
"very RB N
much JJ N
improved" NN N
on IN N
the DT N
Clinical NNP O
Global NNP O
Impressions NNP O
Improvement NNP O
item NN N
coupled VBD N
with IN N
considerable JJ N
reductions NNS N
in IN N
the DT N
parent-rated JJ N
and/or JJ N
teacher-rated JJ N
Aberrant NNP O
Behavior NNP O
Checklist NNP O
hyperactivity NN O
subscale NN O
score NN O
. . O

RESULTS NNP N
Methylphenidate NNP I
was VBD I
superior JJ I
to TO I
placebo VB I
on IN N
the DT N
primary JJ N
outcome JJ N
measure NN N
with IN N
effect NN O
sizes NNS O
ranging VBG N
from IN N
0.20 CD N
to TO N
0.54 CD N
depending VBG N
on IN N
dose NN N
and CC N
rater NN N
. . N

Thirty-five JJ P
(49%) NN P
of IN P
72 CD P
enrolled JJ P
subjects NNS P
were VBD N
classified VBN N
as IN N
methylphenidate NN I
responders NNS N
. . N

Adverse JJ N
effects NNS N
led VBN N
to TO N
the DT N
discontinuation NN N
of IN N
study NN N
medication NN N
in IN N
13 CD P
(18%) NN P
of IN P
72 CD P
subjects NNS P
. . P

CONCLUSIONS NNP P
Methylphenidate NNP I
was VBD N
often RB N
efficacious JJ N
in IN N
treating VBG N
hyperactivity NN N
associated VBN N
with IN N
pervasive JJ N
developmental NN N
disorders NNS N
but CC N
the DT N
magnitude NN N
of IN N
response NN N
was VBD N
less JJR N
than IN N
that DT N
seen VBN N
in IN N
typically RB N
developing VBG N
children NNS N
with IN N
attention-deficit/hyperactivity NN N
disorder NN N
. . N

Adverse JJ N
effects NNS N
were VBD N
more RBR N
frequent JJ N
. . N

-DOCSTART- -X- N

Effects NNS N
of IN N
atropine NN I
and CC I
scopolamine NN I
on IN N
bradycardia NN N
and CC N
emetic JJ N
symptoms NNS P
in IN P
otoplasty NN P
. . P

OBJECTIVE NN N
To TO N
assess VB N
the DT N
effects NNS N
of IN N
unilateral JJ I
or CC I
bilateral JJ I
otoplasty NN I
on IN N
bradycardia NN O
and CC N
postoperative JJ O
nausea NN O
and CC O
vomiting VBG O
(PONV) NN O
and CC N
the DT N
efficiency NN N
of IN N
transdermal JJ I
scopolamine NN I
in IN N
the DT N
prophylaxis NN N
of IN N
PONV NNP N
. . N

STUDY NNP N
DESIGN NNP N
Post NNP N
hoc JJ N
assessment NN N
of IN N
the DT N
data NNS N
from IN N
a DT N
double-blind JJ N
randomized NN N
study NN N
. . N

METHODS NNP N
Fifty NNP P
otoplasty JJ P
patients NNS P
were VBD P
studied; JJ P
half NN N
of IN N
them PRP N
received VBD N
randomly RB N
and CC N
in IN N
double-blind JJ N
fashion NN N
a DT N
transdermal JJ I
therapeutic JJ I
system NN I
(patch) NN I
of IN I
scopolamine JJ I
(TTS-scopolamine) JJ I
as IN N
prophylaxis NN N
against IN N
PONV NNP I
before IN N
general JJ N
anesthesia NN N
. . N

The DT N
placebo NN I
group NN I
received VBD I
atropine JJ I
10 CD I
microg JJ I
x JJ I
kg(-1) JJ I
intravenously RB I
during IN I
induction NN I
. . I

RESULTS VB N
The DT N
scopolamine-treated JJ I
patients NNS N
suffered VBD N
more RBR N
from IN N
moderate JJ N
peroperative JJ O
bradycardia NN O
(8/25; NNP N
P NNP N
< NNP N
.05) NNP N
than IN N
the DT N
atropine-treated JJ I
patients NNS N
(1/25) POS N
. . N

Two CD N
patients NNS N
wearing VBG N
a DT N
half NN N
of IN N
the DT N
TTS-scopolamine NNP I
patch NN N
needed VBD N
intravenous JJ O
atropine NN O
. . O

After IN N
unilateral JJ N
otoplasty JJ N
none NN N
of IN N
the DT N
TTS-scopolamine-treated JJ I
patients NNS N
and CC N
50% CD N
of IN N
the DT N
atropine-treated JJ I
patients NNS N
suffered VBD N
from IN N
PONV NNP O
. . O

After IN N
bilateral JJ N
operation NN N
the DT N
respective JJ N
incidences NNS N
were VBD N
39% CD N
and CC N
81% CD N
(P NN N
< NNP N
.01) NNP N
. . N

After IN N
unilateral JJ I
otoplasty JJ I
no DT N
patient NN N
needed VBN N
droperidol NN I
but CC I
after IN N
bilateral JJ I
otoplasty JJ I
12 CD I
of IN N
19 CD N
of IN N
the DT N
atropine-treated JJ I
and CC N
4 CD N
of IN N
18 CD N
(P JJ N
< NNP N
.05) NN N
of IN N
the DT N
scopolamine-treated JJ I
patients NNS N
needed VBN N
droperidol NN I
. . I

The DT N
mean JJ N
numbers NNS O
of IN O
doses NNS O
of IN O
droperidol NN O
were VBD N
0.8+/-0.9 JJ N
and CC N
0.3+/-0.6 JJ N
(P NNP N
< NNP N
.05) NNP N
respectively RB N
. . N

Two CD N
additional JJ N
patients NNS N
wearing VBG N
half NN N
of IN N
the DT N
TTS-scopolamine NNP I
patch NN N
suffered VBD N
from IN N
mild JJ O
central JJ O
anticholinergic JJ O
syndrome NN O
. . O

CONCLUSION NNP N
TTS-scopolamine NNP I
offers NNS N
effective JJ N
prophylaxis NN N
against IN N
PONV NNP N
(auriculoemetic JJ N
reflex) NN N
but CC N
does VBZ N
not RB N
protect VB N
from IN N
bradycardia JJ N
(auriculocardiac NNP N
reflex) NN N
in IN N
otoplasty NN N
. . N

Cutting VBG N
of IN N
the DT N
TTS-scopolamine NNP I
patch NN N
may MD N
lead VB N
to TO N
undesirable JJ N
side NN N
effects NNS N
. . N

-DOCSTART- -X- N

Intervention NN I
in IN N
children NNS P
with IN P
Developmental NNP P
Coordination NNP P
Disorder: NNP P
the DT P
role NN P
of IN P
parents NNS P
and CC P
teachers NNS P
. . P

BACKGROUND NNP N
Children NNP P
with IN P
Developmental NNP P
Coordination NNP P
Disorder NNP P
(DCD) NNP P
are VBP N
a DT N
heterogeneous JJ N
group NN N
who WP N
have VBP N
a DT N
marked JJ N
impairment NN N
in IN N
the DT N
performance NN N
of IN N
functional JJ N
skills NNS N
. . N

Provision NN N
for IN N
these DT N
children NNS N
is VBZ N
usually RB N
made VBN N
via IN N
a DT N
paediatrician JJ N
through IN N
occupational JJ I
or CC I
physiotherapy JJ I
though IN N
with IN N
a DT N
prevalence NN N
rate NN N
of IN N
5% CD N
regular JJ N
provision NN N
is VBZ N
not RB N
possible JJ N
due JJ N
to TO N
limited JJ N
professional JJ N
resources NNS N
. . N

AIMS IN N
The DT N
study NN N
aimed VBD N
to TO N
determine VB N
the DT N
extent NN N
to TO N
which WDT N
parents NNS P
and CC P
teachers NNS P
with IN P
guidance NN N
can MD N
assist VB N
in IN N
the DT N
management NN N
of IN N
children NNS P
with IN P
DCD; NNP P
whether IN N
children NNS P
with IN P
DCD NNP P
are VBP N
helped VBN N
in IN N
this DT N
way NN N
and CC N
how WRB N
this DT N
may MD N
contribute VB N
to TO N
our PRP$ N
understanding NN N
of IN N
the DT N
condition NN N
. . N

SAMPLE NNP N
Thirty-one CD P
children NNS P
with IN P
DCD NNP P
aged VBD P
7 CD P
to TO P
9 CD P
years NNS P
participated VBN P
in IN P
the DT P
study NN P
. . P

METHODS NNP N
Following NNP N
assessment JJ N
individual JJ N
profiles NNS N
were VBD N
developed VBN N
and CC N
each DT N
week NN N
teachers NNS P
and CC P
parents NNS P
were VBD I
given VBN I
guidelines NNS I
for IN I
working VBG I
with IN I
the DT I
children NNS I
and CC N
each DT N
child NN N
had VBD N
three CD N
to TO N
four CD N
sessions NNS N
a DT N
week NN N
lasting VBG N
approximately RB N
for IN N
20 CD N
minutes NNS N
. . N

In IN N
Phase NNP N
1 CD N
one CD N
group NN N
of IN N
children NNS N
worked VBN N
with IN N
teachers NNS I
and CC N
the DT N
other JJ N
group NN N
worked VBD N
with IN N
parents NNS I
. . I

In IN N
Phase NNP N
2 CD N
the DT N
two CD N
groups NNS N
of IN N
children NNS N
swapped VBN N
over IN N
. . N

The DT N
children NNS N
were VBD N
assessed VBN N
regularly RB N
throughout IN N
the DT N
project NN N
using VBG N
the DT N
Movement NNP N
ABC NNP N
together RB N
with IN N
diaries NNS N
and CC N
comments NNS N
from IN N
teachers NNS N
and CC N
parents NNS N
. . N

RESULTS NN N
At IN N
the DT N
end NN N
of IN N
the DT N
40-week JJ N
study NN P
27 CD P
children NNS P
showed VBD N
significant JJ N
improvement NN N
in IN N
their PRP$ N
motor NN O
skills NNS O
. . O

CONCLUSIONS NNP O
Both NNP N
teachers NNS P
and CC P
parents NNS P
were VBD N
able JJ N
to TO N
provide VB N
effective JJ O
intervention NN O
for IN N
the DT N
majority NN N
of IN N
the DT N
children NNS N
. . N

It PRP N
is VBZ N
possible JJ N
that IN N
the DT N
children NNS N
who WP N
did VBD N
not RB N
improve VB N
have VB N
difficulties NNS N
that WDT N
are VBP N
of IN N
a DT N
more RBR N
complex JJ N
type NN N
which WDT N
require VBP N
more JJR N
specialist JJ I
therapy NN I
to TO N
meet VB N
their PRP$ N
need NN N
. . N

-DOCSTART- -X- N

Cholesterol-lowering JJ N
effect NN N
of IN N
stanol NN I
ester NN I
in IN N
a DT N
US NNP P
population NN P
of IN P
mildly RB P
hypercholesterolemic JJ P
men NNS P
and CC P
women: VB P
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
stanol NN I
esters NNS I
in IN N
lowering VBG N
cholesterol NN N
in IN N
a DT N
US NNP P
population NN P
. . P

SUBJECTS NNP P
AND NNP N
METHODS NNP N
After IN N
a DT N
run-in JJ N
phase NN N
318 CD P
subjects NNS P
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
margarine-like JJ I
spreads NNS I
containing VBG I
stanol JJ I
ester NN I
or CC I
placebo NN I
for IN I
8 CD I
weeks: NNS I
EU NNP N
3 CD N
G: NNP N
1 CD N
g NN N
of IN N
stanol JJ I
(ester NNP I
form) NN I
per IN I
8-g JJ I
serving NN I
of IN I
a DT I
European JJ I
formula NN I
3 CD I
times NNS I
a DT I
day; JJ I
US NNP N
3 CD N
G: NNP N
1 CD N
g NN N
of IN N
stanol JJ I
(ester NNP I
form) NN I
per IN N
8-g JJ N
serving NN N
of IN N
a DT N
US NNP N
reformulation NN N
3 CD N
times NNS N
a DT N
day; JJ N
US NNP N
2 CD N
G: NNP N
0.67 CD N
g NN N
of IN N
stanol JJ I
(ester NNP I
form) NN I
per IN N
8-g JJ N
serving NN N
of IN N
a DT N
US NNP N
reformulation NN N
3 CD N
times NNS N
a DT N
day; NN N
or CC N
placebo NN I
spread NN I
. . I

RESULTS JJ I
Mean NNP O
+/- JJ O
SD NNP O
baseline NN O
total JJ O
cholesterol NN O
(TC) NN O
and CC O
low-density NN O
lipoprotein NNS O
cholesterol VBP O
(LDL-C) JJ O
levels NNS O
were VBD N
233+/-20 JJ N
and CC N
153+21 CD N
mg+/-dL JJ N
respectively RB N
. . N

In IN N
the DT N
US NNP N
3 CD N
G NNP N
group NN N
3 CD N
g JJ N
daily NN N
of IN N
stanol JJ I
esters NNS I
lowered VBD N
TC NNP O
and CC O
LDL-C NNP O
levels NNS O
by IN N
6.4% CD N
and CC N
10.1% CD N
respectively RB N
. . N

There EX N
was VBD N
a DT N
dose-dependent JJ N
response NN N
compared VBN N
with IN N
2 CD N
g NNS N
daily JJ N
(US $ N
2 CD N
G) NNP N
. . N

Triglyceride NNP O
and CC O
high-density NN O
lipoprotein NNS O
cholesterol NN O
levels NNS O
were VBD N
unchanged JJ N
. . N

The DT N
incidence NN N
of IN N
adverse JJ O
effects NNS O
was VBD N
not RB N
different JJ N
from IN N
placebo NN I
. . I

Serum NNP O
vitamin VBZ O
A DT O
and CC O
25-hydroxyvitamin JJ O
D NNP O
levels NNS O
were VBD N
not RB N
affected VBN N
. . N

CONCLUSIONS NNP N
Stanol NNP I
esters NNS I
lowered VBD N
TC NNP O
and CC O
LDL-C NNP O
levels NNS O
in IN N
a DT N
mildly RB P
hypercholesterolemic JJ P
US NNP P
population NN P
without IN N
evidence NN N
of IN N
adverse JJ N
effects NNS N
. . N

It PRP N
may MD N
be VB N
a DT N
useful JJ N
dietary JJ N
adjunct NN N
to TO N
lower VB N
cholesterol NN N
. . N

-DOCSTART- -X- N

Early JJ N
intervention NN N
for IN N
autism NN N
with IN N
a DT N
parent-delivered JJ I
Qigong NNP I
massage NN I
program: VBD I
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

A DT I
recent JJ I
randomized NN I
controlled VBD I
trial NN I
(RCT) NN I
of IN I
a DT I
dual JJ I
parent NN I
and CC I
trainer-delivered JJ I
qigong JJ I
massage NN I
intervention NN I
for IN I
young JJ P
children NNS P
with IN P
autism NN P
resulted VBN I
in IN I
improvement NN I
of IN I
measures NNS I
of IN I
autism NN O
as RB I
well RB I
as IN I
improvement NN I
of IN I
abnormal JJ O
sensory JJ O
responses NNS O
and CC I
self-regulation NN O
. . O

The DT N
RCT NNP N
evaluated VBD N
the DT N
effects NNS N
of IN N
the DT N
parent-delivered JJ I
component NN I
of IN N
the DT N
intervention NN N
. . N

Forty-seven JJ P
children NNS P
were VBD P
randomly RB P
assigned VBN P
to TO P
treatment NN P
and CC P
wait-list JJ P
control NN P
groups NNS P
. . P

Treatment NNP N
group NN N
children NNS N
received VBD N
the DT N
parent-delivered JJ I
program NN I
for IN I
4 CD I
mo NN I
. . I

Trained JJ I
therapists NNS I
provided VBD I
parent NN I
training NN I
and CC I
support NN I
. . I

Improvement NN N
was VBD N
evaluated VBN N
in IN N
two CD N
settings--preschool JJ N
and CC N
home--by JJ N
teachers NNS N
(blind VBP N
to TO N
group) VB N
and CC N
parents NNS N
. . N

Results NNS N
showed VBD N
that IN N
the DT N
parent-delivered JJ I
program NN I
was VBD N
effective JJ N
in IN N
improving VBG N
measures NNS N
of IN N
autism NN N
(medium NN N
effect NN N
size) NN N
and CC N
sensory JJ O
and CC O
self-regulatory JJ O
responses NNS O
(large VBP N
effect NN N
size) NN N
. . N

Teacher NNP N
data NNS N
on IN N
measures NNS N
of IN N
autism NN N
were VBD N
confirmed VBN N
by IN N
parent NN N
data NNS N
. . N

Results NNS N
indicate VBP N
that IN N
the DT N
parent-delivered JJ I
component NN I
of IN I
the DT I
program NN I
provided VBD N
effective JJ N
early JJ N
intervention NN N
for IN N
autism NN N
that WDT N
was VBD N
suitable JJ N
for IN N
delivery NN N
at IN N
home NN N
. . N

-DOCSTART- -X- N

Scaling VBG N
clinical JJ N
judgments NNS N
of IN N
symptom JJ N
pathology NN N
by IN N
means NNS N
of IN N
the DT N
psychophysiological JJ N
method NN N
of IN N
magnitude NN N
estimation NN N
. . N

Summing VBG N
scores NNS N
across IN N
heterogeneous JJ N
symptom NN N
items NNS N
without IN N
consideration NN N
of IN N
their PRP$ N
differing JJ N
psychopathological JJ N
significance NN N
has VBZ N
been VBN N
criticized VBN N
as IN N
producing VBG N
an DT N
inadequate JJ N
picture NN N
of IN N
an DT N
individual's JJ N
clinical JJ N
status NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
derive JJ N
symptom JJ N
item NN N
weights NNS N
representing VBG N
clinically RB N
judged VBN N
seriousness NN N
of IN N
each DT N
symptom NN N
through IN N
the DT N
application NN N
of IN N
Steven's NNP I
psychophysical JJ I
method NN I
of IN I
magnitude NN I
estimation NN I
. . I

A DT N
nationwide JJ N
sample NN N
of IN N
129 CD P
clinicians NNS P
rated VBD N
the DT N
pathological JJ N
significance NN N
of IN N
221 CD N
symptom JJ N
items NNS N
in IN N
a DT N
design NN N
such JJ N
that IN N
every DT N
rater NN N
rated VBD N
121 CD N
items NNS N
21 CD N
of IN N
which WDT N
were VBD N
rated VBN N
by IN N
all DT N
raters NNS N
and CC N
100 CD N
of IN N
which WDT N
were VBD N
rated VBN N
only RB N
by IN N
the DT N
A NNP N
or CC N
B NNP N
subgroup NN N
to TO N
which WDT N
each DT N
rater NN N
was VBD N
randomly RB N
assigned VBN N
. . N

Each DT N
item NN N
was VBD N
rated VBN N
as IN N
to TO N
the DT N
seriousness NN N
of IN N
the DT N
pathology NN N
it PRP N
would MD N
represent VB N
if IN N
manifested VBN N
by IN N
either CC N
a DT N
boy NN N
child NN N
girl NN N
child NN N
boy JJ N
adolescent NN N
or CC N
girl JJ N
adolescent NN N
with IN N
one-fourth NN N
of IN N
the DT N
raters NNS N
assigned VBD N
to TO N
each DT N
condition NN N
. . N

The DT N
results NNS N
of IN N
211 CD N
two-way JJ I
analyses NNS I
of IN I
variance NN I
revealed VBD N
that IN N
age NN N
and CC N
age NN N
and CC N
sex NN N
in IN N
interaction NN N
but CC N
not RB N
sex VB N
alone RB N
significantly RB N
influenced VBD N
the DT N
clinical JJ N
ratings NNS N
. . N

The DT N
resulting VBG N
magnitude JJ O
estimation NN O
ratings NNS O
of IN O
symptom JJ O
pathology NN O
ranged VBD N
from IN N
1.0 CD N
to TO N
9.9 CD N
. . N

They PRP N
were VBD N
demonstrated VBN N
to TO N
have VB N
satisfactoy VBN N
reliability NN N
and CC N
convergent NN N
validity NN N
and CC N
to TO N
have VB N
the DT N
psychophysical JJ N
characteristics NNS N
of IN N
a DT N
prothetic JJ N
continuum NN N
. . N

-DOCSTART- -X- N

Endovascular JJ I
aneurysm NN I
repair NN I
and CC N
outcome NN N
in IN N
patients NNS P
unfit JJ P
for IN P
open JJ P
repair NN P
of IN P
abdominal JJ P
aortic JJ P
aneurysm NN P
(EVAR NNP P
trial NN N
2): CD N
randomised VBD N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Endovascular NNP I
aneurysm VBD I
repair NN I
(EVAR) NN I
to TO N
exclude VB N
abdominal JJ N
aortic JJ N
aneurysm NN N
(AAA) NN N
was VBD N
introduced VBN N
for IN N
patients NNS P
of IN P
poor JJ P
health NN P
status NN P
considered VBN P
unfit NN P
for IN P
major JJ P
surgery NN P
. . P

We PRP N
instigated VBD N
EVAR NNP I
trial NN N
2 CD N
to TO N
identify VB N
whether IN N
EVAR NNP I
improves VBZ N
survival JJ N
compared VBN N
with IN N
no DT N
intervention NN N
in IN N
patients NNS P
unfit JJ P
for IN P
open JJ P
repair NN P
of IN P
aortic JJ P
aneurysm NN P
. . P

METHODS NNP N
We PRP N
did VBD N
a DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
338 CD P
patients NNS P
aged VBN P
60 CD P
years NNS P
or CC P
older JJR P
who WP P
had VBD P
aneurysms NNS P
of IN P
at IN P
least JJS P
5.5 CD P
cm NN P
in IN P
diameter NN P
and CC P
who WP P
had VBD P
been VBN P
referred VBN P
to TO P
one CD P
of IN P
31 CD P
hospitals NNS P
in IN P
the DT P
UK NNP P
. . P

We PRP N
assigned VBD N
patients NNS N
to TO N
receive VB N
either DT N
EVAR NNP I
(n=166) NNP N
or CC I
no DT I
intervention NN I
(n=172) NN N
. . N

Our PRP$ N
primary JJ N
endpoint NN N
was VBD N
all-cause JJ O
mortality NN O
with IN O
secondary JJ N
endpoints NNS N
of IN N
aneurysm-related JJ O
mortality NN O
health-related JJ O
quality NN O
of IN O
life NN O
(HRQL) NNP O
postoperative JJ O
complications NNS O
and CC O
hospital NN O
costs NNS O
. . O

Analyses NNS N
were VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

FINDINGS NNP N
197 CD N
patients NNS N
underwent JJ N
aneurysm JJ I
repair NN I
(47 NNP N
assigned VBD N
no DT N
intervention) NN N
and CC N
80% CD N
of IN N
patients NNS N
adhered VBN N
to TO N
protocol VB I
. . I

The DT N
30-day JJ N
operative JJ N
mortality NN O
in IN N
the DT N
EVAR NNP N
group NN N
was VBD N
9% CD N
(13 NN N
of IN N
150 CD N
95% CD N
CI NNP N
5-15) CD N
and CC N
the DT N
no DT N
intervention NN N
group NN N
had VBD N
a DT N
rupture NN N
rate NN N
of IN N
9.0 CD N
per IN N
100 CD N
person NN N
years NNS N
(95% VBP N
CI NNP N
6.0-13.5) CD N
. . N

By IN N
end NN N
of IN N
follow JJ N
up IN N
142 CD N
patients NNS N
had VBD N
died VBN N
42 CD N
of IN N
aneurysm-related JJ N
factors; NN N
overall JJ N
mortality NN O
after IN N
4 CD N
years NNS N
was VBD N
64% CD N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
EVAR NNP N
group NN N
and CC N
the DT N
no DT N
intervention NN N
group NN N
for IN N
all-cause JJ O
mortality NN O
(hazard NNP N
ratio VBZ N
1.21 CD N
95% CD N
CI NNP N
0.87-1.69 JJ N
p=0.25) NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
aneurysm-related JJ O
mortality NN O
. . O

The DT N
mean JJ N
hospital NN O
costs NNS O
per IN N
patient NN N
over IN N
4 CD N
years NNS N
were VBD N
UK NNP N
pound NN N
sterling NN N
13 CD N
632 CD N
in IN N
the DT N
EVAR NNP N
group NN N
and CC N
pound NN N
sterling NN N
4983 CD N
in IN N
the DT N
no DT N
intervention NN N
group NN N
(mean JJ N
difference NN N
pound NN N
sterling NN N
8649 CD N
SE NNP N
1248) CD N
with IN N
no DT N
difference NN N
in IN N
HRQL NNP N
scores NNS N
. . N

INTERPRETATION NNP N
EVAR NNP N
had VBD N
a DT N
considerable JJ N
30-day JJ N
operative JJ N
mortality NN N
in IN N
patients NNS N
already RB N
unfit JJ N
for IN N
open JJ N
repair NN N
of IN N
their PRP$ N
aneurysm NN N
. . N

EVAR NNP I
did VBD N
not RB N
improve VB N
survival NN N
over IN N
no DT N
intervention NN N
and CC N
was VBD N
associated VBN N
with IN N
a DT N
need NN N
for IN N
continued JJ N
surveillance NN N
and CC N
reinterventions NNS N
at IN N
substantially RB N
increased VBN N
cost NN N
. . N

Ongoing VBG N
follow-up NN N
and CC N
improved JJ N
fitness NN N
of IN N
these DT N
patients NNS N
is VBZ N
a DT N
priority NN N
. . N

-DOCSTART- -X- N

The DT N
in IN N
vitro JJ N
effects NNS N
of IN N
verbascoside NN I
on IN N
human JJ P
platelet NN P
aggregation NN N
. . N

Preliminary JJ N
in IN N
vitro NN N
and CC N
animal NN N
studies NNS N
have VBP N
shown VBN N
that IN N
verbascoside NN I
a DT I
phenolic JJ N
compound NN N
may MD N
have VB N
several JJ N
favourable JJ N
biological JJ N
activities NNS N
including VBG N
an DT N
influence NN N
on IN N
endothelial JJ N
function NN N
and CC N
on IN N
platelet NN N
aggregation NN N
. . N

We PRP N
sought VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
verbascoside NN I
biotechnologically RB I
produced VBN N
from IN N
plant NN N
cell NN N
cultures NNS N
on IN N
human JJ O
platelet NN O
aggregation NN O
(PA) NN O
. . N

The DT N
blood NN N
from IN N
40 CD P
aspirin-nave JJ P
volunteers NNS P
with IN P
at IN P
least JJS P
one CD P
cardiovascular NN P
risk NN P
factor NN P
was VBD N
preincubated VBN N
in IN N
vitro NN N
with IN I
verbascoside JJ I
(1 NNP I
and CC I
2mg/dL) CD I
and CC I
aspirin JJ I
(100M) NN I
. . N

The DT N
blood NN N
from IN P
20 CD P
patients NNS P
with IN P
a DT P
prior JJ P
diagnosis NN P
of IN P
coronary JJ P
heart NN P
disease NN P
who WP P
were VBD P
chronically RB P
assuming VBG P
aspirin NN P
was VBD I
preincubated VBN I
in IN I
vitro NN I
with IN I
verbascoside JJ I
(1 NNP I
and CC I
2mg/dL) CD I
. . N

PA NNP N
is VBZ N
measured VBN N
with IN I
a DT I
light JJ I
transmission NN I
aggregometry NN I
and CC I
multiplate NN I
analyzer NN I
. . N

As IN N
compared VBN N
to TO N
reference VB N
preincubation NN N
with IN I
verbascoside NN I
resulted VBD N
in IN N
a DT N
significant JJ N
inhibition NN O
of IN O
adenosine JJ O
diphosphate NN O
(ADP) NN O
and CC O
arachidonic JJ O
acid NN O
(AA)-induced JJ O
PA NNP N
(p<0.01 NN N
for IN N
both) NN I
. . I

Verbascoside RB I
2mg/dL CD N
did VBD N
not RB N
show VB N
a DT N
stronger JJR N
effect NN N
as IN N
compared VBN I
to TO I
verbascoside VB I
1mg/dL CD N
(p=0.4) NN N
. . N

As IN N
expected VBN N
the DT N
in IN N
vitro JJ N
addition NN I
of IN N
aspirin NN O
reduced VBN O
AA NNP O
induced VBD N
PA NNP N
(p<0.01) NNP N
but CC N
not RB N
that IN N
induced VBN N
by IN N
ADP NNP N
(p=0.5) NNP N
. . N

The DT I
addition NN I
of IN I
verbascoside NN N
to TO I
the DT I
blood NN I
of IN N
aspirin-treated JJ N
patients NNS N
did VBD N
not RB N
improve VB O
the DT O
values NNS N
of IN N
PA NNP N
after IN N
AA NNP N
stimulus CC N
(p=0.8) NNP N
whereas IN N
it PRP N
ensured VBD O
a DT O
stronger JJR O
inhibition NN N
after IN N
ADP NNP N
stimulus NN I
(p<0.01) NNP I
. . N

Verbascoside NNP N
in IN N
vitro JJ N
affects NNS N
PA VBN N
by IN N
mildly RB N
inhibiting VBG N
aggregation NN N
triggered VBD N
both DT N
by IN N
ADP NNP N
and CC N
AA NNP N
. . N

These DT N
preliminary JJ N
data NNS N
while IN N
intriguing VBG N
require NN N
confirmation NN N
in IN N
subjects NNS I
receiving VBG I
verbascoside NN N
orally RB N
in IN N
order NN N
to TO N
determine VB N
whether IN N
these DT N
findings NNS N
are VBP N
clinically RB N
relevant JJ N
. . N

-DOCSTART- -X- N

The DT N
KRAS-variant NNP N
and CC N
miRNA JJ N
expression NN N
in IN N
RTOG NNP N
endometrial JJ P
cancer NN P
clinical JJ P
trials NNS P
9708 CD P
and CC P
9905 CD P
. . P

OBJECTIVE NN N
To TO N
explore VB N
the DT N
association NN N
of IN N
a DT N
functional JJ N
germline NN N
variant NN N
in IN N
the DT N
3'-UTR CD N
of IN N
KRAS NNP N
with IN N
endometrial JJ O
cancer NN O
risk NN O
as RB O
well RB N
as IN N
the DT N
association NN N
of IN N
microRNA NN N
(miRNA) NN N
signatures NNS N
and CC N
the DT N
KRAS-variant NNP N
with IN N
clinical JJ N
characteristics NNS N
and CC N
survival JJ O
outcomes NNS O
in IN N
two CD N
prospective JJ N
RTOG NNP N
endometrial JJ N
cancer NN N
trials NNS N
. . N

METHODS/MATERIALS NNP N
The DT N
association NN N
of IN N
the DT N
KRAS-variant NNP N
with IN N
endometrial JJ N
cancer NN N
risk NN N
was VBD N
evaluated VBN N
by IN N
case-control JJ N
analysis NN N
of IN N
467 CD P
women NNS P
with IN P
type JJ P
1 CD P
or CC P
2 CD P
endometrial JJ P
cancer NN P
and CC P
582 CD P
age-matched JJ P
controls NNS P
. . P

miRNA NN N
and CC N
DNA NNP N
were VBD N
isolated VBN N
for IN N
expression NN N
profiling NN N
and CC N
genotyping VBG N
from IN N
tumor NN P
specimens NNS P
of IN P
46 CD P
women NNS P
with IN P
type JJ P
1 CD P
endometrial JJ P
cancer NN P
enrolled VBN P
in IN P
RTOG NNP P
trials NNS P
9708 CD P
and CC P
9905 CD P
. . P

miRNA JJ N
expression NN N
levels NNS N
and CC N
KRAS-variant NNP N
genotype NN N
were VBD N
correlated VBN N
with IN N
patient NN N
and CC N
tumor NN N
characteristics NNS N
and CC N
survival JJ O
outcomes NNS O
were VBD N
evaluated VBN N
by IN N
variant JJ N
allele JJ N
type NN N
. . N

RESULTS VB N
The DT N
KRAS-variant NNP N
was VBD N
not RB N
significantly RB N
associated VBN N
with IN N
overall JJ O
endometrial JJ O
cancer NN O
risk NN O
(14% NNP N
controls NNS N
and CC N
17% CD N
type NN N
1 CD N
cancers) NN N
although IN N
was VBD N
enriched VBN N
in IN N
type NN N
2 CD N
endometrial JJ N
cancers NNS N
(24% VBP N
p=0.2) NN N
. . N

In IN N
the DT N
combined JJ N
analysis NN N
of IN N
RTOG NNP N
9708/9905 CD O
miRNA NN O
expression NN O
differed VBN N
by IN N
age NN N
presence NN N
of IN N
lymphovascular JJ N
invasion NN N
and CC N
KRAS-variant JJ N
status NN O
. . O

Overall JJ O
survival NN O
rates NNS O
at IN N
3 CD N
years NNS N
for IN P
patients NNS P
with IN P
the DT P
variant NN P
and CC P
wild-type JJ P
alleles NNS N
were VBD N
100% CD N
and CC N
77% CD N
(HR NNS N
0.3 CD N
p=0.24) NNS N
respectively RB N
favoring VBG N
the DT N
variant NN N
. . N

CONCLUSIONS VB N
The DT N
KRAS-variant NNP N
may MD N
be VB N
a DT N
genetic JJ N
marker NN N
of IN N
risk NN N
for IN N
type NN N
2 CD N
endometrial JJ N
cancers NNS N
. . N

In IN N
addition NN O
tumor NN O
miRNA NN O
expression NN O
appears VBZ N
to TO N
be VB N
associated VBN N
with IN N
patient JJ N
age NN N
lymphovascular JJ N
invasion NN N
and CC N
the DT N
KRAS-variant NNP N
supporting VBG N
the DT N
hypothesis NN N
that WDT N
altered VBD N
tumor NN N
biology NN N
can MD N
be VB N
measured VBN N
by IN N
miRNA JJ N
expression NN N
and CC N
that IN N
the DT N
KRAS-variant NNP N
likely JJ N
impacts NNS O
endometrial JJ O
tumor NN O
biology NN O
. . N

-DOCSTART- -X- N

Effects NNS N
on IN N
parental JJ N
mental JJ N
health NN N
of IN N
an DT N
education NN I
and CC I
skills NNS I
training VBG I
program NN I
for IN N
parents NNS P
of IN P
young JJ P
children NNS P
with IN P
autism: PDT P
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
impact NN N
of IN N
a DT N
parent NN I
education NN I
and CC I
behavior JJ I
management NN I
intervention NN I
(PEBM) NN I
on IN N
the DT N
mental JJ N
health NN N
and CC N
adjustment NN N
of IN N
parents NNS P
with IN P
preschool JJ P
children NNS P
with IN P
autism NN P
. . P

METHOD NNP N
A NNP N
randomized VBD N
group-comparison JJ N
design NN N
involving VBG N
a DT N
parent NN I
education NN I
and CC I
counseling VBG I
intervention NN I
to TO N
control VB N
for IN N
nonspecific JJ N
therapist NN N
effects NNS N
and CC N
a DT N
control NN I
sample NN N
was VBD N
used VBN N
. . N

Two CD P
metropolitan NNS P
and CC P
two CD P
rural JJ P
regions NNS P
were VBD N
randomly RB N
allocated VBN N
to TO N
intervention VB N
groups NNS N
(n NNP N
= VBP N
70) CD N
or CC N
control VB N
(n JJ N
= NNP N
35) CD N
. . N

The DT N
parents NNS P
of IN P
consecutive JJ P
children NNS P
with IN P
autism NN P
(2(1/2)-5 CD P
years NNS P
old) RB P
from IN P
the DT P
autism NN P
assessment NN P
services NNS P
for IN P
the DT P
intervention NN P
regions NNS P
were VBD N
then RB N
randomly RB N
allocated VBN N
to TO N
either VB I
a DT I
20-week JJ I
manual-based JJ I
parent NN I
education NN I
and CC I
behavior JJ I
management NN I
intervention NN I
(n NNP I
= VBZ I
35) CD I
or CC I
a DT I
manual-based JJ I
parent NN I
education NN I
and CC I
counseling VBG I
intervention NN I
(n NNP I
= VBZ I
35) CD I
. . I

The DT N
main JJ N
outcome JJ N
measure NN N
of IN N
parental JJ N
mental JJ N
health NN N
was VBD N
the DT N
General NNP I
Health NNP I
Questionnaire NNP I
used VBD N
pre- NN N
and CC N
postintervention NN N
and CC N
at IN N
6-month JJ N
follow-up NN N
. . N

RESULTS NNP N
Both NNP N
treatments NNS N
resulted VBD N
in IN N
significant JJ N
and CC N
progressive JJ N
improvement NN N
in IN N
overall JJ N
mental JJ O
health NN O
at IN N
follow-up JJ N
(F NNP N
= NNP N
2 CD N
97 CD N
p NN N
=.007) NN N
and CC N
mental JJ N
health NN N
significantly RB N
improved VBN N
over RP N
time NN N
in IN N
the DT N
54% CD N
of IN N
principal JJ N
caregivers NNS N
who WP N
had VBD N
the DT N
highest JJS N
levels NNS N
of IN N
mental JJ N
health NN N
problems NNS N
. . N

The DT N
parent NN I
education NN I
and CC I
behavior JJ I
management NN I
intervention NN I
was VBD N
effective JJ N
in IN N
alleviating VBG N
a DT N
greater JJR N
percentage NN N
of IN N
anxiety NN O
insomnia NN O
and CC O
somatic JJ O
symptoms NNS O
and CC O
family NN O
dysfunction NN O
than IN N
parent NN I
education NN I
and CC I
counseling VBG I
at IN N
6-month JJ N
follow-up NN N
. . N

CONCLUSIONS VB N
A DT N
20-week JJ N
parent NN I
education NN I
and CC I
skills NNS I
training VBG I
program NN I
for IN N
parents NNS P
of IN P
young JJ P
children NNS P
newly RB P
diagnosed VBN P
with IN P
autism NN P
provides VBZ N
significant JJ N
improvements NNS N
in IN N
parental JJ N
mental JJ N
health NN N
and CC N
adjustment NN N
justifying VBG N
its PRP$ N
addition NN N
to TO N
early JJ N
intervention NN N
programs NNS N
at IN N
least JJS N
for IN N
parents NNS P
with IN P
mental JJ P
health NN P
problems NNS P
. . P

-DOCSTART- -X- N

Effects NNS N
of IN N
statins NNS P
on IN P
progression NN P
of IN P
subclinical JJ P
brain NN P
infarct NN P
. . P

BACKGROUND NNP N
Subclinical NNP O
brain NN O
infarct NN O
(SBI) NNP O
is VBZ N
associated VBN N
with IN N
subsequent JJ N
stroke NN N
and CC N
cognitive JJ N
decline NN N
. . N

A DT N
longitudinal JJ N
epidemiological JJ N
study NN N
suggests VBZ N
that IN N
statins NNS I
may MD N
prevent VB N
development NN N
of IN N
SBI NNP O
. . O

We PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
statins NNS I
upon IN N
development NN O
of IN O
brain NN O
infarct NN O
by IN N
performing VBG N
a DT N
post-hoc JJ N
analysis NN N
of IN N
the DT N
Regression NNP N
of IN N
Cerebral NNP N
Artery NNP N
Stenosis NNP N
(ROCAS) NNP P
study NN P
. . P

METHODS NNP P
The DT N
ROCAS NNP N
study NN N
is VBZ N
a DT P
randomized JJ P
double-blind JJ P
placebo-controlled JJ P
study NN P
evaluating VBG P
the DT P
effects NNS P
of IN P
simvastatin NN P
20 CD P
mg JJ P
daily JJ P
upon IN P
progression NN P
of IN P
asymptomatic JJ P
middle JJ P
cerebral JJ P
artery NN P
stenosis NN P
among IN P
stroke-free JJ P
individuals NNS P
over IN P
2 CD P
years NNS P
. . P

A DT P
total NN P
of IN P
227 CD P
subjects NNS P
were VBD N
randomized VBN N
to TO N
either DT N
placebo NN I
(n NNP N
= VBZ N
114) CD N
or CC I
simvastatin VB I
20 CD I
mg JJ I
daily JJ I
(n NNP N
= NNP N
113) CD N
. . N

The DT N
number NN O
of IN O
brain NN O
infarcts NNS O
as IN N
detected VBN N
by IN N
MRI NNP N
was VBD N
recorded VBN N
at IN N
baseline NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
number NN O
of IN O
new JJ O
brain NN O
infarcts NNS O
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

RESULTS NNP N
Among IN P
the DT P
227 CD P
randomized JJ P
subjects NNS P
33 CD P
(14.5%) NNS P
had VBD P
SBI NNP P
at IN P
baseline NN P
. . P

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
significantly RB N
fewer JJR N
subjects NNS N
in IN N
the DT N
active JJ I
group NN I
(n NNP N
= VBZ N
1) CD N
had VBD N
new JJ O
brain NN O
infarcts NNS O
compared VBN N
with IN N
the DT N
placebo NN I
group NN N
(n NNP N
= VBZ N
8; CD N
p NN N
= VBD N
0.018) CD N
. . N

The DT N
new JJ N
brain NN O
infarcts NNS O
of IN N
subjects NNS N
in IN N
the DT N
active JJ I
group NN I
were VBD N
subclinical JJ N
. . N

Among IN N
the DT N
placebo NN I
group NN N
the DT N
new JJ N
brain NN O
infarcts NNS O
of IN N
3 CD N
subjects NNS N
were VBD N
symptomatic JJ N
while IN N
those DT N
of IN N
the DT N
remaining VBG N
5 CD N
subjects NNS N
were VBD N
subclinical JJ N
. . N

Among IN N
putative JJ N
variables NNS N
multivariate VBP N
regression NN N
analysis NN N
showed VBD N
that IN N
only RB N
the DT N
baseline NN N
number NN N
of IN N
SBIs NNP O
(OR NNP N
= VBD N
6.27 CD N
95% CD N
CI NNP N
2.4-16.5) CD N
and CC N
simvastatin VB I
treatment NN N
(OR NNP N
= VBD N
0.09 CD N
95% CD N
CI NNP N
0.01-0.82) CD N
independently RB N
predicted VBD N
the DT N
development NN N
of IN N
new JJ N
brain NN N
infarcts NNS N
. . N

CONCLUSIONS NNP N
Consistent NNP N
with IN N
findings NNS N
of IN N
the DT N
epidemiological JJ N
study NN N
our PRP$ N
study NN N
suggests VBZ N
that IN N
statins NNS I
may MD N
prevent VB N
the DT N
development NN N
of IN N
a DT N
new JJ N
brain NN O
infarct NN O
. . O

-DOCSTART- -X- N

Short-term NNP I
intravenous JJ I
antibiotic JJ I
treatment NN I
of IN N
acute JJ P
hematogenous JJ P
bone NN P
and CC P
joint JJ P
infection NN P
in IN P
children: NN P
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . P

Thirty-three JJ P
cases NNS P
of IN P
acute JJ P
hematogenous JJ P
bone NN P
or CC P
joint JJ P
infection NN P
in IN P
children NNS P
were VBD P
randomly RB P
treated VBN P
with IN P
short-term JJ I
(7 NNP I
days NNS I
for IN I
joint JJ I
infection NN I
10 CD I
days NNS I
for IN I
bone NN I
infection) NN I
or CC N
long-term JJ I
(14 JJ I
days NNS I
and CC I
21 CD I
days NNS I
respectively) VBP I
intravenous JJ I
antibiotics NNS I
after IN N
surgical JJ I
drainage NN I
. . I

The DT N
treatment NN N
outcome NN N
was VBD N
measured VBN N
through IN N
a DT N
detailed JJ O
scoring NN O
system NN O
that WDT O
included VBD O
the DT O
ability NN O
to TO O
eradicate VB O
infection NN O
the DT O
functional JJ O
status NN O
of IN O
the DT O
limb NN O
and CC O
the DT O
radiographic JJ O
appearance NN O
of IN O
the DT O
bone NN O
and CC O
joint NN O
. . O

The DT N
results NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
showing VBG N
the DT N
added JJ N
benefit NN N
of IN N
a DT N
shorter JJR N
hospital NN N
stay NN N
for IN N
children NNS P
with IN P
blood-borne JJ P
musculoskeletal JJ P
infection NN P
. . P

The DT N
use NN N
of IN N
this DT N
scoring VBG N
system NN N
in IN N
choosing VBG N
the DT N
route NN N
of IN N
antibiotic JJ I
administration NN I
is VBZ N
recommended VBN N
. . N

-DOCSTART- -X- N

Effects NNS N
of IN N
the DT N
Quest NNP I
to TO I
Lava NNP I
Mountain NNP I
Computer NNP I
Game NNP I
on IN N
Dietary NNP O
and CC N
Physical NNP O
Activity NNP O
Behaviors NNP O
of IN N
Elementary NNP P
School NNP P
Children: NNP P
A NNP N
Pilot NNP N
Group-Randomized NNP N
Controlled NNP N
Trial NNP N
. . N

BACKGROUND NNP N
Computer-based JJ I
educational JJ I
games NNS I
present VBP N
an DT N
opportunity NN N
for IN N
health NN N
education NN N
in IN N
school; NN N
however RB N
their PRP$ N
feasibility NN N
in IN N
school NN N
settings NNS N
and CC N
effectiveness NN N
in IN N
changing VBG N
behavior NN N
are VBP N
poorly RB N
understood JJ N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
feasibility NN N
acceptability NN N
and CC N
effects NNS N
of IN N
the DT N
Quest NNP I
to TO I
Lava NNP I
Mountain NNP I
(QTLM) NNP I
computer NN I
game NN I
on IN N
dietary JJ O
behaviors NNS O
physical JJ O
activity NN O
behaviors NNS O
and CC O
psychosocial JJ O
factors NNS O
among IN N
ethnically RB P
diverse JJ P
children NNS P
in IN P
Texas NNP P
. . P

DESIGN NNP N
Quasi-experimental JJ N
group-randomized JJ N
controlled VBN N
trial NN N
conducted VBN N
during IN N
the DT N
2012-2013 JJ P
school NN P
year NN P
. . P

PARTICIPANTS/SETTING VBG N
A DT P
total NN P
of IN P
107 CD P
children NNS P
in IN P
fourth JJ P
and CC P
fifth JJ P
grade NN P
consented VBD P
. . P

There EX N
was VBD P
an DT P
attrition NN P
rate NN P
of IN P
8.8% CD P
with IN P
a DT P
final JJ P
sample NN P
size NN P
of IN P
44 CD P
children NNS P
in IN P
three CD P
intervention NN P
schools NNS P
and CC P
a DT P
sample NN P
of IN P
50 CD P
children NNS P
in IN P
three CD P
comparison NN P
schools NNS P
. . P

Dietary NNP O
intake NN O
was VBD N
measured VBN N
using VBG N
two CD N
random JJ N
24-hour JJ N
recalls NNS N
whereas JJ N
child JJ N
self-report JJ N
surveys NNS N
measured VBN N
diet JJ O
physical JJ O
activity NN O
and CC O
psychosocial JJ O
factors NNS O
before IN N
and CC N
after IN N
the DT N
intervention NN N
. . N

Process NNP N
data NNS N
on IN N
QTLM NNP I
usability NN N
and CC N
back-end JJ N
server NN N
data NNS N
on IN N
QTLM NNP I
exposure NN N
and CC N
progress NN N
achieved VBN N
were VBD N
collected VBN N
. . N

INTERVENTION NNP I
QTLM NNP I
was VBD N
implemented VBN N
as IN N
part NN N
of IN N
the DT N
in-school NN P
or CC P
afterschool JJ P
program NN P
. . P

Recommended JJ N
game NN N
exposure NN N
duration NN N
was VBD N
90 CD N
min/wk NN N
for IN N
6 CD N
weeks NNS N
. . N

STATISTICAL JJ N
ANALYSIS NNP N
Analysis NNP N
of IN N
covariance NN N
or CC N
logistic JJ N
regression NN N
models NNS N
evaluated VBN N
effects NNS N
of IN N
QTLM NNP I
on IN N
diet JJ O
physical JJ O
activity NN O
and CC O
psychosocial JJ O
factors NNS O
. . O

Post NNP N
hoc NN N
exploratory NN N
analysis NN N
examined VBD N
the DT N
changes NNS N
before IN N
and CC N
after IN N
the DT N
intervention NN N
in IN N
outcome JJ N
variables NNS N
among IN N
children NNS N
in IN N
the DT N
intervention NN N
group NN N
. . N

Significance NN N
was VBD N
set VBN N
at IN N
P<0.05 NNP N
. . N

RESULTS NNP N
Children NNP N
played VBD N
an DT N
average NN N
of IN N
274110 CD N
minutes NNS N
(approximately RB N
4.6 CD N
hours) NN N
of IN I
QTLM NNP I
during IN N
the DT N
6 CD N
weeks NNS N
(51% NN N
of IN N
recommended JJ N
dosage) NN N
. . N

Compared VBN N
with IN N
the DT N
comparison NN N
group NN N
children NNS N
in IN N
the DT N
intervention NN N
group NN N
reported VBD N
decreased JJ O
sugar NN O
consumption NN O
(P=0.021) NN N
and CC N
higher JJR O
nutrition/physical JJ O
activity NN O
attitudes NNS O
(P=0.041) VBP N
pre- JJ N
to TO N
postintervention NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
effects NNS N
of IN I
QTLM NNP I
on IN O
physical JJ O
activity NN O
. . N

However RB N
post NN N
hoc NN N
analysis NN N
showed VBD N
that IN N
higher JJR I
QTLM NNP I
exposure NN N
and CC N
gaming VBG N
progress NN N
was VBD N
associated VBN N
with IN N
increased JJ O
frequency NN O
of IN O
physical JJ O
activity NN O
(P<0.05) NN N
. . N

CONCLUSIONS NNP I
QTLM NNP I
has VBZ N
some DT N
promising JJ N
acceptability NN N
and CC N
initial JJ N
effects NNS N
on IN O
diet JJ O
and CC O
physical JJ O
activity NN O
behaviors NNS O
among IN P
children NNS P
in IN P
elementary JJ P
school NN P
. . P

-DOCSTART- -X- N

A DT N
further JJ N
investigation NN N
of IN N
goal-directed JJ O
intention NN O
understanding NN O
in IN N
young JJ P
children NNS P
with IN P
autism NN P
spectrum NN P
disorders NNS P
. . P

Findings NNS I
from IN I
research NN I
investigating VBG I
goal-directed JJ O
intention NN O
understanding NN O
in IN I
children NNS P
with IN P
autism NN P
spectrum NN P
disorders NNS P
(ASD) VBP P
have VBP I
been VBN I
equivocal JJ I
in IN I
part NN I
because IN I
of IN I
the DT I
varying NN I
methodologies NNS I
used VBN I
across IN I
studies NNS I
. . I

This DT N
study NN N
compares VBZ N
both DT N
object-oriented JJ I
and CC I
social-communicatively JJ I
cued VBN I
goal-directed JJ I
intention NN I
understanding NN I
in IN N
children NNS P
with IN P
ASD NNP P
and CC P
typically-developing JJ P
children NNS P
. . P

Relative JJ N
to TO N
matched VB N
controls NNS N
children NNS N
with IN N
ASD NNP N
did VBD N
not RB N
exhibit VB N
deficits NNS N
in IN N
object-oriented JJ O
intention NN O
understanding NN O
. . O

While IN N
children NNS P
with IN P
ASD NNP P
also RB N
demonstrated VBD N
the DT N
ability NN N
to TO N
understand VB N
intention NN N
when WRB N
cued VBN N
by IN N
social-communication JJ N
indicators NNS N
typically-developing JJ N
children NNS N
differentiated VBD N
between IN N
intentional JJ N
and CC N
unintentional JJ N
acts NNS N
at IN N
a DT N
significantly RB N
greater JJR N
level NN N
. . N

Group NNP N
differences NNS N
in IN N
performance NN N
were VBD N
eliminated VBN N
if IN N
only JJ N
trials NNS N
in IN N
which WDT N
children NNS N
attended VBD N
to TO N
the DT N
experimenter's JJ N
face NN N
were VBD N
considered VBN N
. . N

Results NNS N
suggest VBP N
that IN N
children NNS P
with IN P
ASD NNP P
have VBP N
intact JJ N
object-oriented JJ O
intention NN O
understanding VBG O
abilities NNS N
and CC N
are VBP N
able JJ N
to TO N
use VB N
social-communicative JJ N
cues NNS N
to TO N
understand VB N
intention NN N
. . N

However RB N
their PRP$ N
ability NN N
to TO N
demonstrate VB N
social-communicatively JJ O
cued VBN O
intention NN O
understanding NN I
is VBZ N
limited VBN N
by IN N
a DT N
lack NN N
of IN N
attention NN N
to TO N
relevant VB N
social-communicative JJ N
information NN N
. . N

-DOCSTART- -X- N

Coagulation NNP I
factor NN I
concentrate NN I
in IN N
the DT N
treatment NN N
of IN N
the DT N
haemorrhagic JJ N
diathesis NN N
of IN P
fulminant JJ P
hepatic JJ P
failure NN P
. . P

To TO N
assess VB N
the DT N
value NN N
of IN N
clotting VBG I
factor NN I
concentrate NN I
infusions NNS I
in IN N
fulminant JJ P
hepatic JJ P
failure NN P
a DT P
controlled JJ N
trial NN N
was VBD N
performed VBN N
in IN N
which WDT N
nine CD P
patients NNS P
were VBD P
randomly RB P
allocated VBN P
to TO P
treatment NN P
with IN P
either DT P
concentrate NN P
alone RB P
or CC P
concentrate VB P
plus CC P
heparin VB P
. . P

The DT N
five CD P
patients NNS P
receiving VBG P
concentrate VB I
alone RB I
all DT N
died VBD O
with IN O
major JJ O
bleeding VBG O
as IN N
the DT N
direct JJ N
cause NN N
of IN N
death NN N
in IN N
three CD N
whereas NNS N
in IN N
the DT N
four CD N
receiving VBG N
heparin NN I
as RB I
well RB I
there EX N
was VBD N
only RB N
one CD N
instance NN N
of IN N
bleeding NN N
and CC N
one CD N
patient NN N
survived VBD N
. . N

Clinical JJ N
evidence NN N
of IN N
intravascular JJ O
coagulation NN O
appeared VBD N
in IN N
two CD N
patients NNS N
treated VBD I
with IN I
concentrate NN I
alone RB I
and CC N
the DT N
laboratory JJ N
evidence NN N
of IN N
this DT N
progressed VBN N
during IN N
the DT N
period NN N
of IN N
infusions NNS I
in IN N
all DT N
patients NNS N
in IN N
both DT N
treatment NN N
groups NNS N
although IN N
to TO N
a DT N
lesser JJR N
extent NN N
in IN N
those DT N
receiving VBG N
heparin NN I
. . I

Additional JJ N
evidence NN N
for IN N
intravascular JJ N
coagulation NN N
came VBD N
from IN N
the DT N
changes NNS N
observed VBN N
in IN N
factor NN O
VIII NNP O
levels NNS O
which WDT N
although IN N
initially RB N
high JJ N
in IN N
all DT N
patients NNS N
fell VBD N
subsequently RB N
particularly RB N
in IN N
those DT N
given VBN N
concentrate VBP I
alone RB I
. . I

There EX N
was VBD N
some DT N
improvement NN N
in IN N
the DT N
prothrombin NN O
ratio NN O
in IN N
both DT N
groups NNS N
of IN N
patients NNS N
but CC N
not RB N
complete JJ N
correction NN N
and CC N
serial JJ N
assays NNS N
of IN N
clotting VBG N
factors NNS N
showed VBD N
that IN N
although IN N
factor NN O
II NNP O
rose VBD N
to TO N
high JJ N
levels NNS N
during IN N
treatment NN N
factors NNS O
IX NNP O
and CC O
X NNP O
showed VBD N
little JJ N
response NN N
. . N

Thus RB N
the DT N
use NN N
of IN N
concentrate NN I
of IN I
factor NN I
IX NNP I
in IN N
this DT N
trial NN N
as RB N
well RB N
as IN N
potentiating VBG N
intravascular JJ N
coagulation NN N
was VBD N
inadequate JJ N
as IN N
replacement NN N
for IN N
the DT N
clotting NN N
factor NN N
deficiencies NNS N
. . N

-DOCSTART- -X- N

Use NNP I
of IN I
an DT I
Internet NNP I
portal NN I
to TO I
improve VB I
community-based JJ P
pediatric JJ P
ADHD NNP P
care: NN P
a DT N
cluster NN N
randomized VBN N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
effectiveness NN I
of IN I
a DT I
quality NN I
improvement NN I
program NN I
to TO N
improve VB N
pediatricians' NN P
adherence NN N
to TO N
existing VBG N
evidence-based JJ N
attention-deficit/hyperactivity JJ N
disorder NN N
(ADHD) NNP N
practice NN N
guidelines NNS N
. . N

METHODS NNP N
Forty-nine NNP P
community-based JJ P
pediatricians NNS P
at IN P
8 CD P
practices NNS P
participated VBN P
in IN P
a DT P
cluster-randomized JJ P
trial NN P
. . P

Practices NNS N
were VBD N
matched VBN N
according VBG N
to TO N
the DT N
numbers NNS P
of IN P
pediatricians NNS P
and CC P
the DT P
proportions NNS P
of IN P
patients NNS P
receiving VBG P
Medicaid NNP P
. . P

The DT N
medical JJ N
charts NNS N
for IN N
a DT N
random JJ N
sample NN N
of IN N
patients NNS P
with IN P
ADHD NNP P
for IN N
each DT N
of IN N
the DT N
participating VBG N
pediatricians NNS N
were VBD N
examined VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
. . N

All DT N
practices NNS N
participated VBN N
in IN N
4 CD I
sessions NNS I
of IN I
training VBG I
including VBG I
didactic JJ I
lectures NNS I
and CC I
office NN I
flow NN I
modification NN I
workshops NNS I
. . I

Practices NNS N
were VBD N
then RB N
given VBN I
access NN I
to TO I
an DT I
ADHD NNP I
Internet NNP I
portal NN I
that WDT N
allowed VBD N
parents NNS N
teachers NNS N
and CC N
pediatricians NNS N
to TO N
input VB N
information NN N
(eg IN N
rating NN N
scales) NN N
about IN N
patients NNS N
after IN N
which WDT N
information NN N
was VBD N
scored VBN N
interpreted JJ N
and CC N
formatted VBN N
in IN N
a DT N
report NN N
style NN N
that WDT N
was VBD N
helpful JJ N
for IN N
assessment NN N
and CC N
treatment NN N
of IN N
patients NNS N
with IN N
ADHD NNP N
. . N

Physicians NNS N
evaluated VBD N
their PRP$ N
practice NN N
behaviors NNS N
quarterly RB N
and CC N
addressed VBD N
underperforming JJ N
areas NNS N
. . N

RESULTS JJ N
Pediatricians NNPS N
in IN N
the DT N
intervention NN I
group NN N
compared VBN N
with IN N
those DT N
in IN N
the DT N
control NN I
group NN N
demonstrated VBD N
significantly RB N
higher JJR N
rates NNS N
of IN N
many JJ N
American JJ N
Academy NNP N
of IN N
Pediatrics-recommended NNP N
ADHD NNP N
care NN N
practices NNS N
including VBG N
collection NN O
of IN O
parent NN O
(Cohen's NNP N
d NN N
= VBD N
0.69) CD N
and CC N
teacher JJR O
(d NNP N
= VBD N
0.68) CD N
rating NN O
scales NNS O
for IN N
assessment NN N
of IN N
children NNS N
with IN N
ADHD NNP N
use NN N
of IN N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
Fourth NNP N
Edition NNP N
criteria NNS N
(d NNP N
= VBD N
0.85) CD N
and CC N
use NN N
of IN N
teacher NN O
rating NN O
scales NNS O
to TO N
monitor VB N
treatment NN N
responses NNS N
(d VBP N
= JJ N
1.01) CD N
. . N

CONCLUSION VB N
A DT I
quality NN I
improvement NN I
intervention NN I
that WDT I
can MD I
be VB I
widely RB I
disseminated VBN I
by IN I
using VBG I
Internet-based JJ I
information NN I
technology NN I
significantly RB N
improved VBD N
the DT N
quality NN N
of IN N
ADHD NNP N
care NN N
in IN N
community-based JJ P
pediatric JJ P
settings NNS P
. . P

-DOCSTART- -X- N

QT/QTc NNP N
study NN N
conducted VBD N
in IN N
Japanese JJ P
adult NN P
healthy JJ P
subjects: NN P
a DT N
novel JJ N
xanthine NN I
oxidase NN I
inhibitor NN I
topiroxostat NN I
was VBD N
not RB N
associated VBN N
with IN N
QT NNP O
prolongation NN O
. . O

A DT N
QT/QTc NNP N
study NN N
was VBD N
conducted VBN N
in IN N
compliance NN N
with IN N
ICH NNP I
E14 NNP I
guideline NN I
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
new JJ I
xanthine JJ I
oxidase NN I
inhibitor NN I
topiroxostat NN I
in IN N
Japanese JJ P
healthy JJ P
subjects NNS P
. . P

Forty-eight JJ P
Japanese JJ P
healthy JJ P
subjects NNS P
(males VBZ P
24; CD P
females NNS P
24) CD P
received VBD N
a DT N
single JJ I
oral JJ I
dose NN I
of IN I
topiroxostat JJ I
(60 NNP I
or CC I
180mg) CD I
moxifloxacin JJ I
(400mg) NN I
or CC I
placebo NN I
in IN P
a DT P
single-center JJ P
double-blind JJ N
four-period JJ N
crossover NN N
design NN O
. . O

Fridericia's NNP O
formula NN O
(QTcF=QT/RR(0.33) NN O
) ) N
was VBD N
used VBN N
as IN N
a DT N
primary JJ N
method NN O
for IN O
QT-interval JJ O
correction NN O
. . O

The DT O
mean JJ O
QTcF NNP N
was VBD N
prolonged VBN I
by IN I
moxifloxacin NN I
of IN N
which WDT N
largest JJS N
time-matched JJ N
difference NN I
from IN I
placebo JJ N
administration NN N
was VBD N
13.6milliseconds CD N
with IN N
90% CD N
confidence NN N
interval JJ N
(CI) NN N
of IN N
11.2 CD N
and CC N
15.9milliseconds CD N
at IN N
4hours CD N
post-dose JJ O
. . O

The DT N
mean JJ N
QTcF NNP N
was VBD N
hardly RB N
affected VBN N
by IN N
either DT I
dose NN I
of IN I
topiroxostat NN N
of IN N
which WDT N
largest JJS N
time-matched JJ N
difference NN I
from IN N
placebo JJ N
administration NN N
was VBD N
2.9milliseconds CD N
with IN N
90% CD N
CI NNP N
of IN N
0.6 CD N
and CC N
5.3milliseconds CD N
at IN N
4hours CD N
post-dose JJ N
for IN N
60mg CD N
and CC N
2.3milliseconds CD N
with IN N
90% CD N
CI NNP N
of IN N
0 CD N
and CC N
4.7milliseconds CD N
at IN N
1hour CD N
post-dose JJ N
for IN N
180mg CD N
. . N

The DT N
results NNS N
were VBD N
essentially RB N
the DT N
same JJ N
in IN I
the DT I
sex NN I
subgroup NN I
analysis NN N
. . N

Moxifloxacin NNP N
can MD N
be VB N
used VBN O
as IN O
a DT N
positive JJ N
control NN P
for IN P
QT/QTc NNP P
studies NNS I
in IN I
Japanese JJ I
subjects; NN N
and CC O
topiroxostat NN O
may MD O
not RB O
cause VB O
QT-interval JJ N
prolongation NN N
in IN N
males NNS N
as RB N
well RB N
as IN N
females NNS N
. . N

-DOCSTART- -X- N

Symptomatic JJ I
treatment NN I
versus NN I
combination NN I
chemotherapy NN I
for IN N
patients NNS P
with IN P
extensive JJ P
non-small NN P
cell NN P
lung NN P
cancer NN P
. . P

In IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
87 CD P
patients NNS P
with IN P
inoperable JJ P
extensive JJ P
non-small NN P
cell NN P
lung NN P
cancer NN P
(NSCLC) NN P
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
combination NN I
chemotherapy NN I
(cisplatin NN I
at IN I
70 CD I
mg/m2 NN I
intravenously RB I
[i.v.] JJ I
on IN I
day NN I
1 CD I
and CC I
etoposide VB I
at IN I
100 CD I
mg/m2 NN I
i.v NN I
. . I

on IN I
day NN I
1 CD I
and CC I
200 CD I
mg/m2 NNS I
orally RB I
on IN I
days NNS I
2 CD I
and CC I
3) CD I
or CC I
symptomatic JJ I
treatment NN I
. . I

No DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
survival JJ O
time NN O
were VBD N
found VBN N
between IN N
the DT N
two CD N
treatment NN N
techniques NNS N
. . N

A DT N
major JJ N
problem NN N
in IN N
the DT N
interpretation NN N
of IN N
the DT N
results NNS N
was VBD N
the DT N
use NN N
of IN N
semicurative JJ I
radiation NN I
therapy NN I
(3000 CD N
to TO N
4200 CD N
cGy) NN N
to TO N
the DT N
primary JJ N
tumor NN N
and CC N
mediastinum NN N
which WDT N
was VBD N
given VBN N
with IN N
symptomatic JJ N
intent NN N
. . N

Three CD N
long-term JJ N
survivors NNS N
were VBD N
seen VBN N
in IN N
the DT N
latter JJ N
group NN N
. . N

-DOCSTART- -X- N

Immunologic NNP O
response NN O
after IN N
laparoscopic NN P
colon NN P
cancer NN P
operation NN P
within IN N
an DT N
enhanced JJ N
recovery NN N
program NN N
. . N

OBJECTIVE NN N
It PRP N
has VBZ N
been VBN N
demonstrated VBN N
that IN N
colon NN I
operation NN I
combined VBN I
with IN I
fast-track JJ I
(FT) NN I
surgery NN I
and CC I
laparoscopic NN I
technique NN I
can MD N
shorten VB N
the DT N
length NN O
of IN O
hospital NN O
stay NN O
accelerate JJ O
recovery NN O
of IN O
intestinal JJ O
function NN O
and CC O
reduce VB N
the DT N
occurrence NN O
of IN O
post-operative JJ O
complications NNS O
. . O

However RB N
there EX N
are VBP N
no DT N
reports NNS N
regarding VBG N
the DT N
combined JJ N
effects NNS N
of IN N
FT NNP I
colon NN I
operation NN I
and CC I
laparoscopic NN I
technique NN I
on IN N
humoral JJ N
inflammatory NN N
cellular JJ N
immunity NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
controlled VBN N
study NN N
. . N

One CD P
hundred VBD P
sixty-three JJ P
colon NN P
cancer NN P
patients NNS P
underwent VBD P
the DT P
traditional JJ P
protocol NN P
and CC P
open JJ P
operation NN P
(traditional NNP P
open JJ P
group NN P
n=42) VBD P
the DT P
traditional JJ P
protocol NN P
and CC P
laparoscopic NN P
operation NN P
(traditional NNP P
laparoscopic NN P
group NN P
n=40) VBD P
the DT P
FT NNP P
protocol NN P
and CC P
open JJ P
operation NN P
(FT NNP P
open JJ P
group NN P
n=41) NN P
or CC P
the DT P
FT NNP P
protocol NN P
and CC P
laparoscopic NN P
operation NN P
(FT NNP P
laparoscopic NN P
group NN N
n=40) NN N
. . N

Blood NN N
samples NNS N
were VBD N
taken VBN N
prior RB N
to TO N
operation NN N
as RB N
well RB N
as IN N
on IN N
days NNS N
1 CD N
3 CD N
and CC N
5 CD N
after IN N
operation NN N
. . N

The DT N
number NN N
of IN N
lymphocyte JJ O
subpopulations NNS O
was VBD N
determined VBN N
by IN N
flow JJ N
cytometry NN N
and CC N
serum JJ O
interleukin-6 JJ O
and CC O
C-reactive JJ O
protein NN O
levels NNS O
were VBD N
measured VBN N
. . N

Post-operative JJ O
hospital NN O
stay VB O
post-operative JJ O
morbidity NN O
readmission NN O
rate NN O
and CC O
in-hospital JJ O
mortality NN O
were VBD N
recorded VBN N
. . N

RESULTS NNS N
Compared VBD N
with IN N
open JJ I
operation NN I
laparoscopic NN I
colon NN I
operation NN I
effectively RB N
inhibited VBD N
the DT N
release NN N
of IN N
post-operative JJ N
inflammatory JJ N
factors NNS N
and CC N
yielded VBD N
good JJ N
protection NN N
via IN N
post-operative JJ N
cell NN N
immunity NN N
. . N

FT NNP I
surgery NN I
had VBD N
a DT N
better RBR N
protective JJ N
role NN N
with IN N
respect NN N
to TO N
the DT N
post-operative JJ N
immune NN N
system NN N
compared VBN N
with IN N
traditional JJ I
peri-operative JJ I
care NN I
. . I

Inflammatory NNP N
reactions NNS N
based VBN N
on IN N
interleukin-6 JJ O
and CC O
C-reactive JJ O
protein NN O
levels NNS O
were VBD O
less JJR N
intense JJ N
following VBG N
FT NNP I
laparoscopic NN I
operation NN I
compared VBN N
to TO N
FT NNP I
open JJ I
operation; NN I
however RB N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
specific JJ O
immunity NN O
(CD3+ NN O
and CC O
CD4+ NNP O
counts NNS O
and CC O
the DT O
CD4+/CD8+ NNP O
ratio) NN O
during IN N
these DT N
two CD N
types NNS N
of IN N
surgical JJ N
procedures NNS N
. . N

Post-operative JJ O
hospital NN O
stay NN O
in IN N
patients NNS N
randomized VBN N
to TO N
the DT N
FT NNP I
laparoscopic NN I
group NN I
was VBD N
significantly RB N
shorter JJR N
than IN N
in IN N
the DT N
other JJ N
three CD N
treatment NN N
groups NNS N
(P<0.01) VBP N
. . N

Post-operative JJ O
complications NNS O
in IN N
patients NNS N
who WP N
underwent VBP N
FT NNP I
laparoscopic NN I
treatment NN I
were VBD N
less JJR N
than IN N
in IN N
the DT N
other JJ N
three CD N
treatment NN N
groups NNS N
(P<0.05) VBP N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
four CD N
treatment NN N
groups NNS N
regarding VBG N
readmission NN N
rate NN N
and CC N
in-hospital JJ N
mortality NN N
. . N

CONCLUSIONS NNP N
The DT N
laparoscopic NN I
technique NN I
and CC I
FT NNP I
surgery NN I
rehabilitation NN N
program NN N
effectively RB N
inhibited VBD N
release NN N
of IN N
post-operative JJ N
inflammatory JJ N
factors NNS N
with IN N
a DT N
reduction NN N
in IN N
peri-operative JJ O
trauma NN O
and CC O
stress NN O
which WDT O
together RB N
played VBD N
a DT N
protective JJ N
role NN N
on IN N
the DT N
post-operative JJ N
immune NN N
system NN N
. . N

Combining VBG N
two CD N
treatment NN N
measures NNS N
during IN N
colon NN I
operation NN I
produced VBD N
better RBR N
protective JJ O
effects NNS O
via IN O
the DT O
immune JJ O
system NN O
. . O

The DT N
beneficial JJ N
clinical JJ N
effects NNS N
support NN N
that IN N
the DT N
better-preserved JJ N
post-operative JJ N
immune NN N
system NN N
may MD N
also RB N
contribute VB N
to TO N
the DT N
improvement NN N
of IN N
post-operative JJ N
results NNS N
in IN N
FT NNP P
laparoscopic NN P
patients NNS P
. . P

-DOCSTART- -X- N

A DT N
comparison NN N
of IN N
once RB N
and CC N
twice RB N
daily JJ N
atenolol NN I
for IN N
angina JJ P
pectoris NN P
. . P

We PRP P
have VBP N
studied VBN N
the DT N
effects NNS N
of IN N
four CD I
doses NNS I
of IN I
atenolol NN I
in IN N
11 CD P
patients NNS P
with IN P
stable JJ P
angina NNS P
pectoris VBP P
using VBG N
a DT N
symptom-limited JJ I
exercise NN I
test NN I
and CC I
angina NN I
diaries NNS I
. . I

The DT N
doses NNS N
100 CD N
mg JJ N
twice RB N
daily RB N
and CC N
50 CD N
mg NN N
100 CD N
mg NN N
and CC N
200 CD N
mg NN N
once RB N
daily JJ N
were VBD N
given VBN N
double-blind NNS N
and CC N
randomised VBD N
within IN N
patients NNS N
following VBG N
run-in NN N
on IN I
placebo NN I
. . I

Measurements NNS N
were VBD N
made VBN N
12 CD N
hours NNS N
after IN N
the DT N
last JJ N
twice JJ N
daily RB N
dose JJ N
and CC N
24 CD N
hours NNS N
after IN N
the DT N
last JJ N
once JJ N
daily JJ N
dose NN N
. . N

Exercise NN O
tolerance NN O
was VBD N
improved VBN N
by IN N
40-74% JJ N
and CC N
exercise JJ O
duration NN O
before IN O
the DT O
onset NN O
of IN O
angina NN O
by IN N
61-94% JJ N
(P NNP N
less JJR N
than IN N
0.01) CD N
. . N

Maximal JJ O
heart NN O
rate NN O
was VBD N
reduced VBN N
further RB N
by IN N
a DT N
total JJ N
daily JJ N
dose NN N
of IN N
200 CD N
mg NNS N
than IN N
by IN N
lower JJR N
doses NNS N
but CC N
no DT N
extra JJ N
benefit NN N
was VBD N
derived VBN N
by IN N
giving VBG N
the DT N
drug NN N
twice RB N
daily RB N
. . N

The DT N
largest JJS N
increase NN N
in IN N
exercise NN O
tolerance NN O
was VBD N
obtained VBN N
during IN N
treatment NN N
with IN N
50 CD N
mg NNS N
once RB N
daily RB N
. . N

Atenolol NNP I
was VBD N
shown VBN N
to TO N
be VB N
an DT N
effective JJ N
anti-anginal JJ N
agent NN N
when WRB N
given VBN N
once RB N
daily JJ N
and CC N
there EX N
were VBD N
no DT N
major JJ N
differences NNS N
between IN N
the DT N
doses NNS N
studied VBN N
. . N

-DOCSTART- -X- N

The DT N
effect NN N
of IN N
person-centred JJ I
dementia NN I
care NN I
to TO N
prevent VB N
agitation NN I
and CC N
other JJ N
neuropsychiatric JJ I
symptoms NNS N
and CC N
enhance JJ N
quality NN N
of IN N
life NN N
in IN N
nursing NN P
home NN P
patients: NN P
a DT N
10-month JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

AIMS IN N
We PRP N
examined VBD N
whether IN N
Dementia NNP I
Care NNP I
Mapping NNP I
(DCM) NN I
or CC I
the DT I
VIPS NNP I
practice NN I
model NN I
(VPM) NN I
is VBZ N
more RBR N
effective JJ N
than IN N
education NN I
of IN I
the DT I
nursing NN I
home NN I
staff NN I
about IN I
dementia NN I
(control NN I
group) NN I
in IN N
reducing VBG I
agitation NN N
and CC N
other JJ N
neuropsychiatric JJ I
symptoms NNS N
as RB N
well RB N
as IN N
in IN N
enhancing VBG N
the DT N
quality NN N
of IN N
life NN N
among IN N
nursing JJ P
home NN P
patients NNS P
. . P

METHODS NNP N
A DT N
10-month JJ N
three-armed JJ N
cluster-randomized JJ N
controlled VBN N
trial NN N
compared VBN N
DCM NNP I
and CC I
VPM NNP I
with IN I
control NN I
. . I

Of IN P
624 CD P
nursing NN P
home NN P
patients NNS P
with IN P
dementia JJ P
446 CD P
completed VBN P
follow-up JJ P
assessments NNS P
. . P

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
change NN N
on IN N
the DT N
Brief JJ O
Agitation NNP O
Rating NNP O
Scale NNP O
(BARS) NNP O
. . O

Secondary JJ N
outcomes NNS N
were VBD N
changes NNS N
on IN N
the DT N
10-item JJ O
version NN O
of IN O
the DT O
Neuropsychiatric NNP O
Inventory NNP O
Questionnaire NNP O
(NPI-Q) CD O
the DT O
Cornell NNP O
Scale NNP O
for IN O
Depression NNP O
in IN O
Dementia NNP O
(CSDD) NNP O
and CC O
the DT O
Quality NN O
of IN O
Life NNP O
in IN O
Late-Stage NNP O
Dementia NNP O
(QUALID) NNP O
scale NN O
. . O

RESULTS NNP N
Changes NNP N
in IN N
the DT N
BARS NNP O
score NN O
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
DCM NNP I
and CC N
the DT N
control NN N
group NN N
or CC N
between IN N
the DT N
VPM NNP I
and CC N
the DT N
control NN N
group NN N
after IN N
10 CD N
months NNS N
. . N

Positive JJ N
differences NNS N
were VBD N
found VBN N
for IN N
changes NNS N
in IN N
the DT N
secondary JJ N
outcomes: IN N
the DT N
NPI-Q NNP O
sum NN O
score NN O
as RB N
well RB N
as IN N
the DT N
subscales NNS N
NPI-Q NNP O
agitation NN O
and CC O
NPI-Q JJ O
psychosis NN O
were VBD N
in IN N
favour NN N
of IN N
both DT N
interventions NNS N
versus VBP N
control VB N
the DT N
QUALID NNP O
score NN O
was VBD N
in IN N
favour NN N
of IN N
DCM NNP I
versus NN N
control NN N
and CC N
the DT N
CSDD NNP O
score NN O
was VBD N
in IN N
favour NN N
of IN N
VPM NNP I
versus NN N
control NN N
. . N

CONCLUSIONS NNP N
This DT N
study NN N
failed VBD N
to TO N
find VB N
a DT N
significant JJ N
effect NN N
of IN N
both DT N
interventions NNS N
on IN N
the DT N
primary JJ N
outcome NN N
. . N

Positive JJ N
effects NNS N
on IN N
the DT N
secondary JJ N
outcomes NNS N
indicate VBP N
that IN N
the DT N
methods NNS N
merit VBP N
further JJ N
investigation NN N
. . N

-DOCSTART- -X- N

Clinical JJ N
benefits NNS N
of IN N
concurrent JJ N
capecitabine NN I
and CC I
cisplatin NN I
versus NN I
concurrent NN I
cisplatin NN I
and CC I
5-flurouracil JJ I
in IN N
locally RB P
advanced JJ P
squamous JJ P
cell NN P
head NN P
and CC P
neck NN P
cancer NN P
. . P

We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
concurrent JJ I
capecitabine NN I
and CC I
cisplatin NN I
over IN I
concurrent JJ I
cisplatin NN I
and CC I
5-flurouracil JJ I
(5-FU) NN I
in IN I
locally RB P
advanced JJ P
squamous JJ P
cell NN P
carcinoma NN P
of IN P
the DT P
head NN P
and CC P
neck NN P
. . P

One CD P
hundred CD P
and CC P
fifty-three JJ P
patients NNS P
(all NN P
of IN P
whom WP P
had VBD P
stage NN P
III NNP P
or CC P
IV NNP P
unresectable JJ P
disease NN P
with IN P
no DT P
distant JJ P
metastases NNS P
and CC P
who WP P
had VBD P
received VBN P
two CD P
cycles NNS P
of IN P
taxol NN P
and CC P
cisplatin NN P
chemotherapy) NN P
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
concurrent NN I
cisplatin NN I
(75 NNP I
mg/m(2) NN I
in IN I
day NN I
1 CD I
and CC I
2) CD I
and CC I
5-FU JJ I
(750 NN I
mg/m(2) NN I
in IN I
day NN N
1 CD N
2 CD N
and CC N
3) CD N
from IN N
the DT N
first JJ N
day NN N
of IN N
radiotherapy NN I
at IN N
an DT N
interval NN N
of IN N
3 CD N
weeks NNS N
(Arm JJ N
I) NNP N
or CC I
cisplatin VB I
(75 JJ N
mg/m(2) NNS N
in IN N
day NN N
1 CD N
and CC N
2) CD N
and CC N
capecitabine VB I
(750 NNP N
mg/m(2) NN N
in IN N
two CD N
divided JJ N
doses NNS N
from IN N
day NN N
1-14) CD N
from IN N
the DT N
first JJ N
day NN N
of IN N
radiotherapy NN N
at IN N
a DT N
3-week JJ N
interval NN N
(Arm NNP N
II) NNP N
. . N

Results NNS N
showed VBD N
that IN N
patients NNS N
in IN N
Arm NNP N
II NNP N
had VBD N
a DT N
significantly RB N
better RBR N
rate NN O
of IN O
complete JJ O
response NN O
fewer JJR O
nodes NNS O
and CC O
better JJR N
overall JJ O
response NN O
compared VBN N
to TO N
those DT N
in IN N
Arm NNP N
I PRP N
. . N

The DT N
two CD N
groups NNS N
had VBD N
a DT N
similar JJ N
3-year JJ O
disease-free JJ O
survival NN O
progression NN O
free JJ O
survival NN O
and CC O
overall JJ O
survival NN O
i.e NN O
. . N

they PRP N
did VBD N
not RB N
differ VB N
significantly RB N
. . N

Variables NNS N
indicating VBG N
the DT N
quality NN O
of IN O
life NN O
of IN N
the DT N
two CD N
groups NNS N
were VBD N
compared VBN N
. . N

Patients NNS N
in IN N
Arm NNP N
II NNP N
had VBD N
a DT N
significantly RB N
higher JJR O
quality NN O
of IN O
life NN O
compared VBN N
to TO N
those DT N
in IN N
Arm NNP N
I PRP N
. . N

The DT N
two CD N
groups NNS N
had VBD N
similar JJ N
treatment-related JJ N
acute NN O
and CC O
late JJ O
toxicity NN O
i.e NN O
. . N

they PRP N
did VBD N
not RB N
differ VB N
significantly RB N
. . N

These DT N
results NNS N
have VBP N
thoroughly RB N
substantiated VBN N
the DT N
contention NN N
that WDT N
concurrent JJ I
chemoradiation NN I
with IN I
capecitabine NN I
and CC I
cisplatin NN I
may MD N
be VB N
regarded VBN N
as IN N
an DT N
effective JJ N
and CC N
well-tolerated JJ N
regimen NNS N
in IN N
the DT N
treatment NN N
of IN N
the DT N
patients NNS P
with IN P
locally RB P
advanced VBN P
head NN P
and CC P
neck NN P
cancer NN P
. . P

-DOCSTART- -X- N

Improved VBN N
acidosis NN N
correction NN N
and CC N
recovery NN N
of IN N
mesothelial JJ N
cell NN N
mass NN N
with IN N
neutral-pH JJ I
bicarbonate JJ I
dialysis NN I
solution NN I
among IN N
children NNS P
undergoing VBG P
automated VBN P
peritoneal JJ P
dialysis NN P
. . P

Acid-base JJ P
balance NN N
and CC N
peritoneal JJ N
membrane NN N
longevity NN N
are VBP N
of IN N
utmost JJ N
relevance NN N
for IN N
pediatric JJ P
patients NNS P
undergoing VBG P
peritoneal JJ P
dialysis NN P
(PD) NN P
. . P

PD NNP N
fluids NNS N
with IN N
neutral JJ N
pH NN N
and CC N
reduced VBD N
glucose JJ N
degradation NN N
product NN N
contents NNS N
are VBP N
considered VBN N
more RBR N
biocompatible JJ N
because IN N
they PRP N
preserve VBP N
peritoneal JJ N
cell NN N
functions NNS N
in IN N
vitro NN N
. . N

To TO N
investigate VB N
the DT N
clinical JJ N
effects NNS O
of IN N
a DT N
novel JJ I
PD NNP I
fluid NN I
buffered VBD I
with IN I
34 CD I
mM NNS I
pure JJ I
bicarbonate NN I
at IN I
neutral JJ I
pH NN I
a DT I
randomized JJ N
prospective JJ N
crossover NN N
comparison NN N
with IN N
conventional JJ I
acidic JJ I
35 CD I
mM NN I
lactate NN I
PD NNP I
fluid NN I
was VBD N
performed VBN N
for IN N
two CD N
consecutive JJ N
12-wk JJ N
periods NNS N
with IN N
28 CD P
children NNS P
(age JJ P
6 CD P
mo NN P
to TO P
15 CD P
yr) NNS P
undergoing VBG P
automated VBD P
PD NNP P
(APD) NNP P
. . P

Blood NNP O
bicarbonate NN O
levels NNS O
and CC O
arterial JJ O
pH NN O
were VBD N
significantly RB N
higher JJR O
after IN N
3 CD N
mo NN N
of IN N
bicarbonate NN O
PD NNP O
(24.6 NNP N
+/- JJ N
2.3 CD N
mM NN N
and CC N
7.43 CD N
+/- JJ N
0.06 CD N
respectively) NNS N
compared VBN N
with IN N
lactate JJ O
PD NNP O
(22.8 NNP N
+/- JJ N
3.9 CD N
mM NN N
and CC N
7.38 CD N
+/- JJ N
0.05 CD N
respectively; NN N
P NNP N
< VBZ N
0.05) CD N
. . N

This DT N
effect NN N
was VBD N
reversible JJ N
among IN N
patients NNS N
who WP N
returned VBD N
from IN N
bicarbonate NN N
to TO N
lactate VB N
fluid NN N
. . N

Low JJ N
initial JJ O
pH NN O
and CC N
young JJ P
patient NN P
age NN P
independently RB N
predicted VBD N
increased VBN N
blood NN O
pH NN O
during IN N
bicarbonate NN O
APD NNP O
. . O

Peritoneal JJ N
equilibration NN N
tests NNS N
revealed VBD N
subtle JJ O
changes NNS O
in IN O
solute NN O
transport NN O
with IN O
a DT N
less RBR O
steep JJ O
creatinine NN O
equilibration NN O
curve NN O
during IN N
bicarbonate JJ N
dialysis NN N
suggesting VBG N
reduced VBN N
peritoneal JJ N
vasodilation NN N
. . N

The DT N
peritoneal JJ O
release NN O
of IN O
carcinogen JJ O
antigen-125 NNS O
increased VBD O
twofold NN N
during IN N
bicarbonate NN N
APD NNP N
(29 NNP N
+/- JJ N
15 CD N
versus NN N
15 CD N
+/- JJ N
8 CD N
U/ml NNP N
per IN N
4 CD N
h NN N
P NNP N
< NNP N
0.01) CD N
which WDT N
is VBZ N
consistent JJ N
with IN N
recovery NN N
of IN N
the DT N
mesothelial JJ N
cell NN N
layer NN N
. . N

This DT N
effect NN N
was VBD N
fully RB N
reversed VBN N
when WRB N
the DT N
patients NNS N
returned VBD N
to TO N
lactate VB N
fluid NN N
. . N

Effluent JJ O
carcinogen NN O
antigen-125 JJ O
levels NNS O
were VBD N
inversely RB N
correlated VBN N
with IN N
peritoneal JJ N
glucose JJ N
exposure NN N
during IN N
lactate NN N
but CC N
not RB N
bicarbonate VB N
APD NNP N
indicating VBG N
improved VBN N
in IN N
vivo JJ N
mesothelial NN N
cell NN N
tolerance NN N
of IN N
high-dose JJ N
glucose NN N
with IN N
the DT N
neutral-pH JJ I
PD NNP I
fluid NN I
with IN I
reduced VBN I
glucose JJ I
degradation NN I
product NN I
content NN I
. . I

Among IN P
children NNS P
undergoing VBG P
APD NNP P
neutral-pH JJ P
bicarbonate-buffered JJ I
PD NNP I
fluid NN I
provides VBZ N
more RBR N
effective JJ N
correction NN N
of IN N
metabolic JJ N
acidosis NN N
and CC N
better JJR N
preservation NN N
of IN N
peritoneal NN N
cell NN N
mass NN N
than IN N
do VBP N
conventional JJ I
acidic VB I
lactate-based JJ I
fluids NNS I
. . I

-DOCSTART- -X- N

Daclizumab NNP I
high-yield JJ N
process NN N
in IN N
relapsing-remitting JJ P
multiple JJ P
sclerosis NN P
(SELECT): VBD P
a DT N
randomised JJ N
double-blind JJ N
placebo-controlled JJ I
trial NN N
. . N

BACKGROUND NNP N
Daclizumab NNP I
a DT I
humanised JJ N
monoclonal JJ N
antibody NN N
modulates VBZ N
interleukin-2 JJ N
signalling NN N
by IN N
blocking VBG N
the DT N
 NNP N
subunit NN N
(CD25) NN N
of IN N
the DT N
interleukin-2 JJ N
receptor NN N
. . N

We PRP N
assessed VBD N
whether IN I
daclizumab JJ I
high-yield JJ I
process NN I
(HYP) NNP I
would MD N
be VB N
effective JJ N
when WRB N
given VBN N
as IN N
monotherapy NN N
for IN N
a DT N
1 CD N
year NN N
treatment NN N
period NN N
in IN P
patients NNS P
with IN P
relapsing-remitting JJ P
multiple JJ P
sclerosis NN P
. . N

METHODS NNP N
We PRP N
did VBD N
a DT N
randomised JJ N
double-blind JJ I
placebo-controlled JJ I
trial NN N
at IN P
76 CD P
centres NNS P
in IN P
the DT P
Czech NNP P
Republic NNP P
Germany NNP P
Hungary NNP P
India NNP P
Poland NNP P
Russia NNP P
Ukraine NNP P
Turkey NNP P
and CC P
the DT P
UK NNP P
between IN P
Feb NNP P
15 CD P
2008 CD P
and CC P
May NNP P
14 CD P
2010 CD P
. . P

Patients NNS P
aged VBN P
18-55 JJ P
years NNS P
with IN P
relapsing-remitting JJ P
multiple JJ P
sclerosis NN P
were VBD N
randomly RB N
assigned VBN N
(1:1:1) NNP N
via IN N
a DT N
central JJ N
interactive JJ N
voice NN N
response NN N
system NN N
to TO N
subcutaneous JJ N
injections NNS N
of IN I
daclizumab NN I
HYP NNP I
150 CD I
mg NN I
or CC I
300 CD I
mg NN I
or CC I
placebo NN I
every DT N
4 CD N
weeks NNS N
for IN N
52 CD N
weeks NNS N
. . N

Patients NNS N
and CC N
study NN N
personnel NNS N
were VBD N
masked VBN N
to TO N
treatment NN N
assignment NN N
except IN N
for IN N
the DT N
site NN N
pharmacist NN N
who WP N
prepared VBD N
the DT N
study NN N
drug NN N
for IN N
injection NN N
but CC N
had VBD N
no DT N
interaction NN N
with IN N
the DT N
patient NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD O
annualised VBN O
relapse NN O
rate NN O
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

The DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
number NN N
NCT00390221 NNP N
. . N

FINDINGS NNP P
204 CD P
patients NNS P
were VBD P
assigned VBN P
to TO P
receive VB P
placebo NN P
208 CD P
to TO P
daclizumab VB I
HYP NNP P
150 CD P
mg NN P
and CC P
209 CD P
to TO P
daclizumab VB I
HYP NNP I
300 CD N
mg NN N
of IN N
whom WP N
188 CD N
(92%) $ N
192 CD N
(92%) NNP N
and CC N
197 CD N
(94%) NN N
respectively RB N
completed VBD N
follow-up NN N
to TO N
week NN N
52 CD N
. . N

The DT N
annualised JJ O
relapse NN O
rate NN N
was VBD N
lower JJR N
for IN N
patients NNS N
given VBN I
daclizumab JJ I
HYP NNP I
150 CD N
mg NN N
(021 VBD N
95% CD N
CI NNP N
016-029; JJ N
54% CD N
reduction NN N
95% CD N
CI NNP N
33-68%; JJ N
p<00001) NN N
or CC N
300 CD N
mg JJ N
(023 NNP N
017-031 NN N
50% CD N
reduction NN N
28-65%; CD N
p=000015) NN N
than IN N
for IN N
those DT I
given VBN I
placebo NNS N
(046 JJ N
037-057) JJ N
. . N

More RBR N
patients NNS O
were VBD O
relapse JJ N
free JJ I
in IN I
the DT I
daclizumab NN I
HYP NNP N
150 CD N
mg NN N
(81%) NN N
and CC N
300 CD N
mg NN N
(80%) NN N
groups NNS N
than IN I
in IN I
the DT N
placebo NN N
group NN N
(64%; NNP N
p<00001 NN N
in IN N
the DT N
150 CD N
mg NN N
group NN N
and CC N
p=00003 NN N
in IN N
the DT N
300 CD N
mg NN N
group) NN N
. . N

12 CD N
(6%) JJ N
patients NNS I
in IN I
the DT N
placebo NN N
group NN N
15 CD N
(7%) NN N
of IN I
those DT I
in IN I
the DT I
daclizumab NN N
150 CD N
mg NN N
group NN N
and CC N
19 CD N
(9%) NN N
in IN N
the DT N
300 CD N
mg NN N
group NN O
had VBD O
serious JJ O
adverse JJ O
events NNS O
excluding VBG O
multiple JJ O
sclerosis NN O
relapse NN N
. . N

One CD N
patient NN I
given VBN I
daclizumab JJ I
HYP NNP N
150 CD N
mg NN N
who WP N
was VBD N
recovering VBG N
from IN N
a DT O
serious JJ O
rash NN N
died VBD N
because IN N
of IN N
local JJ N
complication NN N
of IN N
a DT N
psoas NN N
abscess NN N
. . N

INTERPRETATION NNP I
Subcutaneous NNP I
daclizumab NN I
HYP NNP N
administered VBD N
every DT N
4 CD N
weeks NNS N
led VBD N
to TO N
clinically RB N
important JJ N
effects NNS N
on IN N
multiple JJ N
sclerosis NN N
disease NN N
activity NN N
during IN N
1 CD N
year NN N
of IN N
treatment NN N
. . N

Our PRP$ N
findings NNS N
support VB N
the DT N
potential NN I
for IN I
daclizumab NN I
HYP NNP N
to TO N
offer VB N
an DT N
additional JJ N
treatment NN P
option NN P
for IN P
relapsing-remitting JJ P
disease NN N
. . N

FUNDING NN N
Biogen NNP N
Idec NNP N
and CC N
AbbVie NNP N
Biotherapeutics NNP N
Inc NNP N
. . N

-DOCSTART- -X- N

A DT N
prospective JJ N
placebo-controlled JJ I
randomized VBN N
trial NN N
of IN N
intravenous JJ I
streptokinase NN I
and CC I
angioplasty JJ I
versus NN I
lone NN I
angioplasty JJ I
therapy NN I
of IN N
acute JJ P
myocardial JJ P
infarction NN P
. . P

BACKGROUND IN N
The DT N
value NN N
of IN N
routine JJ N
administration NN N
of IN N
intravenous JJ I
thrombolytic JJ I
agents NNS I
during IN I
percutaneous JJ I
transluminal JJ I
coronary NN I
angioplasty NN I
(PTCA) NNP I
therapy NN I
of IN N
acute JJ P
myocardial JJ P
infarction NN P
(MI) NN P
has VBZ N
not RB N
been VBN N
determined VBN N
. . N

Therefore IN N
we PRP N
prospectively RB N
randomized VBD N
122 CD P
patients NNS P
with IN P
evolving VBG P
MI NNP P
to TO P
PTCA NNP P
therapy NN P
with IN P
or CC P
without IN P
adjunctive JJ P
intravenous JJ P
streptokinase NN P
therapy NN P
. . P

METHODS NNP N
AND CC N
RESULTS NNP N
Patients NNP P
with IN P
ECG NNP P
ST NNP P
segment NN P
elevation NN P
who WP P
presented VBD P
within IN P
4 CD P
hours NNS P
of IN P
symptom JJ P
onset NN P
had VBD P
no DT P
contraindication NN P
to TO P
thrombolytic JJ P
therapy NN P
and CC P
were VBD P
not RB P
in IN P
cardiogenic JJ P
shock NN P
were VBD P
enrolled VBN P
. . P

They PRP N
were VBD N
treated VBN N
immediately RB N
with IN N
intravenous JJ I
heparin NNS I
(10 VBP N
000 CD N
units) JJ N
and CC N
oral JJ I
aspirin NN I
(325 NNP N
mg) NN N
and CC N
randomized VBN N
to TO N
treatment NN N
with IN N
placebo NN I
or CC I
streptokinase VB I
(1.5 JJ I
M NNP I
units) NN I
administered VBD I
intravenously RB I
over IN N
30 CD N
minutes NNS N
. . N

Patients NNS N
then RB N
were VBD N
taken VBN N
immediately RB N
to TO N
the DT N
catheterization NN N
laboratory NN N
and CC N
those DT N
with IN N
suitable JJ N
coronary JJ N
anatomy NN N
underwent JJ N
immediate JJ N
PTCA NNP I
. . I

Subsequent JJ N
clinical JJ N
course NN N
serial JJ N
radionuclide NN N
ventriculography NN N
and CC N
6-month JJ N
repeat NN N
angiography NN N
were VBD N
analyzed VBN N
. . N

A DT N
total NN N
of IN N
106 CD P
patients NNS P
were VBD P
treated VBN P
with IN P
PTCA NNP I
. . I

Use NNP I
of IN I
PTCA NNP I
was VBD N
similar JJ N
for IN N
placebo NN I
(92%) NN N
and CC N
streptokinase VB I
(83%) JJ N
groups NNS N
. . N

Angioplasty NNP I
was VBD N
successful JJ N
in IN N
95% CD N
of IN N
patients NNS N
with IN N
no DT N
difference NN N
in IN N
placebo NN I
(93%) NN N
and CC N
streptokinase VB I
(98%) JJ N
groups NNS N
. . N

Serial JJ N
radionuclide NN N
ventriculography NN N
demonstrated VBD N
no DT N
difference NN N
in IN N
24-hour JJ N
(52 JJ N
+/- JJ N
12% CD N
versus NN N
50 CD N
+/- JJ N
12%) CD N
or CC N
6-week JJ N
(51 JJ N
+/- JJ N
12% CD N
versus NN N
51 CD N
+/- JJ N
13%) CD N
ejection NN O
fraction NN O
values NNS O
for IN N
placebo NN I
and CC I
streptokinase NN I
groups NNS N
respectively RB N
. . N

Contrast NNP N
ventriculography NN N
demonstrated VBD N
improvement NN N
in IN N
immediate JJ N
(54 JJ N
+/- JJ N
12%) CD N
versus IN N
6-month JJ N
(60 JJ N
+/- JJ N
15% CD N
p NN N
< VBD N
0.05) CD N
values NNS N
for IN N
the DT N
overall JJ N
group NN N
. . N

No DT N
differences NNS N
in IN N
6-month JJ O
values NNS O
were VBD N
present JJ N
(58 JJ N
+/- JJ N
15% CD N
versus NN N
62 CD N
+/- JJ N
15% CD N
p NN N
= NNP N
NS) NNP N
for IN N
placebo NN I
and CC I
streptokinase NN I
groups NNS N
respectively RB N
. . N

Coronary JJ O
angiography NN O
was VBD N
performed VBN N
in IN N
75% CD N
of IN N
the DT N
90 CD N
patients NNS N
eligible JJ N
for IN N
restudy NN N
. . N

Arterial JJ O
patency NN O
was VBD N
87% CD N
at IN N
6 CD N
months NNS N
and CC N
coronary JJ O
restenosis NN O
was VBD N
present JJ N
in IN N
38% CD N
of IN N
patients NNS N
. . N

No DT N
differences NNS N
in IN N
chronic JJ O
patency NN O
or CC O
restenosis NN O
were VBD N
detected VBN N
for IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Although IN N
adjunctive JJ N
intravenous JJ N
streptokinase NN I
therapy NN I
did VBD N
not RB N
improve VB N
outcome NN N
it PRP N
did VBD N
complicate VB N
the DT N
hospital NN N
course NN N
. . N

Hospitalization NN O
was VBD N
longer JJR N
(9.3 JJ N
+/- JJ N
5.0 CD N
versus NN N
7.7 CD N
+/- JJ N
4.4 CD N
days NNS N
p VBP N
= JJ N
0.046) CD N
and CC N
more JJR N
costly JJ O
($25 $ N
191 CD N
+/- JJ N
15 CD N
368 CD N
versus NN N
$19 VBD N
643 CD N
+/- JJ N
7 CD N
250 CD N
p NN N
< VBD N
0.02) CD N
. . N

Transfusion NN O
rate NN O
was VBD N
higher JJR N
(39% JJ N
versus NN N
8% CD N
p NN N
= NN N
0.0001) CD N
and CC N
need VB N
for IN N
emergency NN N
coronary JJ N
bypass NN N
surgery NN N
was VBD N
greater JJR N
(10.3% JJ N
versus NN N
1.6% CD N
p NN N
= VBD N
0.03) CD N
for IN N
the DT N
streptokinase-treated JJ I
patients NNS N
. . N

CONCLUSIONS NNP N
Adjunctive NNP I
intravenous JJ I
streptokinase NN I
therapy NN I
does VBZ N
not RB N
enhance VB N
early JJ N
preservation NN N
of IN N
ventricular JJ N
function NN N
improve VB N
arterial JJ O
patency NN O
rates NNS N
or CC N
lower JJR N
restenosis NN O
rates NNS N
after IN N
PTCA NNP I
therapy NN I
of IN N
acute JJ N
MI NNP N
. . N

Hospital NNP N
course NN N
is VBZ N
longer RB N
more RBR N
expensive JJ N
and CC N
more RBR N
complicated JJ N
. . N

For IN N
these DT N
reasons NNS N
PTCA NNP I
therapy NN I
of IN I
acute JJ I
MI NNP I
should MD N
not RB N
be VB N
routinely RB N
performed VBN N
with IN N
adjunctive JJ I
intravenous JJ I
streptokinase NN I
therapy NN I
. . I

-DOCSTART- -X- N

The DT N
effect NN N
of IN N
deep JJ I
brain NN I
stimulation NN I
randomized VBN N
by IN N
site NN N
on IN N
balance NN N
in IN N
Parkinson's NNP P
disease NN P
. . P

BACKGROUND IN N
The DT N
effect NN N
of IN N
the DT N
surgical JJ N
site NN N
of IN N
DBS NNP I
on IN N
balance NN N
and CC N
gait NN N
in IN N
Parkinson's NNP P
Disease NNP P
(PD) NNP P
is VBZ N
uncertain JJ N
. . N

This DT N
is VBZ N
the DT N
first JJ N
double-blind NN N
study NN N
of IN N
subjects NNS P
randomized VBN P
to TO P
either CC P
the DT P
STN NNP P
(N NNP P
= VBZ P
14) CD P
or CC P
GPi NNP P
(N NNP P
= NNP P
14) CD P
who WP P
were VBD P
assessed VBN P
on IN P
a DT P
range NN P
of IN P
clinical JJ P
balance NN P
measures NNS P
. . P

METHODS NNP I
Balance NNP I
testing VBG I
occurred VBD I
before IN I
and CC I
6 CD I
months NNS I
postsurgery NN I
. . I

A DT P
control NN P
PD NNP P
group NN P
was VBD P
tested VBN P
over IN P
the DT P
same JJ P
period NN P
without IN P
surgery NN P
(N NN P
= VBD P
9) CD P
. . P

All DT I
subjects NNS I
were VBD I
tested VBN I
on IN I
and CC I
off IN I
medication NN I
and CC I
DBS NNP I
subjects NNS I
were VBD I
also RB I
tested VBN I
on IN I
and CC I
off IN I
DBS NNP I
. . I

The DT O
Postural NNP O
Instability NNP O
and CC O
Gait NNP O
Disability NNP O
items NNS O
of IN O
the DT O
UPDRS NNP O
and CC O
additional JJ O
functional NN O
tests NNS O
which WDT O
we PRP O
call VBP O
the DT O
Balance NNP O
and CC O
Gait NNP O
scale NN O
were VBD O
assessed VBN N
. . N

Activities NNS O
of IN O
Balance NNP O
Confidence NNP O
and CC O
Activities NNP O
of IN O
Daily NNP O
Living NNP O
questionnaires NNS O
were VBD N
also RB N
recorded VBN N
. . N

RESULTS NNP N
Balance NNP N
was VBD N
not RB N
different JJ N
between IN N
the DT N
best-treated JJ N
states NNS N
before IN N
and CC N
after IN N
DBS NNP I
surgery NN I
for IN N
both DT N
sites NNS N
. . N

Switching VBG N
DBS NNP I
on IN N
improved JJ N
balance NN O
scores NNS O
and CC O
scores NNS N
further RBR N
improved VBN N
with IN N
medication NN N
compared VBN N
to TO N
the DT N
off RP N
state NN N
. . N

The DT N
GPi NNP I
group NN I
showed VBD N
improved JJ N
performance NN N
in IN N
the DT N
postsurgery NN O
off IN O
state NN O
and CC N
better JJR O
ratings NNS O
of IN O
balance NN O
confidence NN O
after IN N
surgery NN N
compared VBN N
to TO N
the DT N
STN NNP I
group NN N
. . N

CONCLUSIONS NNP N
Clinical NNP N
measures NNS N
of IN N
balance NN N
function NN N
for IN N
both DT N
the DT N
STN NNP I
and CC I
GPi NNP I
sites NNS N
showed VBD N
that IN N
balance NN N
did VBD N
not RB N
improve VB N
beyond IN N
the DT N
best JJS N
medically RB N
treated VBN N
state NN N
before IN N
surgery NN N
. . N

Both DT N
clinical JJ N
balance NN N
testing NN N
in IN N
the DT N
off/off NN N
state NN N
and CC N
self-reported JJ N
balance NN N
confidence NN N
after IN N
surgery NN N
showed VBD N
better JJR N
performance NN N
in IN N
the DT N
GPi NNP I
than IN N
the DT N
STN NNP I
group NN N
. . N

-DOCSTART- -X- N

The DT N
effect NN N
of IN N
neighborhood-based JJ I
community NN I
organizing: JJ I
results NNS N
from IN N
the DT N
Seattle NNP P
Minority NNP P
Youth NNP P
Health NNP P
Project NNP P
. . P

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
community NN I
mobilization NN I
and CC I
youth NN I
development NN I
strategy NN I
to TO N
prevent VB N
drug NN N
abuse NN N
violence NN N
and CC N
risky JJ N
sexual JJ N
activity NN N
. . N

DATA NNP N
SOURCES/STUDY NNP N
SETTING NNP N
Primary NNP P
surveys NNS P
of IN P
youth NN P
parents NNS P
and CC P
key JJ P
neighborhood NN P
leaders NNS P
were VBD P
carried VBN P
out RP P
at IN P
baseline NN P
(1994) NN P
and CC P
at IN P
the DT P
end NN P
of IN P
the DT P
intervention NN P
period NN P
(1997) NNP P
. . N

The DT N
study NN N
took VBD N
place NN N
in IN N
four CD P
intervention NN P
and CC P
six CD P
control NN P
neighborhoods NNS P
in IN P
Seattle NNP P
. . P

STUDY NNP N
DESIGN NNP N
The DT N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
with IN N
neighborhood NN N
as IN N
the DT N
unit NN N
of IN N
randomization NN N
. . N

The DT N
intervention NN N
consisted VBD N
of IN N
a DT N
paid VBN I
community NN I
organizer NN I
in IN I
each DT I
neighborhood NN I
who WP I
recruited VBD I
a DT I
group NN I
of IN I
residents NNS P
to TO P
serve VB P
as IN P
a DT P
community NN P
action NN P
board NN P
. . P

Key NNP N
variables NNS N
included VBD N
perceptions NNS O
of IN O
neighborhood NN O
mobilization NN O
by IN N
youth NN N
parents NNS N
and CC N
key JJ N
neighborhood NN N
leaders NNS N
. . N

DATA NNP N
COLLECTION/EXTRACTION NNP N
METHODS NNP N
Youth NNP N
surveys NNS N
were VBD N
self-administered JJ N
during IN N
school NN N
hours NNS N
. . N

Parent NN O
and CC O
neighborhood NN O
leader NN O
surveys NNS O
were VBD N
conducted VBN N
over IN N
the DT N
phone NN N
by IN N
trained JJ N
interviewers NNS N
. . N

PRINCIPAL NNP N
FINDINGS NNP N
Survey NNP N
results NNS N
showed VBD N
that IN N
mobilization NN O
increased VBD N
to TO N
the DT N
same JJ N
degree NN N
in IN N
both DT N
intervention NN N
and CC N
control NN N
neighborhoods NNS N
with IN N
no DT N
evidence NN N
of IN N
an DT N
overall JJ N
intervention NN N
effect NN N
. . N

There EX N
did VBD N
appear VB N
to TO N
be VB N
a DT N
relative JJ N
increase NN N
in IN N
mobilization NN O
in IN I
the DT N
neighborhood NN N
with IN N
the DT N
highest JJS N
level NN O
of IN O
intervention NN O
activity NN O
. . O

CONCLUSION NN N
This DT N
randomized VBN N
study NN N
failed VBD N
to TO N
demonstrate VB N
a DT N
measurable JJ N
effect NN N
for IN N
a DT N
community NN I
mobilization NN I
intervention NN I
. . I

It PRP N
is VBZ N
uncertain JJ N
whether IN N
the DT N
negative JJ N
finding NN N
was VBD N
because IN N
of IN N
a DT N
lack NN N
of IN N
strength NN N
of IN N
the DT N
interventions NNS N
or CC N
problems NNS N
detecting VBG N
intervention NN N
effects NNS N
using VBG N
individual-level JJ N
closed-end JJ N
surveys NNS N
. . N

-DOCSTART- -X- N

[The JJ N
comparison NN N
of IN N
the DT N
effect NN N
of IN N
enalapril NN I
and CC I
indapamide NN I
on IN N
the DT N
peripheral JJ O
blood NN O
pressure NN O
and CC O
central JJ O
blood NN O
pressure NN O
through IN N
pulse JJ N
wave NN N
analysis] NN N
. . N

OBJECTIVES IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS O
of IN N
the DT N
angiotensin-converting JJ I
enzyme NN I
(ACE) NNP I
inhibitor NN I
enalapril NN I
and CC I
diuretic JJ I
indapamide NN I
on IN N
the DT N
peripheral JJ O
blood NN O
pressure NN O
and CC O
the DT O
central JJ O
blood NN O
pressure NN O
in IN N
Chinese JJ P
patients NNS P
with IN P
essential JJ P
hypertension NN P
. . P

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
double JJ N
blind NN N
randomized VBN N
study NN N
. . N

Informed VBN N
consent NN P
were VBD P
given VBN P
by IN P
all DT P
patients NNS P
. . P

After IN N
2 CD N
weeks NNS N
of IN N
placebo JJ I
run-in JJ N
period NN N
105 CD P
patients NNS P
with IN P
mild JJ P
or CC P
moderate JJ P
essential JJ P
hypertension NN P
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
enalapril NN I
(10 NNP N
mg NN N
per IN N
day) NN N
or CC I
indapamide VB I
(2.5 CD N
mg FW N
per IN N
day) NN N
for IN N
8 CD N
weeks NNS N
. . N

Radial JJ N
pulse NN N
wave NN N
recordings NNS N
were VBD N
performed VBN N
in IN N
all PDT N
the DT N
patients NNS N
before IN N
the DT N
active JJ N
treatments NNS N
were VBD N
given VBN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

Only RB N
those DT P
patients NNS P
who WP P
have VBP P
finished VBN P
8 CD P
weeks NNS P
of IN P
active JJ P
treatment NN P
in IN P
both DT P
groups NNS P
were VBD P
included VBN P
into IN P
the DT P
final JJ P
analysis NN P
. . P

RESULTS NNP N
One CD P
hundred VBD P
one CD P
patients NNS P
(51 VBP P
in IN P
enalapril NN P
group NN P
and CC P
50 CD P
in IN P
indapamide NN P
group) NN P
completed VBD P
the DT P
study NN P
. . P

No DT N
significant JJ N
difference NN N
(all NN N
P NNP N
values VBZ N
> $ N
0.05) CD N
was VBD N
found VBN N
in IN N
baseline NN N
data NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

After IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
all PDT N
the DT N
parameters NNS O
of IN O
pulse JJ O
wave NN O
(except NNP N
heart NN N
rates NNS N
in IN N
both DT N
groups NNS N
and CC N
augmentation NN N
index NN N
in IN N
indapamide JJ I
group) NN N
decreased VBN N
significantly RB N
. . N

Comparison NNP N
of IN N
the DT N
2 CD N
groups NNS N
showed VBD N
that IN N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
(all VBP N
P NNP N
values NNS N
> VBP N
0.05) CD N
in IN N
all PDT N
the DT N
parameters NNS N
of IN N
pulse JJ N
wave NN N
except IN N
that IN N
the DT N
central JJ O
systolic JJ O
blood NN O
pressure NN O
augmentation NN O
and CC N
augmentation NN N
index NN N
were VBD N
significantly RB N
lower JJR N
in IN N
enalapril NN I
group NN N
than IN N
in IN N
indapamide JJ I
group NN N
. . N

In IN N
enalapril JJ I
group NN N
the DT N
reduced VBN N
values NNS N
of IN N
systolic JJ O
blood NN O
pressure NN O
and CC O
pulse JJ O
pressure NN O
in IN N
central JJ N
aorta NNS N
were VBD N
significantly RB N
larger JJR N
than IN N
those DT N
in IN N
brachial JJ N
artery NN N
. . N

However RB N
the DT N
difference NN N
was VBD N
not RB N
observed VBN N
in IN N
indapamide JJ I
group NN N
. . N

CONCLUSIONS NNP N
Enalapril NNP I
and CC I
indapamide NN I
are VBP N
both DT N
similarly RB N
effective JJ N
in IN N
reducing VBG N
peripheral JJ O
arterial JJ O
blood NN O
pressure NN O
. . O

Moreover RB N
enalapril NN I
is VBZ N
more RBR N
effective JJ N
in IN N
reducing VBG N
central JJ O
systolic JJ O
pressure NN O
and CC O
augmentation NN O
index NN O
than IN N
indapamide NN I
. . I

The DT N
difference NN N
is VBZ N
probably RB N
due JJ N
to TO N
the DT N
reduction NN N
of IN N
wave NN O
reflection NN O
caused VBN N
by IN N
enalapril NN I
. . I

-DOCSTART- -X- N

A DT N
prospective JJ N
double-blind NN N
randomized VBD N
controlled JJ N
clinical JJ N
trial NN N
comparing VBG N
standard NN I
wound NN I
care NN I
with IN I
adjunctive JJ I
hyperbaric JJ I
oxygen NN I
therapy NN I
(HBOT) NN I
to TO N
standard VB I
wound NN I
care NN I
only RB N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ P
non-healing JJ P
ulcers NNS P
of IN P
the DT P
lower JJR P
limb NN P
in IN P
patients NNS P
with IN P
diabetes NNS P
mellitus: VBP P
a DT N
study NN N
protocol NN N
. . N

BACKGROUND NN N
It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
the DT N
use NN N
of IN N
adjunctive JJ I
hyperbaric JJ I
oxygen NN I
therapy NN I
improves VBZ N
the DT N
healing NN N
of IN N
diabetic JJ P
foot NN P
ulcers NNS P
and CC P
decreases VBZ N
the DT N
risk NN N
of IN N
lower JJR O
extremity NN O
amputations NNS O
. . O

A DT N
limited JJ N
number NN N
of IN N
studies NNS N
have VBP N
used VBN N
a DT N
double JJ N
blind NN N
approach NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
hyperbaric JJ I
oxygen NN I
therapy NN I
in IN I
the DT N
treatment NN N
of IN N
diabetic JJ P
ulcers NNS P
. . P

The DT N
primary JJ N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
hyperbaric JJ I
oxygen NN I
therapy NN I
plus CC I
standard NN I
wound NN I
care NN I
compared VBN N
with IN N
standard NN I
wound NN I
care NN I
alone RB N
in IN N
preventing VBG N
the DT N
need NN N
for IN N
major JJ O
amputation NN O
in IN N
patients NNS P
with IN P
diabetes NNS P
mellitus NNS P
and CC P
chronic JJ P
ulcers NNS P
of IN P
the DT P
lower JJR P
limb NN P
. . P

METHODS/DESIGN NNP N
One CD P
hundred CD P
and CC P
eighteen JJ P
(59 NN P
patients NNS P
per IN P
arm) NN P
patients NNS P
with IN P
non-healing JJ P
diabetic JJ P
ulcers NNS P
of IN P
the DT P
lower JJR P
limb NN P
referred VBD P
to TO P
the DT P
Judy NNP P
Dan NNP P
Research NNP P
and CC P
Treatment NNP P
Centre NNP P
are VBP P
being VBG P
recruited VBN P
if IN P
they PRP P
are VBP P
at IN P
least JJS P
18 CD P
years NNS P
of IN P
age NN P
have VBP P
either DT P
Type NNP P
1 CD P
or CC P
2 CD P
diabetes NNS P
with IN P
a DT P
Wagner NNP P
grading NN P
of IN P
foot NN P
lesions NNS P
2 CD P
3 CD P
or CC N
4 CD N
on IN N
lower JJR N
limb NN N
not RB N
healing VBG N
for IN N
at IN N
least JJS N
4 CD N
weeks NNS N
. . N

Patients NNS N
receive VBP N
hyperbaric JJ I
oxygen NN I
therapy NN I
every DT I
day NN I
for IN I
6 CD I
weeks NNS I
during IN I
the DT I
treatment NN I
phase NN I
and CC N
are VBP N
provided VBN N
ongoing VBG I
wound NN I
care NN I
and CC N
weekly JJ N
assessments NNS N
. . N

Patients NNS N
are VBP N
required VBN N
to TO N
return VB N
to TO N
the DT N
study NN N
centre NN N
every DT N
week NN N
for IN N
an DT N
additional JJ N
6 CD N
weeks NNS N
of IN N
follow-up NN N
for IN N
wound JJ N
evaluation NN N
and CC N
management NN N
. . N

The DT N
primary JJ N
outcome NN N
is VBZ N
freedom RB O
from IN O
having VBG O
or CC O
meeting VBG O
the DT O
criteria NN O
for IN O
a DT O
major JJ O
amputation NN O
(below NNP O
knee NN O
amputation NN O
or CC O
metatarsal NN O
level) VBZ O
up IN N
to TO N
12 CD N
weeks NNS N
after IN N
randomization NN N
. . N

The DT N
decision NN N
to TO N
amputate VB N
is VBZ N
made VBN N
by IN N
a DT N
vascular JJ N
surgeon NN N
. . N

Other JJ N
outcomes NNS N
include VBP N
wound IN O
healing VBG O
effectiveness NN O
safety NN O
healthcare NN O
resource NN O
utilization NN O
quality NN O
of IN O
life NN O
and CC O
cost-effectiveness NN O
. . O

The DT N
study NN N
will MD N
run VB N
for IN N
a DT N
total NN N
of IN N
about IN N
3 CD N
years NNS N
. . N

DISCUSSION NNP N
The DT N
results NNS N
of IN N
this DT N
study NN N
will MD N
provide VB N
detailed JJ N
information NN N
on IN N
the DT N
efficacy NN N
of IN N
hyperbaric JJ I
oxygen NN I
therapy NN I
for IN N
the DT N
treatment NN N
of IN N
non-healing JJ P
ulcers NNS P
of IN P
the DT P
lower JJR P
limb NN P
. . P

This DT N
will MD N
be VB N
the DT N
first JJ N
double-blind JJ N
randomized VBN N
controlled JJ N
trial NN N
for IN N
this DT N
health NN N
technology NN N
which WDT N
evaluates VBZ N
the DT N
efficacy NN N
of IN N
hyperbaric JJ I
oxygen NN I
therapy NN I
in IN N
prevention NN N
of IN N
amputations NNS O
in IN N
diabetic JJ P
patients NNS P
. . P

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
Identifier: NNP N
NCT00621608 NNP N
. . N

-DOCSTART- -X- N

The DT N
effect NN N
of IN N
polyvinylpyrrolidone-iodine NN I
as IN N
an DT N
disinfectant NN N
in IN N
eye NN P
surgery NN P
. . P

105 CD P
patients NNS P
admitted VBN P
for IN P
cataract NN P
surgery NN P
were VBD N
treated VBN N
pre-operatively RB N
with IN N
polyvinylpyrrolidone-iodine JJ I
(PVP-I) JJ I
as IN N
a DT N
disinfectant NN N
and CC N
consecutive JJ N
bacterial JJ N
cultures NNS N
were VBD N
obtained VBN N
before IN N
initiating VBG N
surgery NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
operation NN N
. . N

A DT P
control NN P
group NN P
(n NNP P
= VBZ P
99) CD P
only RB N
had VBD N
a DT N
standard JJ I
disinfection NN I
procedure NN I
of IN I
the DT I
eye NN I
(including VBG N
instillation NN N
of IN N
Terramycin NNP I
cum NN I
polymyxin NN I
B NNP I
cream NN I
in IN N
the DT N
conjunctival NN N
sac VBD N
the DT N
evening NN N
before IN N
surgery) NN N
. . N

The DT N
cultures NNS N
obtained VBN N
from IN N
the DT N
conjunctival NN N
sac NN N
of IN N
the DT N
control NN N
group NN N
principally RB N
showed VBD N
growth NN N
of IN N
Staph NNP N
. . N

albus NN N
and CC N
Staph NNP N
. . N

aureus NN N
and CC N
to TO N
a DT N
minor JJ N
degree NN N
diphtheroids NNS N
(Corynebacterium NN N
species) NN N
. . N

Proteus NNP N
mirabilis PRP N
Escherichia NNP N
coli NNS N
and CC N
micrococci NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
quantitative JJ N
diminished VBN N
growth NN O
(P NNP N
less JJR N
than IN N
0.05) CD N
of IN N
bacteria NNS N
in IN N
the DT N
group NN N
of IN N
patients NNS N
treated VBN N
with IN N
PVP-I NNP I
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Concerning VBG N
the DT N
growth NN N
of IN N
Staph NNP N
. . N

albus NN N
this DT N
was VBD N
reduced VBN N
to TO N
almost RB N
one CD N
third JJ N
and CC N
other JJ N
bacteria NNS N
were VBD N
almost RB N
eliminated VBN N
in IN N
the DT N
group NN N
receiving VBG N
PVP-I NNP I
. . I

As IN N
we PRP N
disclosed VBD N
no DT N
toxic NN O
or CC O
allergic JJ O
reaction NN O
post-operatively RB O
which WDT N
could MD N
be VB N
related VBN N
to TO N
the DT N
use NN N
of IN N
PVP-I NNP I
as IN N
a DT N
disinfectant NN N
this DT N
agent NN N
seems VBZ N
to TO N
constitute VB N
an DT N
effective JJ O
pre-operative JJ N
antimicrobial JJ N
treatment NN N
taking VBG N
into IN N
consideration NN N
the DT N
broad JJ N
antimicrobial JJ N
spectrum NN N
of IN N
PVP-I NNP I
shown VBN N
by IN N
other JJ N
authors NNS N
. . N

-DOCSTART- -X- N

Studies NNS N
on IN N
leptin NN O
and CC O
leptin NN O
receptor NN O
gene NN O
expression NN O
in IN N
myometrium NN P
and CC P
uterine JJ P
myomas NN P
of IN P
gnRH JJ P
analogue-treated JJ P
women NNS P
. . P

AIM NNP N
To TO N
test VB N
if IN N
treatment NN N
with IN N
GnRH NNP I
analogue NN I
which WDT I
leads VBZ N
to TO N
a DT N
significant JJ N
reduction NN N
in IN N
myoma NN O
volume NN O
changes NNS O
expression NN O
of IN O
leptin NN O
genes NNS O
and CC O
gene NN O
coding VBG O
leptin JJ O
receptor NN O
isoforms NNS O
in IN N
uterine JJ N
myomas NN N
and CC N
in IN N
the DT N
surrounding NN N
unaltered JJ N
myometrium NN N
. . N

METHODS NNP N
Using NNP N
RT-PCR NNP N
expression NN N
of IN N
leptin NN N
genes NNS N
and CC N
leptin NN N
receptor NN N
genes NNS N
was VBD N
studied VBN N
in IN N
myomas NN P
and CC P
in IN P
the DT P
surrounding VBG P
myometrium NN P
in IN P
women NNS P
with IN P
uterine JJ P
myomas NN P
untreated VBD P
or CC P
treated VBN P
with IN P
GnRH NNP P
analogue NN P
. . P

In IN N
the DT N
randomly RB N
selected VBN N
cases NNS N
presence NN N
of IN N
leptin NN N
protein NN N
and CC N
of IN N
leptin JJ N
receptor NN N
proteins NNS N
was VBD N
examined VBN N
also RB N
by IN N
Western JJ N
blotting NN N
. . N

RESULTS NNP N
Expression NNP O
of IN O
leptin NN O
genes NNS O
was VBD N
demonstrated VBN N
both DT N
in IN N
myomas NN N
and CC N
in IN N
the DT N
surrounding VBG N
myometrium NN N
and CC N
a DT N
similar JJ N
pattern NN N
of IN N
expression NN N
was VBD N
found VBN N
for IN N
leptin JJ N
receptor NN N
isoforms NNS N
. . N

The DT N
results NNS N
of IN N
RT-PCR NNP N
were VBD N
confirmed VBN N
by IN N
Western NNP N
blotting VBG N
which WDT N
documented VBD N
the DT N
identical JJ N
distribution NN N
of IN N
leptin NN N
proteins NNS N
and CC N
leptin JJ N
receptor NN N
proteins NNS N
in IN N
studied JJ N
tissues NNS N
. . N

Treatment NN N
with IN N
GnRH NNP I
analogue NN I
had VBD N
no DT N
effect NN O
on IN N
the DT N
expression NN O
pattern NN O
of IN N
studied VBN N
genes NNS N
. . N

CONCLUSION NNP N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
on IN N
the DT N
administration NN N
of IN N
GnRH NNP I
analogue NN I
to TO N
females NNS P
with IN P
myomas NN P
suggest VBP N
that IN N
no DT N
direct JJ N
or CC N
immediate JJ N
inter-relationship JJ N
exists NNS N
between IN N
expression NN N
of IN N
leptin NN N
genes NNS N
in IN N
uterine JJ N
myomas NN N
on IN N
one CD N
hand NN N
and CC N
estrogen NN N
progesterone NN N
and CC N
leptin NN N
levels NNS N
in IN N
the DT N
blood NN N
on IN N
the DT N
other JJ N
. . N

Expression NN N
seems VBZ N
to TO N
be VB N
of IN N
a DT N
more RBR N
durable JJ N
nature NN N
but CC N
factors NNS N
that WDT N
induce VBP N
such JJ N
expression NN N
remain VBP N
unknown JJ N
. . N

-DOCSTART- -X- N

Multicomponent NNP I
interdisciplinary JJ I
group NN I
intervention NN I
for IN I
self-management NN I
of IN I
fibromyalgia: NN P
a DT I
mixed-methods NNS I
randomized VBN I
controlled JJ I
trial NN I
. . I

BACKGROUND NNP I
This DT I
study NN I
evaluated VBD I
the DT I
efficacy NN O
of IN I
the DT I
PASSAGE NNP I
Program NNP I
a DT I
structured JJ I
multicomponent NN I
interdisciplinary JJ I
group NN I
intervention NN I
for IN I
the DT I
self-management NN I
of IN I
FMS NNP I
. . I

METHODS NNP I
A DT I
mixed-methods NNS I
randomized VBN I
controlled JJ I
trial NN I
(intervention NN I
(INT) NNP I
vs NN I
. . I

waitlist NN I
(WL)) NN I
was VBD I
conducted VBN I
with IN I
patients NNS P
suffering VBG P
from IN P
FMS NNP P
. . P

Data NNS I
were VBD I
collected VBN I
at IN I
baseline NN I
(T0) NN I
at IN I
the DT I
end NN I
of IN I
the DT I
intervention NN I
(T1) NNP I
and CC I
3 CD I
months NNS I
later RB I
(T2) NNP I
. . I

The DT I
primary JJ I
outcome NN I
was VBD I
change NN O
in IN O
pain NN O
intensity NN O
(0-10) NN I
. . I

Secondary JJ I
outcomes NNS I
were VBD I
fibromyalgia JJ O
severity NN O
pain NN O
interference NN O
sleep JJ O
quality NN O
pain VBP O
coping VBG O
strategies NNS O
depression NN O
health-related JJ O
quality NN O
of IN O
life NN O
patient NN O
global JJ O
impression NN O
of IN O
change NN O
(PGIC) NNP O
and CC O
perceived VBD O
pain NN O
relief NN O
. . O

Qualitative JJ I
group NN I
interviews NNS I
with IN I
a DT I
subset NN I
of IN I
patients NNS I
were VBD I
also RB I
conducted VBN I
. . I

Complete JJ I
data NNS I
from IN I
T0 NNP I
to TO I
T2 NNP I
were VBD I
available JJ I
for IN I
43 CD P
patients NNS P
. . P

RESULTS VB P
The DT I
intervention NN I
had VBD I
a DT I
statistically RB I
significant JJ I
impact NN I
on IN I
the DT I
three CD I
PGIC NNP I
measures NNS I
. . I

At IN I
the DT I
end NN I
of IN I
the DT I
PASSAGE NNP I
Program NNP I
the DT I
percentages NNS I
of IN I
patients NNS I
who WP I
perceived VBD I
overall JJ I
improvement NN I
in IN I
their PRP$ I
pain NN O
levels NNS O
functioning VBG O
and CC O
quality NN O
of IN O
life NN O
were VBD I
significantly RB I
higher JJR I
in IN I
the DT I
INT NNP I
Group NNP I
(73% VBD I
55% CD I
77% CD I
respectively) NN I
than IN I
in IN I
the DT I
WL NNP I
Group NNP I
(8% VBD I
12% CD I
20%) CD I
. . I

The DT I
same JJ I
differences NNS I
were VBD I
observed JJ I
3 CD I
months NNS I
post-intervention JJ I
(Intervention NNP I
group: NN I
62% CD I
43% CD I
38% CD I
vs NNS I
Waitlist NNP I
Group: NNP I
13% CD I
13% CD I
9%) CD I
. . I

The DT I
proportion NN I
of IN I
patients NNS I
who WP I
reported VBD I
 JJ N
50% CD O
pain NN O
relief NN O
was VBD I
also RB I
significantly RB I
higher RBR I
in IN I
the DT I
INT NNP I
Group NNP I
at IN I
the DT I
end NN I
of IN I
the DT I
intervention NN I
(36% NNP I
vs VBZ I
12%) CD I
and CC I
3 CD I
months NNS I
post-intervention JJ I
(33% NNP I
vs NN I
4%) CD I
. . I

Results NNS I
of IN I
the DT I
qualitative JJ I
analysis NN I
were VBD I
in IN I
line NN I
with IN I
the DT I
quantitative JJ I
findings NNS I
regarding VBG I
the DT I
efficacy NN I
of IN I
the DT I
intervention NN I
. . I

The DT I
improvement NN I
however RB I
was VBD I
not RB I
reflected VBN I
in IN I
the DT I
primary JJ I
outcome NN I
and CC I
other JJ I
secondary JJ I
outcome NN I
measures NNS I
. . I

CONCLUSION NNP I
The DT I
PASSAGE NNP I
Program NNP I
was VBD I
effective JJ I
in IN I
helping VBG P
FMS NNP P
patients NNS P
gain VBP I
a DT I
sense NN I
of IN I
control NN I
over IN I
their PRP$ I
symptoms NNS I
. . I

We PRP I
suggest VBP I
including VBG I
PGIC NNP I
in IN I
future JJ I
clinical JJ I
trials NNS I
on IN P
FMS NNP P
as IN I
they PRP I
appear VBP I
to TO I
capture VB I
important JJ I
aspects NNS I
of IN I
the DT I
patients' NN I
experience NN I
. . I

TRIAL NNP I
REGISTRATION NNP I
International NNP I
Standard NNP I
Randomized NNP I
Controlled NNP I
Trial NNP I
Number NNP I
Register NNP I
ISRCTN14526380 NNP I
. . I

-DOCSTART- -X- N

Aminocaproic NNP I
acid VBZ I
versus FW I
prednisone NN I
for IN N
the DT N
treatment NN N
of IN N
traumatic JJ P
hyphema NN P
. . P

A DT N
randomized JJ N
clinical JJ N
trial NN N
. . P

One CD P
hundred CD P
twelve NN P
patients NNS P
who WP P
sustained VBD P
hyphema NN P
after IN P
blunt NN P
trauma NN P
were VBD P
enrolled VBN P
in IN N
a DT N
double-blind JJ N
randomized JJ N
clinical JJ N
trial NN N
to TO N
determine VB N
the DT N
relative JJ N
efficacies NNS N
of IN N
aminocaproic JJ I
acid NN I
(Amicar) NN I
and CC I
systemic JJ I
prednisone NN I
for IN N
reducing VBG N
the DT N
rate NN O
of IN O
secondary JJ O
hemorrhage NN O
. . O

Fifty-six JJ P
patients NNS P
received VBD P
an DT P
oral JJ P
dosage NN I
of IN I
50 CD I
mg/kg NN I
of IN I
aminocaproic JJ I
acid NN I
every DT I
4 CD I
hours NNS I
for IN I
5 CD I
days NNS I
up RB I
to TO N
a DT N
maximum NN N
of IN N
30 CD N
g JJ N
daily JJ N
and CC N
56 CD N
patients NNS N
received VBD N
an DT N
oral JJ I
dosage NN I
of IN I
40 CD I
mg NN I
of IN I
prednisone JJ I
daily JJ I
(adjusted VBN N
for IN N
weight) NN N
in IN N
two CD N
divided JJ N
doses NNS N
. . N

Placebo NNP I
pills NNS I
and CC N
liquids NNS N
were VBD N
given VBN N
to TO N
each DT N
patient NN N
to TO N
mask VB N
the DT N
treatment NN I
schedules NNS N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
patient NN N
populations NNS N
for IN N
any DT N
demographic JJ N
or CC N
clinical JJ N
characteristic JJ N
(e.g NN N
. . N

visual JJ N
acuity NN N
intraocular JJ N
pressure NN N
[IOP] NNP N
initial JJ N
hyphema NN N
size) NN N
measured VBN N
in IN N
the DT N
study NN N
. . N

Blacks NNS P
comprised VBD P
53% CD P
of IN P
the DT P
study NN P
population NN P
and CC P
the DT P
mean JJ P
age NN P
of IN P
the DT P
patients NNS P
was VBD P
23.5 CD P
years NNS P
. . P

Four CD N
patients NNS N
in IN N
each DT N
of IN N
the DT N
treatment NN I
groups NNS N
experienced VBD N
a DT N
secondary JJ O
hemorrhage; NN O
the DT N
rebleed NN O
rate NN O
was VBD N
7.1% CD N
in IN N
each DT N
group NN N
. . N

-DOCSTART- -X- N

[Management NN N
of IN N
the DT N
perineal NN P
wounds NNS P
after IN P
abdominoperineal JJ P
resection: JJ P
simple NN I
drainage NN I
only RB N
or CC N
with IN N
continuous JJ I
irrigation NN I
] NN I
. . N

OBJECTIVE NN N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
presacral JJ I
irrigation NN I
and CC N
simple JJ I
drainage NN I
on IN N
the DT N
perineal NN N
wound NN N
healing NN N
in IN N
patients NNS P
after IN P
abdominoperineal JJ P
resection NN P
(APR) NN P
. . P

METHODS NN N
From IN P
October NNP P
2004 CD P
to TO P
August NNP P
2009 CD P
patients NNS P
with IN P
rectal JJ P
cancer NN P
ulcerative JJ P
colitis NN P
or CC P
rectal JJ P
gastrointestinal JJ P
stromal JJ P
tumor NN P
who WP P
underwent JJ P
APR NNP P
or CC P
proctocolectomy NN P
were VBD P
randomized VBN P
into IN N
two CD N
arms: JJ N
simple JJ I
drainage NN I
group NN N
(n NNP P
= VBZ P
37) CD P
and CC N
continuous JJ I
irrigation NN I
(n NNP P
= VBZ P
37) CD P
. . P

Patients NNS N
randomized VBN N
to TO N
arm VB N
B NNP N
received VBD N
simple JJ I
drainage NN I
only RB I
to TO I
presacral JJ I
space; NN I
while IN N
those DT N
patients NNS N
in IN N
arm NN N
A NNP N
received VBD N
continuous JJ I
irrigation NN I
in IN I
addition NN I
to TO I
simple JJ I
drainage NN I
. . I

Perineal NNP N
wound NN N
healing NN N
was VBD N
taken VBN N
as IN N
endpoint NN N
of IN N
this DT N
study NN N
. . N

Major JJ N
complication NN N
was VBD N
defined VBN N
as IN N
wound JJ O
dehiscence NN O
or CC O
wound NN O
infection NN O
that IN N
the DT N
perineal NN N
wound NN N
should MD N
be VB N
reopened VBN N
for IN N
drainage NN N
. . N

Minor JJ N
complication NN N
was VBD N
defined VBN N
as IN N
delayed JJ O
healing VBG O
wound NN O
with IN N
seroma NN N
or CC N
hematoma NN N
. . N

RESULTS VB N
A NNP P
total NN P
of IN P
74 CD P
patients NNS P
were VBD P
enrolled VBN P
in IN P
present JJ P
study NN P
with IN P
37 CD N
patients NNS N
in IN N
each DT N
arm NN N
and CC N
there EX N
were VBD N
12 CD N
cases NNS N
and CC N
10 CD N
cases NNS N
who WP N
received VBD N
preoperative JJ I
radiation NN I
therapy NN I
respectively RB I
. . N

In IN N
the DT N
arm NN N
A DT N
2 CD N
patients NNS N
developed VBD N
major JJ N
complications NNS N
3 CD N
patients NNS N
incurred VBN N
with IN N
minor JJ N
complications NNS N
and CC N
32 CD N
patients NNS N
got VBD N
primary JJ N
healing NN N
of IN N
the DT N
perineal NN N
wounds NNS N
. . N

In IN N
arm NN N
B NNP N
8 CD N
patients NNS N
suffered VBD N
major JJ N
complications NNS N
3 CD N
patients NNS N
incurred VBN N
with IN N
minor JJ N
complications NNS N
and CC N
26 CD N
patients NNS N
got VBD N
primary JJ N
healing NN N
of IN N
the DT N
perineal NN N
wounds NNS N
. . N

The DT N
incidence NN O
of IN O
major JJ O
complication NN O
was VBD N
significantly RB N
lower JJR N
in IN N
arm NN N
A NNP N
(5.4% NNP N
vs.21.6% NN N
P NNP N
= VBZ N
0.042) CD N
. . N

Patients NNS N
received VBD N
preoperative JJ I
radiation NN I
therapy NN I
had VBD N
significantly RB N
higher JJR N
rate NN N
of IN N
minor JJ N
complications NNS N
than IN N
patients NNS N
underwent JJ N
surgery NN N
only RB N
(18.2% NNP N
vs NN N
. . N

3.9% CD N
P NNP N
= VBD N
0.039) CD N
. . N

CONCLUSIONS NNP N
Simple NNP I
drainage NN I
with IN I
continuous JJ I
irrigation NN I
of IN I
the DT I
presacral JJ I
space NN I
in IN I
patients NNS N
with IN N
abdominoperineal JJ N
resection NN N
or CC N
proctocolectomy NN N
could MD N
significantly RB N
lower VB N
the DT N
incidence NN N
of IN N
major JJ N
complication NN N
and CC N
improve VB N
wound NN N
healing VBG N
for IN N
perineal NN N
wound NN N
when WRB N
compared VBN N
with IN N
simple JJ N
drainage NN N
only RB N
. . N

Preoperative JJ I
radiation NN I
therapy NN I
tends VBZ N
to TO N
increase VB N
the DT N
incidence NN N
of IN N
minor JJ N
complications NNS N
. . N

-DOCSTART- -X- N

The DT N
effect NN N
of IN N
intravenous JJ N
lidocaine NN I
on IN N
QT NNP O
changes NNS O
during IN N
tracheal JJ P
intubation NN P
. . P

Laryngoscopy NNP P
and CC P
tracheal JJ P
intubation NN P
may MD N
provoke VB N
changes NNS N
of IN N
cardiac JJ N
repolarisation NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effect NN N
of IN N
intravenous JJ N
lidocaine NN I
on IN N
the DT N
ECG NNP O
changes NNS O
induced VBN N
by IN N
laryngoscopy NN P
and CC P
tracheal JJ P
intubation NN P
. . P

Forty-three JJ P
female NN P
patients NNS P
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
lidocaine JJ I
(1.5 NNP N
mg.kg(-1)) NN N
or CC N
placebo NN I
immediately RB N
after IN N
induction NN N
of IN N
anaesthesia NN N
and CC N
changes NNS N
in IN N
the DT N
ECG NNP N
and CC N
arterial JJ N
blood NN N
pressure NN N
were VBD N
recorded VBN N
. . N

Correction NN N
of IN N
QT NNP N
interval NN N
was VBD N
calculated VBN N
using VBG N
Bazett's NNP N
formula NN N
(QTcb) NNP N
Fridericia's NNP N
correction NN N
(QTcf) NN N
and CC N
Framingham NNP N
formula NN N
(QTcF) NN N
. . N

Transmural JJ O
dispersion NN O
of IN O
repolarisation NN O
(TDR) NN O
was VBD N
determined VBN N
as IN N
Tpeak-Tend JJ N
time NN N
. . N

There EX N
were VBD N
no DT N
changes NNS N
in IN N
the DT N
QTc NNP O
value NN O
in IN N
the DT N
lidocaine NN I
group NN N
. . N

In IN N
the DT N
placebo NN I
group NN N
significant JJ N
increases NNS N
in IN N
QTcb NNP O
QTcf NNP O
and CC O
QTcF NNP O
values NNS O
were VBD N
observed VBN N
after IN N
intubation NN N
compared VBN N
to TO N
either DT N
control NN N
measurements VBZ N
or CC N
to TO N
comparative JJ N
measurements NNS N
in IN N
the DT N
lidocaine NN I
group NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
TDR NNP O
either CC N
between IN N
or CC N
within IN N
the DT N
groups NNS N
. . N

Lidocaine NNP I
diminishes VBZ N
prolongation NN N
of IN N
QTc NNP O
induced VBN O
by IN N
tracheal JJ P
intubation NN P
but CC N
there EX N
is VBZ N
no DT N
effect NN N
of IN N
intubation NN N
on IN N
TDR NNP O
. . O

-DOCSTART- -X- N

Improving VBG I
patient JJ I
involvement NN I
in IN N
chronic JJ P
disease NN P
management: VBD N
the DT N
views NNS N
of IN N
patients NNS N
GPs NNP N
and CC N
specialists NNS N
on IN N
a DT N
guidebook NN O
for IN O
ulcerative JJ O
colitis NN O
. . O

Patient JJ I
information NN I
shared VBN I
care NN I
and CC I
decision-making NN I
are VBP N
recognised VBN N
as IN N
beneficial JJ N
to TO N
chronic VB N
disease NN N
management NN N
. . N

As IN N
part NN N
of IN N
an DT N
RCT NNP N
opinions NNS N
of IN N
ulcerative JJ P
colitis NN P
patients NNS P
and CC P
their PRP$ P
doctors NNS P
were VBD N
sought VBN N
on IN N
a DT N
guidebook NN I
designed VBN I
to TO I
support VB I
self-care NN I
and CC I
mediate VB I
doctor/patient JJ I
interaction NN I
during IN I
consultations NNS I
. . I

Semi-structured JJ P
interviews NNS P
were VBD P
conducted VBN P
with IN P
6 CD P
specialists NNS P
and CC P
16 CD P
GPs NNP P
. . P

Patients' JJ P
views NNS P
were VBD P
obtained VBN P
from IN P
written VBN P
responses NNS P
to TO P
a DT P
postal JJ P
questionnaire NN P
(136 NN P
replies) NN P
. . P

Inclusion NN I
of IN I
lay NN I
knowledge NN I
and CC N
clarification NN I
of IN I
treatment NN I
decision NN I
processes VBZ I
increased VBN N
patients' JJ N
perception NN N
of IN N
involvement NN N
in IN N
disease NN N
management NN N
through IN N
increased VBN N
identification NN N
and CC N
awareness NN N
of IN N
others' JJ N
self-management JJ N
experiences NNS N
. . N

Doctors NNS N
focused VBD N
on IN N
the DT N
importance NN N
of IN N
improving VBG I
patients' NN I
compliance NN I
and CC I
use NN I
of IN I
services NNS I
. . I

However RB N
the DT N
guidebook NN I
was VBD N
seldom RB N
used VBN N
as IN N
it PRP N
had VBD N
been VBN N
intended VBN N
during IN N
consultations NNS N
. . N

Patients NNS N
felt VBD N
constrained VBN N
by IN N
time NN N
limits NNS N
and CC N
consultants NNS N
did VBD N
not RB N
actively RB N
encourage VB N
guidebook NN N
use NN N
. . N

Based VBN N
on IN N
the DT N
findings NNS N
we PRP N
suggest VBP N
an DT N
approach NN N
utilising VBG O
the DT O
guidebook NN O
to TO N
improve VB I
patient JJ I
participation NN I
in IN N
disease NN N
management NN N
. . N

-DOCSTART- -X- N

Enhancing VBG N
the DT N
experience NN P
of IN P
carers NNS P
in IN P
the DT P
chemotherapy NN P
outpatient NN P
setting: VBD P
an DT N
exploratory NN N
randomised VBD N
controlled VBN N
trial NN N
to TO N
test VB N
impact NN O
acceptability NN O
and CC O
feasibility NN O
of IN N
a DT N
complex JJ I
intervention NN I
co-designed VBN I
by IN I
carers NNS P
and CC P
staff NN P
. . P

PURPOSE NNP N
Supporting VBG N
someone NN N
through IN N
chemotherapy NN N
can MD N
be VB N
emotionally RB N
and CC N
physically RB N
demanding VBG N
. . N

However RB N
research NN N
has VBZ N
yet RB N
to TO N
establish VB N
the DT N
type NN N
of IN N
support NN N
carers NNS N
require VBP N
or CC N
the DT N
best JJS N
way NN N
to TO N
provide VB N
this DT N
. . N

This DT N
study NN N
tested VBD N
the DT N
feasibility NN N
and CC N
acceptability NN N
of IN N
a DT N
complex JJ I
intervention NN I
for IN I
carers NNS P
that WDT P
was VBD P
co-designed VBN P
by IN P
staff NN P
and CC P
carers NNS P
of IN P
patients NNS P
starting VBG P
chemotherapy NN P
. . P

METHODS NNP N
Forty-seven JJ P
carers NNS P
were VBD P
recruited VBN P
randomised VBN P
between IN P
the DT P
intervention NN P
(n NNP P
= VBZ P
24) CD P
and CC P
control VB P
(n NNP P
= NNP P
23) CD P
groups NNS P
. . P

A DT I
questionnaire NN O
was VBD I
completed VBN I
pre- JJ I
and CC I
post-intervention JJ I
measuring NN O
knowledge NN O
of IN O
chemotherapy NN O
and CC I
its PRP$ I
side NN O
effects NNS O
experience NN O
of IN O
care NN O
satisfaction NN O
with IN O
outpatient JJ O
services NNS O
coping VBG O
and CC O
emotional JJ O
wellbeing NN O
. . O

The DT N
intervention NN N
process NN N
was VBD N
evaluated VBN N
by IN N
carers NNS N
and CC N
healthcare NN N
professionals NNS N
(HCPs) VBP N
in IN N
focus NN N
groups NNS N
. . N

RESULTS NNP N
Recruitment NNP N
to TO N
the DT N
study NN N
was VBD N
unproblematic JJ N
and CC N
attrition NN N
from IN N
it PRP N
was VBD N
low JJ N
suggesting VBG N
the DT N
intervention NN N
and CC N
study NN N
processes NNS N
were VBD N
acceptable JJ N
to TO N
patients NNS N
and CC N
carers NNS N
. . N

Carers NNS N
in IN N
receipt NN N
of IN N
the DT N
'Take NNP N
Care' NNP N
intervention NN N
reported VBD N
statistically RB N
significantly RB N
better RBR N
understanding NN N
of IN N
symptoms NNS N
and CC N
side JJ N
effects NNS N
and CC N
their PRP$ N
information NN N
needs VBZ N
being VBG N
more RBR N
frequently RB N
met VBN N
than IN N
carers NNS N
in IN N
the DT N
control NN N
. . N

Confidence NN N
in IN N
coping VBG N
improved VBN N
between IN N
baseline NN N
and CC N
follow-up NN N
for IN N
the DT N
intervention NN N
group NN N
and CC N
declined VBD N
for IN N
the DT N
control NN N
although IN N
differences NNS N
were VBD N
insufficient JJ N
to TO N
achieve VB N
statistical JJ N
significance NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups' JJ N
emotional JJ N
wellbeing NN N
. . N

HCP NNP N
and CC N
carer NN N
focus NN N
groups NNS N
confirmed VBD N
the DT N
feasibility NN N
and CC N
acceptability NN N
of IN N
the DT N
intervention NN N
. . N

CONCLUSIONS NNP N
The DT N
'Take NNP N
Care' NNP N
intervention NN N
proved VBD N
acceptable JJ N
to TO N
carers NNS P
and CC P
HCPs NNP N
and CC N
demonstrates VBZ N
considerable JJ N
promise NN N
and CC N
utility NN N
in IN N
practice NN N
. . N

Study NNP N
findings NNS N
support VBP N
the DT N
conduct NN N
of IN N
a DT N
fully RB N
powered VBN N
RCT NNP N
to TO N
determine VB N
the DT N
intervention's NN N
effectiveness NN N
and CC N
cost-effectiveness NN N
. . N

-DOCSTART- -X- N

Effect NN N
of IN N
selumetinib NN I
vs NN I
chemotherapy NN I
on IN N
progression-free JJ N
survival NN N
in IN N
uveal JJ P
melanoma: NN P
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE NNP N
Uveal NNP N
melanoma NN N
is VBZ N
characterized VBN N
by IN N
mutations NNS N
in IN N
GNAQ NNP N
and CC N
GNA11 NNP N
resulting VBG N
in IN N
mitogen-activated JJ N
protein NN N
kinase VB N
pathway JJ N
activation NN N
. . N

OBJECTIVE NN N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
selumetinib NN I
a DT I
selective JJ I
non-adenosine JJ I
triphosphate NN I
competitive JJ I
inhibitor NN I
of IN I
MEK1 NNP I
and CC I
MEK2 NNP I
in IN I
uveal JJ P
melanoma NN P
. . P

DESIGN NNP N
SETTING NNP N
AND NNP N
PARTICIPANTS NNP N
Randomized NNP N
open-label JJ N
phase NN N
2 CD N
clinical JJ N
trial NN N
comparing VBG N
selumetinib JJ I
vs NN I
chemotherapy NN I
conducted VBN N
from IN P
August NNP P
2010 CD P
through IN P
December NNP P
2013 CD P
among IN P
120 CD P
patients NNS P
with IN P
metastatic JJ P
uveal JJ P
melanoma NN P
at IN P
15 CD P
academic JJ P
oncology NN P
centers NNS P
in IN P
the DT P
United NNP P
States NNPS P
and CC P
Canada NNP P
. . P

INTERVENTIONS NNP N
One CD P
hundred VBD P
one CD P
patients NNS P
were VBD P
randomized VBN P
in IN N
a DT N
1:1 CD N
ratio NN N
to TO N
receive VB N
selumetinib NN I
75 CD I
mg NN I
orally RB I
twice RB I
daily RB I
on IN I
a DT I
continual JJ I
basis NN I
(n=50) NN I
or CC I
chemotherapy NN I
(temozolomide RB I
150 CD I
mg/m2 NNS I
orally RB I
daily RB I
for IN I
5 CD I
of IN I
every DT I
28 CD I
days NNS I
or CC I
dacarbazine JJ I
1000 CD I
mg/m2 NN I
intravenously RB I
every DT I
21 CD I
days NNS I
[investigator NNP N
choice]; VBP N
n=51) RB N
until IN N
disease JJ N
progression NN N
death NN N
intolerable JJ N
adverse JJ N
effects NNS N
or CC N
withdrawal NN N
of IN N
consent NN N
. . N

After IN N
primary JJ N
outcome NN N
analysis NN P
19 CD P
patients NNS P
were VBD P
registered VBN P
and CC P
18 CD P
treated VBN P
with IN I
selumetinib NN I
without IN N
randomization NN N
to TO N
complete VB N
the DT N
planned VBN N
120-patient JJ N
enrollment NN N
. . N

Patients NNS I
in IN I
the DT I
chemotherapy NN I
group NN N
could MD N
receive VB I
selumetinib NN I
at IN N
the DT N
time NN N
of IN N
radiographic JJ N
progression NN N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP O
Progression-free NNP O
survival VBD O
the DT N
primary JJ N
end NN N
point NN N
was VBD N
assessed VBN N
as IN N
of IN N
April NNP N
22 CD N
2013 CD N
. . N

Additional JJ N
end NN N
points NNS N
including VBG O
overall JJ O
survival JJ O
response NN O
rate NN O
and CC O
safety/toxicity NN O
were VBD N
assessed VBN N
as IN N
of IN N
December NNP N
31 CD N
2013 CD N
. . N

RESULTS JJ N
Median JJ N
progression-free JJ N
survival NN N
among IN N
patients NNS N
randomized VBN I
to TO I
chemotherapy VB I
was VBD N
7 CD N
weeks NNS N
(95% JJ N
CI NNP N
4.3-8.4 JJ N
weeks; NN N
median JJ N
treatment NN N
duration NN N
8 CD N
weeks; NN N
interquartile NN N
range NN N
[IQR] NNP N
4.3-16 JJ N
weeks) NN N
and CC N
among IN N
those DT N
randomized VBN I
to TO I
selumetinib VB I
was VBD N
15.9 CD N
weeks NNS N
(95% JJ N
CI NNP N
8.4-21.1 JJ N
weeks; NN N
median JJ N
treatment NN N
duration NN N
16.1 CD N
weeks; NN N
IQR NNP N
8.1-25.3 JJ N
weeks) NN N
(hazard NNP N
ratio VBZ N
0.46; CD N
95% CD N
CI NNP N
0.30-0.71; JJ N
P<.001) NNP N
. . N

Median JJ N
overall JJ N
survival NN N
time NN N
was VBD N
9.1 CD N
months NNS N
(95% JJ N
CI NNP N
6.1-11.1 JJ N
months) NN I
with IN I
chemotherapy NN I
and CC N
11.8 CD N
months NNS N
(95% JJ N
CI NNP N
9.8-15.7 CD N
months) NN I
with IN I
selumetinib JJ N
(hazard NNP N
ratio NN N
0.66; CD N
95% CD N
CI NNP N
0.41-1.06; JJ N
P=.09) NNP N
. . N

No DT N
objective JJ N
responses NNS N
were VBD I
observed VBN I
with IN I
chemotherapy NN N
. . N

Forty-nine JJ N
percent NN N
of IN N
patients NNS I
treated VBN I
with IN I
selumetinib NN N
achieved VBN N
tumor NN N
regression NN N
with IN N
14% CD N
achieving VBG N
an DT N
objective JJ N
radiographic JJ N
response NN N
to TO N
therapy NN N
. . N

Treatment-related JJ N
adverse JJ N
events NNS N
were VBD N
observed VBN N
in IN N
97% CD N
of IN N
patients NNS I
treated VBN I
with IN I
selumetinib NN N
with IN N
37% CD N
requiring VBG N
at IN N
least JJS N
1 CD N
dose JJ N
reduction NN N
. . N

CONCLUSIONS NNP N
AND NNP N
RELEVANCE NNP N
In IN N
this DT N
hypothesis-generating JJ P
study NN P
of IN P
patients NNS P
with IN P
advanced JJ P
uveal JJ I
melanoma NN I
selumetinib NNS I
compared VBN I
with IN I
chemotherapy NN N
resulted VBN N
in IN N
a DT N
modestly RB N
improved VBN N
progression-free JJ N
survival NN N
and CC N
response NN N
rate; NN N
however RB N
no DT N
improvement NN N
in IN N
overall JJ N
survival NN N
was VBD N
observed VBN N
. . N

Improvement NN N
in IN N
clinical JJ N
outcomes NNS N
was VBD N
accompanied VBN N
by IN N
a DT N
high JJ N
rate NN N
of IN N
adverse JJ N
events NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier: NNP N
NCT01143402 NNP N
. . N

-DOCSTART- -X- N

Design NN N
and CC N
implementation NN N
of IN N
the DT N
TRACIA: NNP I
intracoronary JJ I
autologous JJ I
transplant NN I
of IN I
bone NN I
marrow-derived JJ I
stem NN I
cells NNS I
for IN N
acute JJ N
ST NNP N
elevation NN N
myocardial JJ N
infarction NN N
. . N

OBJECTIVE NN N
To TO N
describe VB N
the DT N
design NN N
of IN N
a DT N
protocol NN N
of IN N
intracoronary JJ I
autologous JJ I
transplant NN I
of IN I
bone NN I
marrow-derived JJ I
stem NN I
cells NNS I
for IN N
acute JJ N
ST-elevation NNP N
myocardial JJ N
infarction NN N
(STEMI) NN N
and CC N
to TO N
report VB N
the DT N
safety NN N
of IN N
the DT N
procedure NN N
in IN N
the DT N
first JJ N
patients NNS N
included VBN N
. . N

METHODS NNP N
The DT N
TRACIA NNP I
study NN N
was VBD N
implemented VBN N
following VBG N
predetermined JJ N
inclusion NN N
and CC N
exclusion NN N
criteria NNS N
. . N

The DT I
protocol NN I
includes VBZ I
procedures NNS I
such JJ I
as IN I
randomization NN I
bone NN I
marrow NN I
retrieval JJ I
stem NN I
cells NNS I
processing VBG I
intracoronary JJ I
infusion NN I
of IN I
stem NN I
cells NNS I
in IN I
the DT I
infarct-related JJ I
artery NN I
preand- JJ I
post NN I
MRI NNP I
pre-and-post NN I
SPECT NNP I
with IN I
radioisotope NN I
ventriculography NN I
and CC I
clinical JJ I
follow-up NN I
at IN I
6 CD I
months NNS I
. . I

RESULTS NNP N
Eight NNP P
patients NNS P
with IN P
a DT P
diagnosis NN P
of IN P
acute JJ P
STEMI NNP P
and CC P
duration NN P
of IN P
symptoms NNS P
of IN P
24 CD P
hours NNS P
that WDT P
were VBD P
perfused VBN P
successfully RB P
through IN P
primary JJ P
percutaneous JJ P
coronary JJ P
intervention NN P
(PPCI) NN P
with IN P
a DT P
LVEF NNP P
of IN P
45% CD P
were VBD P
assigned VBN P
randomly RB P
to TO P
two CD P
groups NNS P
(n VBP P
= $ P
4 CD P
each) NN P
. . P

One CD N
group NN N
treated VBD N
with IN N
stem NN I
cells NNS I
and CC N
the DT N
other JJ N
corresponded VBD N
to TO N
the DT N
control NN I
group NN I
. . I

Neither DT N
death NN O
re-infarction NN O
no DT O
need NN O
for IN O
revascularization NN O
or CC O
thrombosis NN O
of IN O
the DT O
stent NN O
were VBD N
observed VBN N
at IN N
follow-up NN N
. . N

CONCLUSIONS NNP N
The DT N
initial JJ N
experience NN N
at IN N
the DT N
Instituto NNP P
Nacional NNP P
de FW P
Cardiologa NNP N
Ignacio NNP N
Chvez NNP N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
STEMI NNP N
by IN N
means NNS N
of IN I
autologous JJ I
transplantation NN I
of IN I
bone NN I
marrow-derived JJ I
stem NN I
cells NNS I
is VBZ N
encouraging VBG N
. . N

Implementation NN N
was VBD N
possible JJ N
in IN N
the DT N
first JJ N
eight CD N
patients NNS N
with IN N
no DT N
complications NNS N
. . N

-DOCSTART- -X- N

Treatment NN N
of IN N
familial JJ N
hypercholesterolemia NN N
with IN N
a DT N
combination NN N
of IN N
bezafibrate NN N
and CC N
guar NN N
. . N

The DT N
effect NN N
of IN N
guar NN N
(15.6 NNP N
g/day) VBZ N
a DT N
dietary JJ N
fibre NN N
and CC N
simultaneous JJ N
administration NN N
of IN N
bezafibrate JJ N
(600 NNP N
mg/day) NN N
during IN N
dietetic JJ N
treatment NN N
on IN N
the DT N
plasma NN N
lipoproteins NNS N
and CC N
apolipoproteins NNS N
was VBD N
investigated VBN N
in IN N
12 CD P
patients NNS P
with IN P
familial JJ P
hypercholesterolemia NN P
(corresponding VBG P
to TO P
the DT P
HLP NNP P
type NN P
IIa NNP P
pattern) NN P
. . P

Either DT N
bezafibrate NN N
alone RB N
or CC N
bezafibrate VB N
in IN N
combination NN N
with IN N
guar NN N
was VBD N
administered VBN N
in IN N
a DT N
cross-over NN N
study NN N
for IN N
3 CD N
months NNS N
. . N

Guar NNP N
led VBD N
to TO N
an DT N
additional JJ N
lowering NN N
of IN N
the DT N
total JJ O
cholesterol NN O
in IN N
the DT N
plasma NN N
by IN N
7% CD N
(P NNS N
less RBR N
than IN N
or CC N
equal JJ N
to TO N
0.05) CD N
associated VBN N
with IN N
a DT N
fall NN N
of IN N
the DT N
low JJ O
density NN O
lipoprotein NN O
cholesterol VBD O
(LDL-cholesterol JJ O
(LDL-cholesterol) JJ N
by IN N
13% CD N
(P NNS N
less RBR N
than IN N
or CC N
equal JJ N
to TO N
0.01) CD N
without IN N
any DT N
changes NNS N
in IN N
the DT N
very RB N
low JJ N
density NN N
lipoprotein NN N
(VLDL) NNP N
and CC N
high JJ N
density NN N
lipoprotein VBP N
(HDL) JJ N
cholesterols NNS N
. . N

In IN N
parallel NN N
with IN N
the DT N
decrease NN N
in IN N
LDL-cholesterol NNP O
the DT O
apoprotein NN O
B NNP O
also RB N
was VBD N
diminished VBN N
by IN N
20% CD N
(P NNS N
less RBR N
than IN N
or CC N
equal JJ N
to TO N
0.05) CD N
. . N

The DT N
plasma NN O
triglyceride IN O
level NN O
and CC O
the DT O
triglyceride JJ O
distribution NN O
within IN N
the DT N
individual JJ N
lipoprotein NN N
fractions NNS N
were VBD N
not RB N
altered VBN N
in IN N
any DT N
consistent JJ N
manner NN N
by IN N
the DT N
addition NN N
of IN N
guar NN N
. . N

Neither CC N
the DT N
fasting NN O
plasma NN O
glucose JJ O
level NN O
nor CC N
the DT N
body NN O
weight WDT O
were VBD N
affected VBN N
. . N

The DT N
side-effects NNS N
due JJ N
to TO N
guar VB N
treatment NN N
consisted VBN N
of IN N
slight JJ O
nausea NN O
meteorism NN O
and CC O
constipation NN O
but CC O
this DT N
did VBD N
not RB N
in IN N
any DT N
of IN N
the DT N
cases NNS N
lead VBP N
to TO N
early JJ N
termination NN N
of IN N
the DT N
study NN N
. . N

These DT N
results NNS N
demonstrate VBP N
that IN N
guar NN N
exerts VBZ N
its PRP$ N
cholesterol-lowering JJ N
effect NN N
in IN N
addition NN N
to TO N
that DT N
of IN N
bezafibrate NN N
. . N

-DOCSTART- -X- N

Prevention NN N
of IN N
type JJ P
2 CD P
(non-insulin-dependent) JJ P
diabetes NNS P
mellitus VBN P
by IN N
diet JJ I
and CC I
physical JJ I
exercise NN I
. . I

The DT N
6-year JJ N
Malm NNP N
feasibility NN N
study NN N
. . N

From IN N
a DT N
previously RB N
reported VBN N
5-year JJ N
screening VBG N
programme NN N
of IN P
6 CD P
956 CD P
47-49-year-old JJ P
Malm NNP P
males VBZ P
a DT P
series NN P
of IN P
41 CD P
subjects NNS P
with IN P
early-stage JJ P
Type NNP P
2 CD P
(non-insulin-dependent) JJ P
diabetes NNS P
mellitus NNS P
and CC P
181 CD P
subjects NNS P
with IN P
impaired JJ P
glucose JJ P
tolerance NN P
were VBD P
selected VBN P
for IN P
prospective JJ P
study NN P
and CC N
to TO N
test VB N
the DT N
feasibility NN N
aspect NN N
of IN N
long-term JJ N
intervention NN N
with IN N
an DT N
emphasis NN N
on IN I
life-style JJ I
changes NNS I
. . N

A DT N
5-year JJ N
protocol NN I
including VBG I
an DT I
initial JJ I
6-months JJ I
(randomised) NN I
pilot NN I
study NN I
consisting VBG I
of IN I
dietary JJ I
treatment NN I
and/or JJ I
increase NN I
of IN I
physical JJ I
activity NN I
or CC I
training NN I
with IN I
annual JJ I
check-ups NN I
was VBD N
completed VBN N
by IN N
90% CD N
of IN N
subjects NNS N
. . O

Body NN O
weight NN O
was VBD N
reduced VBN N
by IN N
2.3-3.7% JJ N
among IN N
participants NNS N
whereas JJ N
values NNS N
increased VBN N
by IN N
0.5-1.7% JJ N
in IN N
non-intervened JJ N
subjects NNS N
with IN N
impaired JJ N
glucose JJ N
tolerance NN N
and CC N
in IN N
normal JJ N
control NN N
subjects VBZ N
(p RB N
less JJR N
than IN N
0.0001); CD O
maximal JJ O
oxygen NN O
uptake JJ O
(ml.min-1.kg-1) NN N
was VBD N
increased VBN N
by IN N
10-14% JJ N
vs NNS N
decreased VBN N
by IN N
5-9% JJ N
respectively RB N
(p VBZ N
less JJR N
than IN N
0.0001) CD N
. . O

Glucose NNP O
tolerance NN O
was VBD N
normalized VBN N
in IN N
greater JJR N
than IN N
50% CD N
of IN N
subjects NNS N
with IN N
impaired JJ N
glucose JJ N
tolerance NN N
the DT N
accumulated JJ N
incidence NN N
of IN O
diabetes NNS O
was VBD N
10.6% CD N
and CC N
more JJR N
than IN N
50% CD N
of IN N
the DT N
diabetic JJ N
patients NNS N
were VBD N
in IN N
remission NN N
after IN N
a DT N
mean JJ N
follow-up NN N
of IN N
6 CD N
years NNS N
. . O

Blood NNP O
pressure NN O
lipids NNS O
and CC O
hyperinsulinaemia NN O
were VBD N
reduced VBN N
and CC N
early JJ O
insulin NN O
responsiveness NN O
to TO N
glucose VB N
loading VBG N
preserved VBN N
. . N

Improvement NN N
in IN O
glucose JJ O
tolerance NN O
was VBD N
correlated VBN N
to TO O
weight VB O
reduction NN O
(r NNP N
= VBZ N
0.19 CD N
p NN N
less JJR N
than IN N
0.02) CD N
and CC N
increased VBD O
fitness NN O
(r NN N
= VBD N
0.22 CD N
p NN N
less JJR N
than IN N
0.02) CD N
. . N

-DOCSTART- -X- N

Supervisor NNP P
tolerance-responsiveness NN P
to TO N
substance VB N
abuse NN N
and CC N
workplace NN I
prevention NN I
training: NN I
use NN N
of IN N
a DT N
cognitive JJ I
mapping NN I
tool NN I
. . P

Supervisor NNP P
tolerance-responsiveness JJ P
referring VBG P
to TO N
the DT N
attitudes NNS N
and CC N
behaviors NNS N
associated VBN N
with IN N
either DT N
ignoring VBG N
or CC N
taking VBG N
proactive JJ N
steps NNS N
with IN P
troubled JJ P
employees NNS P
was VBD P
investigated VBN N
in IN N
two CD N
studies NNS N
. . N

The DT N
studies NNS N
were VBD N
conducted VBN N
to TO N
help VB N
examine VB N
understand NN N
and CC N
improve VB N
supervisor NN P
responsiveness NN P
to TO P
employee NN P
substance NN P
abuse NN P
. . P

Study NNP P
1 CD P
examined VBD P
supervisor NN P
response NN P
to TO P
and CC P
tolerance NN P
of IN P
coworker NN P
substance NN P
use NN P
and CC N
ways NNS N
of IN N
interfacing VBG N
with IN N
the DT N
Employee NNP P
Assistance NNP P
Program NNP P
(EAP) NNP P
in IN P
two CD P
workplaces NNS P
(n VBP P
= JJ P
244 CD P
and CC P
107) CD P
. . P

These DT N
surveys NNS N
suggested VBD N
that IN N
engaging VBG N
supervisors NNS N
in IN N
a DT N
dialogue NN N
about IN N
tolerance NN N
might MD N
improve VB N
their PRP$ N
willingness NN N
to TO N
use VB N
the DT N
EAP NNP I
. . I

Study NNP N
2 CD N
was VBD N
a DT N
randomized JJ I
control NN I
field NN I
experiment NN I
that WDT N
assessed VBD N
a DT N
team-oriented JJ I
training NN I
. . I

This DT I
training NN I
adopted VBD I
a DT I
cognitive JJ I
mapping NN I
technique NN I
to TO N
help VB N
improve VB N
supervisor NN N
responsiveness NN N
. . N

Supervisors NNS P
receiving VBG P
this DT P
training NN P
(n VBZ P
= $ P
29) CD P
were VBD N
more RBR N
likely JJ N
to TO N
improve VB N
on IN N
several JJ O
dimensions NNS O
of IN O
responsiveness NN O
(e.g NN N
. . N

likely RB N
to TO N
contact VB N
the DT N
EAP) NNP I
than IN N
were VBD N
supervisors NNS N
who WP P
received VBD P
a DT P
more RBR P
didactic JJ P
informational JJ P
training NN P
(n NNP P
= VBZ P
23) CD P
or CC P
a DT P
no-training JJ P
control NN P
group NN P
(n NNP P
= VBZ P
17) CD P
. . P

Trained VBN N
supervisors NNS N
also RB N
showed VBD N
increases NNS N
in IN N
their PRP$ N
own JJ O
help-seeking JJ O
behavior NN O
. . O

Procedures NNS N
and CC N
maps NNS N
from IN N
the DT N
mapping NN N
activity NN N
(two-stage JJ N
conversational JJ N
mapping) NN N
are VBP N
described VBN N
. . N

Overall JJ N
results NNS N
indicate VBP N
that IN N
while IN N
supervisor JJ I
tolerance NN I
of IN I
coworker NN I
substance NN I
use NN I
inhibits VBZ I
EAP NNP I
utilization NN N
it PRP N
may MD N
be VB N
possible JJ N
to TO N
address VB N
this DT N
tolerance NN N
using VBG N
team-oriented JJ N
prevention NN N
training NN N
in IN N
the DT N
work-site JJ N
. . N

-DOCSTART- -X- N

Effect NN N
of IN N
increasing VBG N
doses NNS N
of IN N
labetalol NN I
on IN N
blood NN O
pressure NN O
plasma JJ O
renin NN O
activity NN O
and CC O
aldosterone NN O
in IN N
hypertensive JJ P
patients NNS P
. . P

1 CD N
. . N

Four CD N
different JJ N
doses NNS N
of IN N
labetalol JJ I
(150 NNP N
300 CD N
600 CD N
and CC N
900 CD N
mg/day) NN N
were VBD N
given VBN N
for IN N
1 CD N
week NN N
to TO N
each DT P
of IN P
four CD P
groups NNS P
of IN P
patients NNS P
with IN P
essential JJ P
hypertension NN P
(six NN P
patients NNS P
for IN P
each DT P
group) NN P
. . P

2 CD N
. . N

Labetalol NNP I
decreased VBD N
mean JJ N
blood NN O
pressure NN O
and CC O
heart NN O
rate NN O
to TO N
the DT N
same JJ N
extent NN N
on IN N
the DT N
first JJ N
and CC N
the DT N
seventh JJ N
days NNS N
of IN N
treatment NN N
. . N

Only RB N
standing VBG N
blood NN O
pressure NN O
showed VBD N
a DT N
dose-dependent JJ N
inhibition NN N
both DT N
in IN N
the DT N
supine NN N
and CC N
upright JJ N
position NN N
. . N

3 CD N
. . N

Labetalol NNP I
exerted VBD N
a DT N
net JJ N
inhibitory NN N
effect NN N
on IN N
plasma NN O
renin NN O
activity NN O
which WDT O
was VBD N
related VBN N
to TO N
basal VB N
renin NN N
values NNS N
and CC N
was VBD N
already RB N
maximal JJ N
at IN N
the DT N
lowest JJS N
doses NNS N
. . N

This DT N
effect NN N
was VBD N
well RB N
maintained VBN N
in IN N
the DT N
supine JJ N
position NN N
. . N

This DT N
effect NN N
was VBD N
well RB N
maintained VBN N
in IN N
the DT N
supine JJ N
position NN N
although IN N
during IN N
standing VBG N
it PRP N
tended VBD N
to TO N
be VB N
less RBR N
evident JJ N
with IN N
increasing VBG N
doses NNS N
. . N

4 CD N
. . N

Urinary JJ O
aldosterone NN O
was VBD N
decreased VBN N
in IN N
a DT N
dose-dependent JJ N
fashion NN N
and CC N
its PRP$ N
changes NNS N
were VBD N
largely RB N
independent JJ N
fashion NN N
and CC N
its PRP$ N
changes NNS N
were VBD N
largely RB N
independent JJ N
of IN N
plasma JJ N
renin NN N
activity NN N
. . N

5 CD N
. . N

Neither DT N
basal NN N
values VBZ O
nor CC N
changes NNS O
of IN O
renin NN O
and CC O
aldosterone NN O
were VBD N
related VBN N
to TO N
the DT N
hypotensive JJ N
effect NN N
of IN N
labetalol NN I
. . I

6 CD N
. . N

During IN N
labetalol JJ I
treatment NN N
urinary JJ O
sodium NN O
excretion NN O
fell VBD N
for IN N
2-3 JJ N
days NNS N
and CC N
then RB N
returned VBD N
to TO N
basal VB N
values NNS N
. . N

The DT N
retentive JJ N
effect NN N
of IN N
labetalol NN I
on IN N
sodium NN N
was VBD N
directly RB N
related VBN N
to TO N
the DT N
decrease NN N
of IN N
blood NN O
pressure NN O
and CC O
the DT N
successive JJ N
sodium NN N
escape NN N
might MD N
be VB N
explained VBN N
either RB N
by IN N
the DT N
observed JJ N
increase NN N
of IN N
plasma JJ N
volume NN N
(indirectly RB N
measured VBN N
by IN N
packed JJ N
cell NN N
volume) NN N
or CC N
by IN N
aldosterone JJ N
inhibition NN N
. . N

-DOCSTART- -X- N

The DT N
benefit NN N
of IN N
low-dose JJ N
dopamine NN I
during IN N
vigorous JJ N
diuresis NN N
for IN N
congestive JJ P
heart NN P
failure NN P
associated VBN P
with IN P
renal JJ P
insufficiency: NN P
does VBZ N
it PRP N
protect VB N
renal JJ N
function NN N
BACKGROUND NNP N
Low-dose NNP N
dopamine NN I
a DT I
renal JJ I
vasodilator NN I
has VBZ I
been VBN N
used VBN N
empirically RB N
to TO N
improve VB N
renal JJ N
function NN N
or CC N
outcome NN N
in IN N
critically RB P
ill JJ P
patients NNS P
with IN P
oliguria NNS P
or CC P
acute JJ P
renal JJ P
failure NN P
. . P

HYPOTHESIS NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
efficacy NN N
of IN N
low-dose JJ I
dopamine NN I
(2 NNP I
micrograms/kg/min) NN I
as IN N
a DT N
renal-protective JJ N
agent NN N
during IN N
vigorous JJ N
diuresis NN N
for IN N
congestive JJ P
heart NN P
failure NN P
(CHF) NNP P
associated VBN P
with IN P
mild NN P
or CC P
moderate JJ P
renal JJ P
insufficiency NN P
. . N

METHODS NNP N
Of IN N
20 CD P
study NN P
patients NNS P
(mean JJ P
age NN P
74.3 CD P
+/- JJ P
15 CD P
years) NN P
with IN P
severe JJ P
CHF NNP P
10 CD P
(Group NNP P
A) NNP P
were VBD N
randomized VBN N
to TO N
a DT N
treatment NN N
strategy NN N
of IN N
intravenous JJ I
bumetanide NN I
(1 NNP N
mg NN N
b.i.d.) NN N
alone RB N
and CC N
another DT N
10 CD N
(Group NN N
B) NNP N
to TO N
low-dose JJ I
dopamine NN I
and CC I
a DT I
similar JJ I
diuretic JJ I
regimen NNS I
for IN N
a DT N
duration NN N
of IN N
5 CD N
days NNS N
or CC N
less JJR N
if IN N
clinical JJ N
edema NN N
remitted VBD N
. . N

RESULTS NNP N
Group NNP N
B NNP N
patients NNS N
showed VBD N
a DT N
significant JJ N
improvement NN N
in IN N
renal JJ O
function NN O
and CC O
urinary JJ O
output: NN O
serum NN O
blood NN O
urea JJ O
nitrogen RB O
48.9 CD N
+/- JJ N
10.3 CD N
to TO N
32.1 CD N
+/- JJ N
14.4 CD N
mg/dl NN N
(p NNP N
< VBZ N
0.05); CD N
serum NN O
creatinine NN O
1.97 CD N
+/- JJ N
0.24 CD N
to TO N
1.49 CD N
+/- JJ N
0.39 CD N
mg/dl NN N
(p NNP N
< VBZ N
0.05); CD N
creatinine NN O
clearance NN O
35.6 CD N
+/- JJ N
11.6 CD N
to TO N
48.8 CD N
+/- JJ N
12.3 CD N
ml/min NN N
(p NNP N
< VBZ N
0.05); CD N
and CC N
indexed JJ O
urinary JJ O
output NN O
0.56 CD N
+/- JJ N
0.16 CD N
to TO N
2.02 CD N
+/- JJ N
0.72 CD N
ml/kg/h NN N
(p NNP N
< VBZ N
0.05) CD N
. . N

Group NNP N
A NNP N
patients NNS N
showed VBD N
a DT N
significant JJ N
increase NN N
in IN N
urinary JJ O
output NN O
but CC N
nonsignificant JJ O
renal JJ O
functional JJ O
deterioration NN O
. . O

CONCLUSION VB N
The DT N
renal-protective JJ N
effect NN N
of IN N
low-dose JJ N
dopamine NN I
in IN N
the DT N
setting NN N
of IN N
CHF NNP N
and CC N
vigorous JJ N
diuresis NN N
is VBZ N
supported VBN N
by IN N
this DT N
study NN N
. . N

-DOCSTART- -X- N

Effects NNS O
of IN N
surfactant NN I
on IN N
biofilm NN N
formation NN N
on IN N
silicone NN I
nasal NN I
splints NNS I
. . I

Biofilms NNS I
are VBP N
sessile JJ N
communities NNS N
of IN N
bacteria NNS N
embedded VBN N
in IN N
self-produced JJ N
extracellular JJ N
polysaccharide NN N
matrix NN N
and CC N
are VBP N
considered VBN N
to TO N
be VB N
responsible JJ N
for IN N
bacterial JJ N
infections NNS N
in IN N
humans NNS P
. . P

Topical NNP N
surfactant NN N
use NN N
on IN N
silicone NN N
nasal JJ N
splints NNS N
may MD N
have VB N
a DT N
preventive JJ N
effect NN N
on IN N
biofilm NN N
formation NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
surfactant-containing JJ N
nasal JJ N
solutions NNS N
on IN N
biofilm NN N
formation NN N
over IN N
the DT N
surface NN N
of IN N
silicone NN N
nasal JJ N
splints NNS N
. . N

Forty CD P
patients NNS P
were VBD P
randomized VBN P
after IN P
septoplasty NN P
to TO N
receive VB N
surfactant-containing JJ I
saline JJ I
solution NN I
(group VBZ I
1) CD I
or CC I
saline VB I
without IN I
surfactant JJ I
(group NN N
2) CD N
. . N

At IN N
the DT N
postoperative JJ N
48th CD N
72th CD N
and CC N
96th CD N
hours NNS N
pieces NNS N
of IN N
splint NN N
samples NNS N
were VBD N
taken VBN N
and CC N
prepared VBN N
for IN N
scanning VBG N
electron NN N
microscopic NN N
evaluation NN N
. . N

Biofilm NNP O
formation NN O
was VBD N
observed VBN N
in IN N
3 CD N
6 CD N
and CC N
14 CD N
of IN N
20 CD N
samples NNS N
in IN N
group NN N
1 CD N
(surfactant JJ N
used) NN N
and CC N
3 CD N
14 CD N
and CC N
20 CD N
of IN N
20 CD N
samples NNS N
in IN N
group NN N
2 CD N
(control) NN N
at IN N
48th CD N
72th CD N
and CC N
96th CD N
hours NNS N
respectively RB N
. . N

Biofilm NNP O
formation NN O
incidences NNS N
of IN N
groups NNS N
at IN N
48th CD N
hour NN N
were VBD N
similar JJ N
(p NNP N
> NN N
0.05) CD N
whereas IN N
it PRP N
was VBD N
significantly RB N
lower JJR N
at IN N
group NN N
1 CD N
regarding VBG N
72th CD N
and CC N
96th CD N
hours NNS N
(p JJ N
< JJ N
0.05) CD N
. . N

Surfactant-containing JJ I
nasal JJ I
solutions NNS I
have VBP N
an DT N
inhibitory JJ N
effect NN N
on IN N
biofilm NN O
formation NN O
over IN N
the DT N
surface NN N
of IN N
silicone NN N
nasal JJ N
splints NNS N
especially RB N
after IN N
48 CD N
h NN N
. . N

Surfactant-containing JJ I
nasal JJ I
solutions NNS I
may MD N
have VB N
an DT N
important JJ N
role NN N
in IN N
nasal JJ N
septal JJ N
dressing NN N
in IN N
the DT N
future NN N
. . N

-DOCSTART- -X- N

Evaluation NN N
of IN N
the DT N
effect NN N
of IN N
low JJ I
level NN I
laser NN I
on IN N
prevention NN O
of IN O
chemotherapy-induced JJ P
mucositis NN P
. . P

Radiotherapy NN I
in IN I
the DT I
head NN I
and CC I
neck JJ I
region NN I
and CC N
chemotherapy NN I
might MD N
give VB N
rise NN N
to TO N
oral JJ N
mucositis NN N
which WDT N
is VBZ N
a DT N
severe JJ N
and CC N
painful JJ N
inflammation NN N
. . N

There EX N
is VBZ N
no DT N
known JJ N
definite JJ N
cure NN N
for IN N
mucositis NN N
. . N

A DT N
number NN N
of IN N
studies NNS N
have VBP N
attempted VBN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
low-power JJR I
laser NN I
on IN I
radiotherapy- JJ I
and CC I
chemotherapy-induced JJ I
mucositis NN I
. . I

The DT N
present JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
low-power JJR I
laser NN I
on IN N
the DT N
prevention NN O
of IN O
mucositis NN O
xerostomia NN O
and CC O
pain NN O
as IN O
a DT O
result NN O
of IN O
chemotherapy NN O
. . O

The DT N
subjects NNS N
in IN N
this DT N
double-blind JJ N
randomized NN N
controlled VBN N
study NN N
were VBD N
24 CD P
adult NN P
patients NNS P
who WP P
underwent JJ P
chemotherapy NN P
during IN P
2009-2010 JJ P
. . P

The DT N
results NNS N
showed VBD N
that IN N
low-power JJR I
laser NN I
was VBD N
able JJ N
to TO N
decrease VB N
the DT N
effect NN O
of IN O
chemotherapy NN O
on IN O
oral JJ O
mucositis NN O
xerostomia NN O
and CC O
pain NN O
in IN O
a DT O
variety NN O
of IN O
malignancies NNS O
(P&lt;0.05) NNP N
. . N

It PRP N
can MD N
be VB N
concluded VBN N
that IN N
low-power JJR I
laser NN I
might MD N
decrease VB N
the DT N
intensity NN O
of IN O
mucositis NN O
. . O

-DOCSTART- -X- N

The DT N
effects NNS N
of IN N
amantadine NN I
and CC I
pemoline NN I
on IN N
cognitive JJ N
functioning NN N
in IN N
multiple JJ N
sclerosis NN N
. . N

BACKGROUND NNP N
Amantadine NNP I
hydrochloride NN I
and CC I
pemoline VB I
both DT I
frequently RB N
used VBN N
to TO N
treat VB N
the DT N
fatigue NN N
of IN N
multiple JJ N
sclerosis NN N
(MS) NN N
may MD N
also RB N
improve VB N
attention NN N
and CC N
other JJ N
cognitive JJ N
functions NNS N
in IN N
MS NNP N
. . N

To TO N
our PRP$ N
knowledge NN N
these DT N
agents NNS N
have VBP N
never RB N
been VBN N
compared VBN N
in IN N
a DT N
placebo-controlled JJ N
trial NN N
of IN N
patients NNS P
with IN P
MS NNP P
. . P

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
amantadine NN I
and CC I
pemoline NN I
on IN N
cognitive JJ N
functioning NN N
in IN N
MS NNP N
. . N

METHODS NNP N
A NNP P
total NN P
of IN P
45 CD P
ambulatory JJ P
patients NNS P
with IN P
MS NNP P
and CC P
severe JJ P
fatigue NN P
were VBD N
treated VBN N
for IN N
6 CD N
weeks NNS N
with IN N
amantadine JJ I
pemoline NN I
or CC I
placebo NN I
using VBG N
a DT N
parallel JJ N
group NN N
design NN N
. . N

They PRP N
underwent VBP N
comprehensive JJ N
neuropsychological JJ N
testing NN N
to TO N
determine VB N
treatment NN N
effects NNS N
on IN N
cognitive JJ N
functioning NN N
. . N

Primary JJ N
outcome NN N
measures NNS N
were VBD N
tests NNS O
of IN O
attention NN O
(Digit NNP O
Span NNP O
Trail NNP O
Making NNP O
Test NNP O
and CC O
Symbol NNP O
Digit NNP O
Modalities NNP O
Test) NNP O
verbal JJ O
memory NN O
(Selective JJ O
Reminding NNP O
Test) NNP O
nonverbal JJ O
memory NN O
(Benton NNP O
Visual NNP O
Retention NNP O
Test) NNP O
and CC O
motor NN O
speed NN O
(Finger NN O
Tapping NNP O
Test) NNP O
. . O

RESULTS NNP N
Fatigue NNP O
did VBD N
not RB N
significantly RB N
correlate VB N
with IN N
any DT N
of IN N
the DT N
neuropsychological JJ N
outcome NN N
measures NNS N
at IN N
baseline NN N
or CC N
after IN N
treatment NN N
. . N

All DT N
three CD N
treatment NN N
groups NNS N
improved VBN N
on IN N
tests NNS O
of IN O
attention NN O
(P NNP N
< NNP N
.003) NNP N
verbal JJ O
memory NN O
(P NNP N
< NNP N
.001) NNP N
and CC N
motor NN O
speed NN O
(P NNP N
< NNP N
.002) NNP N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
amantadine JJ I
pemoline NN I
and CC I
placebo NN I
. . I

CONCLUSIONS NNP N
Cognitive NNP N
functioning NN N
in IN N
MS NNP N
is VBZ N
independent JJ N
of IN N
fatigue NN N
. . N

Neither DT N
amantadine JJ I
nor CC I
pemoline JJ I
enhances NNS N
cognitive JJ N
performance NN N
in IN N
MS NNP N
compared VBN N
with IN N
placebo NN I
. . I

-DOCSTART- -X- N

Prolonged NNP N
sirolimus NN I
administration NN N
after IN P
allogeneic JJ P
hematopoietic JJ P
cell NN P
transplantation NN P
is VBZ N
associated VBN N
with IN N
decreased JJ N
risk NN N
for IN N
moderate-severe JJ N
chronic JJ N
graft-versus-host NN N
disease NN N
. . N

Effective JJ I
pharmacological JJ I
strategies NNS I
employed VBN I
in IN I
allogeneic JJ P
hematopoietic JJ P
cell NN P
transplantation NN P
should MD I
prevent VB I
serious JJ I
chronic JJ I
graft-versus-host NN I
disease NN I
and CC I
facilitate VB I
donor-recipient JJ I
immune JJ I
tolerance NN I
. . I

Based VBN N
on IN N
demonstrated JJ N
pro-tolerogenic JJ N
activity NN N
sirolimus NN I
(rapamycin) NN I
is VBZ N
an DT N
agent NN N
with IN N
promise NN N
to TO N
achieve VB N
these DT N
goals NNS N
. . N

In IN N
a DT N
long-term JJ N
follow-up JJ N
analysis NN N
of IN N
a DT N
randomized JJ N
phase NN N
II NNP N
trial NN N
comparing VBG N
sirolimus/tacrolimus JJ I
versus NN I
methotrexate/tacrolimus NN I
for IN N
graft-versus-host JJ N
disease NN N
prevention NN N
in IN N
matched JJ P
sibling NN P
or CC P
unrelated JJ P
donor NN P
transplant NN P
we PRP P
examined VBD N
the DT N
impact NN N
of IN N
prolonged JJ P
sirolimus JJ P
administration NN P
( $ P
1 CD P
year NN P
post-transplant) NN P
. . N

Median JJ P
follow-up JJ P
time NN P
for IN P
surviving VBG P
patients NNS P
at IN P
time NN P
of IN P
this DT P
analysis NN P
was VBD P
41 CD P
months NNS P
(range JJ P
27-60) JJ P
for IN P
sirolimus/tacrolimus NN P
and CC P
49 CD P
months NNS P
(range JJ P
29-63) JJ P
for IN P
methotrexate/tacrolimus NN P
. . I

Sirolimus/tacrolimus NNP I
patients NNS N
had VBD N
significantly RB N
lower JJR O
National NNP O
Institutes NNPS O
of IN O
Health NNP O
Consensus NNP O
moderate-severe JJ O
chronic JJ O
graft-versus-host NN O
disease NN O
(34% NNP N
vs NN N
. . N

65%; CD N
P=0.004) NNP N
and CC O
late JJ O
acute NN O
graft-versus-host JJ O
disease NN O
(20% NNP N
vs NN N
. . N

43%; CD N
P=0.04) NNP N
. . N

While IN I
sirolimus/tacrolimus JJ I
patients NNS N
had VBD N
lower JJR I
prednisone NN I
exposure NN N
and CC N
earlier JJR N
discontinuation NN N
of IN I
tacrolimus NN I
(median JJ N
time NN N
to TO N
tacrolimus VB N
discontinuation NN N
368 CD N
days NNS N
vs NN N
. . N

821 CD N
days; JJ N
P=0.002) NNP N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
complete JJ N
immune JJ N
suppression NN N
discontinuation NN N
(60-month JJ N
estimate: NN N
43% CD N
vs NN N
. . N

31%; CD N
P=0.78) NNP N
. . N

Prolonged NNP I
sirolimus NN I
administration NN N
represents VBZ N
a DT N
viable JJ N
approach NN N
to TO N
mitigate VB N
risk NN N
for IN N
moderate-severe JJ N
chronic JJ N
and CC N
late JJ N
acute NN N
graft-versus-host JJ N
disease NN N
. . N

Further RB N
study NN N
of IN N
determinants NNS N
of IN N
successful JJ I
immune JJ I
suppression NN I
discontinuation NN I
is VBZ N
needed VBN N
. . N

-DOCSTART- -X- N

[A RB N
clinical JJ N
study NN N
on IN N
the DT N
effect NN N
of IN N
Yinxing VBG I
Damo NNP I
combined VBN I
with IN I
betahistine JJ I
hydrochloride NN I
injection NN I
on IN N
vertebral JJ P
basilar JJ P
artery NN P
ischemic JJ P
vertigo] NN P
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
therapeutic JJ N
efficacy NN N
of IN N
Yinxing VBG I
Damo NNP I
(YXDM) NNP I
combined VBD I
with IN I
Betahistine NNP I
Hydrochloride NNP I
Injection NNP I
(BHI) NNP I
on IN N
vertebra NN O
basilar JJ O
artery NN O
ischemic JJ O
vertigo NN O
(VBIV) NN O
. . O

METHODS NNP N
Ninety NNP P
patients NNS P
with IN P
VBIV NNP P
were VBD P
randomly RB P
divided VBN P
into IN P
two CD P
groups; JJ P
45 CD P
patients NNS P
(the RB N
treated VBN N
group) NN N
were VBD N
treated VBN N
with IN N
YXDM NNP I
and CC N
BHI NNP I
intravenous JJ I
dripping VBG I
once RB I
a DT N
day NN N
for IN N
14 CD N
days NNS N
. . N

Another DT P
45 CD P
patients NNS P
(control JJ P
group) NNS P
were VBD N
treated VBN N
with IN N
Xueshuantong NNP I
and CC I
BHI NNP I
intravenous JJ I
dripping VBG I
once RB I
daily JJ N
for IN N
14 CD N
days NNS N
. . N

The DT N
clinical JJ O
syndromes NNS O
and CC O
the DT O
index NN O
of IN O
the DT O
transcranial JJ O
Doppler NNP O
(TCD) NNP O
and CC I
hemorheology NN O
were VBD I
observed VBN I
. . I

RESULTS VB N
The DT N
total JJ N
effective JJ N
rate NN N
was VBD N
100% CD N
in IN N
the DT N
treated VBN N
group NN N
which WDT N
was VBD N
better JJR N
than IN N
that DT N
in IN N
the DT N
control NN I
group NN I
90.5% CD N
(P NNP N
< VBD N
0.05) CD N
. . N

The DT N
indexes NNS O
of IN O
TCD NNP O
and CC O
hemorheology NN O
in IN N
the DT N
treated JJ N
group NN N
were VBD N
obviously RB N
improved VBN N
after IN N
treatment NN N
(P NNP N
< VBZ N
0.01) CD N
. . N

CONCLUSION NNP N
YXDM NNP I
combined VBD I
with IN I
BHT NNP I
injection NN I
had VBD N
better RBR N
effect NN O
in IN N
treating VBG N
patients NNS N
with IN N
VBIV NNP N
is VBZ N
an DT N
ideal JJ N
drug NN N
for IN N
VBIV NNP N
. . N

-DOCSTART- -X- N

[Platelet NN N
serotonin NN N
in IN N
infantile JJ P
autism NN P
. . P

Cross-over JJ N
effects NNS N
of IN N
a DT N
dopamine JJ I
agonist NN I
and CC I
an DT I
antagonist] NN I
. . I

In IN N
infantile JJ P
autism NN P
the DT P
serotoninergic JJ N
(5-HT) JJ N
hypothesis NN N
is VBZ N
corroborated VBN N
by IN N
biological JJ N
dosages NNS N
and CC N
therapeutic JJ N
effects NNS N
of IN N
fenfluramine NN I
which WDT N
decrease NN N
blood NN N
serotonin NN N
. . N

However RB N
other JJ N
drugs NNS N
such JJ N
as IN N
dopaminergic JJ I
agonists NNS I
or CC I
antagonists NNS I
have VBP I
therapeutic JJ N
effects NNS N
. . N

Therefore IN N
we PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
two CD I
dopaminergic JJ I
(DA) NNS I
drugs NNS I
have VBP N
a DT N
similar JJ N
5-HT JJ N
effect NN N
underlying VBG N
the DT N
therapeutic JJ N
efficiency NN N
. . N

We PRP N
evaluated VBD N
in IN N
a DT N
randomized JJ N
double-blind NN N
and CC N
cross-over NN N
study NN N
the DT N
effects NNS N
of IN N
a DT N
DA NNP I
agonist NN I
(bromocriptine) NNP I
and CC I
a DT I
DA NNP I
antagonist NN I
(amisulpride) NN I
on IN N
platelet NN N
5-HT JJ N
in IN N
infantile JJ P
autism NN P
. . P

The DT N
prolactinemia NN O
reflecting VBG O
the DT N
DA NNP I
action NN N
has VBZ N
been VBN N
also RB N
measured VBN N
. . N

Nine NNP P
children NNS P
aged VBN P
from IN P
4 CD P
to TO P
13 CD P
years NNS P
according VBG P
to TO P
the DT P
DSM NNP P
III NNP P
for IN P
infantile JJ P
autism NN P
received VBD P
either DT N
drug NN N
in IN N
a DT N
random JJ N
order NN N
during IN N
four CD N
weeks NNS N
with IN N
an DT N
in-between JJ N
placebo NN I
period NN N
of IN N
six CD N
weeks NNS N
. . N

The DT N
dosages NNS N
of IN N
platelet NN I
5-HT JJ I
and CC I
serum JJ I
prolactin NN I
were VBD N
carried VBN N
out RP N
at IN N
the DT N
beginning NN N
and CC N
at IN N
the DT N
end NN N
of IN N
every DT N
phase NN N
of IN N
treatment NN N
(active JJ I
or CC N
placebo) NN I
with IN N
radioenzymology NN I
and CC I
radioimmunoassay VB I
methods NNS I
respectively RB N
. . N

The DT N
principal JJ N
results NNS N
on IN N
serum JJ N
prolactin NN N
show NN N
neither DT N
order NN N
x NNP N
treatment NN N
interaction NN N
nor CC N
order NN N
effect NN N
but CC N
a DT N
significant JJ N
treatment NN N
effect NN N
(p NNP N
< VBZ N
0.01): CD N
amisulpride NN I
increases NNS N
serum VBP O
prolactin JJ O
whereas JJ N
bromocriptine NN I
decreases VBZ N
according VBG N
to TO N
the DT N
usual JJ N
data NN N
. . N

About IN N
platelet JJ N
5-HT JJ N
there EX N
is VBZ N
neither DT N
order NN N
x NNP N
treatment NN N
interaction NN N
nor CC N
treatment NN N
effect NN N
but CC N
a DT N
significant JJ N
order NN N
effect NN N
(p NNP N
< VBZ N
0.01) CD N
. . N

Both DT N
drugs NNS I
increase VBP N
platelet NN N
5-HT JJ N
in IN N
the DT N
first JJ N
phase NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- N

Durability NN O
of IN N
central JJ I
venous JJ I
catheters NNS I
. . I

A DT N
randomized JJ N
trial NN N
in IN N
children NNS P
with IN P
malignant JJ P
diseases NNS P
. . P

In IN P
a DT N
prospective JJ N
randomized NN N
study VBD N
the DT N
durability NN O
of IN N
tunnelled JJ I
and CC I
non-tunnelled JJ I
central JJ I
venous JJ I
catheters NNS I
was VBD N
investigated VBN N
in IN N
children NNS P
with IN P
malignant JJ P
diseases NNS P
. . P

Twenty CD P
children NNS P
were VBD P
included VBN P
in IN P
the DT P
study NN P
but CC P
four CD P
(two NN P
in IN P
each DT P
group) NN P
had VBD P
to TO P
be VB P
excluded; JJ P
three CD P
because IN P
the DT P
entry NN P
criteria NNS P
turned VBD P
out RP P
not RB P
to TO P
be VB P
fulfilled VBN P
and CC P
one CD P
because NN P
of IN P
lack NN P
of IN P
data NNS P
. . P

The DT N
median JJ N
duration NN N
of IN N
the DT N
tunnelled JJ I
catheters NNS I
was VBD N
224 CD N
days NNS N
with IN N
a DT N
range NN N
of IN N
25-846 JJ N
days NNS N
which WDT N
was VBD N
significantly RB N
longer JJR N
than IN N
that DT N
of IN N
conventional JJ I
catheters NNS I
(39.5 VBP N
days NNS N
range VBP N
9-228 JJ N
days) NN N
. . N

In IN N
addition NN N
six CD N
of IN N
eight CD N
conventional JJ N
catheters NNS N
were VBD N
accidentally RB N
removed VBN N
whereas IN N
all DT N
catheters NNS N
in IN N
the DT N
tunnelled JJ N
group NN N
had VBD N
to TO N
be VB N
removed VBN N
via IN N
a DT N
small JJ N
incision NN N
. . N

Three CD N
cases NNS N
of IN N
catheter NN N
related VBN N
sepsis NN N
two CD N
in IN N
the DT N
tunnelled JJ N
group NN N
and CC N
one CD N
in IN N
the DT N
conventional JJ N
group NN N
were VBD N
registered VBN N
. . N

The DT N
corresponding JJ N
number NN O
of IN O
infections NNS O
per IN O
catheter NN O
days NNS N
were VBD N
1 CD N
in IN N
1189 CD N
days NNS N
and CC N
1 CD N
in IN N
522 CD N
days NNS N
respectively RB N
. . N

In IN N
conclusion NN N
cuffed NN I
tunnelled VBD I
central JJ I
venous JJ I
catheters NNS I
are VBP N
less RBR N
prone JJ N
to TO N
displacement VB N
than IN N
traditional JJ I
percutaneous JJ I
central JJ I
venous JJ I
catheters NNS I
when WRB N
used VBN N
in IN N
children NNS P
with IN P
malignant JJ P
diseases NNS P
. . P

-DOCSTART- -X- N

Randomised VBN N
parallel-group JJ N
multicentre JJ N
multinational JJ N
phase NN N
2 CD N
study NN N
comparing VBG N
edoxaban CC I
an DT I
oral JJ I
factor NN I
Xa NNP I
inhibitor NN I
with IN I
warfarin NN I
for IN N
stroke NN P
prevention NN P
in IN P
patients NNS P
with IN P
atrial JJ P
fibrillation NN P
. . P

The DT P
primary JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
safety NN N
of IN N
four CD N
fixed-dose JJ N
regimens NNS N
of IN N
edoxaban NN I
with IN I
warfarin NN I
in IN N
patients NNS P
with IN P
non-valvular JJ P
atrial JJ P
fibrillation NN P
(AF) NN P
. . P

In IN N
this DT N
12-week JJ N
parallel-group NN N
multicentre NN P
multinational JJ P
study NN P
1 CD P
146 CD P
patients NNS P
with IN P
AF NNP P
and CC P
risk NN P
of IN P
stroke NN P
were VBD N
randomised VBN N
to TO N
edoxaban VB I
30 CD I
mg NN I
qd NN I
30 CD I
mg NN I
bid NN I
60 CD I
mg NN I
qd NN I
or CC I
60 CD I
mg JJ I
bid NN I
or CC I
warfarin VB I
dose-adjusted JJ N
to TO N
a DT N
target NN N
international JJ N
normalised JJ N
ratio NN N
of IN N
2.0-3.0 JJ N
. . N

The DT N
study NN N
was VBD N
double-blind JJ N
to TO N
edoxaban VB I
dose JJ N
but CC N
open-label JJ N
to TO N
warfarin VB I
. . I

Primary JJ N
outcomes NNS N
were VBD N
occurrence NN O
of IN O
major JJ O
and/or NNS O
clinically RB O
relevant JJ O
non-major JJ O
bleeding NN O
and CC O
elevated VBD O
hepatic JJ O
enzymes NNS O
and/or VBP O
bilirubin NN O
. . O

Mean JJ N
age NN P
was VBD P
65 CD P
+/- JJ P
8.7 CD P
years NNS P
and CC P
64.4% CD P
were VBD P
warfarin-nave NN P
. . N

Whereas IN N
major JJ N
plus CC N
clinically JJ N
relevant JJ N
non-major JJ N
bleeding NN N
occurred VBD N
in IN N
3.2% CD N
of IN N
patients NNS N
randomised VBN N
to TO I
warfarin VB I
the DT N
incidence NN N
of IN O
bleeding NN O
was VBD N
significantly RB N
higher JJR N
with IN N
the DT I
edoxaban NN I
60 CD N
mg NN N
bid NN N
(10.6%; NNP N
p=0.002) NN N
and CC N
30 CD N
mg NNS N
bid NN N
regimens VBZ N
(7.8%; JJ N
p=0.029) NNS N
but CC N
not RB N
with IN N
the DT I
edoxaban NN I
60 CD N
mg NN N
qd NN N
(3.8%) NNP N
or CC N
30 CD N
mg NNS N
qd JJ N
regimens NNS N
(3.0%) VBP N
. . N

For IN N
the DT N
same JJ N
total JJ N
daily JJ N
dose NN N
of IN N
60 CD N
mg NNS N
both DT N
bleeding VBG N
frequency NN N
and CC I
trough JJ I
edoxaban NN I
concentrations NNS I
were VBD N
higher JJR N
in IN N
the DT N
30-mg JJ N
bid NN N
group NN N
than IN N
in IN N
the DT N
60-mg JJ N
qd NN N
group NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN O
hepatic JJ O
enzyme NN O
elevations NNS O
or CC O
bilirubin JJ O
values NNS O
among IN N
the DT N
groups NNS N
. . N

The DT N
safety NN N
profiles NNS N
of IN I
edoxaban JJ I
30 CD N
and CC N
60 CD N
mg NN N
qd NN N
in IN N
patients NNS N
with IN N
AF NNP N
were VBD N
similar JJ N
to TO I
warfarin VB I
. . N

In IN N
contrast NN N
the DT I
edoxaban JJ I
bid NN N
regimens NNS N
were VBD N
associated VBN N
with IN N
more RBR O
bleeding NN O
than IN I
warfarin NN I
. . N

These DT N
results NNS N
suggest VBP N
that IN N
in IN N
this DT N
three-month JJ N
study NN I
edoxaban VBZ I
30 CD N
or CC N
60 CD N
mg NNS N
qd NNS N
are VBP O
safe JJ O
and CC O
well-tolerated JJ O
. . N

-DOCSTART- -X- N

A DT N
randomized VBN N
controlled VBN N
trial NN N
for IN N
reducing VBG N
risks NNS O
for IN O
sexually RB P
transmitted VBN P
infections NNS P
through IN P
enhanced JJ I
patient-based JJ I
partner NN I
notification NN I
. . I

OBJECTIVES IN N
We PRP N
sought VBD N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
approaches NNS N
targeting VBG N
improved VBN N
sexually RB N
transmitted JJ N
infection NN N
(STI) NNP N
sexual JJ I
partner NN I
notification NN I
through IN I
patient JJ I
referral NN I
. . I

METHODS NN I
From IN P
January NNP P
2002 CD P
through IN P
December NNP P
2004 CD P
600 CD P
patients NNS P
with IN P
Neisseria NNP P
gonorrhoeae NN P
or CC P
Chlamydia NNP P
trachomatis NN P
were VBD P
recruited VBN P
from IN P
STI NNP P
clinics NNS P
and CC P
randomly RB P
assigned VBN P
to TO N
either VB N
a DT N
standard-of-care JJ I
group NN I
or CC I
a DT I
group NN I
that WDT I
was VBD I
counseled VBN I
at IN I
the DT I
time NN I
of IN I
diagnosis NN I
and CC I
given VBN I
additional JJ I
follow-up JJ I
contact NN I
. . I

Participants NNS N
completed VBD N
an DT N
interview NN N
at IN N
baseline JJ N
1 CD N
month NN N
and CC N
6 CD N
months NNS N
and CC N
were VBD N
checked VBN N
at IN N
6 CD N
months NNS N
for IN N
gonorrhea NN N
or CC N
chlamydial JJ N
infection NN N
via IN N
nucleic JJ N
acid JJ N
amplification NN N
testing NN N
of IN N
urine NN N
. . N

RESULTS NNP N
Program NNP N
participants NNS N
were VBD N
more RBR N
likely JJ N
to TO N
report VB N
sexual JJ I
partner NN I
notification NN I
at IN N
1 CD N
month NN N
(86% VBD N
control NN N
92% CD N
intervention; NN N
adjusted VBN N
odds NNS N
ratio VBP N
[AOR] JJ N
= NNP N
1.8; CD N
95% CD N
confidence NN N
interval NN N
[CI] NNP N
= VBD N
1.02 CD N
3.0) CD N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
report VB N
no DT N
unprotected JJ N
sexual JJ N
intercourse NN N
at IN N
6 CD N
months NNS N
(38% VBN N
control VBP N
48% CD N
intervention; JJ N
AOR NNP N
= NNP N
1.5; CD N
95% CD N
CI NNP N
= VBD N
1.1 CD N
2.1) CD N
. . N

Gonorrhea NNP O
or CC O
chlamydial JJ O
infection NN O
was VBD N
detected VBN N
in IN N
6% CD N
of IN N
intervention NN I
and CC N
11% CD N
of IN N
control NN I
participants NNS N
at IN N
follow-up JJ I
(AOR NNP N
= NNP N
2.2; CD N
95% CD N
CI NNP N
= VBD N
1.1 CD N
4.1) CD N
with IN N
greatest JJS N
benefits NNS N
seen VBN N
among IN N
men NNS N
(for JJ N
gender NN N
interaction NN N
P NNP N
= NNP N
.03) NNP N
. . N

CONCLUSIONS VB N
This DT N
patient-based JJ I
sexual JJ I
partner NN I
notification NN I
program NN I
can MD N
help VB N
reduce VB N
risks NNS N
for IN N
subsequent JJ N
STIs NNP N
among IN N
urban JJ P
minority NN P
patients NNS P
presenting VBG P
for IN P
care NN P
at IN P
STI NNP P
clinics NNS P
. . P

-DOCSTART- -X- N

The DT N
Toronto NNP N
prehospital JJ N
hypertonic JJ N
resuscitation--head JJ P
injury NN P
and CC P
multiorgan JJ N
dysfunction NN N
trial: NN N
feasibility NN N
study NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
feasibility NN N
of IN N
a DT N
prehospital JJ N
trial NN N
comparing VBG N
hypertonic JJ I
saline NN I
and CC I
dextran NN I
(HSD) NN I
with IN I
normal JJ I
saline NN I
(NS) NN I
in IN N
blunt JJ P
head NN P
injury NN P
patients NNS P
. . P

DESIGN NNP N
The DT N
study NN N
used VBD N
a DT N
double JJ N
blind NN N
randomized VBN N
trial NN N
. . N

SETTING VBG N
The DT N
study NN N
was VBD N
conducted VBN N
in IN N
air NN P
and CC P
land NN P
emergency NN P
medical JJ P
services NNS P
and CC P
2 CD P
trauma NN P
centers NNS P
serving VBG P
a DT P
population NN P
of IN P
4 CD P
million CD P
people NNS P
. . P

PATIENTS VB N
The DT N
study NN P
population NN P
consisted VBD P
of IN P
head NN P
injured JJ P
blunt NN P
trauma NN P
adult NN P
patients NNS P
with IN P
a DT P
Glasgow NNP P
Coma NNP P
Scale NNP P
of IN P
lower JJR P
than IN P
9 CD P
. . P

INTERVENTIONS NNP N
We PRP N
used VBD N
250 CD I
mL NN I
of IN I
HSD NNP I
vs FW I
NS NNP I
given VBN I
within IN I
4 CD I
hours NNS I
of IN I
the DT I
accident NN I
. . I

MEASUREMENTS NNP I
The DT N
specific JJ N
objectives NNS N
were VBD N
to TO N
assess VB O
protocol-related JJ O
logistical JJ O
issues NNS O
randomization NN O
HSD NNP O
safety NN O
and CC O
follow VB O
up RP O
rates NNS O
and CC N
to TO N
obtain VB N
survival JJ O
and CC O
neurocognitive JJ O
end NN O
point NN O
estimates NNS O
. . O

MAIN NNP N
RESULTS NNP N
Of IN N
132 CD P
eligible JJ P
patients NNS P
113 CD P
were VBD P
randomized VBN P
. . P

Nineteen NNP P
eligible JJ P
patients NNS P
were VBD N
missed VBN N
because IN N
of IN N
lack NN N
of IN N
time NN N
(9 NNP N
[22%]) NNP N
paramedic JJ N
discretion NN N
(3 NNP N
[7%]) VBZ N
the DT N
paramedic JJ N
forgot NN N
(6 NNP N
[15%]) NNP N
and CC N
the DT N
paramedic NN N
refused VBD N
(1 NNP N
[2%]) NNP N
. . N

Randomization NN N
compliance NN N
was VBD N
96% CD N
(109/113) NN N
. . N

Four CD N
randomized JJ N
cases NNS N
met VBD N
exclusion NN N
criteria: NN N
penetrating VBG N
trauma JJ N
(1) JJ N
cardiac JJ N
arrest NN N
(2) NN N
and CC N
fall NN N
from IN N
standing VBG N
(1) NN N
. . N

Three CD N
randomized JJ N
patients NNS N
were VBD N
excluded VBN N
from IN N
the DT N
final JJ N
analysis: NN N
2 CD N
patients NNS N
received VBD N
less JJR N
than IN N
50 CD N
mL NN N
of IN N
study NN N
solution NN N
due JJ N
to TO N
an DT N
interstitial JJ N
intravenous JJ N
line NN N
and CC N
1 CD N
lost VBN N
randomization NN N
identification NN N
. . N

Fifty JJ N
patients NNS N
(47%) WDT N
were VBD N
randomized VBN N
to TO N
HSD NNP N
and CC N
56 CD N
(53%) NN N
to TO N
NS NNP N
. . N

Mean JJ O
injury NN O
severity NN O
score NN O
was VBD N
32.7 CD N
for IN N
HSD NNP N
and CC N
32.6 CD N
for IN N
NS NNP N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
length NN O
of IN O
stay JJ O
Sequential NNP O
Organ NNP O
Failure NNP O
Assessment NNP O
maximum NN O
Multiple NNP O
Organ NNP O
Dysfunction NNP O
Score NNP O
maximum JJ O
delta JJ O
Multiple NNP O
Organ NNP O
Dysfunction NNP O
Score NNP O
or CC O
Apache NNP O
scores NNS O
. . O

Initial JJ O
head NN O
scans NNS O
scored VBD N
3 CD N
or CC N
higher JJR N
by IN N
Marshall NNP N
classification NN N
for IN N
12 CD N
HSD NNP N
and CC N
11 CD N
NS NNP N
patients NNS N
. . N

Zero NNP N
adverse JJ O
events NNS O
occurred VBD N
and CC N
follow-up NN N
for IN N
the DT N
primary JJ N
outcome NN N
was VBD N
100% CD N
. . N

Alive JJ O
at IN O
30 CD O
days NNS O
for IN N
HSD NNP N
and CC N
NS NNP N
respectively RB N
was VBD N
70% CD N
(35/50) NN N
and CC N
75% CD N
(42/56) NN N
and CC N
at IN N
discharge NN N
was VBD N
68% CD N
(34/50) NN N
and CC N
73% CD N
(41/56) NN N
. . N

Only RB N
49.3% CD N
(37/77) NNS N
of IN N
surviving VBG N
patients NNS N
consented VBN N
to TO N
follow-up NN N
at IN N
4 CD N
months NNS N
and CC N
89% CD N
(33/37) NN N
completed VBD N
the DT N
assessment NN N
. . N

Disability NN O
rating NN O
scale NN O
(median JJ N
interquartile NN N
range) NN N
was VBD N
3 CD N
(0 JJ N
6) CD N
for IN N
HSD NNP N
and CC N
was VBD N
0 CD N
(0 JJ N
6) CD N
for IN N
NS NNP N
. . N

Glasgow NNP O
Outcome NNP O
Scale NNP O
Evaluation NNP O
was VBD N
higher JJR N
than IN N
4 CD N
for IN N
HSD NNP N
(12/12 NNP N
[100%]) NNP N
and CC N
NS NNP N
(15/21 NNP N
[72%]) NNP N
. . N

Functional JJ O
Independence NNP O
Measure NNP O
(mean NNP N
SD) NNP N
was VBD N
62 CD N
(37) NN N
for IN N
HSD NNP N
and CC N
80 CD N
(32) NN N
for IN N
NS NNP N
. . N

CONCLUSIONS NN N
It PRP N
is VBZ N
feasible JJ N
to TO N
conduct VB N
a DT N
prehospital JJ N
randomized NN N
controlled VBD N
trial NN N
with IN N
HSD NNP N
for IN N
treatment NN N
of IN N
blunt NN P
trauma NN P
patients NNS P
with IN P
head NN P
injuries; NN P
however RB N
consent NN N
for IN N
neurofunctional JJ O
outcomes NNS O
in IN N
this DT N
cohort NN N
is VBZ N
problematic JJ N
and CC N
threatens VBZ N
the DT N
feasibility NN N
of IN N
definitive JJ N
trials NNS N
using VBG N
these DT N
potentially RB N
meaningful JJ N
end NN N
points NNS N
. . N

-DOCSTART- -X- N

Problem-based JJ I
learning: NN I
is VBZ N
anatomy IN N
a DT N
casualty NN N
INTRODUCTION NNP N
The DT N
teaching NN I
of IN I
medical JJ I
anatomy NN I
is VBZ N
changing VBG N
. . N

Medical JJ N
schools NNS N
worldwide WDT N
are VBP N
moving VBG N
away RB N
from IN N
dissection NN I
and CC I
lectures VBZ I
to TO N
a DT N
more RBR N
integrated JJ I
course NN I
where WRB I
basic JJ I
science NN I
and CC I
clinical JJ I
skills NNS I
are VBP I
taught JJ I
simultaneously RB I
. . I

Medical JJ P
students NNS P
on IN N
these DT N
integrated VBN I
courses NNS I
have VBP N
reported VBN N
a DT N
lack NN N
of IN N
confidence NN N
in IN N
their PRP$ N
basic JJ N
science NN N
knowledge NN N
especially RB N
concerning VBG N
anatomy NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
perform VB N
a DT N
randomised JJ N
controlled VBN N
trial NN N
(RCT) NN N
to TO N
compare VB N
anatomical JJ N
knowledge NN N
of IN N
two CD P
groups NNS P
of IN P
second-year JJ P
medical JJ P
students NNS P
the DT P
first JJ P
group NN P
taught NN P
on IN P
a DT P
traditional JJ P
course NN P
the DT P
second JJ P
on IN P
an DT P
integrated JJ P
course NN P
. . P

MATERIALS NNP P
AND CC N
METHODS NNP N
Testing NNP N
was VBD N
done VBN N
using VBG N
a DT N
Questionnaire NN N
in IN N
a DT N
"True/False" JJ N
format NN N
. . N

There EX N
were VBD N
80 CD P
students NNS P
in IN P
each DT P
group NN P
. . P

There EX N
was VBD N
no DT N
penalty NN N
for IN N
an DT N
incorrect JJ N
answer NN N
. . N

The DT N
test NN N
was VBD N
performed VBN N
under IN N
examination NN N
conditions NNS N
. . N

Papers NNS N
were VBD N
marked VBN N
under IN N
blind JJ N
conditions NNS N
. . N

Results NNS N
were VBD N
analysed VBN N
using VBG N
a DT N
Student's NNP N
t NN N
test NN N
analysis NN N
. . N

RESULTS NNP N
Those DT N
students NNS N
taught VBP N
on IN N
a DT N
traditional JJ I
course NN I
exhibited VBD N
a DT N
significantly RB N
higher JJR N
level NN O
of IN O
basic JJ O
anatomical JJ O
knowledge NN O
(p<0.001) NN N
than IN N
those DT N
taught VBN N
on IN N
an DT N
integrated JJ I
course NN I
. . I

The DT N
students NNS N
taught VBD I
on IN I
an DT I
integrated JJ I
course NN N
showed VBD N
a DT N
much RB N
greater JJR N
range NN N
of IN N
results NNS N
. . N

CONCLUSIONS JJ N
Students NNS N
taught VBD I
on IN I
a DT I
traditional JJ I
course NN N
have VBP N
a DT N
higher JJR N
level NN N
of IN N
anatomical JJ O
knowledge NN O
than IN N
those DT N
taught VBN I
on IN I
an DT I
integrated JJ I
course NN I
. . I

Our PRP$ N
results NNS N
differ VBP N
from IN N
previous JJ N
studies NNS N
done VBN N
in IN N
Europe NNP N
which WDT N
show VBP N
no DT N
difference NN N
between IN N
the DT N
courses NNS I
. . I

-DOCSTART- -X- N

A DT N
comparison NN N
of IN N
acceptance- JJ N
and CC N
control-based JJ N
strategies NNS N
for IN N
coping VBG N
with IN N
food NN N
cravings: NN N
an DT N
analog NN N
study NN N
. . N

The DT N
present JJ N
study NN N
utilized VBD N
an DT N
analog NN O
paradigm NN O
to TO N
investigate VB N
the DT N
effectiveness NN N
of IN N
two CD N
strategies NNS N
for IN N
coping VBG N
with IN N
food NN N
cravings NNS N
which WDT N
was VBD N
theorized VBN N
to TO N
be VB N
critical JJ N
to TO N
the DT N
maintenance NN P
of IN P
weight JJ P
loss NN P
. . P

Ninety-eight JJ P
undergraduate JJ P
students NNS P
were VBD N
given VBN N
transparent JJ N
boxes NNS N
of IN N
chocolate NN N
Hershey's NNP N
Kisses NNP N
and CC N
instructed VBN N
to TO N
keep VB N
the DT N
chocolates NNS N
with IN N
them PRP N
but CC N
not RB N
to TO N
eat VB N
them PRP N
for IN N
48 CD N
h NN N
. . N

Before IN N
receiving VBG N
the DT N
Kisses NNP N
participants NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
(a) NNP N
no DT N
intervention NN N
(b) VBZ N
instruction NN N
in IN N
control-based JJ N
coping VBG N
strategies NNS N
such JJ N
as IN N
distraction NN N
and CC N
cognitive JJ N
restructuring NN N
or CC N
(c) JJ N
instruction NN N
in IN N
acceptance-based JJ N
strategies NNS N
such JJ N
as IN N
experiential JJ N
acceptance NN N
and CC N
defusion NN N
techniques NNS N
. . N

Measures NNS N
included VBD N
the DT N
Power NNP O
of IN O
Food NNP O
Scale NNP O
(PFS; VBD N
a DT N
measure NN N
of IN N
psychological JJ N
sensitivity NN N
to TO N
the DT N
food NN N
environment) JJ N
self-report JJ O
ratings NNS O
of IN N
chocolate NN N
cravings NNS N
and CC N
surreptitiously RB O
recorded VBN O
chocolate NN O
consumption NN O
. . O

Results NNS N
suggested VBD N
that IN N
the DT N
effect NN N
of IN N
the DT N
intervention NN N
depended VBD N
on IN N
baseline NN N
PFS NNP O
levels NNS O
such JJ O
that IN N
acceptance-based JJ N
strategies NNS N
were VBD N
associated VBN N
with IN N
better JJR N
outcomes NNS N
(cravings NNS O
consumption) VBP O
among IN N
those DT N
reporting VBG N
the DT N
highest JJS N
susceptibility NN N
to TO N
the DT N
presence NN N
of IN N
food NN N
but CC N
greater JJR N
cravings NNS N
among IN N
those DT N
who WP N
scored VBD N
lowest JJS N
on IN N
the DT N
PFS NNP N
. . N

It PRP N
was VBD N
observed VBN N
that IN N
craving VBG O
self-report JJ O
measures NNS O
predicted VBN N
chocolate NN N
consumption NN N
and CC N
baseline NN N
PFS NNP O
levels NNS O
predicted VBD N
both DT N
cravings NNS N
and CC N
consumption NN N
. . N

Results NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
the DT N
implications NNS N
for IN N
weight JJ P
loss NN P
maintenance NN P
strategies NNS P
. . P

-DOCSTART- -X- N

Randomised VBN N
placebo-controlled JJ I
double-blind JJ I
clinical JJ N
trial NN N
of IN N
beta-sitosterol NN I
in IN N
patients NNS P
with IN P
benign JJ P
prostatic JJ P
hyperplasia NN P
. . P

Beta-sitosterol NNP N
Study NNP N
Group NNP N
. . N

Medical JJ N
treatments NNS N
have VBP N
become VBN N
available JJ N
for IN N
benign JJ P
hypertrophy NN P
of IN P
the DT P
prostate NN P
including VBG P
alpha-receptor JJ I
blocking NN I
agents NNS I
and CC N
5-alpha-reductase JJ I
inhibitors NNS I
. . I

Drugs NNS N
derived VBN N
from IN N
plants NNS N
for IN N
which WDT N
no DT N
precise NN N
mechanism NN N
of IN N
action NN N
has VBZ N
been VBN N
described VBN N
are VBP N
widely RB N
used VBN N
for IN N
this DT N
purpose NN N
in IN N
Europe NNP N
. . N

In IN N
a DT N
randomised JJ P
double-blind JJ P
placebo-controlled JJ P
multicentre NN P
study NN P
200 CD P
patients NNS P
(recruited VBN P
between IN P
April NNP P
and CC P
October NNP P
1993) CD P
with IN P
symptomatic JJ P
benign NN P
prostatic JJ P
hyperplasia NN P
were VBD P
treated VBN P
with IN N
either DT N
20 CD I
mg NN I
beta-sitosterol NN I
(which NNP I
contains VBZ I
a DT I
mixture NN I
of IN I
phytosterols) NN I
three CD N
times NNS N
per IN N
day NN N
or CC I
placebo NN I
. . I

Primary JJ N
end-point NN N
was VBD N
a DT N
difference NN N
of IN N
modified JJ N
Boyarsky NNP O
score NN O
between IN N
treatment NN N
groups NNS N
after IN N
6 CD N
months; JJ N
secondary JJ N
end-points NNS N
were VBD N
changes NNS N
in IN N
International NNP O
Prostate NNP O
Symptom NNP O
Score NNP O
(IPSS) NNP O
urine NN O
flow NN O
and CC O
prostate JJ O
volume NN O
. . O

Modified NNP O
Boyarsky NNP O
score NN O
decreased VBD N
significantly RB N
with IN N
a DT N
mean NN N
of IN N
-6.7 NNP N
(SD NNP N
4.0) CD N
points NNS N
in IN N
the DT N
beta-sitosterol-treated JJ I
group NN N
versus NN N
-2.1 NNP N
(3.2) NNP N
points NNS N
in IN N
the DT N
placebo NN I
group NN N
p VBD N
< RB N
0.01 CD N
. . N

There EX N
was VBD N
a DT N
decrease NN N
in IN N
IPSS NNP O
(-7.4 JJ N
[3.8] NN N
points NNS N
in IN N
the DT N
beta-sitosterol-treated JJ N
group NN N
vs NN N
-2.1 NNP N
[3.8] NNP N
points NNS N
in IN N
the DT N
placebo NN N
group) NN N
and CC N
changes NNS N
in IN N
urine JJ O
flow JJ O
parameters: NN O
beta-sitosterol JJ I
treatment NN N
resulted VBD N
in IN N
increasing VBG N
peak NN O
flow NN O
(15.2 NNP N
[5.7] NNP N
mL/s NN N
from IN N
9.9 CD N
[2.5] JJ N
mL/s) NN N
and CC N
decrease NN N
of IN N
mean JJ O
residual JJ O
urinary JJ O
volume NN O
(30.4 NNP N
[39.9] NNP N
mL NN N
from IN N
65.8 CD N
[20.8] JJ N
mL) NN N
. . N

These DT N
parameters NNS N
did VBD N
not RB N
change VB N
in IN N
the DT N
placebo NN N
group NN N
(p NNP N
< VBZ N
0.01) CD N
. . N

No DT N
relevant JJ N
reduction NN N
of IN N
prostatic JJ O
volume NN O
was VBD N
observed VBN N
in IN N
either DT N
group NN N
. . N

Significant JJ N
improvement NN N
in IN N
symptoms NNS O
and CC O
urinary JJ O
flow NN O
parameters NNS O
show VBP N
the DT N
effectiveness NN N
of IN N
beta-sitosterol NN I
in IN N
the DT N
treatment NN N
of IN N
benign JJ P
prostatic JJ P
hyperplasia NN P
. . P

-DOCSTART- -X- N

Children NNP P
with IN P
persistent JJ P
conduct NN P
problems NNS P
who WP P
dropout VBP P
of IN P
treatment NN P
. . P

Dropout NN O
of IN N
treatment NN N
is VBZ N
one CD N
of IN N
the DT N
key JJ N
issues NNS N
in IN N
outcome NN N
in IN N
a DT N
child NN P
and CC P
adolescent JJ P
mental JJ P
health NN P
service NN P
. . P

We PRP N
report VBP N
two CD N
studies NNS N
focusing VBG N
on IN N
the DT N
treatment NN N
process NN N
and CC N
the DT N
dropout NN O
rate NN O
of IN O
children NNS P
with IN P
persistent JJ P
conduct NN P
problems NNS P
presenting VBG P
to TO P
a DT P
community NN P
mental JJ P
health NN P
service NN P
using VBG P
a DT N
prospective JJ N
design NN N
. . N

The DT N
first JJ P
study NN P
included VBD P
32 CD P
children NNS P
and CC N
used VBD N
a DT N
randomised JJ N
controlled JJ N
treatment NN N
design NN N
comparing VBG N
a DT N
CBT NNP I
approach NN I
with IN I
conjoint JJ I
family NN I
therapy NN I
and CC I
an DT I
eclectic JJ I
approach NN I
. . I

The DT N
overall JJ O
dropout NN O
rate NN O
was VBD N
36% CD N
. . N

Dropout NN O
occurred VBD N
significantly RB N
less RBR N
frequently RB N
in IN N
the DT N
CBT NNP I
group NN N
. . N

The DT N
dropout NN N
group NN N
was VBD N
associated VBN N
with IN N
mothers NNS P
who WP P
were VBD P
younger JJR P
and CC P
less RBR P
educated VBD P
a DT P
poorer NN O
rating NN O
by IN O
the DT O
clinicians NNS O
at IN N
the DT N
last JJ N
meeting NN N
parental JJ O
dissatisfaction NN O
with IN O
the DT O
treatment NN O
service NN O
and CC N
perception NN O
that IN O
the DT O
treatment NN O
was VBD N
less JJR N
organised JJ N
and CC N
having VBG N
less JJR N
behavioural JJ N
tasks NNS N
. . N

In IN N
the DT N
second JJ N
study NN N
we PRP N
used VBD N
a DT N
naturalistic JJ I
follow-up JJ I
design NN I
. . I

Forty-six JJ P
children NNS P
were VBD P
included VBN P
. . P

The DT N
overall JJ O
dropout NN O
rate NN O
was VBD N
48% CD N
. . N

Again IN N
the DT N
children NNS P
who WP P
defaulted VBD P
were VBD N
rated VBN N
by IN N
clinicians NNS N
as IN N
less RBR N
likely JJ N
to TO N
have VB N
improved VBN N
and CC N
dropout NN N
was VBD N
also RB N
significantly RB N
associated VBN N
with IN N
parental JJ O
perception NN O
of IN O
a DT O
less RBR O
organised JJ O
treatment NN O
. . O

In IN N
both DT N
studies NNS N
dropout VBP O
usually RB N
occurred VBN N
after IN N
assessment NN N
and CC N
at IN N
the DT N
early JJ N
phase NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- N

Acute NNP O
and CC O
late JJ O
toxicity NN O
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
conventional JJ I
versus NN I
hypofractionated VBD I
three-dimensional JJ I
conformal JJ I
radiotherapy NN I
for IN N
prostate NN P
cancer NN P
. . P

PURPOSE NN P
To TO N
compare VB N
the DT N
toxicity NN N
between IN N
hypofractionation NN I
vs NN I
. . I

conventional JJ I
fractionation NN I
schedules NNS N
in IN N
patients NNS P
with IN P
high-risk JJ P
prostate NN P
cancer NN P
. . P

METHODS NNP P
AND CC N
MATERIALS NNP N
Between NNP P
January NNP P
2003 CD P
and CC P
December NNP P
2007 CD P
168 CD P
patients NNS P
were VBD P
randomized VBN P
to TO N
receive VB N
either RB N
hypofractionated VBN I
(62 NN N
Gy NNP N
in IN N
20 CD N
fractions NNS N
within IN N
5 CD N
weeks NNS N
4 CD N
fractions/wk) NNS N
or CC I
conventionally RB I
fractionated VBN I
(80 JJ N
Gy NNP N
in IN N
40 CD N
fractions NNS N
within IN N
8 CD N
weeks) JJ N
three-dimensional JJ I
conformal JJ I
radiotherapy NN I
to TO N
the DT N
prostate NN N
and CC N
seminal JJ N
vesicles NNS N
. . N

All DT P
patients NNS P
had VBD P
undergone RP P
a DT P
9-month JJ P
course NN P
of IN P
total JJ P
androgen NN P
deprivation NN P
with IN P
radiotherapy NN P
starting VBG P
2 CD P
months NNS P
after IN P
initiation NN P
of IN P
the DT P
total JJ P
androgen NN P
deprivation NN P
. . P

RESULTS VB N
The DT N
median JJ N
follow-up NN N
was VBD N
32 CD N
and CC N
35 CD N
months NNS N
in IN N
the DT N
hypofractionation NN I
and CC I
conventional JJ I
fractionation NN I
arms NNS N
respectively RB N
. . N

For IN N
the DT N
patients NNS N
developing VBG N
acute JJ N
toxicity NN N
no DT N
difference NN N
between IN N
the DT N
two CD N
fractionation NN N
groups NNS N
was VBD N
found VBN N
in IN N
either DT N
severity NN O
or CC O
duration NN O
of IN O
gastrointestinal JJ O
or CC O
genitourinary JJ O
toxicity NN O
. . O

Also RB N
no DT N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
late JJ O
gastrointestinal NN O
and CC O
genitourinary JJ O
toxicity NN O
between IN N
the DT N
two CD N
treatment NN N
schedules NNS N
with IN N
a DT N
3-year JJ N
rate NN N
of IN N
Grade NNP N
2 CD N
or CC N
greater JJR N
toxicity NN N
of IN N
17% CD N
and CC N
16% CD N
for IN N
the DT N
hypofractionation NN I
arm NN N
and CC N
14% CD N
and CC N
11% CD N
for IN N
the DT N
conventional JJ I
fractionation NN I
arm NN N
respectively RB N
. . N

A DT N
statistically RB N
significant JJ N
correlation NN N
between IN N
acute NN O
and CC O
late JJ O
gastrointestinal JJ O
toxicity NN O
was VBD N
found VBN N
only RB N
in IN N
the DT N
conventional JJ I
fractionation NN I
group NN N
. . N

CONCLUSION NNP N
Our PRP$ N
findings NNS N
suggest VBP N
that IN N
the DT N
hypofractionation NN I
regimen NNS N
used VBN N
in IN N
our PRP$ N
study NN N
is VBZ N
safe JJ N
with IN N
only RB N
a DT N
slight JJ N
nonsignificant JJ N
increase NN N
in IN N
tolerable JJ N
and CC N
temporary JJ N
acute NN N
toxicity NN O
compared VBN N
with IN N
the DT N
conventional JJ I
fractionation NN I
schedule NN N
. . N

The DT N
severity NN N
and CC N
frequency NN N
of IN N
late JJ N
complications NNS N
was VBD N
equivalent JJ N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

-DOCSTART- -X- N

Fat NNP N
embolism NN N
prophylaxis NN N
with IN N
corticosteroids NNS I
. . I

A DT N
prospective JJ N
study NN N
in IN N
high-risk JJ P
patients NNS P
. . P

The DT P
efficacy NN O
of IN N
corticosteroid JJ I
treatment NN N
in IN N
the DT N
prophylaxis NN N
of IN N
the DT N
fat JJ P
embolism NN P
syndrome NN P
was VBD N
evaluated VBN N
in IN N
a DT N
prospective JJ N
randomized VBN N
double-blind NN N
study NN N
of IN N
high-risk JJ P
patients NNS P
with IN P
long-bone JJ P
fractures NNS P
. . P

Using VBG N
a DT N
set NN N
of IN N
objective JJ N
diagnostic JJ N
criteria NN N
we PRP N
saw VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
the DT N
syndrome NN O
between IN N
corticosteroid- JJ I
(0 NNP P
of IN P
21) CD P
and CC P
placebo-treated JJ P
patients NNS P
(9 CD P
of IN P
41) CD P
(p NNS N
less JJR N
than IN N
0.05) CD N
. . N

There EX N
were VBD N
no DT N
complications NNS N
related VBN N
to TO N
corticosteroid VB I
treatment NN N
. . N

No DT N
routine JJ N
laboratory NN N
or CC N
physical JJ N
findings NNS N
reliably RB N
predicted VBD N
the DT N
development NN O
of IN O
the DT O
fat JJ O
embolism NN O
syndrome NN O
except IN N
petechial JJ O
rash NN O
which WDT O
occurred VBD N
only RB N
in IN N
5 CD N
placebo-treated JJ N
patients NNS N
who WP N
developed VBD N
the DT N
syndrome NN N
. . N

Complement JJ O
activation NN O
was VBD N
present JJ N
in IN N
all DT N
patients NNS N
studied VBN N
who WP N
had VBD N
the DT N
syndrome JJ N
(5 NN N
of IN N
27) CD N
but CC N
also RB N
in IN N
many JJ N
patients NNS N
who WP N
did VBD N
not RB N
meet VB N
our PRP$ N
diagnostic JJ N
criteria NNS N
suggesting VBG N
a DT N
multifactorial JJ N
cause NN N
. . N

These DT N
data NNS N
support NN N
the DT N
prophylactic JJ N
value NN N
of IN N
corticosteroid JJ I
treatment NN N
in IN N
patients NNS P
at IN P
high JJ P
risk NN P
for IN P
the DT P
fat JJ P
embolism NN P
syndrome VBP P
particularly RB P
if IN N
several JJ N
unfavorable JJ N
predictors NNS N
are VBP N
present JJ N
. . N

-DOCSTART- -X- N

A DT N
head-to-head JJ N
comparison NN N
of IN N
aripiprazole NN I
and CC I
risperidone NN I
for IN N
safety NN N
and CC N
treating VBG N
autistic JJ P
disorders NNS P
a DT P
randomized VBN N
double JJ N
blind RB N
clinical JJ N
trial NN N
. . N

Aripiprazole NNP I
and CC I
risperidone NN I
are VBP N
the DT N
only JJ N
FDA NNP N
approved VBD N
medications NNS N
for IN N
treating VBG N
irritability NN N
in IN N
autistic JJ N
disorder NN N
however RB N
there EX N
are VBP N
no DT N
head-to-head JJ N
data NNS N
comparing VBG N
these DT N
agents NNS N
. . N

This DT N
is VBZ N
the DT N
first JJ N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
comparing VBG N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
these DT N
two CD N
medications NNS N
in IN N
patients NNS P
with IN P
autism NN P
spectrum NN P
disorders NNS P
. . P

Fifty NNP P
nine CD P
children NNS P
and CC P
adolescents NNS P
with IN P
autism NN P
spectrum NN P
disorders NNS P
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
aripiprazole NN I
or CC I
risperidone NN I
for IN N
2months CD N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD O
change NN O
in IN O
Aberrant NNP O
Behavior NNP O
Checklist NNP O
(ABC) NNP O
scores NNS O
. . N

Adverse JJ N
events NNS N
were VBD N
assessed VBN N
. . I

Aripiprazole NNP I
as RB N
well RB N
as IN I
risperidone NN I
lowered VBD O
ABC NNP O
scores NNS O
during IN N
2months CD N
. . N

The DT O
rates NNS O
of IN O
adverse JJ O
effects NNS O
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT O
safety NN O
and CC O
efficacy NN O
of IN I
aripiprazole JJ I
(mean JJ N
dose NN N
5.5mg/day) CD N
and CC I
risperidone JJ I
(mean NN N
dose NN N
1.12mg/day) CD N
were VBD N
comparable JJ N
. . N

The DT N
choice NN N
between IN N
these DT N
two CD N
medications NNS N
should MD N
be VB N
on IN N
the DT N
basis NN N
of IN N
clinical JJ N
equipoise NN N
considering VBG N
the DT N
patient's NN N
preference NN N
and CC N
clinical JJ N
profile NN N
. . N

-DOCSTART- -X- N

Efficacy NN O
and CC N
safety NN O
relative VBP N
to TO N
placebo VB I
of IN N
an DT N
oral JJ N
formulation NN N
of IN N
cetirizine NN I
and CC I
sustained-release JJ I
pseudoephedrine NN I
in IN N
the DT N
management NN N
of IN N
nasal JJ P
congestion NN P
. . P

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
clinical JJ O
efficacy NN O
of IN N
an DT N
oral JJ N
formulation NN N
of IN N
cetirizine NN I
5 CD I
mg NN I
with IN I
sustained-release JJ I
pseudoephedrine NN I
(PSE) $ I
120 CD I
mg RBS I
relative JJ N
to TO N
placebo VB I
in IN N
patients NNS P
with IN P
nasal JJ P
congestion NN P
. . P

METHODS NNP P
Twenty-four CD P
patients NNS P
with IN P
perennial JJ P
rhinitis NN P
due JJ P
to TO P
house-dust-mite JJ P
(HDM) NN P
allergy NN P
were VBD P
recruited VBN P
in IN N
this DT N
crossover NN N
study NN N
. . N

A DT N
treatment NN N
period NN N
of IN N
1 CD N
week NN N
in IN N
which WDT N
cetirizine/PSE NN I
was VBD N
administered VBN N
twice RB N
daily RB N
was VBD N
followed VBN N
by IN N
a DT N
washout JJ I
period NN I
of IN I
at IN I
least JJS I
2 CD I
weeks NNS I
and CC I
a DT I
further JJ I
period NN I
of IN I
1 CD I
week NN I
in IN I
which WDT I
the DT I
alternative NN I
treatment NN I
was VBD I
given VBN I
to TO I
each DT I
patient NN I
. . I

Immediately RB N
after IN N
the DT N
first JJ N
dose NN N
of IN N
each DT N
medication NN N
(day RB N
1) CD N
nasal JJ O
congestion NN O
and CC N
related VBN O
symptoms NNS O
were VBD N
assessed VBN N
during IN N
a DT N
7-h JJ N
challenge NN N
with IN N
HDM NNP N
feces NNS N
with IN N
the DT N
Vienna NNP N
Challenge NNP N
Chamber NNP N
(VCC) NNP N
to TO N
investigate VB N
onset NN N
of IN N
action NN N
of IN N
the DT N
preparation NN N
. . N

A DT N
second JJ N
challenge NN N
of IN N
3-h JJ N
duration NN N
carried VBD N
out RP N
at IN N
least JJS N
12 CD N
h NN N
after IN N
the DT N
final JJ N
dose NN N
was VBD N
undertaken VBN N
after IN N
1 CD N
week NN N
(mean) NN N
of IN N
twice-daily JJ N
treatment NN N
to TO N
assess VB N
residual JJ N
effects NNS O
of IN N
the DT N
formulation NN N
after IN N
achievement NN N
of IN N
steady JJ N
state NN N
. . N

RESULTS VB N
The DT N
oral JJ N
formulation NN N
of IN N
cetirizine/PSE NN I
was VBD N
significantly RB N
(P<0.001) JJ N
superior JJ N
to TO N
placebo VB I
in IN N
improving VBG N
nasal JJ O
obstruction NN O
during IN N
both DT N
challenges NNS N
. . N

The DT N
improvement NN O
in IN O
nasal JJ O
airflow NN O
and CC O
nasal JJ O
patency NN O
was VBD N
significantly RB N
greater JJR N
with IN N
cetirizine/PSE NN I
than IN N
with IN N
placebo JJ I
(P<0.02) NN N
. . N

In IN N
addition NN N
subjective JJ N
assessment NN N
of IN N
nasal NN O
symptoms NNS O
showed VBD N
that IN N
cetirizine/PSE NN I
was VBD N
significantly RB N
superior JJ N
to TO N
placebo VB I
in IN N
both DT N
challenges NNS N
for IN N
the DT N
sum NN O
of IN O
nasal JJ O
obstruction NN O
scores NNS O
(P<0.01) VBP N
. . N

Both DT N
medications NNS N
were VBD N
well RB N
tolerated VBN O
and CC O
no DT N
serious JJ N
adverse JJ O
events NNS O
occurred VBD N
during IN N
the DT N
study NN N
. . N

CONCLUSIONS NN N
In IN N
this DT N
study NN N
cetirizine/PSE VBZ I
relieved VBN N
nasal JJ N
congestion NN N
and CC N
other JJ N
objective JJ N
and CC N
subjective JJ N
symptoms NNS N
to TO N
a DT N
significantly RB N
greater JJR N
extent NN N
than IN N
placebo NN I
. . I

No DT N
serious JJ N
adverse JJ N
events NNS N
occurred VBD N
and CC N
both DT N
regimens NNS N
were VBD N
equally RB N
well RB N
tolerated VBN N
. . N

-DOCSTART- -X- N

A DT N
placebo NN N
controlled VBN N
crossover RB N
trial NN N
of IN N
liquid JJ I
fluoxetine NN I
on IN N
repetitive JJ P
behaviors NNS P
in IN P
childhood NN P
and CC P
adolescent JJ P
autism NN P
. . P

Repetitive JJ P
behaviors NNS O
are VBP N
a DT N
core NN N
symptom NN N
domain NN N
in IN N
autism NN N
that WDT N
has VBZ N
been VBN N
linked VBN N
to TO N
alterations NNS N
in IN N
the DT N
serotonin NN N
system NN N
. . N

While IN N
the DT N
selective JJ I
serotonin-receptive JJ I
inhibitor NN I
fluvoxamine NN I
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
adults NNS P
with IN P
autism NN P
as IN P
yet RB N
no DT N
published VBN N
placebo NN I
controlled VBN N
trials NNS N
with IN N
these DT N
agents NNS N
document NN N
safety NN O
and CC N
efficacy NN O
in IN N
children NNS P
with IN P
autism NN P
. . P

This DT N
study NN N
examines VBZ N
the DT N
selective JJ I
serotonin NN I
reuptake NN I
inhibitor NN I
liquid JJ I
fluoxetine NN I
in IN N
the DT N
treatment NN N
of IN N
repetitive JJ P
behaviors NNS P
in IN P
childhood NN P
and CC P
adolescent JJ P
autism NN P
spectrum NN P
disorders NNS P
(ASDs) VBP P
. . P

In IN N
total JJ N
45 CD P
child NN P
or CC P
adolescent JJ P
patients NNS P
with IN P
ASD NNP P
were VBD P
randomized VBN P
into IN P
two CD P
acute JJ P
8-week JJ P
phases NNS P
in IN P
a DT P
double-blind JJ P
placebo-controlled JJ P
crossover NN P
study NN P
of IN P
liquid JJ P
fluoxetine NN P
. . P

Study NNP N
design NN N
included VBD N
two CD N
randomized VBN N
8-week JJ I
fluoxetine NN I
and CC I
placebo NN I
phases NNS N
separated VBN N
by IN N
a DT N
4-week JJ N
washout NN N
phase NN N
. . N

Outcome NNP N
measures NNS N
included VBD N
measures NNS O
of IN O
repetitive JJ O
behaviors NNS O
and CC O
global JJ O
improvement NN O
. . O

Low-dose JJ N
liquid NN I
fluoxetine NN I
(mean JJ N
final JJ N
dose: NN N
9.9+/-4.35 CD N
mg/day) NN N
was VBD N
superior JJ N
to TO N
placebo VB I
in IN N
the DT N
treatment NN N
of IN N
repetitive JJ O
behaviors NNS O
by IN N
CY-BOCS NNP O
compulsion NN O
scale NN O
. . O

The DT N
effect NN N
size NN N
was VBD N
in IN N
the DT N
moderate NN N
to TO N
large JJ N
range NN N
and CC N
the DT N
doses NNS N
used VBN N
were VBD N
low JJ N
. . N

Liquid NNP I
fluoxetine NN I
was VBD N
only RB N
slightly RB N
and CC N
not RB N
significantly RB N
superior JJ N
to TO N
placebo VB I
on IN N
CGI NNP O
autism NN O
score NN O
partially RB N
due JJ N
to TO N
a DT N
phase NN O
order NN O
effect NN O
. . O

However RB N
fluoxetine NN I
was VBD N
marginally RB N
superior JJ N
to TO N
placebo VB I
on IN N
a DT N
composite JJ N
measure NN N
of IN N
global JJ O
effectiveness NN O
. . O

Liquid NNP I
fluoxetine NN I
did VBD N
not RB N
significantly RB N
differ VBP N
from IN N
placebo NN I
on IN N
treatment NN N
emergent JJ O
side NN O
effects NNS O
. . O

Liquid NNP I
fluoxetine NN I
in IN N
low JJ N
doses NNS N
is VBZ N
more RBR N
effective JJ N
than IN N
placebo NN I
in IN N
the DT N
treatment NN N
of IN N
repetitive JJ P
behaviors NNS P
in IN P
childhood NN P
autism NN P
. . P

Limitations NNS N
include VBP N
small JJ N
sample JJ N
size NN N
and CC N
the DT N
crossover NN N
design NN N
of IN N
the DT N
study NN N
. . N

Further JJ N
replication NN N
and CC N
long-term JJ N
maintenance NN N
trials NNS N
are VBP N
needed VBN N
. . N

-DOCSTART- -X- N

Leukocyte-depleted JJ P
reperfusion NN P
of IN P
transplanted JJ P
human JJ P
hearts: NN P
a DT N
randomized VBN N
double-blind NN N
clinical JJ N
trial NN N
. . N

Standard NNP N
methods NNS N
of IN N
myocardial JJ N
preservation NN N
for IN N
heart NN N
transplantation NN N
have VBP N
generally RB N
provided VBN N
good JJ N
results NNS N
. . N

Preservation NNP N
times NNS N
beyond IN N
3 CD N
hours NNS N
however RB N
have VBP N
been VBN N
associated VBN N
with IN N
decreased JJ N
survival NN O
. . O

Leukocyte-mediated JJ I
reperfusion NN I
injury NN N
is VBZ N
partly RB N
responsible JJ N
for IN N
decreased JJ N
graft NN N
function NN N
after IN N
prolonged JJ N
graft NN N
ischemia NN N
. . N

Leukocyte-depleted JJ I
reperfusion NN I
has VBZ N
been VBN N
shown VBN N
experimentally RB N
to TO N
improve VB N
cardiac JJ N
function NN N
after IN N
cold JJ P
ischemic JJ P
arrest NN P
. . P

To TO N
determine VB N
the DT N
efficacy NN O
and CC O
safety NN O
of IN N
leukocyte-depleted JJ I
reperfusion NN I
20 CD P
patients NNS P
were VBD P
enrolled VBN P
in IN P
a DT P
randomized JJ P
double-blind JJ P
clinical JJ P
trial NN P
to TO P
be VB P
treated VBN P
with IN P
either DT P
warm JJ P
whole NN P
blood NN P
reperfusion NN P
(group NNP P
I; NNP P
n VBD P
= JJ P
9) CD P
or CC P
warm JJ P
leukocyte-depleted JJ P
blood NN P
reperfusion NN P
(group NNP P
II; NNP P
n VBD P
= JJ P
11) CD P
. . P

Reperfusion NN I
with IN I
leukocyte-depleted JJ I
blood NN I
or CC I
whole JJ I
blood NN I
was VBD N
carried VBN N
out IN N
for IN N
10 CD N
minutes NNS N
with IN N
enriched JJ I
cardioplegic JJ I
solution NN I
added VBD N
for IN N
the DT N
first JJ N
3 CD N
minutes NNS N
of IN N
reperfusion NN N
. . N

The DT N
mean JJ N
donor NN N
and CC N
recipient JJ N
age NN N
and CC N
the DT N
ischemic JJ N
time NN N
(142 NNP N
versus NN N
153 CD N
minutes) NN N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Coronary JJ N
sinus NN N
release NN N
of IN N
creatinine JJ O
phosphokinase-MB JJ O
5 CD N
minutes NNS N
after IN N
reperfusion NN N
was VBD N
significantly RB N
less RBR N
in IN N
group NN N
II NNP N
(1.65 NNP N
EU/min) NNP N
than IN N
in IN N
group NN N
I PRP N
(3.83 VBP N
units/min; JJ N
p NN N
= VBD N
0.05) CD N
. . N

Thromboxane NNP O
B2 NNP O
release NN O
was VBD N
also RB N
significantly RB N
less RBR N
(p JJ N
= NN N
0.05) CD N
in IN N
group NN N
II NNP N
(33.6 NNP N
pg/min) NN N
than IN N
in IN N
group NN N
I PRP N
(67.0 VBP N
pg/min) NN N
. . N

All DT N
hearts NNS O
functioned VBD N
adequately RB N
in IN N
both DT N
groups NNS N
. . N

The DT N
duration NN O
of IN O
inotropic JJ O
support NN O
was VBD N
shorter JJR N
in IN N
group NN N
II NNP N
than IN N
in IN N
group NN N
I PRP N
but CC N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Postoperative JJ O
hemodynamics NNS O
rejection NN O
episodes NNS O
and CC O
infectious JJ O
complications NNS O
were VBD N
also RB N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
in IN N
a DT N
mean JJ N
follow-up NN N
of IN N
9 CD N
months NNS N
. . N

Mean JJ O
ejection NN O
fraction NN O
1 CD N
month NN N
after IN N
operation NN N
was VBD N
65% CD N
in IN N
both DT N
groups NNS N
. . N

One CD N
early JJ N
death NN O
occurred VBD N
at IN N
66 CD N
days NNS N
secondary JJ N
to TO N
infection; VB N
two CD N
late JJ N
deaths NNS O
occurred VBD N
in IN N
group NN N
II NNP N
both DT N
from IN N
rejection NN N
. . N

Leukocyte-depleted JJ I
reperfusion NN I
is VBZ N
safe JJ N
and CC N
easily RB N
applied VBN N
in IN N
the DT N
operating NN N
room NN N
. . N

Furthermore RB N
leukocyte-depleted JJ I
reperfusion NN I
decreases VBZ N
biochemical JJ O
evidence NN O
of IN N
reperfusion NN N
injury NN N
. . N

Although IN N
not RB N
influencing VBG N
postoperative JJ N
cardiac JJ N
function NN N
when WRB N
the DT N
ischemic JJ N
time NN N
is VBZ N
short RB N
less JJR N
than IN N
3 CD N
hours NNS N
leukocyte-depleted JJ I
reperfusion NN I
may MD N
prevent VB N
significant JJ N
reperfusion NN N
injury NN N
and CC N
improve VB N
posttransplantation NN N
graft NN N
function NN N
when WRB N
ischemic JJ N
times NNS N
are VBP N
long JJ N
. . N

Safe JJ N
extension NN N
of IN N
the DT N
ischemic JJ N
time NN N
would MD N
expand VB N
the DT N
donor NN N
pool NN N
and CC N
allow VB N
for IN N
better JJR N
crossmatching NN N
. . N

-DOCSTART- -X- N

Comparison NNP N
of IN P
synemol JJ P
cream NN P
and CC P
other JJ P
topical JJ P
corticosteroid NN P
creams NNS P
using VBG P
the DT P
vasoconstrictor NN P
bioassay NN P
. . P

The DT N
human JJ P
vasoconstrictor NN P
bioassay NN P
was VBD N
used VBN N
to TO N
assess VB N
the DT N
potency NN N
of IN N
open JJ N
applications NNS I
of IN I
Synemol NNP I
cream NN I
(0.025%) NNP I
Diprosone NNP I
cream NN I
(0.05%) VBD I
Aristocort-A NNP P
cream NN P
(0.5%) NN P
and CC P
Valisone NNP P
cream NN P
(0.1%) NN P
. . P

Intensity NN N
of IN N
vasoconstriction NN N
was VBD N
determined VBN N
eight CD N
twenty-four JJ N
and CC N
thirty-two JJ N
hours NNS N
after IN N
application NN N
. . N

Results NNS N
obtained VBD N
from IN N
the DT N
average JJ N
intensity NN O
scores NNS O
of IN N
the DT N
three CD N
determinations NNS N
indicated VBD N
that IN N
Synemol NNP I
cream NN I
(0.025%) NN N
is VBZ N
actually RB N
a DT N
more RBR N
active JJ N
compound NN N
than IN N
are VBP N
Diprosone NNP I
cream NN I
(0.05%) VBD N
Aristocort-A NNP I
cream NN I
(0.5%) NN N
and CC N
Valisone NNP I
cream NN I
(0.1%) NN N
and CC N
that IN N
its PRP$ N
activity NN N
is VBZ N
longer RBR N
acting VBG N
. . N

-DOCSTART- -X- N

Long-term JJ N
evaluation NN N
of IN N
tamsulosin NN I
in IN N
benign JJ P
prostatic JJ P
hyperplasia: NN P
placebo-controlled JJ I
double-blind JJ I
extension NN N
of IN N
phase NN N
III NNP N
trial NN N
. . N

Tamsulosin NNP N
Investigator NNP N
Group NNP N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
long-term JJ N
efficacy NN N
and CC N
safety NN N
of IN N
once-daily JJ I
tamsulosin NN I
(0.4 NNP I
and CC I
0.8 CD I
mg) NN I
a DT I
unique JJ N
selective JJ N
alpha1A-adrenoceptor NN N
antagonist NN N
in IN N
patients NNS P
with IN P
benign JJ P
prostatic JJ P
hyperplasia NN P
(BPH) NN P
. . P

METHODS NNP N
This DT N
trial NN N
extended VBD N
a DT N
13-week JJ N
Phase NNP N
III NNP N
multicenter RBR N
placebo-controlled JJ N
double-blind JJ N
outpatient NN N
trial NN N
for IN N
an DT N
additional JJ N
40 CD N
weeks NNS N
. . N

Of IN P
618 CD P
patients NNS P
418 CD P
(68%) JJ P
continued VBN N
into IN N
the DT N
extension NN N
phase NN N
on IN N
the DT N
same JJ N
double-blind JJ I
medication NN I
and CC I
dose NN I
. . I

The DT N
primary JJ N
efficacy NN N
parameters NNS N
were VBD N
total JJ N
American NNP N
Urological NNP N
Association NNP N
(AUA) NNP N
symptom NN N
score NN N
and CC N
maximum JJ N
urinary JJ N
flow NN N
(Qmax) NN N
. . N

RESULTS VB N
The DT N
mean JJ N
changes NNS N
in IN N
AUA NNP O
symptom NN O
score NN O
from IN N
baseline NN N
to TO N
end VB N
point NN N
were VBD N
statistically RB N
significant JJ N
in IN N
all DT N
groups NNS N
(P VBP N
<0.001) NN N
. . N

Significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
Qmax NNP O
for IN N
both DT N
tamsulosin JJ I
groups NNS N
but CC N
not RB N
for IN N
the DT N
placebo NN I
group NN N
. . N

The DT N
statistically RB N
significant JJ N
improvements NNS N
from IN N
baseline NN N
in IN N
efficacy NN N
parameters NNS N
observed VBD N
for IN N
each DT N
tamsulosin NN I
group NN N
at IN N
the DT N
end NN N
of IN N
the DT N
13-week JJ N
Phase NNP N
III NNP N
trial NN N
were VBD N
maintained VBN N
during IN N
the DT N
long-term JJ N
extension NN N
phase NN N
. . N

Tamsulosin NN N
at IN N
both DT N
dosages NNS N
was VBD N
well RB N
tolerated VBN N
as IN N
maintenance NN N
therapy NN N
. . N

Clinically RB N
significant JJ N
orthostatic JJ O
hypotension NN O
was VBD N
not RB N
observed VBN N
. . N

Vital NNP N
sign NN N
changes NNS N
in IN N
either DT N
hypertensive JJ N
or CC N
normotensive JJ N
patients NNS N
were VBD N
not RB N
clinically RB N
significantly RB N
different JJ N
across IN N
the DT N
three CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Tamsulosin NNP I
once-daily RB N
at IN N
0.4 CD N
or CC N
0.8 CD N
mg NN N
was VBD N
shown VBN N
to TO N
be VB N
effective JJ N
safe JJ N
and CC N
well RB N
tolerated VBN N
in IN N
the DT N
target NN P
BPH NNP P
population NN P
during IN N
long-term JJ N
use NN N
. . N

-DOCSTART- -X- N

Mass NNP I
inoculation NN I
in IN I
a DT I
community: NN I
the DT I
effect NN I
of IN I
primary JJ I
prevention NN I
of IN I
stress JJ O
reactions NNS O
. . O

This DT I
study NN I
assessed VBD I
the DT I
effectiveness NN I
of IN I
a DT I
brief JJ I
situation-specific JJ I
group-administered JJ I
preparatory NN I
intervention NN I
in IN I
a DT I
nonclient JJ P
school NN P
population NN P
undergoing VBG P
mass NN P
inoculation NN P
against IN P
rubella NN P
. . P

Fifty-one CD P
girls NNS P
were VBD I
randomly RB I
assigned VBN I
to TO I
practice NN I
no-practice RB I
or CC I
control VB I
groups NNS I
. . I

Both DT I
the DT I
practice NN I
and CC I
the DT I
no-practice JJ I
groups NNS I
received VBD I
information NN I
that IN I
described VBD I
the DT I
inoculation NN I
procedure NN I
and CC I
how WRB I
to TO I
cope VB I
with IN N
it PRP N
by IN N
using VBG N
cognitive-behavioral JJ N
coping NN N
skills NNS N
. . N

The DT N
practice NN N
group NN N
was VBD N
encouraged VBN N
to TO N
perform VB N
coping VBG N
techniques NNS N
of IN N
this DT N
type NN N
whereas IN N
the DT N
no-practice JJ N
group NN N
was VBD N
told VBN N
only RB N
that IN N
the DT N
intervention NN N
would MD N
help VB N
them PRP N
during IN N
the DT N
inoculation NN N
. . N

Subjects NNS N
in IN N
both DT N
practice NN N
and CC N
no-practice JJ N
groups NNS N
reported VBD N
less JJR N
anxiety NN O
and CC O
exhibited VBD O
more RBR O
cooperative JJ O
behavior NN O
during IN N
inoculation NN N
than IN N
subjects NNS N
in IN N
the DT N
control NN N
group NN N
and CC N
those DT N
who WP N
were VBD N
guided VBN N
and CC N
prompted VBN N
to TO N
actively RB N
practice NN N
derived VBD N
greater JJR N
benefit NN N
. . N

-DOCSTART- -X- N

Hitting VBG N
the DT N
target: NN N
relatively RB N
easy JJ N
yet RB N
absolutely RB N
difficult JJ N
. . N

It PRP N
is VBZ N
generally RB N
agreed VBN N
that IN N
absolute-direction NN O
judgments NNS O
require VBP N
information NN N
about IN N
eye NN N
position NN N
whereas IN N
relative-direction NN I
judgments NNS I
do VBP N
not RB N
. . N

The DT N
source NN N
of IN N
this DT N
eye-position JJ N
information NN N
particularly RB N
during IN N
monocular JJ N
viewing NN N
is VBZ N
a DT N
matter NN N
of IN N
debate NN N
. . N

It PRP N
may MD N
be VB N
either CC N
binocular VB N
eye NN N
position NN N
or CC N
the DT N
position NN N
of IN N
the DT N
viewing-eye JJ N
only RB N
that WP N
is VBZ N
crucial JJ N
. . N

Using VBG N
more RBR N
ecologically RB N
valid JJ N
stimulus NN N
situations NNS N
than IN N
the DT N
traditional JJ N
LED NNP N
in IN N
the DT N
dark NN N
we PRP N
performed VBD N
two CD N
experiments NNS N
. . N

In IN N
experiment JJ N
1 CD N
observers NNS P
threw VBD P
darts NNS P
at IN P
targets NNS P
that WDT P
were VBD P
fixated VBN P
either RB P
monocularly RB P
or CC P
binocularly RB P
. . P

In IN N
experiment JJ P
2 CD P
observers NNS P
aimed VBD P
a DT P
laser NN P
gun NN P
at IN P
targets NNS P
while IN P
fixating VBG P
either CC P
the DT P
rear NN P
or CC P
the DT P
front JJ P
gunsight JJ P
monocularly RB P
or CC P
the DT P
target NN P
either CC P
monocularly JJ P
or CC P
binocularly RB P
. . P

We PRP N
measured VBD N
the DT O
accuracy NN O
and CC O
precision NN O
of IN N
the DT N
observers' JJ N
absolute- JJ N
and CC N
relative-direction JJ N
judgments NNS N
. . N

We PRP N
found VBD N
that IN N
(a) JJ N
relative-direction NN O
judgments NNS O
were VBD N
precise JJ O
and CC O
independent JJ O
of IN O
phoria NNS O
and CC O
(b) JJ N
monocular JJ O
absolute-direction NN O
judgments NNS O
were VBD N
inaccurate JJ O
and CC O
the DT N
magnitude NN O
of IN O
the DT O
inaccuracy NN O
was VBD O
predictable JJ O
from IN O
the DT O
magnitude NN O
of IN O
phoria NN O
. . O

These DT N
results NNS N
confirm VBP N
that IN N
relative-direction NN O
judgments NNS O
do VBP N
not RB N
require VB N
information NN N
about IN N
eye NN N
position NN N
. . N

Moreover RB N
they PRP N
show VBP N
that IN N
binocular JJ O
eye-position NN O
information NN O
is VBZ N
crucial JJ O
when WRB N
judging VBG N
the DT N
absolute JJ O
direction NN O
of IN I
both DT I
monocular JJ I
and CC I
binocular JJ I
targets NNS I
. . I

-DOCSTART- -X- N

Influence NN I
of IN I
chestnut NN I
tannins NNS I
on IN I
welfare NN I
carcass NN I
characteristics NNS I
meat VBP I
quality NN I
and CC I
lipid JJ I
oxidation NN I
in IN I
rabbits NNS P
under IN P
high JJ P
ambient JJ P
temperature NN P
. . P

A DT I
study NN I
was VBD I
conducted VBN I
to TO I
evaluate VB I
the DT I
influence NN I
of IN I
chestnut NN I
tannins NNS I
(CT) VBP I
on IN I
welfare NN I
carcass NN I
characteristics NNS I
meat VBP I
quality NN I
and CC I
lipid JJ I
oxidation NN I
in IN I
rabbits NNS P
under IN I
high JJ I
ambient JJ I
temperature NN I
. . I

Rabbits NNS P
in IN I
one CD I
group NN I
were VBD I
raised VBN I
at IN I
20C CD I
and CC I
fed VBN I
with IN I
basal NN I
diet JJ I
(N) NNP I
and CC I
other JJ I
three CD I
groups NNS I
(33C) VBP I
were VBD I
fed VBN I
basal JJ I
diet JJ I
with IN I
0 CD I
(C) NNS I
5 CD I
(CT5) NNS I
and CC I
10 CD I
g NN I
(CT10) NN I
of IN I
CT/kg NNP I
of IN I
diet NN I
. . I

Compared VBN I
with IN I
the DT I
C NNP I
group NN I
rabbits VBZ I
in IN I
CT10 NNP I
had VBD I
higher JJR O
pH(24) NN O
and CC I
lower JJR O
cooking NN O
loss NN O
and CC O
thiobarbituric JJ O
acid NN O
reacting VBG O
substance NN O
values NNS O
at IN I
0 CD I
30 CD I
and CC I
60 CD I
min NN I
of IN I
forced JJ I
oxidation NN I
. . P

Rabbits NNS P
in IN I
C NNP I
group NN I
had VBD O
higher JJR O
cortisol NN O
levels NNS O
creatine VBP O
kinase NN O
activities NNS O
white JJ O
blood NN O
cell NN O
counts VBZ O
neutrophil JJ O
percentage NN O
neutrophil:lymphocyte NN O
ratio NN O
and CC O
lower JJR O
T(3) NNP O
T(4) NNP O
levels NNS O
lymphocyte VBP O
percentage NN O
than IN I
N NNP I
and CC I
CT10 NNP I
groups NNS I
. . I

Supplementation NN I
of IN I
CT NNP I
seemed VBD I
to TO I
have VB I
a DT I
positive JJ I
effect NN I
on IN O
growth NN O
performance NN O
welfare NN O
and CC O
meat NN O
quality NN O
of IN P
rabbits NNS P
under IN I
high JJ I
ambient JJ I
temperature NN I
. . I

-DOCSTART- -X- N

Comparison NNP N
of IN N
different JJ N
long-term JJ I
asthma NN I
treatments NNS I
in IN N
subjects NNS P
with IN P
mild-to-moderate JJ P
asthma NN P
. . P

In IN N
order NN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
different JJ N
asthma NN N
treatment NN N
in IN N
subjects NNS P
with IN P
mild-to-moderate JJ P
asthma NNS P
three CD P
groups NNS P
of IN P
11 CD P
patients NNS P
were VBD N
treated VBN N
with IN N
nedocromil JJ I
sodium NN I
(NS) NNP I
beclomethasone NN I
dipropionate NN I
(BDP) NN I
and CC I
beclomethasone NN I
dipropionate NN I
plus CC I
salmeterol NN I
(BDP NNP I
+ NNP I
S) NNP I
in IN N
an DT N
open JJ N
randomized NN N
study NN N
. . N

Symptom NNP O
score NN O
peak NN O
expiratory NN O
flow NN O
(PEF) NNP O
maximal JJ O
amplitude NN O
forced VBD O
expiratory JJ O
volume NN O
in IN O
one CD O
second JJ O
(FEV1) NN O
and CC O
methacholine JJ O
reactivity NN O
were VBD N
measured VBN N
at IN N
the DT N
baseline NN N
and CC N
at IN N
intervals NNS N
of IN N
3 CD N
months NNS N
up RB N
to TO N
12 CD N
months NNS N
. . N

After IN N
3 CD N
months NNS N
symptoms NNS O
reduced VBD N
significantly RB N
in IN N
all DT N
treatment NN N
groups NNS N
while IN N
PEF NNP O
variability NN O
improved VBN O
in IN O
BDP NNP O
and CC O
BDP NNP O
+ NNP O
S NNP O
groups; NN O
FEV1 NNP O
and CC O
bronchial JJ O
responsiveness NN O
to TO O
methacholine VB O
were VBD N
significantly RB N
improved VBN N
in IN N
comparison NN N
with IN N
baseline JJ N
value NN N
in IN N
the DT N
BDP NNP I
+ NNP I
S NNP I
group NN N
only RB N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
of IN N
treatment NN N
in IN N
PEF NNP O
variability NN O
FEV1 NNP O
or CC O
bronchial JJ O
hyperreactivity NN O
in IN N
the DT N
NS NNP N
group NN N
compared VBN N
with IN N
baseline NN N
values NNS N
while IN N
a DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
symptom NN N
score NN N
. . N

BDP NNP N
group NN N
showed VBD N
a DT N
significant JJ N
improvement NN N
in IN N
FEV1 NNP O
and CC O
bronchial JJ O
reactivity NN O
to TO N
methacholine VB N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
of IN N
treatment NN N
. . N

In IN N
the DT N
BDP NNP I
+ NNP I
S NNP I
group NN N
the DT N
improvement NN N
in IN N
symptoms NNS O
and CC O
pulmonary JJ O
function NN O
persisted VBN O
until IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

In IN N
conclusion NN N
the DT N
combination NN N
of IN N
beclomethasone NN N
dipropionate NN N
and CC N
salmeterol NN N
improved VBD N
pulmonary JJ O
function NN O
and CC O
bronchial JJ O
reactivity NN O
earlier RBR O
than IN N
beclomethasone CD I
dipropionate JJ I
alone RB N
while IN N
nedocromil JJ I
sodium NN I
improved VBD N
symptoms NNS O
but CC O
not RB O
pulmonary JJ O
function NN O
. . O

Assuming VBG N
that IN N
bronchial JJ N
reactivity NN N
could MD N
be VB N
an DT N
indirect JJ N
measurement NN N
of IN N
airway JJ N
inflammation NN N
overtreatment NN N
of IN N
asthma NN N
in IN N
relationship NN N
with IN N
the DT N
classification NN N
of IN N
asthma JJ N
severity NN N
of IN N
the DT N
International NNP N
Guidelines NNP N
could MD N
improve VB N
both DT N
airway JJ O
inflammation NN O
and CC O
the DT O
prognosis NN O
of IN O
airway JJ O
obstruction NN O
. . O

-DOCSTART- -X- N

Short-term JJ I
amiodarone NN I
therapy NN I
after IN N
reversion NN N
of IN N
persistent JJ P
atrial JJ P
fibrillation NN P
reduces NNS N
recurrences NNS N
at IN N
18 CD N
months NNS N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
outcome NN N
of IN N
3 CD N
months NNS N
vs NN N
. . N

18 CD N
months NNS N
of IN N
amiodarone NN I
treatment NN N
after IN N
atrial JJ P
fibrillation NN P
(AF) NNP P
conversion NN P
in IN P
patients NNS P
who WP P
experienced VBD P
the DT P
first JJ P
episode NN P
of IN P
persistent JJ P
AF NNP P
. . P

METHODS NNP N
We PRP N
included VBD N
51 CD P
patients NNS P
who WP P
experienced VBD P
the DT P
first JJ P
episode NN P
of IN P
persistent JJ P
AF NNP P
receiving VBG P
amiodarone NN P
(600 NN P
mg) JJ P
daily JJ P
for IN P
4-6 JJ P
weeks NNS P
. . P

If IN N
AF NNP N
persisted VBD N
electrical JJ I
cardioversion NN I
(ECV) NN I
was VBD N
performed VBN N
. . N

All DT N
patients NNS N
received VBD N
amiodarone JJ I
(200 NNP N
mg NN N
daily) NN N
for IN N
3 CD N
months NNS N
and CC N
then RB N
were VBD N
randomized VBN N
to TO N
amiodarone VB I
(Group NNP I
I) NNP I
or CC I
placebo VB I
(Group JJ N
II) NNP N
and CC N
followed VBD N
for IN N
15 CD N
months NNS N
. . N

The DT N
control NN P
group NN P
comprised VBD P
9 CD P
untreated JJ P
patients NNS P
undergoing VBG P
ECV NNP I
. . I

Treatment NNP N
effectiveness NN N
was VBD N
evaluated VBN N
using VBG N
a DT N
Bayesian JJ N
model NN N
. . N

RESULTS NNP N
Eighteen NNP N
months NNS N
after IN N
AF NNP N
reversion NN N
22 CD N
(81.5%) NN N
patients NNS N
in IN N
Group NNP N
I PRP N
13 CD N
(54.2%) JJ N
patients NNS N
in IN N
Group NNP N
II NNP N
and CC N
1 CD N
(11.1%) JJ N
patient NN N
in IN N
the DT N
control NN N
group NN N
remained VBD N
in IN N
sinus NN O
rhythm NN O
. . O

No DT N
differences NNS N
were VBD N
found VBN N
between IN N
Group NNP N
I PRP N
patients NNS N
who WP N
required VBD N
ECV NNP N
and CC N
Group NNP N
II NNP N
patients NNS N
. . N

Sinus NNP O
rhythm NN O
was VBD N
preserved VBN N
in IN N
all DT N
Group NNP N
I PRP N
patients NNS N
when WRB N
it PRP N
was VBD N
achieved VBN N
during IN N
amiodarone JJ N
administration NN N
. . N

Limiting VBG O
adverse JJ O
effects NNS O
occurred VBD N
in IN N
3 CD N
(11.1%) JJ N
patients NNS N
in IN N
Group NNP N
I PRP N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS N
regaining VBG N
sinus NN N
rhythm NN N
after IN N
the DT N
first JJ P
episode NN P
of IN P
persistent JJ P
AF NNP P
a DT P
3-month JJ N
amiodarone NN I
treatment NN N
after IN N
reversion NN N
is VBZ N
a DT N
reasonable JJ N
option NN N
for IN N
rhythm NN N
control NN N
. . N

-DOCSTART- -X- N

Accuracy NN O
of IN N
noninvasive JJ I
haemoglobin NN O
measurement NN O
by IN I
pulse JJ I
oximetry NN I
depends VBZ N
on IN N
the DT N
type NN N
of IN N
infusion NN N
fluid NN N
. . N

CONTEXT NNP N
Measurement NNP N
of IN N
blood NN O
haemoglobin NN O
concentration NN O
by IN N
pulse JJ I
oximetry NN I
could MD N
be VB N
of IN N
value NN N
in IN N
determining VBG N
when WRB N
erythrocytes NNS N
should MD N
be VB N
transfused VBN N
during IN N
surgery NN N
but CC N
the DT N
effect NN N
of IN N
infusion NN N
fluids NNS N
on IN N
the DT N
results NNS N
is VBZ N
unclear JJ N
. . N

OBJECTIVE NN N
To TO N
study VB N
the DT N
effect NN I
of IN I
crystalloid NN I
and CC I
colloid JJ I
fluid NN I
on IN I
the DT I
accuracy NN O
(bias) NNP O
and CC I
precision NN O
of IN I
pulse JJ I
oximetry NN I
haemoglobin NN O
estimation NN O
to TO N
indicate VB N
the DT N
venous JJ N
haemoglobin NN N
concentration NN N
in IN N
volunteers NNS P
. . P

DESIGN NNP N
Open NNP N
interventional JJ N
crossover NN N
study NN N
. . N

SETTING NN N
Single NNP P
university NN P
hospital NN P
. . P

PARTICIPANTS NNS P
Ten CD P
male JJ P
volunteers NNS P
aged VBN P
18-28 JJ P
(mean JJ P
22) CD P
years NNS P
. . P

INTERVENTIONS NNP P
Each DT N
volunteer NN N
underwent JJ N
three CD I
infusion NN I
experiments NNS I
on IN N
separate JJ N
days NNS N
and CC N
in IN N
random JJ N
order NN N
. . N

The DT N
infusions NNS N
were VBD N
Ringer's NNP I
acetate JJ I
(20mlkg) NNP I
hydroxyethyl NN I
starch NN I
130/0.4 CD I
(10mlkg) NN I
and CC I
a DT I
combination NN I
of IN I
both DT N
. . N

RESULTS NN N
At IN N
the DT N
end NN N
of IN N
the DT N
infusions NNS I
of IN I
Ringer's NNP I
acetate NN O
pulse NN O
oximetry NN O
haemoglobin NN O
concentration NN O
had VBD N
decreased VBN N
more RBR N
than IN N
the DT N
true JJ N
haemoglobin NN N
concentration NN N
(15 NNP N
vs NN N
. . N

8%; CD N
P<0.005; NNP N
n=10) JJ I
whereas NNS I
starch VBP N
solution NN O
decreased VBN O
pulse JJ O
oximetry NN O
haemoglobin NN O
concentration NN N
less JJR N
than IN N
true JJ N
haemoglobin JJ N
concentration NN N
(7 NNP N
vs NN N
. . N

11%; CD N
P<0.02; NNP O
n=20) NN O
. . N

The DT N
same JJ N
differences NNS N
were VBD N
seen VBN N
when WRB N
the DT N
fluids NNS N
were VBD N
infused VBN N
separately RB N
and CC N
when WRB N
they PRP N
were VBD N
combined VBN N
. . N

The DT N
overall JJ N
difference NN N
between IN O
all DT O
956 CD O
pairs NNS O
of IN O
pulse JJ O
oximetry NN O
haemoglobin NN O
concentration NN O
and CC O
true JJ O
haemoglobin NN O
concentrations NNS I
(the VBP N
bias) NN N
averaged VBD N
only RB N
-0.7gl JJ N
whereas IN N
the DT N
95% CD N
prediction NN N
interval NN N
was VBD N
wide JJ N
ranging VBG N
from IN N
-24.9 NN N
to TO N
23.7gl CD N
. . N

In IN N
addition NN N
to TO N
the DT N
choice NN N
of IN N
infusion NN N
fluid VBP N
the DT N
bias NN N
was VBD N
strongly RB N
dependent JJ N
on IN N
the DT N
volunteer NN N
(each NNP N
factor NN O
P<0.001) NNP O
. . O

CONCLUSION NNP O
The DT O
bias NN O
of IN O
measuring VBG I
haemoglobin JJ I
concentration NN N
by IN N
pulse JJ I
oximetry NN I
is VBZ I
dependent JJ I
on IN I
whether IN I
a DT N
crystalloid NN N
or CC N
a DT N
colloid JJ N
fluid NN N
is VBZ N
infused VBN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials NNP N
identifier: NN N
NCT01195025 NNP N
. . N

-DOCSTART- -X- N

Effect NN N
of IN N
low-intensity NN I
back RB I
exercise NN I
on IN N
quality NN O
of IN O
life NN O
and CC N
back RB O
extensor JJ O
strength NN O
in IN N
patients NNS P
with IN P
osteoporosis: PRP P
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

UNLABELLED NNP N
Randomized NNP N
controlled VBD N
study NN N
in IN N
80 CD P
postmenopausal JJ P
women NNS P
with IN P
osteoporosis NN P
was VBD N
conducted VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
a DT N
home-based JJ I
simple JJ I
low-intensity NN I
exercise NN I
. . I

Low-intensity JJ I
back-strengthening JJ I
exercise NN I
was VBD N
effective JJ N
in IN N
improving VBG N
the DT N
quality NN O
of IN O
life NN O
and CC O
back RB O
extensor JJ O
strength NN O
. . O

INTRODUCTION NNP N
AND CC N
HYPOTHESIS NNP N
Back-strengthening NNP I
exercise NN I
is VBZ N
effective JJ N
in IN N
increasing VBG N
back RB O
extensor NN O
strength NN O
and CC N
decreasing VBG N
risk NN O
of IN O
vertebral JJ O
fractures NNS O
. . O

We PRP N
hypothesized VBD N
that IN N
a DT N
home-based JJ N
simple JJ N
low-intensity NN I
exercise NN I
could MD N
enhance VB N
back RB O
extensor JJ O
strength NN O
and CC N
improve VB N
the DT N
quality NN O
of IN O
life NN O
and/or IN N
spinal JJ O
range NN O
of IN O
motion NN O
in IN N
postmenopausal JJ P
women NNS P
in IN N
a DT N
short-term JJ N
follow-up NN N
. . N

METHODS NNP N
Eighty NNP P
postmenopausal JJ P
women NNS P
with IN P
osteoporosis NN P
were VBD P
randomly RB P
assigned VBN P
to TO P
a DT P
control NN P
group NN P
(n NNP P
= VBZ P
38) CD P
or CC P
an DT P
exercise NN P
group NN P
(n NNP P
= VBZ P
42) CD P
. . P

Subjects NNS N
were VBD N
instructed VBN N
to TO N
lift VB I
their PRP$ I
upper JJ I
trunk NN I
from IN I
a DT I
prone NN I
position NN I
antigravity NN I
and CC I
maintain VB I
the DT I
neutral JJ I
position NN I
. . I

Isometric NNP N
back RB O
extensor VBZ O
strength NN O
spinal JJ O
range NN O
of IN O
motion NN O
and CC O
scores NNS O
for IN O
quality NN O
of IN O
life NN O
were VBD N
evaluated VBN N
at IN N
baseline NN N
and CC N
4 CD N
months NNS N
. . N

RESULTS NNP N
Back NNP O
extensor NN O
strength NN O
significantly RB N
increased VBD N
both DT N
in IN N
the DT N
exercise NN N
group NN N
(26%) NNP N
and CC N
in IN N
the DT N
control NN N
group NN N
(11%) NNP N
. . N

Scores NNS N
for IN N
quality NN O
of IN O
life NN O
increased VBN N
in IN N
the DT N
exercise NN N
group NN N
(7%) NNP N
whereas IN N
it PRP N
remained VBD N
unchanged JJ N
in IN N
the DT N
control NN N
group NN N
(0%) NNP N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
quality NN O
of IN O
life NN O
score NN N
between IN N
the DT N
groups NNS N
(p VBP N
= JJ N
0.012) CD N
. . N

CONCLUSIONS JJ N
Low-intensity NNP I
back-strengthening NN I
exercise NN I
was VBD N
effective JJ N
in IN N
improving VBG N
the DT N
quality NN O
of IN O
life NN O
and CC O
back RB O
extensor JJ O
strength NN O
in IN N
patients NNS P
with IN P
osteoporosis NN P
. . P

-DOCSTART- -X- N

5% CD N
imiquimod JJ I
cream NN N
and CC N
reflectance-mode JJ I
confocal JJ I
microscopy NN I
as IN N
adjunct JJ N
modalities NNS N
to TO N
Mohs NNP P
micrographic JJ P
surgery NN P
for IN P
treatment NN P
of IN P
basal NN P
cell NN P
carcinoma NN P
. . P

BACKGROUND NNP P
Imiquimod NNP I
is VBZ N
an DT N
immune JJ N
response NN N
modifier NN N
that IN N
up-regulates JJ N
cytokines NNS N
and CC N
has VBZ N
been VBN N
shown VBN N
in IN N
clinical JJ N
studies NNS N
to TO N
reduce VB N
or CC N
clear VB N
basal NN P
cell NN P
carcinoma NN P
tumors NNS P
when WRB N
applied VBN N
topically RB N
. . N

OBJECTIVE IN N
The DT N
objectives NNS N
were VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
5% CD N
imiquimod JJ I
cream NN N
in IN N
treating VBG N
basal NN P
cell NN P
carcinoma NN P
preceding VBG P
excision NN P
by IN P
Mohs NNP P
micrographic JJ P
surgery NN P
and CC N
to TO N
determine VB N
if IN N
reflectance-mode JJ I
confocal JJ I
microscopy NN I
is VBZ N
useful JJ N
to TO N
establish VB N
the DT N
need NN N
for IN N
surgical JJ N
intervention NN N
after IN N
imiquimod JJ I
treatment NN N
. . N

METHODS NNP N
Subjects NNP P
applied VBD P
study NN P
cream NN P
to TO P
one CD P
biopsy-confirmed JJ P
basal NN P
cell NN P
carcinoma NN P
tumor NN P
5 CD P
x/week NN N
for IN N
2 CD N
4 CD N
or CC N
6 CD N
weeks NNS N
in IN N
this DT N
vehicle-controlled JJ P
double-blind NN P
study NN P
. . P

Confocal JJ I
microscopy NN I
was VBD N
used VBN N
for IN N
the DT N
6-week JJ N
treatment NN N
group NN N
to TO N
examine VB N
the DT N
target NN N
tumor NN N
area NN N
at IN N
each DT N
interval JJ N
visit NN N
and CC N
immediately RB N
before IN N
Mohs NNP I
micrographic JJ I
surgery NN I
. . I

After IN N
the DT N
Mohs NNP I
micrographic JJ I
surgery NN I
excision NN I
the DT I
tissue NN N
was VBD N
evaluated VBN N
histologically RB N
and CC N
the DT N
excision NN N
area NN N
was VBD N
measured VBN N
. . N

Confocal JJ I
microscopy NN I
readings NNS N
were VBD N
correlated VBN N
to TO N
the DT N
histologic JJ N
diagnosis NN N
. . N

RESULTS JJ N
Tumors NNS O
cleared VBD O
or CC N
the DT N
target NN O
tumor NN O
area NN O
was VBD N
reduced VBN N
in IN N
subjects NNS N
in IN N
the DT N
4- JJ N
and CC N
6-week JJ N
dosing NN N
regimens NNS N
. . N

Confocal JJ I
microscopy NN I
assessments NNS I
correlated VBN N
well RB N
with IN N
the DT N
histologic JJ N
diagnosis NN N
. . N

CONCLUSION NNP N
Imiquimod NNP I
improved VBD N
excision NN O
results NNS O
relative JJ N
to TO N
vehicle NN N
when WRB N
used VBN N
for IN N
treating VBG N
basal NN P
cell NN P
carcinoma NN P
before IN P
Mohs NNP P
micrographic JJ P
surgery NN P
. . P

Confocal JJ N
microscopy NN N
assessments NNS N
correlated VBN N
well RB N
with IN N
tumor NN I
response NN N
to TO N
therapy VB N
suggesting VBG N
that IN N
confocal JJ N
microscopy NN N
may MD N
help VB N
determine VB N
the DT N
need NN N
for IN N
surgery NN P
. . P

-DOCSTART- -X- N

A DT N
two-filter JJ I
model NN I
for IN N
frequency NN P
discrimination NN P
. . P

In IN N
this DT N
paper NN N
we PRP N
explore VBP N
a DT N
two-filter JJ I
model NN I
the DT I
simplest JJS N
version NN N
of IN N
multi-channel JJ N
models NNS N
for IN N
frequency NN O
discrimination NN O
of IN N
simple JJ N
tones NNS N
. . N

According VBG N
to TO N
this DT N
model NN N
frequency NN N
discrimination NN N
is VBZ N
based VBN N
on IN N
a DT N
change NN N
in IN N
the DT N
relative JJ N
output NN N
levels NNS N
of IN N
two CD N
auditory JJ N
filters NNS N
one CD N
centered VBN N
below IN N
and CC N
the DT N
other JJ N
above IN N
the DT N
frequency NN N
of IN N
the DT N
tone NN N
. . N

This DT N
idea NN N
can MD N
explain VB N
the DT N
experimental JJ N
results NNS N
that IN N
frequency NN N
discrimination NN N
is VBZ N
relatively RB N
unaffected JJ N
by IN N
randomization NN N
of IN N
stimulus JJ N
level NN N
. . N

Moreover RB N
it PRP N
suggests VBZ N
a DT N
close JJ N
relationship NN N
between IN N
the DT N
ability NN N
of IN N
listeners NNS P
to TO N
perform VB N
frequency NN N
discrimination NN N
of IN N
simple JJ N
tones NNS N
and CC N
spectral-shape JJ N
discrimination NN N
of IN N
two-tone NN N
complexes NNS N
. . N

The DT N
ability NN N
of IN N
three CD P
listeners NNS P
to TO N
perform VB N
these DT N
two CD N
tasks NNS N
was VBD N
measured VBN N
at IN N
six CD I
frequencies NNS I
(from VBP I
0.25 CD I
to TO I
8 CD I
kHz) NNS I
. . N

The DT N
results NNS N
from IN N
the DT N
spectral-shape-discrimination NN N
task NN N
were VBD N
used VBN N
to TO N
predict VB N
frequency-difference NN N
limens NNS N
. . N

There EX N
was VBD N
a DT N
high JJ N
correlation NN N
between IN N
obtained VBN N
and CC N
predicted VBN N
values NNS N
. . N

-DOCSTART- -X- N

Effects NNS I
of IN I
bifidobacterium NN I
breve VBP I
supplementation NN I
on IN I
intestinal JJ I
flora NNS I
of IN I
low JJ P
birth NN P
weight NN P
infants NNS P
. . P

BACKGROUND IN P
It PRP I
is VBZ I
known VBN I
that IN I
the DT I
bifidobacteria NN I
flora VBP I
play NN I
important JJ I
roles NNS I
in IN I
mucosal NN I
host NN I
defense NN I
and CC I
can MD I
prevent VB I
infectious JJ I
diseases NNS I
. . I

Because IN I
bacterial JJ I
populations NNS I
develop VBP I
during IN I
the DT I
first JJ I
day NN I
of IN I
life NN I
the DT I
authors NNS I
examined VBD I
whether IN I
the DT I
early JJ I
administration NN I
of IN I
bifidobacteria NN I
has VBZ I
a DT I
positive JJ I
effect NN I
on IN I
the DT I
health NN I
of IN I
low JJ P
birth NN P
weight NN P
infants NNS P
. . P

METHODS NNP P
The DT I
effects NNS I
of IN I
oral JJ I
administration NN I
of IN I
Bifidobacterium NNP I
breve VBP I
(B NN I
. . I

breve) NN I
supplements NNS I
were VBD I
studied VBN I
in IN I
a DT I
controlled JJ I
trial NN I
with IN I
low JJ P
birth NN P
weight NN P
infants NNS P
(average VBP P
birth NN P
weight NN P
1489 CD P
g) NN P
. . P

The DT I
infants NNS P
were VBD P
divided VBN P
into IN P
three CD P
groups: NNS P
Group NNP I
A NNP I
and CC I
B NNP I
received VBD I
a DT I
dose NN I
of IN I
1.6 CD I
x JJ I
10(8) CD I
cells NNS I
of IN I
B NNP I
. . I

breve VB I
supplement NN I
twice RB I
a DT I
day NN I
commencing VBG I
either CC I
from IN I
several JJ I
hours NNS I
after IN I
birth NN I
(group NN I
A) NNP I
or CC I
24 CD I
h NN I
after IN I
birth NN I
(group NN I
B) NNP I
. . I

Group NNP I
C NNP I
the DT I
control NN I
group NN I
received VBD I
no DT I
supplement NN I
. . I

RESULTS RB I
There EX I
were VBD I
no DT I
significant JJ I
differences NNS I
in IN I
birth NN O
weight NN O
treatment NN O
with IN O
antibiotics NNS O
and CC O
the DT O
starting JJ O
time NN O
of IN O
breast-feeding NN O
among IN I
the DT I
three CD I
groups NNS I
. . I

A DT I
Bifidobacterium-predominant JJ O
flora NN O
was VBD I
formed VBN I
at IN I
an DT I
average NN I
of IN I
2 CD I
weeks NNS I
after IN I
birth NN I
in IN I
group NN I
A NNP I
and CC I
at IN I
an DT I
average NN I
of IN I
4 CD I
weeks NNS I
after IN I
birth NN I
in IN I
group NN I
B NNP I
while IN I
no DT I
Bifidobacterium NNP O
was VBD I
isolated VBN I
in IN I
eight CD I
out IN I
of IN I
10 CD I
infants NNS I
in IN I
group NN I
C NNP I
during IN I
the DT I
observation NN I
period NN I
of IN I
7 CD I
weeks NNS I
. . I

In IN I
comparison NN I
between IN I
group NN I
A NNP I
and CC I
B NNP I
Bifidobacterium NNP O
was VBD I
detected VBN I
significantly RB I
earlier RBR I
in IN I
group NN I
A NNP I
and CC I
the DT I
number NN I
of IN I
Enterobacteriaceae NNP I
present NN I
in IN I
the DT I
infants NNS P
at IN P
2 CD P
weeks NNS P
after IN P
birth NN P
was VBD I
significantly RB I
lower JJR I
in IN I
group NN I
A NNP I
. . I

CONCLUSION NNP I
The DT I
results NNS I
of IN I
the DT I
present JJ I
study NN I
suggest VBP I
that IN I
very RB I
early JJ I
administration NN I
of IN I
B NNP I
. . I

breve NNS I
to TO I
low JJ P
birth NN P
weight NN P
infants NNS P
is VBZ I
useful JJ I
in IN I
promoting VBG I
the DT I
colonization NN I
of IN I
the DT I
Bifidobacterium NNP I
and CC I
the DT I
formation NN I
of IN I
a DT I
normal JJ I
intestinal JJ I
flora NN I
. . I

-DOCSTART- -X- N

Anastrozole NNP I
single-dose JJ N
protocol NN N
in IN N
women NNS P
with IN P
oligo- JJ P
or CC P
anovulatory JJ P
infertility: JJ P
results NNS N
of IN N
a DT N
randomized JJ N
phase NN N
II NNP N
dose-response NN N
study NN N
. . N

OBJECTIVE NN N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
anastrozole NN I
and CC I
clomiphene NN I
citrate VBP I
(CC) NN I
on IN N
follicular JJ P
development NN P
and CC P
ovulation NN P
in IN P
infertile JJ P
women NNS P
with IN P
ovulatory JJ P
dysfunction NN P
. . P

DESIGN NNP N
Phase NNP N
II NNP N
prospective JJ N
randomized VBN N
assessor-blind JJ N
multicenter NN N
dose-finding JJ N
noninferiority NN N
study NN N
. . N

SETTING NN N
Outpatient NNP N
. . N

PATIENT(S) NNP N
Infertile NNP P
women NNS P
with IN P
ovulatory JJ P
dysfunction NN P
aged VBN P
18-35 CD P
years NNS P
and CC P
body NN P
mass NN P
index NN P
<35 NNP P
kg/m(2) NN P
. . P

INTERVENTION(S) NNP P
Single-dose JJ I
anastrozole NN I
at IN I
5 CD I
mg NN I
(n NNP N
= VBD N
39) CD N
10 CD N
mg NN N
(n NNP N
= VBD N
39) CD N
20 CD N
mg NN N
(n NNP N
= VBZ N
39) CD N
or CC N
30 CD N
mg NNS N
(n JJ N
= VBP N
38) CD N
or CC N
a DT N
5-day JJ I
course NN I
of IN I
CC NNP I
at IN I
50 CD I
mg/d NN I
(n NNP N
= VBZ N
39) CD N
as IN N
starting VBG N
doses NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE(S) NNP N
The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
ovulation NN O
rate NN O
in IN N
the DT N
first JJ N
treatment NN N
cycle NN N
(cycle NN N
1) CD N
. . N

Ovulation NN N
was VBD N
defined VBN N
as IN N
a DT N
midluteal JJ N
phase NN N
serum NN N
P NNP N
level NN N
 VBD N
10 CD N
ng/mL NN N
or CC N
clinical JJ N
pregnancy NN N
. . N

RESULT(S) NNP N
In IN N
cycle NN N
1 CD N
the DT O
ovulation NN O
rates NNS O
for IN N
a DT N
single JJ N
dose NN N
of IN I
anastrozole NN I
at IN N
5 CD N
10 CD N
20 CD N
and CC N
30 CD N
mg NNS N
were VBD N
46.2% CD N
41.0% CD N
23.1% CD N
and CC N
28.9% CD N
respectively RB N
whereas VBP N
that IN N
for IN I
CC NNP I
at IN N
50 CD N
mg/d NN N
was VBD N
61.5% CD N
. . N

Among IN N
women NNS N
with IN N
fewer JJR N
than IN N
six CD N
menses NNS N
per IN N
year NN N
the DT O
cumulative JJ O
ovulation NN O
rates NNS O
over IN N
three CD N
cycles NNS N
were VBD N
comparable JJ N
in IN N
the DT I
anastrozole JJ I
5 CD N
mg NN N
(52.4%) NN N
and CC I
CC NNP I
50 CD N
mg/d NN N
(42.3%) NN N
groups NNS N
. . N

CONCLUSION(S) NNP N
In IN N
terms NNS N
of IN O
ovulation NN O
rates NNS O
in IN N
cycle NN N
1 CD N
single-dose JJ I
anastrozole NN I
at IN N
5 CD N
10 CD N
20 CD N
and CC N
30 CD N
mg NN N
was VBD N
not RB N
as RB N
effective JJ N
as IN I
CC NNP I
at IN N
50 CD N
mg/d NN N
for IN N
5 CD N
days NNS N
(noninferiority NN N
was VBD N
not RB N
shown) JJ N
. . N

-DOCSTART- -X- N

5-Fluorouracil JJ I
adriamycin NN I
cyclophosphamide NN I
(FAC) NNP I
vs NN I
. . I

5-fluorouracil JJ I
epirubicin NN I
cyclophosphamide NN I
(FEC) NNP I
in IN N
metastatic JJ P
breast NN P
cancer NN P
. . P

94 CD P
evaluable JJ P
patients NNS P
with IN P
metastatic JJ P
breast NN P
cancer NN P
were VBD N
randomly RB N
assigned VBN N
to TO N
5-fluorouracil JJ I
adriamycin NN I
and CC I
cyclophosphamide VB I
(FAC) CD I
or CC I
5-fluorouracil JJ I
epirubicin NN I
and CC I
cyclophosphamide NN I
(FEC) NN I
with IN I
cycles NNS N
repeated VBN N
every DT N
3 CD N
weeks NNS N
. . N

The DT N
objective JJ O
response NN O
rate NN O
to TO N
FAC NNP I
was VBD N
46% CD N
versus NN N
44% CD N
to TO N
FEC NNP I
. . I

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
median JJ O
duration NN O
of IN O
response NN O
and CC O
median JJ O
survival NN O
for IN N
the DT N
two CD N
regimens NNS N
. . N

Toxicity NN O
was VBD N
more RBR N
frequent JJ N
and CC N
more RBR N
pronounced JJ N
in IN N
patients NNS N
receiving VBG N
FAC NNP I
. . I

Results NNS N
indicate VBP N
therapeutic JJ N
equivalence NN N
of IN N
the DT N
two CD N
regimens NNS N
and CC N
reduced JJ N
toxicity NN N
of IN N
the DT N
epirubicin JJ N
arm NN N
. . N

-DOCSTART- -X- N

The DT N
anesthetic JJ N
and CC N
recovery NN N
profile NN N
of IN N
two CD N
doses NNS N
(60 VBP N
and CC N
80 CD N
mg) NN N
of IN N
plain NN I
mepivacaine NN I
for IN N
ambulatory JJ N
spinal JJ P
anesthesia NN P
. . P

UNLABELLED JJ P
Reports NNS N
of IN N
transient JJ N
neurological JJ N
symptoms NNS N
with IN N
the DT N
use NN N
of IN N
subarachnoid JJ I
lidocaine NN I
has VBZ N
generated VBN N
interest NN N
in IN N
alternate JJ N
local JJ N
anesthetics NNS N
of IN N
intermediate JJ N
duration NN N
such JJ N
as IN N
mepivacaine NN I
. . I

This DT N
prospective JJ N
randomized VBN N
double-blinded JJ N
dose-response NN N
study NN N
examined VBD N
the DT N
anesthetic JJ N
and CC N
recovery NN N
profiles NNS N
of IN N
60- JJ I
and CC I
80-mg JJ I
doses NNS I
of IN I
preservative-free JJ I
plain NN I
mepivacaine NN I
for IN N
ambulatory JJ N
spinal JJ N
anesthesia NN N
. . N

Sixty CD P
patients NNS P
undergoing JJ P
ambulatory JJ P
anterior JJ P
cruciate NN P
ligament NN P
repair NN P
of IN P
the DT P
knee NN P
under IN P
spinal JJ P
anesthesia NN P
were VBD P
randomized VBN P
into IN P
two CD P
groups; NNS P
Group NNP P
1 CD P
(29 NNP P
patients) NN P
received VBD N
4 CD N
mL NN N
of IN N
1.5% CD N
(60-mg JJ N
dose) NN N
and CC N
Group NNP P
2 CD P
(31 NNP P
patients) NN P
received VBD N
4 CD N
mL NN N
of IN N
2% CD N
(80-mg JJ N
dose) NN N
of IN N
plain JJ I
mepivacaine NN I
. . I

All DT N
patients NNS N
received VBD N
a DT N
combined JJ I
spinal-epidural JJ I
anesthetic JJ I
technique NN I
. . I

The DT N
epidural JJ I
catheter NN I
was VBD N
used VBN N
only RB N
in IN N
the DT N
event NN N
the DT N
surgery NN N
outlasted VBD N
the DT N
duration NN N
of IN N
surgical JJ N
anesthesia NN N
with IN N
subarachnoid JJ I
mepivacaine NN I
. . I

Epidural JJ I
supplementation NN I
was VBD N
administered VBN N
in IN N
three CD N
patients NNS N
(12%) VBP N
in IN N
Group NNP N
1 CD N
and CC N
one CD N
patient NN N
(3%) NN N
in IN N
Group NNP N
2 CD N
when WRB N
the DT N
sensory JJ N
block NN N
regressed VBD N
to TO N
L-1 NNP N
with IN N
surgery NN N
expected VBN N
to TO N
last JJ N
longer JJR N
than IN N
15 CD N
min NN N
. . N

The DT N
cephalad JJ O
dermatome JJ O
level NN O
of IN O
the DT O
block NN O
and CC O
degree NN O
of IN O
motor NN O
block NN O
was VBD N
comparable JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

Times NNS O
to TO O
two-segment JJ O
and CC N
T-10 JJ O
regression NN O
were VBD N
comparable JJ N
in IN N
the DT N
two CD N
groups NNS N
(112 VBD N
+/- JJ N
26 CD N
min NN N
in IN N
Group NNP N
1 CD N
versus NN N
122 CD N
+/- JJ N
28 CD N
min NN N
in IN N
Group NNP N
2) CD N
. . N

Time NN O
to TO O
L-1 NNP O
regression NN O
was VBD N
significantly RB N
longer RBR N
in IN N
Group NNP N
2 CD N
(146 NNP N
+/- JJ N
28 CD N
min NN N
in IN N
Group NNP N
1 CD N
versus NN N
159 CD N
+/- JJ N
19 CD N
min NN N
in IN N
Group NNP N
2) CD N
. . N

All DT N
of IN N
the DT N
ambulatory JJ N
milestones NNS N
were VBD N
significantly RB N
faster RBR N
in IN N
Group NNP N
1 CD N
. . N

Side JJ N
effects NNS N
such JJ N
as IN N
hypotension NN O
and CC O
emesis NN O
were VBD N
negligible JJ N
severe JJ N
bradycardia NN O
and CC O
urinary JJ O
retention NN O
did VBD N
not RB N
occur VB N
and CC N
none NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
two CD N
groups NNS N
reported VBD N
transient JJ O
neurological JJ O
symptoms NNS O
over IN N
24 CD N
h NNS N
. . N

In IN N
conclusion NN N
plain NN I
mepivacaine NN I
in IN N
a DT N
60- JJ N
or CC N
80-mg JJ N
dose NN N
is VBZ N
a DT N
suitable JJ N
local JJ N
anesthetic JJ N
choice NN N
for IN N
ambulatory JJ N
spinal JJ N
anesthesia NN N
with IN N
respect NN N
to TO N
anesthetic JJ N
as RB N
well RB N
as IN N
recovery NN N
profiles NNS N
. . N

IMPLICATIONS NNP N
We PRP N
evaluated VBD N
the DT N
anesthetic JJ N
and CC N
recovery NN N
profiles NNS N
of IN N
60- JJ N
and CC N
80-mg JJ N
doses NNS N
of IN N
plain NN N
mepivacaine NN N
for IN N
ambulatory JJ N
spinal JJ N
anesthesia NN N
. . N

Both DT N
doses NNS N
produced VBD N
comparable JJ N
sensory NN N
and CC N
motor NN N
block NN N
. . N

Sensory NNP N
and CC N
motor NN N
regression NN N
and CC N
ambulatory JJ N
milestones NNS N
were VBD N
20-30 JJ N
min NN N
longer RBR N
with IN N
the DT N
80-mg JJ N
dose NN N
. . N

Side JJ O
effects NNS O
were VBD N
negligible JJ N
and CC N
transient JJ O
neurological JJ O
symptoms NNS O
were VBD N
not RB N
reported VBN N
during IN N
a DT N
24-h JJ N
follow-up NN N
. . N

-DOCSTART- -X- N

Gradual NNP I
withdrawal NN I
of IN I
diazepam NN I
after IN N
long-term JJ N
therapy NN N
. . P

41 CD P
outpatients NNS P
who WP P
were VBD P
long-term JJ P
consumers NNS P
of IN P
diazepam NN P
in IN P
therapeutic JJ P
dosage NN P
were VBD P
gradually RB P
withdrawn VBN P
from IN P
the DT P
drug NN P
over IN P
3 CD P
months NNS P
by IN P
stepwise NN P
reduction NN P
. . P

In IN N
a DT N
double-blind JJ I
procedure NN I
half PDT N
the DT N
patients NNS N
began VBD N
withdrawal JJ N
immediately RB N
and CC N
half NN N
after IN N
8 CD N
weeks NNS N
. . N

Of IN P
36 CD P
patients NNS P
who WP P
completed VBD P
treatment NN P
16 CD P
(44.4%) NN N
experienced VBD N
true JJ N
withdrawal NN N
phenomena NN N
on IN N
reducing VBG N
their PRP$ N
drugs NNS N
but CC N
8 CD N
other JJ N
patients NNS N
had VBD N
pseudo-withdrawal JJ N
reactions NNS N
at IN N
a DT N
time NN N
when WRB N
their PRP$ N
drug NN I
treatment NN I
was VBD N
unchanged JJ N
. . N

The DT N
pseudo-withdrawal JJ N
reactions NNS N
consisted VBD N
of IN N
an DT N
increase NN N
in IN N
anxiety NN O
symptoms NNS O
only RB N
whereas VBP N
true JJ N
withdrawal NN O
symptoms NNS O
also RB N
included VBD N
perceptual JJ O
changes NNS O
and CC O
psychotic JJ O
symptoms NNS O
. . O

Examination NN N
of IN N
pharmacological JJ N
and CC N
clinical JJ N
predictors NNS N
of IN N
withdrawal NN N
phenomena NN N
and CC N
later RB N
relapse NN N
showed VBD N
that IN N
personality NN N
factors NNS N
were VBD N
the DT N
most RBS N
important JJ N
patients NNS N
with IN N
passive-dependent JJ N
traits NNS N
having VBG N
a DT N
significantly RB N
greater JJR N
prevalence NN N
of IN N
withdrawal NN N
reactions NNS N
. . N

-DOCSTART- -X- N

Alkalinized NNP I
lidocaine NN I
and CC I
heparin NN I
provide VBP N
immediate JJ N
relief NN O
of IN O
pain NN O
and CC O
urgency NN O
in IN N
patients NNS P
with IN P
interstitial JJ P
cystitis NN P
. . P

INTRODUCTION NN N
It PRP N
has VBZ N
been VBN N
reported VBN N
in IN N
an DT N
open-label JJ N
study NN N
that IN N
the DT N
combination NN I
of IN I
alkalinized JJ I
lidocaine NN I
and CC I
heparin NN I
can MD N
immediately RB N
relieve VB N
the DT N
symptoms NNS O
of IN O
urinary JJ O
urgency NN O
frequency NN O
and CC O
pain NN O
associated VBN N
with IN N
interstitial JJ N
cystitis NN N
(IC) NN N
. . N

This DT N
combination NN N
has VBZ N
also RB N
been VBN N
reported VBN N
to TO N
relieve VB N
pain NN P
associated VBN P
with IN P
sex NN P
in IN P
patients NNS P
with IN P
IC NNP P
. . P

AIM IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
corroborate VB N
these DT N
findings NNS N
in IN N
a DT N
multicenter NN N
setting NN N
. . N

METHODS NNP N
The DT N
study NN N
design NN N
was VBD N
a DT N
multicenter JJ N
prospective JJ N
double-blind NN N
crossover NN N
placebo-controlled JJ I
trial NN I
. . I

Each DT N
participant NN P
met VBD P
all DT P
of IN P
the DT P
clinical JJ P
National NNP P
Institute NNP P
of IN P
Diabetes NNP P
and CC P
Digestive NNP P
and CC P
Kidney NNP P
Diseases NNP P
criteria NNS P
(excluding VBG P
cystoscopy) NN P
for IN P
IC NNP P
. . P

Each DT N
patient NN N
received VBN N
drug NN N
and CC N
control NN N
in IN N
random JJ N
order NN N
within IN N
48 CD N
hours NNS N
of IN N
enrolling VBG N
in IN N
the DT N
study NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
percent JJ O
change NN O
in IN O
pain NN O
score NN O
(11-point JJ O
analog NN O
pain NN O
scale) VBD O
12 CD O
hours NNS O
after IN O
receiving VBG O
the DT O
drug NN O
or CC O
control NN O
. . O

Secondary JJ N
measures NNS N
were VBD N
the DT N
global JJ O
assessment NN O
response NN O
(GAR) NN O
of IN O
symptoms NNS O
and CC O
12-hour JJ O
average JJ O
urgency NN O
reduction NN O
determined VBD N
from IN N
11-point JJ N
urgency NN N
scales NNS N
. . N

RESULTS NNP N
Eighteen NNP P
(18) NNP P
patients NNS P
completed VBD P
the DT P
trial NN P
. . P

The DT N
average JJ N
reduction NN O
of IN O
pain NN O
over IN N
12 CD N
hours NNS N
was VBD N
21% CD N
for IN N
control NN N
and CC N
42% CD N
for IN N
active JJ N
drug NN N
(P NNP N
= VBZ N
0.0363) CD N
. . N

GAR NNP N
was VBD N
13% CD N
for IN N
control NN N
and CC N
50% CD N
for IN N
drug NN N
(P NNP N
= VBZ N
0.0137) CD N
. . N

Average JJ O
urgency JJ O
reduction NN O
was VBD N
13% CD N
for IN N
control NN N
and CC N
35% CD N
for IN N
drug NN N
(P NNP N
= VBZ N
0.0328) CD N
. . N

CONCLUSIONS NNP N
The DT N
combination NN I
of IN I
alkalinized JJ I
lidocaine NN I
and CC I
heparin NN I
provides VBZ N
up IN N
to TO N
12 CD N
hours NNS N
of IN N
relief NN N
from IN N
urgency NN O
and CC O
pain NN O
associated VBN N
with IN P
IC NNP P
. . P

This DT N
combination NN I
provides VBZ N
significant JJ N
immediate JJ N
relief NN N
of IN N
symptoms NNS N
for IN N
patients NNS P
with IN P
IC NNP P
. . P

-DOCSTART- -X- N

Collagen NNP I
cross-linking NN I
with IN I
photoactivated JJ I
riboflavin NN I
(PACK-CXL) NN I
for IN N
the DT N
treatment NN N
of IN N
advanced JJ P
infectious JJ P
keratitis NN P
with IN P
corneal JJ P
melting NN P
. . P

PURPOSE NNP N
To TO N
investigate VB N
the DT N
efficacy NN O
and CC O
safety NN O
of IN N
corneal JJ I
collagen NN I
cross-linking JJ I
(CXL) NN I
with IN I
photoactivated JJ I
riboflavin NN I
(photoactivated VBD I
chromophore NN I
for IN I
infectious JJ I
keratitis NN I
[PACK]-CXL) NN I
in IN N
the DT N
management NN N
of IN N
infectious JJ N
keratitis NN N
with IN N
corneal JJ N
melting NN N
. . N

DESIGN NNP N
Prospective NNP N
clinical JJ N
trial NN N
. . N

PARTICIPANTS NNP N
Forty NNP P
eyes NNS P
from IN P
40 CD P
patients NNS P
with IN P
advanced JJ P
infectious JJ P
keratitis NN P
and CC P
coexisting VBG P
corneal NN P
melting NN P
. . P

METHODS NNP N
Twenty-one CD P
patients NNS P
(21 JJ P
eyes) JJ P
underwent JJ P
PACK-CXL JJ I
treatment NN P
in IN P
addition NN P
to TO P
antimicrobial JJ P
therapy NN P
. . P

The DT N
control NN P
group NN P
consisted VBD P
of IN P
19 CD P
patients NNS P
(19 JJ P
eyes) NN P
who WP N
received VBD I
only RB I
antimicrobial JJ I
therapy NN I
. . I

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
slit-lamp JJ O
characteristics NNS O
of IN O
the DT O
corneal JJ O
ulceration NN O
corrected VBD O
distance NN O
visual JJ O
acuity NN O
duration NN O
until IN O
healing VBG O
and CC O
complications NNS O
were VBD N
documented VBN N
in IN N
each DT N
group NN N
. . N

The DT N
Mann-Whitney NNP N
U NNP N
test NN N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

P NNP N
values VBZ N
less JJR N
than IN N
0.05 CD N
were VBD N
considered VBN N
statistically RB N
significant JJ N
. . N

RESULTS VB N
The DT N
average JJ N
time NN O
until IN O
healing VBG O
was VBD N
39.76 CD N
 JJ N
18.22 CD N
days NNS N
in IN N
the DT I
PACK-CXL NNP I
group NN N
and CC N
46.05 CD N
 JJ N
27.44 CD N
days NNS N
in IN N
the DT I
control NN I
group NN I
(P NNP N
= VBZ N
0.68) CD N
. . N

After IN N
treatment NN N
and CC N
healing NN O
corrected VBN O
distance NN O
visual JJ O
acuity NN O
was VBD N
1.64 CD N
 JJ N
0.62 CD N
in IN N
the DT I
PACK-CXL NNP I
group NN N
and CC N
1.67 CD N
 NN N
0.48 CD N
in IN N
the DT I
control NN I
group NN I
(P NNP N
= VBZ N
0.68) CD N
. . N

The DT O
corneal NN O
ulceration's JJ O
width NN O
and CC O
length NN O
was VBD N
significantly RB N
bigger JJR N
in IN N
the DT I
PACK-CXL NNP I
group NN N
(P NNP N
= VBZ N
0.004 CD N
and CC N
P NNP N
= NNP N
0.007) CD N
. . N

Three CD N
patients NNS N
in IN N
the DT I
control NN I
group NN I
demonstrated VBD O
corneal JJ O
perforation; JJ O
infection NN N
recurred VBD N
in IN N
1 CD N
of IN N
them PRP N
. . N

No DT N
serious JJ N
complications NNS N
occurred VBD N
in IN N
the DT I
PACK-CXL NNP I
group NN N
. . N

CONCLUSIONS NNP I
Corneal NNP I
CXL NNP I
with IN I
photoactivated JJ I
riboflavin NN I
did VBD N
not RB N
shorten VB N
the DT O
time NN O
to TO O
corneal VB O
healing; NN O
however RB N
the DT N
complication NN N
rate NN N
was VBD N
21% CD N
in IN N
the DT N
control NN N
group NN N
whereas VBD N
there EX N
was VBD N
no DT N
incidence NN N
of IN N
corneal JJ N
perforation NN O
or CC O
recurrence NN O
of IN O
the DT O
infection NN O
in IN N
the DT I
PACK-CXL NNP I
group NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN I
PACK-CXL NNP I
may MD N
be VB N
an DT N
effective JJ I
adjuvant NN I
therapy NN I
in IN N
the DT N
management NN N
of IN N
severe JJ N
infectious JJ N
keratitis NN N
associated VBN N
with IN N
corneal NN N
melting NN N
. . N

-DOCSTART- -X- N

Factors NNS N
associated VBN N
with IN N
inadequate JJ N
colorectal JJ I
cancer NN I
screening VBG I
with IN I
flexible JJ I
sigmoidoscopy NN I
. . I

BACKGROUND NNP N
AND NNP N
STUDY NNP N
AIM NNP N
Inadequate NNP N
colorectal NN N
cancer NN N
screening VBG N
wastes NNS N
limited VBD N
endoscopic JJ N
resources NNS N
. . N

We PRP N
examined VBD N
patients NNS N
factors NNS N
associated VBN N
with IN N
inadequate JJ I
flexible JJ I
sigmoidoscopy NN I
(FSG) NN I
screening VBG I
at IN I
baseline NN I
screening NN I
and CC I
repeat NN I
screening VBG I
3-5 CD N
years NNS N
later RB N
in IN N
10 CD P
geographically-dispersed JJ P
screening NN P
centers NNS P
participating VBG P
in IN P
the DT P
ongoing JJ P
Prostate NNP P
Lung NNP P
Colorectal NNP P
and CC P
Ovarian JJ P
Cancer NNP P
Screening NNP P
Trial NNP P
. . P

METHODS NNP N
A NNP N
total NN N
of IN N
64 CD P
554 CD P
participants NNS P
(aged VBD P
55-74) JJ P
completed VBN N
baseline NN I
questionnaires NNS I
and CC I
underwent JJ I
FSG NNP I
at IN I
baseline NN I
. . I

Of IN P
these DT P
39 CD P
385 CD P
participants NNS P
returned VBN P
for IN P
repeat NN P
screening NN P
. . P

We PRP N
used VBD N
logistic JJ N
regression NN N
models NNS N
to TO N
assess VB N
factors NNS N
that WDT N
are VBP N
associated VBN N
with IN N
inadequate JJ I
FSG NNP I
(defined VBD I
as IN I
a DT I
study NN I
in IN I
which WDT I
the DT I
depth NN I
of IN I
insertion NN I
of IN I
FSG NNP I
was VBD I
<50 JJ I
cm NN I
or CC I
visual JJ I
inspection NN I
was VBD N
limited VBN N
to TO N
<90% VB N
of IN N
the DT N
mucosal JJ N
surface NN N
but CC N
without IN N
detection NN N
of IN N
a DT N
polyp NN N
or CC N
mass) NN N
. . N

RESULTS NN N
Of IN N
7084 CD N
(11%) JJ N
participants NNS N
with IN N
inadequate JJ I
FSG NNP I
at IN I
baseline NN I
6496 CD I
(91.7%) NN N
had VBD N
<50 VBN N
cm JJ N
depth NN N
of IN N
insertion NN N
(75.3% NNS N
due JJ N
to TO N
patient VB N
discomfort) NN N
and CC N
500 CD N
(7.1%) NN N
participants NNS N
had VBD N
adequate JJ N
depth NN N
of IN N
insertion NN N
but CC N
suboptimal JJ N
bowel NN N
preparation NN N
. . N

Compared VBN N
to TO N
55-59 JJ N
year NN N
age NN N
group NN N
advancing VBG N
age NN N
in IN N
5-year JJ N
increments NNS N
(odds JJ N
ratios NNS N
(OR) VBP N
from IN N
1.08 CD N
to TO N
1.51) CD N
and CC N
female JJ N
sex NN N
(OR NNP N
= VBD N
2.40; CD N
95% CD N
confidence NN N
interval JJ N
(CI): JJ N
2.27-2.54) JJ N
were VBD N
associated VBN N
with IN N
inadequate JJ I
FSG NNP I
. . I

Obesity NNP O
(BMI NNP N
> VBD N
30 CD N
kg/m(2)) NN N
was VBD N
associated VBN N
with IN N
reduced JJ N
odds NNS N
(OR VBP N
= $ N
0.67; CD N
95% CD N
CI: NNP N
0.62-0.72) NN N
. . N

Inadequate NNP I
FSG NNP I
screening VBG I
at IN N
baseline NN N
was VBD N
associated VBN N
with IN N
inadequate JJ I
FSG NNP I
at IN I
repeat NN I
screening VBG I
(OR NNP I
= VBD I
6.24; CD I
95% CD I
CI: NNP I
5.78-6.75) CD I
. . N

CONCLUSIONS NNP N
Sedation NNP I
should MD N
be VB N
considered VBN N
for IN N
patients NNS P
with IN P
inadequate JJ P
FSG NNP I
or CC I
an DT I
alternative JJ I
colorectal NN I
cancer NN I
screening VBG I
method NN I
should MD N
be VB N
recommended VBN N
. . N

-DOCSTART- -X- N

Cognitive-behavioral JJ I
therapy NN I
for IN N
psychogenic JJ P
nonepileptic JJ P
seizures: NN P
a DT N
pilot NN N
RCT NNP N
. . N

OBJECTIVE NN N
To TO N
compare VB N
cognitive-behavioral JJ I
therapy NN I
(CBT) NN I
and CC I
standard JJ I
medical JJ I
care NN I
(SMC) NNP I
as IN N
treatments NNS N
for IN N
psychogenic JJ P
nonepileptic JJ P
seizures NNS P
(PNES) VBP P
. . P

METHODS NNP N
Our PRP$ N
randomized NN N
controlled VBN N
trial NN N
(RCT) NN N
compared VBN N
CBT NNP I
with IN N
SMC NNP I
in IN N
an DT N
outpatient JJ N
neuropsychiatric JJ N
setting NN N
. . N

Sixty-six JJ P
PNES NNP P
patients NNS P
were VBD P
randomized VBN P
to TO N
either DT N
CBT NNP I
(plus CC N
SMC) NNP I
or CC N
SMC NNP I
alone RB N
scheduled VBD N
to TO N
occur VB N
over IN N
4 CD N
months NNS N
. . N

PNES NNP P
diagnosis NN P
was VBD P
established VBN P
by IN P
video-EEG JJ P
telemetry NN P
for IN P
most JJS P
patients NNS P
. . P

Exclusion NN P
criteria NNS P
included VBD P
comorbid JJ P
history NN P
of IN P
epilepsy NN P
<2 NNP P
PNES/month NNP P
and CC P
IQ NNP P
<70 NNP P
. . P

The DT N
primary JJ N
outcome NN N
was VBD N
seizure JJ O
frequency NN O
at IN N
end NN N
of IN N
treatment NN N
and CC N
at IN N
6-month JJ N
follow-up NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
3 CD O
months NNS O
of IN O
seizure NN O
freedom NN O
at IN O
6-month JJ O
follow-up JJ O
measures NNS O
of IN O
psychosocial JJ O
functioning VBG O
health NN O
service NN O
use NN O
and CC O
employment NN O
. . O

RESULTS NNP N
In IN N
an DT N
intention-to-treat JJ N
analysis NN N
seizure NN O
reduction NN O
following VBG N
CBT NNP I
was VBD N
superior JJ N
at IN N
treatment NN N
end NN N
(group NNP N
x NNP N
time NN N
interaction NN N
p NN N
< VBD N
0.0001; CD N
large JJ N
to TO N
medium VB N
effect NN N
sizes) NN N
. . N

At IN N
follow-up JJ N
the DT N
CBT NNP I
group NN N
tended VBD N
to TO N
be VB N
more RBR N
likely JJ N
to TO N
have VB N
experienced VBN N
3 CD N
months NNS N
of IN N
seizure NN O
freedom NN O
(odds NNP N
ratio VBZ N
3.125 CD N
p NN N
= VBD N
0.086) CD N
. . N

Both DT N
groups NNS N
improved VBN N
in IN N
some DT N
health NN O
service NN O
use NN O
measures NNS O
and CC O
on IN O
the DT O
Work NN O
and CC O
Social NNP O
Adjustment NNP O
Scale NNP O
. . O

Mood NN O
and CC O
employment NN O
status NN O
showed VBD N
no DT N
change NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
suggest VBP N
that IN N
cognitive-behavioral JJ I
therapy NN I
is VBZ N
more RBR N
effective JJ N
than IN N
standard RB N
medical JJ N
care NN N
alone RB N
in IN N
reducing VBG N
seizure NN N
frequency NN N
in IN N
PNES NNP P
patients NNS P
. . P

CLASSIFICATION NN N
OF NNP N
EVIDENCE NNP N
This DT N
study NN N
provides VBZ N
Class NNP N
III NNP N
evidence NN N
that WDT N
CBT NNP I
in IN N
addition NN N
to TO N
SMC NNP I
as IN I
compared VBN N
to TO N
SMC NNP I
alone RB N
significantly RB N
reduces VBZ N
seizure NN O
frequency NN O
in IN N
patients NNS P
with IN P
PNES NNP P
(change NNP N
in IN N
median JJ N
monthly JJ N
seizure NN N
frequency: NN N
baseline NN N
to TO N
6 CD N
months NNS N
follow-up JJ N
CBT NNP N
group NN N
12 CD N
to TO N
1.5; CD N
SMC NNP N
alone RB N
group NN N
8 CD N
to TO N
5) CD N
. . N

-DOCSTART- -X- N

Use NNP N
of IN N
abciximab NN I
prior RB N
to TO N
primary JJ I
angioplasty NN I
in IN N
STEMI NNP N
results NNS N
in IN N
early JJ O
recanalization NN O
of IN O
the DT O
infarct-related JJ O
artery NN O
and CC N
improved VBN N
myocardial JJ O
tissue NN O
reperfusion NN O
- : N
results NNS N
of IN N
the DT N
Austrian JJ P
multi-centre JJ P
randomized VBN P
ReoPro-BRIDGING NN P
Study NNP P
. . P

AIMS IN N
The DT N
aim NN N
of IN N
the DT N
ReoPro-BRIDGING JJ P
Austrian JJ P
multi-centre NN P
study NN P
was VBD N
to TO N
investigate VB N
the DT N
effects NNS O
of IN O
abciximab JJ O
(ReoPro) NN O
on IN O
early JJ O
reperfusion NN O
in IN O
ST-elevation NNP O
myocardial JJ O
infarction NN O
prior RB N
to TO N
or CC N
during IN N
primary JJ I
percutaneous JJ I
coronary JJ I
angioplasty NN I
(pPCI) NN I
. . I

METHODS NNP I
AND CC N
RESULTS NNP N
Fifty-five JJ P
patients NNS P
with IN P
STEMI NNP P
were VBD P
randomized VBN P
either RB P
to TO P
start VB P
abciximab VB P
(0.25 NNP P
mg/kg NN P
bolus NN P
followed VBN P
by IN P
10 CD P
microg/min NNS P
infusion) NN P
during IN P
the DT P
organization NN P
phase NN P
for IN P
pPCI NN P
(Group NN P
1 CD P
n=28) NN P
or CC P
immediately RB P
before IN P
pPCI NNS P
(Group VBP P
2 CD P
n=27) NN P
. . P

The DT N
time NN N
between IN N
first JJ N
bolus NN N
of IN N
abciximab NN I
and CC N
first JJ N
balloon NN N
inflation NN N
of IN N
pPCI NN N
was VBD N
83+/-18 JJ N
vs JJ N
21+/-13 JJ N
min NN N
in IN N
Group NNP N
1 CD N
vs NN N
2 CD N
. . N

The DT N
pre-pPCI JJ O
ST-segment JJ O
resolution NN O
(55+/-21.4% JJ N
vs NN N
42.4+/-18.2% JJ N
p=0.005) NN N
TIMI NNP O
flow NN O
grade VBD O
3 CD O
(29% NNP N
vs NN N
7% CD N
p=0.042) NN N
corrected VBN O
TIMI NNP O
frame NN O
count NN O
(58.4+/-32.7 JJ N
vs JJ N
78.9+/-28.4 JJ N
frame NN N
p=0.018) NN N
%diameter NNP N
stenosis NN N
(76.3 NNP N
/63.5-100/ NNP N
vs NN N
100 CD N
/73.5-100/; JJ N
median JJ N
/interquartile NN N
range/ NN N
p=0.023) NN N
were VBD N
significantly RB N
higher JJR N
in IN N
Group NNP N
1 CD N
vs NN N
Group NNP N
2 CD N
. . N

Quantitative JJ N
myocardial JJ N
dye NN N
intensity NN N
measurement NN N
revealed VBD N
a DT N
significantly RB N
higher JJR N
grade NN N
of IN N
myocardial JJ O
tissue NN O
perfusion NN O
(1 IN N
/0-9.25/ JJ N
vs NN N
0 CD N
/0-3.0/ JJ N
grey NNS N
pixel JJ N
unit NN N
p=0.048) NN N
in IN N
Group NNP N
1 CD N
before IN N
pPCI NN I
. . I

Rapid JJ O
release NN O
of IN O
cardiac JJ O
enzymes NNS O
was VBD N
observed VBN N
in IN N
Group NNP N
1 CD N
as IN N
compared VBN N
with IN N
Group NNP N
2: CD N
rate NN N
of IN N
rise NN N
of IN N
CK NNP N
was VBD N
210+/-209 JJ N
vs JJ N
97+/-95 CD N
U/l/h NNP N
(p=0.015) NNP N
. . N

QRS NNP N
score NN N
indicated VBD N
a DT N
smaller JJR N
infarct NN O
size NN O
in IN N
Group NNP N
1 CD N
(4.8+/-3.8 JJ N
vs NN N
7.6+/-3.5 JJ N
p=0.011) NN N
on IN N
day NN N
7 CD N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
abciximab NN I
in IN N
the DT N
organization NN N
phase NN N
for IN N
pPCI JJ N
results NNS N
in IN N
signs NNS O
of IN O
early JJ O
recanalization NN O
of IN O
the DT O
infarct-related JJ O
artery NN O
and CC N
a DT N
subsequent JJ N
improved VBN N
myocardial JJ O
tissue NN O
reperfusion NN O
. . O

-DOCSTART- -X- N

[4 JJ P
years' NN P
experience NN P
with IN P
a DT P
balloon-expandable JJ P
endoprosthesis NN P
. . P

Experimental JJ N
and CC N
clinical JJ N
application] NN N
. . N

During IN N
a DT N
4-year JJ N
period NN N
of IN N
clinical JJ N
application NN N
of IN N
the DT N
balloon-expandable JJ I
Palmaz NNP I
stent NN I
a DT I
randomized JJ N
trial NN N
comparing VBG N
stent JJ I
implantation NN I
and CC I
traditional JJ I
balloon NN I
angioplasty NN I
of IN I
iliac JJ I
arteries NNS P
in IN P
arterial JJ P
occlusive JJ P
disease NN P
was VBD N
started VBN N
. . N

The DT N
first JJ N
long-term JJ N
results NNS N
recorded VBD N
after IN N
2 CD N
years NNS N
indicate VBP N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
complication NN O
rate NN O
(after NNP P
stenting VBG P
2/62 CD P
and CC P
after IN P
angioplasty JJ P
5/69) CD P
and CC N
patency NN O
(greater NN N
than IN N
or CC N
equal JJ N
to TO N
70% CD N
of IN N
original JJ N
lumen NNS N
size NN N
upon IN N
stent JJ I
implantation NN I
or CC I
balloon NN I
inflation: NNS I
95% CD N
after IN N
stenting VBG I
and CC N
72% CD N
after IN N
angioplasty) NN I
. . N

Clinical JJ O
improvement NN O
after IN O
2 CD O
years NNS O
was VBD N
89% CD N
after IN N
stenting VBG I
and CC N
70% CD N
after IN N
angioplasty NN I
. . I

Parallel NNP N
to TO N
the DT N
clinical JJ P
trials NNS P
experimental JJ P
canine JJ P
artery NN P
stenting NN N
was VBD N
performed VBN N
to TO N
evaluate VB N
differences NNS N
in IN N
the DT N
long-term JJ N
patency NN N
of IN N
stents NNS N
exposed VBN N
to TO N
restricted VBN N
flow NN N
. . N

Significant JJ N
differences NNS N
in IN N
neointimal JJ O
healing NN O
were VBD N
found VBN N
between IN N
normally RB I
perfused VBN I
stents NNS I
and CC I
stents NNS I
with IN I
artificially RB I
reduced VBN I
flow: NN I
during IN N
the DT N
total JJ N
observation NN N
period NN N
of IN N
6 CD N
months NNS N
the DT N
neointimal JJ O
height NN O
was VBD N
up RB N
to TO N
200% CD N
higher JJR N
in IN N
flow-restricted JJ I
stents NNS I
while IN I
the DT N
histological JJ O
composition NN O
of IN O
the DT O
neointima NN O
was VBD N
the DT N
same JJ N
as IN N
with IN N
normally RB I
perfused VBN I
stents NNS I
. . I

-DOCSTART- -X- N

Comparison NNP N
of IN N
three-year JJ N
clinical JJ O
outcomes NNS O
between IN N
sirolimus-versus JJ N
paclitaxel-eluting JJ N
stents NNS N
in IN P
diabetic JJ P
patients: NN P
prospective JJ N
randomized VBN N
multicenter NN N
trial NN N
. . N

BACKGROUND NNP N
Three-year JJ N
follow-up NN N
of IN N
major JJ O
adverse JJ O
cardiovascular JJ O
event NN O
(MACE) NNP O
(death NNP O
nonfatal JJ O
myocardial JJ O
infarction NN O
target NN O
lesion NN O
revascularization) NN O
and CC N
the DT N
predictors NNS O
of IN O
MACEs NNP O
in IN P
diabetic JJ P
patients NNS P
after IN P
sirolimus-eluting JJ P
stent NN P
(SES) NN P
or CC P
paclitaxel-eluting JJ P
stent NN P
(PES) NN P
implantation NN P
have VBP N
not RB N
been VBN N
reported VBN N
. . N

METHODS NNP N
Diabetic NNP P
patients NNS P
with IN P
de FW P
novo FW P
coronary JJ P
lesions NNS P
(169 VBP P
patients NNS P
with IN P
190 CD P
lesions) NNS P
were VBD N
randomly RB N
assigned VBN N
prospectively RB N
to TO N
either DT N
SES NNP N
or CC N
PES NNP N
. . N

RESULTS NNP N
Baseline NNP N
characteristics NNS N
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
rates NNS O
of IN O
MACEs NNP O
[5.9% NNP N
(n NNP N
= VBD N
5) CD N
in IN N
the DT N
SES NNP N
vs NN N
. . N

9.5% CD N
(n JJ N
= NN N
8) CD N
in IN N
the DT N
PES NNP N
Group NNP N
P NNP N
= VBZ N
0.374] CD N
and CC N
definite JJ N
stent NN N
thrombosis NN N
[1.2% NNP N
(n NNP N
= VBD N
1) CD N
in IN N
the DT N
SES NNP N
vs NN N
. . N

3.6% CD N
(n JJ N
= NN N
3) CD N
in IN N
the DT N
PES NNP N
Group NNP N
P NNP N
= VBD N
0.368] CD N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
during IN N
the DT N
three-year JJ N
follow-up NN N
. . N

Multivariate NNP N
logistic JJ N
analysis NN N
showed VBD N
that IN N
insulin NN N
treatment NN N
was VBD N
the DT N
only JJ N
independent JJ N
predictor NN N
of IN N
MACE NNP O
[odds NNP N
ratio NN N
(OR) VBD N
8.60 CD N
95% CD N
confidence NN N
interval JJ N
(CI) JJ N
3.25-22.76 JJ N
P NNP N
< NNP N
0.001] CD N
and CC N
target VB O
vessel JJ O
revascularization NN O
(TVR) NNP N
(OR VBD N
9.50 CD N
95% CD N
CI NNP N
3.07-29.44 JJ N
P NNP N
< NNP N
0.001) CD N
during IN N
the DT N
three-year JJ N
follow-up NN N
. . N

CONCLUSIONS VB N
The DT N
rates NNS O
of IN O
MACEs NNP O
TVR NNP O
and CC O
stent JJ O
thrombosis NN O
during IN N
the DT N
three-year JJ N
follow-up NN N
were VBD N
similar JJ N
in IN N
the DT N
SES NNP N
and CC N
PES NNP N
Groups NNP N
. . N

Insulin NNP N
treatment NN N
was VBD N
a DT N
main JJ N
predictor NN N
of IN N
MACEs NNP N
and CC N
TVR NNP N
during IN N
the DT N
three-year JJ N
follow-up NN N
after IN N
either DT N
SES NNP N
or CC N
PES NNP N
implantation NN N
. . N

-DOCSTART- -X- N

Correlations NNS N
between IN N
the DT N
clinical JJ I
histological NN I
and CC I
neurophysiological JJ I
examinations NNS I
in IN N
patients NNS P
before IN P
and CC P
after IN P
parotid JJ P
gland NN P
tumor NN P
surgery: JJ P
verification NN N
of IN N
facial JJ N
nerve NN N
transmission NN N
. . N

Parotid NNP N
gland NN N
tumor NN N
surgery NN N
sometimes RB N
leads VBZ N
to TO N
facial JJ O
nerve NN O
paralysis NN O
. . O

Malignant NNP N
more JJR N
than IN N
benign JJ N
tumors NNS N
determine VBP N
nerve NN N
function NN N
preoperatively RB N
while IN N
postoperative JJ N
observations NNS N
based VBN N
on IN N
clinical JJ I
histological JJ I
and CC I
neurophysiological JJ I
studies NNS I
have VBP N
not RB N
been VBN N
reported VBN N
in IN N
detail NN N
. . N

The DT N
aims NNS N
of IN N
this DT N
pilot NN N
study NN N
were VBD N
evaluation NN I
and CC I
correlations NNS I
of IN I
histological JJ I
properties NNS I
of IN I
tumor NN I
(its NNS I
size NN I
and CC I
location) NN I
and CC I
clinical JJ I
and CC I
neurophysiological JJ I
assessment NN I
of IN I
facial JJ I
nerve NN I
function NN I
pre- NN I
and CC I
post-operatively JJ I
(1 NN N
and CC N
6 CD N
months) NN N
. . N

Comparative JJ N
studies NNS N
included VBD N
17 CD P
patients NNS P
with IN P
benign JJ P
(n NNP P
= NNP P
13) CD P
and CC P
malignant JJ P
(n NNP P
= NNP P
4) CD P
tumors NNS P
. . P

Clinical JJ N
assessment NN N
was VBD N
based VBN N
on IN N
House-Brackmann NNP O
scale JJ O
(H-B) JJ O
neurophysiological JJ O
diagnostics NNS N
included VBD N
facial JJ O
electroneurography NN O
[ENG NNP O
compound NN O
muscle NN O
action NN O
potential JJ O
(CMAP)] NNP O
mimetic JJ O
muscle NN O
electromyography NN O
(EMG) NN O
and CC O
blink-reflex JJ O
examinations NNS O
(BR) VBP O
. . O

Mainly RB N
grade NN N
I PRP N
of IN N
H-B NNP O
was VBD N
recorded VBN N
both DT N
pre- JJ I
(n NN I
= $ I
13) CD I
and CC I
post-operatively RB I
(n NNP N
= NNP N
12) CD N
in IN N
patients NNS P
with IN P
small JJ P
(1.5-2.4 JJ P
cm) NN P
benign NN P
tumors NNS P
located VBN P
in IN P
superficial JJ P
lobes NNS P
. . P

Patients NNS P
with IN P
medium JJ P
size NN P
(2.5-3.4 JJ P
cm) NN P
malignant JJ P
tumors NNS P
in IN P
both DT P
lobes NNS P
were VBD N
scored VBN N
at IN N
grade NN N
I PRP N
(n VBP N
= JJ N
2) CD N
and CC N
III NNP N
(n NNP N
= VBD N
2) CD N
pre- JJ I
and CC N
mainly RB N
VI NNP N
(n NNP N
= VBD N
4) CD N
post-operatively RB I
. . I

CMAP NNP O
amplitudes NNS O
after IN N
stimulation NN N
of IN N
mandibular JJ N
marginal JJ N
branch NN N
were VBD N
reduced VBN N
at IN N
about RB N
25 CD N
% NN N
in IN N
patients NNS P
with IN P
benign JJ P
tumors NNS P
after IN N
surgery NN N
. . N

In IN N
the DT N
cases NNS N
of IN N
malignant JJ N
tumors NNS N
CMAPs NNP O
were VBD N
not RB N
recorded VBN N
following VBG N
stimulation NN N
of IN N
any DT N
branch NN N
. . N

A DT N
similar JJ N
trend NN N
was VBD N
found VBN N
for IN N
BR NNP O
results NNS N
. . N

H-B NNP O
and CC O
ENG NNP O
results NNS N
revealed VBD N
positive JJ N
correlations NNS N
between IN N
the DT N
type NN N
of IN N
tumor NN N
and CC N
surgery NN N
with IN N
facial JJ N
nerve NN N
function NN N
. . N

Neurophysiological JJ I
studies NNS I
detected VBN N
clinically RB N
silent JJ O
facial JJ O
nerve NN O
neuropathy NN O
of IN N
mandibular JJ N
marginal JJ N
branch NN N
in IN N
postoperative JJ I
period NN N
. . N

Needle NNP N
EMG NNP O
ENG NNP O
and CC O
BR NNP O
examinations NNS N
allow VBP N
for IN N
the DT N
evaluation NN N
of IN N
face NN O
muscles NNS O
reinnervation NN O
and CC O
facial JJ O
nerve NN O
regeneration NN O
. . O

-DOCSTART- -X- N

Biventricular JJ I
pacing VBG I
improves NNS N
cardiac JJ O
function NN O
and CC N
prevents NNS N
further RBR N
left VBD N
atrial JJ N
remodeling NN N
in IN N
patients NNS P
with IN P
symptomatic JJ P
atrial JJ P
fibrillation NN P
after IN P
atrioventricular JJ P
node JJ P
ablation NN P
. . P

BACKGROUND NNP N
Randomized NNP N
trials NNS N
have VBP N
demonstrated VBN N
benefits NNS N
of IN N
biventricular JJ I
(BiV) NN I
pacing NN I
in IN N
patients NNS P
with IN P
advanced JJ P
heart NN P
failure NN P
intraventricular JJ P
conduction NN P
delay NN P
and CC P
atrial JJ P
fibrillation NN P
(AF) IN P
post-atrioventricular JJ P
(AV) NNP P
node NN P
ablation NN P
. . P

The DT N
AV NNP N
Node NNP N
Ablation NNP N
with IN N
CLS NNP I
and CC I
CRT NNP I
Pacing NNP I
Therapies NNP I
for IN N
Treatment NNP N
of IN N
AF NNP N
trial NN N
(AVAIL NNP N
CLS/CRT) NNP N
was VBD N
designed VBN N
to TO N
demonstrate VB N
superiority NN N
of IN N
BiV NNP N
pacing VBG N
in IN N
patients NNS N
with IN N
AF NNP N
after IN N
AV NNP N
node JJ N
ablation NN N
to TO N
evaluate VB N
its PRP$ N
effects NNS N
on IN N
cardiac JJ N
structure NN N
and CC N
function NN N
and CC N
to TO N
investigate VB N
additional JJ N
benefits NNS N
of IN N
Closed JJ N
Loop NNP N
Stimulation NNP N
(CLS) NNP N
(BIOTRONIK NNP N
Berlin NNP N
Germany) NNP N
. . N

METHODS NNP N
Patients NNS P
with IN P
refractory JJ P
AF NNP P
underwent NN P
AV NNP P
node CC P
ablation NN P
and CC N
were VBD N
randomized VBN N
(2:2:1) NN N
to TO N
BiV NNP I
pacing VBG I
with IN I
CLS NNP I
BiV NNP I
pacing VBG I
with IN I
accelerometer NN I
or CC I
right JJ I
ventricular NN I
(RV) NN I
pacing NN I
. . I

Echocardiography NN I
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
with IN N
paired JJ N
data NNS N
available JJ N
for IN N
108 CD P
patients NNS P
. . P

RESULTS VB N
The DT N
RV NNP I
pacing NN I
contributed VBD N
to TO N
significant JJ N
increase NN N
in IN N
left JJ O
atrial JJ O
volume NN O
left VBD O
ventricular JJ O
(LV) JJ O
end-systolic JJ O
volume NN O
and CC O
LV NNP O
mass NN O
compared VBN N
to TO N
BiV NNP N
pacing NN N
. . N

Ejection NNP O
fraction NN O
decreased VBD N
insignificantly RB N
with IN N
RV NNP N
pacing VBG N
compared VBN N
to TO N
significant JJ N
increase NN N
with IN N
BiV NNP I
pacing NN I
. . I

Interventricular JJ O
dyssynchrony NN O
significantly RB N
decreased VBN N
with IN N
BiV NNP N
compared VBN N
with IN N
RV NNP N
pacing NN N
. . N

Closed JJ N
Loop NNP N
Stimulation NNP N
did VBD N
not RB N
result VB N
in IN N
additional JJ N
echocardiographic JJ N
changes; JJ N
heart NN O
rate NN O
distribution NN O
was VBD N
significantly RB N
wider JJR N
with IN N
CLS NNP N
. . N

All DT N
groups NNS N
showed VBD N
significant JJ N
improvement NN N
in IN N
6-minute JJ O
walk NN O
distance NN O
quality-of-life JJ O
score NN O
and CC O
New NNP O
York NNP O
Heart NNP O
Association NNP O
class NN O
. . O

CONCLUSION NN N
In IN N
conclusion NN N
RV NNP I
pacing VBG I
results NNS N
in IN N
significant JJ N
increase NN N
in IN N
left JJ O
atrial JJ O
volume NN O
LV NNP O
mass NN O
and CC O
worsening NN O
of IN O
LV NNP O
contractility NN O
compared VBN N
to TO N
patients NNS N
receiving VBG N
BiV NNP I
pacing VBG I
post-AV JJ I
node JJ I
ablation NN I
for IN N
refractory NN N
AF NNP N
. . N

Closed JJ N
Loop NNP N
Stimulation NNP N
was VBD N
not RB N
associated VBN N
with IN N
additional JJ N
structural JJ N
changes NNS N
but CC N
resulted VBD N
in IN N
significantly RB N
wider JJR O
heart NN O
rate NN O
distribution NN O
. . O

-DOCSTART- -X- N

Effects NNS N
of IN N
enalapril NN I
and CC I
eprosartan NN I
on IN N
the DT N
renal JJ N
vascular NN N
nitric JJ N
oxide NN N
system NN N
in IN N
human JJ P
essential JJ P
hypertension NN P
. . P

BACKGROUND NNP P
Experimental NNP N
data NNS N
in IN N
humans NNS N
on IN N
the DT N
contribution NN N
of IN N
angiotensin-converting JJ I
enzyme NN I
inhibitors NNS I
and CC I
angiotensin NN I
II NNP I
type NN I
1 CD I
receptor NN I
blockers NNS I
to TO N
the DT N
nitric JJ N
oxide NN N
system NN N
of IN N
the DT N
renal JJ N
vasculature NN N
are VBP N
inconsistent JJ N
. . N

Enalapril NNP I
and CC I
eprosartan VB I
alone RB I
and CC N
in IN N
combination NN N
were VBD N
used VBN N
to TO N
determine VB N
their PRP$ N
short-term JJ N
effects NNS N
on IN N
the DT N
renal JJ N
nitric JJ N
oxide NN N
system NN N
and CC N
renal JJ N
hemodynamics NNS N
of IN N
human JJ P
subjects NNS P
with IN P
essential JJ P
hypertension NN P
. . P

METHODS NNP N
Twenty NNP P
male JJ P
white JJ P
patients NNS P
(27 JJ P
+/- JJ P
1 CD P
years) NN P
with IN P
mild JJ P
essential JJ P
hypertension NN P
(143 VBD P
+/- JJ P
11/95 CD P
+/- JJ P
6 CD P
mm NN P
Hg) NNP P
were VBD N
included VBN N
in IN N
a DT N
double-blind JJ N
randomized JJ N
placebo-controlled JJ I
fourfold JJ I
cross-over NN N
study NN N
with IN N
placebo NN I
enalapril NN I
(20 NNP I
mg/day) NN I
eprosartan NN I
(600 NNP I
mg/day) NN I
or CC I
combination NN I
of IN I
both DT I
drugs NNS I
(10 VBP N
and CC N
300 CD N
mg/day JJ N
respectively) NNS N
each DT N
over IN N
a DT N
one CD N
week NN N
period NN N
followed VBN N
by IN N
a DT N
two-week JJ N
washout NN N
phase NN N
. . N

After IN N
each DT N
study NN N
phase VBD N
the DT N
glomerular JJ O
filtration NN O
rate NN O
(GFR) NNP O
and CC O
renal JJ O
plasma NN O
flow NN O
(RPF) NN O
were VBD N
determined VBN N
. . N

Basal NNP I
nitric JJ I
oxide JJ I
synthesis NN N
of IN N
the DT N
renal JJ N
vasculature NN N
was VBD N
assessed VBN N
by IN N
the DT N
decrease NN N
in IN N
RPF NNP N
after IN N
inhibition NN N
of IN N
nitric JJ I
oxide JJ I
synthase NN I
with IN I
NG-monomethyl-L-arginine NNP I
(L-NMMA; JJ I
4.25 CD I
mg/kg) NN I
. . I

RESULTS NN N
After IN N
one CD N
week NN N
of IN N
therapy NN N
the DT N
combination NN I
therapy NN I
decreased VBD N
casual JJ O
blood NN O
pressure NN O
by IN N
5 CD N
+/- JJ N
2/3 CD N
+/- JJ N
1 CD N
mm NN N
Hg NNP N
versus NN N
placebo NN I
(P NNP N
< VBZ N
0.01) CD N
. . N

Neither DT N
enalapril JJ I
alone RB I
(-2 JJ N
+/- JJ N
2/1 CD N
+/- JJ N
2 CD N
mm NN N
Hg NNP N
NS NNP N
vs NN N
. . N

placebo) NNS I
nor CC N
eprosartan JJ I
alone RB I
(-1 JJ N
+/- JJ N
1/0 CD N
+/- JJ N
2 CD N
mm NN N
Hg NNP N
NS NNP N
vs NN N
. . N

placebo) NN N
had VBD N
a DT N
clear-cut JJ N
significant JJ N
effect NN N
on IN N
casual JJ O
blood NN O
pressure NN O
. . O

In IN N
the DT N
combination NN N
phase NN N
RPF NNP O
increased VBN N
by IN N
123 CD N
+/- JJ N
36 CD N
mL/min NN N
(P NNP N
< VBZ N
0.01) CD N
. . N

Neither DT N
enalapril NN I
alone RB I
(+59 JJ N
+/- JJ N
46 CD N
mL/min NN N
P NNP N
= VBZ N
0.21) CD N
nor CC N
eprosartan JJ I
alone RB I
(+113 JJ N
+/- JJ N
51 CD N
mL/min NN N
P NNP N
= NNP N
0.06) CD N
had VBD N
a DT N
clear-cut JJ N
significant JJ N
effect NN N
on IN N
RPF NNP O
. . O

Changes NNS N
of IN N
RPF NNP N
induced VBN N
by IN N
treatment NN N
correlated VBN N
with IN N
the DT N
L-NMMA NNP N
induced JJ N
decrease NN N
in IN N
RPF NNP O
in IN N
the DT N
combination NN I
(r NNP I
= VBZ I
0.70 CD I
P NNP I
< VBD I
0.01) CD I
and CC I
eprosartan JJ I
phase NN I
(r NNP I
= VBZ I
0.86 CD I
P NNP I
< VBD I
0.001) CD I
but CC I
not RB N
in IN N
the DT N
enalapril JJ I
phase NN N
(r NNP N
= NNP N
-0.44 NNP N
P NNP N
= VBD N
0.10) CD N
. . N

Renal JJ O
vascular NN O
resistance NN O
was VBD N
reduced VBN N
by IN N
each DT N
active JJ N
treatment NN N
with IN N
the DT N
most RBS N
prominent JJ N
reduction NN N
in IN N
the DT N
combination NN N
phase NN N
. . N

GFR NNP O
was VBD N
unaffected VBN N
by IN N
any DT N
treatment NN N
. . N

CONCLUSIONS NNP N
In IN N
contrast NN N
to TO N
the DT N
effects NNS N
of IN N
either DT N
substance NN N
alone RB N
a DT N
combination NN I
of IN I
half PDT I
the DT I
dose NN I
of IN I
eprosartan NN I
with IN I
half PDT I
the DT I
dose NN I
of IN I
enalapril NN I
had VBD N
a DT N
prominent JJ N
effect NN N
on IN N
renal JJ O
perfusion NN O
. . O

The DT N
effects NNS N
of IN N
eprosartan NN I
on IN N
RPF NNP N
are VBP N
mediated VBN N
at IN N
least JJS N
in IN N
part NN N
by IN N
an DT N
increased JJ N
bioavailability NN N
of IN N
nitric JJ N
oxide NN N
in IN N
the DT N
renal JJ N
vasculature NN N
. . N

-DOCSTART- -X- N

Pentoxifylline NN I
to TO N
treat VB N
radiation NN P
proctitis: IN P
a DT N
small JJ N
and CC N
inconclusive JJ N
randomised VBN N
trial NN N
. . N

This DT N
prospective JJ N
randomised VBN N
controlled VBN I
study NN P
of IN P
40 CD P
patients NNS P
could MD N
not RB N
show VB N
a DT N
statistically RB N
significant JJ N
advantage NN N
with IN N
6 CD I
months NNS I
of IN I
pentoxifylline NN I
compared VBN I
with IN I
standard JJ I
measures NNS I
for IN I
late JJ O
radiation-induced JJ O
rectal NN O
bleeding NN O
. . O

However RB N
a DT N
modest JJ N
benefit NN N
cannot NN N
be VB N
excluded VBN N
and CC N
larger JJR N
randomised VBD N
placebo-controlled JJ I
trials NNS N
with IN N
longer JJR N
durations NNS N
of IN N
pentoxifylline JJ I
treatment NN N
may MD N
be VB N
justified VBN N
. . N

-DOCSTART- -X- N

The DT N
long-term JJ N
effects NNS N
of IN N
auditory JJ I
training NN I
on IN N
children NNS P
with IN P
autism NN P
. . P

Eighty NNP P
children NNS P
3-17 CD P
years NNS P
of IN P
age NN P
with IN P
autism NN P
or CC P
Asperger NNP P
syndrome NN P
and CC P
mild NN P
to TO P
severe VB P
distress NN P
in IN P
the DT P
presence NN P
of IN P
some DT P
sounds NNS P
were VBD P
randomly RB N
allocated VBN N
to TO N
two CD N
groups NNS N
. . N

The DT N
experimental JJ N
group NN N
received VBD N
auditory JJ I
training NN I
and CC I
the DT I
control NN I
group NN I
listened VBD I
to TO I
the DT I
same JJ I
unmodified JJ I
music NN I
under IN I
the DT I
same JJ I
conditions NNS I
. . I

Significant JJ N
improvements NNS N
in IN N
behavior NN O
and CC O
severity NN O
of IN O
autism NN O
were VBD N
maintained VBN N
for IN N
12 CD N
months NNS N
by IN N
both DT N
groups NNS N
. . N

Informal NNP N
data NNS N
suggested VBD N
that IN N
a DT N
range NN O
of IN O
abnormal JJ O
responses NNS O
to TO N
sound VB O
and CC O
other JJ O
sensory JJ O
abnormalities NNS O
may MD N
also RB N
have VB N
improved VBN N
. . N

Verbal NNP O
and CC O
performance NN O
IQ NNP O
increased VBD N
significantly RB N
3 CD N
to TO N
12 CD N
months NNS N
after IN N
interventions NNS I
. . I

Findings NNS N
suggest VBP N
that IN N
some DT N
aspect NN N
of IN N
both DT N
auditory JJ I
training NN I
and CC I
listening VBG I
to TO N
selected VBN N
unmodified JJ I
music NN I
may MD N
have VB N
a DT N
beneficial JJ O
effect NN O
on IN N
children NNS P
with IN P
autism NN P
and CC P
sound JJ P
sensitivity NN P
and CC P
indicate VB N
a DT N
need NN N
for IN N
further JJ N
research NN N
into IN N
the DT N
effects NNS N
that WDT N
led VBD N
to TO N
these DT N
changes NNS N
and CC N
the DT N
mechanisms NNS N
involved VBN N
in IN N
the DT N
sensory JJ N
abnormalities NNS N
commonly RB N
associated VBN N
with IN N
autism NN I
. . I

-DOCSTART- -X- N

A DT I
play NN I
and CC I
joint JJ I
attention NN I
intervention NN I
for IN N
teachers NNS P
of IN P
young JJ P
children NNS P
with IN P
autism: PDT P
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
pilot VB N
test VB N
a DT N
classroom-based JJ I
intervention NN I
focused VBD I
on IN N
facilitating VBG N
play NN I
and CC I
joint JJ I
attention NN I
for IN N
young JJ P
children NNS P
with IN P
autism NN P
in IN P
self-contained JJ P
special JJ P
education NN P
classrooms NNS P
. . P

Thirty-three JJ P
children NNS P
with IN P
autism NN P
between IN P
the DT P
ages NNS P
of IN P
3 CD P
and CC P
6 CD P
years NNS P
participated VBN P
in IN P
the DT P
study NN P
with IN P
their PRP$ P
classroom NN P
teachers NNS P
(n VBP P
= JJ P
14) CD P
. . P

The DT N
14 CD P
preschool NN P
special JJ P
education NN P
teachers NNS P
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups: NNS N
(1) VBP N
symbolic JJ I
play NN I
then RB I
joint JJ I
attention NN I
intervention NN I
(2) NNP I
joint JJ I
attention NN I
then RB I
symbolic JJ I
intervention NN I
and CC I
(3) JJ I
wait-list JJ I
control NN I
period NN I
then RB I
further RB I
randomized VBN I
to TO I
either DT I
group NN I
1 CD I
or CC I
group NN I
2 CD I
. . I

In IN N
the DT N
intervention NN N
teachers NNS N
participated VBD N
in IN N
eight CD N
weekly JJ N
individualized VBN N
1-h JJ N
sessions NNS N
with IN N
a DT N
researcher NN N
that WDT N
emphasized VBD N
embedding VBG N
strategies NNS N
targeting VBG N
symbolic JJ O
play NN O
and CC O
joint JJ O
attention NN O
into IN N
their PRP$ N
everyday JJ N
classroom NN N
routines NNS N
and CC N
activities NNS N
. . N

The DT N
main JJ N
child NN N
outcome NN N
variables NNS O
of IN O
interest NN O
were VBD N
collected VBN N
through IN N
direct JJ N
classroom NN N
observations NNS N
. . N

Findings NNS N
indicate VBP N
that IN N
teachers NNS N
can MD N
implement VB N
an DT N
intervention NN N
to TO N
significantly RB N
improve VB N
joint JJ O
engagement NN O
of IN N
young JJ P
children NNS P
with IN P
autism NN P
in IN P
their PRP$ P
classrooms NNS P
. . P

Furthermore RB N
multilevel NN N
analyses NNS N
showed VBD N
significant JJ N
increases NNS N
in IN N
joint JJ O
attention NN O
and CC O
symbolic JJ O
play NN O
skills NNS O
. . O

Thus RB N
these DT N
pilot NN N
data NNS N
emphasize VBP N
the DT N
need NN N
for IN N
further JJ N
research NN N
and CC N
implementation NN N
of IN N
classroom-based JJ I
interventions NNS I
targeting VBG I
play NN O
and CC O
joint JJ O
attention NN O
skills NNS O
for IN I
young JJ P
children NNS P
with IN P
autism NN P
. . P

-DOCSTART- -X- N

[Effect NN N
of IN N
dopexamine NN I
in IN N
splanchnic JJ N
perfusion NN N
during IN N
surgery NN P
of IN P
the DT P
abdominal JJ P
aorta] NN P
. . N

Abdominal NNP I
aortic JJ I
surgery NN I
has VBZ N
significant JJ N
effects NNS N
on IN N
cardiac NN N
and CC N
splanchnic JJ N
perfusion NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
dopexamine NN I
an DT I
inodilator JJ I
drug NN I
on IN I
hemodynamic JJ N
and CC N
splanchnic JJ N
perfusion NN N
with IN N
measurement NN N
of IN N
gastric JJ N
intramucosal NN N
pH NN N
by IN N
the DT N
method NN N
of IN N
gastric JJ I
tonometry NN I
during IN I
abdominal JJ I
aneurysm JJ I
resection NN I
. . I

Twenty-five JJ P
patients NNS P
undergoing VBG P
excision NN P
of IN P
an DT P
aortic JJ P
abdominal JJ P
aneurysm NN P
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

During IN N
aortic JJ N
cross-clamping JJ N
Group NNP N
II NNP N
patients NNS N
received VBD N
dopexamine JJ I
infusion NN I
at IN I
a DT N
dose NN I
of IN I
1 CD I
microgram/kg/m NN I
and CC I
at IN I
a DT I
dose NN I
of IN I
0.5 CD I
micrograms/kg/m NN I
from IN N
declamping VBG N
to TO N
the DT N
end NN N
of IN N
the DT N
surgery NN N
. . N

Whereas NNP N
Group NNP I
I PRP I
patients NNS I
did VBD I
not RB I
receive VB I
a DT I
dopexamine JJ I
infusion NN I
. . I

During IN N
aortic JJ N
cross-clamping VBG N
the DT N
intramucosal NN O
pH VBZ O
value NN O
decreased VBN N
in IN N
Group NNP N
I PRP N
patients NNS N
but CC N
did VBD N
not RB N
change VB N
in IN N
Group NNP N
II NNP N
patients NNS N
. . N

Heart NNP O
rate NN O
cardiac NN O
index NN O
and CC O
mixed JJ O
venous JJ O
oxygen NN O
saturation NN O
increased VBD N
significantly RB N
during IN N
dopexamine JJ N
infusion NN N
whereas IN N
systemic JJ O
vascular JJ O
resistance NN O
was VBD N
reduced VBN N
. . N

During IN N
aortic JJ N
cross-clamping JJ N
dopexamine NN I
was VBD N
a DT N
useful JJ N
agent NN N
in IN N
improving VBG N
splanchnic JJ O
blood NN O
flow NN O
cardiac JJ O
index NN O
venous JJ O
saturation NN O
. . O

Also RB N
since IN N
the DT N
drug NN N
produces VBZ N
dose RB N
related JJ N
hemodynamic JJ N
changes NNS N
of IN N
rapid JJ N
onset NN N
and CC N
reversibility NN N
it PRP N
is VBZ N
possible JJ N
to TO N
interrupt VB N
the DT N
infusion NN N
before IN N
aortic JJ N
declamping NN N
to TO N
avoid VB N
the DT N
decrease NN N
in IN N
the DT N
intramucosal NN N
pH VBZ N
value NN N
. . N

-DOCSTART- -X- N

Rapid-sequence JJ I
intubation NN I
of IN I
head NN P
trauma NN P
patients: JJ P
prevention NN N
of IN N
fasciculations NNS O
with IN N
pancuronium NN I
versus NN N
minidose JJ I
succinylcholine NN I
. . I

INTRODUCTION NNP N
Fasciculations NNP O
during IN N
rapid-sequence JJ I
intubation NN I
may MD N
lead VB N
to TO N
increased VBN N
intracranial JJ N
pressure NN N
and CC N
emesis NN N
with IN N
aspiration NN N
. . N

Standard JJ I
rapid-sequence NN I
intubation NN I
requires VBZ N
a DT N
nondepolarizing JJ N
blocking NN N
agent NN N
before IN N
succinylcholine JJ I
administration NN I
. . I

HYPOTHESIS NNP N
Prevention NNP N
of IN N
fasciculations NNS O
during IN N
rapid-sequence JJ I
intubation NN I
of IN N
head NN P
trauma IN P
patients NNS P
can MD N
be VB N
accomplished VBN N
as IN N
safely RB N
and CC N
effectively RB N
with IN N
minidose JJ I
succinylcholine NN I
as IN N
with IN N
a DT N
defasciculating VBG N
dose NN N
of IN N
pancuronium NN I
. . I

DESIGN VB N
A DT N
prospective JJ N
randomized VBN N
double-blind NN N
study NN N
. . N

SETTING VBG N
An DT N
inner-city JJ P
county NN P
trauma NN P
center NN P
with IN P
70 CD P
000 CD P
patient JJ P
visits NNS P
per IN P
year NN P
. . P

PARTICIPANTS NNP N
Sequential NNP P
adult NN P
head NN P
trauma NN P
patients NNS P
requiring VBG P
rapid-sequence JJ P
intubation NN P
who WP P
had VBD P
no DT P
contraindications NNS P
to TO P
succinylcholine VB P
or CC P
pancuronium NN P
. . P

INTERVENTIONS NNP P
Each DT N
head NN P
trauma NN P
patient JJ P
requiring VBG N
rapid-sequence NN I
intubation NN I
who WP N
met VBD N
the DT N
inclusion NN N
criteria NNS N
received VBD N
standard JJ I
rapid-sequence NN I
intubation NN I
maneuvers NNS I
and CC I
lidocaine JJ I
(1 NNP N
mg/kg) NN N
IV NNP N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
minidose JJ I
succinylcholine NN I
(0.1 NNP I
mg/kg) NN I
or CC I
pancuronium NN I
(0.03 VBP I
mg/kg) NN I
IV NNP I
one CD I
minute NN I
prior RB I
to TO I
the DT I
full JJ I
paralytic JJ I
dose NN I
of IN I
succinylcholine JJ I
(1.5 NNP N
mg/kg) NN N
IV NNP N
. . N

Fasciculations NNS N
were VBD N
recorded VBN N
using VBG N
a DT N
graded JJ N
visual JJ N
scale NN N
. . N

RESULTS NNP N
Of IN N
46 CD P
patients NNS P
eight CD P
of IN P
19 CD P
(42%) NNS P
in IN P
the DT P
pancuronium NN P
group NN P
and CC P
six CD P
of IN P
27 CD P
(22%) NNS P
in IN P
the DT P
succinylcholine NN P
group NN P
experienced VBD P
fasciculations NNS N
. . N

No DT N
statistically RB N
significant JJ N
difference NN N
in IN N
fasciculations NNS O
was VBD N
detected VBN N
between IN N
the DT N
two CD N
groups NNS N
using VBG N
chi JJ N
2 CD N
analysis NN N
. . N

Complete JJ O
relaxation NN O
of IN O
the DT O
cords NNS O
was VBD N
present JJ N
in IN N
all DT N
but CC N
two CD N
patients NNS N
one CD N
in IN N
each DT N
group NN N
. . N

No DT N
patient NN N
in IN N
either DT N
group NN N
experienced VBD N
emesis NN O
or CC O
significant JJ O
dysrhythmias NN O
. . O

CONCLUSION NNP N
Pretreatment NNP N
with IN N
minidose JJ I
succinylcholine JJ I
causes VBZ N
no DT N
greater JJR N
incidence NN N
of IN N
fasciculations NNS O
than IN N
pancuronium NN I
in IN N
rapid-sequence JJ I
intubation NN I
of IN N
head NN P
trauma NN P
patients NNS P
in IN P
an DT P
ED NNP P
setting NN P
. . P

Thus RB N
succinylcholine NN I
may MD N
be VB N
used VBN N
as IN N
the DT N
sole JJ N
paralytic JJ I
agent NN I
in IN N
rapid-sequence JJ I
intubation NN I
of IN N
head NN P
trauma NN P
patients NNS P
. . P

-DOCSTART- -X- N

Effect NN N
of IN N
intensive JJ I
therapy NN I
on IN N
the DT N
microvascular JJ P
complications NNS P
of IN P
type NN P
1 CD P
diabetes NNS P
mellitus NN P
. . P

The DT P
purpose NN N
of IN N
this DT N
report NN N
is VBZ N
to TO N
summarize VB N
and CC N
integrate VB N
the DT N
findings NNS N
of IN N
the DT N
Diabetes NNP N
Control NNP N
and CC N
Complications NNP N
Trial NNP N
(DCCT) VBD N
a DT N
randomized VBN N
controlled JJ N
clinical JJ N
trial NN N
and CC N
the DT N
succeeding JJ N
observational JJ N
follow-up NN N
of IN N
the DT N
DCCT NNP N
cohort NN N
in IN N
the DT N
Epidemiology NNP N
of IN N
Diabetes NNP N
Interventions NNP N
and CC N
Complications NNP N
(EDIC) NNP N
study NN N
regarding VBG N
the DT N
effects NNS N
of IN N
intensive JJ I
treatment NN I
on IN N
the DT N
microvascular JJ P
complications NNS P
of IN P
type NN P
1 CD P
diabetes NNS P
mellitus NN P
. . P

The DT N
DCCT NNP N
proved VBD N
that IN N
intensive JJ I
treatment NN I
reduced VBD N
the DT N
risks NNS O
of IN O
retinopathy JJ O
nephropathy JJ O
and CC O
neuropathy JJ O
by IN N
35% CD N
to TO N
90% CD N
compared VBN N
with IN N
conventional JJ I
treatment NN I
. . I

The DT N
absolute JJ O
risks NNS O
of IN O
retinopathy NN O
and CC O
nephropathy JJ O
were VBD N
proportional JJ N
to TO N
the DT N
mean NN N
glycosylated VBD N
hemoglobin JJ N
(HbA(1c)) NNP N
level NN N
over IN N
the DT N
follow-up JJ N
period NN N
preceding VBG N
each DT N
event NN N
. . N

Intensive JJ I
treatment NN I
was VBD N
most RBS N
effective JJ N
when WRB N
begun VBN N
early RB N
before IN N
complications NNS N
were VBD N
detectable JJ N
. . N

These DT N
risk NN N
reductions NNS N
achieved VBN N
at IN N
a DT N
median JJ N
HbA(1c) NNP N
level NN N
difference NN N
of IN N
9.1% CD N
for IN N
conventional JJ N
treatment NN N
vs NN N
7.3% CD N
for IN N
intensive JJ I
treatment NN I
have VBP N
been VBN N
maintained VBN N
through IN N
7 CD N
years NNS N
of IN N
EDIC NNP N
even RB N
though IN N
the DT N
difference NN N
in IN N
mean JJ N
HbA(1c) NNP N
levels NNS N
of IN N
the DT N
2 CD N
former JJ N
randomized VBN N
treatment NN N
groups NNS N
was VBD N
only RB N
0.4% CD N
at IN N
1 CD N
year NN N
(P<.001) NN N
(8.3% NN N
in IN N
the DT N
former JJ N
conventional JJ I
treatment NN I
group NN N
vs VBD N
7.9% CD N
in IN N
the DT N
former JJ N
intensive JJ I
treatment NN I
group) NN N
continued VBD N
to TO N
narrow VB N
and CC N
became VBD N
statistically RB N
nonsignificant JJ N
by IN N
5 CD N
years NNS N
(8.1% JJ N
vs RB N
8.2% CD N
P NNP N
=.09) NNP N
. . N

The DT N
further JJ N
rate NN N
of IN N
progression NN N
of IN N
complications NNS N
from IN N
their PRP$ N
levels NNS N
at IN N
the DT N
end NN N
of IN N
the DT N
DCCT NNP N
remains VBZ N
less RBR N
in IN N
the DT N
former JJ N
intensive JJ I
treatment NN I
group NN N
. . N

Thus RB N
the DT N
benefits NNS N
of IN N
6.5 CD N
years NNS N
of IN N
intensive JJ I
treatment NN I
extend VBP N
well RB N
beyond IN N
the DT N
period NN N
of IN N
its PRP$ N
most RBS N
intensive JJ N
implementation NN N
. . N

Intensive JJ I
treatment NN I
should MD N
be VB N
started VBN N
as RB N
soon RB N
as IN N
is VBZ N
safely RB N
possible JJ N
after IN N
the DT N
onset NN N
of IN N
type NN P
1 CD P
diabetes NNS P
mellitus NN P
and CC N
maintained VBD N
thereafter RB N
aiming VBG N
for IN N
a DT N
practicable JJ N
target NN N
HbA(1c) NNP N
level NN N
of IN N
7.0% CD N
or CC N
less JJR N
. . N

-DOCSTART- -X- N

[Study NN N
on IN N
treatment NN N
of IN N
iron-deficiency NN N
anemia NN N
by IN N
shengxuening] NN I
. . N

OBJECTIVE NN N
To TO I
observe VB I
the DT I
therapeutic JJ I
effect NN I
of IN I
shengxuening VBG I
(SXN) NN I
in IN I
treating VBG I
iron-deficiency NN P
anemia NN P
(IDA) NN P
and CC I
to TO I
explore VB I
its PRP$ I
molecular JJ I
mechanism NN I
on IN I
iron NN I
metabolism NN I
balance NN I
regulation NN I
. . I

METHODS NNP I
Patients NNS P
with IN P
IDA NNP P
were VBD P
randomly RB P
divided VBN P
into IN P
the DT P
treated VBN P
group NN P
and CC P
the DT P
control NN P
group NN P
50 CD P
in IN P
each DT P
group NN P
. . P

They PRP I
were VBD I
treated VBN I
with IN I
SXN NNP I
(0.1 NNP I
g VBD I
three CD I
times NNS I
per IN I
day) NN I
and CC I
ferrous JJ I
gluconate NN I
(0.1 NN I
g VBD I
three CD I
times NNS I
per IN I
day) NN I
respectively RB I
for IN I
30 CD I
days NNS I
. . I

Levels NNS O
of IN O
serum NN O
iron NN O
(Fe) NNP O
total JJ O
iron NN O
binding NN O
capacity NN O
(TIBC) NNP O
transferrin NN O
saturation NN O
(TS) NNP O
serum NN O
ferritin NN O
(SF) NNP O
transferrin NN O
(Tf) NNP O
soluble JJ O
transferrin NN O
receptor NN O
(sTfR) NN O
and CC O
blood NN O
routine JJ O
test NN O
as RB O
well RB O
as IN O
scoring NN O
of IN O
TCM NNP O
qi-blood JJ O
deficiency NN O
Syndrome NNP O
were VBD N
conducted VBN N
before IN N
and CC N
after IN N
treatment NN N
. . N

RESULTS VB N
The DT N
total JJ N
effective JJ N
rate NN N
in IN N
the DT N
treated JJ N
group NN N
reached VBD N
92% CD N
it PRP N
was VBD N
shown VBN N
that IN N
SXN NNP I
could MD N
improve VB N
the DT N
iron NN O
metabolism NN O
increase NN O
levels NNS O
of IN O
Fe NNP O
TS NNP O
SF NNP O
and CC O
reduce VB O
levels NNS O
of IN O
TIBC NNP O
Tf NNP O
sTfR NN O
it PRP O
has VBZ N
obvious JJ N
effect NN N
in IN N
promoting VBG N
erythrocyte JJ N
generation NN N
and CC N
could MD N
promote VB N
formation NN N
of IN N
leucocytes NNS N
and CC N
platelets NNS N
. . N

The DT N
total JJ O
effective JJ O
rate NN O
in IN N
the DT N
control NN I
group NN N
was VBD N
32% CD N
which WDT N
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
in IN N
the DT N
treated JJ N
group NN N
(P NNP N
< VBZ N
0.01) CD N
. . N

CONCLUSION NNP N
The DT N
effect NN N
of IN N
SXN NNP I
in IN N
treating VBG N
IDA NNP N
and CC N
qi-blood JJ N
deficiency NN N
Syndrome NNP N
is VBZ N
evident JJ N
it PRP N
could MD N
improve VB N
the DT N
iron NN N
metabolism NN N
increase NN N
levels NNS N
of IN N
Fe NNP N
TS NNP N
SF NNP N
and CC N
lower JJR N
levels NNS N
of IN N
TIBC NNP N
Tf NNP N
sTfR NN N
. . N

-DOCSTART- -X- N

Efficacy NN O
and CC O
safety NN O
of IN N
recombinant JJ I
human JJ I
nerve NN I
growth NN I
factor NN I
in IN N
patients NNS P
with IN P
diabetic JJ P
polyneuropathy: NN P
A NNP N
randomized VBD N
controlled VBN N
trial NN N
. . N

rhNGF VB N
Clinical NNP N
Investigator NNP N
Group NNP N
. . N

CONTEXT NNP N
Nerve NNP N
growth NN N
factor NN N
is VBZ N
a DT N
neurotrophic JJ N
factor NN N
that WDT N
promotes VBZ N
the DT N
survival NN N
of IN N
small JJ N
fiber NNP N
sensory JJ N
neurons NNS N
and CC N
sympathetic JJ N
neurons NNS N
in IN N
the DT N
peripheral JJ N
nervous JJ N
system NN N
. . N

Recombinant JJ I
human JJ I
nerve NN I
growth NN I
factor NN I
(rhNGF) NNP I
has VBZ N
demonstrated VBN N
efficacy NN N
as IN N
treatment NN N
for IN N
peripheral JJ N
neuropathy NN N
in IN N
experimental JJ N
models NNS N
and CC N
phase VB N
2 CD N
clinical JJ N
trials NNS N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
efficacy NN O
and CC O
safety NN O
of IN N
a DT N
12-month JJ N
regimen NN N
of IN N
rhNGF NN N
in IN N
patients NNS P
with IN P
diabetic JJ P
polyneuropathy NN P
. . P

DESIGN NNP N
Randomized NNP N
double-blind JJ N
placebo-controlled JJ I
phase NN N
3 CD N
trial NN N
conducted VBN N
from IN N
July NNP N
1997 CD N
through IN N
May NNP N
1999 CD N
. . N

SETTING NN N
Eighty-four JJ P
outpatient NN P
centers NNS P
throughout IN P
the DT P
United NNP P
States NNPS P
. . P

PATIENTS VB P
A DT P
total NN P
of IN P
1019 CD P
men NNS P
and CC P
women NNS P
aged VBD P
18 CD P
to TO P
74 CD P
years NNS P
with IN P
either DT P
type NN P
1 CD P
or CC P
type VB P
2 CD P
diabetes NNS P
and CC P
a DT P
sensory JJ P
polyneuropathy NN P
attributable JJ P
to TO P
diabetes NNS P
. . P

INTERVENTIONS JJ P
Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
rhNGF NN I
0.1 CD I
microg/kg NN I
(n NNP N
= VBZ N
504) CD N
or CC I
placebo VB I
(n JJ N
= NNS N
515) CD N
by IN N
subcutaneous JJ N
injection NN N
3 CD N
times NNS N
per IN N
week NN N
for IN N
48 CD N
weeks NNS N
. . N

Patients NNS N
were VBD N
assessed VBN N
at IN N
baseline JJ N
12 CD N
weeks NNS N
24 CD N
weeks NNS N
and CC N
48 CD N
weeks NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
a DT N
change NN O
in IN O
neuropathy JJ O
between IN O
baseline NN O
and CC O
week NN O
48 CD O
demonstrated VBN O
by IN O
the DT O
Neuropathy NNP O
Impairment NNP O
Score NNP O
for IN N
the DT N
Lower NNP N
Limbs NNP N
compared VBN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

Secondary JJ N
outcome NN N
measures NNS N
included VBD N
quantitative JJ O
sensory NN O
tests NNS O
using VBG O
the DT O
CASE NNP O
IV NNP O
System NNP O
the DT O
Neuropathy NNP O
Symptom NNP O
and CC O
Change NNP O
questionnaire VBP O
the DT O
Patient NNP O
Benefit NNP O
Questionnaire NNP O
(PBQ) NNP O
and CC O
a DT O
global JJ O
symptom NN O
assessment NN O
as RB O
well RB O
as IN O
nerve NN O
conduction NN O
studies NNS O
and CC O
occurrence NN O
of IN O
new JJ O
plantar JJ O
foot NN O
ulcers NNS O
. . O

Patients NNS N
also RB N
were VBD N
evaluated VBN N
for IN N
presence NN N
of IN N
adverse JJ O
events NNS O
. . O

RESULTS NNP N
Among IN N
patients NNS N
who WP N
received VBD N
rhNGF JJ I
418 CD I
(83%) NN N
completed VBD N
the DT N
regimen NNS N
compared VBN N
with IN N
461 CD N
(90%) NNS N
who WP N
received VBD N
placebo NN I
. . I

Administration NN N
of IN N
rhNGF NN I
was VBD N
safe JJ N
with IN N
few JJ N
adverse JJ O
events NNS O
attributed VBD N
to TO N
treatment NN N
apart RB N
from IN N
injection NN N
site NN O
pain/hyperalgesia NN O
and CC O
other JJ O
pain NN O
syndromes NNS O
. . O

However RB N
neither CC N
the DT N
primary JJ N
end NN N
point NN N
(P NNP N
=.25) NNP N
nor CC N
most JJS N
of IN N
the DT N
secondary JJ N
end NN N
points NNS N
demonstrated VBD N
a DT N
significant JJ N
benefit NN N
of IN N
rhNGF NN I
. . I

Exceptions NNS N
were VBD N
the DT N
global JJ O
symptom NN O
assessment NN O
(P NNP N
=.03) NNP N
and CC N
2 CD N
of IN N
32 CD N
comparisons NNS N
within IN N
the DT N
PBQ NNP N
which WDT N
showed VBD N
a DT N
modest JJ N
but CC N
significant JJ N
benefit NN N
of IN N
rhNGF NN I
(P NNP N
=.05 NNP N
for IN N
severity NN N
of IN N
pain NN N
in IN N
the DT N
legs NN N
and CC N
P NNP N
=.003 NNP N
for IN N
6-month JJ N
symptoms NNS N
in IN N
the DT N
feet NNS N
and CC N
legs) NN N
. . N

CONCLUSION NNP N
Unlike NNP N
previous JJ N
phase NN N
2 CD N
trials NNS N
this DT N
phase NN N
3 CD N
clinical JJ N
trial NN N
failed VBD N
to TO N
demonstrate VB N
a DT N
significant JJ N
beneficial JJ N
effect NN N
of IN N
rhNGF NN N
on IN N
diabetic JJ N
polyneuropathy NN N
. . N

JAMA NNP N
. . N

2000;284:2215-2221 JJ N
. . N

-DOCSTART- -X- N

[Afala NN I
in IN N
the DT N
treatment NN N
of IN N
patients NNS P
with IN P
BPH: NNP P
efficacy NN N
and CC N
safety] NN N
. . N

The DT N
double-blind JJ N
placebo-controlled JJ I
randomized JJ I
clinical JJ N
trial NN N
involving VBG N
94 CD P
patients NNS P
has VBZ N
evaluated VBN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
domestic JJ N
preparation NN N
afala NN I
in IN N
patients NNS P
with IN P
symptoms NNS P
of IN P
I-II NNP P
stages NNS P
benign VBP P
prostatic JJ P
hyperplasia NN P
(BPH) NN P
. . P

It PRP N
was VBD N
shown VBN N
that IN N
a DT N
6-month JJ N
course NN N
of IN N
treatment NN N
with IN N
afala NN I
at IN I
a DT I
dose NN I
of IN I
2 CD I
tablets NNS I
4 CD I
times NNS I
a DT I
day NN I
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
severity NN N
of IN N
urinary JJ N
disorders NNS N
estimated VBN N
by IN N
total JJ N
IPSS NNP N
score NN N
relative NN N
to TO N
baseline VB N
values NNS N
and CC N
compared VBN N
to TO N
placebo VB I
therapy NN N
. . N

The DT N
most RBS N
pronounced JJ N
therapeutic JJ N
effects NNS N
of IN N
the DT N
drug NN N
were VBD N
registered VBN N
in IN N
respect NN N
of IN N
irritative JJ N
symptoms NNS N
of IN N
BPH NNP N
. . N

According VBG N
uroflowmetry NN N
peak NN O
flow NN O
rate NN O
after IN N
6 CD N
months NNS N
of IN N
treatment NN N
was VBD N
increased VBN N
by IN N
more JJR N
than IN N
50% CD N
. . N

Significant JJ N
clinical JJ N
benefit NN N
persisted VBD N
not RB N
only RB N
within IN N
the DT N
6-month JJ N
course NN N
of IN N
therapy NN N
but CC N
3 CD N
months NNS N
after IN N
. . N

Long-term JJ N
therapy NN N
had VBD N
no DT N
effect NN N
on IN N
the DT N
concentration NN O
of IN O
total JJ O
free JJ O
and CC O
complex JJ O
PSA NNP O
testosterone NN O
(total NN O
and CC O
free) VB O
dihydrotestosterone NN O
and CC O
prolactin NN O
in IN O
the DT O
blood NN O
. . O

Absence NN O
of IN O
adverse JJ O
effects NNS O
biochemical JJ O
abnormalities NNS O
changes NNS O
in IN O
clinical JJ O
blood NN O
and CC O
urine NN O
confirmed VBD N
the DT N
safety NN N
of IN N
6-month JJ N
therapy NN N
. . N

-DOCSTART- -X- N

The DT N
SNRI NNP I
venlafaxine NN I
improves VBZ N
emotional JJ O
unawareness NN O
in IN N
patients NNS P
with IN P
post-stroke JJ P
depression NN P
. . P

OBJECTIVE NN N
Patients NNS P
with IN P
stroke NNS P
have VBP N
a DT N
high JJ N
prevalence NN N
of IN N
depression NN N
and CC N
unawareness NN N
of IN N
emotions NNS N
or CC N
alexithymia NN O
. . O

Here RB N
we PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
the DT N
serotoninergic NN I
and CC I
noradrenergic JJ I
reuptake NN I
inhibitor NN I
(SNRI) NNP I
venlafaxine NN I
in IN N
comparison NN N
with IN N
the DT N
SSRI NNP I
fluoxetine NN I
on IN N
alexithymia NN O
severity NN N
in IN N
patients NNS P
with IN P
DSM-IV NNP P
post-stroke JJ P
major JJ P
depressive-like JJ P
episode NN P
(PSD) NN P
. . P

METHODS NNP N
Fifty NNP P
inpatients NNS P
with IN P
first-ever JJ P
stroke NN P
and CC P
PSD NNP P
were VBD P
consecutively RB P
enrolled VBN P
in IN N
this DT N
randomized JJ N
open-label NN N
study NN N
. . N

Twenty-five JJ N
were VBD N
treated VBN N
with IN N
the DT N
SNRI NNP I
venlafaxine NN I
SR NNP I
(75-150 JJ I
mg/die) NN I
and CC I
25 CD I
with IN I
the DT I
SSRI NNP I
fluoxetine JJ I
(20-40 JJ N
mg/die) NN N
. . N

All DT N
patients NNS N
were VBD N
assessed VBN N
at IN N
day NN N
0 CD N
and CC N
after IN N
1 CD N
2 CD N
4 CD N
6 CD N
and CC N
8 CD N
weeks NNS N
using VBG N
the DT N
Mini-Mental JJ N
State NNP N
Examination NNP N
the DT N
Hamilton NNP N
Depression NNP N
Rating NNP N
Scale NNP N
and CC N
the DT N
Toronto NNP N
Alexithymia NNP N
Scale NNP N
(TAS-20) NN N
. . N

RESULTS JJ N
Patients NNS N
treated VBN N
with IN N
fluoxetine NN I
and CC N
those DT N
treated VBN N
with IN N
venlafaxine NN N
showed VBD N
similar JJ N
improvement NN N
in IN N
depressive JJ O
symptoms NNS O
. . O

However RB N
patients NNS N
treated VBN N
with IN N
venlafaxine NN I
had VBD N
a DT N
greater JJR N
improvement NN N
on IN N
alexithymia NN O
severity NN O
than IN N
those DT N
treated VBN N
with IN N
fluoxetine NN I
. . I

The DT N
effect NN N
of IN N
venlafaxine NN I
on IN N
unawareness NN O
of IN O
emotions NNS O
was VBD N
evident JJ N
in IN N
patients NNS N
with IN N
alexithymia JJ N
(TAS-20 JJ N
>or= NN N
61) CD N
at IN N
the DT N
baseline NN N
and CC N
in IN N
those DT N
without IN N
alexithymia JJ N
(TAS-20 JJ N
< NN N
61) CD N
. . N

CONCLUSIONS NNP N
Antidepressants NNP I
acting VBG N
on IN N
both CC N
the DT N
serotoninergic NN N
and CC N
noradrenergic JJ N
systems NNS N
might MD N
represent VB N
a DT N
valid JJ N
resource NN N
not RB N
only RB N
for IN N
the DT N
treatment NN N
of IN N
depression NN N
but CC N
also RB N
for IN N
improving VBG N
emotional JJ O
unawareness NN O
in IN N
stroke NN P
patients NNS P
. . P

-DOCSTART- -X- N

Ventilatory JJ N
function NN N
during IN N
urography: JJ I
a DT N
comparison NN N
of IN N
iopamidol NN I
and CC I
sodium NN I
iothalamate NN I
. . I

The DT I
effects NNS N
on IN N
respiratory JJ N
function NN N
during IN N
intravenous JJ I
urography NN I
of IN N
the DT N
ionic JJ I
contrast NN I
medium NN I
sodium NN I
iothalamate NN I
and CC I
the DT I
non-ionic JJ I
contrast NN I
medium NN I
iopamidol NN I
were VBD N
compared VBN N
. . N

Forced NNP O
expiratory NN O
volume NN O
in IN O
1 CD O
s JJ O
(FEV1) NN O
and CC N
forced VBD O
vital JJ O
capacity NN O
(FVC) NN O
were VBD N
recorded VBN N
in IN N
37 CD P
non-atopic JJ P
patients NNS P
referred VBD P
for IN P
intravenous JJ P
urography NN P
. . P

Nineteen JJ P
patients NNS P
received VBD N
iopamidol JJ I
and CC I
18 CD P
patients NNS P
received VBD I
sodium JJ I
iothalamate NN I
. . I

Both DT N
the DT N
sodium NN I
iothalamate NN I
and CC N
the DT N
iopamidol NN I
groups NNS N
showed VBD N
a DT N
significant JJ N
fall NN N
in IN N
FEV1 NNP O
and CC O
FVC NNP O
(P NNP N
less JJR N
than IN N
0.001) CD N
. . N

The DT N
reductions NNS N
in IN N
FEV1 NNP O
and CC O
FVC NNP O
were VBD N
comparable JJ N
and CC N
were VBD N
not RB N
symptomatic JJ N
. . N

The DT N
differences NNS N
in IN N
the DT N
percentage NN N
changes NNS N
of IN N
the DT N
FEV1 NNP O
and CC O
FVC NNP O
in IN N
the DT N
iopamidol NN I
and CC I
the DT I
sodium NN I
iothalamate NN I
groups NNS I
were VBD N
not RB N
statistically RB N
significant JJ N
(P NNP N
greater JJR N
than IN N
0.5 CD N
and CC N
P NNP N
greater JJR N
than IN N
0.1 CD N
respectively) NN N
. . N

No DT N
significant JJ N
change NN N
in IN N
the DT N
ratio NN O
of IN O
the DT O
FEV1 NNP O
and CC O
the DT O
FVC NNP O
was VBD N
demonstrated VBN N
in IN N
either CC N
the DT N
iopamidol NN I
or CC I
the DT I
sodium NN I
iothalamate NN I
groups NNS I
. . I

Both DT N
the DT N
ionic NN N
and CC N
the DT N
non-ionic JJ N
contrast NN N
media NNS N
produced VBD N
a DT N
measurable JJ N
but CC N
asymptomatic JJ N
and CC N
biologically RB N
insignificant JJ N
fall NN N
in IN N
static JJ O
ventilatory NN O
function NN O
. . O

Bronchospasm NNP O
does VBZ N
not RB N
appear VB N
to TO N
be VB N
an DT N
important JJ N
contrast-induced JJ N
effect NN N
in IN N
non-atopic JJ P
individuals NNS P
. . P

Iopamidol NNP I
offers VBZ N
no DT N
advantage NN N
over IN N
sodium JJ I
iothalamate NN I
with IN N
respect NN N
to TO N
ventilatory JJ N
effects NNS N
in IN N
non-atopic JJ P
patients NNS P
undergoing VBG P
intravenous JJ P
urography NN P
. . P

-DOCSTART- -X- N

Erythrocyte NNP O
deformability NN O
endothelin NN O
levels NNS O
and CC O
renal JJ O
function NN O
in IN N
cyclosporin-treated JJ P
renal JJ P
transplant NN P
recipients: NN P
effects NNS N
of IN N
intervention NN N
with IN N
fish JJ I
oil NN I
and CC I
corn NN I
oil NN I
. . P

Twenty NNP P
nine CD P
stable JJ P
renal JJ P
transplant NN P
recipients NNS P
10 CD P
receiving VBG P
cyclosporin NN P
10 CD P
cyclosporin-prednisolone NN P
and CC P
nine CD P
azathioprine-prednisolone NN I
were VBD N
supplemented VBN N
in IN N
a DT N
double JJ N
blind JJ N
randomization NN N
cross-over NN N
study NN N
with IN N
fish JJ I
oil NN I
and CC I
corn NN I
oil NN I
for IN N
a DT N
period NN N
of IN N
4 CD N
months NNS N
each DT N
. . N

Erythrocyte NNP O
deformability NN O
was VBD O
reduced VBN O
in IN N
the DT N
cyclosporin-treated JJ P
patients NNS P
and CC N
returned VBN N
to TO N
normal JJ N
values NNS N
after IN N
supplementation NN I
of IN I
either DT I
oil NN I
. . I

The DT N
oil NN I
supplementation NN N
resulted VBD N
in IN N
an DT N
increased VBN O
polyunsaturated JJ O
fatty JJ O
acid NN O
content NN O
in IN N
the DT N
plasma NN N
phospholipids NNS N
. . N

An DT N
increased VBN N
erythrocyte NN N
membrane NN N
polyunsaturated VBD N
fatty JJ N
acid JJ N
content NN N
might MD N
correct VB N
the DT N
lower JJR N
erythrocyte NN N
deformability NN N
in IN N
cyclosporin NN I
treated VBD N
patients NNS N
. . N

Therefore IN N
it PRP N
is VBZ N
probable JJ N
that IN N
these DT N
changes NNS N
are VBP N
membrane-related JJ N
. . N

The DT I
oil NN I
supplementation NN I
had VBD N
no DT O
effect NN O
on IN N
glomerular JJ O
filtration NN O
rate NN O
effective JJ O
renal JJ O
plasma NN O
flow NN O
filtration NN O
fraction NN O
or CC O
blood NN O
pressure NN O
which WDT O
does VBZ N
not RB N
exclude VB N
effects NNS N
of IN N
the DT N
cyclosporin-induced JJ I
rigidified JJ N
erythrocytes NNS N
in IN N
the DT N
acute JJ N
phase NN N
of IN N
renal JJ N
transplantation NN N
. . N

Decreased VBN N
erythrocyte JJ O
deformability NN O
could MD N
play VB N
a DT N
role NN N
in IN N
the DT N
cyclosporin-induced JJ I
deterioration NN N
of IN N
renal JJ N
haemodynamics NNS N
. . N

This DT N
may MD N
enhance VB O
the DT O
effects NNS O
of IN N
endothelin NN N
as IN N
these DT N
patients NNS N
also RB N
had VBD N
elevated VBN O
endothelin NN O
levels NNS O
. . O

-DOCSTART- -X- N

Dose NNP N
dependent JJ N
response NN N
of IN N
symptoms NNS N
pituitary JJ N
and CC N
bone NN N
to TO N
transdermal VB N
oestrogen NN I
in IN N
postmenopausal JJ P
women NNS P
. . P

The DT N
effect NN N
of IN N
the DT N
plasma NN N
oestradiol JJ I
concentration NN N
on IN N
climacteric NN N
symptoms NNS N
gonadotrophin JJ I
release NN N
and CC N
bone NN N
resorption NN N
was VBD N
studied VBN N
in IN N
three CD P
groups NNS P
of IN P
postmenopausal JJ P
women NNS P
given VBN P
0.025 CD P
mg JJ P
0.05 CD P
mg NN P
or CC P
0.1 CD P
mg NNS P
transdermal JJ P
oestradiol JJ P
daily NN P
. . P

There EX N
was VBD N
a DT N
dose JJ N
related JJ N
reduction NN O
in IN O
symptoms NNS O
plasma JJ O
follicle NN O
stimulating VBG O
hormone NN O
concentration NN O
and CC O
urinary JJ O
calcium NN O
and CC O
hydroxyproline JJ O
excretion NN O
. . O

The DT N
relation NN N
of IN N
the DT N
response NN O
to TO N
plasma VB N
oestradiol JJ I
values NNS N
was VBD N
similar JJ N
for IN N
each DT N
variable NN N
with IN N
an DT N
initial JJ N
large JJ N
reduction NN N
and CC N
little JJ N
change NN N
in IN N
response NN N
to TO N
increases NNS N
in IN N
the DT N
plasma NN N
oestradiol JJ I
concentration NN N
above IN N
150 CD N
pmol/l NN N
(41 NNP N
pg/ml) NN N
. . N

Hormone CD N
replacement NN N
therapy NN N
producing VBG N
an DT N
effect NN N
equivalent NN N
to TO N
higher JJR N
oestradiol JJ I
concentrations NNS N
is VBZ N
likely JJ N
to TO N
increase VB N
the DT N
risk NN N
of IN N
side NN N
effects NNS N
without IN N
conferring VBG N
any DT N
additional JJ N
benefit NN N
. . N

-DOCSTART- -X- N

Similar JJ N
effects NNS N
of IN N
rofecoxib NN I
and CC I
indomethacin NN I
on IN N
the DT N
incidence NN N
of IN N
heterotopic NN N
ossification NN N
after IN P
hip NN P
arthroplasty NN P
. . P

BACKGROUND NNP N
Although IN N
indomethacin NN I
is VBZ N
effective JJ N
in IN N
preventing VBG N
heterotopic NN O
ossification NN O
(HO) NN O
after IN N
primary JJ P
total JJ P
hip NN P
arthroplasty JJ P
side NN P
effects NNS O
are VBP N
frequently RB N
observed VBN N
. . N

In IN N
the DT N
last JJ N
decade NN N
a DT N
new JJ N
class NN N
of IN N
drugs--the JJ N
COX-2 NNP I
selective JJ I
nonsteroidal JJ I
anti-inflammatory JJ I
drugs--has NN I
been VBN N
developed VBN N
. . N

To TO N
investigate VB N
the DT N
effect NN N
of IN N
these DT N
COX-2 NNP I
selective NN I
NSAIDs NNP O
on IN O
heterotopic NN O
ossification NN O
(HO) NN O
after IN N
primary JJ N
total JJ N
hip NN N
arthroplasty JJ N
(THA) NN N
we PRP N
conducted VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
using VBG N
either CC N
indomethacin NN I
or CC I
rofecoxib NN I
for IN I
7 CD I
days NNS I
. . I

METHODS NNP N
186 CD P
patients NNS P
received VBD P
either RB P
indomethacin JJ P
3 CD P
times NNS P
daily RB P
or CC P
rofecoxib VB P
twice RB P
and CC P
1 CD P
placebo NNS P
daily RB P
for IN P
7 CD P
days NNS P
. . P

HO NNP O
was VBD O
graded VBN O
according VBG N
to TO N
the DT N
1-year JJ N
postoperative NN N
radiographs NN N
according VBG N
to TO N
the DT N
Brooker NNP N
classification NN N
. . N

RESULTS NNP N
12 CD P
of IN P
the DT P
186 CD P
patients NNS P
included VBD P
discontinued VBN P
their PRP$ P
medication NN P
before IN P
the DT P
end NN P
of IN P
the DT P
trial NN P
due JJ P
to TO P
side VB P
effects NNS P
. . P

The DT N
remaining VBG P
174 CD P
patients NNS P
were VBD P
included VBN P
in IN P
the DT P
analysis NN P
. . P

In IN N
the DT P
indomethacin NN P
group NN P
(n NNP P
= VBZ P
89) CD P
77 CD P
patients NNS P
(87%) JJ P
showed VBD P
no DT P
HO NNP P
9 CD P
showed VBD P
HO NNP P
of IN P
grade NN P
1 CD P
and CC P
3 CD P
showed VBD P
HO NNP P
of IN P
grade NN P
2 CD P
according VBG P
to TO P
the DT P
Brooker NNP P
classification NN P
. . P

In IN N
the DT P
rofecoxib NN P
group NN P
(n NNP P
= VBZ P
85) CD P
73 CD P
patients NNS P
(86%) JJ P
showed VBD O
no DT O
ossification NN P
9 CD P
showed VBD P
grade NN P
1 CD P
and CC P
3 CD P
showed VBD P
grade JJ P
2 CD P
. . P

INTERPRETATION NNP P
The DT N
prophylactic JJ N
effect NN N
of IN N
rofecoxib NN I
for IN N
7 CD N
days NNS N
in IN N
preventing VBG N
heterotopic NN N
ossification NN N
after IN N
primary JJ N
total JJ N
hip NN N
arthroplasty NN N
is VBZ N
comparable JJ N
to TO N
the DT N
effect NN N
of IN N
indomethacin NN I
given VBN N
for IN N
7 CD N
days NNS N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
the DT N
development NN N
of IN N
HO NNP N
follows VBZ N
a DT N
COX-2 JJ N
pathway NN N
. . N

-DOCSTART- -X- N

A DT N
blinded JJ N
randomized NN N
controlled VBD N
trial NN N
assessing VBG N
conservative JJ I
management NN I
strategies NNS I
for IN N
frozen JJ P
shoulder NN P
. . P

BACKGROUND NNP N
There EX N
is VBZ N
little JJ N
evidence NN N
for IN N
the DT N
optimal JJ N
form NN N
of IN N
nonoperative JJ N
treatment NN N
in IN N
the DT N
management NN N
of IN N
frozen JJ P
shoulder NN P
. . P

This DT N
study NN N
assesses VBZ N
the DT N
efficacy NN N
of IN N
current JJ N
physiotherapy NN N
strategies NNS N
. . N

METHODS NNP N
All NNP P
primary JJ P
care NN P
referrals NNS P
of IN P
frozen JJ P
shoulder NN P
to TO P
our PRP$ P
physiotherapy NN P
department NN P
were VBD P
included VBN P
during IN P
a DT P
12-month JJ P
period NN P
. . P

Of IN P
these DT P
referrals NNS P
17% CD P
met VBD P
the DT P
inclusion NN P
criteria NNS P
for IN P
primary JJ P
idiopathic JJ P
frozen JJ P
shoulder NN P
. . P

The DT N
75 CD P
patients NNS P
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups: NNS N
group NN I
exercise NN I
class NN I
individual JJ I
physiotherapy NN I
and CC I
home NN I
exercises NNS I
alone RB I
. . I

A DT N
single JJ N
independent JJ N
physiotherapist NN N
who WP N
was VBD N
blinded VBN N
to TO N
the DT N
treatment NN I
groups NNS I
made VBD I
all DT N
assessments NNS N
. . N

Range NN N
of IN N
motion NN N
Constant NNP N
score NN N
Oxford NNP N
Shoulder NNP N
Score NNP N
Short NNP N
Form NNP N
36 CD N
and CC N
Hospital NNP N
Anxiety NNP N
and CC N
Disability NNP N
Scale NNP N
(HADS) NNP N
outcome NN N
measures NNS N
were VBD N
performed VBN N
at IN N
baseline NN N
6 CD N
weeks NNS N
6 CD N
months NNS N
and CC N
1 CD N
year NN N
. . N

RESULTS VB N
The DT N
exercise NN I
class NN I
group NN I
improved VBD N
from IN N
a DT N
mean JJ O
Constant NNP O
score NN O
of IN N
39.8 CD N
at IN N
baseline NN N
to TO N
71.4 CD N
at IN N
6 CD N
weeks NNS N
and CC N
88.1 CD N
at IN N
1 CD N
year NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
shoulder NN O
symptoms NNS O
on IN O
Oxford NNP O
and CC O
Constant NNP O
scores VBZ O
(P NNP N
< NNP N
.001) NNP N
. . N

This DT N
improvement NN N
was VBD N
greater JJR N
than IN N
with IN N
individual JJ O
physiotherapy NN O
or CC O
home NN O
exercises NNS O
alone RB O
(P VBP N
< JJ N
.001) NN N
. . N

The DT N
improvement NN N
in IN N
range NN O
of IN O
motion NN O
was VBD N
significantly RB N
greater JJR N
in IN N
both DT I
physiotherapy NN O
groups NNS O
over IN O
home NN O
exercises NNS O
(P VBP N
< JJ N
.001) NN N
. . N

HADS NNP O
scores VBZ O
significantly RB N
improved VBN N
during IN N
the DT N
course NN N
of IN N
treatment NN N
(P NNP N
< NNP N
.001) NNP N
. . N

The DT N
improvement NN O
in IN O
HADS NNP O
anxiety NN O
score NN O
was VBD N
significantly RB N
greater JJR N
in IN N
both DT I
physiotherapy JJ I
intervention NN I
groups NNS I
than IN N
in IN N
home NN I
exercises NNS I
alone RB I
. . I

CONCLUSIONS VB N
A DT I
hospital-based JJ I
exercise NN I
class NN I
can MD N
produce VB N
a DT N
rapid JJ N
recovery NN N
from IN N
a DT N
frozen JJ N
shoulder NN N
with IN N
a DT N
minimum JJ N
number NN N
of IN N
visits NNS N
to TO N
the DT N
hospital NN N
and CC N
is VBZ N
more RBR N
effective JJ N
than IN N
individual JJ I
physiotherapy NN I
or CC N
a DT N
home NN I
exercise NN I
program NN I
. . I

-DOCSTART- -X- N

Multi-institutional JJ N
randomized JJ N
phase NN N
II NNP N
trial NN N
of IN N
the DT N
epothilone NN I
B NNP I
analog NN I
ixabepilone NN I
(BMS-247550) JJ I
with IN I
or CC I
without IN I
estramustine JJ I
phosphate NN I
in IN I
patients NNS P
with IN P
progressive JJ P
castrate NN P
metastatic JJ P
prostate NN P
cancer NN P
. . P

PURPOSE NN N
To TO N
evaluate VB I
the DT I
antitumor NN I
activity NN I
and CC I
safety NN I
of IN I
the DT I
epothilone NN I
B NNP I
analog NN I
ixabepilone NN I
with IN I
or CC I
without IN I
estramustine JJ I
phosphate NN I
(EMP) NN I
in IN I
chemotherapy-naive JJ P
patients NNS P
with IN P
progressive JJ P
castrate NN P
metastatic JJ P
prostate NN P
cancer NN P
. . P

PATIENTS NNS P
AND CC N
METHODS NNP N
Patients NNPS I
were VBD I
randomly RB I
assigned VBN I
to TO I
receive VB I
ixabepilone NN I
(35 NNP I
mg/m(2)) NN I
by IN I
intravenous JJ I
infusion NN I
every DT I
3 CD I
weeks NNS I
with IN I
or CC I
without IN I
EMP NNP I
280 CD I
mg NN I
orally RB I
three CD I
times NNS I
daily RB I
on IN I
days NNS I
1 CD I
to TO I
5 CD I
. . I

RESULTS NN N
Between NNP P
December NNP P
2001 CD P
and CC P
October NNP P
2003 CD P
92 CD P
patients NNS P
were VBD P
enrolled VBN P
and CC P
randomly RB P
assigned VBN P
to TO P
treatment NN P
with IN P
ixabepilone NN P
alone RB P
(45 JJ P
patients) NN P
or CC P
in IN P
combination NN P
with IN P
EMP NNP P
(47 NNP P
patients) NN P
. . P

Grades NNS O
3 CD O
and CC O
4 CD O
toxicities NNS O
experienced VBN N
by IN N
more JJR N
than IN N
5% CD N
of IN N
patients NNS N
included VBN N
neutropenia JJ O
(22%) NNP N
fatigue NN O
(9%) NN N
and CC N
neuropathy JJ O
(13%) NN N
on IN N
the DT N
ixabepilone NN I
arm NN N
and CC N
neutropenia JJ O
(29%) NNP N
febrile NN O
neutropenia NN O
(9%) NNP N
fatigue NN O
(9%) NNP N
neuropathy JJ O
(7%) NN N
and CC N
thrombosis NN O
(6%) NN N
on IN N
the DT N
ixabepilone NN I
+ NNP I
EMP NNP I
arm NN N
. . N

Post-treatment JJ I
declines NNS N
in IN N
prostate-specific JJ O
antigen NN O
of IN N
> NN N
or CC N
= $ N
50% CD N
were VBD N
achieved VBN N
in IN N
21 CD N
of IN N
44 CD N
patients NNS N
(48%; JJ N
95% CD N
CI NNP N
33% CD N
to TO N
64%) CD N
on IN N
the DT N
ixabepilone NN I
arm NN N
and CC N
31 CD N
of IN N
45 CD N
patients NNS N
(69%; JJ N
95% CD N
CI NNP N
55% CD N
to TO N
82%) CD N
on IN N
the DT N
ixabepilone NN I
+ NNP I
EMP NNP I
arm NN N
. . N

In IN N
patients NNS N
with IN N
measurable JJ N
disease NN N
partial JJ O
responses NNS O
were VBD N
observed VBN N
in IN N
eight CD N
of IN N
25 CD N
patients NNS N
(32%; JJ N
95% CD N
CI NNP N
14% CD N
to TO N
50%) CD N
on IN N
the DT N
ixabepilone NN I
arm NN N
and CC N
11 CD N
of IN N
23 CD N
(48%; JJ N
95% CD N
CI NNP N
27% CD N
to TO N
68%) CD N
on IN N
the DT N
ixabepilone NN I
+ NNP I
EMP NNP I
arm NN N
. . N

Time NN N
to TO N
prostate-specific JJ O
antigen NN O
progression NN O
was VBD N
4.4 CD N
months NNS N
(95% JJ N
CI NNP N
3.1 CD N
to TO N
6.9 CD N
months) NN N
on IN N
the DT N
ixabepilone-alone JJ I
arm NN N
and CC N
5.2 CD N
months NNS N
(95% JJ N
CI NNP N
4.5 CD N
to TO N
6.8 CD N
months) NN N
on IN N
the DT N
combination NN I
arm NN N
. . N

CONCLUSION NNP N
Ixabepilone NNP I
with IN I
or CC I
without IN I
estramustine JJ I
phosphate NN I
is VBZ I
well RB N
tolerated VBN N
and CC N
has VBZ N
antitumor VBN O
activity NN O
in IN N
patients NNS P
with IN P
castrate JJ P
metastatic JJ P
prostate NN P
cancer NN P
. . P

-DOCSTART- -X- N

Intramedullary NNP I
repair NN I
device NN N
against IN N
volar JJ N
plating NN N
in IN N
the DT N
reconstruction NN N
of IN N
extra-articular JJ P
and CC P
simple JJ P
articular JJ P
distal JJ P
radius NN P
fractures; VBD P
a DT N
randomized VBN N
pilot NN N
study NN N
. . N

PURPOSE NN N
This DT N
prospective JJ N
randomized NN N
pilot NN N
study NN N
reports VBZ N
our PRP$ N
institutional JJ N
experience NN N
and CC N
early JJ N
results NNS N
using VBG N
Sonoma NNP I
Wrx NNP I
(Sonoma NNP I
Orthopedic NNP I
Products NNPS I
Santa NNP I
Rosa NNP N
CA) NNP N
in IN N
the DT N
treatment NN N
of IN N
extra-articular JJ N
and CC N
simple JJ P
intra-articular JJ P
distal JJ P
radius NN P
fractures NNS P
. . P

MATERIAL NNP P
AND NNP N
METHODS NNP N
A NNP P
total NN P
of IN P
64 CD P
patients NNS P
were VBD P
enrolled VBN P
in IN P
the DT P
study NN P
. . P

They PRP N
were VBD N
considered VBN N
eligible JJ N
if IN N
they PRP N
had; VBP N
unstable JJ P
extra-articular JJ P
distal JJ P
radius NN P
fractures NNS P
and CC P
simple JJ P
intra-articular JJ P
distal JJ P
radius NN P
fractures NNS P
suitable JJ P
for IN P
closed JJ P
reduction NN P
(AO NNP P
types; NN P
A2.2 NNP P
A2.3 NNP P
A3.1 NNP P
C2.1 NNP P
C2.2) NNP P
. . P

Patients NNS P
in IN P
group NN P
I PRP N
received VBD N
intramedullary JJ I
fixation NN I
using VBG I
the DT I
Sonoma NNP I
Wrx NNP I
device NN I
and CC N
patients NNS N
in IN N
group NN N
II NNP N
received VBD N
standard JJ I
volar JJ I
locking VBG I
plate NN I
fixation NN I
. . I

Radiographic JJ O
criteria NNS O
of IN O
acceptable JJ O
healing NN O
were VBD N
used VBN N
for IN N
evaluation NN N
. . N

RESULTS NNP N
Two CD N
groups NNS N
were VBD N
similar JJ N
in IN N
terms NNS N
of IN N
baseline NN N
characteristics NNS N
. . N

Mean JJ O
time NN O
of IN O
operation NN O
was VBD N
significantly RB N
shorter JJR N
in IN N
Group NNP P
1 CD P
vs NN P
. . P

in IN P
group NN P
2 CD P
(36.817.11 NN N
vs NN N
. . N

48.975.9 CD N
minutes NNS N
p=0.001) RB O
. . O

Time NN O
to TO O
healing NN O
of IN O
the DT N
fracture NN N
was VBD N
not RB N
different JJ N
between IN N
two CD N
groups NNS N
(5.451.09 JJ N
vs NN N
. . N

5.701.04 CD N
weeks NNS N
for IN N
Group NNP N
1 CD N
vs NN N
. . N

2 CD N
respectively RB O
p=0.36) NN O
. . N

Overall JJ P
complications NNS P
occurred VBD P
in IN P
9 CD P
patients NNS P
in IN P
group NN P
1 CD P
and CC P
in IN P
15 CD P
patients NNS P
in IN N
group NN N
2 CD N
(p=0.17) NN N
. . P

Follow-up NN P
was VBD P
completed VBN P
in IN P
all DT P
patients NNS P
with IN P
a DT P
median JJ P
time NN P
of IN P
12 CD P
months NNS P
and CC P
13 CD P
months NNS P
in IN N
group NN N
1 CD N
and CC N
2 CD N
respectively RB O
. . O

On IN O
radiographic JJ O
evaluation NN O
radial JJ O
inclination NN O
radial JJ N
height NN N
and CC N
volar JJ N
tilt NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
group NN N
1 CD N
and CC N
2 CD N
respectively RB N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN O
two CD O
groups NNS O
in IN O
regard NN O
to TO N
wrist VB N
rotational JJ N
degrees NNS N
measured VBN N
in IN N
last JJ I
follow-up JJ I
visit NN I
. . N

CONCLUSION NNP N
Sonoma NNP N
Wrx NNP N
Device NNP N
is VBZ N
reliable JJ N
and CC N
effective JJ N
in IN N
terms NNS N
of IN N
achieving VBG N
satisfactory JJ P
outcomes NNS P
in IN P
treatment NN P
of IN N
distal JJ N
radius NN N
fractures NNS N
. . N

It PRP N
may MD N
be VB N
reasonable JJ N
to TO N
use VB N
this DT N
device NN N
to TO N
prevent VB N
complications NNS N
that WDT N
are VBP N
related VBN N
to TO N
extensive JJ N
soft JJ N
tissue NN N
dissection NN N
. . N

-DOCSTART- -X- N

Combination NNP I
chemotherapy NN I
and CC I
ALVAC-CEA/B7.1 NNP I
vaccine NN I
in IN N
patients NNS P
with IN P
metastatic JJ P
colorectal JJ P
cancer NN P
. . P

PURPOSE VB N
The DT I
combination NN I
of IN I
vaccines NNS I
and CC I
chemotherapy NN I
holds VBZ I
promise NN I
for IN I
cancer NN I
therapy NN I
but CC I
the DT I
effect NN I
of IN I
cytotoxic NN I
chemotherapy NN I
on IN I
vaccine-induced JJ I
antitumor NN I
immunity NN I
is VBZ I
unknown JJ I
. . I

This DT I
study NN I
was VBD I
conducted VBN I
to TO I
assess VB I
the DT I
effects NNS I
of IN I
systemic JJ I
chemotherapy NN I
on IN I
ALVAC-CEA/B7.1-induced NNP I
T-cell NNP I
immunity NN I
in IN I
patients NNS P
with IN P
metastatic JJ P
colorectal JJ P
cancer NN P
. . P

EXPERIMENTAL NNP I
DESIGN NNP I
Patients NNPS P
with IN P
metastatic JJ P
colorectal JJ P
cancer NN P
were VBD I
treated VBN I
with IN I
fluorouracil NN I
leucovorin NN I
and CC I
irinotecan JJ I
and CC I
were VBD I
also RB I
given VBN I
ALVAC-CEA/B7.1 NNP I
vaccine NN I
with IN I
or CC I
without IN I
tetanus JJ I
toxoid NN I
adjuvant NN I
. . I

Eligible JJ I
patients NNS I
were VBD I
randomized VBN I
to TO I
ALVAC NNP I
followed VBN I
by IN I
chemotherapy NN I
and CC I
booster NN I
vaccination NN I
(group VBD I
1) CD I
ALVAC NNP I
and CC I
tetanus NN I
toxoid NN I
followed VBN I
by IN I
chemotherapy NN I
(group NN I
2) CD I
or CC I
chemotherapy VB I
alone RB I
followed VBN I
by IN I
ALVAC NNP I
in IN I
patients NNS P
without IN P
disease JJ P
progression NN P
(group VBZ I
3) CD I
. . I

Humoral NNP N
immune JJ N
responses NNS N
were VBD N
measured VBN N
by IN N
standard JJ I
ELISA NNP I
assay NN I
and CC I
carcinoembryonic JJ N
antigen NN N
(CEA)-specific JJ N
T-cell NNP N
responses NNS N
were VBD N
measured VBN N
by IN N
IFN-gamma NNP I
enzyme-linked JJ I
immunospot NN I
assay NN I
. . I

RESULTS NNP N
One CD P
hundred VBD P
eighteen JJ P
patients NNS P
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
ALVAC NNP I
before IN I
and CC I
concomitantly RB I
with IN I
chemotherapy NN I
(n NNP N
= VBZ N
39) CD N
ALVAC NNP I
with IN I
tetanus NN I
adjuvant NN I
before IN I
and CC I
concomitantly RB I
with IN I
chemotherapy NN I
(n NNP N
= VBZ N
40) CD N
or CC N
chemotherapy NN I
followed VBN I
by IN I
ALVAC NNP I
(n NNP N
= VBD N
39) CD N
. . N

Serious JJ N
adverse JJ N
events NNS N
were VBD N
largely RB N
gastrointestinal JJ O
(n NNP N
= NNP N
30) CD N
and CC N
hematologic JJ O
(n NNP N
= NNP N
24) CD N
. . N

Overall JJ N
42 CD N
patients NNS N
(40.4%) JJ N
showed VBD N
objective JJ N
clinical JJ N
responses NNS N
. . N

All DT N
patients NNS N
developed VBD N
antibody JJ O
responses NNS O
against IN O
ALVAC NNP O
but CC O
increased VBD N
anti-CEA JJ O
antibody NN O
titers NNS O
were VBD N
detected VBN N
in IN N
only RB N
three CD N
patients NNS N
. . N

Increases NNS I
in IN I
CEA-specific NNP O
T NNP O
cells NNS O
were VBD I
detected VBN I
in IN I
50% CD I
37% CD I
and CC I
30% CD I
of IN I
patients NNS I
in IN I
groups NNS I
1 CD I
2 CD I
and CC I
3 CD I
respectively RB I
. . I

There EX N
were VBD N
no DT N
differences NNS N
in IN N
clinical JJ N
or CC N
immune JJ N
responses NNS N
between IN N
the DT N
treatment NN N
groups NNS N
. . N

CONCLUSION NNP N
The DT N
combination NN N
of IN N
ALVAC-CEA/B7.1 NNP I
vaccine NN I
and CC I
systemic JJ I
chemotherapy NN I
has VBZ N
an DT N
acceptable JJ N
safety NN N
profile NN N
in IN N
patients NNS P
with IN P
metastatic JJ P
colorectal JJ P
cancer NN P
. . P

Systemic NNP I
chemotherapy NN I
did VBD N
not RB N
affect VB N
the DT N
generation NN N
of IN N
CEA-specific NNP O
T-cell NNP O
responses NNS O
following VBG N
vaccination NN I
. . I

-DOCSTART- -X- N

Effectiveness NN N
of IN N
erythromycin NN I
in IN N
the DT N
treatment NN N
of IN N
acute JJ P
bronchitis NN P
. . P

BACKGROUND NNP N
Clinical NNP N
trials NNS N
have VBP N
not RB N
shown VBN N
a DT N
consistent JJ N
benefit NN N
of IN N
treating VBG N
bronchitis NN N
with IN N
antibiotics NNS N
. . N

Many JJ N
physicians NNS N
however RB N
treat VBP N
acute JJ N
bronchitis NN N
with IN N
antibiotics NNS N
because IN N
of IN N
the DT N
possibility NN N
of IN N
Mycoplasma NNP N
pneumoniae NN N
or CC N
other JJ N
pathogens NNS N
. . N

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
erythromycin JJ I
treatment NN N
in IN N
patients NNS P
with IN P
acute JJ P
bronchitis NN P
and CC N
to TO N
determine VB N
whether IN N
a DT N
newly RB N
developed VBN N
rapid JJ N
M NNP N
pneumoniae NN N
antibody NN N
test NN N
is VBZ N
useful JJ N
in IN N
predicting VBG N
which WDT N
patients NNS N
will MD N
respond VB N
to TO N
therapy VB N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ I
clinical JJ N
trial NN N
at IN N
three CD P
primary JJ P
care NN P
centers NNS P
in IN P
North NNP P
Carolina NNP P
. . P

A DT N
convenience NN N
sample NN N
of IN N
140 CD P
patients NNS P
presenting VBG P
with IN P
acute JJ P
bronchitis NN P
were VBD P
tested VBN P
for IN P
M NNP P
pneumoniae VBD P
91 CD P
of IN P
whom WP P
were VBD P
treated VBN P
with IN P
either DT I
erythromycin JJ I
250 CD I
mg RB I
four CD I
times NNS I
daily RB I
for IN I
10 CD I
days NNS I
or CC I
an DT I
identical-appearing JJ I
placebo NN I
. . I

RESULTS JJ I
Patients NNS N
treated VBN N
with IN N
erythromycin NN I
missed VBD N
an DT N
average NN N
of IN N
only JJ N
0.81 CD N
+/- JJ N
1.1 CD N
days NNS O
of IN O
work NN O
compared VBN N
with IN N
2.16 CD N
+/- JJ N
3.2 CD N
days NNS N
for IN N
placebo-treated JJ I
patients NNS N
(P JJ N
< NNP N
.02) NNP N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
cough NN O
use NN O
of IN O
cough NN O
medicine NN O
general JJ O
feeling NN O
of IN O
well-being NN O
or CC O
chest JJS O
congestion NN O
between IN N
the DT N
erythromycin NN I
and CC N
placebo NN I
groups NNS N
. . N

Twenty-five JJ N
percent NN N
of IN N
the DT N
patients NNS N
tested VBD N
positive JJ N
for IN N
M NNP N
pneumoniae NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
response NN N
to TO N
erythromycin VB I
based VBN N
on IN N
whether IN N
the DT N
patient NN N
had VBD N
a DT N
positive JJ N
test NN N
for IN N
M NNP N
pneumoniae NN N
. . N

CONCLUSIONS NNP N
Erythromycin NNP I
is VBZ N
effective JJ N
in IN N
significantly RB N
reducing VBG N
lost VBN N
time NN N
from IN N
work NN N
but CC N
it PRP N
is VBZ N
not RB N
effective JJ N
in IN N
reducing VBG N
cough NN N
or CC N
other JJ N
symptoms NNS N
in IN N
patients NNS P
with IN P
acute JJ P
bronchitis NN P
regardless NN P
of IN N
the DT N
outcome NN N
of IN N
the DT N
M NNP N
pneumoniae NN N
antibody NN N
test NN N
. . N

-DOCSTART- -X- N

Compliance NN N
with IN N
continuous JJ O
passive JJ O
movement NN O
is VBZ N
low JJ N
after IN N
surgical JJ N
treatment NN N
of IN N
idiopathic JJ P
club JJ P
foot NN P
in IN P
infants: NN P
a DT N
prospective JJ N
double-blinded JJ N
clinical JJ N
study NN N
. . N

Treatment NN N
by IN N
continuous JJ I
passive JJ I
movement NN I
at IN I
home NN I
is VBZ N
an DT N
alternative JJ N
to TO N
immobilisation NN I
in IN N
a DT N
cast NN N
after IN P
surgery NN P
for IN P
club JJ P
foot NN P
. . P

Compliance NN N
with IN N
the DT N
recommended JJ N
treatment NN N
of IN N
at IN N
least JJS N
four CD N
hours NNS N
daily RB N
is VBZ N
unknown JJ N
. . N

The DT N
duration NN N
of IN N
treatment NN N
was VBD N
measured VBN N
in IN N
24 CD P
of IN P
27 CD P
consecutive JJ P
children NNS P
with IN P
a DT P
mean JJ P
age NN P
of IN P
24 CD P
months NNS P
(5 VBN P
to TO P
75) CD P
following VBG P
posteromedial JJ P
release NN P
for IN P
idiopathic JJ P
club JJ P
foot NN P
. . P

Only RB N
21% CD N
(5) NN N
of IN N
the DT N
children NNS N
used VBD N
the DT N
continuous JJ I
passive JJ I
movement NN I
machine NN I
as IN N
recommended JJ N
. . N

The DT N
mean JJ N
duration NN N
of IN N
treatment NN N
at IN N
home NN N
each DT N
day NN N
was VBD N
126 CD N
minutes NNS N
(11 VBP N
to TO N
496) CD N
. . N

The DT O
mean JJ O
range NN O
of IN O
movement NN O
for IN O
plantar NN O
flexion NN O
improved VBD O
from IN N
15.2 CD N
degrees NNS N
(10.0 VBP N
degrees NNS N
to TO N
20.6 CD N
degrees NNS N
) ) N
to TO N
18.7 CD N
degrees NNS N
(10.0 VBP N
degrees NNS N
to TO N
33.0 CD N
degrees NNS N
) ) N
and CC N
for IN N
dorsiflexion NN O
from IN N
12.3 CD N
degrees NNS N
(7.4 VBP N
degrees NNS N
to TO N
19.4 CD N
degrees NNS N
) ) N
to TO N
18.9 CD N
degrees NNS N
(10.0 VBP N
degrees NNS N
to TO N
24.1 CD N
degrees NNS N
) ) N
(both VBP N
p JJ N
= $ N
0.0001) CD N
when WRB N
the DT N
first JJ N
third NN N
of IN N
therapy NN I
was VBD N
compared VBN N
with IN N
the DT N
last JJ N
third JJ N
. . N

A DT N
low JJ N
level NN N
of IN N
patient JJ N
compliance NN N
must MD N
be VB N
considered VBN N
when WRB N
the DT N
outcome NN N
after IN N
treatment NN N
at IN N
home NN N
is VBZ N
interpreted VBN N
. . N

-DOCSTART- -X- N

Multifaceted VBN N
support NN N
to TO N
improve VB N
clinical JJ N
decision NN N
making NN N
in IN N
diabetes NNS N
care: VBP N
a DT N
randomized NN N
controlled VBN N
trial NN N
in IN N
general JJ N
practice NN N
. . N

AIMS NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
multifaceted VBN N
intervention NN N
to TO N
improve VB N
the DT N
clinical JJ N
decision NN N
making NN N
of IN N
general JJ P
practitioners NNS P
(GPs) VBP P
for IN P
patients NNS P
with IN P
diabetes NNS P
. . P

To TO N
identify VB N
practice NN N
characteristics NNS N
which WDT N
predict VBP N
success NN N
. . N

METHODS NNP N
Cluster NNP P
randomized VBD P
controlled VBN P
trial NN P
with IN P
124 CD P
practices NNS P
and CC P
185 CD P
GPs NNP P
in IN P
The DT P
Netherlands NNP P
. . P

The DT N
intervention NN N
group NN N
received VBD N
feedback JJ N
reports NNS N
and CC N
support NN N
from IN N
a DT N
facilitator; NN N
the DT N
control NN N
group NN N
received VBD N
no DT N
special JJ N
attention NN N
. . N

Outcome NN N
measures NNS N
were VBD N
the DT N
compliance NN O
rates NNS O
with IN O
evidence-based JJ O
recommendations NNS O
pertaining VBG O
to TO O
discussion NN O
of IN O
body NN O
weight JJ O
control NN O
discussion NN O
of IN O
problems NNS O
with IN O
medication NN O
blood NN O
pressure NN O
measurement JJ O
foot NN O
examination NN O
eye NN O
examination NN O
initiating VBG O
anti-diabetic JJ O
medication NN O
or CC O
increasing VBG O
the DT O
dosage NN O
in IN O
cases NNS O
of IN O
uncontrolled JJ O
blood NN O
glucose NN O
and CC O
scheduling VBG O
a DT O
follow-up JJ O
appointment NN O
. . O

RESULTS VB N
The DT N
GPs NNP N
reported VBD N
on IN N
their PRP$ N
clinical JJ N
decision NN N
making NN N
in IN N
1410 CD P
consultations NNS P
with IN P
Type NNP P
2 CD P
diabetic JJ P
patients NNS P
at IN P
baseline NN P
and CC P
1449 CD P
consultations NNS P
after IN N
the DT N
intervention NN N
period NN N
. . N

The DT N
intervention NN N
resulted VBD N
in IN N
statistically RB N
significant JJ N
improvement NN N
for IN N
two CD N
of IN N
the DT N
seven CD N
outcome NN N
measures: JJ N
foot NN O
examination NN O
(odds NNP N
ratio VBD N
1.68; CD N
95% CD N
confidence NN N
interval JJ N
1.19-2.39) JJ N
and CC N
eye NN N
examination NN O
(1.52; POS N
1.07-2.16) JJ N
. . N

Discussion NN O
of IN O
problems NNS O
with IN O
medication NN O
showed VBD N
a DT N
near JJ N
significant JJ N
trend NN N
towards NNS N
increased VBD N
benefit NN N
for IN N
the DT N
intervention NN N
group NN N
(1.52; VBD N
0.99-2.32) CD N
. . N

Practice NNP N
characteristics NNS N
were VBD N
not RB N
found VBN N
to TO N
be VB N
related VBN N
to TO N
the DT N
success NN N
of IN N
the DT N
intervention NN N
. . N

CONCLUSIONS NNP N
Feedback NNP N
reports NNS N
with IN N
support NN N
from IN N
facilitators NNS N
appear VBP N
to TO N
increase VB N
rates NNS N
of IN N
foot NN N
examination NN N
and CC N
eye NN N
examination NN N
in IN N
general JJ N
practice NN N
. . N

Alternative JJ N
interventions NNS N
should MD N
be VB N
explored VBN N
to TO N
improve VB N
the DT N
pursuit NN N
of IN N
metabolic JJ N
control NN N
by IN N
GPs NNP N
. . N

-DOCSTART- -X- N

MR NNP I
imaging NN I
of IN N
pituitary JJ P
region NN P
lesions NNS P
with IN N
gadodiamide JJ I
injection NN I
. . P

Twelve CD P
patients NNS P
with IN P
known VBN P
or CC P
suspected VBN P
pituitary JJ P
lesions NNS P
underwent JJ N
MR NNP I
imaging VBG I
with IN I
gadodiamide JJ I
injection NN I
at IN N
a DT N
dose NN N
of IN N
0.1 CD N
(n NNS N
= JJ N
5) CD N
or CC N
0.3 CD N
(n JJ N
= $ N
7) CD N
mM/kg NN N
. . N

Six CD P
of IN P
the DT P
patients NNS P
were VBD N
also RB N
studied VBN N
with IN N
0.1 CD I
mM/kg NNS I
gadopentetate JJ I
dimeglumine NN I
. . I

Consistent JJ N
with IN N
previous JJ N
reports NNS N
gadodiamide NN I
injection NN N
was VBD N
found VBN N
to TO N
be VB N
a DT N
safe JJ O
and CC O
effective JJ O
contrast NN N
medium NN N
for IN N
MR NNP N
imaging NN N
of IN N
the DT N
pituitary JJ N
region NN N
. . N

No DT N
additional JJ N
diagnostic JJ N
information NN N
was VBD N
obtained VBN N
using VBG N
0.3 CD N
mM/kg JJ N
gadodiamide NN I
injection NN N
compared VBN N
to TO N
0.1 CD N
mM/kg NNS N
gadopentate JJ N
dimeglumine NN N
in IN N
the DT N
same JJ N
patients NNS N
. . N

The DT N
high JJ N
dose NN N
(0.3 NNP N
mM/kg) NN N
gadodiamide NN I
injection NN I
in IN N
7 CD N
patients NNS N
did VBD N
not RB N
shorten VB O
the DT O
T2 NNP O
value NN O
sufficiently RB O
to TO N
overwhelm VB N
the DT N
T1 NNP O
shortening NN O
and CC O
leave VBP O
pathologic JJ O
lesions NNS O
hypointense VBP N
compared VBN N
to TO N
precontrast VB N
studies NNS N
. . N

With IN N
the DT N
comparable JJ N
relaxivities NNS N
of IN N
gadodiamide JJ I
injection NN I
and CC N
gadopentetate NN I
dimeglumine NN I
similarities NNS I
in IN N
results NNS N
have VBP N
to TO N
be VB N
expected VBN N
when WRB N
using VBG N
these DT N
media NNS N
for IN N
MR NNP N
image NN N
enhancement NN N
. . N

-DOCSTART- -X- N

Phenobarbital JJ I
compared VBN N
with IN N
phenytoin NN I
for IN N
the DT N
treatment NN N
of IN N
neonatal JJ P
seizures NNS P
. . P

BACKGROUND NNP N
Seizures NNP N
occur VBP N
in IN N
1 CD N
to TO N
2 CD N
percent NN N
of IN N
neonates NNS P
admitted VBN P
to TO P
an DT P
intensive JJ P
care NN P
unit NN P
. . P

The DT N
treatment NN N
is VBZ N
usually RB N
with IN N
either DT N
phenobarbital NN I
or CC N
phenytoin NN I
but CC I
the DT N
efficacy NN O
of IN N
the DT N
two CD N
drugs NNS N
has VBZ N
not RB N
been VBN N
compared VBN N
directly RB N
. . N

METHODS NN N
From IN N
1990 CD N
to TO N
1995 CD N
we PRP N
studied VBD N
59 CD P
neonates NNS P
with IN P
seizures NNS P
that WDT P
were VBD P
confirmed VBN P
by IN P
electroencephalography NN P
. . P

The DT N
neonates NNS P
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
phenobarbital NN I
or CC I
phenytoin VB I
intravenously RB I
at IN I
doses NNS N
sufficient JJ N
to TO N
achieve VB N
free JJ N
plasma NN N
concentrations NNS N
of IN N
25 CD N
microg NNS N
per IN N
milliliter NN N
for IN N
phenobarbital NN I
and CC I
3 CD I
microg NNS I
per IN I
milliliter NN I
for IN I
phenytoin NN I
. . I

Neonates NNS N
whose WP$ N
seizures NNS N
were VBD N
not RB N
controlled VBN N
by IN N
the DT N
assigned JJ N
drug NN N
were VBD N
then RB N
treated VBN N
with IN N
both DT N
drugs NNS N
. . N

Seizure NN O
control NN O
was VBD N
assessed VBN N
by IN N
electroencephalographic JJ N
criteria NNS N
. . N

RESULTS JJ N
Seizures NNS O
were VBD N
controlled VBN N
in IN N
13 CD N
of IN N
the DT N
30 CD P
neonates NNS P
assigned VBN P
to TO P
receive VB P
phenobarbital JJ N
(43 NNP N
percent) NN N
and CC N
13 CD N
of IN N
the DT N
29 CD P
neonates NNS P
assigned VBN P
to TO P
receive VB P
phenytoin NN P
(45 NNP N
percent; NN N
P=1.00) NNP N
. . N

When WRB N
combined VBN N
treatment NN N
is VBZ N
considered VBN N
seizure NN O
control NN O
was VBD N
achieved VBN N
in IN N
17 CD N
(57 JJ N
percent) NN N
of IN N
the DT N
neonates NNS N
assigned VBD N
to TO N
receive VB N
phenobarbital NN N
first RB N
and CC N
18 CD N
(62 JJ N
percent) NN N
of IN N
those DT N
assigned VBN N
to TO N
receive VB N
phenytoin NN N
first RB N
(P=0.67) NNP N
. . N

The DT N
severity NN O
of IN O
the DT O
seizures NNS O
was VBD N
a DT N
stronger JJR N
predictor NN N
of IN N
the DT N
success NN N
of IN N
treatment NN N
than IN N
was VBD N
the DT N
assigned JJ N
agent NN N
. . N

Neonates NNS P
with IN P
mild JJ P
seizures NNS P
or CC P
with IN P
seizures NNS P
that WDT N
were VBD N
decreasing VBG N
in IN N
severity NN O
before IN N
treatment NN N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
their PRP$ N
seizures NNS O
end VBP O
regardless NN O
of IN N
the DT N
treatment NN N
assignment NN N
. . N

CONCLUSIONS NNP N
Phenobarbital NNP I
and CC N
phenytoin NN I
are VBP N
equally RB N
but CC N
incompletely RB N
effective JJ N
as IN N
anticonvulsants NNS O
in IN N
neonates NNS P
. . P

With IN N
either DT N
drug NN N
given VBN N
alone RB N
the DT N
seizures NNS O
were VBD N
controlled VBN O
in IN N
fewer JJR N
than IN N
half NN N
of IN N
the DT N
neonates NNS N
. . N

-DOCSTART- -X- N

Sulfadoxine/pyrimethamine NNP I
alone RB I
or CC I
with IN I
amodiaquine JJ I
or CC I
artesunate NN I
for IN N
treatment NN O
of IN O
uncomplicated JJ P
malaria: NN P
a DT N
longitudinal JJ N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
New NNP N
antimalarial JJ N
treatments NNS N
are VBP N
urgently RB N
needed VBN N
in IN N
sub-Saharan JJ P
Africa NNP P
. . P

Improved VBN N
therapies NNS N
should MD N
decrease VB N
failure NN N
rates NNS N
in IN N
the DT N
short JJ N
term NN N
but CC N
their PRP$ N
effect NN N
on IN N
incidence NN N
of IN N
subsequent JJ N
episodes NNS N
of IN N
malaria NN N
is VBZ N
little JJ N
studied JJ N
. . N

We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
short-term JJ N
and CC N
long-term JJ N
effectiveness NN N
of IN N
three CD N
antimalarial JJ I
regimens NNS I
in IN N
children NNS P
from IN P
Kampala NNP P
Uganda NNP P
. . P

METHODS NNP N
We PRP N
randomly RB N
allocated VBD N
healthy JJ P
children NNS P
aged VBD P
6 CD P
months NNS P
to TO P
5 CD P
years NNS P
to TO N
receive VB N
25 CD I
mg/kg JJ I
sulfadoxine NN I
and CC I
1.25 CD I
mg/kg NN I
pyrimethamine NN I
plus CC I
either CC I
placebo JJ I
25 CD I
mg/kg JJ I
amodiaquine NN I
or CC I
12 CD I
mg/kg JJ I
artesunate NN I
. . I

Participants NNS N
were VBD N
followed VBN N
up RP N
for IN N
1 CD N
year NN N
and CC N
received VBD N
the DT N
same JJ N
preassigned JJ N
treatment NN N
for IN N
every DT N
new JJ N
episode NN N
of IN N
uncomplicated JJ N
malaria NNS N
diagnosed VBN N
during IN N
follow-up NN N
. . N

Recrudescent NNP N
and CC N
new JJ N
infections NNS N
were VBD N
distinguished VBN N
by IN N
comparison NN N
of IN N
polymorphisms NNS N
in IN N
merozoite JJ N
surface NN N
protein NN N
2 CD N
(MSP2) NN N
. . N

Our PRP$ N
primary JJ N
endpoint NN N
was VBD N
the DT N
total JJ O
number NN O
of IN O
treatments NNS O
for IN O
malaria NNS O
per IN O
time NN O
at IN O
risk NN O
. . O

Analyses NNS N
were VBD N
done VBN N
per IN N
protocol NN N
. . N

FINDINGS NNP N
183 CD N
(61%) NN N
of IN N
316 CD P
participants NNS P
were VBD N
diagnosed VBN N
with IN N
at IN N
least JJS N
one CD N
episode NN N
of IN N
uncomplicated JJ N
malaria NNS N
. . N

A DT N
total NN N
of IN N
577 CD N
episodes NNS N
of IN N
uncomplicated JJ N
Plasmodium NNP N
falciparum NN N
malaria NNS N
were VBD N
treated VBN N
with IN N
study NN N
drugs; VBP N
all DT N
regimens NNS N
were VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
. . N

Clinical JJ O
treatment NN O
failure NN O
after IN N
14 CD N
days NNS N
was VBD N
significantly RB N
more RBR N
frequent JJ N
in IN N
the DT N
sulfadoxine/pyrimethamine NN I
group NN N
(38 NNP N
of IN N
215 CD N
18%) CD N
compared VBN N
with IN N
either CC N
the DT N
sulfadoxine/pyrimethamine NN I
plus CC I
amodiaquine JJ I
group NN N
(two NNP N
of IN N
164 CD N
1%; CD N
p<0.0001) NN N
or CC N
sulfadoxine/pyrimethamine JJ I
plus CC I
artesunate JJ I
group NN N
(one NN N
of IN N
198 CD N
1%; CD N
p<0.0001) NN N
. . N

After IN N
28 CD N
and CC N
42 CD N
days NNS N
patients NNS N
in IN N
the DT N
sulfadoxine/pyrimethamine NN I
plus CC I
amodiaquine JJ I
group NN N
were VBD N
significantly RB N
less RBR N
likely JJ N
to TO N
develop VB N
malaria NNS O
than IN N
were VBD N
those DT N
in IN N
the DT N
other JJ N
groups NNS N
. . N

Overall JJ N
sulfadoxine/pyrimethamine NN I
plus CC I
amodiaquine NN I
reduced VBD N
the DT N
rate NN O
of IN O
subsequent JJ O
treatments NNS O
for IN O
malaria NN O
by IN N
54% CD N
(95% JJ N
CI NNP N
36-66 JJ N
p<0.0001) NNS N
compared VBN N
with IN N
sulfadoxine/ JJ I
pyrimethamine NN I
alone RB I
and CC N
by IN N
37% CD N
(12-54 JJ N
p=0.007) NNS N
compared VBN N
with IN N
sulfadoxine/pyrimethamine JJ I
plus JJ I
artesunate NN I
. . I

INTERPRETATION NNP N
Sulfadoxine/pyrimethamine NNP I
plus CC I
amodiaquine NN I
could MD N
be VB N
used VBN N
as IN N
an DT N
inexpensive JJ O
regimen NNS O
to TO O
decrease VB O
the DT O
rate NN O
of IN O
subsequent JJ O
episodes NNS O
of IN O
malaria NN O
. . O

-DOCSTART- -X- N

Effect NN N
of IN N
phenylephrine NN I
on IN N
the DT N
haemodynamic JJ O
state NN O
and CC O
cerebral JJ O
oxygen NN O
saturation NN O
during IN N
anaesthesia NN N
in IN N
the DT N
upright JJ N
position NN N
. . N

BACKGROUND IN N
The DT N
upright JJ N
sitting NN N
or CC N
beachchair NN N
position NN N
is VBZ N
associated VBN N
with IN N
hypotension NN N
risk NN N
of IN N
cerebral JJ N
hypoperfusion NN N
and CC N
cerebral JJ N
injury NN N
. . N

We PRP N
hypothesized VBD N
that IN N
by IN N
increasing VBG N
arterial JJ N
pressure NN N
with IN N
phenylephrine JJ I
administration NN N
cerebral JJ N
perfusion NN N
and CC N
postoperative JJ N
recovery NN N
would MD N
be VB N
improved VBN N
. . N

METHODS NNP N
Thirty-four CD P
patients NNS P
undergoing JJ P
elective JJ P
shoulder NN P
surgery NN P
were VBD P
randomized VBN P
to TO N
receive VB N
either DT N
saline NN I
or CC I
phenylephrine JJ I
infusion NN I
(PE) VBD I
5 CD I
min NN I
before IN I
being VBG I
placed VBN I
in IN I
the DT I
upright JJ I
position NN I
. . I

Simultaneous JJ N
measurements NNS N
of IN N
mean JJ O
arterial JJ O
pressure NN O
cerebral JJ O
oxygen NN O
saturation NN O
middle JJ O
cerebral JJ O
artery NN O
velocity NN O
and CC O
cardiac JJ O
function NN O
using VBG N
transthoracic JJ N
echocardiography NN N
were VBD N
made VBN N
. . N

Postoperative JJ N
neurocognitive JJ N
function NN N
was VBD N
assessed VBN N
. . N

RESULTS NN N
At IN N
the DT N
commencement NN N
of IN N
PE NNP I
mean FW I
(SD) NNP N
cerebral JJ O
oxygen NN O
saturation NN O
significantly RB N
decreased VBN N
from IN N
77 CD N
(10) NNS N
to TO N
67 CD N
(13)% NNS N
(P=0.02) CD N
and CC N
further RB N
to TO N
59 CD N
(11) CD N
% NN N
on IN N
upright JJ N
positioning NN N
. . N

The DT N
level NN O
of IN O
cerebral JJ O
saturation NN O
upright NN N
was VBD N
not RB N
significantly RB N
different JJ N
to TO N
patients NNS N
receiving VBG N
saline JJ N
(P=0.07) NN N
with IN N
values NNS N
remaining VBG N
at IN N
room-air JJ N
levels NNS N
. . N

Middle NNP O
cerebral JJ O
artery RB O
blood NN O
velocity NN O
increased VBN N
by IN N
20% CD N
(P=0.04) NNS N
. . N

Phenylephrine NNP I
prevented VBD N
hypotension NN O
in IN N
the DT N
upright JJ N
position NN N
primarily RB N
by IN N
maintaining VBG N
preload NN N
and CC N
increasing VBG N
systemic JJ O
vascular JJ O
resistance NN O
(P=0.01) NN N
and CC N
was VBD N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
cardiac JJ O
output NN O
. . O

No DT N
postoperative JJ O
neurocognitive JJ O
dysfunction NN O
was VBD N
identified VBN N
. . N

CONCLUSIONS NNP N
Despite IN N
maintaining VBG N
arterial JJ N
pressure NN N
with IN N
phenylephrine JJ I
cerebral JJ O
desaturation NN O
occurred VBD N
with IN N
upright JJ N
positioning NN N
. . N

Cerebral NNP O
oxygen NN O
saturation NN O
can MD N
provide VB N
a DT N
valuable JJ N
endpoint NN N
when WRB N
evaluating VBG N
the DT N
effect NN N
of IN N
vasopressor NN N
therapy NN N
on IN N
cerebral JJ N
perfusion NN N
. . N

-DOCSTART- -X- N

Evaluation NN N
of IN N
the DT N
effects NNS N
of IN N
human JJ I
leukocyte JJ I
IFN-alpha NN I
on IN N
the DT N
immune JJ O
response NN O
to TO O
the DT O
HBV NNP O
vaccine NN O
in IN N
healthy JJ P
unvaccinated JJ P
individuals NNS P
. . P

HBV NNP I
vaccine NN I
needs VBZ N
3 CD N
injections NNS N
over IN N
6 CD N
months NNS N
to TO N
induce VB N
immunity NN N
. . N

Thus RB N
the DT I
use NN I
of IN I
adjuvants NNS I
capable JJ N
of IN N
inducing VBG N
earlier JJR O
immune JJ O
protection NN O
would MD N
be VB N
highly RB N
desirable JJ N
. . N

Most JJS N
adjuvants NNS I
may MD N
act VB N
by IN N
inducing VBG N
cytokines NNS N
and CC N
among IN N
them PRP N
type VBP N
I PRP N
interferons NNS N
(IFNs) VBP I
deserve VB N
a DT N
special JJ N
attention NN N
in IN N
view NN N
of IN N
the DT N
potent JJ N
immunomostimulatory NN N
activity NN N
observed VBN N
in IN N
mouse NN N
models NNS N
and CC N
on IN N
dendritic JJ N
cell NN N
functions NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
IFN-alpha NNP I
administered VBD I
as IN I
an DT I
adjuvant NN I
of IN I
HBV NNP I
vaccine NN I
in IN N
healthy JJ P
unvaccinated JJ P
individuals NNS P
. . P

No DT N
significant JJ N
enhancing VBG N
effect NN N
on IN N
the DT N
antibody NN O
response NN O
was VBD N
observed VBN N
in IN N
spite NN N
of IN N
an DT N
early JJ N
and CC N
transient JJ N
upregulation NN N
of IN N
costimulatory NN N
molecule NN N
expression NN N
on IN N
peripheral JJ O
blood NN O
mononuclear NN O
cells NNS O
which WDT O
may MD N
be VB N
suggestive JJ N
of IN N
an DT N
IFN-mediated JJ I
activation NN I
of IN I
antigen NN I
presenting VBG I
cells NNS I
. . I

We PRP N
conclude VBP N
that DT N
under IN N
the DT N
conditions NNS N
used VBN N
in IN N
this DT N
trial NN N
natural JJ I
IFN-alpha NNP I
does VBZ N
not RB N
act VB N
as IN N
an DT N
adjuvant NN N
of IN N
the DT N
HBV NNP N
vaccine NN N
in IN N
healthy JJ P
unvaccinated JJ P
individuals NNS P
. . P

-DOCSTART- -X- N

High-dose JJ I
pyridoxine NN I
and CC I
magnesium NN I
administration NN I
in IN N
children NNS P
with IN P
autistic JJ P
disorder: NN P
an DT N
absence NN N
of IN N
salutary JJ N
effects NNS N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
study NN N
. . N

Several JJ N
reports NNS N
have VBP N
described VBN N
salutary JJ N
effects NNS N
such JJ N
as IN N
decreased JJ N
physical JJ N
aggression NN N
and CC N
improved VBN N
social JJ N
responsiveness NN N
being VBG N
associated VBN N
with IN N
the DT N
administration NN N
of IN N
high JJ N
doses NNS N
of IN N
pyridoxine NN I
and CC I
magnesium NN I
(HDPM) NN I
in IN N
open-labeled JJ N
and CC N
controlled JJ N
studies NNS N
of IN N
patients NNS P
with IN P
autism NN P
. . P

Despite IN N
this DT N
fact NN N
this DT N
intervention NN N
remains VBZ N
controversial JJ N
. . N

A DT N
10-week JJ N
double-blind JJ N
placebo-controlled JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
examine VB N
both DT N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
HDPM NNP I
in IN N
autism NN N
. . N

Twelve CD P
patients NNS P
were VBD P
enrolled VBN P
and CC P
10 CD P
patients NNS P
(mean JJ P
age NN P
6 CD P
years NNS P
3 CD P
months) NNS P
were VBD P
able JJ P
to TO P
complete VB P
the DT P
study NN P
. . P

HDPM NNP I
at IN N
an DT N
average JJ N
dose NN N
of IN N
638.9 CD N
mg NN N
of IN N
pyridoxine NN I
and CC N
216.3 CD N
mg NN N
of IN N
magnesium NN I
oxide NN I
was VBD N
ineffective JJ N
in IN N
ameliorating VBG O
autistic JJ O
behaviors NNS O
as IN N
assessed VBN N
by IN N
the DT N
Children's NNP O
Psychiatric NNP O
Rating NNP O
Scale NNP O
(CPRS) VBD O
the DT O
Clinical NNP O
Global NNP O
Impression NNP O
Scale NNP O
and CC O
the DT O
NIMH NNP O
Global NNP O
Obsessive NNP O
Compulsive NNP O
Scale NNP O
. . O

Furthermore RB N
no DT N
clinically RB N
significant JJ N
side NN N
effects NNS N
were VBD N
noted VBN N
during IN N
HDPM NNP I
administration NN N
. . N

A DT N
trend NN N
for IN N
a DT N
transient JJ N
change NN N
on IN N
the DT N
CPRS NNP N
was VBD N
found VBN N
that IN N
was VBD N
possibly RB N
due JJ N
to TO N
a DT N
placebo NN N
response NN N
. . N

This DT N
study NN N
raises VBZ N
doubts NNS N
about IN N
the DT N
clinical JJ N
effectiveness NN N
of IN N
HDPM NNP I
in IN N
autistic JJ N
disorder NN N
. . N

-DOCSTART- -X- N

Comparative NNP I
in IN I
vitro JJ I
dissolution NN I
and CC I
in IN I
vivo JJ I
bioavailability NN I
of IN I
diflunisal/naproxen JJ I
fixed-dose JJ I
combination NN I
tablets NNS I
and CC I
concomitant JJ I
administration NN I
of IN I
diflunisal NN I
and CC I
naproxen NN I
in IN I
healthy JJ P
adult NN P
subjects NNS P
. . P

A DT I
simple JJ I
validated JJ I
high-performance NN I
liquid NN I
chromatography NN I
(HPLC) NNP I
assay NN I
was VBD I
developed VBN I
for IN I
determination NN I
of IN I
diflunisal NN I
and CC I
naproxen NN I
in IN I
human JJ I
plasma NN I
samples NNS I
. . I

This DT I
is VBZ I
to TO I
compare VB I
the DT I
bioavailability NN O
of IN O
diflunisal-naproxen JJ O
fixed-dose JJ O
combination NN O
(FDC) NN O
with IN I
their PRP$ I
separate JJ I
dosage NN I
forms NNS I
. . I

The DT I
in IN I
vitro JJ I
dissolution NN I
study NN I
was VBD I
adopted VBN I
to TO I
compare VB I
the DT I
dissolution NN I
behavior NN I
of IN I
FDC NNP O
with IN I
respect NN I
to TO I
separate VB I
marketed VBN I
tablets NNS I
. . I

In IN I
vivo NN I
study NN I
was VBD I
conducted VBN I
according VBG I
to TO I
a DT I
single-center JJ I
randomized JJ I
single-dose JJ I
laboratory-blinded JJ I
2 CD I
Way NNP I
Cross-Over NNP I
Study NNP I
with IN I
a DT I
washout JJ I
period NN I
of IN I
10 CD I
days NNS I
. . I

Under IN I
fasting VBG P
conditions NNS P
24 CD P
healthy JJ P
Egyptian JJ P
male NN P
volunteers NNS P
were VBD I
randomly RB I
allocated VBN I
to TO I
receive VB I
a DT I
single JJ I
oral JJ I
dose NN I
of IN I
either DT I
one CD I
FDC NNP I
tablet NN I
or CC I
co-administration NN I
of IN I
two CD I
separate JJ I
diflunisal NN I
and CC I
naproxen RB I
marketed VBN I
tablets NNS I
. . I

Plasma NN I
samples NNS I
were VBD I
obtained VBN I
over IN I
a DT I
72-h JJ I
interval NN I
and CC I
analyzed VBN I
for IN I
diflunisal NN I
and CC I
naproxen NN I
by IN I
reversed JJ I
phase NN I
liquid NN I
chromatography NN I
with IN I
UV NNP I
detection NN I
. . I

The DT I
pharmacokinetic JJ I
parameters NNS I
Cmax NNP O
AUC0-t NNP O
AUC0- NNP O
tmax NN O
and CC O
t1/2 NN O
were VBD I
determined VBN I
from IN I
plasma JJ I
concentration-time JJ I
profiles NNS I
. . I

The DT I
90% CD I
confidence NN I
intervals NNS I
for IN I
the DT I
ratio NN I
of IN I
log NN I
transformed VBN I
values NNS I
of IN O
Cmax NNP O
AUC0-t NNP O
and CC O
AUCt- NNP O
of IN I
the DT I
2 CD I
treatments NNS I
were VBD I
within IN I
the DT I
acceptable JJ I
range NN I
(0.8-1.25) NN I
for IN I
bioequivalence NN I
. . I

From IN I
pharmacokinetic JJ I
and CC I
in IN I
vitro JJ I
studies NNS I
perspectives VBZ I
1 CD I
FDC NNP I
tablet NN I
demonstrated VBD I
similar JJ I
relative JJ I
bioavailability NN I
with IN I
the DT I
2 CD I
individual JJ I
-reference NN I
tablets NNS I
. . N

-DOCSTART- -X- N

Famotidine NNP I
treatment NN N
of IN N
children NNS P
with IN P
autistic JJ P
spectrum NN P
disorders: NN P
pilot NN N
research NN N
using VBG N
single JJ N
subject JJ N
research NN N
design NN N
. . N

Using VBG N
single JJ N
subject JJ N
research NN N
design NN N
we PRP N
performed VBD N
pilot JJ N
research NN N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
famotidine NN I
for IN N
the DT N
treatment NN N
of IN N
children NNS P
with IN P
autistic JJ P
spectrum NN P
disorders NNS P
. . P

We PRP N
studied VBD N
9 CD P
Caucasian JJ P
boys NNS P
3.8-8.1 CD P
years NNS P
old JJ P
with IN P
a DT P
DSM-IV JJ P
diagnosis NN P
of IN P
a DT P
pervasive JJ P
developmental NN P
disorder NN P
living VBG P
with IN P
their PRP$ P
families NNS P
receiving VBG P
no DT P
chronic JJ P
medications NNS P
and CC P
without IN P
significant JJ P
gastrointestinal JJ P
symptoms NNS P
. . P

The DT I
dose NN I
of IN I
oral JJ I
famotidine NN I
was VBD I
2 CD I
mg/kg/day JJ I
(given VBN I
in IN I
two CD I
divided VBD I
doses); IN I
the DT I
maximum JJ I
total JJ I
daily JJ I
dose NN I
was VBD I
100 CD I
mg NN I
. . I

Using VBG N
single-subject JJ N
research NN N
analysis NN N
and CC N
medication NN N
given VBN N
in IN N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ I
cross-over NN N
design NN N
4 CD N
of IN N
9 CD N
children NNS N
randomized VBN N
(44%) NN N
had VBD N
evidence NN N
of IN N
behavioral JJ N
improvement NN N
. . N

Primary JJ N
efficacy NN N
was VBD N
based VBN N
on IN N
data NNS N
kept VBN N
by IN N
primary JJ N
caregivers NNS N
including VBG N
a DT N
daily JJ O
diary; JJ O
daily JJ O
visual JJ O
analogue NN O
scales NNS O
of IN O
affection NN O
reciting NN O
or CC O
aspects NNS O
of IN O
social JJ O
interaction; NN O
Aberrant NNP O
Behavior NNP O
Checklists NNP O
(ABC NNP O
Aman); NNP O
and CC O
Clinical NNP O
Global NNP O
Improvement NNP O
scales NNS O
. . O

Children NNP P
with IN P
marked JJ P
stereotypy NN P
(meaningless NNP P
repetitive JJ P
behaviors) NN P
did VBD N
not RB N
respond VB N
. . N

Our PRP$ N
subjects NNS P
did VBD P
not RB P
have VB P
prominent JJ P
gastrointestinal JJ P
symptoms NNS P
and CC N
endoscopy NN N
was VBD N
not RB N
part NN N
of IN N
our PRP$ N
protocol; NN N
thus RB N
we PRP N
cannot VBP N
exclude VB N
the DT N
possibility NN N
that IN N
our PRP$ N
subjects NNS N
improved VBN N
due JJ N
to TO N
the DT N
effective JJ N
treatment NN N
of IN N
asymptomatic JJ P
esophagitis NN P
. . P

The DT N
use NN N
of IN N
famotidine NN I
for IN N
the DT N
treatment NN N
of IN N
children NNS P
with IN P
autistic JJ P
spectrum NN P
disorders NNS P
warrants NNS N
further JJ N
investigation NN N
. . N

-DOCSTART- -X- N

Pegylated VBN I
feline JJ I
granulocyte NN I
colony-stimulating JJ I
factor NN I
increases NNS N
neutrophil JJ O
levels NNS O
in IN N
cats NNS P
. . P

Neutropenia NNP P
can MD N
often RB N
be VB N
corrected VBN N
by IN N
treatment NN N
with IN N
granulocyte-colony JJ I
stimulating JJ I
factor NN I
(G-CSF) JJ I
and CC I
off-label JJ I
use NN I
of IN I
commercial JJ I
human JJ I
G-CSF NNP I
(HuG-CSF) NN I
is VBZ N
a DT N
commonly RB N
used VBN N
treatment NN N
for IN N
neutropenic JJ P
animals NNS P
. . P

However RB N
long-term JJ N
HuG-CSF NNP I
treatment NN I
can MD N
be VB N
associated VBN N
with IN N
adverse JJ O
effects NNS O
including VBG O
neutropenia NN O
. . O

Here RB N
feline JJ I
(Fe) NNP I
G-CSF NNP I
was VBD N
produced VBN N
in IN N
Pichia NNP N
pastoris NN N
pegylated VBD I
(Peg) JJ I
FeG-CSF NNP I
and CC N
tested VBN N
in IN N
cats NNS N
. . N

A DT N
randomized VBN N
controlled JJ N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
efficacy NN O
of IN N
PegFeG-CSF NNP I
compared VBN N
to TO N
FeG-CSF NNP I
or CC I
HuG-CSF NNP I
in IN N
FIV-infected NNP P
(n=14) NNP P
FIV-uninfected NNP P
healthy JJ P
cats NNS P
(n=19) VBP P
and CC P
in IN P
HuG-CSF-induced NNP P
neutropenic JJ P
cats NNS P
(n=4) VBP P
. . P

Daily JJ N
FeG-CSF NNP I
doses NNS N
induced VBD N
higher JJR O
neutrophil NN O
production NN O
than IN N
HuG-CSF NNP O
after IN N
the DT N
second JJ N
week NN N
of IN N
treatment NN N
(P NNP N
 VBZ N
0.002) CD N
. . N

Weekly JJ N
doses NNS N
of IN I
PegFeG-CSF NNP O
induced VBD O
higher JJR O
neutrophil JJ O
counts NNS O
and CC N
showed VBD O
greater JJR O
sustained VBN O
activity NN O
than IN N
weekly JJ N
doses NNS N
of IN I
FeG-CSF NNP I
. . I

PegFeG-CSF NNP I
provided VBD N
the DT N
most RBS N
therapeutic JJ N
and CC N
sustainable JJ O
neutrophil JJ O
production NN O
(P<0.001) NN N
in IN N
both DT P
FIV-uninfected JJ P
and CC P
FIV-infected JJ P
cats NNS P
without IN N
the DT N
development NN N
of IN O
neutralizing VBG O
antibodies NNS O
. . N

Conversely RB N
all DT P
HuG-CSF-treated JJ P
cats NNS P
developed VBD O
neutralizing VBG O
antibodies NNS O
suggesting VBG N
cross-reactive JJ N
antibodies NNS N
to TO N
endogenous JJ I
G-CSF NNP I
in IN N
a DT N
majority NN N
of IN N
the DT N
cases NNS N
with IN N
severe JJ N
neutropenia NN N
. . N

Strikingly RB N
when WRB I
PegFeG-CSF NNP I
was VBD N
used VBN N
to TO N
rescue VB N
cats NNS N
with IN I
HuG-CSF-induced NNP O
neutropenia NNP O
clinically RB N
normal JJ O
neutrophil JJ O
numbers NNS N
returned VBN N
. . N

Thus RB I
PegFeG-CSF NNP I
appears VBZ N
to TO N
be VB N
a DT N
superior JJ N
treatment NN N
for IN N
neutropenia NN N
in IN P
feline JJ P
patients NNS P
. . N

-DOCSTART- -X- N

Acute NNP N
effect NN N
of IN N
pegvisomant NN I
on IN N
cardiovascular JJ N
risk NN N
markers NNS N
in IN N
healthy JJ P
men: NN P
implications NNS N
for IN N
the DT N
pathogenesis NN N
of IN N
atherosclerosis NN N
in IN N
GH NNP N
deficiency NN N
. . N

Cardiovascular JJ N
risk NN N
is VBZ N
increased VBN N
in IN N
GH NNP N
deficiency NN N
(GHD) NNP N
. . N

GHD NNP P
adults NNS P
are VBP N
frequently RB N
abdominally RB N
obese JJ N
and CC N
display JJ N
features NNS N
of IN N
the DT N
metabolic JJ N
syndrome NN N
. . N

Otherwise RB N
healthy JJ N
abdominally RB N
obese JJ N
subjects NNS N
have VBP N
low JJ N
GH NNP N
levels NNS N
and CC N
show NN N
features NNS N
of IN N
the DT N
metabolic JJ N
syndrome NN N
as RB N
well RB N
. . N

We PRP N
investigated VBD N
in IN N
healthy JJ P
nonobese JJ P
males NNS P
the DT N
effect NN N
of IN N
the DT N
GH NNP N
receptor NN N
antagonist NN N
pegvisomant NN I
in IN N
different JJ N
metabolic JJ N
conditions NNS N
. . N

This DT N
is VBZ N
a DT N
model NN N
for IN N
acute JJ N
GHD NNP N
without IN N
the DT N
alterations NNS N
in IN N
body NN N
composition NN N
associated VBN N
with IN N
GHD NNP N
. . N

We PRP N
compared VBN N
the DT N
effect NN N
of IN N
pegvisomant NN I
with IN N
that DT N
of IN N
placebo NN I
before IN I
and CC I
after IN I
3 CD I
d NN I
of IN I
fasting NN I
. . I

In IN N
addition NN N
we PRP N
investigated VBD N
the DT N
effect NN N
of IN N
pegvisomant JJ I
under IN I
normal JJ I
i.e NN I
. . I

fed JJ I
conditions NNS I
. . I

Three CD N
days NNS N
of IN N
fasting NN N
as RB N
well RB N
as IN N
pegvisomant JJ I
alone NN I
decreased VBD N
serum JJ O
free JJ O
IGF-I NN O
levels NNS O
(1.0 VBP N
+/- JJ N
0.15 CD N
vs NN N
. . N

0.31 CD N
+/- JJ N
0.05 CD N
ng/ml NN N
and CC N
0.86 CD N
+/- JJ N
0.23 CD N
vs NN N
. . N

0.46 CD N
+/- JJ N
0.23 CD N
ng/ml JJ N
respectively) NN N
. . N

Fasting VBG N
in IN N
combination NN N
with IN N
pegvisomant NN I
also RB N
decreased VBD N
serum JJ O
free JJ O
IGF-I NN O
levels NNS O
(1.0 VBP N
+/- JJ N
0.15 CD N
vs NN N
. . N

0.31 CD N
+/- JJ N
0.07 CD N
ng/ml) NN N
. . N

Treatment NN N
with IN N
pegvisomant NN I
had VBD N
no DT N
additional JJ N
influence NN N
on IN N
the DT N
decline NN N
of IN N
free JJ O
IGF-I NNP O
induced VBN N
by IN N
fasting VBG N
. . N

Pegvisomant NNP I
alone RB I
had VBD N
no DT N
influence NN N
on IN N
insulin NN O
sensitivity NN O
. . O

The DT N
increase NN N
in IN N
insulin JJ O
sensitivity NN O
induced VBN N
by IN N
fasting VBG N
was VBD N
comparable JJ N
to TO N
the DT N
increase NN N
in IN N
insulin JJ O
sensitivity NN O
induced VBN N
by IN N
fasting VBG N
combined VBN N
with IN N
pegvisomant NN I
. . I

Among IN N
serum JJ N
lipid JJ N
concentrations NNS N
only RB N
serum VBP O
triglycerides NNS O
increased VBD N
significantly RB N
as IN N
a DT N
result NN N
of IN N
pegvisomant NN I
alone JJ I
(1.0 NNP N
+/- JJ N
0.2 CD N
vs NN N
. . N

1.6 CD N
+/- JJ N
0.4 CD N
mmol/liter) NN N
. . N

The DT N
changes NNS N
in IN N
lipid JJ O
concentrations NNS O
induced VBN N
by IN N
fasting VBG N
alone RB N
or CC N
pegvisomant VB I
were VBD N
not RB N
different JJ N
from IN N
those DT N
induced VBN N
by IN N
pegvisomant JJ I
alone NN I
. . I

von NN N
Willebrand NNP N
factor NN N
antigen NN N
levels NNS N
declined VBD N
significantly RB N
under IN N
the DT N
influence NN N
of IN N
pegvisomant NN I
alone JJ I
(1.1 NNP N
+/- JJ N
0.07 CD N
vs NN N
. . N

0.8 CD N
+/- JJ N
0.06 CD N
U/ml) NNP N
. . N

In IN N
conclusion NN N
in IN N
different JJ N
metabolic JJ N
conditions NNS N
the DT N
GH NNP N
receptor NN N
antagonist NN N
pegvisomant NN I
induces VBZ N
no DT N
significant JJ N
acute NN N
changes NNS N
in IN N
the DT N
major JJ N
risk NN O
markers NNS O
for IN N
cardiovascular JJ N
disease NN N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
the DT N
secondary JJ N
metabolic NN N
changes NNS N
e.g VBP N
. . N

abdominal JJ N
obesity NN N
or CC N
inflammatory JJ N
factors NNS N
that WDT N
develop VBP N
as IN N
a DT N
result NN N
of IN N
long-standing JJ N
GHD NNP N
are VBP N
of IN N
primary JJ N
importance NN N
in IN N
the DT N
pathogenesis NN N
of IN N
atherosclerosis NN N
in IN N
patients NNS N
with IN N
GHD NNP N
. . N

-DOCSTART- -X- N

Haloperidol NNP I
blood NN N
levels NNS N
and CC N
effects NNS N
in IN N
schizophrenia NN P
and CC P
schizoaffective JJ P
disorder: NN P
a DT N
progress NN N
report NN N
. . N

To TO N
test VB N
the DT N
hypothesis NN N
of IN N
a DT N
"therapeutic JJ N
window NN N
" NN N
we PRP N
have VBP N
randomly RB N
assigned VBN N
acutely RB N
exacerbating VBG N
schizophrenic JJ P
or CC P
schizoaffective JJ P
patients NNS P
to TO N
one CD I
of IN I
three CD I
plasma NN O
levels NNS O
of IN O
haloperidol NN O
(HAL): JJ I
2-13 JJ N
13.1-24 JJ N
or CC N
24.1-35 JJ N
ng/ml NN N
. . N

Patients NNS N
who WP N
did VBD N
not RB N
improve VB N
after IN N
6 CD N
weeks NNS N
of IN N
this DT N
treatment NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
three CD N
haloperidol NN I
levels NNS N
for IN N
another DT N
6 CD N
weeks NNS N
. . N

The DT N
improvement NN N
was VBD N
defined VBN N
as IN N
at IN N
least JJS N
50 CD N
percent JJ N
reduction NN N
of IN N
the DT N
Brief NNP O
Psychiatric NNP O
Rating NNP O
Scale NNP O
(BPRS) NNP O
total JJ O
score NN O
. . O

The DT N
results NNS N
obtained VBD N
in IN N
111 CD P
patients NNS P
do VBP N
not RB N
support VB N
any DT N
consistent JJ N
relationship NN N
between IN N
plasma JJ N
level NN N
of IN N
haloperidol NN I
and CC N
clinical JJ O
improvement NN O
. . O

Patients NNS N
in IN N
the DT N
high JJ N
haloperidol NN I
plasma NN N
range NN N
tended VBD N
to TO N
have VB N
more JJR N
side JJ N
effects NNS N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
haloperidol NN I
doses NNS I
used VBN N
in IN N
clinical JJ N
practice NN N
may MD N
be VB N
higher JJR N
than IN N
necessary JJ N
. . N

-DOCSTART- -X- N

Treatment NN N
of IN N
beta-hemolytic JJ P
streptococcal JJ P
pharyngitis NN P
with IN N
cefaclor NN I
or CC I
penicillin NN I
. . I

Efficacy NN O
and CC N
interaction NN O
with IN N
beta-lactamase-producing JJ I
organisms NNS I
in IN N
the DT N
pharynx NN N
. . N

The DT N
recommended JJ N
treatment NN N
for IN N
group NN P
A NNP P
beta-hemolytic JJ P
streptococcal JJ P
pharyngitis NN P
has VBZ N
continued VBN N
to TO N
be VB N
penicillin JJ I
given VBN N
in IN N
parenteral JJ N
or CC N
oral JJ N
form NN N
. . N

Treatment NN O
failures NNS O
as IN O
determined VBN N
by IN N
the DT N
continued JJ N
presence NN N
of IN N
the DT N
streptococcal JJ O
organism NN O
in IN O
the DT O
pharynx NN O
however RB O
do VBP N
occur NNS N
in IN N
6% CD N
to TO N
25% CD N
of IN N
patients NNS N
treated VBN N
with IN N
penicillin NN I
. . I

Furthermore RB N
beta-lactamase NN N
produced VBN N
by IN N
other JJ N
bacteria NNS N
in IN N
the DT N
pharynx NN N
could MD N
potentially RB N
inactivate VB N
the DT N
penicillin NN N
resulting VBG N
in IN N
increased VBN N
treatment NN N
failures NNS N
or CC N
infection NN N
relapses NNS N
. . N

A DT N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
cefaclor NN I
which WDT I
is VBZ N
relatively RB N
resistant JJ N
to TO N
inactivation VB N
by IN N
beta-lactamase NN N
with IN N
penicillin NN N
for IN N
eradicating VBG N
the DT N
group NN P
A DT P
beta-hemolytic JJ P
streptococcal JJ P
organism NN P
from IN P
the DT P
throats NNS P
of IN P
93 CD P
patients NNS P
with IN P
pharyngitis NN P
. . P

Additionally RB N
extensive JJ N
cultures NNS N
for IN N
potential JJ N
beta-lactamase-producing JJ O
organisms NNS O
were VBD N
conducted VBN N
on IN N
37 CD P
patients; JJ P
27% CD P
of IN P
these DT P
had VBD P
one CD P
or CC P
more JJR P
pharyngeal JJ P
organisms NNS P
that WDT P
were VBD P
producing VBG P
beta-lactamase NN P
. . P

No DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
clinical JJ O
responses NNS O
or CC O
the DT O
bacteriological JJ O
cure NN O
rates NNS O
of IN N
those DT N
treated VBN N
with IN N
cefaclor NN N
and CC N
those DT N
treated VBN N
with IN N
penicillin NN I
when WRB N
stratified VBN N
by IN N
the DT N
presence NN N
or CC N
absence NN N
of IN N
beta-lactamase-producing JJ N
organisms NNS N
. . N

The DT N
prevalence NN N
of IN N
beta-lactamase-producing JJ O
organisms NNS O
in IN N
the DT N
pharynx NN N
however RB N
was VBD N
increased VBN N
after IN N
treatment NN N
with IN N
penicillin JJ I
whereas JJ I
no DT N
change NN N
was VBD N
noted VBN N
following VBG N
treatment NN N
with IN N
cefaclor NN N
. . N

-DOCSTART- -X- N

Prospective JJ N
randomized VBN N
multicenter RBR N
trial NN N
of IN N
sevelamer NN I
hydrochloride NN I
and CC I
calcium NN I
carbonate NN I
for IN N
the DT N
treatment NN N
of IN N
hyperphosphatemia NN P
in IN P
hemodialysis NN P
patients NNS P
in IN P
Japan NNP P
. . P

A DT N
prospective JJ N
randomized VBN N
open-label JJ N
trial NN N
of IN N
sevelamer JJ I
hydrochloride NN I
with IN I
or CC I
without IN I
calcium JJ I
carbonate NN I
(CC) NNS I
involved VBD I
86 CD P
hemodialysis NN P
patients NNS P
in IN P
Japan NNP P
. . P

The DT N
dosage NN N
of IN N
CC NNP I
was VBD N
fixed VBN N
at IN N
3.0 CD N
g/day NN N
for IN N
the DT N
12-week JJ N
study NN N
. . N

After IN N
the DT N
first JJ N
4 CD N
weeks NNS N
all DT N
subjects NNS N
were VBD N
changed VBN I
from IN I
CC NNP I
to TO I
sevelamer VB I
3.0 CD N
g/day NN N
for IN N
another DT N
4 CD N
weeks NNS N
then RB N
allocated VBD N
randomly RB N
to TO N
three CD N
groups NNS N
for IN N
the DT N
final JJ N
4 CD N
weeks: NN N
group NN I
A NNP I
sevelamer NN I
6.0 CD I
g/day; NN I
group NN I
B NNP I
sevelamer VBZ I
3.0 CD I
g/day NN I
and CC I
CC NNP I
3.0 CD I
g/day; NN I
group NN I
C NNP I
CC NNP I
3.0 CD I
g/day NN I
. . I

The DT N
target NN N
serum NN O
phosphorous JJ O
concentration NN O
(P)=5.5 NNP N
mg/dL NN N
and CC N
the DT N
corrected JJ O
calcium NN O
concentration NN O
(Ca) NNP N
was VBD N
9.0-10.0 JJ N
mg/dL NN N
. . N

Of IN P
the DT P
86 CD P
patients NNS P
62 CD P
finished VBD P
the DT P
study NN P
without IN P
a DT P
change NN P
of IN P
dosage NN P
and CC P
their PRP$ P
data NNS P
were VBD P
analyzed VBN P
(group FW P
A NNP P
N=16; NNP P
group NN P
B NNP P
N=26; NNP P
group NN P
C NNP P
N=20) NNP P
. . P

At IN N
week NN N
8 CD N
compared VBN N
with IN N
week NN N
4 CD N
the DT N
concentration NN O
of IN O
P NNP O
increased VBD N
from IN N
5.7+/-1.4 JJ N
to TO N
6.4+/-1.7 JJ N
mg/dL NN N
in IN N
group NN N
A NNP N
and CC N
decreased VBN N
significantly RB N
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
and CC N
in IN N
group NN N
B NNP N
compared VBN N
with IN N
groups NNS N
A NNP N
and CC N
C; NNP N
groups NNS N
A NNP N
and CC N
C NNP N
had VBD N
similar JJ N
concentrations NNS N
at IN N
week NN N
8 CD N
. . N

The DT N
Ca NNP O
concentration NN O
decreased VBD N
significantly RB N
from IN N
9.7+/-1.0 CD N
to TO N
9.1+/-0.7 CD N
mg/dL NNS N
after IN N
the DT N
change NN N
to TO N
sevelamer VB I
. . I

At IN N
week NN N
8 CD N
Ca NNP O
was VBD N
not RB N
significantly RB N
changed VBN N
in IN N
group NN N
A NNP N
whereas VBZ N
a DT N
significant JJ N
increase NN N
occurred VBD N
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
. . N

Side-effects NNS O
with IN N
sevelamer JJ I
administration NN I
occurred VBD N
in IN N
34 CD N
of IN N
the DT N
86 CD N
patients NNS N
and CC N
24 CD N
dropped VBD N
out IN N
of IN N
the DT N
study NN N
with IN N
a DT N
high JJ N
frequency NN N
in IN N
group NN N
A NNP N
(13/29; VBZ N
44.8%) CD N
. . N

In IN N
conclusion NN N
there EX N
was VBD N
an DT N
additive JJ O
effect NN O
of IN N
sevelamer NN I
for IN N
the DT N
treatment NN N
of IN N
hyperphosphatemia NN N
with IN I
CC NNP I
. . I

The DT N
combination NN I
therapy NN I
was VBD N
better RBR N
tolerated VBN O
and CC N
showed VBD N
higher JJR O
patient NN O
compliance NN O
than IN N
CC NNP I
or CC I
sevelamer JJR I
monotherapy NN I
. . I

-DOCSTART- -X- N

Evaluation NN N
of IN N
mood NN N
profiles NNS N
during IN N
malaria NNS P
chemoprophylaxis: VBP P
a DT N
randomized JJ N
double-blind JJ N
four-arm NN N
study NN N
. . N

BACKGROUND NNP N
To TO N
objectively RB N
compare VB N
the DT N
mood NN N
profiles NNS N
of IN N
users NNS P
of IN P
malaria NNS P
chemoprophylaxis JJ P
regimens NNS P
(atovaquone-proguanil JJ P
chloroquine-proguanil JJ P
doxycycline NN P
or CC P
mefloquine) NN P
in IN P
a DT P
group NN P
of IN P
nonimmune JJ P
tourists NNS P
to TO P
sub-Saharan JJ P
Africa NNP P
. . P

METHODS NNP N
In IN N
a DT N
randomized JJ N
double-blind JJ N
four-arm NN N
study NN N
with IN N
placebo JJ I
run-in JJ N
phase NN N
conducted VBN N
at IN N
travel NN P
clinics NNS P
in IN P
Switzerland NNP P
Germany NNP P
and CC P
Israel NNP P
we PRP P
compared VBN N
moods NNS N
and CC N
feelings NNS N
in IN N
chemoprophylaxis NN P
users NNS P
(n= VBP P
547) CD P
by IN N
administering VBG I
the DT I
standardized JJ I
"Profile NN I
of IN I
Mood NNP I
States" NNP I
(POMS) NNP I
questionnaire NN I
. . I

This DT N
is VBZ N
designed VBN N
to TO N
provide VB N
data NNS N
on IN N
six CD N
categories NNS N
of IN N
feelings: JJ N
tension NN N
depression NN N
anger NN N
vigor NN N
fatigue NN N
and CC N
confusion NN N
. . N

The DT N
questionnaire NN N
was VBD N
administered VBN N
at IN N
four CD N
time NN N
points: NN N
recruitment NN N
(T1) $ N
13 CD N
to TO N
11 CD N
days NNS N
before IN N
departure NN N
(T2) $ N
6 CD N
to TO N
4 CD N
days NNS N
before IN N
departure NN N
(T3) NN N
and CC N
7 CD N
to TO N
14 CD N
days NNS N
after IN N
return NN N
from IN N
Africa NNP N
(T4) NNP N
. . N

RESULTS RB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
with IN N
respect NN N
to TO N
overall JJ N
mood NN N
impact NN N
between IN N
the DT N
medication NN N
arms NNS N
. . N

All DT N
scores NNS N
were VBD N
in IN N
the DT N
normal JJ N
range NN N
and CC N
no DT N
means NNS N
were VBD N
more JJR N
than IN N
1 CD N
SD NN N
from IN N
the DT N
norm NN N
. . N

The DT N
POMS NNP N
data NNS N
were VBD N
reanalyzed VBN N
with IN N
respect NN N
to TO N
sex NN N
age NN N
medication NN N
group NN N
and CC N
control NN N
time NN N
points NNS N
(T1-T4) JJ N
. . N

There EX N
were VBD N
significant JJ N
interaction NN N
effects NNS N
between IN N
sex NN N
and CC N
medication NN N
group--women NNS N
in IN N
the DT N
mefloquine NN N
group NN N
showed VBD N
more JJR N
"fatigue" JJ O
(p= NNP N
.011) NNP N
and CC N
"confusion" NNP O
(p= NNP N
.011) NNP N
than IN N
men NNS N
. . N

Significant JJ N
effects NNS N
of IN N
age NN P
group NN P
(below NNP P
median JJ P
age NN P
34 CD P
y NN P
vs NN P
median JJ P
age NN P
and CC P
above) NN P
were VBD N
noted VBN N
on IN N
the DT N
"tension" NN O
and CC O
"fatigue" JJ O
scales NNS N
in IN N
that DT N
less JJR N
"tension" JJ O
(p= NN N
.045) NNP N
and CC N
less JJR N
"fatigue" JJ O
(p= NN N
.000) NNS N
were VBD N
noted VBN N
in IN N
those DT N
aged VBN P
34 CD P
years NNS P
and CC P
older JJR P
. . P

Younger JJR P
participants NNS P
aged VBN P
<34 CD P
years NNS P
reported VBD P
more RBR N
"confusion" JJ O
(p= JJ N
.013) NN N
at IN N
T2 NNP N
than IN N
at IN N
T1 NNP N
and CC N
T4 NNP N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
overall JJ N
mood NN N
profiles NNS N
were VBD N
similar JJ N
for IN N
the DT N
users NNS N
of IN N
any DT N
of IN N
the DT N
standard JJ P
malaria NN P
chemoprophylaxis NN P
regimens VBZ P
we PRP P
found VBD N
that IN N
women NNS N
using VBG N
mefloquine NN I
showed VBD N
more JJR N
fatigue NN N
and CC N
confusion NN N
than IN N
men NNS N
and CC N
that IN N
younger JJR P
persons NNS P
aged VBD P
less JJR P
than IN P
34 CD P
years NNS P
regardless RB P
of IN N
chemoprophylaxis NN I
used VBN N
reported VBD N
more JJR N
tension NN N
and CC N
fatigue NN N
than IN N
their PRP$ N
older JJR N
counterparts NNS N
. . N

-DOCSTART- -X- N

Internet-based JJ I
Mindfulness NNP I
Meditation NNP I
for IN N
Cognition NNP N
and CC N
Mood NNP O
in IN N
Older NNP P
Adults: NNP P
A NNP N
Pilot NNP N
Study NNP N
. . N

CONTEXT NNP N
Older NNP P
adults NNS P
are VBP N
at IN N
risk NN N
for IN N
greater JJR N
chronic JJ O
stress NN O
and CC N
cognitive JJ O
decline NN O
. . O

Training NN N
in IN N
mindfulness JJ I
meditation NN I
(MM) NN I
may MD N
help VB N
reduce VB N
stress NN O
and CC N
thus RB N
cognitive JJ O
decline NN O
in IN N
older JJR P
adults NNS P
but CC N
little JJ N
research NN N
has VBZ N
explored VBN N
that IN N
hypothesis NN N
. . N

OBJECTIVE IN N
The DT N
current JJ N
study's NN N
primary JJ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
feasibility NN O
and CC O
acceptability NN O
for IN N
use NN N
by IN N
older JJR P
adults NNS P
of IN N
the DT N
Internet NNP I
Mindfulness NNP I
Meditation NNP I
Intervention NNP I
(IMMI) VBD I
a DT I
program NN N
that WDT N
had VBD N
been VBN N
developed VBN N
by IN N
the DT N
research NN N
team NN N
as RB N
well RB N
as IN N
of IN N
an DT N
Internet-based JJ N
health-and-wellness JJ N
education NN N
program NN N
the DT N
control NN N
. . N

The DT N
secondary JJ N
aim NN N
was VBD N
to TO N
collect VB N
preliminary JJ N
pre- NN N
and CC N
postintervention NN N
data NNS N
on IN N
mood NN O
and CC N
cognitive JJ O
function NN O
. . O

DESIGN NNP N
The DT N
study NN N
was VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
(RCT) NN N
a DT N
pilot NN N
study NN N
with IN N
participants NNS N
randomized VBN N
either RB N
to TO N
the DT N
meditation NN I
group NN N
or CC N
the DT N
education NN I
group NN N
. . N

SETTING NN N
Participants NNS N
obtained VBD N
access NN N
to TO N
the DT N
programs NNS N
from IN N
their PRP$ N
homes NNS N
and CC N
the DT N
baseline NN N
and CC N
endpoint NN N
assessments NNS N
occurred VBD N
in IN N
their PRP$ N
homes NNS N
as RB N
well RB N
. . N

PARTICIPANTS NNS N
Older JJR P
adults NNS P
aged VBD P
65-90 JJ P
y NN P
were VBD P
recruited VBN P
from IN P
the DT P
Portland NNP P
OR NNP P
metropolitan JJ P
area NN P
. . P

Twenty-one CD P
people NNS P
enrolled VBN P
in IN P
the DT P
study NN P
. . P

INTERVENTION NN P
Participants NNS N
in IN N
both DT N
groups NNS N
took VBD N
part NN N
in IN N
a DT N
1-h JJ I
online NN I
session NN I
each DT I
week NN I
for IN I
6 CD I
wk NN I
with IN I
30 CD I
min NNS I
of IN I
daily JJ I
home NN I
practice NN I
. . I

OUTCOME NNP N
MEASURES NNP N
Feasibility NNP O
and CC O
acceptability NN O
were VBD N
assessed VBN N
through IN N
measures NNS N
of IN N
adherence NN N
to TO N
the DT N
protocol NN N
and CC N
a DT N
client NN O
satisfaction NN O
questionnaire NN N
. . N

Mood NN O
and CC O
cognitive JJ O
outcomes NNS O
were VBD N
also RB N
evaluated VBN N
before IN N
and CC N
after IN N
the DT N
interventions NNS N
. . N

RESULTS NNP N
Sixteen NNP P
participants NNS P
completed VBD P
the DT P
study NN P
8 CD P
in IN P
each DT P
group NN P
and CC P
5 CD P
dropped VBD P
out RP P
for IN P
a DT P
76% CD P
completion NN P
rate NN P
. . P

Participants' NNP P
mean JJ P
age NN P
was VBD P
76.2 CD P
y; RB P
88% CD P
were VBD P
Caucasian JJ P
and CC P
50% CD P
were VBD P
female JJ P
. . P

Acceptability NNP N
was VBD N
high JJ N
for IN N
the DT N
interventions NNS N
based VBN N
on IN N
above-average JJ N
scores NNS N
on IN N
the DT N
client NN N
satisfaction NN N
questionnaire NN N
. . N

The DT N
IMMI NNP I
participants NNS N
completed VBD N
(1) JJ N
4.25 CD N
 JJ N
2.4 CD N
sessions NNS N
with IN N
a DT N
range NN N
of IN N
0-6; JJ N
(2) NN N
604 CD N
 JJ N
506 CD N
home-practice JJ N
minutes NNS N
with IN N
a DT N
range NN N
0-1432; NN N
and CC N
(3) $ N
21.3 CD N
 $ N
15.5 CD N
d NN N
of IN N
practice NN N
with IN N
a DT N
range NN N
of IN N
0-46 NN N
. . N

The DT I
education NN I
group NN N
completed VBD N
(1) $ N
4.75 CD N
 $ N
1.8 CD N
sessions NNS N
with IN N
a DT N
range NN N
of IN N
2-6; JJ N
(2) NN N
873 CD N
 JJ N
395 CD N
home-practice JJ N
minutes NNS N
with IN N
a DT N
range NN N
of IN N
327-1524; JJ N
and CC N
(3) JJ N
25.6 CD N
d NN N
of IN N
practice NN N
with IN N
a DT N
range NN N
of IN N
11-35 JJ N
. . N

The DT N
intervention NN N
and CC N
control NN N
formats NNS N
were VBD N
both DT N
feasible JJ N
and CC N
the DT N
control NN N
group NN N
was VBD N
appropriate JJ N
. . N

As IN N
expected VBN N
due JJ N
to TO N
the DT N
pilot JJ N
nature NN N
of IN N
the DT N
study NN N
no DT N
differences NNS N
existed VBD N
between IN N
groups NNS N
for IN O
the DT O
mood NN O
or CC O
cognitive JJ O
outcomes NNS O
. . N

CONCLUSIONS NNP N
Administering NNP I
interventions NNS I
via IN I
the DT I
Internet NNP I
to TO N
older VB N
adults NNS N
is VBZ N
feasible JJ N
. . N

The DT N
2 CD N
interventions NNS N
were VBD N
acceptable JJ N
to TO N
participants NNS N
and CC N
equal JJ N
with IN N
regard NN N
to TO N
perceived VBN N
credibility NN N
and CC N
acceptability NN N
. . N

Future JJ I
RCTs NNP N
are VBP N
planned VBN N
to TO N
evaluate VB N
the DT N
clinical JJ N
efficacy NN N
of IN N
the DT N
2 CD N
interventions NNS N
. . N

-DOCSTART- -X- N

Resource NNP N
utilization NN N
and CC N
economic JJ N
costs NNS N
of IN N
care NN N
based VBN N
on IN N
a DT N
randomized JJ N
trial NN N
of IN N
vacuum-assisted JJ I
closure NN I
therapy NN I
in IN N
the DT N
treatment NN N
of IN N
diabetic JJ P
foot NN P
wounds NNS P
. . P

BACKGROUND NNP N
To TO N
evaluate VB N
resource NN N
utilization NN N
and CC N
direct JJ N
economic JJ N
costs NNS N
of IN N
care NN N
for IN N
patients NNS P
treated VBN P
with IN P
negative-pressure JJ P
wound NN P
therapy NN P
(NPWT) NN P
using VBG P
the DT I
Vacuum-Assisted JJ I
Closure NNP I
(V.A.C.) NNP I
system NN I
compared VBN I
to TO N
standard VB I
moist NN I
wound IN I
therapy NN I
(MWT) NN I
. . I

METHODS NNP N
A NNP N
total NN N
of IN N
162 CD P
diabetic JJ P
patients NNS P
with IN P
post-amputation JJ P
wounds NNS P
(up VBP P
to TO P
the DT P
trans-metatarsal JJ P
level) NN P
entered VBD P
a DT N
16-week JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

Patients NNS P
randomized VBN P
to TO P
V.A.C NNP P
. . P

(n JJ P
= $ P
77) CD P
received VBN P
therapy NN P
with IN P
dressing NN P
changes NNS P
every DT P
48 CD P
hours NNS P
. . P

Control NN P
patients NNS P
(n VBP P
= JJ P
85) CD P
received JJ P
standard JJ P
MWT NNP I
. . I

Resource NNP O
utilization NN O
procedures NNS O
and CC O
direct JJ O
costs NNS O
were VBD N
calculated VBN N
and CC N
analyzed VBN N
in IN N
this DT N
post NN N
hoc NN N
retrospective NN N
study NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
between IN N
groups NNS P
for IN P
in-patient JJ P
hospital NN P
stay NN P
(number NNP O
of IN O
admissions NNS O
or CC O
length NN O
of IN O
stay) NN O
. . N

More RBR N
surgical JJ N
procedures NNS N
(including VBG N
debridement) NNS N
were VBD N
required VBN N
in IN N
the DT N
MWT NNP I
group NN N
(120 NNP N
vs VBZ N
43 CD N
NPWT NNP I
P NNP I
<.001) NNP N
. . N

The DT N
average JJ O
number NN O
of IN O
dressing VBG O
changes NNS O
performed VBN O
per IN O
patient NN O
was VBD N
118.0 CD N
(range JJ N
12-226) JJ N
for IN N
MWT NNP I
versus NN N
41 CD N
(6-140) NN N
for IN N
NPWT NNP I
(P NNP N
= NNP N
.0001) NNP N
. . N

The DT N
MWT NNP I
group NN N
had VBD N
11 CD N
(range JJ N
0-106) JJ N
outpatient NN O
treatment NN O
visits NNS O
during IN N
the DT N
study NN N
versus VBD N
4 CD N
(range NN N
0-47) NN N
in IN N
the DT N
NPWT NNP I
group NN N
(P NNP N
<.05) NNP N
. . N

The DT N
average JJ O
direct JJ O
cost NN O
per IN O
patient NN O
treated VBN N
for IN N
8 CD N
weeks NNS N
or CC N
longer JJR N
(independent NN N
of IN N
clinical JJ N
outcome) NN N
was VBD N
$27 JJ N
270 CD N
and CC N
$36 $ N
096 CD N
in IN N
the DT N
NPWT NNP I
and CC N
MWT NNP I
groups NNS N
respectively RB N
. . N

The DT N
average JJ O
total JJ O
cost NN O
to TO O
achieve VB O
healing NN O
was VBD N
$25 JJ N
954 CD N
for IN N
patients NNS N
treated VBN N
with IN N
NPWT NNP I
(n NNP N
= VBD N
43) CD N
compared VBN N
with IN N
$38 JJ N
806 CD N
for IN N
the DT N
MWT NNP I
group NN N
(n NNP N
= VBZ N
33) CD N
. . N

CONCLUSION NNP N
Treatment NNP N
of IN N
diabetic JJ P
patients NNS P
with IN P
post NN P
amputation NN P
wounds VBZ P
using VBG I
NPWT NNP I
resulted VBD N
in IN N
lower JJR N
resource NN N
utilization NN N
and CC N
a DT N
greater JJR N
proportion NN N
of IN N
patients NNS N
obtaining VBG N
wound IN N
healing VBG N
at IN N
a DT N
lower JJR O
overall JJ O
cost NN O
of IN N
care NN N
when WRB N
compared VBN N
to TO N
MWT NNP I
. . I

-DOCSTART- -X- N

[Gluten-free JJ N
diet NN N
in IN N
infantile JJ P
autism NN P
. . P

A DT N
therapeutic JJ N
trial] NN N
. . N

It PRP N
has VBZ N
been VBN N
postulated VBN N
that IN N
there EX N
may MD N
be VB N
a DT N
connection NN N
between IN N
wheat-gluten/milk-casein NN N
and CC N
mental JJ N
disorders NNS N
such JJ N
as IN N
schizophrenia NN N
hyperactivity NN N
and CC N
autism NN N
. . N

In IN N
this DT N
study NN N
seven CD P
patients NNS P
with IN P
infantile JJ P
autism NN P
three CD P
before IN P
puberty NN P
and CC P
four CD P
after IN P
puberty NN P
were VBD P
given VBN N
a DT N
gluten-free JJ N
diet NN N
. . N

Three CD N
children NNS N
were VBD N
provoked VBN N
with IN N
gluten/placebo NN N
in IN N
a DT N
double-blind NN N
study NN N
. . N

Four CD P
young JJ P
patients NNS P
participated VBN N
in IN N
an DT N
open JJ N
study NN N
and CC N
were VBD N
given VBN N
a DT N
gluten-free JJ N
diet NN N
in IN N
six CD N
months NNS N
. . N

Behaviour NNP O
was VBD N
registered VBN N
before IN N
during IN N
and CC N
after IN N
the DT N
period NN N
with IN N
a DT N
gluten-free JJ N
diet NN N
. . N

Visual NNP O
Analogue NNP O
Scale NNP O
and CC O
Real NNP O
Life NNP O
Rating NNP O
Scale NNP O
were VBD N
used VBN N
to TO N
register VB N
changes NNS N
in IN N
behaviour NN N
. . N

No DT N
connection NN N
was VBD N
observed VBN N
between IN N
gluten NNS N
and CC N
behaviour VB O
typical JJ N
for IN N
these DT N
patients NNS N
. . N

On IN N
the DT N
contrary JJ N
the DT N
gluten-free JJ N
diet NN N
seemed VBD N
to TO N
be VB N
another DT N
negative JJ N
factor NN N
leading VBG N
to TO N
further JJ N
social JJ O
isolation NN O
in IN N
this DT N
group NN P
of IN P
highly RB P
socially RB P
handicapped JJ P
patients NNS P
and CC P
families NNS P
. . P

-DOCSTART- -X- N

Oral JJ I
6-mercaptopurine JJ I
versus NN I
oral JJ I
6-thioguanine JJ I
and CC N
veno-occlusive JJ N
disease NN N
in IN P
children NNS P
with IN P
standard-risk JJ P
acute JJ P
lymphoblastic JJ P
leukemia: JJ P
report NN P
of IN P
the DT P
Children's NNP P
Oncology NNP P
Group NNP P
CCG-1952 NNP P
clinical JJ P
trial NN P
. . P

The DT P
Children's NNP P
Cancer NNP P
Group NNP P
1952 CD P
(CCG-1952) JJ P
clinical JJ P
trial NN P
studied VBD P
the DT N
substitution NN I
of IN I
oral JJ I
6-thioguanine JJ I
(TG) NN I
for IN I
6-mercaptopurine JJ I
(MP) NN P
and CC P
triple JJ P
intrathecal JJ P
therapy NN P
(ITT) NN P
for IN P
intrathecal JJ P
methotrexate NN P
(IT-MTX) NN P
in IN P
the DT P
treatment NN P
of IN P
standard-risk JJ P
acute JJ P
lymphoblastic JJ P
leukemia NN P
. . P

After IN N
remission NN P
induction NN P
2027 CD P
patients NNS P
were VBD N
randomized VBN I
to TO I
receive VB I
MP NNP I
(n NNP I
= VBZ I
1010) CD I
or CC I
TG NNP I
(n NNP I
= NNP I
1017) CD I
and CC I
IT-MTX NNP I
(n NNP I
= VBZ I
1018) CD I
or CC I
ITT NNP I
(n NNP I
= NNP I
1009) CD I
. . I

The DT N
results NNS N
of IN N
the DT N
thiopurine NN I
comparison NN N
are VBP N
as IN N
follows VBZ N
. . N

The DT N
estimated VBN N
7-year JJ N
event-free JJ O
survival NN O
(EFS) NN N
for IN N
subjects NNS N
randomized VBN N
to TO N
TG NNP I
was VBD N
84.1% CD N
(+/- JJ N
1.8%) CD N
and CC N
to TO N
MP NNP I
was VBD N
79.0% CD N
(+/- JJ N
2.1%; CD N
P NNP N
= NNP N
.004 NNP N
log NN N
rank) NN N
although IN N
overall JJ O
survival NN O
was VBD N
91.9% CD N
(+/- JJ N
1.4%) CD N
and CC N
91.2% CD N
(+/- JJ N
1.5%) CD N
respectively RB N
(P JJ N
= NNP N
.6 NNP N
log NN N
rank) NN N
. . N

The DT N
TG NNP I
starting VBG N
dose NN N
was VBD N
reduced VBN N
from IN N
60 CD N
to TO N
50 CD N
mg/m(2) NNS N
per IN N
day NN N
after IN N
recognition NN N
of IN N
hepatic JJ N
veno-occlusive JJ O
disease NN O
(VOD) NNP O
. . N

A DT N
total NN N
of IN N
257 CD N
patients NNS N
on IN N
TG NNP I
(25%) NNP N
developed VBD N
VOD NNP N
or CC N
disproportionate VB O
thrombocytopenia NN O
and CC N
switched VBD N
to TO N
MP NNP I
. . I

Once RB N
portal JJ O
hypertension NN O
occurred VBD N
all DT N
subjects NNS N
on IN N
TG NNP I
were VBD N
changed VBN N
to TO N
MP NNP I
. . I

The DT N
benefit NN N
of IN N
randomization NN N
to TO N
TG NNP I
over RB N
MP NNP I
as IN I
measured VBN N
by IN N
EFS NNP N
was VBD N
evident JJ N
primarily RB N
in IN N
boys NNS N
who WP N
began VBD N
TG NNP I
at IN N
60 CD N
mg/m(2) NNS N
(relative JJ N
hazard NN N
rate NN N
[RHR] $ N
0.65 CD N
P NNP N
= NNP N
.002) NNP N
. . N

The DT N
toxicities NNS N
of IN N
TG NNP I
preclude VBP N
its PRP$ N
protracted JJ N
use NN N
as IN N
given VBN N
in IN N
this DT N
study NN N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
at IN N
http://clinicaltrials.gov NN N
as IN N
NCT00002744 NNP N
. . N

-DOCSTART- -X- N

[Intraoperative JJ I
continuous JJ I
epidural JJ I
block NN I
influences NNS I
postoperative JJ I
changes NNS I
in IN I
breathing VBG I
pattern NN I
and CC I
thoracoabdominal JJ I
movement NN I
associated VBN I
with IN I
upper JJ I
abdominal JJ I
surgery] NN I
. . I

We PRP I
have VBP I
examined VBN I
the DT I
changes NNS I
in IN I
breathing VBG I
pattern NN I
and CC I
thoracoabdominal JJ I
movement NN I
associated VBN I
with IN I
upper JJ I
abdominal JJ I
surgery NN I
in IN I
order NN I
to TO I
evaluate VB I
the DT I
possible JJ I
influences NNS I
of IN I
nociceptive JJ I
input NN I
on IN I
respiration NN I
. . I

Sixteen JJ P
patients NNS P
scheduled VBN P
for IN P
gastrectomy NN P
were VBD P
studied VBN P
. . P

Continuous JJ I
epidural JJ I
block NN I
was VBD I
instituted VBN I
prior RB I
to TO I
the DT I
induction NN I
of IN I
anesthesia NN I
and CC I
maintained VBD I
throughout IN I
the DT I
surgery NN I
in IN I
8 CD I
of IN I
16 CD I
patients NNS I
(Group JJ I
1) CD I
while IN I
it PRP I
was VBD I
instituted VBN I
upon IN I
the DT I
peritoneal JJ I
closure NN I
and CC I
maintained VBD I
thereafter RB I
in IN I
the DT I
remaining VBG I
8 CD I
patients NNS I
(Group JJ I
2) CD I
. . I

Breathing NNP O
pattern NN O
and CC O
thoracoabdominal JJ O
motion NN O
were VBD I
determined VBN I
before IN I
and CC I
after IN I
surgery NN I
while IN I
the DT I
patients NNS I
awake VBP I
by IN I
respiratory NN I
inductance NN I
plethysmography NN I
(Respisomnography NN I
Chest NNP I
MI) NNP I
. . I

Breathing NNP O
frequency NN O
and CC O
minute JJ O
ventilation NN O
increased VBD I
significantly RB I
while IN I
tidal JJ I
volume NN I
was VBD I
unchanged JJ I
after IN I
the DT I
operation NN I
regardless NN I
of IN I
the DT I
intraoperative JJ I
epidural JJ I
block NN I
. . I

Furthermore RB I
there EX I
were VBD I
identical JJ I
shortening NN I
of IN I
inspiratory JJ O
time NN O
and CC O
prolongation NN O
of IN O
duty NN O
ratio NN O
(inspiratory JJ I
time/duration NN I
of IN I
a DT I
breath) NN I
in IN I
the DT I
two CD I
groups NNS I
. . I

Contribution NN I
of IN I
rib JJ O
cage NN O
movement NN O
on IN O
tidal JJ O
volume NN O
increased VBD I
significantly RB I
postoperatively RB I
in IN I
all PDT I
the DT I
patients NNS I
. . I

However RB I
the DT I
changes NNS I
were VBD I
significantly RB I
smaller JJR I
in IN I
patients NNS P
receiving VBG P
intraoperative JJ P
epidural JJ P
block NN P
. . P

These DT I
results NNS I
indicate VBP I
that IN I
the DT I
causes NNS I
of IN I
tachypnea NN I
and CC I
increased VBD I
minute NN I
ventilation NN I
are VBP I
different JJ I
from IN I
the DT I
mechanism NN I
responsible JJ I
for IN I
the DT I
alteration NN I
of IN I
thoracoabdominal JJ I
partitioning NN I
of IN I
ventilation NN I
after IN I
upper JJ I
abdominal JJ I
surgery NN I
. . I

The DT I
former JJ I
may MD I
be VB I
related VBN I
to TO I
the DT I
metabolic JJ I
changes NNS I
and CC I
conceivably RB I
unaffected VBN I
by IN I
continuous JJ I
epidural JJ I
block NN I
. . I

While IN I
the DT I
latter NN I
may MD I
be VB I
the DT I
consequence NN I
of IN I
the DT I
reflex JJ I
inhibition NN I
of IN I
the DT I
diaphragmatic JJ I
function NN I
that WDT I
can MD I
be VB I
at IN I
least JJS I
partially RB I
modified VBN I
by IN I
continuous JJ I
epidural JJ I
block NN I
. . I

-DOCSTART- -X- N

Reduced VBN N
mortality NN N
among IN N
children NNS P
in IN P
southern JJ P
India NNP P
receiving VBG P
a DT P
small JJ P
weekly JJ P
dose NN P
of IN P
vitamin NN P
A NNP P
. . P

BACKGROUND NNP I
Clinical NNP N
vitamin VBD N
A DT N
deficiency NN N
affects VBZ N
millions NNS N
of IN N
children NNS N
worldwide JJ N
and CC N
subclinical JJ N
deficiency NN N
is VBZ N
even RB N
more RBR N
common JJ N
. . N

Supplemental JJ N
vitamin NN I
A NNP I
has VBZ N
been VBN N
reported VBN N
to TO N
reduce VB N
mortality NN N
among IN N
these DT N
children NNS N
but CC N
the DT N
results NNS N
have VBP N
been VBN N
questioned VBN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
controlled VBN N
masked VBD N
clinical JJ N
trial NN N
for IN N
one CD N
year NN N
in IN P
southern JJ P
India NNP P
involving VBG P
15 CD P
419 CD P
preschool-age JJ P
children NNS P
who WP P
received VBD P
either CC P
8.7 CD P
mumol NN P
(8333 NNP P
IU) NNP P
of IN P
vitamin NN P
A NNP P
and CC P
46 CD P
mumol NN P
(20 NNP P
mg) NN P
of IN P
vitamin NN P
E NNP P
(the NNP P
treated VBD P
group) NN P
or CC P
vitamin NN P
E NNP P
alone RB P
(the VBZ P
control NN P
group) NN P
. . P

Vitamin NNP I
supplements NNS I
were VBD I
delivered VBN I
weekly JJ I
by IN I
community NN I
health NN I
volunteers NNS I
who WP I
also RB I
recorded VBD I
mortality NN O
and CC O
morbidity NN O
. . O

Weekly JJ N
contact NN N
was VBD N
made VBN N
with IN N
at IN N
least JJS N
88 CD N
percent NN N
of IN N
the DT N
children NNS N
in IN N
both DT N
study NN N
groups NNS N
. . N

The DT N
base-line JJ N
characteristics NNS N
of IN N
the DT N
children NNS N
were VBD N
similar JJ N
and CC N
documented VBD N
a DT N
high JJ N
prevalence NN N
of IN N
vitamin NN N
A NNP N
deficiency NN N
and CC N
undernutrition NN N
. . N

RESULTS NNP N
One CD N
hundred VBD N
twenty-five JJ N
deaths NNS N
occurred VBD N
of IN N
which WDT N
117 CD N
were VBD N
not RB N
accidental JJ N
. . N

The DT N
risk NN O
of IN O
death NN O
in IN N
the DT N
group NN N
treated VBD N
with IN N
vitamin NN I
A NNP I
was VBD N
less JJR N
than IN N
half NN N
that IN N
in IN N
the DT N
control NN N
group NN N
(relative NNP N
risk NN N
0.46; CD N
95 CD N
percent NN N
confidence NN N
interval NN N
0.30 CD N
to TO N
0.71) CD N
. . N

The DT N
risk NN N
was VBD N
most RBS N
reduced JJ N
among IN N
children NNS N
under IN N
3 CD N
years NNS N
of IN N
age NN N
(6 NN N
to TO N
11 CD N
months--relative JJ N
risk NN N
0.28; CD N
95 CD N
percent NN N
confidence NN N
interval NN N
0.09 CD N
to TO N
0.85; CD N
12 CD N
to TO N
35 CD N
months--relative JJ N
risk NN N
0.46; CD N
95 CD N
percent NN N
confidence NN N
interval NN N
0.26 CD N
to TO N
0.81) CD N
and CC N
among IN N
those DT N
who WP N
were VBD N
chronically RB N
undernourished VBN N
as IN N
manifested VBN N
by IN N
stunting VBG N
(relative JJ N
risk NN N
0.11; CD N
95 CD N
percent NN N
confidence NN N
interval NN N
0.03 CD N
to TO N
0.36) CD N
. . N

The DT N
symptom-specific JJ N
risk NN N
of IN N
mortality NN O
was VBD N
significantly RB N
associated VBN N
with IN N
diarrhea JJ O
convulsions NNS O
and CC O
other JJ O
infection-related JJ O
symptoms NNS O
. . O

CONCLUSIONS NNP N
The DT N
regular JJ N
provision NN N
of IN N
a DT N
supplement NN N
of IN N
vitamin NN I
A NNP I
to TO N
children NNS P
at IN P
a DT N
level NN N
potentially RB N
obtainable JJ N
from IN N
foods NNS N
in IN N
an DT N
area NN N
where WRB N
vitamin NN N
A DT N
deficiency NN N
and CC N
under-nutrition NN N
are VBP N
documented VBN N
public JJ N
health NN N
problems NNS N
contributed VBD N
substantially RB N
to TO N
children's VB N
survival; JJ N
mortality NN N
was VBD N
reduced VBN N
on IN N
average NN N
by IN N
54 CD N
percent NN N
. . N

-DOCSTART- -X- N

A DT I
randomized JJ I
pilot NN I
study NN I
with IN I
daily JJ I
walking VBG I
during IN I
adjuvant JJ I
chemotherapy NN I
for IN I
patients NNS P
with IN P
breast NN P
and CC P
colorectal JJ P
cancer NN P
. . P

BACKGROUND NNP P
Physical NNP I
activity NN I
during IN I
chemotherapy NN I
has VBZ I
been VBN I
shown VBN I
in IN I
several JJ I
studies NNS I
to TO I
reduce VB I
fatigue NN O
improve NN O
symptoms NNS O
and CC I
impact NN O
positively RB O
on IN O
health-related JJ O
quality NN O
of IN O
life NN O
(HRQoL) NN O
. . O

Challenges NNS I
associated VBN I
with IN I
intervention NN I
studies NNS I
on IN I
physical JJ I
activity NN I
during IN I
cancer NN I
treatment NN I
relate NN I
to TO I
consistent JJ I
adherence NN I
. . I

The DT I
primary JJ I
objective NN I
was VBD I
to TO I
study VB I
feasibility NN I
and CC I
adherence NN I
of IN I
physical JJ I
activity NN I
intervention NN I
among IN I
patients NNS P
with IN P
cancer NN P
during IN P
adjuvant JJ P
chemotherapy NN P
treatment NN P
. . P

The DT I
secondary JJ I
objective NN I
was VBD I
to TO I
investigate VB I
the DT I
effects NNS I
of IN I
physical JJ I
activity NN I
on IN I
health NN I
aspects NNS I
including VBG I
HRQoL NNP O
symptoms NNS O
and CC I
surrogate JJ I
markers NNS I
for IN I
cardiovascular JJ I
disease NN I
. . I

MATERIAL NNP I
AND CC I
METHODS NNP I
This DT I
randomized VBD I
controlled JJ I
trial NN I
included VBD I
patients NNS P
with IN P
breast JJ P
cancer NN P
(BRCA) NN P
and CC P
colorectal JJ P
cancer NN P
(CRC) NN P
during IN P
adjuvant JJ P
chemotherapy NN P
. . P

The DT I
intervention NN I
continued VBD I
for IN I
10 CD I
weeks NNS I
and CC I
included VBD I
daily JJ I
walks NNS I
of IN I
10 CD I
000 CD I
steps NNS I
and CC I
a DT I
weekly JJ I
supervised VBN I
group NN I
walk NN I
. . I

Adherence NN O
was VBD I
assessed VBN I
by IN I
a DT I
pedometer NN I
and CC I
the DT I
number NN I
of IN I
participants NNS I
who WP I
reported VBD I
step NN I
counts NNS I
every DT I
week NN I
and CC I
percentage NN I
of IN I
participants NNS I
who WP I
achieved VBD I
the DT I
target NN I
steps NNS I
every DT I
week NN I
. . I

RESULTS NNP I
Adherence NNP O
average JJ I
reached VBD I
91% CD I
during IN I
the DT I
intervention NN I
period; NN I
in IN I
total JJ I
74% CD I
completed VBD I
the DT I
exercise NN I
intervention NN I
. . I

The DT I
majority NN I
of IN I
the DT I
participants NNS I
achieved VBD I
an DT I
average NN I
of IN I
83% CD I
of IN I
the DT I
target NN I
of IN I
10 CD I
000 CD I
steps NNS I
per IN I
day NN I
for IN I
10 CD I
weeks NNS I
. . I

There EX I
was VBD I
a DT I
significant JJ I
increase NN I
in IN I
daily JJ O
physical JJ O
activity NN O
(p NNP I
= VBZ I
0.016) CD I
in IN I
the DT I
intervention NN P
group NN P
. . P

Significant JJ I
differences NNS I
were VBD I
also RB I
found VBN I
for IN I
some DT I
breast NN I
cancer-specific JJ I
symptoms NNS I
[swelling VBG O
mobility NN O
and CC O
pain NN O
(p NNP I
= VBZ I
0.045)] CD I
. . I

The DT I
study NN I
showed VBD I
a DT I
relatively RB I
small JJ O
weight NN O
gain NN O
an DT I
average NN I
of IN I
0.9 CD I
kg NNS I
in IN I
the DT I
intervention NN I
group NN I
and CC I
1.3 CD I
kg NN I
in IN I
the DT I
control NN I
group NN I
. . I

CONCLUSION NNP I
Physical NNP I
activity NN I
in IN I
the DT I
form NN I
of IN I
walking NN I
is VBZ I
feasible JJ I
during IN I
adjuvant JJ I
chemotherapy NN I
treatment NN I
despite IN I
increasing VBG I
symptoms NNS I
. . I

The DT I
physical JJ I
activity NN I
increased VBN I
in IN I
the DT I
intervention NN I
group NN I
during IN I
the DT I
study NN I
time NN I
and CC I
had VBD I
a DT I
positive JJ I
impact NN I
on IN I
breast NN I
symptoms NNS I
and CC I
the DT I
weight NN I
gain NN I
was VBD I
lower JJR I
in IN I
comparison NN I
to TO I
previous JJ I
studies NNS I
. . I

-DOCSTART- -X- N

Comparison NNP N
of IN N
four CD N
continuously RB N
administered VBN N
progestogen NN I
plus CC I
oestradiol JJ I
combinations NNS I
for IN N
climacteric JJ P
complaints NNS P
. . P

Sixty JJ P
women NNS P
with IN P
climacteric JJ P
complaints NNS P
who WP P
had VBD P
not RB P
menstruated VBN P
for IN P
at IN P
least JJS P
1 CD P
year NN P
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
one CD N
of IN N
four CD N
hormonal JJ I
replacement NN I
regimens NNS I
. . I

All DT N
four CD N
formulations NNS N
were VBD N
administered VBN N
daily RB N
and CC N
continuously RB N
and CC N
each DT N
contained VBD N
2 CD N
mg NN N
of IN N
micronized JJ I
oestradiol-17 JJ I
beta NN I
in IN I
combination NN I
with IN I
either DT I
norethisterone NN I
acetate NN I
1 CD I
mg NN I
(group NNP I
A) NNP I
or CC I
0.5 CD I
mg NNS I
(group JJ I
B) NNP I
or CC I
megestrol VB I
acetate JJ I
5 CD I
mg NN I
(group NNP I
C) NNP I
or CC I
2.5 CD I
mg NNS I
(group JJ I
D) NNP I
. . I

The DT N
clinical JJ O
efficacy NN O
was VBD N
the DT N
same JJ N
although IN N
the DT N
alleviation NN N
of IN N
vasomotor NN O
symptoms NNS O
was VBD N
somewhat RB N
slower JJR N
in IN N
those DT N
women NNS N
receiving VBG N
preparation NN I
A DT I
. . I

The DT N
endometrium NN N
was VBD N
atrophied VBN N
in IN N
nearly RB N
all DT N
biopsies NNS O
. . O

Irregular JJ O
uterine NN O
bleeding NN O
was VBD N
almost RB N
entirely RB N
confined VBN N
to TO N
the DT N
earlier JJR N
phase NN N
of IN N
the DT N
study NN N
and CC N
was VBD N
substantially RB N
less JJR N
with IN N
the DT N
formulation NN N
containing VBG N
1 CD N
mg JJ N
norethisterone NN I
acetate NN I
. . I

It PRP N
is VBZ N
concluded VBN N
that IN N
a DT N
continuous JJ I
oestradiol-progestogen JJ I
combination NN I
can MD N
be VB N
used VBN N
for IN N
long-term JJ N
treatment NN N
of IN N
climacteric JJ P
complaints NNS P
in IN P
postmenopausal JJ P
women NNS P
and CC N
that IN N
after IN N
4 CD N
months NNS N
the DT N
clinical JJ N
efficacy NN N
is VBZ N
the DT N
same JJ N
irrespective NN N
of IN N
the DT N
type NN N
and CC N
dose NN N
of IN N
progestogen NN I
administered VBN N
. . N

-DOCSTART- -X- N

Clinical JJ I
pharmacokinetics NNS I
of IN I
buffered JJ I
propranolol JJ I
sublingual JJ I
tablet NN I
(Promptol)-application NN I
of IN I
a DT I
new JJ I
"physiologically RB I
based" JJ I
model NN I
to TO I
assess VB I
absorption NN I
and CC I
disposition NN I
. . I

Sublingual JJ I
administration NN I
of IN I
certain JJ I
buffered JJ I
propranolol NN I
may MD I
improve VB I
the DT I
rate NN I
and CC I
extent NN I
of IN I
absorption NN I
compared VBN I
to TO I
oral JJ I
administration NN I
. . I

The DT I
main JJ I
objectives NNS I
of IN I
this DT I
study NN I
were VBD I
to TO I
(1) VB I
compare VB I
the DT I
plasma NN I
propranolol JJ I
concentrations NNS I
(Cp-prop) JJ I
following VBG I
sublingual JJ I
administration NN I
of IN I
a DT I
specially RB I
buffered VBN I
formulation NN I
(Promptol) NN I
to TO I
that DT I
following VBG I
oral JJ I
administration NN I
of IN I
Inderal() NNP I
and CC I
(2) NNP I
evaluate VBP I
the DT I
utility NN I
of IN I
a DT I
special JJ I
pharmacokinetic JJ I
model NN I
in IN I
describing VBG I
the DT I
Cp-prop NNP I
following VBG I
sublingual JJ I
administration NN P
. . P

Eighteen NNP P
healthy JJ P
volunteers NNS P
received VBD P
10mg CD I
sublingual JJ I
Promptol NNP I
or CC I
oral JJ I
Inderal() NNP I
. . I

Multiple JJ I
Cp-prop NNP I
were VBD I
determined VBN I
and CC I
their PRP$ I
pharmacokinetics NNS I
compared VBN I
. . I

Additional NNP I
data NN I
following VBG I
sublingual JJ I
40mg CD I
Promptol NNP I
or CC I
Inderal() NNP I
were VBD I
utilized VBN I
for IN I
evaluation NN I
of IN I
a DT I
special JJ I
advanced JJ I
compartmental JJ I
absorption NN I
and CC I
transit NN I
(ACAT) NNP I
model NN I
. . I

For IN I
model NN I
simulation NN I
the DT I
physicochemical JJ I
parameters NNS I
were VBD I
imported VBN I
from IN I
AMET NNP I
predictor NN I
whereas VBD I
the DT I
pharmacokinetic JJ I
parameters NNS I
were VBD I
calculated VBN I
and CC I
optimized VBN I
by IN I
Gastroplus() NNP I
. . I

Based VBN I
on IN I
this DT I
model NN I
the DT I
quantity NN I
of IN I
drug NN O
absorbed VBN O
via IN O
buccal/sublingual JJ O
mucosa NN I
was VBD O
estimated VBN O
. . I

Cp-prop NN I
was VBD I
higher JJR I
at IN I
earlier JJR I
times NNS I
with IN I
3-fold JJ I
greater JJR I
relative JJ I
bioavailability NN I
following VBG I
sublingual JJ I
Promptol NNP I
compared VBN I
to TO I
that DT I
from IN I
oral JJ I
Inderal() NNP I
. . I

The DT I
special JJ I
ACAT NNP I
model NN I
provided VBD I
excellent JJ I
goodness NN O
of IN O
fit NN O
of IN O
Cp-prop-time NNP O
curve NN I
and CC I
estimated VBD I
a DT I
56.6% CD O
increase NN O
in IN O
absorption NN I
rate NN I
from IN I
Promptol NNP I
and CC O
higher JJR O
initial JJ I
Cp-prop NNP I
compared VBN I
to TO I
the DT I
regular JJ I
formulation NN I
. . I

The DT I
modified JJ I
ACAT NNP I
model NN I
provided VBD I
a DT I
useful JJ I
approach NN I
to TO I
describe VB I
sublingual JJ I
absorption NN I
of IN I
propranolol NN I
and CC I
clearly RB I
demonstrated VBD I
an DT I
improvement NN I
of IN I
absorption NN I
of IN I
Promptol NNP I
. . I

The DT I
sublingual JJ I
10mg CD I
Promptol NNP I
achieved VBD I
not RB I
only RB I
a DT I
similar JJ I
systemic JJ I
exposure NN I
as IN I
30mg CD I
oral JJ I
Inderal() NNP I
but CC I
an DT I
earlier JJR I
effective JJ I
Cp-prop NNP I
which WDT I
may MD I
be VB I
advantageous JJ I
for IN I
certain JJ I
clinical JJ N
conditions NNS N
. . N

-DOCSTART- -X- N

Adjuvant JJ N
L-arginine NNP N
treatment NN N
for IN N
in-vitro JJ P
fertilization NN P
in IN P
poor JJ P
responder NN P
patients NNS P
. . P

The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
prospectively RB N
and CC N
randomly RB N
to TO N
evaluate VB N
the DT N
role NN N
of IN N
L-arginine NNP N
in IN N
improving VBG N
uterine JJ N
and CC N
follicular JJ N
Doppler NNP N
flow NN N
and CC N
in IN N
improving VBG N
ovarian JJ N
response NN N
to TO N
gonadotrophin VB N
in IN N
poor JJ P
responder NN P
women NNS P
. . P

A DT P
total NN P
of IN P
34 CD P
patients NNS P
undergoing JJ P
assisted JJ P
reproduction NN P
was VBD N
divided VBN N
in IN N
two CD N
groups NNS N
according VBG N
to TO N
different JJ N
ovarian JJ N
stimulation NN N
protocols: NN N
(i) JJ N
flare-up JJ N
gonadotrophin-releasing NN N
hormone NN N
analogue NN N
(GnRHa) NNP N
plus CC N
elevated JJ N
pure NN N
follicle NN N
stimulating VBG N
hormone NN N
(pFSH) NNP N
(n NNP N
= NNP N
17); CD N
and CC N
(ii) JJ N
flare-up JJ N
GnRHa NNP N
plus CC N
elevated VBN N
pFSH JJ N
plus CC N
oral JJ N
L-arginine NNP N
(n NNP N
= NNP N
17) CD N
. . N

During IN N
the DT N
ovarian JJ N
stimulation NN N
regimen NNS N
the DT N
patients NNS N
were VBD N
submitted VBN N
to TO N
hormonal VB N
(oestradiol NN N
and CC N
growth NN N
hormone) VBP N
ultrasonographic JJ N
(follicular JJ N
number NN N
and CC N
diameter JJ N
endometrial JJ N
thickness) NN N
and CC N
Doppler NNP N
(uterine NNP N
and CC N
perifollicular JJ N
arteries) NN N
evaluations NNS N
. . N

Furthermore RB N
the DT N
plasma NN N
and CC N
follicular JJ N
fluid NN N
concentrations NNS N
of IN N
arginine JJ N
citrulline NN N
nitrite/nitrate JJ N
(NO2-/NO3-) JJ N
and CC N
insulin-like JJ N
growth NN N
factor-1 JJ N
(IGF-1) JJ N
were VBD N
assayed VBN N
. . N

All DT P
34 CD P
patients NNS P
completed VBD P
the DT P
study NN P
. . P

In IN N
the DT N
L-arginine NNP N
treated VBD N
group NN N
a DT N
lower JJR N
cancellation NN O
rate NN O
an DT O
increased VBN N
number NN O
of IN O
oocytes NNS O
collected VBN O
and CC O
embryos RB O
transferred VBN O
were VBD N
observed VBN N
. . N

In IN N
the DT N
same JJ N
group NN N
increased VBD O
plasma NN O
and CC O
follicular JJ O
fluid NN O
concentrations NNS O
of IN O
arginine JJ O
citrulline NN O
NO2-/NO3- NNP O
and CC O
IGF-1 NNP O
was VBD N
observed VBN N
. . N

Significant JJ N
Doppler NNP O
flow NN O
improvement NN O
was VBD N
obtained VBN N
in IN N
the DT N
L-arginine NNP N
supplemented VBD N
group NN N
. . N

Three CD N
pregnancies NNS O
were VBD N
registered VBN N
in IN N
these DT N
patients NNS N
. . N

No DT N
pregnancies NNS O
were VBD N
observed VBN N
in IN N
the DT N
other JJ N
group NN N
. . N

It PRP N
was VBD N
concluded VBN N
that IN N
oral JJ N
L-arginine JJ N
supplementation NN N
in IN N
poor JJ P
responder NN P
patients NNS P
may MD N
improve VB N
ovarian JJ O
response NN O
endometrial JJ O
receptivity NN O
and CC O
pregnancy NN O
rate NN O
. . O

-DOCSTART- -X- N

A DT I
potent JJ I
oral JJ I
P-selectin NNP I
blocking NN I
agent NN I
improves VBZ N
microcirculatory JJ N
blood NN N
flow NN N
and CC N
a DT N
marker NN N
of IN N
endothelial JJ N
cell NN N
injury NN N
in IN N
patients NNS P
with IN P
sickle JJ P
cell NN P
disease NN P
. . P

Abnormal JJ N
blood NN N
flow NN N
accounts NNS N
for IN N
most JJS N
of IN N
the DT N
clinical JJ N
morbidity NN N
of IN N
sickle NN N
cell NN N
disease NN N
(SCD) NNP N
[1 VBZ N
2] CD N
. . N

Most JJS N
notably RB N
occlusion NN N
of IN N
flow NN N
in IN N
the DT N
microvasculature NN N
causes VBZ N
the DT N
acute NN N
pain NN N
crises NNS N
[3] VBP N
that WDT N
are VBP N
the DT N
commonest NN N
cause NN N
for IN N
patients NNS P
with IN P
SCD NNP P
to TO P
seek VB N
medical JJ N
attention NN N
[4] NN N
and CC N
major JJ N
determinants NNS N
of IN N
their PRP$ N
quality NN N
of IN N
life NN N
[5] NN N
. . N

Based VBN N
on IN N
evidence NN N
that IN N
endothelial JJ I
P-selectin NNP I
is VBZ N
central JJ N
to TO N
the DT N
abnormal JJ N
blood NN N
flow NN N
in IN N
SCD NNP N
we PRP N
provide VBP N
results NNS N
from IN N
four CD N
of IN N
our PRP$ N
studies NNS N
that WDT N
are VBP N
germane VBN N
to TO N
microvascular VB N
blood NN N
flow NN N
in IN N
SCD NNP N
. . N

A DT N
proof-of-principle JJ N
study NN N
established VBD N
that IN N
doses NNS I
of IN I
heparin NN I
lower JJR N
than IN N
what WP N
are VBP N
used VBN N
for IN N
anticoagulation NN N
but CC N
sufficient JJ N
to TO N
block VB N
P-selectin NNP N
improved JJ N
microvascular JJ N
blood NN N
flow NN N
inpatients NNS P
with IN P
SCD NNP P
. . P

An DT N
in IN N
vitro NN N
study NN N
showed VBD N
that IN N
Pentosan NNP I
Polysulfate NNP I
Sodium NNP I
(PPS) NNP I
had VBD N
greater JJR N
P-selectin JJ N
blocking NN N
activity NN N
than IN N
heparin NN I
. . I

A DT N
Phase NNP N
I PRP N
clinical VBP N
study NN N
demonstrated VBD N
that IN N
a DT N
single JJ N
oral JJ N
dose NN N
of IN N
PPS NNP I
increased VBD N
microvascular JJ O
blood NN O
flow NN O
in IN N
patients NNS N
with IN N
SCD NNP N
. . N

A DT N
Phase NNP N
II NNP N
clinical JJ N
study NN N
that WDT N
was VBD N
not RB N
completed VBN N
documented VBD N
that IN N
daily JJ N
oral JJ N
doses NNS N
of IN N
PPS NNP I
administered VBD N
for IN N
8 CD N
weeks NNS N
lowered VBD N
plasma JJ O
levels NNS O
of IN O
sVCAM-1 NN O
and CC N
tended VBD N
to TO N
improve VB N
microvascular JJ O
blood NN O
flow NN O
in IN N
patients NNS N
with IN N
SCD NNP N
. . N

These DT N
data NNS N
support NN N
the DT N
concept NN N
that IN N
P-selectin NNP I
on IN N
the DT N
microvascular JJ N
endothelium NN N
is VBZ N
critical JJ N
to TO N
both DT N
acute JJ O
vascular NN O
occlusion NN O
and CC O
chronically RB O
impaired JJ O
microvascular JJ O
blood NN O
flow NN O
in IN N
SCD NNP N
. . N

They PRP N
also RB N
demonstrate VBP N
that IN N
oral JJ N
PPS NNP I
is VBZ N
beneficial JJ N
to TO N
microvascular VB N
sickle NN N
cell NN N
blood NN N
flow NN N
and CC N
has VBZ N
potential JJ N
as IN N
an DT N
efficacious JJ N
agent NN N
for IN N
long-term JJ N
prophylactic JJ N
therapy NN N
of IN N
SCD NNP N
. . N

